PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hiraoka, D; Okumura, E; Kishimoto, T				Hiraoka, D.; Okumura, E.; Kishimoto, T.			Turn motif phosphorylation negatively regulates activation loop phosphorylation in Akt	ONCOGENE			English	Article						activation-loop; Akt; starfish oocytes; TOR; turn motif	PROTEIN-KINASE-B; RICTOR-MTOR COMPLEX; BETA-GAMMA-SUBUNIT; SIGNALING PATHWAY; STARFISH OOCYTES; MAMMALIAN TARGET; CELL-CYCLE; MATURATION; INSULIN; AKT/PKB	Akt, also known as protein kinase B, has a central role in various signaling pathways that regulate cellular processes such as metabolism, proliferation and survival. On stimulation, phosphorylation of the activation loop (A-loop) and hydrophobic motif (HM) of Akt by the kinase phosphoinositide-dependent kinase 1 (PDK1) and the mammalian target of rapamycin complex 2 (mTORC2), respectively, results in Akt activation. A well-conserved threonine in the turn motif (TM) is also constitutively phosphorylated by mTORC2 and contributes to the stability of Akt. The role of TM phosphorylation in HM and A-loop phosphorylation has not been sufficiently evaluated. Using starfish oocytes as a model system, this study provides the first evidence that TM phosphorylation has a negative role in A-loop phosphorylation. In this system, the maturation-inducing hormone, 1-methyladenine, stimulates Akt to reinitiate meiosis through activation of cyclin B-Cdc2. The phosphorylation status of Akt was monitored via introduction of exogenous human Akt (hAkt) in starfish oocytes. TM and HM phosphorylation was inhibited by microinjection of an anti-starfish TOR antibody, but not by rapamycin treatment, suggesting that both phosphorylation events depend on TORC2, as reported in mammalian cells. A single or double alanine substitution at each of three phosphorylation residues revealed that TM phosphorylation renders Akt susceptible to dephosphorylation on the A-loop. When A-loop phosphatase was inhibited by okadaic acid (OA), TMphosphorylation still reduced A-loop phosphorylation, suggesting that the effect is caused at least partially through reduction of sensitivity to PDK1. Negative regulation by TM phosphorylation was also observed in constitutively active Akt and was functionally reflected in meiosis resumption. By contrast, HM phosphorylation enhanced A-loop phosphorylation and achieved full activation of Akt via a mechanism at least partially independent of TM phosphorylation. These observations provide new insight into the mechanism controlling Akt phosphorylation in the cell. Oncogene (2011) 30, 4487-4497; doi:10.1038/onc.2011.155; published online 16 May 2011	[Kishimoto, T.] Tokyo Inst Technol, Grad Sch Biosci, Lab Cell & Dev Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Kishimoto, T (corresponding author), Tokyo Inst Technol, Grad Sch Biosci, Lab Cell & Dev Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan.	tkishimo@bio.titech.ac.jp			Ministry of Education, Science and Culture, Japan	Ministry of Education, Science and Culture, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Mark Terasaki for the gift of the pSP64-S vector and Dr Masatoshi Hara for suggestion of eIF4E and 4E-BP1. This work was supported by grants from the Ministry of Education, Science and Culture, Japan to TK.	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Borgatti P, 2003, J CELL PHYSIOL, V196, P79, DOI 10.1002/jcp.10279; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027; Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fayard E, 2005, J CELL SCI, V118, P5675, DOI 10.1242/jcs.02724; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Goren I, 2008, BIOCHEM BIOPH RES CO, V372, P103, DOI 10.1016/j.bbrc.2008.04.185; GUERRIER P, 1975, DEV BIOL, V47, P341, DOI 10.1016/0012-1606(75)90288-2; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Hara M, 2009, DEVELOPMENT, V136, P1687, DOI 10.1242/dev.035261; Hauge C, 2007, EMBO J, V26, P2251, DOI 10.1038/sj.emboj.7601682; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Hiraoka D, 2004, DEV BIOL, V276, P330, DOI 10.1016/j.ydbio.2004.08.036; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kalous J, 2006, BIOL CELL, V98, P111, DOI 10.1042/BC20050020; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; KISHIMOTO T, 1986, METHOD CELL BIOL, V27, P379, DOI 10.1016/S0091-679X(08)60359-3; Kishimoto T, 2003, CURR OPIN CELL BIOL, V15, P654, DOI 10.1016/j.ceb.2003.10.010; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Restuccia DF, 2010, DIS MODEL MECH, V3, P705, DOI 10.1242/dmm.004671; Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tomek W, 2005, REPRODUCTION, V130, P423, DOI 10.1530/rep.1.00754; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004	47	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2011	30	44					4487	4497		10.1038/onc.2011.155	http://dx.doi.org/10.1038/onc.2011.155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	844FN	21577208				2022-12-17	WOS:000296733200004
J	Bakiri, L; Reschke, MO; Gefroh, HA; Idarraga, MH; Polzer, K; Zenz, R; Schett, G; Wagner, EF				Bakiri, L.; Reschke, M. O.; Gefroh, H. A.; Idarraga, M. H.; Polzer, K.; Zenz, R.; Schett, G.; Wagner, E. F.			Functions of Fos phosphorylation in bone homeostasis, cytokine response and tumourigenesis	ONCOGENE			English	Article						AP-1; Fos; knock-in; mouse; phosphorylation	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; SKIN TUMOR-DEVELOPMENT; LACKING C-FOS; TRANSCRIPTIONAL ACTIVATION; PROTEASOMAL DEGRADATION; TRANSFORMING ACTIVITY; TRANSGENIC MICE; GROWTH-FACTOR; GENE	Mice lacking c-fos develop osteopetrosis due to a block in osteoclast differentiation. Carboxy-terminal phosphorylation of Fos on serine 374 by ERK1/2 and serine 362 by RSK1/2 regulates Fos stability and transactivation potential in vitro. To assess the physiological relevance of Fos phosphorylation in vivo, serine 362 and/or serine 374 was replaced by alanine (Fos362A, Fos374A and FosAA) or by phospho-mimetic aspartic acid (FosDD). Homozygous mutants were healthy and skeletogenesis was largely unaffected. Fos C-terminal phosphorylation, predominantly on serine 374, was found important for osteoclast differentiation in vitro and affected lipopolysaccharide (LPS)-induced cytokine response in vitro and in vivo. Importantly, skin papilloma development was delayed in FosAA, Fos362A and Rsk2-deficient mice, accelerated in FosDD mice and unaffected in Fos374A mutants. Furthermore, the related Fos protein and putative RSK2 target Fra1 failed to substitute for Fos in papilloma development. This indicates that phosphorylation of serines 362 and 374 exerts context-dependent roles in modulating Fos activity in vivo. Inhibition of Fos C-terminal phosphorylation on serine 362 by targeting RSK2 might be of therapeutic relevance for skin tumours. Oncogene (2011) 30, 1506-1517; doi: 10.1038/onc.2010.542; published online 29 November 2010	[Bakiri, L.; Reschke, M. O.; Gefroh, H. A.; Idarraga, M. H.; Polzer, K.; Zenz, R.; Schett, G.; Wagner, E. F.] CNIO, Canc Cell Biol Programme, F BBVA, Genes Dev & Dis Grp, E-28029 Madrid, Spain; [Idarraga, M. H.] Research Inst Mol Pathol IMP, Vienna, Austria; [Polzer, K.; Schett, G.] Univ Erlangen Nurenberg, Dept Internal Med 3, Erlangen, Germany	Centro Nacional de Investigaciones Oncologicas (CNIO); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Erlangen Nuremberg	Wagner, EF (corresponding author), CNIO, Canc Cell Biol Programme, F BBVA, Genes Dev & Dis Grp, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	ewagner@cnio.es	Bakiri, Latifa/AAP-1674-2020; Bakiri, Latifa/N-5780-2014	Wagner, Erwin F/0000-0001-7872-0196; bakiri, latifa/0000-0002-6300-2420	Boehringer Ingelheim (BI); BBVA-Foundation; ERC; EMBO; European Community [LSHM-CT-2003-504468]	Boehringer Ingelheim (BI)(Boehringer Ingelheim); BBVA-Foundation(BBVA Foundation); ERC(European Research Council (ERC)European Commission); EMBO(European Molecular Biology Organization (EMBO)); European Community(European Commission)	We are very grateful to Drs K Matsuo, Y Takada and R Khokha for critical comments and helpful suggestions, Drs F Mulero and RP Marshall for help with micro-computed tomography, U Moehle-Steinlein, E Andres, HC Theussl and V Komnenovic for technical assistance. The project was initiated at the IMP, which is funded by Boehringer Ingelheim (BI). EFW is funded by the BBVA-Foundation and by an ERC advanced Grant. Part of this work was funded by an EMBO postdoctoral fellowship to LB and the NoE Cells into Organs (LSHM-CT-2003-504468) program of the European Community.	Bakiri L, 2007, BONE, V40, P867, DOI 10.1016/j.bone.2006.11.005; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Basbous J, 2007, MOL CELL BIOL, V27, P3936, DOI 10.1128/MCB.01776-06; Casalino L, 2007, EMBO J, V26, P1878, DOI 10.1038/sj.emboj.7601617; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Chen RH, 1996, ONCOGENE, V12, P1493; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; CURRAN T, 1984, CELL, V36, P259; David JP, 2005, J CLIN INVEST, V115, P664, DOI 10.1172/JCI200522877; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Durchdewald M, 2008, CANCER RES, V68, P6877, DOI 10.1158/0008-5472.CAN-08-0299; Dymecki SM, 1996, P NATL ACAD SCI USA, V93, P6191, DOI 10.1073/pnas.93.12.6191; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Fleischmann A, 2003, J NEUROSCI, V23, P9116; Fleischmann A, 2000, GENE DEV, V14, P2695, DOI 10.1101/gad.187900; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Fu LN, 2005, CELL, V122, P803, DOI 10.1016/j.cell.2005.06.028; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Koga K, 2009, IMMUNITY, V30, P372, DOI 10.1016/j.immuni.2008.12.021; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nakakuki T, 2010, CELL, V141, P884, DOI 10.1016/j.cell.2010.03.054; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pellegrino MJ, 2006, J NEUROCHEM, V99, P1480, DOI 10.1111/j.1471-4159.2006.04250.x; Ray N, 2006, INT IMMUNOL, V18, P671, DOI 10.1093/intimm/dxl004; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sasaki T, 2006, MOL CELL, V24, P63, DOI 10.1016/j.molcel.2006.08.005; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Takada Y, 2010, J IMMUNOL, V184, P1014, DOI 10.4049/jimmunol.0901196; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WANG ZQ, 1995, CANCER RES, V55, P6244; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	43	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2011	30	13					1506	1517		10.1038/onc.2010.542	http://dx.doi.org/10.1038/onc.2010.542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119595	Green Accepted			2022-12-17	WOS:000288998300002
J	Kanai, M; Crowe, MS; Zheng, Y; Vande Woude, GF; Fukasawa, K				Kanai, M.; Crowe, M. S.; Zheng, Y.; Vande Woude, G. F.; Fukasawa, K.			RhoA and RhoC are both required for the ROCK II-dependent promotion of centrosome duplication	ONCOGENE			English	Article						centrosome; Rho; ROCK II; CDK2; cyclin E; NPM/B23	CDK2/CYCLIN E; KINASE; GTPASES; NUCLEOPHOSMIN/B23; INVOLVEMENT; TARGET; CYCLE; CDK2	CDK2-cyclin E triggers centrosome duplication, and nucleophosmin (NPM/B23) is found to be one of its targets. NPM/B23 phosphorylated by CDK2-cyclin E acquires a high binding affinity to Rho-associated kinase (ROCK II), and physically associates with ROCK II. The NPM/B23-binding results in superactivation of ROCK II, which is a critical event for initiation of centrosome duplication. The activation of ROCK II also requires the binding of Rho small GTPase to the auto-inhibitory region; hence the availability of the active Rho protein is an important aspect of the centrosomally localized ROCK II to properly initiate centrosome duplication. There are three isoforms of Rho (RhoA, B and C), all of which are capable of binding to and priming the activation of ROCK II. Here, we investigated which Rho isoform(s) are involved in the activation of ROCK II in respect to the initiation of centrosome duplication. We found that both RhoA and RhoC, but not RhoB, were required for initiation of centrosome duplication, and overactivation of RhoA, as well as RhoC, but not RhoB, promoted centrosome duplication and centrosome amplification. Oncogene (2010) 29, 6040 6050; doi:10.1038/onc.2010.328; published online 9 August 2010	[Kanai, M.; Crowe, M. S.; Fukasawa, K.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; [Zheng, Y.] Univ Cincinnati, Childrens Hosp Res Fdn, Div Expt Hematol, Cincinnati, OH USA; [Zheng, Y.] Univ Cincinnati, Childrens Hosp Res Fdn, Mol Dev Biol Program, Cincinnati, OH USA; [Vande Woude, G. F.] Van Andel Res Inst, Grand Rapids, MI USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Van Andel Institute	Fukasawa, K (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr,SRB 2, Tampa, FL 33612 USA.	Kenji.Fukasawa@moffitt.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074; Crowe, Matthew/0000-0001-5251-0238	National Institute of Health [CA90522]; James & Esther King Biomedical Research Program [09KN-05-23139]; NATIONAL CANCER INSTITUTE [R01CA090522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087328] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James & Esther King Biomedical Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank M Rowland and B Nepon-Sixt for technical assistance and core staff at the analytical microscopy core facility and molecular biology core facility in H Lee Moffitt Cancer Center. We also thank Dr Sebti for providing RhoB cDNA. This study is supported by the National Institute of Health (CA90522 to KF) and James & Esther King Biomedical Research Program (09KN-05-23139 to MK).	Aoki T, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-56; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Canguilhem B, 2005, J BIOL CHEM, V280, P43257, DOI 10.1074/jbc.M508650200; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Chevrier V, 2002, J CELL BIOL, V157, P807, DOI 10.1083/jcb.200203034; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Ho TTG, 2008, J BIOL CHEM, V283, P21588, DOI 10.1074/jbc.M710033200; Kabuyama Y, 2009, MOL CELL PROTEOMICS, V8, P2308, DOI 10.1074/mcp.M900178-MCP200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Ma Z, 2006, MOL CELL BIOL, V26, P9016, DOI 10.1128/MCB.01383-06; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Milia J, 2005, CELL DEATH DIFFER, V12, P492, DOI 10.1038/sj.cdd.4401586; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Reed SI, 1997, CANCER SURV, V29, P7; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Salisbury JL, 2007, J CELL PHYSIOL, V213, P420, DOI 10.1002/jcp.21226; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Simpson KJ, 2004, CANCER RES, V64, P8694, DOI 10.1158/0008-5472.CAN-04-2247; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wang L, 2003, J BIOL CHEM, V278, P44617, DOI 10.1074/jbc.M308929200; Wheeler AP, 2004, EXP CELL RES, V301, P43, DOI 10.1016/j.yexcr.2004.08.012; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504	39	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6040	6050		10.1038/onc.2010.328	http://dx.doi.org/10.1038/onc.2010.328			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20697357	Green Accepted			2022-12-17	WOS:000284108700006
J	Vigneron, S; Brioudes, E; Burgess, A; Labbe, JC; Lorca, T; Castro, A				Vigneron, S.; Brioudes, E.; Burgess, A.; Labbe, J-C; Lorca, T.; Castro, A.			RSK2 is a kinetochore-associated protein that participates in the spindle assembly checkpoint	ONCOGENE			English	Article						Rsk2; SAC; kinetochore; Mad2; CENP-E	CELL-CYCLE EXTRACTS; CENP-E; MITOTIC CHECKPOINT; MAP KINASE; ERK; ATTACHMENT; EGGS; LOCALIZATION; ACTIVATION; PATHWAY	The spindle assembly checkpoint (SAC) prevents anaphase onset until all the chromosomes have successfully attached to the spindle microtubules. The MAP kinase (MAPK) is an important player in this pathway, however its exact role is not fully understood. One major target of MAPK is the p90 ribosomal protein S6 kinase (RSKs) family. In this study, we analyse whether Rsk2 could participate in the activation of the SAC. Our data indicate that this protein is localized at the kinetochores under checkpoint conditions. Moreover, it is essential for the SAC activity in Xenopus egg extracts as its depletion prevents metaphase arrest as well as the kinetochore localization of the other SAC components. We also show that this kinase might also participate in the maintenance of the SAC in mammalian cells as Rsk2 knockdown in these cells prevents the kinetochore localization of Mad1, Mad2 and CENP-E under checkpoint conditions. Oncogene (2010) 29, 3566-3574; doi:10.1038/onc.2010.105; published online 12 April 2010	[Castro, A.] Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS, UMR 5237,IFR 122, F-34293 Montpellier 5, France; [Castro, A.] Univ Montpellier 1, Ctr Rech Biochim Macromol, CNRS, UMR 5237,IFR 122, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Castro, A (corresponding author), Univ Montpellier 2, Ctr Rech Biochim Macromol, CNRS, UMR 5237,IFR 122, 1919 Route Mende, F-34293 Montpellier 5, France.	thierry.lorca@crbm.cnrs.fr; anna.castro@crbm.cnrs.fr	CASTRO, ANNA/F-4350-2010; labbe, jean-claude/B-2277-2009; Burgess, Andrew/C-7952-2009; Burgess, Andrew/H-3339-2019	CASTRO, ANNA/0000-0002-3655-1352; Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Lorca, Thierry/0000-0003-2007-8924	Ligue Nationale Contre le Cancer (Equipe Labellisee)	Ligue Nationale Contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer)	We thank Dr JE Ferrell for the generous gift of the pFast-Rsk2 WT and the pFast-Rsk2 KD constructs. We thank Julian Cau from the Montpellier RIO Imaging facility (CRBM). This work was supported by the Ligue Nationale Contre le Cancer (Equipe Labellisee). AB and EB are fellows from the Fondation pour la Recherche Medicale and the Ligue Nationale Contre le Cancer, respectively.	Abrieu A, 2000, CELL, V102, P817, DOI 10.1016/S0092-8674(00)00070-2; Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Bhatt RR, 2000, J BIOL CHEM, V275, P32983, DOI 10.1074/jbc.M006386200; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nam HJ, 2008, CELL SIGNAL, V20, P1349, DOI 10.1016/j.cellsig.2008.03.008; Nebreda AR, 2000, CURR OPIN CELL BIOL, V12, P666, DOI 10.1016/S0955-0674(00)00150-2; Nishiyama T, 2007, NATURE, V446, P1096, DOI 10.1038/nature05696; Pinsky BA, 2005, TRENDS CELL BIOL, V15, P486, DOI 10.1016/j.tcb.2005.07.005; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; Tanudji M, 2004, MOL BIOL CELL, V15, P3771, DOI 10.1091/mbc.E03-07-0482; Tunquist BJ, 2003, GENE DEV, V17, P683, DOI 10.1101/gad.1071303; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Wu JQ, 2007, P NATL ACAD SCI USA, V104, P16564, DOI 10.1073/pnas.0707537104; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	24	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 17	2010	29	24					3566	3574		10.1038/onc.2010.105	http://dx.doi.org/10.1038/onc.2010.105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	611QN	20383198	Green Published			2022-12-17	WOS:000278835400011
J	Chung, H; Lopez, CG; Young, DJ; Lai, JF; Holmstrom, J; Ream-Robinson, D; Cabrera, BL; Carethers, JM				Chung, H.; Lopez, C. G.; Young, D. J.; Lai, J. F.; Holmstrom, J.; Ream-Robinson, D.; Cabrera, B. L.; Carethers, J. M.			Flanking sequence specificity determines coding microsatellite heteroduplex and mutation rates with defective DNA mismatch repair (MMR)	ONCOGENE			English	Article							NONPOLYPOSIS COLON-CANCER; COLORECTAL-CANCER; INSTABILITY; GENE; RECEPTOR; INACTIVATION; ACTIVIN; BETA; HOMOLOG; GROWTH	The activin type II receptor (ACVR2) contains two identical microsatellites in exons 3 and 10, but only the exon 10 microsatellite is frameshifted in mismatch repair (MMR)-defective colonic tumors. The reason for this selectivity is not known. We hypothesized that ACVR2 frameshifts were influenced by DNA sequences surrounding the microsatellite. We constructed plasmids in which exons 3 or 10 of ACVR2 were cloned vertical bar 1 bp out of frame of enhanced green fluorescent protein (EGFP), allowing -1 bp frameshift to express EGFP. Plasmids were stably transfected into MMR-deficient cells, and subsequent non-fluorescent cells were sorted, cultured and harvested for mutation analysis. We swapped DNA sequences flanking the exon 3 and 10 microsatellites to test our hypothesis. Native ACVR2 exon 3 and 10 microsatellites underwent heteroduplex formation (A7/T8) in hMLH1(-/-) cells, but only exon 10 microsatellites fully mutated (A7/T7) in both hMLH1(-/-) and hMSH6(-/-) backgrounds, showing selectivity for exon 10 frameshifts and inability of exon 3 heteroduplexes to fully mutate. Substituting nucleotides flanking the exon 3 microsatellite for nucleotides flanking the exon 10 microsatellite significantly reduced heteroduplex and full mutation in hMLH1(-/-) cells. When the exon 3 microsatellite was flanked by nucleotides normally surrounding the exon 10 microsatellite, fully mutant exon 3 frameshifts appeared. Mutation selectivity for ACVR2 lies partly with flanking nucleotides surrounding each microsatellite. Oncogene (2010) 29, 2172-2180; doi: 10.1038/onc.2009.508; published online 8 February 2010	[Chung, H.; Lopez, C. G.; Lai, J. F.; Holmstrom, J.; Ream-Robinson, D.; Cabrera, B. L.; Carethers, J. M.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Young, D. J.; Carethers, J. M.] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, San Diego, CA 92103 USA; [Carethers, J. M.] VA San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Carethers, JM (corresponding author), Univ Michigan, Dept Internal Med, 3100A Taubman Ctr,1500 E Med Ctr Dr,SPC 5368, Ann Arbor, MI 48109 USA.	jcarethe@umich.edu			United States Public Health Service [DK067287]; UCSD Digestive Diseases Research Development Center [DK080506]; VA Research Service; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067287, R24DK080506] Funding Source: NIH RePORTER	United States Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); UCSD Digestive Diseases Research Development Center; VA Research Service(US Department of Veterans Affairs); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by the United States Public Health Service (DK067287 to JMC), the UCSD Digestive Diseases Research Development Center (DK080506), and the VA Research Service (Merit Review Award to JMC). We thank the support of Moores UCSD Cancer Center Flow Cytometry and DNA Sequencing Shared Resources.	Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Akiyama Y, 1997, CANCER RES, V57, P3920; Barbara JT, 2006, INT J CANCER, V118, P2509, DOI 10.1002/ijc.21710; Carethers JM, 1999, GASTROENTEROLOGY, V117, P123, DOI 10.1016/S0016-5085(99)70558-5; Chung H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003463; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Harrington JA, 2007, MOL CELL BIOL, V27, P6546, DOI 10.1128/MCB.00855-07; Hempen PM, 2003, CANCER RES, V63, P994; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Jung B, 2004, GASTROENTEROLOGY, V126, P654, DOI 10.1053/j.gastro.2004.01.008; Jung BH, 2007, GASTROENTEROLOGY, V132, P633, DOI 10.1053/j.gastro.2006.11.018; Luria SE, 1943, GENETICS, V28, P491; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Modrich P, 2006, J BIOL CHEM, V281, P30305, DOI 10.1074/jbc.R600022200; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, CANCER RES, V55, P5548; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456	23	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	15					2172	2180		10.1038/onc.2009.508	http://dx.doi.org/10.1038/onc.2009.508			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20140012	Green Accepted			2022-12-17	WOS:000276685200003
J	Sehgal, PB				Sehgal, P. B.			Interleukin-6 induces increased motility, cell-cell and cell-substrate dyshesion and epithelial-to-mesenchymal transformation in breast cancer cells	ONCOGENE			English	Letter							CARCINOMA CELLS; GROWTH-INHIBITION; SEPARATION; MIGRATION; LINES; IL-6		[Sehgal, P. B.] New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; [Sehgal, P. B.] New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Sehgal, PB (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA.	pravin_sehgal@nymc.edu			NHLBI NIH HHS [R01 HL087176-02, R01 HL087176] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BROMBERG J, 2009, CANCER CELL, V15, P17; CHEN L, 1991, J BIOL REG HOMEOS AG, V5, P125; CHEN L, 1988, P NATL ACAD SCI USA, V85, P8037, DOI 10.1073/pnas.85.21.8037; Chiu JJ, 1996, CLIN CANCER RES, V2, P215; CHOPPIN PW, 2007, BIOGRAPHICAL MEMOIR, P1; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; SEHGAL PB, 1991, EXP SUPPL, V59, P178; SEHGAL PB, 1990, P SOC EXP BIOL MED, V195, P183; Sehgal PB, 1998, MOL ASPECTS CANC ITS, P89; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; TABIBZADEH SS, 1989, AM J PATHOL, V135, P427; TAMM I, 1991, P NATL ACAD SCI USA, V88, P4414, DOI 10.1073/pnas.88.10.4414; TAMM I, 1991, CYTOKINE, V3, P212, DOI 10.1016/1043-4666(91)90019-A; TAMM I, 1994, P NATL ACAD SCI USA, V91, P3329, DOI 10.1073/pnas.91.8.3329; TAMM I, 1994, P NATL ACAD SCI USA, V91, P4338, DOI 10.1073/pnas.91.10.4338; TAMM I, 1989, J EXP MED, V170, P1649, DOI 10.1084/jem.170.5.1649; TAMM I, 1998, MOL ASPECTS CANC ITS, P89; Walter M, 2009, ONCOGENE, V28, P2745, DOI 10.1038/onc.2009.130	19	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2599	2600		10.1038/onc.2010.4	http://dx.doi.org/10.1038/onc.2010.4			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20140019	Green Accepted			2022-12-17	WOS:000277169400015
J	Liu, BH; Goh, CHK; Ooi, LLPJ; Hui, KM				Liu, B. H.; Goh, C. H. K.; Ooi, L. L. P. J.; Hui, K. M.			Identification of unique and common low abundance tumour-specific transcripts by suppression subtractive hybridization and oligonucleotide probe array analysis	ONCOGENE			English	Article						affymetrix GeneChip arrays; breast cancer; hepatocellular carcinoma; low abundance transcripts; nasopharyngeal carcinoma; suppression subtractive hybridization	GENE-EXPRESSION SIGNATURE; EPSTEIN-BARR-VIRUS; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; DNA; SURVIVAL	Most human cancers are characterized by genetic aberrations accompanied by altered expression and function of numerous genes. Applying genome-wide, microarray gene expression analysis to identify deregulated genes in different tumour types can provide potential gene candidates as diagnostic and prognostic tools and promising targets for drug development. However, the detection of deregulated genes with low levels of expression remains a major challenge. In this study, we have designed a strategy, termed modified suppression subtractive hybridization ( mSSH), to identify genes encoding rare transcripts. The strategy entails incorporating the T-7-promoter sequence at the 5 ' end of the noncoding cDNA strand during first strand cDNA synthesis to generate unidirectional antisense RNA from the resultant cDNA following conventional SSH. These transcripts are subsequently analysed by Affymetrix oligonucleotide gene arrays. Here, we have used five hepatocellular carcinoma ( HCC), five breast carcinoma and four nasopharyngeal carcinoma ( NPC) biopsies separately as testers and their corresponding normal biopsies as drivers to enrich for low abundance tumour type-specific transcripts. The total detectable number of probe sets following mSSH was reduced almost 10-fold in comparison to those detected for the same resected tumour tissues without undergoing subtraction, thus yielding a subtraction efficacy of over 90%. Using this experimental approach, we have identified 48 HCC-specific, 45 breast carcinoma-specific, and 83 NPC-specific genes. In addition, 115 genes were upregulated in all the three cancer types. When compared to gene-profiling data obtained without mSSH, the majority of these identified transcripts were of low abundance in the original cancer tissues. mSSH can therefore serve as a comprehensive molecular strategy for pursuing functional genomic studies of human cancers.	[Liu, B. H.; Hui, K. M.] Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Bek Chai Heah Lab Canc Genom, Singapore 169610, Singapore; [Goh, C. H. K.] Singapore Gen Hosp, Dept Otolaryngol, Singapore 0316, Singapore; [Ooi, L. L. P. J.] Natl Canc Ctr, Div Surg Oncol, Singapore, Singapore	National Cancer Centre Singapore (NCCS); Singapore General Hospital; National Cancer Centre Singapore (NCCS)	Hui, KM (corresponding author), Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Cellular & Mol Res, Bek Chai Heah Lab Canc Genom, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhkm@nccs.com.sg	Ooi, London Lucien/AGK-1395-2022; Hui, Kam/C-6186-2011	Hui, Kam/0000-0003-1820-1399				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bonavida B, 2007, ONCOGENE, V26, P3629, DOI 10.1038/sj.onc.1210365; Brentani H, 2003, P NATL ACAD SCI USA, V100, P13418, DOI 10.1073/pnas.1233632100; Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Del Rio M, 2007, J CLIN ONCOL, V25, P773, DOI 10.1200/JCO.2006.07.4187; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Draghici S, 2006, TRENDS GENET, V22, P101, DOI 10.1016/j.tig.2005.12.005; Kirk GD, 2005, ONCOGENE, V24, P5858, DOI 10.1038/sj.onc.1208732; Lah TT, 2000, CLIN CANCER RES, V6, P578; Lau WM, 2007, ONCOGENE, V26, P6050, DOI 10.1038/sj.onc.1210405; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Qin LX, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-23; Russo G, 2003, ONCOGENE, V22, P6497, DOI 10.1038/sj.onc.1206865; Sander C, 2000, SCIENCE, V287, P1977, DOI 10.1126/science.287.5460.1977; Shiota G, 1997, J HEPATOL, V27, P661, DOI 10.1016/S0168-8278(97)80083-9; Thornburg NJ, 2006, ONCOGENE, V25, P288, DOI 10.1038/sj.onc.1209023; Thuerigen O, 2006, J CLIN ONCOL, V24, P1839, DOI 10.1200/JCO.2005.04.7019; Tsopanomichalou M, 1999, LIVER, V19, P305, DOI 10.1111/j.1478-3231.1999.tb00054.x; Wang SM, 2007, CLIN CANCER RES, V13, P6275, DOI 10.1158/1078-0432.CCR-06-2236; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556; Yu K, 2006, CLIN CANCER RES, V12, P3288, DOI 10.1158/1078-0432.CCR-05-1530	27	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4128	4136		10.1038/onc.2008.50	http://dx.doi.org/10.1038/onc.2008.50			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18332864				2022-12-17	WOS:000257325100013
J	Johnson, J; Lagowski, J; Lawson, S; Liu, Y; Kulesz-Martin, M				Johnson, J.; Lagowski, J.; Lawson, S.; Liu, Y.; Kulesz-Martin, M.			P73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis	ONCOGENE			English	Article						p73; squamous cell carcinoma; keratinocyte; p53 family interplay	TRANSCRIPTIONAL ACTIVITY; ACTIVATION; CARCINOMA; CANCER; ANTAGONISTS; ISOFORMS; DOMAIN; DEATH; FORMS	The expression of p73 and p63 isoforms is frequently deregulated in human epithelial tumors. We previously showed that loss of p73 protein expression associates with malignant conversion in vivo and ionizing radiation (IR) resistance in vitro in a clonal model of mouse epidermal carcinogenesis. Here we show that loss of endogenous p73 expression in squamous cell carcinoma (SCC) cells and tumors was concomitant with preferential DNA binding of the inhibitory Delta Np63 alpha isoform and reduction of transcriptionally active p63 gamma isoforms binding to a p21 promoter sequence in vitro. Reconstitution of TAp73 alpha in malignant cells increased the steady state DNA-binding capabilities of the endogenous transcriptionally active TAp63 gamma and Delta Np63 gamma isoforms, correlating with restoration of tumor suppression but not IR sensitivity. Loss of p73 in malignant cells also coincided with increased presence of p53 family inhibitor Mdm2 in p53-specific DNA-bound complexes, whereas reconstitution of TAp73 alpha expression resulted in exclusion of Mdm2 from these complexes. These results suggest a dual mechanism for TAp73 alpha to foster tumor suppression through enhancement of the DNA-binding activity of p63 gamma isoforms, and through inhibition of transcriptional repressors Mdm2 or DNp63a.	[Johnson, J.; Lagowski, J.; Lawson, S.; Liu, Y.; Kulesz-Martin, M.] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97239 USA; [Johnson, J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; [Kulesz-Martin, M.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Kulesz-Martin, M (corresponding author), Oregon Hlth & Sci Univ, Dept Dermatol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	kuleszma@ohsu.edu			NCI NIH HHS [CA98893, 1-T32-CA106195, CA98577, CA69533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098577, T32CA106195, P30CA069533, R01CA098893] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2000, ONCOGENE, V19, P831, DOI 10.1038/sj.onc.1203311; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; Goldschneider D, 2003, CANCER LETT, V197, P99, DOI 10.1016/S0304-3835(03)00089-2; Gu JJ, 2001, CANCER RES, V61, P6703; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Johnson J, 2007, CANCER RES, V67, P7723, DOI 10.1158/0008-5472.CAN-07-1195; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; King KE, 2006, CARCINOGENESIS, V27, P53, DOI 10.1093/carcin/bgi200; Knights CD, 2003, J BIOL CHEM, V278, P52890, DOI 10.1074/jbc.M300279200; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KULESZMARTIN MF, 1988, CARCINOGENESIS, V9, P171, DOI 10.1093/carcin/9.1.171; Liu G, 2005, J BIOL CHEM, V280, P20111, DOI 10.1074/jbc.M413889200; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Liu YG, 2001, CANCER RES, V61, P5402; Liu YG, 2004, CANCER BIOL THER, V3, P1102, DOI 10.4161/cbt.3.11.1189; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Moll UM, 2004, MOL CANCER RES, V2, P371; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Rocco JW, 2006, CELL CYCLE, V5, P936, DOI 10.4161/cc.5.9.2716; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wu Y, 1997, P NATL ACAD SCI USA, V94, P8982, DOI 10.1073/pnas.94.17.8982; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	35	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2780	2787		10.1038/sj.onc.1210941	http://dx.doi.org/10.1038/sj.onc.1210941			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	18026135				2022-12-17	WOS:000255259500013
J	Sano, A; Kage, H; Sugimoto, K; Kitagawa, H; Aki, N; Goto, A; Fukayama, M; Nakajima, J; Takamoto, S; Nagase, T; Yatomi, Y; Ohishi, N; Takai, D				Sano, A.; Kage, H.; Sugimoto, K.; Kitagawa, H.; Aki, N.; Goto, A.; Fukayama, M.; Nakajima, J.; Takamoto, S.; Nagase, T.; Yatomi, Y.; Ohishi, N.; Takai, D.			A second-generation profiling system for quantitative methylation analysis of multiple gene promoters: application to lung cancer	ONCOGENE			English	Article						lung cancer; DNA methylation; CpG islands; EGFR mutation; epigenetic change; real-time PCR	DNA METHYLATION; CPG-ISLANDS; CELL-LINES; PCR ASSAY; HYPERMETHYLATION; ADENOCARCINOMA; EXPRESSION; SURVIVAL; PATTERNS; DISPLAY	Cancer-specific gene promoter methylation has been described in many types of cancers, and various semi-quantified results have shown their usefulness. Here, we show a more sensitive and specific second-generation system for pro. ling the DNA methylation status. This method is based on bisulfate reaction of DNA and real-time PCR using two TaqMan MGB probes labeled with different fluorescence, followed by clustering analysis. Primers were designed with CpG-less sequences, and TaqMan MGB probes were designed to contain three or four CpG sites and to be shorter than conventional TaqMan probes. We have added new criteria for primer and probe design for further specificity. We confirmed the reliability of this system and applied it to analysis of lung cancers. Using 10 promoters, 90 primary lung cancers were clustered into six groups consisting of cases having similar smoking status and pathological findings. EGFR mutation and p16 promoter DNA methylation were exclusive, as previously reported; however, DNA methylation in other genes was unrelated to EGFR mutation. This system was also useful to distinguish double primary lung cancers from a single cancer with intrapulmonary metastasis. As above, our system has widespread availability in clinical use and biological research.	Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Hosp, Dept Gen Thorac Surg, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Hosp, Dept Med Res, Bunkyo Ku, Tokyo 113, Japan; Tokyo Univ Hosp, Dept Pathol, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Takai, D (corresponding author), Tokyo Univ Hosp, Dept Clin Lab, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.	dtakai-ind@umin.ac.jp	Goto, Akiteru/P-5775-2014; Sano, Atsushi/E-5868-2013	Nakajima, Jun/0000-0003-1174-0816; Goto, Akiteru/0000-0001-8776-9004; Yatomi, Yutaka/0000-0003-1719-4297				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Brabender J, 2001, ONCOGENE, V20, P3528, DOI 10.1038/sj.onc.1204455; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feil R, 1999, TRENDS GENET, V15, P431, DOI 10.1016/S0168-9525(99)01822-3; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Gu J, 2006, CLIN CANCER RES, V12, P7329, DOI 10.1158/1078-0432.CCR-06-0894; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kim YT, 2005, J THORAC CARDIOV SUR, V130, P1378, DOI 10.1016/j.jtcvs.2005.06.015; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lehmann U, 2001, LAB INVEST, V81, P635, DOI 10.1038/labinvest.3780272; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; Mitsudomi T, 1997, J THORAC CARDIOV SUR, V114, P354, DOI 10.1016/S0022-5223(97)70180-6; Panning B, 1998, CELL, V93, P305, DOI 10.1016/S0092-8674(00)81155-1; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; SAMBROOK J, 2001, MOL CLONING, V2, pCH9; Suzuki M, 2006, CANCER-AM CANCER SOC, V106, P2200, DOI 10.1002/cncr.21853; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Takai D, 2001, ONCOGENE, V20, P7505, DOI 10.1038/sj.onc.1204940; Toyooka S, 2006, CANCER RES, V66, P1371, DOI 10.1158/0008-5472.CAN-05-2625; Tsou JA, 2005, LUNG CANCER, V47, P193, DOI 10.1016/j.lungcan.2004.08.003; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; USUDA K, 1996, JAPANESE J LUNG CANC, V36, P359; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Wang PZ, 2004, ADV CEM RES, V16, P1, DOI 10.1680/adcr.16.1.1.36257; Zeschnigk M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh122	32	10	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	45					6518	6525		10.1038/sj.onc.1210483	http://dx.doi.org/10.1038/sj.onc.1210483			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	217AF	17452971				2022-12-17	WOS:000249919800005
J	Fan, Y; Gelinas, C				Fan, Y.; Gelinas, C.			An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activation	ONCOGENE			English	Article						Rel; NF-kappa B; transcription; transactivation; transformation	CLASSICAL HODGKIN LYMPHOMA; CHICKEN SPLEEN-CELLS; V-REL; TRANSACTIVATION DOMAIN; MALIGNANT TRANSFORMATION; BREAST-CANCER; DNA-BINDING; EXPRESSION; MUTATIONS; PROTEIN	c-Rel is overexpressedin several B-cell lymphomas and c-rel gene overexpression can transform primary chicken lymphoid cells and induce tumors in animals. Although c-Rel is generally a stronger transcriptional activator than its viral derivative v-Rel, its oncogenic activity is significantly weaker. Among the mutations acquired during c-Rel's evolution into v-Rel are deletion of c-Rel's transactivation domain 2 ( cTAD2) and mutations in cTAD1. Given the critical role of the Rel TADs in cell transformation, we investigated how mutations in c-Rel's cTAD1 and cTAD2 contribute to its oncogenicity and that of v-Rel. Mutations in cTAD2 noticeably increased c-Rel's transforming activity by promoting its nuclear localization and gene-specific transactivation, despite an overall decrease in kappa B site-dependent transactivation potency. Conversely, substitution of vTAD by cTAD1 increased v-Rel's transactivation and transforming efficiencies, whereas its substitution by the stronger cTAD2 compromised activation of mip-1b but not irf-4 and was detrimental to cell transformation. These results suggest that the Rel TADs differentially contribute to gene specific activation and that an optimal range of transcription potency is necessary for efficient transformation. These findings may have important implications for understanding how Rel TAD mutations can lead to a more oncogenic phenotype.	Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, New Brunswick, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu			NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen CL, 2001, MOL CELL BIOL, V21, P7115; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Iwai K, 2005, FEBS LETT, V579, P141, DOI 10.1016/j.febslet.2004.11.060; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STARCZYNOWSKI DT, 2006, ONCOGENE        1030	33	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					4038	4043		10.1038/sj.onc.1210164	http://dx.doi.org/10.1038/sj.onc.1210164			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17173064				2022-12-17	WOS:000247144500015
J	Yang, J; Runeberg-Roos, P; Leppanen, VM; Saarma, M				Yang, J.; Runeberg-Roos, P.; Leppanen, V-M; Saarma, M.			The mouse soluble GFR alpha 4 receptor activates RET independently of its ligand persephin	ONCOGENE			English	Article						GFR alpha 4; RET; PSPN; neurite outgrowth; survival	NEURONAL SURVIVAL; LIPID RAFTS; GDNF; BINDING; DIFFERENTIATION; PROTOONCOGENE; MECHANISM; FAMILY; MODEL	Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs) all signal through the transmembrane receptor tyrosine kinase RET. The signalling complex consists of GFLs, GPI-anchored ligand binding GDNF family receptor alphas (GFRas) and RET. Signalling via RET is required for the development of the nervous system and the kidney, as well as for spermatogenesis. However, constitutive activation of RET is implicated as a cause in several diseases. Mutations of the RET proto-oncogene cause the inherited cancer syndrome multiple endocrine neoplasia type 2 (MEN 2). Recently, it has been suggested that mutations in the persephin binding GFR alpha 4 receptor may have a potentially modifying role in MEN 2. Several naturally occurring, different splice variants of the mammalian GFRa4 have been reported. A 7 bp insertion - mutation in the human GFRa4 gene causes a shift of reading frame and thereby changes the balance between the transcripts encoding GPI-anchored and soluble GFRa4 receptors. We report here that the mammalian soluble GFRa4 can activate RET independently of its preferential ligand, persephin. Our data show that soluble GFRa4 can associate with, and induce, phosphorylation of RET. In addition, our data show that this isoform of GFRa4 can induce downstream signalling, as well as neuronal survival and differentiation, in the absence of persephin. These results suggest that, in line with the previous report, GFRa4 may be a candidate gene for, or modi. er of, the MEN 2 diseases.	Univ Helsinki, Inst Biotechnol, Viikki Bioctr, FIN-00014 Helsinki, Finland	University of Helsinki	Saarma, M (corresponding author), Univ Helsinki, Inst Biotechnol, Viikki Bioctr, Viikinkaari 9,POB 56, FIN-00014 Helsinki, Finland.	mart.saarma@helsinki.fi		Leppanen, Veli-Matti/0000-0001-7100-965X				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Kato M, 2000, MOL BIOL CELL, V11, P93, DOI 10.1091/mbc.11.1.93; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Lindahl M, 2001, J BIOL CHEM, V276, P9344, DOI 10.1074/jbc.M008279200; Lindfors PH, 2006, ENDOCRINOLOGY, V147, P2237, DOI 10.1210/en.2005-1620; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Milbrandt J, 1998, NEURON, V20, P245, DOI 10.1016/S0896-6273(00)80453-5; Paratcha G, 2001, NEURON, V29, P171, DOI 10.1016/S0896-6273(01)00188-X; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vanhorne JB, 2005, ONCOGENE, V24, P1091, DOI 10.1038/sj.onc.1207826; Virtanen H, 2005, BIOCHEM J, V387, P817, DOI 10.1042/BJ20041257; Wang XQ, 2006, STRUCTURE, V14, P1083, DOI 10.1016/j.str.2006.05.010; Yang JM, 2004, FEBS LETT, V569, P267, DOI 10.1016/j.febslet.2004.06.007	21	10	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3892	3898		10.1038/sj.onc.1210161	http://dx.doi.org/10.1038/sj.onc.1210161			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17213820				2022-12-17	WOS:000247026400012
J	Kakinuma, S; Kodama, Y; Amasaki, Y; Yi, S; Tokairin, Y; Arai, M; Nishimura, M; Monobe, M; Kojima, S; Shimada, Y				Kakinuma, S.; Kodama, Y.; Amasaki, Y.; Yi, S.; Tokairin, Y.; Arai, M.; Nishimura, M.; Monobe, M.; Kojima, S.; Shimada, Y.			Ikaros is a mutational target for lymphomagenesis in Mlh1-deficient mice	ONCOGENE			English	Article						T-cell lymphoma; DNA mismatch repair; coding microsatellites; microsatellite instability; mutational target gene	ACUTE LYMPHOBLASTIC-LEUKEMIA; MISMATCH REPAIR DEFICIENCY; NONPOLYPOSIS COLON-CANCER; MOUSE THYMIC LYMPHOMAS; ETHYL-N-NITROSOUREA; MICROSATELLITE INSTABILITY; TRANSCRIPTION FACTOR; POINT MUTATIONS; MURINE LYMPHOMAS; GENE	Deficiencies in DNA mismatch repair (MMR) result in replication errors within key tumor suppressor genes or oncogenes, and cause hereditary nonpolyposis colorectal cancer (HNPCC). Hematological malignancy with microsatellite instability is also associated with defective MMR, but little is known about the target genes for MMR. Here we identified Ikaros, a master transcription factor of lymphoid lineage commitment and differentiation, as a mutational target in spontaneous and radiation-induced T-cell lymphomas in Mlh1-deficient mice. Three quarters of lymphomas lacked Ikaros protein expression, which resulted from a frameshift mutation that created a stop codon. Mononucleotide repeat sequences at 1029-1034(C)6 and 1567-1572(G)6 in Ikaros were mutational hot spots with a one-base deletion occurring with a frequency of 45 and 50%, respectively. Point mutations and splicing alterations were also observed. In total, 85% of the lymphomas showed aberrations in Ikaros. The characteristic of Mlh1-deficient lymphomas is harboring of multiple mutations simultaneously in the same tumor, displaying a combination of two frameshift mutations at different repeats, frameshift and point mutations, and/or deletion mutations. This is the first report of Ikaros mutations coupled with Mlh1 deficiency in lymphoma-genesis.	Natl Inst Radiol Sci, Expt Radiobiol Childrens Hlth Res Grp, Inage Ku, Chiba 2638555, Japan; Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Radiat Biosci, Chiba, Japan; Tokyo Med & Dent Univ, Dept Surg, Tokyo, Japan; Japanese Fdn Canc Res, Canc Inst Hosp, Clin Lab Genet Diag, Tokyo, Japan	National Institutes for Quantum Science & Technology; Tokyo University of Science; Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Kakinuma, S (corresponding author), Natl Inst Radiol Sci, Expt Radiobiol Childrens Hlth Res Grp, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	skakinum@nirs.go.jp; y_shimad@nirs.go.jp						Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Campbell MR, 2000, CARCINOGENESIS, V21, P2281, DOI 10.1093/carcin/21.12.2281; De Vos M, 2006, JNCI-J NATL CANCER I, V98, P358, DOI 10.1093/jnci/djj073; Duval A, 2002, CANCER RES, V62, P2447; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; Kakinuma S, 2005, MUTAT RES-FUND MOL M, V572, P132, DOI 10.1016/j.mrfmmm.2005.01.010; Kakinuma S, 2002, RADIAT RES, V157, P331, DOI 10.1667/0033-7587(2002)157[0331:SOZIIA]2.0.CO;2; Karlsson A, 2002, CANCER RES, V62, P2650; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; Nakanishi M, 2001, INT J RADIAT BIOL, V77, P687, DOI 10.1080/095530000110047537; Nakayama H, 1999, CANCER RES, V59, P3931; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Ricciardone MD, 1999, CANCER RES, V59, P290; Shimada Y, 2000, RADIAT RES, V154, P293, DOI 10.1667/0033-7587(2000)154[0293:RALOHA]2.0.CO;2; Shimada Y, 2003, INT J RADIAT BIOL, V79, P423, DOI 10.1080/0955300031000139371; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tokairin Y, 2006, INT J EXP PATHOL, V87, P89, DOI 10.1111/j.0959-9673.2006.00464.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang Q, 1997, INT J CANCER, V73, P831, DOI 10.1002/(SICI)1097-0215(19971210)73:6<831::AID-IJC11>3.0.CO;2-7; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	33	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2945	2949		10.1038/sj.onc.1210100	http://dx.doi.org/10.1038/sj.onc.1210100			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17086208				2022-12-17	WOS:000246210800014
J	Iotti, G; Ferrari-Amorotti, G; Rosafio, C; Corradini, F; Lidonnici, MR; Ronchetti, M; Bardini, M; Zhang, Y; Martinez, R; Blasi, F; Calabretta, B				Iotti, G.; Ferrari-Amorotti, G.; Rosafio, C.; Corradini, F.; Lidonnici, M. R.; Ronchetti, M.; Bardini, M.; Zhang, Y.; Martinez, R.; Blasi, F.; Calabretta, B.			Expression of CCL9/MIP-1 gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells	ONCOGENE			English	Article						CML; STI571; CCL9; transcription regulation; chemokine production; in vivo leukemogenesis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; MULTIPOTENT HEMATOPOIETIC-CELLS; C/EBP-ALPHA EXPRESSION; PROTEIN-KINASE PATHWAY; BCR-ABL; CHEMOTACTIC RESPONSE; TRANSCRIPTION-FACTOR; IMATINIB MESYLATE; MOLECULAR-CLONING	Transformation of hematopoietic cells by the BCR/ABL oncogene is caused by perturbation of signal transduction pathways leading to altered patterns of gene expression and activity. By oligonucleotide microarray hybridization of polysomal RNA of untreated and STI571-treated 32DBCR/ABL cells, we identified the beta-chemokine CCL9 as a gene regulated by BCR/ABL in a tyrosine kinasedependent manner. BCR/ABL repressed CCL9 expression at the transcriptional level by mechanisms involving suppression of p38 MAP kinase, and modulation of the activity of CDP/cut and C/EBP alpha, two transcription regulators of myeloid differentiation. However, repression of C/EBP-dependent transcription did not prevent the induction of CCL9 expression by STI571, suggesting that C/EBP alpha is involved in maintaining rather than in inducing CCL9 expression. Restoration of CCL9 expression in 32D-BCR/ABL cells had no effect on the in vitro proliferation of these cells, but reduced their leukemogenic potential in vivo, possibly by recruitment of CD3-positive immune cells. Together, these findings suggest that downregulation of chemokine expression may be involved in BCR/ABL-dependent leukemogenesis by altering the relationship between transformed cells and the microenvironment.	Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; FIRC Inst Mol Oncol, IFOM, Milan, Italy; Wyeth Genet Inst, Cambridge, MA USA	Jefferson University; Universita di Modena e Reggio Emilia; IFOM - FIRC Institute of Molecular Oncology; Pfizer	Calabretta, B (corresponding author), Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	B_Calabretta@mail.jci.tju.edu	Lidonnici, Maria Rosa/AAN-2208-2020	Lidonnici, Maria Rosa/0000-0003-3413-8414; Blasi, Francesco/0000-0001-9406-1784; BARDINI, MICHELA/0000-0002-6942-2274	PHS HHS [P01 78890] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Berahovich RD, 2005, J IMMUNOL, V174, P7341, DOI 10.4049/jimmunol.174.11.7341; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Ferrari-Amorotti G, 2006, BLOOD, V108, P1353, DOI 10.1182/blood-2006-01-011833; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Guerzoni C, 2006, BLOOD, V107, P4080, DOI 10.1182/blood-2005-08-3181; HARA T, 1995, J IMMUNOL, V155, P5352; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Jongen-Lavrencic M, 2005, LEUKEMIA, V19, P373, DOI 10.1038/sj.leu.2403626; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KANTARJIAN HM, 1993, BLOOD, V82, P691; Khanna-Gupta A, 2003, BLOOD, V101, P3460, DOI 10.1182/blood-2002-09-2767; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lane CM, 1999, MOL MED, V5, P55, DOI 10.1007/BF03402139; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Okuda K, 1996, ONCOGENE, V13, P1147; Parmar S, 2004, J BIOL CHEM, V279, P25345, DOI 10.1074/jbc.M400590200; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Pierce A, 2002, ONCOGENE, V21, P3068, DOI 10.1038/sj.onc.1205424; POLTORAK AN, 1995, J INFLAMM, V45, P207; Ptasznik A, 2002, J EXP MED, V196, P667, DOI 10.1084/jem.20020519; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 2003, SEMIN HEMATOL, V40, P4, DOI 10.1053/shem.2003.50034; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; Tavor S, 2003, J BIOL CHEM, V278, P52651, DOI 10.1074/jbc.M307077200; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wark G, 1998, ONCOGENE, V16, P1319, DOI 10.1038/sj.onc.1201914; Wong S, 2003, BLOOD, V101, P4088, DOI 10.1182/blood-2002-11-3376; YOUN BS, 1995, J IMMUNOL, V155, P2661	42	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3482	3491		10.1038/sj.onc.1210146	http://dx.doi.org/10.1038/sj.onc.1210146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160016				2022-12-17	WOS:000246799200004
J	Bowie, ML; Troch, MM; Delrow, J; Dietze, EC; Bean, GR; Ibarra, C; Pandiyan, G; Seewaldt, VL				Bowie, M. L.; Troch, M. M.; Delrow, J.; Dietze, E. C.; Bean, G. R.; Ibarra, C.; Pandiyan, G.; Seewaldt, V. L.			Interferon regulatory factor-1 regulates reconstituted extracellular matrix (rECM)-mediated apoptosis in human mammary epithelial cells	ONCOGENE			English	Article						mammary epithelial cells; IRF-1; apoptosis; extracellular matrix; tamoxifen	INDUCED NUCLEAR FACTORS; CREB-BINDING PROTEIN; PROMOTER ELEMENT; GROWTH; EXPRESSION; IRF-1; TAMOXIFEN; ARREST; ALPHA; FASLODEX	Interactions between extracellular matrix (ECM) and mammary epithelial cells are critical for mammary gland homeostasis and apoptotic signaling. Interferon regulatory factor-1 (IRF-1) is a transcriptional regulator that promotes apoptosis during mammary gland involution and p53-independent apoptosis. We have recently shown that rapid cell surface tamoxifen (Tam) signa ling promotes apoptosis in normal human mammary epithelial cells that were acutely damaged by expression of human papillomavirus type-16 E6 protein (*HMEC-E6). Apoptosis was mediated by recruitment of CREB-binding protein (CBP) to the gamma-activating sequence (GAS) element of the IRF-1 promoter, induction of IRF-1 and caspase-1/-3 activation. Here, we show that growth factor-depleted, reconstituted ECM (rECM), similar to Tam, promotes apoptosis in *HMEC-E6 cells through induction of IRF-1. Apoptosis was temporally associated with recruitment of CBP to the GAS element of the IRF-1 promoter, induction of IRF-1 expression and caspase-1/-3 activation. Small interfering RNA-mediated suppression of IRF-1 protein expression in *HMEC-E6 cells blocked (1) induct ion of IRF-1, (2) caspase-1/-3 activation and (3) apoptosis. These observations demonstrate that IRF-1 promotes rECM-mediated apoptosis and provide evidence that both rECM and rapid Tam signaling transcriptionally activate IRF-1 through recruitment of CBP to the IRF- 1 GAS promoter complex.	Duke Univ, Dept Med, Durham, NC 27710 USA; Fred Hutchinson Canc Res Ctr, Dept Genom Shared Resources, Seattle, WA 98104 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Fred Hutchinson Cancer Center; Duke University	Seewaldt, VL (corresponding author), Duke Univ, Dept Med, Box 2628,MRSB, Durham, NC 27710 USA.	seewa001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA114068, P50CA068438, R01CA088799, P30CA014236, R01CA098441] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA114068, R01CA098441, P30CA14236, P50CA68438, R01CA088799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304; Dietze EC, 2005, J CELL SCI, V118, P5005, DOI 10.1242/jcs.02616; Dietze EC, 2004, ONCOGENE, V23, P3851, DOI 10.1038/sj.onc.1207480; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Goodman RH, 2000, GENE DEV, V14, P1553; Gu ZP, 2002, CANCER RES, V62, P3428; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; KELLY JM, 1986, EMBO J, V5, P1601, DOI 10.1002/j.1460-2075.1986.tb04402.x; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pizzoferrato E, 2004, CANCER RES, V64, P8381, DOI 10.1158/0008-5472.CAN-04-2223; Porta C, 2005, ONCOGENE, V24, P605, DOI 10.1038/sj.onc.1208204; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Yokota S, 2004, J VIROL, V78, P4591, DOI 10.1128/JVI.78.9.4591-4598.2004	36	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2017	2026		10.1038/sj.onc.1210013	http://dx.doi.org/10.1038/sj.onc.1210013			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016442				2022-12-17	WOS:000245313400004
J	Obeid, D; Nguyen, J; Lesavre, P; Bauvois, B				Obeid, D.; Nguyen, J.; Lesavre, P.; Bauvois, B.			Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells	ONCOGENE			English	Article						interferon; ACE; TACE; monocyte; leukemia; ADAM-17	ENDOTHELIAL-CELLS; GENE-EXPRESSION; DOWN-REGULATION; IFN-GAMMA; INHIBITORS; CANCER; MATRIX-METALLOPROTEINASE-9; ADHESION; GROWTH; INTERNALIZATION	The transmembrane metalloproteases angiotensin-converting enzyme (ACE) and tumor necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE/ADAM-17) have been associated with inflammation, cancer progression and angiogenesis. Few investigations into the regulation of these enzymes by physiological stimuli have been reported. In this study, we investigated the influence of interferons (IFNs) type I (alpha, beta) and II (gamma) on ACE and TACE expression of human leukemic NB4 cells and monocytes. We assessed the expression of proteases by reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay and immunofluorescence analyses. IFN gamma, but not type I IFNs, upregulated membrane ACE in a dose- and time-dependency and this was reflected by the increase of ACE enzymatic activity and ACE mRNA. ACE upregulation was dependent on protein synthesis. Treatment of the interferon responsive factor 1 (IRF1)-unresponsive HepG2 cell line with IFN gamma did not affect ACE expression, thus suggesting the participation of the IRF1 signaling pathway in IFN gamma-mediated ACE upregulation in myeloid cells. In contrast, both types of IFNs, in a dose- and time-dependent manner, downregulated surface TACE without affecting TACE transcript. Soluble TACE was not detected in the medium of IFN-treated cells. IFN gamma-mediated decrease of surface TACE in NB4 cells was reversible, and correlated with an increase in intracellular TACE, suggesting that cell surface TACE was internalized in response to IFNs. These findings, showing the presence of IFN-dependent controlled mechanisms by which ACE and TACE levels are regulated in human normal and leukemic myeloid cells, may have implications in the context of current investigations on the therapeutic potential of IFNs.	Hop Necker Enfants Malad, INSERM 507, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bauvois, B (corresponding author), Hop Necker Enfants Malad, INSERM 507, Batiment Lavoisier,161 Rue Sevres, F-75015 Paris, France.	bauvois@necker.fr	Bauvois, Brigitte/F-6776-2013	Bauvois, Brigitte/0000-0002-1751-6922				Bauvois B, 1996, EXP CELL RES, V222, P209, DOI 10.1006/excr.1996.0026; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Borden EC, 2005, J INTERF CYTOK RES, V25, P511, DOI 10.1089/jir.2005.25.511; Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x; Caceres William, 2003, P R Health Sci J, V22, P149; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; Deshayes F, 2005, TRENDS ENDOCRIN MET, V16, P293, DOI 10.1016/j.tem.2005.07.009; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Eyries M, 2002, CIRC RES, V91, P899, DOI 10.1161/01.RES.0000042703.39845.B4; Fuchs S, 2004, CURR HYPERTENS REP, V6, P124, DOI 10.1007/s11906-004-0087-4; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Golikov P P, 1998, Klin Lab Diagn, P11; Guilhot F, 2004, HEMATOL ONCOL CLIN N, V18, P585, DOI 10.1016/j.hoc.2004.03.002; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KAPLAN G, 1982, J EXP MED, V156, P1101, DOI 10.1084/jem.156.4.1101; Le Page C, 2000, Rev Immunogenet, V2, P374; Levin JI, 2004, CURR TOP MED CHEM, V4, P1289, DOI 10.2174/1568026043387935; Lindberg H, 2004, ACTA ONCOL, V43, P142, DOI 10.1080/02841860310022346; Lindner Daniel J, 2002, Curr Oncol Rep, V4, P510, DOI 10.1007/s11912-002-0065-4; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; Lovering F, 2005, CNS NEUROL DISORD-DR, V4, P161, DOI 10.2174/1568007053544147; MAGUIRE GA, 1985, ANN CLIN BIOCHEM, V22, P204, DOI 10.1177/000456328502200218; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Matikainen S, 1998, LEUKEMIA LYMPHOMA, V30, P63, DOI 10.3109/10428199809050930; Moschos S, 2005, CANC TREAT, V126, P207, DOI 10.1007/0-387-24361-5_9; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; NEWTON RC, 2001, ANN RHEUM DIS     S3, V60, P25; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nguyen J, 2005, FEBS LETT, V579, P5487, DOI 10.1016/j.febslet.2005.09.012; OHMANN HB, 1990, LYMPHOKINE RES, V9, P43; OKABE T, 1987, BIOCHEM BIOPH RES CO, V145, P1211, DOI 10.1016/0006-291X(87)91566-X; Rocken C, 2005, CLIN CANCER RES, V11, P2526, DOI 10.1158/1078-0432.CCR-04-1922; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Saijonmaa O, 2001, J VASC RES, V38, P370, DOI 10.1159/000051068; Saijonmaa O, 2001, AM J PHYSIOL-HEART C, V280, pH885, DOI 10.1152/ajpheart.2001.280.2.H885; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Taki S, 2002, CYTOKINE GROWTH F R, V13, P379, DOI 10.1016/S1359-6101(02)00023-0; Tnani M, 1999, BBA-MOL CELL RES, V1451, P59, DOI 10.1016/S0167-4889(99)00089-0; Tsakadze NL, 2006, J BIOL CHEM, V281, P3157, DOI 10.1074/jbc.M510797200; Worley JR, 2003, J BIOL CHEM, V278, P51340, DOI 10.1074/jbc.M310865200; Yoshiji H, 2004, CURR CANCER DRUG TAR, V4, P555, DOI 10.2174/1568009043332790	50	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					102	110		10.1038/sj.onc.1209779	http://dx.doi.org/10.1038/sj.onc.1209779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799629				2022-12-17	WOS:000243236500010
J	Leoncini, L; Bellan, C; De Falco, G				Leoncini, L.; Bellan, C.; De Falco, G.			Retinoblastoma gene family expression in lymphoid tissues	ONCOGENE			English	Review						RB family; cell cycle; lymphoma	E2F TRANSCRIPTIONAL NETWORK; CELL-CYCLE CONTROL; MALIGNANT-LYMPHOMAS; DISTINCT MECHANISMS; PROTEIN EXPRESSION; CDK INHIBITORS; RB FAMILY; IN-VIVO; P107; PRB	It appears more and more clear that retinoblastoma (RB) family of proteins represents key molecules in tumour suppression. This family consists of pRb/p105, p107 and pRb2/p130, which participate in a gene regulatory network that governs the cellular response to antimitogenic signals, and whose deregulation constitutes one of the hallmarks of cancer. Irrespective of their structural and biochemical similarities, RB proteins carry out different functional tasks. The expression of RB gene family in the reactive lymphoid tissues again confirms the different role of each member in cell cycle control and differentiation of normal cells. These different functional properties appear to be maintained in tumours lymphoid tissues, where alterations of the RB/p105 gene appear to be relatively rare. In this review, we will summarize the current knowledge about the role of the RB proteins in reactive and neoplastic lymphoid tissue.	Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Leoncini, L (corresponding author), Univ Siena, Dept Human Pathol & Oncol, Via Laterina 8, I-53100 Siena, Italy.	leoncinil@unisi.it	leoncini, lorenzo/P-8361-2018; BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; BELLAN, CRISTIANA/L-3903-2013	leoncini, lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007				Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BARTEK J, 1992, ONCOGENE, V7, P101; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Decker T, 2002, LEUKEMIA, V16, P327, DOI 10.1038/sj.leu.2402389; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dreyling MH, 1997, CANCER RES, V57, P4608; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Erlanson M, 1998, BLOOD, V92, P770; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Guo SX, 2000, LEUKEMIA RES, V24, P39, DOI 10.1016/S0145-2126(99)00158-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Jares P, 1996, AM J PATHOL, V148, P1591; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kramer AK, 2002, LEUKEMIA, V16, P1844, DOI 10.1038/sj.leu.2402609; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Leoncini L, 1999, CLIN CANCER RES, V5, P4065; Lindstrom MS, 2002, SEMIN CANCER BIOL, V12, P381, DOI 10.1016/S1044-579X(02)00058-5; Moller MB, 2000, LEUKEMIA, V14, P898, DOI 10.1038/sj.leu.2401761; Nakayama K, 2000, LEUKEMIA RES, V24, P299, DOI 10.1016/S0145-2126(99)00186-1; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Putzer BM, 1997, J VIROL, V71, P9538; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; SanchezBeato M, 1996, BRIT J CANCER, V74, P1056, DOI 10.1038/bjc.1996.489; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stiegler P, 1998, J CELL BIOCHEM, P30; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268	48	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5309	5314		10.1038/sj.onc.1209619	http://dx.doi.org/10.1038/sj.onc.1209619			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936752				2022-12-17	WOS:000240064100017
J	Sprangers, M; Feldhahn, N; Herzog, S; Hansmann, ML; Reppel, M; Hescheler, J; Jumaa, H; Siebert, R; Muschen, M				Sprangers, M.; Feldhahn, N.; Herzog, S.; Hansmann, M-L; Reppel, M.; Hescheler, J.; Jumaa, H.; Siebert, R.; Mueschen, M.			The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells	ONCOGENE			English	Article						pre-B cell receptor; SRC kinases; linker molecules; leukemia; tyrosine phosphorylation	ACUTE LYMPHOBLASTIC-LEUKEMIA; BRUTONS TYROSINE KINASE; ANTIGEN-RECEPTOR; LINKER PROTEIN; TUMOR-SUPPRESSOR; ACTIVATION; EXPRESSION; SLP-65; BLNK; REQUIREMENT	SLP65 represents a critical component in (pre-)B cell receptor signal transduction but is compromised in a subset of pre-B cell-derived acute lymphoblastic leukemia. Based on these findings, we investigated (i.) whether SLP65-deficiency also occurs in mature B cell-derived lymphoma and (ii.) whether SLP65-deficient B cell lymphoma cells use an alternative B cell receptor signaling pathway in the absence of SLP65. Indeed, expression of SLP65 protein was also missing in a fraction of B cell lymphoma cases. While SLP65 is essential for B cell receptor-induced Ca2+ mobilization in normal B cells, B cell receptor engagement in SLP65-deficient as compared to SLP65-reconstituted B cell lymphoma cells resulted in an accelerated yet shortlived Ca2+-signal. B cell receptor engagement of SLP65-deficient lymphoma cells involves SRC kinase activation, which is critical for B cell receptor-dependent Ca2+-mobilisation in the absence but not in the presence of SLP65. As shown by RNA interference, the SRC kinase LYN is required for B cell receptor-induced Ca2+ release in SLP65-deficient B cell lymphoma cells but dispensable after SLP65-reconstitution. B cell receptor engagement in SLP65-deficient B cell lymphoma cells also resulted in tyrosine-phosphorylation of the proliferation- and survival-related MAPK1 and STAT5 molecules, which was sensitive to silencing of the SRC kinase LYN. Inhibition of SRC kinase activity resulted in growth arrest and cell death specifically in SLP65-deficient lymphoma cells. These findings indicate that LYN can short-circuit conventional B cell receptor signaling in SLP65-deficient B cell lymphoma cells and thereby promote activation of survival and proliferation-related molecules.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunobiol, D-7800 Freiburg, Germany; Univ Frankfurt, Dept Pathol, D-6000 Frankfurt, Germany; Univ Cologne, Inst Neurophysiol, D-5000 Cologne 41, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany	Heinrich Heine University Dusseldorf; Max Planck Society; Goethe University Frankfurt; University of Cologne; University of Kiel; Schleswig Holstein University Hospital	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de	Siebert, Reiner/A-8049-2010	Herzog, Sebastian/0000-0001-7167-3489				Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Cooperman J, 2004, STEM CELLS, V22, P1111, DOI 10.1634/stemcells.22-6-1111; Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; Flemming A, 2003, NAT IMMUNOL, V4, P38, DOI 10.1038/ni862; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Ishiai M, 1999, J IMMUNOL, V163, P1746; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Karras JG, 1996, J IMMUNOL, V157, P39; Kersseboom R, 2003, J EXP MED, V198, P91, DOI 10.1084/jem.20030615; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Li FJ, 2005, BLOOD, V105, P3295, DOI 10.1182/blood-2004-10-4083; Middendorp S, 2003, J IMMUNOL, V171, P5988, DOI 10.4049/jimmunol.171.11.5988; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Prakash O, 2005, BLOOD, V105, P3987, DOI 10.1182/blood-2004-07-2781; Ptasznik A, 2004, NAT MED, V10, P1187, DOI 10.1038/nm1127; Reppel M, 2005, J BIOL CHEM, V280, P36019, DOI 10.1074/jbc.M504750200; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791	23	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2006	25	36					5056	5062		10.1038/sj.onc.1209510	http://dx.doi.org/10.1038/sj.onc.1209510			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	075XR	16568084				2022-12-17	WOS:000239921300011
J	Phillips, A; Darley, M; Blaydes, J				Phillips, A.; Darley, M.; Blaydes, J. P.			GC-selective DNA-binding antibiotic, Mithramycin A, reveals multiple points of control in the regulation of Hdm2 protein synthesis	ONCOGENE			English	Article						Hdm2; Mdm2; transcription; mRNA export; promoter	SINGLE NUCLEOTIDE POLYMORPHISM; OPEN READING FRAMES; MESSENGER-RNA; MDM2 EXPRESSION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; NUCLEAR EXPORT; P53; GENE; ACTIVATION	The primary role of the Hdm2/Mdm2 oncoprotein is to regulate the levels and activity of the transcription factor p53. Hdm2 synthesis is itself tightly controlled and, as demonstrated by a recently described SNP (SNP309) in the hdm2-P2 promoter, minor variations in Hdm2 expression have phenotypic consequences on radiation sensitivity and cancer predisposition. To further de. ne mechanisms regulating Hdm2 expression, we have investigated the effects of the GC-selective DNA-binding drug, Mithramycin A ( MA) on hdm2 mRNA transcription, trafficking, and translation. Firstly we show that the constitutive hdm2-P1 promoter is inhibited by MA. We de. ne, for the first time, the minimal sequence elements that are required for P1-promoter activity and identify those which confer MA sensitivity. Secondly, MA induces p53-dependent transcription from the hdm2-P2 promoter. Thirdly, and critically, MA also inhibits Hdm2 synthesis at the post-transcriptional level, with negative effects on hdm2 mRNA nuclear export and translation. This study highlights the complex interplay between the pathways that regulate Hdm2 protein synthesis in cancer cells, and furthermore emphasizes the export of hdm2 mRNA from the nucleus to the cytoplasm as a key point of control in this process.	Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Sch Med, Southampton SO16 6YD, Hants, England	University of Southampton	Blaydes, J (corresponding author), Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Sch Med, Somers Canc Res Bldg,MP 824, Southampton SO16 6YD, Hants, England.	j.p.blaydes@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Arriola EL, 1999, ONCOGENE, V18, P1081, DOI 10.1038/sj.onc.1202391; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bar-Or RL, 2000, P NATL ACAD SCI USA, V97, P11250, DOI 10.1073/pnas.210171597; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brown CY, 1999, ONCOGENE, V18, P5631, DOI 10.1038/sj.onc.1202949; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Ferrante RJ, 2004, J NEUROSCI, V24, P10335, DOI 10.1523/JNEUROSCI.2599-04.2004; Harris SL, 2005, P NATL ACAD SCI USA, V102, P16297, DOI 10.1073/pnas.0508390102; Hsing A, 2000, J BIOL CHEM, V275, P26024, DOI 10.1074/jbc.M002455200; Huang QH, 2004, P NATL ACAD SCI USA, V101, P3456, DOI 10.1073/pnas.0308562100; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; Jin XP, 2003, J BIOL CHEM, V278, P25716, DOI 10.1074/jbc.M300316200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; Koutsodontis G, 2004, ONCOGENE, V23, P9190, DOI 10.1038/sj.onc.1208141; Landers JE, 1997, CANCER RES, V57, P3562; LUNA RMD, 1995, NATURE, V378, P203; Ma L, 2005, P NATL ACAD SCI USA, V102, P14266, DOI 10.1073/pnas.0501352102; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Onel K, 2004, MOL CANCER RES, V2, P1; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Qi JS, 1999, MOL CELL BIOL, V19, P864; Remsing LL, 2003, J AM CHEM SOC, V125, P5745, DOI 10.1021/ja034162h; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wynford-Thomas D, 1998, CARCINOGENESIS, V19, P29, DOI 10.1093/carcin/19.1.29; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhang TT, 2001, J BIOL CHEM, V276, P29702, DOI 10.1074/jbc.M011326200	56	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4183	4193		10.1038/sj.onc.1209451	http://dx.doi.org/10.1038/sj.onc.1209451			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501602	Green Accepted			2022-12-17	WOS:000239004800006
J	Ridgeway, AG; McMenamin, J; Leder, P				Ridgeway, A. G.; McMenamin, J.; Leder, P.			P53 levels determine outcome during beta-catenin tumor initiation and metastasis in the mammary gland and male germ cells	ONCOGENE			English	Article						oncogene; tumor suppressor; teratomas; metastasis; breast cancer	WNT SIGNALING PATHWAY; ADENOMATOUS POLYPOSIS-COLI; FUNCTIONAL INTERACTION; NEGATIVE REGULATOR; P53-DEFICIENT MICE; PROGENITOR CELLS; DOWN-REGULATION; CYCLIN D1; TUMORIGENESIS; CANCER	beta-catenin, an oncogene, and P53, a tumor suppressor, are common targets of mutation in human cancers. It has been observed that P53 is often inactivated in tumors involving b-catenin activation. In an attempt to model this situation in vivo, we crossed the previously characterized MMTV-Delta N-beta- catenin mouse with the P53 knockout mouse. Female multiparous mice that carry the MMTV-Delta N-beta-catenin transgene and that are heterozygous for P53 (Tg(Delta N-beta Cat)/+, P53 +/-) display an increased tumor burden (2.05 vs 1.31 tumors/animal), with a generally more advanced pathology, and increased metastatic rate (39 vs 0%) relative to transgenic female mice that are wild type for P53 (Tg(Delta N-beta Cat)/ +, P53 +/+). These differences were not due to complete loss of P53 as only one of 21 tumors demonstrated loss of heterozygosity at the P53 locus. Furthermore, no mutations were present in tumors retaining a single wild-type allele. Tg(Delta N-beta Cat)/ +, P53 -/- male mice developed testicular teratomas and survived an average of 65 days, whereas non-Tg(Delta N-beta Cat), P53 -/- males survived an average of 84 days. Sixty-two percent of Tg(Delta N-beta Cat), P53 -/- mice developed testicular teratomas, whereas only 10% of the non-Tg(Delta N-beta Cat), P53 -/- mice developed these tumors. These results indicate that the level of P53 and the tissue of origin are important factors in determining outcome of cancer caused by oncogene activation.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Leder, P (corresponding author), Harvard Univ, Sch Med, Dept Genet, NRB 356B,77 Ave Louis Pasteur, Boston, MA 02115 USA.	leder@genetics.med.harvard.edu						Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brennan KR, 2004, J MAMMARY GLAND BIOL, V9, P119, DOI 10.1023/B:JOMG.0000037157.94207.33; Brodie SG, 2001, ONCOGENE, V20, P1445, DOI 10.1038/sj.onc.1204222; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Gunther EJ, 2003, GENE DEV, V17, P488, DOI 10.1101/gad.1051603; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hatsell S, 2003, J MAMMARY GLAND BIOL, V8, P145, DOI 10.1023/A:1025944723047; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HENRARD D, 1988, J VIROL, V62, P3046, DOI 10.1128/JVI.62.8.3046-3049.1988; Honecker F, 2004, J PATHOL, V204, P167, DOI 10.1002/path.1614; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Jones JM, 1997, CELL GROWTH DIFFER, V8, P829; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; KOZMA S, 1980, J GEN VIROL, V51, P327, DOI 10.1099/0022-1317-51-2-327; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Polakis P, 2000, GENE DEV, V14, P1837; Rodriguez I, 1997, EMBO J, V16, P2262, DOI 10.1093/emboj/16.9.2262; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Smalley MJ, 2001, J MAMMARY GLAND BIOL, V6, P37, DOI 10.1023/A:1009564431268; STEVENS LC, 1967, J NATL CANCER I, V38, P549; STEVENS LC, 1961, J NATL CANCER I, V27, P443; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yin YZ, 1998, DEV BIOL, V204, P165, DOI 10.1006/dbio.1998.9074	51	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2006	25	25					3518	3527		10.1038/sj.onc.1209391	http://dx.doi.org/10.1038/sj.onc.1209391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KC	16434961				2022-12-17	WOS:000238448200004
J	Togashi, Y; Kobayashi, T; Momose, S; Ueda, M; Okimoto, K; Hino, O				Togashi, Y.; Kobayashi, T.; Momose, S.; Ueda, M.; Okimoto, K.; Hino, O.			Transgenic rescue from embryonic lethality and renal carcinogenesis in the Nihon rat model by introduction of a wild-type Bhd gene	ONCOGENE			English	Article						renal carcinoma; Bhd gene; Nihon rat; transgenic rescue	EKER RAT; PREDISPOSING GENE; CARCINOMA; MUTATIONS; INSERTION; TUMORS; RISE	We recently reported that a germline insertion of a single nucleotide in the rat homologue of the human Birt - Hogg Dube ' gene ( BHD) gives rise to dominantly inherited cancer in the Nihon rat model. In this study, we constructed transgenic Nihon rats with introduction of a wild- type Bhd gene to ascertain whether suppression of the Nihon phenotype is possible. Rescue from embryonic lethality of mutant homozygotes ( Nihon/ Nihon) and suppression of renal carcinogenesis in heterozygotes ( Nihon/ +) were both observed, de. ning the germline Bhd mutation in the Nihon rat as an embryonal lethal and tumor predisposing mutation. This transgenic rescue system will be useful to analyse Bhd gene function, its relation to tumorigenesis in vivo, and genetic - environmental interactions in carcinogenesis.	Juntendo Univ, Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 1138421, Japan; YS Inst Inc, Utsunomiya, Tochigi, Japan; Dainippon Pharmaceut Co Ltd, Toxicol Grp, Safety Res Labs, Suita, Osaka 564, Japan	Juntendo University; Dainippon Sumitomo Pharmaceutical Company	Hino, O (corresponding author), Juntendo Univ, Sch Med, Dept Pathol, Bunkyo Ku, Tokyo 1138421, Japan.	ohino@med.juntendo.ac.jp						BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674; EKER R, 1961, NATURE, V189, P858, DOI 10.1038/189858b0; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1994, BIOCHEM BIOPH RES CO, V203, P1302, DOI 10.1006/bbrc.1994.2324; Hino O, 2001, JPN J CANCER RES, V92, P1147, DOI 10.1111/j.1349-7006.2001.tb02133.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P3990, DOI 10.1073/pnas.94.8.3990; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Majima S, 2000, JPN J CANCER RES, V91, P869, DOI 10.1111/j.1349-7006.2000.tb01027.x; Momose S, 2002, HUM MOL GENET, V11, P2997, DOI 10.1093/hmg/11.24.2997; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Okimoto K, 2004, CURR MOL MED, V4, P887, DOI 10.2174/1566524043359737; Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100; Okimoto K, 2000, JPN J CANCER RES, V91, P1096, DOI 10.1111/j.1349-7006.2000.tb00890.x; Satake N, 1999, CANCER RES, V59, P849; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413	15	10	10	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2885	2889		10.1038/sj.onc.1209317	http://dx.doi.org/10.1038/sj.onc.1209317			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16369488				2022-12-17	WOS:000237448200006
J	Bloor, AJC; Kotsopoulou, E; Hayward, P; Champion, BR; Green, AR				Bloor, AJC; Kotsopoulou, E; Hayward, P; Champion, BR; Green, AR			RFP represses transcriptional activation by bHLH transcription factors	ONCOGENE			English	Article						RFP; SCL; bHLH; transcription factor; repression	RET FINGER PROTEIN; LOOP-HELIX PROTEINS; ACUTE PROMYELOCYTIC LEUKEMIA; TRIPARTITE MOTIF; NUCLEAR-BODIES; FUSION PROTEIN; SCL GENE; MYOD; EXPRESSION; INTERACTS	Basic helix-loop-helix (bHLH) transcription factors play a pivotal role in the regulation of tumorigenesis, and also in a wide range of other developmental processes in diverse species from yeast to humans. Here we demonstrate for the first time that Ret finger protein (RFP), a member of the TRIM family of proteins initially identified as a recombined transforming gene from a human lymphoma, is a novel interaction partner for four different bHLH proteins (SCL, E47, MyoD and mASH-1), but does not interact with GATA-1 or PU.1. Interaction with SCL required the B-box and first coiled-coil region of RFP together with the bHLH domain of SCL. RFP was able to repress transcriptional activation by E47, MyoD and mASH-1, but not by members of several other transcription factor families. Transcriptional repression by RFP was trichostatin A sensitive and did not involve an Id-like mechanism or ubiquitination with subsequent degradation of bHLH proteins. Instead, our results suggest that bHLH transcription factors are regulated by a previously undescribed interaction with RFP, which functions to recruit HDAC and/or Polycomb proteins and thus repress target genes of bHLH proteins. These results reveal an unexpected link between the bHLH and TRIM protein families.	Univ Cambridge, Dept Haematol, Cambridge Inst Met Res, Cambridge CB2 2XY, England; Lorantis Ltd, Cambridge CB4 0WG, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England	University of Cambridge; University of Cambridge	Green, AR (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Met Res, Hills Rd, Cambridge CB2 2XY, England.	arg1000@cam.ac.uk		Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bailey P, 1999, MOL ENDOCRINOL, V13, P1155, DOI 10.1210/me.13.7.1155; Begley CG, 1999, BLOOD, V93, P2760; Bloor AJC, 2002, J HEMATOTH STEM CELL, V11, P195, DOI 10.1089/152581602753658402; BOCKAMP EO, 1995, BLOOD, V86, P1502, DOI 10.1182/blood.V86.4.1502.bloodjournal8641502; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Cao TY, 1998, J CELL SCI, V111, P1319; Cao TY, 1997, J CELL SCI, V110, P1563; CHANG KS, 1992, MOL CELL BIOL, V12, P800, DOI 10.1128/MCB.12.2.800; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Farah MH, 2000, DEVELOPMENT, V127, P693; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; Hall MA, 2003, P NATL ACAD SCI USA, V100, P992, DOI 10.1073/pnas.0237324100; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Shimono Y, 2003, J BIOL CHEM, V278, P51638, DOI 10.1074/jbc.M309198200; Shimono Y, 2000, J BIOL CHEM, V275, P39411, DOI 10.1074/jbc.M006585200; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Sinclair AM, 2002, BLOOD, V99, P3931, DOI 10.1182/blood.V99.11.3931; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TANIGAWA T, 1994, CELL GROWTH DIFFER, V5, P557; Tezel G, 1999, PATHOL INT, V49, P881, DOI 10.1046/j.1440-1827.1999.00957.x; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yokota Y, 2002, J CELL PHYSIOL, V190, P21, DOI 10.1002/jcp.10042; Zhang JS, 2004, SCIENCE, V305, P1286, DOI 10.1126/science.1097937	39	10	10	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6729	6736		10.1038/sj.onc.1208828	http://dx.doi.org/10.1038/sj.onc.1208828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007160				2022-12-17	WOS:000232527800001
J	Lee, S; Privalsky, ML				Lee, S; Privalsky, ML			Multiple mutations contribute to repression by the v-Erb A oncoprotein	ONCOGENE			English	Article						v-Erb A; c-Erb A; thyroid hormone receptor; T3R; dominant negative; c-Jun	THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTORS; DOMINANT-NEGATIVE ACTIVITY; AVIAN ERYTHROBLASTOSIS VIRUS; DNA-BINDING; X-RECEPTOR; C-ERBA; RESPONSE ELEMENTS; TRANSCRIPTIONAL REPRESSION; ERYTHROID-DIFFERENTIATION	The v-Erb A oncoprotein of avian erythroblastosis virus is derived from c-Erb A, a hormone-activated transcription factor. Notably, v-Erb A has sustained multiple mutations relative to c-Erb A and functions as a constitutive transcriptional repressor. We report here an analysis of the contributions of these different mutations to v-Erb A function. Our experiments demonstrate that two amino-acid differences between v-Erb A and c-Erb A, located in the 'I-box,' alter the dimerization properties of the viral protein, resulting in more stable homodimer formation, increased corepressor binding, and increased target gene repression. An additional amino-acid difference between v-and c-Erb A, located in helix 3 of the hormone binding domain, renders corepressor binding by the viral protein more resistant to release by thyroid hormone. Finally, we report that a C-terminal truncation in v-Erb A not only inhibits exchange of corepressor and coactivator, as previously noted, but also permits v-Erb A to recruit both SMRT and N-CoR corepressors, whereas c-Erb A is selective for N-CoR. The latter two mutations in v-Erb A also impair its ability to suppress c-Jun function in response to T3 hormone. We propose that the acquisition of oncogenic potential by the v-Erb A protein was a multistep process involving a series of mutations that alter the transcriptional repressive properties of the viral protein through multiple mechanisms.	Univ Calif Davis, Biol Sect, Div Biol Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Privalsky, ML (corresponding author), Univ Calif Davis, Biol Sect, Div Biol Sci, 1 Shields Ave, Davis, CA 95616 USA.	mlprivalsky@ucdavis.edu		Lee, Sangho/0000-0003-3771-7761	NCI NIH HHS [R37-CA53394, R37 CA053394-10, R37 CA053394] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; Bauer A, 1997, ONCOGENE, V15, P701, DOI 10.1038/sj.onc.1201208; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Beug H, 1996, BBA-REV CANCER, V1288, pM35, DOI 10.1016/S0304-419X(96)00032-7; Chatterjee VKK, 1997, HORM RES, V48, P43, DOI 10.1159/000191312; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Cohen RN, 2001, MOL ENDOCRINOL, V15, P1049, DOI 10.1210/me.15.7.1049; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DeGroot LJ, 1996, ANN INTERN MED, V125, P623, DOI 10.7326/0003-4819-125-7-199610010-00022; DESBOIS C, 1991, ONCOGENE, V6, P2129; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS RM, 1989, INT J CANCER, P26; Farboud B, 2004, MOL ENDOCRINOL, V18, P2839, DOI 10.1210/me.2004-0236; FORMAN B M, 1990, New Biologist, V2, P587; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; FORREST D, 1990, ONCOGENE, V5, P309; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GHYSDAEL J, 1992, CANCER SURV, V14, P169; Glass CK, 1996, J ENDOCRINOL, V150, P349, DOI 10.1677/joe.0.1500349; Glass CK, 2000, GENE DEV, V14, P121; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Goodson ML, 2005, J BIOL CHEM, V280, P7493, DOI 10.1074/jbc.M411514200; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harbers M, 1998, J STEROID BIOCHEM, V67, P181, DOI 10.1016/S0960-0760(98)00100-9; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; Lee S, 2005, MOL ENDOCRINOL, V19, P863, DOI 10.1210/me.2004-0210; LENG XH, 1993, J STEROID BIOCHEM, V46, P643, DOI 10.1016/0960-0760(93)90306-H; Makowski A, 2003, MOL ENDOCRINOL, V17, P273, DOI 10.1210/me.2002-0310; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; PAIN B, 1990, New Biologist, V2, P284; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; PINCUS MR, 1992, ANN CLIN LAB SCI, V22, P323; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; PRIVALSKY ML, 1992, BIOCHIM BIOPHYS ACTA, V1114, P51, DOI 10.1016/0304-419X(92)90006-K; REFETOFF S, 1993, CLIN LAB MED, V13, P563, DOI 10.1016/S0272-2712(18)30426-8; Reginato MJ, 1996, J BIOL CHEM, V271, P28199, DOI 10.1074/jbc.271.45.28199; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, RECENT PROG HORM RES, V53, P351; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; Rietveld LEG, 2001, ONCOGENE, V20, P3100, DOI 10.1038/sj.onc.1204335; Saatcioglu F, 1997, MOL CELL BIOL, V17, P4687, DOI 10.1128/MCB.17.8.4687; Samarut J, 1996, CURR TOP MICROBIOL, V212, P163; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1992, ONCOGENE, V7, P217; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1992, ONCOGENE, V7, P953; Shen Q, 2000, J BIOL CHEM, V275, P41018, DOI 10.1074/jbc.M006111200; Soucek L, 2002, CANCER CELL, V1, P406, DOI 10.1016/S1535-6108(02)00077-6; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Stunnenberg HG, 1999, BBA-REV CANCER, V1423, pF15, DOI 10.1016/S0304-419X(98)00036-5; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; Subauste JS, 1998, MOL ENDOCRINOL, V12, P1380, DOI 10.1210/me.12.9.1380; Thormeyer D, 1999, INT J MOL MED, V4, P351; Tzagarakis-Foster C, 1998, J BIOL CHEM, V273, P10926, DOI 10.1074/jbc.273.18.10926; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Urnov FD, 2000, EMBO J, V19, P4074, DOI 10.1093/emboj/19.15.4074; Usala S J, 1991, Thyroid, V1, P361, DOI 10.1089/thy.1991.1.361; Vennstrom B, 1987, Horm Metab Res Suppl, V17, P14; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wahlstrom GM, 1996, ONCOGENE, V13, P843; Webb P, 2000, MOL ENDOCRINOL, V14, P1976, DOI 10.1210/me.14.12.1976; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; Wondisford FE, 2003, J INVEST MED, V51, P215, DOI 10.1136/jim-51-04-22; YEN PM, 1994, J BIOL CHEM, V269, P903; YEN PM, 1992, J BIOL CHEM, V267, P23248; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; Yoh Sunnie M, 2002, Methods Mol Biol, V202, P129; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; Zubkova I, 2004, MOL BIOL REP, V31, P131, DOI 10.1023/B:MOLE.0000031412.25988.30; Zubkova I, 2003, MOL CELL ENDOCRINOL, V199, P61, DOI 10.1016/S0303-7207(02)00299-X; Zubkova I, 2002, BIOCHEM BIOPH RES CO, V294, P35, DOI 10.1016/S0006-291X(02)00428-X	94	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6737	6752		10.1038/sj.onc.1208826	http://dx.doi.org/10.1038/sj.onc.1208826			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007162	Green Accepted			2022-12-17	WOS:000232527800002
J	Boehden, GS; Baumann, C; Siehler, S; Wiesmuller, L				Boehden, GS; Baumann, C; Siehler, S; Wiesmuller, L			Wild-type p53 stimulates homologous recombination upon sequence-specific binding to the ribosomal gene cluster repeat	ONCOGENE			English	Article						homologous recombination; microsatellite repeat; p53 recognition sequence; replication-associated recombination	REPLICATION FORK BLOCKING; MICROSATELLITE INSTABILITY; DNA-REPLICATION; TETRANUCLEOTIDE REPEATS; FOB1 PROTEIN; TRANSCRIPTION; DISSOCIATION; INHIBITION; COMPLEX; SITES	p53 plays a central role in the maintenance of the genome integrity, both as a gatekeeper and a caretaker. Sequence-specific recognition of DNA is underlying the ability of p53 to transcriptionally transactivate target genes during checkpoint control and to regulate DNA replication at the TGCCT repeat from the ribosomal gene cluster (RGC). In contrast, suppression of recombination by p53 has been observed with nonconsensus DNA sequences. In this study, we discovered that wild-type p53 stimulates homologous recombination adjacent to the RGC repeat, whereas downregulation is seen with a mutated version thereof and with a microsatellite repeat sequence. Analysis of the causes possibly underlying the enhancement of homologous recombination revealed that p53 binding to the RGC element delays DNA synthesis. This was demonstrated after integration of the corresponding DNA fragments into our Simian virus 40-based model system, which was used to study recombination on replicating minichromosomes. Differently, with plasmid-based substrates, p53 did not stimulate recombination at the RGC sequence. Thus, in combination with our previous findings, p53 may promote homologous recombination by two separate mechanisms involving either molecular interactions with topoisomerase I or/and by specific binding to certain genomic regions, thereby causing replication fork stalling and recombination.	Univ Frauenklin, D-89075 Ulm, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Ulm University; Heinrich Pette Institute; University of Hamburg	Wiesmuller, L (corresponding author), Univ Frauenklin, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@medizin.uni-ulm.de						Achanta G, 2001, CANCER RES, V61, P8723; Ahrendt SA, 2000, CANCER RES, V60, P2488; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ARIIZUMI K, 1993, MOL CELL BIOL, V13, P5629, DOI 10.1128/MCB.13.9.5629; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; Boehden GS, 2004, CARCINOGENESIS, V25, P1305, DOI 10.1093/carcin/bgh092; Boehden GS, 2003, ONCOGENE, V22, P4111, DOI 10.1038/sj.onc.1206632; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Brazdova M, 2002, NUCLEIC ACIDS RES, V30, P4966, DOI 10.1093/nar/gkf616; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Danaee H, 2002, ONCOGENE, V21, P4894, DOI 10.1038/sj.onc.1205619; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Flores-Rozas H, 2000, TRENDS BIOCHEM SCI, V25, P196, DOI 10.1016/S0968-0004(00)01568-1; Gebow D, 2000, MOL CELL BIOL, V20, P4028, DOI 10.1128/MCB.20.11.4028-4035.2000; Gerber JK, 1997, CELL, V90, P559, DOI 10.1016/S0092-8674(00)80515-2; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; JAXEL C, 1988, NUCLEIC ACIDS RES, V16, P11157, DOI 10.1093/nar/16.23.11157; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kobayashi T, 1998, GENE DEV, V12, P3821, DOI 10.1101/gad.12.24.3821; Kobayashi T, 1996, GENES CELLS, V1, P465, DOI 10.1046/j.1365-2443.1996.d01-256.x; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Pluciennik A, 2002, J BIOL CHEM, V277, P34074, DOI 10.1074/jbc.M202127200; Richard GF, 2000, EMBO REP, V1, P122, DOI 10.1093/embo-reports/kvd031; Rothstein R, 2000, GENE DEV, V14, P1; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Stephan H, 2002, NUCLEIC ACIDS RES, V30, P5087, DOI 10.1093/nar/gkf659; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; TSUI S, 1989, J VIROL, V63, P5175, DOI 10.1128/JVI.63.12.5175-5183.1989; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142; Xiao G, 1998, ONCOGENE, V16, P1171, DOI 10.1038/sj.onc.1201631; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	47	10	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4183	4192		10.1038/sj.onc.1208592	http://dx.doi.org/10.1038/sj.onc.1208592			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15782112				2022-12-17	WOS:000229815300003
J	Gemmill, RM; Lee, JP; Chamovitz, DA; Segal, D; Hooper, JE; Drabkin, HA				Gemmill, RM; Lee, JP; Chamovitz, DA; Segal, D; Hooper, JE; Drabkin, HA			Growth suppression induced by the TRC8 hereditary kidney cancer gene is dependent upon JAB1/CSN5	ONCOGENE			English	Article						TRC8; CSN5; CSN6; CSN7; VHL; Cul-1; NEDD8; COP9 signalosome; Drosophila	MODULATE AP-1 ACTIVITY; COP9 SIGNALOSOME; CELL-CYCLE; DROSOPHILA-MELANOGASTER; TRANSLOCATION; CARCINOMA; DEGRADATION; SUBCOMPLEX; P27(KIP1); CLEAVAGE	TRC8 encodes an E3-ubiquitin ligase disrupted in a family with hereditary renal cell carcinoma (RCC). We previously reported that Drosophila Trc8 (DTrc8) overexpression inhibits growth and that human and fly proteins interact with with the COP9 signalosome (CSN) subunit JAB1/CSN5. However, further mechanistic evidence linking DTrc8 growth suppression to CSN5 was lacking. Here, we show that haploinsufficiency of CSN5, or a T100I point mutation (CSN5(3)), relieved growth suppression by DTrc8, whereas CSN5(1) (E160V) and CSN5(2) (G147D) mutations had no effect. The strength of yeast two-hybrid interactions between DTrc8 and CSN5 were in complete agreement with the observed phenotypes. DTrc8 overexpression resulted in elevated levels of CSN5 and CSN7, but had no effect on NEDD8-modified Cul-1. In contrast to CSN5, heterozygosity for CSN4(null) had no effect on the DTrc8 phenotype. We also looked for genetic interactions between DTrc8 and other MPN domain proteins in the CSN and 26S proteasome lid. CSN6 haploinsufficiency restored growth, whereas reduction of proteasome subunits RPN8 or RPN11 had no effect. DTrc8 expression increased the level of digitonin-extractable CSN complex, consistent with elevated levels of CSN5 and 7. Our genetic results confirm that DTrc8-induced growth suppression is CSN5 (and CSN6) dependent. While there was no obvious influence on CSN deneddylation activity, the increase in CSN subunits and holocomplex suggests that TRC8 modulates signalosome levels or compartmentalization.	Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Aurora, CO 80010 USA; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Dev Biol, Aurora, CO 80010 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; Tel Aviv University; Tel Aviv University; University of Colorado System; University of Colorado Anschutz Medical Campus	Gemmill, RM (corresponding author), Univ Colorado, Fitzsimons Army Med Ctr, Hlth Sci Ctr, MailStop 8117,POB 6511,12801 E 17th Ave, Aurora, CO 80045 USA.	robert.gemmill@uchsc.edu	Chamovitz, Daniel/S-5021-2019	Chamovitz, Daniel/0000-0002-2815-2909; Segal, Daniel/0000-0002-6777-505X	NATIONAL CANCER INSTITUTE [R01CA076035] Funding Source: NIH RePORTER; NCI NIH HHS [CA76035] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Freilich S, 1999, CURR BIOL, V9, P1187, DOI 10.1016/S0960-9822(00)80023-8; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Kim M, 1998, BIOCHEM BIOPH RES CO, V253, P672, DOI 10.1006/bbrc.1998.9839; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Maytal-Kivity V, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-28; Mundt KE, 2002, MOL BIOL CELL, V13, P493, DOI 10.1091/mbc.01-10-0521; Oron E, 2002, DEVELOPMENT, V129, P4399; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Suh GSB, 2002, NEURON, V33, P35, DOI 10.1016/S0896-6273(01)00576-1; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tomoda K, 2005, BLOOD, V105, P775, DOI 10.1182/blood-2004-04-1242; Wei N, 2003, ANNU REV CELL DEV BI, V19, P261, DOI 10.1146/annurev.cellbio.19.111301.112449	23	10	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 12	2005	24	21					3503	3511		10.1038/sj.onc.1208509	http://dx.doi.org/10.1038/sj.onc.1208509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735686				2022-12-17	WOS:000229038800012
J	Matthews, JR; Clarke, AR				Matthews, JR; Clarke, AR			p53 mediates a default programme of mammary gland involution in the absence of STAT3	ONCOGENE			English	Article						p53; STAT3; p21Waf1; involution; mammary	CELL PROLIFERATION; APOPTOSIS; MICE; PATHWAYS; SUPPRESSION; ACTIVATION; DELETION; TARGETS; CANCER	Previous studies have demonstrated a proapoptotic role for the transcription factor STAT3 in involuting murine mammary epithelium, resulting in delayed involution and lower levels of apoptosis in the STAT3 null gland relative to wild-type controls. As p53 was implicated in the eventual involution of the STAT3 null gland, we examined the effect of STAT3 loss in the mammary gland in a p53 null background. Combined loss of STAT3 and p53 severely perturbed involution, with hyperdelayed loss of epithelium and reappearance of adipocytes. The early apoptotic response was almost completely abrogated, although elevated levels of delayed apoptosis persisted at days 6, 17 and 4 weeks of involution in STAT3-p53 doubly null mammary glands. A 5.7-fold upregulation of the cyclin-dependent kinase inhibitor p21Waf1 at 3 days of involution in STAT3 null glands was abolished in STAT3-p53 doubly null glands - suggesting that the critical factor triggering delayed involution in the STAT3 null gland is a p53-dependent rise in p21Waf1 levels around day 3 of involution. Further, STAT3-p53 doubly null glands showed significantly higher levels of proliferation compared to STAT3 or p53 singly null ( or wild-type) glands at days 6, 17 and 4 weeks of involution. Combined loss of STAT3 and p53 therefore results in hyperdelayed involution, demonstrating their synergistic physiological roles in normal involution. This inappropriate retention of p53-deficient cells may represent a novel mechanism of tumour predisposition.	Cardiff Univ, Sch Biosci, Dept Mammalian Genet, BIOSI 3, Cardiff CF1 3US, S Glam, Wales	Cardiff University	Clarke, AR (corresponding author), Cardiff Univ, Sch Biosci, Dept Mammalian Genet, BIOSI 3, Museum Ave, Cardiff CF1 3US, S Glam, Wales.	clarkear@cf.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tonner E, 2002, DEVELOPMENT, V129, P4547; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yi YJ, 2004, MOL BIOL CELL, V15, P2302, DOI 10.1091/mbc.E03-11-0785; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	18	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3083	3090		10.1038/sj.onc.1208512	http://dx.doi.org/10.1038/sj.onc.1208512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735683				2022-12-17	WOS:000228728100002
J	Pall, T; Gad, A; Kasak, L; Drews, M; Stromblad, S; Kogerman, P				Pall, T; Gad, A; Kasak, L; Drews, M; Stromblad, S; Kogerman, P			Recombinant CD44-HABD is a novel and potent direct angiogenesis inhibitor enforcing endothelial cell-specific growth inhibition independently of hyaluronic acid binding	ONCOGENE			English	Article						CD44; angiogenesis; hyaluronic acid	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; TUMOR-GROWTH; EXTRACELLULAR-MATRIX; ADHESION MOLECULE; CARCINOMA-CELLS; SOLUBLE CD44; E-SELECTIN; IN-VIVO; MIGRATION; RECEPTOR	CD44 is the main cellular receptor for hyaluronic acid (HA). We previously found that overexpression of CD44 inhibited tumor growth of mouse fibrosarcoma cells in mice. Here, we show that soluble recombinant CD44 HA-binding domain (CD44-HABD) acts directly onto endothelial cells by inhibiting endothelial cell proliferation in a cell-specific manner. Consequently, soluble recombinant CD44-HABD also blocked angiogenesis in vivo in chick and mouse, and thereby inhibited tumor growth of various origins at very low doses (0.25 mg/kg x day). The antiangiogenic effect of CD44 is independent of its HA-binding capacity, since mutants deficient in HA binding still maintain their antiangiogenic and antiproliferative properties. Recombinant CD44-HABD represents a novel class of angiogenesis inhibitors based on a cell-surface receptor.	NICPB, Mol Genet Lab, EE-12618 Tallinn, Estonia; Huddinge Univ Hosp F 46, Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-19086 Tallinn, Estonia	National Institute of Chemical Physics & Biophysics (NICPB); Karolinska Institutet; Tallinn University of Technology	Kogerman, P (corresponding author), NICPB, Mol Genet Lab, Akadeemia 23, EE-12618 Tallinn, Estonia.	priit@kbfi.ee	Kogerman, Priit/B-6333-2008; Gad, Annica/X-8294-2018; Gad, Annica/H-8758-2017	Gad, Annica/0000-0002-1098-9129; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Ahrens T, 2001, ONCOGENE, V20, P3399, DOI 10.1038/sj.onc.1204435; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Brooks PC, 1999, METH MOL B, V129, P257; Cichy J, 2002, J BIOL CHEM, V277, P44440, DOI 10.1074/jbc.M207437200; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; Griffioen AW, 1997, BLOOD, V90, P1150, DOI 10.1182/blood.V90.3.1150.1150_1150_1159; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Guo NH, 1997, CANCER RES, V57, P1735; GUO YJ, 1994, CANCER RES, V54, P1561; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; KATOH S, 1994, J IMMUNOL, V153, P3440; Kaya G, 1997, GENE DEV, V11, P996, DOI 10.1101/gad.11.8.996; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; Kogerman P, 1997, ONCOGENE, V15, P1407, DOI 10.1038/sj.onc.1201306; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Lokeshwar VB, 1996, J BIOL CHEM, V271, P23853, DOI 10.1074/jbc.271.39.23853; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Savani RC, 2001, J BIOL CHEM, V276, P36770, DOI 10.1074/jbc.M102273200; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; Trochon V, 1996, INT J CANCER, V66, P664, DOI 10.1002/(SICI)1097-0215(19960529)66:5<664::AID-IJC14>3.0.CO;2-4; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Zhang HQ, 2002, J CELL BIOL, V158, P1287, DOI 10.1083/jcb.200207008	51	10	12	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7874	7881		10.1038/sj.onc.1208083	http://dx.doi.org/10.1038/sj.onc.1208083			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361838				2022-12-17	WOS:000224331600013
J	Pike, J; Holmes, D; Kamalati, T; Davies, D; Tolhurst, R; Mazhar, D; Fishpool, S; al-Jehani, R; Waxman, J; Zelent, A; Lemoine, NR; Ali, S; Buluwela, L				Pike, J; Holmes, D; Kamalati, T; Davies, D; Tolhurst, R; Mazhar, D; Fishpool, S; al-Jehani, R; Waxman, J; Zelent, A; Lemoine, NR; Ali, S; Buluwela, L			Silencing of androgen-regulated genes using a fusion of AR with the PLZF transcriptional repressor	ONCOGENE			English	Article						prostate cancer; androgen receptor; PLZF; gene expression	ACID RECEPTOR-ALPHA; DNA-BINDING DOMAIN; HISTONE DEACETYLASE; PROSTATE-CANCER; RAR-ALPHA; NUCLEAR RECEPTORS; PROMYELOCYTIC LEUKEMIA; CELL-LINE; EXPRESSION; ESTROGEN	The androgen receptor (AR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors and plays a key role in the development and progression of prostate cancer. Current therapies include the use of antiandrogens aimed at inhibiting the transcriptional activation of AR-regulated genes by AR. Here, we explore a strategy aimed at obtaining silencing of AR-regulated genes, based on the properties of the transcriptional repressor promyelocytic leukamia zinc-finger protein ( PLZF). In order to do this, we have made a fusion protein between PLZF and AR, named PLZF-AR, and show that PLZF-AR is able to bring about silencing of genomically encoded AR-regulated genes and inhibit the androgen-regulated growth of LNCaP prostate cancer cells. Together, our results show that this strategy is able to bring about potent repression of AR-regulated responses and, therefore, could be of value in the development of new therapies for prostate cancer.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Canc Res UK, Lincolns Inn Fields Labs, London WC2A 3PX, England; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England	Imperial College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Du Cane Rd, London W12 0NN, England.	simak.ali@imperial.ac.uk; l.buluwela@imperial.ac.uk	Zelent, Arthur/B-3532-2009; Ali, Simak/M-6912-2018	Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816; Zelent, Arthur/0000-0002-7968-9888; Holmes, David/0000-0002-4560-3572; Davies, Derek/0000-0002-6977-4181				Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Blankvoort BMG, 2001, ANAL BIOCHEM, V298, P93, DOI 10.1006/abio.2001.5352; Bramlett KS, 2001, MOL CELL ENDOCRINOL, V183, P19, DOI 10.1016/S0303-7207(01)00636-0; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen DS, 1999, MOL CELL BIOL, V19, P1002; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DAVIES P, 1991, J ENDOCRINOL, V131, P5, DOI 10.1677/joe.0.1310005; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Glass CK, 2000, GENE DEV, V14, P121; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heemers H, 2000, BIOCHEM BIOPH RES CO, V269, P209, DOI 10.1006/bbrc.2000.2262; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsieh ML, 1997, CANCER RES, V57, P2651; HUGGINS C, 1967, CANCER RES, V27, P1925; LABRIE F, 1993, CLIN INVEST MED, V16, P475; LABRIE F, 1986, ENDOCR REV, V7, P67, DOI 10.1210/edrv-7-1-67; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu QY, 1996, CANCER RES, V56, P1155; Mabjeesh NJ, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090115; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MONNE M, 1994, CANCER RES, V54, P6344; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SADI MV, 1991, CANCER, V67, P3057, DOI 10.1002/1097-0142(19910615)67:12<3057::AID-CNCR2820671221>3.0.CO;2-S; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Takane KK, 1996, MOL CELL ENDOCRINOL, V119, P83, DOI 10.1016/0303-7207(96)03800-2; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; ZEGERS ND, 1991, BIOCHIM BIOPHYS ACTA, V1073, P23, DOI 10.1016/0304-4165(91)90178-J; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4; ZHOU ZX, 1994, J BIOL CHEM, V269, P13115	59	10	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7561	7570		10.1038/sj.onc.1208030	http://dx.doi.org/10.1038/sj.onc.1208030			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15334066				2022-12-17	WOS:000224176500013
J	Molist, R; Reinvikos, Y; Dutrillaux, B; Muleris, M				Molist, R; Reinvikos, Y; Dutrillaux, B; Muleris, M			Characterization of a new cytogenetic subtype of ductal breast carcinomas	ONCOGENE			English	Article						comparative genomic hybridization; ductal breast carcinomas; chromosome aberrations; TP53; chromosome gain	COMPARATIVE GENOMIC HYBRIDIZATION; REPLICATION ERROR PHENOTYPE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; CHROMOSOMAL EVOLUTION; GENETIC ALTERATIONS; SOLID TUMORS; DNA; PATHWAYS; CARCINOGENESIS	About 50% of ductal breast carcinomas do not yield analysable karyotypes after short-term culturing. Comparison of the cytogenetic subset to the whole data set of tumors revealed that slightly hyperdiploid tumors, that is, with DNA index between 1.05 and 1.3, were under-represented in tumors for which cytogenetic analysis was successful. The purpose of this study was to determine whether the pattern of chromosome imbalances in this subset differs from that generally reported. Comparative genomic hybridization (CGH) was used on 43 primary ductal breast carcinomas selected for slight hyperdiploidy. Microsatellite instability (MSI), TP53 mutation and expression were also investigated. All tumors were MSI negative. In all, 18 tumors (42%) presented mostly unbalanced chromosome rearrangements and DNA amplifications, with only few or no whole chromosome gains (WCG). This pattern of chromosome imbalances corresponds to that described in most breast tumors by previous cytogenetic and CGH analyses. It was associated with TP53 mutation in 17% of tumors. Another subset of 17 tumors (39%) displayed different and new features, characterized by recurrent gains of whole chromosomes 5, 7 and 8 with few chromosome rearrangements, rare DNA amplifications and no TP53 mutation. Eight tumors with as many rearrangements as WCG were left unclassified. We propose that, beside a major pathway characterized by multiple chromosome rearrangements, there is a minor pathway mainly characterized by WCG.	Inst Curie, CNRS, FRE 2584, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Cite	Muleris, M (corresponding author), Inst Curie, CNRS, FRE 2584, 26 Rue Ulm, F-75248 Paris, France.	martme.muleris@curie.fr						AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Anbazhagan R, 1999, CLIN CANCER RES, V5, P839; Bernardino J, 1997, GENE CHROMOSOME CANC, V19, P195; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Buerger H, 2001, J PATHOL, V194, P165, DOI 10.1002/path.875; Courjal F, 1997, CANCER RES, V57, P4368; DELATTRE O, 1989, LANCET, V2, P353; Dellas A, 2002, CLIN CANCER RES, V8, P1210; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; DUTRILLAUX B, 1991, BREAST CANCER RES TR, V19, P245, DOI 10.1007/BF01961161; DUTRILLAUX B, 2000, CHROMOSOME GENE ALTE; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Haydon AMM, 2002, LANCET ONCOL, V3, P83, DOI 10.1016/S1470-2045(02)00649-6; Hoang JM, 1997, CANCER RES, V57, P300; Hoglund M, 2002, CANCER RES, V62, P2675; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ISOLA JJ, 1995, AM J PATHOL, V147, P905; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lesec G, 1997, INT J ONCOL, V10, P747; LOTHE RA, 1993, CANCER RES, V53, P5849; Loveday RL, 2000, INT J CANCER, V86, P494, DOI 10.1002/(SICI)1097-0215(20000515)86:4<494::AID-IJC8>3.3.CO;2-F; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Muleris M, 1996, CANCER GENET CYTOGEN, V92, P11, DOI 10.1016/S0165-4608(96)00116-1; Murata H, 2002, ONCOGENE, V21, P5696, DOI 10.1038/sj.onc.1205683; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PANDIS N, 1995, GENE CHROMOSOME CANC, V12, P173, DOI 10.1002/gcc.2870120304; Paulson TG, 1996, CANCER RES, V56, P4021; Remvikos Y, 1997, CANCER GENET CYTOGEN, V93, P63, DOI 10.1016/S0165-4608(96)00305-6; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; RIED T, 1995, CANCER RES, V55, P5415; Roylance R, 1999, CANCER RES, V59, P1433; Sandberg AA, 2000, CANCER GENET CYTOGEN, V123, P1, DOI 10.1016/S0165-4608(00)00295-8; Shackney SE, 1997, CYTOMETRY, V29, P1; Shaw JA, 1996, BRIT J CANCER, V73, P1393, DOI 10.1038/bjc.1996.264; Soulie P, 1999, ONCOGENE, V18, P775, DOI 10.1038/sj.onc.1202336; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Walsh T, 1998, J PATHOL, V185, P18, DOI 10.1002/(SICI)1096-9896(199805)185:1<18::AID-PATH41>3.0.CO;2-G; Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4	49	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5986	5993		10.1038/sj.onc.1207799	http://dx.doi.org/10.1038/sj.onc.1207799			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15208688				2022-12-17	WOS:000222941100013
J	Phelps, CB; Ghosh, G				Phelps, CB; Ghosh, G			Discreet mutations from c-Rel to v-Rel alter kappa B DNA recognition, I kappa B alpha binding, and dimerization: implications for v-Rel oncogenicity	ONCOGENE			English	Article						DNA binding; v-Rel; NF-kappa B; I kappa B alpha; fluorescence; anisotropy	VIRUS STRAIN-T; CHICKEN-EMBRYO FIBROBLASTS; RAY CRYSTAL-STRUCTURE; CASEIN KINASE-II; GENE-EXPRESSION; SPLEEN-CELLS; MALIGNANT-TRANSFORMATION; P50/P65 HETERODIMER; CELLULAR HOMOLOG; IMMUNE-SYSTEM	The avian Rev-T retrovirus encodes the oncoprotein v-Rel, a member of the Rel/nuclear factor (NF)-kappaB transcription factor family. The aggressive oncogenic potential of v-Rel has arisen from multiple mutations within the coding sequence of the avian cellular protein c-Rel. In this study, using quantitative biochemical experiments, we have tested the role of a limited set of alterations between v-Rel and c-Rel located within the Rel homology region (RHR) of the family that might confer functional differences. Our results show that only a set of six mutations within the RHR of v-Rel are responsible for its ability to bind to a broad spectrum of kappaB-DNA that are normally regulated by distinct NF-kappaB dimers. We also observe that both v-Rel homodimer and p50/v-Rel heterodimer bind IkappaBalpha weakly compared to other cellular Rel/NF-kappaB dimers with transcription activation potential. We suggest that the ability of v-Rel homodimer to deregulate subunit-specific gene expression and its ability to evade IkappaB inhibition are crucial to its strong oncogenic potential.	Univ Calif San Diego, Dept Chem & Biochem, San Diego, CA 92103 USA	University of California System; University of California San Diego	Ghosh, G (corresponding author), 9500 Gilman Dr,MC 0359, La Jolla, CA 92093 USA.	gghosh@ucsd.edu						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen CL, 1999, MOL CELL BIOL, V19, P307; Chen FE, 1999, PROTEIN ENG, V12, P423, DOI 10.1093/protein/12.5.423; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; CHENG Q, 1994, J BIOL CHEM, V269, P13551; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Epinat JC, 2000, ONCOGENE, V19, P3131, DOI 10.1038/sj.onc.1203651; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HRDLICKOVA R, 1995, J VIROL, V69, P403; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Huxford T, 2000, J BIOL CHEM, V275, P32800, DOI 10.1074/jbc.M006037200; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liss AS, 2002, J VIROL, V76, P4928, DOI 10.1128/JVI.76.10.4928-4939.2002; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MORRISON LE, 1992, ONCOGENE, V7, P1137; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; THEILEN GH, 1966, J NATL CANCER I, V37, P731; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Walker AK, 1996, ONCOGENE, V12, P2515; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; WILHELMSEN KC, 1984, J VIROL, V49, P521, DOI 10.1128/JVI.49.2.521-529.1984; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328	63	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1229	1238		10.1038/sj.onc.1207242	http://dx.doi.org/10.1038/sj.onc.1207242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14961076				2022-12-17	WOS:000188892200007
J	Horn, S; Meyer, J; Stocking, C; Ostertag, W; Jucker, M				Horn, S; Meyer, J; Stocking, C; Ostertag, W; Jucker, M			An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1)	ONCOGENE			English	Article						p(60c-Src); GM-CSF; acute myeloid leukemia; TF-1	COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; V-SRC ONCOGENE; NIH 3T3 CELLS; ACUTE MYELOBLASTIC-LEUKEMIA; HEMATOPOIETIC GROWTH-FACTOR; COMMON BETA-SUBUNIT; ROUS-SARCOMA-VIRUS; TYROSINE KINASE; AUTOCRINE GROWTH	Growth factor independence of hematopoietic cells can be induced by ectopic expression of a variety of oncogenes encoding receptor or cytoplasmic tyrosine kinases. To examine whether the activation of tyrosine kinases occurs in factor-independent mutants in vivo, the tyrosine-phosphorylated proteins from 14 factor-independent mutants of a GM-CSF-dependent cell line (TF-1) were analysed. These mutants did not secrete any growth-stimulating activity for TF-1 cells, suggesting that activation of intracellular signaling rather than an autocrine stimulation by secreted growth factors is responsible for their factor-independent growth. In 11 out of 14 GM-CSF-independent mutants analysed, a constitutively tyrosine-phosphorylated protein of 60 kDa was detected, which was subsequently identified as p60(c-Src). The kinase activity of p60(c-Src) was increased up to 12-fold in these mutants, which was at least in part due to overexpression of the c-src gene on the RNA and protein level. The Src substrate Sam68 showed an increased phosphorylation in mutants with high Src activity, suggesting that p60(c-Src) triggers downstream signaling in these cells. Treatment of the factor-independent mutants with the Src kinase inhibitor PP2 resulted in a reduced proliferation, demonstrating that Src kinases are essential for these cells for maximal proliferation. Further analysis of factor-independent mutants with low or undetectable Src activity revealed a constitutive phosphorylation of the common beta chain of the GM-CSF receptor and STAT5. Our data indicate an increase in the expression and total activity of endogenous p60(c-Src) in several GM-CSF-independent TF-1 mutants, further underlining the role of Src in the process of autonomous growth of hematopoietic cells.	Univ Hamburg, Klinikum Eppendorf, Zentrum Expt Med, Inst Biochem & Mol Biol 1, D-20246 Hamburg, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Abt Zell & Virusgenet, D-20251 Hamburg, Germany	University of Hamburg; Heinrich Pette Institute; University of Hamburg	Jucker, M (corresponding author), Univ Hamburg, Klinikum Eppendorf, Zentrum Expt Med, Inst Biochem & Mol Biol 1, Martinistr 52, D-20246 Hamburg, Germany.							ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDERSON SM, 1990, ONCOGENE, V5, P317; ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BENDALL LJ, 1994, EXP HEMATOL, V22, P1252; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; CHANG JM, 1989, BLOOD, V73, P1487; Chao JR, 1997, ONCOGENE, V14, P721, DOI 10.1038/sj.onc.1200884; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GABERT JA, 1994, LEUKEMIA, V8, P1359; GRIFFIN JD, 1986, BLOOD, V68, P1185; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JUCKER M, 1991, BLOOD, V77, P2413; JUCKER M, 1992, ONCOGENE, V7, P943; Jucker M, 1997, J BIOL CHEM, V272, P2104; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Jucker M, 1997, BLOOD, V89, P2024, DOI 10.1182/blood.V89.6.2024; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; KATZAV S, 1989, ONCOGENE, V4, P1129; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kitayama H, 1996, BLOOD, V88, P995; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LACONIQUE V, 1997, SCIENCE, V278, P1309; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWENBERG B, 1993, NEW ENGL J MED, V328, P614, DOI 10.1056/NEJM199303043280904; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MECKLINGGILL KA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P65, DOI 10.1016/0167-4889(92)90101-G; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nijhuis E, 2002, J LEUKOCYTE BIOL, V71, P115; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Ostermeyer AG, 1996, EXP HEMATOL, V24, P176; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1984, P NATL ACAD SCI-BIOL, V81, P2374, DOI 10.1073/pnas.81.8.2374; Prassolov V, 2001, EXP HEMATOL, V29, P756, DOI 10.1016/S0301-472X(01)00648-8; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REILLY IAG, 1989, BRIT J HAEMATOL, V72, P363, DOI 10.1111/j.1365-2141.1989.tb07717.x; SCHRADER JW, 1983, P NATL ACAD SCI-BIOL, V80, P6892, DOI 10.1073/pnas.80.22.6892; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; Steelman LS, 1996, LEUKEMIA, V10, P528; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STOCKING C, 1989, CURR TOP MICROBIOL, V149, P117; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANBOKHOVEN A, 1992, MOL BIOL REP, V16, P17, DOI 10.1007/BF00788749; WATSON JD, 1987, J IMMUNOL, V139, P123; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; YOUNG DC, 1986, BLOOD, V68, P1178; ZHOU H, 1990, P NATL ACAD SCI USA, V87, P9128, DOI 10.1073/pnas.87.23.9128	70	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7170	7180		10.1038/sj.onc.1206856	http://dx.doi.org/10.1038/sj.onc.1206856			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562045				2022-12-17	WOS:000185955000008
J	Malcolm, T; Ettehadieh, E; Sadowski, I				Malcolm, T; Ettehadieh, E; Sadowski, I			Mitogen-responsive expression of RhoB is regulated by RNA stability	ONCOGENE			English	Article						RhoB; RNA stability; immediate early gene; growth factor inducible; AU-rich element	P38 MAP KINASE; CYCLOOXYGENASE-2 MESSENGER-RNA; EPIDERMAL-GROWTH-FACTOR; GTP-BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; TRANSCRIPTIONAL ACTIVATION; TYROSINE KINASE; GENE-EXPRESSION; CELL-GROWTH; C-FOS	The small GTPase-encoding gene RhoB is strongly induced as part of the immediate early response of serum-stimulated. broblasts. In this report, we have characterized the mechanism for growth factor responsiveness of RhoB in Rat-2. broblasts. By Northern blotting and ribonuclease protection, we observed low or barely detectable levels of RhoB mRNA in quiescent cells, but expression was transiently induced in response to serum stimulation, such that the mRNA peaked within 30 min and then declined over the next hour. Analysis of the rat promoter revealed cis-elements conserved with the mouse and human genes, including a pair of CEBP sites near the transcriptional start site. However, in contrast to the analysis of RNA, RhoB promoter fusions were constitutively expressed in quiescent cells in transient transfections, and were unaffected by serum. Similarly, stable RhoB promoter integrants were highly expressed in quiescent cells, and growth factor caused a slight decrease in activity. This indicates that growth factor-inducible RhoB expression cannot be mediated by transcriptional activation. We then examined decay of the RhoB mRNA and found that serum caused significant stabilization. Additionally, fusion of the 30 RhoB untranslated region (UTR) to a constitutively expressed reporter gene caused serum and growth factor as well as DNA damage-inducible expression. These observations are consistent with the view that RhoB mRNA is produced constitutively but its abundance is controlled in response to growth factors, and other signals including DNA damage, by stabilization through elements within the 3' UTR.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Sadowski, I (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; Bell B, 1996, ONCOGENE, V13, P2687; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, MOL CELL BIOL, V19, P1831; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fritz G, 2001, NUCLEIC ACIDS RES, V29, P792, DOI 10.1093/nar/29.3.792; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; Leng E, 2002, J BIOMED SCI, V9, P59, DOI 10.1007/BF02256579; Li QDQ, 2001, INT J MOL MED, V7, P187; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; RIERA FC, 1984, SOMAT CELL MOLEC GEN, V10, P123, DOI 10.1007/BF01534901; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; ZALCMAN G, 1995, ONCOGENE, V10, P1935	40	10	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 18	2003	22	40					6142	6150		10.1038/sj.onc.1206638	http://dx.doi.org/10.1038/sj.onc.1206638			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679852				2022-12-17	WOS:000185506200003
J	Miro-Mur, F; Meiller, A; Haddada, H; May, E				Miro-Mur, F; Meiller, A; Haddada, H; May, E			p73 alpha expression induces both accumulation and activation of wt-p53 independent of the p73 alpha transcriptional activity	ONCOGENE			English	Article						p53; p73 alpha; p73 alpha R292H; recombinant adenovirus; protein stability; transcriptional activity	DNA-DAMAGE; P53-DEPENDENT MANNER; FEEDBACK LOOP; P53 PROTEIN; MCF7 CELLS; P73; APOPTOSIS; P63; DEGRADATION; DELTA-NP73	The p53 tumor suppressor gene belongs to a multigene family that includes two paralogues, p63 and p73. p73alpha has common activities with p53, such as DNA binding and transactivation, and can thus activate the transcription of p53-responsive genes. Using the adenoviral system, we report that an overexpression of either wt-p73alpha or one of the two transcriptional inactive mutants, DeltaNp73alpha or p73alpha:R292H, induces an accumulation of the endogenous wt-p53 expressed in the three transformed cell lines, SK-N-SH, MCF-7 and U-2OS, without stimulating the p53 gene transcription. p73-mediated accumulation of p53 protein coincides with an increase of p53-target gene expression in cells expressing either wt-p73alpha or the transcriptional inactive mutant p73alphaR292H, but not DeltaNp73alpha: that encodes a dominant-negative mutant of both p73 and p53. The fact that an ectopic expression of p73alpha:R292H leads to both accumulation of p53 and stimulation of p53 target gene expression strongly suggests that p73alpha is able to induce activation of p53. This was confirmed by showing that p73alphaR292H no longer stimulated Waf1/p21 expression in MCF7/R-A1 cells that expressed a transcriptional inactive mutant of p53. We thus conclude that p73alpha: protein was able to both stabilize and activate wt-p53 protein, independent of the p73alpha transcriptional activity.	CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, F-92265 Fontenay Aux Roses, France; Univ Autonoma Barcelona, Fac Ciencies, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Inst Gustave Roussy, INSERM, U3652, F-94805 Villejuif, France	CEA; Autonomous University of Barcelona; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	May, E (corresponding author), CEA, Lab Cancerogenese Mol, UMR 217, CEA CNRS,DRR,DSV, Route Panorama,BP 6, F-92265 Fontenay Aux Roses, France.		Miro-Mur, Francesc A./AAT-3013-2020	Miro-Mur, Francesc A./0000-0003-3936-2693				Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Drane P, 2002, CELL DEATH DIFFER, V9, P527, DOI 10.1038/sj.cdd.4400983; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Levrero M, 2000, J CELL SCI, V113, P1661; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2002, CANCER RES, V62, P3598; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516	24	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5451	5456		10.1038/sj.onc.1206538	http://dx.doi.org/10.1038/sj.onc.1206538			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934105				2022-12-17	WOS:000184735000010
J	Colombo, R; Draetta, GF; Chiocca, S				Colombo, R; Draetta, GF; Chiocca, S			Modulation of p120(E4F) transcriptional activity by the Gam1 adenoviral early protein	ONCOGENE			English	Article						HDAC1; Gam1; adenoviral protein; P120(E4F) transcriptional activity	MOUSE HISTONE DEACETYLASE-1; FACTOR E4F; GENE; IDENTIFICATION; GROWTH; CELO; ARREST	Gam1, an early adenoviral CELO protein, is required for viral replication. Consistent with its ability to inhibit histone deacetylation by HDAC1, Gam1 activates transcription. In this report, we identify the cellular transcription factor p120(E4F) as a Gam1 interaction partner. p120(E4F) is a low-abundance transcription factor that represses the adenovirus E4 promoter. Here we demonstrate that p120(E4F) interacts with HDAC1 in vivo and in vitro, and that E4F-mediated transcriptional repression is alleviated by the HDAC inhibitor trichostatin A or by overexpressing Gam1. A mutant E4 promoter unresponsive to E4F-mediated transcriptional repression is also not stimulated by Gam1. Moreover, our cofractionation experiments demonstrate that p120(E4F), HDAC1 and Gam1 may be concomitantly present in protein complexes. We conclude that Gam1 activates E4-dependent transcription possibly by inactivating HDAC1.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Chiocca, S (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.		Chiocca, Susanna/AAC-8863-2019; Chiocca, Susanna/K-5233-2016	Chiocca, Susanna/0000-0002-9721-0850	Telethon [E.0865] Funding Source: Medline	Telethon(Fondazione Telethon)		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Chiocca S, 1997, J VIROL, V71, P3168, DOI 10.1128/JVI.71.4.3168-3177.1997; Chiocca S, 1996, J VIROL, V70, P2939, DOI 10.1128/JVI.70.5.2939-2949.1996; Chiocca S, 2002, CURR BIOL, V12, P594, DOI 10.1016/S0960-9822(02)00720-0; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; FOGNANI C, 1993, EMBO J, V12, P4985, DOI 10.1002/j.1460-2075.1993.tb06192.x; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; Johnson CA, 1999, SEMIN CELL DEV BIOL, V10, P179, DOI 10.1006/scdb.1999.0299; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lehrmann H, 1999, J VIROL, V73, P6517, DOI 10.1128/JVI.73.8.6517-6525.1999; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; RAYCHAUDHURI P, 1989, GENE DEV, V3, P620, DOI 10.1101/gad.3.5.620; RIZOS H, 2002, J BIOL CHEM, V21, P21; Rooney RJ, 2001, CELL GROWTH DIFFER, V12, P505; Rooney RJ, 1998, MAMM GENOME, V9, P320, DOI 10.1007/s003359900758; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	26	10	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2541	2547		10.1038/sj.onc.1206379	http://dx.doi.org/10.1038/sj.onc.1206379			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730668				2022-12-17	WOS:000182569000001
J	Usui, K; Saijo, Y; Narumi, K; Koyama, S; Maemondo, M; Kikuchi, T; Tazawa, R; Hagiwara, K; Ishibashi, Y; Ohta, S; Nukiwa, T				Usui, K; Saijo, Y; Narumi, K; Koyama, S; Maemondo, M; Kikuchi, T; Tazawa, R; Hagiwara, K; Ishibashi, Y; Ohta, S; Nukiwa, T			N-terminal deletion augments the cell-death-inducing activity of BAX in adenoviral gene delivery to nonsmall cell lung cancers	ONCOGENE			English	Article						BAX; apoptosis; gene therapy	MITOCHONDRIAL DYSFUNCTION; BACTERIAL DEATH; BCL-2 PROTEIN; CYTOCHROME-C; IN-VIVO; APOPTOSIS; EXPRESSION; THERAPY; OVEREXPRESSION; DIMERIZATION	Therapeutic modalities that overcome the antiapoptotic function of Bcl-2 that is often overexpressed in cancer cells are expected to be a novel strategy for cancer treatment. We previously reported that the leukemic cell death induced by an N-terminally truncated Bax (DeltaN Bax: corresponding to amino acid 112-192 of full-length Bax) was not blocked by Bcl-2 or Bcl-x(L) owing to the lack of the BH3 domain needed to interact with the antiapoptotic Bcl-2 family molecules. In this study, we used the Cre-loxP system that allowed us to propagate adenoviruses expressing DeltaN Bax, and investigated the effects of the DeltaN Bax gene transfer into A549 and NCI-H1299 nonsmall cell lung cancer cell tines. DeltaN Bax showed more cell-death-inducing activity in both cells than did the full-length Bax in vitro. It was found that the DeltaN Bax-induced cell death was not inhibited by the pan-caspase inhibitor z-VAD-fmk, suggesting that DeltaN Bax induces cell death through a caspase-independent mechanism. Intratumoral injection of adenoviruses expressing AN Bax into A549 tumors in Balb/c nude mice showed a significantly stronger suppression of tumor growth (74%) than full-length Bax (25%) compared to the control. Our results suggest that DeltaN Bax may provide a better alternative than currently used cytotoxic genes in cancer gene therapy trials.	Tohoku Univ, Grad Sch Med, Dept Mol Med & Gene Transfer Res, Aoba Ku, Sendai, Miyagi 9808575, Japan; Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Aoba Ku, Sendai, Miyagi 9808575, Japan; Nippon Med Coll, Inst Gerontol, Dept Biochem & Cell Biol, Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Tohoku University; Tohoku University; Nippon Medical School	Saijo, Y (corresponding author), Tohoku Univ, Grad Sch Med, Dept Mol Med & Gene Transfer Res, Aoba Ku, 2-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.	yasoj@idac.tohoku.ac.jp	Tazawa, Ryushi/AAM-6915-2020; Koyama, Shohei/AAU-4113-2021	Tazawa, Ryushi/0000-0002-4580-004X; Koyama, Shohei/0000-0002-6897-9417; Usui, Kazuhiro/0000-0002-4492-9327				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Aritomi M, 1997, J BIOL CHEM, V272, P27886, DOI 10.1074/jbc.272.44.27886; Asoh S, 1998, J BIOL CHEM, V273, P11384, DOI 10.1074/jbc.273.18.11384; BECK WT, 1997, CANER PRINCIPLES PRA, P333; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gu J, 2002, GENE THER, V9, P30, DOI 10.1038/sj.gt.3301619; Gu J, 2000, CANCER RES, V60, P5359; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; Hunter JJ, 1996, J BIOL CHEM, V271, P8521, DOI 10.1074/jbc.271.15.8521; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; IKEGAKI N, 1994, CANCER RES, V54, P6; Ishibashi Y, 1998, BIOCHEM BIOPH RES CO, V243, P609, DOI 10.1006/bbrc.1998.8145; Joseph B, 2002, ONCOGENE, V21, P65, DOI 10.1038/sj/onc/1205018; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kagawa S, 2000, GENE THER, V7, P75, DOI 10.1038/sj.gt.3301048; Kagawa S, 2000, CANCER RES, V60, P1157; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P186; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Mohiuddin M, 2001, CANCER GENE THER, V8, P547, DOI 10.1038/sj.cgt.7700332; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tai YT, 1999, CANCER RES, V59, P2121; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Tamm I, 1998, CANCER RES, V58, P5315; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; Wu CH, 2002, ONCOGENE, V21, P5160, DOI 10.1038/sj.onc.1205639; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yamashita YI, 2002, HUM GENE THER, V13, P275, DOI 10.1089/10430340252769798; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	45	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2003	22	17					2655	2663		10.1038/sj.onc.1206331	http://dx.doi.org/10.1038/sj.onc.1206331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730679	Bronze			2022-12-17	WOS:000182569000013
J	Maclaren, A; Clark, W; Black, EJ; Gregory, D; Fujii, H; Gillespie, DAF				Maclaren, A; Clark, W; Black, EJ; Gregory, D; Fujii, H; Gillespie, DAF			v-Jun stimulates both cdk2 kinase activity and G1/S progression via transcriptional repression of p2l CIP1	ONCOGENE			English	Article						Jun; p21CIP1; p53	S-PHASE ENTRY; C-JUN; CELL-CYCLE; GROWTH-FACTOR; GENE-EXPRESSION; HUMAN CANCER; DNA-DAMAGE; TRANSFORMATION; PROMOTER; P53	Previous studies have shown that the viral Jun (v-Jun) oncoprotein induces marked alterations in cell cycle control, which are associated with, and may be caused by, increased cdk2 kinase activity. Since p21 CIP1 is an important regulator of cdk2, we investigated whether aberrant expression of this cyclin-dependent kinase inhibitor might contribute to cell cycle deregulation by v-Jun. We find that the basal levels of p21 CIP1 mRNA and protein expression are greatly reduced in chick embryo fibroblasts (CEF) transformed by v-Jun, and that v-Jun blocks the increases in p21 CIP1 expression that normally accompany growth inhibition induced by serum deprivation or confluency in untransformed CEF. Importantly, ectopic expression of p21 CIP1 in v-Juntransformed CEF inhibits both cdk2 kinase activity and cell cycle progression, indicating that these alterations in p21 CIP1 expression are likely to be functionally significant for growth deregulation. We also investigated the mechanism through which v-Jun disturbs p21 CIP1 expression and the possible involvement of a known p21 CIP1 regulator, p53, as an intermediate in this process. This analysis revealed that repression is mediated primarily at the level of p21 CIP1 gene transcription, however the mechanism is complex; both p53-dependent and -independent mechanisms contribute as judged by analysis of p21 CIP1 promoter mutants and other assays of p53 transcriptional activity.	Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Canc Res UK Dev Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England	Beatson Institute; University of Glasgow; University of Dundee; Cancer Research UK	Maclaren, A (corresponding author), Beatson Inst Canc Res, Garscube Estate,Switchback Rd,Bearsden, Glasgow G61 1BD, Lanark, Scotland.		Gregory, David/P-2582-2015; Gillespie, David/R-4771-2019	Gregory, David/0000-0001-6534-7150; Gillespie, David/0000-0002-6338-0544				Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, ONCOGENE, V16, P443, DOI 10.1038/sj.onc.1201577; Fu SL, 2000, ONCOGENE, V19, P3537, DOI 10.1038/sj.onc.1203691; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Givol I, 1995, ONCOGENE, V11, P2609; Haapajarvi T, 1999, EXP CELL RES, V248, P272, DOI 10.1006/excr.1999.4403; Hadman M, 1996, ONCOGENE, V12, P135; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JUVEN T, 1993, ONCOGENE, V8, P3411; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kilbey A, 1996, ONCOGENE, V12, P2409; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MacLaren A, 2000, ONCOGENE, V19, P5906, DOI 10.1038/sj.onc.1203954; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wu RC, 1997, J BIOL CHEM, V272, P29091, DOI 10.1074/jbc.272.46.29091	41	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2003	22	16					2383	2395		10.1038/sj.onc.1206329	http://dx.doi.org/10.1038/sj.onc.1206329			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	670AD	12717415				2022-12-17	WOS:000182383500001
J	Loreto, MP; McGlade, CJ				Loreto, MP; McGlade, CJ			Cloning and characterization of human Src-like adaptor protein 2 and a novel splice isoform, SLAP-2-v	ONCOGENE			English	Article						adaptor protein; SLAP-2; SLAP; splice variant; TCR; myeloid; chromosome 20q	T-CELL RECEPTOR; TYROSINE KINASE; C-CBL; PHOSPHORYLATION SITE; NEGATIVE REGULATOR; MYELOID-LEUKEMIA; ZAP-70; LAT; IDENTIFICATION; THYMOCYTES	Src-like adaptor protein 2 (SLAP-2) is a recently characterized adaptor protein bearing sequence and structural similarity to the Src-like adaptor protein (SLAP). SLAP-2 expression is hematopoietic-specific, and it has been demonstrated to function as a negative regulator of T-cell antigen receptor (TCR)-mediated signalling by virtue of its interaction with c-Cbl. Here we report the cloning of a cDNA encoding the human homologue of SLAP-2, as well as the genomic structure of the human SLAP-2 gene. Similar to its murine counterpart, two human SLAP-2 protein isoforms exist because of alternative translation initiation, and SLAP-2 protein expression is observed in a variety of hernatopoietic cell tines of both lymphoid and myeloid lineages. The human SLAP-2 gene is located on chromosome 20q, and the SLAP-2 coding region consists of seven exons. Concurrent with the cloning of the full-length SLAP-2 cDNA, a unique cDNA encoding an alternatively spliced SLAP-2 isoform has been identified, and designated as SLAP-2-v. The SLAP-2-v transcript encodes a putative protein of 210 amino acids that lacks the c-Cbl interaction region, and consequently is impaired in its ability to both bind to c-Cbl, and inhibit TCR signalling relative to SLAP-2.	Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	McGlade, CJ (corresponding author), Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, 555 Univ Ave,Rm 3020B, Toronto, ON M5G 1X8, Canada.							Berry DM, 2001, ONCOGENE, V20, P1203, DOI 10.1038/sj.onc.1204218; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Holland SJ, 2001, J EXP MED, V194, P1263, DOI 10.1084/jem.194.9.1263; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kratchmarova I, 2001, GENE, V262, P267, DOI 10.1016/S0378-1119(00)00516-3; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Loreto MP, 2002, MOL CELL BIOL, V22, P4241, DOI 10.1128/MCB.22.12.4241-4255.2002; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; MacGrogan D, 2001, ONCOGENE, V20, P4150, DOI 10.1038/sj.onc.1204540; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Pandey A, 2002, J BIOL CHEM, V277, P19131, DOI 10.1074/jbc.M110318200; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; ROULSTON D, 1993, BLOOD, V82, P3424; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Thien CBF, 1999, J IMMUNOL, V162, P7133; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	23	10	12	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 16	2003	22	2					266	273		10.1038/sj.onc.1206114	http://dx.doi.org/10.1038/sj.onc.1206114			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527895				2022-12-17	WOS:000180322400011
J	Soe, K; Hartmann, H; Schlott, B; Stevnsner, T; Grosse, F				Soe, K; Hartmann, H; Schlott, B; Stevnsner, T; Grosse, F			The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro	ONCOGENE			English	Article						topoisomerase I; p53; DNA damage; repair; recombination; genomic instability	DOUBLE-STRAND BREAKS; INDUCED DNA-DAMAGE; WILD-TYPE; COVALENT COMPLEXES; TERMINAL DOMAIN; REPLICATING DNA; T-ANTIGEN; REPAIR; CAMPTOTHECIN; CELLS	Previous studies have shown that human topoisomerase I interacts directly with the tumor-suppressor protein p53. In the past few years it has repeatedly been suggested that topoisomerase I and p53 may play a joint role in the response to genotoxic stress. This led to the suggestion that p53 and human topoisomerase I may cooperate in the process of DNA repair and/or apoptosis. Recently we have demonstrated that a human topoisomerase I cleavage complex can be recognized by an additional topoisomerase I molecule and thereby form a so-called double cleavage complex. The double cleavage complex creates an about 13 nucleotides long single-stranded gap that may provide an entry site for recombinational repair events. Here we demonstrate that p53 stimulates both the DNA relaxation activity as well as the formation of the human topoisomerase I double cleavage complex by at least a factor of six. Stimulation of topoisomerase I activity by p53 is mediated via the central part of topoisomerase I. We also show that human, bovine, and murine p53 stimulate human topoisomerase I relaxation activity equally well. From these results it is conceivable that p53's stimulatory activity on topoisomerase I may play a role in DNA recombination and repair as well as in apoptosis.	Inst Mol Biotechnol, Dept Biochem, D-07745 Jena, Germany; Aarhus Univ, Dept Biol Mol & Struct, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark	Aarhus University	Grosse, F (corresponding author), Inst Mol Biotechnol, Dept Biochem, Beutenbergstr 11, D-07745 Jena, Germany.		Soe, Kent/N-3618-2017	Soe, Kent/0000-0001-7402-314X; Hartmann, Hella/0000-0002-7133-7474; Stevnsner, Tinna/0000-0003-1007-0427				Albor A, 1998, CANCER RES, V58, P2091; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao YA, 1997, CANCER RES, V57, P5584; Christiansen K, 1999, BBA-GENE STRUCT EXPR, V1489, P249, DOI 10.1016/S0167-4781(99)00198-0; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEQUIEDT F, 1995, DNA SEQUENCE, V5, P261, DOI 10.3109/10425179509030977; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FROSINA G, 1992, CARCINOGENESIS, V13, P1371, DOI 10.1093/carcin/13.8.1371; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JONES JC, 1991, MUTAT RES, V255, P155, DOI 10.1016/0921-8777(91)90049-U; Labourier E, 1998, NUCLEIC ACIDS RES, V26, P2955, DOI 10.1093/nar/26.12.2955; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sigal A, 2000, CANCER RES, V60, P6788; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; Soe K, 2001, NUCLEIC ACIDS RES, V29, P3195, DOI 10.1093/nar/29.15.3195; SQUIRES S, 1991, J CELL SCI, V100, P883; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; STEWART AF, 1990, CELL, V60, P141; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Subramanian D, 1998, CANCER RES, V58, P976; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; TSAO YP, 1993, CANCER RES, V53, P5908; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	50	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6614	6623		10.1038/sj.onc.1205912	http://dx.doi.org/10.1038/sj.onc.1205912			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242659				2022-12-17	WOS:000178202300007
J	Dupre, A; Suziedelis, K; Valuckaite, R; de Gunzburg, J; Ozon, R; Jessus, C; Haccard, O				Dupre, A; Suziedelis, K; Valuckaite, R; de Gunzburg, J; Ozon, R; Jessus, C; Haccard, O			Xenopus H-RasV12 promotes entry into meiotic M phase and cdc2 activation independently of Mos and p42(MAPK)	ONCOGENE			English	Article						Ras; Xenopus oocyte; cdc2; p42(MAPK); Mos	MAP KINASE PATHWAY; SIGNAL-TRANSDUCTION; MPF ACTIVATION; ONCOGENIC RAS; IN-VITRO; OOCYTES; MATURATION; PROTEINS; INDUCTION; PHOSPHORYLATION	In the Xenopus oocyte, progesterone triggers M phase Promoting Factor (MPF) activation in a protein synthesis dependent manner. Although the synthesis of the p42(MAPK) activator Mos appears to be required for MPF activation, p42(MAPK) activity has been shown to be dispensable. To clarify this paradox, we attempted to activate the p42(MAPK) pathway independently of Mos synthesis by cloning and using Xenopus H-Ras in the oocyte. We demonstrate that the injection of the constitutively active Xe H-RasV12 mutant induces p42(MAPK) and MPF activation through two independent pathways. Xe H-RasV12 induces only a partial activation of p42(MAPK) when protein synthesis and MPF activation are prevented. A full level of p42(MAPK) activation is reached when MPF is activated and Mos is present. In contrast, MPF activation induced by Xe H-RasV12 is achieved independently of Mos synthesis and p42(MAPK) activation but still depends on protein synthesis. Therefore, the amphibian oocyte represents a new model system to analyse an original H-Ras pathway ending to MPF activation and distinct from the p42(MAPK) pathway. The identification of the proteins synthesized in response to Xe H-RasV12 and required for MPF activation, represents an important clue in understanding the mechanism of progesterone action.	Univ Paris 06, INRA, Dev Biol Lab, CNRS,UMR 7622, F-75252 Paris 05, France; Vilnius State Univ, Dept Biochem & Biophys, LT-2009 Vilnius, Lithuania; Inst Curie, INSERM, U528, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Vilnius University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jessus, C (corresponding author), Univ Paris 06, INRA, Dev Biol Lab, CNRS,UMR 7622, Boite 24,4 Pl Jussieu, F-75252 Paris 05, France.	jessus@ccr.jussieu.fr		Haccard, Olivier/0000-0002-4305-2746				ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CARNERO A, 1994, J CELL BIOCHEM, V55, P465, DOI 10.1002/jcb.240550406; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DESMEDT V, 1995, FEBS LETT, V375, P249, DOI 10.1016/0014-5793(95)01183-F; Fisher DL, 1999, DEVELOPMENT, V126, P4537; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; FUKUDA M, 1994, J BIOL CHEM, V269, P33097; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gelb MH, 1997, SCIENCE, V275, P1750, DOI 10.1126/science.275.5307.1750; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; Hochegger H, 2001, DEVELOPMENT, V128, P3795; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; JESSUS C, 1987, J CELL SCI, V87, P705; Jessus C, 1998, BIOL CELL, V90, P573, DOI 10.1016/S0248-4900(99)80015-X; JESSUS C, 1991, DEVELOPMENT, V111, P813; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez-Hernandez E, 1999, FEBS LETT, V451, P284, DOI 10.1016/S0014-5793(99)00595-5; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; MULNERLORILLON O, 1995, DEV BIOL, V170, P223, DOI 10.1006/dbio.1995.1209; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; Pomerance M, 1996, MOL CELL BIOL, V16, P3179; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Rime H, 1998, DEV BIOL, V204, P592, DOI 10.1006/dbio.1998.9069; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Taieb F, 1997, MOL REPROD DEV, V48, P397, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;397::AID-MRD14&gt;3.0.CO;2-T; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1	39	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6425	6433		10.1038/sj.onc.1205827	http://dx.doi.org/10.1038/sj.onc.1205827			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226746				2022-12-17	WOS:000177925300003
J	Shakked, Z; Yavnilovitch, M; Kalb, AJ; Kessler, N; Wolkowicz, R; Rotter, V; Haran, TE				Shakked, Z; Yavnilovitch, M; Kalb, AJ; Kessler, N; Wolkowicz, R; Rotter, V; Haran, TE			DNA binding and 3 '-5 ' exonuclease activity in the murine alternatively-spliced p53 protein	ONCOGENE			English	Article						alternatively-spliced p53; DNA binding; exonuclease activity; phosphorothioate-modified DNA-binding sites	SUBSTRATE-SPECIFICITY; TERMINAL DOMAIN; IN-VITRO; EXONUCLEASE; INVOLVEMENT; EXCISION; SITE; INHIBITION; TARGET; LATENT	In this study we show that the naturally occurring C-terminally alternative spliced p53 (referred to as AS-p53) is active as a sequence-specific DNA binding protein as well as a 3'-5'-exonuclease in the presence of Mg2+ ions. The two activities are positively correlated as the sequence-specific DNA target is more efficiently degraded than a non-specific target. In contrast, a mutated AS-p53 protein that is deficient in DNA binding lacks exonuclease activity. The use of modified p53 binding sites, where the 3'-phosphate is replaced by a phosphorothioate group, enabled the inhibition of DNA degradation under the binding conditions. We demonstrate that AS-p53 interacts with its specific DNA target by two distinct binding modes: a high-affinity mode characterized by a low-mobility protein-DNA complex at the nanomolar range, and a low-affinity mode shown by a high-mobility complex at the micromolar range. Comparison of the data on the natural and the modified p53 binding sites suggests that the high-affinity mode is related to AS-p53 function as a transcription factor and that the low-affinity mode is associated with its exonuclease activity. The implications of these findings to a specific cellular role of AS-p53 are discussed.	Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Technion Israel Institute of Technology	Shakked, Z (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	zippi.shakked@weizmann.ac.il; bitali@techunix.technion.ac.il	Haran, Tali E./AAF-7816-2021	Haran, Tali E./0000-0002-9700-3392				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Almog N, 2000, ONCOGENE, V19, P3395, DOI 10.1038/sj.onc.1203673; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Brautigam CA, 1998, J MOL BIOL, V277, P363, DOI 10.1006/jmbi.1997.1586; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.biochem.54.1.367; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Janus F, 1999, MOL CELL BIOL, V19, P2155; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kuhn C, 1999, ONCOGENE, V18, P769, DOI 10.1038/sj.onc.1202327; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LONGLEY MJ, 1991, J BIOL CHEM, V266, P24702; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Molinari M, 1996, ONCOGENE, V13, P2077; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Nichols NM, 2001, BIOCHEMISTRY-US, V40, P3847, DOI 10.1021/bi002088z; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; OKOROKOV AL, 1999, ONC RES, V9, P267; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Wang XW, 1997, J CELL PHYSIOL, V173, P247, DOI 10.1002/(SICI)1097-4652(199711)173:2<247::AID-JCP30>3.0.CO;2-A; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	51	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2002	21	33					5117	5126		10.1038/sj.onc.1205667	http://dx.doi.org/10.1038/sj.onc.1205667			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140762				2022-12-17	WOS:000176975900010
J	Dilla, T; Romero, J; Sanstisteban, P; Velasco, JA				Dilla, T; Romero, J; Sanstisteban, P; Velasco, JA			The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation	ONCOGENE			English	Article						radiation; MDM2; E2F-1; medullary thyroid carcinoma	TRANSCRIPTION FACTOR E2F-1; DOWN-REGULATION; DNA-DAMAGE; WILD-TYPE; P53; ONCOGENE; APOPTOSIS; CYCLE; OVEREXPRESSION; SUPPRESSION	We have analysed the radiation response of a human medullary thyroid carcinoma cell line (MTT), characterized by the absence of a functional p53 protein, and the consequences of MDM2 overexpression in this process. We show that the product of the mdm2 proto-oncogene is able to sensitize MTT cells to ionizing radiation. After radiation treatment, MTT cells display histograms consistent with a G2M arrest. MTT cells expressing MDM2 (MTT-mdm2) are unable to respond to DNA damage with G2M arrest, and display a high percentage of apoptosis. MTT-mdm2 cells show high levels of E2F-1 protein, suggesting that the induction of apoptosis observed upon MDM2 overexpression could be dependent on E2F-1. This observation is further supported with assays showing that E2F-1 binding to specific DNA sequences is enhanced in MTT-mdm2 cells. Likewise, transactivation of reporter constructs exclusively dependent on E2F-1 is also elevated after transfection with MDM2. This effect can be reverted by transient transfection with p19(ARF). To link the expression of E2F-1 with the induction of apoptosis, we generated clonal cell lines overexpressing E2F-1. Transfection with E2F-1 results in a low number of outgrowing colonies with reduced proliferation rates, indicating that E2F-1 is deleterious for cell growth. This negative regulation correlates with an increase in the percentage of the cell population with DNA content below 2N, suggesting that E2F-1 promotes apoptosis. Finally, overexpression of E2F-1 sensitizes MTT cells to radiation exposure. We conclude that the effects observed by MDM2 overexpression could be mediated by E2F-1.	CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Hosp Puerta Hierro, Dept Oncol Radioterap, Madrid, Spain; Ctr Nacl Invest Oncol Carlos III, Mol Oncol Lab, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda	Sanstisteban, P (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	psantisteban@iib.uam.es	Romero, Jesús/AAE-1899-2021	Romero, Jesús/0000-0001-8778-1388				ALBRIGHT N, 1987, RADIAT RES, V112, P331, DOI 10.2307/3577260; Alkhalaf M, 1999, ONCOGENE, V18, P1419, DOI 10.1038/sj.onc.1202448; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Banerjee D, 1998, CANCER RES, V58, P4292; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CACHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235; CARLOMAGNO F, 1995, BIOCHEM BIOPH RES CO, V207, P1022, DOI 10.1006/bbrc.1995.1287; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Dilla T, 2000, ENDOCRINOLOGY, V141, P420, DOI 10.1210/en.141.1.420; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Ganguli G, 2000, EMBO J, V19, P5135, DOI 10.1093/emboj/19.19.5135; Giuffrida D, 1998, ANN ONCOL, V9, P695, DOI 10.1023/A:1008242302749; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Heshmati HM, 1997, AM J MED, V103, P60, DOI 10.1016/S0002-9343(97)00024-7; Hunt KK, 1997, CANCER RES, V57, P4722; Hwang A, 1998, RADIAT RES, V150, pS52, DOI 10.2307/3579808; Iliakis G, 1997, SEMIN ONCOL, V24, P602; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KELLE DE, 1995, CELL, V83, P993; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leong S, 1981, ADV THYROID NEOPLASI, P95; Lin WC, 2001, GENE DEV, V15, P1833; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; Lozano G, 1998, BBA-REV CANCER, V1377, pM55, DOI 10.1016/S0304-419X(97)00037-1; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NELKIN BD, 1989, JAMA-J AM MED ASSOC, V261, P3130, DOI 10.1001/jama.261.21.3130; Ohtani Kiyoshi, 1999, Frontiers in Bioscience, V4, pd793, DOI 10.2741/Ohtani; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OSWALD F, 1994, ONCOGENE, V9, P2029; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; Pruschy M, 1999, CELL GROWTH DIFFER, V10, P141; Puxeddu E, 2001, ENDOCRIN METAB CLIN, V30, P493, DOI 10.1016/S0889-8529(05)70196-1; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932; Varghese S, 1998, ARCH PHARM RES, V21, P640, DOI 10.1007/BF02976750; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; Velasco JA, 1997, INT J CANCER, V73, P449, DOI 10.1002/(SICI)1097-0215(19971104)73:3<449::AID-IJC21>3.0.CO;2-6; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang RW, 2000, CURR PHARM DESIGN, V6, P393, DOI 10.2174/1381612003400911; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	52	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2376	2386		10.1038/sj.onc.1205307	http://dx.doi.org/10.1038/sj.onc.1205307			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948421				2022-12-17	WOS:000174635600010
J	Hu, J; Schuster, AE; Fritsch, MK; Schneider, DT; Lauer, S; Perlman, EJ				Hu, J; Schuster, AE; Fritsch, MK; Schneider, DT; Lauer, S; Perlman, EJ			Deletion mapping of 6q21-26 and frequency of 1p36 deletion in childhood endodermal sinus tumors by microsatellite analysis	ONCOGENE			English	Article						germ cell tumor; endodermal sinus tumor; 6q; 1p36; IGF2R	GERM-CELL TUMORS; COMPARATIVE GENOMIC HYBRIDIZATION; PEDIATRIC-ONCOLOGY-GROUP; ALLELIC LOSS; GENETIC-ANALYSIS; PROSTATE-CANCER; SUPPRESSOR GENE; BREAST-CANCER; CHROMOSOME 6Q; HETEROZYGOSITY	The most common malignant germ cell tumor of early childhood is the endodermal sinus tumor (CEST), also known as yolk sac tumor. Previous cytogenetic studies of CEST have demonstrated recurrent deletion of distal regions of chromosomes lp and 6q. Studies utilizing comparative genomic hybridization have likewise demonstrated loss of distal 6q, however these studies show discrepant data concerning chromosome I abnormalities. This study analyses 18 CESTs for loss of heterozygosity (LOH) of distal chromosome 6q utilizing 17 microsatellite markers and 13 tumors were analysed for LOH of distal lp using two microsatellite markers. LOH of 6q was found in 13/18 tumors (72%). This data confirms that loss of genetic material on 6q is one of the most common abnormalities in CESTs and narrows the region of loss, enabling candidate tumor suppressor genes to be identified and analysed. In addition, LOH of 1p36 was identified in five of 11 informative tumors, clarifying prior conflicting data and confirming that lp deletion is a common event in CESTs.	Johns Hopkins Med Inst, Div Pediat Pathol, Baltimore, MD 21287 USA; Emory Univ, Div Pediat Hematol Oncol, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins Medicine; Emory University	Perlman, EJ (corresponding author), Johns Hopkins Univ Hosp, Meyer 7-181,600 N Wolfe St, Baltimore, MD 21287 USA.			Schneider, Dominik T./0000-0001-8153-1601; Hu, Jie/0000-0001-9314-9506; Perlman, Elizabeth/0000-0001-6853-6221	NATIONAL CANCER INSTITUTE [U10CA020549, U10CA028476] Funding Source: NIH RePORTER; NCI NIH HHS [CA28476, CA20549] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGHORN A, 2001, AM J PATHOL, V158, P1903; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CASTEDO SMMJ, 1989, CANCER RES, V49, P5696; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooney KA, 1996, CANCER RES, V56, P4150; DEMANOIR S, 1995, CYTOMETRY, V19, P27; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; GIBAS Z, 1984, J UROLOGY, V131, P762, DOI 10.1016/S0022-5347(17)50613-8; Hankins GR, 1996, ONCOGENE, V12, P2003; MATHEW S, 1994, CANCER RES, V54, P6265; OOSTERHUIS JW, 1988, CANCER GENET CYTOGEN, V36, P7; Perlman EJ, 1996, GENE CHROMOSOME CANC, V16, P15, DOI 10.1002/(SICI)1098-2264(199605)16:1<15::AID-GCC2>3.0.CO;2-6; Perlman EJ, 2000, J PEDIAT HEMATOL ONC, V22, P100, DOI 10.1097/00043426-200003000-00003; PERLMAN EJ, 1994, PEDIATR PATHOL, V14, P695, DOI 10.3109/15513819409023342; Riopel MA, 1998, CANCER RES, V58, P3105; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; SAITO S, 1992, CANCER RES, V52, P5815; Srikantan V, 1999, INT J CANCER, V84, P331, DOI 10.1002/(SICI)1097-0215(19990621)84:3<331::AID-IJC23>3.0.CO;2-J; STOCK C, 1994, GENE CHROMOSOME CANC, V11, P40, DOI 10.1002/gcc.2870110107; Theile M, 1996, ONCOGENE, V13, P677; Utada Y, 2000, JPN J CANCER RES, V91, P293, DOI 10.1111/j.1349-7006.2000.tb00944.x	24	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 29	2001	20	55					8042	8044		10.1038/sj.onc.1204961	http://dx.doi.org/10.1038/sj.onc.1204961			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	494NL	11753688	Bronze			2022-12-17	WOS:000172288700014
J	Steinman, RA; Lu, YL; Yaroslavskiy, B; Stehle, C				Steinman, RA; Lu, YL; Yaroslavskiy, B; Stehle, C			Cell cycle-independent upregulation of p27Kip1 by p21Waf1 in K562 cells	ONCOGENE			English	Article						p21Waf1; p27Kip1; differentiation; cell cycle	DEPENDENT-KINASE INHIBITOR; CDK-INHIBITOR; MYELOID CELLS; IN-VITRO; P27(KIP1); P27; DIFFERENTIATION; PHOSPHORYLATION; P21(WAF1/CIP1); EXPRESSION	Cellular differentiation frequently involves sequential peaks in the expression of cyclin-dependent kinase inhibitors (cdki's). For example, an increase in levels of the cdki p27Kip1 follows upregulation of p21Waf1 in several cell types induced to differentiate by diverse stimuli. In this study, we have investigated whether p21Waf1 expression itself, rather than the differentiating agent, could be increasing p27Kip1 protein levels. We used an inducible p21Waf1 expression vector in a K562 leukemic cell model which we had previously shown to initiate differentiation following p21Waf1 upregulation. The current study reports that p21Waf1 upregulated p27Kip1 protein without altering p27Kip1 mRNA levels. This effect did not depend on Gl-phase arrest-the increase in p27Kip1 occurred at all phases of the cell cycle. p21Waf1-expressing extracts inhibited phosphorylation of p27Kip1 on threonine-187, leading to decreased ubiquitination and decreased proteasomal destruction of p27Kip1. In K562 cells, upregulation of p27Kip1 by p21Waf1 during differentiation facilitated an ordered transition between these two cdki's, each of which may distinctly influence the differentiation process.	Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Steinman, RA (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, E1052 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.	Steinman@imap.pitt.edu						Alessandrini A, 1997, LEUKEMIA, V11, P342, DOI 10.1038/sj.leu.2400581; Baldassarre G, 2000, CELL GROWTH DIFFER, V11, P517; Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chen YJ, 1999, EUR J CELL BIOL, V78, P824, DOI 10.1016/S0171-9335(99)80033-8; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Ghiani CA, 1999, DEVELOPMENT, V126, P1077; Harvat BL, 1998, J CELL SCI, V111, P1185; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hsieh FF, 2000, BLOOD, V96, P2746, DOI 10.1182/blood.V96.8.2746.h8002746_2746_2754; Huss R, 1999, BRIT J CANCER, V81, P808, DOI 10.1038/sj.bjc.6690768; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Liu JB, 2000, ONCOGENE, V19, P661, DOI 10.1038/sj.onc.1203373; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Morisaki H, 1997, BIOCHEM BIOPH RES CO, V240, P386, DOI 10.1006/bbrc.1997.7590; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Muto A, 1999, BLOOD, V93, P2225, DOI 10.1182/blood.V93.7.2225.407a05_2225_2233; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Panzenbock B, 1998, BLOOD, V92, P3658, DOI 10.1182/blood.V92.10.3658.422k18_3658_3668; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Tam S. W., 1997, Leukemia (Basingstoke), V11, P363; Taniguchi T, 1999, BLOOD, V93, P4167, DOI 10.1182/blood.V93.12.4167.412k05_4167_4178; Tian JQ, 1999, AM J PHYSIOL-CELL PH, V276, pC1245, DOI 10.1152/ajpcell.1999.276.6.C1245; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Urashima M, 1997, BLOOD, V90, P279; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Wagner EF, 1998, J IMMUNOL, V161, P1123; Xu X, 1999, BIOCHEMISTRY-US, V38, P8713; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	46	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2001	20	45					6524	6530		10.1038/sj.onc.1204800	http://dx.doi.org/10.1038/sj.onc.1204800			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641776				2022-12-17	WOS:000171404200004
J	de Leeuw, WJF; van Puijenbroek, M; Merx, R; Wijnen, JT; Brocker-Vriends, AHJT; Tops, C; Vasen, H; Cornelisse, CJ; Morreau, H				de Leeuw, WJF; van Puijenbroek, M; Merx, R; Wijnen, JT; Brocker-Vriends, AHJT; Tops, C; Vasen, H; Cornelisse, CJ; Morreau, H			Bias in detection of instability of the (C)8 mononucleotide repeat of MSH6 in tumours from HNPCC patients	ONCOGENE			English	Article						HNPCC; MSI; MSH6; repeat; microsatellite	NONPOLYPOSIS COLORECTAL-CANCER; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATIONS; CARCINOMAS; TUMORS	Recently, we and others reported instability in the (C)8 repeat in exon 5 of MSH6 as a preferential target for somatic mutations in tumours from MSH6 germline mutation carriers. Here, we report that in 45% of tumours from MLH1, MSH2 and MSH6 germline mutation carriers no sequence change in the (C)8 repeat of MSH6 was found upon DNA sequencing analysis of PCR products with a shift in electrophoresis mobility. Using 'standard' PCR primers a high frequency of instability (50-86%) of the (C)8 repeat was found, but using a modified PCR reverse primer, accomplishing modulation of non-templated addition of adenine during in vitro PCR amplification by the Taq polymerase, a markedly lower frequency of instability was found in turnours from MLH1, MSH2 and MSH6 mutation carriers (6, 13 and 40%, respectively). Furthermore, a significant difference of the frequency of instability of the (C)8 repeat in tumours from MSH6 mutation carriers was found compared to MLH1, MSH2 mutation carriers. These results might have important implications for the detection of instability of other short mononucleotide repeats, e.g. TGF beta RII, BAX, IGFRII, PTEN, BRCA2.	Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Human & Clin Genet, MGC, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Fdt Detect Hereditary Tumours, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	de Leeuw, WJF (corresponding author), Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RA Leiden, Netherlands.			Vasen, Hans/0000-0003-2682-2603				Akiyama Y, 1996, CANCER-AM CANCER SOC, V78, P2478, DOI 10.1002/(SICI)1097-0142(19961215)78:12<2478::AID-CNCR5>3.0.CO;2-G; Akiyama Y, 1997, CANCER RES, V57, P3920; Boland CR, 1998, CANCER RES, V58, P5248; Brownstein MJ, 1996, BIOTECHNIQUES, V20, P1004, DOI 10.2144/96206st01; de Leeuw WJF, 2000, J PATHOL, V192, P328, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kolodner RD, 1999, CANCER RES, V59, P5068; Koul A, 1999, GENE CHROMOSOME CANC, V24, P207, DOI 10.1002/(SICI)1098-2264(199903)24:3<207::AID-GCC5>3.0.CO;2-3; Magnuson VL, 1996, BIOTECHNIQUES, V21, P700, DOI 10.2144/96214rr03; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; PARSONS R, 1995, CANCER RES, V55, P5548; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Planck M, 2000, GENE CHROMOSOME CANC, V29, P33, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1004>3.0.CO;2-R; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SMITH JR, 1995, GENOME RES, V5, P312, DOI 10.1101/gr.5.3.312; SOUZA RF, 1996, NAT GENET, V14, P2255; Togo G, 1996, CANCER RES, V56, P5620; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773; Wu Y, 1999, AM J HUM GENET, V65, P1291, DOI 10.1086/302612	23	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6241	6244		10.1038/sj.onc.1204795	http://dx.doi.org/10.1038/sj.onc.1204795			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593433				2022-12-17	WOS:000171206300016
J	Matthews, CP; Shera, K; Kiviat, N; McDougall, JK				Matthews, CP; Shera, K; Kiviat, N; McDougall, JK			Expression of truncated FHIT transcripts in cervical cancers and in normal human cells	ONCOGENE			English	Article						cervical carcinoma; FHIT; alternative transcripts	TUMOR-SUPPRESSOR GENE; SPLICE-SITE SELECTION; FREQUENT ALLELIC LOSS; MESSENGER-RNA; CHROMOSOME 3P; HUMAN HOMOLOG; UPF1 PROTEIN; CARCINOMA; TUMORIGENICITY; ABNORMALITIES	To analyse FHIT transcription patterns in cervical cancer, a series of primary cervical tumors and normal control samples were studied using RT - PCR. Full length and truncated FHIT transcripts were detectable in all samples tested. Interestingly, the expression of truncated FHIT transcripts by primary epithelial cells in vitro was associated with confluency. The breakpoints of most transcript deletions coincided with genuine splice site sequences, suggesting that they resulted from alternative splicing. These findings demonstrate that truncated FHIT transcripts are commonly detected in both normal and tumor tissues, and suggest that these altered transcripts are not causally related to tumorigenesis in cervical cancer.	Fred Hutchinson Canc Res Ctr, Canc Biol Program, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Matthews, CP (corresponding author), Fred Hutchinson Canc Res Ctr, Canc Biol Program, 1100 Fairview Ave N,POB 19024, Seattle, WA 98109 USA.				NCI NIH HHS [CA42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Applequist SE, 1997, NUCLEIC ACIDS RES, V25, P814, DOI 10.1093/nar/25.4.814; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Chaudhuri AR, 1999, J BIOL CHEM, V274, P24378, DOI 10.1074/jbc.274.34.24378; Chu TY, 1998, INT J CANCER, V75, P199, DOI 10.1002/(SICI)1097-0215(19980119)75:2<199::AID-IJC6>3.0.CO;2-P; Cooper TA, 1997, AM J HUM GENET, V61, P259, DOI 10.1086/514856; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Ferrer M, 1999, MOL CARCINOGEN, V25, P55, DOI 10.1002/(SICI)1098-2744(199905)25:1<55::AID-MC7>3.0.CO;2-3; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; Julicher K, 1999, J NATL CANCER I, V91, P1563, DOI 10.1093/jnci/91.18.1563; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KOHNO T, 1993, ONCOGENE, V8, P1825; Larson AA, 1997, CANCER RES, V57, P4082; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Lima CD, 1996, P NATL ACAD SCI USA, V93, P5357, DOI 10.1073/pnas.93.11.5357; Mao L, 1998, J NATL CANCER I, V90, P412, DOI 10.1093/jnci/90.6.412; Mao L, 1996, CANCER RES, V56, P5128; Matthews CP, 2000, P SOC EXP BIOL MED, V223, P316, DOI 10.1046/j.1525-1373.2000.22345.x; MATTHEWS CP, 2000, THESIS U WASHINGTON; MITRA AB, 1994, CANCER RES, V54, P4481; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Otterson GA, 1998, J NATL CANCER I, V90, P426, DOI 10.1093/jnci/90.6.426; Panagopoulos I, 1997, GENE CHROMOSOME CANC, V19, P215, DOI 10.1002/(SICI)1098-2264(199708)19:4<215::AID-GCC2>3.0.CO;2-#; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; Sambrook J, 1989, MOL CLONING LAB MANU; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Segawa T, 1999, CANCER, V85, P2001, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2001::AID-CNCR18>3.0.CO;2-R; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sun XL, 1998, P NATL ACAD SCI USA, V95, P10009, DOI 10.1073/pnas.95.17.10009; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; vandenBerg A, 1997, GENE CHROMOSOME CANC, V19, P220, DOI 10.1002/(SICI)1098-2264(199708)19:4<220::AID-GCC3>3.0.CO;2-Z; Virgilio L, 1996, P NATL ACAD SCI USA, V93, P9770, DOI 10.1073/pnas.93.18.9770; Wang NM, 1999, INT J MOL MED, V3, P491; WHITE RA, 1990, CYTOMETRY, V11, P314, DOI 10.1002/cyto.990110214; Wistuba II, 1997, CANCER RES, V57, P3154; Wu R, 2000, J NATL CANCER I, V92, P338, DOI 10.1093/jnci/92.4.338; YOKOTA J, 1989, CANCER RES, V49, P3598; Zimonjic DB, 1997, CANCER RES, V57, P1166	47	10	15	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2001	20	34					4665	4675		10.1038/sj.onc.1204622	http://dx.doi.org/10.1038/sj.onc.1204622			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498789				2022-12-17	WOS:000170208600007
J	Brett, D; Kemmner, W; Koch, G; Roefzaad, C; Gross, S; Schlag, PM				Brett, D; Kemmner, W; Koch, G; Roefzaad, C; Gross, S; Schlag, PM			A rapid bioinformatic method identifies novel genes with direct clinical relevance to colon cancer	ONCOGENE			English	Article						EST; splicing variants; bioinformatic; colon cancer; metastasis; patient survival	COLORECTAL-CANCER; TUMOR	Identifying genes whose differential expression affect the survival of patients after primary tumor surgery is a major aim of clinical cancer research. To address this issue we combined rapid bioinformatic search algorithms with quantitative RT-PCR in a panel of clearly defined cases of colorectal carcinomas with detailed patient histories. Search algorithms were written that identified Expressed Sequence Tags (ESTs) from the Unigene EST collection of putative open reading frames (ORFs). Expression ratios of healthy to cancerous tissue of each Unigene ORF were calculated. The first 35 candidates arising from bioinformatic searches were examined for mRNA expression in a panel of 20 well documented cases of colon cancer. Four of these 35 genes showed significant correlations with histopathological parameters. Therefore, their expression was further analysed by quantitative RT-PCR in a larger patient cohort. Kaplan-Meier/log rank statistical tests of up to 49 patients in three of the four genes demonstrated significant association of gene expression with poor survival. All four genes demonstrated a strong association with metastatic tumor progression. Expression of the genes was localized to epithelial cells by in-situ hybridization.	Max Delbruck Ctr Mol Med, Klinikum Charite, Robert Rossle Klin, Dept Surg & Surg Oncol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Bioinformat, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kemmner, W (corresponding author), Max Delbruck Ctr Mol Med, Klinikum Charite, Robert Rossle Klin, Dept Surg & Surg Oncol, Lindenberger Weg 80, D-13125 Berlin, Germany.							BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Gazelle GS, 2000, RADIOLOGY, V215, P327, DOI 10.1148/radiology.215.2.r00ma19327; Halaschek-Wiener J, 2000, MOL MED, V6, P693, DOI 10.1007/BF03402049; Kim JC, 2000, CANCER RES, V60, P4825; Lal A, 1999, CANCER RES, V59, P5403; McLeod HL, 1999, BRIT J CANCER, V79, P191, DOI 10.1038/sj.bjc.6690033; Schmitt AO, 1999, NUCLEIC ACIDS RES, V27, P4251, DOI 10.1093/nar/27.21.4251; SCHNEIDER F, 2001, IN PRESS CANC RES; STEINBERG SM, 1986, CANCER-AM CANCER SOC, V57, P1866, DOI 10.1002/1097-0142(19860501)57:9<1866::AID-CNCR2820570928>3.0.CO;2-T; Verdecchia A, 1998, INT J CANCER, V77, P322, DOI 10.1002/(SICI)1097-0215(19980729)77:3<322::AID-IJC2>3.0.CO;2-Q	10	10	10	1	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2001	20	33					4581	4585		10.1038/sj.onc.1204610	http://dx.doi.org/10.1038/sj.onc.1204610			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456GN	11494154				2022-12-17	WOS:000170074900016
J	Montpetit, A; Sinnett, D				Montpetit, A; Sinnett, D			Comparative analysis of the ETV6 gene in vertebrate genomes from pufferfish to human	ONCOGENE			English	Article						ETV6; transcription factor; comparative genetics; vertebrate genomes; Fugu rubripes	CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FUGU RUBRIPES; TYROSINE KINASE; FUSION GENES; TEL; SEQUENCE; PROTEIN; MICE; TRANSFORMATION	The ETV6 gene encodes an Ets-like transcription factor that is frequently rearranged in leukemias. While some of the functions of ETV6 have been uncovered recently, little is known about the key structural elements involved. Comparative genome analysis may provide novel insights into gene evolution and functions. In this study, me cloned and sequenced the homologue of ETV6 from the compact genome of the pufferfish Fugu rubripes (fETV6). The genomic structure of the fETV6 gene was investigated by sequence analysis of a contig of genomic clones. The fETV6 gene, composed of eight exons, spans about 15 kb and is 16 times smaller than its human counterpart mainly because of the reduced intron size. Three of the seven introns of fETV are unusually large (more than 2 kb), including the 8.2 kb intron 2. The gene codes for a protein of 465 amino acids that is highly related to its human homologue, exhibiting an overall identity of 58% (72% similarity). To investigate the functional and evolutionary aspects of ETV6, we undertook a comparative analysis of this gene from various vertebrates (human, mouse, chicken, zebrafish and Fugu). As expected, the PNT and ETS domains were highly conserved, with on average 81 and 95% peptide sequence identity, respectively. In addition, we found several new highly conserved regions within the central section of the protein that are likely to represent further functional or structural domains, which may be associated with the transcription repression capacity of this protein. We also found conserved putative regulatory elements in the promoter as well as in the large intron 2 of fETV6. The information derived from this comparative analysis will serve as the basis for more precise functional studies of ETV6 gene regulation and function.	Hop St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Sinnett, D (corresponding author), Hop St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.		sinnett, daniel/S-4589-2017	sinnett, daniel/0000-0003-3625-6676				Aissani B, 1999, LEUKEMIA LYMPHOMA, V34, P231, DOI 10.3109/10428199909050948; APARICIO S, 1995, P NATL ACAD SCI USA, V92, P1684, DOI 10.1073/pnas.92.5.1684; Baens M, 1996, GENOME RES, V6, P404, DOI 10.1101/gr.6.5.404; BAXENDALE S, 1995, NAT GENET, V10, P67, DOI 10.1038/ng0595-67; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Caldas C, 1998, ONCOGENE, V16, P3233, DOI 10.1038/sj.onc.1201873; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carron C, 2000, BLOOD, V95, P3891; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Elgar G, 1996, TRENDS GENET, V12, P145, DOI 10.1016/0168-9525(96)10018-4; Gellner K, 1999, GENOME RES, V9, P251; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; How GF, 1996, GENOME RES, V6, P1185, DOI 10.1101/gr.6.12.1185; Kimura C, 1997, DEVELOPMENT, V124, P3929; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MASON PJ, 1995, GENOMICS, V26, P587, DOI 10.1016/0888-7543(95)80179-P; Miles C, 1998, P NATL ACAD SCI USA, V95, P13068, DOI 10.1073/pnas.95.22.13068; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowitch DH, 1998, DEVELOPMENT, V125, P2735; Rubnitz JE, 1999, LEUKEMIA, V13, P6, DOI 10.1038/sj.leu.2401258; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Van Rompaey L, 2000, ONCOGENE, V19, P5244, DOI 10.1038/sj.onc.1203899; Venkatesh B, 2000, FEBS LETT, V476, P3, DOI 10.1016/S0014-5793(00)01659-8; Villard L, 1998, GENE, V210, P17, DOI 10.1016/S0378-1119(98)00032-8; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0	41	10	10	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3437	3442		10.1038/sj.onc.1204444	http://dx.doi.org/10.1038/sj.onc.1204444			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423994				2022-12-17	WOS:000169248800014
J	Acquaviva, C; Salvat, C; Brockly, F; Bossis, G; Ferrara, P; Piechaczyk, M; Jariel-Encontre, I				Acquaviva, C; Salvat, C; Brockly, F; Bossis, G; Ferrara, P; Piechaczyk, M; Jariel-Encontre, I			Cellular and viral Fos proteins are degraded by different proteolytic systems	ONCOGENE			English	Article						c-Fos; v-Fos; proteasome; protein degradation	OSTEO-SARCOMA VIRUS; DEGRADATION IN-VIVO; FBR V-FOS; C-FOS; TRANSCRIPTION FACTORS; TRANSGENIC MICE; FAMILY MEMBERS; ACTIVE SRC; PROTEASOME; JUN	c-Fos proto-oncoprotein is a short-lived transcription factor degraded by the proteasome in vivo. Its mutated forms expressed by the mouse osteosarcomatogenic retroviruses, FBJ-MSV and FBR-MSV, are stabilized two- and threefold, respectively, To elucidate the mechanisms underlying v-Fos(FBJ) and v-Fos(FBR) protein stabilization, we conducted a genetic analysis in which the half-lives and the sensitivities to various cell-permeable protease inhibitors of a variety of cellular and viral protein mutants were measured. Our data showed that the decreased degradation of v-Fos(FBJ) and v-FOSFBR is not simply explained by the deletion of a c-Fos destabilizing C-terminal domain. Rather, it involves a complex balance between opposing destabilizing and stabilizing mutations which are distinct and which include virally-introduced peptide motifs in both cases. The mutations in viral Fos proteins conferred both total insensitivity to proteasomal degradation and sensitivity to another proteolytic system not naturally operating on c-Fos, explaining the limited stabilization of the two proteins. This observation is consistent with the idea that FBR-MSV and FBJ-MSV expression machineries have evolved to ensure controlled protein levels. Importantly, our data illustrate that the degradation of unstable proteins does not necessarily involve the proteasome and provide support to the notion that highly related proteins can be broken down by different proteolytic systems in living cells.	Inst Genet Mol, CNRS, UMR 5535, IFR24, F-34293 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Piechaczyk, M (corresponding author), Inst Genet Mol, CNRS, UMR 5535, IFR24, 1919 Route Mende, F-34293 Montpellier 05, France.		PIECHACZYK, Marc/E-7896-2013; Acquaviva, Claire/N-4306-2017	PIECHACZYK, Marc/0000-0003-1367-2597; Acquaviva, Claire/0000-0002-0227-9813; bossis, guillaume/0000-0002-3349-8250				Abbott DW, 1997, J BIOL CHEM, V272, P32454, DOI 10.1074/jbc.272.51.32454; Abbott DW, 1997, J BIOL CHEM, V272, P14005, DOI 10.1074/jbc.272.22.14005; AHMED NN, 1993, ONCOGENE, V8, P1957; Aniento F, 1996, FEBS LETT, V390, P47, DOI 10.1016/0014-5793(96)00625-4; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CARILLO S, 1994, ONCOGENE, V9, P1679; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; CURRAN T, 1984, CELL, V36, P259; Curran T, 1988, ONCOGENE HDB, P307; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Dick LR, 1997, J BIOL CHEM, V272, P182; DIECHANOVER A, 2000, BIOESSAYS, V22, P442; DOHERTY FJ, 1992, INTRACELLULAR PROTEI; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harlow, 1999, USING ANTIBODIES LAB; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; He HL, 1998, J BIOL CHEM, V273, P25015, DOI 10.1074/jbc.273.39.25015; HermidaMatsumoto ML, 1996, J BIOL CHEM, V271, P4930; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Jotte RM, 1996, J CELL BIOL, V135, P457, DOI 10.1083/jcb.135.2.457; JOTTE RM, 1994, J BIOL CHEM, V269, P16383; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KAMATA N, 1991, MOL CELL BIOL, V11, P765, DOI 10.1128/MCB.11.2.765; Matsuda S, 1999, J BIOL CHEM, V274, P34515, DOI 10.1074/jbc.274.49.34515; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; OLSON EN, 1985, J BIOL CHEM, V260, P3784; Osmulski PA, 1998, CURR BIOL, V8, P1023, DOI 10.1016/S0960-9822(07)00423-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Salvat C, 1999, MOL BIOL REP, V26, P45, DOI 10.1023/A:1006960021281; Salvat C, 1998, ONCOGENE, V17, P327, DOI 10.1038/sj.onc.1201922; Salvat C, 2000, EUR J BIOCHEM, V267, P3712, DOI 10.1046/j.1432-1327.2000.01404.x; Sambrook J., 1989, MOL CLONING; SCHMIDT J, 1995, VIROLOGY, V206, P85, DOI 10.1016/S0042-6822(95)80022-0; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; Steff AM, 1997, BIOCHEM J, V323, P685, DOI 10.1042/bj3230685; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Verma R, 2000, CELL, V101, P341, DOI 10.1016/S0092-8674(00)80843-0; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348	55	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2001	20	8					942	950		10.1038/sj.onc.1204155	http://dx.doi.org/10.1038/sj.onc.1204155			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314029				2022-12-17	WOS:000167097000005
J	Stoneley, M; Spencer, JP; Wright, SC				Stoneley, M; Spencer, JP; Wright, SC			An internal ribosome entry segment in the 5 ' untranslated region of the mnt gene	ONCOGENE			English	Article						mnt; 5 ' UTR; internal initiation; IRES	MESSENGER-RNA; C-MYC; TRANSLATION; INITIATION; PROTEIN; REPRESSION; CELLS; SITES; MAX; BIP	Mnt is a transcriptional repressor related to the Myc/ Mad family of transcription factors. It is expressed in proliferating, resting and differentiating cells and is believed to antagonize the function of Myc. Here we have characterized the major transcription initiation site of the mnt gene. In doing so we noted a remarkable level of sequence conservation between the murine and human 5' untranslated regions, Our experiments revealed that this sequence contains an internal ribosome entry segment (IRES), In addition, we show that sequences at both the 5' and 3' end of the IRES are essential for its function. These findings indicate that mnt can be translated by internal initiation. Such a mechanism may allow efficient Mnt synthesis when cap-dependent translation initiation is reduced.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Wright, SC (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.							Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iizuka N, 1995, CURR TOP MICROBIOL, V203, P155; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Meroni G, 2000, ONCOGENE, V19, P3266, DOI 10.1038/sj.onc.1203634; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; Sommer A, 1998, J BIOL CHEM, V273, P6632, DOI 10.1074/jbc.273.12.6632; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800	17	10	10	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					893	897		10.1038/sj.onc.1204157	http://dx.doi.org/10.1038/sj.onc.1204157			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314024				2022-12-17	WOS:000166924400014
J	Posern, G; Rapp, UR; Feller, SM				Posern, G; Rapp, UR; Feller, SM			The Crk signaling pathway contributes to the bombesin-induced activation of the small GTPase Rap1 in Swiss 3T3 cells	ONCOGENE			English	Article						Crk; CRKL; Rap1; bombesin; SH3 domains; signal transduction	NUCLEOTIDE-EXCHANGE FACTOR; TYROSINE PHOSPHORYLATION; ADAPTER PROTEINS; BINDING PROTEINS; GROWTH-FACTOR; FACTOR C3G; KINASE; RAS; FAMILY; GENE	Rap1 is a small GTPase implicated in cell proliferation and differentiation, The mechanisms how endogenous Rapt is activated by many mitogenic stimuli including the neuropeptide bombesin remained unclear. Here we analyse which signaling pathways are necessary for Rapt activation. Bombesin-mediated Rap1 activation in Swiss 3T3 and primary mouse embryo fibroblasts requires signaling components similar to those being essential for complex formation between p130Cas and Crk adapter proteins. The Crk/CRKL-binding region of the Rap1-specific exchange factor C3G (CBR) inhibits the bombesin-stimulated Rap1 activity in transfected Swiss 3T3 cells. Further characterization in COS cells showed that the CBR or a c-Crk I SH3 mutant specifically reduces both the basal as well as the stimulated Rap1 activity in a dose-dependent manner, whereas Ras is not affected. The CBR is complexed with endogenous c-Crk II and CRKL and blocks the protein association with catalytically active C3G, Such suppressors of Crk signaling do not affect Erk-phosphorylation induced by bombesin, Embryonic fibroblasts from b-raf knockout mice showed a bombesin-inducible Erk-phosphorylation, providing evidence that B-Raf does not link Rap1, to Erk-activation in bombesin-stimulated fibroblasts, We conclude that cellular Crk/CRKL complexes, recruited to upstream signaling components, contribute to basal and bombesin-induced Rapt activity, which is independent from the Ras-Raf-Erk pathway under these circumstances.	Univ Wurzburg, MSZ, Inst Med Strahlenkunde & Zellforschung, D-97078 Wurzburg, Germany	University of Wurzburg	Feller, SM (corresponding author), Univ Wurzburg, MSZ, Inst Med Strahlenkunde & Zellforschung, Versbacher Str 5, D-97078 Wurzburg, Germany.							Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; MITCHELL FM, 1995, J BIOL CHEM, V270, P8623, DOI 10.1074/jbc.270.15.8623; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PIZON V, 1988, ONCOGENE, V3, P201; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Ruff SJ, 1997, J BIOL CHEM, V272, P1263, DOI 10.1074/jbc.272.2.1263; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; Serebriiskii I, 1997, ONCOGENE, V15, P1043, DOI 10.1038/sj.onc.1201268; Seufferlein T, 1996, J BIOL CHEM, V271, P21471, DOI 10.1074/jbc.271.35.21471; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tsukamoto N, 1999, J BIOL CHEM, V274, P18463, DOI 10.1074/jbc.274.26.18463; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	38	10	11	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6361	6368		10.1038/sj.onc.1204027	http://dx.doi.org/10.1038/sj.onc.1204027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175351				2022-12-17	WOS:000166210500020
J	Morini, M; Astigiano, S; Mora, M; Ricotta, C; Ferrari, N; Mantero, S; Levi, G; Rossini, M; Barbieri, O				Morini, M; Astigiano, S; Mora, M; Ricotta, C; Ferrari, N; Mantero, S; Levi, G; Rossini, M; Barbieri, O			Hyperplasia and impaired involution in the mammary gland of transgenic mice expressing human FGF4	ONCOGENE			English	Article						transgenic mice; fibroblast growth factors; mammary gland	GROWTH-FACTOR FAMILY; BREAST-CANCER; EPITHELIAL-CELLS; GENE-EXPRESSION; K-FGF; PROVIRAL INSERTION; TUMOR VIRUS; MCF-7 CELLS; INT-2; HST	Fgf4, a member of the fibroblast growth factor family, is frequently amplified in a variety of human cancers, however, its expression in neoplastic tissues is rarely detectable, This makes uncertain its involvement in tumour aetiology, although several in-vitro studies link Fgf4 overexpression to malignant transformation and metastatization of culture cells, We generated a transgenic mouse model in which the whey acidic protein (WAP) promoter directs expression of human Fgf4 to mammary tissues during late pregnancy and throughout lactation, with the purpose of studying the involvement of this growth factor in mammary tumorigenesis, Expression of the transgene was specifically detected in lobular-alveolar cells of lactating mammary glands that, by histological analysis, displayed hyperplastic areas and a disorganized structure, This was accompanied by an increased number of red blood cells and expression, in alveolar epithelial cells, of the vascular endothelial growth factor, which is absent in wild type controls, The most striking effect caused by FGF4 overexpression was on the remodelling of mammary tissue at the end of lactation, Indeed, transgenic animals showed a delayed involution of the gland due to a dramatic reduction in the overall number of apoptotic cells, which are normally present in the organ after weaning, Nevertheless, none of the animals examined developed neoplastic lesions of the mammary gland even after several pregnancies and at old age. Our work represents the first in-vivo demonstration of the anti-apoptotic and angiogenic properties of FGF4.	Univ Genoa, Dipartimento Oncol Biol & Genet, I-16132 Genoa, Italy; Univ Siena, Dipartimento Fisiopatol & Med Sperimentale, I-53100 Siena, Italy; MNHN, URA CNRS 8572, Lab Physiol Gen & Comparee, Paris, France; Chiron SPA, Iris, Siena, Italy; Ist Nazl Ric Canc, Unita Morfogenesi Mol, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Serv Biol Mol, I-16132 Genoa, Italy; Ist Nazl Ric Canc, Unita Transgenici, I-16132 Genoa, Italy	University of Genoa; University of Siena; Museum National d'Histoire Naturelle (MNHN); Novartis; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS AOU San Martino IST	Barbieri, O (corresponding author), Univ Genoa, Dipartimento Oncol Biol & Genet, Largo R Banzi 10, I-16132 Genoa, Italy.		Ferrari, Nicoletta/AAG-6049-2019; Barbieri, Ottavia/E-8768-2011; Mantero, Stefano/AAE-5515-2021; Astigiano, Simonetta/AAG-7766-2019	Ferrari, Nicoletta/0000-0002-6027-1035; Astigiano, Simonetta/0000-0002-8200-0666; Mantero, Stefano/0000-0003-0608-2724; Levi, Giovanni/0000-0002-7041-6787				ADNANE J, 1991, ONCOGENE, V6, P659; Baik MG, 1998, INT J MOL MED, V2, P39; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRUSTLE O, 1992, ONCOGENE, V7, P1177; Chodosh LA, 2000, DEV BIOL, V219, P259, DOI 10.1006/dbio.2000.9614; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Deroanne CF, 1997, CANCER RES, V57, P5590; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON RB, 1991, BIOESSAYS, V13, P591, DOI 10.1002/bies.950131109; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hajitou A, 2000, BREAST CANCER RES TR, V60, P15, DOI 10.1023/A:1006302602261; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; HOGAN B, 1994, MANIPULATING MOUSE E; JAAKKOLA S, 1993, INT J CANCER, V54, P378, DOI 10.1002/ijc.2910540305; Jackson D, 1997, J CELL SCI, V110, P1261; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Kiuru-Kuhlefelt S, 2000, MODERN PATHOL, V13, P433, DOI 10.1038/modpathol.3880074; Labosky PA, 1997, DEVELOPMENT, V124, P1263; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MERLO GR, 1994, ONCOGENE, V9, P443; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; MURPHY LJ, 1986, MOL ENDOCRINOL, V46, P4555; Neuenschwander S, 1996, J CLIN INVEST, V97, P2225, DOI 10.1172/JCI118663; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1991, P NATL ACAD SCI USA, V88, P698, DOI 10.1073/pnas.88.3.698; Payson RA, 1996, ONCOGENE, V13, P47; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS G, 1989, P NATL ACAD SCI USA, V86, P5678, DOI 10.1073/pnas.86.15.5678; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Shimon I, 1996, J CLIN INVEST, V97, P187, DOI 10.1172/JCI118388; Shimon I, 1998, CLIN ENDOCRINOL, V48, P23, DOI 10.1046/j.1365-2265.1998.00332.x; Souttou B, 1996, INT J CANCER, V68, P675, DOI 10.1002/(SICI)1097-0215(19961127)68:5<675::AID-IJC19>3.0.CO;2-0; TALARICO D, 1993, MOL CELL BIOL, V13, P1998, DOI 10.1128/MCB.13.4.1998; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THEILLET C, 1989, ONCOGENE, V4, P915; Vaahtokari A, 1996, DEVELOPMENT, V122, P121; Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5	50	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2000	19	52					6007	6014		10.1038/sj.onc.1204011	http://dx.doi.org/10.1038/sj.onc.1204011			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146552				2022-12-17	WOS:000165827900007
J	Alarcon-Vargas, D; Fuchs, SY; Deb, S; Ronai, Z				Alarcon-Vargas, D; Fuchs, SY; Deb, S; Ronai, Z			p73 transcriptional activity increases upon cooperation between its spliced forms	ONCOGENE			English	Article						p73; p53; Mdm2; gain of function; transcription	FUNCTION PHENOTYPE; MUTATION ANALYSIS; P53 HOMOLOG; CELL-CYCLE; GENE; APOPTOSIS; GAIN; NEUROBLASTOMA; ONCOPROTEINS; CARCINOMAS	The p53 homologue p73 efficiently activates p53-responsive genes. The well documented over-expression of p73 spliced forms in a wide variety of tumor types promoted us to elucidate the mechanisms underlying p73-mediated transcription. Using the luciferase reporter gene driven by Mdm2-minimal promoter in p53 null cells, we demonstrate that the weak transcriptional activity mediated by p73 alpha was increased by the mutant form p73 beta(292), which by itself is transcriptionally inactive. Similarly, cooperation between p73 beta and an inactive form of p73 alpha increased p73 beta-mediated transcriptional activities. Conversely, p73 beta elicited a silencing effect on a gain of function mutant, p53(281), which by itself mediated efficient transactivation of the MDR promoter. Neither anisomycin nor actinomycin D altered p73-mediated transcriptional activities, whereas sorbitol profoundly inhibited them through a rapid proteasome-dependent degradation of p73, Our observations point to plausible scenarios in which p73, through cooperation between p73 spliced forms and suppression of gain of function mutant p53 may elicit changes in the transcription of p53 target genes that play key roles in cell growth and death.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27157 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Wake Forest University	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1425 Madison Ave, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER; NCI NIH HHS [CA78419] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; ELDIERY WS, 1993, CELL, V75, P817; Gorgoulis VG, 1998, BRIT J CANCER, V77, P374, DOI 10.1038/bjc.1998.60; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HANS S, 1999, EUR J SURG ONCOL, V25, P194; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; Iwamoto KS, 1996, CANCER RES, V56, P3862; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lomax ME, 1998, ONCOGENE, V17, P643, DOI 10.1038/sj.onc.1201974; LOTEM J, 1995, P NATL ACAD SCI USA, V92, P9672, DOI 10.1073/pnas.92.21.9672; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Oren M, 1996, BBA-REV CANCER, V1288, pR13, DOI 10.1016/S0304-419X(96)00030-3; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; STENGER JE, 1994, EMBO J, V13, P11; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; Tsao H, 1999, CANCER RES, V59, P172; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yokomizo A, 1999, PROSTATE, V39, P94; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	42	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					831	835		10.1038/sj.onc.1203311	http://dx.doi.org/10.1038/sj.onc.1203311			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698502				2022-12-17	WOS:000085192100014
J	Takakura, S; Kohno, T; Shimizu, K; Ohwada, S; Okamoto, A; Yokota, J				Takakura, S; Kohno, T; Shimizu, K; Ohwada, S; Okamoto, A; Yokota, J			Somatic mutations and genetic polymorphisms of the PPP1R3 gene in patients with several types of cancers	ONCOGENE			English	Article						protein phosphatase 1; PPP1R3; mutation; single nucleotide polymorphism; tumor suppressor gene	TUMOR-SUPPRESSOR GENE; GERMLINE MUTATIONS; COWDEN-DISEASE; PROTEIN-PHOSPHORYLATION; REGULATORY SUBUNIT; INSULIN-RESISTANCE; PTEN/MMAC1 GENE; CODING REGION; FREQUENT LOSS; HUMAN-LUNG	Recently, we found nonsense and missense mutations of the PPP1R3 (protein phosphatase 1, regulatory submit 3) gene in diverse human cancer cell lines and primary lung carcinomas, indicating that PPP1R3 functions as a tumor suppressor in human carcinogenesis. In this study, to assess the prevalence of PPP1R3 mutations in human primary cancers and the genetic diversity of the PPP1R3 gene in the human population, somatic mutations and genetic polymorphisms in the PPP1R3 gene were examined in 137 pairs of cancerous and non-cancerous tissues of patients with cancers of colon, ovary, and liver. Five somatic mutations including two missense mutations were detected in three cancerous tissues consisting of two colorectal carcinomas and one ovarian carcinoma, Five novel single nucleotide polymorphisms (SNPs) associated with the substitution of amino acids were also identified in cancer patients, in addition to five known nonsynonymous SNPs, including three previously reported ones as having an impact on the susceptibility to insulin resistant disorders. Differences in the activities and properties of multiple PPP1R3 proteins, which are produced in human cells due to variable somatic mutations and genetic polymorphisms in the PPP1R3 gene, can be involved in human carcinogenesis and susceptibility to diseases.	Natl Canc Ctr, Div Biol, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Jikei Univ, Dept Obstet & Gynecol, Sch Med, Minato Ku, Tokyo 1058461, Japan; Gunma Univ, Dept Surg 2, Sch Med, Maebashi, Gumma 3718511, Japan	National Cancer Center - Japan; Jikei University; Gunma University	Yokota, J (corresponding author), Natl Canc Ctr, Div Biol, Res Inst, Chuo Ku, 1-1 Tsukiji 5-Chome, Tokyo 1040045, Japan.							CHEN YH, 1994, DIABETES, V43, P1234, DOI 10.2337/diabetes.43.10.1234; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eng C, 1998, INT J ONCOL, V12, P701; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; HANSEN L, 1995, HUM MOL GENET, V4, P1313, DOI 10.1093/hmg/4.8.1313; ISACCHI A, 1989, GENE, V81, P129, DOI 10.1016/0378-1119(89)90343-0; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kohno T, 1998, JPN J CANCER RES, V89, P471, DOI 10.1111/j.1349-7006.1998.tb03285.x; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kohno T, 1999, CANCER RES, V59, P4170; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; Kukita Y, 1997, HUM MUTAT, V10, P400, DOI 10.1002/(SICI)1098-1004(1997)10:5<400::AID-HUMU11>3.3.CO;2-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Milland J, 1996, EUR J BIOCHEM, V238, P221, DOI 10.1111/j.1432-1033.1996.0221q.x; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Rubin Ethel, 1998, Frontiers in Bioscience, V3, pD1209; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Strauss BS, 1998, SEMIN CANCER BIOL, V8, P431, DOI 10.1006/scbi.1998.0092; Takenoshita S, 1998, CARCINOGENESIS, V19, P803, DOI 10.1093/carcin/19.5.803; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xia J, 1998, DIABETES, V47, P1519, DOI 10.2337/diabetes.47.9.1519; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011	31	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2000	19	6					836	840		10.1038/sj.onc.1203388	http://dx.doi.org/10.1038/sj.onc.1203388			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698503				2022-12-17	WOS:000085192100015
J	Kannabiran, C; Morris, GF; Mathews, MB				Kannabiran, C; Morris, GF; Mathews, MB			Dual action of the adenovirus E1A 243R oncoprotein on the human proliferating cell nuclear antigen promoter: repression of transcriptional activation by p53	ONCOGENE			English	Article						PCNA; transcription; p53; E1A	CYCLIN-DEPENDENT KINASES; DNA POLYMERASE-DELTA; 19-KILODALTON PROTEIN; FUNCTIONAL DOMAINS; AUXILIARY PROTEIN; COACTIVATOR P300; TUMOR SUPPRESSOR; HOST-CELL; GENE; TRANSFORMATION	The promoter of the human proliferating cell nuclear antigen (PCNA) gene is activated by the adenovirus oncoprotein E1A 243R in HeLa cells. To understand the effect of this oncoprotein on PCNA expression in cells that are sensitive to oncogenic transformation by adenovirus, we studied the effect of E1A 243R on PCNA promoter-directed reporter gene expression in cloned rat embryo fibroblast (CREF) and primary baby rat kidney cells. In contrast to the results obtained in HeLa cells, EIA repressed the PCNA promoter in both cell-types. Promoter analysis identified a p53-responsive element that mediates E1A-induced repression. Repression required the intact N-terminus of EIA 243R, as shown by the ability of mutant EIA proteins to repress the promoter, and correlated with the p300-binding region of EIA. The adenovirus E1B 19K protein relieved repression by EIA 243R. These results reveal dual pathways for induction of this essential DNA replication factor and suggest a mechanism for oncogenic cooperativity between the EIA and E1B oncoproteins.	Cold Spring Harbor Lab, New York, NY 11724 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Cold Spring Harbor Laboratory; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mathews, MB (corresponding author), LV Prasad Eye Inst, Rd 2,Banjara Hills, Hyderabad 500034, Andhra Pradesh, India.		Kannabiran, Chitra/S-9361-2019	Kannabiran, Chitra/0000-0001-8435-0320	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; Chen H, 1997, J BIOL CHEM, V272, P6101, DOI 10.1074/jbc.272.10.6101; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARPER JW, 1993, CELL, V75, P805; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HERRMANN CH, 1987, ONCOGENE, V2, P25; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu MS, 1999, J BIOL CHEM, V274, P15433, DOI 10.1074/jbc.274.22.15433; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MATSUMOTO K, 1987, EMBO J, V6, P637, DOI 10.1002/j.1460-2075.1987.tb04802.x; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NEVINS JR, 1992, SCIENCE, V258, P424; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1990, CANCER CELL-MON REV, V2, P258; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1990, MOL CELL BIOL, V10, P120, DOI 10.1128/MCB.10.1.120; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	69	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7825	7833		10.1038/sj.onc.1203294	http://dx.doi.org/10.1038/sj.onc.1203294			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618724				2022-12-17	WOS:000084256900013
J	Kriebel, P; Patel, BKR; Nelson, SA; Grusby, MJ; LaRochelle, WJ				Kriebel, P; Patel, BKR; Nelson, SA; Grusby, MJ; LaRochelle, WJ			Consequences of Stat6 deletion on Sis/PDGF- and IL-4-induced proliferation and transcriptional activation in murine fibroblasts	ONCOGENE			English	Article						PDGF; IL-4; Stat-6; transcriptional activation	SIMIAN SARCOMA-VIRUS; HUMAN RECOMBINANT INTERLEUKIN-4; GROWTH-FACTOR RECEPTORS; JAK-3 JANUS KINASE; NF-KAPPA-B; TYROSINE PHOSPHORYLATION; FACTOR-I; HEMATOPOIETIC-CELLS; MYELOID CELLS; GENE	Aberrant communication among growth factors and cytokines that regulate tissue homeostasis often results in malignancy. Among the many cell types that participate in this process, stromal fibroblasts communicate in a paracrine and juxtracrine manner with cells of epithelial, endothelial, and hematopoietic origin. For fibroblasts, platelet-derived growth factor (PDGF) is a major proliferative and differentiation agent, Interleukin-4 (IL-4), however, possesses only modulating functions in this cell type. Here, we investigated the consequences of deleting Stat6 on PDGF and IL-4 signaling, proliferation, and transcriptional activation by establishing and characterizing early passage fibroblasts from wild-type and Stat6 null mice. Both wild-type and Stat6(-/-) fibroblasts showed nearly identical PDGFR and IL-4R activation, gross substrate tyrosine phosphorylation, PI 3-kinase activation, as well as Stat1, 3 and 5 DNA binding activities. Unexpectedly, IL-4's enhancement of PDGF-induced [H-3]thymidine incorporation was greatly diminished in Stat6(-/-), but not wild-type fibroblasts, PDGF-induced [H-3]thymidine uptake was largely unaffected. Strikingly, IL-3, but not PDGF induction of the proinflammatory gene products, IL-6 and MCP-1 was markedly reduced in Stat6(-/-) fibroblasts. Thus, Stat6 is an important and specific mediator of IL-1-enhanced PDGF-induced proliferation as well as IL-4's transcriptional activation of IL-6 and MCP-1.	NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health	LaRochelle, WJ (corresponding author), NCI, Cellular & Mol Biol Lab, Bldg 37,Room 1E24, Bethesda, MD 20892 USA.		Nelson, Stefanie/GRN-7686-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040171, R01AI040171] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40171] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Ataliotis P, 1997, INT REV CYTOL, V172, P95, DOI 10.1016/S0074-7696(08)62359-1; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Betsholtz C, 1997, KIDNEY INT, V51, P1361, DOI 10.1038/ki.1997.186; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; Dirks RPH, 1996, MOL BIOL REP, V22, P1, DOI 10.1007/BF00996300; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; FEGHALI CA, 1992, CLIN IMMUNOL IMMUNOP, V63, P182, DOI 10.1016/0090-1229(92)90011-C; FLEMING TP, 1992, CANCER RES, V52, P4550; Freter RR, 1996, J BIOL CHEM, V271, P17417, DOI 10.1074/jbc.271.29.17417; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; HALL DJ, 1989, MOL CELL BIOL, V9, P1705, DOI 10.1128/MCB.9.4.1705; Heldin Carl-Henrik, 1991, Critical Reviews in Oncogenesis, V2, P109; HONDA M, 1992, J IMMUNOL, V148, P2175; HOU J, 1994, SCIENCE, V165, P1701; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JENSEN RA, 1992, BIOCHEMISTRY-US, V31, P10887, DOI 10.1021/bi00159a032; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KAPLAN MH, 1996, IMMUNITY, V4, P1; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; Kotanides H, 1996, J BIOL CHEM, V271, P25555, DOI 10.1074/jbc.271.41.25555; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423; NEEDLEMAN BW, 1992, ARTHRITIS RHEUM, V35, P67, DOI 10.1002/art.1780350111; NELSON SA, 1999, SOURCEBOOK ASBESTOS, V19, P291; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; OLASHAW NE, 1992, MOL BIOL CELL, V3, P1131, DOI 10.1091/mbc.3.10.1131; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; Paquet P, 1996, INT ARCH ALLERGY IMM, V109, P308, DOI 10.1159/000237257; Patel BKR, 1998, GENOMICS, V52, P192, DOI 10.1006/geno.1998.5436; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; Patel BKR, 1998, P NATL ACAD SCI USA, V95, P172, DOI 10.1073/pnas.95.1.172; Paul WE, 1997, CIBA F SYMP, V204, P208; Peden K, 1987, Prog Clin Biol Res, V253, P101; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROTH M, 1995, P NATL ACAD SCI USA, V92, P1312, DOI 10.1073/pnas.92.5.1312; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takemura H, 1998, J RHEUMATOL, V25, P1534; Trautmann A, 1998, J IMMUNOL, V160, P5053; VANDERMEEREN A, 1993, AM J RESP CELL MOL, V8, P214, DOI 10.1165/ajrcmb/8.2.214; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VIGNAUD JM, 1994, CANCER RES, V54, P5455; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	65	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7294	7302		10.1038/sj.onc.1203148	http://dx.doi.org/10.1038/sj.onc.1203148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602484				2022-12-17	WOS:000084119400014
J	Siegel, J; Li, Y; Whyte, P				Siegel, J; Li, Y; Whyte, P			SHIP-mediated inhibition of K562 erythroid differentiation requires an intact catalytic domain and Shc binding site	ONCOGENE			English	Article						SHIP; erythroid differentiation; K562 cells	INOSITOL POLYPHOSPHATE 5-PHOSPHATASE; TYROSINE-PHOSPHORYLATED PROTEIN; FULL-LENGTH CDNA; CELL-LINE K562; FC-GAMMA-RIIB; PHOSPHATASE SHIP; MEGAKARYOCYTIC DIFFERENTIATION; ERYTHROLEUKEMIA-CELLS; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION	Growing evidence supports a role for the SHIP inositol 5'-phosphatase in the negative regulation of a variety of receptor-mediated signaling pathways in hematopoietic cells. SHIP expression among cultured cell lines was examined and found to be restricted to cells of hematopoietic origin, with the exception of the K562 erythroleukemia cell line, in which SHIP protein and mRNA were undetectable. The absence of endogenous SHIP in K562 cells provided a useful system to study the role of SHIP in growth and differentiation. When stably expressed in K562 cells, SHIP was found to be constitutively tyrosine phosphorylated and associated with endogenous Shc and Grb-2. Stable expression of SHIP did not affect growth of the cells but resulted in decreased synthesis of hemoglobin protein and E-globin mRNA in response to hemin, an inducer of erythroid differentiation. This effect was not due to increased cell death in the SHIP-expressing lines following hemin stimulation, but was likely the result of an impaired differentiation program in these cells. Mutational analysis indicated that SHIP must retain both an intact catalytic domain and Shc binding site to efficiently inhibit K562 erythroid differentiation.	McMaster Univ, Inst Mol Biol & Biotechnol, Ctr Hlth Sci, Dept Pathol, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Whyte, P (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Ctr Hlth Sci, Dept Pathol, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							BARALLE FE, 1980, CELL, V21, P621, DOI 10.1016/0092-8674(80)90425-0; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Bolland S, 1998, IMMUNITY, V8, P509, DOI 10.1016/S1074-7613(00)80555-5; Chacko GW, 1996, J IMMUNOL, V157, P2234; CHARNAY P, 1983, SCIENCE, V220, P1281, DOI 10.1126/science.6574602; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DAMEN JE, 1993, BLOOD, V82, P2296; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; GROSVELD G, 1986, MOL CELL BIOL, V6, P607, DOI 10.1128/MCB.6.2.607; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; HENSOLD JO, 1991, BLOOD, V77, P1362; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kubota Y, 1996, LEUKEMIA, V10, P720; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; LEIBOWITZ D, 1991, LEUKEMIA RES, V15, P65, DOI 10.1016/0145-2126(91)90146-K; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; Liu QR, 1998, J EXP MED, V188, P1333, DOI 10.1084/jem.188.7.1333; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASONGARCIA M, 1991, FASEB J, V5, P2958, DOI 10.1096/fasebj.5.14.1752362; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; NISHIMURA J, 1988, LEUKEMIA RES, V12, P875, DOI 10.1016/0145-2126(88)90014-8; OKABEKADO J, 1986, CANCER RES, V46, P1239; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Rivero JA, 1996, BIOCHEM BIOPH RES CO, V224, P796, DOI 10.1006/bbrc.1996.1102; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; SAXTON TM, 1994, J IMMUNOL, V153, P623; Schaefer A, 1997, CELL SIGNAL, V9, P483, DOI 10.1016/S0898-6568(97)00094-6; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Tilbrook PA, 1996, J BIOL CHEM, V271, P3453; TORTI M, 1992, J BIOL CHEM, V267, P8293; Tridandapani S, 1997, IMMUNOL TODAY, V18, P424, DOI 10.1016/S0167-5699(97)01112-2; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; Ware MD, 1996, BLOOD, V88, P2833, DOI 10.1182/blood.V88.8.2833.bloodjournal8882833; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	54	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7135	7148		10.1038/sj.onc.1203212	http://dx.doi.org/10.1038/sj.onc.1203212			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597315				2022-12-17	WOS:000083901900021
J	Veldhoen, N; Metcalfe, S; Milner, J				Veldhoen, N; Metcalfe, S; Milner, J			A novel exon within the mdm2 gene modulates translation initiation in vitro and disrupts the p53-binding domain of mdm2 protein	ONCOGENE			English	Article						mdm2; p53; regulatory exon; alternative splicing	P53 PROTEIN; ONCOPROTEIN MDM2; MESSENGER-RNAS; EXPRESSION; CELLS; TRANSCRIPTS; EFFICIENCY; MICE; TRANSACTIVATION; AMPLIFICATION	The mdm2 protein interacts with a number of proteins involved in cell growth control. Such interactions favour cell proliferation and may explain the oncogenic potential of mdm2 when over-expressed in cells. Interaction with the tumour suppressor p53 involves the N-terminus of mdm2 and targets p53 for rapid degradation by the ubiquitin pathway, We now describe a novel, highly conserved exon of mdm2 (exon alpha) which includes an in-frame UGA stop codon. Expression of exon alpha disrupts in vitro translation of the p53 binding domain of mdm2. We propose that exon alpha induces translation re-initiation at an internal AUG codon within the mdm2 alpha mRNA isoform. The putative mdm2 alpha protein lacks the N-terminus of mdm2 and shows little, if any, binding capacity for p53. Mdm2 alpha mRNA is expressed in a tissue-specific manner and is observed predominantly in testis and peripheral blood lymphocytes. We propose that mdm2 alpha expression may provide a mechanism for uncoupling mdm2-p53 interaction in certain cell types and/or under specific conditions of cell growth.	Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England	University of York - UK; Addenbrooke's Hospital; University of Cambridge	Milner, J (corresponding author), Univ York, Dept Biol, YCR Res Grp P53, York YO10 5DD, N Yorkshire, England.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bottger A, 1997, J MOL BIOL, V269, P744, DOI 10.1006/jmbi.1997.1078; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; Gellersen B, 1997, MOL ENDOCRINOL, V11, P97, DOI 10.1210/me.11.1.97; GUDAS JM, 1995, CLIN CANCER RES, V1, P71; Haines DS, 1997, LEUKEMIA LYMPHOMA, V26, P227, DOI 10.3109/10428199709051772; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jones SN, 1996, GENE, V175, P209, DOI 10.1016/0378-1119(96)00151-5; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; KAUFMAN RJ, 1987, EMBO J, V6, P187, DOI 10.1002/j.1460-2075.1987.tb04737.x; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; Luna RMDO, 1996, GENOMICS, V33, P352, DOI 10.1006/geno.1996.0210; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Matsumoto R, 1998, CANCER RES, V58, P609; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.biochem.55.1.1119; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Shick L, 1997, CELL GROWTH DIFFER, V8, P121; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Veldhoen N, 1998, ONCOGENE, V16, P1077, DOI 10.1038/sj.onc.1201863; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	52	10	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 25	1999	18	50					7026	7033		10.1038/sj.onc.1203182	http://dx.doi.org/10.1038/sj.onc.1203182			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259PH	10597303				2022-12-17	WOS:000083901900009
J	Honda, H; Harada, K; Komuro, I; Terasaki, F; Ueno, H; Tanaka, Y; Kawamura, K; Yazaki, Y; Hirai, H				Honda, H; Harada, K; Komuro, I; Terasaki, F; Ueno, H; Tanaka, Y; Kawamura, K; Yazaki, Y; Hirai, H			Heart-specific activation of LTK results in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming in transgenic mice	ONCOGENE			English	Article						leukocyte tyrosine kinase (LTK); protein tyrosine kinase; transgenic mice	LEUKOCYTE TYROSINE KINASE; IN-VIVO; EXPRESSION; GROWTH; PROTEIN; DOMAIN; CELLS; OVEREXPRESSION; APOPTOSIS; MOLECULE	Leukocyte tyrosine kinase (LTK) is a receptor-type protein tyrosine kinase belonging to the insulin receptor superfamily. To elucidate its biological role, we generated transgenic mice expressing LTK under the control of cytomegarovirus enhancer and beta-actin promoter. The transgenic mice exhibited growth retardation and most of the transgenic mice died within several months after birth, Interestingly, although LTK was expressed in several major organs, the activation (tyrosine-phosphorylation, kinase activity, and multimerization) of LTK was observed selectively in the heart, where LTK was localized on intracellular membrane, presumably on endoplasmic reticulum. Echocardiography showed that the transgenic heart underwent severe concentric hypertrophy, which resulted in reduced cardiac output, low blood pressure, and increased heart rate. Histological examination of the heart exhibited focal degeneration of cardiomyocytes. These histological changes were considered to be due to apoptosis, based on the finding that the sarcolemmas of the degenerative cardiomyocytes were well preserved. In addition, expression of fetal genes, such as atrial natriuretic peptide and skeletal alpha-actin, was markedly induced in the transgenic heart. These results indicate that a certain tissue-specific mechanism of activating LTK exists in the heart and that the activated LTK resulted in cardiac hypertrophy, cardiomyocyte degeneration and gene reprogramming. These findings will provide novel insights into the activating mechanism and biological role of LTK in vivo.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 113, Japan; Osaka Med Coll, Fac Med, Dept Internal Med 3, Takatsuki, Osaka 569, Japan	University of Tokyo; Osaka Medical College	Hirai, H (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.							BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BRASKIN AR, 1991, CELL, V66, P685; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CONTI FG, 1995, GROWTH REGULAT, V5, P101; Edwards JG, 1996, CIRC RES, V78, P379, DOI 10.1161/01.RES.78.3.379; FURUTA Y, 1993, TRANSGENIC RES, V2, P199, DOI 10.1007/BF01977350; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HASSANKHANI A, 1995, DEV BIOL, V169, P309, DOI 10.1006/dbio.1995.1146; HASSE VH, 1995, TRANSGENICS, V1, P487; HASSE VH, 1991, ONCOGENE, V6, P2319; HAYASHI T, 1995, AM HEART J, V129, P946, DOI 10.1016/0002-8703(95)90116-7; HERREN B, 1993, J BIOL CHEM, V268, P15088; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; JAMES TN, 1993, J LAB CLIN MED, V122, P309; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KOZUTSUMI H, 1993, BIOCHEM BIOPH RES CO, V190, P674, DOI 10.1006/bbrc.1993.1101; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; Kubota T, 1997, CIRC RES, V81, P627, DOI 10.1161/01.RES.81.4.627; MARU Y, 1990, ONCOGENE RES, V5, P199; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHWARTZ K, 1986, CIRC RES, V59, P551, DOI 10.1161/01.RES.59.5.551; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; YEE SP, 1989, P NATL ACAD SCI USA, V86, P5873, DOI 10.1073/pnas.86.15.5873	38	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	1999	18	26					3821	3830		10.1038/sj.onc.1202736	http://dx.doi.org/10.1038/sj.onc.1202736			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445845				2022-12-17	WOS:000081171700003
J	Hubbs, AE; Majidi, M; Lichy, JH				Hubbs, AE; Majidi, M; Lichy, JH			Expression of an isoform of the novel signal transduction protein ST5 is linked to cell morphology	ONCOGENE			English	Article						ST5; signal transduction; cytoskeleton; contact-inhibition	KINASE-ACTIVITY; IDENTIFICATION; MICROTUBULES; INVOLVEMENT; DISRUPTION; HYBRIDS; LINES; GENE	The human ST5 gene is expressed as 4.6, 3.1 and 2.8 kb transcripts encoding putative 126, 82 and 70 kDa proteins that function in the MAP kinase signaling pathway in transient expression assays, Expression of the 2.8 kb transcript correlates with reduced tumorigenicity in HeLa-fibroblast hybrids, suggesting a role in tumor suppression. We now report the detection of ST5 proteins in cellular extracts, demonstrate specific expression of p70 in non-tumorigenic HeLa-fibroblast hybrids, extend the correlation between p70 expression and cellular morphology to a wide variety of cell lines, and provide direct evidence that p70 can effect changes in cell growth and morphology. ST5 proteins were identified in extracts of human, mouse and simian epithelial cells and fibroblasts, but were absent from lymphoid cells. Transfection of the 2.8 kb cDNA into a p70-negative mouse fibroblast line yielded stable transfectants with a Battened, less refractile morphology relative to controls. The p70 expressing clones had initial growth rates similar to those of control cells but their saturation density was reduced threefold, suggesting a restoration of contact-regulated growth. In conjunction with previous findings, these results suggest that ST5 proteins participate directly in events affecting cytoskeletal organization and tumorigenicity.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	Lichy, JH (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA.				NATIONAL CANCER INSTITUTE [R01CA064114] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA64114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V1, pCH9; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; KAJSTURA J, 1993, CELL BIOL INT, V17, P1023, DOI 10.1006/cbir.1993.1032; Lichy JH, 1996, NUCLEIC ACIDS RES, V24, P4700, DOI 10.1093/nar/24.23.4700; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; Lu Q, 1998, MOL CELL BIOL, V18, P3257, DOI 10.1128/MCB.18.6.3257; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; Majidi M, 1998, J BIOL CHEM, V273, P16608, DOI 10.1074/jbc.273.26.16608; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; STANBRIDGE EJ, 1980, INT J CANCER, V26, P1, DOI 10.1002/ijc.2910260102; Sudhof TC, 1997, NEURON, V18, P519, DOI 10.1016/S0896-6273(00)80292-5; Taubenberger JK, 1996, CELL IMMUNOL, V171, P41, DOI 10.1006/cimm.1996.0170; Zhu JY, 1996, MOL CELL BIOL, V16, P7054	19	10	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	1999	18	15					2519	2525		10.1038/sj.onc.1202554	http://dx.doi.org/10.1038/sj.onc.1202554			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AC	10229203				2022-12-17	WOS:000079703300012
J	Rojas, JM; Subleski, M; Coque, JJR; Guerrero, C; Saez, R; Li, BQ; Lopez, E; Zarich, N; Aroca, P; Kamata, T; Santos, E				Rojas, JM; Subleski, M; Coque, JJR; Guerrero, C; Saez, R; Li, BQ; Lopez, E; Zarich, N; Aroca, P; Kamata, T; Santos, E			Isoform-specific insertion near the Grb2-binding domain modulates the intrinsic guanine nucleotide exchange activity of hSos1	ONCOGENE			English	Article						hSos1; isoforms; Ras activation; GEF activity; oocyte maturation	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASE; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; OOCYTE MATURATION; FACTOR SON; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODIES; XENOPUS OOCYTES	Two human hSos1 isoforms (Isf I and Isf II; Rojas et al,, Oncogene 12, 2291-2300, 1996) defined by the presence of a distinct 15 amino acid stretch in one of them, were compared biologically and biochemically using representative NIH3T3 transfectants overexpressing either one. We showed that hSos1-Isf II is significantly more effective than hSos1-Isf I to induce proliferation or malignant transformation of rodent fibroblasts when transfected alone or in conjunction with normal H-Ras (Gly12), The hSos1-Isf II-Ras cotransfectants consistently exhibited higher saturation density, lower cell-doubling times, increased focus-forming activity and higher ability to grow on semisolid medium and at low serum concentration than their hSos1-Isf I-Ras counterparts. Furthermore, the ratio of GTP/GDP bound to cellular p21(ras) was consistently higher in the hSos1-Isf II-transfected clones, both under basal and stimulated conditions. However, no significant differences were detected in vivo between Isf I- and Isf II-transfected clones regarding the amount, stability and subcellular localization of Sos1-Grb2 complex, or the level of hSos1 phosphorylation upon cellular stimulation, Interestingly, direct Ras guanine nucleotide exchange activity assays in cellular lysates showed that Isf II transfectants consistently exhibited about threefold higher activity than Isf I transfectants under basal, unstimulated conditions. Microinjection into Xenopus oocytes of purified peptides corresponding to the C-terminal region of both isoforms (encompassing the 15 amino acid insertion area and the first Grb2-binding motif) showed that only the Isf II peptide, but not its corresponding Isf I peptide, was able to induce measurable rates of meiotic maturation, and synergyzed with insulin, but not progesterone, in induction of GVBD. Our results suggest that the increased biological potency displayed by hSos1-Isf II is due to higher intrinsic guanine nucleotide exchange activity conferred upon this isoform by the 15 a.a. insertion located in proximity to its Grb2 binding region.	NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Lab Biochem Physiol, Frederick, MD 21071 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Santos, E (corresponding author), NCI, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA.		Guerrero, Carmen/F-1776-2010; Rojas, José M./AAA-3354-2021; Aroca, Pilar/P-2141-2017; Rojas, José M/D-3718-2018; Coque, Juan Jose Rubio/AAV-2049-2021	Guerrero, Carmen/0000-0002-8747-6831; Rojas, José M./0000-0002-7547-2825; Aroca, Pilar/0000-0002-7557-6931; Rojas, José M/0000-0002-5383-3482; Coque, Juan Jose Rubio/0000-0001-8221-7817; Zarich, Natasha/0000-0003-1058-6191				Aroca P, 1996, ONCOGENE, V13, P1839; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HEIDARAN MA, 1992, ONCOGENE, V7, P147; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KATZAV S, 1995, ONCOGENE, V11, P1079; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Mendelsohn Andrew R., 1994, Current Opinion in Biotechnology, V5, P482, DOI 10.1016/0958-1669(94)90061-2; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; PAWSON T, 1993, CURR BIOL, V3, P4345; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rojas JM, 1996, ONCOGENE, V12, P2291; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SORRENTINO V, 1989, ONCOGENE, V4, P215; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	56	10	11	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1651	1661		10.1038/sj.onc.1202483	http://dx.doi.org/10.1038/sj.onc.1202483			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208427				2022-12-17	WOS:000079025000001
J	Fridman, JS; Rehemtulla, A; Hofmann, A; Blau, HM; Maybaum, J				Fridman, JS; Rehemtulla, A; Hofmann, A; Blau, HM; Maybaum, J			Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells	ONCOGENE			English	Article						Bcl-X; programmed cell death; apoptosis; cell cycle; K12	TETRACYCLINE-REGULATED SYSTEM; INDUCIBLE GENE-EXPRESSION; LEUKEMIA HL-60 CELLS; INDUCED APOPTOSIS; CYCLE ENTRY; TRANSGENIC MICE; CANCER-CELLS; BCL-X(S); BAX; DEATH	bcl-XS, a member of the bcl-2 family, has been shown to induce and/or sensitize some cells to undergo programmed cell death, and to negate the anti-apoptotic activity of bcl-XL and bcl-2 by mechanisms which are still uncertain. To help understand these mechanisms we have established stable derivatives of the K12 rat colon carcinoma cell line that express bcl-XS in a tetracycline-regulated manner, using an autoregulatory retroviral cassette. When bcl-XS expression is induced, we observe two phenotypic responses. A small fraction of cells appear to undergo spontaneous apoptosis while the majority of cells undergo a form of cytostasis. In the latter case, the cells stop dividing (or divide a limited number of times at a retarded rate) and swell to many times their original size. These cells can take on a ghostlike appearance and subsequently detach from the culture plates and die or they may remain intact in a hindered state of proliferation. Doubling times were calculated to be 31.4 h in the presence of tetracycline and 50.4 h without tetracycline, bcl-XS expression also causes dramatic alterations in the cell cycle distribution of K12 cells manifesting as a substantial decrease (approximate to 50%) in the fraction of S phase cells with a concomitant increase in the G1 population. Continuous expression of bcl-XS, at levels approximately equal to that of bcl-XL, decreased the viability of K12 cells as demonstrated by a log decline in clonogenic survival. This decrease occurred without considerable apoptosis or a compensatory increase in the level of bcl-XL. None of these phenotyes were present in control cells expressing beta-galactosidase in a similar retroviral cassette. These observations demonstrate that bcl-XS can have substantial cytokinetic effects under circumstances that produce relatively little apoptosis.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Univ Cologne, Fak Med, Inst Biochem 1, D-5000 Cologne 41, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Stanford University; University of Cologne	Maybaum, J (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA.				NCI NIH HHS [CA59717, CA56663] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056663, R01CA059717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEDI A, 1995, CANCER RES, V55, P1811; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSARI S, 1995, HUM PATHOL, V26, P534, DOI 10.1016/0046-8177(95)90250-3; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; CLARKE MF, 1995, P NATL ACAD SCI USA, V92, P11024, DOI 10.1073/pnas.92.24.11024; DHAWAN J, 1995, SOMAT CELL MOLEC GEN, V21, P233, DOI 10.1007/BF02255778; Dole MG, 1996, CANCER RES, V56, P5734; Ealovega MW, 1996, CANCER RES, V56, P1965; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Han ZY, 1996, CANCER RES, V56, P1621; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Ibrado AM, 1996, CANCER RES, V56, P4743; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; Kitanaka C, 1997, ONCOGENE, V15, P1763, DOI 10.1038/sj.onc.1201349; Krajewska M, 1996, CANCER RES, V56, P2422; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Merchant AK, 1996, ONCOGENE, V13, P2631; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; MIYASHITA T, 1994, CANCER RES, V54, P3131; NOEL RA, 1994, J PEDIATR GASTR NUTR, V19, P43, DOI 10.1097/00005176-199407000-00007; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; Ray S, 1996, CELL GROWTH DIFFER, V7, P1617; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SINICROPE FA, 1995, CANCER RES, V55, P237; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; ZHAN QM, 1994, ONCOGENE, V9, P3743	35	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	1998	17	23					2981	2991		10.1038/sj.onc.1202224	http://dx.doi.org/10.1038/sj.onc.1202224			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146KL	9881700				2022-12-17	WOS:000077427800005
J	Zhu, WJ; Eicher, A; Leber, B; Andrews, DW				Zhu, WJ; Eicher, A; Leber, B; Andrews, DW			At the onset of transformation polyomavirus middle-T recruits shc and src to a perinuclear compartment coincident with condensation of endosomes	ONCOGENE			English	Article						middle-T antigen; polyomavirus; perinuclear; shc; transformation	SIZED TUMOR-ANTIGEN; CELLULAR-LOCALIZATION; PROTEIN PHOSPHATASE; MEMBRANE-PROTEINS; EGF RECEPTOR; RAT-CELLS; VIRUS; BINDING; ASSOCIATION; ACTIVATION	To examine the early cellular changes that accompany transformation, middle-T antigen (the transforming protein of polyomavirus), was expressed from an inducible promoter in Rat2 fibroblasts and in normal diploid human fibroblast (MRCS) cells using a replication defective adenovirus vector. The earliest detectable expression of middle-T antigen correlated closely with the initial changes in cellular morphology. At this time, expression of middle-T antigen resulted in the redistribution of shc and src to a brefeldin A resistant perinuclear compartment coincident with the formation of kinase active complexes containing middle-T antigen, she and src. The first detectable changes directly related to altered morphology was reorganization of actin filaments, and the condensation of tubular endosomes in the perinuclear region of the cell. These results suggest a potential role for perinuclear localized mT molecules in some of the morphologic changes associated with the initial phase of cellular transformation.	McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University; McMaster University	Andrews, DW (corresponding author), McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada.			Andrews, David/0000-0002-9266-7157; Leber, Brian/0000-0001-5502-1480				AGUZZI A, 1991, ONCOGENE, V6, P113; ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; BALLMERHOFER K, 1985, EMBO J, V4, P2321, DOI 10.1002/j.1460-2075.1985.tb03933.x; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; BRUNETTI CR, 1995, J VIROL, V69, P3517, DOI 10.1128/JVI.69.6.3517-3528.1995; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CARLEY WW, 1981, J CELL BIOL, V90, P797, DOI 10.1083/jcb.90.3.797; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; CHENG SH, 1990, EMBO J, V7, P384; COHEN B, 1990, MOL CELL BIOL, V10, P2909, DOI 10.1128/MCB.10.6.2909; COOK DN, 1990, J VIROL, V64, P2392, DOI 10.1128/JVI.64.5.2392-2395.1990; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; DRUCKER B, 1990, J VIROL, V64, P4454; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GRIFFIN BE, 1983, ADV CANCER RES, V39, P183, DOI 10.1016/S0065-230X(08)61036-2; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; Kim PK, 1997, BIOCHEMISTRY-US, V36, P8873, DOI 10.1021/bi970090t; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORNBLUTH S, 1997, J VIROL, V64, P1584; KRAUZEWICZ N, 1994, ONCOGENE, V9, P2283; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lotti LV, 1996, MOL CELL BIOL, V16, P1946; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; OKAMURA H, 1994, ONCOGENE, V9, P2293; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; TUCKER RW, 1978, CELL, V13, P629, DOI 10.1016/0092-8674(78)90213-1; ULUG ET, 1992, J VIROL, V66, P1458, DOI 10.1128/JVI.66.3.1458-1467.1992; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Yi XD, 1997, J VIROL, V71, P6279, DOI 10.1128/JVI.71.9.6279-6286.1997; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	61	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 6	1998	17	5					565	576		10.1038/sj.onc.1201979	http://dx.doi.org/10.1038/sj.onc.1201979			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	107EZ	9704922				2022-12-17	WOS:000075195300004
J	Mixan, B; Cohen, BD; Bacus, SS; Fell, HP; Siegall, CB				Mixan, B; Cohen, BD; Bacus, SS; Fell, HP; Siegall, CB			Betacellulin-Pseudomonas toxin fusion proteins bind but are not cytotoxic to cells expressing HER4; correlation of EGFR for cytotoxic activity	ONCOGENE			English	Article						cancer; toxin; betacellulin; cytotoxicity; receptor	EPIDERMAL GROWTH-FACTOR; SINGLE-CHAIN IMMUNOTOXIN; FACTOR RECEPTOR; BIOLOGICAL-ACTIVITIES; RECOMBINANT TOXINS; CANCER-TREATMENT; ERBB RECEPTORS; BR96 SFV-PE40; DISTINCT; EXOTOXIN	Betacellulin (BTC) is a member of the EGF ligand family that directly binds to both EGFR and HER4 and induces the growth of certain epithelial cell types, Fusion proteins composed of the terminal 48 or 50 amino acids of mature betacellulin and a binding defective form of Pseudomonas exotoxin (BTC-TX48 and BTC-TX50, respectively), have been produced, BTC-TX50 induced tyrosine phosphorylation of both EGFR and HER4, whereas BTC-TX48 induced phosphorylation of HER4 but to a much lesser extent EGFR, indicating that the presence of two additional amino acid residues, Arg(62) and Lys(63), contribute to full kinase activity, BTC-TX50 was up to 300-fold more active at inhibiting protein synthesis than BTC-TX48 on cell lines expressing EGFR, most likely due to the >tenfold higher affinity of BTC-TX50. MDA-MB-453 breast carcinoma cells which express HER4 but not EGFR, were not sensitive to either BTC-TX form, These data indicate that despite the ability of BTC-TX to bind and phosphorylate HER4, it was only cytotoxic to cells expressing EGFR, The inability of BTC-TX to kill cells was likely due to its failure to internalize through HER4.	Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Mol Immunol, Seattle, WA 98121 USA; Adv Cellular Diagnost Inc, Elmhurst, IL 60126 USA	Bristol-Myers Squibb	Siegall, CB (corresponding author), Bristol Myers Squibb Co, Pharmaceut Res Inst, Dept Mol Immunol, 3005 1st Ave, Seattle, WA 98121 USA.							BACUS SS, 1993, CANCER RES, V53, P5251; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Cohen BM, 1996, J BIOL CHEM, V271, P4813; COLOUSCOU JM, 1995, J BIOL CHEM, V270, P12857; Francisco JA, 1996, J IMMUNOL, V157, P1652; FRIEDMAN PN, 1993, CANCER RES, V53, P334; GOLDBERG MR, 1995, CLIN CANCER RES, V1, P57; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Kreitman R J, 1994, Adv Pharmacol, V28, P193, DOI 10.1016/S1054-3589(08)60496-2; LEMAISTRE CF, 1994, BREAST CANCER RES TR, V32, P97, DOI 10.1007/BF00666210; MESRI EA, 1994, J CELL SCI, V107, P2599; Pai L H, 1994, Important Adv Oncol, P3; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; Seno M, 1996, GROWTH FACTORS, V13, P181, DOI 10.3109/08977199609003220; SHAW JP, 1991, J BIOL CHEM, V266, P21118; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SIEGALL CB, 1994, J IMMUNOL, V152, P2377; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; WATANABE T, 1994, J BIOL CHEM, V269, P9966; Zhang K, 1996, J BIOL CHEM, V271, P3884	25	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1209	1215		10.1038/sj.onc.1201632	http://dx.doi.org/10.1038/sj.onc.1201632			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528863				2022-12-17	WOS:000072336000012
J	Bessard, ACH; Garay, E; Lacronique, V; Legros, Y; Demarquay, C; Houque, A; Portefaix, JM; Granier, C; Soussi, T				Bessard, ACH; Garay, E; Lacronique, V; Legros, Y; Demarquay, C; Houque, A; Portefaix, JM; Granier, C; Soussi, T			Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein	ONCOGENE			English	Article						p53; xenopus; manoclonal antibodies; transactivation	TUMOR-SUPPRESSOR PROTEIN; WILD-TYPE P53; MONOCLONAL-ANTIBODIES; STRUCTURAL ASPECTS; GENE EVOLUTION; MURINE P53; CYCLIN-G; MUTANT; TRANSACTIVATION; MUTATIONS	Recombinant human p53 isolated either from E. coli or from insect cells is poorly active for binding to DNA but it can be dramatically stimulated by phosphorylation, antibody binding to the carboxy-terminal negative regulatory domain, short peptides derived from this negative regulatory domain or short single strands of DNA. We report here that Xenopus p53 has a very similar behavior. Using a new set of monoclonal antibodies directed either to the amino- or the carboxy-terminus of Xenopus p53, we demonstrate that the frog protein can be activated by specific carboxy-terminus monoclonal antibodies in order to bind to human p53 DNA response element. In addition, we report that such activation of both humans and frogs protein can also be achieved by small peptides derived from the carboxy-terminus of both p53. Although, the sequence of this region is not conserved in the various p53 species, the presence of conserved basic residues indicates that such activation is charge-dependent. This is confirmed by the finding that small poly-lysine peptides can activate both human and Xenopus p53. In vivo expression of Xenopus p53 indicates that this protein is able to transactivate a wide variety of human p53 response elements as long as the experiments are performed at 32 degrees C since activity at 37 degrees C, a temperature well above the natural temperature of Xenopus, is lost. Finally, we demonstrate that human mdm2 is able to down regulate the transcriptional activity of Xenopus p53.	Inst Genet Mol, INSERM, U301, F-75010 Paris, France; UFR Pharm, CNRS, UMR 9921, F-34060 Montpellier 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Soussi, T (corresponding author), Inst Curie, CNRS, UMR 218, Pavillon Trouillet Rossignol,26 Rue Ulm, F-75231 Paris 05, France.		Penard-Lacronique, Virginie/E-5729-2016; GRANIER, Claude/A-8841-2008; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; soussi, thierry/0000-0001-8184-3293				ABARZUA P, 1995, CANCER RES, V55, P3490; Beroud C, 1997, NUCLEIC ACIDS RES, V25, P138, DOI 10.1093/nar/25.1.138; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hall PA, 1997, CURR BIOL, V7, pR144, DOI 10.1016/S0960-9822(97)70074-5; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lane DP, 1996, ONCOGENE, V12, P2461; LEGROS Y, 1993, B CANCER, V80, P102; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; MIYASHITA T, 1995, CELL, V80, P293; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shaw P, 1996, ONCOGENE, V12, P921; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SOUSSI T, 1987, ONCOGENE, V1, P71; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; SOUSSI T, 1990, ONCOGENE, V5, P945; TCHANG F, 1993, DEV BIOL, V159, P163, DOI 10.1006/dbio.1993.1230; WAGNER P, 1991, ONCOGENE, V6, P1539; WANG Y, 1995, ONCOGENE, V10, P779; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	45	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					883	890		10.1038/sj.onc.1201598	http://dx.doi.org/10.1038/sj.onc.1201598			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484779				2022-12-17	WOS:000072053200007
J	Eng, C; Myers, SM; Kogon, MD; Sanicola, M; Hession, C; Cate, RL; Mulligan, LM				Eng, C; Myers, SM; Kogon, MD; Sanicola, M; Hession, C; Cate, RL; Mulligan, LM			Genomic structure and chromosomal localization of the human GDNFR-alpha gene	ONCOGENE			English	Article						RET; GFR alpha-1; GDNF; Exon-intron; 10q	MICE LACKING GDNF; MEDULLARY-THYROID CARCINOMA; TYROSINE KINASE DOMAIN; NEOPLASIA TYPE 2B; RET PROTOONCOGENE; DISEASE PHENOTYPE; POINT MUTATION; MEN 2A; RECEPTOR; FMTC	GDNFR-alpha is a glycosyl-phosphotidylinositol-linked receptor for glial cell line-derived neurotrophic factor (GDNF), GDNF binds to GDNFR-alpha and this complex, in turn, is believed to interact with the RET receptor tyrosine kinase to effect downstream signalling. GDNFR-alpha belongs to a novel gene family without strong homology to known genes. Thus, little information has been available to help predict genomic structure or location of this gene. In this study, the genomic organization of human GDNFR-alpha was delineated through a combination of PAC clone characterization, long distance PCR and sequence analyses. Exon-intron boundaries were defined by comparing the size and sequence of the genomic PCR products to those predicted by the cDNA sequence. The human GDNFR-alpha gene comprises 9 exons. GDNFR-alpha PAC clones were used for FISH analysis to map this gene to 10q26.	Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Richard & Sara Smith Labs, Boston, MA 02115 USA; Univ Cambridge, CRC, Human Canc Genet Res Grp, Cambridge CB2 2QQ, England; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Paediat, Kingston, ON K7L 3N6, Canada; Biogen Inc, Dept Mol Biol, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; University of Cambridge; Queens University - Canada; Queens University - Canada; Biogen	Eng, C (corresponding author), Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Richard & Sara Smith Labs, SM822 1 Jimmy Fund Way, Boston, MA 02115 USA.			Eng, Charis/0000-0002-3693-5145				Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BOLINO A, 1995, ONCOGENE, V10, P2415; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Ivanchuk SM, 1996, HUM MOL GENET, V5, P2023, DOI 10.1093/hmg/5.12.2023; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Leong S, 1981, ADV THYROID NEOPLASI, P95; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Moore DD, 1995, GLOB MOB SURV; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1990, ONCOGENE, V5, P1595; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0	30	10	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					597	601		10.1038/sj.onc.1201573	http://dx.doi.org/10.1038/sj.onc.1201573			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482105				2022-12-17	WOS:000071816600004
J	Weyman, CM; Wolfman, A				Weyman, CM; Wolfman, A			Oncogenic Ras-induced secretion of a novel inhibitor of skeletal myoblast differentiation	ONCOGENE			English	Article						myoblast; differentiation; inhibition; oncogenic Ras	FIBROBLAST GROWTH-FACTOR; PROTEIN-KINASE KINASE; MYOGENIC DIFFERENTIATION; CELL-CYCLE; MUSCLE DIFFERENTIATION; EPITHELIAL-CELLS; G1 PHASE; N-RAS; EXPRESSION; INDUCTION	Expression of oncogenic H-Ras in 23A2 myoblasts (A2:H-Ras cells) is sufficient to induce both a transformed phenotype and a differentiation-defective phenotype, Because oncogenic Pas is known to induce the secretion of several different growth factors involved in maintaining the transformed phenotype of both fibroblast and epithelial cells, we explored the possibility that expression of oncogenic Ras in 23A2 myoblasts might lead to the secretion of a factor which inhibits differentiation, The differentiation of 23A2 myoblasts was inhibited (i) by coculture with an equal number of A2:H-Ras cells, (ii) by culture with an equal number of A2:H-Ras cells in the same tissue culture medium on an insert which allowed equilibration of molecules smaller than I micron, and (iii) by culture in media previously conditioned by A2:H-Ras cells, Similar results were obtained when 23A2 myoblasts expressing oncogenic N-Ras were substituted for A2:H-Ras cells in each assay, No inhibition of differentiation was observed, however, when differentiation-defective E1A-expressing 23A2 cells or C3H10T1/2 fibroblasts were substituted for A2:H-Ras cells, The differentiation inhibitor(s) in media conditioned by A2:K-Ras cells is heat stable, larger than 3 kD, and sensitive to the non-specific growth factor antagonist, suramin, Western analyses failed to detect either FGF-2 or TGF beta (the known inhibitors of myoblast differentiation) in media conditioned by A2:H-Ras cells, Furthermore, while FGF-2 is a potent activator of MAP kinase and TGF beta is a potent inhibitor of mink lung epithelial cell (CCL64) growth, conditioned media from A2:H-Ras cells does not activate MAP kinase and does not inhibit the growth of CCL64 cells. These results indicate that expression of oncogenic Pas induces the secretion of a novel inhibitor of skeletal myoblast differentiation, Furthermore, these results are the first to implicate an autocrine/paracrine mechanism in the inhibition of differentiation by oncogenic Ras.			Weyman, CM (corresponding author), CLEVELAND CLIN FDN,DEPT CELL BIOL,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049652, R55GM049652] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49652] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Berkowitz EA, 1996, ONCOGENE, V12, P1991; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DAWSON TP, 1995, CANCER RES, V55, P915; ENKEMANN SA, 1990, CELL GROWTH DIFFER, V1, P375; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; GIOVANNI C, 1995, BRIT J CANCER, V72, P1224; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; KONIECZNY SF, 1989, ONCOGENE, V4, P473; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; LATHROP B, 1985, J CELL BIOL, V101, P2194, DOI 10.1083/jcb.101.6.2194; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PIRONIN M, 1992, INT J CANCER, V51, P908; RAK J, 1995, CANCER RES, V55, P4575; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; SCHRELL UMH, 1995, J NEUROSURG, V82, P600, DOI 10.3171/jns.1995.82.4.0600; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VISSCHER DA, 1996, ADV ONCOBIOLOGY; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; WEYMAN CM, 1996, ADV ONCOBIOLOGY	37	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2521	2528		10.1038/sj.onc.1201423	http://dx.doi.org/10.1038/sj.onc.1201423			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399640	Bronze			2022-12-17	WOS:A1997YG73200002
J	Sun, Q; Tang, SC; Pater, MM; Pater, A				Sun, Q; Tang, SC; Pater, MM; Pater, A			Different HPV16 E6/E7 oncogene expression patterns in epithelia reconstructed from HPV16-immortalized human endocervical cells and genital keratinocytes	ONCOGENE			English	Article						human papillomavirus type 16; E6/E7 oncogene expression; metaplasia; stratified squamous epithelium; endocervical cells; keratinocytes	HUMAN PAPILLOMAVIRUS TYPE-16; CERVICAL-CARCINOMA CELLS; EARLY GENE-EXPRESSION; CYTOKERATIN-EXPRESSION; RETINOIC ACID; SHORT ARM; E7 GENES; DNA; GROWTH; INVITRO	Human papillomavirus type 16 (HPV16) E6/E7 oncogenes immortalize two types of human genital epithelial cells in vitro, endocervical cells and ectocervical or foreskin keratinocytes. Epithelia reconstructed in in vivo nude mouse implants or in vitro organotypic raft cultures from immortalized endocervical cells form higher grade dysplasia than those from keratinocytes, Here, we compared viral E6/E7 mRNA expression in immortalized cell lines of the three cell types using implants, rafts and in situ hybridization assays, Endocervical cells expressed E6/E7 throughout their reconstructed epithelia. In contrast, oncogenes were limited to basal cells for keratinocyte lower grade dysplasias, To study the role of the HPV16 promoter/enhancer in this repression in the upper layers of keratinocyte epithelia, new cell lines were established by immortalization with E6/E7 controlled by the SV40 promoter, The oncogenes were shown to be controlled from the SV40 elements after immortalization, Nevertheless, E6/E7 in the two cell types had the same cell-specific expression pattern as that controlled from the homologous HPV16 promoter, In addition, naturally occurring premalignant lesions having integrated HPV16 DNA expressed E6/E7 extensively in the high-grade dysplastic region of undifferentiated metaplasia, On the other hand, oncogene expression was restricted to lower layers in the lower grade dysplastic region of more mature differentiation, Our data suggest that keratinocytes have an inherent HPV16 promoter-nonspecific mechanism of repression, Apparently this mechanism, which can be acquired during maturation, is initially nonfunctional in in vitro and in vivo epithelia derived from metaplastic endocervical cells.	MEM UNIV NEWFOUNDLAND, FAC MED, DIV BASIC MED SCI, St John, NF A1B 3V6, CANADA	Memorial University Newfoundland								AVERETTE HE, 1970, AM J OBSTET GYNECOL, V108, P8, DOI 10.1016/0002-9378(70)90195-X; BARBOSA MS, 1989, ONCOGENE, V4, P1529; BELAGULI NS, 1992, J VIROL, V66, P2724, DOI 10.1128/JVI.66.5.2724-2730.1992; BLANTON RA, 1991, AM J PATHOL, V138, P673; BOSCH FX, 1990, J VIROL, V64, P4743, DOI 10.1128/JVI.64.10.4743-4754.1990; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1990, DIFFERENTIATION, V44, P150, DOI 10.1111/j.1432-0436.1990.tb00548.x; BOURGHARDT E, 1986, VIRAL ETIOLOGY CERVI, P81; BRAUN L, 1992, MOL CARCINOGEN, V6, P100, DOI 10.1002/mc.2940060205; BRAUN L, 1990, CANCER RES, V50, P7324; COOPER K, 1991, J CLIN PATHOL, V44, P406, DOI 10.1136/jcp.44.5.406; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; DURST M, 1991, J VIROL, V65, P796; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FU YS, 1989, PATHOLOGY UTERINE CE, P28; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1986, LANCET, V2, P489; JENSON AB, 1990, PAPILLOMAVIRUSES HUM, P11; Kessis TD, 1996, ONCOGENE, V13, P427; KNAPP AC, 1989, CELL, V59, P67, DOI 10.1016/0092-8674(89)90870-2; LECHNER MS, 1991, VIROLOGY, V185, P563, DOI 10.1016/0042-6822(91)90526-H; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MUNGER K, 1989, J VIROL, V63, P4417; NUOVO GJ, 1991, AM J PATHOL, V139, P847; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PATER MM, 1988, J MED VIROL, V26, P185, DOI 10.1002/jmv.1890260210; PATER MM, 1985, VIROLOGY, V145, P313, DOI 10.1016/0042-6822(85)90164-3; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; RADER JS, 1990, ONCOGENE, V5, P571; ROSL F, 1988, EMBO J, V7, P1321, DOI 10.1002/j.1460-2075.1988.tb02947.x; ROSL F, 1991, EMBO J, V10, P1337, DOI 10.1002/j.1460-2075.1991.tb07653.x; Sarma D, 1996, INT J CANCER, V65, P345, DOI 10.1002/(SICI)1097-0215(19960126)65:3<345::AID-IJC12>3.3.CO;2-L; SCHELLHAS HF, 1969, AM J OBSTET GYNECOL, V104, P617, DOI 10.1016/0002-9378(69)90595-X; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHINDOH M, 1995, OBSTET GYNECOL, V85, P721, DOI 10.1016/0029-7844(95)00043-Q; SMITS HL, 1988, J VIROL, V62, P4538, DOI 10.1128/JVI.62.12.4538-4543.1988; SMITS HL, 1991, VIROLOGY, V182, P870, DOI 10.1016/0042-6822(91)90632-L; SMITS PHM, 1993, J GEN VIROL, V74, P121, DOI 10.1099/0022-1317-74-1-121; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; SUN Q, 1992, CANCER RES, V52, P4254; SUN Q, 1993, INT J CANCER, V54, P656, DOI 10.1002/ijc.2910540422; TSUTSUMI K, 1992, AM J PATHOL, V140, P255; TURYK ME, 1989, IN VITRO CELL DEV B, V25, P544, DOI 10.1007/BF02623567; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1988, CANCER RES, V48, P4620; WOODWORTH CD, 1990, J VIROL, V64, P4767, DOI 10.1128/JVI.64.10.4767-4775.1990; Yang XL, 1996, INT J CANCER, V65, P338, DOI 10.1002/(SICI)1097-0215(19960126)65:3<338::AID-IJC11>3.0.CO;2-6; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	53	10	13	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	1997	15	20					2399	2408		10.1038/sj.onc.1201425	http://dx.doi.org/10.1038/sj.onc.1201425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395236				2022-12-17	WOS:A1997YE96300002
J	Chi, KD; McPhee, RA; Wagner, AS; Dietz, JJ; Pantazis, P; Goustin, AS				Chi, KD; McPhee, RA; Wagner, AS; Dietz, JJ; Pantazis, P; Goustin, AS			Integration of proviral DNA into the PDGF beta-receptor gene in HTLV-I-infected T-cells results in a novel tyrosine kinase product with transforming activity	ONCOGENE			English	Article						receptor tyrosine kinase; PDGF; insertional mutagenesis; HTLV-I; long terminal repeat; T-lymphocyte	VIRUS TYPE-I; DIFFERENT SIGNALING PATHWAYS; BOVINE LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; CHROMOSOMAL TRANSLOCATION; NUCLEOTIDE-SEQUENCE; HUMAN RETROVIRUS; RNA EXPRESSION	We have previously shown that noninfected human T-cell lines express the canonical 5.7 kb mRNA coding for the type beta platelet-derived growth factor-receptor (PDGF beta-receptor), whereas HTLV-I-infected T-cell lines express a novel PDGF beta-receptor mRNA of 3.8 kb, In this report, we have extended those studies to molecularly characterize the 3.8 kb PDGF beta-receptor mRNA and show that it has resulted from integration of an apparently undeleted HTLV-I provirus into the PDGF beta-receptor gene in an orientation enabling expression of a truncated PDGF beta-receptor mRNA using the 3' HTLV-I long terminal repeat as a promoter, Further, NIH3T3 cells transfected with a plasmid containing the truncated PDGF beta-receptor ORF plasmid generate colonies in soft agar with more cells per colony than untransfected cells, or cells transfected with the Tax 1 or PDGF-B (c-sis) plasmids, These results indicate that the truncated PDGF beta-receptor protein acquires transforming capability and that HTLV-I-induced truncation of PDGF beta-receptor may correlate with HTLV-I-associated neoplasia of human T-cells.	WAYNE STATE UNIV,SCH MED,CTR MOL MED & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,DETROIT,MI 48201; STEHLIN FDN CANC RES,HOUSTON,TX 77003	Wayne State University; Wayne State University			Goustin, Anton Scott/A-2136-2011	Goustin, Anton Scott/0000-0002-4483-5101	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027444] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD27444] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARYA SK, 1984, SCIENCE, V223, P1086, DOI 10.1126/science.6320374; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEPPER JM, 1984, J IMMUNOL, V133, P1691; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3425; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; KETTMANN R, 1982, P NATL ACAD SCI-BIOL, V79, P2465, DOI 10.1073/pnas.79.8.2465; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; Kubota S, 1996, ONCOGENE, V12, P1441; MARKHAM PD, 1983, INT J CANCER, V31, P413, DOI 10.1002/ijc.2910310404; MARRIOTT SJ, 1992, ONCOGENE, V7, P1749; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; OHSHIMA K, 1991, CANCER RES, V51, P4639; PANTAZIS P, 1990, EUR J HAEMATOL, V45, P127; PANTAZIS P, 1987, ONCOGENE, V1, P285; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1983, SCIENCE, V219, P856, DOI 10.1126/science.6600519; RAO VN, 1993, ONCOGENE, V8, P2167; RATNER L, 1985, J VIROL, V54, P781, DOI 10.1128/JVI.54.3.781-790.1985; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; SAGGIORO D, 1990, CANCER RES, V50, P4968; SAKURAI H, 1992, LEUKEMIA RES, V16, P941, DOI 10.1016/0145-2126(92)90040-E; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SEIGEL LJ, 1986, VIROLOGY, V154, P67, DOI 10.1016/0042-6822(86)90430-7; SEIKI M, 1982, P NATL ACAD SCI-BIOL, V79, P6899, DOI 10.1073/pnas.79.22.6899; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHIMOTOHNO K, 1984, P NATL ACAD SCI-BIOL, V81, P6657, DOI 10.1073/pnas.81.21.6657; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SODROSKI J, 1992, BIOCHIM BIOPHYS ACTA, V1114, P19, DOI 10.1016/0304-419X(92)90003-H; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; UMADOME H, 1988, J CLIN INVEST, V81, P52, DOI 10.1172/JCI113309; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDENBROEKE A, 1988, P NATL ACAD SCI USA, V85, P9263, DOI 10.1073/pnas.85.23.9263; WATANABE T, 1984, VIROLOGY, V133, P238, DOI 10.1016/0042-6822(84)90446-X	48	10	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 28	1997	15	9					1051	1057		10.1038/sj.onc.1201267	http://dx.doi.org/10.1038/sj.onc.1201267			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XT161	9285559				2022-12-17	WOS:A1997XT16100006
J	Sugiyama, H; Papst, P; Fujita, M; Gelfand, EW; Terada, N				Sugiyama, H; Papst, P; Fujita, M; Gelfand, EW; Terada, N			Overexpression of wild type p70 S6 kinase interferes with cytokinesis	ONCOGENE			English	Article						p70 S6 kinase; overexpression; cytokinesis; rapamycin; cell cycle	PROTEIN-KINASE; CYTOCHALASIN-B; MAP2 KINASE; RAPAMYCIN; ACTIVATION; PHOSPHORYLATION; CELLS; INACTIVATION; STIMULATION; TRANSLATION	p70 S6 kinase (p70(s6k)) is a serine/threonine kinase which is activated through an unidentified pathway by mitogenic stimuli, Here we demonstrate that stable- and transient-overexpression of wild type (WT)-p70(s6k) results in perturbation of cytokinesis in NIH3T3 cells. Cells overexpressing WT-p70(s6k) demonstrated a slow growth rate and lower viability, whereas cells overexpressing a mutant T229A-p70(s6k) had a similar growth rate and viability as those of parental NIH3T3 cells. Moreover, WT-p70(s6k) cells demonstrated several abnormalities in cellular morphology; both the cytoplasm and the nuclei were large and a proportion of the cells was multinucleated. Flow cytometric analysis of propidium iodide-stained cells demonstrated that about 50% of the cells had 4N or greater content of DNA, When cell division in WT-p70(s6k) cells was monitored by time-lapse video microscopy, cytokines was often incomplete after mitosis, producing binucleated cells, Addition of rapamycin to WT-p70(s6k) cells, which inactivates endogenous and transfected p70(s6k), failed to reverse any of the morphological abnormalities. These indicate that overexpression of p70(s6k) but not increases in activity of p70(s6k), is responsible for the phenotype. A molecule which interacts with p70(s6k) may be involved in this regulation of cytokinesis.	NATL JEWISH MED & RES CTR,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT DERMATOL,DENVER,CO 80206	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NCI NIH HHS [CA-64685] Funding Source: Medline; NIAID NIH HHS [AI-26940, AI-29704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI026940, R01AI026940, R01AI029704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P4530; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KRISHAN A, 1972, J CELL BIOL, V54, P657, DOI 10.1083/jcb.54.3.657; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; MORELLI JG, 1992, J INVEST DERMATOL, V98, P290, DOI 10.1111/1523-1747.ep12497951; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SANGER JW, 1972, AM J ANAT, V135, P293, DOI 10.1002/aja.1001350214; Sugiyama H, 1996, J IMMUNOL, V157, P656; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1993, J BIOL CHEM, V268, P12062; TERADA N, 1995, J IMMUNOL, V155, P3418; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	36	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					443	452		10.1038/sj.onc.1201207	http://dx.doi.org/10.1038/sj.onc.1201207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242381				2022-12-17	WOS:A1997XM23800009
J	Nakamura, T; WilliamsSimons, L; Westphal, H				Nakamura, T; WilliamsSimons, L; Westphal, H			A human papillomavirus type 18 E6/E7 transgene sensitizes mouse lens cells to human wild-type p53-mediated apoptosis	ONCOGENE			English	Article						lens; transgenic; HPV18; p53	RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; CERVICAL-CARCINOMA; HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR; CYCLE REGULATION; E6 PROTEIN; E7 GENES; MICE; P53	We have studied the concerted action of factors that influence the balance between cell proliferation and cell death in the developing lens of transgenic mice. We show that a human papillomavirus type 18 (HPV18) E6/E7 transgene that predominantly expresses the viral E7 gene product triggers apoptosis in a dose dependent manner, and causes retardation of lens growth or microphakia. E7 is known to inactivate pRB, the product of the retinoblastoma gene, and to enhance the action of p53. Our earlier work had demonstrated that over-expression of p53 itself can cause apoptosis of lens cells, and that a mutant p53 allele can interfere with this process. In the present study, we examined lenses that simultaneously express different constellations of the HPV18 E6/E7, wild-type and mutant human p53, and wild-type human PRE transgenes. We observed that lens cells expressing the HPV18 transgene are more sensitive to mild-type human p53 action than normal lens cells. As a result, there is severe microphakia in lenses that express both the HPV18 and the wild-type p53 transgenes. By contrast, apoptosis was reduced in lenses that coexpressed the HPV18 and either the PRE or the mutant p53 transgene. We conclude that levels of wild-type p53 are critical, and that any excess of p53 or suppression of PRE can cause cell death. Our results encourage attempts to counteract the deleterious action of human papillomaviruses in cervical cancer by a combination of measures that decrease cell proliferation and enhance apoptosis.			Nakamura, T (corresponding author), NICHHD,LAB MAMMALIAN GENES & DEV,NIH,BETHESDA,MD 20892, USA.							ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1993, AM J PATHOL, V142, P1187; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; BOSHART M, 1984, EMBO J, V3, P1151, DOI 10.1002/j.1460-2075.1984.tb01944.x; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; COMERFORD SA, 1995, ONCOGENE, V10, P587; COULOMBRE AJ, 1964, J EXP ZOOL, V156, P39, DOI 10.1002/jez.1401560104; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENHALGH DA, 1994, CELL GROWTH DIFFER, V5, P667; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GROSSMAN SR, 1989, J VIROL, V63, P366, DOI 10.1128/JVI.63.1.366-374.1989; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KONDOH G, 1991, J VIROL, V65, P3335, DOI 10.1128/JVI.65.6.3335-3339.1991; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; NAKAMURA T, 1989, New Biologist, V1, P193; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROMANCZUK H, 1991, J VIROL, V65, P2739, DOI 10.1128/JVI.65.5.2739-2744.1991; SASAGAWA T, 1992, CANCER RES, V52, P4420; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SMOTKIN D, 1989, J VIROL, V63, P1441, DOI 10.1128/JVI.63.3.1441-1447.1989; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; TSUNOKAWA Y, 1986, P NATL ACAD SCI USA, V83, P2200, DOI 10.1073/pnas.83.7.2200; VILLA LL, 1991, VIROLOGY, V181, P374; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YASUMOTO S, 1986, J VIROL, V57, P572, DOI 10.1128/JVI.57.2.572-577.1986; Yatsudo M, 1988, VIROLOGY, V166, P594; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	57	10	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					2991	2998		10.1038/sj.onc.1201155	http://dx.doi.org/10.1038/sj.onc.1201155			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223662				2022-12-17	WOS:A1997XG10000001
J	Xu, X; Gelinas, C				Xu, X; Gelinas, C			A mutant Rel-homology domain promotes transcription by p50/NF kappa B1	ONCOGENE			English	Article						c-Rel; p50; NF kappa B; transcription; protein conformation	NF-KAPPA-B; DNA-BINDING SUBUNIT; C-REL; V-REL; ONCOGENIC TRANSFORMATION; MAMMALIAN-CELLS; GENE ACTIVATION; FAMILY PROTEINS; NUCLEAR FACTOR; P50 SUBUNIT	Previous studies showed that the binding of p50/NF kappa B1 to particular kappa B DNA sites altered its conformation in a way that correlated with transcriptional activation. Here, we investigated the effects of protein-protein interactions on the transcriptional activity of p50. We show that the association of p50 with a mutant Rel-homology domain (RHD) defective for DNA binding led to synergistic activation of kappa B site-dependent transcription, whereas neither protein alone had any effect. Partial proteolytic analysis showed that the conformation of p50 in these complexes differed from that in wild-type c-Rel-RHD/p50 complexes, and correlated with activated transcription. These results suggest that the Rel-homology domain can act as an allosteric effector to promote transcription by p50/NF kappa B1 and that the configuration of p50 is important for its activity. This also suggests that Rel proteins can promote transcription by other Rel-family members without binding to their DNA recognition site. These studies emphasize the important role of protein-protein interactions in Rel and NF kappa B-mediated transcription.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,GRAD PROGRAM BIOCHEM & MOL BIOL,PISCATAWAY,NJ 08854; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854; INST CANC RES,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999] Funding Source: NIH RePORTER; NCI NIH HHS [CA54999] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KEIDEL S, 1994, MOL CELL BIOL, V14, P287, DOI 10.1128/MCB.14.1.287; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRETZSCHMAR M, 1992, GENE DEV, V6, P761, DOI 10.1101/gad.6.5.761; KUMAR S, 1993, P NATL ACAD SCI USA, V90, P8962, DOI 10.1073/pnas.90.19.8962; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU J, 1994, P NATL ACAD SCI USA, V91, P908, DOI 10.1073/pnas.91.3.908; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; MCDONNELL PC, 1992, ONCOGENE, V7, P163; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; White DW, 1996, MOL CELL BIOL, V16, P1169; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733	60	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 3	1997	14	13					1521	1530		10.1038/sj.onc.1200985	http://dx.doi.org/10.1038/sj.onc.1200985			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WQ548	9129142				2022-12-17	WOS:A1997WQ54800002
J	Hall, AR; Milner, J				Hall, AR; Milner, J			Specific p53-DNA complexes contain an mdm2-related protein	ONCOGENE			English	Article						p53; mdm-2; specific DNA binding	P53 QUATERNARY STRUCTURE; DNA-BINDING; WILD-TYPE; TUMOR-SUPPRESSOR; ONCOPROTEIN MDM2; GENE; IDENTIFICATION; EXPRESSION; ACTIVATION; ONCOGENE	The mdm2 gene encodes a family of proteins, a subset of which bind p53 and negatively regulate its function as a transcription factor. We now show that an anti-mdm-2 monoclonal antibody, 2A10, recognises a protein present in rabbit reticulocyte lysate which binds murine p53 translated in vitro. Deletion of p53 residues 10-35, which encompass the mdm-2 binding site, abolished binding of this 2A10-reactive protein. Binding was also dependent upon p53 protein conformation and may require nascent p53 polypeptide since binding was lost following conformational shifting of the temperature-sensitive mutant: A135V. Previous studies have shown that mdm-2-p53 complexes fail to exhibit detectable sequence-specific DNA binding. However, our present results demonstrate that p53 in complex with an mdm-2-related protein in vitro retained sequence-specific DNA binding capacity. Non-transformed (but not transformed) 3T3 cells were also found to express a similar 2A10-reactive protein, detectable by gel shift analysis of cellular p53 in complex with a specific DNA target. Mdm-2 in rabbit reticulocyte lysate and in normal, nontransformed 3T3 cells may represent constitutively expressed protein. Our results raise the possibility that constitutive mdm-2 may enhance and/or suppress functions of p53 as yet unidentified.	UNIV YORK,DEPT BIOL,YCRC P53 RES GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK								BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARAK Y, 1993, EMBO J, V12, P2799; BUESORAMOS CE, 1995, LEUKEMIA LYMPHOMA, V17, P13, DOI 10.3109/10428199509051698; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HAINAUT P, 1994, ONCOGENE, V9, P299; HAINAUT P, 1993, CANCER RES, V53, P4463; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MAXWELL SA, 1994, ANTICANCER RES, V14, P2541; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1993, ONCOGENE, V8, P2001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZERRAHN J, 1992, ONCOGENE, V7, P1371	36	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 20	1997	14	11					1371	1376		10.1038/sj.onc.1200962	http://dx.doi.org/10.1038/sj.onc.1200962			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WP109	9178897				2022-12-17	WOS:A1997WP10900012
J	Wahlstrom, GM; Harbers, M; Vennstrom, B				Wahlstrom, GM; Harbers, M; Vennstrom, B			The oncoprotein P75(gag-v-erbA) represses thyroid hormone induced transcription only via response elements containing palindromic half-sites	ONCOGENE			English	Article						v-erbA; homodimers; repression; transcription factor; response elements	AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTORS; DOMINANT NEGATIVE ACTIVITY; V-ERBA; C-ERBA; CELL-TRANSFORMATION; AUXILIARY PROTEINS; LIGAND-BINDING; DOMAIN; GENE	The v-erbA oncoprotein p75(gag-v-erbA), derived from the thyroid hormone receptor alpha (TR alpha), functions as transdominant transcriptional repressor, The mechanism by which P75(gag-v-erbA) acts is however poorly characterized. Here, we show that repression of TR alpha mediated transcription by P75(gag-v-erbA) in transformed erythroblasts is dependent on the structure of the thyroid hormone response element to which it binds. A very efficient repression was seen with hormone response elements having half-sites organized as everted repeats (ER), whereas repression was inefficient with directly repeated half-sites (DR), Promoters containing half-sites organized as an inverted palindrome (IR) gave an intermediate repression, Although P75(gag-v-erbA) failed to associate with the ligand binding domain of retinoid X (RXR) receptor in a two-hybrid test, the oncoprotein in nuclear extracts from transformed cells heterodimerised quantitatively with RXR upon binding to response elements of the DR type, On the other hand, both RXR/P75(gag-v-erb) heterodimers and other types of dimers formed on ER elements, P75(gag-v-erbA) also failed to bind to elements that contained only one half-site in vivo and in vitro, The data demonstrate that P75(gag-v-erbA) represses gene expression efficiently as a dimer, and suggest that thyroid hormone responsive genes that may be targets for the action of the oncoprotein are repressed most efficiently if they contain elements of the ER type.	KAROLINSKA INST,DEV BIOL LAB,DEPT CELLULAR & MOL BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet				Harbers, Matthias/0000-0002-5613-7220				AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P2725; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN DJ, 1995, NATURE, V377, P454; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORREST D, 1990, ONCOGENE, V5, P309; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARBERS H, 1996, NUCLEIC ACIDS RES, V24, P12; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HERMANN T, 1993, ONCOGENE, V8, P55; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; RASCLE A, 1994, ONCOGENE, V9, P2853; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1992, ONCOGENE, V7, P953; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; TRAINOR CD, 1995, MOL ENDOCRINOL, V9, P1135, DOI 10.1210/me.9.9.1135; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	60	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					843	852						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761306				2022-12-17	WOS:A1996VD43300020
J	Rojas, JM; Coque, JJR; Guerrero, C; Aroca, P; deMora, JF; delaCruz, X; Lorenzi, MV; Esteban, LM; Santos, E				Rojas, JM; Coque, JJR; Guerrero, C; Aroca, P; deMora, JF; delaCruz, X; Lorenzi, MV; Esteban, LM; Santos, E			A 15 amino acid stretch close to the Grb2-binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity	ONCOGENE			English	Article						hSos1; isoforms; Ras activation; Grb2 binding; differential expression	RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; SEVENLESS GENE; SH3 DOMAINS; RAS; PROTEIN; CELLS; IDENTIFICATION	We compared structure, expression and functional properties of two hSos1 cDNA isoforms (IsfI and Isf II) isolated, respectively, from human fetal brain and adult skeletal muscle libraries, IsfI and IsfII nucleotide sequences differ only by the presence in IsfII of an in-frame 45 bp insertion located near the first proline-rich motif required for Grb2 binding, Some human tissues express only one isoform whereas others express different proportions of both in fetal and adult stages, In vitro binding assays and in vivo functional studies showed that IsfII exhibits significantly higher Grb2 binding affinity and biological activity than IsfI, These results suggest that functionally different hSos1 isoforms, with differential tissue expression and distribution, play important regulatory roles in the mechanisms controlling Ras activation in different tissues and/or developmental stages.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Rojas, José M/D-3718-2018; de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021; Rojas, José M./AAA-3354-2021; Coque, Juan Jose Rubio/AAV-2049-2021; Aroca, Pilar/P-2141-2017; Guerrero, Carmen/F-1776-2010	Rojas, José M/0000-0002-5383-3482; de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095; Rojas, José M./0000-0002-7547-2825; Coque, Juan Jose Rubio/0000-0001-8221-7817; Aroca, Pilar/0000-0002-7557-6931; Guerrero, Carmen/0000-0002-8747-6831; De la Cruz Montserrat, Fco. Xavier/0000-0002-9738-8472				ADHUBEI AA, 1993, J MOL BIOL, V229, P472; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HERTOG J, 1994, EMBO J, V13, P3020; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NISHI T, 1991, ONCOGENE, V6, P1555; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	58	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2291	2300						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649768				2022-12-17	WOS:A1996UQ22000005
J	Dolnikov, A; Ward, RL; Hawkins, NJ; Symonds, G				Dolnikov, A; Ward, RL; Hawkins, NJ; Symonds, G			Apoptosis in v-myc transformation of myelomonocytic cells and its modulation by CSF-1	ONCOGENE			English	Article						v-myc; apoptosis; CSF-1; transformation	C-MYC; ACTIVATES TRANSCRIPTION; PROTEIN; BCL-2; GENE; EXPRESSION; DEATH; LINE; INDUCTION; MAX	c-myc is a proto-oncogene essential for cell growth. When activated, its expression can lead to uncontrolled cell proliferation, transformation and tumorigenesis. The cell line tEMmyc4 is a murine myelomonocytic cell line that was established following transformation by v-myc. It has a high level of v-myc expression and constitutively expresses endogenous CSF-1, the monocytic growth and viability factor. Under growth restricting conditions (high cell density, serum deprivation, heat shock, or dexamethasone addition) cells of this line were found to undergo cell death through apoptosis. The induction of apoptosis by dexamethasone was associated with a decrease in constitutive CSF-1 expression without significant change in v-myc expression. Exogenous CSF-1 rescued these cells from dexamethasone induced-apoptosis. In vivo studies showed that tEMmyc4 cells were tumorigenic in syngeneic animals despite exhibiting some spontaneous apoptosis within the tumour mass. Co-administration of dexamethasone with the tumour cells significantly inhibited tumor development and the administration of dexamethasone to mice with established tumors resulted in tumor regression in all mice. This regression was associated with a high level of apoptosis and necrosis in the tumors. This study shows a correlation between the in vitro and in vivo induction of apoptosis and indicates that cancer cells bearing activated oncogenes may be more sensitive to apoptosis induction by chemotherapeutic agents.	ST VINCENTS HOSP, DEPT MED ONCOL, DARLINGHURST, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, DEPT MED & HAEMATOL, DARLINGHURST, NSW 2010, AUSTRALIA; UNIV NEW S WALES, SCH PHYSIOL & PHARMACOL, SYDNEY, NSW 2052, AUSTRALIA; UNIV NEW S WALES, SCH PATHOL, SYDNEY, NSW 2052, AUSTRALIA	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney	Dolnikov, A (corresponding author), ST VINCENTS HOSP, DEPT CLIN PHARMACOL & TOXICOL, DARLINGHURST, NSW 2010, AUSTRALIA.		Hawkins, Nicholas J/A-8461-2008; Ward, Robyn L/I-2313-2013	Hawkins, Nicholas J/0000-0002-2204-3189; Ward, Robyn L/0000-0002-6877-8906				ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONHAM L, 1992, ONCOGENE, V7, P2219; BOURGEOIS S, 1977, CELL, V11, P423, DOI 10.1016/0092-8674(77)90060-5; BRADBURY D, 1992, BLOOD S1, V80, pA924; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAVIDOFF AN, 1993, EXP HEMATOL, V21, P922; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DOLNIKOV A, 1995, INT J ONCOL, V6, P633; DOLNIKOV A, 1996, IN PRESS CANCER GENE; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FUKASAWA Y, 1994, AM J PATHOL, V144, P480; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOWLES KA, 1994, GENE DEV, V8, P1300; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NORMAN MR, 1977, CANCER RES, V37, P3785; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SIBLEY CH, 1974, CELL, V2, P213, DOI 10.1016/0092-8674(74)90013-0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STAPLETON P, 1991, ONCOGENE, V6, P807; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991	49	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1189	1198						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649820				2022-12-17	WOS:A1996UC06700003
J	Tsang, SX; Morris, GF; Lu, M; Morris, CB				Tsang, SX; Morris, GF; Lu, M; Morris, CB			TATA-dependent repression of human immunodeficiency virus type-1 transcription by the adenovirus E1A 243R oncoprotein	ONCOGENE			English	Article						transcription; E1A; HIV; gene regulation; TATA	LONG-TERMINAL REPEAT; NUCLEAR ANTIGEN PROMOTER; BINDING PROTEIN; ACTIVATES TRANSCRIPTION; FUNCTIONAL DOMAINS; CELLULAR PROTEINS; T-CELLS; GENE; EXPRESSION; IDENTIFICATION	Human adenovirus E1A oncoprotein activates or represses transcription from a variety of viral and cellular promoters by several complex mechanisms. The E1A products, 289R and 243R, have differential effects on transcription directed by the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). Previous reports indicate that repression of HIV-1 LTR-directed gene expression by E1A 243R is mediated through the kappa B enhancer elements located between nucleotides -105 and -82 relative to the transcription initiation start site (+1). Results from this study suggest a novel mechanism for transcriptional repression of the HIV-1 LTR by E1A 243R that is enhancer-independent and that is mediated through basal HIV-1 promoter elements. Transient expression assays, in which 5'-truncated or site-directed mutant HIV-1 LTR-CAT reporters were tested for their response to repression mediated by wild-type or mutant 243R, demonstrate that LTR sequences upstream of -31 relative to the transcription initiation start site (+1) and inclusive of the enhancer elements are dispensable for 243R-mediated repression. The ability of 243R to repress HIV-1 basal promoter activity requires both an intact N-terminus of E1A 243R and the TATA element within the HIV-1 promoter. These results support a novel mechanism for E1A 243R-induced transcriptional repression that is enhancer-independent and that targets directly the general transcription machinery.	TULANE UNIV, MED CTR, CTR CANC, DEPT LAB MED & PATHOL, NEW ORLEANS, LA 70112 USA; GEORGIA INST TECHNOL, SCH BIOL, ATLANTA, GA 30332 USA	Tulane University; University System of Georgia; Georgia Institute of Technology					NIAID NIH HHS [AI32880] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032880] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BASU A, 1993, J BIOL CHEM, V268, P4188; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FANG L, 1994, NATURE, V368, P520; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; GLENN GM, 1985, J VIROL, V56, P66, DOI 10.1128/JVI.56.1.66-74.1985; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA JA, 1992, CELL, V70, P477; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NEVINS JR, 1992, SCIENCE, V258, P424; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; RICE AP, 1988, P NATL ACAD SCI USA, V85, P4200, DOI 10.1073/pnas.85.12.4200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VENTURA AM, 1990, P NATL ACAD SCI USA, V87, P1310, DOI 10.1073/pnas.87.4.1310; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	58	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					819	826						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632904				2022-12-17	WOS:A1996TW68600013
J	Evans, MK; Chin, KV; Gottesman, MM; Bohr, VA				Evans, MK; Chin, KV; Gottesman, MM; Bohr, VA			Gene-specific DNA repair and steady state transcription of the MDR1 gene in human tumor cell lines	ONCOGENE			English	Article						DNA repair; drug resistance; tumor cells	COMPLEMENTATION GROUP-C; STRAND-SPECIFIC REPAIR; KB CARCINOMA-CELLS; PYRIMIDINE DIMERS; DEFECTIVE REPAIR; COUPLING FACTOR; ACTIVE GENE; RESISTANT; AMPLIFICATION; FIBROBLASTS	We have explored the relationship between DNA repair and transcription in vivo, A gene-specific repair assay has been employed to study removal of ultraviolet light-induced cyclobutane pyrimidine diners in the MDR1 gene at different levels of MDR1 mRNA expression, The parental human adenocarcinoma cell line, KB-3-1, has very low levels of MDR1 mRNA expression, but its multidrug resistant derivatives KB-8-5 and KB-C1 have 42-fold and 3800-fold increases in MDR1 mRNA expression, respectively, In the KB-3-1 cell line that has a low level of MDR1 mRNA expression, we find a low level of MDR1 gene-specific repair and inefficient repair of the transcribed strand of the gene, In the KB-8-5 cell line that has a modest increase in MDR1 mRNA expression, we find only a minor increase in dimer repair in the MDR1 gene, Here, the repair in the transcribed strand is not significantly higher than that in the KB-3-1 cell line, However, in the KB-C1 derivative, where there is a 3800-fold increase in the level of MDR1 mRNA expression, we find a substantial increase in the level of dimer repair in the MDR1 gene, In addition, the MDR1 transcribed strand repair is markedly more efficient than the repair in the nontranscribed strand, Our data suggest that the rate of transcription in the MDR1 gene must be substantially increased before there is any measurable effect on DNA repair, Repair in the housekeeping gene, dihydrofolate reductase (DHFR), was similar in all three tumor cell lines, Repair in its transcribed strand was markedly lower than previously reported in normal human fibroblasts, We suspect that these human HeLa-derived tumor cell lines have deficient gene-specific DNA repair, This may be an important aspect of their malignant phenotype.	NIA,MOLEC GENET LAB,NIH,BALTIMORE,MD 21224; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,PISCATAWAY,NJ 08854; NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Evans, Michele Kim/AAE-4776-2019; Bohr, Vilhelm/AAP-5931-2020; Chin, Khew-Voon/F-2670-2013	Evans, Michele/0000-0002-8546-2831				AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; ARRAND JE, 1982, NUCLEIC ACIDS RES, V10, P1547, DOI 10.1093/nar/10.5.1547; BEECHAM EJ, 1994, MOL CELL BIOL, V14, P1204, DOI 10.1128/MCB.14.2.1204; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; EVANS MK, 1993, CANCER RES, V53, P5377; EVANS MK, 1993, J BIOL CHEM, V268, P4839; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; FOJO AT, 1985, P NATL ACAD SCI USA, V82, P7661, DOI 10.1073/pnas.82.22.7661; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; JI J, 1995, P AM ASOCATION CANCE, V36, P550; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LARMINAT F, 1995, ONCOGENE, V10, P1639; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MAYNE LV, 1984, MUTAT RES, V131, P187, DOI 10.1016/0167-8817(84)90023-3; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELON I, 1987, CELL, V51, P241; MELON I, 1989, NATURE, V342, P95; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10602; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; PARSHAD R, 1984, CANCER RES, V44, P5577; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; RAINBOW AJ, 1989, CARCINOGENESIS, V10, P1073, DOI 10.1093/carcin/10.6.1073; SANFORD KK, 1992, CARCINOGENESIS, V13, P1137, DOI 10.1093/carcin/13.7.1137; SANFORD KK, 1985, ENHANCED G2 CHROMOSO, P811; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHOENLEIN PV, 1992, MOL BIOL CELL, V3, P507, DOI 10.1091/mbc.3.5.507; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SHEN D, 1986, J BIOL CHEM, V216, P7762; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; THIEBAUT F, 1993, FEBS LETT, V319, P133, DOI 10.1016/0014-5793(93)80052-V; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; YAROSH DB, 1985, MUTAT RES, V145, P1, DOI 10.1016/0167-8817(85)90034-3	42	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					651	658						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637722				2022-12-17	WOS:A1996TV59700022
J	Srinivasan, R; Maxwell, SA				Srinivasan, R; Maxwell, SA			A cellular protein activates the sequence-specific DNA-binding of p53 by interacting with the central conserved region	ONCOGENE			English	Article						p53; DNA-binding; regulation; non-small cell lung carcinoma; tumor suppressors	WILD-TYPE P53; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; SIMIAN VIRUS-40; MOUSE P53; TRANSCRIPTIONAL ACTIVATION; CONFORMATIONAL DOMAIN; GENE-PRODUCT; RAT-CELLS	Mutational inactivation of the p53 gene product is one of the most common genetic aberrations so far identified in human cancers. The p53 protein suppresses the transformed phenotype by transactivation or repression of genes involved in cell growth control. Missense mutations in the p53 protein coding sequence observed in human cancers are clustered within a central conserved (conformational) domain spanning amino acid residues 100-300 of a total of 393. Using the conformational domain of p53 fused with protein A, we have shown that the p53 conformational domain possesses Zn+2-dependent, sequence-specific DNA-binding activity. In addition to binding DNA, this domain interacts with at least five cellular proteins ranging in sizes from 30K to 90K M(r) and with the SV40 large T antigen viral oncoprotein. We investigated these cellular proteins for their modulatory effects on the sequence-specific DNA binding activity of full-length wild-type p53. A mixture of p53 conformational domain-binding proteins in bulk enhanced the DNA-binding activity of p53 greater than two-fold. Selective elution of the p53-binding proteins from the p53 hybrid protein by using a sequential step-wise NaCl gradient implicated one protein of 35K M(r) as contributing to a greater than four-fold activation of p53 DNA-binding activity. A p53 conformational domain protein containing a tumor-derived mutation at amino acid 175 failed to associate with the 35K M(r) protein. We propose that proteins interacting with the conformational domain of wild type p53 regulate the DNA-binding activity of p53, thus providing a biochemical basis for the alterations in its function induced by point mutations.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT THORAC & CARDIOVASC SURG,SECT THORAC MOLEC ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045187, P30CA016672, R37CA045187] Funding Source: NIH RePORTER; NCI NIH HHS [CA45187, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARTEK J, 1993, EUR J CANCER, V29A, P101, DOI 10.1016/0959-8049(93)90584-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EFRAT S, 1987, EMBO J, V6, P2699, DOI 10.1002/j.1460-2075.1987.tb02562.x; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKASAWA K, 1991, MOL CELL BIOL, V11, P3472, DOI 10.1128/MCB.11.7.3472; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARPER JW, 1993, CELL, V75, P805; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAO CC, 1990, VIROLOGY, V179, P806, DOI 10.1016/0042-6822(90)90148-K; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MAXWELL SA, 1995, ONCOL REP, V2, P81; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RIDGWAY PJ, 1993, ONCOGENE, V8, P1069; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SRINIVASAN R, 1993, CANCER RES, V53, P5361; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; TISHLER RB, 1993, CANCER RES, V53, P2212; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG WW, 1994, CANCER GENE THER, V1, P1; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	81	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 4	1996	12	1					193	200						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TQ014	8552392				2022-12-17	WOS:A1996TQ01400024
J	KOUHARA, H; KUREBAYASHI, S; HASHIMOTO, K; KASAYAMA, S; KOGA, M; KISHIMOTO, T; SATO, B				KOUHARA, H; KUREBAYASHI, S; HASHIMOTO, K; KASAYAMA, S; KOGA, M; KISHIMOTO, T; SATO, B			LIGAND-INDEPENDENT ACTIVATION OF TYROSINE KINASE IN FIBROBLAST GROWTH-FACTOR RECEPTOR-1 BY FUSION WITH BETA-GALACTOSIDASE	ONCOGENE			English	Article						FIBROBLAST GROWTH FACTOR RECEPTOR 1; TETRAMERIZATION; TYROSINE KINASE; TRANSFORMATION	FGF RECEPTOR; POINT MUTATION; MITOGENIC ACTIVITY; CODING SEQUENCE; CELLS; EXPRESSION; GENE; IDENTIFICATION; BINDING; CANCER	To examine the biological role of fibroblast growth factor receptor 1 (FGFR1) oligomerization far its signal transduction, we construct an expression vector encoding a FGFR1-beta-galactosidase fusion protein, This vector is designed to fuse the 3'-portion of FGPR1 to beta-galactosidase. Transfection of this vector into FGFR-negative rat L6 myoblast cells results in ligand-indpendent inhibition of differentiation into myocytes, suggesting that FGFR1 within this fusion protein is constitutively activated, This can be confirmed by demonstrating that this fusion protein exhibits the tyrosine kinase activity and phaspholipase C-gamma I is tyrosine-phosphorylated even in the absence of ligand stimuli, Since the transfected cells also exhibit the enzyme activity of beta-galactosidase which is known to be active only in a tetramer form, this constitutive activation can be elicited by tetramerization of FGFR1, Furthermore, deletion of a region corresponding to C terminal 10 amino acids important for tetramerization of beta-galactosidase from this expression vector abolishes the constitutively active nature of FGFR1 with simultaneous loss of P-galactosidase activity, Transfection of non-deleted expression vector into NIH3T3 cells results in acquisition of focus-forming activity while a deleted form of expression vector fails to show this activity even in the presence of basic FGF, These results would suggest that tetramerization of FGFR1 can produce a constitutively active form responsible for transformation of NIH3T3 cells.	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN	Osaka University			Kishimoto, Tadamitsu/C-8470-2009					AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASADABAN MJ, 1983, METHOD ENZYMOL, V100, P293; FOWLER AV, 1966, SCIENCE, V25, P1027; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KOUHARA H, 1994, ONCOGENE, V9, P455; KOUHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P31, DOI 10.1016/0006-291X(91)90885-B; LI YH, 1992, J CLIN ENDOCR METAB, V75, P1436, DOI 10.1210/jc.75.6.1436; MARICS I, 1989, ONCOGENE, V4, P335; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NONOMURA N, 1990, CANCER RES, V50, P2316; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; POON B, 1991, P NATL ACAD SCI USA, V88, P877, DOI 10.1073/pnas.88.3.877; RODRIGUES CA, 1994, CURR OPIN GENE DEV, V4, P15; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SAMBROOK L, 1989, MOL CLONING, V16, P66; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUN 15	1995	10	12					2315	2322						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784079				2022-12-17	WOS:A1995RE54300006
J	GRUBB, GR; YUN, K; REEVE, AE; ECCLES, MR				GRUBB, GR; YUN, K; REEVE, AE; ECCLES, MR			EXCLUSION OF THE WILMS-TUMOR GENE (WT1) PROMOTER AS A SITE OF FREQUENT MUTATION IN WILMS-TUMOR	ONCOGENE			English	Note						WT1; PROMOTER; MUTATION; SCCP; WILMS TUMOR; TUMOR SUPPRESSOR GENE	DENYS-DRASH SYNDROME; DOMINANT NEGATIVE MUTATIONS; HUMAN RETINOBLASTOMA GENE; SUPPRESSOR GENE; GENITOURINARY DEVELOPMENT; EXPRESSION; KIDNEY; REGION; LOCUS; INACTIVATION	WT1 is a tumour suppressor gene expressed in a specific temporal and spatial pattern in the developing kidney. Up to 15% of Wilms tumours have point mutations in the WT1 gene coding sequence. We have now investigated whether mutations in the WT1 promoter could be associated with loss of control WT1 expression and subsequent Wilms tumour formation. Using single-strand conformational polymorphism (SSCP) analysis we analysed 39 sporadic Wilms tumours for WT1 promoter mutations. We found six linked common sequence polymorphisms and two unlinked less frequent polymorphisms which allowed us to identify four tumours with loss of heterozygosity but none with point mutations, small deletions, insertions or rearrangements. We therefore conclude that WT1 promoter mutations are unlikely to play an important role in Wilms tumorigenesis.	UNIV OTAGO, SCH MED, DEPT BIOCHEM, CANC GENET LAB, DUNEDIN, NEW ZEALAND; UNIV OTAGO, SCH MED, DEPT PATHOL, DUNEDIN, NEW ZEALAND	University of Otago; University of Otago								ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Campbell C., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P541; CAMPBELL CE, 1994, ONCOGENE, V9, P583; COPPES MJ, 1993, J PEDIATR-US, V123, P673, DOI 10.1016/S0022-3476(05)80839-X; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; ECCLES MR, 1995, AM J PATHOL, V146, P40; ECCLES MR, 1994, ONCOGENE, V9, P2059; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1993, GENOMICS, V17, P499, DOI 10.1006/geno.1993.1355; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HABER DA, 1992, CANCER SURV, V12, P105; Hastie Nicholas D., 1992, Human Molecular Genetics, V1, P293; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HOFMANN W, 1993, ONCOGENE, V8, P3123; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; HUFF V, 1993, BIOCHIM BIOPHYS ACTA, V1155, P295, DOI 10.1016/0304-419X(93)90011-Z; KONIG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NORDENSKJOLD A, 1994, HUM GENET, V93, P115; OGAWA O, 1993, HUM MOL GENET, V2, P203, DOI 10.1093/hmg/2.2.203; PARK S, 1993, NAT GENET, V5, P363, DOI 10.1038/ng1293-363; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SCHNEIDER S, 1993, HUM GENET, V91, P599; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; VANHEYNINGEN V, 1990, P NATL ACAD SCI USA, V87, P5383, DOI 10.1073/pnas.87.14.5383; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; YEGER H, 1992, CELL GROWTH DIFFER, V3, P855	45	10	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1677	1681						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731725				2022-12-17	WOS:A1995QU68100027
J	SHOR, J; BENASHER, E; ALONI, Y				SHOR, J; BENASHER, E; ALONI, Y			TRANSCRIPTION ELONGATION OF THE MURINE ORNITHINE DECARBOXYLASE (ODC) GENE IS REGULATED IN-VITRO AT 2 DOWNSTREAM ELEMENTS BY DIFFERENT ATTENUATION MECHANISMS	ONCOGENE			English	Article						ELONGATION FACTORS; IN VITRO TRANSCRIPTION; NUCLEAR EXTRACT; ODC TRANSCRIPTION; TRANSCRIPTION ELONGATION	RNA POLYMERASE-II; HAMSTER OVARY CELLS; C-MYC GENE; CALF THYMUS; MESSENGER-RNA; FACTOR-SII; TERMINATION; DNA; PURIFICATION; SEQUENCE	Ornithine decarboxylase (ODC) plays an important role in cell proliferation. Its expression is tightly regulated at the mRNA and protein levels and is found to be deregulated in various malignancies. The rapid acid dramatic induction of cellular ODC mRNA upon serum addition raised the possibility that a transcriptional attenuation mechanism may be involved in the regulation of ODC gene expression, Using transcription in HeLa nuclear extract acid isolated transcription complexes, we have identified two sites of transcription arrest downstream to the transcription start site: Attenuator 1 (Att.1) located at +220, near two repeats of a USF/ Myc-Max binding consensus sequence and attenuator 2 (Att.2) located at +1590 near a long stretch of T-residues, The two attenuators exhibit distinct properties as revealed by elongation of briefly initiated and partially purified transcription complexes: Att.l serves as transient pause site while arrest at Att,2 is more prolonged. The arrest at both attenuators is modulated by the general elongation factor TFIIS. In a promoter independent transcription system, using partially purified RNA polymerase II, only Att.2 was recognized efficiently. This suggests that the recognition of Att.2 is an intrinsic property of the polymerase while Att.1 recognition has to be facilitated by an auxiliary factor/s.	WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science					NCI NIH HHS [CA 14995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BAEK KH, 1986, P NATL ACAD SCI USA, V83, P7623, DOI 10.1073/pnas.83.20.7623; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENGAL E, 1989, J BIOL CHEM, V264, P9791; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CONNELLY S, 1989, MOL CELL BIOL, V9, P5254, DOI 10.1128/MCB.9.11.5254; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLORES O, 1990, J BIOL CHEM, V265, P5629; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HODO HG, 1977, BIOCHEMISTRY-US, V16, P2334, DOI 10.1021/bi00630a005; Janne J, 1983, Spec Top Endocrinol Metab, V5, P227; KADESCH TR, 1982, J BIOL CHEM, V257, P5286; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KATZ A, 1988, J BIOL CHEM, V263, P7604; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; KESSLER M, 1991, J BIOL CHEM, V266, P13019; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUK GD, 1984, NEW ENGL J MED, V311, P80, DOI 10.1056/NEJM198407123110202; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; POHJANPELTO P, 1985, MOL CELL BIOL, V5, P1385, DOI 10.1128/MCB.5.6.1385; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; RAPPAPORT J, 1987, J BIOL CHEM, V262, P5227; REINES D, 1989, J BIOL CHEM, V264, P10799; RESNEKOV O, 1988, GENE, V72, P91, DOI 10.1016/0378-1119(88)90130-8; RESNEKOV O, 1989, P NATL ACAD SCI USA, V86, P12, DOI 10.1073/pnas.86.1.12; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SPENCER CA, 1990, ONCOGENE, V5, P777; STEGLICH C, 1982, J BIOL CHEM, V257, P4603; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TONIN PN, 1989, ONCOGENE, V4, P1117; UNEO A, 1992, P NATL ACAD SCI USA, V89, P3676; WIEST DK, 1992, J BIOL CHEM, V267, P7733; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; YANOFSKY C, 1988, J BIOL CHEM, V263, P609	47	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1587	1596						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7537363				2022-12-17	WOS:A1995QU68100015
J	MURRELL, AM; GREEN, AR				MURRELL, AM; GREEN, AR			REGULATION OF LINEAGE RESTRICTED HEMATOPOIETIC TRANSCRIPTION FACTORS IN CELL HYBRIDS	ONCOGENE			English	Article						SCL/TAL1; GATA-1; GATA-2; GATA-3; CELL HYBRIDS	GATA-BINDING PROTEINS; SCL GENE-PRODUCT; LOOP-HELIX GENE; ERYTHROID-DIFFERENTIATION; HEMATOPOIETIC-CELLS; DNA METHYLATION; MESSENGER-RNA; OCTAMER MOTIF; GLOBIN GENES; EXPRESSION	SCL, GATA-1, GATA-2 and GATA-3 encode lineage restricted haemopoietic transcription factors. We have previously shown that SCL, GATA-1 and GATA-2 are expressed in multipotent progenitors prior to lineage commitment, but are down-regulated during granulocyte/monocyte differentiation. The phenomenon of gene extinction in cell hybrids may reveal negative regulatory mechanisms operating during normal differentiation. We have therefore analysed the regulation of SCL, GATA-1, GATA-2 and GATA-3 in cell hybrids formed by the fusion of cell lines representing different haemopoietic lineages. Expression of GATA-3 was extinguished in both human and murine erythroid x T cell hybrids, an observation which suggests that erythroid cells contain factors capable of repressing GATA-3 expression. By contrast expression of SCL, GATA-1 and GATA-2 was not extinguished in erythroid x T or in erythroid x B cell hybrids. These data suggest that T cells and B cells do not contain trams-acting factors capable of down-regulating expression of SCL, GATA-1 or GATA-2 and therefore raise the possibility that a 'hit and run' mechanism may repress these genes during normal haemopoiesis, HpaII sites within the SCL promoter were unmethylated in erythroid cells but methylated in T cells. Erythroid x T and erythroid x B cell hybrids both methylated and unmethylated SCL thus implicating a heritable cis-acting mechanism in the regulation of the SCL gene in lymphoid cell lines. These results provide the first analysis of SCL and GATA gene regulation in stable cell hybrids.	UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND	University of Cambridge				Green, Anthony/0000-0002-9795-0218	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKROYD J, 1987, ONCOGENE, V1, P347; ALBERTS B, 1990, NATURE, V344, P193, DOI 10.1038/344193a0; ALITALO R, 1990, LEUKEMIA RES, V14, P501, DOI 10.1016/0145-2126(90)90002-Q; ANDERSSON LC, 1979, NATURE, V278, P364, DOI 10.1038/278364a0; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BAUMANN H, 1985, MOL GEN GENET, V201, P505, DOI 10.1007/BF00331347; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BEGLEY CG, 1994, GENE, V138, P93, DOI 10.1016/0378-1119(94)90787-0; BERGMAN Y, 1990, EMBO J, V9, P849, DOI 10.1002/j.1460-2075.1990.tb08182.x; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOSHART M, 1993, TRENDS GENET, V9, P240, DOI 10.1016/0168-9525(93)90088-Y; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1993, SCIENCE, V262, P56; CROSS MA, 1994, ONCOGENE, V9, P3013; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; DEISSEROTH A, 1975, P NATL ACAD SCI USA, V72, P1102, DOI 10.1073/pnas.72.3.1102; DEISSEROTH A, 1979, P NATL ACAD SCI USA, V76, P21; ELWOOD NJ, 1994, LEUKEMIA, V8, P106; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GOURDEAU H, 1990, ANNU REV CELL BIOL, V6, P69, DOI 10.1146/annurev.cb.06.110190.000441; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, INT J CELL CLONING, V10, P269, DOI 10.1002/stem.5530100504; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN AR, 1993, EXP HEMATOL, V21, P525; GRIEGEL S, 1986, INT J CANCER, V38, P697, DOI 10.1002/ijc.2910380513; HECHT F, 1984, SCIENCE, V226, P1445, DOI 10.1126/science.6438800; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HWANG LY, 1993, ONCOGENE, V8, P3043; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KALLIANPUR AR, 1994, BLOOD, V83, P1200; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KIM KJ, 1979, J IMMUNOL, V122, P549; LESHKOWITZ D, 1991, MOL CELL BIOL, V11, P1547, DOI 10.1128/MCB.11.3.1547; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MCCORMICK A, 1988, CELL, V55, P379, DOI 10.1016/0092-8674(88)90061-X; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MOUTHON MA, 1993, BLOOD, V81, P647; NITSCH D, 1993, GENE DEV, V7, P308, DOI 10.1101/gad.7.2.308; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; PAPAYANNOPOULOU T, 1985, P NATL ACAD SCI USA, V82, P780, DOI 10.1073/pnas.82.3.780; PETERSEN JA, 1972, P NATL ACAD SCI USA, V69, P571, DOI 10.1073/pnas.69.3.571; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PYATI J, 1980, P NATL ACAD SCI-BIOL, V77, P3435, DOI 10.1073/pnas.77.6.3435; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SHEN LY, 1993, MOL CELL BIOL, V13, P3530, DOI 10.1128/MCB.13.6.3530; SPOSI NM, 1992, P NATL ACAD SCI USA, V89, P6353, DOI 10.1073/pnas.89.14.6353; STRUHL G, 1981, NATURE, V293, P36, DOI 10.1038/293036a0; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TSAI FY, 1993, BLOOD, V82, pA86; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P195; WEINTRAUB H, 1983, CELL, V32, P1191, DOI 10.1016/0092-8674(83)90302-1; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WORTON RG, 1979, METHOD ENZYMOL, P322; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZANG CC, 1992, P NATL ACAD SCI USA, V89, P7511; ZON LI, 1991, J BIOL CHEM, V266, P22948; ZON LI, 1992, NUCLEIC ACIDS RES, V20, P1812, DOI 10.1093/nar/20.7.1812; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668; ZON LI, 1993, BLOOD, V81, P3234	76	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					631	639						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862440				2022-12-17	WOS:A1995QH61200002
J	SENFTEN, M; SCHENKER, G; SOWADSKI, JM; BALLMERHOFER, K				SENFTEN, M; SCHENKER, G; SOWADSKI, JM; BALLMERHOFER, K			CATALYTIC ACTIVITY AND TRANSFORMATION POTENTIAL OF V-SRC REQUIRE ARGININE-385 IN THE SUBSTRATE-BINDING POCKET	ONCOGENE			English	Note						SRC; TYROSINE KINASE; ONCOGENE; CATALYSIS; PHOSPHORYLATION; RSV	ROUS-SARCOMA VIRUS; DEPENDENT PROTEIN-KINASE; MIDDLE-T-ANTIGEN; TYROSINE PHOSPHORYLATION; CELL-TRANSFORMATION; MONOCLONAL-ANTIBODIES; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; PP60C-SRC KINASE; TUMOR-ANTIGEN	Tyrosine kinases are important mediators of signal transduction in eukaryotic cells. In order to better understand the mechanism of catalysis we studied a set of mutants of the prototype tyrosine kinase, the c-Src protein, a homologue of the Rous Sarcoma virus oncogene. Based on an X-ray structure of cAMP-dependent protein kinase (cAPK) we mutated an arginine residue conserved in subdomain VI of all known kinases to a non-charged residue. This residue coordinates phosphate of the autophosphorylation site located in subdomain VII of cAPK and this interaction has been proposed to be crucial for substrate binding. The mutant R385A of c-Src had low kinase activity towards exogenous substrates yet was able to autophosphorylate at tyrosine 416. When introduced into an activated v-src gene the R385A, mutation totally blocked cell transformation. Our data suggest that the function of the conserved arginine 385 is to coordinate the phosphate of the autophosphorylation site and to provide in this way a stable template for substrate binding.	FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Friedrich Miescher Institute for Biomedical Research; University of California System; University of California San Diego				Ballmer-Hofer, Kurt/0000-0002-3800-9129				BALLMERHOFER K, 1987, VIRUS RES, V6, P345, DOI 10.1016/0168-1702(87)90066-9; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CZERNILOFSKY AP, 1980, NATURE, V287, P198, DOI 10.1038/287198a0; ERIKSON RL, 1984, ADV CYCLIC NUCL PROT, V17, P457; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUJITA DJ, 1981, VIROLOGY, V111, P223, DOI 10.1016/0042-6822(81)90667-X; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KARLSSON R, 1993, ACTA CRYSTALLOGR D, V49, P381, DOI 10.1107/S0907444993002306; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KELLIE S, 1987, BIOCHEM SOC T, V15, P791, DOI 10.1042/bst0150791; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LINDER ME, 1988, P NATL ACAD SCI USA, V85, P2608, DOI 10.1073/pnas.85.8.2608; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MANESS PF, 1983, MOL CELL BIOL, V3, P102, DOI 10.1128/MCB.3.1.102; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MUSER J, 1989, ONCOGENE, V4, P1433; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; OKADA M, 1991, J BIOL CHEM, V266, P24249; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEREZ L, 1993, P NATL ACAD SCI USA, V90, P8113, DOI 10.1073/pnas.90.17.8113; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	48	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					199	203						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7529917				2022-12-17	WOS:A1995QA98000023
J	MACLEANHUNTER, S; MAKELA, TP; GRZESCHICZEK, A; ALITALO, K; MOROY, T				MACLEANHUNTER, S; MAKELA, TP; GRZESCHICZEK, A; ALITALO, K; MOROY, T			EXPRESSION OF A RLF L-MYC MINIGENE INHIBITS DIFFERENTIATION OF EMBRYONIC STEM-CELLS AND EMBROID BODY FORMATION	ONCOGENE			English	Article							C-MYC; DNA-BINDING; N-MYC; PROVIRAL INSERTION; MYELOID-LEUKEMIA; PROTEIN; GENE; GROWTH; ACTIVATION; APOPTOSIS	Rearrangements of the L-myc proto-oncogene with the cellular gene rlf occur in a subset of human small cell lung carcinoma (SCLC) resulting in the expression of a fusion protein. To investigate whether expression of such a rlf/L-myc fusion protein could contribute to the development of SCLC we constructed a chimeric minigene where the rlf first exon and the L-myc second and third exon are under the control of the rlf promoter thereby recapitulating the events of the rearrangement. Attempts to generate transgenic mice with this minigene showed that mouse embryos containing high copy numbers of the rlf/L-myc minigene fail to develop, suggesting that the expression of a rlf/L-myc fusion protein interferes with early differentiation processes. To investigate the nature of this potential embryonic lethality further, we transfected the rlf/L-myc construct stably into embryonic stem (ES) cells. Transfected ES lines that express the rlf/L-myc construct do not show a higher proliferation rate than the parental ES line but fail to properly develop embroid bodies. In addition, outgrowth and differentiation of cells from embroid bodies was severely impaired in ES cells expressing the rlf/L-myc construct when compared to normal ES cells, again suggesting an interference of rlf/L-myc expression with proper differentiation. Expression of a rlf/L-myc fusion may therefore be of critical importance in tumorigenesis by blocking differentiation and thereby allowing continued proliferation of cells and the aquisition of further mutations leading to a fully malignant tumor.	UNIV MARBURG, INST MOLEKULARBIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY; UNIV CAMBRIDGE, SCION HLTH LTD, CAMBRIDGE CB3 0JQ, ENGLAND; UNIV HELSINKI, DEPT PATHOL, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND	Philipps University Marburg; University of Cambridge; University of Helsinki			Alitalo, Kari K/J-5013-2014; Moroy, Tarik/D-9923-2011; makela, tomi/B-3734-2009	Alitalo, Kari K/0000-0002-7331-0902; makela, tomi/0000-0002-4869-8044				ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ASKEW DS, 1991, ONCOGENE, V6, P1915; BIRRER MJ, 1989, MOL CELL BIOL, V9, P2734, DOI 10.1128/MCB.9.6.2734; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOLLER K, 1993, COLD SPRING HARBOR C, P39; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DOLCETTI R, 1989, ONCOGENE, V4, P1009; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HARLOW E, 1988, ANTIBODIES LABORATOR; HOGAN B, 1986, MANIPULATION MOUSE E; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KONGSUWAN K, 1989, NUCLEIC ACIDS RES, V17, P1881, DOI 10.1093/nar/17.5.1881; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MAKELA TP, 1992, ONCOGENE, V7, P405; MAKELA TP, 1991, MOL CELL BIOL, V11, P4015; MAKELA TP, 1991, EMBO J, V10, P1331, DOI 10.1002/j.1460-2075.1991.tb07652.x; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8398, DOI 10.1073/pnas.87.21.8398; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROSENBAUM H, 1989, EMBO J, V8, P748; Sambrook J., 1989, MOL CLONING LAB MANU; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SEWING A, 1993, J CELL SCI, V104, P545; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VASTRIK I, 1994, IN PRESS CRIT REV ON; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	35	10	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3509	3517						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970711				2022-12-17	WOS:A1994PT39200013
J	CORBO, L; LEROUX, F; SERGEANT, A				CORBO, L; LEROUX, F; SERGEANT, A			THE EBV EARLY GENE-PRODUCT EB2 TRANSFORMS RODENT CELLS THROUGH A SIGNALING PATHWAY INVOLVING C-MYC	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; LYMPHOCYTE GROWTH TRANSFORMATION; DNA-BINDING; MAX; PROTEINS; TRANSCRIPTION; EXPRESSION; SEQUENCE; ONCOGENE; REQUIRES	Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus associated with several neoplasia. We present evidence here that the protein EB2, an EBV posttranscriptional activator, has transforming properties not only when expressed in established cell lines such as Rat1 or NIH3T3 but also in primary rat fibroblasts (REF). EB2 transformation in Rat1 cells correlates with an increase in the steady-state level of the cellular oncogenic protein c-Myc, and cotransfection of a plasmid expressing Max suppresses the transformation. These results implicate c-Myc in EB2-mediated cell transformation and help define the pathway by which this EBV early protein causes transformation.			CORBO, L (corresponding author), ECOLE NORMALE SUPER LYON,INSERM,U412,UNITE VIROL HUMAINE,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.			Le Roux, Frederique/0000-0002-9112-6199				AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BAICHWALL VR, 1988, ONCOGENE, V2, P416; BILLAUD M, 1993, P NATL ACAD SCI USA, V90, P2739, DOI 10.1073/pnas.90.7.2739; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BUISSON M, 1989, J VIROL, V63, P5276, DOI 10.1128/JVI.63.12.5276-5284.1989; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CORBO L, 1993, EPSTEINBARR VIRUS AS, V225, P51; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hinnebusch A, 1993, CURR OPIN CELL BIOL, V5, P941, DOI 10.1016/0955-0674(93)90073-Y; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JOAB I, 1991, J INFECT DIS, V163, P53, DOI 10.1093/infdis/163.1.53; KAROMILAS AE, 1992, SCIENCE, V257, P1685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KENNEY S, 1989, J VIROL, V63, P3870, DOI 10.1128/JVI.63.9.3870-3877.1989; KIEFF E, 1990, VIROLOGY, P1889; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MANET E, 1989, EMBO J, V8, P1819, DOI 10.1002/j.1460-2075.1989.tb03576.x; MARCU KB, 1992, ANN REV BIOCH, V61, P808; MCLAUCHLAN J, 1992, J VIROL, V66, P6939, DOI 10.1128/JVI.66.12.6939-6945.1992; MIKAELIAN I, 1993, J VIROL, V67, P734; MILLER G, 1990, VIROLOGY, P1921; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PALLESEN G, 1991, BLOOD, V78, P1162; PHELAN A, 1993, P NATL ACAD SCI USA, V90, P9056, DOI 10.1073/pnas.90.19.9056; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SANDRIGOLDIN RM, 1992, GENE DEV, V6, P848, DOI 10.1101/gad.6.5.848; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SHIC C, 1982, CELL, V29, P161; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; SU IJ, 1991, BLOOD, V77, P799; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WONG KM, 1989, VIROLOGY, V168, P101, DOI 10.1016/0042-6822(89)90408-X; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; ZENG Y, 1982, INT J CANCER, V29, P193	47	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3299	3304						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936654				2022-12-17	WOS:A1994PM65800023
J	GALLOHENDRIKX, E; COPPS, J; PERCY, D; CROY, BA; WILDEMAN, AG				GALLOHENDRIKX, E; COPPS, J; PERCY, D; CROY, BA; WILDEMAN, AG			ENHANCEMENT OF PANCREATIC TUMOR-METASTASIS IN TRANSGENIC IMMUNODEFICIENT MICE	ONCOGENE			English	Article							NATURAL-KILLER-CELLS; T-ANTIGEN; ACINAR-CELLS; MOUSE MODEL; NUDE-MICE; SCID MICE; GROWTH; GENE; EXPRESSION; NK	Metastatic pancreatic cancer presents a bleak prognosis. Typically, human tumor development has been modelled in animals by generating transgenic mice carrying an oncogene, and metastasis studied by engrafting human tumor cells into immunodeficient mice. We derived mouse lines that spontaneously develop metastatic pancreatic cancer by crossing a transgenic line that develops primary pancreatic adenocarcinomas with lines that are deficient for different lymphocyte components of the immune system. We obtained transgenics carrying the SCID mutation resulting in loss of B and T cell function, those carrying the beige mutation resulting in impaired NK cell and macrophage activity, and those carrying both mutations. Although human graft studies indicated that the SCID mutation permits metastasis of different types of tumor cells, in our mice its effect on metastasis of the pancreatic tumor was minimal. In contrast, the beige mutation resulted in metastasis in almost 90% of the animals. The SCID and beige mutations synergistically resulted in faster growing tumors. Both primary tumors and metastases contained undifferentiated and differentiated cell types. The tissue distribution of metastases was similar to that recorded from human patients with pancreatic cancer, suggesting that mechanisms underlying metastasis in these mice could be similar to those involved in human disease.	UNIV GUELPH, DEPT MOLEC BIOL & GENET, GUELPH N1G 2W1, ON, CANADA; UNIV GUELPH, DEPT PATHOL, GUELPH N1G 2W1, ON, CANADA; UNIV GUELPH, DEPT BIOMED SCI, GUELPH N1G 2W1, ON, CANADA	University of Guelph; University of Guelph; University of Guelph								ALOSCO T, 1993, CANCER IMMUNOL IMMUN, V36, P364, DOI 10.1007/BF01742252; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BREUER M, 1991, RADIAT ENVIRON BIOPH, V30, P181, DOI 10.1007/BF01226614; BRUBAKER PL, 1992, J BIOL CHEM, V267, P20728; CECI JD, 1991, ONCOGENE, V6, P323; CONNELLY CS, 1989, EXP CELL RES, V183, P257, DOI 10.1016/0014-4827(89)90387-X; CROY BA, 1990, J REPROD FERTIL, V88, P231, DOI 10.1530/jrf.0.0880231; CROY BA, 1982, J REPROD IMMUNOL, V4, P277; DECKHUT AM, 1992, J VIROL, V66, P440, DOI 10.1128/JVI.66.1.440-447.1992; DRISCOLL J, 1992, CELL, V68, P823, DOI 10.1016/0092-8674(92)90024-7; FODSTAD O, 1984, CANCER RES, V44, P4403; FU XY, 1992, P NATL ACAD SCI USA, V89, P5645, DOI 10.1073/pnas.89.12.5645; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GARRIDO F, 1993, IMMUNOL TODAY, V14, P491, DOI 10.1016/0167-5699(93)90264-L; GLASNER S, 1992, AM J PATHOL, V140, P1237; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HENNING R, 1981, VIROLOGY, V108, P325, DOI 10.1016/0042-6822(81)90441-4; HILL LL, 1991, CANCER RES, V51, P4937; Hogan B., 1986, MANIPULATING MOUSE E; HOWARD JM, 1977, CURR PROBL CANCER, V2, P1; INOHARA H, 1992, CARCINOGENESIS, V13, P845, DOI 10.1093/carcin/13.5.845; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867; KERBEL RS, 1991, CANCER METAST REV, V10, P201, DOI 10.1007/BF00050792; KIM YB, 1980, J IMMUNOL, V125, P755; LANIER LL, 1992, CURR OPIN IMMUNOL, V4, P38, DOI 10.1016/0952-7915(92)90121-T; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; MORETTA A, 1993, J EXP MED, V178, P597, DOI 10.1084/jem.178.2.597; MUELLER BM, 1991, CANCER METAST REV, V10, P193, DOI 10.1007/BF00050791; NOMURA T, 1990, J RADIAT RES, V31, P288, DOI 10.1269/jrr.31.288; NOMURA T, 1991, JPN J CANCER RES, V82, P701, DOI 10.1111/j.1349-7006.1991.tb01906.x; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; PATTENGALE PK, 1989, AM J PATHOL, V135, P39; PHILLIPS RA, 1989, CURR TOP MICROBIOL, V152, P259; PROSS HF, 1993, NAT IMMUN, V12, P279; QIAN JH, 1991, J IMMUNOL, V146, P3250; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REDDY S, 1987, CANCER RES, V47, P2456; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; STUTMAN O, 1981, NATURE, V290, P254, DOI 10.1038/290254a0; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TANAKA Y, 1989, VIROLOGY, V171, P205, DOI 10.1016/0042-6822(89)90527-8; TEVETHIA SS, 1980, VIROLOGY, V107, P13, DOI 10.1016/0042-6822(80)90268-8; TEVETHIA SS, 1980, VIRAL ONCOLOGY, P581; WEINER LM, 1993, CANCER RES, V53, P94; WILLIAMS SS, 1993, LAB ANIM SCI, V43, P139; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	58	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2983	2990						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084602				2022-12-17	WOS:A1994PG82200025
J	BOUWMEESTER, T; VANWIJK, I; WEDLICH, D; PIELER, T				BOUWMEESTER, T; VANWIJK, I; WEDLICH, D; PIELER, T			FUNCTIONAL-ASPECTS OF B-MYB IN EARLY XENOPUS DEVELOPMENT	ONCOGENE			English	Article							C-MYB; DNA-BINDING; A-MYB; EXPRESSION; PROTEIN; DIFFERENTIATION; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; INVITRO	The gene encoding Xenopus B-Myb (XB-Myb), a protein structurally related to the nuclear protooncogene product c-Myb, is expressed in early Xenopus embryogenesis. We report on developmental alterations in the nucleocytoplasmic distribution and phosphorylation of XB-Myb in Xenopus oocytes and embryos, as well as on a negative regulatory role of the carboxyl terminus in sequence specific DNA binding. In growing oocytes and early embryonic stages the protein is primarily located in the nucleus; in the full-grown oocyte, however, it remains sequestered in the cytoplasmic compartment. Upon meiotic maturation of the oocyte, XB-Myb becomes hyperphosphorylated. Oocyte/egg isolates of XB-Myb are inhibited in their specific DNA binding activity; truncation of the carboxyl terminal region relieves this block in nucleic acid recognition. Furthermore, we have used overexpression of XB-Myb in Xenopus embryos by means of mRNA injection as an assay for gene function in vivo. Overexpression of full-length XB-Myb, not of the carboxyl terminal deletion mutant, results in an altered morphology of lateral plate mesoderm.	MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-14195 BERLIN,GERMANY; UNIV ULM,BIOCHEM ABT,D-89081 ULM,GERMANY	Max Planck Society; Ulm University								ARSURA M, 1992, BLOOD, V79, P2708; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DANKER K, 1992, DEV DYNAM, V193, P136, DOI 10.1002/aja.1001930205; DENT JA, 1989, DEVELOPMENT, V105, P61; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GARCIA A, 1991, ONCOGENE, V6, P265; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HARLOW E, 1988, ANTIBODIES LABORATOR; HERZBERG F, 1991, MECH DEVELOP, V35, P33, DOI 10.1016/0925-4773(91)90039-9; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MCMAHON J, 1988, ONCOGENE, V3, P717; MILLER M, 1991, DEVELOPMENT, V113, P569; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; NIETFELD W, 1993, J MOL BIOL, V230, P400, DOI 10.1006/jmbi.1993.1158; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	44	10	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1029	1038						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134106				2022-12-17	WOS:A1994NC04800004
J	YE, XH; KRALLI, A; GE, R; RICCIARDI, RP; KNOWLES, BB				YE, XH; KRALLI, A; GE, R; RICCIARDI, RP; KNOWLES, BB			DOWN-REGULATION OF MHC CLASS-I ANTIGEN IN INSULINOMA CELLS CONTROLLED BY THE R1 ELEMENT OF THE H-2 ENHANCER	ONCOGENE			English	Article							TRANSFORMED RAT-CELLS; PANCREATIC BETA-CELLS; GENE-EXPRESSION; NEGATIVE REGULATION; TRANSGENIC MICE; FACTOR BINDING; T-ANTIGEN; N-MYC; MOUSE; COMPLEX	Tumorigenesis in mice of the rat insulin promoter [RIP]-simian virus 40 tumor antigen [SV40 Tag] transgenic lineages, RIP1-Tag2 and RIP1-Tag4, is a process initiated by expression of SV40 Tag in pancreatic beta cells, evolution of islet cell hyperplasia and insulinoma appearance. Analysis of major histocompatibility complex [MHC] class I gene expression during this process revealed a normal level of MHC class I molecules at the surface of pancreatic islet cells of RIP1-Tag4 mice, while hyperplastic islets from the same mice contained cells expressing a normal level and cells expressing a low level of MHC class I antigen. Insulinomas themselves expressed very low levels or no MHC class I gene product. Thus, down-regulation of MHC class I gene appears to accompany tumor progression of SV40 Tag-transformed beta islet cells. MHC class I antigen expression in a series of clonally derived cell lines of beta cell origin from different SV40 Tag-induced insulinomas ranged from quite low to undetectable, although expression was inducible by interferon-gamma. Nuclear run-on and transient transfection analyses indicated that expression of the MHC class I gene in these cells is controlled at the transcriptional level, and that the decreased expression is paralleled by reduced binding of transcription factors to the R1 element of the H-2 enhancer.	WISTAR INST ANAT & BIOL, 36TH & SPRUCE ST, PHILADELPHIA, PA 19104 USA; UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; AMER CYANAMIDE, PEARL RIVER, NY 10965 USA; UNIV PENN, SCH DENT MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute; University of California System; University of California San Francisco; University of Pennsylvania			Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336; Knowles, Barbara B./0000-0002-2597-5619	NATIONAL CANCER INSTITUTE [R01CA029797, P30CA010815, R01CA018470] Funding Source: NIH RePORTER; NCI NIH HHS [CA18470, CA10815, CA29797] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ADAMS TE, 1987, NATURE, V325, P223, DOI 10.1038/325223a0; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BALDWIN AS, 1990, MOL CELL BIOL, V10, P1406, DOI 10.1128/MCB.10.4.1406; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLIEDEN TM, 1991, INT J CANCER, P82; BURKE PA, 1989, J EXP MED, V169, P1309, DOI 10.1084/jem.169.4.1309; CAMPBELL IL, 1985, DIABETES, V34, P1205, DOI 10.2337/diabetes.34.11.1205; CHEN E, 1986, MOL CELL BIOL, V6, P1698, DOI 10.1128/MCB.6.5.1698; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; GE R, 1992, THESIS U PENNSYLVANI; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; GILLIGAN A, 1989, DIABETES, V38, P1056, DOI 10.2337/diabetes.38.8.1056; GOODING LR, 1979, J IMMUNOL, V122, P1002; GOTOH M, 1985, TRANSPLANTATION, V40, P437, DOI 10.1097/00007890-198510000-00018; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HENSELING U, 1990, MOL CELL BIOL, V10, P4100, DOI 10.1128/MCB.10.8.4100; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL A, 1987, P NATL ACAD SCI USA, V84, P2653, DOI 10.1073/pnas.84.9.2653; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JEFFERIES WA, 1988, EMBO J, V7, P3423, DOI 10.1002/j.1460-2075.1988.tb03216.x; JONES B, 1981, NATURE, V292, P547, DOI 10.1038/292547a0; JUULMADSEN HR, 1990, APMIS, V98, P624, DOI 10.1111/j.1699-0463.1990.tb04980.x; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KNOWLES BB, 1979, J IMMUNOL, V122, P1798; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; KRALLI A, 1991, THESIS U PENNSYLVANI; LENARDO M, 1989, EMBO J, V8, P3351, DOI 10.1002/j.1460-2075.1989.tb08497.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LEW AM, 1986, IMMUNOLOGY, V57, P3; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; OZATO K, 1985, P NATL ACAD SCI USA, V82, P2427, DOI 10.1073/pnas.82.8.2427; PAN S, 1982, J IMMUNOL, V128, P243; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P806, DOI 10.1210/endo-117-3-806; ROSA F, 1983, EMBO J, V2, P239, DOI 10.1002/j.1460-2075.1983.tb01412.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; SOONG TW, 1991, CANCER DETECT PREV, V15, P231; TANAKA K, 1988, ANNU REV IMMUNOL, V6, P359; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; TEVETHIA SS, 1990, J VIROL, V64, P1192, DOI 10.1128/JVI.64.3.1192-1200.1990; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; YE X, 1994, IN PRESS P NATL ACAD; YE X, 1993, THESIS U PENNSYLVANI; ZIJLSTRA M, 1989, NATURE, V342, P435, DOI 10.1038/342435a0	56	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1994	9	4					1195	1204						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134122				2022-12-17	WOS:A1994NC04800023
J	LERHUN, Y; DUTHU, A; EHRHART, JC; MICHIELS, F; MAY, E; MAY, P				LERHUN, Y; DUTHU, A; EHRHART, JC; MICHIELS, F; MAY, E; MAY, P			DIRECTIONAL SELECTION ASSOCIATED WITH CLONAL EXPANSION OF P53 MUTANT-CELLS DURING NEOPLASTIC DEVELOPMENT OF CARCINOGEN-TREATED RAT EMBRYO LUNG EPITHELIAL-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; CELLULAR TUMOR-ANTIGEN; HEAT-SHOCK PROTEINS; SV40-TRANSFORMED CELLS; SUPPRESSOR GENE; CYCLE CONTROL; TRANSFORMATION; MUTATIONS; ONCOGENE; SEQUENCE	In this study, rat embryo lung organ cultures were exposed to benzo[a]pyrene (B[a]P). After carcinogen-treatment the cells were dissociated and an epithelial cell line (BP) was developed from the primary cell culture derived from the carcinogen-treated explants. Investigations were performed on the sequential changes occurring in the course of neoplastic progression of BP cells and in the tumor cells that arose in vivo from implanted BP cells. During the neoplastic progression a mutation was shown to occur in p53 gene at codon 130 (AAG > AGG; Lys > Arg) in a single cell which expanded and gave rise to a predominant subpopulation. This mutational event was already detected at passage 14 but was probably not a direct consequence of a specific alteration caused by the carcinogen in the target cell. This mutation was retained through the subsequent progressional steps first as a heterozygous mutation, then converted to a homozygous state. From passage 18 on, it was possible in BP cell. cultures to detect foci of larger morphologically distinct cells emerging on a background of cells maintaining the original morphology. These foci were shown to derive from a single cell carrying the p53 mutation in a homozygous state. During the neoplastic progression the mutant p53 allele frequency steadily increased and this mutant allele eventually came to predominate completely in the late stages of the neoplastic progression, including in the transplantation-induced tumors. The pattern of a directional selection for mutant p53 gene towards fixation is probably applicable to a wide range of human malignancies and may reflect the particular importance of this gene for tumorigenesis.	IRSC,ONCOL MOLEC LAB,CNRS,F-94801 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTKOVA J, 1993, EUR J CANCER, V29A, P881, DOI 10.1016/S0959-8049(05)80431-9; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DUTHU A, 1985, VIROLOGY, V147, P275, DOI 10.1016/0042-6822(85)90130-8; EHRHART JC, 1988, ONCOGENE, V3, P595; EISENSTADT E, 1982, P NATL ACAD SCI-BIOL, V79, P1945, DOI 10.1073/pnas.79.6.1945; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUJIMOTO K, 1992, CANCER RES, V52, P1393; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JONES PA, 1991, CANCER RES, V51, P3617; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LILLEBERG SL, 1992, MOL CARCINOGEN, V6, P159, DOI 10.1002/mc.2940060211; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAKINO H, 1992, P NATL ACAD SCI USA, V89, P4850, DOI 10.1073/pnas.89.11.4850; MANIATIS T, 1982, MOL CLONING LABORATO, P368; MERCER WE, 1990, ONCOGENE, V5, P973; MICHIELS F, 1981, CARCINOGENESIS, V2, P885, DOI 10.1093/carcin/2.9.885; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTHFELS KH, 1958, STAIN TECHNOL, V33, P73, DOI 10.3109/10520295809111827; RUGGERI B, 1993, P NATL ACAD SCI USA, V90, P1013, DOI 10.1073/pnas.90.3.1013; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1993, CARCINOGENESIS, V14, P503, DOI 10.1093/carcin/14.3.503; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STURZBECHER HW, 1990, ONCOGENE, V5, P795; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	63	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					263	271						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302588				2022-12-17	WOS:A1994MW24700032
J	SHAUGHNESSY, J; WIENER, F; HUPPI, K; MUSHINSKI, JF; POTTER, M				SHAUGHNESSY, J; WIENER, F; HUPPI, K; MUSHINSKI, JF; POTTER, M			A NOVEL C-MYC-ACTIVATING RECIPROCAL T(1215) CHROMOSOMAL TRANSLOCATION JUXTAPOSES S-ALPHA TO PVT-1 IN A MOUSE PLASMACYTOMA	ONCOGENE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; DNA FRAGMENTS; NEOPLASTIC DEVELOPMENT; ATAXIA-TELANGIECTASIA; MURINE PLASMACYTOMAS; AGAROSE GELS; CELL-LINES; LOCUS; SEQUENCES; ONCOGENE	Oil-induced murine plasmacytomas typically carry c-myc-activating non-random reciprocal chromosomal translocations that take the form of either a T(12;15) that fuses the c-myc proto-oncogene to an immunoglobulin heavy chain switch region or a T(6;15) that juxtaposes the Pvt-l locus, located 220 kb 3' of c-myc, to the immunoglobulin light china locus, C-kappa. In this report we show that the plasmacytoma ABPC 60 harbors a novel c-myc-activating T(12;15) in which the chromosome 15 breakpoint occurs in the Pvt-1 region, resulting in the head-to-tail juxtaposition of the Pvt-1 major breakpoint cluster to the IgA switch region. Restriction mapping and nucleotide sequencing of this atypical translocation indicate that a paracentric inversion in chromosome 12 must have preceeded the translocation. This is the first example of a T(12;15) with a break 3' of the c-myc gene. The rearrangement places the 3' C alpha enhancer (3'alpha E) greater than 200 kb downstream of the c-myc promoters, however c-myc mRNA levels are similar to those observed in plasmacytomas with typical T(12;15)s that translocate 3'alpha E much closer (15-25 kb) and upstream of c-myc. The up regulation of c-myc that results from this rearrangement is thought to be brought about by the interaction of the c-myc promoters with the IgA enhancer element that has been strategically relocated into the Pvt-1 region.	NCI,GENET LAB,BETHESDA,MD 20892; KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet								AXELSON H, 1991, ONCOGENE, V6, P2263; BAER R, 1985, CELL, V43, P705, DOI 10.1016/0092-8674(85)90243-0; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CALVO CF, 1991, J IMMUNOL, V146, P1353; CITRI Y, 1987, J EXP MED, V165, P1188, DOI 10.1084/jem.165.4.1188; CLURMAN BE, 1988, CELLULAR ONCOGENE AC, P55; COCKERILL PN, 1990, NUCLEIC ACIDS RES, V18, P2643, DOI 10.1093/nar/18.9.2643; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; DAVIS MM, 1980, SCIENCE, V209, P1360, DOI 10.1126/science.6774415; DENNY CT, 1986, NATURE, V320, P549, DOI 10.1038/320549a0; EARLY PW, 1979, P NATL ACAD SCI USA, V76, P857, DOI 10.1073/pnas.76.2.857; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HUPPI K, 1993, INT J CANCER, V53, P493, DOI 10.1002/ijc.2910530323; HUPPI K, 1990, P NATL ACAD SCI USA, V87, P6964, DOI 10.1073/pnas.87.18.6964; HUPPI K, 1992, IMMUNOGENETICS, V37, P288; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LIPKOWITZ S, 1990, J EXP MED, V172, P409, DOI 10.1084/jem.172.2.409; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MOUNTZ JD, 1984, SCIENCE, V226, P1087, DOI 10.1126/science.6494925; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; NESBITT MN, 1973, CHROMOSOMA, V41, P145, DOI 10.1007/BF00319691; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; RADCLIFFE G, 1990, MOL CELL BIOL, V10, P382, DOI 10.1128/MCB.10.1.382; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO MA, 1987, MOL CELL BIOL, V7, P4130, DOI 10.1128/MCB.7.11.4130; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STERN MH, 1989, BLOOD, V74, P2076; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANNESS BG, 1983, NATURE, V301, P425, DOI 10.1038/301425a0; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; WILLIAMS BG, 1980, GENETIC ENG, P201; 1972, J HERED, V63, P69	49	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					247	253						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302586				2022-12-17	WOS:A1994MW24700030
J	SHAUGHNESSY, JD; OWENS, JD; WIENER, F; HILBERT, DM; HUPPI, K; POTTER, M; MUSHINSKI, JF				SHAUGHNESSY, JD; OWENS, JD; WIENER, F; HILBERT, DM; HUPPI, K; POTTER, M; MUSHINSKI, JF			RETROVIRAL ENHANCER INSERTION 5' OF C-MYC IN 2 TRANSLOCATION-NEGATIVE MOUSE PLASMACYTOMAS UP-REGULATES C-MYC EXPRESSION TO DIFFERENT EXTENTS	ONCOGENE			English	Article							MURINE LEUKEMIA-VIRUS; MESSENGER-RNA; DNA FRAGMENTS; TRANSCRIPTIONAL ACTIVATION; CHROMOSOME TRANSLOCATIONS; NUCLEOTIDE-SEQUENCE; AGAROSE GELS; T-LYMPHOMAS; ONC GENE; V-ABL	Essentially all murine plasmacytomas have deregulated c-myc expression that is typically brought about by chromosomal translocations between the c-myc/Pvt-1 locus and one of the immunoglobulin loci. ABPC 22 and RFPC 2782 are BALB/c plasmacytomas that lack chromosomal translocations yet have Southern blot evidence of c-myc gene rearrangements. In this report we show that proviral integrations 5' of the c-myc gene can deregulate c-myc expression in mouse plasmacytomas. Analysis of DNA sequences 5' of the c-myc genes from both tumors demonstrated that rearrangements were caused by retroviral integrations 5' of c-myc exon 1. The proviral insertion in RFPC 2782 was associated with a high steady-state c-myc mRNA level comparable to that seen in plasmacytomas with typical translocations. An analogous proviral insertion in ABPC 22 was associated with a c-myc RNA level that was only 38% of that of RFPC 2782. Nuclear run-on studies of c-myc transcription showed that ABPC 22 has both a lower rate of transcription and a greater degree of transcriptional attenuation than RFPC 2782. DNA sequencing of the long terminal repeat of each tumor provirus showed that the ABPC 22 provirus harbors a deletion of one of the two direct repeats in the viral enhancer, whereas both repeats are present in the RFPC 2782 provirus. These data indicate that maximum LTR enhancer effectiveness in plasmacytomas in vivo requires the presence of both LTR direct repeats. The documentation of the low level of steady-state c-myc mRNA in ABPC 22 supports the notion that deregulated c-myc expression, even at low steady state levels, is effective in supporting the development of plasmacytomas.	NCI,GENET LAB,BETHESDA,MD 20892; UNIV MARYLAND,DEPT ZOOL,COLL PK,MD 20742; KAROLINSKA INST,DEPT TUMOR BIOL,S-10401 STOCKHOLM 60,SWEDEN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland College Park; Karolinska Institutet								AXELSON H, 1991, ONCOGENE, V6, P2263; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BAUER SR, 1989, ONCOGENE, V4, P615; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; CLURMAN BE, 1988, CELLULAR ONCOGENE AC, P55; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CORY S, 1985, EMBO J, V4, P675, DOI 10.1002/j.1460-2075.1985.tb03682.x; CROUSE GF, 1982, J BIOL CHEM, V257, P7887; CUYPERS HT, 1984, CELL, V37, P141; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAHAM M, 1985, NATURE, V314, P740, DOI 10.1038/314740a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KRAFT R, 1988, BIOTECHNIQUES, V6, P554; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MUSHINSKI JF, 1988, CELLULAR ONCOGENE AC, P181; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; OHNO S, 1991, INT J CANCER, V49, P102, DOI 10.1002/ijc.2910490119; OHNO S, 1984, J EXP MED, V159, P1762, DOI 10.1084/jem.159.6.1762; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; POTTER M, 1990, CARCINOGENESIS, V11, P1, DOI 10.1093/carcin/11.1.1; POTTER M, 1987, SCIENCE, V235, P787, DOI 10.1126/science.3810165; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REICIN A, 1986, MOL CELL BIOL, V6, P4088, DOI 10.1128/MCB.6.11.4088; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SKALKA AM, 1988, GENETIC RECOMBINATIO, P701; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SRINIVASAN A, 1984, SCIENCE, V233, P286; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEISSINGER EM, 1991, P NATL ACAD SCI USA, V88, P8735, DOI 10.1073/pnas.88.19.8735; WIENER F, 1984, P NATL ACAD SCI-BIOL, V81, P1159, DOI 10.1073/pnas.81.4.1159; WIENER F, 1984, J EXP MED, V159, P276, DOI 10.1084/jem.159.1.276; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1972, J HERED, V63, P69	53	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3111	3121						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414513				2022-12-17	WOS:A1993MC09300028
J	VANTVEER, LJ; VANDERFELTZ, MJM; VANDENBERGBAKKER, CAM; CHENG, NC; HERMENS, RPMG; VANOORSCHOT, DAJ; KIEVITS, T; SCHRIER, PI				VANTVEER, LJ; VANDERFELTZ, MJM; VANDENBERGBAKKER, CAM; CHENG, NC; HERMENS, RPMG; VANOORSCHOT, DAJ; KIEVITS, T; SCHRIER, PI			ACTIVATION OF THE MAS ONCOGENE INVOLVES COUPLING TO HUMAN ALPHOID SEQUENCES	ONCOGENE			English	Article								We have shown previously that mouse NIH3T3 cells transfected with DNA from a human ovarian carcinoma were rendered tumourigenic by an activated mas oncogene in four independent transfection experiments. In all cases the 5'-noncoding region was rearranged in comparison to the original ovarian tumour DNA. We now report that in all four transfectants the newly acquired sequences consist of human centromeric alpha satellite repeat DNA. In at least three transfectants the alphoid DNA originates from the centromere of chromosome three. Analysis of the sequences of the recombination site in one transfectant revealed that a homologous sequence of five base pairs (CAGCA) is present in both parental strands, and might thus have contributed to the recombinational event. To establish a conclusive role for alphoid DNA in the activation of mas, we performed a co-transfection experiment in NIH3T3 cells with cloned alphoid DNA and the mas coding sequence. We show that the transfectants expressing a transformed phenotype contain amplified mas linked to alphoid DNA. NIH3T3 cells transfected with plasmids that contained alphoid sequences cloned directly upstream of the mas coding sequence, and injected into nude mice, gave rise to tumours with amplified mas sequences (7/7). In six of these tumours the alphoid sequences were amplified as well. Our data suggest a novel mechanism of oncogene activation: recombination with normal alphoid repeat DNA resulting in amplification of the oncogene.	UNIV HOSP LEIDEN, DEPT CLIN ONCOL, BLDG 1, K-1-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS; LEIDEN UNIV, DEPT HUMAN GENET, SYLVIUS LABS, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC			Hermens, Rosella P.M.G./N-3581-2014	Hermens, Rosella P.M.G./0000-0001-7624-7120				AMBROZ C, 1991, BIOCHIM BIOPHYS ACTA, V1133, P107, DOI 10.1016/0167-4889(91)90248-V; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; DELATTRE O, 1988, HUM HERED, V38, P156, DOI 10.1159/000153777; DEVILEE P, 1988, CANCER RES, V48, P5825; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; HEARTLEIN MW, 1988, MOL CELL BIOL, V8, P3611, DOI 10.1128/MCB.8.9.3611; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JANSSEN JWG, 1988, LEUKEMIA, V2, P318; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KIYAMA R, 1987, J MOL BIOL, V198, P589, DOI 10.1016/0022-2836(87)90202-6; KONOPKA AK, 1988, NUCLEIC ACIDS RES, V16, P1739, DOI 10.1093/nar/16.5.1739; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MANUELIDIS L, 1978, CHROMOSOMA, V66, P23, DOI 10.1007/BF00285813; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; VANTVEER LJ, 1988, ONCOGENE RES, V3, P247; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WAYE JS, 1987, NUCLEIC ACIDS RES, V15, P7549, DOI 10.1093/nar/15.18.7549; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; YUNIS JJ, 1987, ONCOGENE, V1, P59; ZANCA DM, 1986, NATURE, V319, P743	34	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2673	2681						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378079				2022-12-17	WOS:A1993LX34300008
J	SENECA, S; PUNYAMMALEE, B; SUREAU, A; PERBAL, B; DVORAK, M; CRABEEL, M				SENECA, S; PUNYAMMALEE, B; SUREAU, A; PERBAL, B; DVORAK, M; CRABEEL, M			THE CARBOXY-TERMINAL DOMAIN OF C-MYB ACTIVATES REPORTER GENE-EXPRESSION IN YEAST	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; V-MYB; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; FUNCTIONAL DOMAINS; ONCOGENE PRODUCT; SPLICING FACTOR; CELLS; PROTOONCOGENE	We have shown previously that c-myb expressed in the yeast S. cerevisiae mediated efficient transcriptional activation of reporter genes designed with specific Myb Recognition Elements (MRE's), confirming that this proto-oncogene is able to function as a regulator of transcription in that heterologous context. Here we show that in yeast, as in higher eucaryotic cells, the central domain of c-Myb displays transactivating capacity. In yeast, however, the carboxy-terminal region, defined as a negative regulatory domain in higher cells, activates transcription as well and appears to be a more potent transactivating domain than the central domain itself. Within this region two domains, namely C1 and C2, have been defined that contribute about equally to the activity of the carboxy-terminal region. C1 spans the sequences missing in AMV v-myb while C2, which contains the leucine-zipper motif is specifically absent in the E26 v-myb in addition to C1. The c-Myb DNA-binding domain itself has no effect on the level of transcription in yeast. We also show that AMV v-Myb stimulates gene expression in yeast with about half the efficiency of full length c-Myb. The fact that the carboxy-terminal region either stimulates or inhibits transactivation properties of c-Myb, depending on the cellular context, stresses the participation of putative c-Myb partner proteins in Myb regulated processes and reopens the question of whether the oncogenic activation of c-myb is indeed due to the increased transactivation capacity of its onco derivatives.	INST CURIE, ONCOL VIRALE & MOLEC LAB, F-91405 ORSAY, FRANCE; CZECHOSLOVAK ACAD SCI, INST MOLEC GENET, CS-16637 PRAGUE 6, CZECHOSLOVAKIA; UNIV PARIS 07, UFR BIOCHIM, F-75221 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; UDICE-French Research Universities; Universite Paris Cite	SENECA, S (corresponding author), VRIJE UNIV BRUSSELS, RES INST CERIA COOVI, 1 E GRYSONLANE, B-1070 BRUSSELS, BELGIUM.		Dvorak, Michal/G-5861-2014; Dvořák, Michal/I-9939-2014; Sureau, Alain/M-1998-2017	Sureau, Alain/0000-0003-1523-0207; Seneca, Sara/0000-0002-0853-9890				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARTUNEK P, 1992, VIROLOGY, V190, P882, DOI 10.1016/0042-6822(92)90930-N; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Broach J. R., 1983, EXPT MANIPULATION GE, P83; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FITZPATRICK VD, 1989, NATURE, V337, P666, DOI 10.1038/337666a0; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JONES RH, 1988, CELL, V53, P659, DOI 10.1016/0092-8674(88)90581-8; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KENNEY SC, 1992, MOL CELL BIOL, V12, P136, DOI 10.1128/MCB.12.1.136; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAURENT BC, 1992, IN PRESS GENES DEV; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MA J, 1988, NATURE, V334, P631, DOI 10.1038/334631a0; METZGER D, 1988, NATURE, V334, P31, DOI 10.1038/334031a0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; PERBAL B, 1986, BIOCHIMIE, V68, P969, DOI 10.1016/S0300-9084(86)80040-2; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; RAMSAY RG, 1991, ONCOGENE, V6, P1875; ROSSON D, 1990, VIROLOGY, V175, P562, DOI 10.1016/0042-6822(90)90441-S; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHENA M, 1988, SCIENCE, V241, P965, DOI 10.1126/science.3043665; SENECA S, 1991, ONCOGENE, V6, P357; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SORET J, 1990, FEBS LETT, V263, P254, DOI 10.1016/0014-5793(90)81387-4; STRUHL K, 1988, NATURE, V332, P649, DOI 10.1038/332649a0; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; VELLARD M, 1991, ONCOGENE, V6, P505; WEBSTER N, 1988, CELL, V52, P169, DOI 10.1016/0092-8674(88)90505-3; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	43	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1993	8	9					2335	2342						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361752				2022-12-17	WOS:A1993LT36800003
J	SHIIO, Y; YAMAMOTO, T; YAMAGUCHI, N				SHIIO, Y; YAMAMOTO, T; YAMAGUCHI, N			IDENTIFICATION OF A DNA ELEMENT THAT CAN ENHANCE P53-MEDIATED TRANSACTIVATION	ONCOGENE			English	Article							TUMOR SUPPRESSOR GENES; WILD-TYPE P53; BINDING-SITE; EXPRESSION; PROTEIN; PRODUCT	Recent studies have demonstrated that p53 binds to specific DNA sequences and the consensus sequence for the p53 binding site has been proposed. The p53 binding site has also been shown to act as positive p53-responsive element. Here we report the identification of a GC3 element that enhances p53-mediated transactivation when placed adjacent to the consensus p53 site. The GC3 element alone cannot act as a positive p53-responsive element. We also show that p53 activates transcription of the c-erbA-alpha gene through a DNA element that consists of the p53 quarter-sites and GC3 elements. Using gel mobility-shift assay, we identified a possible GC3 binding factor distinct from p53.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,TOKYO 108,JAPAN	University of Tokyo	SHIIO, Y (corresponding author), UNIV TOKYO,INST MED SCI,DEPT VIROL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN.							AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mackett M., 1985, DNA CLONING PRACTICA, P191; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	18	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2059	2065						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8393159				2022-12-17	WOS:A1993LP17100005
J	OGRIS, E; MUDRAK, I; WINTERSBERGER, E				OGRIS, E; MUDRAK, I; WINTERSBERGER, E			DISTINCT AMOUNTS OF POLYOMAVIRUS LARGE T-ANTIGEN ARE REQUIRED FOR DIFFERENT FUNCTIONS OF THE PROTEIN	ONCOGENE			English	Article							SIMIAN VIRUS-40; BINDING-SITES; TUMOR-ANTIGEN; DNA HELICASE; REPLICATION; FIBROBLASTS; INFECTION; PHOSPHORYLATION; IMMORTALIZATION; TRANSFORMATION	Many cellular and some virally coded proteins regulating key events in higher cells have been found to be multifunctional. One example of such a protein is the polyomavirus large T antigen, which is involved not only in viral DNA replication and gene expression but also in the induction of the S phase in host cells, in the immortalization of various cell types and in the transactivation of some cellular genes. We recently constructed cell lines in which T antigen was synthesized under the control of a hormone-inducible promoter. This allowed us to induce different concentrations of the protein in the cell and to investigate the levels of large T antigen required for replication, S-phase induction and transactivation of a growth-regulated promoter. We found that significantly higher concentrations of large T antigen are required for the replication function of the protein than for either S phase induction or transactivation. These observations for the first time provide clear evidence for a potential regulation of different functions of a pleiotropic protein by the amount of that protein produced in the cell.	UNIV VIENNA,INST MOLEK BIOL,DR BOHR GASSE 9,A-1030 VIENNA,AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)				Ogris, Egon/0000-0001-5950-9264				BERGER H, 1986, J VIROL, V60, P768, DOI 10.1128/JVI.60.2.768-770.1986; BOCKUS BJ, 1987, J VIROL, V61, P1147, DOI 10.1128/JVI.61.4.1147-1154.1987; CHENG SH, 1990, MOL CELL BIOL, V10, P5569, DOI 10.1128/MCB.10.10.5569; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; COWIE A, 1986, MOL CELL BIOL, V6, P4344, DOI 10.1128/MCB.6.12.4344; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; KINGSTON RE, 1986, MOL CELL BIOL, V10, P3343; LORIMER HE, 1991, J VIROL, V65, P687, DOI 10.1128/JVI.65.2.687-699.1991; MARTENS I, 1989, J VIROL, V63, P2126, DOI 10.1128/JVI.63.5.2126-2133.1989; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; POMERANTZ BJ, 1984, J VIROL, V49, P925, DOI 10.1128/JVI.49.3.925-937.1984; PRIVES C, 1990, CELL, V61, P735, DOI 10.1016/0092-8674(90)90179-I; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; ROTHENEDER H, 1991, NUCLEIC ACIDS RES, V19, P6805, DOI 10.1093/nar/19.24.6805; Sambrook J., 1989, MOL CLONING LAB MANU; SEKI M, 1990, BIOCHEMISTRY-US, V29, P1003, DOI 10.1021/bi00456a024; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRAUSS M, 1990, ONCOGENE, V5, P1223; TEMPLETON D, 1986, J VIROL, V57, P367, DOI 10.1128/JVI.57.1.367-370.1986; TOOZE J, 1980, DNA TUMOURS VIRUSES; TURLER H, 1985, J VIROL, V53, P579; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WANG EH, 1991, J BIOL CHEM, V266, P12668; WEICHSELBRAUN I, 1989, J VIROL, V63, P961, DOI 10.1128/JVI.63.2.961-964.1989; WEINBERG RA, 1990, TRENDS BIOCHEM SCI, V15, P199, DOI 10.1016/0968-0004(90)90162-5; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989	34	10	10	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1277	1283						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8386826				2022-12-17	WOS:A1993KY32800020
J	MAHER, DW; STRAWN, LM; DONOGHUE, DJ				MAHER, DW; STRAWN, LM; DONOGHUE, DJ			ALANINE MUTAGENESIS OF CONSERVED RESIDUES IN THE PLATELET-DERIVED GROWTH-FACTOR FAMILY - IDENTIFICATION OF RESIDUES NECESSARY FOR DIMERIZATION AND TRANSFORMATION	ONCOGENE			English	Article							V-SIS GENE; ENDOTHELIAL-CELL MITOGEN; TERMINAL CODING REGION; PDGF-B-CHAIN; BOVINE PAPILLOMAVIRUS; AMINO-ACIDS; RECEPTOR; PROTEIN; BINDING; AUTOPHOSPHORYLATION	Platelet-derived growth factor (PDGF) and vascular endothelial growth factor define a family of dimeric proteins characterized by eight conserved cysteine residues involved in disulfide bonds. Thirteen non-cysteine residues conserved among the platelet-derived/vascular endothelial growth factors were individually mutated to alanine in v-sis/PDGF-B. In addition, five other residues flanking F148 were also mutated to alanine. The resulting mutants were assayed for transformation of NIH3T3 cells, and the mutant proteins were assayed for their ability to dimerize. Four residues were found to be crucial for disulfide-linked dimer formation: P152 and (;162 were mandatory, while R159 and H205 also contributed to efficient dimerization. Four of the mutant proteins (at residues N147, F148, L149 and K185) dimerized efficiently yet exhibited less than 50% transforming activity compared with wild-type v-sis. Two mutants (at residues D142 and F148) were located in a region important for PDGF receptor interaction and were further studied with regard to secretion and PDGF receptor autophosphorylation. A series of substitutions at residue F148 revealed a strong preference for aromatic amino acids. One mutant from this series (F148G) dimerized but was completely inactive for transformation. This study thus identifies four residues in v-sis/PDGF-B important for dimerization and also identifies additional residues critical for full activation of PDGF receptors. The E5 oncoprotein encoded by bovine papillomavirus type I exhibits two short regions of amino acid similarity when compared with the minimal transforming region of v-sis/PDGF-B. Several of the v-sis mutants discussed in this work affect residues that are also present in the E5 oncoprotein, including F148, L149 and H205.	UNIV CALIF SAN DIEGO,DEPT CHEM,DIV BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA040573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLEMENTS JM, 1991, EMBO J, V10, P4113, DOI 10.1002/j.1460-2075.1991.tb04988.x; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEUEL TF, 1981, J BIOL CHEM, V256, P8896; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; GIESE N, 1990, MOL CELL BIOL, V10, P5496, DOI 10.1128/MCB.10.10.5496; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; HANNINK M, 1986, MOL CELL BIOL, V6, P1304, DOI 10.1128/MCB.6.4.1304; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG JS, 1983, J CELL BIOL, V97, P383, DOI 10.1083/jcb.97.2.383; IBANEZ CF, 1990, EMBO J, V9, P1477, DOI 10.1002/j.1460-2075.1990.tb08265.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LAROCHELLE WJ, 1989, MOL CELL BIOL, V9, P3538, DOI 10.1128/MCB.9.8.3538; LEE BA, 1991, J CELL BIOL, V113, P361, DOI 10.1083/jcb.113.2.361; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; OSTMAN A, 1991, J BIOL CHEM, V266, P10073; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAINES EW, 1984, P NATL ACAD SCI USA, V81, P3423; RAMACHANDRAN GN, 1966, BIOPHYS J, V6, P849, DOI 10.1016/S0006-3495(66)86699-7; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; SAUER MK, 1986, J VIROL, V59, P292, DOI 10.1128/JVI.59.2.292-300.1986; SAUER MK, 1988, MOL CELL BIOL, V8, P1011, DOI 10.1128/MCB.8.3.1011	36	10	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					533	541						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8437840				2022-12-17	WOS:A1993KN00800002
J	SIRINIAN, MI; MARCHETTI, A; DIROCCO, G; STARACE, G; JUCKER, R; NASI, S				SIRINIAN, MI; MARCHETTI, A; DIROCCO, G; STARACE, G; JUCKER, R; NASI, S			RAS ONCOGENE TRANSFORMATION OF HUMAN B-LYMPHOBLASTS IS ASSOCIATED WITH LYMPHOCYTE-ACTIVATION AND WITH A BLOCK OF DIFFERENTIATION	ONCOGENE			English	Article							MOLECULAR-CLONING; INTERLEUKIN-2 RECEPTOR; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; CELL ACTIVATION; PC12 CELLS; H-RAS; TRANSCRIPTION; GENE; ADHESION	The p21ras small GTP binding proteins participate in signal transduction from cell surface receptors and affect neoplastic transformation and development in many different cell types. In the present study, we examined the relationship between ras transformation and differentiation of human B lymphocytes. We show that the constitutive expression of the T24 Ha-ras oncogene in EBV-immortalized B lymphoblasts was associated with the induction of the interleukin 2 receptor alpha subunit, with an impaired immunoglobulin gene expression, altered adhesion properties and increased survival in serum-free medium. Since induction of the IL-2 receptor alpha subunit is a hallmark of lymphocyte activation, we suggest that p21ras naturally triggers B cell activation. The ras-transformed lymphocytes displayed a fully functional IL-2r, as assessed by c-fos induction following treatment with IL-2; nevertheless, they were not growth stimulated by this lymphokine. The decreased expression of immunoglobulin genes indicates that the ras oncogene blocks terminal differentiation to plasma cells, possibly by inhibiting the activity of lymphocyte-specific transcription factors. Somewhat unexpectedly, the constitutive p21ras activity did not cause an increased DNA binding of transcription factors PEA1 (AP1), PEA3, Oct-2 or NF-kB.	UNIV ROME LA SAPIENZA,DIPARTIMENTO GENET & BIOL MOLEC,CNR,CTR ACIDI NUCL,I-00185 ROME,ITALY; CNR,IST MED SPERIMENTALE,ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)			Di Rocco, Giuliana/G-5682-2012; Di Rocco, Giuliana/P-1413-2019; Di Rocco, Giuliana/J-4776-2018; Marchetti, Alessandra/AAD-5498-2019	Di Rocco, Giuliana/0000-0003-1210-6008; Di Rocco, Giuliana/0000-0003-1210-6008; MARCHETTI, ALESSANDRA/0000-0001-9706-848X				ARIMA N, 1987, J IMMUNOL, V138, P3069; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BICHTHUY LT, 1990, CELL IMMUNOL, V128, P22, DOI 10.1016/0008-8749(90)90003-A; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CARUSO M, 1990, EMBO J, V9, P947, DOI 10.1002/j.1460-2075.1990.tb08193.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DANG LH, 1991, J IMMUNOL, V146, P3273; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ENDO K, 1991, ONCOGENE, V6, P1391; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GILLIS S, 1978, J IMMUNOL, V120, P2027; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; LANGDON WY, 1989, ONCOGENE RES, V4, P253; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MINGARI MC, 1984, NATURE, V312, P641, DOI 10.1038/312641a0; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NASI S, 1990, ONCOGENE, V5, P117; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; YAGURA H, 1990, BLUT, V60, P181, DOI 10.1007/BF01720273	45	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					157	163						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423993				2022-12-17	WOS:A1993KN00500019
J	KUSSICK, SJ; COOPER, JA				KUSSICK, SJ; COOPER, JA			OVEREXPRESSED DROSOPHILA SRC 64B IS PHOSPHORYLATED AT ITS CARBOXY-TERMINAL TYROSINE, BUT IS NOT CATALYTICALLY REPRESSED, IN CULTURED DROSOPHILA CELLS	ONCOGENE			English	Article							EGF RECEPTOR HOMOLOG; EXPRESS HIGH-LEVELS; FAINT-LITTLE-BALL; KINASE-ACTIVITY; PROTEIN-KINASE; C-SRC; PP60C-SRC; GENE; TRANSFORMATION; DOMAIN	Little is known about the regulation of non-receptor tyrosine kinases in invertebrates. We have studied the relationship between the phosphorylation state of the Drosophila src 64B (Dsrc) gene product, p62D, and its tyrosine kinase activity in Drosophila Schneider 2 cells, using wild-type and mutated Dsrc constructs that were overexpressed by transient transfection. Phosphopeptide mapping showed that the putative regulatory C-terminal tyrosine (Tyr-547) of p62D was phosphorylated in vivo. In contrast to vertebrate src family kinases overexpressed in fibroblasts, wild-type p62D overexpressed in Schneider 2 cells was phosphorylated at additional tyrosines outside of the C-terminus. These tyrosines corresponded to the major in vitro autophosphorylation sites. Overexpression of wild-type p62D or several catalytically active p62D mutants significantly increased the phosphorylation of numerous Schneider cell proteins on tyrosine, while expression of catalytically inactive mutants of p62D had no such effect. Thus, in contrast to the repression of src family kinase activity in fibroblasts, p62D is catalytically active when overexpressed in Drosophila cells, perhaps because of substoichiometric C-terminal tyrosine phosphorylation. These results raise the possibility that fly development will be sensitive to ectopic expression of p62D.	UNIV WASHINGTON, SCH MED, DEPT PATHOL, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA041072, R37CA041072] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BOULTER CA, 1991, DEVELOPMENT, V111, P357; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1991, J VIROL, V65, P170, DOI 10.1128/JVI.65.1.170-179.1991; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1983, CELL, V35, P393, DOI 10.1016/0092-8674(83)90172-1; HURLEY TR, 1989, ONCOGENE, V4, P265; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KUSSICK SJ, 1991, CELLULAR REGULATIO H, V56, P295; KUSSICK SJ, 1992, IN PRESS ONCOGENE; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MCKEOWN M, 1990, NEW BIOL, V2, P828; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PETERSEN RB, 1989, CELL REGUL, V1, P135, DOI 10.1091/mbc.1.1.135; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHIELDS G, 1977, DROSOPHILA INF SERVI, V52, P161; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SIMON MA, 1983, NATURE, V302, P837, DOI 10.1038/302837a0; SIMON MA, 1987, THESIS U CALIFORNIA; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WEINMASTER GA, 1988, J VIROL, V62, P2016, DOI 10.1128/JVI.62.6.2016-2025.1988; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x	54	10	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1992	7	12					2461	2470						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1281305				2022-12-17	WOS:A1992KA85600011
J	JOOSS, K; MULLER, R				JOOSS, K; MULLER, R			ANALYSIS OF TEMPERATURE-SENSITIVE FUNCTIONS OF FOS - LACK OF A CORRELATION BETWEEN TRANSFORMATION AND TRE-DEPENDENT TRANSACTIVATION	ONCOGENE			English	Article							INDUCE CELLULAR-TRANSFORMATION; ROUS-SARCOMA VIRUS; PROTO-ONCOGENE FOS; C-FOS; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; AUTO-REGULATION; BINDING DOMAIN; JUN; CELLS	We have identified and characterized a mutant v-Fos protein (DN16G) that is temperature sensitive for transformation. This protein contains an asparagine to glycine substitution at position 156 in the basic region encompassing the DNA contact site. This point mutation also strongly decreases trans-activation in a transient expression assay, using the collagenase 12-O-tetradecanoyl phorbol 13-acetate (TPA)-responsive element (TRE) as the target element. However, the apparent correlation between trans-activation and transformation does not hold in view of the observation that under certain temperature conditions (DN16G at 39.5-degrees-C and E300 at 37-degrees-C) both proteins showed similarly poor transactivation properties, but dramatically differed in their transforming potential. These findings clearly suggest that the activation of transcription via TREs as analysed in this study is not a crucial mechanism in Fos-induced transformation.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4784; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAMATA N, 1992, MOL CELL BIOL, V12, P876, DOI 10.1128/MCB.12.2.876; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; LUCIBELLO FC, 1990, EMBO J, V9, P2828; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NEUBERG M, 1991, ONCOGENE, V6, P1325; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VERMA IM, 1986, TRENDS GENET, V2, P93, DOI 10.1016/0168-9525(86)90191-5; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x	48	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1933	1939						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408134				2022-12-17	WOS:A1992JP42400005
J	SUDO, T; MIYAZAWA, H; HANAOKA, F; ISHII, S				SUDO, T; MIYAZAWA, H; HANAOKA, F; ISHII, S			THE C-MYB PROTOONCOGENE PRODUCT BINDS TO BUT DOES NOT ACTIVATE THE PROMOTER OF THE DNA POLYMERASE-ALPHA GENE	ONCOGENE			English	Article							TEMPERATURE-SENSITIVE MUTANT; V-MYB; CELL-PROLIFERATION; NUCLEOTIDE-SEQUENCE; EXPRESSION; REPLICATION; PROGENITOR; REGION	The myb proto oncogene product (c-Myb) is a transcriptional reglator and its expression and function are tightly linked to the cellular entry into S phase and DNA synthesis. It has been shown [Venturelli, D., Travali, S. & Calabretta, B. (1990). Proc. Natl. Acad. Sci. USA, 87, 5963-59671 that inhibition of T-cell proliferation by a myb antisense oligomer is accompanied by down-regulation of DNA polymerase-alpha-expression. To examine whether the transcription of the DNA polymerase-alpha-gene is directly regulated by c-Myb, we have identified and characterized the 5' regulatory region of the human DNA polymerase-alpha-gene. Two major and several minor transcription start sites were identified by nuclease S1 mapping. DNA sequence analysis showed that the promoter region contains no TATA box, one CCAAT box and putative Ap-1, AP-2 and E2F binding sites. In DNAase I footprinting, the bacterially expressed c-Myb protected six sites in the 5' flanking region of the human DNA polymerase-alpha-gene. However, c-Myb did not activate the DNA polymerase-alpha-gene promoter in a cotransfection assay. Our results suggest that an unknown factor(s) is required for the c-Myb-induced activation of the DNA polymerase-alpha-gene promoter, or c-Myb does not directly activate this promoter.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; INST PHYS & CHEM RES,CELLULAR PHYSIOL LAB,SAITAMA 35101,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	RIKEN; RIKEN; University of Tokyo			Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				ARAKI E, 1988, NUCLEIC ACIDS RES, V16, P1627, DOI 10.1093/nar/16.4.1627; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CAMPBELL JL, 1986, ANNU REV BIOCHEM, V55, P733, DOI 10.1146/annurev.bi.55.070186.003505; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HU YL, 1991, ONCOGENE, V6, P1549; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Maniatis T., 1982, MOL CLONING; MIYAZAWA H, 1986, BIOCHEM BIOPH RES CO, V139, P135; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAGASE T, 1990, J BIOL CHEM, V265, P17300; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NAKAGOSHI H, 1992, IN PRESS ONCOGENE; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAKADATAKAYAMA R, 1991, J BIOL CHEM, V266, P15716; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; VENTURELLI D, 1990, P NATL ACAD SCI USA, V87, P5963, DOI 10.1073/pnas.87.15.5963; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; [No title captured]	36	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1999	2006						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1408140				2022-12-17	WOS:A1992JP42400013
J	KOTANI, K; KIKUCHI, A; DOI, K; KISHIDA, S; SAKODA, T; KISHI, K; TAKAI, Y				KOTANI, K; KIKUCHI, A; DOI, K; KISHIDA, S; SAKODA, T; KISHI, K; TAKAI, Y			THE FUNCTIONAL DOMAIN OF THE STIMULATORY GDP GTP EXCHANGE PROTEIN (SMG GDS) WHICH INTERACTS WITH THE C-TERMINAL GERANYLGERANYLATED REGION OF RAP-1/KREV-1/SMG-P21	ONCOGENE			English	Article							BOVINE BRAIN MEMBRANES; BINDING PROTEIN; MOLECULAR-WEIGHT; EFFECTOR DOMAIN; HUMAN-PLATELETS; RAS PROTEINS; ACTIVATING PROTEINS; PLASMA-MEMBRANE; PURIFICATION; P21	rap1/Krev-1/smg p21 (smg p21), a member of the small GTP-binding protein (G protein) superfamily, has a geranylgeranylated cysteine residue and clustered basic amino acids in the C-terminal region. The GDP/GTP exchange reaction of smg p21 is regulated by smg GDS, which is also active on Ki-ras p21 and rho p21. The C-terminal region of smg p21 is essential for its interaction with smg GDS. Moreover, smg p21 is phosphorylated by cyclic AMP- and cyclic GMP-dependent protein kinases at the serine residue between the polybasic region and the prenylated cysteine residue, and this phosphorylation initiates the smg GDS-induced smg p21 activation. Thus, the C-terminal cationic and hydrophobic region is important for the regulation of the smg p21 activity. In the present study, we attempted to determine the functional domain of smg GDS which interacts with the C-terminal region of smg p21 by use of a cross-link method and a site-directed mutagenesis method. The region of smg GDS cross-linked with the C-terminal region of smg p21B was residues 444-492, which is located at the C-terminal fifth of smg GDS. On deletion of these residues, smg GDS became inactive on smg p21B, Ki-ras p21 and rhoA p21. These results indicate that residues 444-492 of smg GDS are at least one of the domains which interact with the C-terminal region of its substrate small G proteins.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University				kishida, shosei/0000-0003-0405-851X				BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NICE EC, 1992, J BIOL CHEM, V267, P1546; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Sambrook J., 1989, MOL CLONING LAB MANU; SHIRATAKI H, 1991, J BIOL CHEM, V266, P20672; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	33	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1699	1704						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501882				2022-12-17	WOS:A1992JJ37600004
J	PARK, JG; REDDY, EP				PARK, JG; REDDY, EP			LARGE-SCALE MOLECULAR MAPPING OF HUMAN C-MYB LOCUS - C-MYB PROTOONCOGENE IS NOT INVOLVED IN 6Q- ABNORMALITIES OF LYMPHOID TUMORS	ONCOGENE			English	Article							HUMAN-MALIGNANT MELANOMA; CELL-LINES ML-1; HUMAN CANCER; CYTOGENETIC CHARACTERIZATION; MYELOGENOUS LEUKEMIA; BURKITT-LYMPHOMA; TRANSLOCATION; GENE; DNA; RETINOBLASTOMA	Chromosomal abnormalities in the 6q region have been observed frequently in several T-cell and myeloid leukemias. Interestingly, this region was found to contain three cellular oncogenes, c-myb, c-fyn and c-ros. Several of the tumors that exhibit 6q- abnormalities have also been found to express high levels of c-myb and, in some cases, amplification of the c-myb gene, leading to the suggestion that this gene could tie in proximity to the deletions observed in these tumors. To determine if c-myb gene activation is associated with 6q- abnormalities, we developed a megabase map of the human c-myb locus using pulsed-field gel electrophoresis. We then examined the occurrence of abnormalities near the c-myb gene in several hematopoietic tumor cell lines containing well-characterized 6q- abnormalities. Our results show that no rearrangements or deletions occur within a region of 1.0 Mbp of the c-myb locus in these cell lines. However, several of the cell lines exhibited differential and partial methylation patterns which seem to be prevalent amongst different cell lines.	WISTAR INST, PHILADELPHIA, PA 19104 USA	The Wistar Institute			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA21124, CAS52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009, P01CA021124] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BROWN WRA, 1986, NATURE, V322, P477, DOI 10.1038/322477a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DASGUPTA P, 1989, ONCOGENE, V4, P1201; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GEMMILL RM, 1989, GENOMICS, V4, P28, DOI 10.1016/0888-7543(89)90310-8; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARPER ME, 1983, NATURE, V304, P169, DOI 10.1038/304169a0; HAYATA I, 1975, IN VITRO CELL DEV B, V11, P361; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KATHELEEN G, 1986, SOM CELL MOL GEN, V12, P185; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MEESE E, 1989, GENE CHROMOSOME CANC, V1, P88, DOI 10.1002/gcc.2870010114; MITELMAN F, 1984, NATURE, V310, P325, DOI 10.1038/310325a0; MITELMAN F, 1983, CYTOGENET CELL GENET, V36, P1, DOI 10.1159/000131930; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; NOWELL PC, 1988, FASEB J, V2, P3054, DOI 10.1096/fasebj.2.15.3056765; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; OHYASHIKI K, 1986, CANCER RES, V46, P3642; OKADA M, 1990, CANCER GENET CYTOGEN, V48, P229, DOI 10.1016/0165-4608(90)90125-T; OSHIMURA HM, 1975, IN VITRO, V11, P361; OSHIMURA M, 1977, CANCER, V40, P1161, DOI 10.1002/1097-0142(197709)40:3<1161::AID-CNCR2820400327>3.0.CO;2-2; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; RABBITTS TH, 1988, TRENDS GENET, V4, P300, DOI 10.1016/0168-9525(88)90106-0; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SMITH SD, 1986, BLOOD, V67, P650; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; TRENT JM, 1983, CANCER GENET CYTOGEN, V9, P177, DOI 10.1016/0165-4608(83)90039-0	40	10	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1992	7	8					1603	1609						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE813	1630821				2022-12-17	WOS:A1992JE81300017
J	ADLER, HT; SEFTON, BM				ADLER, HT; SEFTON, BM			GENERATION AND CHARACTERIZATION OF TRANSFORMING VARIANTS OF THE LCK TYROSINE PROTEIN-KINASE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; RETROVIRUS PROMOTER INSERTION; COMPLETE NUCLEOTIDE-SEQUENCE; RIBOSOMAL-RNA GENE; CELLULAR ONCOGENE; MAMMALIAN-CELLS; CD4 RECEPTOR; CDNA CLONE; SRC GENE; PHOSPHORYLATION	p56lck, a tyrosine protein kinase of the src family, is overexpressed in two murine thymoma cell lines, LSTRA and Thy19, as a result of the integration of Moloney murine leukemia virus sequences upstream of the kk gene. The majority of the p56lck in these cell lines is translated from a hybrid mRNA comprised of the 5' untranslated region of the murine leukemia virus env mRNA and lck coding sequences. The retroviral promoter giving rise to this transcript has been molecularly cloned. To examine whether overexpression of unmutated p56lck might induce cellular transformation, we constructed a plasmid in which the murine leukemia virus promoter from LSTRA cells directed the expression of p56lck. This construct gave rise to foci when transfected into rat 208F fibroblasts. Cells from many of the foci also grew in soft agar. Tryptic peptide mapping showed that the p56lck in the transformed cells was phosphorylated at Tyr-394, the autophosphorylation site, but not detectably at Tyr-505, an inhibitory site. Because an antiserum made to the carboxy terminus of p56lck could not immunoprecipitate p56lck from these transformed cells, the possibility arose that the proteins expressed in the transformed fibroblasts contained mutations that altered the carboxy terminus of the protein. cDNAs derived from the 3' ends of the lck mRNAs in two of the foci were cloned, and both were found to be derived from an kk gene that was truncated upstream of the codon for Tyr-505 and fused to random sequences derived from other parts of the construct used for transfection. kk therefore resembles several other src family members in that it can be rendered oncogenic by replacement of the region encoding the inhibitory, carboxyterminal phosphorylation site by random amino acid sequences.	SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186; UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093	Salk Institute; University of California System; University of California San Diego					NCI NIH HHS [CA14195, CA42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042350, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GLYNN JP, 1964, CANCER RES, V24, P502; HASSOUNA N, 1984, NUCLEIC ACIDS RES, V12, P3563, DOI 10.1093/nar/12.8.3563; HURLEY TR, 1989, ONCOGENE, V4, P265; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KAPLAN PL, 1987, J VIROL, V61, P1731, DOI 10.1128/JVI.61.5.1731-1734.1987; KAWAKAMI T, 1988, P NATL ACAD SCI USA, V85, P3870, DOI 10.1073/pnas.85.11.3870; KITAMURA N, 1982, NATURE, V297, P205, DOI 10.1038/297205a0; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; LUO K, 1990, ONCOGENE, V5, P921; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MILLER AD, 1984, CELL, V36, P51; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; QUADE K, 1979, VIROLOGY, V98, P461, DOI 10.1016/0042-6822(79)90569-5; RAYNAL F, 1984, FEBS LETT, V167, P263, DOI 10.1016/0014-5793(84)80139-8; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SWANSTROM R, 1983, P NATL ACAD SCI-BIOL, V80, P2519, DOI 10.1073/pnas.80.9.2519; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383	41	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1191	1199						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594248				2022-12-17	WOS:A1992HU64200017
J	SCHUH, AC; KEATING, SJ; YEUNG, MC; BREITMAN, ML				SCHUH, AC; KEATING, SJ; YEUNG, MC; BREITMAN, ML			SKELETAL-MUSCLE ARISES AS A LATE EVENT DURING DEVELOPMENT OF WOUND SARCOMAS IN V-JUN TRANSGENIC MICE	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; C-JUN; PROTO-ONCOGENE; DNA-BINDING; GLUCOCORTICOID RECEPTOR; ENHANCER ELEMENTS; GROWTH-FACTORS; GENE FAMILY; EXPRESSION; DIFFERENTIATION	Mice carrying an H-2K-v-jun transgene develop malignant sarcomas by a multistage mechanism following wounding. Here we show that these malignancies are often heterogeneous in composition, containing both undifferentiated mesenchymal cells as well as focal areas of skeletal muscle. Such myogenic areas are not detectable in premalignant precursor lesions, suggesting that cells competent for muscle differentiation arise at a late stage of tumorigenesis. Immunohistochemical staining of transgenic sarcomas reveals that levels of v-Jun correlate inversely with muscle-specific gene expression, suggesting that high levels may be inhibitory to myogenesis. Consistent with this idea, we demonstrate that whereas high levels of v-Jun are able to block MyoD-dependent gene expression in vitro, the levels of v-Jun in sarcoma-derived myogenic cells are below the threshold required to produce this effect. The cell of origin of v-jun wound sarcomas, as well as the relationship between myogenic determination and multistage tumorigenesis, are discussed in the light of these results.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; MT SINAI HOSP,DEPT PATHOL,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute								ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRAS T, 1988, DEV BIOL, V127, P209, DOI 10.1016/0012-1606(88)90202-3; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clark RA, 1988, WOUND REPAIR MOL CEL, P3, DOI [10.1007/978-1-4615-1795-5_1, DOI 10.1007/978-1-4615-1795-5_1]; CONSTANTINIDES PG, 1977, NATURE, V267, P364, DOI 10.1038/267364a0; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P448; FLORINI JR, 1989, AM J PHYSIOL, V256, pC701, DOI 10.1152/ajpcell.1989.256.4.C701; GARCIA M, 1990, J VIROL, V64, P4684, DOI 10.1128/JVI.64.10.4684-4690.1990; GILMAN M, 1987, CURRENT PROTOCOLS MO, V1; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSSI M, 1991, ONCOGENE, V6, P1767; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MEAKIN SO, 1989, EXP EYE RES, V48, P131, DOI 10.1016/0014-4835(89)90026-2; MEAKIN SO, 1987, MOL CELL BIOL, V7, P2671, DOI 10.1128/MCB.7.8.2671; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Skalli O, 1988, MOL CELLULAR BIOL WO, P373; SU HY, 1991, ONCOGENE, V6, P1759; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; VOGT PK, 1988, ONCOGENE, V3, P3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YU CCK, 1990, DEVELOPMENT, V110, P131	53	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1992	7	4					667	676						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ682	1314368				2022-12-17	WOS:A1992HQ68200008
J	HAHN, S; WODNARFILIPOWICZ, A; NAIR, APK; MORONI, C				HAHN, S; WODNARFILIPOWICZ, A; NAIR, APK; MORONI, C			RAS ONCOGENES AMPLIFY LYMPHOKINE (INTERLEUKIN-3, GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR) INDUCTION BY CALCIUM IONOPHORE	ONCOGENE			English	Article							CSF MESSENGER-RNA; GM-CSF; MAST-CELLS; GROWTH-FACTORS; EXPRESSION; GENE; TRANSFORMATION; TUMOR; ACTIVATION; TRANSCRIPTION	Interleukin 3 (IL-3) expression in PB-3c mastocytes is transiently induced in vitro by treatment with the drug A23187, a calcium ionophore, or constitutively following ras-dependent transformation in vivo. While the mechanism of oncogenically induced IL-3 expression is not clear, A23187-mediated lymphokine mRNA accumulation is primarily the result of calcium-dependent mRNA stabilization. We investigated whether the expression of various ras alleles influenced IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA induction by A23187. It was found that activated forms of ras potentiated ionophore-mediated lymphokine mRNA accumulation. This enhancement involves a post-transcriptional mechanism, as ionophore-induced lymphokine mRNAs are significantly more stable in ras oncogene-expressing lines than in the control line. We propose that one way by which ras genes exert their oncogenic potential is by extending the half-life of short-lived growth factor mRNAs.	UNIV BASEL, INST MED MIKROBIOL, CH-4003 BASEL, SWITZERLAND	University of Basel								ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; BALL PE, 1983, DIFFERENTIATION, V24, P74, DOI 10.1111/j.1432-0436.1983.tb01305.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIAMANTIS ID, 1989, P NATL ACAD SCI USA, V86, P9299, DOI 10.1073/pnas.86.23.9299; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; GOUGH NM, 1985, EMBO J, V4, P645, DOI 10.1002/j.1460-2075.1985.tb03678.x; GRIMALDI JC, 1989, BLOOD, V73, P2081; HOFSTETTER P, 1987, MOL CELL BIOL, V7, P4535, DOI 10.1128/MCB.7.12.4535; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; METCALF D, 1984, HEMOPOIETIC COLONIES; METZGER H, 1988, ADV IMMUNOL, V43, P277; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	28	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1991	6	12					2327	2332						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1722572				2022-12-17	WOS:A1991GX73500022
J	ZHAO, X; SINGH, B; ARLINGHAUS, RB				ZHAO, X; SINGH, B; ARLINGHAUS, RB			INHIBITION OF C-MOS PROTEIN-KINASE BLOCKS MOUSE ZYGOTES AT THE PRONUCLEI STAGE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; V-MOS; MEIOTIC MATURATION; DEVELOPMENTAL REGULATION; PROTOONCOGENE PRODUCT; XENOPUS OOCYTES; GERM-CELLS; ONCOGENE; EXPRESSION; SEQUENCE	The c-mos gene product is required for activation of the maturation-promoting factor (MPF) during oocyte maturation. The c-mos protein also acts as a cytostatic factor which is responsible for meiotic metaphase arrest of vertebrate eggs via stabilization of MPF. Here we show that mouse zygotes contain the c-mos protein. Introduction of a kinase-inhibitory anti-mos antibody into mouse zygotes 12 h after fertilization prevented the first cleavage of zygotes at the pronuclei stage. A second anti-mos antibody, known to allow the mos kinase to function, did not interfere with the formation of two-cell embryos. In addition to its known role in MPF activation in oocyte maturation and meiotic metaphase arrest, our findings indicate that the c-mos protein kinase is also required for completion of pronuclei breakdown following fertilization of mouse eggs.	STANFORD UNIV,MED CTR,SCH MED,DEPT MED,STANFORD,CA 94305; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	Stanford University; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GOLDMAN DS, 1988, ONCOGENE, V3, P159; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P255; Hogan B., 1986, MANIPULATING MOUSE E; KESHET E, 1988, ONCOGENE, V2, P235; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; ZHAO X, 1990, ONCOGENE, V5, P1727; Zhao X., 1989, TECHNIQUES J METHODS, V1, P37	31	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1423	1426						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1832216				2022-12-17	WOS:A1991GX27200019
J	BACHNOU, N; LAUDET, V; JAFFREDO, T; QUATANNENS, B; SAULE, S; DIETERLENLIEVRE, F				BACHNOU, N; LAUDET, V; JAFFREDO, T; QUATANNENS, B; SAULE, S; DIETERLENLIEVRE, F			COOPERATIVE EFFECT OF V-MYC AND V-ERBA IN THE CHICK-EMBRYO	ONCOGENE			English	Article							THYROID-HORMONE RECEPTOR; AVIAN ERYTHROBLASTOSIS VIRUS; TRANSGENIC MICE; NEURORETINA CELLS; ONCOGENES; INVITRO; PROTEIN; EXPRESSION; TRANSFORMATION; INVIVO	We show that a construct designated as MAHEVA, which encodes oncogenes v-myc from MH2 virus and v-erbA from AEV under the control of the LTR of MH2, induces rapidly growing heart rhabdomyosarcomas, when it is injected in E3 but not E5 chick embryos. A similar pathology has previously been observed with MC29, within the same limited time frame. The tumors, which expressed P61-63myc, P75gag-erbA and Pr76gag proteins were detectable from E14 onwards. Compared with MC29, MAHEVA induced a secondary anomaly, not detectable prior to E17. This is the appearance of cartilage nodules within the heart rhabdomyosarcomas. The constant location of these nodules inside the rhabdomyosarcomas and their delayed appearance suggests that the chondrocytes originate from myoblasts prevented from differentiating by the expression of the v-myc product. This interpretation is supported by the appearance of chondrocytes in E3 heart muscle cells infected in vitro with MAHEVA.	CNRS, INST EMBRYOL CELLULAIRE & MOLEC, 49 BIS AV BELLE GABRIELLE, F-94736 NOGENT SUR MARNE, FRANCE; COLL FRANCE, F-94736 NOGENT SUR MARNE, FRANCE; COLL FRANCE, F-94736 NOGENT SUR MARNE, FRANCE; INST PASTEUR, INSERM, U186, F-59019 LILLE, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	DIETERLENLIEVRE, F (corresponding author), CNRS, INST EMBRYOL CELLULAIRE & MOLEC, 49 BIS AV BELLE GABRIELLE, F-94736 NOGENT SUR MARNE, FRANCE.		JAFFREDO, Thierry/K-7870-2017	JAFFREDO, Thierry/0000-0002-8724-3261				ADAMSON ED, 1987, DEVELOPMENT, V99, P449; ALMOUSTAFA AE, 1988, CELL DIFFER DEV, V25, P119, DOI 10.1016/0922-3371(88)90005-6; AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BETTEXGALLAND M, 1987, EXPERIENTIA, V43, P610, DOI 10.1007/BF02126349; BEUG H, 1985, MODERN TRENDS HUMAN, V4, P290; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DEHAAN RL, 1967, DEV BIOL, V16, P216, DOI 10.1016/0012-1606(67)90025-5; DOLBERG DS, 1984, NATURE, V309, P552, DOI 10.1038/309552a0; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Gabe M., 1968, TECHNIQUES HISTOLOGI; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRIGORIADIS AE, 1988, J CELL BIOL, V106, P2139, DOI 10.1083/jcb.106.6.2139; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; ITOH Y, 1986, DEV BIOL, V115, P353, DOI 10.1016/0012-1606(86)90255-1; JAFFREDO T, 1989, DEVELOPMENT, V105, P679; JAFFREDO T, 1991, EXP CELL RES, V192, P481, DOI 10.1016/0014-4827(91)90067-5; KAWAMURA M, 1988, DEV BIOL, V130, P435, DOI 10.1016/0012-1606(88)90339-9; Le Lievre C S, 1975, J Embryol Exp Morphol, V34, P125; OHLSSON RI, 1987, EXP CELL RES, V173, P1, DOI 10.1016/0014-4827(87)90327-2; OKADA TS, 1983, CELL DIFFER DEV, V13, P177, DOI 10.1016/0045-6039(83)90087-8; Romanoff A., 1960, THE AVIAN EMBRYO, V1, P429; RONG PM, 1987, DEV BIOL, V122, P338, DOI 10.1016/0012-1606(87)90299-5; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SAULE S, 1987, P NATL ACAD SCI USA, V84, P7982, DOI 10.1073/pnas.84.22.7982; SIMONS EV, 1971, ACTA MORPHOL NEER SC, V8, P281; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STIEFEL KARL, 1926, ANAT ANZEIGER, V61, P177; SUMIDA H, 1989, ANAT EMBRYOL, V180, P29, DOI 10.1007/BF00321897; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; YAMADA K, 1970, HISTOCHEMISTRY, V23, P13, DOI 10.1007/BF00309485	42	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1041	1047						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1676836				2022-12-17	WOS:A1991GU62200021
J	GRANDORI, C; SUDOL, M; HANAFUSA, H				GRANDORI, C; SUDOL, M; HANAFUSA, H			C-YES PROTEIN-KINASE IS ASSOCIATED WITH A 38-KD PROTEIN IN CEREBELLUM	ONCOGENE			English	Note							MIDDLE-T-ANTIGEN; GENE-PRODUCT; TYROSINE PHOSPHORYLATION; PP60C-SRC; POLYOMAVIRUS; ACTIVATION; P56LCK; DEPHOSPHORYLATION; TRANSFORMATION; IDENTIFICATION	p62c-yes, the protein product of the yes proto-oncogene, was found in association with a cellular protein of 38 kD in chicken cerebella. The complex was detected by immunoprecipitation of cerebellar membranes with affinity purified anti-yes IgG followed by in vitro phosphorylation of the immunocomplex. Both proteins were found to be phosphorylated exclusively on tyrosine. The sedimentation profile of the yes kinase indicated that a fraction of p62c-yes was complexed with the 38 kD protein and comigrated in the gradient with a molecular mass of approximately 150 kD. We have previously described the association of p60c-src with a 38 kD protein, referred to as p38 [Grandori, C. and Hanafusa, H., J. Cell Biol. (1988), 107: 2125-2135]. Comparison of the src-associated p38 with the yes-associated 38 kD protein indicates that they are indistinguishable by one-dimensional peptide mapping. Association of p38 with more than one member of the src-family of tyrosine kinases makes this protein an attractive probe to study the structural and functional aspects of these enzymes.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,1230 YORK AVE,NEW YORK,NY 10021	Rockefeller University	SUDOL, M (corresponding author), ROCKEFELLER UNIV,MOLEC ONCOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R29CA045757, R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA45757, CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE S, 1984, NATURE, V303, P435; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; GRANDORI C, 1989, THESIS ROCKEFELLER U; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; SUDOL M, 1988, ONCOGENE RES, V2, P345; SUDOL M, 1988, NUCLEIC ACIDS RES, V16, P9876, DOI 10.1093/nar/16.20.9876; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	27	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1063	1066						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067844				2022-12-17	WOS:A1991GU62200024
J	LEE, EB; HAYMAN, MJ				LEE, EB; HAYMAN, MJ			ANALYSIS OF THE ROLE OF THE EXTRACELLULAR DOMAIN OF THE NU-ERBB ONCOGENE IN CELLULAR-TRANSFORMATION	ONCOGENE			English	Article									SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA 28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASSIRI M, 1987, VIROLOGY, V159, P20, DOI 10.1016/0042-6822(87)90343-6; BASSIRI M, 1986, J VIROL, V59, P525, DOI 10.1128/JVI.59.2.525-530.1986; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1986, ONCOGENES GROWTH CON; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ENGELBRETH-HOLM J., 1935, Acta Pathologica et Microbiologica Scandinavica, V12, P352; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; HAYMAN MJ, 1978, VIROLOGY, V85, P241, DOI 10.1016/0042-6822(78)90428-2; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HAYMAN MJ, 1986, TRENDS GENET, V2, P260, DOI 10.1016/0168-9525(86)90259-3; HAYMAN MJ, 1987, VIROLOGY, V85, P475; HIHARA H, 1983, J NATL CANCER I, V70, P891; HUNTER E, 1988, PROTEIN TRANSFER ORG, P109; JANSSON M, 1987, ONCOGENE, V1, P167; KAMPS MP, 1988, ONCOGENE, V2, P305; KAWAI S, 1987, J VIROL, V61, P1665, DOI 10.1128/JVI.61.5.1665-1669.1987; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KNIGHT J, 1988, ONCOGENE, V2, P317; KOWENZ E, 1987, MODERN TRENDS HUMAN, V4, P417; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MARTIN GS, 1986, CANCER SURV, V5, P199; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NG M, 1986, J VIROL, V58, P542, DOI 10.1128/JVI.58.2.542-553.1986; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SCOTTING P, 1987, ONCOGENE RES, V1, P265; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; YAMAMOTO T, 1983, CELL, V34, P225, DOI 10.1016/0092-8674(83)90153-8	34	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1165	1172						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2168029				2022-12-17	WOS:A1990DX36100008
J	MOREAUGACHELIN, F				MOREAUGACHELIN, F			CORRECTION	ONCOGENE			English	Correction, Addition																		KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449	2	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					941	941						1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553					2022-12-17	WOS:A1990DP55300023
J	SISTONEN, L; KOSKINEN, PJ; LEHVASLAIHO, H; LEHTOLA, L; BRAVO, R; ALITALO, K				SISTONEN, L; KOSKINEN, PJ; LEHVASLAIHO, H; LEHTOLA, L; BRAVO, R; ALITALO, K			DOWN-REGULATION OF THE EARLY GENOMIC GROWTH-FACTOR RESPONSE IN NEU ONCOGENE-TRANSFORMED CELLS	ONCOGENE			English	Article									UNIV HELSINKI, DEPT VIROL, CANC BIOL LAB, HAARTMANINK 3, SF-00290 HELSINKI 29, FINLAND; UNIV HELSINKI, DEPT PATHOL, CANC BIOL LAB, SF-00290 HELSINKI, FINLAND; SQUIBB INST MED RES, DEPT MOLEC BIOL, PRINCETON, NJ 08543 USA	University of Helsinki; University of Helsinki			Alitalo, Kari K/J-5013-2014; Koskinen, Päivi J/G-8939-2014	Alitalo, Kari K/0000-0002-7331-0902; Sistonen, Lea/0000-0003-1341-2867				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BRAVO R, 1990, IN PRESS GROWTH FACT; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; KOSKINEN P, 1990, ONCOGENE, V5, P615; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LEHVASLAIHO H, 1990, J CELL BIOCHEM, V42, P123, DOI 10.1002/jcb.240420303; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIN AH, 1988, MOL CELL BIOL, V8, P5052, DOI 10.1128/MCB.8.11.5052; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NESTOR JJ, 1985, BIOCHEM BIOPH RES CO, V129, P226, DOI 10.1016/0006-291X(85)91426-3; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	44	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					815	821						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	1972791				2022-12-17	WOS:A1990DP55300006
J	LUBBERT, M; JONAS, D; MILLER, CW; HERRMANN, F; MERTELSMANN, R; MCCORMICK, F; KOEFFLER, HP				LUBBERT, M; JONAS, D; MILLER, CW; HERRMANN, F; MERTELSMANN, R; MCCORMICK, F; KOEFFLER, HP			RETROSPECTIVE ANALYSIS OF RAS GENE ACTIVATION IN MYELOID LEUKEMIC-CELLS	ONCOGENE			English	Article									UNIV CALIF LOS ANGELES, DEPT MED,DIV HEMATOL ONCOL,11-240 FACTOR BLDG, 10833 LE CONTE AVE, LOS ANGELES, CA 90024 USA; UNIV FREIBURG, DEPT MED 1, W-7800 FREIBURG, GERMANY; CETUS CORP, DEPT MOLEC BIOL, EMERYVILLE, CA 94608 USA	University of California System; University of California Los Angeles; University of Freiburg					NCI NIH HHS [CA 32737, CA 26038, CA 33936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033936, R01CA026038, P01CA032737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDY KJ, 1985, P NATL ACAD SCI USA, V82, P8173, DOI 10.1073/pnas.82.23.8173; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; JANSSEN JWG, 1987, ONCOGENE, V1, P175; JANSSEN JWG, 1989, LEUKEMIA, V3, P235; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JANSSEN JWG, 1987, NUCLEIC ACIDS RES, V15, P5669, DOI 10.1093/nar/15.14.5669; JOLLY DJ, 1983, NUCLEIC ACIDS RES, V11, P1855, DOI 10.1093/nar/11.6.1855; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; LYONS J, 1988, BLOOD, V71, P1707; PAABO S, 1989, J BIOL CHEM, V264, P9709; PADUA RA, 1988, LEUKEMIA, V2, P503; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SPANDIDOS DA, 1984, NATURE, V304, P602; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333	22	10	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1990	5	4					583	587						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183160				2022-12-17	WOS:A1990DB85300019
J	IKEGAKI, N; KENNETT, RH				IKEGAKI, N; KENNETT, RH			MOLECULAR GENETIC-CHARACTERIZATION OF EPITOPE-SPECIFIC MONOCLONAL-ANTIBODIES AGAINST THE MYC FAMILY PROTEINS	ONCOGENE			English	Article											IKEGAKI, N (corresponding author), UNIV PENN, SCH MED, DEPT HUMAN GENET, PHILADELPHIA, PA 19104 USA.				NCI NIH HHS [CA 24263] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA024263] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Ikegaki N, 1988, Prog Clin Biol Res, V271, P133; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; IKEGAKI N, 1989, EMBO J, V8, P1793, DOI 10.1002/j.1460-2075.1989.tb03573.x; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KENNETT RH, 1980, MONOCLONAL ANTIBODIE, P365; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; Maniatis T., 1982, MOL CLONING; MEHRA V, 1986, P NATL ACAD SCI USA, V83, P7013, DOI 10.1073/pnas.83.18.7013; MOCARSKI ES, 1985, P NATL ACAD SCI USA, V82, P1266, DOI 10.1073/pnas.82.4.1266; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; REINACH FC, 1985, J MOL BIOL, V181, P411, DOI 10.1016/0022-2836(85)90229-3; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; TAYA Y, 1986, EMBO J, V5, P1215, DOI 10.1002/j.1460-2075.1986.tb04349.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	45	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1990	5	3					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW415	1690381				2022-12-17	WOS:A1990CW41500018
J	CACERES, J; GLIKIN, G; BRAVO, R; WEINMANN, R				CACERES, J; GLIKIN, G; BRAVO, R; WEINMANN, R			C-FOS MEDIATED STIMULATION OF AN AP-1 DNA-BINDING ACTIVITY IN UNDIFFERENTIATED TERATOCARCINOMA CELL-LINES	ONCOGENE			English	Article									WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; SQUIBB INST MED RES,PRINCETON,NJ 08543; UNIV BUENOS AIRES,INST INVEST INGN GENET & BIOL MOLEC,RA-1428 BUENOS AIRES,ARGENTINA; UNIV BUENOS AIRES,FAC CIENCIAS EXACTAS & NAT,RA-1428 BUENOS AIRES,ARGENTINA	The Wistar Institute; University of Buenos Aires; University of Buenos Aires			Caceres, Javier F/D-5260-2013	Caceres, Javier F/0000-0001-8025-6169	NCI NIH HHS [CA-44466, CA-10815] Funding Source: Medline; NIAID NIH HHS [AI-13231] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815, R01CA044466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI013231] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BUNICK D, 1982, CELL, V29, P877, DOI 10.1016/0092-8674(82)90449-4; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JACOB F, 1977, P ROY SOC LOND B BIO, V201, P249; JAKOB H, 1973, ANN INST PASTEUR MIC, VB124, P269; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KELLY F, 1982, BIOCHIM BIOPHYS ACTA, V651, P105, DOI 10.1016/0304-419X(82)90009-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEHMAN JM, 1974, J CELL PHYSIOL, V84, P13, DOI 10.1002/jcp.1040840103; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MUELLER CR, 1984, MOL CELL BIOL, V4, P2594, DOI 10.1128/MCB.4.12.2594; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NICOLAS JF, 1976, CANCER RES, V36, P4224; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHONTHAL A, 1989, ONCOGENE, V4, P629; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5556; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; VELDMAN GM, 1985, MOL CELL BIOL, V5, P649, DOI 10.1128/MCB.5.4.649; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WIRAK DO, 1985, MOL CELL BIOL, V5, P2924, DOI 10.1128/MCB.5.11.2924; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	45	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					59	67						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157182				2022-12-17	WOS:A1990CM62000009
J	KARLIN, S; BRENDEL, V				KARLIN, S; BRENDEL, V			CHARGE CONFIGURATIONS IN ONCOGENE PRODUCTS AND TRANSFORMING PROTEINS	ONCOGENE			English	Article											KARLIN, S (corresponding author), STANFORD UNIV,DEPT MATH,STANFORD,CA 94305, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010452, R01GM039907] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39907-01, GM10452-26] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GAMBLE JR, 1988, SCIENCE, V242, P97; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARLIN S, 1988, P NATL ACAD SCI USA, V85, P9396, DOI 10.1073/pnas.85.24.9396; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KARLIN S, IN PRESS METHODS ENZ; KARLIN S, 1990, IN PRESS 6TH P CONV, V1; KINGSTON RE, 1985, CELL, V41, P3, DOI 10.1016/0092-8674(85)90049-2; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LEGOUY E, 1987, EMBO J, V6, P3359, DOI 10.1002/j.1460-2075.1987.tb02657.x; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; PERUTZ MF, 1988, NATURE, V336, P202, DOI 10.1038/336202a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REDDY EPA, 1988, ONCOGENE HDB; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STREBHARDT K, 1987, P NATL ACAD SCI USA, V84, P8778, DOI 10.1073/pnas.84.24.8778; STRUHL K, 1987, CELL, V50, P841, DOI 10.1016/0092-8674(87)90511-3; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UZVOLGYI E, 1988, P NATL ACAD SCI USA, V85, P3034, DOI 10.1073/pnas.85.9.3034; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VARMUS H, 1988, SCIENCE, V240, P1427, DOI 10.1126/science.3287617; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	72	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					85	95						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181379				2022-12-17	WOS:A1990CM62000012
J	BIRCHENALLROBERTS, MC; ENGELMANN, GL; KELLER, JR; LOHREY, N; RUSCETTI, FW				BIRCHENALLROBERTS, MC; ENGELMANN, GL; KELLER, JR; LOHREY, N; RUSCETTI, FW			RETROVIRAL V-MYC INFECTION OF PRIMARY FETAL LIVER-CELLS - TRANSFORMATION OF MONOCYTES INVITRO	ONCOGENE			English	Article									CLEVELAND CLIN FDN,RES INST,DEPT HEART & HYPERTENS,CLEVELAND,OH 44195; NCI,FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,BIOL CARCINOGENESIS DEV PROGRAM,FREDERICK,MD 21701	Cleveland Clinic Foundation; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	BIRCHENALLROBERTS, MC (corresponding author), NCI,FREDERICK CANC RES FACIL,DIV CANC TREATMENT,BIOL RESPONSE MODIFIERS PROGRAM,FREDERICK,MD 21701, USA.		Keller, Jonathan R./O-6677-2018		OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74102] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BAUMBACH WR, 1987, MOL CELL BIOL, V7, P664, DOI 10.1128/MCB.7.2.664; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DALLAFAVERA R, 1982, NATURE, V299, P61; FALTYNEK CR, 1988, J BIOL CHEM, V263, P7112; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MINNA JD, 1986, COLD SPRING HARB SYM, V51, P843, DOI 10.1101/SQB.1986.051.01.098; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; MULLER R, 1984, EMBO J, V3, P1887, DOI 10.1002/j.1460-2075.1984.tb02063.x; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REIN A, 1985, MOL CELL BIOL, V5, P2257, DOI 10.1128/MCB.5.9.2257; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSCETTI FW, 1986, J IMMUNOL, V136, P3619; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	25	10	10	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					731	735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2786619				2022-12-17	WOS:A1989AA66000009
J	SMITH, KJ; GALLIMORE, PH; GRAND, RJA				SMITH, KJ; GALLIMORE, PH; GRAND, RJA			THE EXPRESSION OF AD12 E1B 19K PROTEIN ON THE SURFACE OF ADENOVIRUS TRANSFORMED AND INFECTED HUMAN-CELLS	ONCOGENE			English	Article									UNIV BIRMINGHAM, DEPT CANC STUDIES, CANC RES CAMPAIGN LABS, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham								BELLGRAU D, 1988, J VIROL, V62, P1513, DOI 10.1128/JVI.62.5.1513-1519.1988; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BOS JL, 1981, CELL, V27, P121, DOI 10.1016/0092-8674(81)90366-4; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; BYRD P, 1982, NATURE, V298, P69, DOI 10.1038/298069a0; BYRD PJ, 1988, ONCOGENE, V2, P477; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; DEPPERT W, 1982, VIROLOGY, V122, P56, DOI 10.1016/0042-6822(82)90377-4; DEPPERT W, 1976, P NATL ACAD SCI USA, V73, P2505, DOI 10.1073/pnas.73.7.2505; FATT RBL, 1982, J VIROL, V42, P969, DOI 10.1128/JVI.42.3.969-977.1982; FLINT SJ, 1976, VIROLOGY, V72, P456, DOI 10.1016/0042-6822(76)90174-4; FREEMAN AARON E., 1967, J VIROL, V1, P362; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; GALLIMORE PH, 1974, J MOL BIOL, V89, P49, DOI 10.1016/0022-2836(74)90162-4; GALLIMORE PH, 1985, CANCER RES, V45, P2670; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRAND RJA, 1985, FEBS LETT, V181, P229, DOI 10.1016/0014-5793(85)80265-9; GRAND RJA, 1987, INT J CANCER, V40, P213, DOI 10.1002/ijc.2910400215; GRAND RJA, 1987, ONCOGENE, V1, P305; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 1986, EMBO J, V5, P1253, DOI 10.1002/j.1460-2075.1986.tb04354.x; GUISO N, 1984, EMBO J, V3, P1769, DOI 10.1002/j.1460-2075.1984.tb02044.x; HERRMANN CH, 1987, ONCOGENE, V2, P25; HUEBNER RJ, 1962, P NATL ACAD SCI USA, V48, P2051, DOI 10.1073/pnas.48.12.2051; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KLOCKMANN U, 1983, EMBO J, V2, P1151, DOI 10.1002/j.1460-2075.1983.tb01560.x; KOCH N, 1986, J BIOL CHEM, V261, P3434; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Logan J, 1984, CANCER CELL, V2, P527; MCGLADE CJ, 1987, J VIROL, V61, P3227, DOI 10.1128/JVI.61.10.3227-3234.1987; PARASKEVA C, 1982, J VIROL, V44, P759, DOI 10.1128/JVI.44.2.759-764.1982; PERSSON H, 1982, J VIROL, V42, P905, DOI 10.1128/JVI.42.3.905-917.1982; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; ROWE DT, 1983, VIROLOGY, V129, P456, DOI 10.1016/0042-6822(83)90183-6; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAWADA Y, 1986, J EXP MED, V163, P563, DOI 10.1084/jem.163.3.563; SCHMIDT MFG, 1979, CELL, V17, P813, DOI 10.1016/0092-8674(79)90321-0; SCHULTZ AM, 1988, IN PRESS ANN REV CEL, V4; SHIROKI K, 1979, COLD SPRING HARB SYM, V44, P533; SOLNICK D, 1982, J VIROL, V42, P106, DOI 10.1128/JVI.42.1.106-113.1982; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; STARCICH BR, 1986, CELL, V45, P637, DOI 10.1016/0092-8674(86)90778-6; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; TAKEMORI N, 1968, VIROLOGY, V36, P575, DOI 10.1016/0042-6822(68)90189-X; TEVETHIA SS, 1986, CONCEPTS VIRAL PATHO, V2, P182; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1986, MOL CELL BIOL, V6, P3763, DOI 10.1128/MCB.6.11.3763; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILSON MC, 1981, J MOL BIOL, V148, P231, DOI 10.1016/0022-2836(81)90537-4	55	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1989	4	4					489	497						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2541391				2022-12-17	WOS:A1989U567700014
J	HENRIKSSON, M; CLASSON, M; INGVARSSON, S; KOSKINEN, P; SUMEGI, J; KLEIN, G; THYBERG, J				HENRIKSSON, M; CLASSON, M; INGVARSSON, S; KOSKINEN, P; SUMEGI, J; KLEIN, G; THYBERG, J			ELEVATED EXPRESSION OF C-MYC AND N-MYC PRODUCES DISTINCT CHANGES IN NUCLEAR FINE-STRUCTURE AND CHROMATIN ORGANIZATION	ONCOGENE			English	Article									UNIV HELSINKI,DEPT VIROL,SF-00290 HELSINKI 29,FINLAND; KAROLINSKA INST,DEPT MED CELL BIOL,S-10401 STOCKHOLM 60,SWEDEN	University of Helsinki; Karolinska Institutet	HENRIKSSON, M (corresponding author), KAROLINSKA INST,DEPT TUMOR BIOL,BOX 60400,S-10401 STOCKHOLM 60,SWEDEN.		Koskinen, Päivi J/G-8939-2014; Henriksson, Marie Arsenian/F-5010-2015; Ingvarsson, Sigurdur/E-7448-2011	Ingvarsson, Sigurdur/0000-0003-4125-1714	NCI NIH HHS [5RO1 CA14054-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; HAMMARSKJOLD ML, 1986, GENE, V43, P41, DOI 10.1016/0378-1119(86)90006-5; HANCOCK R, 1982, INT REV CYTOL, V79, P165; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOHL NE, 1986, NATURE, V319, P73, DOI 10.1038/319073a0; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NAU MM, 1986, P NATL ACAD SCI USA, V83, P1092, DOI 10.1073/pnas.83.4.1092; PERRSON H, 1984, SCIENCE, V225, P718; PERSSON H, 1986, MOL CELL BIOL, V6, P942, DOI 10.1128/MCB.6.3.942; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEJERSEN T, 1987, EXP CELL RES, V172, P304, DOI 10.1016/0014-4827(87)90389-2; SPECTOR DL, 1987, ONCOGENE, V1, P5; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; WINQVIST R, 1984, EMBO J, V3, P2947, DOI 10.1002/j.1460-2075.1984.tb02237.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	28	10	10	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					587	593						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078963				2022-12-17	WOS:A1988R516300016
J	BIZUB, D; BLAIR, D; ALVORD, G; SKALKA, AM				BIZUB, D; BLAIR, D; ALVORD, G; SKALKA, AM			CORRELATION BETWEEN H-RAS P21TLEU61 PROTEIN-CONTENT AND TUMORIGENICITY OF NIH3T3 CELLS	ONCOGENE			English	Article									FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA; NCI, FREDERICK CANC RES FACIL, DIV CANC ETIOL, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES FACIL, DATA MANAGEMENT SERV, FREDERICK, MD 21701 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NCI NIH HHS [N01-CO-74103, CA-06927] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DENHARDT DT, 1987, ONCOGENE, V2, P55; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOVITS I, 1977, 2ND P INT WORKSH NUD, P557; OHARA BM, 1986, CANCER RES, V46, P4695; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDMOND SMS, 1988, ONCOGENE, V2, P259; REYNOLDS VL, 1987, ONCOGENE, V1, P323; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SRIVASTAVA SK, 1985, P NATL ACAD SCI USA, V82, P38, DOI 10.1073/pnas.82.1.38; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	24	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1988	3	4					443	448						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3078952				2022-12-17	WOS:A1988Q773900013
J	MAUELER, W; BARNEKOW, A; EIGENBRODT, E; RAULF, F; FALK, HF; TELLING, A; SCHARTL, M				MAUELER, W; BARNEKOW, A; EIGENBRODT, E; RAULF, F; FALK, HF; TELLING, A; SCHARTL, M			DIFFERENT REGULATION OF ONCOGENE EXPRESSION IN TUMOR AND EMBRYONAL CELLS OF XIPHOPHORUS	ONCOGENE			English	Article									MAX PLANCK INST BIOCHEM,DEPT CANC CELL RES,D-8033 MARTINSRIED,FED REP GER; INST MED VIROL,D-6300 GIESSEN,FED REP GER; INST BIOCHEM & ENDOCRINOL,D-6300 GIESSEN,FED REP GER	Max Planck Society	MAUELER, W (corresponding author), MAX PLANCK INST BIOCHEM,CTR GENE,AM KLOPERSPITZ 18 A,D-8033 MARTINSRIED,FED REP GER.			Schartl, Manfred/0000-0001-9882-5948				ADAM D, IN PRESS NUCLEIC ACI; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AZARNIA R, 1988, SCIENCE, V239, P398, DOI 10.1126/science.2447651; BARNEKOW A, 1984, BIOCHIM BIOPHYS ACTA, V782, P94, DOI 10.1016/0167-4781(84)90110-6; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; DEAN M, 1986, J BIOL CHEM, V261, P9161; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EIGENBRODT E, 1983, EMBO J, V2, P1565, DOI 10.1002/j.1460-2075.1983.tb01625.x; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GASCH A, 1988, MOL GEN GENET, V211, P8, DOI 10.1007/BF00338387; GELMANN EP, 1981, P NATL ACAD SCI-BIOL, V78, P3373, DOI 10.1073/pnas.78.6.3373; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; Hopkinson, 1978, HDB ENZYME ELECTROPH; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAPLAN PL, 1981, VIROLOGY, V108, P484, DOI 10.1016/0042-6822(81)90455-4; KAPLAN PL, 1982, VIROLOGY, V123, P372, DOI 10.1016/0042-6822(82)90270-7; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P105; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEOF EB, 1986, P NATL ACAD SCI USA, V83, P2453, DOI 10.1073/pnas.83.8.2453; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MANIATIS T, 1982, MOL CLONING LABORATO; MATRISIAN LM, 1985, NUCLEIC ACIDS RES, V13, P711, DOI 10.1093/nar/13.3.711; MAUELER W, 1988, ONCOGENE, V2, P421; MAUELER W, 1987, COMP BIOCHEM PHYS B, V88, P481; MOSES HL, 1981, CANCER RES, V41, P2842; NEWBOLD RF, 1983, NATURE, V304, P684; OHARA B, 1986, CYTOGENET CELL GENET, V43, P97, DOI 10.1159/000132303; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3; POWERS S, 1984, MOL CELL BIOL, V4, P1572, DOI 10.1128/MCB.4.8.1572; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; RAN W, 1986, CURR TOP MICROBIOL, V132, P313; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; REINACHER M, 1986, CARCINOGENESIS, V7, P1351, DOI 10.1093/carcin/7.8.1351; RIGAUT JP, 1984, COMP BIOCHEM PHYS B, V77, P451, DOI 10.1016/0305-0491(84)90259-1; RUBSAMEN H, 1982, P NATL ACAD SCI US, V79, P549; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHARTL M, 1985, INT J CANCER, V36, P199, DOI 10.1002/ijc.2910360212; SCHARTL M, 1982, CANCER RES, V42, P4222; SCHARTL M, 1988, IN PRESS GENETICS; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANDIDOS DA, 1985, ANTICANCER RES, V5, P221; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SUMI S, 1984, ENDOCRINOL JAPON, V31, P117; SURSOR WA, 1971, ANAL BIOCH, V43, P147; VALET G, 1980, FLOW CYTOMETRY, V4, P125; VANBENEDEN RJ, 1986, P NATL ACAD SCI USA, V83, P3698; VENNSTROM B, 1980, J VIROL, V36, P575; WAKAMATSU Y, 1984, DEV GROWTH DIFFER, V26, P503; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHAN X, 1986, MOL CELL BIOL, V6, P3541, DOI 10.1128/MCB.6.10.3541; ZIEMIECKI A, 1980, J GEN VIROL, V50, P211, DOI 10.1099/0022-1317-50-1-211	68	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					113	122						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400016
J	SADOWSKI, I; PAWSON, T; LAGARDE, A				SADOWSKI, I; PAWSON, T; LAGARDE, A			V-FPS PROTEIN-TYROSINE KINASE COORDINATELY ENHANCES THE MALIGNANCY AND GROWTH-FACTOR RESPONSIVENESS OF PRE-NEOPLASTIC LUNG FIBROBLASTS	ONCOGENE			English	Article									MT SINAI HOSP,RES INST,DIV CANC & CELL BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; MT SINAI HOSP,RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5G 1X5,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOSCA L, 1986, BIOCHEM J, V236, P595, DOI 10.1042/bj2360595; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARMIER JF, 1986, CELL, V44, P159, DOI 10.1016/0092-8674(86)90494-0; CHAMBARD JC, 1983, J BIOL CHEM, V258, P1706; COLLARD JG, 1987, CANCER RES, V47, P754; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FOSTER DA, 1983, J VIROL, V48, P744, DOI 10.1128/JVI.48.3.744-751.1983; GARBISA S, 1987, CANCER RES, V47, P1523; GUYDEN JC, 1982, VIROLOGY, V122, P71, DOI 10.1016/0042-6822(82)90378-6; HANAFUSA T, 1981, J VIROL, V38, P347, DOI 10.1128/JVI.38.1.347-355.1981; HANAFUSA T, 1980, P NATL ACAD SCI-BIOL, V77, P3009, DOI 10.1073/pnas.77.5.3009; JACKOWSKI S, 1986, J BIOL CHEM, V261, P4978; KAPLAN PL, 1982, P NATL ACAD SCI-BIOL, V79, P485, DOI 10.1073/pnas.79.2.485; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOHNO M, 1986, BIOCHEM J, V238, P451, DOI 10.1042/bj2380451; LALLEMAIN G, 1986, J CELL PHYSIOL, V129, P167, DOI 10.1002/jcp.1041290207; LEE WH, 1981, J VIROL, V38, P1064, DOI 10.1128/JVI.38.3.1064-1076.1981; LEE WH, 1980, P NATL ACAD SCI-BIOL, V77, P2018, DOI 10.1073/pnas.77.4.2018; MCDONALD I, 1985, MOL CELL BIOL, V5, P2543; MOSS P, 1984, J VIROL, V52, P557, DOI 10.1128/JVI.52.2.557-565.1984; PEREZRODRIGUEZ R, 1981, CELL BIOL INT REP, V5, P347, DOI 10.1016/0309-1651(81)90004-7; PEREZRODRIGUEZ R, 1981, J CELL PHYSIOL, V109, P387, DOI 10.1002/jcp.1041090303; PEREZRODRIGUEZ R, 1982, INT J CANCER, V29, P309, DOI 10.1002/ijc.2910290314; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RENWICK DE, 1986, JNCI-J NATL CANCER I, V77, P105; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SAMARUT J, 1985, MOL CELL BIOL, V5, P1067, DOI 10.1128/MCB.5.5.1067; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; VANOBBERGHENSCHILLING E, 1983, J CELL PHYSIOL, V115, P123, DOI 10.1002/jcp.1041150204; VANOBBERGHENSCHILLING E, 1983, EXP CELL RES, V147, P369, DOI 10.1016/0014-4827(83)90219-7; VOUSDEN KH, 1986, INT J CANCER, V37, P425, DOI 10.1002/ijc.2910370315; WAGHORNE C, 1987, ONCOGENE, V1, P149; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	43	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					241	247						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	3281093				2022-12-17	WOS:A1988M593100006
J	VANDERRAUWELAERT, E; MAISIN, JR; MERREGAERT, J				VANDERRAUWELAERT, E; MAISIN, JR; MERREGAERT, J			PROVIRUS INTEGRATION AND MYC AMPLIFICATION IN SR-90 INDUCED OSTEOSARCOMAS OF CF1 MICE	ONCOGENE			English	Article									UNIV INSTELLING ANTWERP,DEPT BIOCHEM,BIOTECHNOL LAB,UNIV PLEIN 1,B-2610 WILRIJK,BELGIUM; CEN SCK,DEPT BIOL,B-2400 MOL,BELGIUM	University of Antwerp; Belgian Nuclear Research Centre (SCK-CEN)								ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; BUCKLER CE, 1982, J VIROL, V41, P228, DOI 10.1128/JVI.41.1.228-236.1982; BUCKLER CE, 1982, J VIROL, V43, P629, DOI 10.1128/JVI.43.2.629-640.1982; CHATTOPADHYAY SK, 1981, VIROLOGY, V113, P465, DOI 10.1016/0042-6822(81)90175-6; CORCORAN LM, 1984, CELL, V37, P113, DOI 10.1016/0092-8674(84)90306-4; CUYPERS HTM, 1986, J VIROL, V60, P230, DOI 10.1128/JVI.60.1.230-241.1986; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DUESBERG PH, 1987, CANCER RES, V47, P1199; ERFLE V, 1980, INT J CANCER, V26, P107, DOI 10.1002/ijc.2910260117; ERFLE V, 1986, LEUKEMIA RES, V10, P905, DOI 10.1016/0145-2126(86)90322-X; FINKEL MP, 1961, RADIOLOGY, V77, P269, DOI 10.1148/77.2.269; FINKEL MP, 1976, MALIGNANT BONE TUMOR, P92; FINKEL MP, 1973, BONE CERTAIN ASPECTS, P353; GOSSNER W, 1986, LEUKEMIA RES, V10, P897, DOI 10.1016/0145-2126(86)90321-8; HERR W, 1982, NATURE, V296, P865, DOI 10.1038/296865a0; HERR W, 1983, J VIROL, V46, P70, DOI 10.1128/JVI.46.1.70-82.1983; JANOWSKI M, 1986, LEUKEMIA RES, V10, P833, DOI 10.1016/0145-2126(86)90304-8; JOLICOEUR P, 1983, MOL CELL BIOL, V3, P1675, DOI 10.1128/MCB.3.9.1675; KHAN AS, 1982, J VIROL, V44, P625, DOI 10.1128/JVI.44.2.625-636.1982; KHAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P2699, DOI 10.1073/pnas.80.9.2699; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; LOUTIT JF, 1977, NATURE, V266, P355, DOI 10.1038/266355a0; MCGRATH MS, 1979, CELL, V17, P65, DOI 10.1016/0092-8674(79)90295-2; MERREGAERT J, 1984, CR SOC BIOL, V178, P171; MOORE JL, 1982, J VIROL, V43, P1038, DOI 10.1128/JVI.43.3.1038-1045.1982; NEEL BG, 1981, CELL, V23, P323, DOI 10.1016/0092-8674(81)90128-8; ODONNELL PV, 1985, J VIROL, V55, P500, DOI 10.1128/JVI.55.2.500-503.1985; ONEILL RR, 1986, J VIROL, V58, P359, DOI 10.1128/JVI.58.2.359-366.1986; OU CY, 1983, NUCLEIC ACIDS RES, V11, P5603, DOI 10.1093/nar/11.16.5603; PEDERSEN FS, 1986, LEUKEMIA RES, V10, P923, DOI 10.1016/0145-2126(86)90324-3; REICIN A, 1986, MOL CELL BIOL, V6, P4088, DOI 10.1128/MCB.6.11.4088; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SCHON A, 1986, INT J CANCER, V38, P67, DOI 10.1002/ijc.2910380112; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEFFEN D, 1984, P NATL ACAD SCI-BIOL, V81, P2097, DOI 10.1073/pnas.81.7.2097; STEFFEN D, 1984, P NATL ACAD SCI US, V81, P2101; TEICH N, 1985, RNA TUMOR VIRUSES MO, P187; TSICHLIS PN, 1985, J VIROL, V56, P938, DOI 10.1128/JVI.56.3.938-942.1985; TSICHLIS PN, 1983, NATURE, V302, P445, DOI 10.1038/302445a0; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	43	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1988	2	3					215	222						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M5931	2832803				2022-12-17	WOS:A1988M593100002
J	de Wet, L; Williams, A; Gillard, M; Kregel, S; Lamperis, S; Gutgesell, LC; Vellky, JE; Brown, R; Conger, K; Paner, GP; Wang, H; Platz, EE; De Marzo, AM; Mu, P; Coloff, JL; Szmulewitz, RZ; Vander Griend, DJ				de Wet, Larischa; Williams, Anthony; Gillard, Marc; Kregel, Steven; Lamperis, Sophia; Gutgesell, Lisa C.; Vellky, Jordan E.; Brown, Ryan; Conger, Kelly; Paner, Gladell P.; Wang, Heng; Platz, Elizabeth E.; De Marzo, Angelo M.; Mu, Ping; Coloff, Jonathan L.; Szmulewitz, Russell Z.; Vander Griend, Donald J.			SOX2 mediates metabolic reprogramming of prostate cancer cells	ONCOGENE			English	Article							LINEAGE PLASTICITY; SIGNALING PATHWAY; STEM; EXPRESSION; RESISTANCE; ADULT; AMPLIFICATION; ABIRATERONE; METASTASIS; MARKERS	New strategies are needed to predict and overcome metastatic progression and therapy resistance in prostate cancer. One potential clinical target is the stem cell transcription factor SOX2, which has a critical role in prostate development and cancer. We thus investigated the impact of SOX2 expression on patient outcomes and its function within prostate cancer cells. Analyses of SOX2 expression among a case-control cohort of 1028 annotated tumor specimens demonstrated that SOX2 expression confers a more rapid time to metastasis and decreased patient survival after biochemical recurrence. SOX2 ChIP-Seq analyses revealed SOX2-binding sites within prostate cancer cells which differ significantly from canonical embryonic SOX2 gene targets, and prostate-specific SOX2 gene targets are associated with multiple oncogenic pathways. Interestingly, phenotypic and gene expression analyses after CRISPR-mediated deletion of SOX2 in castration-resistant prostate cancer cells, as well as ectopic SOX2 expression in androgen-sensitive prostate cancer cells, demonstrated that SOX2 promotes changes in multiple metabolic pathways and metabolites. SOX2 expression in prostate cancer cell lines confers increased glycolysis and glycolytic capacity, as well as increased basal and maximal oxidative respiration and increased spare respiratory capacity. Further, SOX2 expression was associated with increased quantities of mitochondria, and metabolomic analyses revealed SOX2-associated changes in the metabolism of purines, pyrimidines, amino acids and sugars, and the pentose phosphate pathway. Analyses of SOX2 gene targets with central functions metabolism (CERK, ECHS1, HS6SDT1, LPCAT4, PFKP, SLC16A3, SLC46A1, and TST) document significant expression correlation with SOX2 among RNA-Seq datasets derived from patient tumors and metastases. These data support a key role for SOX2 in metabolic reprogramming of prostate cancer cells and reveal new mechanisms to understand how SOX2 enables metastatic progression, lineage plasticity, and therapy resistance. Further, our data suggest clinical opportunities to exploit SOX2 as a biomarker for staging and imaging, as well as a potential pharmacologic target.	[de Wet, Larischa; Kregel, Steven] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Williams, Anthony; Gillard, Marc; Szmulewitz, Russell Z.] Univ Chicago, Dept Med, Sect Hematol Oncol, Chicago, IL 60637 USA; [Lamperis, Sophia; Gutgesell, Lisa C.; Vellky, Jordan E.; Brown, Ryan; Vander Griend, Donald J.] Univ Illinois, Dept Pathol, Chicago, IL 60637 USA; [Conger, Kelly; Coloff, Jonathan L.] Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60637 USA; [Paner, Gladell P.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Wang, Heng] Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60607 USA; [Platz, Elizabeth E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Dept Urol, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Brady Urol Res Inst, Baltimore, MD 21218 USA; [De Marzo, Angelo M.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD 21218 USA; [Mu, Ping] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Southwestern Medical Center Dallas	Vander Griend, DJ (corresponding author), Univ Illinois, Dept Pathol, Chicago, IL 60637 USA.	dvanderg@uic.edu		Lamperis, Sophia/0000-0001-9346-1639	University of Chicago Comprehensive Cancer Center Support Grant [P30CA014599]; The Brinson Foundation; Alvin Baum Family Fund; The Pierce Foundation; National Center for Advancing Translational Sciences [UL1TR002003]; Department of Defense Prostate Cancer Research Program [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH14-2-0186, W81XWH-15-2-0062, W81XWH-18-1-0411]; Goldblatt Foundation Fellowship; Cancer Biology Training Grant [T32 CA 009594]; CPRIT [RR170050]; Welch Foundation [I-2005-20190330]; Prostate Cancer Foundation [17YOUN12];  [R01CA178431];  [R00CA218885-04]	University of Chicago Comprehensive Cancer Center Support Grant; The Brinson Foundation; Alvin Baum Family Fund; The Pierce Foundation; National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Department of Defense Prostate Cancer Research Program(United States Department of Defense); Goldblatt Foundation Fellowship; Cancer Biology Training Grant; CPRIT; Welch Foundation(The Welch Foundation); Prostate Cancer Foundation; ; 	R01CA178431 (DJ Vander Griend), R00CA218885-04 (P.M.); University of Chicago Comprehensive Cancer Center Support Grant (P30CA014599); The Brinson Foundation; Alvin Baum Family Fund; The Pierce Foundation; and National Center for Advancing Translational Sciences (UL1TR002003). The Prostate Cancer Biorepository Network is funded by the Department of Defense Prostate Cancer Research Program Award No. W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH14-2-0186, and W81XWH-15-2-0062, and W81XWH-18-1-0411 (P.M.). L. de Wet was supported by the Goldblatt Foundation Fellowship; S. Kregel was supported by a Cancer Biology Training Grant (T32 CA 009594). P.M. is also supported by CPRIT (RR170050), Welch Foundation (I-2005-20190330) and Prostate Cancer Foundation (17YOUN12).	Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740; Annovazzi L, 2011, CANCER GENOM PROTEOM, V8, P139; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bergers G, 2021, NAT REV CANCER, V21, P162, DOI 10.1038/s41568-020-00320-2; Bhanvadia RR, 2018, CLIN CANCER RES, V24, P3668, DOI 10.1158/1078-0432.CCR-17-3673; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chen S, 2014, CARCINOGENESIS, V35, P613, DOI 10.1093/carcin/bgt371; Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036784, 10.1371/journal.pone.0045763, 10.1371/journal.pone.0049275, 10.1371/journal.pone.0050456]; Cutruzzola F, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00097; Dracopoli NC, 1994, CURRENT PROTOCOLS HU; Elia I, 2018, TRENDS CELL BIOL, V28, P673, DOI 10.1016/j.tcb.2018.04.002; Fraum TJ, 2018, CAN J UROL, V25, P9371; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Griend DJV, 2008, CANCER RES, V68, P9703, DOI 10.1158/0008-5472.CAN-08-3084; Han X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041335; Hempel HA, 2017, PROSTATE, V77, P412, DOI 10.1002/pros.23280; Herreros-Villanueva M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.23; Hutz K, 2014, CARCINOGENESIS, V35, P942, DOI 10.1093/carcin/bgt410; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Jadvar H, 2016, SEMIN NUCL MED, V46, P502, DOI 10.1053/j.semnuclmed.2016.07.004; Ji J, 2010, HUM PATHOL, V41, P1438, DOI 10.1016/j.humpath.2009.11.021; Jia XP, 2011, J MOL CELL BIOL, V3, P230, DOI 10.1093/jmcb/mjr002; Kar S, 2017, BBA-MOL BASIS DIS, V1863, P253, DOI 10.1016/j.bbadis.2016.11.001; Kregel S, 2016, ONCOTARGET, V7, P26259, DOI 10.18632/oncotarget.8456; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Ku SY, 2017, SCIENCE, V355, P78, DOI 10.1126/science.aah4199; Kwon OJ, 2020, ONCOGENE, V39, P7142, DOI 10.1038/s41388-020-01487-6; Li HY, 2020, LAB INVEST, V100, P570, DOI 10.1038/s41374-019-0343-5; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu P, 2016, GENOME RES, V26, P1124, DOI 10.1101/gr.199174.115; Lou XY, 2013, OMICS, V17, P510, DOI 10.1089/omi.2013.0058; Lowrance WT, 2021, J UROLOGY, V205, P22, DOI 10.1097/JU.0000000000001376; Maier S, 2011, HUM PATHOL, V42, P1078, DOI 10.1016/j.humpath.2010.11.010; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Matsika A, 2015, PATHOLOGY, V47, P622, DOI 10.1097/PAT.0000000000000325; McAuley E, 2019, STEM CELLS, V37, P690, DOI 10.1002/stem.2987; Metz EP, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07370-7; Metz EP, 2020, J CELL PHYSIOL, V235, P3731, DOI 10.1002/jcp.29267; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Pflueger D, 2011, GENOME RES, V21, P56, DOI 10.1101/gr.110684.110; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Russo MV, 2016, ONCOTARGET, V7, P12372, DOI 10.18632/oncotarget.6029; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Schlomm T, 2016, EUR UROL, V69, P1157, DOI 10.1016/j.eururo.2016.02.024; Sedelaar JPM, 2013, PROSTATE, V73, P1316, DOI 10.1002/pros.22677; Stolzenburg S, 2012, TARGETED SILENCING O; Sun C, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0503-1; Toubaji A, 2011, MODERN PATHOL, V24, P1511, DOI 10.1038/modpathol.2011.111; Ugolkov AV, 2011, PROSTATE, V71, P18, DOI 10.1002/pros.21217; Van den Broeck T, 2019, EUR UROL, V75, P967, DOI 10.1016/j.eururo.2018.10.011; Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914; Vazquez-Martin A, 2013, CELL CYCLE, V12, P3471, DOI 10.4161/cc.26692; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Wang MH, 2009, CANCER EPIDEM BIOMAR, V18, P706, DOI 10.1158/1055-9965.EPI-08-0839; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wegner M, 2010, INT J BIOCHEM CELL B, V42, P381, DOI 10.1016/j.biocel.2009.07.006; Whitburn J, 2021, CURR OSTEOPOROS REP, V19, P494, DOI 10.1007/s11914-021-00695-7; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Yoo YA, 2019, JNCI-J NATL CANCER I, V111, P311, DOI 10.1093/jnci/djy142; Yu X, 2014, PROSTATE CANCER P D, V17, P301, DOI 10.1038/pcan.2014.29; Zhang Shuchen, 2014, World J Stem Cells, V6, P305, DOI 10.4252/wjsc.v6.i3.305; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang ZD, 2020, CANCER CELL, V37, P584, DOI 10.1016/j.ccell.2020.03.001; Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011	68	9	9	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2022	41	8					1190	1202		10.1038/s41388-021-02157-x	http://dx.doi.org/10.1038/s41388-021-02157-x		JAN 2022	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC9WS	35067686	Green Accepted			2022-12-17	WOS:000745771900001
J	Alzial, G; Renoult, O; Paris, F; Gratas, C; Clavreul, A; Pecqueur, C				Alzial, Gabriel; Renoult, Ophelie; Paris, Francois; Gratas, Catherine; Clavreul, Anne; Pecqueur, Claire			Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma	ONCOGENE			English	Review							HYPOXIA-INDUCIBLE FACTORS; MUTANT IDH1; REDUCTIVE CARBOXYLATION; ALPHA-KETOGLUTARATE; PROMOTES DIFFERENTIATION; ADJUVANT TEMOZOLOMIDE; SUPPORTS GROWTH; DNA-REPAIR; GLIOMA; CELLS	Brain tumors actively reprogram their cellular metabolism to survive and proliferate, thus offering potential therapeutic opportunities. Over the past decade, extensive research has been done on mutant IDH enzymes as markers of good prognosis in glioblastoma, a highly aggressive brain tumor in adults with dismal prognosis. Yet, 95% of glioblastoma are IDH wild-type. Here, we review current knowledge about IDH wild-type enzymes and their putative role in mechanisms driving tumor progression. After a brief overview on tumor metabolic adaptation, we present the diverse metabolic function of IDH enzymes and their roles in glioblastoma initiation, progression and response to treatments. Finally, we will discuss wild-type IDH targeting in primary glioblastoma.	[Alzial, Gabriel; Renoult, Ophelie; Paris, Francois; Pecqueur, Claire] Univ Nantes, CNRS, INSERM, CRCINA, F-44000 Nantes, France; [Paris, Francois] Inst Cancerol Ouest, St Herblain, France; [Gratas, Catherine] Univ Nantes, CRCINA, INSERM, CHU Nantes, F-44000 Nantes, France; [Clavreul, Anne] Univ Angers, CRCINA, CHU Angers, F-49000 Angers, France; [Clavreul, Anne] CHU Angers, Dept Neurochirurg, Angers, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Pecqueur, C (corresponding author), Univ Nantes, CNRS, INSERM, CRCINA, F-44000 Nantes, France.	claire.pecqueur@univ-nantes.fr	Paris, francois/L-4915-2015	Paris, francois/0000-0002-0176-7348; Renoult, Ophelie/0000-0003-0916-8611; Alzial, Gabriel/0000-0001-6619-5179	ARC foundation; Ligue Contre le Cancer	ARC foundation(Australian Research Council); Ligue Contre le Cancer(Ligue nationale contre le cancer)	This work was supported by funding from ARC foundation and Ligue Contre le Cancer.	Anderson DD, 2012, J BIOL CHEM, V287, P7051, DOI 10.1074/jbc.M111.333120; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044; Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001; Blazek ER, 2007, INT J RADIAT ONCOL, V67, P1, DOI 10.1016/j.ijrobp.2006.09.037; Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; Bogdanovic E, 2014, NEUROSCI LETT, V582, P87, DOI 10.1016/j.neulet.2014.09.015; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Caravella JA, 2020, J MED CHEM, V63, P1612, DOI 10.1021/acs.jmedchem.9b01423; Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981; Cho YS, 2017, ACS MED CHEM LETT, V8, P1116, DOI 10.1021/acsmedchemlett.7b00342; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; Cooper LAD, 2012, AM J PATHOL, V180, P2108, DOI 10.1016/j.ajpath.2012.01.040; DADAMO AF, 1965, J BIOL CHEM, V240, P613; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; DiNardo CD, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.1073.1073; Du JH, 2016, P NATL ACAD SCI USA, V113, P14710, DOI 10.1073/pnas.1604572113; Fack F, 2017, EMBO MOL MED, V9, P1681, DOI 10.15252/emmm.201707729; Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473; Fendt SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3236; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Francisco A, 2022, ANTIOXID REDOX SIGN, V36, P864, DOI 10.1089/ars.2021.0111; Garofano L, 2021, NAT CANCER, V2, DOI 10.1038/s43018-020-00159-4; Gaude E, 2018, MOL CELL, V69, P581, DOI 10.1016/j.molcel.2018.01.034; Golub D, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00417; Grassian AR, 2014, CANCER RES, V74, P3317, DOI 10.1158/0008-5472.CAN-14-0772-T; Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Jiang L, 2016, NATURE, V532, P255, DOI 10.1038/nature17393; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Koh HJ, 2004, J BIOL CHEM, V279, P39968, DOI 10.1074/jbc.M402260200; Konteatis Z, 2020, ACS MED CHEM LETT, V11, P101, DOI 10.1021/acsmedchemlett.9b00509; Lee P, 2002, ARCH BIOCHEM BIOPHYS, V401, P81, DOI 10.1016/S0003-9861(02)00041-3; Lee W, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07967-4; Lemons JMS, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000514; Leonardi R, 2012, J BIOL CHEM, V287, P14615, DOI 10.1074/jbc.C112.353946; Liu GT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-67; Louis DN, 2021, NEURO-ONCOLOGY, V23, P1231, DOI 10.1093/neuonc/noab106; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237; Ma R, 2018, BIOCHEM BIOPH RES CO, V503, P2912, DOI 10.1016/j.bbrc.2018.08.068; Mailloux RJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000690; Maus A, 2017, AMINO ACIDS, V49, P21, DOI 10.1007/s00726-016-2342-9; May JL, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aat0456; McGregor GH, 2020, CANCER RES, V80, P175, DOI 10.1158/0008-5472.CAN-19-0644; Mellinghoff IK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.03327; Mergenthaler P, 2013, TRENDS NEUROSCI, V36, P587, DOI 10.1016/j.tins.2013.07.001; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Molinaro AM, 2019, NAT REV NEUROL, V15, P405, DOI 10.1038/s41582-019-0220-2; Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nam WS, 2012, BBA-MOL BASIS DIS, V1822, P1181, DOI 10.1016/j.bbadis.2012.04.003; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; Nunez FJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1427; Ohka F, 2014, TUMOR BIOL, V35, P5911, DOI 10.1007/s13277-014-1784-5; Oizel K, 2020, CANCER METAB, V8, DOI 10.1186/s40170-020-00215-8; Oizel K, 2017, CLIN CANCER RES, V23, P6292, DOI 10.1158/1078-0432.CCR-16-3102; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pellegatta S, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-014-0180-0; Platten M, 2021, NATURE, V592, P463, DOI 10.1038/s41586-021-03363-z; Polewski MD, 2016, MOL CANCER RES, V14, P1229, DOI 10.1158/1541-7786.MCR-16-0028; Poon MTC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68011-4; Popovici-Muller J, 2018, ACS MED CHEM LETT, V9, P300, DOI 10.1021/acsmedchemlett.7b00421; Popovici-Muller J, 2012, ACS MED CHEM LETT, V3, P850, DOI 10.1021/ml300225h; Pusch S, 2017, ACTA NEUROPATHOL, V133, P629, DOI 10.1007/s00401-017-1677-y; Qi F, 2008, BBA-PROTEINS PROTEOM, V1784, P1641, DOI 10.1016/j.bbapap.2008.07.001; Reitman ZJ, 2014, J BIOL CHEM, V289, P23318, DOI 10.1074/jbc.M114.575183; Reitman ZJ, 2010, JNCI-J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Semenza GL, 2019, ANNU REV PHARMACOL, V59, P379, DOI 10.1146/annurev-pharmtox-010818-021637; Seyfried TN, 2010, LANCET ONCOL, V11, P811, DOI 10.1016/S1470-2045(10)70166-2; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tardito S, 2015, NAT CELL BIOL, V17, P1556, DOI 10.1038/ncb3272; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; van Noorden CJF, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030705; Venneti S, 2017, ANNU REV PATHOL-MECH, V12, P515, DOI 10.1146/annurev-pathol-012615-044329; Wahl DR, 2017, CANCER RES, V77, P960, DOI 10.1158/0008-5472.CAN-16-2008; Wang D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05955-0; Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769; Wang P, 2015, CELL REP, V13, P2353, DOI 10.1016/j.celrep.2015.11.029; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Yamashita AS, 2019, NEURO-ONCOLOGY, V21, P189, DOI 10.1093/neuonc/noy146; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang LQ, 2012, EXP CELL RES, V318, P2417, DOI 10.1016/j.yexcr.2012.07.017; Yoo H, 2008, J BIOL CHEM, V283, P20621, DOI 10.1074/jbc.M706494200; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944	98	9	9	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2022	41	5					613	621		10.1038/s41388-021-02056-1	http://dx.doi.org/10.1038/s41388-021-02056-1		NOV 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ4FN	34764443	hybrid, Green Published			2022-12-17	WOS:000717402200001
J	Cheradame, L; Guerrera, IC; Gaston, J; Schmitt, A; Jung, V; Goudin, N; Pouillard, M; Radosevic-Robin, N; Modesti, M; Judde, JG; Cairo, S; Goffin, V				Cheradame, Laura; Guerrera, Ida Chiara; Gaston, Julie; Schmitt, Alain; Jung, Vincent; Goudin, Nicolas; Pouillard, Marion; Radosevic-Robin, Nina; Modesti, Mauro; Judde, Jean-Gabriel; Cairo, Stefano; Goffin, Vincent			STING protects breast cancer cells from intrinsic and genotoxic-induced DNA instability via a non-canonical, cell-autonomous pathway	ONCOGENE			English	Article							DOUBLE-STRAND BREAK; I INTERFERON; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL INSTABILITY; NUCLEAR-DNA; DAMAGE; ACTIVATION; REPAIR; CGAS; METASTASIS	STING (Stimulator of Interferon Genes) is an endoplasmic reticulum-anchored adaptor of the innate immunity best known to trigger pro-inflammatory cytokine expression in response to pathogen infection. In cancer, this canonical pathway can be activated by intrinsic or drug-induced genomic instability, potentiating antitumor immune responses. Here we report that STING downregulation decreases cell survival and increases sensitivity to genotoxic treatment in a panel of breast cancer cell lines in a cell-autonomous manner. STING silencing impaired DNA Damage Response (53BP1) foci formation and increased DNA break accumulation. These newly identified properties were found to be independent of STING partner cGAS and of its canonical pro-inflammatory pathway. STING was shown to partially localize at the inner nuclear membrane in a variety of breast cancer cell models and clinical tumor samples. Interactomics analysis of nuclear STING identified several proteins of the DNA Damage Response, including the three proteins of the DNA-PK complex, further supporting a role of STING in the regulation of genomic stability. In breast and ovarian cancer patients that received adjuvant chemotherapy, high STING expression is associated with increased risk of relapse. In summary, this study highlights an alternative, non-canonical tumor-promoting role of STING that opposes its well-documented function in tumor immunosurveillance.	[Cheradame, Laura; Gaston, Julie; Pouillard, Marion; Goffin, Vincent] Univ Paris, CNRS, Inst Necker Enfants Malades INEM, INSERM,U1151,UMR8253, F-75015 Paris, France; [Cheradame, Laura; Gaston, Julie; Judde, Jean-Gabriel; Cairo, Stefano] XenTech, F-91000 Evry, France; [Guerrera, Ida Chiara; Jung, Vincent] Univ Paris Struct Federat Rech Necker, CNRS, Prote Platform Necker, INSERM,US24,UMS3633, F-75015 Paris, France; [Schmitt, Alain] Univ Paris, CNRS, Inst Cochin, INSERM, F-75014 Paris, France; [Goudin, Nicolas] CNRS, Necker Bioimage Anal, INSERM, US24,UMS 3633, F-75015 Paris, France; [Radosevic-Robin, Nina] Univ Clermont Auvergne, INSERM, Ctr Jean Perrin, Dept Pathol,U1240, F-63011 Clermont Ferrand, France; [Modesti, Mauro] Aix Marseille Univ, CNRS, Canc Res Ctr Marseille, INSERM,Inst Paoli Calmettes,U1068,UMR7258, F-13009 Marseille, France; [Gaston, Julie] Yubsis, 4 Rue Pierre Fontaine, F-91000 Evry, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Jean Perrin; Universite Clermont Auvergne (UCA); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Goffin, V (corresponding author), Univ Paris, CNRS, Inst Necker Enfants Malades INEM, INSERM,U1151,UMR8253, F-75015 Paris, France.	vincent.goffin@inserm.fr	GUERRERA, Ida Chiara/GOJ-9151-2022; Modesti, Mauro/D-6258-2017; GOFFIN, Vincent/G-3322-2013	GUERRERA, Ida Chiara/0000-0002-4832-6793; Modesti, Mauro/0000-0002-4964-331X; GOFFIN, Vincent/0000-0002-8021-3086; Jung, Vincent/0000-0003-0530-1737; Cheradame, Laura/0000-0002-8369-9923; gaston, julie/0000-0002-2660-1651	XenTech; Inserm; University Paris Descartes; ECLER; CIFRE fellowship from the Association Nationale de la Recherche et de la Technologie (ANRT); Ligue Nationale contre le Cancer	XenTech; Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); University Paris Descartes; ECLER; CIFRE fellowship from the Association Nationale de la Recherche et de la Technologie (ANRT)(French National Research Agency (ANR)); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	This study was funded by XenTech, annual funding from Inserm and the University Paris Descartes, and ECLER non-profit association. JG and LC were recipient of a CIFRE fellowship from the Association Nationale de la Recherche et de la Technologie (ANRT). MM is supported by the Ligue Nationale contre le Cancer. We are grateful to Patrice Codogno, Etienne Morel, Ganna Panasyuk, Thierry Dubois and Frederic Rieux-Laucat for helpful discussions, to Dr Orgunc and Pr S. Fillatreau for providing biological materials, and to Katheryn Meek for critical reading of the manuscript.	Abe T, 2014, J VIROL, V88, P5328, DOI 10.1128/JVI.00037-14; Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6166; Baghirova S, 2015, METHODSX, V2, P440, DOI 10.1016/j.mex.2015.11.001; Baird JR, 2016, CANCER RES, V76, P50, DOI 10.1158/0008-5472.CAN-14-3619; Bakhoum SF, 2018, CELL, V174, P1347, DOI 10.1016/j.cell.2018.08.027; Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432; Barber GN, 2014, TRENDS IMMUNOL, V35, P88, DOI 10.1016/j.it.2013.10.010; Basit A, 2020, EXP MOL MED, V52, P643, DOI 10.1038/s12276-020-0416-y; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x; Britton S, 2013, J CELL BIOL, V202, P579, DOI 10.1083/jcb.201303073; Brown JS, 2018, BRIT J CANCER, V118, P312, DOI 10.1038/bjc.2017.376; Bu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165681; Burleigh K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba4219; Chen H, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8941; Chen HH, 2014, J IMMUNOL, V192, P1162, DOI 10.4049/jimmunol.1300798; Chen HH, 2011, CELL, V147, P436, DOI 10.1016/j.cell.2011.09.022; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Chen YF, 2017, J EXP MED, V214, P991, DOI 10.1084/jem.20161387; Chung DKC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8742; Clarke TL, 2017, MOL CELL, V65, P900, DOI 10.1016/j.molcel.2017.01.019; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Ding L, 2015, BBA-MOL BASIS DIS, V1852, P2494, DOI 10.1016/j.bbadis.2015.08.011; Dobrzynska A, 2016, NUCLEUS-PHILA, V7, P233, DOI 10.1080/19491034.2016.1183848; Dunphy G, 2018, MOL CELL, V71, P745, DOI 10.1016/j.molcel.2018.07.034; Erdal E, 2017, GENE DEV, V31, P353, DOI 10.1101/gad.289769.116; Ferguson BJ, 2012, ELIFE, V1, DOI 10.7554/eLife.00047; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gaston Julie, 2019, Oncotarget, V10, P4249, DOI 10.18632/oncotarget.27042; Gaston J, 2016, ONCOTARGET, V7, P77205, DOI 10.18632/oncotarget.12858; Gonugunta VK, 2017, CELL REP, V21, P3234, DOI 10.1016/j.celrep.2017.11.061; Goodwin JF, 2014, CANCER DISCOV, V4, P1126, DOI 10.1158/2159-8290.CD-14-0358; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jiang H, 2019, EMBO J, V38, DOI 10.15252/embj.2019102718; Katta SS, 2014, TRENDS CELL BIOL, V24, P221, DOI 10.1016/j.tcb.2013.10.006; Kondo T, 2013, P NATL ACAD SCI USA, V110, P2969, DOI 10.1073/pnas.1222694110; Konno H, 2018, ONCOGENE, V37, P2037, DOI 10.1038/s41388-017-0120-0; Lan YY, 2014, CELL REP, V9, P180, DOI 10.1016/j.celrep.2014.08.074; Lans H, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-4; Legrier ME, 2016, BRIT J CANCER, V114, P177, DOI 10.1038/bjc.2015.398; Lemaitre C, 2014, GENE DEV, V28, P2450, DOI 10.1101/gad.248369.114; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Linsley PS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109760; Litvin O, 2015, MOL CELL, V57, P784, DOI 10.1016/j.molcel.2014.12.030; Liu HP, 2018, NATURE, V563, P131, DOI 10.1038/s41586-018-0629-6; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Mackenzie KJ, 2017, NATURE, V548, P461, DOI 10.1038/nature23449; Malik P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111851; Malik P, 2010, CELL MOL LIFE SCI, V67, P1353, DOI 10.1007/s00018-010-0257-2; Marangoni E, 2007, CLIN CANCER RES, V13, P3989, DOI 10.1158/1078-0432.CCR-07-0078; Marnef A, 2017, CURR OPIN CELL BIOL, V46, P1, DOI 10.1016/j.ceb.2016.12.003; Mazur L, 2012, ANTICANCER RES, V32, P2783; Mohiuddin IS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00635; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Neal JA, 2011, MUTAT RES-FUND MOL M, V711, P73, DOI 10.1016/j.mrfmmm.2011.02.010; Ochi T, 2015, SCIENCE, V347, P185, DOI 10.1126/science.1261971; Oliveira DV, 2014, J CELL SCI, V127, P763, DOI 10.1242/jcs.135855; Oza P, 2009, GENE DEV, V23, P912, DOI 10.1101/gad.1782209; Parkes EE, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw199; Potts PR, 2006, EMBO J, V25, P3377, DOI 10.1038/sj.emboj.7601218; Ranoa DRE, 2019, CANCER RES, V79, P1465, DOI 10.1158/0008-5472.CAN-18-1972; Ryu T, 2015, NAT CELL BIOL, V17, P1401, DOI 10.1038/ncb3258; Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106; Sawasdichai Anyaporn, 2010, J Vis Exp, DOI 10.3791/1958; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schirmer EC, 2003, SCIENCE, V301, P1380, DOI 10.1126/science.1088176; Schmidt U, 2018, LECT NOTES COMPUT SC, V11071, P265, DOI 10.1007/978-3-030-00934-2_30; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shang GJ, 2019, NATURE, V567, P389, DOI 10.1038/s41586-019-0998-5; Shin YJ, 2013, CANCER BIOL THER, V14, P213, DOI 10.4161/cbt.23292; Smeenk G, 2013, J CELL SCI, V126, P889, DOI 10.1242/jcs.109413; Song SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep39858; Sui HY, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah5054; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Wang H, 2017, P NATL ACAD SCI USA, V114, P1637, DOI 10.1073/pnas.1621363114; Wu Z, 2019, NAT METAB, V1, P1209, DOI 10.1038/s42255-019-0150-8; Xia TL, 2016, CANCER RES, V76, P6747, DOI 10.1158/0008-5472.CAN-16-1404; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029	85	9	9	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6627	6640		10.1038/s41388-021-02037-4	http://dx.doi.org/10.1038/s41388-021-02037-4		OCT 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34625708				2022-12-17	WOS:000705760400001
J	Yang, G; Huang, L; Jia, HT; Aikemu, B; Zhang, S; Shao, YF; Hong, HJ; Yesseyeva, G; Wang, CX; Li, SC; Sun, J; Zheng, MH; Ma, JJ				Yang, Guang; Huang, Ling; Jia, Hongtao; Aikemu, Batuer; Zhang, Sen; Shao, Yanfei; Hong, Hiju; Yesseyeva, Galiya; Wang, Chenxing; Li, Shuchun; Sun, Jing; Zheng, Minhua; Ma, Junjun			NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; METASTASIS SUPPRESSOR NDRG1; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; ENDOCYTOSIS; CHEMOTHERAPY; MECHANISMS; STATISTICS; RESISTANCE; MIGRATION	N-myc downstream-regulated gene 1 (NDRG1) is a key regulator that interacts with many classic tumor signaling pathways, including some molecules downstream of the epidermal growth factor receptor (EGFR). However, whether NDRG1 is involved in the mechanism of resistance to cetuximab (CTX), the first monoclonal antibody targeting the EGFR has not been reported. Here, we found that NDRG1 enhanced the sensitivity of CTX in colorectal cancer (CRC) cell lines. Afterwards, we determined the underlying mechanism of this phenomenon. We demonstrated that NDRG1 inhibited the expression of EGFR; blocked EGFR phosphorylation and reduced the EGFR distribution in the cell membrane, cytoplasm and nucleus. And then, NDRG1 suppressed the EGFR downstream signaling: RAS/RAF/ERK and PI3k/AKT/mTOR pathways. Moreover, we discovered that NDRG1 attenuated the endocytosis and degradation of EGFR induced by caveolin-1 (Cav1). Additionally, our findings were further observed in an animal model and human tissues. Our results represent a potentially significant discovery that explains the mechanisms of NDRG1 in CTX resistance. NDRG1 could be a promising biomarker to predict optimum responses to CTX, and a key target to enhance CTX activity in the treatment of metastatic CRC (mCRC).	[Yang, Guang; Huang, Ling; Jia, Hongtao; Aikemu, Batuer; Zhang, Sen; Shao, Yanfei; Hong, Hiju; Yesseyeva, Galiya; Wang, Chenxing; Li, Shuchun; Sun, Jing; Zheng, Minhua; Ma, Junjun] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China; [Yang, Guang; Huang, Ling; Jia, Hongtao; Aikemu, Batuer; Zhang, Sen; Shao, Yanfei; Hong, Hiju; Yesseyeva, Galiya; Wang, Chenxing; Li, Shuchun; Sun, Jing; Zheng, Minhua; Ma, Junjun] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Minimally Invas Surg Ctr, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Sun, J; Zheng, MH; Ma, JJ (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Gen Surg, Shanghai, Peoples R China.; Sun, J; Zheng, MH; Ma, JJ (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai Minimally Invas Surg Ctr, Shanghai, Peoples R China.	sj11788@rjh.com.cn; zmhtiger@yeah.net; marsnew1997@163.com	zhang, sen/GXH-3513-2022	huang, ling/0000-0001-5584-0419	National Nature Science Foundation of China (NSFC) [81871984, 81572818]	National Nature Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work is supported by National Nature Science Foundation of China (NSFC) (Grant No. 81871984, 81572818).	Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050; Brankatschk B, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002351; Caldieri G, 2018, PROG MOL SUBCELL BIO, V57, P235, DOI 10.1007/978-3-319-96704-2_9; Cercek A, 2010, CURR ONCOL REP, V12, P153, DOI 10.1007/s11912-010-0096-1; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Dixon KM, 2013, BRIT J CANCER, V108, P409, DOI 10.1038/bjc.2012.582; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Koo CL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-25; Kovacevic Z, 2006, CARCINOGENESIS, V27, P2355, DOI 10.1093/carcin/bgl146; Kovacevic Z, 2013, ANTIOXID REDOX SIGN, V18, P874, DOI 10.1089/ars.2011.4273; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liao HJ, 2009, CANCER RES, V69, P6179, DOI 10.1158/0008-5472.CAN-09-0049; Melotte V, 2010, FASEB J, V24, P4153, DOI 10.1096/fj.09-151464; Menezes SV, 2019, J BIOL CHEM, V294, P4045, DOI 10.1074/jbc.RA118.006279; Mi L, 2017, ONCOGENE, V36, P4323, DOI 10.1038/onc.2017.74; Morandell S, 2008, PROTEOMICS, V8, P4383, DOI 10.1002/pmic.200800204; Motley A, 2003, J CELL BIOL, V162, P909, DOI 10.1083/jcb.200305145; Nishimura Noriyuki, 2008, V440, P89, DOI 10.1007/978-1-59745-178-9_7; Pinilla-Macua I, 2015, METHOD CELL BIOL, V130, P347, DOI 10.1016/bs.mcb.2015.05.008; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Sousa LP, 2012, P NATL ACAD SCI USA, V109, P4419, DOI 10.1073/pnas.1200164109; Sun J, 2013, CARCINOGENESIS, V34, P1943, DOI 10.1093/carcin/bgt163; Sun J, 2013, MOL PHARMACOL, V83, P454, DOI 10.1124/mol.112.083097; SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Teis D, 2006, J CELL BIOL, V175, P861, DOI 10.1083/jcb.200607025; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Venook AP, 2005, CLIN COLORECTAL CANC, V5, P292, DOI 10.3816/CCC.2005.n.043; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wasan H, 2014, LANCET ONCOL, V15, P631, DOI 10.1016/S1470-2045(14)70106-8; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Yang G, 2021, ONCOL REP, V45, DOI 10.3892/or.2021.7983; Yu CR, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819858507	41	9	9	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					5993	6006		10.1038/s41388-021-01962-8	http://dx.doi.org/10.1038/s41388-021-01962-8		AUG 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34385595	hybrid, Green Published			2022-12-17	WOS:000684526700001
J	Yuan, SK; Zhang, PT; Wen, LQ; Jia, SK; Wu, YF; Zhang, ZL; Guan, LZ; Yu, ZQ; Zhao, L				Yuan, Shukai; Zhang, Peitao; Wen, Liqi; Jia, Shikai; Wu, Yufan; Zhang, Zhenlei; Guan, Lizhao; Yu, Zhengquan; Zhao, Li			miR-22 promotes stem cell traits via activating Wnt/beta-catenin signaling in cutaneous squamous cell carcinoma	ONCOGENE			English	Article							COMPREHENSIVE CLINICOPATHOLOGICAL CLASSIFICATION; TUMOR-INITIATING CELLS; TGF-BETA; CANCER; SUPPRESSOR; TARGETS	Emerging evidence suggests that the cancer stem cells (CSCs) are key culprits of cancer metastasis and drug resistance. Understanding mechanisms regulating the critical oncogenic pathways and CSCs function could reveal new diagnostic and therapeutic strategies. We now report that miR-22, a miRNA critical for hair follicle stem/progenitor cell differentiation, promotes tumor initiation, progression, and metastasis by maintaining Wnt/beta-catenin signaling and CSCs function. Mechanistically, we find that miR-22 facilitates beta-catenin stabilization through directly repressing citrullinase PAD2. Moreover, miR-22 also relieves DKK1-mediated repression of Wnt/beta-catenin signaling by targeting a FosB-DDK1 transcriptional axis. miR-22 knockout mice showed attenuated Wnt/beta-catenin activity and Lgr5(+) CSCs penetrance, resulting in reduced occurrence, progression, and metastasis of chemically induced cutaneous squamous cell carcinoma (cSCC). Clinically, miR-22 is abundantly expressed in human cSCC. Its expression is even further elevated in the CSCs proportion, which negatively correlates with PAD2 and FosB expression. Inhibition of miR-22 markedly suppressed cSCC progression and increased chemotherapy sensitivity in vitro and in xenograft mice. Together, our results revealed a novel miR-22-WNT-CSCs regulatory mechanism in cSCC and highlight the important clinical application prospects of miR-22, a common target molecule for Wnt/beta-catenin signaling and CSCs, for patient stratification and therapeutic intervention.	[Yuan, Shukai; Wen, Liqi; Jia, Shikai; Wu, Yufan; Zhang, Zhenlei; Guan, Lizhao; Zhao, Li] Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Sch Basic Med Sci,Dept Biochem & Mol Biol, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China; [Zhang, Peitao] Tianjin Med Univ Gen Hosp, Dept Nucl Med, 154 Anshan Rd, Tianjin 300052, Peoples R China; [Yu, Zhengquan] China Agr Univ, Coll Biol Sci, State Key Labs Agrobiotechnol, 2 Yuanmingyuan West Rd, Beijing 100094, Peoples R China	Tianjin Medical University; Tianjin Medical University; China Agricultural University	Zhao, L (corresponding author), Tianjin Med Univ, Tianjin Med Univ Canc Inst & Hosp, Sch Basic Med Sci,Dept Biochem & Mol Biol, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, 22 Qixiangtai Rd, Tianjin 300070, Peoples R China.	shzhaoli@tmu.edu.cn			National Natural Science Foundation of China [81872235, 81702710]; Tianjin Municipal Science and Technology Commission [17JCQNJC11200]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Municipal Science and Technology Commission	This research work was supported by grants from the National Natural Science Foundation of China (81872235 to LZ, 81702710 to SY) and The Tianjin Municipal Science and Technology Commission (17JCQNJC11200 to SY).	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Cammareri P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12493; Cassarino DS, 2006, J CUTAN PATHOL, V33, P191, DOI 10.1111/j.0303-6987.2006.00516_1.x; Cassarino DS, 2006, J CUTAN PATHOL, V33, P261, DOI 10.1111/j.0303-6987.2006.00516.x; da Silva-Diz V, 2016, CANCER RES, V76, P1245, DOI 10.1158/0008-5472.CAN-15-1631; Garcia-Sancha N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092181; Ge YJ, 2016, NAT CELL BIOL, V18, P111, DOI 10.1038/ncb3275; Goldie SJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092201; Han MZ, 2020, BRAIN, V143, P512, DOI 10.1093/brain/awz406; Hussein NA, 2017, J CANCER RES CLIN, V143, P83, DOI 10.1007/s00432-016-2248-7; Jafarzadeh-Samani Z, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.03.01; Jian Z, 2017, J INVEST DERMATOL, V137, P31, DOI 10.1016/j.jid.2016.07.033; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Latil M, 2017, CELL STEM CELL, V20, P191, DOI 10.1016/j.stem.2016.10.018; Li S, 2018, ONCOGENE, V37, P884, DOI 10.1038/onc.2017.381; Lohcharoenkal W, 2016, J INVEST DERMATOL, V136, P2485, DOI 10.1016/j.jid.2016.06.630; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Mizrahi A, 2018, ONCOGENE, V37, P218, DOI 10.1038/onc.2017.315; Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001; Oshimori N, 2015, CELL, V160, P963, DOI 10.1016/j.cell.2015.01.043; Patel GK, 2012, J INVEST DERMATOL, V132, P401, DOI 10.1038/jid.2011.317; Qu Y, 2018, NAT CHEM BIOL, V14, P94, DOI [10.1038/NCHEMBIO.2510, 10.1038/nchembio.2510]; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Ra SH, 2011, MODERN PATHOL, V24, P963, DOI 10.1038/modpathol.2011.39; Riemondy K, 2015, ELIFE, V4, DOI 10.7554/eLife.07004; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Sanchez-Danes A, 2018, NATURE, V562, P434, DOI 10.1038/s41586-018-0603-3; Schober M, 2011, P NATL ACAD SCI USA, V108, P10544, DOI 10.1073/pnas.1107807108; Shao YX, 2019, CLIN LAB, V65, P491, DOI 10.7754/Clin.Lab.2018.180825; Sherwood V, 2016, J INVEST DERMATOL, V136, P1760, DOI 10.1016/j.jid.2016.05.108; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Sun RF, 2019, FASEB J, V33, P5411, DOI 10.1096/fj.201801798RR; Tsuchiya N, 2011, CANCER RES, V71, P4628, DOI 10.1158/0008-5472.CAN-10-2475; Wang DP, 2019, ONCOL LETT, V17, P3355, DOI 10.3892/ol.2019.10011; Wang X, 2014, BIOCHEM BIOPH RES CO, V445, P175, DOI 10.1016/j.bbrc.2014.01.160; Yuan SK, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005253	39	9	9	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5799	5813		10.1038/s41388-021-01973-5	http://dx.doi.org/10.1038/s41388-021-01973-5		AUG 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345013	hybrid, Green Published			2022-12-17	WOS:000681523500003
J	Zhang, F; Li, P; Liu, S; Yang, MQ; Zeng, SS; Deng, JJ; Chen, DY; Yi, YM; Liu, H				Zhang, Fan; Li, Pan; Liu, Shuang; Yang, Mingqiang; Zeng, Shanshan; Deng, Junjian; Chen, Danyang; Yi, Yanmei; Liu, Hao			beta-Catenin-CCL2 feedback loop mediates crosstalk between cancer cells and macrophages that regulates breast cancer stem cells	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; BETA-CATENIN; CHEMOATTRACTANT PROTEIN-1; CCL2; ACTIVATION; EXPRESSION; COMPLEX; TRANSACTIVATION; POLARIZATION; FIBROBLASTS	Breast cancer is the most frequently diagnosed cancer among women worldwide. Though advances in diagnosis and treatment have prolonged overall survival (OS) for patients with breast cancer, metastasis remains the major obstacles to improved survival for breast cancer patients. The existence of breast cancer stem cells (BCSCs) is a major reason underlying cancer metastasis and recurrence. Therefore, understanding the molecular pathways sustaining BCSC properties and targeting BCSCs will ultimately improve breast cancer treatments. In this study, we found that activation of beta-Catenin directly regulated CCL2 expression at the transcriptional level, and in turn promoted macrophages infiltration and M2 polarization. Moreover, macrophages co-cultured with breast cancer cells showed a significant increase in CCL2 expression and promoted beta-Catenin-induced BCSCs properties, whereas depletion of CCL2 by adding neutralizing antibodies suppressed BSCSs properties. In addition, we found that beta-Catenin-mediated CCL2 secretion recruited macrophages into tumor microenvironment and promoted breast cancer growth and metastasis in vivo. Clinically, we observed a significant positive correlation between beta-Catenin, CCL2 and CD163 expression, and increased expression of beta-Catenin, CCL2 and CD163 predicted poor prognosis in breast cancer. Furthermore, pharmacological inhibition of CCR2 and beta-Catenin synergistically suppressed BCSC properties and breast cancer growth. Collectively, our findings suggested that beta-Catenin-mediated CCL2 secretion forms a paracrine feedback loop between breast cancer cells and macrophages, which in turn promotes BCSC properties and supports breast cancer growth and metastasis. Targeting beta-Catenin/CCL2 signaling might be an effective strategy for breast cancer therapy.	[Zhang, Fan] Wuhan Univ, Renmin Hosp, Dept Pharm, Wuhan, Hubei, Peoples R China; [Li, Pan; Liu, Shuang; Yang, Mingqiang; Zeng, Shanshan; Chen, Danyang; Liu, Hao] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou, Guangdong, Peoples R China; [Deng, Junjian] Wuhan Univ, Renmin Hosp, Dept Canc Ctr, Wuhan, Hubei, Peoples R China; [Yi, Yanmei] Guangdong Med Univ, Sch Basic Med, Zhanjiang, Guangdong, Peoples R China	Wuhan University; Guangzhou Medical University; Wuhan University; Guangdong Medical University	Chen, DY; Liu, H (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou Key Lab Translat Med Malignant Tumor Tr, Guangzhou, Guangdong, Peoples R China.; Yi, YM (corresponding author), Guangdong Med Univ, Sch Basic Med, Zhanjiang, Guangdong, Peoples R China.	cdy026@126.com; yiymei@gdmu.edu.cn; haoliu2020@163.com		Chen, Danyang/0000-0002-7894-9457; Liu, Hao/0000-0001-6338-4003	National Natural Science Foundation of China [81702819, 81772825, 81972194]; Guangdong Natural Science Funds [2017A030313500, 2019A1515010113]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Funds	This work was supported by the National Natural Science Foundation of China (81702819, 81772825, 81972194), grants from Guangdong Natural Science Funds (2017A030313500, 2019A1515010113).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Amini-Nik S, 2014, J CLIN INVEST, V124, P2599, DOI 10.1172/JCI62059; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Bai XP, 2018, CANCER TREAT REV, V69, P152, DOI 10.1016/j.ctrv.2018.07.004; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Brown JM, 2017, CLIN CANCER RES, V23, P3241, DOI 10.1158/1078-0432.CCR-16-3122; Chen CH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06152-x; Chen JQ, 2011, CANCER CELL, V19, P541, DOI 10.1016/j.ccr.2011.02.006; Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818; Daly C, 2003, MICROCIRCULATION, V10, P247, DOI 10.1038/sj.mn.7800190; Dehnel N, 2017, CURR OPIN PHARMACOL, V35, P12, DOI 10.1016/j.coph.2017.04.007; Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gilles C, 2003, CANCER RES, V63, P2658; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Hamburg-Shields E, 2015, J PATHOL, V235, P686, DOI 10.1002/path.4481; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Jamiyan T, 2020, VIRCHOWS ARCH, V477, P767, DOI 10.1007/s00428-020-02855-z; Jang GB, 2015, CANCER RES, V75, P1691, DOI 10.1158/0008-5472.CAN-14-2041; Jemal A., 2019, CA-CANCER J CLIN, V69, P7, DOI [DOI 10.3322/caac.21551, DOI 10.3322/CAAC.21551]; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; KOELWYN GJ, 2017, NAT REV CANCER, V17, P620, DOI DOI 10.1038/NRC.2017.78; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu M, 2018, CELL PHYSIOL BIOCHEM, V51, P1679, DOI 10.1159/000495673; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mestdagt M, 2006, INT J CANCER, V118, P35, DOI 10.1002/ijc.21291; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; Obeid E, 2013, INT J ONCOL, V43, P5, DOI 10.3892/ijo.2013.1938; Ou BC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1906-5; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Raggi C, 2016, ONCOGENE, V35, P671, DOI 10.1038/onc.2015.132; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Sarode P, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz6105; Schade B, 2013, CANCER RES, V73, P4474, DOI 10.1158/0008-5472.CAN-12-3925; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567; Ueno T, 2000, CLIN CANCER RES, V6, P3282; van Zoelen MAD, 2011, MOL IMMUNOL, V48, P1468, DOI 10.1016/j.molimm.2011.04.001; Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323; Watson AL, 2013, CANCER DISCOV, V3, P674, DOI 10.1158/2159-8290.CD-13-0081; Webster S, 2020, SUPPORT CARE CANCER, V28, P1041, DOI 10.1007/s00520-019-05218-w; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281; Yang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0818-0; Yao M, 2016, MODERN PATHOL, V29, P810, DOI 10.1038/modpathol.2016.78; Ye YC, 2019, CANCER RES, V79, P4160, DOI 10.1158/0008-5472.CAN-18-1691; Yoshimura T, 2018, CELL MOL IMMUNOL, V15, P335, DOI 10.1038/cmi.2017.135; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang F, 2015, PROTEOMICS, V15, P773, DOI 10.1002/pmic.201300494; Zhao SJ, 2018, ONCOGENE, V37, P1049, DOI 10.1038/onc.2017.403	61	9	10	4	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5854	5865		10.1038/s41388-021-01986-0	http://dx.doi.org/10.1038/s41388-021-01986-0		AUG 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345015				2022-12-17	WOS:000681523500005
J	Liu, CF; Armstrong, CM; Ning, S; Yang, JC; Lou, W; Lombard, AP; Zhao, JG; Wu, CY; Yu, AM; Evans, CP; Tepper, CG; Li, PK; Gao, AC				Liu, Chengfei; Armstrong, Cameron M.; Ning, Shu; Yang, Joy C.; Lou, Wei; Lombard, Alan P.; Zhao, Jinge; Wu, Chun-Yi; Yu, Aiming; Evans, Christopher P.; Tepper, Clifford G.; Li, Pui-kai; Gao, Allen C.			ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling	ONCOGENE			English	Article							SPLICE VARIANTS; FULL-LENGTH; INCREASED SURVIVAL; ENZALUTAMIDE; DEGRADATION; RESISTANCE; EXPRESSION; THERAPY; PROTEOSTASIS; ABIRATERONE	Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CRPC). While these treatments are effective initially, resistance occurs frequently. Continued expression of androgen receptor (AR) and its variants such as AR-V7 despite AR-targeted therapy contributes to treatment resistance and cancer progression in advanced CRPC patients. This highlights the need for new strategies blocking continued AR signaling. Here, we identify a novel AR/AR-V7 degrader (ARVib) and found that ARVib effectively degrades AR/AR-V7 protein and attenuates AR/AR-V7 downstream target gene expression in prostate cancer cells. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation. ARVib suppresses HSP70 expression and promotes STUB1 nuclear translocation, where STUB1 binds to AR/AR-V7 and promotes its ubiquitination and degradation. ARVib significantly inhibits resistant prostate tumor growth and improves enzalutamide treatment in vitro and in vivo. These data suggest that ARVib has potential for development as an AR/AR-V7 degrader to treat resistant CRPC.	[Liu, Chengfei; Armstrong, Cameron M.; Ning, Shu; Yang, Joy C.; Lou, Wei; Lombard, Alan P.; Zhao, Jinge; Evans, Christopher P.; Gao, Allen C.] Univ Calif Davis, Dept Urol Surg, Davis, CA 95616 USA; [Liu, Chengfei; Wu, Chun-Yi; Yu, Aiming; Evans, Christopher P.; Tepper, Clifford G.; Gao, Allen C.] Univ Calif Davis, UC Davis Comprehens Canc Ctr, Davis, CA 95616 USA; [Wu, Chun-Yi; Yu, Aiming; Tepper, Clifford G.] Univ Calif Davis, Dept Biochem & Mol Med, Davis, CA 95616 USA; [Li, Pui-kai] Ohio State Univ, Div Med Chem & Pharmacognosy, Coll Pharm, Columbus, OH 43210 USA; [Gao, Allen C.] VA Northern Calif Hlth Care Syst, Sacramento, CA 94553 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; University System of Ohio; Ohio State University	Gao, AC (corresponding author), Univ Calif Davis, Dept Urol Surg, Davis, CA 95616 USA.; Gao, AC (corresponding author), Univ Calif Davis, UC Davis Comprehens Canc Ctr, Davis, CA 95616 USA.; Gao, AC (corresponding author), VA Northern Calif Hlth Care Syst, Sacramento, CA 94553 USA.	acgao@ucdavis.edu	Ning, Shu/GYE-0167-2022	Ning, Shu/0000-0002-6514-0376; Wu, Chun-Yi/0000-0003-2642-0380; Yu, Aiming/0000-0003-1441-4012; Li, Pui Kai/0000-0002-4831-7213	U.S. Department of Veterans Affairs, Office of Research & Development BLD [I01BX0002653]; BLR&D Research Career Scientist Award [IK6BX005222]; NCI [P30CA093373];  [CA179970];  [CA 225836];  [DOD PC150229];  [DOD PC180180]	U.S. Department of Veterans Affairs, Office of Research & Development BLD(US Department of Veterans Affairs); BLR&D Research Career Scientist Award; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; ; ; 	This work was supported in part by grants CA179970 (ACG), CA 225836 (ACG), DOD PC150229 (ACG), DOD PC180180 (ACG), and the U.S. Department of Veterans Affairs, Office of Research & Development BL&D grant number I01BX0002653 (ACG), BLR&D Research Career Scientist Award IK6BX005222 (ACG). ACG is also a Senior Research Career Scientist at VA Northern California Health Care System, Mather, California. The Genomics Shared Resource is supported by Cancer Center Support Grant P30CA093373 awarded by the NCI.	Abe Miyako, 2004, Clin Prostate Cancer, V3, P49, DOI 10.3816/CGC.2004.n.013; Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Azad AA, 2015, NAT REV UROL, V12, P26, DOI 10.1038/nrurol.2014.320; Balch WE, 2008, SCIENCE, V319, P916, DOI 10.1126/science.1141448; Cardile V, 2003, ANTICANCER RES, V23, P4921; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001; Dalal K, 2018, EUR J MED CHEM, V157, P1164, DOI 10.1016/j.ejmech.2018.08.059; Dalal K, 2014, J BIOL CHEM, V289, P26417, DOI 10.1074/jbc.M114.553818; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Fizazi K, 2019, NEW ENGL J MED, V380, P1235, DOI 10.1056/NEJMoa1815671; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/NCHEMBIO.2329, 10.1038/nchembio.2329]; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Ippolito JE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159675; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Khan S, 2019, NAT MED, V25, P1938, DOI 10.1038/s41591-019-0668-z; Kregel S, 2020, NEOPLASIA, V22, P111, DOI 10.1016/j.neo.2019.12.003; Kwegyir-Afful AK, 2015, ONCOTARGET, V6, P27440, DOI 10.18632/oncotarget.4578; Lallous N, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-015-0864-1; Liu CF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07178-x; Liu CF, 2016, ONCOTARGET, V7, P32210, DOI 10.18632/oncotarget.8493; Liu CF, 2015, CANCER RES, V75, P1413, DOI 10.1158/0008-5472.CAN-14-3080; Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296; Liu YF, 2011, CELL RES, V21, P867, DOI 10.1038/cr.2011.75; Lu CX, 2013, TRANSL ANDROL UROL, V2, P178, DOI 10.3978/j.issn.2223-4683.2013.09.08; Markowski MC, 2017, JCO PRECIS ONCOL, V1; Martinez-Jimenez F, 2020, NAT CANCER, V1, P122, DOI 10.1038/s43018-019-0001-2; McGrath MJ, 2013, CANCER RES, V73, P5066, DOI 10.1158/0008-5472.CAN-12-4520; Moses MA, 2018, CANCER RES, V78, P4022, DOI 10.1158/0008-5472.CAN-17-3728; Nguyen HM, 2017, PROSTATE, V77, P654, DOI 10.1002/pros.23313; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Raina K, 2016, P NATL ACAD SCI USA, V113, P7124, DOI 10.1073/pnas.1521738113; Ren AX, 2008, CANCER RES, V68, P2266, DOI 10.1158/0008-5472.CAN-07-6248; Rerole AL, 2011, METHODS MOL BIOL, V787, P205, DOI 10.1007/978-1-61779-295-3_16; Rodriguez-Gonzalez A, 2008, ONCOGENE, V27, P7201, DOI 10.1038/onc.2008.320; Salami J, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0105-8; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shi XB, 2002, CANCER RES, V62, P1496; Smith MR, 2018, NEW ENGL J MED, V378, P1408, DOI 10.1056/NEJMoa1715546; Stanton BZ, 2018, SCIENCE, V359, DOI 10.1126/science.aao5902; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wang H, 2016, MOL CLIN ONCOL, V5, P326, DOI 10.3892/mco.2016.963; Wang RH, 2017, EUR UROL, V72, P835, DOI 10.1016/j.eururo.2017.04.005; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Zhao Y, 2014, J INTERCULT ETHNOPHA, V3, P68, DOI 10.5455/jice.20140123040224	53	9	9	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5379	5392		10.1038/s41388-021-01914-2	http://dx.doi.org/10.1038/s41388-021-01914-2		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34272475	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000673332300001
J	Liebs, S; Eder, T; Klauschen, F; Schutte, M; Yaspo, ML; Keilholz, U; Tinhofer, I; Kidess-Sigal, E; Braunholz, D				Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Yaspo, Marie-Laure; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana			Applicability of liquid biopsies to represent the mutational profile of tumor tissue from different cancer entities	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; ACQUIRED-RESISTANCE; DNA; HETEROGENEITY; BLOOD; HEAD; METASTASIS; EVOLUTION; BIOMARKER; SURVIVAL	Genetic investigation of tumor heterogeneity and clonal evolution in solid cancers could be assisted by the analysis of liquid biopsies. However, tumors of various entities might release different quantities of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) into the bloodstream, potentially limiting the diagnostic potential of liquid biopsy in distinct tumor histologies. Patients with advanced colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and melanoma (MEL) were enrolled in the study, representing tumors with different metastatic patterns. Mutation profiles of cfDNA, CTCs, and tumor tissue were assessed by panel sequencing, targeting 327 cancer-related genes. In total, 30 tissue, 18 cfDNA, and 7 CTC samples from 18 patients were sequenced. Best concordance between the mutation profile of tissue and cfDNA was achieved in CRC and MEL, possibly due to the remarkable heterogeneity of HNSCC (63%, 55% and 11%, respectively). Concordance especially depended on the amount of cfDNA used for library preparation. While 21 of 27 (78%) tissue mutations were retrieved in high-input cfDNA samples (30-100 ng, N = 8), only 4 of 65 (6%) could be detected in low-input samples (<30 ng, N = 10). CTCs were detected in 13 of 18 patients (72%). However, downstream analysis was limited by poor DNA quality, allowing targeted sequencing of only seven CTC samples isolated from four patients. Only one CTC sample reflected the mutation profile of the respective tumor. Private mutations, which were detected in CTCs but not in tissue, suggested the presence of rare subclones. Our pilot study demonstrated superiority of cfDNA- compared to CTC-based mutation profiling. It was further shown that CTCs may serve as additional means to detect rare subclones possibly involved in treatment resistance. Both findings require validation in a larger patient cohort.	[Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Braunholz, Diana] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Liebs, Sandra; Keilholz, Ulrich] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany; [Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Free Univ Berlin, Berlin, Germany; [Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Humboldt Univ, Berlin, Germany; [Liebs, Sandra; Eder, Theresa; Klauschen, Frederick; Schuette, Moritz; Keilholz, Ulrich; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Berlin Inst Hlth, Berlin, Germany; [Eder, Theresa; Tinhofer, Ingeborg; Kidess-Sigal, Evelyn; Braunholz, Diana] Charite Univ Med Berlin, Dept Radiooncol & Radiotherapy, Berlin, Germany; [Klauschen, Frederick] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Schuette, Moritz] Alacris Theranost GmbH, Berlin, Germany; [Yaspo, Marie-Laure] Max Planck Inst Mol Genet, Dept Vertebrate Genom, Otto Warburg Lab Gene Regulat & Syst Biol Canc, Berlin, Germany; [Kidess-Sigal, Evelyn] Charite Univ Med Berlin, Dept Med, Div Hepatol & Gastroenterol, Berlin, Germany; [Kidess-Sigal, Evelyn] Berlin Inst Hlth BIH, Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Liebs, S (corresponding author), German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany.; Liebs, S (corresponding author), Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany.; Liebs, S (corresponding author), Free Univ Berlin, Berlin, Germany.; Liebs, S (corresponding author), Humboldt Univ, Berlin, Germany.; Liebs, S (corresponding author), Berlin Inst Hlth, Berlin, Germany.	sandra.liebs@charite.de	Klauschen, Frederick/C-5637-2015	Klauschen, Frederick/0000-0002-9131-2389; Kidess-Sigal, Evelyn/0000-0002-8590-9699; Liebs, Sandra/0000-0002-7099-0340	Berliner Krebsgesellschaft [BRFF201520]; German Cancer Consortium (DKTK) - National German Health Centers by the Federal German Ministry of Education and Research; Projekt DEAL	Berliner Krebsgesellschaft; German Cancer Consortium (DKTK) - National German Health Centers by the Federal German Ministry of Education and Research; Projekt DEAL	Our analysis was financed by the Berliner Krebsgesellschaft (BRFF201520) and partly supported by the German Cancer Consortium (DKTK), which is funded as one of the National German Health Centers by the Federal German Ministry of Education and Research. Open Access funding enabled and organized by Projekt DEAL.	Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Bhak, COMPREHENSIVE MUTATI, V2019; Castro-Giner F, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00728-3; Cayrefourcq L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070755; Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923; COSMIC, 2004, CAT SOM MUT CANC; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Luca F, 2016, ONCOTARGET, V7, P26107, DOI 10.18632/oncotarget.8431; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Eder T, 2019, EUR J CANCER, V116, P67, DOI 10.1016/j.ejca.2019.04.015; Fernandez-Garcia D, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1235-8; Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581; Freidin MB, 2015, CLIN CHEM, V61, P1299, DOI 10.1373/clinchem.2015.242453; Galot R, 2020, ORAL ONCOL, V104, DOI 10.1016/j.oraloncology.2020.104631; Genna A, 2020, CANCERS, V12, DOI 10.3390/cancers12061632; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gorges K, 2019, CANCERS, V11, DOI 10.3390/cancers11111685; Gray ES, 2015, ONCOTARGET, V6, P42008, DOI 10.18632/oncotarget.5788; Grisanti S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103918; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hristozova T, 2011, ANN ONCOL, V22, P1878, DOI 10.1093/annonc/mdr130; Hu BG, 2020, CANCER MED-US, V9, P2686, DOI 10.1002/cam4.2871; Institute for Research in Biomedicine, 2018, CANC GEN INT; Khan KH, 2018, CANCER DISCOV, V8, P1270, DOI 10.1158/2159-8290.CD-17-0891; Khoja L, 2013, J INVEST DERMATOL, V133, P1582, DOI 10.1038/jid.2012.468; Kidess E, 2015, ONCOTARGET, V6, P2549, DOI 10.18632/oncotarget.3041; Kidess E, 2013, GENOME MED, V5, DOI 10.1186/gm474; Kuhlmann JD, 2014, CLIN CHEM, V60, P1282, DOI 10.1373/clinchem.2014.224808; Lack J, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1138-3; Lebofsky R, 2015, MOL ONCOL, V9, P783, DOI 10.1016/j.molonc.2014.12.003; Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11; Liebs S, 2019, CANCER MED-US, V8, P3761, DOI 10.1002/cam4.2219; Lin SY, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00225; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Majidpoor J, 2021, MED ONCOL, V38, DOI 10.1007/s12032-020-01447-w; Manier S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04001-5; Martelotto LG, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3658; Mazurek AM, 2016, ORAL ONCOL, V54, P36, DOI 10.1016/j.oraloncology.2015.12.002; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Oellerich M, 2019, THER DRUG MONIT, V41, P115, DOI 10.1097/FTD.0000000000000566; Onidani K, 2019, CANCER SCI, V110, P2590, DOI 10.1111/cas.14092; Pailler E, 2015, ANN ONCOL, V26, P1408, DOI 10.1093/annonc/mdv165; Pestrin M, 2015, MOL ONCOL, V9, P749, DOI 10.1016/j.molonc.2014.12.001; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Salvianti F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049843; Siravegna G, 2015, NAT MED, V21, P795, DOI 10.1038/nm.3870; Tamborero D, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0531-8; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tayoun T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101145; Wang YX, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8507; Yap SA, 2020, BIOTECHNIQUES, V69, P99, DOI 10.2144/btn-2020-0028; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522	54	9	9	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 19	2021	40	33					5204	5212		10.1038/s41388-021-01928-w	http://dx.doi.org/10.1038/s41388-021-01928-w		JUL 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC8LP	34230613	hybrid, Green Published			2022-12-17	WOS:000670148000001
J	Zhang, JG; Guan, WC; Xu, XL; Wang, FC; Li, X; Xu, GX				Zhang, Jinguo; Guan, Wencai; Xu, Xiaolin; Wang, Fanchen; Li, Xin; Xu, Guoxiong			A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer	ONCOGENE			English	Article							CALCIUM-BINDING PROTEIN; MULTIDRUG-RESISTANCE; MESENCHYMAL TRANSITION; COLORECTAL-CANCER; UP-REGULATION; TGF-BETA; OVEREXPRESSION; MICRORNA; CELLS; EMT	The primary chemotherapy of ovarian cancer (OC) often acquires chemoresistance. Sorcin (SRI), a soluble resistance-related calcium-binding protein, has been reported to be an oncogenic protein in cancer. However, the molecular mechanisms of SRI regulation and the role and aberrant expression of SRI in chemoresistant OC remain unclear. Here, we identified SRI as a key driver of paclitaxel (PTX)-resistance and explored its regulatory mechanism. Using transcriptome profiles, qRT-PCR, proteomics, Western blot, immunohistochemistry, and bioinformatics analyses, we found that SRI was overexpressed in PTX-resistant OC cells and the overexpression of SRI was related to the poor prognosis of patients. SRI was a key molecule required for growth, migration, and PTX-resistance in vitro and in vivo and was involved in epithelial-mesenchymal transition (EMT) and stemness. Mechanistic studies showed that miR-142-5p directly bound to the 3MODIFIER LETTER PRIME-UTR of SRI to suppress its expression, whereas a transcription factor zinc-finger E-box binding homeobox 1 (ZEB1) inhibited the transcription of miR-142-5p by directly binding to the E-box fragment in the miR-142 promoter region. Furthermore, ZEB1 was negatively regulated by SRI which physically interacted with Smad4 to block its translocation from the cytosol to the nucleus. Taken together, our findings unveil a novel homeostatic loop of SRI that drives the PTX-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human OC. Targeting this SRI/Smad4/ZEB1/miR-142-5p loop may reverse the PTX-resistance.	[Zhang, Jinguo; Guan, Wencai; Xu, Xiaolin; Wang, Fanchen; Li, Xin; Xu, Guoxiong] Fudan Univ, Jinshan Hosp, Res Ctr Clin Med, Shanghai 201508, Peoples R China; [Zhang, Jinguo; Xu, Xiaolin; Wang, Fanchen; Li, Xin; Xu, Guoxiong] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Xu, Guoxiong] Fudan Univ, Jinshan Hosp, Ctr Tumor Diag & Therapy, Shanghai 201508, Peoples R China	Fudan University; Fudan University; Fudan University	Xu, GX (corresponding author), Fudan Univ, Jinshan Hosp, Res Ctr Clin Med, Shanghai 201508, Peoples R China.; Xu, GX (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Xu, GX (corresponding author), Fudan Univ, Jinshan Hosp, Ctr Tumor Diag & Therapy, Shanghai 201508, Peoples R China.	guoxiong.xu@fudan.edu.cn		Zhang, Jinguo/0000-0001-9952-9307; wencai, guan/0000-0001-8168-0711	National Natural Science Foundation of China [81872121]; Natural Science Foundation of Shanghai [17ZR1404100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	We are thankful for all research participants and technical assistants involved in this research project. This work was supported by grants from the National Natural Science Foundation of China (grant no. 81872121) and the Natural Science Foundation of Shanghai (grant no. 17ZR1404100) to GX.	Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; Baird RD, 2010, NAT REV CLIN ONCOL, V7, P575, DOI 10.1038/nrclinonc.2010.120; Battista T, 2020, CANCERS, V12, DOI 10.3390/cancers12040887; Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7; Caramel J, 2018, CANCER RES, V78, P30, DOI 10.1158/0008-5472.CAN-17-2476; Colotti G, 2014, MOLECULES, V19, P13976, DOI 10.3390/molecules190913976; Dabaghi M, 2016, GENET TEST MOL BIOMA, V20, P516, DOI 10.1089/gtmb.2016.0031; Deng LM, 2019, INT J ONCOL, V55, P451, DOI 10.3892/ijo.2019.4831; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Gao YY, 2015, MOL MED REP, V11, P2118, DOI 10.3892/mmr.2014.2936; Genovese I, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.342; Gong ZH, 2014, ONCOL LETT, V8, P2393, DOI 10.3892/ol.2014.2543; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; He QC, 2011, ONCOL REP, V25, P237, DOI 10.3892/or_00001066; Hu H, 2020, ANTI-CANCER DRUG, V31, P483, DOI 10.1097/CAD.0000000000000894; Hu YH, 2014, BREAST CANCER RES TR, V143, P287, DOI 10.1007/s10549-013-2809-2; Ilari A, 2015, SCI REP-UK, V5, DOI 10.1038/srep16828; Islam F, 2018, EXP MOL PATHOL, V104, P98, DOI 10.1016/j.yexmp.2018.01.006; Jolly MK, 2019, PHARMACOL THERAPEUT, V194, P161, DOI 10.1016/j.pharmthera.2018.09.007; Katsuno Y, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aau8544; Kim JJ, 2013, J CELL BIOCHEM, V114, P1286, DOI 10.1002/jcb.24464; Koti M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-549; Lloyd KL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1101-8; Long L, 2019, EXP MOL PATHOL, V106, P116, DOI 10.1016/j.yexmp.2019.01.001; Madany Mecca, 2018, Discoveries (Craiova), V6, pe86, DOI 10.15190/d.2018.7; Maddalena F, 2011, CANCER RES, V71, P7659, DOI 10.1158/0008-5472.CAN-11-2172; Marmugi A, 2016, DIABETES, V65, P1009, DOI 10.2337/db15-1334; Mladinich Megan, 2016, Stem Cells Int, V2016, P5285892; Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001; Monk BJ, 2016, CURR PHARM DESIGN, V22, P4717, DOI 10.2174/1381612822666160505114326; NOMAN M, 2018, ONCOIMMUNOLOGY, V7; Orellana-Serradell O, 2019, ASIAN J ANDROL, V21, P460, DOI 10.4103/aja.aja_1_19; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Parekh HK, 2002, BIOCHEM PHARMACOL, V63, P1149, DOI 10.1016/S0006-2952(02)00850-X; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Suarez J, 2013, AM J PHYSIOL-CELL PH, V304, pC248, DOI 10.1152/ajpcell.00039.2012; Sun YT, 2018, J CELL PHYSIOL, V233, P3066, DOI 10.1002/jcp.26087; Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Wang FC, 2020, AGING-US, V12, P11042, DOI 10.18632/aging.103317; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xie N, 2017, CELL DEATH DIS, V8, DOI 10.1038/s41419-017-0015-6; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yoshida T., 2016, PLOS ONE, V11, P0147344; Yu WX, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819892264; Zhang LY, 2016, CURR CANCER DRUG TAR, V16, P429, DOI 10.2174/1568009616666160404121105; Zhang XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0176-3; Zhou DB, 2017, CELL SIGNAL, V35, P197, DOI 10.1016/j.cellsig.2017.04.009; Zhu W, 2020, EUR REV MED PHARMACO, V24, P4306, DOI 10.26355/eurrev_202004_21011	53	9	9	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4906	4918		10.1038/s41388-021-01891-6	http://dx.doi.org/10.1038/s41388-021-01891-6		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163033	Green Published, hybrid			2022-12-17	WOS:000664853000002
J	Launonen, KM; Paakinaho, V; Sigismondo, G; Malinen, M; Sironen, R; Hartikainen, JM; Laakso, H; Visakorpi, T; Krijgsveld, J; Niskanen, EA; Palvimo, JJ				Launonen, Kaisa-Mari; Paakinaho, Ville; Sigismondo, Gianluca; Malinen, Marjo; Sironen, Reijo; Hartikainen, Jaana M.; Laakso, Hanna; Visakorpi, Tapio; Krijgsveld, Jeroen; Niskanen, Einari A.; Palvimo, Jorma J.			Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells	ONCOGENE			English	Article							TRANSCRIPTION FACTOR SIM2; RESPONSE ELEMENT; LUNG-CANCER; GENE; COREGULATOR; METASTASIS; THERAPY; INHIBITION; EXPRESSION; PHENOTYPE	Treatment of prostate cancer confronts resistance to androgen receptor (AR)-targeted therapies. AR-associated coregulators and chromatin proteins hold a great potential for novel therapy targets. Here, we employed a powerful chromatin-directed proteomics approach termed ChIP-SICAP to uncover the composition of chromatin protein network, the chromatome, around endogenous AR in castration resistant prostate cancer (CRPC) cells. In addition to several expected AR coregulators, the chromatome contained many nuclear proteins not previously associated with the AR. In the context of androgen signaling in CRPC cells, we further investigated the role of a known AR-associated protein, a chromatin remodeler SMARCA4 and that of SIM2, a transcription factor without a previous association with AR. To understand their role in chromatin accessibility and AR target gene expression, we integrated data from ChIP-seq, RNA-seq, ATAC-seq and functional experiments. Despite the wide co-occurrence of SMARCA4 and AR on chromatin, depletion of SMARCA4 influenced chromatin accessibility and expression of a restricted set of AR target genes, especially those involved in cell morphogenetic changes in epithelial-mesenchymal transition. The depletion also inhibited the CRPC cell growth, validating SMARCA4's functional role in CRPC cells. Although silencing of SIM2 reduced chromatin accessibility similarly, it affected the expression of a much larger group of androgen-regulated genes, including those involved in cellular responses to external stimuli and steroid hormone stimulus. The silencing also reduced proliferation of CRPC cells and tumor size in chick embryo chorioallantoic membrane assay, further emphasizing the importance of SIM2 in CRPC cells and pointing to the functional relevance of this potential prostate cancer biomarker in CRPC cells. Overall, the chromatome of AR identified in this work is an important resource for the field focusing on this important drug target.	[Launonen, Kaisa-Mari; Paakinaho, Ville; Laakso, Hanna; Niskanen, Einari A.; Palvimo, Jorma J.] Univ Eastern Finland, Fac Hlth Sci, Inst Biomed, Kuopio, Finland; [Sigismondo, Gianluca; Krijgsveld, Jeroen] German Canc Res Ctr, Heidelberg, Germany; [Malinen, Marjo] Univ Eastern Finland, Dept Environm & Biol Sci, Joensuu, Finland; [Sironen, Reijo; Hartikainen, Jaana M.] Univ Eastern Finland, Inst Clin Med Clin Pathol & Forens Med, Kuopio, Finland; [Sironen, Reijo] Kuopio Univ Hosp, Dept Clin Pathol, Kuopio, Finland; [Visakorpi, Tapio] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Visakorpi, Tapio] Tampere Univ Hosp, Tays Canc Ctr, Tampere, Finland; [Visakorpi, Tapio] Fimlab Labs, Tampere, Finland; [Krijgsveld, Jeroen] Heidelberg Univ, Fac Med, Heidelberg, Germany	University of Eastern Finland; Helmholtz Association; German Cancer Research Center (DKFZ); University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Tampere University; Tampere University; Tampere University Hospital; Ruprecht Karls University Heidelberg	Palvimo, JJ (corresponding author), Univ Eastern Finland, Fac Hlth Sci, Inst Biomed, Kuopio, Finland.	jorma.palvimo@uef.fi	Niskanen, Einari/F-2883-2017; Hartikainen, Jaana/E-6256-2015	Niskanen, Einari/0000-0001-9471-7026; Paakinaho, Ville/0000-0003-4204-1436; Hartikainen, Jaana/0000-0001-8267-1905; Launonen, Kaisa-Mari/0000-0003-2770-0464; Palvimo, Jorma/0000-0003-2373-0578	Excellence Cluster CellNetworks [EXC81]; UEF DPMM; Academy of Finland; Sigrid Juselius Foundation; Cancer Foundation Finland; Paavo Koistinen Foundation; University of Eastern Finland (UEF); Kuopio University Hospital	Excellence Cluster CellNetworks; UEF DPMM; Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Cancer Foundation Finland; Paavo Koistinen Foundation; University of Eastern Finland (UEF); Kuopio University Hospital	G.S. and J.K. acknowledge the Excellence Cluster CellNetworks (EXC81). This paper was supported by UEF DPMM, Academy of Finland, Sigrid Juselius Foundation, Cancer Foundation Finland, and Paavo Koistinen Foundation. Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Agoulnik IU, 2009, STEROIDS, V74, P669, DOI 10.1016/j.steroids.2009.02.007; Ailiken G, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0205-4; Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; Annala M, 2015, ONCOTARGET, V6, P6235, DOI 10.18632/oncotarget.3359; Arredouani MS, 2009, CLIN CANCER RES, V15, P5794, DOI 10.1158/1078-0432.CCR-09-0911; Centenera MM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030478; Cyrta J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19328-1; DAHMANE N, 1995, P NATL ACAD SCI USA, V92, P9191, DOI 10.1073/pnas.92.20.9191; DeYoung MP, 2003, CANCER LETT, V200, P25, DOI 10.1016/S0304-3835(03)00409-9; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Ding YF, 2019, J CLIN INVEST, V129, P759, DOI 10.1172/JCI123557; Fine SW, 2018, MODERN PATHOL, V31, pS122, DOI 10.1038/modpathol.2017.164; Giles KA, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01023-7; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; Hankey W, 2020, CANCER RES, V80, P2427, DOI 10.1158/0008-5472.CAN-19-3447; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363; Hu J, 2020, ARCH PATHOL LAB MED, V144, P320, DOI 10.5858/arpa.2019-0434-RA; Huang Y, 2010, CANCER BIOL THER, V9, P204, DOI 10.4161/cbt.9.3.10960; Karvonen U, 1997, J BIOL CHEM, V272, P15973, DOI 10.1074/jbc.272.25.15973; Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Labrecque MP, 2019, J CLIN INVEST, V129, P4492, DOI 10.1172/JCI128212; Lambert JP, 2014, J PROTEOMICS, V100, P55, DOI 10.1016/j.jprot.2013.12.022; Lambert JP, 2012, PROTEOMICS, V12, P1609, DOI 10.1002/pmic.201100547; Lazar JE, 2020, CELL REP, V31, DOI [10.1015/j.celrep.2020.107788, 10.1016/j.celrep.2020.107788]; Lempiainen JK, 2017, MOL CELL PROTEOMICS, V16, P1462, DOI 10.1074/mcp.M117.067488; Lu B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028837; Lv DJ, 2019, THERANOSTICS, V9, P5166, DOI 10.7150/thno.33972; Matsubara D, 2013, CANCER SCI, V104, P266, DOI 10.1111/cas.12065; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Morris SA, 2014, NAT STRUCT MOL BIOL, V21, P73, DOI 10.1038/nsmb.2718; Muthuswami R, 2019, J CELL PHYSL; O'Rourke DJ, 2012, CLIN CHIM ACTA, V413, P561, DOI 10.1016/j.cca.2011.11.027; Paakinaho V, 2019, CELL REP, V28, P3523, DOI 10.1016/j.celrep.2019.08.039; Paakinaho V, 2014, NUCLEIC ACIDS RES, V42, P1575, DOI 10.1093/nar/gkt1033; Paltoglou S, 2017, CANCER RES, V77, P3417, DOI 10.1158/0008-5472.CAN-16-1616; Pearson SJ, 2019, ONCOGENE, V38, P2611, DOI 10.1038/s41388-018-0622-4; Pomerantz MM, 2015, NAT GENET, V47, P1346, DOI 10.1038/ng.3419; Qin Q, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1934-6; Rachidi M, 2005, INT J DEV NEUROSCI, V23, P475, DOI 10.1016/j.ijdevneu.2005.05.004; Rafiee MR, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199370; Rafiee MR, 2016, MOL CELL, V64, P624, DOI 10.1016/j.molcel.2016.09.019; Rajaram P, 2020, MOLECULES, V25, DOI 10.3390/molecules25102448; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Roesley SNA, 2018, CELL CYCLE, V17, P1559, DOI 10.1080/15384101.2018.1493414; Roy N, 2015, GENE DEV, V29, P658, DOI 10.1101/gad.256628.114; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sandoval GJ, 2018, MOL CELL, V71, P554, DOI 10.1016/j.molcel.2018.06.040; Schick S, 2019, NAT GENET, V51, P1399, DOI 10.1038/s41588-019-0477-9; Sharma A, 2017, MOL ONCOL, V11, P655, DOI 10.1002/1878-0261.12059; Sharma NL, 2014, NUCLEIC ACIDS RES, V42, P6256, DOI 10.1093/nar/gku281; Stelloo S, 2018, ONCOGENE, V37, P313, DOI 10.1038/onc.2017.330; Swinstead EE, 2016, BIOESSAYS, V38, P1150, DOI 10.1002/bies.201600137; Toropainen S, 2015, NUCLEIC ACIDS RES, V43, P848, DOI 10.1093/nar/gku1375; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Wong YNS, 2014, NAT REV CLIN ONCOL, V11, P365, DOI 10.1038/nrclinonc.2014.72; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Woods S, 2008, NUCLEIC ACIDS RES, V36, P3716, DOI 10.1093/nar/gkn247; Wu DL, 2017, CURR OPIN STRUC BIOL, V43, P1, DOI 10.1016/j.sbi.2016.09.011; Xu LY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221051; Yang YY, 2019, BBA-GENE REGUL MECH, V1862, P834, DOI 10.1016/j.bbagrm.2019.05.005; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6; Zhou Z, 2015, ONCOTARGETS THER, V8, P3603, DOI 10.2147/OTT.S95500	67	9	9	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4567	4579		10.1038/s41388-021-01887-2	http://dx.doi.org/10.1038/s41388-021-01887-2		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34127815	hybrid, Green Published			2022-12-17	WOS:000661408100003
J	McAndrews, KM; Vazquez-Arreguin, K; Kwak, C; Sugimoto, H; Zheng, XF; Li, BR; Kirtley, ML; LeBleu, VS; Kalluri, R				McAndrews, Kathleen M.; Vazquez-Arreguin, Karina; Kwak, Changsoo; Sugimoto, Hikaru; Zheng, Xiaofeng; Li, Bingrui; Kirtley, Michelle L.; LeBleu, Valerie S.; Kalluri, Raghu			alpha SMA(+) fibroblasts suppress Lgr5(+) cancer stem cells and restrain colorectal cancer progression	ONCOGENE			English	Article							CARCINOMA-ASSOCIATED FIBROBLASTS; GROWTH-FACTOR-BETA; MOLECULAR SUBTYPES; GENE-EXPRESSION; TUMOR; METASTASIS; IDENTIFICATION; PHENOTYPE; STROMA; MODEL	The development and progression of solid tumors is dependent on cancer cell autonomous drivers and the tumor microenvironment (TME). Cancer-associated fibroblasts (CAFs) in the TME possess both tumor-promoting and tumor-restraining functions. In the current study, we interrogated the role of alpha SMA(+) CAFs in a genetic mouse model of metastatic colorectal cancer (CRC). Selective depletion of alpha SMA(+) CAFs resulted in increased tumor invasiveness, lymph node metastasis, and reduced overall survival. Depletion of alpha SMA(+) CAFs reduced BMP4 and increased TGF beta 1 secretion from stromal cells, and was associated with increased Lgr5(+) cancer stem-like cells (CSCs) and the generation of an immunosuppressive TME with increased frequency of Foxp3(+) regulatory T cells and suppression of CD8(+) T cells. This study demonstrates that alpha SMA(+) CAFs in CRC exert tumor-restraining functions via BMP4/TGF beta 1 paracrine signaling that serves to suppress Lgr5(+) CSCs and promote anti-tumor immunity, ultimately limiting CRC progression.	[McAndrews, Kathleen M.; Vazquez-Arreguin, Karina; Kwak, Changsoo; Sugimoto, Hikaru; Zheng, Xiaofeng; Li, Bingrui; Kirtley, Michelle L.; LeBleu, Valerie S.; Kalluri, Raghu] Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Dept Canc Biol, Houston, TX 77030 USA; [LeBleu, Valerie S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Kalluri, Raghu] Rice Univ, Dept Bioengn, Houston, TX 77005 USA; [Kalluri, Raghu] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Feinberg School of Medicine; Rice University; Baylor College of Medicine	Kalluri, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Metastasis Res Ctr, Dept Canc Biol, Houston, TX 77030 USA.; Kalluri, R (corresponding author), Rice Univ, Dept Bioengn, Houston, TX 77005 USA.; Kalluri, R (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	rkalluri@mdanderson.org	Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; McAndrews, Kathleen/0000-0002-4092-4991	MD Anderson Cancer Center; Ruth L. Kirschstein National Research Service Award [5T32CA186892, CA016672]	MD Anderson Cancer Center; Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported by research funds provided by the MD Anderson Cancer Center. KV-A is supported by Ruth L. Kirschstein National Research Service Award 5T32CA186892. We thank Dr. Ronald DePinho for providing the iKAP mouse model and for insightful comments on the manuscript. We thank Dr. Adam Boutin for his generous help with the project, Dr. Krishnan Mahadevan for advice on proliferative index determination, and Patience Kelly for assistance with slide scanning and staining. The Advanced Technology Genomics Core is supported by the core grant CA016672(ATCG).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Becker LM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107701; Blockhuys S, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.10.106006; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Centers for Disease Control and Prevention, 2019, COL CANC STAT; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Damaghi M, 2020, EVOL APPL, V13, P2689, DOI 10.1111/eva.13075; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; HAGGITT RC, 1985, GASTROENTEROLOGY, V89, P326; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Karagiannis GS, 2012, MOL CANCER RES, V10, P1403, DOI 10.1158/1541-7786.MCR-12-0307; Kobayashi H, 2021, GASTROENTEROLOGY, V160, P1224, DOI 10.1053/j.gastro.2020.11.011; LeBleu VS, 2020, FASEB J, V34, P3519, DOI 10.1096/fj.201903188R; LeBleu VS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.029447; LeBleu VS, 2013, NAT MED, V19, P1047, DOI 10.1038/nm.3218; LeBleu VS, 2013, NAT MED, V19, P227, DOI 10.1038/nm.2989; Liu L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159947; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma HJ, 2014, CANCER LETT, V344, P74, DOI 10.1016/j.canlet.2013.10.017; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Martin M, 2011, EMBNET J, V17, P1, DOI [10.14806/ej.17.1.200, DOI 10.14806/EJ.17.1.200]; Moo-Young TA, 2009, J IMMUNOTHER, V32, P12, DOI 10.1097/CJI.0b013e318189f13c; Nakanishi Y, 2013, NAT GENET, V45, P98, DOI 10.1038/ng.2481; Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Otranto M, 2012, CELL ADHES MIGR, V6, P203, DOI 10.4161/cam.20377; Powell DW, 2011, ANNU REV PHYSIOL, V73, P213, DOI 10.1146/annurev.physiol.70.113006.100646; Qi Z, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13824; Roulis M, 2020, NATURE, V580, P524, DOI 10.1038/s41586-020-2166-3; Sadanandam A, 2014, CELL CYCLE, V13, P353, DOI 10.4161/cc.27769; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Stzepourginski I, 2017, P NATL ACAD SCI USA, V114, pE506, DOI 10.1073/pnas.1620059114; Vellinga TT, 2016, ONCOGENE, V35, P5263, DOI 10.1038/onc.2016.60; Veschi V, 2020, ONCOGENE, V39, P987, DOI 10.1038/s41388-019-1047-4; WAHL SM, 1994, J EXP MED, V180, P1587, DOI 10.1084/jem.180.5.1587; Wan YY, 2007, IMMUNOL REV, V220, P199, DOI 10.1111/j.1600-065X.2007.00565.x; Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013; Wu XB, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108708; Zhang YC, 2020, ANNU REV PHYSIOL, V82, P251, DOI 10.1146/annurev-physiol-021119-034500; Zhang ZY, 2018, INT J ONCOL, V53, P1869, DOI 10.3892/ijo.2018.4536	53	9	9	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2021	40	26					4440	4452		10.1038/s41388-021-01866-7	http://dx.doi.org/10.1038/s41388-021-01866-7		JUN 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC8LA	34108617	Green Accepted			2022-12-17	WOS:000659470200006
J	Ramsden, DA; Nussenzweig, A				Ramsden, Dale A.; Nussenzweig, Andre			Mechanisms driving chromosomal translocations: lost in time and space	ONCOGENE			English	Review							DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE-1; SPATIAL PROXIMITY; LIGASE-III; DNA; REPAIR; RECOMBINATION; MOBILITY; REPLICATION; GENOME	Translocations arise when an end of one chromosome break is mistakenly joined to an end from a different chromosome break. Since translocations can lead to developmental disease and cancer, it is important to understand the mechanisms leading to these chromosome rearrangements. We review how characteristics of the sources and the cellular responses to chromosome breaks contribute to the accumulation of multiple chromosome breaks at the same moment in time. We also discuss the important role for chromosome break location; how translocation potential is impacted by the location of chromosome breaks both within chromatin and within the nucleus, as well as the effect of altered mobility of chromosome breaks. A common theme in work addressing both temporal and spatial contributions to translocation is that there is no shortage of examples of factors that promote translocation in one context, but have no impact or the opposite impact in another. Accordingly, a clear message for future work on translocation mechanism is that unlike normal DNA metabolic pathways, it isn't easily modeled as a simple, linear pathway that is uniformly followed regardless of differing cellular contexts.	[Ramsden, Dale A.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27515 USA; [Ramsden, Dale A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Ramsden, Dale A.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA; [Nussenzweig, Andre] NIH, Lab Genome Integr, Bldg 10, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA	Ramsden, DA (corresponding author), Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27515 USA.; Ramsden, DA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.; Ramsden, DA (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA.	dale_ramsden@med.unc.edu			NCI [CA222092, CA097096]; DOD [W81XWH-18-1-004]; Intramural Research Program of the NIH	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	D.A.R's laboratory was supported by NCI grants CA222092 and CA097096 and DOD grant W81XWH-18-1-004. The A.N. laboratory is supported by the Intramural Research Program of the NIH.	Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Aymard F, 2017, NAT STRUCT MOL BIOL, V24, P353, DOI 10.1038/nsmb.3387; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Boboila C, 2010, J EXP MED, V207, P417, DOI 10.1084/jem.20092449; Bredemeyer AL, 2008, J IMMUNOL, V181, P2620, DOI 10.4049/jimmunol.181.4.2620; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Brunet E, 2018, ADV EXP MED BIOL, V1044, P15, DOI 10.1007/978-981-13-0593-1_2; Bunting SF, 2013, NAT REV CANCER, V13, P443, DOI 10.1038/nrc3537; Caldecott KW, 2014, DNA REPAIR, V19, P108, DOI 10.1016/j.dnarep.2014.03.021; Callen E, 2007, CELL, V130, P63, DOI 10.1016/j.cell.2007.06.016; Canela A, 2019, MOL CELL, V75, P252, DOI 10.1016/j.molcel.2019.04.030; Canela A, 2017, CELL, V170, P507, DOI 10.1016/j.cell.2017.06.034; Caridi CP, 2018, NATURE, V559, P54, DOI 10.1038/s41586-018-0242-8; Carvajal-Garcia J, 2020, P NATL ACAD SCI USA, V117, P8476, DOI 10.1073/pnas.1921791117; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Cho NW, 2014, CELL, V159, P108, DOI 10.1016/j.cell.2014.08.030; Day TA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15110; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Difilippantonio S, 2008, NATURE, V456, P529, DOI 10.1038/nature07476; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Dion V, 2012, NAT CELL BIOL, V14, P502, DOI 10.1038/ncb2465; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Gao SJ, 2016, DNA REPAIR, V42, P1, DOI 10.1016/j.dnarep.2016.03.013; Ghezraoui H, 2014, MOL CELL, V55, P829, DOI 10.1016/j.molcel.2014.08.002; Gomez-Herreros F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00307-y; Gothe HJ, 2019, MOL CELL, V75, P267, DOI 10.1016/j.molcel.2019.05.015; Gunn A, 2011, J BIOL CHEM, V286, P42470, DOI 10.1074/jbc.M111.309252; Hanzlikova H, 2017, NUCLEIC ACIDS RES, V45, P2546, DOI 10.1093/nar/gkw1246; Kramara J, 2018, TRENDS GENET, V34, P518, DOI 10.1016/j.tig.2018.04.002; Krawczyk PM, 2012, J CELL SCI, V125, P2127, DOI 10.1242/jcs.089847; Kruhlak MJ, 2006, J CELL BIOL, V172, P823, DOI 10.1083/jcb.200510015; Layer JV, 2018, P NATL ACAD SCI USA, V115, P10076, DOI 10.1073/pnas.1801591115; Lee K, 2008, NATURE, V454, P543, DOI 10.1038/nature07054; Li YL, 2020, NATURE, V578, P112, DOI 10.1038/s41586-019-1913-9; Lin SG, SUPPRESSES ALTERNATI, V2021; Lobachev K, 2004, CURR BIOL, V14, P2107, DOI 10.1016/j.cub.2004.11.051; Lobrich M, 1998, RADIAT RES, V150, P619, DOI 10.2307/3579884; Lottersberger F, 2015, CELL, V163, P880, DOI 10.1016/j.cell.2015.09.057; Lu GQ, 2016, P NATL ACAD SCI USA, V113, P1256, DOI 10.1073/pnas.1521597113; Mateos-Gomez PA, 2015, NATURE, V518, P254, DOI 10.1038/nature14157; Mine-Hattab J, 2012, NAT CELL BIOL, V14, P510, DOI 10.1038/ncb2472; Morton LM, 2021, SCIENCE, V372, P705, DOI 10.1126/science.abg2538; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Pannunzio NR, 2018, TRENDS BIOCHEM SCI, V43, P490, DOI 10.1016/j.tibs.2018.04.004; Pannunzio NR, 2014, DNA REPAIR, V17, P74, DOI 10.1016/j.dnarep.2014.02.006; Pommier Y, 2016, NAT REV MOL CELL BIO, V17, P703, DOI 10.1038/nrm.2016.111; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Richardson CD, 2016, NAT BIOTECHNOL, V34, P339, DOI 10.1038/nbt.3481; Roix JJ, 2003, NAT GENET, V34, P287, DOI 10.1038/ng1177; Roukos V, 2013, SCIENCE, V341, P660, DOI 10.1126/science.1237150; Rulten SL, 2011, MOL CELL, V41, P33, DOI 10.1016/j.molcel.2010.12.006; Sakofsky CJ, 2017, CRIT REV BIOCHEM MOL, V52, P395, DOI 10.1080/10409238.2017.1314444; Schrank BR, 2018, NATURE, V559, P61, DOI 10.1038/s41586-018-0237-5; Scully R, 2019, NAT REV MOL CELL BIO, V20, P698, DOI 10.1038/s41580-019-0152-0; Shima N, 2004, MOL CELL BIOL, V24, P10381, DOI 10.1128/MCB.24.23.10381-10389.2004; Simsek D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002080; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Sternberg SH, 2014, NATURE, V507, P62, DOI 10.1038/nature13011; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Sudmant PH, 2015, NATURE, V526, P75, DOI 10.1038/nature15394; Sunder S, 2019, P NATL ACAD SCI USA, V116, P9481, DOI 10.1073/pnas.1818595116; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Uuskula-Reimand L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1043-8; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Waters CA, 2014, DNA REPAIR, V17, P39, DOI 10.1016/j.dnarep.2014.02.008; Weinstock David M, 2007, Nat Cell Biol, V9, P978; Whalen JM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107635; Wray J, 2013, BLOOD, V121, P4359, DOI 10.1182/blood-2012-10-460527; Wyatt DW, 2016, MOL CELL, V63, P662, DOI 10.1016/j.molcel.2016.06.020; Yousefzadeh MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004654; Yu W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19060-w; Zhang F, 2009, NAT GENET, V41, P849, DOI 10.1038/ng.399; Zhang Y, 2012, CELL, V148, P908, DOI 10.1016/j.cell.2012.02.002; Zhang Y, 2011, NAT STRUCT MOL BIOL, V18, P80, DOI 10.1038/nsmb.1940	79	9	9	3	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4263	4270		10.1038/s41388-021-01856-9	http://dx.doi.org/10.1038/s41388-021-01856-9		JUN 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103687	Green Accepted			2022-12-17	WOS:000659032900001
J	Walter, W; Haferlach, C; Nadarajah, N; Schmidts, I; Kuhn, C; Kern, W; Haferlach, T				Walter, Wencke; Haferlach, Claudia; Nadarajah, Niroshan; Schmidts, Ines; Kuhn, Constanze; Kern, Wolfgang; Haferlach, Torsten			How artificial intelligence might disrupt diagnostics in hematology in the near future	ONCOGENE			English	Review							FLOW-CYTOMETRY DATA; LYMPHOID-CELLS; CLASSIFICATION; BLOOD	Artificial intelligence (AI) is about to make itself indispensable in the health care sector. Examples of successful applications or promising approaches range from the application of pattern recognition software to pre-process and analyze digital medical images, to deep learning algorithms for subtype or disease classification, and digital twin technology and in silico clinical trials. Moreover, machine-learning techniques are used to identify patterns and anomalies in electronic health records and to perform ad-hoc evaluations of gathered data from wearable health tracking devices for deep longitudinal phenotyping. In the last years, substantial progress has been made in automated image classification, reaching even superhuman level in some instances. Despite the increasing awareness of the importance of the genetic context, the diagnosis in hematology is still mainly based on the evaluation of the phenotype. Either by the analysis of microscopic images of cells in cytomorphology or by the analysis of cell populations in bidimensional plots obtained by flow cytometry. Here, AI algorithms not only spot details that might escape the human eye, but might also identify entirely new ways of interpreting these images. With the introduction of high-throughput next-generation sequencing in molecular genetics, the amount of available information is increasing exponentially, priming the field for the application of machine learning approaches. The goal of all the approaches is to allow personalized and informed interventions, to enhance treatment success, to improve the timeliness and accuracy of diagnoses, and to minimize technically induced misclassifications. The potential of AI-based applications is virtually endless but where do we stand in hematology and how far can we go?	[Walter, Wencke; Haferlach, Claudia; Nadarajah, Niroshan; Schmidts, Ines; Kuhn, Constanze; Kern, Wolfgang; Haferlach, Torsten] MLL Munich Leukemia Lab, Munich, Germany	MLL Munich Leukemia Laboratory	Haferlach, T (corresponding author), MLL Munich Leukemia Lab, Munich, Germany.	torsten.haferlach@mll.com	Walter, Wencke/ABA-6205-2021	Walter, Wencke/0000-0002-5083-9838				Ai C, 2018, J GENET GENOMICS, V45, P489, DOI 10.1016/j.jgg.2018.08.002; Albaradei Somayah, 2020, Gene X, V5, P100035, DOI 10.1016/j.gene.2020.100035; Alferez S, 2016, INT J LAB HEMATOL, V38, P209, DOI 10.1111/ijlh.12473; Alferez S, 2014, INT J LAB HEMATOL, V36, P472, DOI 10.1111/ijlh.12175; Alferez S, 2015, AM J CLIN PATHOL, V143, P168, DOI 10.1309/AJCP78IFSTOGZZJN; Alomari YM, 2014, COMPUT MATH METHOD M, V2014, DOI 10.1155/2014/979302; Amann J, 2020, BMC MED INFORM DECIS, V20, DOI 10.1186/s12911-020-01332-6; Angeletti Cesar, 2018, J Pathol Inform, V9, P16, DOI 10.4103/jpi.jpi_76_17; Biehl M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059401; Bigorra L, 2019, BRIT J HAEMATOL, V184, P1035, DOI 10.1111/bjh.15230; Bigorra L, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22024; Bjornsson B, 2019, GENOME MED, V12, DOI 10.1186/s13073-019-0701-3; Boldu L, 2019, J CLIN PATHOL, V72, P755, DOI 10.1136/jclinpath-2019-205949; Castillo D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212127; Cutillo CM, 2020, NPJ DIGIT MED, V3, DOI 10.1038/s41746-020-0254-2; Delshadpour S, 2003, P ANN INT IEEE EMBS, V25, P2249, DOI 10.1109/IEMBS.2003.1280243; Dias R, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0689-8; Dimitriou N, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00264; Duetz C, 2020, CURR OPIN ONCOL, V32, P162, DOI 10.1097/CCO.0000000000000607; Dundar M, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-314; El Achi H, 2020, CANCERS, V12, DOI 10.3390/cancers12040797; Esteva A, 2017, NATURE, V542, P115, DOI 10.1038/nature21056; Fjelland R, 2020, HUM SOC SCI COMMUN, V7, DOI 10.1057/s41599-020-0494-4; Fu XY, 2020, ACTA CYTOL, V64, P588, DOI 10.1159/000509524; Gagula-Palalic S, 2014, 2014 IEEE-EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS (BHI), P626, DOI 10.1109/BHI.2014.6864442; Grisan E, 2007, P ANN INT IEEE EMBS, P5513, DOI 10.1109/IEMBS.2007.4353594; Haferlach C, 2020, BLOOD, V136, DOI 10.1182/blood-2020-137463; Hilton CB, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126967; Hoffman GE, 2019, NUCLEIC ACIDS RES, V47, P10597, DOI 10.1093/nar/gkz808; Holzinger A, 2019, WIRES DATA MIN KNOWL, V9, DOI 10.1002/widm.1312; Jaganathan K, 2019, CELL, V176, P535, DOI 10.1016/j.cell.2018.12.015; Jobin A, 2019, NAT MACH INTELL, V1, P389, DOI 10.1038/s42256-019-0088-2; Kimura K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49942-z; Ko BS, 2018, EBIOMEDICINE, V37, P91, DOI 10.1016/j.ebiom.2018.10.042; Lai CM, 2020, HUM MUTAT, V41, P1079, DOI 10.1002/humu.24011; Lakoumentas J, 2009, J BIOMED INFORM, V42, P251, DOI 10.1016/j.jbi.2008.11.003; Licandro R, 2018, P 7 INT C PATT REC A; Madhavan S, 2021, NAT CANCER, V2, P9, DOI 10.1038/s43018-020-00163-8; Mallick PK, 2020, PERS UBIQUIT COMPUT, DOI 10.1007/s00779-020-01467-3; Manninen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072932; Meggendorfer M, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126449; Menden K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba2619; Moshavash Z, 2018, J DIGIT IMAGING, V31, P702, DOI 10.1007/s10278-018-0074-y; Muller ML, 2020, BLOOD, V136, DOI 10.1182/blood-2020-140927; Nazha Aziz, 2019, JCO Precis Oncol, V3, DOI 10.1200/po.19.00119; Neoh SC, 2015, SCI REP-UK, V5, DOI 10.1038/srep14938; Nicora G, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01030; Oskouei B. C., 2010, Proceedings 2010 International Conference on Digital Image Computing: Techniques and Applications (DICTA 2010), P605, DOI 10.1109/DICTA.2010.107; Pansombut T, 2019, COMPUT INTEL NEUROSC, V2019, DOI 10.1155/2019/7519603; Parida L, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007332; Patel-Murray NL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57691-7; Patkar N, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0244-2; Pohlkamp C, 2020, BLOOD, V136, DOI 10.1182/blood-2020-140215; Poplin R, 2018, NAT BIOTECHNOL, V36, P983, DOI 10.1038/nbt.4235; Pouyan MB, 2016, BMC MED GENOMICS, V9, DOI 10.1186/s12920-016-0201-x; Qin YL, 2019, IEEE T MED IMAGING, V38, P2569, DOI 10.1109/TMI.2019.2905841; Qiu YC, 2016, PROC SPIE, V9709, DOI 10.1117/12.2217418; Quang D, 2015, BIOINFORMATICS, V31, P761, DOI 10.1093/bioinformatics/btu703; Radakovich N, 2020, BLOOD, V136, DOI 10.1182/blood-2020-139412; Roshtkhari MJ, 2008, INT CONF SIGN PROCES, P849, DOI 10.1109/ICOSP.2008.4697261; Saez-Rodriguez J, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199042; Sakellaropoulos T, 2019, CELL REP, V29, P3367, DOI 10.1016/j.celrep.2019.11.017; Samek W., 2017, ITU J ICT DISCOVERIE; Shafique S, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818802789; Shaikh AF, 2020, LEUKEMIA LYMPHOMA, V61, P3154, DOI 10.1080/10428194.2020.1798951; Sharma M, 2017, IEEE COMPUT SOC CONF, P786, DOI 10.1109/CVPRW.2017.109; Shouval R, 2021, BRIT J HAEMATOL, V192, P239, DOI 10.1111/bjh.16915; Sirinukunwattana K, 2020, BLOOD ADV, V4, P3284, DOI 10.1182/bloodadvances.2020002230; Swati, 2017, IEEE INT CONF COMP V, P72, DOI 10.1109/ICCVW.2017.17; Swerdlow SH., 2017, WHO CLASSIFICATION T; Topol EJ, 2019, NAT MED, V25, P44, DOI 10.1038/s41591-018-0300-7; Wagner S, 2019, BLOOD ADV, V3, P1330, DOI 10.1182/bloodadvances.2018030726; Wu JT, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.22779; Wu YY, 2020, JMIR MED INF, V8, DOI 10.2196/15963; Yurkovich JT, 2020, NAT REV CLIN ONCOL, V17, P183, DOI 10.1038/s41571-019-0273-6; Zare H, 2012, AM J CLIN PATHOL, V137, P75, DOI 10.1309/AJCPMMLQ67YOMGEW; Zhao M, 2020, CYTOM PART A, V97, P1073, DOI 10.1002/cyto.a.24159; Zou J, 2019, NAT GENET, V51, P12, DOI 10.1038/s41588-018-0295-5	78	9	9	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4271	4280		10.1038/s41388-021-01861-y	http://dx.doi.org/10.1038/s41388-021-01861-y		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34103684	hybrid, Green Published			2022-12-17	WOS:000659032900005
J	You, J; Li, JY; Ke, CL; Xiao, YR; Lu, CH; Huang, FK; Mi, YJ; Xia, RM; Li, QY				You, Jun; Li, Jiayi; Ke, Chunlin; Xiao, Yanru; Lu, Chuanhui; Huang, Fakun; Mi, Yanjun; Xia, Rongmu; Li, Qiyuan			Oncogenic long intervening noncoding RNA Linc00284 promotes c-Met expression by sponging miR-27a in colorectal cancer	ONCOGENE			English	Article							THERAPEUTIC TARGET; HGF/C-MET; REGULATORY NETWORK; SIGNALING PATHWAY; MICRORNA; CONSTRUCTION; BIOMARKERS; MIRNA	Emerging evidences suggest that long noncoding RNA (lncRNA) plays a vital role in tumorigenesis and cancer progression. Here, the aim of this study is to investigate the biological function of long intervening noncoding RNA Linc00284 in colorectal cancer (CRC). The expression levels of Linc00284, miR-27a and c-Met were evaluated by qPCR and/or Western blotting. Immunohistochemistry was used to detect the expression of Ki67 and Phh3 in tumor tissues. The interaction between Linc00284, miR-27a and c-Met was validated by luciferase reporter assay and RNA immunoprecipitation (RIP) assay. Cell function experiments, including CCK-8, wound-healing and transwell invasion assays, were conducted. The in vivo studies were performed with the subcutaneous tumor xenograft mouse models. Our findings reveal that Linc00284 is upregulated in CRC tissues and colorectal cancer cell lines HCT116 and SW480 in comparison with corresponding para-carcinoma tissues and human fetal colonic mucosa cells FHC. High expression of Linc00284 in tumor tissues is associated with tumor metastasis and predicts a poor clinical outcome in CRC patients. Serum Linc00284 is increased, while miR-27a is decreased in CRC patients compared to healthy controls. ROC curve analysis indicates that serum Linc00284 and miR-27a produce the area under the curve (AUC) value of at 0.8151 and 0.7316 in patients with colorectal cancer compared to healthy individuals, respectively. Additionally, results in vitro and in vivo experiments suggest that Linc00284 silencing significantly suppresses CRC cell proliferation and/or invasion. Mechanistically, Linc00284 promotes c-Met expression by acting as miR-27a sponge, leading to the activation of downstream signaling pathways, thereby causing malignant phenotypes of CRC cells. Taken together, Linc00284 exhibits oncogenic function and the disturbance of Linc00284/miR-27a/c-Met regulatory axis contributes to CRC progression, providing new insight into the pathogenesis of colorectal cancer. Importantly, the expression levels of serum Linc00284 and miR-27a may serve as clinical biomarkers for CRC diagnosis.	[You, Jun] Xiamen Univ, Canc Ctr, Affiliated Hosp 1, Dept Gastrointestinal Oncol Surg, Xiamen, Fujian, Peoples R China; [You, Jun] Fujian Med Univ, Sch Clin Med, Fuzhou, Fujian, Peoples R China; [Li, Jiayi] Fujian Med Univ, Sch Clin Med, Dept Med Oncol,Xiamen Univ, Xiamen Key Lab Antitumor Drug Transformat Res,Aff, Xiamen, Fujian, Peoples R China; [Ke, Chunlin] Fujian Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China; [Xiao, Yanru] Fujian Med Univ, Dept Med Oncol, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China; [Lu, Chuanhui] Fujian Med Univ, Teaching Hosp, Xiamen Canc Ctr, Dept Colorectal Canc Surg,Xiamen Univ,Affiliated, Xiamen, Fujian, Peoples R China; [Huang, Fakun] Fujian Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China; [Mi, Yanjun] Fujian Med Univ, Xiamen Key Lab Thorac Tumor Diag & Treatment, Inst Lung Canc, Dept Med Oncol,Sch Clin Med,Xiamen Univ,Affiliate, Xiamen, Fujian, Peoples R China; [Xia, Rongmu] Xiamen Univ, Sch Med, Xiamen, Fujian, Peoples R China; [Li, Qiyuan] Xiamen Univ, Natl Inst Data Sci Hlth & Med, Sch Med, Xiamen, Fujian, Peoples R China	Xiamen University; Fujian Medical University; Fujian Medical University; Xiamen University; Fujian Medical University; Fujian Medical University; Fujian Medical University; Xiamen University; Fujian Medical University; Fujian Medical University; Xiamen University; Xiamen University; Xiamen University	Ke, CL (corresponding author), Fujian Med Univ, Dept Radiotherapy, Affiliated Hosp 1, Fuzhou, Fujian, Peoples R China.; Mi, YJ (corresponding author), Fujian Med Univ, Xiamen Key Lab Thorac Tumor Diag & Treatment, Inst Lung Canc, Dept Med Oncol,Sch Clin Med,Xiamen Univ,Affiliate, Xiamen, Fujian, Peoples R China.; Xia, RM (corresponding author), Xiamen Univ, Sch Med, Xiamen, Fujian, Peoples R China.; Li, QY (corresponding author), Xiamen Univ, Natl Inst Data Sci Hlth & Med, Sch Med, Xiamen, Fujian, Peoples R China.	ke_chunlin@yeah.net; Miyj77@xmu.edu.cn; xiarongmu@126.com; liqiyuanxm@126.com	rongmu, xia/CAG-5933-2022	rongmu, xia/0000-0002-8678-1367; Li, Qiyuan/0000-0002-8934-8948	National Natural Science Foundation of China [81871877]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 81871877).	Acunzo Mario, 2015, Adv Biol Regul, V57, P1, DOI 10.1016/j.jbior.2014.09.013; Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chae DK, 2017, MOL CARCINOGEN, V56, P1992, DOI 10.1002/mc.22655; Chen SY, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0959-5; Chi Victor, 2007, J Vis Exp, P308, DOI 10.3791/308; Czyz M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123844; Drobatz Kenneth J, 2009, J Vet Cardiol, V11 Suppl 1, pS33, DOI 10.1016/j.jvc.2009.03.004; Gupta SC, 2017, INT J CANCER, V140, P1955, DOI 10.1002/ijc.30546; Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jae N, 2019, VASC PHARMACOL, V114, P13, DOI 10.1016/j.vph.2018.03.003; Li XW, 2019, J CANCER, V10, P2836, DOI 10.7150/jca.31361; Liang JT, 2017, ONCOTARGET, V8, P82991, DOI 10.18632/oncotarget.19635; Liu JW, 2019, DIGEST DIS SCI, V64, P1868, DOI 10.1007/s10620-019-05506-9; Lu SR, 2018, EXP THER MED, V16, P4879, DOI 10.3892/etm.2018.6775; Matsumoto K, 2017, CANCER SCI, V108, P296, DOI 10.1111/cas.13156; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mo Hong-Nan, 2017, Chronic Dis Transl Med, V3, P148, DOI 10.1016/j.cdtm.2017.06.002; Parizadeh SM, 2019, IUBMB LIFE, V71, P802, DOI 10.1002/iub.2063; Pothula SP, 2017, ONCOTARGET, V8, P76722, DOI 10.18632/oncotarget.20822; Puccini A, 2019, DRUG SAFETY, V42, P211, DOI 10.1007/s40264-018-0780-x; Ruan ZY, 2019, FASEB J, V33, P12047, DOI 10.1096/fj.201900101RR; Shen P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092003; Shin VY, 2014, WORLD J GASTROENTERO, V20, P10432, DOI 10.3748/wjg.v20.i30.10432; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song MY, 2015, GASTROENTEROLOGY, V148, P1244, DOI 10.1053/j.gastro.2014.12.035; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Vidovic D, 2020, CELL DEATH DIFFER, V27, P363, DOI 10.1038/s41418-019-0362-1; Vishnoi A, 2017, METHODS MOL BIOL, V1509, P1, DOI 10.1007/978-1-4939-6524-3_1; Wan WB, 2019, EUR REV MED PHARMACO, V23, P6453, DOI 10.26355/eurrev_201908_18528; Wang SS, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/9696285; Wang Z, 2014, DIAGN PATHOL, V9; Xing C, 2018, CLIN LAB, V64, P1661, DOI 10.7754/Clin.Lab.2018.180419; Xu J, 2019, MOL MED REP, V20, P5021, DOI 10.3892/mmr.2019.10736; You WK, 2008, BMB REP, V41, P833, DOI 10.5483/BMBRep.2008.41.12.833; Zhang HL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113295; Zhang JC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00893; Zhao YJ, 2018, ONCOL REP, V39, P1197, DOI 10.3892/or.2018.6207; Zhen Q, 2015, CYTOGENET GENOME RES, V146, P1, DOI 10.1159/000434741; Zhou L, 2016, ONCOTARGET, V7, P51943, DOI 10.18632/oncotarget.10460	42	9	9	2	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4151	4166		10.1038/s41388-021-01839-w	http://dx.doi.org/10.1038/s41388-021-01839-w		MAY 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34050266	Green Published, hybrid			2022-12-17	WOS:000655826000001
J	Kunou, S; Shimada, K; Takai, M; Sakamoto, A; Aoki, T; Hikita, T; Kagaya, Y; Iwamoto, E; Sanada, M; Shimada, S; Hayakawa, F; Oneyama, C; Kiyoi, H				Kunou, Shunsuke; Shimada, Kazuyuki; Takai, Mika; Sakamoto, Akihiko; Aoki, Tomohiro; Hikita, Tomoya; Kagaya, Yusuke; Iwamoto, Eisuke; Sanada, Masashi; Shimada, Satoko; Hayakawa, Fumihiko; Oneyama, Chitose; Kiyoi, Hitoshi			Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma	ONCOGENE			English	Article							PROMOTE TUMOR-GROWTH; B-CELL LYMPHOMA; HODGKIN-LYMPHOMA; PHASE-II; APOPTOSIS; RITUXIMAB; DEXAMETHASONE; MICROVESICLES; GEMCITABINE; SURVIVAL	The tumor microenvironment is deeply involved in the process of tumor growth and development. In this study, we focused on cancer-associated fibroblasts (CAFs) and their derived exosomes on the lymphoma microenvironment to uncover their clinical significance. CAFs were established from primary lymphoma samples, and exosomes secreted from CAFs were obtained by standard procedures. We then investigated the roles of CAFs and their derived exosomes in the survival and drug resistance of lymphoma cells. CAFs supported the survival of lymphoma cells through increased glycolysis, and the extent differed among CAFs. Exosomes were identified as a major component of the extracellular vesicles from CAFs, and they also supported the survival of lymphoma cells. The suppression of RAB27B, which is involved in the secretion of exosomes, using a specific siRNA resulted in reduced exosome secretion and decreased survival of lymphoma cells. Moreover, anti-pyrimidine drug resistance was induced in the presence of exosomes through the suppression of the pyrimidine transporter, equilibrative nucleoside transporter 2 (ENT2), and the suppression of ENT2 was significant in in vivo experiments and clinical samples. RNA sequencing analysis of miRNAs in exosomes identified miR-4717-5p as one of the most abundant miRNAs in the exosome, which suppressed the expression of ENT2 and induced anti-pyrimidine drug resistance in vitro. Our results suggest that exosomes including miR-4717-5p secreted from CAFs play a pivotal role in the lymphoma microenvironment, indicating that they are a promising therapeutic target.	[Kunou, Shunsuke; Shimada, Kazuyuki; Takai, Mika; Sakamoto, Akihiko; Aoki, Tomohiro; Kagaya, Yusuke; Hayakawa, Fumihiko; Kiyoi, Hitoshi] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan; [Takai, Mika] Otsuka Pharmaceut Co Ltd, Fujii Mem Res Inst, Otsu, Shiga, Japan; [Hikita, Tomoya; Oneyama, Chitose] Aichi Canc Ctr, Div Canc Cell Regulat, Res Inst, Nagoya, Aichi, Japan; [Hikita, Tomoya; Oneyama, Chitose] Nagoya Univ, Dept Target & Drug Discovery, Grad Sch Med, Nagoya, Aichi, Japan; [Iwamoto, Eisuke; Sanada, Masashi] Natl Hosp Org Nagoya Med Ctr, Dept Adv Diag, Clin Res Ctr, Nagoya, Aichi, Japan; [Shimada, Satoko] Nagoya Univ Hosp, Dept Pathol & Clin Labs, Nagoya, Aichi, Japan	Nagoya University; Otsuka Pharmaceutical; Aichi Cancer Center; Nagoya University; Nagoya Medical Center; Nagoya University	Shimada, K (corresponding author), Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan.	kshimada@med.nagoya-u.ac.jp	Sakamoto, Akihiko/GXH-2664-2022; Shimada, Kazuyuki/I-7120-2014	Sakamoto, Akihiko/0000-0003-0788-3646; Shimada, Kazuyuki/0000-0002-1075-9219	Program to Disseminate Tenure Tracking System, MEXT, Japan; JSPS [17K09922, 20K08751]; Practical Research for Innovative Cancer Control, MHLW/AMED, Japan; Hori Sciences and Arts Foundation; Takeda Science Foundation; JST PRESTO [JP1005457]	Program to Disseminate Tenure Tracking System, MEXT, Japan; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Practical Research for Innovative Cancer Control, MHLW/AMED, Japan; Hori Sciences and Arts Foundation; Takeda Science Foundation(Takeda Science Foundation (TSF)); JST PRESTO(Japan Science & Technology Agency (JST))	This work was supported by the Program to Disseminate Tenure Tracking System, MEXT, Japan, by a JSPS Grant-in-Aid for Scientific Research (C) 17K09922 and 20K08751; by the Practical Research for Innovative Cancer Control, MHLW/AMED, Japan; by The Hori Sciences and Arts Foundation; by The Takeda Science Foundation grant to K.S.; and by JST PRESTO JP1005457 to C.O. We thank Mr. Kuniyoshi Kitou, Ms. Kazuko Matsuba, Ms. Yuko Katayama, and Mr. Yoshiaki Inagaki (Nagoya University) for IHC work; and Ms. Yoko Matsuyama, Ms. Chika Wakamatsu, Ms. Manami Kira, Ms. Yukie Konishi, Ms. Yuko Kojima, Ms. Konomi Ooyama, and Ms. Saori Kanamori (Nagoya University) for assistance with laboratory work.	An J, 2013, J CANCER RES CLIN, V139, P379, DOI 10.1007/s00432-012-1328-6; Aoki T, 2017, ONCOTARGET, V8, P13085, DOI 10.18632/oncotarget.14393; Arimany-Nardi C, 2015, PHARMACOGENOMICS J, V15, P363, DOI 10.1038/tpj.2014.77; Armand P, 2016, J CLIN ONCOL, V34, P3733, DOI 10.1200/JCO.2016.67.3467; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Coiffier B, 2010, BLOOD, V116, P2040, DOI 10.1182/blood-2010-03-276246; Crump M, 2004, CANCER-AM CANCER SOC, V101, P1835, DOI 10.1002/cncr.20587; Crump M, 2017, BLOOD, V130, P1800, DOI 10.1182/blood-2017-03-769620; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Gopal AK, 2010, LEUKEMIA LYMPHOMA, V51, P1523, DOI 10.3109/10428194.2010.491137; Hagos Y, 2015, AM J PHYSIOL-RENAL, V308, pF330, DOI 10.1152/ajprenal.00467.2014; Horwitz S, 2019, LANCET, V393, P229, DOI 10.1016/S0140-6736(18)32984-2; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353; Sakamoto A, 2019, CANCER SCI, V110, P269, DOI 10.1111/cas.13873; Shimada K, 2016, LEUKEMIA, V30, P1568, DOI 10.1038/leu.2016.67; Shimada K, 2012, EXP HEMATOL, V40, P724, DOI 10.1016/j.exphem.2012.05.007; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Smith A, 2015, BRIT J CANCER, V112, P1575, DOI 10.1038/bjc.2015.94; Sugimoto K, 2015, SCI REP-UK, V5, DOI 10.1038/srep13054; Svensson KJ, 2011, P NATL ACAD SCI USA, V108, P13147, DOI 10.1073/pnas.1104261108; Takagi Y, 2016, CANCER SCI, V107, P1270, DOI 10.1111/cas.13001; Taskinen M, 2007, CLIN CANCER RES, V13, P5784, DOI 10.1158/1078-0432.CCR-07-0778; Taylor DD, 2003, CLIN CANCER RES, V9, P5113	32	9	9	1	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3989	4003		10.1038/s41388-021-01829-y	http://dx.doi.org/10.1038/s41388-021-01829-y		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33994542	hybrid, Green Published			2022-12-17	WOS:000651026600001
J	Lin, YL; Zhou, XH; Yang, KF; Chen, YT; Wang, LZ; Luo, WX; Li, YJ; Liao, JR; Zhou, YT; Lei, YM; Zhang, YT; Wu, DH; Cai, LM				Lin, Yanling; Zhou, Xiaohan; Yang, Kaifan; Chen, Yuting; Wang, Lingzhi; Luo, Wenxiao; Li, Yujiang; Liao, Jinrong; Zhou, Yingtong; Lei, Yiming; Zhang, Yanting; Wu, Dehua; Cai, Longmei			Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma	ONCOGENE			English	Article								Radiotherapy is essential to the treatment of nasopharyngeal carcinoma (NPC) and acquired or innate resistance to this therapeutic modality is a major clinical problem. However, the underlying molecular mechanisms in the radiation resistance in NPC are not fully understood. Here, we reanalyzed the microarray data from public databases and identified the protein tyrosine phosphatase receptor type D (PTPRD) as a candidate gene. We found that PTPRD was downregulated in clinical NPC tissues and NPC cell lines with its promoter hypermethylated. Functional assays revealed that PTPRD overexpression sensitized NPC to radiation in vitro and in vivo. Importantly, miR-454-3p directly targets PTPRD to inhibit its expression and biological effect. Interestingly, mechanistic analyses indicate that PTPRD directly dephosphorylates STAT3 to enhance Autophagy-Related 5 (ATG5) transcription, resulting in triggering radiation-induced autophagy. The immunohistochemical staining of 107 NPC revealed that low PTPRD and high p-STAT3 levels predicted poor clinical outcome. Overall, we showed that PTPRD promotes radiosensitivity by triggering radiation-induced autophagy via the dephosphorylation of STAT3, thus providing a potentially useful predictive biomarker for NPC radiosensitivity and drug target for NPC radiosensitization.	[Lin, Yanling; Zhou, Xiaohan; Chen, Yuting; Luo, Wenxiao; Zhou, Yingtong; Wu, Dehua; Cai, Longmei] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China; [Yang, Kaifan] Southern Med Univ, Nanfang Hosp, Dept Orthopaed, Div Spine Surg, Guangzhou, Peoples R China; [Wang, Lingzhi; Lei, Yiming; Zhang, Yanting] Southern Med Univ, Nanfang Hosp, Clin Med Coll 1, Guangzhou, Peoples R China; [Li, Yujiang] Southern Med Univ, Huiqiao Med Ctr, Dept Thorac & Cardiovasc Surg, Guangzhou, Peoples R China; [Li, Yujiang] Southern Med Univ, Dongguan Peoples Hosp, Affiliated Dongguan Peoples Hosp, Dept Thorac & Cardiovasc Surg, Dongguan, Peoples R China; [Liao, Jinrong] Southern Med Univ, Zhujiang Hosp, Clin Med Coll 2, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Wu, DH; Cai, LM (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou, Peoples R China.	wudehua.gd@gmail.com; cailongmeibestlove@163.com		Chen, Yuting/0000-0002-0262-9721; Wu, De-Hua/0000-0003-0560-0016; Yang, Kaifan/0000-0003-4166-0198	National Natural Science Foundation of China [81773111, 81702696]; Natural Science Foundation of Guangdong Province [2017A030310040]; Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University [2017J004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University	We are grateful to Prof. Musheng Zeng (Sun Yat-sen University Cancer Center, China) and Prof. George S.W. Tsao (University of Hong Kong, China) for their support. This work was supported by the National Natural Science Foundation of China (grant Nos. 81773111 and 81702696), the Natural Science Foundation of Guangdong Province (grant No. 2017A030310040), and the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (grant No. 2017J004).	Blanchard P, 2015, LANCET ONCOL, V16, P645, DOI 10.1016/S1470-2045(15)70126-9; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai LM, 2015, ONCOGENE, V34, P2156, DOI 10.1038/onc.2014.341; Cai LM, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00939; Cai LM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8353; Chai EZP, 2016, PHARMACOL THERAPEUT, V162, P86, DOI 10.1016/j.pharmthera.2015.10.004; Chan ATC, 2012, ANN ONCOL, V23, P83, DOI 10.1093/annonc/mds266; Chang LH, 2019, AM J CANCER RES, V9, P1922; Chen QP, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00232; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Cui DR, 2020, CELL REP, V30, P497, DOI 10.1016/j.celrep.2019.12.032; Digomann D, 2019, AUTOPHAGY, V15, P1850, DOI 10.1080/15548627.2019.1639302; Funato K, 2011, EXP THER MED, V2, P457, DOI 10.3892/etm.2011.231; Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273; Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270; Jiang W, 2015, MOL CANCER THER, V14, P2864, DOI 10.1158/1535-7163.MCT-15-0260; Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058; Kim M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092708; Kim W, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091105; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li H, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0618-0; Li L, 2020, CURR MOL PHARMACOL, V13, P31, DOI 10.2174/1874467212666190809154518; Li Y, 2019, BIOSCIENCE REP, V39, DOI [10.1038/s41388-021-01768-8, DOI 10.1038/S41388-021-01768-8]; Li YQ, 2018, CLIN CANCER RES, V24, P6495, DOI 10.1158/1078-0432.CCR-18-0532; Liu DD, 2018, J AGR FOOD CHEM, V66, P11757, DOI 10.1021/acs.jafc.8b04704; Liu YL, 2020, J CELL MOL MED, V24, P9135, DOI 10.1111/jcmm.15550; Luftig M, 2013, J CLIN INVEST, V123, P4999, DOI 10.1172/JCI73416; Meng J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2327-1; Nunez FJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1427; Peng H, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0997-7; Peyser ND, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135750; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Thilakasiri PS, 2021, SEMIN CANCER BIOL, V68, P31, DOI 10.1016/j.semcancer.2019.09.022; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Vehlow A, 2019, AUTOPHAGY, V15, P1487, DOI 10.1080/15548627.2019.1618540; Wang XH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01120; Wu AH, 2019, INT J CLIN EXP PATHO, V12, P4222; Yang SM, 2019, BIOCHEM CELL BIOL, V97, P364, DOI 10.1139/bcb-2017-0343; Yu HY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0660-4; Yu XT, 2017, ONCOTARGET, V8, P98798, DOI 10.18632/oncotarget.22000; Zhang J, 2019, NEOPLASIA, V21, P311, DOI 10.1016/j.neo.2019.01.006; Zhang J, 2019, CANCER RES, V79, P747, DOI 10.1158/0008-5472.CAN-18-1754; Zhu QW, 2021, AUTOPHAGY, V17, P1667, DOI 10.1080/15548627.2020.1781368	45	9	9	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2021	40	17					3101	3117		10.1038/s41388-021-01768-8	http://dx.doi.org/10.1038/s41388-021-01768-8		APR 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RV2NJ	33824475	hybrid, Green Published			2022-12-17	WOS:000637478800005
J	Bernardino-Sgherri, J; Siberchicot, C; Auvre, F; Busso, D; Brocas, C; El Masri, G; Lioutsko, A; Ferri, F; Radicella, JP; Romeo, PH; Bravard, A				Bernardino-Sgherri, Jacqueline; Siberchicot, Capucine; Auvre, Frederic; Busso, Didier; Brocas, Clementine; El Masri, Ghazi; Lioutsko, Anna; Ferri, Federica; Radicella, J. Pablo; Romeo, Paul-Henri; Bravard, Anne			Tumor resistance to radiotherapy is triggered by an ATM/TAK1-dependent-increased expression of the cellular prion protein	ONCOGENE			English	Article							BREAST-CANCER CELLS; GENE-EXPRESSION; STEM-CELLS; TAK1; TRANSCRIPTION; INHIBITION; ACTIVATION; SURVIVAL; ATM	In solid cancers, high expression of the cellular prion protein (PrPC) is associated with stemness, invasiveness, and resistance to chemotherapy, but the role of PrPC in tumor response to radiotherapy is unknown. Here, we show that, in neuroblastoma, breast, and colorectal cancer cell lines, PrPC expression is increased after ionizing radiation (IR) and that PrPC deficiency increases radiation sensitivity and decreases radiation-induced radioresistance in tumor cells. In neuroblastoma cells, IR activates ATM that triggers TAK1-dependent phosphorylation of JNK and subsequent activation of the AP-1 transcription factor that ultimately increases PRNP promoter transcriptional activity through an AP-1 binding site in the PRNP promoter. Importantly, we show that this ATM-TAK1-PrPC pathway mediated radioresistance is activated in all tumor cell lines studied and that pharmacological inhibition of TAK1 activity recapitulates the effects of PrPC deficiency. Altogether, these results unveil how tumor cells activate PRNP to acquire resistance to radiotherapy and might have implications for therapeutic targeting of solid tumors radioresistance.	[Bernardino-Sgherri, Jacqueline; Ferri, Federica; Romeo, Paul-Henri; Bravard, Anne] Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRTS,UMRE008,Inserm,U1274,CEA, Fontenay Aux Roses, France; [Bernardino-Sgherri, Jacqueline; Siberchicot, Capucine; Auvre, Frederic; El Masri, Ghazi; Lioutsko, Anna; Radicella, J. Pablo; Bravard, Anne] Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRIG,UMRE008,CEA, Fontenay Aux Roses, France; [Busso, Didier; Brocas, Clementine] Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, CIGEX,UMRE008,Inserm,U1274,CEA, Fontenay Aux Roses, France; [Auvre, Frederic] CEA, LGRK, DRF, IBFJ,iRCM,SCSR, Evry, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Bernardino-Sgherri, J; Bravard, A (corresponding author), Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRTS,UMRE008,Inserm,U1274,CEA, Fontenay Aux Roses, France.; Bernardino-Sgherri, J; Bravard, A (corresponding author), Univ Paris Saclay, Univ Paris, Genet Stabil Stem Cells & Radiat, LRIG,UMRE008,CEA, Fontenay Aux Roses, France.	Jacqueline.bernardino@cea.fr; anne.bravard@cea.fr	Radicella, J. Pablo/AAU-3178-2020	Radicella, J. Pablo/0000-0002-8807-7226; BRAVARD, Anne/0000-0002-0314-9092; Bernardino-Sgherri, Jacqueline/0000-0003-3980-4041	DIM-Stem-Pole; INSERM; Foundation ARC; CEA; French National Electricity Company (EDF); Transverse Division No 4 [4]; Radiobiology Program (PRIONRAD) of the French Alternative Energies and Atomic Energy Commission (CEA)	DIM-Stem-Pole; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Foundation ARC; CEA(French Atomic Energy Commission); French National Electricity Company (EDF); Transverse Division No 4; Radiobiology Program (PRIONRAD) of the French Alternative Energies and Atomic Energy Commission (CEA)	The authors thank Guillaume Pitton for lentiviruses productions; Nathalie Dechamps for flow cytometric cell sorting, at the IRCM Flow Cytometry Shared Resource (established by equipment grants from DIM-Stem-Pole, INSERM, Foundation ARC, and CEA); Marilene Lopes (Lab of Neurobiology and Stem Cells, Sao-Paulo, Brazil) for kindly providing the plasmid used for generating SH-SY5Y CRISPR KO cells; Sophie Mouillet-Richard, Francois Leteurtre and Jerome Lebeau for providing colorectal, and breast cancer cell lines.This work was supported by the French National Electricity Company (EDF), the Transverse Division No 4 (Segment no 4 Radiobiology headed by Christophe Carles) and the Radiobiology Program (PRIONRAD) of the French Alternative Energies and Atomic Energy Commission (CEA).	Atkinson CJ, 2019, MOL ONCOL, V13, P725, DOI 10.1002/1878-0261.12411; Bellingham SA, 2009, J BIOL CHEM, V284, P1291, DOI 10.1074/jbc.M804755200; Berger ND, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0283; Bravard A, 2015, NUCLEIC ACIDS RES, V43, P904, DOI 10.1093/nar/gku1342; Buch K, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-1; Cheng YY, 2014, MOL CARCINOGEN, V53, P686, DOI 10.1002/mc.22021; Dery MA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3398; Du L, 2013, CANCER RES, V73, P2682, DOI 10.1158/0008-5472.CAN-12-3759; Fan YH, 2013, APOPTOSIS, V18, P1224, DOI 10.1007/s10495-013-0864-0; Gil M, 2016, BIOCHEM BIOPH RES CO, V470, P213, DOI 10.1016/j.bbrc.2016.01.038; Giorgia M, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20222; Guan S, 2017, ONCOTARGET, V8, P33666, DOI 10.18632/oncotarget.16895; Han MW, 2014, ANTICANCER RES, V34, P1449; Huang YWA, 2017, CELL, V168, P427, DOI 10.1016/j.cell.2016.12.044; Iglesia RP, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0518-1; Kefayat A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55605-w; Le Corre D, 2019, EBIOMEDICINE, V46, P94, DOI 10.1016/j.ebiom.2019.07.036; Lee JH, 2018, BIOMOL THER, V26, P313, DOI 10.4062/biomolther.2017.033; Liu XJ, 2017, CELL RES, V27, P764, DOI 10.1038/cr.2017.41; Mahal SP, 2001, GENE, V268, P105, DOI 10.1016/S0378-1119(01)00424-3; Martin-Lanneree S, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00055; Melisi D, 2011, JNCI-J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Meslin F, 2007, CANCER RES, V67, P10910, DOI 10.1158/0008-5472.CAN-07-0512; Piro G, 2015, BRIT J CANCER, V113, P878, DOI 10.1038/bjc.2015.283; Qin KF, 2009, J BIOL CHEM, V284, P4582, DOI 10.1074/jbc.M808410200; Ryskalin L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205107; Salvesen O, 2019, NEUROCHEM INT, V130, DOI 10.1016/j.neuint.2018.11.010; Santoro R, 2017, DRUG RESIST UPDATE, V33-35, P36, DOI 10.1016/j.drup.2017.10.004; Schulz A, 2019, CANCERS, V11, DOI 10.3390/cancers11060862; Siberchicot C, 2020, HAEMATOLOGICA, V105, P1216, DOI 10.3324/haematol.2018.205716; Span PN, 2019, CANCERS, V11, DOI 10.3390/cancers11101555; Wang ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep32737; Watt NT, 2007, FREE RADICAL BIO MED, V43, P959, DOI 10.1016/j.freeradbiomed.2007.06.004; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; Wiegmans AP, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124092; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Zhou SN, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102961; Zhuang DX, 2012, INT J CANCER, V130, P309, DOI 10.1002/ijc.25985	39	9	9	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2021	40	19					3460	3469		10.1038/s41388-021-01746-0	http://dx.doi.org/10.1038/s41388-021-01746-0		MAR 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SB1JB	33767435				2022-12-17	WOS:000632820300006
J	Moreno, T; Monterde, B; Gonzalez-Silva, L; Betancor-Fernandez, I; Revilla, C; Agraz-Doblas, A; Freire, J; Isidro, P; Quevedo, L; Blanco, R; Montes-Moreno, S; Cereceda, L; Astudillo, A; Casar, B; Crespo, P; Torres, CM; Scaffidi, P; Gomez-Roman, J; Salido, E; Varela, I				Moreno, Thaidy; Monterde, Beatriz; Gonzalez-Silva, Laura; Betancor-Fernandez, Isabel; Revilla, Carlos; Agraz-Doblas, Antonio; Freire, Javier; Isidro, Pablo; Quevedo, Laura; Blanco, Rosa; Montes-Moreno, Santiago; Cereceda, Laura; Astudillo, Aurora; Casar, Berta; Crespo, Piero; Morales Torres, Cristina; Scaffidi, Paola; Gomez-Roman, Javier; Salido, Eduardo; Varela, Ignacio			ARID2 deficiency promotes tumor progression and is associated with higher sensitivity to chemotherapy in lung cancer	ONCOGENE			English	Article								The survival rate in lung cancer remains stubbornly low and there is an urgent need for the identification of new therapeutic targets. In the last decade, several members of the SWI/SNF chromatin remodeling complexes have been described altered in different tumor types. Nevertheless, the precise mechanisms of their impact on cancer progression, as well as the application of this knowledge to cancer patient management are largely unknown. In this study, we performed targeted sequencing of a cohort of lung cancer patients on genes involved in chromatin structure. In addition, we studied at the protein level the expression of these genes in cancer samples and performed functional experiments to identify the molecular mechanisms linking alterations of chromatin remodeling genes and tumor development. Remarkably, we found that 20% of lung cancer patients show ARID2 protein loss, partially explained by the presence of ARID2 mutations. In addition, we showed that ARID2 deficiency provokes profound chromatin structural changes altering cell transcriptional programs, which bolsters the proliferative and metastatic potential of the cells both in vitro and in vivo. Moreover, we demonstrated that ARID2 deficiency impairs DNA repair, enhancing the sensitivity of the cells to DNA-damaging agents. Our findings support that ARID2 is a bona fide tumor suppressor gene in lung cancer that may be exploited therapeutically.	[Moreno, Thaidy; Monterde, Beatriz; Gonzalez-Silva, Laura; Revilla, Carlos; Agraz-Doblas, Antonio; Quevedo, Laura; Blanco, Rosa; Casar, Berta; Crespo, Piero; Varela, Ignacio] Univ Cantabria, Inst Biomed & Biotecnol Cantabria, CSIC, Santander, Spain; [Betancor-Fernandez, Isabel; Salido, Eduardo] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Dept Patol, Tenerife, Spain; [Freire, Javier; Montes-Moreno, Santiago; Cereceda, Laura; Gomez-Roman, Javier] HUMV IDIVAL, Serv Anat Patol & Biobanco Valdecilla, Santander, Spain; [Isidro, Pablo; Astudillo, Aurora] Hosp Univ Cent Asturias, Biobanco Principado Asturias BBPA, Oviedo, Spain; [Casar, Berta; Crespo, Piero] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain; [Morales Torres, Cristina; Scaffidi, Paola] Francis Crick Inst, Canc Epigenet Lab, London, England	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital Universitario Marques de Valdecilla (HUMV); Central University Hospital Asturias; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Francis Crick Institute	Varela, I (corresponding author), Univ Cantabria, Inst Biomed & Biotecnol Cantabria, CSIC, Santander, Spain.	ignacio.varela@unican.es	Astudillo, Aurora/AAA-5487-2022; Montes-Moreno, Santiago/E-7008-2011; José Javier, Gómez-Román/AAC-8156-2021; Scaffidi, Paola/GRS-9019-2022; Crespo, Piero/M-3273-2014; Varela, Ignacio/G-1699-2016	Astudillo, Aurora/0000-0001-8947-8809; Montes-Moreno, Santiago/0000-0002-3565-8262; José Javier, Gómez-Román/0000-0002-2849-9435; Scaffidi, Paola/0000-0002-3642-4193; Gonzalez-Silva, Laura/0000-0001-8625-1473; Quevedo, Laura/0000-0001-8902-5818; Moreno Rodriguez, Thaidy/0000-0003-3588-3889; Crespo, Piero/0000-0003-2825-7783; Varela, Ignacio/0000-0002-0969-506X; CERECEDA, LAURA/0000-0002-0106-1898	Spanish Ministerio de Economia y Competitividad (MINECO) [SAF2012-31627, SAF2016-76758-R]; Fundacion Ramon Areces grant; European Research Council [ERC2014-StG637904]; Ayudas para la formacion de profesorado universitario (FPU, Ministerio de Educacion y Formacion Profesional, Spain); MINECO/FEDER, UE [SAF-2015-63638R]; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC); Asociacion Espanola Contra el Cancer (AECC) [GCB141423113]; Retos Jovenes Investigadores grant (AEI/FEDER, UE) [SAF-2015-73364-JIN]; Fundacion Francisco Cobos; Francis Crick Institute; Cancer Research UK [FC001152]; UK Medical Research Council [FC001152]; Servicio de Salud del Principado de Asturias; Fundacion Bancaria Cajastur; Wellcome Trust [FC001152]; Instituto de Salud Carlos III; Programa Ramon y Cajal (MINECO, Spain); Ayudas para la contratacion de investigadores predoctorales (MINECO, Spain)	Spanish Ministerio de Economia y Competitividad (MINECO); Fundacion Ramon Areces grant; European Research Council(European Research Council (ERC)European Commission); Ayudas para la formacion de profesorado universitario (FPU, Ministerio de Educacion y Formacion Profesional, Spain)(German Research Foundation (DFG)); MINECO/FEDER, UE; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC); Asociacion Espanola Contra el Cancer (AECC); Retos Jovenes Investigadores grant (AEI/FEDER, UE); Fundacion Francisco Cobos; Francis Crick Institute; Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Servicio de Salud del Principado de Asturias; Fundacion Bancaria Cajastur; Wellcome Trust(Wellcome TrustEuropean Commission); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Programa Ramon y Cajal (MINECO, Spain); Ayudas para la contratacion de investigadores predoctorales (MINECO, Spain)	IV is supported by SAF2012-31627 and SAF2016-76758-R grants from the Spanish Ministerio de Economia y Competitividad (MINECO), by a Fundacion Ramon Areces grant and by ERC2014-StG637904 grant from the European Research Council. IV has been awardee of the Programa Ramon y Cajal (MINECO, Spain). TM has been awardee of the Ayudas para la contratacion de investigadores predoctorales (MINECO, Spain). BM is awardee of the Ayudas para la formacion de profesorado universitario (FPU, Ministerio de Educacion y Formacion Profesional, Spain). PC laboratory is supported by grant SAF-2015-63638R (MINECO/FEDER, UE); by Centro de Investigacion Biomedica en Red de Cancer (CIBERONC) and by Asociacion Espanola Contra el Cancer (AECC), grant GCB141423113. BC has been supported by a Retos Jovenes Investigadores grant SAF-2015-73364-JIN (AEI/FEDER, UE) and a grant from Fundacion Francisco Cobos. PS is supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001152) and the UK Medical Research Council (FC001152). HUCA/IUOPA is jointly financed by Servicio de Salud del Principado de Asturias, Instituto de Salud Carlos III, and Fundacion Bancaria Cajastur. This research was funded in part by the Wellcome Trust [FC001152].	Alver BH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14648; Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Fishilevich S, 2017, DATABASE-OXFORD, DOI 10.1093/database/bax028; Flowers S, 2010, CANCER RES, V70, P8282, DOI 10.1158/0008-5472.CAN-10-2205; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Gelsomino F, 2014, CANCERS, V6, P2100, DOI 10.3390/cancers6042100; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Kayser G, 2015, BRIT J CANCER, V112, P866, DOI 10.1038/bjc.2015.2; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Lauand C, 2015, BRAZ J MED BIOL RES, V48, P382, DOI 10.1590/1414-431X20144262; Lee HS, 2010, EMBO J, V29, P1434, DOI 10.1038/emboj.2010.27; Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lovly CM, 2011, NAT REV CLIN ONCOL, V8, P68, DOI 10.1038/nrclinonc.2010.224; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Martinez N, 2014, LEUKEMIA, V28, P1334, DOI 10.1038/leu.2013.365; Masliah-Planchon J, 2015, ANNU REV PATHOL-MECH, V10, P145, DOI 10.1146/annurev-pathol-012414-040445; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mularoni L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0994-0; Nakayama RT, 2017, NAT GENET, V49, P1613, DOI 10.1038/ng.3958; Niimi A, 2012, NUCLEIC ACIDS RES, V40, P7393, DOI 10.1093/nar/gks453; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Ramirez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257; Ray A, 2009, MOL CELL BIOL, V29, P6206, DOI 10.1128/MCB.00503-09; Reisman DN, 2003, CANCER RES, V63, P560; Robinson JT, 2017, CANCER RES, V77, pE31, DOI 10.1158/0008-5472.CAN-17-0337; Romero OA, 2014, CANCER DISCOV, V4, P292, DOI 10.1158/2159-8290.CD-13-0799; Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749; Sheffield NC, 2013, GENOME RES, V23, P777, DOI 10.1101/gr.152140.112; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taylor MD, 2018, CLIN EXP METASTAS, V35, P15, DOI 10.1007/s10585-017-9869-3; Tordella L, 2016, GENE DEV, V30, P2187, DOI 10.1101/gad.286112.116; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394; Yu GC, 2015, BIOINFORMATICS, V31, P2382, DOI 10.1093/bioinformatics/btv145; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	44	9	9	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2923	2935		10.1038/s41388-021-01748-y	http://dx.doi.org/10.1038/s41388-021-01748-y		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742126	Green Accepted			2022-12-17	WOS:000630655600001
J	Ni, MD; Li, JJ; Zhao, HY; Xu, F; Cheng, JY; Yu, M; Ke, GH; Wu, XH				Ni, Mengdong; Li, Jiajia; Zhao, Haiyun; Xu, Fei; Cheng, Jingyi; Yu, Min; Ke, Guihao; Wu, Xiaohua			BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair	ONCOGENE			English	Article							PHASE-II; BINDING PROTEIN; STEM-CELLS; BROMODOMAIN; CARCINOMA; RADIORESISTANCE; EPIGENETICS; COMBINATION; VORINOSTAT; CHROMATIN	Cisplatin-based chemoradiotherapy is the recommended treatment for local advanced cervical cancer, but radioresistance remains one of the most important and unresolved clinical problems. Investigations have revealed aberrant epigenetic modifications as one of the chief culprits for the development of radioresistance. Here, we attempt to identify a radiosensitizer from an epigenetic drug synergy screen and explore the underlying mechanism. We integrated epigenetic inhibitors and radiotherapy in cervical cancer cell lines to identify potential radiosensitizers. We further verified the sensitization effect of the drug and the function of its target gene both in vitro and in vivo. Finally, we validated the clinical significance of its target gene in clinical cervical cancer specimens. We identified JQ1, a BRD4 inhibitor, as a potent radiosensitizer. Functional assays demonstrated that repressing BRD4 activity led to significant radiosensitization and potentiation of DNA damage in cervical cancer cell lines. By using RNA-seq to determine JQ1-mediated changes in transcription, we identified RAD51AP1 as a major BRD4 target gene involved in radiosensitivity. A dual-luciferase reporter assay and ChIP-qPCR showed that BRD4 binds to the promoter region of RAD51AP1 and promotes its transcription, whereas this activity was attenuated by BRD4 inhibition. The in vivo experiments also suggested a synergy between BRD4 inhibition and radiotherapy. High BRD4 expression was found to be related to a worse prognosis and radiation resistance. BRD4 inhibition sensitizes cervical cancer to radiotherapy by inhibiting RAD51AP1 transcription. The combination of JQ1 with radiotherapy merits further evaluation as a therapeutic strategy for improving local control in cervical cancer.	[Ni, Mengdong; Li, Jiajia; Zhao, Haiyun; Xu, Fei; Cheng, Jingyi; Yu, Min; Ke, Guihao; Wu, Xiaohua] Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Ni, Mengdong; Li, Jiajia; Zhao, Haiyun; Xu, Fei; Cheng, Jingyi; Yu, Min; Ke, Guihao; Wu, Xiaohua] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China	Fudan University; Fudan University	Ke, GH; Wu, XH (corresponding author), Fudan Univ, Dept Gynecol Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China.; Ke, GH; Wu, XH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.	kegh5734@126.com; wu.xh@fudan.edu.cn		Yu, Min/0000-0001-9197-2101	National Natural Science Foundation of China [81672569, 81902660]; Natural Science Foundation of Shanghai [19ZR1410700]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	This study was supported by grants from the National Natural Science Foundation of China to XW (No. 81672569), the Natural Science Foundation of Shanghai to GK (No. 19ZR1410700), and the National Natural Science Foundation of China to JL (No. 81902660).	Abramson JS, 2015, BLOOD, V126, P1491, DOI DOI 10.1182/BLOOD.V126.23.1491.1491; Aggarwal R, 2017, J CLIN ONCOL, V35, P1231, DOI 10.1200/JCO.2016.70.5350; Bagratuni T, 2020, EUR J CANCER, V126, P125, DOI 10.1016/j.ejca.2019.11.017; Balbous A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2647-9; Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958; Bates SE, 2020, NEW ENGL J MED, V383, P650, DOI 10.1056/NEJMra1805035; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bitzer M, 2016, J HEPATOL, V65, P280, DOI 10.1016/j.jhep.2016.02.043; Cao LJ, 2019, INT J GYNECOL CANCER, V29, P1244, DOI 10.1136/ijgc-2019-000556; Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Glasspool RM, 2014, BRIT J CANCER, V110, P1923, DOI 10.1038/bjc.2014.116; Harkenrider MM, 2020, JNCI-J NATL CANCER I, V112, P1081, DOI 10.1093/jnci/djaa041; Hatzi VI, 2015, CANCER LETT, V356, P34, DOI 10.1016/j.canlet.2013.11.018; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Jiang ZF, 2019, LANCET ONCOL, V20, P806, DOI 10.1016/S1470-2045(19)30164-0; Karakashev S, 2017, CELL REP, V21, P3398, DOI 10.1016/j.celrep.2017.11.095; Kovalenko OV, 1997, NUCLEIC ACIDS RES, V25, P4946, DOI 10.1093/nar/25.24.4946; Krause M, 2017, ADV DRUG DELIVER REV, V109, P63, DOI 10.1016/j.addr.2016.02.002; Kwon NH, 2008, J CLIN IMMUNOL, V28, P139, DOI 10.1007/s10875-007-9148-1; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li N, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0789-1; Li XY, 2018, CELL REP, V22, P796, DOI 10.1016/j.celrep.2017.12.078; Lin LL, 2020, INT J GYNECOL CANCER, V30, P409, DOI 10.1136/ijgc-2020-001227; Marie-Egyptienne DT, 2013, CANCER LETT, V341, P63, DOI 10.1016/j.canlet.2012.11.019; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Modesti M, 2007, MOL CELL, V28, P468, DOI 10.1016/j.molcel.2007.08.025; Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156; Najafova Z, 2017, NUCLEIC ACIDS RES, V45, P127, DOI 10.1093/nar/gkw826; Postel-Vinay S, 2019, EUR J CANCER, V109, P103, DOI 10.1016/j.ejca.2018.12.020; Prabakaran PJ, 2017, CLIN CANCER RES, V23, P6044, DOI 10.1158/1078-0432.CCR-17-0969; Rashmi R, 2018, CANCER RES, V78, P1392, DOI 10.1158/0008-5472.CAN-17-2367; Rataj O, 2019, INT J CANCER, V144, P2330, DOI 10.1002/ijc.31986; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Stanlie A, 2014, MOL CELL, V55, P97, DOI 10.1016/j.molcel.2014.05.018; Stonestrom Aaron J, 2016, Drug Discov Today Technol, V19, P23, DOI 10.1016/j.ddtec.2016.05.004; Sun CY, 2018, CANCER CELL, V33, P401, DOI 10.1016/j.ccell.2018.01.019; Tsai CL, 2018, HEPATOLOGY, V67, P586, DOI 10.1002/hep.29328; Wang J, 2017, CANCER LETT, V391, P141, DOI 10.1016/j.canlet.2017.01.031; Wang ZW, 2014, CELL MOL BIOL LETT, V19, P233, DOI 10.2478/s11658-014-0191-7; Welti J, 2018, CLIN CANCER RES, V24, P3149, DOI 10.1158/1078-0432.CCR-17-3571; Williams KE, 2015, STEM CELLS, V33, P327, DOI 10.1002/stem.1843; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645; Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251; Zhuang HQ, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0109-5; Zibelman M, 2015, INVEST NEW DRUG, V33, P1040, DOI 10.1007/s10637-015-0261-3	51	9	9	4	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2711	2724		10.1038/s41388-021-01735-3	http://dx.doi.org/10.1038/s41388-021-01735-3		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33712705				2022-12-17	WOS:000628201500002
J	Riedel, M; Berthelsen, MF; Cai, HQ; Haldrup, J; Borre, M; Paludan, SR; Hager, H; Vendelbo, MH; Wagner, EF; Bakiri, L; Thomsen, MK				Riedel, Maria; Berthelsen, Martin F.; Cai, Huiqiang; Haldrup, Jakob; Borre, Michael; Paludan, Soren R.; Hager, Henrik; Vendelbo, Mikkel H.; Wagner, Erwin F.; Bakiri, Latifa; Thomsen, Martin K.			In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun	ONCOGENE			English	Article								Prostate cancer is a major global health concern with limited treatment options for advanced disease. Its heterogeneity challenges the identification of crucial driver genes implicated in disease progression. Activating protein-1 (AP-1) transcription factor is associated with cancer since the first identification of its subunits, the proto-oncogenes JUN and FOS. Whereas both JUN and FOS have been implicated in prostate cancer, this study provides the first functional evidence that FOS acts as a tumor suppressor during prostate cancer progression and invasion. Data mining revealed decreased FOS expression in prostate cancer and a further downregulation in metastatic disease, consistent with FOS expression in cell lines derived from different prostate cancer stages. FOS deficiency in prostate cancer cell lines increases cell proliferation and induces oncogenic pathway alterations. Importantly, in vivo CRISPR/Cas9-mediated Fos and Pten double mutation in murine prostate epithelium results in increased proliferation and invasiveness compared to the abrogation of Pten alone. Interestingly, enhanced Jun expression is observed in the murine prostatic intraepithelial neoplasia lacking Fos. CRISPR/Cas9-mediated knockout of Jun combined with Fos and Pten deficiency diminishes the increased proliferation rate in vivo but not the ability to form invasive disease. Overall, we demonstrate that loss of Fos promotes disease progression from clinical latent prostate cancer to advanced disease through accelerated proliferation and invasiveness, partly through Jun.	[Riedel, Maria; Berthelsen, Martin F.; Cai, Huiqiang; Haldrup, Jakob] Aarhus Univ, Dept Clin Med, Aarhus, Denmark; [Borre, Michael] Aarhus Univ Hosp, Dept Clin Med & Urol, Aarhus, Denmark; [Paludan, Soren R.; Thomsen, Martin K.] Aarhus Univ, Dept Biomed, Aarhus, Denmark; [Hager, Henrik] South Denmark Hosp, Vejle, Denmark; [Vendelbo, Mikkel H.] Aarhus Univ Hosp, Dept Nucl Med & PET Ctr, Aarhus, Denmark; [Wagner, Erwin F.] Med Univ Vienna MUV, Dept Dermatol, Lab Genes & Dis, Vienna, Austria; [Wagner, Erwin F.; Bakiri, Latifa] Med Univ Vienna MUV, Dept Lab Med, Lab Genes & Dis, Vienna, Austria; [Thomsen, Martin K.] Aarhus Univ, Aarhus Inst Adv Studies AIAS, Aarhus, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Medical University of Vienna; Medical University of Vienna; Aarhus University	Thomsen, MK (corresponding author), Aarhus Univ, Dept Biomed, Aarhus, Denmark.; Thomsen, MK (corresponding author), Aarhus Univ, Aarhus Inst Adv Studies AIAS, Aarhus, Denmark.	mkt@biomed.au.dk	Thomsen, Martin/AAU-5014-2021	Thomsen, Martin/0000-0002-5055-7531; Vendelbo, Mikkel Holm/0000-0003-0431-2522; Paludan, Soren Riis/0000-0001-9180-4060; bakiri, latifa/0000-0002-6300-2420; Riedel, Maria/0000-0002-6545-0243; Wagner, Erwin F/0000-0001-7872-0196	Danish cancer society [R146-A9394, R204-A12490]; Ministry of health [4-1612-236/7]; AUFF NOVA [E-2o15-FLS-9-8]; Dagmar Marshalls Fond; Einar Willumsens Mindelegat; Harboefonden; Helge Peetz og Verner og hustru Vilma Peetz legat; Raimond og Dagmar Ringgaed-Bohns Fond; Aarhus University Research Foundation; Thora og Viggo Grove's Mindelegat; European Research Council [741888]; Medical University of Vienna	Danish cancer society(Danish Cancer Society); Ministry of health; AUFF NOVA; Dagmar Marshalls Fond; Einar Willumsens Mindelegat; Harboefonden; Helge Peetz og Verner og hustru Vilma Peetz legat; Raimond og Dagmar Ringgaed-Bohns Fond; Aarhus University Research Foundation; Thora og Viggo Grove's Mindelegat; European Research Council(European Research Council (ERC)European Commission); Medical University of Vienna	We thank Mette Simonsen for assistance with PET/MRI scanning. This work was funded by Danish cancer society (R146-A9394 and R204-A12490), Ministry of health (4-1612-236/7), AUFF NOVA (E-2o15-FLS-9-8), Dagmar Marshalls Fond, Einar Willumsens Mindelegat, Harboefonden, Helge Peetz og Verner og hustru Vilma Peetz legat, Raimond og Dagmar Ringgaed-Bohns Fond, The Aarhus University Research Foundation, and Thora og Viggo Grove's Mindelegat (all to MKT). EFW and LB are supported by the European Research Council (grant: ERC-AdG 2016 CSI-Fun-741888 to EFW) and the Medical University of Vienna.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chandran UR, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-45; Edwards J, 2004, J PATHOL, V204, P153, DOI 10.1002/path.1605; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Evans AJ, 2018, MODERN PATHOL, V31, pS110, DOI 10.1038/modpathol.2017.158; Feng ZW, 1998, ONCOGENE, V17, P2593, DOI 10.1038/sj.onc.1202195; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Guo JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120332; Haeussler M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1012-2; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Hubner A, 2012, P NATL ACAD SCI USA, V109, P12046, DOI 10.1073/pnas.1209660109; Konishi N, 2008, CLIN CANCER RES, V14, P4408, DOI 10.1158/1078-0432.CCR-07-4120; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Millena AC, 2016, J BIOL CHEM, V291, P17964, DOI 10.1074/jbc.M116.714899; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Parisotto M, 2013, MOL ONCOL, V7, P190, DOI 10.1016/j.molonc.2013.02.005; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Riedel M, 2018, JOVE-J VIS EXP, DOI 10.3791/57525; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Thomsen MK, 2015, CELL DEATH DIFFER, V22, P574, DOI 10.1038/cdd.2014.213; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wenzel A, 2002, J NEUROCHEM, V80, P1089, DOI 10.1046/j.0022-3042.2002.00807.x; Xu RY, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109679; Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76	32	9	10	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2437	2447		10.1038/s41388-021-01724-6	http://dx.doi.org/10.1038/s41388-021-01724-6		MAR 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33674748	Green Accepted, Green Submitted			2022-12-17	WOS:000625607100006
J	Avila-Lopez, PA; Guerrero, G; Nunez-Martinez, HN; Peralta-Alvarez, CA; Hernandez-Montes, G; Alvarez-Hilario, LG; Herrera-Goepfert, R; Albores-Saavedra, J; Villegas-Sepulveda, N; Cedillo-Barron, L; Montes-Gomez, AE; Vargas, M; Schnoor, M; Recillas-Targa, F; Hernandez-Rivas, R				Avila-Lopez, P. A.; Guerrero, G.; Nunez-Martinez, H. N.; Peralta-Alvarez, C. A.; Hernandez-Montes, G.; Alvarez-Hilario, L. G.; Herrera-Goepfert, R.; Albores-Saavedra, J.; Villegas-Sepulveda, N.; Cedillo-Barron, L.; Montes-Gomez, A. E.; Vargas, M.; Schnoor, M.; Recillas-Targa, F.; Hernandez-Rivas, R.			H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article								Pancreatic ductal adenocarcinoma (PDAC) is one of the most intractable and devastating malignant tumors. Epigenetic modifications such as DNA methylation and histone modification regulate tumor initiation and progression. However, the contribution of histone variants in PDAC is unknown. Here, we demonstrated that the histone variant H2A.Z is highly expressed in PDAC cell lines and PDAC patients and that its overexpression correlates with poor prognosis. Moreover, all three H2A.Z isoforms (H2A.Z.1, H2A.Z.2.1, and H2A.Z.2.2) are highly expressed in PDAC cell lines and PDAC patients. Knockdown of these H2A.Z isoforms in PDAC cell lines induces a senescent phenotype, cell cycle arrest in phase G2/M, increased expression of cyclin-dependent kinase inhibitor CDKN2A/p16, SA-beta-galactosidase activity and interleukin 8 production. Transcriptome analysis of H2A.Z-depleted PDAC cells showed altered gene expression in fatty acid biosynthesis pathways and those that regulate cell cycle and DNA damage repair. Importantly, depletion of H2A.Z isoforms reduces the tumor size in a mouse xenograft model in vivo and sensitizes PDAC cells to gemcitabine. Overexpression of H2A.Z.1 and H2A.Z.2.1 more than H2A.Z.2.2 partially restores the oncogenic phenotype. Therefore, our data suggest that overexpression of H2A.Z isoforms enables cells to overcome the oncoprotective barrier associated with senescence, favoring PDAC tumor grow and chemoresistance. These results make H2A.Z a potential candidate as a diagnostic biomarker and therapeutic target for PDAC.	[Avila-Lopez, P. A.; Alvarez-Hilario, L. G.; Villegas-Sepulveda, N.; Cedillo-Barron, L.; Montes-Gomez, A. E.; Vargas, M.; Schnoor, M.; Hernandez-Rivas, R.] Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City, DF, Mexico; [Guerrero, G.; Nunez-Martinez, H. N.; Peralta-Alvarez, C. A.; Recillas-Targa, F.] Univ Nacl Autonoma Mexico, Dept Genet Mol, Inst Fisiol Celular, Ciudad Univ, Mexico City, DF, Mexico; [Hernandez-Montes, G.] Univ Nacl Autonoma Mexico, Coordinac Invest Cient, Red Apoyo Invest, Ciudad Univ, Mexico City, DF, Mexico; [Herrera-Goepfert, R.] Inst Nacl Cancerol, Dept Patol, Mexico City, DF, Mexico; [Albores-Saavedra, J.] Med Clin & Fdn, Dept Patol, Mexico City, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; Universidad Nacional Autonoma de Mexico; Universidad Nacional Autonoma de Mexico; Instituto Nacional de Cancerologia (INCAN)	Hernandez-Rivas, R (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Biomed Mol, Mexico City, DF, Mexico.	rohernan@cinvestav.mx		Herrera-Goepfert, Roberto/0000-0001-7901-2378; Villegas-Sepulveda, Nicolas/0000-0001-9489-2545; Hernandez, Rosaura/0000-0002-5275-0730; Peralta-Alvarez, Carlos Alberto/0000-0001-6103-5133; Avila Lopez, Pedro Antonio/0000-0002-0104-0771; VARGAS, MIGUEL/0000-0002-3031-9798; Nunez, Hober Nelson/0000-0003-1726-2499	Fondo Sectorial de Investigacion en Salud y Seguridad Social [SS/IMSS/ISSSTE-CONACyt (272364)]; Consejo Nacional de Ciencia y Tecnologia fellowship [396917]	Fondo Sectorial de Investigacion en Salud y Seguridad Social; Consejo Nacional de Ciencia y Tecnologia fellowship	This work was supported by the Fondo Sectorial de Investigacion en Salud y Seguridad Social SS/IMSS/ISSSTE-CONACyt (272364) to RHR; PAA-L was supported by the Consejo Nacional de Ciencia y Tecnologia fellowship 396917.	Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; BALL DJ, 1983, FEBS LETT, V154, P166, DOI 10.1016/0014-5793(83)80896-5; Bauden M, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0139-4; Bonisch C, 2012, NUCLEIC ACIDS RES, V40, P5951, DOI 10.1093/nar/gks267; Buschbeck M, 2017, NAT REV MOL CELL BIO, V18, P299, DOI 10.1038/nrm.2016.166; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Dryhurst D, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-86; Faast R, 2001, CURR BIOL, V11, P1183, DOI 10.1016/S0960-9822(01)00329-3; Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707; Gire V, 2015, CELL CYCLE, V14, P297, DOI 10.1080/15384101.2014.1000134; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hu GQ, 2013, CELL STEM CELL, V12, P180, DOI 10.1016/j.stem.2012.11.003; Iguchi Eriko, 2016, Yale Journal of Biology and Medicine, V89, P575; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kikuchi I, 2010, CELL BIOL INT, V34, P645, DOI 10.1042/CBI20090398; Kim K, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-34; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lamaa A, 2020, ELIFE, V9, DOI 10.7554/eLife.53375; Lomberk G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04383-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Maeda M, 2009, LIFE SCI, V84, P119, DOI 10.1016/j.lfs.2008.11.009; Mattera L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000983; Maze I, 2014, NAT REV GENET, V15, P259, DOI 10.1038/nrg3673; Meneghini MD, 2003, CELL, V112, P725, DOI 10.1016/S0092-8674(03)00123-5; Muniz L, 2017, CELL REP, V21, P2433, DOI 10.1016/j.celrep.2017.11.006; Neureiter D, 2014, WORLD J GASTROENTERO, V20, P7830, DOI 10.3748/wjg.v20.i24.7830; Oldfield LE, 2017, TRENDS CANCER, V3, P336, DOI 10.1016/j.trecan.2017.04.005; Prieur A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1473; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Ridgway P, 2004, J BIOL CHEM, V279, P43815, DOI 10.1074/jbc.M408409200; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Skene PJ, 2013, DEVELOPMENT, V140, P2513, DOI 10.1242/dev.091439; Surface LE, 2016, CELL REP, V14, P1142, DOI 10.1016/j.celrep.2015.12.100; Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465; Talbert PB, 2017, NAT REV MOL CELL BIO, V18, P115, DOI 10.1038/nrm.2016.148; Valdes-Mora F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01393-8; Vardabasso C, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1073417; Vardabasso C, 2015, MOL CELL, V59, P75, DOI 10.1016/j.molcel.2015.05.009; Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z; Yang B, 2018, INT J ONCOL, V52, P1235, DOI 10.3892/ijo.2018.4292; Yang HD, 2016, ONCOTARGET, V7, P11412, DOI 10.18632/oncotarget.7194	42	9	9	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2065	2080		10.1038/s41388-021-01664-1	http://dx.doi.org/10.1038/s41388-021-01664-1		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627784	Green Published, hybrid			2022-12-17	WOS:000621289100006
J	Monsivais, D; Vasquez, YM; Chen, FJ; Zhang, YQ; Chandrashekar, DS; Faver, JC; Masand, RP; Scheurer, ME; Varambally, S; Matzuk, MM; Creighton, CJ				Monsivais, Diana; Vasquez, Yasmin M.; Chen, Fengju; Zhang, Yiqun; Chandrashekar, Darshan S.; Faver, John C.; Masand, Ramya P.; Scheurer, Michael E.; Varambally, Sooryanarayana; Matzuk, Martin M.; Creighton, Chad J.			Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers	ONCOGENE			English	Article								Proteomic signatures associated with clinical measures of more aggressive cancers could yield molecular clues as to disease drivers. Here, utilizing the Clinical Proteomic Tumor Analysis Consortium (CPTAC) mass-spectrometry-based proteomics datasets, we defined differentially expressed proteins and mRNAs associated with higher grade or higher stage, for each of seven cancer types (breast, colon, lung adenocarcinoma, clear cell renal, ovarian, uterine, and pediatric glioma), representing 794 patients. Widespread differential patterns of total proteins and phosphoproteins involved some common patterns shared between different cancer types. More proteins were associated with higher grade than higher stage. Most proteomic signatures predicted patient survival in independent transcriptomic datasets. The proteomic grade signatures, in particular, involved DNA copy number alterations. Pathways of interest were enriched within the grade-associated proteins across multiple cancer types, including pathways of altered metabolism, Warburg-like effects, and translation factors. Proteomic grade correlations identified protein kinases having functional impact in vitro in uterine endometrial cancer cells, including MAP3K2, MASTL, and TTK. The protein-level grade and stage associations for all proteins profiled-along with corresponding information on phosphorylation, pathways, mRNA expression, and copy alterations-represent a resource for identifying new potential targets. Proteomic analyses are often concordant with corresponding transcriptomic analyses, but with notable exceptions.	[Monsivais, Diana; Vasquez, Yasmin M.; Faver, John C.; Matzuk, Martin M.] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA; [Monsivais, Diana; Vasquez, Yasmin M.; Faver, John C.; Masand, Ramya P.; Matzuk, Martin M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Chen, Fengju; Zhang, Yiqun; Scheurer, Michael E.; Creighton, Chad J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Div Biostat, Houston, TX 77030 USA; [Chandrashekar, Darshan S.; Varambally, Sooryanarayana] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL 35294 USA; [Chandrashekar, Darshan S.; Varambally, Sooryanarayana] Univ Alabama Birmingham, Dept Pathol, Mol & Cellular Pathol, Birmingham, AL 35294 USA; [Scheurer, Michael E.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Scheurer, Michael E.] Texas Childrens Hosp, Texas Childrens Canc Ctr, Houston, TX 77030 USA; [Varambally, Sooryanarayana] Univ Alabama Birmingham, Informat Inst, Birmingham, AL USA; [Creighton, Chad J.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Creighton, Chad J.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA; [Creighton, Chad J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Baylor College of Medicine; Baylor College of Medicine; Texas Children's Cancer Center; University of Alabama System; University of Alabama Birmingham; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine	Monsivais, D (corresponding author), Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA.; Monsivais, D (corresponding author), Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Div Biostat, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.; Creighton, CJ (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	diana.monsivais@bcm.edu; creighto@bcm.edu	Zhang, YiQun/HCI-2427-2022	Scheurer, Michael/0000-0002-8379-6088; Faver, John/0000-0002-0181-9283; Monsivais, Diana/0000-0001-5660-6392	National Institutes of Health (NIH) [P30CA125123, P20CA221729, R00HD096057]; Cancer Prevention Research Institute of Texas [RP160805]; Burroughs Wellcome Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; Burroughs Wellcome Fund(Burroughs Wellcome Fund)	This research was conducted using data made available by The Clinical Proteomic Tumor Analysis Consortium (CPTAC), The Children's Brain Tumor Tissue Consortium (CBTTC), and The Cancer Genome Atlas (TCGA) Consortium. This work was supported by National Institutes of Health (NIH) grants P30CA125123 (CJC), P20CA221729 (MMM), R00HD096057 (DM), and a Core Facility Support Award from the Cancer Prevention Research Institute of Texas (RP160805 (MMM)). Diana Monsivais holds a PDEP Award from the Burroughs Wellcome Fund. We thank Jonathan Kurie for critical reading of the manuscript.	Ahmad S, 2018, BIOCHEM BIOPH RES CO, V496, P205, DOI 10.1016/j.bbrc.2018.01.027; Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen F, 2017, ONCOGENE, V36, P1384, DOI 10.1038/onc.2016.303; Chen FJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13528-0; Chen FJ, 2018, CLIN CANCER RES, V24, P2182, DOI 10.1158/1078-0432.CCR-17-3378; Chen GA, 2003, P NATL ACAD SCI USA, V100, P13537, DOI 10.1073/pnas.2233850100; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Clark DJ, 2019, CELL, V179, P964, DOI 10.1016/j.cell.2019.10.007; Creighton C, 2003, FEBS LETT, V540, P167, DOI 10.1016/S0014-5793(03)00259-X; Creighton CJ, 2008, RNA, V14, P2290, DOI 10.1261/rna.1188208; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Creighton CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034546; Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024; Denkert C, 2009, J PATHOL, V218, P273, DOI 10.1002/path.2547; Dou YC, 2020, CELL, V180, P729, DOI 10.1016/j.cell.2020.01.026; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Edwards NJ, 2015, J PROTEOME RES, V14, P2707, DOI 10.1021/pr501254j; Ellis MJ, 2013, CANCER DISCOV, V3, P1108, DOI 10.1158/2159-8290.CD-13-0219; Fatima I, 2020, CANCER MED-US, V9, P6322, DOI 10.1002/cam4.3141; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Gillette MA, 2020, CELL, V182, P200, DOI 10.1016/j.cell.2020.06.013; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Libouban MAA, 2017, ONCOTARGET, V8, P38309, DOI 10.18632/oncotarget.16213; Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522; Louis DN, 2014, BRAIN PATHOL, V24, P429, DOI 10.1111/bpa.12171; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064; Sridhar R, 2000, PHARM RES-DORDR, V17, P1345, DOI 10.1023/A:1007507224529; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Yoshihara K, 2012, CLIN CANCER RES, V18, P1374, DOI 10.1158/1078-0432.CCR-11-2725; Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y; Yuan Y, 2014, NAT BIOTECHNOL, V32, P644, DOI 10.1038/nbt.2940; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069; Zhao HJ, 2006, PLOS MED, V3, P115, DOI 10.1371/journal.pmed.0030013	46	9	9	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2081	2095		10.1038/s41388-021-01681-0	http://dx.doi.org/10.1038/s41388-021-01681-0		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627787	Green Accepted			2022-12-17	WOS:000621289100003
J	Fletcher, R; Tong, JS; Risnik, D; Leibowitz, BJ; Wang, YJ; Concha-Benavente, F; DeLiberty, JM; Stolz, DB; Pai, RK; Ferris, RL; Schoen, RE; Yu, J; Zhang, L				Fletcher, Rochelle; Tong, Jingshan; Risnik, Denise; Leibowitz, Brian J.; Wang, Yi-Jun; Concha-Benavente, Fernando; DeLiberty, Jonathan M.; Stolz, Donna B.; Pai, Reet K.; Ferris, Robert L.; Schoen, Robert E.; Yu, Jian; Zhang, Lin			Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED-PROTEIN-RESPONSE; APC-DEFICIENT CELLS; INDUCED APOPTOSIS; CANCER CHEMOPREVENTION; SULINDAC; MECHANISMS; PATHWAYS; NSAIDS; COLON	Use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated with reduced risk of colorectal cancer (CRC). However, the mechanism by which NSAIDs suppress colorectal tumorigenesis remains unclear. We previously showed that NSAIDs selectively kill emerging tumor cells via death receptor (DR) signaling and a synthetic lethal interaction mediated by the proapoptotic Bcl-2 family protein BID. In this study, we found NSAIDs induce endoplasmic reticulum (ER) stress to activate DR signaling and BID in tumor suppression. Importantly, our results unveiled an ER stress- and BID-dependent immunogenic effect of NSAIDs, which may be critical for tumor suppression. NSAID treatment induced hallmarks of immunogenic cell death (ICD) in CRC cells and colonic epithelial cells upon loss of APC tumor suppressor, and elevated tumor-infiltrating lymphocytes (TILs) in the polyps of APC(Min/+) mice. ER stress inhibition or BID deletion abrogated the antitumor and immunogenic effects of NSAIDs. Furthermore, increased ER stress and TILs were detected in human advanced adenomas from NSAID-treated patients. Together, our results suggest that NSAIDs induce ER stress- and BID-mediated ICD to restore immunosurveillance and suppress colorectal tumor formation.	[Fletcher, Rochelle; Tong, Jingshan; Risnik, Denise; Leibowitz, Brian J.; Wang, Yi-Jun; Concha-Benavente, Fernando; Stolz, Donna B.; Pai, Reet K.; Ferris, Robert L.; Schoen, Robert E.; Yu, Jian; Zhang, Lin] UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA; [Fletcher, Rochelle; Tong, Jingshan; Risnik, Denise; Wang, Yi-Jun; DeLiberty, Jonathan M.; Zhang, Lin] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Leibowitz, Brian J.; Pai, Reet K.; Yu, Jian] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA USA; [Concha-Benavente, Fernando; Ferris, Robert L.] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; [Concha-Benavente, Fernando; Ferris, Robert L.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Stolz, Donna B.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA USA; [Schoen, Robert E.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Schoen, Robert E.] Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zhang, L (corresponding author), UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA.; Zhang, L (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	zhanglx@upmc.edu	Zhang, Lin/A-7389-2009; Wang, Yin/HCI-9352-2022; Yu, Jian/A-8301-2009; Wang, Yixuan/GZK-6559-2022; Wang, Yijun/GXW-1763-2022; Wang, Yu/GZL-9655-2022; wang, yixuan/GXW-2866-2022; wang, yi/GVT-8516-2022	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Risnik, Denise/0000-0001-8843-7968; DeLiberty, Jonathan/0000-0001-6001-6678; Tong, Jingshan/0000-0003-1640-5769	U.S. National Institute of Health [R01CA172136, R01CA203028, R01CA217141, R01CA236271, R01CA247231, U19AI068021, R01CA215481, U01CA152753, P30CA047904]	U.S. National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors thank Dr. Michael T. Lotze and our lab members for discussion and critical reading and Ms. Dorothy Coe for technical assistance. This work is supported by U.S. National Institute of Health grants (R01CA172136, R01CA203028, R01CA217141, R01CA236271, and R01CA247231 to LZ; U19AI068021 and R01CA215481 to JY; U01CA152753 to RES). This project used the UPMC Hillman Cancer Center shared facilities that were supported in part by award P30CA047904.	Bank A, 2008, CANCER RES, V68, P276, DOI 10.1158/0008-5472.CAN-07-5242; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Berg AK, 2013, J CLIN PHARMACOL, V53, P403, DOI 10.1002/jcph.26; Bezu L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00187; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cao Y, 2016, GASTROENTEROLOGY, V151, P879, DOI 10.1053/j.gastro.2016.07.030; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115; Drew DA, 2016, NAT REV CANCER, V16, P173, DOI 10.1038/nrc.2016.4; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Fletcher R, 2018, BBA-REV CANCER, V1869, P138, DOI 10.1016/j.bbcan.2017.12.002; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Gurpinar E, 2014, CLIN CANCER RES, V20, P1104, DOI 10.1158/1078-0432.CCR-13-1573; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Huang Y, 2001, CANCER RES, V61, P6918; Keller JJ, 2003, CANCER BIOL THER, V2, pS140; Kepp O, 2015, SEMIN CANCER BIOL, V33, P86, DOI 10.1016/j.semcancer.2015.02.004; Kim JY, 2016, ANTICANCER RES, V36, P2705; Knickelbein K, 2018, ONCOGENE, V37, P4599, DOI 10.1038/s41388-018-0289-x; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Kratochvilova K, 2016, EUR J CELL BIOL, V95, P115, DOI 10.1016/j.ejcb.2016.02.002; LEE SC, 1995, BIOCHEM PHARMACOL, V49, P1567, DOI 10.1016/0006-2952(95)00093-F; Leibowitz B, 2014, P NATL ACAD SCI USA, V111, P16520, DOI 10.1073/pnas.1415178111; Lonnroth Christina, 2008, Cancer Immun, V8, P5; Lopez-Abaitero A, 2009, J IMMUNOTHER, V32, P465, DOI 10.1097/CJI.0b013e3181a1c24e; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; Ma L, 2019, SCIENCE, V365, P162, DOI 10.1126/science.aav8692; Marzbani E, 2013, CANCER PREV RES, V6, P764, DOI 10.1158/1940-6207.CAPR-13-0036; Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0; Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1; Pereira Felipe V, 2018, Oncotarget, V9, P25808, DOI 10.18632/oncotarget.25380; Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Qiu W, 2009, CANCER RES, V69, P4999, DOI 10.1158/0008-5472.CAN-09-0262; Rufo N, 2017, TRENDS CANCER, V3, P643, DOI 10.1016/j.trecan.2017.07.002; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schuler PJ, 2014, CLIN CANCER RES, V20, P2433, DOI 10.1158/1078-0432.CCR-13-2617; Seed MP, 1997, CANCER RES, V57, P1625; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; STRONG HA, 1987, XENOBIOTICA, V17, P685, DOI 10.3109/00498258709043976; STRONG HA, 1985, CLIN PHARMACOL THER, V38, P387, DOI 10.1038/clpt.1985.192; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Tan X, 2019, CANCER RES, V79, P1191, DOI 10.1158/0008-5472.CAN-18-3223; Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356; Tong J, 2017, ONCOGENE, V36, P787, DOI 10.1038/onc.2016.247; Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Wang YJ, 2018, GENES DIS, V5, P194, DOI 10.1016/j.gendis.2018.05.003; Yamaguchi H, 2004, J BIOL CHEM, V279, P45495, DOI 10.1074/jbc.M406933200; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang XB, 2013, CANCER PREV RES, V6, P1337, DOI 10.1158/1940-6207.CAPR-13-0220	55	9	9	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2035	2050		10.1038/s41388-021-01687-8	http://dx.doi.org/10.1038/s41388-021-01687-8		FEB 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603166	Green Accepted			2022-12-17	WOS:000619405600002
J	Pan, JK; Lin, CH; Kuo, YL; Ger, LP; Cheng, HC; Yao, YC; Hsiao, MC; Lu, PJ				Pan, Jhih-Kai; Lin, Cheng-Han; Kuo, Yao-Lung; Ger, Luo-Ping; Cheng, Hui-Chuan; Yao, Yun-Chin; Hsiao, Michael; Lu, Pei-Jung			MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer	ONCOGENE			English	Article								Brian metastasis, which is diagnosed in 30% of triple-negative breast cancer (TNBC) patients with metastasis, causes poor survival outcomes. Growing evidence has characterized miRNAs involving in breast cancer brain metastasis; however, currently, there is a lack of prognostic plasma-based indicator for brain metastasis. In this study, high level of miR-211 can act as brain metastatic prognostic marker in vivo. High miR-211 drives early and specific brain colonization through enhancing trans-blood-brain barrier (BBB) migration, BBB adherence, and stemness properties of tumor cells and causes poor survival in vivo. SOX11 and NGN2 are the downstream targets of miR-211 and negatively regulate miR-211-mediated TNBC brain metastasis in vitro and in vivo. Most importantly, high miR-211 is correlated with poor survival and brain metastasis in TNBC patients. Our findings suggest that miR-211 may be used as an indicator for TNBC brain metastasis.	[Pan, Jhih-Kai; Lin, Cheng-Han; Cheng, Hui-Chuan; Lu, Pei-Jung] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan; [Kuo, Yao-Lung] Natl Cheng Kung Univ Hosp, Dept Gen Surg, Tainan, Taiwan; [Ger, Luo-Ping] Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung, Taiwan; [Yao, Yun-Chin] Natl Cheng Kung Univ Hosp, Clin Med Res Ctr, Tainan, Taiwan; [Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Hsiao, Michael] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung, Taiwan; [Lu, Pei-Jung] Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Veterans General Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Academia Sinica - Taiwan; Kaohsiung Medical University; National Cheng Kung University; National Cheng Kung University Hospital	Lu, PJ (corresponding author), Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan.; Lu, PJ (corresponding author), Natl Cheng Kung Univ Hosp, Dept Clin Med Res, Tainan, Taiwan.	pjlu2190@mail.ncku.edu.tw	Hsiao, Michael/U-6238-2019	Hsiao, Michael/0000-0001-8529-9213; Lu, Pei-Jung/0000-0002-8143-5668; Lin, Cheng-Han/0000-0001-5444-3999	Ministry of Science and Technology, Taiwan [MOST 105-2320-B-006-054, 106-2320-B-006-066-MY3, MOST 107-2320-B-006-064-MY3]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by the Ministry of Science and Technology, Taiwan [MOST 105-2320-B-006-054, 106-2320-B-006-066-MY3 and MOST 107-2320-B-006-064-MY3] to P-JL.	Achrol AS, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-018-0055-y; Avraham HK, 2014, J PATHOL, V232, P369, DOI 10.1002/path.4304; Banks WA, 2016, NAT REV DRUG DISCOV, V15, P275, DOI 10.1038/nrd.2015.21; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chang CC, 2018, ONCOL LETT, V15, P8107, DOI 10.3892/ol.2018.8295; Chen LL, 2017, BRIT J CANCER, V117, P78, DOI 10.1038/bjc.2017.150; Chen WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0047-0; Chen YF, 2016, CANCER RES, V76, P4872, DOI 10.1158/0008-5472.CAN-15-1664; Croset M, 2018, CANCER RES, V78, P5259, DOI 10.1158/0008-5472.CAN-17-3058; Debeb BG, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw026; Gril B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05030-w; Hide T, 2009, CANCER RES, V69, P7953, DOI 10.1158/0008-5472.CAN-09-2006; Hsu TI, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.12; Jilaveanu LB, 2015, CLIN CANCER RES, V21, P2138, DOI 10.1158/1078-0432.CCR-14-0861; Li B, 2013, ONCOGENE, V32, P2952, DOI 10.1038/onc.2012.313; Li HY, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0918-2; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu DT, 2014, ASIAN PAC J CANCER P, V15, P5483, DOI 10.7314/APJCP.2014.15.13.5483; Lyle LT, 2016, CLIN CANCER RES, V22, P5287, DOI 10.1158/1078-0432.CCR-15-1836; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037; Pardridge WM, 2016, EXPERT OPIN DRUG DEL, V13, P963, DOI 10.1517/17425247.2016.1171315; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Sevenich L, 2014, NAT CELL BIOL, V16, P876, DOI 10.1038/ncb3011; Shepherd JH, 2016, ONCOTARGET, V7, P13106, DOI 10.18632/oncotarget.7437; Sirkisoon Sherona R, 2016, Front Biosci (Elite Ed), V8, P245; Tiwary S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26636-6; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Wu KR, 2015, J BIOL CHEM, V290, P9842, DOI 10.1074/jbc.M114.602185; Xiao YS, 2020, J CELL PHYSIOL, V235, P7295, DOI 10.1002/jcp.29629; Xing F, 2016, CANCER RES, V76, P4970, DOI 10.1158/0008-5472.CAN-15-3541; Yang Z, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919853449; Zhang LX, 2011, CANCER RES, V71, P645, DOI 10.1158/0008-5472.CAN-10-1910; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhou WC, 2017, CELL STEM CELL, V21, P591, DOI 10.1016/j.stem.2017.10.002	36	9	9	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1737	1751		10.1038/s41388-021-01654-3	http://dx.doi.org/10.1038/s41388-021-01654-3		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33536579	Green Published, hybrid			2022-12-17	WOS:000614320700001
J	Gu, GW; Tian, L; Herzog, SK; Rechoum, Y; Gelsomino, L; Gao, M; Du, LL; Kim, JA; Dustin, D; Lo, HC; Beyer, AR; Edwards, DG; Gonzalez, T; Tsimelzon, A; Huang, HJ; Fernandez, NM; Grimm, SL; Hilsenbeck, SG; Liu, D; Xu, J; Alaniz, A; Li, SQ; Mills, GB; Janku, F; Kittler, R; Zhang, XHF; Coarfa, C; Foulds, CE; Symmans, WF; Ando, S; Fuqua, SAW				Gu, Guowei; Tian, Lin; Herzog, Sarah K.; Rechoum, Yassine; Gelsomino, Luca; Gao, Meng; Du, Lili; Kim, Jin-Ah; Dustin, Derek; Lo, Hin Ching; Beyer, Amanda R.; Edwards, David G.; Gonzalez, Thomas; Tsimelzon, Anna; Huang, Helen J.; Fernandez, Natalie M.; Grimm, Sandra L.; Hilsenbeck, Susan G.; Liu, Dan; Xu, Jun; Alaniz, Alyssa; Li, Shunqiang; Mills, Gordon B.; Janku, Filip; Kittler, Ralf; Zhang, Xiang H. -F.; Coarfa, Cristian; Foulds, Charles E.; Symmans, W. Fraser; Ando, Sebastiano; Fuqua, Suzanne A. W.			Hormonal modulation of ESR1 mutant metastasis	ONCOGENE			English	Article							BREAST-CANCER; ANDROGEN RECEPTOR; ER-ALPHA; TAMOXIFEN RESISTANCE; ESTROGEN-RECEPTORS; MUTATIONS; INHIBITOR; BIOMARKERS; THERAPY; SNAIL	Estrogen receptor alpha gene (ESR1) mutations occur frequently in ER-positive metastatic breast cancer, and confer clinical resistance to aromatase inhibitors. Expression of the ESR1 Y537S mutation induced an epithelial-mesenchymal transition (EMT) with cells exhibiting enhanced migration and invasion potential in vitro. When small subpopulations of Y537S ESR1 mutant cells were injected along with WT parental cells, tumor growth was enhanced with mutant cells becoming the predominant population in distant metastases. Y537S mutant primary xenograft tumors were resistant to the antiestrogen tamoxifen (Tam) as well as to estradiol (E-2) withdrawal. Y537S ESR1 mutant primary tumors metastasized efficiently in the absence of E-2; however, Tam treatment significantly inhibited metastasis to distant sites. We identified a nine-gene expression signature, which predicted clinical outcomes of ER-positive breast cancer patients, as well as breast cancer metastasis to the lung. Androgen receptor (AR) protein levels were increased in mutant models, and the AR agonist dihydrotestosterone significantly inhibited estrogen-regulated gene expression, EMT, and distant metastasis in vivo, suggesting that AR may play a role in distant metastatic progression of ESR1 mutant tumors.	[Gu, Guowei; Herzog, Sarah K.; Rechoum, Yassine; Kim, Jin-Ah; Dustin, Derek; Lo, Hin Ching; Beyer, Amanda R.; Edwards, David G.; Gonzalez, Thomas; Tsimelzon, Anna; Hilsenbeck, Susan G.; Alaniz, Alyssa; Zhang, Xiang H. -F.; Fuqua, Suzanne A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Gu, Guowei; Zhang, Xiang H. -F.; Foulds, Charles E.; Fuqua, Suzanne A. W.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gu, Guowei; Gelsomino, Luca; Ando, Sebastiano] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Arcavacata Di Rende, Italy; [Tian, Lin] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave, New York, NY 10021 USA; [Herzog, Sarah K.] Baylor Coll Med, Integrat Mol & Biomed Sci Program, Houston, TX 77030 USA; [Gao, Meng] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Du, Lili; Symmans, W. Fraser] Univ Texas MD Anderson Canc Ctr, Dept Pathol & Translat Mol Pathol, Houston, TX 77030 USA; [Dustin, Derek] Baylor Coll Med, Interdept Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Huang, Helen J.; Janku, Filip] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Fernandez, Natalie M.; Liu, Dan; Xu, Jun] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Grimm, Sandra L.; Hilsenbeck, Susan G.; Zhang, Xiang H. -F.; Coarfa, Cristian; Foulds, Charles E.; Fuqua, Suzanne A. W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Li, Shunqiang] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA; [Mills, Gordon B.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA; [Kittler, Ralf] UT Southwestern Med Ctr, Eugene McDermott Ctr Human Growth & Dev, Dallas, TX USA; [Kittler, Ralf] UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX USA; [Foulds, Charles E.] Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of Calabria; Memorial Sloan Kettering Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Washington University (WUSTL); Oregon Health & Science University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine	Fuqua, SAW (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.; Fuqua, SAW (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Fuqua, SAW (corresponding author), Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.	sfuqua@bcm.edu	Kittler, Ralf/I-4662-2013; Kittler, Ralf/AAD-4258-2020	Kittler, Ralf/0000-0002-0098-6792; Kittler, Ralf/0000-0002-0098-6792; Zhang, Xiang/0000-0002-5674-8670; Gonzalez, Thomas/0000-0003-4497-3106; Tian, Lin/0000-0003-3661-4453; Herzog, Sarah/0000-0003-3782-7389	Breast Cancer Research Foundation [BCRF 19-055, BCRF-19-110]; NIH [R01 CA207270, R01CA072038]; Cancer Prevention Institute of Texas CPRIT MIRA; Adrienne Helis Malvin Medical Research Foundation Cancer Program M-2017; Dan L Duncan Cancer Center Cell-based assay screening core [P30 CA125123-05]; Translational Breast Cancer Research Training Program [T32-CA203690-02]; Predoctoral Institutional Research Training Grant (T32) Training Grant [5T32GM008231-30]; Cancer Prevention Institute of Texas (CPRIT) [T32 2389301302, RP170005]; NIEHS [P30 ES030285, P42 ES027725]; Susan G. Komen Breast Cancer Foundation [U01 CA217842, SAC110052]	Breast Cancer Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Institute of Texas CPRIT MIRA; Adrienne Helis Malvin Medical Research Foundation Cancer Program M-2017; Dan L Duncan Cancer Center Cell-based assay screening core; Translational Breast Cancer Research Training Program; Predoctoral Institutional Research Training Grant (T32) Training Grant; Cancer Prevention Institute of Texas (CPRIT); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation)	Breast Cancer Research Foundation BCRF 19-055, NIH R01 CA207270, NIH R01CA072038, Cancer Prevention Institute of Texas CPRIT MIRA (Kelly Hunt, PI) to SAWF; Adrienne Helis Malvin Medical Research Foundation Cancer Program M-2017 to CEF; P30 CA125123-05 Dan L Duncan Cancer Center Cell-based assay screening core; Translational Breast Cancer Research Training Program T32-CA203690-02; Predoctoral Institutional Research Training Grant (T32) Training Grant 5T32GM008231-30; T32 2389301302, Cancer Prevention Institute of Texas (CPRIT) RP170005; NIEHS grants P30 ES030285, P42 ES027725; U01 CA217842, Susan G. Komen Breast Cancer Foundation SAC110052, Breast Cancer Research Foundation BCRF-19-110.	Barone I, 2011, JNCI-J NATL CANCER I, V103, P538, DOI 10.1093/jnci/djr058; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chandarlapaty S, 2016, JAMA ONCOL, V2, P1310, DOI 10.1001/jamaoncol.2016.1279; Chiang KC, 2019, CANCER MANAG RES, V11, P1893, DOI 10.2147/CMAR.S196485; Ciupek A, 2015, BREAST CANCER RES TR, V154, P225, DOI 10.1007/s10549-015-3609-7; Cochrane DR, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3599; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; De Amicis F, 2010, BREAST CANCER RES TR, V121, P1, DOI 10.1007/s10549-009-0436-8; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Fuqua SAW, 2001, J MAMMARY GLAND BIOL, V6, P407, DOI 10.1023/A:1014782813943; Fuqua SAW, 2014, BREAST CANCER RES TR, V144, P11, DOI 10.1007/s10549-014-2847-4; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gates LA, 2018, ONCOGENE, V37, P4581, DOI 10.1038/s41388-018-0284-2; Gelsomino L, 2016, BREAST CANCER RES TR, V157, P253, DOI 10.1007/s10549-016-3829-5; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010; Hickey TE, 2012, MOL ENDOCRINOL, V26, P1252, DOI 10.1210/me.2012-1107; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Howlader N., 2016, SEER CANC STAT REV 1; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jiang J, 2011, ONCOGENE, V30, P4498, DOI 10.1038/onc.2011.154; Jin LT, 2018, CANCER BIOL THER, V19, P858, DOI 10.1080/15384047.2018.1456599; Kim JA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12991; Klein CA, 2013, NATURE, V501, P365, DOI 10.1038/nature12628; Kollipara RK, 2015, GENOM DATA, V3, P80, DOI 10.1016/j.gdata.2014.11.015; Krop I, 2018, P 2017 SAN ANT BREAS; Lambert Jr, 2001, METH MOL B, V176, P273; Li C, 2014, ONCOTARGET, V5, P8429, DOI 10.18632/oncotarget.2316; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Li YQ, 2015, INT J ONCOL, V46, P1461, DOI 10.3892/ijo.2015.2878; Lima JF, 2016, J CLIN MED, V5, DOI 10.3390/jcm5070065; Martin M, 2017, NAT COMMUN, V8, DOI [10.1038/ncomms15127, 10.1038/s41467-017-01864-y]; Mihaly Z, 2013, BREAST CANCER RES TR, V140, P219, DOI 10.1007/s10549-013-2622-y; Narayanan R, 2018, MOL CELL ENDOCRINOL, V465, P134, DOI 10.1016/j.mce.2017.06.013; O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264; Park SH, 2008, MOL ENDOCRINOL, V22, P2085, DOI 10.1210/me.2007-0512; Pidugu VK, 2019, ONCOGENE, V38, P3232, DOI 10.1038/s41388-018-0662-9; Ponnusamy S, 2019, ISCIENCE, V21, P341, DOI 10.1016/j.isci.2019.10.038; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rangel N, 2018, ENDOCR-RELAT CANCER, V25, P163, DOI 10.1530/ERC-17-0417; Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008; Rechoum Y, 2014, BREAST CANCER RES TR, V147, P473, DOI 10.1007/s10549-014-3082-8; Selever J, 2011, CLIN CANCER RES, V17, P6510, DOI 10.1158/1078-0432.CCR-11-1403; Sinn BV, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0111-0; Takeshita T, 2015, TRANSL RES, V166, P540, DOI 10.1016/j.trsl.2015.09.003; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Wallden B, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0129-6; Zhang QX, 1997, CANCER RES, V57, P1244	49	9	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					997	1011		10.1038/s41388-020-01563-x	http://dx.doi.org/10.1038/s41388-020-01563-x		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33323970	Green Accepted			2022-12-17	WOS:000599126500001
J	Li, CS; Yao, H; Wang, HB; Fang, JY; Xu, J				Li, Chushu; Yao, Han; Wang, Huanbin; Fang, Jing-Yuan; Xu, Jie			Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity	ONCOGENE			English	Article							SELECTIVE AUTOPHAGY; SIGNALING PATHWAYS; MEDIATED CLEAVAGE; CANCER; EXPRESSION; CALPAIN; REVEALS; COMPLEX; CA2+; MEK	Cancer cell expression of PD-L1 leads to T cells exhaustion by transducing co-inhibitory signal, and further understanding the regulation of PD-L1 in cancer cells may provide additional therapeutic strategies. Here by drug repurposing screen, we identified amlodipine as a potent inhibitor of PD-L1 expression in cancer cells. Further survey of calcium-associated pathways revealed calpain-dependent stabilization of the PD-L1 protein. Intracellular calcium delivered an operational signal to calpain-dependent Beclin-1 cleavage, blocking autophagic degradation of PD-L1 accumulated on recycling endosome (RE). Blocking calcium flux by amlodipine depleted PD-L1 expression and increased CD8+ T-cell infiltration in tumor tissues but not in myocardium, causing dose-dependent tumor suppression in vivo. Rescuing PD-L1 expression eliminated the effects of amlodipine, suggesting the PD-L1-dependent effect of amlodipine. These results reveal a calcium-dependent mechanism controlling PD-L1 degradation, and highlight calcium flux blockade as a potential strategy for combinatorial immunotherapy.	[Li, Chushu; Yao, Han; Wang, Huanbin; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Renji Hosp,Sch Med,Minist Hlth, Div Gastroenterol & Hepatol,Key Lab Gastroenterol, State Key Lab Oncogenes & Related Genes,Shanghai, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Xu, Jie] Fudan Univ, Zhongshan Xuhui Hosp, Inst Biomed Sci, Shanghai, Peoples R China; [Xu, Jie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong University	Xu, J (corresponding author), Fudan Univ, Zhongshan Xuhui Hosp, Inst Biomed Sci, Shanghai, Peoples R China.; Xu, J (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.	jie_xu@fudan.edu.cn	li, chu/GPS-7224-2022; Xu, Jie/K-3712-2019	Xu, Jie/0000-0001-9163-3898; Li, Chushu/0000-0001-6658-2208	National Natural Science Foundation of China [82030104, 81874050, 81572326]; Basic Research Projects of Shanghai Science and Technology Innovation Action Plan [20JC1410700]; National Key R & D Program of China [2016YFC0906002]; Fudan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Research Projects of Shanghai Science and Technology Innovation Action Plan; National Key R & D Program of China; Fudan University	This work was supported by National Natural Science Foundation of China (No: 82030104, 81874050, 81572326), Basic Research Projects of Shanghai Science and Technology Innovation Action Plan (20JC1410700); National Key R & D Program of China (2016YFC0906002, 2016YFC0906002), Tang Scholar (JX), and Startup Research Funding of Fudan University.	Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016; Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Barcelo C, 2020, CANCERS, V12, DOI 10.3390/cancers12020391; Beese CJ, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00373; Blander JM, 2018, ANNU REV IMMUNOL, V36, P717, DOI 10.1146/annurev-immunol-041015-055523; Bong AHL, 2018, BBA-MOL CELL RES, V1865, P1786, DOI 10.1016/j.bbamcr.2018.05.015; Bootman MD, 2018, CELL CALCIUM, V70, P32, DOI 10.1016/j.ceca.2017.08.005; Bulsara K.G., 2020, STATPEARLS; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Cao DL, 2019, CANCER RES, V79, P2604, DOI 10.1158/0008-5472.CAN-18-3842; Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Geng Y, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125326; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guo YJ, 2012, J CELL SCI, V125, P1706, DOI 10.1242/jcs.093203; Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Hong SD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1094598; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kang SH, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1515057; Kaplon H, 2019, MABS-AUSTIN, V11, P219, DOI 10.1080/19420862.2018.1556465; Kayamori H, 2018, INT HEART J, V59, P607, DOI 10.1536/ihj.17-265; Kim I, 2011, ANTIOXID REDOX SIGN, V14, P1919, DOI 10.1089/ars.2010.3768; Knaevelsrud H, 2013, AUTOPHAGY, V9, P1639, DOI 10.4161/auto.26124; KOIDE Y, 1988, P NATL ACAD SCI USA, V85, P3120, DOI 10.1073/pnas.85.9.3120; Kon E, 2019, DRUG RESIST UPDATE, V45, P13, DOI 10.1016/j.drup.2019.07.004; Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009; Li CW, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12632; Li J, 2019, EXP CELL RES, V374, P304, DOI 10.1016/j.yexcr.2018.12.001; Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Longatti A, 2012, J CELL BIOL, V197, P659, DOI 10.1083/jcb.201111079; Ma L, 2019, INTERDISCIP SCI, V11, P266, DOI 10.1007/s12539-019-00331-0; Maher CM, 2018, MOL CANCER RES, V16, P243, DOI 10.1158/1541-7786.MCR-17-0166; Marie N, 2005, BIOCHEM J, V389, P223, DOI 10.1042/BJ20042116; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mohan N, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1624128; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Ota K, 2015, CLIN CANCER RES, V21, P4014, DOI 10.1158/1078-0432.CCR-15-0016; Pan MR, 2020, CANCERS, V12, DOI 10.3390/cancers12010094; Pavel M, 2017, FEBS J, V284, P672, DOI 10.1111/febs.13931; Pimentel-Muinos FX, 2014, AUTOPHAGY, V10, P397, DOI 10.4161/auto.27244; Puri C, 2018, DEV CELL, V45, P114, DOI 10.1016/j.devcel.2018.03.008; Puri C, 2013, CELL, V154, P1285, DOI 10.1016/j.cell.2013.08.044; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29; Shaughnessy M, 2019, INT J ONCOL, V55, P1090, DOI 10.3892/ijo.2019.4873; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun F, 2016, TUMOR BIOL, V37, P15467, DOI 10.1007/s13277-016-5353-y; Syn NL, 2017, LANCET ONCOL, V18, pE731, DOI 10.1016/S1470-2045(17)30607-1; Wang HB, 2019, NAT CHEM BIOL, V15, P42, DOI 10.1038/s41589-018-0161-x; Wang L, 2008, NAT IMMUNOL, V9, P186, DOI 10.1038/ni1548; Wang XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1148-5; Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79; Xia HG, 2010, AUTOPHAGY, V6, P61, DOI 10.4161/auto.6.1.10326; Yamashita S, 2017, AUTOPHAGY, V13, P980, DOI 10.1080/15548627.2017.1291113; Yao H, 2019, NAT BIOMED ENG, V3, P306, DOI 10.1038/s41551-019-0375-6; Yen WL, 2010, J CELL BIOL, V188, P101, DOI 10.1083/jcb.200904075; Yla-Anttila P, 2009, AUTOPHAGY, V5, P1180; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang Z, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00213-8; Zhao Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.66; Zhou CH, 2012, AUTOPHAGY, V8, P1215, DOI 10.4161/auto.20284	66	9	10	5	18	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1128	1146		10.1038/s41388-020-01592-6	http://dx.doi.org/10.1038/s41388-020-01592-6		DEC 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323966	Green Submitted			2022-12-17	WOS:000599126500011
J	Singh, KB; Hahm, ER; Kim, SH; Wendell, SG; Singh, SV				Singh, Krishna B.; Hahm, Eun-Ryeong; Kim, Su-Hyeong; Wendell, Stacy G.; Singh, Shivendra V.			A novel metabolic function of Myc in regulation of fatty acid synthesis in prostate cancer	ONCOGENE			English	Article							C-MYC; CHROMOSOMAL-ANOMALIES; GENE; EXPRESSION; SYNTHASE; AMPLIFICATION; CARCINOMA; OVEREXPRESSION; ADENOCARCINOMA; ONCOGENE	A subset of human prostate cancer exhibits increased de novo synthesis of fatty acids, but the molecular driver(s) of this metabolic abnormality remains obscure. This study demonstrates a novel metabolic function of c-Myc (Myc) in regulation of fatty acid synthesis. The role of Myc in regulation of fatty acid synthesis was investigated by: (a) interrogation of the prostate cancer The Cancer Genome Atlas (TCGA) dataset, (b) chromatin immunoprecipitation, and (c) determination of the expression of fatty acid synthesis enzymes and targeted metabolomics using a mouse model and human specimens. The expression of MYC was positively associated with that of key fatty acid synthesis genes including ACLY, ACC1, and FASN in prostate cancer TCGA dataset. Chromatin immunoprecipitation revealed Myc occupancy at the promoters of ACLY, ACC1, and FASN. Prostate-specific overexpression of Myc in Hi-Myc transgenic mice resulted in overexpression of ACLY, ACC1, and FASN proteins in neoplastic lesions and increased circulating levels of total free fatty acids. Targeted metabolomics confirmed increased circulating levels of individual fatty acids in the plasma of Hi-Myc mice and human subjects when compared to corresponding controls. Immunohistochemistry also revealed a positive and statistically significant association in expression of Myc with that of ACC1 in human prostate adenocarcinoma specimens. We propose that Myc-regulated fatty acid synthesis is a valid target for therapy and/or prevention of prostate cancer.	[Singh, Krishna B.; Hahm, Eun-Ryeong; Kim, Su-Hyeong; Wendell, Stacy G.; Singh, Shivendra V.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA; [Singh, Shivendra V.] Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Singh, SV (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.; Singh, SV (corresponding author), Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Pittsburgh, PA 15213 USA.	singhs@upmc.edu	Singh, Krishna Beer/AAT-9496-2021	/0000-0002-4052-4373	National Cancer Institute [P30 CA047904]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the National Cancer Institute grant R01 CA225716 (to S.V.S.). This study used the Animal Facility and the Tissue and Research Pathology Facility partly supported by the National Cancer Institute grant P30 CA047904. The funders had no role in the design of the study, data collection, analysis or interpretation of the data, manuscript preparation or decision to submit the manuscript for publication.	BUTTYAN R, 1987, PROSTATE, V11, P327, DOI 10.1002/pros.2990110405; Chavarro JE, 2013, AM J EPIDEMIOL, V178, P1246, DOI 10.1093/aje/kwt136; Chen HW, 2012, PROSTATE CANCER P D, V15, P260, DOI 10.1038/pcan.2012.15; Edwards J, 2003, CLIN CANCER RES, V9, P5271; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; FOX SB, 1993, J UROLOGY, V150, P490, DOI 10.1016/S0022-5347(17)35533-7; Gao LN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063563; Gao YJ, 2014, CANCER LETT, V349, P15, DOI 10.1016/j.canlet.2014.03.015; Gouw AM, 2019, CELL METAB, V30, P556, DOI 10.1016/j.cmet.2019.07.012; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WW, 1997, GENOMICS, V43, P69, DOI 10.1006/geno.1997.4715; Jenkins RB, 1997, CANCER RES, V57, P524; Li XN, 2011, ANAL CHEM, V83, P3192, DOI 10.1021/ac103093w; Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Miyoshi Y, 2000, PROSTATE, V43, P225, DOI 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7; NAG A, 1989, PROSTATE, V15, P115, DOI 10.1002/pros.2990150205; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Rossi S, 2003, MOL CANCER RES, V1, P707; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Schmidt LJ, 2013, CURR DRUG TARGETS, V14, P401; Scott KEN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029761; Shah US, 2006, HUM PATHOL, V37, P401, DOI 10.1016/j.humpath.2005.11.022; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh KB, 2019, CARCINOGENESIS, V40, P1545, DOI 10.1093/carcin/bgz155; Singh KB, 2019, MOL CANCER THER, V18, P1800, DOI 10.1158/1535-7163.MCT-19-0046; Singh KB, 2018, CARCINOGENESIS, V39, P826, DOI 10.1093/carcin/bgy051; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Suburu J, 2012, PROSTAG OTH LIPID M, V98, P1, DOI 10.1016/j.prostaglandins.2012.03.003; Sun JS, 2007, PROSTATE, V67, P692, DOI 10.1002/pros.20543; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Vyas AR, 2016, J CELL BIOCHEM, V117, P2482, DOI 10.1002/jcb.25541; Wang SI, 1998, CLIN CANCER RES, V4, P811; WARBURG O, 1956, SCIENCE, V124, P269; Wu XY, 2014, AM J CLIN EXP UROL, V2, P111; Zeng W, 2015, INT J CLIN EXP PATHO, V8, P1878; Zhang Q, 2019, ONCOL LETT, V18, P4237, DOI 10.3892/ol.2019.10765	42	9	9	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					592	602		10.1038/s41388-020-01553-z	http://dx.doi.org/10.1038/s41388-020-01553-z		NOV 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33199826	Green Accepted			2022-12-17	WOS:000590042900002
J	Kim, JY; Kim, HJ; Jung, CW; Choi, BI; Lee, DH; Park, MJ				Kim, Jeong-Yub; Kim, Hee-Jin; Jung, Chan-Woong; Choi, Byung-Il; Lee, Dea-Hee; Park, Myung-Jin			PARK7 maintains the stemness of glioblastoma stem cells by stabilizing epidermal growth factor receptor variant III	ONCOGENE			English	Article							PARKINSONS-DISEASE; CANCER-CELLS; DJ-1; IDENTIFICATION; EXPRESSION; TARGET; GLIOMA; EGFR; SOX2; ONCOGENE	PARK7 is involved in many key cellular processes, including cell proliferation, transcriptional regulation, cellular differentiation, oxidative stress protection, and mitochondrial function maintenance. Deregulation of PARK7 has been implicated in the pathogenesis of various human diseases, including cancer. Here, we aimed to clarify the effect of PARK7 on stemness and radioresistance of glioblastoma stem cells (GSCs). Serum differentiation and magnetic cell sorting of GSCs revealed that PARK7 was preferentially expressed in GSCs rather than differentiated GSCs. Immunohistochemical staining showed enhanced expression of PARK7 in glioma tissues compared to that in normal brain tissues. shRNA-mediated knockdown of PARK7 inhibited the self-renewal activity of GSCs in vitro, as evidenced by the results of neurosphere formation, limiting dilution, and soft-agar clonogenic assays. In addition, PARK7 knockdown suppressed GSC invasion and enhanced GSC sensitivity to ionizing radiation (IR). PARK7 knockdown suppressed expression of GSC signatures including nestin, epidermal growth factor receptor variant III (EGFRvIII), SOX2, NOTCH1, and OCT4. Contrarily, overexpression of PARK7 in CD133(-) non-GSCs increased self-renewal activities, migration, and IR resistance, and rescued the reduction of GSC factors under shPARK7-transfected and serum-differentiation conditions. Intriguingly, PARK7 acted as a co-chaperone of HSP90 by binding to it, protecting EGFRvIII from proteasomal degradation. Knockdown of PARK7 increased the production of reactive oxygen species, inducing partial apoptosis and enhancing IR sensitivity in GSCs. Finally, PARK7 knockdown increased mouse survival and IR sensitivity in vivo. Based on these data, we propose that PARK7 plays a pivotal role in the maintenance of stemness and therapeutic resistance in GSCs.	[Kim, Jeong-Yub; Kim, Hee-Jin; Jung, Chan-Woong; Park, Myung-Jin] Korea Inst Radiol & Med Sci, Div Radiat Canc Sci, Radiat Therapeut Dev Team, Seoul, South Korea; [Kim, Hee-Jin] Korea Univ, Sch Biomed Sci, Seoul, South Korea; [Jung, Chan-Woong] Korea Univ, Dept Life Sci, Seoul, South Korea; [Choi, Byung-Il] Korea Univ, Coll Med, Guro Hosp, Div Gastroenterol,Dept Internal Med, 148 Gurodong Ro, Seoul, South Korea; [Lee, Dea-Hee] Gangneung Wonju Natl Univ, Dept Marine Food Sci & Technol, Gangwon, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; Korea University; Korea University; Korea University Medicine (KU Medicine); Kangnung Wonju National University	Park, MJ (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Canc Sci, Radiat Therapeut Dev Team, Seoul, South Korea.; Lee, DH (corresponding author), Gangneung Wonju Natl Univ, Dept Marine Food Sci & Technol, Gangwon, South Korea.	neogene@gwnu.ac.kr; mjpark@kirams.re.kr			Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), Republic of Korea [50531-2019]; Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) - MSIT, Republic of Korea [NRF-2017M2A2A7A02019889]; NRF - MSIT, Republic of Korea [NRF-2019R1A2C2089249]	Korea Institute of Radiological and Medical Sciences (KIRAMS) - Ministry of Science and ICT (MSIT), Republic of Korea(Ministry of Science & ICT (MSIT), Republic of KoreaMinistry of Science, ICT & Future Planning, Republic of Korea); Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) - MSIT, Republic of Korea(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea); NRF - MSIT, Republic of Korea(National Research Foundation of KoreaMinistry of Science & ICT (MSIT), Republic of Korea)	This study was supported by a grant of the Korea Institute of Radiological and Medical Sciences (KIRAMS), funded by Ministry of Science and ICT (MSIT), Republic of Korea. (No. 50531-2019), Nuclear Research and Development Program of the National Research Foundation of Korea (NRF) funded by MSIT, Republic of Korea (No. NRF-2017M2A2A7A02019889), and NRF grant funded by MSIT, Republic of Korea (No. NRF-2019R1A2C2089249).	Ahsan A, 2012, NEOPLASIA, V14, P670, DOI 10.1593/neo.12986; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Bradley E, 2012, STEM CELLS, V30, P1624, DOI 10.1002/stem.1143; Canet-Aviles RM, 2004, P NATL ACAD SCI USA, V101, P9103, DOI 10.1073/pnas.0402959101; Cao J, 2017, ADV EXP MED BIOL, V1037, P203, DOI 10.1007/978-981-10-6583-5_13; Cao J, 2015, BIOCHEM PHARMACOL, V93, P241, DOI 10.1016/j.bcp.2014.11.012; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chen Y, 2012, J CANCER RES CLIN, V138, P1463, DOI 10.1007/s00432-012-1205-3; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Echeverria PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026044; Emlet DR, 2014, CANCER RES, V74, P1238, DOI 10.1158/0008-5472.CAN-13-1407; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Gao X, 2011, DRUG TODAY, V47, P215, DOI 10.1358/dot.2011.47.3.1519657; Giaime E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040501; Girotto S, 2014, J BIOL CHEM, V289, P10887, DOI 10.1074/jbc.M113.535112; Hammoud MA, 1996, J NEURO-ONCOL, V27, P65, DOI 10.1007/BF00146086; Im JY, 2012, HUM MOL GENET, V21, P3013, DOI 10.1093/hmg/dds131; Jahani-Asl A, 2016, NAT NEUROSCI, V19, P798, DOI 10.1038/nn.4295; Junn E, 2009, J NEUROSCI RES, V87, P123, DOI 10.1002/jnr.21831; Kawate T, 2017, ADV EXP MED BIOL, V1037, P45, DOI 10.1007/978-981-10-6583-5_4; Kim J, 2015, STEM CELLS DEV, V24, P284, DOI 10.1089/scd.2014.0210; Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010; Kim Y, 2012, MOL CELL PROTEOMICS, V11, P1870, DOI 10.1074/mcp.M112.017889; Knobbe CB, 2011, J PROTEOME RES, V10, P4388, DOI 10.1021/pr200225c; Kudryavtsev VA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173640; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lavictoire SJ, 2003, J BIOL CHEM, V278, P5292, DOI 10.1074/jbc.M209494200; Le Naour F, 2001, CLIN CANCER RES, V7, P3328; Lee DH, 2018, AUTOPHAGY, V14, P1870, DOI 10.1080/15548627.2018.1491212; Macedo MG, 2003, HUM MOL GENET, V12, P2807, DOI 10.1093/hmg/ddg304; Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Oh SE, 2017, ADV EXP MED BIOL, V1037, P97, DOI 10.1007/978-981-10-6583-5_8; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Osuka S, 2017, J CLIN INVEST, V127, P415, DOI 10.1172/JCI89587; Parsanejad M, 2014, J NEUROSCI, V34, P8043, DOI 10.1523/JNEUROSCI.1244-13.2014; Raninga PV, 2017, ADV EXP MED BIOL, V1037, P67, DOI 10.1007/978-981-10-6583-5_6; Raninga Prahlad V, 2014, Oncoscience, V1, P95; Ren HG, 2011, J BIOL CHEM, V286, P35308, DOI 10.1074/jbc.M110.207134; Rybak AP, 2013, CELL SIGNAL, V25, P2734, DOI 10.1016/j.cellsig.2013.08.041; Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696; Shendelman S, 2004, PLOS BIOL, V2, P1764, DOI 10.1371/journal.pbio.0020362; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Takahashi-Niki K, 2017, ADV EXP MED BIOL, V1037, P89, DOI 10.1007/978-981-10-6583-5_7; Takahashi-Niki K, 2015, J BIOL CHEM, V290, P17838, DOI 10.1074/jbc.M115.666271; Thorne AH, 2016, NEURO-ONCOLOGY, V18, P914, DOI 10.1093/neuonc/nov319; Tillman JE, 2007, CANCER RES, V67, P4630, DOI 10.1158/0008-5472.CAN-06-4556; Vasseur S, 2009, P NATL ACAD SCI USA, V106, P1111, DOI 10.1073/pnas.0812745106; Wang B, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0065-1; Xu K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705504; Yin J, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002152; Zhang S, 2016, ONCOTARGET, V7, P65758, DOI 10.18632/oncotarget.11613; Zhong HQ, 2015, REDOX BIOL, V4, P193, DOI 10.1016/j.redox.2014.12.011; Zhou L, 2011, PLOS ONE, V6, pe1672; Zou ZZ, 2017, APOPTOSIS, V22, P1321, DOI 10.1007/s10495-017-1424-9	59	9	10	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					508	521		10.1038/s41388-020-01543-1	http://dx.doi.org/10.1038/s41388-020-01543-1		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33188296				2022-12-17	WOS:000589573800003
J	Schmidt, AK; Pudelko, K; Boekenkamp, JE; Berger, K; Kschischo, M; Bastians, H				Schmidt, Ann-Kathrin; Pudelko, Karoline; Boekenkamp, Jan-Eric; Berger, Katharina; Kschischo, Maik; Bastians, Holger			The p53/p73-p21(CIP1) tumor suppressor axis guards against chromosomal instability by restraining CDK1 in human cancer cells	ONCOGENE			English	Article							DNA-REPLICATION; CYCLE; P53; P21; ARREST; KINASE; PROLIFERATION; INACTIVATION; EXPRESSION; P21(WAF1)	Whole chromosome instability (W-CIN) is a hallmark of human cancer and contributes to the evolvement of aneuploidy. W-CIN can be induced by abnormally increased microtubule plus end assembly rates during mitosis leading to the generation of lagging chromosomes during anaphase as a major form of mitotic errors in human cancer cells. Here, we show that loss of the tumor suppressor genes TP53 and TP73 can trigger increased mitotic microtubule assembly rates, lagging chromosomes, and W-CIN. CDKN1A, encoding for the CDK inhibitor p21(CIP1), represents a critical target gene of p53/p73. Loss of p21(CIP1) unleashes CDK1 activity which causes W-CIN in otherwise chromosomally stable cancer cells. Consequently, induction of CDK1 is sufficient to induce abnormal microtubule assembly rates and W-CIN. Vice versa, partial inhibition of CDK1 activity in chromosomally unstable cancer cells corrects abnormal microtubule behavior and suppresses W-CIN. Thus, our study shows that the p53/p73 - p21(CIP1) tumor suppressor axis, whose loss is associated with W-CIN in human cancer, safeguards against chromosome missegregation and aneuploidy by preventing abnormally increased CDK1 activity.	[Schmidt, Ann-Kathrin; Pudelko, Karoline; Berger, Katharina; Bastians, Holger] Georg August Univ Gottingen, Gottingen Ctr Mol Biosci GZMB, D-37077 Gottingen, Germany; [Schmidt, Ann-Kathrin; Pudelko, Karoline; Berger, Katharina; Bastians, Holger] Univ Med Ctr Gottingen UMG, Inst Mol Oncol, Sect Cellular Oncol, D-37077 Gottingen, Germany; [Boekenkamp, Jan-Eric; Kschischo, Maik] Univ Appl Sci Koblenz, Dept Math & Technol, D-53424 Remagen, Germany	University of Gottingen	Bastians, H (corresponding author), Georg August Univ Gottingen, Gottingen Ctr Mol Biosci GZMB, D-37077 Gottingen, Germany.; Bastians, H (corresponding author), Univ Med Ctr Gottingen UMG, Inst Mol Oncol, Sect Cellular Oncol, D-37077 Gottingen, Germany.	holger.bastians@uni-goettingen.de		Boekenkamp, Jan-Eric/0000-0002-1662-0349; Bastians, Holger/0000-0001-7915-3648; Schmidt, Ann-Kathrin/0000-0001-8100-5177	Wilhelm Sander-Stiftung; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft [FOR2800]; Projekt DEAL	Wilhelm Sander-Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Projekt DEAL	We thank Magdalena Hennecke for technical assistance. We are grateful to Thorsten Stiewe, Linda Wordeman, Matthias Schmidt, Makato Iimori, and Lienhard Schmitz for providing plasmids and cell lines. This work was supported by grants from the Wilhelm Sander-Stiftung, from the Deutsche Krebshilfe, and from the Deutsche Forschungsgemeinschaft to HB and by the FOR2800 funded by the Deutsche Forschungsgemeinschaft (MK and HB). Open Access funding enabled and organized by Projekt DEAL.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Bakhoum SF, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a029611; Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bohly N, 2019, CELL CYCLE, V18, P2770, DOI 10.1080/15384101.2019.1658477; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Crncec A, 2019, FEBS LETT, V593, P2868, DOI 10.1002/1873-3468.13635; Di CX, 2013, CELL CYCLE, V12, P1861, DOI 10.4161/cc.24967; Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204; Engelmann D, 2015, ONCOGENE, V34, P4287, DOI 10.1038/onc.2014.365; Ertych N, 2016, P NATL ACAD SCI USA, V113, P1817, DOI 10.1073/pnas.1525129113; Ertych N, 2014, NAT CELL BIOL, V16, P779, DOI 10.1038/ncb2994; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Garcia-Gutierrez L, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030244; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Harms K, 2004, CELL MOL LIFE SCI, V61, P822, DOI 10.1007/s00018-003-3304-4; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518; Kreis NN, 2019, CANCERS, V11, DOI 10.3390/cancers11091220; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li JX, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01817-8; Luddecke S, 2016, ONCOGENE, V35, P2398, DOI 10.1038/onc.2015.290; Maas AM, 2013, CANCER LETT, V332, P229, DOI 10.1016/j.canlet.2011.07.030; Maia ARR, 2012, J CELL BIOL, V199, P285, DOI 10.1083/jcb.201203091; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nam HJ, 2014, NAT CELL BIOL, V16, P535, DOI 10.1038/ncb2952; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ogino S, 2006, J PATHOL, V210, P147, DOI 10.1002/path.2030; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Sansregret L, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a028373; Santaguida S, 2017, DEV CELL, V41, P638, DOI 10.1016/j.devcel.2017.05.022; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Schmidt M, 2017, MOLECULES, V22, DOI 10.3390/molecules22122045; Sheltzer JM, 2011, TRENDS GENET, V27, P446, DOI 10.1016/j.tig.2011.07.003; Silkworth WT, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-19; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Stepanova T, 2003, J NEUROSCI, V23, P2655; Stolz A, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.960768; Stolz A, 2015, EMBO REP, V16, P490, DOI 10.15252/embr.201439410; Stolz A, 2010, BIOCHEM SOC T, V38, P1704, DOI 10.1042/BST0381704; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Sur S, 2016, MOL CELL BIOCHEM, V416, P33, DOI 10.1007/s11010-016-2693-2; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; Umbreit NT, 2020, SCIENCE, V368, P282, DOI 10.1126/science.aba0712; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; WALDMAN T, 1995, CANCER RES, V55, P5187; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Zhang CZ, 2015, NATURE, V522, P179, DOI 10.1038/nature14493	60	9	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					436	451		10.1038/s41388-020-01524-4	http://dx.doi.org/10.1038/s41388-020-01524-4		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33168930	Green Published, hybrid			2022-12-17	WOS:000587997700001
J	Abdullah, A; Akhand, SS; Paez, JSP; Brown, W; Pan, L; Libring, S; Badamy, M; Dykuizen, E; Solorio, L; Tao, WA; Wendt, MK				Abdullah, Ammara; Akhand, Saeed Salehin; Paez, Juan Sebastian Paez; Brown, Wells; Pan, Li; Libring, Sarah; Badamy, Michael; Dykuizen, Emily; Solorio, Luis; Tao, W. Andy; Wendt, Michael K.			Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; CELL MIGRATION; ACTIVATION; EXPRESSION; FAMILY; COMBINATION; BEVACIZUMAB; INHIBITION; ERLOTINIB; OUTGROWTH	Human epidermal growth factor receptor 2 (HER2)-amplified breast cancers are treated using targeted antibodies and kinase inhibitors, but resistance to these therapies leads to systemic tumor recurrence of metastatic disease. Herein, we conducted gene expression analyses of HER2 kinase inhibitor-resistant cell lines as compared to their drug-sensitive counterparts. These data demonstrate the induction of epithelial-mesenchymal transition (EMT), which included enhanced expression of fibroblast growth factor receptor 1 (FGFR1) and axonal guidance molecules known as neuropilins (NRPs). Immunoprecipitation of FGFR1 coupled with mass spectroscopy indicated that FGFR1 forms a physical complex with NRPs, which is enhanced upon induction of EMT. Confocal imaging revealed that FGFR1 and NRP1 predominantly interact throughout the cytoplasm. Along these lines, short hairpin RNA-mediated depletion of NRP1, but not the use of NRP1-blocking antibodies, inhibited FGFR signaling and reduced tumor cell growth in vitro and in vivo. Our results further indicate that NRP1 upregulation during EMT is mediated via binding of the chromatin reader protein, bromodomain containing 4 (BRD4) in the NRP1 proximal promoter region. Pharmacological inhibition of BRD4 decreased NRP1 expression and ablated FGF-mediated tumor cell growth. Overall, our studies indicate that NRPs facilitate aberrant growth factor signaling during EMT-associated drug resistance and metastasis. Pharmacological combination of epigenetic modulators with FGFR-targeted kinase inhibitors may provide improved outcomes for breast cancer patients with drug-resistant metastatic disease.	[Abdullah, Ammara; Akhand, Saeed Salehin; Paez, Juan Sebastian Paez; Brown, Wells; Pan, Li; Badamy, Michael; Dykuizen, Emily; Tao, W. Andy; Wendt, Michael K.] Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; [Libring, Sarah; Solorio, Luis] Purdue Univ, Dept Biomed Engn, W Lafayette, IN 47907 USA; [Dykuizen, Emily; Solorio, Luis; Tao, W. Andy; Wendt, Michael K.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Wendt, MK (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA.; Wendt, MK (corresponding author), Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA.	mwendt@purdue.edu		dykhuizen, emily/0000-0003-3072-1469; Libring, Sarah/0000-0001-8336-5862	American Cancer Society Research Scholar Grant [RSG-CSM-130259]; National Cancer Institute [R01CA207751]; METavivor Translational Research Award; Purdue Center for Cancer Research via its NIH NCI [P30CA023168]; NIH-funded Indiana Clinical and Translational Sciences Institute	American Cancer Society Research Scholar Grant(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); METavivor Translational Research Award; Purdue Center for Cancer Research via its NIH NCI; NIH-funded Indiana Clinical and Translational Sciences Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by an American Cancer Society Research Scholar Grant (RSG-CSM-130259), the National Cancer Institute (R01CA207751), and a METavivor Translational Research Award, to M. K.W. We also acknowledge the support of the Purdue Center for Cancer Research via its NIH NCI grant (P30CA023168). We thank Genentech for supplying the antiNRP1 antibody YW107.4. We also acknowledge the personnel for the use of the facilities within the Bindley Bioscience Center, a core facility of the NIH-funded Indiana Clinical and Translational Sciences Institute.	Ali R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1034-7; Azuma K, 2014, ONCOTARGET, V5, P5908, DOI 10.18632/oncotarget.1866; Azuma K, 2011, BIOCHEM BIOPH RES CO, V407, P219, DOI 10.1016/j.bbrc.2011.03.002; Benedetti R, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201810116; Brown WS, 2016, ONCOTARGET, V7, P83424, DOI 10.18632/oncotarget.13117; Brown WS, 2016, MOL CANCER THER, V15, P2096, DOI 10.1158/1535-7163.MCT-16-0136; Bumbaca D, 2012, BRIT J PHARMACOL, V166, P368, DOI 10.1111/j.1476-5381.2011.01777.x; Cagnoni G, 2014, ONCOGENE, V33, P4795, DOI 10.1038/onc.2013.474; Chen CX, 2016, MOL MED REP, V13, P188, DOI 10.3892/mmr.2015.4556; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Chua V, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809081; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Elsheikh SE, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1665; Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556-018-0138-8; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Grandclement Camille, 2011, Cancers (Basel), V3, P1899, DOI 10.3390/cancers3021899; Hanker AB, 2017, CLIN CANCER RES, V23, P4323, DOI 10.1158/1078-0432.CCR-16-2287; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; Herzog B, 2011, MOL BIOL CELL, V22, P2766, DOI 10.1091/mbc.E09-12-1061; Issitt T, 2019, ISCIENCE, V11, P205, DOI 10.1016/j.isci.2018.12.005; Jarvis A, 2010, J MED CHEM, V53, P2215, DOI 10.1021/jm901755g; Kachel P, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1135-y; Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019; Lee TW, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0443-3; Liang WC, 2007, J MOL BIOL, V366, P815, DOI 10.1016/j.jmb.2006.11.021; Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444; Patnaik A, 2014, CANCER CHEMOTH PHARM, V73, P951, DOI 10.1007/s00280-014-2426-8; Qian X, 2014, ONCOGENE, V33, P3411, DOI 10.1038/onc.2013.310; Rastelli F, 2010, TUMORI J, V96, P875, DOI 10.1177/548.6505; Rexer Brent N., 2012, Critical Reviews in Oncogenesis, V17, P1; Rizzolio S, 2018, J CLIN INVEST, V128, P3976, DOI 10.1172/JCI99257; Rizzolio S, 2012, CANCER RES, V72, P5801, DOI 10.1158/0008-5472.CAN-12-0995; Sharpe R, 2011, CLIN CANCER RES, V17, P5275, DOI 10.1158/1078-0432.CCR-10-2727; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shinde A, 2018, MOL CANCER RES, V16, P1579, DOI 10.1158/1541-7786.MCR-18-0151; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Smith IE, 2007, J CLIN ONCOL, V25, P3816, DOI 10.1200/JCO.2006.09.6578; Stuhlmiller TJ, 2015, CELL REP, V11, P390, DOI 10.1016/j.celrep.2015.03.037; Sutton LM, 2010, AM J CLIN PATHOL, V134, P782, DOI 10.1309/AJCPRMD3ARUO5WPN; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Valdembri D, 2009, PLOS BIOL, V7, P115, DOI 10.1371/journal.pbio.1000025; Vivekanandhan S, 2019, SEMIN CANCER BIOL, V54, P72, DOI 10.1016/j.semcancer.2018.01.014; Weekes CD, 2014, INVEST NEW DRUG, V32, P653, DOI 10.1007/s10637-014-0071-z; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Wendt MK, 2015, NEOPLASIA, V17, P124, DOI 10.1016/j.neo.2014.11.009; Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306; WENDT MK, 2014, BREAST CANCER RES, V16; West DC, 2005, J BIOL CHEM, V280, P13457, DOI 10.1074/jbc.M410924200; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Yates LR, 2017, CANCER CELL, V32, P169, DOI 10.1016/j.ccell.2017.07.005; Zhang L, 2013, CANCER RES, V73, P3316, DOI 10.1158/0008-5472.CAN-12-3015; Zhao MF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12713	56	9	9	4	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					322	333		10.1038/s41388-020-01530-6	http://dx.doi.org/10.1038/s41388-020-01530-6		OCT 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33128042	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000585769600002
J	Li, Y; Li, L; Qin, J; Wu, JY; Dai, XM; Xu, JM				Li, Yang; Li, Lei; Qin, Jun; Wu, Junyi; Dai, Xueming; Xu, Junming			OSR1 phosphorylates the Smad2/3 linker region and induces TGF-beta 1 autocrine to promote EMT and metastasis in breast cancer	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; STEM-CELLS; EXPRESSION; ACTIVATION; RESISTANCE; TURNOVER; GENE; WNK1	Oxidative stress-responsive kinase 1 (OSR1) plays a critical role in multiple carcinogenic signal pathways, and its overexpression has been found in various types of cancer; however, the pathophysiological role of OSR1 in breast cancer has not been evaluated. This study aims to elaborate on the role of OSR1 in breast cancer metastasis and the specific regulatory mechanism. Our results showed that OSR1 mRNA and protein were upregulated in both human breast cancer samples and cell lines. Moreover, phosphorylated OSR1 (p-OSR1) was an independent poor prognostic indicator in patients with breast cancer. OSR1 upregulation induced epithelial-to-mesenchymal transition (EMT) in normal and malignant mammary epithelial cells with the increasing metastatic capacity. In contrast, deleting OSR1 in aggressive breast cancer cells inhibited these phenotypes. OSR1 is the critical activator for transcription factors of EMT. Mechanistically, we found that OSR1 can directly interact and phosphorylate the linker region of Smad2 at Thr220 and Smad3 at Thr179. Phosphorylated Smad2/3 translocated into the nucleus to enhance transforming growth factor-beta 1 (TGF-beta 1) autocrine signalling and increase the transcription of EMT regulators. Importantly, interruption of the OSR1-Smad2/3-TGF-beta 1 signalling axis elicited a robust anti-EMT and anti-metastatic effect in vitro and in vivo. Taken together, we conclude that OSR1-mediated Smad2/3-TGF-beta 1 signalling promotes EMT and metastasis representing a promising therapeutic target in breast cancer treatment.	[Li, Yang; Li, Lei; Qin, Jun; Wu, Junyi; Dai, Xueming; Xu, Junming] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, 100 Haining Rd, Shanghai 200080, Peoples R China	Shanghai Jiao Tong University	Xu, JM (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, 100 Haining Rd, Shanghai 200080, Peoples R China.	junmingxusur@hotmail.com		Li, Yang/0000-0002-5882-2301	National Natural Science Foundation of China [81670595, 81970568]; Shanghai Natural Science Funds [16ZR1428200]; Excellent Youth Medical Talents Program of Shanghai General Hospital [06N1702011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Natural Science Funds; Excellent Youth Medical Talents Program of Shanghai General Hospital	This work was supported by the National Natural Science Foundation of China (81670595, 81970568), Shanghai Natural Science Funds (16ZR1428200), and the Excellent Youth Medical Talents Program of Shanghai General Hospital (06N1702011).	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; AlAmri MA, 2017, CHEMMEDCHEM, V12, P639, DOI 10.1002/cmdc.201700077; Alarcon C, 2009, CELL, V139, P757, DOI 10.1016/j.cell.2009.09.035; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Aragon E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Burington B, 2008, CLIN CANCER RES, V14, P4821, DOI 10.1158/1078-0432.CCR-07-4568; Chen W, 2004, J BIOL CHEM, V279, P11129, DOI 10.1074/jbc.M313562200; Chen ZH, 2011, RESP PHYSIOL NEUROBI, V176, P110, DOI 10.1016/j.resp.2011.02.001; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Conti A, 2018, PROTEOM CLIN APPL, V12, DOI 10.1002/prca.201800041; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Ernest NJ, 2005, AM J PHYSIOL-CELL PH, V288, pC1451, DOI 10.1152/ajpcell.00503.2004; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Galliher Amy J, 2006, Future Oncol, V2, P743, DOI 10.2217/14796694.2.6.743; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Hung JY, 2017, ONCOTARGET, V8, P63691, DOI 10.18632/oncotarget.19475; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ju HR, 2003, CANCER LETT, V196, P197, DOI 10.1016/S0304-3835(03)00237-4; Kankanamalage SG, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0287-1; Krueger EM, 2011, ANN NEUROSCI, V18, P70, DOI 10.5214/ans.0972.7531.1118212; Lampropoulos P, 2012, CANCER LETT, V314, P1, DOI 10.1016/j.canlet.2011.09.041; Li Y, 2020, BREAST CANCER RES TR, V182, P35, DOI 10.1007/s10549-020-05671-w; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Niimi H, 2007, J CELL BIOL, V176, P695, DOI 10.1083/jcb.200612129; Nishida H, 2012, HYPERTENSION, V60, P981, DOI 10.1161/HYPERTENSIONAHA.112.201509; Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253; Ruan HY, 2017, AM J CANCER RES, V7, P543; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shi XN, 2018, ONCOL REP, V40, P1592, DOI 10.3892/or.2018.6533; Shyamasundar S, 2016, INT J ONCOL, V49, P2629, DOI 10.3892/ijo.2016.3761; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Solomon A, 2004, GENETICS, V167, P161, DOI 10.1534/genetics.167.1.161; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Tamari M, 1999, J HUM GENET, V44, P116, DOI 10.1007/s100380050121; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tu SW, 2011, P NATL ACAD SCI USA, V108, P1385, DOI 10.1073/pnas.1018567108; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wang GN, 2009, J BIOL CHEM, V284, P9663, DOI 10.1074/jbc.M809281200; Wtighton KH, 2008, CELL SIGNAL, V20, P1579, DOI 10.1016/j.cellsig.2008.02.003; Yeh HW, 2018, NAT CELL BIOL, V20, P479, DOI 10.1038/s41556-018-0062-y; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zeng GC, 2000, INT J CANCER, V88, P53, DOI 10.1002/1097-0215(20001001)88:1<53::AID-IJC8>3.0.CO;2-7; Zhou YY, 2017, ONCOTARGET, V8, P66328, DOI 10.18632/oncotarget.20240; Zhu W, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-31	53	9	10	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					68	84		10.1038/s41388-020-01499-2	http://dx.doi.org/10.1038/s41388-020-01499-2		OCT 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051597				2022-12-17	WOS:000577556100004
J	Xu, J; Brosseau, JP; Shi, HB				Xu, Jie; Brosseau, Jean-Philippe; Shi, Hubing			Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy	ONCOGENE			English	Review							CELL-INTRINSIC PD-1; LYSOSOMAL DEGRADATION; DOWN-REGULATION; HIV-1 NEF; OPPORTUNITIES; MOTIF	Cancer immunotherapy using immune-checkpoint blockade has displayed promising clinical effects, but prevalent antibody-based inhibitors face multiple challenges such as low response rate, acquired resistance, and adverse effects. The intracellular expression of PD-1/PD-L1 in recycling endosomes and their active trafficking to membrane highlight the importance of depleting rather than interfering with checkpoint proteins. Preclinical investigations on the therapeutic effects of lead compounds that function by degrading immune checkpoint ligands and receptors have reported highly promising results. By harnessing the degradation capabilities of the lysosome, proteasome and autophagosomes, different small molecules and peptides potently induced degradation of checkpoint proteins and enhanced anti-tumor immunity. Both in vitro and in vivo experiments support the therapeutic efficacy of these molecules. Thus, targeted degradation through endo-lysosomal, autophagic, proteasomal, or endoplasmic reticulum-related pathways may provide promising strategies for tackling the challenges in cancer immunotherapy.	[Xu, Jie] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China; [Xu, Jie] Fudan Univ, Zhongshan Xuhui Hosp, Key Lab Epigenet & Metab, Shanghai, Peoples R China; [Brosseau, Jean-Philippe] Ctr Hosp Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada; [Brosseau, Jean-Philippe] Univ Sherbrooke, Dept Biochem & Funct Genom, Sherbrooke, PQ, Canada; [Shi, Hubing] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Lab Tumor Targeted & Immune Therapy,Clin Res Ctr, Chengdu, Peoples R China; [Shi, Hubing] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China	Fudan University; Fudan University; University of Sherbrooke; Sichuan University	Xu, J (corresponding author), Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.; Xu, J (corresponding author), Fudan Univ, Zhongshan Xuhui Hosp, Key Lab Epigenet & Metab, Shanghai, Peoples R China.	jie_xu@fudan.edu.cn	Xu, Jie/K-3712-2019	Xu, Jie/0000-0001-9163-3898; Shi, Hubing/0000-0002-2926-3440	National Natural Science Foundation of China [82030104, 81874050, 81572326]; Basic Research Projects of Shanghai Science and Technology Innovation Action Plan [20JC1410700]; National Key R & D Program of China [2016YFC0906002]; Startup Research Funding of Fudan University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Research Projects of Shanghai Science and Technology Innovation Action Plan; National Key R & D Program of China; Startup Research Funding of Fudan University	This work was supported by National Natural Science Foundation of China (No: 82030104, 81874050, 81572326), Basic Research Projects of Shanghai Science and Technology Innovation Action Plan (20JC1410700); National Key R & D Program of China (2016YFC0906002, 2016YFC0906002), Tang Scholar (JX), and Startup Research Funding of Fudan University.	Baek K, 2020, NAT CHEM BIOL, V16, P2, DOI 10.1038/s41589-019-0414-3; Brosseau JP, 2020, ADV EXP MED BIOL, V1248, P251, DOI 10.1007/978-981-15-3266-5_11; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Cha JH, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036863; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Cha JH, 2018, MOL CELL, V71, P606, DOI 10.1016/j.molcel.2018.07.030; Chamberlain PP, 2019, NAT CHEM BIOL, V15, P937, DOI 10.1038/s41589-019-0362-y; Chen SL, 2019, CURR TOP MED CHEM, V19, P180, DOI 10.2174/1568026619666190308131805; Delport A, 2019, MOLECULES, V24, DOI 10.3390/molecules24183272; Deng SY, 2020, ADV EXP MED BIOL, V1248, P431, DOI 10.1007/978-981-15-3266-5_18; Dong PX, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00386; Dua P, 2015, NUCLEIC ACID THER, V25, P180, DOI 10.1089/nat.2014.0516; Dvela-Levitt M, 2019, CELL, V178, P521, DOI 10.1016/j.cell.2019.07.002; Endicott SJ, 2021, AUTOPHAGY, V17, P612, DOI 10.1080/15548627.2020.1725378; Esfahani K, 2019, NEW ENGL J MED, V380, P2375, DOI 10.1056/NEJMc1903064; Fan XL, 2014, NAT NEUROSCI, V17, P471, DOI 10.1038/nn.3637; Gao HY, 2020, ACS MED CHEM LETT, V11, P237, DOI 10.1021/acsmedchemlett.9b00597; Gao HL, 2013, SCI REP-UK, V3, DOI 10.1038/srep02534; Gomez-Navarro N, 2016, J CELL BIOL, V215, P769, DOI 10.1083/jcb.201610031; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; Greillier L, 2018, TRANSL LUNG CANCER R, V7, P639, DOI 10.21037/tlcr.2018.10.08; Hakenberg OW, 2017, EXPERT OPIN BIOL TH, V17, P1309, DOI 10.1080/14712598.2017.1353076; Hsu JM, 2018, CANCER RES, V78, P6349, DOI 10.1158/0008-5472.CAN-18-1892; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Kiran S, 2020, CHEM COMMUN, V56, P285, DOI 10.1039/c9cc09131a; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Li H, 2017, HEPATOLOGY, V66, P1920, DOI 10.1002/hep.29360; Liang LX, 2018, CELL CHEM BIOL, V25, P761, DOI 10.1016/j.chembiol.2018.03.010; Liu Y, 2019, TRANSL LUNG CANCER R, V8, P1125, DOI 10.21037/tlcr.2019.11.26; Lyle C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56208-1; Meng XB, 2018, NATURE, V564, P130, DOI 10.1038/s41586-018-0756-0; Neklesa T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.259; Pu N, 2019, CANCER LETT, V460, P42, DOI 10.1016/j.canlet.2019.06.013; Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168; Riggs NL, 1999, VIROLOGY, V258, P203, DOI 10.1006/viro.1999.9736; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Steven B, 2019, LYSOSOME TARGETING C, V584, P291; Sun XY, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0101-6; Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055; Valdor R, 2019, P NATL ACAD SCI USA, V116, P20655, DOI 10.1073/pnas.1903542116; Verdura S, 2020, AGING-US, V12, P8, DOI 10.18632/aging.102646; Wang HB, 2020, ADV EXP MED BIOL, V1248, P325, DOI 10.1007/978-981-15-3266-5_14; Wang HB, 2019, NAT CHEM BIOL, V15, P42, DOI 10.1038/s41589-018-0161-x; Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591-019-0374-x; Wang XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1148-5; Wang Y, 2020, ACTA PHARMACOL SIN B, V10, P207, DOI 10.1016/j.apsb.2019.08.001; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Wang YG, 2020, CANCER BIOL MED, V17, P583, DOI 10.20892/j.issn.2095-3941.2020.0066; Wei Z, 2019, CELL REP, V28, P554, DOI 10.1016/j.celrep.2019.05.033; Wu JJ, 2018, CANCER MED-US, V7, P4004, DOI 10.1002/cam4.1675; Yang Q, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00447; Yao H, 2019, PALMITOYLATION IS CR; Yao H, 2020, ADV EXP MED BIOL, V1248, P295, DOI 10.1007/978-981-15-3266-5_13; Yao H, 2019, NAT BIOMED ENG, V3, P306, DOI 10.1038/s41551-019-0375-6; Yao H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01774; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015	56	9	9	3	41	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7106	7113		10.1038/s41388-020-01491-w	http://dx.doi.org/10.1038/s41388-020-01491-w		OCT 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33024277				2022-12-17	WOS:000575700700001
J	Xu, ZZ; Li, XM; Li, HX; Nie, C; Liu, WC; Li, SW; Liu, ZL; Wang, WB; Wang, JD				Xu, Zhanzhan; Li, Xiaoman; Li, Hanxiao; Nie, Chen; Liu, Wanchang; Li, Shiwei; Liu, Zelin; Wang, Weibin; Wang, Jiadong			Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA	ONCOGENE			English	Article							STRAND-BREAK REPAIR; DEXH/D BOX PROTEIN; NUCLEAR EXPORT; UAP56; TREX; COMPLEX; MRE11; EXPRESSION; MUTATIONS; COMPONENT	Multiple RNA processing events including transcription, mRNA splicing, and export are delicately coordinated by the TREX complex. As one of the essential subunits, DDX39B couples the splicing and export machineries by recruiting ALYREF onto mRNA. In this study, we further explore the functions of DDX39B in handling damaged DNA, and unexpectedly find that DDX39B facilitates DNA repair by homologous recombination through upregulating BRCA1. Specifically, DDX39B binds to and stabilizes BRCA1 mRNA. DDX39B ensures ssDNA formation and RAD51 accumulation at DSB sites by maintaining BRCA1 levels. Without DDX39B being present, ovarian cancer cells exhibit hypersensitivity to DNA-damaging chemotherapeutic agents like platinum or PARPi. Moreover, DDX39B-deficient mice show embryonic lethality or developmental retardation, highly reminiscent of those lacking BRCA1. High DDX39B expression is correlated with worse survival in ovarian cancer patients. Thus, DDX39B suppression represents a rational approach for enhancing the efficacy of chemotherapy in BRCA1-proficient ovarian cancers.	[Xu, Zhanzhan; Li, Xiaoman; Li, Hanxiao; Nie, Chen; Liu, Wanchang; Li, Shiwei; Wang, Weibin; Wang, Jiadong] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Radiat Med,Inst Syst Biomed, Beijing 100191, Peoples R China; [Liu, Zelin] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Med Bioinformat,Inst Syst Biomed, Beijing 100191, Peoples R China	Peking University; Peking University	Wang, WB; Wang, JD (corresponding author), Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Radiat Med,Inst Syst Biomed, Beijing 100191, Peoples R China.	weibinwang@bjmu.edu.cn; wangjd@bjmu.edu.cn	Liu, Zelin/AAR-6795-2021	Liu, Zelin/0000-0002-3516-3999; Nie, Chen/0000-0002-4221-4643; Wang, Weibin/0000-0003-3087-7973	National Key R&D Program of China [2017YFA0503900, 2016YFC1302100]; National Natural Science Foundation of China [81672981, 81872282, 81903255, 81972608]; Beijing Municipal Natural Science Foundation [7182082]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation)	We are grateful to members of the Wang laboratory for insightful discussions and technical assistance. This study was supported by grants from the National Key R&D Program of China (2017YFA0503900 and 2016YFC1302100), the National Natural Science Foundation of China (81672981, 81872282, 81903255, and 81972608), and Beijing Municipal Natural Science Foundation (7182082).	Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Buis J, 2012, NAT STRUCT MOL BIOL, V19, P246, DOI 10.1038/nsmb.2212; Chang CT, 2013, EMBO J, V32, P473, DOI 10.1038/emboj.2012.342; Choi JH, 2010, P NATL ACAD SCI USA, V107, P13660, DOI 10.1073/pnas.1007856107; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dufu K, 2010, GENE DEV, V24, P2043, DOI 10.1101/gad.1898610; Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871; Fan J, 2018, NUCLEIC ACIDS RES, V46, P8404, DOI 10.1093/nar/gky650; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Hautbergue GM, 2009, CURR BIOL, V19, P1918, DOI 10.1016/j.cub.2009.09.041; He YJ, 2018, NATURE, V563, P522, DOI 10.1038/s41586-018-0670-5; Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997; Houseley J, 2009, CELL, V136, P763, DOI 10.1016/j.cell.2009.01.019; Huang C, 2018, GENE DEV, V32, P639, DOI 10.1101/gad.314856.118; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang M, 2018, NUCLEIC ACIDS RES, V46, P4560, DOI 10.1093/nar/gky220; Jensen RB, 2010, NATURE, V467, P678, DOI 10.1038/nature09399; Jiang QQ, 2015, J BIOL CHEM, V290, P17724, DOI 10.1074/jbc.R115.667931; Kapadia F, 2006, GENE, V384, P37, DOI 10.1016/j.gene.2006.07.010; Katahira J, 2009, RNA BIOL, V6, P149, DOI 10.4161/rna.6.2.8046; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Kriege M, 2012, CANCER-AM CANCER SOC, V118, P899, DOI 10.1002/cncr.26351; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Mavaddat N, 2013, JNCI-J NATL CANCER I, V105, P812, DOI 10.1093/jnci/djt095; Mirza MR, 2016, NEW ENGL J MED, V375, P2154, DOI 10.1056/NEJMoa1611310; Pryor A, 2004, NUCLEIC ACIDS RES, V32, P1857, DOI 10.1093/nar/gkh347; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Scully R, 2019, NAT REV MOL CELL BIO, V20, P698, DOI 10.1038/s41580-019-0152-0; Shen JP, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702304200; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/s1470-2045(16)30559-9, 10.1016/S1470-2045(16)30559-9]; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Thakurta AG, 2007, J BIOL CHEM, V282, P17507, DOI 10.1074/jbc.M609727200; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Xu GT, 2015, NATURE, V521, P541, DOI 10.1038/nature14328; Yamazaki T, 2010, MOL BIOL CELL, V21, P2953, DOI 10.1091/mbc.E09-10-0913; Yu ZB, 2012, CELL RES, V22, P305, DOI 10.1038/cr.2011.128; Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955; Zhao WX, 2017, NATURE, V550, P360, DOI 10.1038/nature24060	41	9	9	3	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2020	39	47					7051	7062		10.1038/s41388-020-01482-x	http://dx.doi.org/10.1038/s41388-020-01482-x		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OT7KA	32989256				2022-12-17	WOS:000573446900004
J	Sun, QQ; Ye, Z; Qin, Y; Fan, GX; Ji, SR; Zhuo, QF; Xu, WY; Liu, WS; Hu, QS; Liu, MQ; Zhang, Z; Xu, XW; Yu, XJ				Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun			Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis	ONCOGENE			English	Article							E3 LIGASE; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; GLUCOSE-METABOLISM; SIGNALING PATHWAY; GENE-EXPRESSION; DOWN-REGULATION; NRF2; GROWTH; INHIBITION	Evidence suggests that tripartite motif-containing 2 (TRIM2) is associated with carcinogenic effects in several malignancies. However, the expression patterns and roles of TRIM2 in pancreatic cancer are rarely studied. Our study demonstrated that TRIM2 was expressed in a high percentage of pancreatic tumors. High TRIM2 expression was negatively correlated with the outcome of pancreatic cancer. TRIM2 silencing significantly inhibited the proliferation, migration, invasion, and in vivo tumorigenicity of pancreatic cancer cells. Regarding the mechanism involved, TRIM2 activated ROS-related E2-related factor 2 (NRF2)/antioxidant response element (ARE) signaling and the integrin/focal adhesion kinase (FAK) pathway. Treatment of pancreatic cancer cells with the antioxidant N-acetyl-L-cysteine decreased ROS activity and expression level of NRF2 and ITGB7. Increased translocation of NRF2 protein into nucleus further rescued the inhibited ITGB7 transcription. Moreover, NRF2 bound to the potential ARE on the promoter region and enhanced the transcriptional activity ofITGB7, indicating the bridging effect of NRF2 between the two signaling pathways. In summary, our study provides evidence that upregulated TRIM2 in pancreatic cancer predicts short survival for pancreatic cancer patients. TRIM2 accelerates pancreatic cancer progression via the ROS-related NRF2/ITGB7/FAK axis.	[Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai 200032, Peoples R China; [Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Sun, Qiqing; Ye, Zeng; Qin, Yi; Fan, Guixiong; Ji, Shunrong; Zhuo, Qifeng; Xu, Wenyan; Liu, Wensheng; Hu, Qiangsheng; Liu, Mengqi; Zhang, Zheng; Xu, Xiaowu; Yu, Xianjun] Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University	Xu, XW; Yu, XJ (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai 200032, Peoples R China.; Xu, XW; Yu, XJ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Xu, XW; Yu, XJ (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China.; Xu, XW; Yu, XJ (corresponding author), Shanghai Pancreat Canc Inst, Shanghai 200032, Peoples R China.	xuxiaowu@fudanpci.org; yuxianjun@fudanpci.org	liu, wen/HGE-3071-2022; Liu, Meng/GRF-0962-2022		National Natural Science Foundation of China (CN) [81871950, 81972250]; China National Funds for Distinguished Young Scientists (CN) [81625016]; Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]	National Natural Science Foundation of China (CN)(National Natural Science Foundation of China (NSFC)); China National Funds for Distinguished Young Scientists (CN); Scientific Innovation Project of Shanghai Education Committee	This work was supported by the National Natural Science Foundation of China (CN) (81871950 and 81972250); the China National Funds for Distinguished Young Scientists (CN) (81625016); the Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057).	Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744; Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Balastik M, 2008, P NATL ACAD SCI USA, V105, P12016, DOI 10.1073/pnas.0802261105; Bellezza I, 2018, BBA-MOL CELL RES, V1865, P721, DOI 10.1016/j.bbamcr.2018.02.010; Bui CB, 2011, BIOCHEM BIOPH RES CO, V412, P347, DOI 10.1016/j.bbrc.2011.07.101; Cao H, 2019, SCAND J GASTROENTERO, V54, P210, DOI 10.1080/00365521.2019.1575463; Caratozzolo MF, 2012, CELL CYCLE, V11, P511, DOI 10.4161/cc.11.3.19008; Chai ZH, 2019, ONCOTARGETS THER, V12, P10415, DOI 10.2147/OTT.S228631; Chen XB, 2015, GYNECOL ONCOL, V139, P513, DOI 10.1016/j.ygyno.2015.10.008; Chen X, 2018, CELL PHYSIOL BIOCHEM, V50, P1201, DOI 10.1159/000494547; Chio IIC, 2016, CELL, V166, P963, DOI 10.1016/j.cell.2016.06.056; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Dinkova-Kostova AT, 2015, FREE RADICAL BIO MED, V88, P179, DOI 10.1016/j.freeradbiomed.2015.04.036; Duong HQ, 2014, INT J ONCOL, V44, P959, DOI 10.3892/ijo.2013.2229; Farrow B, 2003, J GASTROINTEST SURG, V7, P864, DOI 10.1016/S1091-255X(03)00142-2; Ge WJ, 2017, CANCER CELL, V32, P561, DOI 10.1016/j.ccell.2017.09.008; Hamada S, 2017, CARCINOGENESIS, V38, P661, DOI 10.1093/carcin/bgx043; Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Hayes AJ, 2015, INT J BIOCHEM CELL B, V65, P288, DOI 10.1016/j.biocel.2015.06.017; Hedrick E, 2017, MOL CARCINOGEN, V56, P2066, DOI 10.1002/mc.22662; Duong HQ, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6030052; Hu QS, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12456; Hu QS, 2017, ONCOL REP, V38, P2069, DOI 10.3892/or.2017.5856; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Ji SR, 2016, CLIN CANCER RES, V22, P3950, DOI 10.1158/1078-0432.CCR-15-2380; Ji SR, 2015, CELL RES, V25, P561, DOI 10.1038/cr.2015.30; Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123; Kielosto M, 2009, INT J CANCER, V125, P1065, DOI 10.1002/ijc.24391; Kim H, 2010, J BIOL CHEM, V285, P34419, DOI 10.1074/jbc.M110.126839; Krajka-Kuzniak V, 2017, PHARMACOL REP, V69, P393, DOI 10.1016/j.pharep.2016.12.011; Kuninty PR, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax2770; Lee DF, 2009, MOL CELL, V36, P131, DOI 10.1016/j.molcel.2009.07.025; Lin Z, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01407-4; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Logsdon CD, 2003, CANCER RES, V63, P2649; Lu YB, 2016, ONCOTARGETS THER, V9, P99, DOI 10.2147/OTT.S92758; Martinez-Useros J, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030029; Masuda Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8299; Meng QC, 2018, ONCOGENE, V37, P5843, DOI 10.1038/s41388-018-0392-z; Meng XL, 2020, BOSNIAN J BASIC MED, V20, P106, DOI 10.17305/bjbms.2019.4255; Midha S, 2016, CANCER LETT, V381, P269, DOI 10.1016/j.canlet.2016.07.022; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moore Alexandra, 2019, JAMA, V322, P1426, DOI 10.1001/jama.2019.14699; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Neri P, 2011, BLOOD, V117, P6202, DOI 10.1182/blood-2010-06-292243; Niture SK, 2014, J BIOL CHEM, V289, P11568, DOI 10.1074/jbc.A110.175802; Ough M, 2005, CANCER BIOL THER, V4, P95; Qi ZX, 2016, J NEURO-ONCOL, V126, P19, DOI 10.1007/s11060-015-1897-8; Qin Y, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0344-4; Qin Y, 2018, INT J ONCOL, V53, P1643, DOI 10.3892/ijo.2018.4494; Reigan P, 2007, BIOCHEMISTRY-US, V46, P5941, DOI 10.1021/bi700008y; Sato T, 2012, J CELL SCI, V125, P1544, DOI 10.1242/jcs.095273; Schonrock N, 2012, J MOL NEUROSCI, V46, P324, DOI 10.1007/s12031-011-9587-2; Shibata T, 2010, CANCER RES, V70, P9095, DOI 10.1158/0008-5472.CAN-10-0384; Siegel RL, 2018, CA-CANCER J CLIN, V68, P30; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Soini Y, 2014, PATHOL RES PRACT, V210, P35, DOI 10.1016/j.prp.2013.10.001; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Theodore M, 2008, J BIOL CHEM, V283, P8984, DOI 10.1074/jbc.M709040200; Thompson S, 2011, J BIOL CHEM, V286, P19331, DOI 10.1074/jbc.M110.197707; Tomar D, 2015, FREE RADICAL BIO MED, V89, P1036, DOI 10.1016/j.freeradbiomed.2015.10.425; Venuto S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050510; Wakabayashi N, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000762; Wang LD, 2019, GENE DEV, V33, P641, DOI 10.1101/gad.323303.118; Wang LD, 2014, CANCER RES, V74, P1778, DOI 10.1158/0008-5472.CAN-13-2289; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087; Watanabe M, 2009, BIOCHEM BIOPH RES CO, V388, P422, DOI 10.1016/j.bbrc.2009.08.028; Wei L, 2019, NEUROCHEM RES, V44, P2182, DOI 10.1007/s11064-019-02857-7; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Xiao W, 2018, CANCER MANAG RES, V10, P5951, DOI 10.2147/CMAR.S185270; Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971; Yin H, 2017, INT J ONCOL, V51, P1191, DOI 10.3892/ijo.2017.4117; You A, 2011, ARCH BIOCHEM BIOPHYS, V507, P356, DOI 10.1016/j.abb.2010.12.034; Zhang WY, 2014, CANCER LETT, V355, P273, DOI 10.1016/j.canlet.2014.09.031; ZHANG YY, 2019, J IMMUNOTHER CANCER, V7; Zoranovic Tamara, 2013, JAKSTAT, V2, pe25408, DOI 10.4161/jkst.25408	80	9	9	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6572	6588		10.1038/s41388-020-01452-3	http://dx.doi.org/10.1038/s41388-020-01452-3		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32929153				2022-12-17	WOS:000569499000003
J	Lian, EY; Hyndman, BD; Moodley, S; Maritan, SM; Mulligan, LM				Lian, Eric Y.; Hyndman, Brandy D.; Moodley, Serisha; Maritan, Sarah M.; Mulligan, Lois M.			RET isoforms contribute differentially to invasive processes in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							CANCER CELL INVASION; NEUROTROPHIC FACTOR; PERINEURAL INVASION; UP-REGULATION; RHO-GTPASES; RECEPTOR; INVADOPODIA; GDNF; FILOPODIA; TKS5	Pancreatic ductal adenocarcinoma (PDAC) is a therapeutically challenging disease with poor survival rates, owing to late diagnosis and early dissemination. These tumors frequently undergo perineural invasion, spreading along nerves regionally and to distant sites. The RET receptor tyrosine kinase is implicated in increased aggressiveness, local invasion, and metastasis in multiple cancers, including PDAC. RET mediates directional motility and invasion towards sources of its neurotrophic factor ligands, suggesting that it may enhance perineural invasion of tumor cells towards nerves. RET is expressed as two main isoforms, RET9 and RET51, which differ in their protein interactions and oncogenic potentials, however, the contributions of RET isoforms to neural invasion have not been investigated. In this study, we generated total RET and isoform-specific knockdown PDAC cell lines and assessed the contributions of RET isoforms to PDAC invasive spread. Our data show that RET activity induces cell polarization and actin remodeling through activation of CDC42 and RHOA GTPases to promote directional motility in PDAC cells. Further, we show that RET interacts with the adaptor protein TKS5 to induce invadopodia formation, enhance matrix degradation and promote tumor cell invasion through a SRC and GRB2-dependent mechanism. Finally, we show that RET51 is the predominant isoform contributing to these RET-mediated invasive processes in PDAC. Together, our work suggests that RET expression in pancreatic cancers may enhance tumor aggressiveness by promoting perineural invasion, and that RET expression may be a valuable marker of invasiveness, and a potential therapeutic target in the treatment of these cancers.	[Lian, Eric Y.; Hyndman, Brandy D.; Moodley, Serisha; Maritan, Sarah M.; Mulligan, Lois M.] Queens Univ, Div Canc Biol & Genet, Canc Res Inst, Kingston, ON K7L 3N6, Canada; [Lian, Eric Y.; Hyndman, Brandy D.; Moodley, Serisha; Maritan, Sarah M.; Mulligan, Lois M.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; McMaster University; Queens University - Canada	Mulligan, LM (corresponding author), Queens Univ, Div Canc Biol & Genet, Canc Res Inst, Kingston, ON K7L 3N6, Canada.; Mulligan, LM (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	mulligal@queensu.ca	Mulligan, Lois/D-1893-2010	Maritan, Sarah/0000-0002-9703-7429; Lian, Eric/0000-0002-2147-5422; Mulligan, Lois/0000-0002-9308-8245; /0000-0003-4096-0922	Cancer Research Society of Canada [19439]; Canadian Institutes for Health Research [MOP-142303, 398979]; Canadian Graduate Scholarship; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	Cancer Research Society of Canada; Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Graduate Scholarship; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	This work was supported by an operating grant from the Cancer Research Society of Canada (19439) and a Canadian Institutes for Health Research operating grant (MOP-142303 (LMM)) and postdoctoral fellowship (398979 (SM)), and Canadian Graduate Scholarship (SMM) and by Ontario Graduate Scholarships and studentships from the Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research (EYL, SMM).	Abella JV, 2010, J BIOL CHEM, V285, P24956, DOI 10.1074/jbc.M110.127985; Amit M, 2017, ONCOGENE, V36, P3232, DOI 10.1038/onc.2016.483; Amit M, 2019, INT J CANCER, V144, P3014, DOI 10.1002/ijc.32040; Arjonen A, 2011, CELL ADHES MIGR, V5, P421, DOI 10.4161/cam.5.5.17723; Bakst RL, 2016, J NEUROL SURG PART B, V77, P96, DOI 10.1055/s-0036-1571835; Beaty BT, 2014, EUR J CELL BIOL, V93, P438, DOI 10.1016/j.ejcb.2014.07.003; Ben-Chetrit N, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005537; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bhinge K, 2017, ONCOTARGET, V8, P27155, DOI 10.18632/oncotarget.15676; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Burger KL, 2014, PROSTATE, V74, P134, DOI 10.1002/pros.22735; Cavel O, 2012, CANCER RES, V72, P5733, DOI 10.1158/0008-5472.CAN-12-0764; Ceyhan GO, 2008, BIOCHEM BIOPH RES CO, V374, P442, DOI 10.1016/j.bbrc.2008.07.035; Ceyhan GO, 2006, ANN SURG, V244, P274, DOI 10.1097/01.sla.0000217642.68697.55; Chermenina M, 2014, NEUROSCIENCE, V270, P1, DOI 10.1016/j.neuroscience.2014.04.008; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Crupi MJF, 2020, ONCOGENE, V39, P1361, DOI 10.1038/s41388-019-1068-z; Crupi MJF, 2015, TRAFFIC, V16, P1155, DOI 10.1111/tra.12315; Di Martino J, 2014, CELL ADHES MIGR, V8, P280, DOI 10.4161/cam.28833; Drinkut A, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.263; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Encinas M, 2004, J BIOL CHEM, V279, P18262, DOI 10.1074/jbc.M400505200; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Fischer RS, 2019, DEV BIOL, V451, P86, DOI 10.1016/j.ydbio.2018.08.015; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Griseri P, 2016, ONCOTARGET, V7, P26465, DOI 10.18632/oncotarget.8417; Gujral TS, 2008, CANCER RES, V68, P1338, DOI 10.1158/0008-5472.CAN-07-6052; Gupton Stephanie L, 2007, Sci STKE, V2007, pre5, DOI 10.1126/stke.4002007re5; He SB, 2014, P NATL ACAD SCI USA, V111, pE2008, DOI 10.1073/pnas.1402944111; Hickey JG, 2009, GENE CHROMOSOME CANC, V48, P429, DOI 10.1002/gcc.20653; Hirai I, 2002, PANCREAS, V24, P15, DOI 10.1097/00006676-200201000-00003; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Hoshino D, 2013, J CELL SCI, V126, P2979, DOI 10.1242/jcs.079475; Huang L, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1120-9; Hyndman BD, 2017, J CELL SCI, V130, P3282, DOI 10.1242/jcs.203885; Ibanez CF, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009134; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Ito Y, 2005, SURGERY, V138, P788, DOI 10.1016/j.surg.2005.07.007; Itoh Y, 2015, MATRIX BIOL, V44-46, P207, DOI 10.1016/j.matbio.2015.03.004; Jacquemet G, 2015, CURR OPIN CELL BIOL, V36, P23, DOI 10.1016/j.ceb.2015.06.007; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Kramer ER, 2015, FEBS LETT, V589, P3760, DOI 10.1016/j.febslet.2015.11.006; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Leong HS, 2014, CELL REP, V8, P1558, DOI 10.1016/j.celrep.2014.07.050; Lian EY, 2017, ENDOCR-RELAT CANCER, V24, P53, DOI 10.1530/ERC-16-0393; Liang DK, 2016, BBA-REV CANCER, V1865, P111, DOI 10.1016/j.bbcan.2016.01.002; Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396; Marchesi F, 2010, CYTOKINE GROWTH F R, V21, P77, DOI 10.1016/j.cytogfr.2009.11.001; Maritan SM, 2017, JOVE-J VIS EXP, DOI 10.3791/55544; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Mayor R, 2010, TRENDS CELL BIOL, V20, P319, DOI 10.1016/j.tcb.2010.03.005; Meka DP, 2015, J CLIN INVEST, V125, P1873, DOI 10.1172/JCI79300; Menard L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4907; Moodley S, 2020, LUNG CANCER, V142, P123, DOI 10.1016/j.lungcan.2020.02.004; Morandi A, 2011, TRENDS MOL MED, V17, P149, DOI 10.1016/j.molmed.2010.12.007; Mulligan LM, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01873; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Murphy DM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021436; MYERS SM, 1995, ONCOGENE, V11, P2039; Nevalainen N, 2010, NEUROSCIENCE, V171, P1357, DOI 10.1016/j.neuroscience.2010.10.010; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; Parachoniak CA, 2012, TRENDS CELL BIOL, V22, P231, DOI 10.1016/j.tcb.2012.02.002; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Partridge MA, 2006, MOL BIOL CELL, V17, P4237, DOI 10.1091/mbc.E06-06-0496; Paz H, 2014, ONCOGENE, V33, P4193, DOI 10.1038/onc.2013.393; Poteryaev D, 1999, FEBS LETT, V463, P63, DOI 10.1016/S0014-5793(99)01590-2; Radhakrishna H, 1999, J CELL SCI, V112, P855; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rajadurai CV, 2012, J CELL SCI, V125, P2940, DOI 10.1242/jcs.100834; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Richardson DS, 2012, MOL BIOL CELL, V23, P3838, DOI 10.1091/mbc.E12-02-0114; Rodrigues DM, 2011, NEUROGASTROENT MOTIL, V23, pe44, DOI 10.1111/j.1365-2982.2010.01626.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Saad AM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4610-4; Sawai H, 2005, CANCER RES, V65, P11536, DOI 10.1158/0008-5472.CAN-05-2843; Sharma VP, 2013, CURR BIOL, V23, P2079, DOI 10.1016/j.cub.2013.08.044; Sit ST, 2011, J CELL SCI, V124, P679, DOI 10.1242/jcs.064964; Stylli SS, 2009, J CELL SCI, V122, P2727, DOI 10.1242/jcs.046680; SUTERCRAZZOLARA C, 1994, NEUROREPORT, V5, P2486, DOI 10.1097/00001756-199412000-00020; TAHIRA T, 1990, ONCOGENE, V5, P97; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Williams KC, 2019, ONCOGENE, V38, P3598, DOI 10.1038/s41388-018-0667-4; Yang CS, 2011, CELL ADHES MIGR, V5, P402, DOI 10.4161/cam.5.5.16971; Zeng Q, 2008, J INT MED RES, V36, P656, DOI 10.1177/147323000803600406	88	9	9	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6493	6510		10.1038/s41388-020-01448-z	http://dx.doi.org/10.1038/s41388-020-01448-z		SEP 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32884116				2022-12-17	WOS:000565829600001
J	Murray, AS; Hyland, TE; Sala-Hamrick, KE; Mackinder, JR; Martin, CE; Tanabe, LM; Varela, FA; List, K				Murray, Andrew S.; Hyland, Thomas E.; Sala-Hamrick, Kimberley E.; Mackinder, Jacob R.; Martin, Carly E.; Tanabe, Lauren M.; Varela, Fausto A.; List, Karin			The cell-surface anchored serine protease TMPRSS13 promotes breast cancer progression and resistance to chemotherapy	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; BARRIER FUNCTION; PROSTASIN; EXPRESSION; MATRIPTASE; CHEMOSENSITIVITY; LOCALIZATION; INVASION; CASCADE; ZYMOGEN	Breast cancer progression is accompanied by increased expression of extracellular and cell-surface proteases capable of degrading the extracellular matrix as well as cleaving and activating downstream targets. The type II transmembrane serine proteases (TTSPs) are a family of cell-surface proteases that play critical roles in numerous types of cancers. Therefore, the aim of this study was to identify novel and uncharacterized TTSPs with differential expression in breast cancer and to determine their potential roles in progression. Systematic in silico data analysis followed by immunohistochemical validation identified increased expression of the TTSP family member, TMPRSS13 (transmembrane protease, serine 13), in invasive ductal carcinoma patient tissue samples compared to normal breast tissue. To test whether loss of TMPRSS13 impacts tumor progression, TMPRSS13 was genetically ablated in the oncogene-induced transgenic MMTV-PymT tumor model. TMPRSS13 deficiency resulted in a significant decrease in overall tumor burden and growth rate, as well as a delayed formation of detectable mammary tumors, thus suggesting a causal relationship between TMPRSS13 expression and the progression of breast cancer. Complementary studies using human breast cancer cell culture models revealed that siRNA-mediated silencing of TMPRSS13 expression decreases proliferation, induces apoptosis, and attenuates invasion. Importantly, targeting TMPRSS13 expression renders aggressive triple-negative breast cancer cell lines highly responsive to chemotherapy. At the molecular level, knockdown of TMPRSS13 in breast cancer cells led to increased protein levels of the tumor-suppressive protease prostasin. TMPRSS13/prostasin co-immunoprecipitation and prostasin zymogen activation experiments identified prostasin as a potential novel target for TMPRSS13. Regulation of prostasin levels may be a mechanism that contributes to the pro-oncogenic properties of TMPRSS13 in breast cancer. TMPRSS13 represents a novel candidate for targeted therapy in combination with standard of care chemotherapy agents in patients with hormone receptor-negative breast cancer or in patients with tumors refractory to endocrine therapy.	[Murray, Andrew S.; Hyland, Thomas E.; Sala-Hamrick, Kimberley E.; Mackinder, Jacob R.; Martin, Carly E.; Tanabe, Lauren M.; Varela, Fausto A.; List, Karin] Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA; [Murray, Andrew S.; Martin, Carly E.; List, Karin] Wayne State Univ, Dept Oncol, Detroit, MI 48202 USA	Wayne State University; Wayne State University	List, K (corresponding author), Wayne State Univ, Dept Pharmacol, Detroit, MI 48201 USA.; List, K (corresponding author), Wayne State Univ, Dept Oncol, Detroit, MI 48202 USA.	klist@med.wayne.edu		Murray, Andrew/0000-0002-2899-4970; List, Karin/0000-0002-5847-5637	NIH/NCI [R01CA160565, R01CA160565-04S, R01CA222359, F31CA217148]; NIGMS/NIH [R25 GM 058905-15]; NIH Ruth L. Kirschstein National Research Service Award [T32-CA009531]; DeRoy Testamentary Foundation	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DeRoy Testamentary Foundation	This work was supported by NIH/NCI R01CA160565 grant (KL), NIH/NCI R01CA160565-04S grant (KL, FAV), NIH/NCI R01CA222359 (KL), NIH/NCI F31CA217148 (FAV), NIGMS/NIH grant R25 GM 058905-15 (FAV), NIH Ruth L. Kirschstein National Research Service Award T32-CA009531 (ASM and CEM) and The DeRoy Testamentary Foundation (ASM).	Amundson SA, 2000, CANCER RES, V60, P6101; Antalis TM, 2011, PROG MOL BIOL TRANSL, V99, P1, DOI 10.1016/S1877-1173(11)99001-2; Antalis TM, 2010, BIOCHEM J, V428, P325, DOI 10.1042/BJ20100046; Bao YH, 2019, ONCOGENE, V38, P497, DOI 10.1038/s41388-018-0453-3; Bao YH, 2016, ONCOTARGET, V7, P28540, DOI 10.18632/oncotarget.8677; Bao YH, 2016, ONCOTARGET, V7, P26780, DOI 10.18632/oncotarget.8511; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Chen LM, 2006, AM J PHYSIOL-RENAL, V291, pF567, DOI 10.1152/ajprenal.00047.2006; Chen LM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-377; Chen LM, 2001, J BIOL CHEM, V276, P21434, DOI 10.1074/jbc.M011423200; Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601; Chen M, 2008, BBA-MOL CELL RES, V1783, P896, DOI 10.1016/j.bbamcr.2007.10.019; Chen MQ, 2007, BBA-MOL CELL RES, V1773, P1133, DOI 10.1016/j.bbamcr.2007.04.013; Chen MQ, 2010, MOL CELL BIOCHEM, V337, P259, DOI 10.1007/s11010-009-0307-y; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; Friis S, 2016, J BIOL CHEM, V291, P2577, DOI 10.1074/jbc.C115.706721; Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hashimoto T, 2010, FEBS J, V277, P4888, DOI 10.1111/j.1742-4658.2010.07894.x; Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Kido H, 2008, FRONT BIOSCI-LANDMRK, V13, P754, DOI 10.2741/2717; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leyvraz C, 2005, J CELL BIOL, V170, P487, DOI 10.1083/jcb.200501038; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2006, MOL MED, V12, P1, DOI 10.2119/2006-00022.List; Madsen DH, 2014, BIOCHEM J, V461, P487, DOI 10.1042/BJ20140337; Martin CE, 2019, CANCER METAST REV, V38, P357, DOI 10.1007/s10555-019-09811-7; Murray AS, 2017, J BIOL CHEM, V292, P14867, DOI 10.1074/jbc.M117.775999; Murray AS, 2016, BIOL CHEM, V397, P815, DOI 10.1515/hsz-2016-0131; Netzel-Arnett S, 2003, CANCER METAST REV, V22, P237, DOI 10.1023/A:1023003616848; Netzel-Arnett S, 2006, J BIOL CHEM, V281, P32941, DOI 10.1074/jbc.C600208200; Okumura Y, 2010, J VIROL, V84, P5089, DOI 10.1128/JVI.02605-09; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Peters DE, 2014, J BIOL CHEM, V289, P14740, DOI 10.1074/jbc.M113.541318; Quinn JE, 2003, CANCER RES, V63, P6221; Sakashita K, 2008, J SURG ONCOL, V98, P559, DOI 10.1002/jso.21158; Selzer-Plon J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-201; Shipway A, 2004, BIOCHEM BIOPH RES CO, V324, P953, DOI 10.1016/j.bbrc.2004.09.123; Szabo R, 2008, INT J BIOCHEM CELL B, V40, P1297, DOI 10.1016/j.biocel.2007.11.013; Takahashi S, 2003, PROSTATE, V54, P187, DOI 10.1002/pros.10178; Tanabe LM, 2017, FEBS J, V284, P1421, DOI 10.1111/febs.13971; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Trecesson SD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01079-1; Wahba HA, 2015, CANCER BIOL MED, V12, P106, DOI 10.7497/j.issn.2095-3941.2015.0030; Wang J, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0661-5; Wei G, 2012, CANCER CELL, V21, P547, DOI 10.1016/j.ccr.2012.02.028; Yamamoto Koji, 2018, Oncotarget, V9, P11691, DOI 10.18632/oncotarget.24450; Yan BX, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.523; Yang HY, 2017, ONCOL RES, V25, P923, DOI 10.3727/096504016X14798241682647; YU JX, 1995, J BIOL CHEM, V270, P13483, DOI 10.1074/jbc.270.22.13483; YU JX, 1994, J BIOL CHEM, V269, P18843; Zmora P, 2014, J VIROL, V88, P12087, DOI 10.1128/JVI.01427-14; Zoratti GL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7776	59	9	9	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6421	6436		10.1038/s41388-020-01436-3	http://dx.doi.org/10.1038/s41388-020-01436-3		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32868877	Green Accepted			2022-12-17	WOS:000564507300001
J	Yang, RS; Zhao, YL; Gu, Y; Yang, Y; Gao, X; Yuan, Y; Xiao, LM; Zhang, J; Sun, C; Yang, H; Qin, JH; Li, J; Zhang, F; Zhang, LJ; Jing,				Yang, Risheng; Zhao, Yuanlin; Gu, Yu; Yang, Ying; Gao, Xing; Yuan, Yuan; Xiao, Liming; Zhang, Jin; Sun, Chao; Yang, Han; Qin, Junhui; Li, Jing; Zhang, Feng; Zhang, Lijun; Ye, Jing			Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma	ONCOGENE			English	Article							CENTRAL-NERVOUS-SYSTEM; BRAIN CHOLESTEROL; IDH1 MUTATION; RECEPTOR LXR; METABOLISM; CANCER; 24S-HYDROXYCHOLESTEROL; TURNOVER; 24-HYDROXYLASE; EXPRESSION	Isocitrate dehydrogenase (IDH) mutation is the most important initiating event in gliomagenesis, and the increasing evidence shows that IDH mutation is associated with the metabolic reprogramming in the tumor. Dysregulated cholesterol metabolism is a hallmark of tumor cells, but the cholesterol homeostasis in IDH-mutated glioma is still unknown. In this study, we found that astrocyte-specific mutant IDH1(R132H) knockin reduced the cholesterol contents and damaged the structure of myelin in mouse brains. In U87 and U251 cells, the expression of mutant IDH1 consistently reduced the cholesterol levels. Furthermore, we found that IDH1 mutation enhanced the production of 24(S)-hydroxycholesterol (24-OHC), which is not only the metabolite of cholesterol elimination, but also functions as an endogenous ligand for the liver X receptors (LXRs). In IDH1-mutant glioma cells, the elevated 24-OHC activated LXRs, which consequently accelerated the low-density lipoprotein receptor (LDLR) degradation by upregulating the inducible degrader of the LDLR (IDOL). The reduced LDLR expressions in IDH1-mutant glioma cells abated the uptakes of low-density lipoprotein (LDL) to decrease the cholesterol influx. In addition, the activated LXRs also promoted the cholesterol efflux by elevating the ATP-binding cassette transporter A1 (ABCA1), ABCG1, and apolipoprotein E (ApoE) in both IDH1-mutant astrocytes and glioma cells. As a feedback, the reduced cholesterol levels stimulated the cholesterol biosynthesis, which made IDH1-mutated glioma cells more sensitive to atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase. The altered cholesterol homeostasis regulated by mutant IDH provides a pivotal therapeutical strategy for the IDH-mutated gliomas.	[Yang, Risheng; Zhao, Yuanlin; Gu, Yu; Yang, Ying; Gao, Xing; Yuan, Yuan; Xiao, Liming; Yang, Han; Qin, Junhui; Li, Jing; Zhang, Feng; Ye, Jing] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China; [Yang, Risheng; Zhao, Yuanlin; Gu, Yu; Yang, Ying; Gao, Xing; Yuan, Yuan; Xiao, Liming; Yang, Han; Qin, Junhui; Li, Jing; Zhang, Feng; Ye, Jing] Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Shaanxi, Peoples R China; [Zhang, Jin] Army Med Univ, Inst Canc, Xinqiao Hosp, Chongqing 400037, Peoples R China; [Sun, Chao] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian 710038, Shaanxi, Peoples R China; [Zhang, Lijun] Fourth Mil Med Univ, Tangdu Hosp, Dept Clin Diag, Xian 710038, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Army Medical University; Air Force Military Medical University; Air Force Military Medical University	Jing, (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.; Jing, (corresponding author), Fourth Mil Med Univ, Sch Basic Med, Xian 710032, Shaanxi, Peoples R China.; Zhang, LJ (corresponding author), Fourth Mil Med Univ, Tangdu Hosp, Dept Clin Diag, Xian 710038, Shaanxi, Peoples R China.	zhanglijun_fmmu@163.com; yejing@fmmu.edu.cn		Yang, Risheng/0000-0001-6663-6114	National Natural Science Foundation of China [81972342, 81772659, 81670792]; State Key Laboratory of Cancer Biology of China [CBSKL2017Z20]; Natural Science Basic Research Plan in Shaanxi Province [2020JZ-29, 2020JQ-462]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); State Key Laboratory of Cancer Biology of China; Natural Science Basic Research Plan in Shaanxi Province	The research work was supported by the National Natural Science Foundation of China (81972342, 81772659 to JY, 81670792 to LZ), State Key Laboratory of Cancer Biology of China (CBSKL2017Z20 to YG), and Natural Science Basic Research Plan in Shaanxi Province (2020JZ-29 to JY, 2020JQ-462 to XG).	Adaikalakoteswari A, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0046-8; An ZY, 2016, CANCER CELL, V30, P653, DOI 10.1016/j.ccell.2016.10.011; Bjorkhem I, 2006, J INTERN MED, V260, P493, DOI 10.1111/j.1365-2796.2006.01725.x; Bjorkhem I, 2004, ARTERIOSCL THROM VAS, V24, P806, DOI 10.1161/01.ATV.0000120374.59826.1b; Bjorkhem I, 1998, J LIPID RES, V39, P1594; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bogdanovic E, 2015, BBA-GEN SUBJECTS, V1850, P1781, DOI 10.1016/j.bbagen.2015.04.014; Bovenga F, 2015, CELL METAB, V21, P517, DOI 10.1016/j.cmet.2015.03.002; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Clendening JW, 2012, ONCOGENE, V31, P4967, DOI 10.1038/onc.2012.6; de Nigris F, 2018, JAMA CARDIOL, V3, P1184, DOI 10.1001/jamacardio.2018.3546; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dietschy JM, 2004, J LIPID RES, V45, P1375, DOI 10.1194/jlr.R400004-JLR200; Dietschy JM, 2009, BIOL CHEM, V390, P287, DOI 10.1515/BC.2009.035; Ferris JS, 2012, INT J CANCER, V131, pE1031, DOI 10.1002/ijc.27536; Fujiyoshi M, 2007, J NEUROCHEM, V100, P968, DOI 10.1111/j.1471-4159.2006.04240.x; Gallagher EJ, 2017, ONCOGENE, V36, P6462, DOI 10.1038/onc.2017.247; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Guillaumond F, 2015, P NATL ACAD SCI USA, V112, P2473, DOI 10.1073/pnas.1421601112; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Iannelli F, 2018, RECENT PAT ANTI-CANC, V13, P184, DOI 10.2174/1574892812666171129141211; Izquierdo-Garcia JL, 2015, CANCER RES, V75, P2999, DOI 10.1158/0008-5472.CAN-15-0840; Korade Z, 2008, NEUROPHARMACOLOGY, V55, P1265, DOI 10.1016/j.neuropharm.2008.02.019; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Leonardi R, 2012, J BIOL CHEM, V287, P14615, DOI 10.1074/jbc.C112.353946; Lokody I, 2014, NAT REV CANCER, V14, P706, DOI 10.1038/nrc3840; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lund EG, 1999, P NATL ACAD SCI USA, V96, P7238, DOI 10.1073/pnas.96.13.7238; Lund EG, 2003, J BIOL CHEM, V278, P22980, DOI 10.1074/jbc.M303415200; Lutjohann D, 1996, P NATL ACAD SCI USA, V93, P9799, DOI 10.1073/pnas.93.18.9799; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Miyata S, 2013, NEUROL MED-CHIR, V53, P645, DOI 10.2176/nmc.oa2012-0409; Peterse EFP, 2018, BRIT J CANCER, V118, P1074, DOI 10.1038/s41416-018-0050-9; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Saher G, 2005, NAT NEUROSCI, V8, P468, DOI 10.1038/nn1426; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787; Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043; Tateishi K, 2015, CANCER CELL, V28, P773, DOI 10.1016/j.ccell.2015.11.006; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Venur VA, 2015, CANCER TREAT RES, V163, P103, DOI 10.1007/978-3-319-12048-5_7; Villa GR, 2016, CANCER CELL, V30, P683, DOI 10.1016/j.ccell.2016.09.008; Viswanath P, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1077922; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974; Zhang J, 2019, LIPIDS HEALTH DIS, V18, DOI 10.1186/s12944-019-1022-7; Zhu ZY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2710693	49	9	9	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6340	6353		10.1038/s41388-020-01439-0	http://dx.doi.org/10.1038/s41388-020-01439-0		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32855525				2022-12-17	WOS:000565020000001
J	Zhang, XJ; Li, F; Tang, Y; Ren, QL; Xiao, B; Wan, Y; Jiang, S				Zhang, Xingju; Li, Fei; Tang, Ying; Ren, Qinglan; Xiao, Bin; Wan, Ying; Jiang, Shan			miR-21a in exosomes from Lewis lung carcinoma cells accelerates tumor growth through targeting PDCD4 to enhance expansion of myeloid-derived suppressor cells	ONCOGENE			English	Article							CLINICAL CANCER STAGE; DENDRITIC CELLS; T-CELLS; MICRORNA-21; EXPRESSION; METASTASIS; INDUCTION; MIGRATION; CORRELATE; PROMOTE	In patients with lung cancer, myeloid-derived suppressor cells (MDSCs) have been reported to be significantly increased. Tumor-derived exosomes (TDEs) from various cancers played a critical role in MDSC induction. However, studies on the molecular mechanism underlying MDSC expansion induced by exosomes from lung cancer cells are still limited. In this study, we demonstrated that LLC-Exo accelerated tumor growth along with a significant accumulation of MDSCs in mouse tumor model. miRNA profiling showed that miR-21a was enriched in LLC-Exo. The depletion of miR-21a in LLC-Exo leads to the loss of their ability to induce MDSC expansion. Further results showed that miR-21a of LLC-Exo induced MDSC expansion via downregulation of the programmed cell death protein 4 (PDCD4) protein. The results of gain-and loss-of-function experiments validated that PDCD4 function as a critical inhibitor to negatively regulate expansion of MDSCs via inhibition Il-6 production in bone marrow cells. In addition, our data showed that exosomes derived from human lung cancer cell lines expressing miR-21a, also induced expansion of MDSCs in human CD14(+)monocytes in vitro. Overall, our results demonstrated that miR-21a enriched in lung carcinoma cell-derived exosomes could promote functional expansion of MDSCs through targeting PDCD4.	[Zhang, Xingju; Tang, Ying] Shenzhen Univ, Coll Optoelect Engn, Key Lab Optoelect Devices & Syst, Minist Educ & Guangdong Prov, Shenzhen 518060, Peoples R China; [Zhang, Xingju; Tang, Ying; Jiang, Shan] Shenzhen Univ, Inst Adv Study, Shenzhen 518060, Peoples R China; [Li, Fei; Wan, Ying] Army Med Univ, Biomed Anal Ctr, Chongqing 400038, Peoples R China; [Ren, Qinglan] Chongqing Med Univ, Affiliated Hosp 1, Dept Oncol, Chongqing 400016, Peoples R China; [Xiao, Bin] Chongqing Med Univ, Coll Pharm, Chongqing 400016, Peoples R China	Shenzhen University; Shenzhen University; Army Medical University; Chongqing Medical University; Chongqing Medical University	Jiang, S (corresponding author), Shenzhen Univ, Inst Adv Study, Shenzhen 518060, Peoples R China.; Wan, Y (corresponding author), Army Med Univ, Biomed Anal Ctr, Chongqing 400038, Peoples R China.; Xiao, B (corresponding author), Chongqing Med Univ, Coll Pharm, Chongqing 400016, Peoples R China.	binxiaotmmu@163.com; wanying516@foxmail.com; shan.jiang1975@szu.edu.cn		Zhang, Xingju/0000-0003-0717-2510; Li, Fei/0000-0002-4695-944X; Wan, Ying/0000-0001-7922-4434	Natural Science Foundation of Shenzhen [KQJSCX20180328094239048]; National Key Research and Development Program of China [2016YFA0502201]; Scientific Research Foundation for Introduced High-level Personnel in Chongqing Medical University [41021300160256]	Natural Science Foundation of Shenzhen; National Key Research and Development Program of China; Scientific Research Foundation for Introduced High-level Personnel in Chongqing Medical University	This work was supported by grants from the Natural Science Foundation of Shenzhen (KQJSCX20180328094239048) of Shan Jiang, National Key Research and Development Program of China (2016YFA0502201) of Ying, Wan and Scientific Research Foundation for Introduced High-level Personnel in Chongqing Medical University of Bin Xiao (41021300160256).	Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Ashiru O, 2010, CANCER RES, V70, P481, DOI 10.1158/0008-5472.CAN-09-1688; Berrondo C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147236; Brimnes MK, 2010, SCAND J IMMUNOL, V72, P540, DOI 10.1111/j.1365-3083.2010.02463.x; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bunt SK, 2007, CANCER RES, V67, P10019, DOI 10.1158/0008-5472.CAN-07-2354; Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483; Chen WZ, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/1073947; Cheng YQ, 2017, DEV COMP IMMUNOL, V77, P200, DOI 10.1016/j.dci.2017.08.011; Chow A, 2014, SCI REP-UK, V4, DOI 10.1038/srep05750; Cohen TS, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003682; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; Cramer Z, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26625-9; Das A, 2014, J IMMUNOL, V192, P1120, DOI 10.4049/jimmunol.1300613; de Goeje PL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1014242; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Dikshit B, 2013, ONCOGENE, V32, P3798, DOI 10.1038/onc.2012.393; Frydrychowicz M, 2015, SCAND J IMMUNOL, V81, P2, DOI 10.1111/sji.12247; Gabrilovich Dmitry, 1998, Blood, V92, P4150; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Galicia-Vazquez G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087237; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Guo XF, 2018, ONCOGENE, V37, P4239, DOI 10.1038/s41388-018-0261-9; He LQ, 2019, THERANOSTICS, V9, P8206, DOI 10.7150/thno.37455; Heuvers ME, 2013, LUNG CANCER, V81, P468, DOI 10.1016/j.lungcan.2013.06.005; Hingorani SR, 2015, CANCER CELL, V28, P151, DOI 10.1016/j.ccell.2015.07.015; Hoffmann SHL, 2019, THERANOSTICS, V9, P5869, DOI 10.7150/thno.33275; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Huber V, 2018, J CLIN INVEST, V128, P5505, DOI 10.1172/JCI98060; Ingenito F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194687; Jiang S, 2011, BLOOD, V118, P5487, DOI 10.1182/blood-2011-05-355644; Kamran N, 2018, CLIN IMMUNOL, V189, P34, DOI 10.1016/j.clim.2016.10.008; Kannan A, 2016, CLIN CANCER RES, V22, P3348, DOI 10.1158/1078-0432.CCR-15-2456; Kortylewski M, 2005, NAT MED, V11, P1314, DOI 10.1038/nm1325; Kusmartsev S, 2002, CANCER IMMUNOL IMMUN, V51, P293, DOI 10.1007/s00262-002-0280-8; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; Li J, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12724; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li Y, 2015, CELL BIOCHEM FUNCT, V33, P308, DOI 10.1002/cbf.3115; Liu SL, 2019, BIOMED PHARMACOTHER, V111, P338, DOI 10.1016/j.biopha.2018.12.088; Liu YF, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1027472; Liu YL, 2010, AM J PATHOL, V176, P2490, DOI 10.2353/ajpath.2010.090777; Mao XH, 2017, MOL CARCINOGEN, V56, P886, DOI 10.1002/mc.22542; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; MULLER L, 2016, SCI REP UK, V6; Nasri M, 2014, CYTOTECHNOLOGY, V66, P1031, DOI 10.1007/s10616-013-9652-5; Niu HQ, 2018, INT IMMUNOPHARMACOL, V61, P45, DOI 10.1016/j.intimp.2018.05.014; Ochoa AC, 2007, CLIN CANCER RES, V13, p721S, DOI 10.1158/1078-0432.CCR-06-2197; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Ruiz-Martinez M, 2016, ONCOTARGET, V7, P51515, DOI 10.18632/oncotarget.9862; Schulz I, 2014, BBA-MOL CELL RES, V1843, P965, DOI 10.1016/j.bbamcr.2014.01.022; Song XP, 2005, J IMMUNOL, V175, P8200, DOI 10.4049/jimmunol.175.12.8200; Spaggiari GM, 2009, BLOOD, V113, P6576, DOI 10.1182/blood-2009-02-203943; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Strand-Rosenberg S, 2018, CURR OPIN IMMUNOL, V51, P68, DOI 10.1016/j.coi.2018.03.007; Su Z, 2016, SCAND J IMMUNOL, V84, P255, DOI 10.1111/sji.12473; Sundararajan V, 2018, CELL ONCOL, V41, P223, DOI 10.1007/s13402-018-0378-4; Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3-15; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tian XY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0772-z; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van den Bosch MWM, 2014, J BIOL CHEM, V289, P22980, DOI 10.1074/jbc.M114.573089; Vetsika EK, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/659294; Wang Q, 2018, BIOL CELL, V110, P169, DOI 10.1111/boc.201800014; Weber R, 2019, J CLIN INVEST, V129, P4080, DOI 10.1172/JCI131649; Weston WW, 2019, BIODRUGS, V33, P137, DOI 10.1007/s40259-019-00338-5; Whiteside TL, 2017, CLIN EXP IMMUNOL, V189, P259, DOI 10.1111/cei.12974; Wieckowski EU, 2009, J IMMUNOL, V183, P3720, DOI 10.4049/jimmunol.0900970; Wu CT, 2012, J MOL MED, V90, P1343, DOI 10.1007/s00109-012-0916-x; Wu LL, 2017, ONCOTARGET, V8, P76843, DOI 10.18632/oncotarget.20164; Xiang XY, 2009, INT J CANCER, V124, P2621, DOI 10.1002/ijc.24249; Xie Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0984-4; Yang Y, 2015, CANCER GENE THER, V22, P23, DOI 10.1038/cgt.2014.66; YOUNG MRI, 1992, CANCER RES, V52, P6335; Yuan XK, 2011, J INT MED RES, V39, P1381, DOI 10.1177/147323001103900424; Zhang KL, 2020, THERANOSTICS, V10, P411, DOI 10.7150/thno.33482; Zhang ZP, 2013, J BIOL CHEM, V288, P37082, DOI 10.1074/jbc.M113.517953; Zhou L, 2017, CANCER LETT, V407, P84, DOI 10.1016/j.canlet.2017.08.003; Zhou M, 2014, CELL IMMUNOL, V292, P65, DOI 10.1016/j.cellimm.2014.09.004; Zhu JM, 2019, THERANOSTICS, V9, P6901, DOI 10.7150/thno.37357	82	9	10	2	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6354	6369		10.1038/s41388-020-01406-9	http://dx.doi.org/10.1038/s41388-020-01406-9		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32855524				2022-12-17	WOS:000565020000003
J	Kanamori, A; Matsubara, D; Saitoh, Y; Fukui, Y; Gotoh, N; Kaneko, S; Seiki, M; Murakami, Y; Inoue, J; Sakamoto, T				Kanamori, Akane; Matsubara, Daisuke; Saitoh, Yurika; Fukui, Yuya; Gotoh, Noriko; Kaneko, Shuichi; Seiki, Motoharu; Murakami, Yoshinori; Inoue, Jun-ichiro; Sakamoto, Takeharu			Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1	ONCOGENE			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; UBIQUITIN LIGASE; PROSTATE-CANCER; DEGRADATION; RESISTANCE; PROTEINS; BIOLOGY; P21; EMT	Pancreatic cancer is one of the most fatal cancers without druggable molecular targets. Hypoxia inducible factor-1 (HIF-1) is a heterodimeric transcriptional factor that promotes malignancy in various cancers including pancreatic cancer. Herein, we found that HIF-1 is accumulated in normoxic or moderate hypoxic areas of pancreatic cancer xenografts in vivo and is active even during normoxia in pancreatic cancer cells in vitro. This prompted us to analyze whether the HIF-1 activator Mint3 contributes to malignant features of pancreatic cancer. Mint3 depletion by shRNAs attenuated HIF-1 activity during normoxia and cell proliferation concomitantly with accumulated p21 and p27 protein in pancreatic cancer cells. Further analyses revealed that Mint3 increased transcription of the oncogenic ubiquitin ligase SKP2 in pancreatic cancer cells via HIF-1. This Mint3-HIF-1-SKP2 axis also promoted partial epithelial-mesenchymal transition, stemness features, and chemoresistance in pancreatic cancer cells. Even in vivo, Mint3 depletion attenuated tumor growth of orthotopically inoculated human pancreatic cancer AsPC-1 cells. Database and tissue microarray analyses showed that Mint3 expression is correlated with SKP2 expression in human pancreatic cancer specimens and high Mint3 expression is correlated with poor prognosis of pancreatic cancer patients. Thus, targeting Mint3 may be useful for attenuating the malignant features of pancreatic cancer.	[Kanamori, Akane; Saitoh, Yurika; Fukui, Yuya; Inoue, Jun-ichiro] Univ Tokyo, Inst Med Sci, Div Cellular & Mol Biol, Minato Ku, Tokyo, Japan; [Matsubara, Daisuke] Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi, Japan; [Saitoh, Yurika] Teikyo Univ Sci, Ctr Med Educ, Adachi Ku, Tokyo, Japan; [Gotoh, Noriko] Kanazawa Univ, Canc Res Inst, Div Canc Cell Biol, Kakuma Machi, Kanazawa, Ishikawa, Japan; [Kaneko, Shuichi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Gastroenterol, Takaramachi, Kanazawa, Ishikawa, Japan; [Seiki, Motoharu] Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo, Japan; [Murakami, Yoshinori] Univ Tokyo, Inst Med Sci, Div Mol Pathol, Minato Ku, Tokyo, Japan; [Sakamoto, Takeharu] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Syst Biol, Takaramachi, Kanazawa, Ishikawa, Japan	University of Tokyo; Jichi Medical University; Kanazawa University; Kanazawa University; University of Tokyo; University of Tokyo; Kanazawa University	Sakamoto, T (corresponding author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Syst Biol, Takaramachi, Kanazawa, Ishikawa, Japan.	t-saka@staff.kanazawa-u.ac.jp		Sakamoto, Takeharu/0000-0002-1225-1902; Inoue, Jun-ichiro/0000-0001-6389-7036	MEXT [19K07659]; P-CREATE (Project for Cancer Research and Therapeutic Evolution) grant from The Japan Agency for Medical Research and Development [16770655]; Kobayashi Foundation for Cancer Research; Extramural Collaborative Research Grant of the Cancer Research Institute, Kanazawa University	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); P-CREATE (Project for Cancer Research and Therapeutic Evolution) grant from The Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); Kobayashi Foundation for Cancer Research(Kobayashi Foundation for Cancer Research); Extramural Collaborative Research Grant of the Cancer Research Institute, Kanazawa University	This work was supported by a Grant-in-Aid for Scientific Research (C) (19K07659) from MEXT; a P-CREATE (Project for Cancer Research and Therapeutic Evolution) grant (16770655) from The Japan Agency for Medical Research and Development; the Kobayashi Foundation for Cancer Research; and partly by the Extramural Collaborative Research Grant of the Cancer Research Institute, Kanazawa University (to TS).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Ciliberto D, 2013, EUR J CANCER, V49, P593, DOI 10.1016/j.ejca.2012.08.019; Einama T, 2006, PANCREAS, V32, P376, DOI 10.1097/01.mpa.0000220862.78248.c4; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gartel AL, 2002, MOL CANCER THER, V1, P639; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hara T, 2017, P NATL ACAD SCI USA, V114, pE4416, DOI 10.1073/pnas.1703171114; Hara T, 2011, J BIOL CHEM, V286, P32542, DOI 10.1074/jbc.M111.271726; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Ho A, 2006, J NEUROSCI, V26, P13089, DOI 10.1523/JNEUROSCI.2855-06.2006; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang TH, 2017, ONCOTARGETS THER, V10, P439, DOI 10.2147/OTT.S125789; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Nakaoka HJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.27; Raleigh JA, 1999, RADIAT RES, V151, P580, DOI 10.2307/3580034; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Ruan D, 2017, ONCOGENE, V36, P4299, DOI 10.1038/onc.2017.64; Sakamoto T, 2017, CANCER SCI, V108, P1095, DOI 10.1111/cas.13231; Sakamoto T, 2014, MOL CELL BIOL, V34, P30, DOI 10.1128/MCB.01169-13; Sakamoto T, 2011, J BIOL CHEM, V286, P14691, DOI 10.1074/jbc.M110.188714; Sakamoto T, 2010, J BIOL CHEM, V285, P29951, DOI 10.1074/jbc.M110.132704; Sakamoto T, 2009, J BIOL CHEM, V284, P30350, DOI 10.1074/jbc.M109.019216; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sobhanifar S, 2005, CANCER RES, V65, P7259, DOI 10.1158/0008-5472.CAN-04-4480; Solomon S, 2007, AR4 CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P1; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Vervoorts J, 2008, CELL MOL LIFE SCI, V65, P3255, DOI 10.1007/s00018-008-8296-7; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang YG, 2016, ONCOL REP, V36, P559, DOI 10.3892/or.2016.4809; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang HM, 2015, P NATL ACAD SCI USA, V112, pE6215, DOI 10.1073/pnas.1520032112	45	9	9	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2020	39	39					6218	6230		10.1038/s41388-020-01423-8	http://dx.doi.org/10.1038/s41388-020-01423-8		AUG 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NS8XO	32826949	hybrid, Green Published			2022-12-17	WOS:000561519300003
J	Qi, L; Wang, ZY; Shao, XR; Li, M; Chen, SN; Liu, XQ; Yan, S; Zhang, B; Zhang, XD; Li, X; Zhao, WX; Pan, JA; Zhao, B; Zhang, XD				Qi, Lin; Wang, Zhong-Yong; Shao, Xin-Rong; Li, Miao; Chen, Shu-Na; Liu, Xue-Qi; Yan, Shi; Zhang, Bo; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Pan, Ji-An; Zhao, Bo; Zhang, Xing-Ding			ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma	ONCOGENE			English	Article							GRADE II; RADIOTHERAPY; TEMOZOLOMIDE; PROGRESSION; MECHANISMS; CYTOKINE; SURVIVAL; GLIOMAS; GROWTH; CANCER	Oligodendroglioma is an important type of lower-grade glioma (LGG), which is a slowly progressing brain tumor. Many LGGs eventually transform into a more aggressive or malignant type. Enhanced angiogenesis is a characteristic of malignantly transformed oligodendroglioma (m-oligodendroglioma). However, the pathogenesis and signaling pathways associated with angiogenesis and proliferation in m-oligodendroglioma are not well understood. In this study, we identified that Insulin Gene Enhancer Protein (ISL2) and its angiogenic capacity were inversely related to survival according to LGG patient data from an online database, and this was further confirmed with pathological LGG patient samples, including malignantly transformed samples, by detecting the expression of ISL2, the angiogenic markers vascular endothelial growth factor (VEGFA) and CD31 and the proliferation marker Ki-67. We then established novel oligodendroglioma patient tumor-derived orthotopic xenograft mouse models and cell lines to verify the role of ISL2 in regulating angiogenesis to promote oligodendroglioma growth and malignant transformation. Furthermore, ISL2 regulated ANGPT2 transcription by binding to the ANGPT2 promoter. Then, ANGPT2, a downstream gene, activated angiogenesis through VEGFA to promote oligodendroglioma malignant transformation. Finally, combining AAV-ISL2-shRNA with temozolomide suppressed oligodendroglioma progression more effectively than either monotherapy in vivo and in vitro. Thus, hypoxia-induced ISL2 regulated ANGPT2, which subsequently induced angiogenesis to promote oligodendroglioma growth and malignant transformation. Malignancy was accompanied by worsened hypoxia inside the tumor mass, creating a positive feedback loop. In conclusion, this study suggests that ISL2 is a biomarker for oligodendroglioma progression and that anti-ISL2 therapy may offer a potential clinical strategy for treating m-oligodendroglioma.	[Qi, Lin; Shao, Xin-Rong; Li, Miao; Chen, Shu-Na; Liu, Xue-Qi; Zhang, Xu-Dong; Li, Xin; Zhao, Wenxue; Pan, Ji-An; Zhao, Bo; Zhang, Xing-Ding] Sun Yat Sen Univ, Sch Med, Dept Pharmacol, Mol Canc Res Ctr, Shenzhen, Peoples R China; [Qi, Lin] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; [Wang, Zhong-Yong] Soochow Univ, Affiliated Hosp 2, Dept Neurosurg, Suzhou, Peoples R China; [Yan, Shi] Univ Vet Med Vienna, Inst Parasitol, Dept Pathobiol, Vienna, Austria; [Zhang, Bo] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Intervent Radiol, Guangzhou, Peoples R China	Sun Yat Sen University; Northwestern University; Feinberg School of Medicine; Soochow University - China; University of Veterinary Medicine Vienna; Sun Yat Sen University	Qi, L; Zhang, XD (corresponding author), Sun Yat Sen Univ, Sch Med, Dept Pharmacol, Mol Canc Res Ctr, Shenzhen, Peoples R China.; Qi, L (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA.	qilin23@mail.sysu.edu.cn; zhangxd39@mail.sysu.edu.cn	zhang, xian/GYA-0290-2022; Zhao, Bo/GVT-7665-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022; zhang, xu/GYE-3558-2022; Li, Xin/A-4137-2011; Yan, Shi/H-9091-2013	Zhao, Bo/0000-0002-2163-6484; WANG, ZHONGYONG/0000-0003-1131-3849; Li, Xin/0000-0001-8328-4894; Yan, Shi/0000-0003-4949-9140; Liu, Xueqi/0000-0002-8295-032X	National Natural Science Foundation of China [81970191, 31971161, 31971224, 81301978]; Guangdong Natural Science Foundation of China [2018A0303130090, 2019A1515011332]; Youth Medical Doctors Project of Jiangsu Province of China [QNRC2016870]; Fundamental Research Funds for the Central Universities of China [19ykpy149]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Youth Medical Doctors Project of Jiangsu Province of China; Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities)	This work was supported in part by the National Natural Science Foundation of China (grant nos. 81970191, 31971161, 31971224, and 81301978), the Guangdong Natural Science Foundation of China (grant nos. 2018A0303130090 and 2019A1515011332), the Youth Medical Doctors Project of Jiangsu Province of China (QNRC2016870), and the Fundamental Research Funds for the Central Universities of China (grant no. 19ykpy149).	Alfonso JCL, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2017.0490; Bachy I, 2002, NEUROREPORT, V13, pA23, DOI 10.1097/00001756-200202110-00002; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Chen Z, 2016, GUT, V65, P925, DOI 10.1136/gutjnl-2014-308416; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279; Edqvist PHD, 2006, EUR J HISTOCHEM, V50, P147; Esencay M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-347; Feller C, 2020, ACTA NEUROPATHOL, V139, P211, DOI 10.1007/s00401-019-02096-8; Fischer I, 2005, BRAIN PATHOL, V15, P297; Fuchs Q, 2020, CANCERS, V12, DOI 10.3390/cancers12040979; Gagliardi F, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104705; Gill Gordon N, 2003, Trans Am Clin Climatol Assoc, V114, P179; Heindryckx F, 2015, WORLD J HEPATOL, V7, P165, DOI 10.4254/wjh.v7.i2.165; Karamysheva AF, 2008, BIOCHEMISTRY-MOSCOW+, V73, P751, DOI 10.1134/S0006297908070031; Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115; Kay RB, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00073; Krenzlin H, 2019, J CLIN INVEST, V129, P1671, DOI 10.1172/JCI123375; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Martinez-Gonzalez A, 2016, ADV EXP MED BIOL, V936, P11, DOI 10.1007/978-3-319-42023-3_2; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Onishi M, 2011, BRAIN TUMOR PATHOL, V28, P13, DOI 10.1007/s10014-010-0007-z; Osterberg N, 2016, NEURO-ONCOLOGY, V18, P939, DOI 10.1093/neuonc/now005; Podbielska M, 2016, J LIPID RES, V57, P2028, DOI 10.1194/jlr.M070664; POST GR, 1992, MOL CHEM NEUROPATHOL, V16, P303, DOI 10.1007/BF03159976; Qi L, 2015, PLOS ONE, V10; Reyes-Botero G, 2018, ONCOLOGIST, V23, P524, DOI 10.1634/theoncologist.2017-0689; Schiffer D, 2018, NEUROL SCI, V39, P1161, DOI 10.1007/s10072-018-3408-0; Scholz A, 2015, ANN NY ACAD SCI, V1347, P45, DOI 10.1111/nyas.12726; Seano G, 2020, ANGIOGENESIS, V23, P9, DOI 10.1007/s10456-019-09691-z; Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541-7786.MCR-07-0072; Shirasaki R, 2002, ANNU REV NEUROSCI, V25, P251, DOI 10.1146/annurev.neuro.25.112701.142916; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Suzuki H, 2015, NAT GENET, V47, P458, DOI 10.1038/ng.3273; Swanson KR, 2011, CANCER RES, V71, P7366, DOI 10.1158/0008-5472.CAN-11-1399; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Vallee A, 2018, REV NEUROSCIENCE, V29, P71, DOI 10.1515/revneuro-2017-0032; van den Bent MJ, 2018, LANCET ONCOL, V19, P1170, DOI 10.1016/S1470-2045(18)30362-0; van den Bent MJ, 2018, NEUROL CLIN, V36, P467, DOI 10.1016/j.ncl.2018.04.005; Wang ML, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0533-1; Wang X, 2014, ONCOL REP, V31, P1975, DOI 10.3892/or.2014.3112; Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8; Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17; Wesseling P, 2015, ACTA NEUROPATHOL, V129, P809, DOI 10.1007/s00401-015-1424-1; Yazdani Yasaman, 2016, Asian Pac J Cancer Prev, V17, P5303; Zhang XD, 2016, CANCER CELL, V29, P639, DOI 10.1016/j.ccell.2016.03.026	46	9	9	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					5964	5978		10.1038/s41388-020-01411-y	http://dx.doi.org/10.1038/s41388-020-01411-y		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32753650				2022-12-17	WOS:000555747100004
J	Maeda, T; Kitamura, S; Nishihara, H; Yanagi, T				Maeda, Takuya; Kitamura, Shinya; Nishihara, Hiroshi; Yanagi, Teruki			Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies	ONCOGENE			English	Article							COMBINATION CHEMOTHERAPY; ANTITUMOR-ACTIVITY; BREAST-CANCER; DOCETAXEL; EFFICACY; ERIBULIN; OUTCOMES; PROTEIN; GROWTH; TUMOR	Although the prognosis of advanced extramammary Paget's disease (EMPD) is poor, there have been no preclinical research models for the development of novel therapeutics. This study aims to establish a preclinical research model for EMPD. We transplanted EMPD tissue into immunodeficient NOD/Scid mice. Histopathological and genetic analyses using a comprehensive cancer panel were performed. For in vivo preclinical treatments, trastuzumab, lapatinib, docetaxel, or eribulin were administered to patient-derived xenograft (PDX) models. Tissue transplanted from the EMPD patient was enlarged in NOD/Scid mice and was transplanted into further generations. Both the transplantation of PDX intonu/numice and the reanimation of the cryopreserved xenografted tumors in NOD/Scid mice were successful. We also established an EMPD-PDX-derived primary cell culture. Histopathologically, the xenografted tumors were positive for CK7, which was consistent with the patient's tumors. Genetically, the pathogenic mutationERBB2S310F was detected in the patient's tumors (primary intraepidermal lesion, metastatic lymph node) and was observed in the xenografted tumors even after continued passages. The xenografted tumors responded well to trastuzumab and lapatinib therapy. Also, cytotoxic agents (docetaxel and eribulin) were effective against the xenografted tumors. This PDX model (EMPD-PDX-H1) could be a powerful tool for the research and development of EMPD treatments.	[Maeda, Takuya; Kitamura, Shinya; Yanagi, Teruki] Hokkaido Univ, Fac Med, Dept Dermatol, Sapporo, Hokkaido, Japan; [Maeda, Takuya; Kitamura, Shinya; Yanagi, Teruki] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan; [Nishihara, Hiroshi] Keio Univ, Sch Med, Keio Canc Ctr, Genom Unit, Tokyo, Japan	Hokkaido University; Hokkaido University; Keio University	Yanagi, T (corresponding author), Hokkaido Univ, Fac Med, Dept Dermatol, Sapporo, Hokkaido, Japan.; Yanagi, T (corresponding author), Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan.	yanagi@med.hokudai.ac.jp	Yanagi, Teruki/D-4222-2017	Yanagi, Teruki/0000-0003-2196-7600	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology in Japan [18K08259]	KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology in Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms. Yuko Tateda for her technical assistance. This work was supported in part by KAKENHI grant #18K08259 to TY from the Ministry of Education, Culture, Sports, Science and Technology in Japan.	Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Greulich H, 2012, P NATL ACAD SCI USA, V109, P14476, DOI 10.1073/pnas.1203201109; Hatta N, 2008, BRIT J DERMATOL, V158, P313, DOI 10.1111/j.1365-2133.2007.08314.x; Hendrikx JJMA, 2016, INT J CANCER, V138, P758, DOI 10.1002/ijc.29812; Herrel LA, 2015, ANN SURG ONCOL, V22, P1625, DOI 10.1245/s10434-014-4139-y; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hirai I, 2019, ONCOLOGIST, V24, pE394, DOI 10.1634/theoncologist.2018-0856; Hirakawa S, 2009, AM J PATHOL, V175, P2235, DOI 10.2353/ajpath.2009.090420; Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475; Ivanics T, 2018, LAB INVEST, V98, P947, DOI 10.1038/s41374-018-0042-7; Kanitakis J, 2007, J EUR ACAD DERMATOL, V21, P1450, DOI 10.1111/j.1468-3083.2007.02438.x; Karam A, 2012, GYNECOL ONCOL, V125, P346, DOI 10.1016/j.ygyno.2012.01.032; Karam A, 2008, GYNECOL ONCOL, V111, P568, DOI 10.1016/j.ygyno.2007.12.014; Kato M, 2019, BRIT J DERMATOL, V181, P831, DOI 10.1111/bjd.17922; Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211; Kiniwa Y, 2019, J DERMATOL SCI, V94, P229, DOI 10.1016/j.jdermsci.2019.03.006; Koga Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050418; Ma CX, 2017, CLIN CANCER RES, V23, P5687, DOI 10.1158/1078-0432.CCR-17-0900; NISHI M, 1992, J NATL CANCER I, V84, P519, DOI 10.1093/jnci/84.7.519; Nonagase Y, 2016, ONCOTARGET, V7, P84860, DOI 10.18632/oncotarget.12743; Oashi K, 2014, BRIT J DERMATOL, V170, P1354, DOI 10.1111/bjd.12788; Ohara K, 2016, J DERMATOL SCI, V83, P234, DOI 10.1016/j.jdermsci.2016.06.004; Paget J, 1874, ST BARTHOLOMEWS HOSP, V10, P87; Richter CE, 2010, J CLIN PATHOL, V63, P544, DOI 10.1136/jcp.2010.077446; Takahagi S, 2009, J DERMATOL, V36, P457, DOI 10.1111/j.1346-8138.2009.00676.x; Takeichi T, 2020, CANCERS, V12, DOI 10.3390/cancers12040820; Tanaka R, 2013, BRIT J DERMATOL, V168, P1259, DOI 10.1111/bjd.12249; Tanaka R, 2016, CLIN EXP METASTAS, V33, P687, DOI 10.1007/s10585-016-9804-z; Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015; Tokuda Y, 2015, INT J CLIN ONCOL, V20, P194, DOI 10.1007/s10147-014-0686-2; Towle MJ, 2012, ANTICANCER RES, V32, P1611; Twelves C, 2014, BREAST CANCER RES TR, V148, P553, DOI 10.1007/s10549-014-3144-y; Vornicova O, 2014, ONCOLOGIST, V19, P1006, DOI 10.1634/theoncologist.2014-0054; Wainberg ZA, 2010, CLIN CANCER RES, V16, P1509, DOI 10.1158/1078-0432.CCR-09-1112; Wolff AC, 2018, J CLIN ONCOL, V36, P2105, DOI 10.1200/JCO.2018.77.8738; Yanagi T, 2018, CANCER RES, V78, P6795, DOI 10.1158/0008-5472.CAN-18-1495; Yanagi T, 2014, CANCER RES, V74, P5795, DOI 10.1158/0008-5472.CAN-14-0872; Yoshino K, 2016, J DERMATOL, V43, P633, DOI 10.1111/1346-8138.13200; Zhang GH, 2019, J INVEST DERMATOL, V139, P789, DOI 10.1016/j.jid.2018.08.030	39	9	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5867	5875		10.1038/s41388-020-01404-x	http://dx.doi.org/10.1038/s41388-020-01404-x		JUL 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32724160	Green Submitted			2022-12-17	WOS:000553333400002
J	Green, D; Eyre, H; Singh, A; Taylor, JT; Chu, J; Jeys, L; Sumathi, V; Coonar, A; Rassl, D; Babur, M; Forster, D; Alzabin, S; Ponthan, F; McMahon, A; Bigger, B; Reekie, T; Kassiou, M; Williams, K; Dalmay, T; Fraser, WD; Finegan, KG				Green, Darrell; Eyre, Heather; Singh, Archana; Taylor, Jessica T.; Chu, Jason; Jeys, Lee; Sumathi, Vaiyapuri; Coonar, Aman; Rassl, Doris; Babur, Muhammad; Forster, Duncan; Alzabin, Saba; Ponthan, Frida; McMahon, Adam; Bigger, Brian; Reekie, Tristan; Kassiou, Michael; Williams, Kaye; Dalmay, Tamas; Fraser, William D.; Finegan, Katherine G.			Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer	ONCOGENE			English	Article							OSTEOSARCOMA CELL; LUNG METASTASIS; ERK5; EXPRESSION; GROWTH; INFLAMMATION; PERFORMANCE; INHIBITOR; INVASION	Metastasis is the leading cause of cancer-related death. This multistage process involves contribution from both tumour cells and the tumour stroma to release metastatic cells into the circulation. Circulating tumour cells (CTCs) survive circulatory cytotoxicity, extravasate and colonise secondary sites effecting metastatic outcome. Reprogramming the transcriptomic landscape is a metastatic hallmark, but detecting underlying master regulators that drive pathological gene expression is a key challenge, especially in childhood cancer. Here we used whole tumour plus single-cell RNA-sequencing in primary bone cancer and CTCs to perform weighted gene co-expression network analysis to systematically detect coordinated changes in metastatic transcript expression. This approach with comparisons applied to data collected from cell line models, clinical samples and xenograft mouse models revealed mitogen-activated protein kinase 7/matrix metallopeptidase 9 (MAPK7/MMP9) signalling as a driver for primary bone cancer metastasis. RNA interference knockdown ofMAPK7reduces proliferation, colony formation, migration, tumour growth, macrophage residency/polarisation and lung metastasis. Parallel to these observations were reduction of activated interleukinsIL1B,IL6,IL8plus mesenchymal markersVIMandVEGFin response toMAPK7loss. Our results implicate a newly discovered, multidimensional MAPK7/MMP9 signalling hub in primary bone cancer metastasis that is clinically actionable.	[Green, Darrell; Fraser, William D.] Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England; [Eyre, Heather; Taylor, Jessica T.; Chu, Jason; Babur, Muhammad; Bigger, Brian; Williams, Kaye; Finegan, Katherine G.] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England; [Singh, Archana] Earlham Inst, Digital Biol, Norwich, Norfolk, England; [Jeys, Lee] Royal Orthopaed Hosp, Orthopaed Oncol, Birmingham, W Midlands, England; [Sumathi, Vaiyapuri] Royal Orthopaed Hosp, Musculoskeletal Pathol, Birmingham, W Midlands, England; [Coonar, Aman] Royal Papworth Hosp, Thorac Surg, Cambridge, England; [Rassl, Doris] Royal Papworth Hosp, Pathol, Cambridge, England; [Forster, Duncan; McMahon, Adam] Univ Manchester, Wolfson Mol Imaging Ctr, Manchester, Lancs, England; [Alzabin, Saba; Ponthan, Frida] Epistem Ltd, Manchester, Lancs, England; [Reekie, Tristan; Kassiou, Michael] Univ Sydney, Sch Chem, Sydney, NSW, Australia; [Dalmay, Tamas] Univ East Anglia, Sch Biol Sci, Norwich, Norfolk, England; [Fraser, William D.] Norfolk & Norwich Univ Hosp, Clin Biochem, Norwich, Norfolk, England; [Fraser, William D.] Norfolk & Norwich Univ Hosp, Diabet & Endocrinol, Norwich, Norfolk, England	University of East Anglia; University of Manchester; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Earlham Institute; Royal Orthopaedic Hospital; Royal Orthopaedic Hospital; Papworth Hospital; Papworth Hospital; University of Manchester; University of Sydney; University of East Anglia; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital	Fraser, WD (corresponding author), Univ East Anglia, Norwich Med Sch, Norwich, Norfolk, England.; Finegan, KG (corresponding author), Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.; Fraser, WD (corresponding author), Norfolk & Norwich Univ Hosp, Clin Biochem, Norwich, Norfolk, England.; Fraser, WD (corresponding author), Norfolk & Norwich Univ Hosp, Diabet & Endocrinol, Norwich, Norfolk, England.	w.fraser@uea.ac.uk; k.g.finegan@manchester.ac.uk	williams, kaye/HHN-5342-2022; McMahon, Adam/C-3660-2018	McMahon, Adam/0000-0002-6130-2008; Taylor, Jessica/0000-0001-8565-8589; Green, Darrell/0000-0002-0217-3322; Alzabin, Saba/0000-0003-3474-1846; Archana, Archana/0000-0002-5027-4582; Kassiou, Michael/0000-0002-6655-0529; Eyre, Heather/0000-0001-9932-3595; Finegan, Katie/0000-0003-2885-0122	Humane Research Trust; Paget's Association; BBSRC [BBS/E/T/000PR9819] Funding Source: UKRI	Humane Research Trust; Paget's Association; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by The Humane Research Trust, Friends of Rosie, Big C and Paget's Association. We thank Teresa Brodie, Dionne Wortley, Emma Bruce, Jenny Ledwidge, Jennifer Gill, Joanne Taylor, Sukhpal Singh and staff at the FBMH Research Facilities: Histology and Bioimaging for technical support. We also thank Dr. Luisa Martinez-Pomares for the MR antibody. We are indebted to the patients for their contribution to this study.	Anderson ND, 2018, SCIENCE, V361, DOI 10.1126/science.aam8419; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt0816-888d; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Farina AR, 2014, CANCERS, V6, P240, DOI 10.3390/cancers6010240; Finegan KG, 2015, CANCER RES, V75, P742, DOI 10.1158/0008-5472.CAN-13-3043; Finegan KG, 2010, CANCER RES, V70, P5797, DOI 10.1158/0008-5472.CAN-09-3669; Gerrand C, 2016, CLIN SARCOMA RES, V6, DOI 10.1186/s13569-016-0047-1; Giurisato E, 2018, P NATL ACAD SCI USA, V115, pE2801, DOI 10.1073/pnas.1707929115; Green D, 2019, PATHOLOGY, V51, P113, DOI 10.1016/j.pathol.2018.08.014; Green D, 2017, ENDOCR-RELAT CANCER, V24, pL27, DOI 10.1530/ERC-16-0487; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Heymann MF, 2017, CELL IMMUNOL, V343, P1; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Jalili A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069064; Javaid S, 2015, MOL CANCER RES, V13, P934, DOI 10.1158/1541-7786.MCR-14-0604; Katz Y, 2015, BIOINFORMATICS, V31, P2400, DOI 10.1093/bioinformatics/btv034; Kim SM, 2012, J ORTHOP RES, V30, P1040, DOI 10.1002/jor.22025; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lin ECK, 2016, P NATL ACAD SCI USA, V113, P11865, DOI 10.1073/pnas.1609019113; Lochhead PA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15031-3; Lopez-Nieva P, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4304-y; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270; Mohorianu I, 2011, PLANT J, V67, P232, DOI 10.1111/j.1365-313X.2011.04586.x; Pearson AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030929; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013; Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080; Shaw B, 2019, P NATL ACAD SCI USA, V116, P10463, DOI 10.1073/pnas.1820556116; Shen SH, 2014, P NATL ACAD SCI USA, V111, pE5593, DOI 10.1073/pnas.1419161111; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tesser-Gamba F, 2016, MOL CARCINOGEN, V55, P1700, DOI 10.1002/mc.22420; Tesser-Gamba F, 2012, HUM PATHOL, V43, P994, DOI 10.1016/j.humpath.2011.08.003; Tome Y, 2013, ANTICANCER RES, V33, P3623; Vasiliadou I, 2013, J BONE ONCOL, V2, P158, DOI 10.1016/j.jbo.2013.07.002; Wang J, 2014, CLIN CHIM ACTA, V433, P225, DOI 10.1016/j.cca.2014.03.023; Waschkau B, 2013, CONTRAST MEDIA MOL I, V8, P1, DOI 10.1002/cmmi.1486; Weekes D, 2016, ONCOGENE, V35, P2852, DOI 10.1038/onc.2015.344; Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6; Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646; Yue B, 2014, EUR REV MED PHARMACO, V18, P2640; Zhao W, 2010, J BIOPHARM STAT, V20, P281, DOI 10.1080/10543400903572753; Zheng JZ, 2016, MOL IMAGING BIOL, V18, P127, DOI 10.1007/s11307-015-0877-x; Zheng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14344; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhou J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013051	52	9	9	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5553	5569		10.1038/s41388-020-1379-0	http://dx.doi.org/10.1038/s41388-020-1379-0		JUL 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32655131	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000547821000001
J	Braggio, D; Zewdu, A; Londhe, P; Yu, P; Lopez, G; Batte, K; Koller, D; de Faria, FCC; Casadei, L; Strohecker, AM; Lev, D; Pollock, RE				Braggio, Danielle; Zewdu, Abeba; Londhe, Priya; Yu, Peter; Lopez, Gonzalo; Batte, Kara; Koller, David; de Faria, Fernanda Costas Casal; Casadei, Lucia; Strohecker, Anne M.; Lev, Dina; Pollock, Raphael E.			beta-catenin S45F mutation results in apoptotic resistance	ONCOGENE			English	Article							GASTRIC-CANCER; TUMOR-SUPPRESSOR; BREAST-CANCER; DESMOID TUMOR; EXON 3; EXPRESSION; CTNNB1; RUNX3; ACTIVATION; GENE	Wnt/beta-catenin signaling is one of the key cascades regulating embryogenesis and tissue homeostasis; it has also been intimately associated with carcinogenesis. This pathway is deregulated in several tumors, including colorectal cancer, breast cancer, and desmoid tumors. It has been shown thatCTNNB1exon 3 mutations are associated with an aggressive phenotype in several of these tumor types and may be associated with therapeutic tolerance. Desmoid tumors typically have a stable genome with beta-catenin mutations as a main feature, making these tumors an ideal model to study the changes associated with different types of beta-catenin mutations. Here, we show that the apoptosis mechanism is deregulated in beta-catenin S45F mutants, resulting in decreased induction of apoptosis in these cells. Our findings also demonstrate thatRUNX3plays a pivotal role in the inhibition of apoptosis found in the beta-catenin S45F mutants. Restoration ofRUNX3overcomes this inhibition in the S45F mutants, highlighting it as a potential therapeutic target for malignancies harboring this specificCTNNB1mutation. While the regulatory effect of RUNX3 in beta-catenin is already known, our results suggest the possibility of a feedback loop involving these two genes, with theCTNNB1S45F mutation downregulating expression ofRUNX3, thus providing additional possible novel therapeutic targets for tumors having deregulated Wnt/beta-catenin signaling induced by this mutation.	[Braggio, Danielle; Zewdu, Abeba; Lopez, Gonzalo; Batte, Kara; Koller, David; de Faria, Fernanda Costas Casal; Casadei, Lucia; Pollock, Raphael E.] Ohio State Univ, James Comprehens Canc Ctr, Program Translat Therapeut, Columbus, OH 43210 USA; [Braggio, Danielle; Zewdu, Abeba; Lopez, Gonzalo; Batte, Kara; Koller, David; de Faria, Fernanda Costas Casal; Casadei, Lucia; Strohecker, Anne M.; Pollock, Raphael E.] Ohio State Univ, Dept Surg, Columbus, OH 43210 USA; [Londhe, Priya] Millipore Sigma, Burlington, MA 01803 USA; [Yu, Peter] Ohio State Univ, Med Student Res Program, Columbus, OH 43210 USA; [Strohecker, Anne M.] Ohio State Univ, James Comprehens Canc Ctr, Program Mol Biol & Canc Genet, Columbus, OH 43210 USA; [Strohecker, Anne M.] Ohio State Univ, Coll Med, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Lev, Dina] Sheba Med Ctr, Surg B, Tel Aviv, Israel; [Lev, Dina] Tel Aviv Univ, Tel Aviv, Israel	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Merck KGaA; MilliporeSigma; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Chaim Sheba Medical Center; Tel Aviv University	Braggio, D; Pollock, RE (corresponding author), Ohio State Univ, James Comprehens Canc Ctr, Program Translat Therapeut, Columbus, OH 43210 USA.; Braggio, D; Pollock, RE (corresponding author), Ohio State Univ, Dept Surg, Columbus, OH 43210 USA.	dabraggio@gmail.com; raphael.pollock@osumc.edu		CASADEI, Lucia/0000-0002-5731-8197	Desmoid Tumor Research Foundation Seed Grant; National Cancer Institute of the National Institutes of Health [U54CA168512, 1K22CA187931]; National Institutes of Health [P30 CA016058]	Desmoid Tumor Research Foundation Seed Grant; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by a Desmoid Tumor Research Foundation Seed Grant, and the following grants from the National Cancer Institute of the National Institutes of Health: U54CA168512 (REP), 1K22CA187931 (AMS) and a grant from the National Institutes of Health to The OSU Comprehensive Cancer Center (P30 CA016058).	Aitken SJ, 2015, VIRCHOWS ARCH, V467, P203, DOI 10.1007/s00428-015-1765-0; Bhattacharya B, 2005, AM J SURG PATHOL, V29, P653, DOI 10.1097/01.pas.0000157938.95785.da; Braggio D, 2019, CANCER-AM CANCER SOC, V125, P2693, DOI 10.1002/cncr.32120; Bui N, 2017, ONCOTARGET, V8, P90608, DOI 10.18632/oncotarget.21293; Chilov D, 2011, DEV BIOL, V357, P259, DOI 10.1016/j.ydbio.2011.06.029; Cieply B, 2009, HEPATOLOGY, V49, P821, DOI 10.1002/hep.22695; Colombo C, 2013, CANCER-AM CANCER SOC, V119, P3696, DOI 10.1002/cncr.28271; Crago AM, 2015, GENE CHROMOSOME CANC, V54, P606, DOI 10.1002/gcc.22272; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hamada S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096391; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Iwao K, 1998, CANCER RES, V58, P1021; Jamora C, 2002, NAT CELL BIOL, V4, pE101, DOI 10.1038/ncb0402-e101; Ju XL, 2014, CANCER SCI, V105, P418, DOI 10.1111/cas.12356; Kasper B, 2016, ANN SURG ONCOL, V23, P1924, DOI 10.1245/s10434-016-5132-4; Kotiligam D, 2008, HISTOL HISTOPATHOL, V23, P117, DOI 10.14670/HH-23.117; Kurnit KC, 2017, MODERN PATHOL, V30, P1032, DOI 10.1038/modpathol.2017.15; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Lecarpentier Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01248; Lento W, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008011; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; Liu YX, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju245; McCarty Mark F, 2004, Integr Cancer Ther, V3, P349, DOI 10.1177/1534735404270757; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mullen JT, 2013, ONCOLOGIST, V18, P1043, DOI 10.1634/theoncologist.2012-0449; Nejak-Bowen KN, 2010, HEPATOLOGY, V51, P1603, DOI 10.1002/hep.23538; Nelson WJ, 2008, BIOCHEM SOC T, V36, P149, DOI 10.1042/BST0360149; Nishio M, 2010, ANTICANCER RES, V30, P2673; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Rebouissou S, 2016, HEPATOLOGY, V64, P2047, DOI 10.1002/hep.28638; Salas S, 2010, GENE CHROMOSOME CANC, V49, P560, DOI 10.1002/gcc.20766; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sun JK, 2018, J NEURO-ONCOL, V140, P15, DOI 10.1007/s11060-018-2927-0; Tornesello ML, 2013, GENOMICS, V102, P74, DOI 10.1016/j.ygeno.2013.04.001; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Xu JH, 2016, MOL CARCINOGEN, V55, P431, DOI 10.1002/mc.22292; Yamamura Y, 2005, RUNX3 COOPERATES FOX, DOI [10.1074/jbc.M512151200, DOI 10.1074/JBC.M512151200]; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607; Zhu QS, 2008, CANCER RES, V68, P2895, DOI 10.1158/0008-5472.CAN-07-6268	45	9	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5589	5600		10.1038/s41388-020-1382-5	http://dx.doi.org/10.1038/s41388-020-1382-5		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32651460	hybrid, Green Published			2022-12-17	WOS:000547254200001
J	Wang, MN; Long, KL; Li, EJ; Li, LL; Li, BH; Ci, SS; He, LF; Pan, FY; Hu, ZG; Guo, ZG				Wang, Meina; Long, Kaili; Li, Enjie; Li, Lulu; Li, Binghua; Ci, Shusheng; He, Lingfeng; Pan, Feiyan; Hu, Zhigang; Guo, Zhigang			DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation	ONCOGENE			English	Article							BASE EXCISION-REPAIR; ADHESION MOLECULES; BREAST-CANCER; T-CADHERIN; METASTASIS; MUTATION; METHYLATION; MIGRATION; INVASION; IMPAIRS	DNA polymerase beta (Pol beta) plays a critical role in DNA base excision repair (BER), which is involved in maintaining genomic stability and in the modulation of DNA demethylation. Numerous studies implicated deficiency of Pol beta in the genomic instability and dysregulation of genes expression, leading to affecting initiation of cancer. However, the role of Pol beta in cancer progression is still unclear. Here, we show that Pol beta depresses migratory and invasive capabilities of both breast and lung carcinomas, which were evident in human breast and lung cancer cells, as well as in mouse xenograft tumors. On the molecular basis, overexpression of Pol beta enhanced expression of CDH13, which show function on cell adhesion and migration. Knockdown of CDH13 restores the migratory, invasive capabilities and angiogenesis in tumor, which gets impaired by Pol beta. According to the function of BER on modulation of DNA demethylation, our studies on CDH13 expression and the DNA methylation levels of CDH13 promoter suggested that Pol beta promotes expression of CDH13 by augmenting DNA demethylation of CDH13 promoter. Our findings elucidated a novel possibility that Pol beta impair cancer cell metastasis during cancer progression and shed light on the role of Pol beta in cancer therapy.	[Wang, Meina; Long, Kaili; Li, Enjie; Li, Lulu; Ci, Shusheng; He, Lingfeng; Pan, Feiyan; Hu, Zhigang; Guo, Zhigang] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China; [Li, Binghua] Nanjing Univ, Dept Hepatobiliary Surg, Affiliated Drum Tower Hosp, Sch Med, Nanjing 210008, Peoples R China	Nanjing Normal University; Nanjing University	Hu, ZG; Guo, ZG (corresponding author), Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China.	huzg_2000@126.com; guo@njnu.edu.cn	Wang, Meina/AAP-3020-2021	Li, Binghua/0000-0001-7209-2854; guo, zhigang/0000-0001-7771-1829	National Natural Science Foundation of China [81872284]; Natural Science Foundation of Colleges and Universities in Jiangsu Province [19KJA180010]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Colleges and Universities in Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions	The authors would like to thank Dr. Binghui Shen (Beckman Research Institute, City of Hope, Duarte, CA, USA) for the MEF cell lines. This work was supported by the National Natural Science Foundation of China (81872284), the Natural Science Foundation of Colleges and Universities in Jiangsu Province (19KJA180010), and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Abdel-Fatah TMA, 2014, MOL ONCOL, V8, P520, DOI 10.1016/j.molonc.2014.01.001; Andreeva AV, 2010, GENE CHROMOSOME CANC, V49, P775, DOI 10.1002/gcc.20787; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergoglio V, 2002, CANCER RES, V62, P3511; Broustas CG, 2014, RADIAT RES, V181, P111, DOI 10.1667/RR13515.1; Chan DW, 2008, INT J CANCER, V123, P1043, DOI 10.1002/ijc.23634; Chen F, 2016, BMC UROL, V16, DOI 10.1186/s12894-016-0171-5; Chen ZX, 2011, J BIOL CHEM, V286, P18347, DOI 10.1074/jbc.R110.205286; Choi EB, 2016, ONCOGENE, V35, P4569, DOI 10.1038/onc.2016.3; Eccles SA, 2007, LANCET, V369, P1742, DOI 10.1016/S0140-6736(07)60781-8; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fletcher SC, 2018, NUCLEIC ACIDS RES, V46, P1834, DOI 10.1093/nar/gkx1291; Gugnoni M, 2017, ONCOGENE, V36, P667, DOI 10.1038/onc.2016.237; Guo ZG, 2009, NUCLEIC ACIDS RES, V37, P3431, DOI 10.1093/nar/gkp201; Hajkova P, 2010, SCIENCE, V329, P78, DOI 10.1126/science.1187945; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Ju JY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00988-5; Kuphal S, 2009, PIGM CELL MELANOMA R, V22, P296, DOI 10.1111/j.1755-148X.2009.00568.x; Levy N, 2006, NUCLEIC ACIDS RES, V34, P32, DOI 10.1093/nar/gkj409; Li JF, 2012, AM J CANCER RES, V2, P699; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Lu X, 2020, ONCOGENE, V39, P234, DOI 10.1038/s41388-019-0986-0; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; Matakidou A, 2007, HUM MOL GENET, V16, P2333, DOI 10.1093/hmg/ddm190; Nicolay Nils H, 2012, Curr Mol Pharmacol, V5, P54; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; PIGNATELLI M, 1994, HUM PATHOL, V25, P849, DOI 10.1016/0046-8177(94)90002-7; Rubina Kseniya, 2007, Angiogenesis, V10, P183, DOI 10.1007/s10456-007-9072-2; Rytelewski M, 2014, MOL ONCOL, V8, P1429, DOI 10.1016/j.molonc.2014.05.017; Schar P, 2011, PROG DRUG RES, V67, P51, DOI 10.1007/978-3-7643-8989-5_3; Sobol RW, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003086; Sun H, 2017, ONCOGENE, V36, P194, DOI 10.1038/onc.2016.188; Tan XH, 2016, J CANCER, V7, P1472, DOI 10.7150/jca.14844; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vens C, 2002, NUCLEIC ACIDS RES, V30, P2995, DOI 10.1093/nar/gkf403; Walsh CP, 2006, CURR TOP MICROBIOL, V301, P283; Wang MN, 2019, MOL CANCER RES, V17, P2077, DOI 10.1158/1541-7786.MCR-19-0482; Weber AR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10806; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wiegmans AP, 2014, ONCOTARGET, V5, P3261, DOI 10.18632/oncotarget.1923; Yamtich J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003052; Yamtich J, 2010, BBA-PROTEINS PROTEOM, V1804, P1136, DOI 10.1016/j.bbapap.2009.07.008; Ye M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005956; Zheng WL, 2018, LIFE SCI, V192, P270, DOI 10.1016/j.lfs.2017.11.011; Zhou T, 2016, ONCOTARGET, V7, P6902, DOI 10.18632/oncotarget.6849	46	9	9	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2020	39	33					5507	5519		10.1038/s41388-020-1386-1	http://dx.doi.org/10.1038/s41388-020-1386-1		JUL 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NB0QV	32641859				2022-12-17	WOS:000546526000002
J	Shrestha, S; Adhikary, G; Xu, W; Kandasamy, S; Eckert, RL				Shrestha, Suruchi; Adhikary, Gautam; Xu, Wen; Kandasamy, Sivaveera; Eckert, Richard L.			ACTL6A suppresses p21(Cip1)expression to enhance the epidermal squamous cell carcinoma phenotype	ONCOGENE			English	Article							CHROMATIN REMODELING COMPLEX; BAF53A SUBUNIT; STEM-CELLS; PKC-DELTA; P53; TRANSGLUTAMINASE; PROLIFERATION; INVASION; SURVIVAL; PROTEIN	Epidermal squamous cell carcinoma (SCC) is a common and highly invasive form of cancer. SCC arises due to ultraviolet light exposure and is associated with increased expression of pro-cancer genes and reduced expression of cancer suppressors. Actin-Like Protein 6A (ACTL6A, BAF53a) is an important protein subunit of the SWI/SNF epigenetic chromatin regulatory complex. ACTL6A is elevated in cancer cells and has been implicated as a driver of cancer cell proliferation and tumor growth. In the present study, we show that ACTL6A drives SCC cell proliferation, spheroid formation, invasion and migration, and that these activities are markedly reduced by ACTL6A knockdown. We further show that ACTL6A expression is associated with reduced levels of the p21(Cip1)cyclin-dependent kinase inhibitor and tumor suppressor protein. Molecular studies show that ACTL6A interacts with p53 DNA response elements in the p21(Cip1)gene promoter to suppress p21(Cip1)promoter activity and mRNA and protein level. Additional studies show that an increase in p21(Cip1)expression in ACTL6A knockdown cells is required for suppression of the SCC cell phenotype, suggesting that p21(Cip1)is a mediator of ACTL6A action. We further show that this regulation is p53 independent. These findings suggest that ACTL6A suppresses p21(Cip1)promoter activity to reduce p21(Cip1)protein as a mechanism to maintain the aggressive epidermal SCC phenotype.	[Shrestha, Suruchi; Adhikary, Gautam; Xu, Wen; Eckert, Richard L.] Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; [Kandasamy, Sivaveera] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Kandasamy, Sivaveera] Rutgers Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ USA; [Eckert, Richard L.] Dept Dermatol, Baltimore, MD 21201 USA; [Eckert, Richard L.] Dept Reprod Biol, Baltimore, MD 21205 USA; [Eckert, Richard L.] Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; Rutgers State University New Brunswick; Rutgers State University Medical Center	Eckert, RL (corresponding author), Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.; Eckert, RL (corresponding author), Dept Dermatol, Baltimore, MD 21201 USA.; Eckert, RL (corresponding author), Dept Reprod Biol, Baltimore, MD 21205 USA.; Eckert, RL (corresponding author), Marlene & Stewart Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA.	reckert@umaryland.edu			National Institutes of Health [CA184027, CA211909]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by National Institutes of Health R01 grants CA184027 and CA211909 awarded to RLE, Ph.D.	Adhikary Gautam, 2018, Oncotarget, V9, P34495, DOI 10.18632/oncotarget.26130; Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Adhikary G, 2010, J INVEST DERMATOL, V130, P2017, DOI 10.1038/jid.2010.108; Bao XM, 2013, CELL STEM CELL, V12, P193, DOI 10.1016/j.stem.2012.12.014; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Chew YC, 2012, J BIOL CHEM, V287, P16168, DOI 10.1074/jbc.M111.305292; Chew YC, 2011, J BIOL CHEM, V286, P28772, DOI 10.1074/jbc.M110.205245; Christenson LJ, 2005, JAMA-J AM MED ASSOC, V294, P681, DOI 10.1001/jama.294.6.681; Cranmer LD, 2010, ONCOLOGIST, V15, P1320, DOI 10.1634/theoncologist.2009-0210; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fisher ML, 2017, ONCOTARGET, V8, P110257, DOI 10.18632/oncotarget.22628; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; Fisher ML, 2015, ONCOTARGET, V6, P20525, DOI 10.18632/oncotarget.3890; Fisher ML, 2015, MOL CANCER RES, V13, P1083, DOI 10.1158/1541-7786.MCR-14-0685-T; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Ji JX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0548-3; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kerr C, 2018, MOL CARCINOGEN, V57, P3, DOI 10.1002/mc.22714; Krasteva V, 2012, BLOOD, V120, P4720, DOI 10.1182/blood-2012-04-427047; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lee JH, 2005, MOL CELLS, V19, P289; Lee JH, 2003, MOL CELLS, V16, P78; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Lessard J, 2007, NEURON, V55, P201, DOI 10.1016/j.neuron.2007.06.019; Lu WS, 2015, STEM CELLS, V33, P1782, DOI 10.1002/stem.2000; Meng L, 2017, ONCOL REP, V38, P3327, DOI 10.3892/or.2017.6019; MOLLER R, 1979, ARCH DERMATOL, V115, P703, DOI 10.1001/archderm.115.6.703; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Ronan JL, 2013, NAT REV GENET, V14, P347, DOI 10.1038/nrg3413; Saha K, 2014, J BIOL CHEM, V289, P11443, DOI 10.1074/jbc.M113.543165; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; St Pierre R, 2017, CURR OPIN GENET DEV, V42, P56, DOI 10.1016/j.gde.2017.02.004; Sun W, 2017, ONCOL REP, V37, P2405, DOI 10.3892/or.2017.5473; Taulli R, 2014, ONCOGENE, V33, P2354, DOI 10.1038/onc.2013.188; Wang M, 2007, J BIOCHEM, V142, P613, DOI 10.1093/jb/mvm176; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Xiao S, 2016, HEPATOLOGY, V63, P1256, DOI 10.1002/hep.28417; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zhu B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14362-4; ZIRVI KA, 1993, CANCER BIOCHEM BIOPH, V13, P283	44	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5855	5866		10.1038/s41388-020-1371-8	http://dx.doi.org/10.1038/s41388-020-1371-8		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32616890	Green Accepted			2022-12-17	WOS:000545059900003
J	de Krijger, I; van der Torre, J; Peuscher, MH; Eder, M; Jacobs, JJL				de Krijger, Inge; van der Torre, Jaco; Peuscher, Marieke H.; Eder, Mathias; Jacobs, Jacqueline J. L.			H3K36 dimethylation by MMSET promotes classical non-homologous end-joining at unprotected telomeres	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HISTONE H3; HOMOLOGOUS RECOMBINATION; LYSINE 36; DYSFUNCTIONAL TELOMERES; MAMMALIAN TELOMERES; REPAIR; 53BP1; CHROMATIN; METHYLATION	The epigenetic environment plays an important role in DNA damage recognition and repair, both at DNA double-strand breaks and at deprotected telomeres. To increase understanding on how DNA damage responses (DDR) at deprotected telomeres are regulated by modification and remodeling of telomeric chromatin we screened 38 methyltransferases for their ability to promote telomere dysfunction-induced genomic instability. As top hit we identified MMSET, a histone methyltransferase (HMT) causally linked to multiple myeloma and Wolf-Hirschhorn syndrome. We show that MMSET promotes non-homologous end-joining (NHEJ) at deprotected telomeres through Ligase4-dependent classical NHEJ, and does not contribute to Ligase3-dependent alternative NHEJ. Moreover, we show that this is dependent on the catalytic activity of MMSET, enabled by its SET-domain. Indeed, in absence of MMSET H3K36-dimethylation (H3K36me2) decreases, both globally and at subtelomeric regions. Interestingly, the level of MMSET-dependent H3K36me2 directly correlates with NHEJ-efficiency. We show that MMSET depletion does not impact on recognition of deprotected telomeres by the DDR-machinery or on subsequent recruitment of DDR-factors acting upstream or at the level of DNA repair pathway choice. Our data are most consistent with an important role for H3K36me2 in more downstream steps of the DNA repair process. Moreover, we find additional H3K36me2-specific HMTs to contribute to NHEJ at deprotected telomeres, further emphasizing the importance of H3K36me2 in DNA repair.	[de Krijger, Inge; van der Torre, Jaco; Peuscher, Marieke H.; Eder, Mathias; Jacobs, Jacqueline J. L.] Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Jacobs, JJL (corresponding author), Netherlands Canc Inst, Div Oncogen, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.jacobs@nki.nl	Jacobs, Jacqueline/ABA-5652-2020	Jacobs, Jacqueline/0000-0002-7704-4795; Peuscher, Marieke/0000-0001-9410-4350; van der Torre, Jaco/0000-0002-5405-3824				Arnoult N, 2015, NAT STRUCT MOL BIOL, V22, P859, DOI 10.1038/nsmb.3092; Aymard F, 2014, NAT STRUCT MOL BIOL, V21, P366, DOI 10.1038/nsmb.2796; Bartocci C, 2014, CELL REP, V7, P1320, DOI 10.1016/j.celrep.2014.04.002; Benetti R, 2007, NAT GENET, V39, P243, DOI 10.1038/ng1952; Bennett RL, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026708; Bergemann AD, 2005, TRENDS GENET, V21, P188, DOI 10.1016/j.tig.2005.01.008; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Boersma V, 2015, NATURE, V521, P537, DOI 10.1038/nature14216; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Cao LL, 2016, ONCOGENE, V35, P301, DOI 10.1038/onc.2015.81; Carvalho S, 2014, ELIFE, V3, DOI 10.7554/eLife.02482; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Chapman JR, 2013, MOL CELL, V49, P858, DOI 10.1016/j.molcel.2013.01.002; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Clouaire T, 2015, NUCLEUS-PHILA, V6, P107, DOI 10.1080/19491034.2015.1010946; Clouaire T, 2018, MOL CELL, V72, P250, DOI 10.1016/j.molcel.2018.08.020; Coussens NP, 2018, J BIOL CHEM, V293, P13750, DOI 10.1074/jbc.RA118.004274; de Lange T, 2010, COLD SH Q B, V75, P167, DOI 10.1101/sqb.2010.75.017; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Di Virgilio M, 2013, SCIENCE, V339, P711, DOI 10.1126/science.1230624; Dimitrova N, 2009, MOL CELL BIOL, V29, P5552, DOI 10.1128/MCB.00476-09; Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967; Escribano-Diaz C, 2013, MOL CELL, V49, P872, DOI 10.1016/j.molcel.2013.01.001; Fnu S, 2011, P NATL ACAD SCI USA, V108, P540, DOI 10.1073/pnas.1013571108; Fortuny A, 2018, CHROMOSOMA, V127, P291, DOI 10.1007/s00412-018-0669-6; Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318; Nguyen HV, 2017, P NATL ACAD SCI USA, V114, pE10560, DOI 10.1073/pnas.1701366114; Hajdu I, 2011, P NATL ACAD SCI USA, V108, P13130, DOI 10.1073/pnas.1110081108; Hartlerode AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049211; Hsiao KY, 2013, J MOL CELL BIOL, V5, P157, DOI 10.1093/jmcb/mjs066; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Jacquet K, 2016, MOL CELL, V62, P409, DOI 10.1016/j.molcel.2016.03.031; Jha DK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4965; Jiang WX, 2015, MOL CELL, V58, P172, DOI 10.1016/j.molcel.2015.02.024; Kassambara A, 2009, BIOCHEM BIOPH RES CO, V379, P840, DOI 10.1016/j.bbrc.2008.12.093; Kim JY, 2008, MOL CELL BIOL, V28, P2023, DOI 10.1128/MCB.02130-07; Konishi A, 2008, GENE DEV, V22, P1221, DOI 10.1101/gad.1634008; Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042; Lauring J, 2008, BLOOD, V111, P856, DOI 10.1182/blood-2007-05-088674; Li Y, 2009, J BIOL CHEM, V284, P34283, DOI 10.1074/jbc.M109.034462; Luijsterburg MS, 2016, MOL CELL, V61, P547, DOI 10.1016/j.molcel.2016.01.019; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Nimura K, 2009, NATURE, V460, P287, DOI 10.1038/nature08086; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Pai CC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5091; Pei HD, 2013, J IMMUNOL, V190, P756, DOI 10.4049/jimmunol.1201811; Pei HD, 2011, NATURE, V470, P124, DOI 10.1038/nature09658; Peuscher MH, 2011, NAT CELL BIOL, V13, P1139, DOI 10.1038/ncb2326; Pfister SX, 2014, CELL REP, V7, P2006, DOI 10.1016/j.celrep.2014.05.026; Popovic R, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004566; Porro A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6379; Ribes-Zamora A, 2013, CELL REP, V5, P194, DOI 10.1016/j.celrep.2013.08.040; Sallmyr A, 2018, J BIOL CHEM, V293, P10536, DOI 10.1074/jbc.TM117.000375; Sfeir A, 2012, SCIENCE, V336, P593, DOI 10.1126/science.1218498; Shah MY, 2016, ONCOGENE, V35, P5905, DOI 10.1038/onc.2016.116; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Symington LS, 2016, CRIT REV BIOCHEM MOL, V51, P195, DOI 10.3109/10409238.2016.1172552; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tang JB, 2013, NAT STRUCT MOL BIOL, V20, P317, DOI 10.1038/nsmb.2499; Todoerti K, 2005, BRIT J HAEMATOL, V131, P214, DOI 10.1111/j.1365-2141.2005.05741.x; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Tuzon CT, 2014, CELL REP, V8, P429, DOI 10.1016/j.celrep.2014.06.013; Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274; Zhang JF, 2019, CANCER DISCOV, V9, P1306, DOI 10.1158/2159-8290.CD-18-0083; Zimmermann M, 2013, SCIENCE, V339, P700, DOI 10.1126/science.1231573	73	9	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4814	4827		10.1038/s41388-020-1334-0	http://dx.doi.org/10.1038/s41388-020-1334-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32472076	Green Published, hybrid			2022-12-17	WOS:000541119400003
J	Zhang, YH; Shi, WN; Wu, SH; Miao, RR; Sun, SY; Luo, DD; Wan, SB; Guo, ZK; Wang, WY; Yu, XF; Cui, SX; Qu, XJ				Zhang, Yu-Hang; Shi, Wen-Na; Wu, Shu-Hua; Miao, Rong-Rong; Sun, Shi-Yue; Luo, Dong-Dong; Wan, Sheng-Biao; Guo, Zhi-Kun; Wang, Wen-Yu; Yu, Xin-Feng; Cui, Shu-Xiang; Qu, Xian-Jun			SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression	ONCOGENE			English	Article							IN-VITRO; SPHINGOSINE KINASE-1; SPHINGOSINE-1-PHOSPHATE; CHEMOTHERAPY; INHIBITOR; ABC294640; FLUOROURACIL; SENSITIVITY; STRATEGIES; TOXICITY	Aberrant sphingolipid metabolism has been implicated in chemoresistance, but the underlying mechanisms are still poorly understood. Herein we revealed a previously unrecognized mechanism of 5-fluorouracil (5-FU) resistance contributed by high SphK2-upregulated dihydropyrimidine dehydrogenase (DPD) in colorectal cancer (CRC), which is evidenced from human CRC specimens, animal models, and cancer cell lines. TMA samples from randomly selected 60 CRC specimens firstly identified the clinical correlation between high SphK2 and increased DPD (p < 0.001). Then the regulatory mechanism was explored in CRC models of villin-SphK2 Tg mice,SphK2(-/-)mice, and human CRC cells xenografted nude mice. Assays of ChIP-Seq and luciferase reporter gene demonstrated that high SphK2 upregulated DPD through promoting the HDAC1-mediated H3K56ac, leading to the degradation of intracellular 5-FU into inactive alpha-fluoro-beta-alanine (FBAL). Lastly, inhibition of SphK2 by SLR080811 exhibited excellent inhibition on DPD expression and potently reversed 5-FU resistance in colorectal tumors of villin-SphK2 Tg mice. Overall, this study manifests that SphK2(high)conferred 5-FU resistance through upregulating tumoral DPD, which highlights the strategies of blocking SphK2 to overcome 5-FU resistance in CRC.	[Zhang, Yu-Hang; Miao, Rong-Rong; Sun, Shi-Yue; Wang, Wen-Yu; Yu, Xin-Feng; Qu, Xian-Jun] Capital Med Univ, Dept Pharmacol, Sch Basic Med Sci, Beijing, Peoples R China; [Shi, Wen-Na] Shandong First Med Univ & Shandong Acad Med Sci, Dept Pharm, Shandong Canc Hosp & Inst, Jinan, Peoples R China; [Wu, Shu-Hua] Hosp Binzhou Med Univ, Dept Pathol, Yantai, Shandong, Peoples R China; [Luo, Dong-Dong; Wan, Sheng-Biao] Ocean Univ China, Qingdao Natl Lab Marine Sci & Technol, Key Lab Marine Drugs, Lab Marine Drugs & Bioprod,Minist Educ,Sch Med &, Qingdao, Peoples R China; [Guo, Zhi-Kun; Cui, Shu-Xiang] Capital Med Univ, Dept Toxicol & Sanit Chem, Sch Publ Hlth, Beijing, Peoples R China	Capital Medical University; Shandong First Medical University & Shandong Academy of Medical Sciences; Binzhou Medical University; Ocean University of China; Qingdao National Laboratory for Marine Science & Technology; Capital Medical University	Qu, XJ (corresponding author), Capital Med Univ, Dept Pharmacol, Sch Basic Med Sci, Beijing, Peoples R China.; Cui, SX (corresponding author), Capital Med Univ, Dept Toxicol & Sanit Chem, Sch Publ Hlth, Beijing, Peoples R China.	sxccui@ccmu.edu.cn; qxj@ccmu.edu.cn		zhang, yuhang/0000-0001-9752-983X; luo, dongdong/0000-0001-6428-9729; Guo, Zhikun/0000-0003-1639-4342	National Natural Science Foundation of China [91629303/81673449/81872884/81973350]; Beijing Natural Science Foundation and Scientific Research Program of Municipal Commission of Education [KZ201710025020/KZ201810025033]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Natural Science Foundation and Scientific Research Program of Municipal Commission of Education	This work was supported by National Natural Science Foundation of China (91629303/81673449/81872884/81973350) and Beijing Natural Science Foundation and Scientific Research Program of Municipal Commission of Education (KZ201710025020/KZ201810025033).	Adjei AA, 2002, J CLIN ONCOL, V20, P1683, DOI 10.1200/JCO.20.6.1683; Afzal S, 2011, CLIN CANCER RES, V17, P3822, DOI 10.1158/1078-0432.CCR-11-0304; Amstutz U, 2018, CLIN PHARMACOL THER, V103, P210, DOI 10.1002/cpt.911; Britten CD, 2017, CLIN CANCER RES, V23, P4642, DOI 10.1158/1078-0432.CCR-16-2363; Camp ER, 2017, CANCER BIOL THER, V18, P640, DOI 10.1080/15384047.2017.1345396; Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107; Fitzpatrick Leo R., 2011, Inflammopharmacology, V19, P75, DOI 10.1007/s10787-010-0060-6; French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444; Grassi S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00807; Guillermet-Guibert J, 2009, MOL CANCER THER, V8, P809, DOI 10.1158/1535-7163.MCT-08-1096; Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Kharel Y, 2012, BIOCHEM J, V447, P149, DOI 10.1042/BJ20120609; Kidder BL, 2011, NAT IMMUNOL, V12, P918, DOI 10.1038/ni.2117; Lee AM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju298; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Manca A, 2012, VALUE HEALTH, V15, P22, DOI 10.1016/j.jval.2011.07.008; Micoli G, 2001, J CHROMATOGR B, V750, P25, DOI 10.1016/S0378-4347(00)00377-7; Min JX, 2005, EUKARYOT CELL, V4, P178, DOI 10.1128/EC.4.1.178-189.2005; O'Sullivan S, 2017, NEUROPHARMACOLOGY, V113, P597, DOI 10.1016/j.neuropharm.2016.11.006; Offer SM, 2013, CANCER RES, V73, P1958, DOI 10.1158/0008-5472.CAN-12-3858; Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Rosa R, 2013, CLIN CANCER RES, V19, P138, DOI 10.1158/1078-0432.CCR-12-1050; Rosmarin D, 2015, GUT, V64, P111, DOI 10.1136/gutjnl-2013-306571; Salas A, 2011, BLOOD, V117, P5941, DOI 10.1182/blood-2010-08-300772; Sarkar S, 2005, FEBS LETT, V579, P5313, DOI 10.1016/j.febslet.2005.08.055; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Sun CC, 2014, PATHOL RES PRACT, V210, P668, DOI 10.1016/j.prp.2014.06.016; Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097; Venant H, 2015, MOL CANCER THER, V14, P2744, DOI 10.1158/1535-7163.MCT-15-0279; Xun C, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0205-y	34	9	10	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5214	5227		10.1038/s41388-020-1352-y	http://dx.doi.org/10.1038/s41388-020-1352-y		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32546724				2022-12-17	WOS:000540679400001
J	Awah, CU; Chen, L; Bansal, M; Mahajan, A; Winter, J; Lad, M; Warnke, L; Gonzalez-Buendia, E; Park, C; Zhang, D; Feldstein, E; Yu, D; Zannikou, M; Balyasnikova, IV; Martuscello, R; Konerman, S; Gyorffy, B; Burdett, KB; Scholtens, DM; Stupp, R; Ahmed, A; Hsu, P; Sonabend, AM				Awah, Chidiebere U.; Chen, Li; Bansal, Mukesh; Mahajan, Aayushi; Winter, Jan; Lad, Meeki; Warnke, Louisa; Gonzalez-Buendia, Edgar; Park, Cheol; Zhang, Daniel; Feldstein, Eric; Yu, Dou; Zannikou, Markella; Balyasnikova, Irina, V; Martuscello, Regina; Konerman, Silvana; Gyorffy, Balazs; Burdett, Kirsten B.; Scholtens, Denise M.; Stupp, Roger; Ahmed, Atique; Hsu, Patrick; Sonabend, Adam M.			Ribosomal protein S11 influences glioma response to TOP2 poisons	ONCOGENE			English	Article							SCALE CRISPR-CAS9 KNOCKOUT; BRAIN-BARRIER DISRUPTION; DNA TOPOISOMERASE-II; METRONOMIC CHEMOTHERAPY; ORAL ETOPOSIDE; PHASE-II; GLIOBLASTOMA; DOXORUBICIN; ACTIVATION; ULTRASOUND	Topoisomerase II poisons are one of the most common class of chemotherapeutics used in cancer. We and others had shown that a subset of glioblastomas, the most malignant of all primary brain tumors in adults, is responsive to TOP2 poisons. To identify genes that confer susceptibility to this drug in gliomas, we performed a genome-scale CRISPR knockout screen with etoposide. Genes involved in protein synthesis and DNA damage were implicated in etoposide susceptibility. To define potential biomarkers for TOP2 poisons, CRISPR hits were overlapped with genes whose expression correlates with susceptibility to this drug across glioma cell lines, revealing ribosomal protein subunit RPS11, 16, and 18 as putative biomarkers for response to TOP2 poisons. Loss of RPS11 led to resistance to etoposide and doxorubicin and impaired the induction of proapoptotic gene APAF1 following treatment. The expression of these ribosomal subunits was also associated with susceptibility to TOP2 poisons across cell lines from gliomas and multiple other cancers.	[Awah, Chidiebere U.; Chen, Li; Warnke, Louisa; Gonzalez-Buendia, Edgar; Park, Cheol; Zhang, Daniel; Feldstein, Eric; Yu, Dou; Zannikou, Markella; Balyasnikova, Irina, V; Scholtens, Denise M.; Stupp, Roger; Ahmed, Atique; Sonabend, Adam M.] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA; [Bansal, Mukesh] Psychogen Inc, Paramus, NJ USA; [Mahajan, Aayushi] Columbia Univ, Dept Neurol Surg, Med Ctr, New York, NY USA; [Winter, Jan] German Ctr Canc Res, Funct Genom & Signaling, Heidelberg, Germany; [Lad, Meeki] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; [Martuscello, Regina] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA; [Konerman, Silvana; Hsu, Patrick] Salk Inst Biol Studies, Mol & Cell Biol, La Jolla, CA USA; [Gyorffy, Balazs] Hungarian Acad Sci, MTA TTK Lendulet Canc Biomarker Res Grp, Inst Enzymol, Budapest, Hungary; [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Burdett, Kirsten B.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Columbia University; Columbia University; Columbia University; Salk Institute; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University; Northwestern University	Sonabend, AM (corresponding author), Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.	adam.sonabend@nm.org	Feldstein, Eric/GLS-1215-2022; Hsu, Patrick/ABD-5749-2021; Gyorffy, Balazs/AAA-9135-2021; Mahajan, Aayushi/ABC-1481-2021	Gyorffy, Balazs/0000-0002-5772-3766; Mahajan, Aayushi/0000-0003-3966-2936; Zhang, Daniel Yang/0000-0001-9962-9295; Feldstein, Eric/0000-0002-1952-4555	SPORE for Translational Approaches to Brain Cancer [5DP5OD021356-05, P50CA221747]; Robert H. Lurie NCI Cancer Center Support Grant [P30CA060553]; NCI CCSG [P30 CA060553]; NVKP [16-1-2016-0037]	SPORE for Translational Approaches to Brain Cancer; Robert H. Lurie NCI Cancer Center Support Grant; NCI CCSG; NVKP	This work was funded by 5DP5OD021356-05 (AMS), P50CA221747 SPORE for Translational Approaches to Brain Cancer (AMS), and Developmental funds from The Robert H. Lurie NCI Cancer Center Support Grant #P30CA060553 (AMS), and generous philanthropic support from Dan and Sharon Moceri. We thank Dr. Ichiro Nakano (University of Alabama), Dr. Charles David James (Northwestern University), and Dr. Shi-Yuan Cheng (Northwestern University) for the kind gift of the GBM xenografts. We thank Dr. Peng Zhang (Northwestern University) for technical support with culture of GBM PDX. We thank Synthego, CA, USA, for the gifts of RPS11 sgRNA guides. Immunofluorescence imaging work was performed at the Center for Advanced Microscopy/Nikon Imaging Center and RHLCCC - Flow Cytometry Core, Northwestern University supported by NCI CCSG P30 CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center. BG was supported by the NVKP 16-1-2016-0037 grant.	Alli S, 2018, J CONTROL RELEASE, V281, P29, DOI 10.1016/j.jconrel.2018.05.005; Barnoud D, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27038; Carpentier A, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6086; Ceccaldi R, 2016, NAT REV MOL CELL BIO, V17, P337, DOI 10.1038/nrm.2016.48; Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028; Dennis G, 2003, GENOME BIOL, V4; Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437; Forbes S A, 2016, Curr Protoc Hum Genet, V91, DOI 10.1002/cphg.21; Forester CM, 2018, P NATL ACAD SCI USA, V115, P2353, DOI 10.1073/pnas.1707514115; Franceschi E, 2004, BRIT J CANCER, V91, P1038, DOI 10.1038/sj.bjc.6602105; Girling DJ, 1996, LANCET, V348, P563, DOI 10.1016/S0140-6736(96)02005-3; Guschin DY, 2010, METHODS MOL BIOL, V649, P247, DOI 10.1007/978-1-60761-753-2_15; Haapaniemi E, 2018, NAT MED, V24, P927, DOI 10.1038/s41591-018-0049-z; Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010; Idbaih A, 2019, CLIN CANCER RES, V25, P3793, DOI 10.1158/1078-0432.CCR-18-3643; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kesari S, 2007, NEURO-ONCOLOGY, V9, P354, DOI 10.1215/15228517-2007-006; Koschmann C, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aac8228; Krisp C, 2018, BR J CANC; Leonard A, 2013, ANTICANCER RES, V33, P3307; Lin YL, 2018, J PHARMACEUT BIOMED, V149, P482, DOI 10.1016/j.jpba.2017.11.047; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Mainprize T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36340-0; Mehta A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00459; Michlits G, 2017, NAT METHODS, V14, P1191, DOI [10.1038/NMETH.4466, 10.1038/nmeth.4466]; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Mjelle R, 2015, DNA REPAIR, V30, P53, DOI 10.1016/j.dnarep.2015.03.007; Moreno P, 2018, MOL ONCOL, V12, P1778, DOI 10.1002/1878-0261.12369; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Nitiss JL, 2009, NAT REV CANCER, V9, P327, DOI 10.1038/nrc2608; Pitz MW, 2011, J NEURO-ONCOL, V104, P629, DOI 10.1007/s11060-011-0564-y; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Pop C, 2005, CELL, V123, P192, DOI 10.1016/j.cell.2005.10.010; Reardon DA, 2009, BRIT J CANCER, V101, P1986, DOI 10.1038/sj.bjc.6605412; Sapio RT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09002-w; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Sonabend AM, 2019, CLIN CANCER RES, V25, P3750, DOI 10.1158/1078-0432.CCR-19-0932; Sonabend AM, 2014, NEURO-ONCOLOGY, V16, P1210, DOI 10.1093/neuonc/nou026; STEWART DJ, 1984, J NEURO-ONCOL, V2, P133; Stransky N, 2015, NATURE, V528, P84, DOI 10.1038/nature15736; Stupp R, 2017, JAMA-J AM MED ASSOC, V318, P2306, DOI 10.1001/jama.2017.18718; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Sun T, 2017, P NATL ACAD SCI USA, V114, pE10281, DOI 10.1073/pnas.1713328114; Tsai Cheng-Han, 2018, Oncotarget, V9, P30731, DOI 10.18632/oncotarget.24578; Uuskula-Reimand L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1043-8; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wijdeven RH, 2015, CANCER RES, V75, P4176, DOI 10.1158/0008-5472.CAN-15-0380; Winter J, 2017, CRIS PRANALYZER INTE; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; ZUCCHETTI M, 1991, ANN ONCOL, V2, P63, DOI 10.1093/oxfordjournals.annonc.a057826	52	9	9	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5068	5081		10.1038/s41388-020-1342-0	http://dx.doi.org/10.1038/s41388-020-1342-0		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32528131	Green Submitted, Green Accepted			2022-12-17	WOS:000539817600002
J	Tabatabaeian, H; Rao, A; Ramos, A; Chu, T; Sudol, M; Lim, YP				Tabatabaeian, Hossein; Rao, Angad; Ramos, Alisha; Chu, Tinghine; Sudol, Marius; Lim, Yoon Pin			The emerging roles of WBP2 oncogene in human cancers	ONCOGENE			English	Review							DOMAIN BINDING PROTEIN-2; WW-DOMAIN; BREAST-CANCER; SIGNALING PATHWAY; HIPPO PATHWAY; TUMOR-SUPPRESSOR; ESTROGEN; COACTIVATOR; TARGET; MECHANISMS	WW domain-binding protein 2 (WBP2) is an emerging oncoprotein. Over the past decade, WBP2 surfaced as a key node connecting key signaling pathways associated with ER/PR, EGFR, PI3K, Hippo, and Wnt in cancer. In addition to the oncogenic functions of WBP2, this review discusses the latest research regarding the multilevel regulation and modes of action of WBP2 and how they can be exploited for molecular medicine. In translational research, evidence supports the role of WBP2 as a biomarker for early detection, prognosis, and companion diagnostics in breast cancer. Finally, we envision new trends in WBP2 research in the space of molecular etiology of cancer, targeted therapeutics, and precision medicine.	[Tabatabaeian, Hossein] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore; [Tabatabaeian, Hossein; Rao, Angad; Ramos, Alisha; Chu, Tinghine; Lim, Yoon Pin] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117545, Singapore; [Chu, Tinghine; Lim, Yoon Pin] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore; [Sudol, Marius] Natl Univ Singapore, Mechanobiol Inst, Dept Physiol, Singapore 117597, Singapore; [Sudol, Marius] ASTAR, IMCB, Singapore 138673, Singapore; [Sudol, Marius] Icahn Sch Med Mt Sinai, New York, NY 10029 USA; [Lim, Yoon Pin] Natl Univ Canc Inst, Singapore 119082, Singapore	National University of Singapore; National University of Singapore; National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Icahn School of Medicine at Mount Sinai; National University of Singapore	Lim, YP (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 117545, Singapore.; Lim, YP (corresponding author), Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore.; Lim, YP (corresponding author), Natl Univ Canc Inst, Singapore 119082, Singapore.	bchlyp@nus.edu.sg	Tabatabaeian, Hossein/I-2235-2019	Tabatabaeian, Hossein/0000-0001-9757-6150	Ministry of Education, Singapore [MOE2016-T2-2-007]; National Medical Research Council, Ministry of Health, Singapore [NMRC/OFIRG/0034/2017]; National University of Singapore [R-185-000-2710-133-733]; Mechanobiology Institute [R-714-018-006-271]; Institute of Molecular and Cell Biology [M-R02010]	Ministry of Education, Singapore(Ministry of Education, Singapore); National Medical Research Council, Ministry of Health, Singapore(National Medical Research Council, Singapore); National University of Singapore(National University of Singapore); Mechanobiology Institute; Institute of Molecular and Cell Biology	This work is supported by funding from the Ministry of Education, Singapore (MOE2016-T2-2-007), the National Medical Research Council, Ministry of Health, Singapore (NMRC/OFIRG/0034/2017), the National University of Singapore (R-185-000-2710-133-733), Mechanobiology Institute (R-714-018-006-271), and the Institute of Molecular and Cell Biology (M-R02010). The figures were created using BioRender.	Aoudjit Fawzi, 2012, Chemother Res Pract, V2012, P283181, DOI 10.1155/2012/283181; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; Bidwell GL, 2009, EXPERT OPIN DRUG DEL, V6, P1033, DOI 10.1517/17425240903143745; Bradley CA, 2019, NAT REV CLIN ONCOL, V16, P465, DOI 10.1038/s41571-019-0215-3; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown SDM, 2012, MAMM GENOME, V23, P632, DOI 10.1007/s00335-012-9427-x; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Buffa L, 2013, IUBMB LIFE, V65, P76, DOI 10.1002/iub.1105; Buniello A, 2016, EMBO MOL MED, V8, P191, DOI 10.15252/emmm.201505523; Chan SW, 2011, ONCOGENE, V30, P600, DOI 10.1038/onc.2010.438; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; CHEN S, 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9; Chen S, 2018, BRIT J CANCER, V119, P182, DOI 10.1038/s41416-018-0119-5; Chen S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0376-5; Chen S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0693-9; Chen YH, 2007, MOL CELL PROTEOMICS, V6, P2072, DOI 10.1074/mcp.M700395-MCP200; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dai YX, 2020, EUR J MED CHEM, V187, DOI 10.1016/j.ejmech.2019.111967; Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987; Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Doroshow JH, 2014, NAT REV CLIN ONCOL, V11, P649, DOI 10.1038/nrclinonc.2014.158; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fisher SL, 2018, CURR OPIN CHEM BIOL, V44, P47, DOI 10.1016/j.cbpa.2018.05.004; Gao J, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109466; Glisovic T, 2008, FEBS LETT, V582, P1977, DOI 10.1016/j.febslet.2008.03.004; Hamilton LE, 2018, BIOL REPROD, V99, P1171, DOI 10.1093/biolre/ioy156; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Howlader N, 2018, CANCER EPIDEM BIOMAR, V27, P619, DOI 10.1158/1055-9965.EPI-17-0627; Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31; Isfort I, 2019, HIPPO PATHWAY TRANSC; Iyer VV, 2016, CURR MED CHEM, V23, P3025, DOI 10.2174/0929867323666160627103134; Jackson Richard J, 2007, Sci STKE, V2007, pre1, DOI 10.1126/stke.3672007re1; Jiang ZF, 2019, LANCET ONCOL, V20, P806, DOI 10.1016/S1470-2045(19)30164-0; Jolliffe CN, 2000, BIOCHEM J, V351, P557, DOI 10.1042/0264-6021:3510557; Kang SA, 2019, CLIN CANCER RES, V25, P2588, DOI 10.1158/1078-0432.CCR-18-3228; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Khosrow-Khavar F, 2017, ANN ONCOL, V28, P487, DOI 10.1093/annonc/mdw673; Kim Y, 2018, BMB REP, V51, P143, DOI 10.5483/BMBRep.2018.51.3.017; Li SS, 2007, CELL SIGNAL, V19, P1101, DOI 10.1016/j.cellsig.2007.02.002; Li XB, 2016, AM J CLIN PATHOL, V145, P871, DOI 10.1093/ajcp/aqw045; Li ZL, 2018, J BIOL CHEM, V293, P20014, DOI 10.1074/jbc.RA118.005796; Lim SK, 2016, CANCER RES, V76, P6278, DOI 10.1158/0008-5472.CAN-15-3537; Lim SK, 2011, FASEB J, V25, P3004, DOI 10.1096/fj.10-169136; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Marqus S, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0328-x; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Mazzoni SM, 2014, CANCER LETT, V355, P1, DOI 10.1016/j.canlet.2014.09.018; McDonald CB, 2012, J MOL BIOL, V422, P58, DOI 10.1016/j.jmb.2012.05.015; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Munoz-Fuentes V, 2018, CONSERV GENET, V19, P995, DOI 10.1007/s10592-018-1072-9; Nitsch R, 2004, BIOCHEM J, V377, P553, DOI 10.1042/BJ20031233; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Parbin S, 2014, J HISTOCHEM CYTOCHEM, V62, P11, DOI 10.1369/0022155413506582; Patel HK, 2018, PHARMACOL THERAPEUT, V186, P1, DOI 10.1016/j.pharmthera.2017.12.012; Pereira B, 2016, NAT COMMUN, V7, P1; Pisamai S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200619; Poulard C, 2017, EMBO REP, V18, P1442, DOI 10.15252/embr.201744060; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ramos A, 2018, FASEB J, V32, P6982, DOI 10.1096/fj.201801167RR; Ren YQ, 2017, CANCER CHEMOTH PHARM, V79, P1003, DOI 10.1007/s00280-017-3302-0; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rimawi MF, 2015, ANNU REV MED, V66, P111, DOI 10.1146/annurev-med-042513-015127; Roche J, 2016, EUR J MED CHEM, V121, P451, DOI 10.1016/j.ejmech.2016.05.047; Rubio-Somoza I, 2011, CELL, V147, P1431, DOI 10.1016/j.cell.2011.12.003; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Song HM, 2018, CELL PHYSIOL BIOCHEM, V48, P1968, DOI 10.1159/000492520; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; Spoel SH, 2010, NEW PHYTOL, V186, P333, DOI 10.1111/j.1469-8137.2009.03125.x; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Tokunaga Eriko, 2006, Breast Cancer, V13, P137, DOI 10.2325/jbcs.13.137; Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vandghanooni S, 2018, J MOL MED, V96, P885, DOI 10.1007/s00109-018-1669-y; Vogel C, 1998, BREAST CANC RES TREA, V;50, P232; Volmar C.H., 2015, NEUROEPIGENETICS, V1, P20, DOI [10.1016/j.nepig.2014.10.002, DOI 10.1016/J.NEPIG.2014.10.002]; Vorobyeva NE, 2009, P NATL ACAD SCI USA, V106, P11049, DOI 10.1073/pnas.0901801106; Walko G, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14744; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Welboren WJ, 2007, MOL ONCOL, V1, P138, DOI 10.1016/j.molonc.2007.04.001; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang SH, 2019, CURR OPIN CELL BIOL, V61, P64, DOI 10.1016/j.ceb.2019.07.006; Zhang X, 2011, CELL DEATH DIFFER, V18, P1346, DOI 10.1038/cdd.2011.6	96	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	24					4621	4635		10.1038/s41388-020-1318-0	http://dx.doi.org/10.1038/s41388-020-1318-0		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LY0HO	32393834	hybrid, Green Published			2022-12-17	WOS:000531752500001
J	Huang, M; Feng, X; Su, D; Wang, G; Wang, C; Tang, MF; Paulucci-Holthauzen, A; Hart, T; Chen, JJ				Huang, Min; Feng, Xu; Su, Dan; Wang, Gang; Wang, Chao; Tang, Mengfan; Paulucci-Holthauzen, Adriana; Hart, Traver; Chen, Junjie			Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; PHOSPHORYLATED HISTONE H3; THR-3 PHOSPHORYLATION; STRUCTURAL BASIS; FEEDBACK LOOP; OVEREXPRESSION; RECOGNITION; CARCINOMA; MLN8054; POTENT	Aurora kinases are a family of serine/threonine kinases vital for cell division. Because of the overexpression of Aurora kinases in a broad range of cancers and their important roles in mitosis, inhibitors targeting Aurora kinases have attracted attention in cancer therapy. VX-680 is an effective pan-Aurora kinase inhibitor; however, its clinical efficacy was not satisfying. In this study, we performed CRISPR/Cas9 screens to identify genes whose depletion shows synthetic lethality with VX-680. The top hit from these screens was GSG2 (also known as Haspin), a serine/threonine kinase that phosphorylates histone H3 at Thr-3 during mitosis. Moreover, both Haspin knockout and Haspin inhibitor-treated HCT116 cells were hypersensitive to VX-680. Furthermore, we showed that the synthetic lethal interaction between Haspin depletion and VX-680 was mediated by the inhibition of Haspin with Aurora kinase B (AURKB), but not with Aurora kinase A (AURKA). Strikingly, combined inhibition of Haspin and AURKB had a better efficacy than single-agent treatment in both head and neck squamous cell carcinoma and non-small cell lung cancer. Taken together, our findings have uncovered a synthetic lethal interaction between AURKB and Haspin, which provides a strong rationale for this combination therapy for cancer patients.	[Huang, Min; Feng, Xu; Su, Dan; Wang, Chao; Tang, Mengfan; Chen, Junjie] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Wang, Gang; Hart, Traver] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Paulucci-Holthauzen, Adriana] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chen, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	jchen8@mdanderson.org		Feng, Xu/0000-0003-1603-7070; Wang, Andy/0000-0001-6798-1032	NCI NIH HHS [R01 CA210929, P30 CA016672] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amoussou NG, 2018, DRUG DISCOV TODAY, V23, P409, DOI 10.1016/j.drudis.2017.10.005; Araki K, 2004, J NEURO-ONCOL, V67, P53, DOI 10.1023/B:NEON.0000021784.33421.05; Balzano D, 2011, CHEM BIOL, V18, P966, DOI 10.1016/j.chembiol.2011.04.013; Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278; Bebbington D, 2009, BIOORG MED CHEM LETT, V19, P3586, DOI 10.1016/j.bmcl.2009.04.136; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Borisa AC, 2017, EUR J MED CHEM, V140, P1, DOI 10.1016/j.ejmech.2017.08.045; Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019; Burdova K, 2019, EMBO J, V38, DOI 10.15252/embj.2018101443; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chieffi P, 2004, J ENDOCRINOL, V181, P263, DOI 10.1677/joe.0.1810263; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; dos Santos EO, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0494-6; Du JM, 2012, STRUCTURE, V20, P185, DOI 10.1016/j.str.2011.12.001; Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106; Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208; Ghenoiu C, 2013, MOL CELL, V52, P734, DOI 10.1016/j.molcel.2013.10.002; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Helfrich BA, 2016, MOL CANCER THER, V15, P2314, DOI 10.1158/1535-7163.MCT-16-0298; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Hoar K, 2007, MOL CELL BIOL, V27, P4513, DOI 10.1128/MCB.02364-06; Jeyaprakash AA, 2011, STRUCTURE, V19, P1625, DOI 10.1016/j.str.2011.09.002; Katayama H, 2010, BBA-GENE REGUL MECH, V1799, P829, DOI 10.1016/j.bbagrm.2010.09.004; Kelly AE, 2010, SCIENCE, V330, P235, DOI 10.1126/science.1189505; Kestav K, 2017, CURR MED CHEM, V24, P2276, DOI 10.2174/0929867324666170414155520; Li Y, 2010, AM J TRANSL RES, V2, P296; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Marur S, 2016, MAYO CLIN PROC, V91, P386, DOI 10.1016/j.mayocp.2015.12.017; Mehra R, 2013, LANCET ONCOL, V14, pE425, DOI 10.1016/S1470-2045(13)70128-1; Niedzialkowska E, 2012, MOL BIOL CELL, V23, P1457, DOI 10.1091/mbc.E11-11-0904; Potting C, 2018, P NATL ACAD SCI USA, V115, pE180, DOI 10.1073/pnas.1711023115; Reichardt W, 2003, ONCOL REP, V10, P1275; Sells TB, 2015, ACS MED CHEM LETT, V6, P630, DOI 10.1021/ml500409n; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shimada M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12059; Sorrentino R, 2005, J CLIN ENDOCR METAB, V90, P928, DOI 10.1210/jc.2004-1518; Takeshita M, 2013, LUNG CANCER, V80, P85, DOI 10.1016/j.lungcan.2012.12.018; Tanaka T, 1999, CANCER RES, V59, P2041; Tang AQ, 2017, ONCOTARGET, V8, P23937, DOI 10.18632/oncotarget.14893; Wang C, 2019, ONCOGENE, V38, P2451, DOI 10.1038/s41388-018-0606-4; Wang FW, 2012, J CELL BIOL, V199, P251, DOI 10.1083/jcb.201205106; Wang FW, 2011, CURR BIOL, V21, P1061, DOI 10.1016/j.cub.2011.05.016; Wang FW, 2010, SCIENCE, V330, P231, DOI 10.1126/science.1189435; Willems E, 2018, CELL DIV, V13, DOI 10.1186/s13008-018-0040-6; Yamagishi Y, 2010, SCIENCE, V330, P239, DOI 10.1126/science.1194498; Yu FZ, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2016.49; Zappa C, 2016, TRANSL LUNG CANCER R, V5, P288, DOI 10.21037/tlcr.2016.06.07; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhou LL, 2014, EMBO REP, V15, P273, DOI 10.1002/embr.201338080	51	9	9	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4312	4322		10.1038/s41388-020-1296-2	http://dx.doi.org/10.1038/s41388-020-1296-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32300176	Green Accepted			2022-12-17	WOS:000534819000012
J	Manjili, MH				Manjili, Masoud H.			The premise of personalized immunotherapy for cancer dormancy	ONCOGENE			English	Review							CIRCULATING TUMOR-CELLS; BREAST-CANCER; BONE-MARROW; NEOANTIGENS; EQUILIBRIUM; CARCINOMA; REVEALS; ENDOTHELIN-1; CHEMOTHERAPY; TRASTUZUMAB	Progress in cancer therapies has resulted in improved survival of patients with early stage breast cancer. However, mortality remains high in patients with distant recurrence of the disease after initially successful treatment of early stage breast cancer. To this end, tumor recurrences have been attributed to the presence of dormant tumor cells in breast cancer patients and cancer survivors. Current clinical practice guidelines recommend a "wait-and-watch" approach for tumor recurrence. This is because of our limited understanding of tumor dormancy. Dormant tumor cells are quiescent, and thus, do not respond to chemotherapies or radiation therapies, and they are not operable. Therefore, immunotherapy is the only option for the treatment of tumor dormancy. However, gaps in our knowledge as to dormancy-specific antigens prevent a relapse preventing vaccine design. Here, I provide a critical review of cancer immunotherapy, and discuss empirical evidence related to naturally occurring tumor dormancy and treatment-induced tumor dormancy at the site of primary tumor and in distant organs before and after cancer therapies. Finally, I suggest that personalized vaccines targeting dormancy-associated neoantigens, which can be given to patients with early stage disease after the completion of neoadjuvant therapies and tumor resection as well as to cancer survivors could eliminate relapse causing dormant cells and offer a cure for cancer.	[Manjili, Masoud H.] Massey Canc Ctr, VCU Sch Med, VCU Inst Mol Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA	Virginia Commonwealth University	Manjili, MH (corresponding author), Massey Canc Ctr, VCU Sch Med, VCU Inst Mol Med, Dept Microbiol & Immunol, Richmond, VA 23298 USA.	masoud.manjili@vcuhealth.org			Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program [W81XWH-14-1-0087]; VCU Massey Cancer Center; NIH-NCI Cancer Center Support Grant [P30 CA016059]	Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program; VCU Massey Cancer Center; NIH-NCI Cancer Center Support Grant	This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Breast Cancer Research Program under Award No. W81XWH-14-1-0087 (MHM), pilot funding from the VCU Massey Cancer Center supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30 CA016059.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; American Cancer Society, 2016, CANC TREATM SURV FAC; Aqbi Hussein F, 2018, Oncotarget, V9, P22113, DOI 10.18632/oncotarget.25197; Ascierto PA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0798-3; Bai Y, 2018, METHODS MOL BIOL, V1802, P193, DOI 10.1007/978-1-4939-8546-3_13; Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728; Bartkowiak K, 2010, J PROTEOME RES, V9, P3158, DOI 10.1021/pr100039d; Baxevanis CN, 2015, VACCINES-BASEL, V3, P597, DOI 10.3390/vaccines3030597; Bidard FC, 2018, JNCI-J NATL CANCER I, V110, P560, DOI 10.1093/jnci/djy018; Boegel S, 2012, GENOME MED, V4, DOI 10.1186/gm403; Butturini E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174305; Cackowski FC, 2017, J CELL BIOCHEM, V118, P891, DOI 10.1002/jcb.25768; Cameron D, 2017, LANCET, V389, P1195, DOI 10.1016/S0140-6736(16)32616-2; Chen WY, 2018, J MATER CHEM B, V6, P327, DOI 10.1039/c7tb02608k; Clements ME, 2019, CURR OSTEOPOROS REP, V17, P353, DOI 10.1007/s11914-019-00532-y; Demicheli R, 2019, BREAST, V45, P61, DOI 10.1016/j.breast.2019.03.001; Dimco G, 2010, CELL CYCLE, V9, P4638, DOI 10.4161/cc.9.23.13955; Ebinger S, 2016, CANCER CELL, V30, P849, DOI 10.1016/j.ccell.2016.11.002; Eide N, 2019, PATHOL ONCOL RES, V25, P255, DOI 10.1007/s12253-017-0355-7; Emens LA, 2019, JAMA ONCOL, V5, P74, DOI 10.1001/jamaoncol.2018.4224; FELDMAN AR, 1986, NEW ENGL J MED, V315, P1394, DOI 10.1056/NEJM198611273152206; Folkman J, 2004, NATURE, V427, P787, DOI 10.1038/427787a; Francescangeli F, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1505-4; Gil M, 2013, P NATL ACAD SCI USA, V110, pE1291, DOI 10.1073/pnas.1220580110; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; HARACH HR, 1985, CANCER-AM CANCER SOC, V56, P531, DOI 10.1002/1097-0142(19850801)56:3<531::AID-CNCR2820560321>3.0.CO;2-3; Hellmann MD, 2017, IMMUNITY, V47, P221, DOI 10.1016/j.immuni.2017.08.001; Hilf N, 2019, NATURE, V565, P240, DOI 10.1038/s41586-018-0810-y; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Iyengar NM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.16211; Jahanban-Esfahlan R, 2019, CANCERS, V11, DOI 10.3390/cancers11081207; Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0787-5; Johanns TM, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561106; Kaplan MA, 2016, BREAST CARE, V11, P248, DOI 10.1159/000448186; Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026; Khazali AS, 2018, BRIT J CANCER, V118, P566, DOI 10.1038/bjc.2017.414; Kimura W, 1998, CANCER, V82, P1839, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1839::AID-CNCR5>3.0.CO;2-I; Kiyotani K, 2017, J HUM GENET, V62, P397, DOI 10.1038/jhg.2016.141; Kodumudi KN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01939; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kortylewski M, 2004, J INVEST DERMATOL, V122, P414, DOI 10.1046/j.0022-202X.2004.22237.x; Krall JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3464; Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006; Liang H, 2013, J IMMUNOL, V190, P5874, DOI 10.4049/jimmunol.1202612; Linette GP, 2017, TRENDS MOL MED, V23, P869, DOI 10.1016/j.molmed.2017.08.007; Linnemann C, 2015, NAT MED, V21, P81, DOI 10.1038/nm.3773; Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207; Loi S, 2019, LANCET ONCOL, V20, P371, DOI 10.1016/S1470-2045(18)30812-X; Loi S, 2016, JAMA ONCOL, V2, P1040, DOI 10.1001/jamaoncol.2016.0339; Luo XL, 2018, CANCER RES, V78, P3532, DOI 10.1158/0008-5472.CAN-18-0134; Ma KY, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.121387; Magbanua MJM, 2019, CLIN CANCER RES, V25, P5388, DOI 10.1158/1078-0432.CCR-18-3888; Manjili MH, 2018, ADV CANCER RES, V137, P17, DOI 10.1016/bs.acr.2017.11.005; Manjili MH, 2017, CANCER RES, V77, P2564, DOI 10.1158/0008-5472.CAN-17-0068; Manser RL, 2005, RESP MED, V99, P501, DOI 10.1016/j.rmed.2004.08.017; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; Meng SD, 2004, CLIN CANCER RES, V10, P8152, DOI 10.1158/1078-0432.CCR-04-1110; Merlino G, 2016, PIGM CELL MELANOMA R, V29, P404, DOI 10.1111/pcmr.12475; Montagner M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00037; Namjoshi P, 2016, ONCOTARGET, V10, P6006; Nariai N, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S2-S7; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Nelson JB, 2005, NEOPLASIA, V7, P631, DOI 10.1593/neo.04787; Nichols Erin E, 2017, Int Ophthalmol Clin, V57, P1; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pan RY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4325874; Payne KK, 2016, J LEUKOCYTE BIOL, V100, P625, DOI 10.1189/jlb.5A1215-580R; Perez EA, 2019, CANCER-AM CANCER SOC, V125, P3974, DOI 10.1002/cncr.32392; Planes-Laine G, 2019, CANCERS, V11, DOI 10.3390/cancers11071033; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661; Sanger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895; Satelli A, 2015, CLIN CHEM, V61, P259, DOI 10.1373/clinchem.2014.228122; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; Schmitt MJ, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-41; Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shah SA, 2017, IMMUNOTHERAPY-UK, V9, P943, DOI 10.2217/imt-2017-0044; Sinha G, 2012, J NATL CANCER I, V104, P1693, DOI 10.1093/jnci/djs478; Spirig R, 2009, MOL IMMUNOL, V46, P3178, DOI 10.1016/j.molimm.2009.05.179; Szikriszt B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0963-7; Tan SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142466; Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774; Thery L, 2019, JNCI CANCER SPECT, V3, DOI 10.1093/jncics/pkz026; Tjensvoll K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6268-y; Tonnessen-Murray CA, 2019, J CELL BIOL, V218, P3827, DOI 10.1083/jcb.201904051; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Tran E, 2017, NAT IMMUNOL, V18, P255, DOI 10.1038/ni.3682; Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102; Triana-Martinez F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020346; Trujillo JA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0780-0; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; van Buuren MM, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28836; van Maaren MC, 2019, INT J CANCER, V144, P263, DOI 10.1002/ijc.31914; Ward JP, 2016, ADV IMMUNOL, V130, P25, DOI 10.1016/bs.ai.2016.01.001; Zhang XN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4295; Zhu GZ, 2017, ACS NANO, V11, P2387, DOI 10.1021/acsnano.7b00978; Zolkind P, 2017, ORAL ONCOL, V71, P169, DOI 10.1016/j.oraloncology.2016.09.010	102	9	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4323	4330		10.1038/s41388-020-1295-3	http://dx.doi.org/10.1038/s41388-020-1295-3		APR 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32322001	Green Accepted			2022-12-17	WOS:000528504800001
J	Roh, E; Han, YP; Reddy, K; Zykova, TA; Lee, MH; Yao, K; Bai, RH; Curiel-Lewandrowski, C; Dong, ZG				Roh, Eunmiri; Han, Yaping; Reddy, Kanamata; Zykova, Tatyana A.; Lee, Mee Hyun; Yao, Ke; Bai, Ruihua; Curiel-Lewandrowski, Clara; Dong, Zigang			Suppression of the solar ultraviolet-induced skin carcinogenesis by TOPK inhibitor HI-TOPK-032	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; C-JUN; CANCER; KINASE; POPULATION; ACTIVATION; RADIATION; MELANOMA; GROWTH; JNK1	Nonmelanoma skin cancer (NMSC) such as cutaneous squamous cell carcinoma (cSCC) is caused by solar ultraviolet (SUV) exposure and is the most common cancer in the United States. T-LAK cell-originated protein kinase (TOPK), a serine-threonine kinase is activated by SUV irradiation and involved in skin carcinogenesis. Strategies with research focusing on the TOPK signaling pathway and targeted therapy in skin carcinogenesis may helpful for the discovery of additional treatments against skin cancer. In this study, we found that TOPK can directly bind to and phosphorylate c-Jun (as one of the core member of AP-1) at Ser63 and Ser73 after SSL exposure in a JNKs-independent manner. TOPK knocking down, or HI-TOPK-032 (TOPK specific inhibitor) attenuated colony formation and cell proliferation of skin cancer cells. Phosphorylated levels of c-Jun were overexpressed in human AK and cSCC compared with normal skin tissues, and HI-TOPK-032 inhibited the phosphorylation of c-Jun in SCC cell line in a dose-dependent manner. Furthermore, HI-TOPK-032 decreased SSL-induced AP-1 transactivation activity. Moreover, acute SSL-induced inflammation was attenuated by the topical application of HI-TOPK-032 in SKH1 hairless mice. Importantly, HI-TOPK-032 suppressed chronic SSL-induced skin carcinogenesis and c-Jun phosphorylation levels in SKH1 hairless mice. Our results demonstrate that TOPK can phosphorylate and activate c-Jun at Ser63 and Ser73 in the process of skin carcinogenesis and HI-TOPK-032 could be used as a potential chemopreventive drug against cSCC development.	[Roh, Eunmiri; Han, Yaping; Reddy, Kanamata; Zykova, Tatyana A.; Yao, Ke; Bai, Ruihua; Dong, Zigang] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Lee, Mee Hyun] China US Henan Hormel Canc Inst, Zhengzhou 450008, Henan, Peoples R China; [Lee, Mee Hyun] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou 450001, Henan, Peoples R China; [Curiel-Lewandrowski, Clara] Univ Arizona, Canc Ctr, Tucson, AZ 85719 USA; [Dong, Zigang] Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China	University of Minnesota System; Zhengzhou University; University of Arizona; Zhengzhou University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Dong, ZG (corresponding author), Zhengzhou Univ, Coll Med, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.	dongzg@zzu.edu.cn		Roh, Eunmiri/0000-0003-4385-2046	Hormel Foundation; National institutes of Health [CA229112]	Hormel Foundation; National institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr Richard Flavell (Yale University School of Medicine, New Haven, CT) for providing JNK1<SUP>-/-</SUP> and JNK2<SUP>-/-</SUP> mice, and Dr Dirk Bohmann (European Molecular Biology Laboratory, Germany) for providing His6-tagged c-Jun expression plasmid. This work was supported by The Hormel Foundation and National institutes of Health grants (CA229112).	Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Burton KA, 2016, AM J CLIN DERMATOL, V17, P491, DOI 10.1007/s40257-016-0207-3; D'Orazio J, 2013, INT J MOL SCI, V14, P12222, DOI 10.3390/ijms140612222; Decean HP, 2018, J ENVIRON PATHOL TOX, V37, P261, DOI 10.1615/JEnvironPatholToxicolOncol.2018027009; Edlund K, 2012, P NATL ACAD SCI USA, V109, P9551, DOI 10.1073/pnas.1200019109; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Gao G, 2017, MOL CANCER THER, V16, P1843, DOI 10.1158/1535-7163.MCT-17-0212; Gassmann P, 2008, CLIN EXP METASTAS, V25, P171, DOI 10.1007/s10585-007-9130-6; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Jin JY, 2011, J INVEST DERMATOL, V131, P1149, DOI 10.1038/jid.2011.1; Katiyar SK, 2007, TOXICOL APPL PHARM, V224, P220, DOI 10.1016/j.taap.2006.11.017; Kim DJ, 2012, CANCER RES, V72, P3060, DOI 10.1158/0008-5472.CAN-11-3851; Kim JE, 2016, ONCOGENE, V35, P4091, DOI 10.1038/onc.2015.471; Koh HK, 1996, ARCH DERMATOL, V132, P436, DOI 10.1001/archderm.132.4.436; Li GC, 2003, DEV CELL, V4, P865, DOI 10.1016/S1534-5807(03)00159-X; Li Y, 2016, ONCOTARGET, V7, P6748, DOI 10.18632/oncotarget.6826; Liu J, 2004, MOL CELL BIOL, V24, P10844, DOI 10.1128/MCB.24.24.10844-10856.2004; Liu KD, 2013, CANCER RES, V73, P2181, DOI 10.1158/0008-5472.CAN-12-3408; Loyo M, 2013, HEAD NECK-J SCI SPEC, V35, P454, DOI 10.1002/hed.23100; Matsumura Y, 2004, TOXICOL APPL PHARM, V195, P298, DOI 10.1016/j.taap.2003.08.019; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Rogers HW, 2015, JAMA DERMATOL, V151, P1081, DOI 10.1001/jamadermatol.2015.1187; Roh E, 2018, ONCOGENE, V37, P5633, DOI 10.1038/s41388-018-0350-9; Sabapathy K, 2004, MOL CELL, V15, P713, DOI 10.1016/j.molcel.2004.08.028; Shain AH, 2018, CANCER CELL, V34, P45, DOI 10.1016/j.ccell.2018.06.005; Stern RS, 2010, ARCH DERMATOL, V146, P279, DOI 10.1001/archdermatol.2010.4; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Wang LJ, 2019, ANTI-CANCER AGENT ME, V19, P1029, DOI 10.2174/1871520619666190301123131; Wiser I, 2016, ISR MED ASSOC J, V18, P275; Xue PP, 2017, ONCOTARGET, V8, P27093, DOI 10.18632/oncotarget.15636; Yamamoto H, 2017, J INVEST DERMATOL, V137, P1322, DOI 10.1016/j.jid.2016.12.026; Yin Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09844-0; Yokogawa M, 2013, MOL CARCINOGEN, V52, P760, DOI 10.1002/mc.21901; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048	36	9	9	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4170	4182		10.1038/s41388-020-1286-4	http://dx.doi.org/10.1038/s41388-020-1286-4		APR 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32277233	Green Accepted			2022-12-17	WOS:000524959200001
J	Choi, PW; So, WW; Yang, JZ; Liu, SB; Tong, KK; Kwan, KM; Kwok, JSL; Tsui, SKW; Ng, SK; Hales, KH; Hales, DB; Welch, WR; Crum, CP; Fong, WP; Berkowitz, RS; Ng, SW				Choi, Pui-Wah; So, Wai Wing; Yang, Junzheng; Liu, Shubai; Tong, Ka Kui; Kwan, Kin Ming; Kwok, Jamie S. -L.; Tsui, Stephen K. W.; Ng, Shu-Kay; Hales, Karen H.; Hales, Dale B.; Welch, William R.; Crum, Christopher P.; Fong, Wing-Ping; Berkowitz, Ross S.; Ng, Shu-Wing			MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread	ONCOGENE			English	Article							E-CADHERIN; SEROUS CARCINOMAS; MIR-200 FAMILY; FALLOPIAN-TUBE; CELL; RISK; SRC; PHENOTYPE; INVASION; INTEGRIN	Epidemiologic and histopathologic findings and the laying hen model support the long-standing incessant ovulation hypothesis and cortical inclusion cyst involvement in sporadic ovarian cancer development. MicroRNA-200 (miR-200) family is highly expressed in ovarian cancer. Herewith, we show that ovarian surface epithelial (OSE) cells with ectopic miR-200 expression formed stabilized cysts in three-dimensional (3D) organotypic culture with E-cadherin fragment expression and steroid hormone pathway activation, whereas ovarian cancer 3D cultures with miR-200 knockdown showed elevated TGF-beta expression, mitotic spindle disorientation, increased lumenization, disruption of ROCK-mediated myosin II phosphorylation, and SRC signaling, which led to histotype-dependent loss of collective movement in tumor spread. Gene expression profiling revealed that epithelial-mesenchymal transition and hypoxia were the top enriched gene sets regulated by miR-200 in both OSE and ovarian cancer cells. The molecular changes uncovered by the in vitro studies were verified in both human and laying hen ovarian cysts and tumor specimens. As miR-200 is also essential for ovulation, our results of estrogen pathway activation in miR-200-expressing OSE cells add another intriguing link between incessant ovulation and ovarian carcinogenesis.	[Choi, Pui-Wah; Yang, Junzheng; Liu, Shubai; Berkowitz, Ross S.; Ng, Shu-Wing] Harvard Med Sch, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; [Choi, Pui-Wah; So, Wai Wing; Tong, Ka Kui; Kwan, Kin Ming; Fong, Wing-Ping] Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China; [Kwan, Kin Ming] Chinese Univ Hong Kong, Ctr Cell & Dev Biol, Hong Kong, Peoples R China; [Kwan, Kin Ming] Chinese Univ Hong Kong, State Key Lab Agrobiotechnol, Hong Kong, Peoples R China; [Kwok, Jamie S. -L.; Tsui, Stephen K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Ng, Shu-Kay] Griffith Univ, Sch Med, Nathan, Qld 4111, Australia; [Ng, Shu-Kay] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld 4111, Australia; [Hales, Karen H.; Hales, Dale B.] Southern Illinois Sch Med, Dept Obstet Gynecol, Carbondale, IL 62901 USA; [Hales, Dale B.] Southern Illinois Sch Med, Dept Physiol Biochem & Mol Biol, Carbondale, IL 62901 USA; [Welch, William R.; Crum, Christopher P.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Ng, Shu-Wing] Tufts Med Ctr, Mother Infant Res Inst, Dept Obstet & Gynecol, 800 Washington St, Boston, MA 02111 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Griffith University; Griffith University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts Medical Center	Fong, WP (corresponding author), Chinese Univ Hong Kong, Sch Life Sci, Hong Kong, Peoples R China.	wpfong@cuhk.edu.hk; sng1@tuftsmedicalcenter.org	Tsui, Stephen Kwok-Wing/E-4385-2015	Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Ng, Shu Kay/0000-0002-6865-9384; liu, shubai/0000-0001-8929-4209	Robert and Deborah First Fund; Sperling Family Fund Foundation; Ruth N. White Gynecologic Oncology Research Fund; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute; CNOOC	Robert and Deborah First Fund; Sperling Family Fund Foundation; Ruth N. White Gynecologic Oncology Research Fund; Women's Cancer Program; Gillette Center for Women's Cancer from Dana-Farber Cancer Institute; Ovarian Cancer Research Foundation; Adler Foundation, Inc.; Friends of Dana-Farber Cancer Institute; CNOOC	We acknowledge Dr. Gregory Goodall for the provision of lentiviral miR-200 expression constructs and control, Mr. Shi-Kin Ma for the help of constructing the polar graphs, the support of the CNOOC Grants to the first author, and the Robert and Deborah First Fund, the Sperling Family Fund Foundation, Ruth N. White Gynecologic Oncology Research Fund, Women's Cancer Program and Gillette Center for Women's Cancer from Dana-Farber Cancer Institute, Ovarian Cancer Research Foundation, Adler Foundation, Inc., and Friends of Dana-Farber Cancer Institute to The Laboratory of Gynecologic Oncology at Brigham and Women's Hospital.	Aguilar-Rojas A, 2016, INT J ONCOL, V48, P861, DOI 10.3892/ijo.2016.3346; Ansenberger K, 2009, GYNECOL ONCOL, V113, P362, DOI 10.1016/j.ygyno.2009.02.011; ATFI A, 1994, J BIOL CHEM, V269, P30688; Avizienyte E, 2004, MOL BIOL CELL, V15, P2794, DOI 10.1091/mbc.E03-12-0879; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; Barnes MN, 2002, GYNECOL ONCOL, V87, P57, DOI 10.1006/gyno.2002.6806; Bryant DM, 2010, NAT CELL BIOL, V12, P1035, DOI 10.1038/ncb2106; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Canel M, 2013, J CELL SCI, V126, P393, DOI 10.1242/jcs.100115; Choi PW, 2016, ONCOTARGET, V7, P4110, DOI 10.18632/oncotarget.6588; Cochrane DR, 2017, J PATHOL, V243, P26, DOI 10.1002/path.4934; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; David JM, 2012, CANCER RES, V72, P2917, DOI 10.1158/0008-5472.CAN-11-3498; Drapkin R, 2004, HUM PATHOL, V35, P1014, DOI 10.1016/j.humpath.2004.04.014; Esselen KM, 2014, GYNECOL ONCOL, V132, P316, DOI 10.1016/j.ygyno.2013.12.007; FATHALLA MF, 1971, LANCET, V2, P163; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Giles JR, 2010, INT J GYNECOL CANCER, V20, P738, DOI 10.1111/IGC.0b013e3181da2c49; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gruessner C, 2014, AM J CANCER RES, V4, P61; HANKINSON SE, 1993, JAMA-J AM MED ASSOC, V270, P2813, DOI 10.1001/jama.270.23.2813; Hasuwa H, 2013, SCIENCE, V341, P71, DOI 10.1126/science.1237999; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Howitt BE, 2015, AM J SURG PATHOL, V39, P287, DOI 10.1097/PAS.0000000000000369; Hua YY, 2016, ONCOTARGET, V7, P66077, DOI 10.18632/oncotarget.11808; Johnson PA, 2013, NAT REV CANCER, V13, P432, DOI 10.1038/nrc3535; Kim J, 2015, ENDOCRINOLOGY, V156, P1975, DOI 10.1210/en.2014-1977; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kolin DL, 2018, J PATHOL, V244, P131, DOI 10.1002/path.5009; Kommoss F, 2017, AM J SURG PATHOL, V41, P161, DOI 10.1097/PAS.0000000000000757; Konecny GE, 2009, BRIT J CANCER, V101, P1699, DOI 10.1038/sj.bjc.6605381; Konze SA, 2014, MOL CELL PROTEOMICS, V13, P990, DOI 10.1074/mcp.M113.033423; Kurman RJ, 2011, HUM PATHOL, V42, P918, DOI 10.1016/j.humpath.2011.03.003; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110; McDaniel AS, 2015, JAMA ONCOL, V1, P1128, DOI 10.1001/jamaoncol.2015.1618; Mertens-Walker I, 2012, CANCER LETT, V324, P152, DOI 10.1016/j.canlet.2012.05.017; Messina A, 2016, NAT NEUROSCI, V19, P835, DOI 10.1038/nn.4298; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Parsons JT, 2010, NAT REV MOL CELL BIO, V11, P633, DOI 10.1038/nrm2957; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Przybycin CG, 2010, AM J SURG PATHOL, V34, P1407, DOI 10.1097/PAS.0b013e3181ef7b16; Rauh-Hain Jose A, 2011, Rev Obstet Gynecol, V4, P15; Rodriguez-Fraticelli AE, 2011, CURR OPIN CELL BIOL, V23, P638, DOI 10.1016/j.ceb.2011.07.002; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Sampson JA, 1927, AM J PATHOL, V3, P93; Scully RE, 1995, J CELL BIOCHEM, P208; Seidman JD, 2003, AM J SURG PATHOL, V27, P985, DOI 10.1097/00000478-200307000-00014; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Whiteman DC, 2000, JNCI-J NATL CANCER I, V92, P1172, DOI 10.1093/jnci/92.14.1172; Worley MJ, 2013, INT J MOL SCI, V14, P5367, DOI 10.3390/ijms14035367; Wu R, 2013, AM J PATHOL, V182, P1391, DOI 10.1016/j.ajpath.2012.12.031; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yang JZ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3417-z; Zhao S, 2015, INT J CLIN EXP PATHO, V8, P10412	56	9	9	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	20					4045	4060		10.1038/s41388-020-1264-x	http://dx.doi.org/10.1038/s41388-020-1264-x		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LN3GC	32214198				2022-12-17	WOS:000521526300003
J	Qian, T; Liu, CM; Ding, YY; Guo, C; Cai, RW; Wang, XX; Wang, R; Zhang, K; Zhou, L; Deng, Y; Wu, CY; Sun, Y				Qian, Tao; Liu, Chengmin; Ding, Yanyan; Guo, Chen; Cai, Renwei; Wang, Xiaoxia; Wang, Rong; Zhang, Kuo; Zhou, Li; Deng, Yi; Wu, Chuanyue; Sun, Ying			PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis	ONCOGENE			English	Article							INTEGRIN-LINKED KINASE; CELL-MATRIX ADHESION; THERAPEUTIC TARGET; ADAPTER PROTEIN; EXPRESSION; ILK; GENE; ANGIOGENESIS; ENDOCYTOSIS; ACTIVATION	PINCH-1 is a cytoplasmic component of the cell-extracellular matrix (ECM) adhesion machine that is frequently overexpressed in cancer. The functions and mechanism of PINCH-1 in cancer, however, remain to be determined. Here, we show that PINCH-1 interacts with myoferlin, a transmembrane protein that is critical for cancer progression. High expression of both PINCH-1 and myoferlin correlates with poor clinical outcome in human breast cancer patients. Ablation of PINCH-1 from breast cancer cells diminished myoferlin level and suppressed breast cancer cell proliferation, migration, and endothelial cell tube formation in vitro and breast tumor growth, angiogenesis and metastasis in vivo. Mechanistically, PINCH-1 controls myoferlin level through its interaction with myoferlin and regulation of its ubiquitination and proteasome-dependent degradation. Functionally, re-expression of PINCH-1, but not that of a myoferlin-binding defective Delta LIM2 mutant, effectively reversed the inhibition of myoferlin expression and breast cancer progression induced by loss of PINCH-1. Finally, restoration of myoferlin expression was sufficient to reverse PINCH-1-deficiency induced inhibition on breast cancer progression. These results reveal a PINCH-1-myoferlin signaling axis that is critical for breast cancer progression and suggest a new strategy for therapeutic control of breast cancer.	[Qian, Tao; Liu, Chengmin; Ding, Yanyan; Guo, Chen; Cai, Renwei; Wang, Xiaoxia; Wang, Rong; Zhang, Kuo; Zhou, Li; Deng, Yi; Sun, Ying] Southern Univ Sci & Technol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Dept Biol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China; [Wu, Chuanyue] Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15260 USA; [Wu, Chuanyue] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA	Southern University of Science & Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, Y (corresponding author), Southern Univ Sci & Technol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Dept Biol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China.; Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15260 USA.; Wu, CY (corresponding author), Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15260 USA.	carywu@pitt.edu; suny@sustech.edu.cn	Liu, Chengmin/GRO-0365-2022	kuo, zhang/0000-0003-2875-2581; Liu, Chengmin/0000-0002-0882-582X	National Natural Science Foundation of China [81772983, 81430068, 31471311]; Chinese Ministry of Science and Technology [2016YFC1302100]; Natural Science Foundation of Guangdong Province [1914050005629, 2017B030301018]; Shenzhen Innovation Committee of Science and Technology, China [JCYJ20170817104854302, ZDSYS20140509142721429, JCYJ20150831142427959]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Shenzhen Innovation Committee of Science and Technology, China	We thank Dr. Ruijun Tian of the Department of Chemistry, Southern University of Science and Technology, for help with nano-LC-MS/MS analysis; Dr. Jiahuai Han (Xiamen University, China) for the myoferlin cDNA; Drs. Jason D. Weber (Washington University) and Yandong Zhang (Southern University of Science and Technology) for the 3x Flag tagged pLVX-IRES-Hyg vector; Dr. Andrew Hutchins (Southern University of Science and Technology) for comments on the manuscript. This work was supported by the National Natural Science Foundation of China (81772983, 81430068, and 31471311), the Chinese Ministry of Science and Technology (2016YFC1302100), the Natural Science Foundation of Guangdong Province (1914050005629 and 2017B030301018), the Shenzhen Innovation Committee of Science and Technology, China (JCYJ20170817104854302, ZDSYS20140509142721429, and JCYJ20150831142427959).	Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Barnhouse Victoria R, 2018, Oncotarget, V9, P19209, DOI 10.18632/oncotarget.24971; Bernatchez PN, 2007, J BIOL CHEM, V282, P30745, DOI 10.1074/jbc.M704798200; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Blackstone BN, 2015, AM J PHYSIOL-CELL PH, V308, pC642, DOI 10.1152/ajpcell.00276.2014; Blomme A, 2017, ONCOGENE, V36, P2116, DOI 10.1038/onc.2016.369; Chen K, 2008, J BIOL CHEM, V283, P2508, DOI 10.1074/jbc.M707307200; Chen WD, 2016, ANAL CHEM, V88, P4864, DOI 10.1021/acs.analchem.6b00631; Cipta S, 2009, AM J PHYSIOL-CELL PH, V297, pC481, DOI 10.1152/ajpcell.00288.2009; Davis DB, 2000, HUM MOL GENET, V9, P217, DOI 10.1093/hmg/9.2.217; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Dong YY, 2014, CELL RES, V24, P1354, DOI 10.1038/cr.2014.129; Eke I, 2010, J CLIN INVEST, V120, P2516, DOI 10.1172/JCI41078; Fahmy K, 2016, INT J CANCER, V138, P652, DOI 10.1002/ijc.29820; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Gkretsi V, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00145; Goodman SL, 2012, TRENDS PHARMACOL SCI, V33, P405, DOI 10.1016/j.tips.2012.04.002; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hamidi H, 2016, BRIT J CANCER, V115, P1017, DOI 10.1038/bjc.2016.312; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Harisi R, 2015, ONCOTARGETS THER, V8, P1387, DOI 10.2147/OTT.S48883; Hermanns C, 2017, ONCOGENE, V36, P3464, DOI 10.1038/onc.2016.496; Hu WB, 2017, ELIFE, V6, DOI 10.7554/eLife.28021; Humphries JD, 2019, CURR OPIN CELL BIOL, V56, P14, DOI 10.1016/j.ceb.2018.08.004; Kim MH, 2018, J PATHOL TRANSL MED, V52, P93, DOI 10.4132/jptm.2017.11.29; Kovalevich J, 2011, J CELL PHYSIOL, V226, P940, DOI 10.1002/jcp.22437; Kumar B, 2016, ONCOTARGET, V7, P18665, DOI 10.18632/oncotarget.7625; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Leung C, 2013, AM J PATHOL, V182, P1900, DOI 10.1016/j.ajpath.2013.01.041; Li R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039766; Li SH, 2005, J CELL SCI, V118, P2913, DOI 10.1242/jcs.02422; Liang XQ, 2005, MOL CELL BIOL, V25, P3056, DOI 10.1128/MCB.25.8.3056-3062.2005; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Longmate Whitney, 2017, F1000Res, V6, P1612, DOI 10.12688/f1000research.11877.1; Loof J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-103; Moon S, 2014, SCI REP-UK, V4, DOI 10.1038/srep04376; Qin J, 2012, CURR OPIN CELL BIOL, V24, P607, DOI 10.1016/j.ceb.2012.06.003; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rademaker G, 2018, ONCOGENE, V37, P4398, DOI 10.1038/s41388-018-0287-z; Seager R J, 2017, Converg Sci Phys Oncol, V3, DOI 10.1088/2057-1739/aa7e86; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Song DH, 2016, ONCOL LETT, V11, P998, DOI 10.3892/ol.2015.3988; Sun Y, 2019, ONCOGENE, V38, P4856, DOI 10.1038/s41388-019-0762-1; Sun Y, 2017, J AM SOC NEPHROL, V28, P3545, DOI 10.1681/ASN.2016091021; Sun Y, 2012, J CELL SCI, V125, P4507, DOI 10.1242/jcs.105023; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Ungefroren H, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-18; Vakaloglou KM, 2016, CELL REP, V16, P596, DOI 10.1016/j.celrep.2016.06.079; Volakis LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086110; Wang MW, 2007, ONCOLOGY-BASEL, V72, P343, DOI 10.1159/000113064; Wang-Rodriguez J, 2002, CANCER-AM CANCER SOC, V95, P1387, DOI 10.1002/cncr.10878; Whittaker CA, 2006, DEV BIOL, V300, P252, DOI 10.1016/j.ydbio.2006.07.044; Wickstrom SA, 2010, EMBO J, V29, P281, DOI 10.1038/emboj.2009.376; Winograd-Katz SE, 2014, NAT REV MOL CELL BIO, V15, P273, DOI 10.1038/nrm3769; Wu CY, 2005, TRENDS CELL BIOL, V15, P460, DOI 10.1016/j.tcb.2005.07.002; Wu CY, 2004, BBA-MOL CELL RES, V1692, P55, DOI 10.1016/j.bbamcr.2004.01.006; Yu C, 2011, VASC PHARMACOL, V55, P26, DOI 10.1016/j.vph.2011.04.001; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858; Zhang TY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02748-x; Zhang YJ, 2002, J CELL SCI, V115, P4777, DOI 10.1242/jcs.00166; Zhang YJ, 2002, J BIOL CHEM, V277, P38328, DOI 10.1074/jbc.M205576200; Zheng CC, 2019, AM J CANCER RES, V9, P186; Zhu ZL, 2008, DIS MARKERS, V25, P75, DOI 10.1155/2008/473860	67	9	9	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2069	2087		10.1038/s41388-019-1135-5	http://dx.doi.org/10.1038/s41388-019-1135-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31801973				2022-12-17	WOS:000518584000004
J	Luo, SQ; Xiong, DH; Li, J; Li, GD; Wang, YL; Zhang, JM; Bu, XF; Hu, WX; Hu, JP				Luo, Sai-Qun; Xiong, De-Hui; Li, Jiang; Li, Guangdi; Wang, Yali; Zhang, Jia-Ming; Bu, Xiu-Fen; Hu, Wei-Xin; Hu, Jingping			C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma	ONCOGENE			English	Article							BINDING-PROTEIN; CELL-CYCLE; PROGNOSTIC-SIGNIFICANCE; DNA; PROGRESSION; ABNORMALITIES; EXPRESSION; ADDICTION; TRANSLATION; PROMOTER	Multiple myeloma (MM) is a clinically and biologically heterogenous event that accounts for approximately 10% of all hematological malignancies. Chromosome 1 open reading frame 35 (C1orf35) is a gene cloned and identified in our laboratory from a MM cell line (GenBank: AY137773), but little is known about its function. In the current study, we have confirmed that C1orf35 is a candidate oncogene, and it can promote cell cycle progression from G1 to S. Later, we found that C1orf35 is able to affect the cell proliferation by modulating the expression of c-MYC (v-myc myelocytomatosis viral oncogene homolog), and the oncogenic property of C1orf35 can be rescued by c-MYC inhibition. Herein, we found positive association between C1orf35 and c-MYC in MM patients and in MM cell lines. The correlation analysis of the genes coamplified in MM patients from GEO datasets showed a correlation between C1orf35 and c-MYC, and the expression data of different stages of plasma cell neoplasm acquired from GEO datasets showed that the expression of C1orf35 increase with the progression of the disease. This indicates that C1orf35 may play a role in the disease progression. Moreover, C1orf35 can modulate c-MYC expression and rescue c-MYC transcription inhibited by Act D. Finally, we have shown that C1orf35 activates c-MYC transcription by binding to the i-motif of Nuclease hypersensitivity element III1 (NHE III1) in the c-MYC promoter. Not only does our current study advance our knowledge of the pathogenesis and therapeutic landscape of MM, but also of other cancer types and diseases that are initiated with deregulated c-MYC transcription.	[Luo, Sai-Qun; Xiong, De-Hui; Li, Jiang; Zhang, Jia-Ming; Bu, Xiu-Fen; Hu, Wei-Xin; Hu, Jingping] Cent South Univ, Mol Biol Res Ctr, Sch Life Sci, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China; [Li, Guangdi; Wang, Yali] Cent South Univ, Xiangya Sch Publ Hlth, Dept Epidemiol & Hlth Stat, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China	Central South University; Central South University	Hu, WX; Hu, JP (corresponding author), Cent South Univ, Mol Biol Res Ctr, Sch Life Sci, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.	weixinhu@mail.csu.edu.cn; jingpinghu@csu.edu.cn	Li, Guangdi/AAU-6951-2020	Li, Guangdi/0000-0001-8852-034X; Hu, Jingping/0000-0001-5548-1241	National Natural Science Foundation of China [81372538, 81400819, 81071947, 39880021, 30770906]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported with grants from the National Natural Science Foundation of China (Nos. 81372538, 81400819, 81071947, 39880021 and 30770906).	Agnelli L, 2009, GENE CHROMOSOME CANC, V48, P603, DOI 10.1002/gcc.20668; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Armas P, 2008, J CELL BIOCHEM, V103, P1013, DOI 10.1002/jcb.21474; Avet-Loiseau H, 2012, J CLIN ONCOL, V30, P1949, DOI 10.1200/JCO.2011.36.5726; Avet-Loiseau H, 2009, J CLIN ONCOL, V27, P4585, DOI 10.1200/JCO.2008.20.6136; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Chesi M, 2008, CANCER CELL, V13, P167, DOI 10.1016/j.ccr.2008.01.007; Chng WJ, 2011, LEUKEMIA, V25, P1026, DOI 10.1038/leu.2011.53; Chng WJ, 2007, CANCER RES, V67, P2982, DOI 10.1158/0008-5472.CAN-06-4046; Decaux O, 2008, J CLIN ONCOL, V26, P4798, DOI 10.1200/JCO.2007.13.8545; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Eddy J, 2006, NUCLEIC ACIDS RES, V34, P3887, DOI 10.1093/nar/gkl529; Geltinger C, 1996, GENE EXPRESSION, V6, P113; Gonzalez V, 2010, ANNU REV PHARMACOL, V50, P111, DOI 10.1146/annurev.pharmtox.48.113006.094649; Grand CL, 2002, MOL CANCER THER, V1, P565; Hanamura I, 2006, BLOOD, V108, P1724, DOI 10.1182/blood-2006-03-009910; Holien T, 2012, BLOOD, V120, P2450, DOI 10.1182/blood-2011-08-371567; Hu JP, 2018, CANCER LETT, V414, P214, DOI 10.1016/j.canlet.2017.11.020; Jovanovic KK, 2018, LEUKEMIA, V32, P1295, DOI 10.1038/s41375-018-0036-x; Kuehl WM, 2012, BLOOD, V120, P2351, DOI 10.1182/blood-2012-08-445262; Kumar SK, 2018, NAT REV CLIN ONCOL, V15, P409, DOI 10.1038/s41571-018-0018-y; Le Baccon P, 2001, GENE CHROMOSOME CANC, V32, P250, DOI 10.1002/gcc.1189; MAJELLO B, 1995, ONCOGENE, V10, P1841; Manier S, 2017, NAT REV CLIN ONCOL, V14, P100, DOI 10.1038/nrclinonc.2016.122; Marzin Y, 2006, ANTICANCER RES, V26, P953; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Mathur V, 2004, BIOCHEM BIOPH RES CO, V320, P1220, DOI 10.1016/j.bbrc.2004.06.074; Melton PE, 2019, J HYPERTENS, V37, P997, DOI 10.1097/HJH.0000000000002023; Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257; Neben K, 2013, J CLIN ONCOL, V31, P4325, DOI 10.1200/JCO.2012.48.4923; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pawlyn C, 2017, NAT REV CANCER, V17, P543, DOI 10.1038/nrc.2017.63; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; Rajkumar SV, 2009, CURR PROB CANCER, V33, P7, DOI 10.1016/j.currproblcancer.2009.01.001; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Sawyer JR, 2011, CANCER GENET-NY, V204, P3, DOI 10.1016/j.cancergencyto.2010.11.002; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Snead NM, 2013, NUCLEIC ACIDS RES, V41, P6209, DOI 10.1093/nar/gkt200; SOBELL HM, 1985, P NATL ACAD SCI USA, V82, P5328, DOI 10.1073/pnas.82.16.5328; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Tian JY, 2003, ACTA BIOCH BIOPH SIN, V35, P143; Wiegering A, 2015, CANCER DISCOV, V5, P768, DOI 10.1158/2159-8290.CD-14-1040; Zeraati M, 2018, NAT CHEM, V10, P631, DOI 10.1038/s41557-018-0046-3	48	9	9	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3354	3366		10.1038/s41388-020-1222-7	http://dx.doi.org/10.1038/s41388-020-1222-7		FEB 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32103167				2022-12-17	WOS:000516683100001
J	Kato, H; Asamitsu, K; Sun, WD; Kitajima, S; Yoshizawa-Sugata, N; Okamoto, T; Masai, H; Poellinger, L				Kato, Hiroyuki; Asamitsu, Kaori; Sun, Wendi; Kitajima, Shojiro; Yoshizawa-Sugata, Naoko; Okamoto, Takashi; Masai, Hisao; Poellinger, Lorenz			Cancer-derived UTX TPR mutations G137V and D336G impair interaction with MLL3/4 complexes and affect UTX subcellular localization	ONCOGENE			English	Article							MAKE-UP SYNDROME; KABUKI-SYNDROME; DEMETHYLASE UTX; PROTEIN; KDM6A; MLL2; GENES; INACTIVATION; RETARDATION; METHYLATION	The ubiquitously transcribed tetratricopeptide repeat on X chromosome (UTX) is a major histone H3 lysine 27 (H3K27) demethylase and the mixed-lineage leukemia (MLL) proteins are the H3K4 methyltransferases. UTX is one of the major components of MLL3- and MLL4-containing (MlLL3/4) complexes and likely has functions within the complexes. Although UTX is frequently mutated in various types of cancer and is thought to play a crucial role as a tumor suppressor, the importance of UTX interaction with MLL3/4 complexes in cancer formation is poorly understood. Here, we analyzed the ability of cancer-derived UTX mutant proteins to interact with ASH2L, which is a common core component of all the MLL complexes, and MLL3/4-specific components PTIP and PA1, and found that several single-amino acid substitution mutations in the tetratricopeptide repeat (TPR) affect UTX interaction with these components. Interaction-compromised mutants G137V and D336G and a TPR-deleted mutant Delta 80-397 were preferentially localized to the cytoplasm, suggesting that UTX is retained in the nucleus by MLL3/4 complexes through their interaction with the TPR. Intriguingly, WT UTX suppressed colony formation in soft agar, whereas G137V failed. This suggests that interaction of UTX with MLL3/4 complex plays a crucial role in their tumor suppressor function. Preferential cytoplasmic localization was also observed for endogenous proteins of G137V and another mutant G137V Delta 138 in HCT116 created by CRISPR-Cas9 gene editing. Interestingly, expression levels of these mutants were low and MG312 stabilized both endogenous as well as exogenous G137V proteins. These results reveal a novel mechanism of UTX regulation and reinforce the importance of UTX interaction with MLL3/4 complexes in cancer formation.	[Kato, Hiroyuki; Sun, Wendi; Kitajima, Shojiro; Poellinger, Lorenz] Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr, Singapore 117599, Singapore; [Kato, Hiroyuki; Yoshizawa-Sugata, Naoko; Masai, Hisao] Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan; [Kato, Hiroyuki; Asamitsu, Kaori; Okamoto, Takashi] Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 467860, Japan; [Kitajima, Shojiro] Keio Univ, Inst Adv Biosci, Kakuganji 246-2, Tsuruoka, Yamagata 9970052, Japan; [Poellinger, Lorenz] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden	National University of Singapore; Tokyo Metropolitan Institute of Medical Science; Nagoya City University; Keio University; Karolinska Institutet	Kato, H (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr, Singapore 117599, Singapore.; Kato, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Genome Med, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.; Kato, H (corresponding author), Nagoya City Univ, Dept Mol & Cellular Biol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 467860, Japan.	csihkato@gmail.com		Masai, Hisao/0000-0003-1268-5302; Yoshizawa-Sugata, Naoko/0000-0001-8792-8669; Asamitsu, Kaori/0000-0001-5333-8011	Singapore National Research Foundation [R-713-005-014-271, R-713-000-162-511]; Singapore Ministry of Education; Singapore Ministry of Health's National Medical Research Council [NMRC/CIRG/1389/2014]; Japan Society for the Promotion of Science KAKENHI [17K08638, 23247031, 26251004]; Takeda Science Foundation	Singapore National Research Foundation(National Research Foundation, Singapore); Singapore Ministry of Education(Ministry of Education, Singapore); Singapore Ministry of Health's National Medical Research Council(National Medical Research Council, Singapore); Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank all the LP lab members for technical assistance. This work was supported by grants from the Singapore National Research Foundation (R-713-005-014-271 and R-713-000-162-511), the Singapore Ministry of Education under the Research Centres of Excellence Programme, and the Singapore Ministry of Health's National Medical Research Council (Clinician Scientist Individual Research Grant, NMRC/CIRG/1389/2014) to LP, and Japan Society for the Promotion of Science KAKENHI (17K08638) to KA and (Scientific Research A, 23247031 and 26251004) to HM, and the Takeda Science Foundation to HM. In the midst of this project, Prof. Lorenz Poellinger passed away, to whom we dedicate this work.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Ahn J, 2016, ONCOTARGET, V7, P63252, DOI 10.18632/oncotarget.11207; Andricovich J, 2018, CANCER CELL, V33, P512, DOI 10.1016/j.ccell.2018.02.003; Banka S, 2015, CLIN GENET, V87, P252, DOI 10.1111/cge.12363; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.3.CO;2-E; Bouazzi H, 2015, CLIN CASE REP, V3, P604, DOI 10.1002/ccr3.301; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200; D'Andrea LD, 2003, TRENDS BIOCHEM SCI, V28, P655, DOI 10.1016/j.tibs.2003.10.007; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; Greenfield A, 1998, HUM MOL GENET, V7, P737, DOI 10.1093/hmg/7.4.737; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Hannibal MC, 2011, AM J MED GENET A, V155A, P1511, DOI 10.1002/ajmg.a.34074; Hernandez-Ramirez LC, 2016, J CLIN ENDOCR METAB, V101, P3144, DOI 10.1210/jc.2016-1307; Herz HM, 2016, BIOESSAYS, V38, P1003, DOI 10.1002/bies.201600106; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Ijichi O, 1996, ACTA PAEDIATR JAPON, V38, P66; Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Kim DE, 2004, NUCLEIC ACIDS RES, V32, pW526, DOI 10.1093/nar/gkh468; Kim J, 2017, ANN CLIN LAB SCI, V47, P229; Kitajima S, 2017, ONCOTARGET, V8, P114481, DOI 10.18632/oncotarget.23010; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Lederer D, 2012, AM J HUM GENET, V90, P119, DOI 10.1016/j.ajhg.2011.11.021; Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042; Ler LD, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8312; Leusen JHW, 1996, J EXP MED, V184, P1243, DOI 10.1084/jem.184.4.1243; Lindgren AM, 2013, HUM GENET, V132, P537, DOI 10.1007/s00439-013-1263-x; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Mar BG, 2012, LEUKEMIA, V26, P1881, DOI 10.1038/leu.2012.56; Merks JHM, 2005, AM J MED GENET A, V134A, P132, DOI 10.1002/ajmg.a.30603; Micale L, 2014, HUM MUTAT, V35, P841, DOI 10.1002/humu.22547; Miyake N, 2013, AM J MED GENET A, V161, P2234, DOI 10.1002/ajmg.a.36072; Ng SB, 2010, NAT GENET, V42, P790, DOI 10.1038/ng.646; NIIKAWA N, 1988, AM J MED GENET, V31, P565, DOI 10.1002/ajmg.1320310312; NIIKAWA N, 1981, J PEDIATR-US, V99, P565, DOI 10.1016/S0022-3476(81)80255-7; Niranjan TS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116454; Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Scherer S, 2003, AM J MED GENET A, V122A, P76, DOI 10.1002/ajmg.a.20261; Shpargel KB, 2017, P NATL ACAD SCI USA, V114, pE9046, DOI 10.1073/pnas.1705011114; Shpargel KB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002964; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Sun WD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05685-3; Tumino M, 2010, AM J MED GENET A, V152A, P1536, DOI 10.1002/ajmg.a.33405; Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Vandamme J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002647; Walport LJ, 2014, J BIOL CHEM, V289, P18302, DOI 10.1074/jbc.M114.555052; Wang CC, 2012, P NATL ACAD SCI USA, V109, P15324, DOI 10.1073/pnas.1204166109; Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610; Wang SP, 2017, MOL CELL, V67, P308, DOI 10.1016/j.molcel.2017.06.028; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Willems AP, 2017, J BIOL CHEM, V292, P12621, DOI 10.1074/jbc.M117.790097; Zhang SY, 2016, NATURE, V533, P260, DOI 10.1038/nature17973	62	9	9	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3322	3335		10.1038/s41388-020-1218-3	http://dx.doi.org/10.1038/s41388-020-1218-3		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32071397				2022-12-17	WOS:000514262600001
J	Gong, C; Tsoi, H; Mok, KC; Cheung, J; Man, EPS; Fujino, K; Wong, AH; Lam, EWF; Khoo, US				Gong, Chun; Tsoi, Ho; Mok, Ka Chun; Cheung, Jenny; Man, Ellen P. S.; Fujino, Kazunari; Wong, Ashely; Lam, Eric W. F.; Khoo, Ui-Soon			Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; INITIATION-FACTORS; PROTEIN-SYNTHESIS; ER-ALPHA; THERAPY; EXPRESSION; FOXM1; SENSITIVITY; MECHANISMS; RECEPTOR	Eukaryotic translation initiation factor 4E (eIF4E) selectively promotes translation of mRNAs with atypically long and structured 5 '-UTRs and has been implicated in drug resistance. Through genome-wide transcriptome and translatome analysis we revealed eIF4E overexpression could promote cellular activities mediated by ER alpha and FOXM1 signalling pathways. Whilst eIF4E overexpression could enhance the translation of both ER alpha and FOXM1, it also led to enhanced transcription of FOXM1. Polysome fractionation experiments confirmed eIF4E could modulate the translation of ER alpha and FOXM1 mRNA. The enhancement of FOXM1 transcription was contingent upon the presence of ER alpha, and it was the high levels of FOXM1 that conferred Tamoxifen resistance. Furthermore, tamoxifen resistance was conferred by phosphorylation independent eIF4E overexpression. Immunohistochemistry on 134 estrogen receptor (ER+) primary breast cancer samples confirmed that high eIF4E expression was significantly associated with increased ER alpha and FOXM1, and significantly associated with tamoxifen resistance. Our study uncovers a novel mechanism whereby phosphorylation independent eIF4E translational reprogramming in governing the protein synthesis of ER alpha and FOXM1 contributes to anti-estrogen insensitivity in ER+ breast cancer. In eIF4E overexpressing breast cancer, the increased ER alpha protein expression in turn enhances FOXM1 transcription, which together with its increased translation regulated by eIF4E, contributes to tamoxifen resistance. Coupled with eIF4E translational regulation, our study highlights an important mechanism conferring tamoxifen resistance via both ER alpha dependent and independent pathways.	[Gong, Chun; Tsoi, Ho; Mok, Ka Chun; Cheung, Jenny; Man, Ellen P. S.; Wong, Ashely; Khoo, Ui-Soon] Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Gong, Chun; Fujino, Kazunari; Lam, Eric W. F.] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London, England	University of Hong Kong; Imperial College London	Khoo, US (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Hong Kong, Peoples R China.; Lam, EWF (corresponding author), Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London, England.	eric.lam@imperial.ac.uk; uskhoo@pathology.hku.hk	Khoo, Ui Soon/C-4293-2009; Lam, Eric W-F/AAW-8566-2020	Khoo, Ui Soon/0000-0003-2200-7505; Lam, Eric W-F/0000-0003-1274-3576; tsoi, ho/0000-0003-2037-9575	Committee on Research and Conference Grants from the University of Hong Kong [201109176081, 201209176093, 201711159147]; MRC [MR/N012097/1]; CRUK [A12011]; Breast Cancer Now [2012MayPR070, 2012NovPhD016]; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Imperial ECMC	Committee on Research and Conference Grants from the University of Hong Kong; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CRUK(Cancer Research UK); Breast Cancer Now; Cancer Research UK Imperial Centre; NIHR Imperial BRC; Imperial ECMC	The study was supported by grants from the Committee on Research and Conference Grants from the University of Hong Kong Project numbers 201109176081, 201209176093 and 201711159147. We thank Dr Robert Clarke (Georgetown University Medical Center) for providing the cell lines. EW-FL work is supported by MRC (MR/N012097/1), CRUK (A12011), Breast Cancer Now (2012MayPR070; 2012NovPhD016), the Cancer Research UK Imperial Centre, Imperial ECMC and NIHR Imperial BRC.	Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280-012-2043-3; Busch S, 2015, CANCER RES, V75, P1457, DOI 10.1158/0008-5472.CAN-14-1583; Chen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012293; Chimge NO, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3073; Chu J, 2016, TRENDS CELL BIOL, V26, P918, DOI 10.1016/j.tcb.2016.06.005; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Droog M, 2013, EUR J PHARMACOL, V717, P47, DOI 10.1016/j.ejphar.2012.11.071; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Fagan DH, 2017, HORM CANCER-US, V8, P219, DOI 10.1007/s12672-017-0296-3; Ferrari N, 2015, SCI REP-UK, V5, DOI 10.1038/srep15658; Geter PA, 2017, GENE DEV, V31, P2235, DOI 10.1101/gad.305631.117; Gong C, 2018, CLIN CANCER RES, V24, P3681, DOI 10.1158/1078-0432.CCR-17-2259; Halasi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031761; Hassan MK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191377; HORWITZ KB, 1975, SCIENCE, V189, P726, DOI 10.1126/science.168640; Hou Y, 2015, NAT IMMUNOL, V16, P810, DOI 10.1038/ni.3204; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Ito Y, 2015, NAT REV CANCER, V15, P81, DOI 10.1038/nrc3877; Jordan VC, 2008, EUR J CANCER, V44, P30, DOI 10.1016/j.ejca.2007.11.002; Kamburov A, 2011, NUCLEIC ACIDS RES, V39, pD712, DOI 10.1093/nar/gkq1156; Karadedou CT, 2006, HIPPOKRATIA, V10, P128; Kevil C, 1995, ONCOGENE, V11, P2339; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Leng N, 2013, BIOINFORMATICS, V29, P1035, DOI 10.1093/bioinformatics/btt087; Leppek K, 2018, NAT REV MOL CELL BIO, V19, P158, DOI 10.1038/nrm.2017.103; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Ruggero D, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012336; SHANTZ LM, 1994, CANCER RES, V54, P2313; Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126; Sonenberg N, 2007, MOL CELL, V28, P721, DOI 10.1016/j.molcel.2007.11.018; Uttam S, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00470; Zhang LD, 2013, CANCER RES, V73, P246, DOI 10.1158/0008-5472.CAN-12-2241; Zhu YH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03951-0; Zilli M, 2009, BBA-REV CANCER, V1795, P62, DOI 10.1016/j.bbcan.2008.08.003; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420	42	9	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3206	3217		10.1038/s41388-020-1210-y	http://dx.doi.org/10.1038/s41388-020-1210-y		FEB 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32066877	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000514052700005
J	Yoshimi, A; Trippett, TM; Zhang, N; Chen, XY; Penson, AV; Arcila, ME; Pichardo, J; Baik, J; Sigler, A; Harada, H; Fajgenbaum, DC; Dogan, A; Abdel-Wahab, O; Xiao, WB				Yoshimi, Akihide; Trippett, Tanya M.; Zhang, Nan; Chen, Xueyan; Penson, Alexander, V; Arcila, Maria E.; Pichardo, Janine; Baik, Jeeyeon; Sigler, Allison; Harada, Hironori; Fajgenbaum, David C.; Dogan, Ahmet; Abdel-Wahab, Omar; Xiao, Wenbin			Genetic basis for iMCD-TAFRO	ONCOGENE			English	Article							PLATELET DISORDER; DISEASE; THROMBOCYTOPENIA; PREDISPOSITION; ANASARCA; MUTATION	TAFRO syndrome, a clinical subtype of idiopathic multicentric Castleman disease (iMCD), consists of a constellation of symptoms/signs including thrombocytopenia, anasarca, fever, reticulin fibrosis/renal dysfunction, and organomegaly. The etiology of iMCD-TAFRO and the basis for cytokine hypersecretion commonly seen in iMCD-TAFRO patients has not been elucidated. Here, we identified a somatic MEK2(P128L) mutation and a germline RUNX1(G60C) mutation in two patients with iMCD-TAFRO, respectively. The MEK2(P128L) mutation, which has been identified previously in solid tumor and histiocytosis patients, caused hyperactivated MAP kinase signaling, conferred IL-3 hypersensitivity and sensitized the cells to various MEK inhibitors. The RUNX1(G60C) mutation abolished the transcriptional activity of wild-type RUNX1 and functioned as a dominant negative form of RUNX1, resulting in enhanced self-renewal activity in hematopoietic stem/progenitor cells. Interestingly, ERK was heavily activated in both patients, highlighting a potential role for activation of MAPK signaling in iMCD-TAFRO pathogenesis and a rationale for exploring inhibition of the MAPK pathway as a therapy for iMCD-TAFRO. Moreover, these data suggest that iMCD-TAFRO might share pathogenetic features with clonal inflammatory disorders bearing MEK and RUNX1 mutations such as histiocytoses and myeloid neoplasms.	[Yoshimi, Akihide; Penson, Alexander, V; Abdel-Wahab, Omar; Xiao, Wenbin] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Trippett, Tanya M.] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA; [Zhang, Nan] SUNY Buffalo, Dept Pathol, Buffalo Gen Med Ctr, Buffalo, NY 14206 USA; [Chen, Xueyan] Univ Washington, Dept Lab Med, Seattle, WA 98109 USA; [Penson, Alexander, V] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Arcila, Maria E.; Pichardo, Janine; Baik, Jeeyeon; Sigler, Allison; Dogan, Ahmet; Xiao, Wenbin] Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, New York, NY 10065 USA; [Arcila, Maria E.] Mem Sloan Kettering Canc Ctr, Dept Pathol, Diagnost Mol Lab, New York, NY 10065 USA; [Harada, Hironori] Tokyo Univ Pharm & Life Sci, Sch Life Sci, Lab Oncol, Tokyo 1920392, Japan; [Fajgenbaum, David C.] Castleman Dis Collaborat Network, Philadelphia, PA USA; [Abdel-Wahab, Omar] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10065 USA; [Zhang, Nan] Rochester Gen Hosp, Dept Pathol, Rochester, NY 14621 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Buffalo General Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Tokyo University of Pharmacy & Life Sciences; Memorial Sloan Kettering Cancer Center; Rochester General Hospital	Xiao, WB (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.; Xiao, WB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, Hematopathol Serv, New York, NY 10065 USA.	xiaow@mskcc.org	Yoshimi, Akihide/I-3792-2019; Arcila, Maria/ABE-2235-2021	Yoshimi, Akihide/0000-0002-0664-7281; 	NIH/NCI Cancer Center Support Grant [P30 CA008748]; Aplastic Anemia and MDS International Foundation (AAMDSIF); Lauri Strauss Leukemia Foundation; Leukemia and Lymphoma Society Special Fellow Award; JSPS Overseas Research Fellowships; NIH/NHLBI [R01 HL128239]; Department of Defense Bone Marrow Failure Research Program [W81XWH-16-1-0059]; Starr Foundation [I8-A8-075]; Henry & Marilyn Taub Foundation; Edward P. Evans Foundation; Josie Robertson Investigator Program; Leukemia and Lymphoma Society; Pershing Square Sohn Cancer Research Alliance; Castleman's Awareness and Research Effort/Castleman Disease Collaborative Network	NIH/NCI Cancer Center Support Grant; Aplastic Anemia and MDS International Foundation (AAMDSIF); Lauri Strauss Leukemia Foundation; Leukemia and Lymphoma Society Special Fellow Award(Leukemia and Lymphoma Society); JSPS Overseas Research Fellowships; NIH/NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Department of Defense Bone Marrow Failure Research Program; Starr Foundation; Henry & Marilyn Taub Foundation; Edward P. Evans Foundation; Josie Robertson Investigator Program; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Pershing Square Sohn Cancer Research Alliance(Pershing Square Sohn Cancer Research Alliance); Castleman's Awareness and Research Effort/Castleman Disease Collaborative Network	This study was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. AY is a Special Fellow of The Leukemia and Lymphoma Society and supported by grants from the Aplastic Anemia and MDS International Foundation (AA&MDSIF), the Lauri Strauss Leukemia Foundation, the Leukemia and Lymphoma Society Special Fellow Award, and JSPS Overseas Research Fellowships. OA-W is supported by grants from NIH/NHLBI (R01 HL128239), the Department of Defense Bone Marrow Failure Research Program (W81XWH-16-1-0059), the Starr Foundation (I8-A8-075), the Henry & Marilyn Taub Foundation, the Edward P. Evans Foundation, the Josie Robertson Investigator Program, the Leukemia and Lymphoma Society, and the Pershing Square Sohn Cancer Research Alliance. WX is supported by a grant from Castleman's Awareness and Research Effort/Castleman Disease Collaborative Network.	Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6; Baker TS, 2018, BLOOD ADV, V2, P2959, DOI 10.1182/bloodadvances.2018023911; Bolze A, 2010, AM J HUM GENET, V87, P873, DOI 10.1016/j.ajhg.2010.10.028; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Fajgenbaum DC, 2017, BLOOD, V129, P1646, DOI 10.1182/blood-2016-10-746933; Inoue M, 2013, J CLIN EXP HEMATOP, V53, P95, DOI 10.3960/jslrt.53.95; Iwaki N, 2017, SCI REP-UK, V7, DOI 10.1038/srep42316; Iwaki N, 2016, AM J HEMATOL, V91, P220, DOI 10.1002/ajh.24242; Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617; Kawabata H, 2013, J CLIN EXP HEMATOP, V53, P57, DOI 10.3960/jslrt.53.57; Li ZM, 2019, LEUKEMIA, V33, P1035, DOI 10.1038/s41375-018-0323-6; Liu AY, 2016, LANCET HAEMATOL, V3, pE163, DOI 10.1016/S2352-3026(16)00006-5; Michaud J, 2002, BLOOD, V99, P1364, DOI 10.1182/blood.V99.4.1364; Nagy A, 2018, BLOOD ADV, V2, P481, DOI 10.1182/bloodadvances.2017009654; Ozkaya N, 2018, MODERN PATHOL, V31, P581, DOI 10.1038/modpathol.2017.160; Pierson SK, 2018, AM J HEMATOL, V93, P902, DOI 10.1002/ajh.25123; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002; Yoshimi A, 2016, ANN ONCOL, V27, P887, DOI 10.1093/annonc/mdw066; Yoshimi A, 2019, NATURE, V574, P273, DOI 10.1038/s41586-019-1618-0; Yoshimi A, 2011, BLOOD, V117, P3617, DOI 10.1182/blood-2009-12-261602	21	9	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3218	3225		10.1038/s41388-020-1204-9	http://dx.doi.org/10.1038/s41388-020-1204-9		FEB 2020	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32051554	Green Accepted			2022-12-17	WOS:000513108500001
J	Dong, KS; Chen, Y; Yang, G; Liao, ZB; Zhang, HW; Liang, HF; Chen, XP; Dong, HH				Dong, Ke-shuai; Chen, Yan; Yang, Guang; Liao, Zhi-bin; Zhang, Hong-wei; Liang, Hui-fang; Chen, Xiao-ping; Dong, Han-hua			TGF-beta 1 accelerates the hepatitis B virus X-induced malignant transformation of hepatic progenitor cells by upregulating miR-199a-3p	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; CANCER STEM-CELLS; TUMOR-INITIATING CELLS; HEPATOCELLULAR-CARCINOMA; TGF-BETA; HUMAN LIVER; ACTIVATION; MECHANISMS; MICRORNA; IDENTIFICATION	Increasing evidence has suggested that liver cancer arises partially from transformed hepatic progenitor cells (HPCs). However, the detailed mechanisms underlying HPC transformation are poorly understood. In this study, we provide evidence linking the coexistence of hepatitis B virus X protein (HBx) and transforming growth factor beta 1 (TGF-beta 1) with miR-199a-3p in the malignant transformation of HPCs. The examination of liver cancer specimens demonstrated that HBx and TGF-beta 1 expression was positively correlated with epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 90 (CD90). Importantly, EpCAM and CD90 expression was much higher in the specimens expressing both high HBx and high TGF-beta 1 than in those with high HBx or high TGF-beta 1 and the double-low-expression group. HBx and TGF-beta 1 double-high expression was significantly associated with poor prognosis in primary liver cancer. We also found that HBx and TGF-beta 1 induced the transformation of HPCs into hepatic cancer stem cells and promoted epithelial-mesenchymal transformation, which was further enhanced by concomitant HBx and TGF-beta 1 exposure. Moreover, activation of the c-Jun N-terminal kinase (JNK)/c-Jun pathway was involved in the malignant transformation of HPCs. miR-199a-3p was identified as a significantly upregulated microRNA in HPCs upon HBx and TGF-beta 1 exposure, which were shown to promote miR-199a-3p expression via c-Jun-mediated activation. Finally, we found that miR-199a-3p was responsible for the malignant transformation of HPCs. In conclusion, our results provide evidence that TGF-beta 1 cooperates with HBx to promote the malignant transformation of HPCs through a JNK/c-Jun/miR-199a-3p-dependent pathway. This may open new avenues for therapeutic interventions targeting the malignant transformation of HPCs in treating liver cancer.	[Dong, Ke-shuai; Yang, Guang; Liao, Zhi-bin; Zhang, Hong-wei; Liang, Hui-fang; Chen, Xiao-ping; Dong, Han-hua] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr,Dept Hepat Surg, Wuhan, Peoples R China; [Dong, Ke-shuai] Wuhan Univ, Renmin Hosp, Dept Hepatobiliary & Laparoscop Surg, Hubei Key Lab Digest Syst Dis, Wuhan, Peoples R China; [Chen, Yan] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gen Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Wuhan University; Huazhong University of Science & Technology	Dong, HH (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr,Dept Hepat Surg, Wuhan, Peoples R China.	hanhua_dong@hotmail.com		Liao, Zhibin/0000-0003-0305-2079	National Natural Science Foundation of China [81402410, 81802767]; Edanz Group China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Edanz Group China	This work was supported by the National Natural Science Foundation of China (Grant No. 81402410, 81802767). We thank Sarah Williams, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn), for editing the English text of a draft of this manuscript.	Alemdehy MF, 2015, BLOOD, V125, P3937, DOI 10.1182/blood-2014-11-612507; Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Arzumanyan A, 2011, CANCER RES, V71, P3701, DOI 10.1158/0008-5472.CAN-10-3951; Celia-Terrassa T, 2017, NAT CELL BIOL, V19, P711, DOI 10.1038/ncb3533; Chen J, 2016, J CLIN INVEST, V126, P527, DOI 10.1172/JCI80937; Deng XG, 2014, LIVER INT, V34, P281, DOI 10.1111/liv.12239; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Gao Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11365; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Henkler F, 1996, J VIRAL HEPATITIS, V3, P109, DOI 10.1111/j.1365-2893.1996.tb00001.x; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Jung KH, 2016, STEM CELLS, V34, P1284, DOI 10.1002/stem.2283; Kuo KK, 2016, STEM CELLS, V34, P2613, DOI 10.1002/stem.2447; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li CH, 2011, CANCER LETT, V311, P1, DOI 10.1016/j.canlet.2011.05.035; Liu FY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.46; Liu JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076651; Liu Y, 2016, ONCOTARGET, V7, P33125, DOI 10.18632/oncotarget.8884; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Ma S, 2010, CELL STEM CELL, V7, P694, DOI 10.1016/j.stem.2010.11.010; Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matsumoto T, 2017, CANCER RES, V77, P6131, DOI 10.1158/0008-5472.CAN-17-1800; Michalopoulos GK, 2015, GASTROENTEROLOGY, V149, P876, DOI 10.1053/j.gastro.2015.08.004; Mikhail S, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/486954; Mishra L, 2005, SCIENCE, V310, P68, DOI 10.1126/science.1118389; Motavaf M, 2013, ACTA VIROL, V57, P389, DOI 10.4149/av_2013_04_389; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Oikawa T, 2016, HEPATOLOGY, V64, P645, DOI 10.1002/hep.28485; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Sia D, 2017, GASTROENTEROLOGY, V152, P745, DOI 10.1053/j.gastro.2016.11.048; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Singh M, 2018, PHARMACOL THERAPEUT, V182, P80, DOI 10.1016/j.pharmthera.2017.08.009; Song WQ, 2014, CANCER RES, V74, P2444, DOI 10.1158/0008-5472.CAN-13-2136; Tanaka Y, 2006, ONCOGENE, V25, P633, DOI 10.1038/sj.onc.1209093; Teng CF, 2018, MOL ONCOL, V12, P1175, DOI 10.1002/1878-0261.12318; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tummala KS, 2017, CELL REP, V19, P584, DOI 10.1016/j.celrep.2017.03.059; Wang C, 2012, HEPATOLOGY, V55, P108, DOI 10.1002/hep.24675; Weng HL, 2009, HEPATOLOGY, V50, P230, DOI 10.1002/hep.22934; Wu K, 2012, HEPATOLOGY, V56, P2255, DOI 10.1002/hep.26007; Wu QH, 2019, MED RES REV, V39, P2082, DOI 10.1002/med.21574; Wu Y, 2018, BIOCHIMIE, V148, P87, DOI 10.1016/j.biochi.2018.03.003; Xie X, 2017, ONCOGENE, V36, P2599, DOI 10.1038/onc.2016.417; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zhou SJ, 2017, CELL DEATH DIFFER, V24, P1577, DOI 10.1038/cdd.2017.87	58	9	10	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1807	1820		10.1038/s41388-019-1107-9	http://dx.doi.org/10.1038/s41388-019-1107-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740785	hybrid, Green Published			2022-12-17	WOS:000514923000014
J	Guan, CJ; He, L; Chang, ZY; Gu, XJ; Liang, J; Liu, R				Guan, Chengjian; He, Lin; Chang, Zhenyu; Gu, Xinjin; Liang, Jing; Liu, Rong			ZNF774 is a potent suppressor of hepatocarcinogenesis through dampening the NOTCH2 signaling	ONCOGENE			English	Article							BILE-DUCT DEVELOPMENT; HEPATOCELLULAR-CARCINOMA; GAMMA-SECRETASE; CANCER; CELLS; INACTIVATION; INHIBITORS; PATHWAY; GROWTH; EMT	Discerning oncogenic drivers from passengers remain a major effort in understanding of the essence of the initiation and development of hepatocellular carcinoma (HCC), which is the most common primary liver malignancy and the third leading cause of cancer mortality worldwide. Here we report that ZNF774, a novel zinc-finger protein, inhibits the proliferation and invasion of HCC cells. Molecular characterization of this protein indicated that ZNF774 acts as a transcription repressor, and interrogation of ZNF774 interactome by affinity purification-coupled mass spectrometry revealed that ZNF774 is physically associated with the Mi-2/nucleosome remodeling and deacetylase (NuRD) complex in cells. Genome-wide identification of the transcriptional targets of the ZNF774/NuRD complex by ChIP-seq indicated that ZNF774 represses a cohort of genes including NOTCH2 that are critically involved in the growth and mobility of HCC. We demonstrated that the ZNF774/NuRD complex inhibits the proliferation and invasion of HCC cells in vitro and suppresses HCC growth and metastasis in vivo. Importantly, the expression of ZNF774 is significantly downregulated in HCC, and low ZNF774 expression strongly correlated with high NOTCH2 expression, advanced pathological stages, and poor overall survival of the patients. Together, these results uncover a key role for the ZNF774/NuRD-NOTCH2 axis in hepatocarcinogenesis.	[Guan, Chengjian] Capital Med Univ, Beijing Friendship Hosp, Gen Surg Dept, Beijing 100050, Peoples R China; [Guan, Chengjian; Chang, Zhenyu; Gu, Xinjin; Liu, Rong] Chinese Peoples Liberat Army, Med Sch, Beijing 100853, Peoples R China; [Guan, Chengjian; Chang, Zhenyu; Gu, Xinjin; Liu, Rong] Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary & Pancreat Surg Oncol, Beijing 100853, Peoples R China; [He, Lin; Liang, Jing] Peking Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hlth Sci Ctr,Minist Educ,Key Lab Carcinogenesis &, Beijing 100191, Peoples R China	Capital Medical University; Chinese People's Liberation Army General Hospital; Peking University	Liu, R (corresponding author), Chinese Peoples Liberat Army, Med Sch, Beijing 100853, Peoples R China.; Liu, R (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hepatobiliary & Pancreat Surg Oncol, Beijing 100853, Peoples R China.	liurong301@126.com			Capital Health Research and Special Development [2016-1-1111]; National Key Technologies RD Program [2015BAI13B09]; Beijing Municipal Administration of Hospitals Incubator Program [PX2016001, PX2019004]; Miaopu" Innovation Foundation of the Chinese PLA General Hospital [17KMM07]	Capital Health Research and Special Development; National Key Technologies RD Program(National Key Technology R&D Program); Beijing Municipal Administration of Hospitals Incubator Program; Miaopu" Innovation Foundation of the Chinese PLA General Hospital	This paper was supported by Capital Health Research and Special Development (No. 2016-1-1111), National Key Technologies R&D Program (No. 2015BAI13B09), Beijing Municipal Administration of Hospitals Incubator Program (No. PX2016001 and No. PX2019004) and "Miaopu" Innovation Foundation of the Chinese PLA General Hospital (No. 17KMM07).	Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Cai QY, 2014, NAT GENET, V46, P886, DOI 10.1038/ng.3041; Capra JA, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0025; Dill MT, 2013, HEPATOLOGY, V57, P1607, DOI 10.1002/hep.26165; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2; Gebelein B, 1998, J CLIN INVEST, V102, P1911, DOI 10.1172/JCI1919; Geisler F, 2008, HEPATOLOGY, V48, P607, DOI 10.1002/hep.22381; Geisler F, 2015, HEPATOLOGY, V61, P382, DOI 10.1002/hep.27268; Goriki A, 2018, NAT REV UROL, V15, P345, DOI 10.1038/s41585-018-0005-1; Hayashi T, 2016, CLIN CANCER RES, V22, P2981, DOI 10.1158/1078-0432.CCR-15-2360; He L, 2018, CELL RES, V28, P934, DOI 10.1038/s41422-018-0079-6; Hori K, 2013, J CELL SCI, V126, P2135, DOI 10.1242/jcs.127308; Hubmann R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00319; Huntzicker EG, 2015, HEPATOLOGY, V61, P942, DOI 10.1002/hep.27566; Jung KH, 2016, HEPATOLOGY, V63, P864, DOI 10.1002/hep.28367; Klinakis A, 2011, NATURE, V473, P230, DOI 10.1038/nature09999; KNIGHT RD, 2001, GENOME BIOL, V2; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Krushkal J, 1999, CIRCULATION, V99, P1407, DOI 10.1161/01.CIR.99.11.1407; Li WJ, 2017, J CLIN INVEST, V127, P3427, DOI 10.1172/JCI94233; Lorsch ZS, 2019, NAT NEUROSCI, V22, P1413, DOI 10.1038/s41593-019-0462-8; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; McCright B, 2001, DEVELOPMENT, V128, P491; Ong HT, 2013, J HEPATOL, V59, P999, DOI 10.1016/j.jhep.2013.07.010; Riccio O, 2008, EMBO REP, V9, P377, DOI 10.1038/embor.2008.7; Ringelhan M, 2018, NAT IMMUNOL, V19, P222, DOI 10.1038/s41590-018-0044-z; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Serra H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8935; Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958; Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011; Siebel C, 2017, PHYSIOL REV, V97, P1235, DOI 10.1152/physrev.00005.2017; Suzuki IK, 2018, CELL, V173, P1370, DOI 10.1016/j.cell.2018.03.067; Totaro A, 2018, TRENDS CELL BIOL, V28, P560, DOI 10.1016/j.tcb.2018.03.001; Totoki Y, 2014, NAT GENET, V46, P1267, DOI 10.1038/ng.3126; Urrutia R, 2003, GENOME BIOL, V4, DOI [10.1186/gb-2003-1184-1110-1231, DOI 10.1186/GB-2003-1184-1110-1231]; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wang JX, 2018, ONCOGENE, V37, P3229, DOI 10.1038/s41388-018-0188-1; Wu N, 2017, LAB INVEST, V97, P843, DOI 10.1038/labinvest.2017.29; Wu Y, 2010, NATURE, V464, P1052, DOI 10.1038/nature08878; Xiao W, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0507-3	45	9	9	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1665	1680		10.1038/s41388-019-1075-0	http://dx.doi.org/10.1038/s41388-019-1075-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31659254				2022-12-17	WOS:000514923000004
J	Loveridge, CJ; Slater, S; Campbell, KJ; Nam, NA; Knight, J; Ahmad, I; Hedley, A; Lilla, S; Repiscak, P; Patel, R; Salji, M; Fleming, J; Mitchell, L; Nixon, C; Strathdee, D; Neilson, M; Ntala, C; Bryson, S; Zanivan, S; Edwards, J; Robson, CN; Goodyear, CS; Blyth, K; Leung, HY				Loveridge, Carolyn J.; Slater, Sarah; Campbell, Kirsteen J.; Nam, Noor A.; Knight, John; Ahmad, Imran; Hedley, Ann; Lilla, Sergio; Repiscak, Peter; Patel, Rachana; Salji, Mark; Fleming, Janis; Mitchell, Louise; Nixon, Colin; Strathdee, Douglas; Neilson, Matthew; Ntala, Chara; Bryson, Sheila; Zanivan, Sara; Edwards, Joanne; Robson, Craig N.; Goodyear, Carl S.; Blyth, Karen; Leung, Hing Y.			BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration	ONCOGENE			English	Article							RNA-POLYMERASE III; MOUSE MODEL; CANCER; OVEREXPRESSION; COMPLEMENT	BRF1 is a rate-limiting factor for RNA Polymerase III-mediated transcription and is elevated in numerous cancers. Here, we report that elevated levels of BRF1 associate with poor prognosis in human prostate cancer. In vitro studies in human prostate cancer cell lines demonstrated that transient overexpression of BRF1 increased cell proliferation whereas the transient downregulation of BRF1 reduced proliferation and mediated cell cycle arrest. Consistent with our clinical observations, BRF1 overexpression in a Pten-deficient mouse (Pten(Delta/Delta)BRF1(Tg)) prostate cancer model accelerated prostate carcinogenesis and shortened survival. In Pten(Delta/Delta)BRF1(Tg) tumours, immune and inflammatory processes were altered, with reduced tumoral infiltration of neutrophils and CD4 positive T cells, which can be explained by decreased levels of complement factor D (CFD) and C7 components of the complement cascade, an innate immune pathway that influences the adaptive immune response. We tested if the secretome was involved in BRF1-driven tumorigenesis. Unbiased proteomic analysis on BRF1-overexpresing PC3 cells confirmed reduced levels of CFD in the secretome, implicating the complement system in prostate carcinogenesis. We further identify that expression of C7 significantly correlates with expression of CD4 and has the potential to alter clinical outcome in human prostate cancer, where low levels of C7 associate with poorer prognosis.	[Loveridge, Carolyn J.; Campbell, Kirsteen J.; Ahmad, Imran; Salji, Mark; Ntala, Chara; Zanivan, Sara; Edwards, Joanne; Leung, Hing Y.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland; [Loveridge, Carolyn J.; Slater, Sarah; Campbell, Kirsteen J.; Nam, Noor A.; Knight, John; Ahmad, Imran; Hedley, Ann; Lilla, Sergio; Repiscak, Peter; Patel, Rachana; Salji, Mark; Fleming, Janis; Mitchell, Louise; Nixon, Colin; Strathdee, Douglas; Neilson, Matthew; Ntala, Chara; Bryson, Sheila; Zanivan, Sara; Blyth, Karen; Leung, Hing Y.] CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland; [Robson, Craig N.] Newcastle Univ, Med Sch, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Goodyear, Carl S.] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland; [Nam, Noor A.] Univ Sains Islam Malaysia, Fac Dent, Dept Basic Sci & Oral Biol, Kuala Lumpur, Malaysia	University of Glasgow; Beatson Institute; Newcastle University - UK; University of Glasgow; Universiti Sains Islam Malaysia	Leung, HY (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Inst Canc Sci, Glasgow G61 1QH, Lanark, Scotland.; Leung, HY (corresponding author), CRUK Beatson Inst, Glasgow G61 1BD, Lanark, Scotland.	h.leung@beatson.gla.ac.uk	Edwards, Joanne/J-1903-2015; Zanivan, Sara/GOV-5505-2022; Knight, John/V-2922-2019; NAM, NOOR AKMAR/AAG-2571-2019	Edwards, Joanne/0000-0002-7192-6906; Knight, John/0000-0002-8771-5484; Ahmad, Imran/0000-0002-4404-1926; Zanivan, Sara/0000-0002-9880-9099; Loveridge, Carolyn/0000-0002-6237-8661; NAM, NOOR AKMAR/0000-0002-7703-2049; Campbell, Kirsteen/0000-0002-0201-8736; Repiscak, Peter/0000-0002-7335-8324	Cancer Research UK [A15151, A10419, A17196]; Prostate Cancer UK [PG10-10]; Medical Research Council Clinical Research Training Fellowship; Ministry of Higher Education, Malaysia; SLAI Fellowship from University of Malaya	Cancer Research UK(Cancer Research UK); Prostate Cancer UK; Medical Research Council Clinical Research Training Fellowship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Ministry of Higher Education, Malaysia(Ministry of Education, Malaysia); SLAI Fellowship from University of Malaya	This work was funded by Cancer Research UK (A15151, A10419 and A17196; HYL) and Prostate Cancer UK (PG10-10; HYL). SS's PhD was supported by Medical Research Council Clinical Research Training Fellowship. NAN's PhD was sponsored by Ministry of Higher Education, Malaysia and SLAI Fellowship from University of Malaya. We thank the Cancer Research UK Beatson Institute core research services, including the biological services unit and the histology department. We acknowledge Arnaud Blomme for helpful discussions and commenting on the manuscript. We are grateful to Bob White for involvement and useful discussions in the initial stage of this project, and to Owen Sansom for general support in the development of the BRF1 mouse model.	Afshar-Kharghan V, 2017, J CLIN INVEST, V127, P780, DOI 10.1172/JCI90962; Arthurs C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186047; Birch J, 2016, BIOL OPEN, V5, P1371, DOI 10.1242/bio.019075; Bryant G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071542; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Clarke CJ, 2016, CURR BIOL, V26, P755, DOI 10.1016/j.cub.2016.01.045; Fang Z, 2017, MOL ONCOL, V11, P1752, DOI 10.1002/1878-0261.12141; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Hernandez MDLL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00563; Gingold H, 2014, CELL, V158, P1281, DOI 10.1016/j.cell.2014.08.011; Goodfellow SJ, 2006, EMBO J, V25, P1522, DOI 10.1038/sj.emboj.7601040; Graczyk D, 2015, MOL CELL BIOL, V35, P1848, DOI 10.1128/MCB.00990-14; Kourtzelis I, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.26; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Liko D, 2019, CELL DEATH DIFFER, V26, P2535, DOI 10.1038/s41418-019-0316-7; Loveridge CJ, 2017, CANCER RES, V77, P3158, DOI 10.1158/0008-5472.CAN-16-2565; Moschini M, 2017, EUR UROL, V72, P238, DOI 10.1016/j.eururo.2017.03.009; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thakur Archana, 2013, Cancers (Basel), V5, P569, DOI 10.3390/cancers5020569; Uemura M, 2012, ONCOGENE, V31, P1254, DOI 10.1038/onc.2011.319; Wu XT, 2001, MECH DEVELOP, V101, P61, DOI 10.1016/S0925-4773(00)00551-7; Wurzner R, 2000, CLIN EXP IMMUNOL, V121, P8, DOI 10.1046/j.1365-2249.2000.01263.x; Zhang YY, 2018, AM J PATHOL, V188, P367, DOI 10.1016/j.ajpath.2017.10.010; Zhong Q, 2016, ONCOTARGET, V7, P6243, DOI 10.18632/oncotarget.6668	26	9	9	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	8					1797	1806		10.1038/s41388-019-1106-x	http://dx.doi.org/10.1038/s41388-019-1106-x			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN6CG	31740786	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000514923000013
J	Ricci, B; Millner, TO; Pomella, N; Zhang, XY; Guglielmi, L; Badodi, S; Ceric, D; Gemma, C; Cognolato, E; Zhang, Y; Brandner, S; Barnes, MR; Marino, S				Ricci, Barbara; Millner, Thomas O.; Pomella, Nicola; Zhang, Xinyu; Guglielmi, Loredana; Badodi, Sara; Ceric, Dario; Gemma, Carolina; Cognolato, Erica; Zhang, Ying; Brandner, Sebastian; Barnes, Michael R.; Marino, Silvia			Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma	ONCOGENE			English	Article							GENE-EXPRESSION; MESENCHYMAL TRANSFORMATION; MALIGNANT GLIOMA; SELF-RENEWAL; STEM-CELLS; BMI1; TUMOR; PROLIFERATION; MUTATIONS; NETWORK	Glioblastoma (GBM) is the most common and most aggressive intrinsic brain tumour in adults. Integrated transcriptomic and epigenomic analyses of glioblastoma initiating cells (GIC) in a mouse model uncovered a novel epigenetic regulation of EfnA5. In this model, Bmi1 enhances H3K27me3 at the EfnA5 locus and reinforces repression of selected target genes in a cellular context-dependent fashion. EfnA5 mediates Bmi1-dependent proliferation and invasion in vitro and tumour formation in an allograft model. Importantly, we show that this novel Polycomb feed-forward loop is also active in human GIC and we provide pre-clinical evidence of druggability of the EFNA5 signalling pathway in GBM xenografts overexpressing Bmi1.	[Ricci, Barbara; Millner, Thomas O.; Pomella, Nicola; Zhang, Xinyu; Guglielmi, Loredana; Badodi, Sara; Ceric, Dario; Cognolato, Erica; Marino, Silvia] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England; [Gemma, Carolina] Imperial Coll London, Dept Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England; [Zhang, Ying; Brandner, Sebastian] Univ Coll London Hosp NHS Fdn, Natl Hosp Neurol & Neurosurg, Div Neuropathol, Queen Sq, London WC1N 3BG, England; [Barnes, Michael R.] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, Ctr Translat Bioinformat, London EC1M 6BQ, England	University of London; Queen Mary University London; Imperial College London; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; Queen Mary University London	Marino, S (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, 4 Newark St, London E1 2AT, England.	s.marino@qmul.ac.uk	Badodi, Sara/GNH-3404-2022; Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Pomella, Nicola/0000-0003-0028-4878; Zhang, Ying/0000-0003-2194-7116; Marino, Silvia/0000-0002-9612-2883; Millner, Thomas/0000-0001-5638-3918; Badodi, Sara/0000-0002-8407-8336; Gemma, Carolina/0000-0002-4890-9972	MRC [1365533]; Brain Tumour Charity [BTC 8/128, GN-000389]; Barts Charity; Brain Tumour Research (Centre of Excellence award); UCL-ORS; UCLH; National Institute of Health Research; Medical Research Council [1365533] Funding Source: researchfish	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Brain Tumour Charity; Barts Charity; Brain Tumour Research (Centre of Excellence award); UCL-ORS; UCLH; National Institute of Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work is funded by grants from the MRC (1365533.studentship to BR), The Brain Tumour Charity (GN-000389 clinical research training fellowship to TM and BTC 8/128 to SB), Barts Charity (project and programme grants to SM) and Brain Tumour Research (Centre of Excellence award to SM); YZ was supported by a PhD Overseas research scholarship, UCL-ORS and UCLH Trustees. This research also forms a part of the research themes contributing to the translational research portfolio of Barts and the London Biomedical Research Centre, which is supported and funded by the National Institute of Health Research. LC-MS measurements of doxazosin were carried out by Dr Roberto Buccafusca, SBCS Mass Spectrometry Facility, QMUL. All xenograft tumour histology was performed by IQPath, UCLH, London.	Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Acquati S, 2013, STEM CELLS, V31, P190, DOI 10.1002/stem.1274; Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Blackledge NP, 2015, NAT REV MOL CELL BIO, V16, P643, DOI 10.1038/nrm4067; Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Burgold T, 2012, CELL REP, V2, P1244, DOI 10.1016/j.celrep.2012.09.013; Burgold T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003034; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Danussi C, 2013, CANCER RES, V73, P5140, DOI 10.1158/0008-5472.CAN-13-1168-T; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; Day BW, 2014, BRIT J CANCER, V111, P1255, DOI 10.1038/bjc.2014.73; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Ene CI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051407; Entrevan M, 2016, TRENDS CELL BIOL, V26, P511, DOI 10.1016/j.tcb.2016.04.009; Fasano CA, 2007, CELL STEM CELL, V1, P87, DOI 10.1016/j.stem.2007.04.001; Ferluga S, 2016, ONCOTARGET, V7, P59860, DOI 10.18632/oncotarget.10978; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gil J, 2014, TRENDS CELL BIOL, V24, P632, DOI 10.1016/j.tcb.2014.06.005; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Gucciardo E, 2014, CELL MOL LIFE SCI, V71, P3685, DOI 10.1007/s00018-014-1633-0; Hashizume R, 2014, NAT MED, V20, P1394, DOI 10.1038/nm.3716; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Henrich CJ, 2007, MOL CANCER THER, V6, P3271, DOI 10.1158/1535-7163.MCT-07-0352; Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107; Hu BL, 2016, CELL, V167, P1281, DOI 10.1016/j.cell.2016.10.039; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415; KAYE B, 1986, BRIT J CLIN PHARMACO, V21, pS19, DOI 10.1111/j.1365-2125.1986.tb02849.x; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kuang SQ, 2010, BLOOD, V115, P2412, DOI 10.1182/blood-2009-05-222208; Kyprianou N, 2000, CANCER RES, V60, P4550; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li JJ, 2009, ONCOGENE, V28, P1759, DOI 10.1038/onc.2009.15; Lin Fan, 2013, CNS Oncol, V2, P271, DOI 10.2217/cns.13.15; Lisabeth EM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009159; Mohammad F, 2017, NAT MED, V23, P483, DOI 10.1038/nm.4293; Morey L, 2013, CELL REP, V3, P60, DOI 10.1016/j.celrep.2012.11.026; Overman JJ, 2012, P NATL ACAD SCI USA, V109, pE2230, DOI 10.1073/pnas.1204386109; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Petty A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042120; Pollak J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172884; Rheinbay E, 2013, CELL REP, V3, P1567, DOI 10.1016/j.celrep.2013.04.021; Robey RW, 2003, BRIT J CANCER, V89, P1971, DOI 10.1038/sj.bjc.6601370; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Segerman A, 2016, CELL REP, V17, P2994, DOI 10.1016/j.celrep.2016.11.056; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Subkhankulova T, 2010, MOL CELL NEUROSCI, V45, P151, DOI 10.1016/j.mcn.2010.06.006; Testa G, 2011, BIOESSAYS, V33, P519, DOI 10.1002/bies.201100021; Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486; Tu YY, 2013, CANCER RES, V73, P6046, DOI 10.1158/0008-5472.CAN-13-0358; van den Boom V, 2016, CELL REP, V14, P332, DOI 10.1016/j.celrep.2015.12.034; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Voncken JW, 1999, J CELL SCI, V112, P4627; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Yadirgi G, 2011, STEM CELLS, V29, P700, DOI 10.1002/stem.614; Yan Y, 2015, FEBS LETT, V589, P756, DOI 10.1016/j.febslet.2015.02.005; Yu CH, 2009, DIGEST DIS SCI, V54, P2362, DOI 10.1007/s10620-008-0629-8; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329	66	9	10	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2523	2538		10.1038/s41388-020-1161-3	http://dx.doi.org/10.1038/s41388-020-1161-3		JAN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988455	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000509655100004
J	Esteves, P; Dard, L; Brillac, A; Hubert, C; Sarlak, S; Rousseau, B; Dumon, E; Izotte, J; Bonneu, M; Lacombe, D; Dupuy, JW; Amoedo, N; Rossignol, R				Esteves, Pauline; Dard, Laetitia; Brillac, Aurelia; Hubert, Christophe; Sarlak, Saharnaz; Rousseau, Benoit; Dumon, Elodie; Izotte, Julien; Bonneu, Marc; Lacombe, Didier; Dupuy, Jean-William; Amoedo, Nivea; Rossignol, Rodrigue			Nuclear control of lung cancer cells migration, invasion and bioenergetics by eukaryotic translation initiation factor 3F	ONCOGENE			English	Article							METASTASIS; HALLMARKS; INDUCTION; PHENOTYPE; APOPTOSIS; PATHWAY; GROWTH; STAT3	The basic understanding of the biological effects of eukaryotic translation initiation factors (EIFs) remains incomplete, notably for their roles independent of protein translation. Different EIFs exhibit nuclear localization and DNA-related functions have been proposed, but the understanding of EIFs novel functions beyond protein translation lacks of integrative analyses between the genomic and the proteomic levels. Here, the noncanonical function of EIF3F was studied in human lung adenocarcinoma by combining methods that revealed both the protein-protein and the protein-DNA interactions of this factor. We discovered that EIF3F promotes cell metastasis in vivo. The underpinning molecular mechanisms involved the regulation of a cluster of 34 metastasis-promoting genes including Snail2, as revealed by proteomics combined with immuno-affinity purification of EIF3F and ChIP-seq/Q-PCR analyses. The interaction between EIF3F and signal transducer and activator of transcription 3 (STAT3) controlled the EIF3F-mediated increase in Snail2 expression and cellular invasion, which were specifically abrogated using the STAT3 inhibitor Nifuroxazide or knockdown approaches. Furthermore, EIF3F overexpression reprogrammed energy metabolism through the activation of AMP-activated protein kinase and the stimulation of oxidative phosphorylation. Our findings demonstrate the role of EIF3F in the molecular control of cell migration, invasion, bioenergetics, and metastasis. The discovery of a role for EIF3F-STAT3 interaction in the genetic control of cell migration and metastasis in human lung adenocarcinoma could lead to the development of diagnosis and therapeutic strategies.	[Esteves, Pauline; Dard, Laetitia; Brillac, Aurelia; Hubert, Christophe; Sarlak, Saharnaz; Rousseau, Benoit; Dumon, Elodie; Izotte, Julien; Bonneu, Marc; Lacombe, Didier; Dupuy, Jean-William; Rossignol, Rodrigue] Bordeaux Univ, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Esteves, Pauline; Dard, Laetitia; Brillac, Aurelia; Hubert, Christophe; Sarlak, Saharnaz; Dumon, Elodie; Lacombe, Didier; Rossignol, Rodrigue] INSERM U1211, F-33000 Bordeaux, France; [Rousseau, Benoit; Izotte, Julien] Univ Bordeaux, Transgen Anim Facil A2, F-33000 Bordeaux, France; [Bonneu, Marc; Dupuy, Jean-William] Funct Genom Ctr CGFB, Prote Facil, 146 Rue Leo Saignat, F-33076 Bordeaux, France; [Bonneu, Marc] Bordeaux INP, Ave Fac, F-33405 Talence, France; [Amoedo, Nivea; Rossignol, Rodrigue] Funct Genom Ctr CGFB, CELLOMET, 146 Rue Leo Saignat, F-33000 Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Rossignol, R (corresponding author), Bordeaux Univ, 146 Rue Leo Saignat, F-33000 Bordeaux, France.; Rossignol, R (corresponding author), INSERM U1211, F-33000 Bordeaux, France.; Rossignol, R (corresponding author), Funct Genom Ctr CGFB, CELLOMET, 146 Rue Leo Saignat, F-33000 Bordeaux, France.	rodrigue.rossignol@u-bordeaux.fr	Dupuy, Jean-William JWD/F-5335-2012	Dupuy, Jean-William JWD/0000-0002-2448-4797; sarlak, saharnaz/0000-0001-6949-3753; Esteves, Pauline/0000-0002-4787-339X	French National Institute for Scientific and Medical Research (INSERM); Brazilian National Council for Scientific and Technological Development (CnPq); CAPES-COFECUB; Fondation ARC; French National Institute against Cancer (Inca); Ligue Regionale contre le cancer; Plan Cancer;  [H2020-MSCA-ITN-2016/722605]	French National Institute for Scientific and Medical Research (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Brazilian National Council for Scientific and Technological Development (CnPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); CAPES-COFECUB(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); Fondation ARC; French National Institute against Cancer (Inca); Ligue Regionale contre le cancer(Ligue nationale contre le cancer); Plan Cancer; 	This work was supported, in part, by the French National Institute for Scientific and Medical Research (INSERM), the Brazilian National Council for Scientific and Technological Development (CnPq), CAPES-COFECUB, Plan Cancer, Fondation ARC (N.A), French National Institute against Cancer (Inca), Ligue Regionale contre le cancer, and H2020-MSCA-ITN-2016/722605 - TRANSMIT (Translating the Role of Mitochondria in Tumorigenesis).	Aguilar E, 2016, STEM CELLS, V34, P1163, DOI 10.1002/stem.2286; Aitken CE, 2012, NAT STRUCT MOL BIOL, V19, P568, DOI 10.1038/nsmb.2303; Anjomshoaa A, 2009, BRIT J CANCER, V101, P822, DOI 10.1038/sj.bjc.6605229; Benard G, 2006, AM J PHYSIOL-CELL PH, V291, pC1172, DOI 10.1152/ajpcell.00195.2006; BERNDTSON WE, 1991, J ANIM SCI, V69, P67; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Chu J, 2016, TRENDS CELL BIOL, V26, P918, DOI 10.1016/j.tcb.2016.06.005; Deutsch EW, 2017, NUCLEIC ACIDS RES, V45, pD1100, DOI 10.1093/nar/gkw936; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019; Gao BC, 2015, BBA-GENE REGUL MECH, V1849, P753, DOI 10.1016/j.bbagrm.2014.11.006; Giese A, 1996, INT J CANCER, V67, P275, DOI 10.1002/(SICI)1097-0215(19960717)67:2<275::AID-IJC20>3.0.CO;2-9; Grossman RL, 2016, NEW ENGL J MED, V375, P1109, DOI 10.1056/NEJMp1607591; Han SY, 2018, INT J MOL MED, V42, P1644, DOI 10.3892/ijmm.2018.3733; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henriet E, 2017, HEPATOLOGY, V66, P2016, DOI 10.1002/hep.29336; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Higareda-Mendoza AE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-10; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Gutierrez-Fernandez MJ, 2015, BMC BIOCHEM, V16, DOI 10.1186/s12858-015-0054-5; Jia DY, 2017, PHYS BIOL, V14, DOI 10.1088/1478-3975/aa6f90; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kall L, 2007, NAT METHODS, V4, P923, DOI 10.1038/NMETH1113; Kathagen-Buhmann A, 2016, NEURO-ONCOLOGY, V18, P1219, DOI 10.1093/neuonc/now024; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Liu MH, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060822; Melser S, 2013, CELL METAB, V17, P719, DOI 10.1016/j.cmet.2013.03.014; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Moretti J, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000545; Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Perego M, 2018, ONCOGENE, V37, P302, DOI 10.1038/onc.2017.341; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rodrigues MF, 2016, BIOCHEM J, V473, P703, DOI 10.1042/BJ20150645; Rosland GV, 2019, CANCER METAB, V7, DOI 10.1186/s40170-019-0197-8; Shi J, 2006, ONCOGENE, V25, P4923, DOI 10.1038/sj.onc.1209495; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Sinnberg T, 2016, EBIOMEDICINE, V8, P132, DOI 10.1016/j.ebiom.2016.04.037; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15; Tamura T, 2015, MOL CLIN ONCOL, V3, P217, DOI 10.3892/mco.2014.410; Taylor CA, 2007, EXP CELL RES, V313, P437, DOI 10.1016/j.yexcr.2006.09.030; Vaklavas C, 2015, CANCER BIOL THER, V16, P1471, DOI 10.1080/15384047.2015.1071729; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Wen FS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034194; Williams D, 2019, CLIN EXP METASTAS, V36, P211, DOI 10.1007/s10585-019-09967-0; Wu KL, 2015, LUNG CANCER, V88, P187, DOI 10.1016/j.lungcan.2015.02.012; Zhu YX, 2016, SCI REP-UK, V6, DOI 10.1038/srep20253	51	9	9	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					617	636		10.1038/s41388-019-1009-x	http://dx.doi.org/10.1038/s41388-019-1009-x			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31527668	Green Published, hybrid			2022-12-17	WOS:000509718300010
J	Sava, GP; Fan, HL; Fisher, RA; Lusvarghi, S; Pancholi, S; Ambudkar, SV; Martin, LA; Coombes, RC; Buluwela, L; Ali, S				Sava, Georgina P.; Fan, Hailing; Fisher, Rosemary A.; Lusvarghi, Sabrina; Pancholi, Sunil; Ambudkar, Suresh, V; Martin, Lesley-Ann; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak			ABC-transporter upregulation mediates resistance to the CDK7 inhibitors THZ1 and ICEC0942	ONCOGENE			English	Article							DEPENDENT KINASE INHIBITOR; MESSENGER-RNA EXPRESSION; BREAST-CANCER; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; IN-VITRO; TRANSCRIPTIONAL ADDICTION; LUNG-CANCER; PROTEIN; GLYCOPROTEIN	The CDK7 inhibitors (CDK7i) ICEC0942 and THZ1, are promising new cancer therapeutics. Resistance to targeted drugs frequently compromises cancer treatment. We sought to identify mechanisms by which cancer cells may become resistant to CDK7i. Resistant lines were established through continuous drug selection. ABC-transporter copy number, expression and activity were examined using real-time PCR, immunoblotting and flow cytometry. Drug responses were measured using growth assays. ABCB1 was upregulated in ICEC0942-resistant cells and there was cross-resistance to THZ1. THZ1-resistant cells upregulated ABCG2 but remained sensitive to ICEC0942. Drug resistance in both cell lines was reversible upon inhibition of ABC-transporters. CDK7i response was altered in adriamycin- and mitoxantrone-resistant cell lines demonstrating ABC-transporter upregulation. ABCB1 expression correlated with ICEC0942 and THZ1 response, and ABCG2 expression with THZ2 response, in a panel of cancer cell lines. We have identified ABCB1 upregulation as a common mechanism of resistance to ICEC0942 and THZ1, and confirmed that ABCG2 upregulation is a mechanism of resistance to THZ1. The identification of potential mechanisms of CDK7i resistance and differences in susceptibility of ICEC0942 and THZ1 to ABC-transporters, may help guide their future clinical use.	[Sava, Georgina P.; Fan, Hailing; Fisher, Rosemary A.; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak] Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London, England; [Lusvarghi, Sabrina; Ambudkar, Suresh, V] NCI, Lab Cell Biol, Ctr Canc Res, Bethesda, MD 20892 USA; [Pancholi, Sunil; Martin, Lesley-Ann] Breast Canc Now Toby Robins Res Ctr, Inst Canc Res, London, England	Imperial College London; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus, London, England.	simak.ali@imperial.ac.uk	; Ali, Simak/M-6912-2018	Ambudkar, Suresh/0000-0002-2639-4955; Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816; Lusvarghi, Sabrina/0000-0003-1793-0450; Pancholi, Sunil/0000-0002-0880-1588; Fisher, Rosemary/0000-0002-2721-8726; Sava, Georgina/0000-0001-5904-3978	Cancer Research UK [C37/A18784]; Breast Cancer Now's Catalyst Programme - Pfizer	Cancer Research UK(Cancer Research UK); Breast Cancer Now's Catalyst Programme - Pfizer	This study was supported by Cancer Research UK grant C37/A18784. HF is funded by Breast Cancer Now's Catalyst Programme, which is supported by funding from Pfizer.	Ali S, 2009, CANCER RES, V69, P6208, DOI 10.1158/0008-5472.CAN-09-0301; Allen JD, 2002, MOL CANCER THER, V1, P417; Amiri-Kordestani L, 2012, DRUG RESIST UPDATE, V15, P50, DOI 10.1016/j.drup.2012.02.002; Bondke A, 2016, US patent, Patent No. [0362410 A1, 0362410]; Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013; Bugde P, 2017, EXPERT OPIN THER TAR, V21, P511, DOI 10.1080/14728222.2017.1310841; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Christensen CL, 2014, CANCER CELL, V26, P909, DOI 10.1016/j.ccell.2014.10.019; Christie EL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09312-9; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Clarke R, 2005, SEMIN ONCOL, V32, pS9, DOI 10.1053/j.seminoncol.2005.09.009; CORNWELL MM, 1987, J BIOL CHEM, V262, P2166; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Durbin AD, 2018, NAT GENET, V50, P1240, DOI 10.1038/s41588-018-0191-z; Eliades P, 2018, J INVEST DERMATOL, V138, P1582, DOI 10.1016/j.jid.2017.09.056; Fisher RP, 2005, J CELL SCI, V118, P5171, DOI 10.1242/jcs.02718; Gao Y, 2018, CELL CHEM BIOL, V25, P135, DOI 10.1016/j.chembiol.2017.11.007; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Hu SH, 2019, CANCER RES, V79, P3479, DOI 10.1158/0008-5472.CAN-19-0119; Huff LM, 2005, CANCER RES, V65, P11694; Iniguez AB, 2018, CANCER CELL, V33, P202, DOI 10.1016/j.ccell.2017.12.009; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jiang YY, 2017, GUT, V66, P1358, DOI 10.1136/gutjnl-2016-311818; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kaliszczak M, 2013, BRIT J CANCER, V109, P2356, DOI 10.1038/bjc.2013.584; Katayama R, 2016, EBIOMEDICINE, V3, P54, DOI 10.1016/j.ebiom.2015.12.009; Kim Yeo-Kyeoung, 2014, Chonnam Med J, V50, P102, DOI 10.4068/cmj.2014.50.3.102; Kim YH, 2009, LUNG CANCER, V65, P105, DOI 10.1016/j.lungcan.2008.10.008; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041; Martin C, 1999, BRIT J PHARMACOL, V128, P403, DOI 10.1038/sj.bjp.0702807; McDermott M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00040; Mistry P, 2001, CANCER RES, V61, P749; NAKAGAWA M, 1992, CANCER RES, V52, P6175; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Patel H, 2018, MOL CANCER THER, V17, P1156, DOI 10.1158/1535-7163.MCT-16-0847; Pick A, 2010, CHEMMEDCHEM, V5, P1498, DOI 10.1002/cmdc.201000216; Robey RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/s41568-018-0005-8; Robinson AN, 2019, DRUG METAB DISPOS, V47, P715, DOI 10.1124/dmd.118.086181; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Roschke AV, 2003, CANCER RES, V63, P8634; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; Sadik H, 2016, CANCER RES, V76, P4443, DOI 10.1158/0008-5472.CAN-16-0774; Schachter MM, 2013, CELL CYCLE, V12, P3239, DOI 10.4161/cc.26355; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Shiozawa K, 2004, INT J CANCER, V108, P146, DOI 10.1002/ijc.11528; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Skuta C, 2017, NAT METHODS, V14, P758, DOI 10.1038/nmeth.4365; Szafraniec MJ, 2014, DRUG METAB REV, V46, P459, DOI 10.3109/03602532.2014.942037; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; UEDA K, 1986, BIOCHEM BIOPH RES CO, V141, P956, DOI 10.1016/S0006-291X(86)80136-X; Uggla B, 2005, LEUKEMIA RES, V29, P141, DOI 10.1016/j.leukres.2004.06.004; Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063	57	9	10	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					651	663		10.1038/s41388-019-1008-y	http://dx.doi.org/10.1038/s41388-019-1008-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31530935	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000509718300012
J	Wegert, J; Zauter, L; Appenzeller, S; Otto, C; Bausenwein, S; Vokuhl, C; Ernestus, K; Furtwangler, R; Graf, N; Gessler, M				Wegert, Jenny; Zauter, Lisa; Appenzeller, Silke; Otto, Christoph; Bausenwein, Sabrina; Vokuhl, Christian; Ernestus, Karen; Furtwaengler, Rhoikos; Graf, Norbert; Gessler, Manfred			High-risk blastemal Wilms tumor can be modeled by 3D spheroid cultures in vitro	ONCOGENE			English	Article							STEM-CELLS; MUTATIONS; CANCER; PROGENITORS; MARKERS; KIDNEY; GENES; MOUSE; LINE	In vitro models represent a critical tool in cancer research to study tumor biology and to evaluate new treatment options. Unfortunately, there are no effective preclinical models available that represent Wilms tumor (WT) - the most common pediatric renal tumor. Especially the high-risk blastemal WT subtype is not represented by the few primary cell lines established until now. Here, we describe a new 3D approach for in vitro cultivation of blastemal WT cells, where primary cultures grown in suspension as spheroids could be propagated long-term. Besides blastemal cultures, we could generate spheroids representing epithelial and stromal WT. Spheroid cultures were analyzed by immunohistochemistry in comparison to corresponding tumor sections and were further characterized by RNA sequencing. Histological appearance of spheroids resembled the original tumor and they expressed marker genes characteristic of early renal development and blastemal WT elements. The cultures were amenable to genetic manipulation and they formed xenograft tumors, which resemble the primary human tumor. This collection of WT spheroids that carry different genetic drivers forms a long-sought tool for drug testing and in vitro modeling.	[Wegert, Jenny; Zauter, Lisa; Bausenwein, Sabrina; Gessler, Manfred] Univ Wurzburg, Theodor Boveri Inst, Dev Biochem, Bioctr, Wurzburg, Germany; [Appenzeller, Silke; Gessler, Manfred] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany; [Otto, Christoph] Univ Hosp Wuerzburg, Dept Gen Visceral Vasc & Pediat Surg, Expt Surg, Wurzburg, Germany; [Vokuhl, Christian] Univ Hosp Kiel, Dept Pathol, Sect Pediat Pathol, Kiel Pediat Tumor Registry, Kiel, Germany; [Ernestus, Karen] Univ Wurzburg, Inst Pathol, Wurzburg, Germany; [Furtwaengler, Rhoikos; Graf, Norbert] Saarland Univ, Childrens Hosp, Pediat Oncol & Hematol, Homburg, Germany; [Furtwaengler, Rhoikos; Graf, Norbert] Saarland Univ, Med Ctr, Homburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Kiel; Schleswig Holstein University Hospital; University of Wurzburg; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Gessler, M (corresponding author), Univ Wurzburg, Theodor Boveri Inst, Dev Biochem, Bioctr, Wurzburg, Germany.; Gessler, M (corresponding author), Univ Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.	gessler@biozentrum.uni-wuerzburg.de	Furtwängler, Rhoikos/V-3519-2018; Vokuhl, Christian/M-1511-2017; Graf, Norbert/H-1328-2011	Furtwängler, Rhoikos/0000-0002-1967-8343; Graf, Norbert/0000-0002-2248-323X; Appenzeller, Silke/0000-0002-5472-8692; Gessler, Manfred/0000-0002-7915-6045	Deutsche Forschungsgemeinschaft [DFG Ge539/13]; Wilhelm-Sander-Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm-Sander-Stiftung	We thank patients for participating in our research and the members of the GPOH WT study group for their efforts in collecting precious samples and data. This study was supported by the Deutsche Forschungsgemeinschaft (DFG Ge539/13) and the Wilhelm-Sander-Stiftung.	Alami J, 2003, INT J CANCER, V107, P365, DOI 10.1002/ijc.11429; Bhakta N, 2017, LANCET, V390, P2569, DOI 10.1016/S0140-6736(17)31610-0; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Chagtai T, 2016, J CLIN ONCOL, V34, P3195, DOI 10.1200/JCO.2015.66.0001; Dome JS, 2015, J CLIN ONCOL, V33, P2999, DOI 10.1200/JCO.2015.62.1888; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Faussilion M, 2008, CANCER GENET CYTOGEN, V184, P22, DOI 10.1016/j.cancergencyto.2008.02.018; Gadd S, 2017, NAT GENET, V49, P1487, DOI 10.1038/ng.3940; GARVIN AJ, 1987, AM J PATHOL, V129, P353; Hochane M, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000152; Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078; Hu QH, 2011, J CLIN INVEST, V121, P174, DOI 10.1172/JCI43772; Huff V, 2011, NAT REV CANCER, V11, P111, DOI 10.1038/nrc3002; Kumar SV, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.172361; Li ZW, 2016, CELL STEM CELL, V19, P516, DOI 10.1016/j.stem.2016.07.016; Lindstrom NO, 2018, DEV CELL, V45, P651, DOI 10.1016/j.devcel.2018.05.010; Magella B, 2018, DEV BIOL, V434, P36, DOI 10.1016/j.ydbio.2017.11.006; Pode-Shakked N, 2013, EMBO MOL MED, V5, P18, DOI 10.1002/emmm.201201516; Royer-Pokora B, 2010, HUM MOL GENET, V19, P1651, DOI 10.1093/hmg/ddq042; Sachs N, 2014, CURR OPIN GENET DEV, V24, P68, DOI 10.1016/j.gde.2013.11.012; Sadak KT, 2013, NAT REV UROL, V10, P15, DOI 10.1038/nrurol.2012.218; Schutgens F, 2019, NAT BIOTECHNOL, V37, P303, DOI 10.1038/s41587-019-0048-8; Shukrun R, 2014, STEM CELL REP, V3, DOI 10.1016/j.stemcr.2014.05.013; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Urbach A, 2014, GENE DEV, V28, P971, DOI 10.1101/gad.237149.113; Vujanic GM, 2018, NAT REV UROL, V15, P693, DOI 10.1038/s41585-018-0100-3; Walz AL, 2015, CANCER CELL, V27, P286, DOI 10.1016/j.ccell.2015.01.003; Wegert J, 2015, CANCER CELL, V27, P298, DOI 10.1016/j.ccell.2015.01.002; Wegert J, 2012, GENE CHROMOSOME CANC, V51, P92, DOI 10.1002/gcc.20936; Wittmann S, 2008, GENE CHROMOSOME CANC, V47, P386, DOI 10.1002/gcc.20544; Zweigerdt R, 2003, CYTOTHERAPY, V5, P399, DOI 10.1080/14653240310003062	31	9	10	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					849	861		10.1038/s41388-019-1027-8	http://dx.doi.org/10.1038/s41388-019-1027-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31562394	hybrid, Green Published			2022-12-17	WOS:000509197200008
J	Xu, BS; Chen, HY; Que, Y; Xiao, W; Zeng, MS; Zhang, X				Xu, Bu-Shu; Chen, Huo-Ying; Que, Yi; Xiao, Wei; Zeng, Mu-Sheng; Zhang, Xing			ALK(ATI) interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma	ONCOGENE			English	Article							CASSETTE TRANSPORTER GENES; SOFT-TISSUE SARCOMAS; LUNG-CANCER; ALK; EXPRESSION; PHENOTYPE; MUTATIONS; RECEPTOR; PATHWAY; TUMORS	Soft tissue sarcoma (STS) is a highly malignant tumor with limited targeted therapies. A novel anaplastic lymphoma kinase (ALK) transcript, ALK(ATI), was identified recently and could be targeted by ALK inhibitors in melanoma. However, the clinical and functional role of aberrant ALK(ATI) expression in STS remains unknown. Here we demonstrate that as a new ALK transcript, ALK(ATI) is frequently found in STS. ALK(ATI) expression correlates with a lower probability of progression-free survival in STS patients. Compared with the other ALK isoforms, ALK(ATI) expresses not only in the cytoplasm, but also in the nucleus of sarcoma cells. Functionally, overexpression of ALK(ATI) promoted cancer stem cell (CSC)-like properties in sarcoma cells by promoting sphere formation and upregulating the expression of stem cell markers. Moreover, the ALK inhibitors not only suppressed the oncogenic functions of ALK(ATI) but also attenuated ALK(ATI)-induced CSC-like properties by reducing the expression of stem cell markers such as c-Myc, ABCG2, BMI1, and OCT4 both in vitro and in vivo. Furthermore, ALK(ATI) interacted with c-Myc and increased the binding of c-Myc to the ABCG2 promoter, resulting in the induction of stem cell-like properties. Together, these findings indicate that ALK(ATI) may be a potential prognostic marker and therapeutic target for STS patients harboring such ALK aberrations.	[Xu, Bu-Shu; Chen, Huo-Ying; Que, Yi; Xiao, Wei; Zhang, Xing] Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China; [Chen, Huo-Ying] Guilin Med Univ, Affiliated Hosp 2, Dept Lab Med, Guilin 541100, Peoples R China; [Zeng, Mu-Sheng] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Guilin Medical University; State Key Lab Oncology South China; Sun Yat Sen University	Zhang, X (corresponding author), Sun Yat Sen Univ, Melanoma & Sarcoma Med Oncol Unit, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med,Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Peoples R China.	zhangxing@sysucc.org.cn		zeng, musheng/0000-0003-3509-5591	National Key Research and Development Program [2017YFA0505600]; National Natural Science Foundation of China Programs [81772863, 81572403]	National Key Research and Development Program; National Natural Science Foundation of China Programs(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key Research and Development Program (2017YFA0505600) and the National Natural Science Foundation of China Programs (Grant Nos 81772863 and 81572403). We thank Dr Deng Xianming (Principal Investigator for Chemical Biology and Medicinal Chemistry School of Life Sciences, Xiamen University, China) for generously providing the plasmids.	[Anonymous], 2013, FDA APPR PAZ HYDR; [Anonymous], 2016, FDA APPR 1 DRUG SHOW; Armstrong F, 2007, EUR J CANCER, V43, P640, DOI 10.1016/j.ejca.2006.12.005; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Bonvini P, 2013, BRIT J CANCER, V109, P3084, DOI 10.1038/bjc.2013.653; Brown HK, 2017, CANCER LETT, V386, P189, DOI 10.1016/j.canlet.2016.11.019; Busam KJ, 2016, AM J SURG PATHOL, V40, P786, DOI 10.1097/PAS.0000000000000611; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dandawate PR, 2016, SEMIN CANCER BIOL, V40-41, P192, DOI 10.1016/j.semcancer.2016.09.001; Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x; FDA, 2015, LAB CHANG REQ SOFT T; FDA, 2016, FDA GRANTS ACC APPR; Feng BH, 2013, ONCOL REP, V30, P815, DOI 10.3892/or.2013.2486; Fujiwara T, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2603092; Grande E, 2011, MOL CANCER THER, V10, P569, DOI 10.1158/1535-7163.MCT-10-0615; Gravina GL, 2016, RADIAT RES, V185, P411, DOI 10.1667/RR14237.1; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Huang FF, 2013, CANCER LETT, V336, P96, DOI 10.1016/j.canlet.2013.04.006; Ishibashi Y, 2015, ONCOL REP, V33, P1667, DOI 10.3892/or.2015.3806; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jiang Q, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0647-8; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kimbara S, 2014, JPN J CLIN ONCOL, V44, P868, DOI 10.1093/jjco/hyu069; Kuo CY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0317-9; Lee JC, 2017, J PATHOL, V241, P316, DOI 10.1002/path.4836; Lewis JJ, 1997, J CLIN ONCOL, V15, P646, DOI 10.1200/JCO.1997.15.2.646; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Mansfield AS, 2016, ANN ONCOL, V27, P2111, DOI 10.1093/annonc/mdw405; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; Porro A, 2011, MOL CANCER RES, V9, P1054, DOI 10.1158/1541-7786.MCR-10-0510; Porro A, 2010, J BIOL CHEM, V285, P19532, DOI 10.1074/jbc.M109.078584; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Schulte JH, 2011, CLIN CANCER RES, V17, P5082, DOI 10.1158/1078-0432.CCR-10-2809; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Sheng JY, 2016, SURG CLIN N AM, V96, P1141, DOI 10.1016/j.suc.2016.06.006; Subbiah V, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0160-2; Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063; Toro JR, 2006, INT J CANCER, V119, P2922, DOI 10.1002/ijc.22239; Van Roosbroeck K, 2010, HAEMATOL-HEMATOL J, V95, P509, DOI 10.3324/haematol.2009.014761; Wang YW, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0307-y; Wiesner T, 2015, NATURE, V526, P453, DOI 10.1038/nature15258; Xia P, 2015, AM J CANCER RES, V5, P1602; Xie XK, 2013, MOL MED REP, V8, P168, DOI 10.3892/mmr.2013.1484; Zhou JX, 2013, ANN ONCOL, V24, P1319, DOI 10.1093/annonc/mds626	44	9	9	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					151	163		10.1038/s41388-019-0973-5	http://dx.doi.org/10.1038/s41388-019-0973-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462708				2022-12-17	WOS:000509849200010
J	Koh, XY; Koh, XH; Hwang, LA; Ferrer, FJ; Rahmat, SAB; Lama, D; Lane, DP				Koh, Xin Yu; Koh, Xiao Hui; Hwang, Le-ann; Ferrer, Fernando Jose; Rahmat, Siti Aishah Binte; Lama, Dilraj; Lane, David P.			Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase	ONCOGENE			English	Article							MACROPHAGE-STIMULATING PROTEIN; N-LINKED GLYCOSYLATION; C-MET; MONOCLONAL-ANTIBODY; CANCER-CELLS; GROWTH; PATHOGENESIS; ACTIVATION; PHENOTYPES; HALLMARKS	Recepteur d'origine nantais (RON) receptor tyrosine kinase (RTK) and its ligand, serum macrophage-stimulating protein (MSP), are well-established oncogenic drivers for tumorigenesis and metastasis. RON is often found to be alternatively spliced resulting in various isoforms that are constitutively active. RON is therefore an attractive target for cancer therapeutics, including small molecular inhibitors and monoclonal antibodies. While small molecule inhibitors of RON may inhibit other protein kinases including the highly similar MET kinase, monoclonal antibodies targeting RON are more specific, potentially inducing fewer side effects. Although anti-RON monoclonal antibody therapies have been developed and tested in clinical trials, they were met with limited success. Cancer cells have been associated with aberrant glycosylation mechanisms. Notably for RON, the loss of N-bisected glycosylation is a direct cause for tumorigenesis and poorer prognosis in cancer patients. Particularly in gastric cancer, aberrant RON glycosylation augments RON activation. Here, we present a novel panel of monoclonal antibodies which potentially widens the specific targeting of not only the glycosylated RON, but also unglycosylated and aberrantly glycosylated RON. Our antibodies can bind strongly to deglycosylated RON from tunicamycin treated cells, recognise RON in IHC/IF and possess superior therapeutic efficacy in RON expressing xenograft tumours. Our most potent antibody in xenograft assays, is directed to the RON alpha chain and targets a sulfhydryl bond constrained epitope that appears to be cryptic in the crystal structure. This establishes the paradigm that such constrained and cryptic epitopes represent good targets for therapeutic antibodies.	[Koh, Xin Yu; Koh, Xiao Hui; Hwang, Le-ann; Ferrer, Fernando Jose; Rahmat, Siti Aishah Binte; Lane, David P.] ASTAR, P53 Lab, Singapore, Singapore; [Lama, Dilraj] ASTAR, Bioinformat Inst, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII)	Lane, DP (corresponding author), ASTAR, P53 Lab, Singapore, Singapore.	dplane@p53Lab.a-star.edu.sg	Lama, Dilraj/ABG-9950-2020	Lama, Dilraj/0000-0001-8603-9368; Lane, David/0000-0003-0551-3545	A*STAR	A*STAR(Agency for Science Technology & Research (A*STAR))	This work was supported by A*STAR.	Andrade K, 2017, SCI TRANSL MED, V9, P1, DOI 10.1126/scitranslmed.aai9338; Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; Beers SA, 2016, BLOOD, V127, P1097, DOI 10.1182/blood-2015-09-625343; Benham AM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012872; Benz I, 2002, MOL MICROBIOL, V45, P267, DOI 10.1046/j.1365-2958.2002.03030.x; Case VB DA, 2014, AMBER 14; Catenacci DVT, 2011, CANCER BIOL THER, V12, P9, DOI 10.4161/cbt.12.1.15747; Cazet A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2577; Chakedis J, 2016, ONCOTARGET, V7, P45959, DOI 10.18632/oncotarget.10009; Chang K, 2015, ONCOTARGET, V6, P3507, DOI 10.18632/oncotarget.3420; Chao KLL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041912; Chen JF, 2017, ONCOL REP, V37, P721, DOI 10.3892/or.2017.5356; de-Freitas JCM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091921; Dussault I, 2009, ANTI-CANCER AGENT ME, V9, P221, DOI 10.2174/187152009787313792; Ellis CR, 2012, J AM CHEM SOC, V134, P8184, DOI 10.1021/ja301005f; Ferreira IG, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020580; Gomes C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066737; Gorlatova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027269; Greenbaum A, 2016, HELIYON, V2, DOI 10.1016/j.heliyon.2016.e00153; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haynes PA, 1998, GLYCOBIOLOGY, V8, P1, DOI 10.1093/glycob/8.1.1; Ho WL, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0334-6; Itkonen HM, 2015, METHODS MOL BIOL, V1233, P103, DOI 10.1007/978-1-4939-1789-1_10; Johns TG, 2004, J BIOL CHEM, V279, P30375, DOI 10.1074/jbc.M401218200; Kang JG, 2011, BMB REP, V44, P765, DOI 10.5483/BMBRep.2011.44.12.765; Kaszuba K, 2015, P NATL ACAD SCI USA, V112, P4334, DOI 10.1073/pnas.1503262112; Krishnaswamy S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3747-x; Lama D, 2013, SCI REP-UK, V3, DOI 10.1038/srep03451; Ling Y, 2017, ONCOTARGET, V8, P39101, DOI 10.18632/oncotarget.16603; LoRusso PM, 2017, INVEST NEW DRUG, V35, P442, DOI 10.1007/s10637-016-0413-0; Mereiter S, 2016, BBA-GEN SUBJECTS, V1860, P1795, DOI 10.1016/j.bbagen.2015.12.016; Meyer SE, 2009, DEV BIOL, V333, P173, DOI 10.1016/j.ydbio.2009.06.028; Morrison AC, 2004, J IMMUNOL, V172, P1825, DOI 10.4049/jimmunol.172.3.1825; Munkley J, 2016, ONCOTARGET, V7, P35478, DOI 10.18632/oncotarget.8155; Phuc Vinh Nguyen Lam, 2013, Genomics Proteomics & Bioinformatics, V11, P96, DOI 10.1016/j.gpb.2012.11.003; RONSIN C, 1993, ONCOGENE, V8, P1195; Sarabipour S, 2013, BIOPHYS J, V105, P165, DOI 10.1016/j.bpj.2013.05.053; Very N, 2018, ONCOTARGET, V9, P1380, DOI 10.18632/oncotarget.22377; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Wang MH, 2007, J PATHOL, V213, P402, DOI 10.1002/path.2245; Wang MH, 2013, J BIOMED RES, V27, P345, DOI 10.7555/JBR.27.20130038; Wong CH, 2005, J ORG CHEM, V70, P4219, DOI 10.1021/jo050278f; Wong JS, 2013, ONCOTARGET, V4, P1019, DOI 10.18632/oncotarget.1075; Yao HP, 2013, NAT REV CANCER, V13, P466, DOI 10.1038/nrc3545; Yao HP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-82; Yao HP, 2006, CANCER BIOL THER, V5, P1179, DOI 10.4161/cbt.5.9.3073; Zhang K, 2010, INT J ONCOL, V36, P255, DOI 10.3892/ijo_00000496; Zou Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069992	48	9	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2019	38	48					7342	7356		10.1038/s41388-019-0946-8	http://dx.doi.org/10.1038/s41388-019-0946-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JR4XX	31417186	hybrid			2022-12-17	WOS:000499631000005
J	Silva-Evangelista, C; Barret, E; Menez, V; Merlevede, J; Kergrohen, T; Saccasyn, A; Oberlin, E; Puget, S; Beccaria, K; Grill, J; Castel, D; Debily, MA				Silva-Evangelista, Claudia; Barret, Emilie; Menez, Virginie; Merlevede, Jane; Kergrohen, Thomas; Saccasyn, Ambre; Oberlin, Estelle; Puget, Stephanie; Beccaria, Kevin; Grill, Jacques; Castel, David; Debily, Marie-Anne			A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival	ONCOGENE			English	Article							VIVO RNAI SCREEN; THERAPEUTIC TARGETS; BRAIN; INHIBITION; REGULATOR; PATHWAYS; CANCER; MUTATIONS; GROWTH	Diffuse intrinsic pontine glioma (or DIPG) are pediatric high-grade gliomas associated with a dismal prognosis. They harbor specific substitution in histone H3 at position K27 that induces major epigenetic dysregulations. Most clinical trials failed so far to increase survival, and radiotherapy remains the most efficient treatment, despite only transient tumor control. We conducted the first lentiviral shRNA dropout screen in newly diagnosed DIPG to generate a cancer-lethal signature as a basis for the development of specific treatments with increased efficacy and reduced side effects compared to existing anticancer therapies. The analysis uncovered 41 DIPG essential genes among the 672 genes of human kinases tested, for which several distinct interfering RNAs impaired cell expansion of three different DIPG stem-cell cultures without deleterious effect on two control neural stem cells. Among them, PLK1, AURKB, CHEK1, EGFR, and GSK3A were previously identified by similar approach in adult GBM indicating common dependencies of these cancer cells and pediatric gliomas. As expected, we observed an enrichment of genes involved in proliferation and cell death processes with a significant number of candidates belonging to PTEN/PI3K/AKT and EGFR pathways already under scrutiny in clinical trials in this disease. We highlighted VRK3, a gene involved especially in cell cycle regulation, DNA repair, and neuronal differentiation, as a non-oncogenic addiction in DIPG. Its repression totally blocked DIPG cell growth in the four cellular models evaluated, and induced cell death in H3.3-1(27M cells specifically but not in H3.1-K27M cells, supporting VRK3 as an interesting and promising target in DIPG.	[Silva-Evangelista, Claudia; Barret, Emilie; Menez, Virginie; Merlevede, Jane; Kergrohen, Thomas; Saccasyn, Ambre; Beccaria, Kevin; Grill, Jacques; Castel, David; Debily, Marie-Anne] Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, Vectorol & Therapeut Anticanc,CNRS,UMR8203, Villejuif, France; [Oberlin, Estelle] Univ Paris Saclay, Univ Paris Sud, Inserm UMRS MD 1197, Villejuif, France; [Puget, Stephanie; Beccaria, Kevin] Univ Paris V Descartes, Dept Pediat Neurosurg, Sorbonne Paris Cite, Hop Necker Enfants Malad, Paris, France; [Grill, Jacques; Castel, David] Univ Paris Sud, Univ Paris Saclay, Gustave Roussy, Dept Cancerol Enfant & Adolescent, Villejuif, France; [Debily, Marie-Anne] Univ Evry Val dEssonne, Blvd Francois Mitterrand, Evry, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Debily, MA (corresponding author), Univ Paris Saclay, Univ Paris Sud, Gustave Roussy, Vectorol & Therapeut Anticanc,CNRS,UMR8203, Villejuif, France.; Debily, MA (corresponding author), Univ Evry Val dEssonne, Blvd Francois Mitterrand, Evry, France.	marie-anne.debily@gustaveroussy.fr	BECCARIA, Kévin/AAL-5122-2021; Castel, David/D-5353-2018; Debily, Marie-Anne/X-7697-2018; Oberlin, Estelle/M-4915-2018	Castel, David/0000-0003-0247-080X; Debily, Marie-Anne/0000-0002-8509-6165; Oberlin, Estelle/0000-0002-8200-9548; MENEZ, Virginie/0000-0002-3748-7428	Canceropole Ile de France; INCa; La Ligue Contre le Cancer [DILESS-DM/CB/003-17]; charity l'Etoile de Martin; National Council for Scientific and Technological Development (CNPq)/Program "Science without borders" in Brasil	Canceropole Ile de France(Region Ile-de-France); INCa(Institut National du Cancer (INCA) France); La Ligue Contre le Cancer(Ligue nationale contre le cancer); charity l'Etoile de Martin; National Council for Scientific and Technological Development (CNPq)/Program "Science without borders" in Brasil(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	DC, JG, and MAD acknowledge financial support from Canceropole Ile de France, INCa, La Ligue Contre le Cancer (projet DILESS-DM/CB/003-17) and the charity l'Etoile de Martin. The authors are grateful to the Necker hospital tumor and DNA banks and the Necker operating room nurses/assistants for their technical assistance. CSE acknowledges financial support from National Council for Scientific and Technological Development (CNPq)/Program "Science without borders" in Brasil. We thank N. Droin and the genomic core facility of Gustave Roussy.	Barde I, 2010, CURR PROTOC NEUROSCI; Chang JT, 2006, BIOINFORMATICS, V22, P2926, DOI 10.1093/bioinformatics/btl483; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Cheng P, 2015, STEM CELL REP, V4, P899, DOI 10.1016/j.stemcr.2015.03.005; Cohen KJ, 2017, NEURO-ONCOLOGY, V19, P1025, DOI 10.1093/neuonc/nox021; Di Stefano AL, 2015, CLIN CANCER RES, V21, P3307, DOI 10.1158/1078-0432.CCR-14-2199; Ding Y, 2013, CANCER DISCOV, V3, P198, DOI 10.1158/2159-8290.CD-12-0353; Du ZH, 2018, INT J ONCOL, V52, P1415, DOI 10.3892/ijo.2018.4324; Farhan M, 2017, INT J BIOL SCI, V13, P815, DOI 10.7150/ijbs.20052; Fedorov O, 2007, P NATL ACAD SCI USA, V104, P20523, DOI 10.1073/pnas.0708800104; Filbin MG, 2018, SCIENCE, V360, P331, DOI 10.1126/science.aao4750; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Goidts V, 2012, ONCOGENE, V31, P3235, DOI 10.1038/onc.2011.490; Grasso CS, 2015, NAT MED, V21, P555, DOI 10.1038/nm.3855; Grill J, 2012, PEDIATR BLOOD CANCER, V58, P489, DOI 10.1002/pbc.24060; Hargrove D, 2006, LANCET ONCOL, V7, P241, DOI 10.1016/S1470-2045(06)70615-5; Hart T, 2017, G3-GENES GENOM GENET, V7, P2719, DOI 10.1534/g3.117.041277; Hart T, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145216; Kang MS, 2017, J EXP MED, V214, P2947, DOI 10.1084/jem.20160974; Korur S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007443; Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850; Kulkarni S, 2018, MOL CANCER RES, V16, P103, DOI 10.1158/1541-7786.MCR-17-0146; Lee N, 2017, MOL CELLS, V40, P621, DOI 10.14348/molcells.2017.0108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Misuraca KL, 2016, NEOPLASIA, V18, P60, DOI 10.1016/j.neo.2015.12.002; ORAHILLY R, 1987, AM J ANAT, V180, P69, DOI 10.1002/aja.1001800106; Plessier A, 2017, ONCOTARGET, V8, P52543, DOI 10.18632/oncotarget.15002; Sa JK, 2015, ONCOTARGET, V6, P20145, DOI 10.18632/oncotarget.3980; Shriver M, 2016, ONCOTARGET, V7, P45414, DOI 10.18632/oncotarget.9985; Song H, 2016, SCI REP-UK, V6, DOI 10.1038/srep38452; Tandle AT, 2013, EUR J CANCER, V49, P3020, DOI 10.1016/j.ejca.2013.05.013; Tang YY, 2013, J MOL NEUROSCI, V50, P324, DOI 10.1007/s12031-013-9981-z; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Taylor KR, 2014, NAT GENET, V46, P457, DOI 10.1038/ng.2925; Truffaux N, 2015, NEURO-ONCOLOGY, V17, P953, DOI 10.1093/neuonc/nou330; Varlet P, 2018, NEURO-ONCOLOGY, V20, P52; Warren KE, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00205; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002; Yang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061915; Zarghooni M, 2010, J CLIN ONCOL, V28, P1337, DOI 10.1200/JCO.2009.25.5463	41	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6479	6490		10.1038/s41388-019-0884-5	http://dx.doi.org/10.1038/s41388-019-0884-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31324890				2022-12-17	WOS:000486609000001
J	Nicolae, CM; O'Connor, MJ; Schleicher, EM; Song, CH; Gowda, R; Robertson, G; Dovat, S; Moldovan, GL				Nicolae, Claudia M.; O'Connor, Michael J.; Schleicher, Emily M.; Song, Chunhua; Gowda, Raghavendra; Robertson, Gavin; Dovat, Sinisa; Moldovan, George-Lucian			PARI (PARPBP) suppresses replication stress-induced myeloid differentiation in leukemia cells	ONCOGENE			English	Article							NF-KAPPA-B; DNA-DAMAGE; HOMOLOGOUS RECOMBINATION; GENOMIC INSTABILITY; FORK REVERSAL; ACTIVATION; PROTEIN; EXPRESSION; PCNA; TUMORIGENESIS	Hyperproliferative cancer cells face increased replication stress, which can result in accumulation of DNA damage. As DNA damage can arrest proliferation, and, in the case of myeloid leukemia, induce differentiation of cancer cells, understanding the mechanisms that regulate the replication stress response is paramount. Here, we show that PARI, a replisome protein involved in regulating DNA repair and replication stress, suppresses differentiation of myeloid leukemia cells. We show that PARI is overexpressed in myeloid leukemia cells, and its knockdown reduces leukemia cell proliferation in vitro and in vivo in xenograft mouse models. PARI depletion enhances replication stress and DNA-damage accumulation, coupled with increased myeloid differentiation. Mechanistically, we show that PARI inhibits activation of the NF-kappa B pathway, which can initiate p21-mediated differentiation and proliferation arrest. Finally, we show that PARI expression negatively correlates with expression of differentiation markers in clinical myeloid leukemia samples, suggesting that targeting PARI may restore differentiation ability of leukemia cells and antagonize their proliferation.	[Nicolae, Claudia M.; O'Connor, Michael J.; Schleicher, Emily M.; Moldovan, George-Lucian] Penn State Univ, Dept Biochem & Mol Biol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA; [Song, Chunhua; Dovat, Sinisa] Penn State Univ, Dept Pediat, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA; [Gowda, Raghavendra; Robertson, Gavin] Penn State Univ, Dept Pharmacol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Moldovan, GL (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.	glm29@psu.edu	; song, chunhua/K-7882-2016	George-Lucian, Moldovan/0000-0003-3825-149X; song, chunhua/0000-0002-4081-2543; Schleicher, Emily/0000-0002-2315-346X; Dovat, Sinisa/0000-0003-3906-6165	Department of Defense [CA140303]; St. Baldrick Foundation; Alex's Lemonade Stand; Hyundai Hope on Wheels Scholar Grant; Bear Necessities Pediatric Cancer Foundation; NIH [R01CA209829, R01CA213912]; NATIONAL CANCER INSTITUTE [R01CA209829, R01CA213912] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); St. Baldrick Foundation; Alex's Lemonade Stand; Hyundai Hope on Wheels Scholar Grant; Bear Necessities Pediatric Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr. Alan D'Andrea for EUFA130 cells, Dr. Chandrika Gowda for experimental advice, Daniel Constantin for technical support, and the Penn State College of Medicine Flow Cytometry and Genome Sciences cores. This work was supported by: the Department of Defense (award CA140303) and the St. Baldrick Foundation (to GLM); NIH R01CA209829, R01CA213912, Alex's Lemonade Stand, Hyundai Hope on Wheels Scholar Grant, and Bear Necessities Pediatric Cancer Foundation (to SD).	Allen C, 2011, J MOL CELL BIOL, V3, P4, DOI 10.1093/jmcb/mjq049; Ammon C, 2000, IMMUNOLOGY, V100, P364, DOI 10.1046/j.1365-2567.2000.00056.x; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Vallerga MB, 2015, P NATL ACAD SCI USA, V112, pE6624, DOI 10.1073/pnas.1508543112; Bhat KP, 2018, NAT STRUCT MOL BIOL, V25, P446, DOI 10.1038/s41594-018-0075-z; Bruserud O, 2000, Oncologist, V5, P454, DOI 10.1634/theoncologist.5-6-454; Burkovics P, 2016, NUCLEIC ACIDS RES, V44, P3176, DOI 10.1093/nar/gkw024; Cheung KJJ, 2009, BRIT J HAEMATOL, V146, P257, DOI 10.1111/j.1365-2141.2009.07739.x; Choe KN, 2016, EMBO REP, V17, P874, DOI 10.15252/embr.201541685; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; de The H, 2018, NAT REV CANCER, V18, P117, DOI 10.1038/nrc.2017.103; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fey MF, 2007, ANN ONCOL, V18, pI9, DOI 10.1093/annonc/mdl444; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Hou HA, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.59; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2001, MOL CELL BIOL, V21, P4737, DOI 10.1128/MCB.21.14.4737-4747.2001; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Mao ZY, 2008, DNA REPAIR, V7, P1765, DOI 10.1016/j.dnarep.2008.06.018; Melo Monica B, 2002, Hematology, V7, P13, DOI 10.1080/10245330290020090; Mochizuki AL, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00117-17; Moldovan GL, 2012, MOL CELL, V45, P75, DOI 10.1016/j.molcel.2011.11.010; Nicolae CM, 2018, ONCOGENE, V37, P3647, DOI 10.1038/s41388-018-0219-y; O'Connor KW, 2013, CANCER RES, V73, P2529, DOI 10.1158/0008-5472.CAN-12-3313; Piao L, 2011, GENE CHROMOSOME CANC, V50, P13, DOI 10.1002/gcc.20828; Pitroda SP, 2017, CLIN CANCER RES, V23, P4493, DOI 10.1158/1078-0432.CCR-16-2845; Pitroda SP, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008291; Quinet A, 2017, MOL CELL, V68, P830, DOI 10.1016/j.molcel.2017.11.022; Santos MA, 2014, NATURE, V514, P107, DOI 10.1038/nature13483; Schleicher EM, 2018, NUCLEIC ACIDS RES, V46, P8908, DOI 10.1093/nar/gky658; Song CH, 2015, BLOOD, V126, P1813, DOI 10.1182/blood-2015-06-651505; Talati C, 2018, LEUKEMIA RES, V73, P58, DOI 10.1016/j.leukres.2018.09.001; Tilstra JS, 2011, AGING DIS, V2, P449; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; Vassen L, 2012, AM J BLOOD RES, V2, P228; Wang J, 2011, J CELL BIOCHEM, V112, P2443, DOI 10.1002/jcb.23165; Wang XN, 2014, J CELL PHYSIOL, V229, P856, DOI 10.1002/jcp.24513; Watts JM, 2014, BLOOD REV, V28, P205, DOI 10.1016/j.blre.2014.07.001; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Xie CZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079106; Yoon SW, 2014, STEM CELLS DEV, V23, P2700, DOI 10.1089/scd.2014.0129; Zafar MK, 2017, CHEM RES TOXICOL, V30, P1942, DOI 10.1021/acs.chemrestox.7b00157; Zellweger R, 2015, J CELL BIOL, V208, P563, DOI 10.1083/jcb.201406099; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	52	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5530	5540		10.1038/s41388-019-0810-x	http://dx.doi.org/10.1038/s41388-019-0810-x			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967629				2022-12-17	WOS:000473842500014
J	Yamazaki, D; Hasegawa, A; Funato, Y; Tran, HN; Mori, MX; Mori, Y; Sato, T; Miki, H				Yamazaki, Daisuke; Hasegawa, Ayaka; Funato, Yosuke; Ha Nam Tran; Mori, Masayuki X.; Mori, Yasuo; Sato, Toshiro; Miki, Hiroaki			Cnnm4 deficiency suppresses Ca2+ signaling and promotes cell proliferation in the colon epithelia	ONCOGENE			English	Article							CONE-ROD DYSTROPHY; ION-CHANNEL; SMALL-INTESTINE; STEM-CELLS; MG2+; MUTATIONS; ORGANOIDS	CNNM4 is a Mg2+ transporter highly expressed in the colon epithelia. Its importance in regulating intracellular Mg2+ levels and cancer development has been documented, but how CNNM4 function affects the dynamic homeostasis of the epithelial tissue remains unclear. Here, we show that Cnnm4 deficiency promotes cell proliferation and partly suppresses cell differentiation in the colon epithelia, making them vulnerable to cancer development. Such phenotypic characteristics are highly similar to those of mice lacking Trpv1, which encodes the cation channel involved in capsaicin-stimulated Ca2+ influx. Indeed, Ca2+-imaging analyses using the organoid culture reveal that Ca2+ influx stimulated by capsaicin is greatly impaired by Cnnm4 deficiency. Moreover, EGF receptor signaling is constitutively activated in the colon epithelia of Cnnm4-deficient mice, as is the case with Trpv1-deficient mice. The administration of gefitinib, a clinically available inhibitor of EGF receptor, cancels the augmented proliferation of cells observed in Cnnm4-deficient mice. Collectively, these results establish the functional interplay between Mg2+ and Ca2+ in the colon epithelia, which is crucial for maintaining the dynamic homeostasis of the epithelial tissue.	[Yamazaki, Daisuke; Hasegawa, Ayaka; Funato, Yosuke; Miki, Hiroaki] Osaka Univ, Microbial Dis Res Inst, Dept Cellular Regulat, Suita, Osaka 5650871, Japan; [Ha Nam Tran; Mori, Masayuki X.; Mori, Yasuo] Kyoto Univ, Grad Sch Engn, Dept Synthet Chem & Biol Chem, Kyoto 6158510, Japan; [Ha Nam Tran] Kyoto Univ, Grad Sch Global Environm Studies, Dept Technol & Ecol, Kyoto 6158510, Japan; [Sato, Toshiro] Keio Univ, Sch Med, Dept Gastroenterol, Shinjuku Ku, Tokyo 1608582, Japan	Osaka University; Kyoto University; Kyoto University; Keio University	Miki, H (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Cellular Regulat, Suita, Osaka 5650871, Japan.	hmiki@biken.osaka-u.ac.jp	Mori, Masayuki/AAI-6992-2020; Sato, Toshiro/J-3522-2014	TRAN, Ha Nam/0000-0002-4802-4541; Sato, Toshiro/0000-0001-8353-8137				Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Basak O, 2017, CELL STEM CELL, V20, P177, DOI 10.1016/j.stem.2016.11.001; Bessette DC, 2008, CANCER METAST REV, V27, P231, DOI 10.1007/s10555-008-9121-3; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; de Jong PR, 2014, J CLIN INVEST, V124, P3793, DOI 10.1172/JCI72340; Funato Y, 2018, J PHYSIOL-LONDON, V596, P743, DOI 10.1113/JP275248; Funato Y, 2014, J CLIN INVEST, V124, P5398, DOI 10.1172/JCI76614; Gimenez-Mascarell P, 2017, J BIOL CHEM, V292, P786, DOI 10.1074/jbc.M116.759944; Gunther T, 2006, MAGNESIUM RES, V19, P225; Gulerez I, 2016, EMBO REP, V17, P1890, DOI 10.15252/embr.201643393; Hardy S, 2015, ONCOGENE, V34, P986, DOI 10.1038/onc.2014.33; Hirata Y, 2014, J BIOL CHEM, V289, P14731, DOI 10.1074/jbc.M114.551176; ITO S, 1965, J CELL BIOL, V27, P475, DOI 10.1083/jcb.27.3.475; Luo JL, 2012, J INVEST DERMATOL, V132, P2158, DOI 10.1038/jid.2012.144; Miyoshi H, 2012, SCIENCE, V338, P108, DOI 10.1126/science.1223821; OCONNOR DT, 1983, LIFE SCI, V33, P1657, DOI 10.1016/0024-3205(83)90721-X; Parry DA, 2009, AM J HUM GENET, V84, P266, DOI 10.1016/j.ajhg.2009.01.009; Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617; Polok B, 2009, AM J HUM GENET, V84, P259, DOI 10.1016/j.ajhg.2009.01.006; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Romani AMP, 2011, ARCH BIOCHEM BIOPHYS, V512, P1, DOI 10.1016/j.abb.2011.05.010; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Vinuesa AG, 2012, CANCER RES, V72, P1705, DOI 10.1158/0008-5472.CAN-11-3693; Yamazaki D, 2016, J CELL SCI, V129, P1940, DOI 10.1242/jcs.182220; Yamazaki D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003983; Yang F, 2014, J GEN PHYSIOL, V143, P91, DOI 10.1085/jgp.201311024	30	9	9	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3962	3969		10.1038/s41388-019-0682-0	http://dx.doi.org/10.1038/s41388-019-0682-0			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670776				2022-12-17	WOS:000468035600014
J	Palmbos, PL; Wang, Y; Bankhead, A; Kelleher, AJ; Wang, LD; Yang, HB; Ahmet, ML; Gumkowski, ER; Welling, SD; Magnuson, B; Leflein, J; Hiles, GL; Abel, EV; Dziubinski, ML; Urs, S; Day, ML; Ljungman, ME; Simeone, DM				Palmbos, Phillip L.; Wang, Yin; Bankhead, Armand, III; Kelleher, Alan J.; Wang, Lidong; Yang, Huibin; Ahmet, McKenzie L.; Gumkowski, Erica R.; Welling, Samuel D.; Magnuson, Brian; Leflein, Jacob; Hiles, Guadalupe Lorenzatti; Abel, Ethan V.; Dziubinski, Michele L.; Urs, Sumithra; Day, Mark L.; Ljungman, Mats E.; Simeone, Diane M.			ATDC mediates a TP63-regulated basal cancer invasive program	ONCOGENE			English	Article							BLADDER-CANCER; MOLECULAR CLASSIFICATION; TRIM29; GENOME; SUBTYPES; PROGNOSIS; MIGRATION; TAXONOMY; ISOFORMS; REQUIRES	Basal subtype cancers are deadly malignancies but the molecular events driving tumor lethality are not completely understood. Ataxia-telangiectasia group D complementing gene (ATDC, also known as TRIM29), is highly expressed and drives tumor formation and invasion in human bladder cancers but the factor(s) regulating its expression in bladder cancer are unknown. Molecular subtyping of bladder cancer has identified an aggressive basal subtype, which shares molecular features of basal/squamous tumors arising in other organs and is defined by activation of a TP63-driven gene program. Here, we demonstrate that ATDC is linked with expression of TP63 and highly expressed in basal bladder cancers. We find that TP63 binds to transcriptional regulatory regions of ATDC and KRT14 directly, increasing their expression, and that ATDC and KRT14 execute a TP63-driven invasive program. In vivo, ATDC is required for TP63-induced bladder tumor invasion and metastasis. These results link TP63 and the basal gene expression program to ATDC and to aggressive tumor behavior. Defining ATDC as a molecular determinant of aggressive, basal cancers may lead to improved biomarkers and therapeutic approaches.	[Palmbos, Phillip L.; Wang, Yin; Kelleher, Alan J.; Ahmet, McKenzie L.; Gumkowski, Erica R.] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA; [Palmbos, Phillip L.; Wang, Yin; Bankhead, Armand, III; Welling, Samuel D.; Magnuson, Brian; Leflein, Jacob; Hiles, Guadalupe Lorenzatti; Abel, Ethan V.; Dziubinski, Michele L.; Urs, Sumithra; Ljungman, Mats E.] Univ Michigan, Med Ctr, Rogel Canc Ctr, Ann Arbor, MI 48109 USA; [Bankhead, Armand, III; Magnuson, Brian] Univ Michigan, Med Ctr, Dept Biostat, Ann Arbor, MI 48109 USA; [Bankhead, Armand, III] Univ Michigan, Med Ctr, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Wang, Lidong; Simeone, Diane M.] NYU Langone Hlth, Dept Surg, New York, NY 10016 USA; [Wang, Lidong; Simeone, Diane M.] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY 10016 USA; [Yang, Huibin; Ljungman, Mats E.] Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; [Hiles, Guadalupe Lorenzatti; Day, Mark L.] Univ Michigan, Med Ctr, Dept Urol, Ann Arbor, MI 48109 USA; [Dziubinski, Michele L.] Univ Michigan, Med Ctr, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Simeone, Diane M.] NYU Langone Hlth, Dept Pathol, New York, NY 10016 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; NYU Langone Medical Center; NYU Langone Medical Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; NYU Langone Medical Center	Palmbos, PL (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA.; Palmbos, PL (corresponding author), Univ Michigan, Med Ctr, Rogel Canc Ctr, Ann Arbor, MI 48109 USA.	ppalmbos@med.umich.edu		Lorenzatti, Guadalupe/0000-0002-8423-3279	University of Michigan Cancer Center Core Grant [CA046592-26S3]; NIH [K08 CA201335, R01 CA17483601]; BCAN YIA; ASCO YIA; NATIONAL CANCER INSTITUTE [K08CA201335, P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002240] Funding Source: NIH RePORTER	University of Michigan Cancer Center Core Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); BCAN YIA; ASCO YIA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	This work was funded by grants from the University of Michigan Cancer Center Core Grant CA046592-26S3, NIH K08 CA201335 (PLP), BCAN YIA (PLP), ASCO YIA (PLP), and NIH R01 CA17483601 (DMS).	Cai BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041742; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Choi W, 2017, EUR UROL, V72, P354, DOI 10.1016/j.eururo.2017.03.010; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Choi W, 2012, PLOS ONE, V7, P453, DOI 10.1371/journal.pone.0030206; Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111; Dukel M, 2016, J BIOL CHEM, V291, P21541, DOI 10.1074/jbc.M116.730960; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gaya JM, 2015, J UROLOGY, V193, P1144, DOI 10.1016/j.juro.2014.10.098; Guo GC, 2017, CELL ONCOL, V40, P157, DOI 10.1007/s13402-016-0312-6; Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798; Han AL, 2017, ONCOGENE, V36, P5243, DOI 10.1038/onc.2017.149; Hedegaard J, 2016, CANCER CELL, V30, P27, DOI 10.1016/j.ccell.2016.05.004; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Hovelson DH, 2018, EUR UROL, V74, P741, DOI 10.1016/j.eururo.2018.06.047; Karni-Schmidt O, 2011, AM J PATHOL, V178, P1350, DOI 10.1016/j.ajpath.2010.11.061; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lai W, 2013, DIS ESOPHAGUS, V26, P817, DOI 10.1111/j.1442-2050.2012.01400.x; Lee SH, 2015, J EXP MED, V212, P1061, DOI 10.1084/jem.20141601; Leivo MZ, 2016, PATHOLOGY, V48, P543, DOI 10.1016/j.pathol.2016.05.008; Lerner SP, 2016, BLADDER CANCER, V2, P37, DOI 10.3233/BLC-150037; Masuda Y, 2015, BBA-MOL CELL RES, V1853, P2296, DOI 10.1016/j.bbamcr.2015.05.035; McDade SS, 2012, NUCLEIC ACIDS RES, V40, P7190, DOI 10.1093/nar/gks389; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Palmbos PL, 2015, CANCER RES, V75, P5155, DOI 10.1158/0008-5472.CAN-15-0603; Qiu F, 2015, INT J CLIN EXP PATHO, V8, P5053; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Seiler Roland, 2017, Eur Urol, V72, P544, DOI 10.1016/j.eururo.2017.03.030; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sjodahl G, 2017, J PATHOL, V242, P113, DOI 10.1002/path.4886; Sjodahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T; Su XH, 2013, NAT REV CANCER, V13, P136, DOI 10.1038/nrc3446; Tamura S, 2018, BLADDER CANCER, V4, P77, DOI 10.3233/BLC-170144; Tang ZP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063676; Velez-delValle C, 2016, SCI REP-UK, V6, DOI 10.1038/srep24389; Wang FR, 2018, J CELL BIOL, V217, P4314, DOI 10.1083/jcb.201712130; Wang LD, 2015, GENE DEV, V29, P171, DOI 10.1101/gad.253591.114; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; Wang Y, 2018, JOVE-J VIS EXP, DOI 10.3791/58345; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Xu WH, 2016, ONCOL REP, V36, P1411, DOI 10.3892/or.2016.4941; 2010, MOL CELL BIOL, V30, P3004, DOI DOI 10.1128/MCB.01023-09	44	9	10	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3340	3354		10.1038/s41388-018-0646-9	http://dx.doi.org/10.1038/s41388-018-0646-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643195	Green Accepted			2022-12-17	WOS:000466610000002
J	Khater, F; Langlois, S; Cassart, P; Roy, AM; Lajoie, M; Healy, J; Richer, C; St-Onge, P; Piche, N; Perreault, S; Cellot, S; Marzouki, M; Jabado, N; Sinnett, D				Khater, Fida; Langlois, Sylvie; Cassart, Pauline; Roy, Anne-Marie; Lajoie, Mathieu; Healy, Jasmine; Richer, Chantal; St-Onge, Pascal; Piche, Nelson; Perreault, Sebastien; Cellot, Sonia; Marzouki, Monia; Jabado, Nada; Sinnett, Daniel			Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma	ONCOGENE			English	Article							MAPK PATHWAY ACTIVATION; B-RAF; KINASE; INHIBITORS; CLASSIFICATION; DIMERIZATION; PROGRESSION; CHILDHOOD; DELETIONS; ALIGNMENT	Pilocytic astrocytoma (PA) is emerging as a tumor entity with dysregulated RAS/RAF/MEK/ERK signaling. In this study, we report the identification of a novel recurrent BRAF insertion (p.V504_R506dup) in five PA cases harboring exclusively this somatic tandem duplication. This recurrent alteration leads to an addition of three amino acids in the kinase domain of BRAF and has functional impact on activating MAPK phosphorylation. Importantly, we show that this mutation confers resistance to RAF inhibitors without changing effectiveness while downstream MEK inhibitors remain effective. Our results further emphasize the importance of BRAF alterations in PA and the need to characterize them in a given tumor as this can affect therapeutic strategies and their potential use as tumor marker in molecular diagnostics.	[Khater, Fida; Langlois, Sylvie; Cassart, Pauline; Roy, Anne-Marie; Lajoie, Mathieu; Healy, Jasmine; Richer, Chantal; St-Onge, Pascal; Cellot, Sonia; Marzouki, Monia; Sinnett, Daniel] CHU St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, Montreal, PQ, Canada; [Khater, Fida; Cellot, Sonia; Marzouki, Monia; Sinnett, Daniel] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ, Canada; [Piche, Nelson] CHU St Justine, Dept Pediat Surg, Montreal, PQ, Canada; [Perreault, Sebastien] CHU St Justine, Div Neurol, Montreal, PQ, Canada; [Jabado, Nada] McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine; McGill University	Sinnett, D (corresponding author), CHU St Justine, Div Hematol Oncol, Charles Bruneau Canc Ctr, Montreal, PQ, Canada.; Sinnett, D (corresponding author), Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ, Canada.	daniel.sinnett@umontreal.ca	sinnett, daniel/S-4589-2017; Jabado, Nada/AAN-4026-2020	sinnett, daniel/0000-0003-3625-6676; KHATER, Fida/0000-0003-2810-3928	Ministere de l'Economie, de la Science et de l'Innovation du Quebec; Charles-Bruneau Cancer Center Foundation; RMGA/Fonds de recherche du Quebec-Sante; Canadian Institutes of Health Research; Cole Foundation Fellowship	Ministere de l'Economie, de la Science et de l'Innovation du Quebec; Charles-Bruneau Cancer Center Foundation; RMGA/Fonds de recherche du Quebec-Sante; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cole Foundation Fellowship	The authors are indebted to the personal involvement of the patient and his parents who fully participated in this study. Patient tissue samples were provided by the CHU Sainte-Justine Pediatric Cancer biobank. Whole-exome sequencing was performed at the Integrated Clinical Genomics Centre in Pediatrics, CHU SainteJustine; Sanger sequencing and targeted ultra-deep re-sequencing were performed at the McGill University and Genome Quebec Innovation Centre; Computations were made on the supercomputer Briaree from Universite de Montreal, managed by Calcul Quebec and Compute Canada. This study was supported by research funds provided by the Ministere de l'Economie, de la Science et de l'Innovation du Quebec, the Charles-Bruneau Cancer Center Foundation, RMGA/Fonds de recherche du Quebec-Sante and the Canadian Institutes of Health Research (D.S.). F.K. is the recipient of a Cole Foundation Fellowship. D.S. holds the Francois-Karl-Viau Research Chair in Pediatric Oncogenomics.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Baccichet A, 1997, LEUKEMIA RES, V21, P817, DOI 10.1016/S0145-2126(97)00075-1; Belirgen M, 2012, CHILD NERV SYST, V28, P375, DOI 10.1007/s00381-011-1676-6; Bergthold G, 2014, BBA-REV CANCER, V1845, P294, DOI 10.1016/j.bbcan.2014.02.004; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; BUDKA H, 1975, ACTA NEUROCHIR, V32, P139, DOI 10.1007/BF01405911; Chen SH, 2016, CANCER DISCOV, V6, P300, DOI 10.1158/2159-8290.CD-15-0896; Choi J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12197; Collins VP, 2015, ACTA NEUROPATHOL, V129, P775, DOI 10.1007/s00401-015-1410-7; Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018; Gajjar A, 2014, CLIN CANCER RES, V20, P5630, DOI 10.1158/1078-0432.CCR-14-0833; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Heritier S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0690-z; Jones DTW, 2006, J NEUROPATH EXP NEUR, V65, P1049, DOI 10.1097/01.jnen.0000240465.33628.87; Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682; Jones DTW, 2012, CELL MOL LIFE SCI, V69, P1799, DOI 10.1007/s00018-011-0898-9; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Karoulia Z, 2016, CANCER CELL, V30, P501, DOI 10.1016/j.ccell.2016.08.008; KATSETOS CD, 1994, CLIN NEUROPATHOL, V13, P295; Koboldt DC, 2009, BIOINFORMATICS, V25, P2283, DOI 10.1093/bioinformatics/btp373; Krieger MD, 1997, PEDIATR NEUROSURG, V27, P1, DOI 10.1159/000121218; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ma JZ, 2013, BIOINFORMATICS, V29, P257, DOI 10.1093/bioinformatics/btt210; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Orr LC, 2002, MED PEDIATR ONCOL, V38, P173, DOI 10.1002/mpo.1305; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Potter N, 2008, NEOPLASIA, V10, P757, DOI 10.1593/neo.07914; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Rahman MA, 2014, CRIT REV ONCOL HEMAT, V90, P220, DOI 10.1016/j.critrevonc.2013.12.008; Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771; Rodriguez FJ, 2010, AM J SURG PATHOL, V34, P147, DOI 10.1097/PAS.0b013e3181c75238; Roskoski R, 2016, PHARMACOL RES, V103, P26, DOI 10.1016/j.phrs.2015.10.021; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Sanoudou D, 2000, BRIT J CANCER, V82, P1218; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Spinella JF, 2016, ONCOTARGET, V7, P65485, DOI 10.18632/oncotarget.11796; Stuer C, 2007, CANCER-AM CANCER SOC, V110, P2799, DOI 10.1002/cncr.23148; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Wagenaar TR, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12171; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Zhang JH, 2013, NAT GENET, V45, P602, DOI 10.1038/ng.2611	46	9	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					2994	3002		10.1038/s41388-018-0623-3	http://dx.doi.org/10.1038/s41388-018-0623-3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575814	Green Published, hybrid			2022-12-17	WOS:000465167600009
J	Shirai, YT; Mizutani, A; Nishijima, S; Horie, M; Kikuguchi, C; Elisseeva, O; Yamamoto, T				Shirai, Yo-Taro; Mizutani, Anna; Nishijima, Saori; Horie, Masafumi; Kikuguchi, Chisato; Elisseeva, Olga; Yamamoto, Tadashi			CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development	ONCOGENE			English	Article							MESSENGER-RNA DEADENYLATION; KRUPPEL-LIKE FACTOR-2; GENE-EXPRESSION; CCR4-NOT COMPLEX; DNA METHYLATION; ROLES; ADENOCARCINOMA; SUBUNITS; LEVEL	Lung cancer is one of the major causes of cancer death and clarification of its molecular pathology is highly prioritized. The physiological importance of mRNA degradation through the CCR4-NOT deadenylase has recently been highlighted. For example, mutation in CNOT3, a gene coding for CNOT3 subunit of the CCR4-NOT complex, is found to be associated with T-cell acute lymphoblastic leukemia, T-ALL, though its contribution to other cancers has not been reported. Here, we provide evidence suggesting that CNOT3 is required for the growth of non-small cell lung cancer. Depletion of CNOT3 suppresses proliferation of A549 human non-small cell lung cancer cells with enhanced mRNA stability and subsequent elevated expression of p21. In addition, we identified the mRNA for Kruppel-like factor 2 transcription factor, an inducer of p21, as a novel mRNA degradation target of CNOT3 in non-small cell lung cancer cells. Aberrant up-regulation of Kruppel-like factor 2 by CNOT3 depletion leads to impairment in the proliferation of A549 cells. Consistent with these findings, elevated mRNA expression of CNOT3 in non-small cell lung cancer in comparison with the paired normal lung epithelium was confirmed through scrutinization of the RNA-sequencing datasets from The Cancer Genome Atlas. Moreover, we found an inverse correlation between CNOT3 and CDKN1A (encoding p21) mRNA expression using the combined datasets of normal lung epithelium and non-small cell lung cancer. Thus, we propose that the up-regulation of CNOT3 facilitates the development of non-small cell lung cancer through down-regulation of Kruppel-like factor 2 and p21, contrary to tumor suppressive functions of CNOT3 in T-ALL.	[Shirai, Yo-Taro; Nishijima, Saori; Kikuguchi, Chisato; Elisseeva, Olga; Yamamoto, Tadashi] Grad Univ, Okinawa Inst Sci & Technol, Cell Signal Unit, Onna Son, Okinawa, Japan; [Mizutani, Anna] Japanese Fdn Canc Res, Canc Chemotherapy Ctr, Div Mol Biotherapy, Koto Ku, Tokyo, Japan; [Horie, Masafumi] Univ Tokyo, Grad Sch Med, Dept Resp Med, Bunkyo Ku, Tokyo, Japan; [Horie, Masafumi] Univ Tokyo, Div Hlth Serv Promot, Bunkyo Ku, Tokyo, Japan; [Kikuguchi, Chisato; Elisseeva, Olga; Yamamoto, Tadashi] RIKEN Ctr Integrat Sci, Lab Immunogenet, Yokohama, Kanagawa, Japan; [Shirai, Yo-Taro] NCI, Lab Metab, NIH, Bethesda, MD 20892 USA	Okinawa Institute of Science & Technology Graduate University; Japanese Foundation for Cancer Research; University of Tokyo; University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shirai, YT; Yamamoto, T (corresponding author), Grad Univ, Okinawa Inst Sci & Technol, Cell Signal Unit, Onna Son, Okinawa, Japan.; Yamamoto, T (corresponding author), RIKEN Ctr Integrat Sci, Lab Immunogenet, Yokohama, Kanagawa, Japan.; Shirai, YT (corresponding author), NCI, Lab Metab, NIH, Bethesda, MD 20892 USA.	yo-taro.shirai@nih.gov; tadashi.yamamoto@oist.jp			OIST; KAKENHI from the Japan Society for the Promotion of Science (JSPS) [21229006, 25121734, 26830066, 16K18437, 24890289, 26893050]	OIST(Okinawa Institute of Science & Technology Graduate University); KAKENHI from the Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	The authors would like to thank Dr. Hiroyuki Miyoshi (RIKEN) for lentivirus vector system. The authors also thank all the members of Cell Signal Unit at the Okinawa Institute of Science and Technology Graduate University (OIST) for discussion and advice. This research was supported by subsidiary of OIST and KAKENHI Grants-in-Aid for scientific research (S) (21229006 to TY), for Scientific Research on Innovative Areas (25121734 to TY), for Young Scientists (B) (26830066 to AM and 16K18437 to MH), and for Research Activity Start-up (24890289 to Y-TS and 26893050 to MH) from the Japan Society for the Promotion of Science (JSPS).	Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Aslam A, 2009, MOL BIOL CELL, V20, P3840, DOI 10.1091/mbc.E09-02-0146; Bartlam M, 2010, PROTEIN CELL, V1, P443, DOI 10.1007/s13238-010-0060-8; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Castro D, 2017, ONCOTARGET, V8, P81679, DOI 10.18632/oncotarget.20955; Cejas P, 2017, CANCER RES, V77, P766, DOI 10.1158/0008-5472.CAN-16-1346; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; Dela Cruz CS, 2011, CLIN CHEST MED, V32, P605, DOI 10.1016/j.ccm.2011.09.001; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Faraji F, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005820; Faraji F, 2014, GENOME RES, V24, P227, DOI 10.1101/gr.166223.113; Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldstrohm AC, 2008, NAT REV MOL CELL BIO, V9, P337, DOI 10.1038/nrm2370; Harris T, 2011, CLIN CANCER RES, V17, P690, DOI 10.1158/1078-0432.CCR-10-1892; Horie M, 2017, MOL CANCER RES, V15, P1354, DOI 10.1158/1541-7786.MCR-17-0191; Horie M, 2016, SCI REP-UK, V6, DOI 10.1038/srep33666; Hoshina N, 2013, NEURON, V78, P839, DOI 10.1016/j.neuron.2013.03.031; Hoshino Y, 2011, J BIOCHEM, V149, P55, DOI 10.1093/jb/mvq114; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Inoue T, 2015, J EXP MED, V212, P1465, DOI 10.1084/jem.20150384; Ito K, 2011, PROTEIN CELL, V2, P755, DOI 10.1007/s13238-011-1092-4; Jiang WB, 2017, AM J TRANSL RES, V9, P2024; Kanamori-Katayama M, 2011, GENOME RES, V21, P1150, DOI 10.1101/gr.115469.110; Kawabe S, 2000, ONCOGENE, V19, P5359, DOI 10.1038/sj.onc.1203935; Landi MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001651; Lau NC, 2009, BIOCHEM J, V422, P443, DOI 10.1042/BJ20090500; Li WG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13770; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Mittal S, 2011, MOL BIOL CELL, V22, P748, DOI 10.1091/mbc.E10-11-0898; Morita M, 2007, MOL CELL BIOL, V27, P4980, DOI 10.1128/MCB.02304-06; Morita M, 2011, EMBO J, V30, P4678, DOI 10.1038/emboj.2011.320; Nabel EG, 2002, NAT REV DRUG DISCOV, V1, P587, DOI 10.1038/nrd869; Neely GG, 2010, CELL, V141, P142, DOI 10.1016/j.cell.2010.02.023; Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403; Petersen I, 2016, J CANCER RES CLIN, V142, P895, DOI 10.1007/s00432-015-2004-4; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schuster K, 2014, MOL CANCER RES, V12, P912, DOI 10.1158/1541-7786.MCR-13-0620-T; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Shirai YT, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00286; Shirai Y, 2011, AM J PATHOL, V179, P2920, DOI 10.1016/j.ajpath.2011.08.022; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Suzuki T, 2015, SCI REP-UK, V5, DOI 10.1038/srep14779; Takahashi A, 2012, BIOCHEM BIOPH RES CO, V419, P268, DOI 10.1016/j.bbrc.2012.02.007; Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582; Wani MA, 1999, J BIOL CHEM, V274, P21180, DOI 10.1074/jbc.274.30.21180; Watanabe C, 2014, P NATL ACAD SCI USA, V111, P2692, DOI 10.1073/pnas.1316932111; Wehrkamp CJ, 2018, RNA BIOL, V15, P391, DOI 10.1080/15476286.2017.1422471; Winkelmann R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097953; Wu JH, 2004, ONCOGENE, V23, P8088, DOI 10.1038/sj.onc.1207996; Yin L, 2015, TUMOR BIOL, V36, P3075, DOI 10.1007/s13277-014-2943-4; Zheng XF, 2016, STEM CELL REP, V7, P897, DOI 10.1016/j.stemcr.2016.09.007; Zheng XF, 2012, STEM CELLS, V30, P910, DOI 10.1002/stem.1070	59	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2580	2594		10.1038/s41388-018-0603-7	http://dx.doi.org/10.1038/s41388-018-0603-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531840	Green Submitted			2022-12-17	WOS:000463335200010
J	Tessari, A; Parbhoo, K; Pawlikowski, M; Fassan, M; Rulli, E; Foray, C; Fabbri, A; Embrione, V; Ganzinelli, M; Capece, M; Campbell, MJ; Broggini, M; La Perle, K; Farina, G; Cole, S; Marabese, M; Hernandez, M; Amann, JM; Pruneri, G; Carbone, DP; Garassino, MC; Croce, CM; Palmieri, D; Coppola, V				Tessari, Anna; Parbhoo, Kareesma; Pawlikowski, Meghan; Fassan, Matteo; Rulli, Eliana; Foray, Claudia; Fabbri, Alessandra; Embrione, Valerio; Ganzinelli, Monica; Capece, Marina; Campbell, Moray J.; Broggini, Massimo; La Perle, Krista; Farina, Gabriella; Cole, Sara; Marabese, Mirko; Hernandez, Marianna; Amann, Joseph M.; Pruneri, Giancarlo; Carbone, David P.; Garassino, Marina C.; Croce, Carlo M.; Palmieri, Dario; Coppola, Vincenzo			RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; DOUBLE-EDGED-SWORD; LUNG-CANCER; CHEMOTHERAPY; CISPLATIN; THERAPY; EXPRESSION; TUMORS; RESISTANCE; STABILITY	Although limited by severe side effects and development of resistance platinum-based therapies still represent the most common first-line treatment for non-small cell lung cancer (NSCLC). However a crucial need in the clinical management of NSCLC is represented by the identification of cases sensitive to DNA damage response (DDR)-targeting drugs such as cisplatin or PARP inhibitors. Here we provide a molecular rationale for the stratification of NSCLC patients potentially benefitting from platinum compounds based on the expression levels of RANBP9 a recently identified player of the cellular DDR. RANBP9 was found overexpressed by immunohistochemistry (IHC) in NSCLC compared to normal adjacent tissues (NATs) (n = 147). Moreover a retrospective analysis of 132 platinum-treated patients from the multi-centric TAILOR trial showed that RANBP9 overexpression levels are associated with clinical response to platinum compounds [Progression Free Survival Hazard Ratio ((RANBP9 high vs low) )1.73, 95% CI 1.15-2.59, p = 0.0084 Overall Survival HR (RANBP9 high vs low) 1.99, 95% CI 1.27-3.11, p = 0.003]. Accordingly RANBP9 KO cells showed higher sensitivity to cisplatin in comparison with WT controls both in vitro and in vivo models. NSCLC RANBP9 KO cells were also more sensitive than control cells to the PARP inhibitor olaparib alone and in combination with cisplatin due to defective ATM-dependent and hyper-activated PARP-dependent DDR. The current investigation paves the way to prospective studies to assess the clinical value of RANBP9 protein levels as prognostic and predictive biomarker of response to DDR-targeting drugs leading to the development of new tools for the management of NSCLC patients.	[Tessari, Anna; Parbhoo, Kareesma; Pawlikowski, Meghan; Foray, Claudia; Embrione, Valerio; Capece, Marina; Hernandez, Marianna; Croce, Carlo M.; Palmieri, Dario; Coppola, Vincenzo] Ohio State Univ, Coll Med, Dept Canc Biol & Genet, Columbus, OH 43210 USA; [Tessari, Anna; Parbhoo, Kareesma; Pawlikowski, Meghan; Foray, Claudia; Embrione, Valerio; Capece, Marina; La Perle, Krista; Hernandez, Marianna; Amann, Joseph M.; Carbone, David P.; Croce, Carlo M.; Palmieri, Dario; Coppola, Vincenzo] Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA; [Fassan, Matteo] Univ Padua, Surg Pathol Unit, Dept Med DIMED, Padua, Italy; [Rulli, Eliana; Broggini, Massimo; Marabese, Mirko] IRCCS Ist Ric Farmacol Mario Negri, Dept Oncol, Milan, Italy; [Fabbri, Alessandra] Fdn IRCCS Ist Nazl Tumori, Dept Pathol & Lab Med, Milan, Italy; [Ganzinelli, Monica; Garassino, Marina C.] Ist Nazl Tumori, Fdn IRCCS, Dept Med Oncol, Thorac Oncol Unit, Milan, Italy; [Campbell, Moray J.] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmaceut Chem, 536 Pk Hall, Columbus, OH 43210 USA; [La Perle, Krista] Ohio State Univ, Coll Vet Med, Dept Vet Biosci & Comparat Pathol & Mouse Phenoty, Columbus, OH 43210 USA; [Farina, Gabriella] Osped Fatebenefratelli & Oftalm, Dept Oncol, Milan, Italy; [Cole, Sara] Ohio State Univ, Campus Microscopy & Imaging Facil, Columbus, OH 43210 USA; [Amann, Joseph M.; Carbone, David P.] Ohio State Univ, Dept Internal Med, Coll Med, James Thorac Ctr, Columbus, OH 43210 USA; [Pruneri, Giancarlo] Ist Nazl Tumori, Fdn IRCCS, Div Pathol, Milan, Italy	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Padua; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Fondazione IRCCS Istituto Nazionale Tumori Milan	Coppola, V (corresponding author), Ohio State Univ, Coll Med, Dept Canc Biol & Genet, Columbus, OH 43210 USA.; Coppola, V (corresponding author), Arthur G James Comprehens Canc Ctr, Columbus, OH 43210 USA.	vincenzo.coppola@osumc.edu	Ganzinelli, Monica/K-4548-2016; Pruneri, Giancarlo/AAC-7767-2022; Foray, Claudia/AAU-5895-2021; Marabese, Mirko/AAA-6876-2019; Coppola, Vincenzo/D-5352-2014; Embrione, Valerio/AAB-3897-2019; Cole, Sara L/GYQ-5700-2022; La Perle, Krista Marie DuBray/B-3099-2015; Campbell, Moray/ABF-1264-2021; broggini, massimo/AAA-6460-2020; Rulli, Eliana/K-3211-2018; Fassan, Matteo/F-5152-2012	Ganzinelli, Monica/0000-0002-0526-0835; Pruneri, Giancarlo/0000-0002-7963-7172; Marabese, Mirko/0000-0001-9379-0301; Coppola, Vincenzo/0000-0001-6163-1779; Embrione, Valerio/0000-0003-0184-3862; Campbell, Moray/0000-0002-3355-0928; Palmieri, Dario/0000-0002-0797-4268; Rulli, Eliana/0000-0003-1058-4137; Foray, Claudia/0000-0003-0384-5765; Parbhoo, Kareesma/0000-0002-4806-9571; Fassan, Matteo/0000-0001-6515-5482	Pelotonia Fellowship for Cancer Research; College of Medicine of the Ohio State University; Office of Research of the Ohio State University; Comprehensive Cancer Center of the Ohio State University; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER	Pelotonia Fellowship for Cancer Research; College of Medicine of the Ohio State University; Office of Research of the Ohio State University; Comprehensive Cancer Center of the Ohio State University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Authors are thankful to Dr. R. Shakya and the Target Validation Shared Resource, the Campus Microscopy & Imaging Facility, the Analytical Cytometry Shared Resource, the Comparative Pathology and Mouse Phenotyping Shared Resource, the Genetically Engineered Mouse Modeling Core, and N. Single and L. Monovich of the Biospecimen Services Shared Resource of the Ohio State University-Comprehensive Cancer Center. A.T. and M.P. are recipients of a Pelotonia Fellowship for Cancer Research. This work was supported by start-up funds to V.C. from the College of Medicine, Office of Research, and Comprehensive Cancer Center of the Ohio State University.	Arafa HMM, 2006, TOXICOLOGY, V222, P103, DOI 10.1016/j.tox.2006.02.007; Atabakhsh E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047803; Atabakhsh E, 2009, MOL CANCER RES, V7, P1962, DOI 10.1158/1541-7786.MCR-09-0098; Ballestrero A, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1296-3; Bonanno L, 2013, TRANSL LUNG CANCER R, V2, P160, DOI 10.3978/j.issn.2218-6751.2013.03.07; Brouwers Elke E M, 2008, BMC Clin Pharmacol, V8, P7, DOI 10.1186/1472-6904-8-7; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Ceccaldi R, 2015, NATURE, V518, P258, DOI 10.1038/nature14184; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; Chaudhary UB, 2003, DRUGS, V63, P1565, DOI 10.2165/00003495-200363150-00004; Chen MK, 2016, AM J CANCER RES, V6, P827; Drottar M, 2006, LARYNGOSCOPE, V116, P292, DOI 10.1097/01.mlg.0000197630.85208.36; Eustermann S, 2015, MOL CELL, V60, P742, DOI 10.1016/j.molcel.2015.10.032; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Garassino MC, 2013, LANCET ONCOL, V14, P981, DOI 10.1016/S1470-2045(13)70310-3; Ghosal G, 2013, TRANSL CANCER RES, V2, P107, DOI 10.3978/j.issn.2218-676X.2013.04.01; Hatzopoulos S, 1999, ANN NY ACAD SCI, V884, P211, DOI 10.1111/j.1749-6632.1999.tb08643.x; Hoernes TP, 2016, RNA BIOL, V13, P760, DOI 10.1080/15476286.2016.1203504; Horibe S, 2015, LIFE SCI, V124, P31, DOI 10.1016/j.lfs.2015.01.011; Jin HO, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.63; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kellar A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/621324; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Kris MG, 2017, J CLIN ONCOL; Kuribayashi K, 2016, J CANCER RES THER, V12, P528, DOI 10.4103/0973-1482.174185; Lee SM, 2017, J CLIN ONCOL, V35, P402, DOI 10.1200/JCO.2016.68.1841; Leung AWY, 2017, CLIN CANCER RES, V23, P6555, DOI 10.1158/1078-0432.CCR-17-0700; Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014; Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Palmieri D, 2016, ONCOTARGET, V7, P18371, DOI 10.18632/oncotarget.7813; Pawlowska E, 2015, INT J MOL SCI, V16, P27535, DOI 10.3390/ijms161126049; Pisters KMW, 2007, J CLIN ONCOL, V25, P5506, DOI 10.1200/JCO.2007.14.1226; Postel-Vinay S, 2012, NAT REV CLIN ONCOL, V9, P144, DOI 10.1038/nrclinonc.2012.3; Quinn JE, 2003, CANCER RES, V63, P6221; Reinhold WC, 2017, TRENDS CANCER, V3, P2, DOI 10.1016/j.trecan.2016.11.002; Rosell R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001129; Salemi LM, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170081; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Sears CR, 2016, DNA REPAIR, V40, P35, DOI 10.1016/j.dnarep.2016.02.004; Shao S, 2016, ANTICANCER RES, V36, P1295; Shukuya T, 2016, J THORAC ONCOL, V11, P976, DOI 10.1016/j.jtho.2016.02.015; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Socinski MA, 2018, J THORAC ONCOL, V13, P165, DOI 10.1016/j.jtho.2017.11.111; Suresh B, 2012, DRUG DISCOV TODAY, V17, P379, DOI 10.1016/j.drudis.2011.10.030; Suresh B, 2010, J BIOL CHEM, V285, P35340, DOI 10.1074/jbc.M110.156836; Swift LH, 2014, INT J MOL SCI, V15, P3403, DOI 10.3390/ijms15033403; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Woods D, 2013, CANCER BIOL THER, V14, P379, DOI 10.4161/cbt.23761; Xiong Y, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0905-6; Yard BD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11428; Zhao ZH, 2017, ANTICANCER RES, V37, P4389, DOI 10.21873/anticanres.11833; Zhu LL, 2016, J BIOL REG HOMEOS AG, V30, P103	54	9	9	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2018	37	50					6463	6476		10.1038/s41388-018-0424-8	http://dx.doi.org/10.1038/s41388-018-0424-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HE0WA	30076413	Green Accepted			2022-12-17	WOS:000452989100006
J	Cai, H; Cho, EA; Li, Y; Sockler, J; Parish, CR; Chong, BH; Edwards, J; Dodds, TJ; Ferguson, PM; Wilmott, JS; Scolyer, RA; Halliday, GM; Khachigian, LM				Cai, Hong; Cho, Eun-Ae; Li, Yue; Sockler, Jim; Parish, Christopher R.; Chong, Beng H.; Edwards, Jarem; Dodds, Tristan J.; Ferguson, Peter M.; Wilmott, James S.; Scolyer, Richard A.; Halliday, Gary M.; Khachigian, Levon M.			Melanoma protective antitumor immunity activated by catalytic DNA	ONCOGENE			English	Article							CD4 T-CELLS; C-JUN; EXPRESSION; INHIBITION; SURVIVAL; DNAZYME; GROWTH; GENE; CARCINOMA; MUTATION	Melanoma incidence is increasing worldwide, and although drugs such as BRAF/MEK small-molecule inhibitors and immune checkpoint antibodies improve patient outcomes, most patients ultimately fail these therapies and alternative treatment strategies are urgently needed. DNAzymes have recently undergone clinical trials with signs of efficacy and no serious adverse events attributable to the DNAzyme. Here we investigated c-Jun expression in human primary and metastatic melanoma. We also explored the role of T cell immunity in DNAzyme inhibition of primary melanoma growth and the prevention of growth in non-treated tumors after the cessation of treatment in a mouse model. c-Jun was expressed in 80% of melanoma cells in human primary melanomas (n = 17) and in 83% of metastatic melanoma cells (n = 38). In contrast, c-Jun was expressed in only 11% of melanocytes in benign nevi (n = 24). Dz13, a DNAzyme targeting c-Jun/AP-1, suppressed both Dz13-injected and untreated B16F10 melanoma growth in the same mice, an abscopal effect relieved in each case by administration of anti-CD4/anti-CD8 antibodies. Dz13 increased levels of cleaved caspase-3 within the tumors. New, untreated melanomas grew poorly in mice previously treated with Dz13. Administration of anti-CD4/anti-CD8 antibodies ablated this inhibitory effect and the tumors grew rapidly. Dz13 inhibited c-Jun expression, reduced intratumoral vascularity (vascular lumina area defined by CD31 staining), and increased CD4(+) cells within the tumors. This study provides the first demonstration of an abscopal effect of a DNAzyme on tumor growth and shows that Dz13 treatment prevents growth of subsequent new tumors in the same animal. Dz13 may be useful clinically as a therapeutic antitumor agent by preventing tumor relapse through adaptive immunity.	[Cai, Hong; Li, Yue; Khachigian, Levon M.] Univ New South Wales, Sch Med Sci, Vasc Biol & Translat Res, Sydney, NSW 2052, Australia; [Cai, Hong; Li, Yue; Khachigian, Levon M.] Univ New South Wales, UNSW Med, Sydney, NSW 2052, Australia; [Cho, Eun-Ae; Halliday, Gary M.] Univ Sydney, Dermatol Res Labs, Sydney, NSW 2006, Australia; [Cho, Eun-Ae; Halliday, Gary M.] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Sockler, Jim] Datapharm Australia, Stat Operat & Programming, Sydney, NSW 2047, Australia; [Parish, Christopher R.] Australian Natl Univ, John Curtin Sch Med Res, Canc & Vasc Biol Grp, Bldg 131,Garran Rd, Canberra, ACT 2601, Australia; [Chong, Beng H.] Univ New South Wales, St George Clin Sch, Kogarah, NSW 2217, Australia; [Chong, Beng H.] St George Hosp, Dept Haematol, Kogarah, NSW 2217, Australia; [Edwards, Jarem; Dodds, Tristan J.; Ferguson, Peter M.; Wilmott, James S.; Scolyer, Richard A.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2050, Australia	University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; University of Sydney; Australian National University; John Curtin School of Medical Research; University of New South Wales Sydney; St George Hospital; Melanoma Institute Australia; University of Sydney	Khachigian, LM (corresponding author), Univ New South Wales, Sch Med Sci, Vasc Biol & Translat Res, Sydney, NSW 2052, Australia.; Khachigian, LM (corresponding author), Univ New South Wales, UNSW Med, Sydney, NSW 2052, Australia.	L.Khachigian@unsw.edu.au	Chong, Beng/AAM-9010-2021; Chong, Beng/AAE-2617-2019; Scolyer, Richard/AAE-8511-2019; Wilmott, James/AGA-8227-2022; Li, Yue/AAB-3024-2019; Khachigian, Levon/AAZ-7458-2020	Scolyer, Richard/0000-0002-8991-0013; Wilmott, James/0000-0002-6750-5244; Parish, Christopher/0000-0001-7740-0430; Ferguson, Peter M./0000-0002-8335-0406; Li, Yue/0000-0002-5304-9188	Translational Program Grant from Cancer Institute of New South Wales; National Health and Medical Research Council of Australia	Translational Program Grant from Cancer Institute of New South Wales; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This study was supported by a Translational Program Grant from Cancer Institute of New South Wales, and Program and Fellowship support from National Health and Medical Research Council of Australia.	Apalla Zoe, 2017, Dermatol Pract Concept, V7, P1, DOI 10.5826/dpc.0702a01; BARTH A, 1995, J AM COLL SURGEONS, V181, pA193; Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010; Bhindi R, 2007, AM J PATHOL, V171, P1079, DOI 10.2353/ajpath.2007.070120; Cai H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003960; Cao Y, 2014, MOL THER, V22, P371, DOI 10.1038/mt.2013.257; Castle JC, 2012, CANCER RES, V72, P1081, DOI 10.1158/0008-5472.CAN-11-3722; Cho EA, 2013, LANCET, V381, P1835, DOI 10.1016/S0140-6736(12)62166-7; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588; Hoefer F, 2017, ANAL METHODS-UK, V9, P697, DOI 10.1039/c6ay03061k; Hooijkaas AI, 2012, ONCOIMMUNOLOGY, V1, P609, DOI 10.4161/onci.20226; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Johnson DB, 2015, JAMA ONCOL, V1, P380, DOI 10.1001/jamaoncol.2015.0565; Kahan-Hanum M, 2013, SCI REP-UK, V3, DOI 10.1038/srep01535; Kakavand H, 2015, MODERN PATHOL, V28, P1535, DOI 10.1038/modpathol.2015.110; Kappelmann M, 2014, EUR J CELL BIOL, V93, P76, DOI 10.1016/j.ejcb.2013.10.003; Khachigian LM, 2000, J CLIN INVEST, V106, P1189, DOI 10.1172/JCI11620; Khachigian LM, 2002, J BIOL CHEM, V277, P22985, DOI 10.1074/jbc.M200977200; Korn EL, 2008, J CLIN ONCOL, V26, P527, DOI 10.1200/JCO.2007.12.7837; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; Lardone RD, 2016, ONCOTARGET, V7, P14415, DOI 10.18632/oncotarget.7361; Li Y, 2013, INT J CARDIOL, V168, P3659, DOI 10.1016/j.ijcard.2013.05.092; Liu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep21319; Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43; Madore J, 2016, CLIN CANCER RES, V22, P3915, DOI 10.1158/1078-0432.CCR-15-1714; Mann GJ, 2013, J INVEST DERMATOL, V133, P509, DOI 10.1038/jid.2012.283; Melanoma-Institute-Australia, 2015, MEL FACTS STAT; Nedergaard BS, 2007, BRIT J CANCER, V97, P1135, DOI 10.1038/sj.bjc.6604001; Perales MA, 2004, ANN SURG ONCOL, V11, P881, DOI 10.1245/ASO.2004.08.911; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shklovskaya E, 2016, IMMUNOL CELL BIOL, V94, P593, DOI 10.1038/icb.2016.14; Tan ML, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-9; Xie JJ, 2014, BBA-MOL BASIS DIS, V1842, P2479, DOI 10.1016/j.bbadis.2014.04.017; Yan SF, 2016, ANTICANCER RES, V36, P6449, DOI 10.21873/anticanres.11243; Zanetti M, 2015, J IMMUNOL, V194, P2049, DOI 10.4049/jimmunol.1402669; Zhang G, 2006, ONCOGENE, V25, P7260, DOI 10.1038/sj.onc.1209726; Zhang GS, 2004, JNCI-J NATL CANCER I, V96, P683, DOI 10.1093/jnci/djh120; Zhang ZP, 2017, MICROB PATHOGENESIS, V103, P155, DOI 10.1016/j.micpath.2016.12.024	42	9	10	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5115	5126		10.1038/s41388-018-0306-0	http://dx.doi.org/10.1038/s41388-018-0306-0			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29844573				2022-12-17	WOS:000444405300007
J	Corkery, DP; Clarke, LE; Gebremeskel, S; Salsman, J; Pinder, J; Le Page, C; Meunier, L; Xu, Z; Mes-Masson, AM; Berman, JN; Johnston, B; Dellaire, G				Corkery, D. P.; Clarke, L. E.; Gebremeskel, S.; Salsman, J.; Pinder, J.; Le Page, C.; Meunier, L.; Xu, Z.; Mes-Masson, A-M; Berman, J. N.; Johnston, B.; Dellaire, G.			Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking	ONCOGENE			English	Article							GYNECOLOGIC-ONCOLOGY-GROUP; EPITHELIAL-MESENCHYMAL TRANSITION; OVARIAN-CANCER; MALIGNANT ASCITES; DOWN-REGULATION; CELL-SURVIVAL; EGF RECEPTOR; SR PROTEINS; SPLICING FACTORS; TYROSINE KINASE	Anoikis acts as a critical barrier to metastasis by inducing cell death upon cancer cell detachment from the extracellular matrix (ECM), thereby preventing tumor cell dissemination to secondary sites. The induction of anoikis requires the lysosomal-mediated downregulation of epidermal growth factor receptors (EGFRs) leading to termination of pro-survival signaling. In this study, we demonstrate that depletion of pre-mRNA splicing factor 4 kinase (PRP4K; also known as PRPF4B) causes dysregulation of EGFR trafficking and anoikis resistance. We also report a novel cytoplasmic localization of PRP4K at the late endosome, and demonstrate both nuclear and cytoplasmic localization in breast, lung and ovarian cancer tissue. Mechanistically, depletion of PRP4K leads to reduced EGFR degradation following cell detachment from the ECM and correlates with increased TrkB, vimentin and Zeb1 expression. As a result, PRP4K loss promotes sustained growth factor signaling and increased cellular resistance to anoikis in vitro and in a novel zebrafish xenotransplantation model of anoikis sensitivity, as well as increased metastasis in a mouse model of ovarian cancer. Thus, PRP4K may serve as a potential biomarker of anoikis sensitivity in ovarian and other epithelial cancers.	[Corkery, D. P.; Dellaire, G.] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada; [Corkery, D. P.; Clarke, L. E.; Salsman, J.; Pinder, J.; Xu, Z.; Berman, J. N.; Johnston, B.; Dellaire, G.] Dalhousie Univ, Dept Pathol, POB 15000, Halifax, NS B3H 4R2, Canada; [Gebremeskel, S.; Berman, J. N.; Johnston, B.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada; [Le Page, C.; Meunier, L.; Mes-Masson, A-M] Ctr Hosp Univ Montreal CRCHUM, Ctr Rech, Montreal, PQ, Canada; [Le Page, C.; Meunier, L.; Mes-Masson, A-M] Inst Canc Montreal, Montreal, PQ, Canada; [Mes-Masson, A-M] Univ Montreal, Dept Med, Montreal, PQ, Canada; [Berman, J. N.] IWK Hlth Ctr, Dept Pediat, Halifax, NS, Canada; [Berman, J. N.; Johnston, B.; Dellaire, G.] Beatrice Hunter Canc Res Inst, Halifax, NS, Canada; [Johnston, B.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Universite de Montreal; Universite de Montreal; Universite de Montreal; Dalhousie University; Dalhousie University	Dellaire, G (corresponding author), Dalhousie Univ, Dept Pathol, POB 15000, Halifax, NS B3H 4R2, Canada.; Johnston, B (corresponding author), Dalhousie Univ, Dept Microbiol, POB 15000, Halifax, NS B3H 4R2, Canada.; Johnston, B (corresponding author), Dalhousie Univ, Dept Immunol, POB 15000, Halifax, NS B3H 4R2, Canada.	brent.johnston@dal.ca; dellaire@dal.ca	gebremeskel, Simon/AAZ-3334-2020; Le Page, Cecile/B-3215-2010; Johnston, Brent/E-2607-2013; Dellaire, Graham/L-9948-2014	gebremeskel, Simon/0000-0002-8484-8177; Le Page, Cecile/0000-0002-8020-1544; Johnston, Brent/0000-0001-5456-2824; Dellaire, Graham/0000-0002-3466-6316; Corkery, Dale/0000-0001-7930-0134; Mes-Masson, Anne-Marie/0000-0002-6498-266X	Cancer Research Network Tissue Bank of the Fonds de recherche du Quebec-Sante (FRQS); Canadian Breast Cancer Foundation (CBCF); Breast Cancer Society/QEII Foundation; Canadian Institutes of Health Research (CIHR) [MOP-110988, PJT-153285]; BHCRI; CBCF-Atlantic; Canadian Cancer Society, Nova Scotia Division as part of The Terry Fox Foundation Strategic Health Research Training (STIHR) Program in Cancer Research at the CIHR; Killam Trusts; CIHR	Cancer Research Network Tissue Bank of the Fonds de recherche du Quebec-Sante (FRQS); Canadian Breast Cancer Foundation (CBCF); Breast Cancer Society/QEII Foundation; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); BHCRI; CBCF-Atlantic; Canadian Cancer Society, Nova Scotia Division as part of The Terry Fox Foundation Strategic Health Research Training (STIHR) Program in Cancer Research at the CIHR; Killam Trusts; CIHR(Canadian Institutes of Health Research (CIHR))	We thank the Gynecology-Oncology and Pathology services of the CHUM-Hopital Notre-Dame for tumor procurement, Gretchen Wagner for fish care, and Monique Bernard for technical assistance. Ovarian and breast tumor banking was supported by the Cancer Research Network Tissue Bank of the Fonds de recherche du Quebec-Sante (FRQS). This work was funded by research grants from the Canadian Breast Cancer Foundation (CBCF) and the Breast Cancer Society/QEII Foundation awarded to GD, and research grants to BJ from the Canadian Institutes of Health Research (CIHR) (MOP-110988, PJT-153285). GD, JB and BJ are Senior Scientists of the Beatrice Hunter Cancer Research Institute (BHCRI), and DPC, LC, JS and JP were supported by trainee awards from the BHCRI with funds provided by CBCF-Atlantic, The Canadian Cancer Society, Nova Scotia Division as part of The Terry Fox Foundation Strategic Health Research Training (STIHR) Program in Cancer Research at the CIHR. SG is the recipient of doctoral awards from the Killam Trusts, CIHR, and BHCRI.	Adam RA, 2004, J AM COLL SURGEONS, V198, P999, DOI 10.1016/j.jamcollsurg.2004.01.035; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Alanko J, 2015, NAT CELL BIOL, V17, P1412, DOI 10.1038/ncb3250; Ayantunde AA, 2007, ANN ONCOL, V18, P945, DOI 10.1093/annonc/mdl499; Bedard K, 2009, HUM MUTAT, V30, P1123, DOI 10.1002/humu.21029; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bookman MA, 1996, J CLIN ONCOL, V14, P1895, DOI 10.1200/JCO.1996.14.6.1895; Cai Q, 2015, ONCOGENE, V34, P3315, DOI 10.1038/onc.2014.264; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Corkery DP, 2015, CELL CYCLE, V14, P1059, DOI 10.1080/15384101.2015.1007775; Corkery DP, 2011, BRIT J HAEMATOL, V153, P786, DOI 10.1111/j.1365-2141.2011.08661.x; Dellaire G, 2002, MOL CELL BIOL, V22, P5141, DOI 10.1128/MCB.22.14.5141-5156.2002; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; EARP HS, 1986, J BIOL CHEM, V261, P4777; Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9; FELDMAN GB, 1972, CANCER RES, V32, P1663; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; GARRISON RN, 1986, ANN SURG, V203, P644, DOI 10.1097/00000658-198606000-00009; Gebremeskel S, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.995562; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giannoni E, 2008, CELL DEATH DIFFER, V15, P867, DOI 10.1038/cdd.2008.3; Grassian AR, 2011, J BIOL CHEM, V286, P79, DOI 10.1074/jbc.M110.169821; Gross T, 1997, NUCLEIC ACIDS RES, V25, P1028, DOI 10.1093/nar/25.5.1028; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Herzog TJ, 2004, CLIN CANCER RES, V10, P7439, DOI 10.1158/1078-0432.CCR-04-0683; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kojima T, 2001, J BIOL CHEM, V276, P32247, DOI 10.1074/jbc.M103790200; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lai MC, 2000, J BIOL CHEM, V275, P7950, DOI 10.1074/jbc.275.11.7950; Lam AJ, 2012, NAT METHODS, V9, P1005, DOI [10.1038/NMETH.2171, 10.1038/nmeth.2171]; Le Page C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038541; Letourneau IJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-379; MARKMAN M, 1992, J CLIN ONCOL, V10, P1485, DOI 10.1200/JCO.1992.10.9.1485; Martin MJ, 2006, MOL CELL BIOL, V26, P1754, DOI 10.1128/MCB.26.5.1754-1769.2006; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Montembault E, 2007, J CELL BIOL, V179, P601, DOI 10.1083/jcb.200703133; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nguyen LN, 2006, CLIN CANCER RES, V12, P6952, DOI 10.1158/1078-0432.CCR-06-0317; Ozols RF, 2003, J CLIN ONCOL, V21, P3194, DOI 10.1200/JCO.2003.02.153; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Parsons SL, 1996, EUR J SURG ONCOL, V22, P237, DOI 10.1016/S0748-7983(96)80009-6; Pinder J, 2015, NUCLEIC ACIDS RES, V43, P9379, DOI 10.1093/nar/gkv993; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; ROSENBERG GH, 1991, MOL GEN GENET, V226, P305, DOI 10.1007/BF00273617; Scharaw S, 2016, J CELL BIOL, V215, P543, DOI 10.1083/jcb.201601090; Schneider M, 2010, NAT STRUCT MOL BIOL, V17, P216, DOI 10.1038/nsmb.1718; Smit MA, 2011, ONCOGENE, V30, P3735, DOI 10.1038/onc.2011.96; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Wang PP, 2014, MOL CELL, V54, P378, DOI 10.1016/j.molcel.2014.03.007; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; WILEY HS, 1991, J BIOL CHEM, V266, P11083; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	65	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					174	184		10.1038/onc.2017.318	http://dx.doi.org/10.1038/onc.2017.318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28892043	Green Published, hybrid			2022-12-17	WOS:000422631700004
J	Weijts, BGMW; Westendorp, B; Hien, BT; Martinez-Lopez, LM; Zijp, M; Thurlings, I; Thomas, RE; Schulte-Merker, S; Bakker, WJ; de Bruin, A				Weijts, B. G. M. W.; Westendorp, B.; Hien, B. T.; Martinez-Lopez, L. M.; Zijp, M.; Thurlings, I.; Thomas, R. E.; Schulte-Merker, S.; Bakker, W. J.; de Bruin, A.			Atypical E2Fs inhibit tumor angiogenesis	ONCOGENE			English	Article							CELL-MIGRATION; TRANSCRIPTION; VASCULATURE; ACTIVATION; NETWORK; GROWTH; CANCER; ROLES; DLL4	Atypical E2F transcription factors (E2F7 and E2F8) function as key regulators of cell cycle progression and their inactivation leads to spontaneous cancer formation in mice. However, the mechanism of the tumor suppressor functions of E2F7/8 remain obscure. In this study we discovered that atypical E2Fs control tumor angiogenesis, one of the hallmarks of cancer. We genetically inactivated atypical E2Fs in epithelial and mesenchymal neoplasm and analyzed blood vessel formation in three different animal models of cancer. Tumor formation was either induced by application of 7,12-Dimethylbenz(a) anthracene/12-O-Tetradecanoylphorbol-13-acetate or by Myc/Ras overexpression. To our surprise, atypical E2Fs suppressed tumor angiogenesis in all three cancer models, which is in a sharp contrast to previous findings showing that atypical E2Fs promote angiogenesis during fetal development in mice and zebrafish. Real-time imaging in zebrafish displayed that fluorescent-labeled blood vessels showed enhanced intratumoral branching in xenografted E2f7/8-deficient neoplasms compared with E2f7/8-proficient neoplasms. DLL4 expression, a key negative inhibitor of vascular branching, was decreased in E2f7/8-deficient neoplastic cells, indicating that E2F7/8 might inhibit intratumoral vessel branching via induction of DLL4.	[Weijts, B. G. M. W.; Westendorp, B.; Hien, B. T.; Martinez-Lopez, L. M.; Zijp, M.; Thurlings, I.; Thomas, R. E.; Bakker, W. J.; de Bruin, A.] Univ Utrecht, Fac Vet Med, Dept Pathobiol, Utrecht, Netherlands; [Weijts, B. G. M. W.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Schulte-Merker, S.] Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands; [Schulte-Merker, S.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Bakker, W. J.] Univ Munster, Inst Cardiovasc Organogenesis & Regenerat, Cells In Mot Cluster Excellence, Munster, Germany; [de Bruin, A.] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, Amsterdam, Netherlands; [Weijts, B. G. M. W.; Westendorp, B.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, Div Mol Genet, Groningen, Netherlands	Utrecht University; University of California System; University of California San Diego; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; University of Munster; University of Amsterdam; Academic Medical Center Amsterdam; University of Groningen	Bakker, WJ; de Bruin, A (corresponding author), Acad Med Ctr UvA, Lab Expt Dermatol, Room L3-119,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	w.j.bakker@amc.uva.nl; a.debruin@uu.nl	Weijts, Bart/O-7107-2019; de Bruin, Alain/AAL-9195-2020	Weijts, Bart/0000-0003-4843-3019; Westendorp, Bart/0000-0003-1043-3638	Dutch Cancer Society [UU2009-4353, UU2013-5777]; Association of International Cancer Research [09-0718]; Netherlands Organization for Scientific Research [NWO-ALW 11-28]	Dutch Cancer Society(KWF Kankerbestrijding); Association of International Cancer Research; Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	This study was financially supported by grants from the Dutch Cancer Society (UU2009-4353) to WJB, and (UU2013-5777) to BW and AdB. From the Association of International Cancer Research (09-0718) to WJB, and from the Netherlands Organization for Scientific Research (NWO-ALW 11-28) to AdB.	Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183; Bakker WJ, 2013, TRANSCR-AUSTIN, V4, P62, DOI 10.4161/trns.23680; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Chen DN, 2009, NATURE, V462, P925, DOI 10.1038/nature08544; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868; de Bruin A, 2016, NUCLEIC ACIDS RES, V44, P3549, DOI 10.1093/nar/gkv1471; DeGregori J, 2006, CURR MOL MED, V6, P739; Deng Q, 2010, CANCER RES, V70, P782, DOI 10.1158/0008-5472.CAN-09-3082; Diez H, 2007, EXP CELL RES, V313, P1, DOI 10.1016/j.yexcr.2006.09.009; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Djordjevic S, 2013, DRUG DISCOV TODAY, V18, P447, DOI 10.1016/j.drudis.2012.11.013; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He SN, 2012, J PATHOL, V227, P431, DOI 10.1002/path.4013; Hogan BM, 2009, DEVELOPMENT, V136, P4001, DOI 10.1242/dev.039990; Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006; Kent LN, 2016, J CLIN INVEST, V126, P2955, DOI 10.1172/JCI85506; Li J, 2008, DEV CELL, V14, P62, DOI 10.1016/j.devcel.2007.10.017; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Magliozzi R, 2013, DEV CELL, V27, P574, DOI 10.1016/j.devcel.2013.10.023; Merdzhanova G, 2010, ONCOGENE, V29, P5392, DOI 10.1038/onc.2010.281; Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355; Pandit SK, 2012, NAT CELL BIOL, V14, P1181, DOI 10.1038/ncb2585; Park SA, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv151; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Raimondi C, 2013, SEMIN CELL DEV BIOL, V24, P172, DOI 10.1016/j.semcdb.2013.01.001; Thurlings I, 2017, ONCOGENE, V36, P829, DOI 10.1038/onc.2016.251; Weijts BGMW, 2012, EMBO J, V31, P3871, DOI 10.1038/emboj.2012.231; Westendorp B, 2012, NUCLEIC ACIDS RES, V40, P3511, DOI 10.1093/nar/gkr1203	31	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					271	276		10.1038/onc.2017.336	http://dx.doi.org/10.1038/onc.2017.336			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925392	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000422631700013
J	Gonyo, P; Bergom, C; Brandt, AC; Tsaih, SW; Sun, Y; Bigley, TM; Lorimer, EL; Terhune, SS; Rui, H; Flister, MJ; Long, RM; Williams, CL				Gonyo, P.; Bergom, C.; Brandt, A. C.; Tsaih, S-W; Sun, Y.; Bigley, T. M.; Lorimer, E. L.; Terhune, S. S.; Rui, H.; Flister, M. J.; Long, R. M.; Williams, C. L.			SmgGDS is a transient nucleolar protein that protects cells from nucleolar stress and promotes the cell cycle by regulating DREAM complex gene expression	ONCOGENE			English	Article							RNA-POLYMERASE-I; C-MYC; RIBOSOME BIOGENESIS; EMERGING TARGET; BRAIN CYTOSOL; TRANSCRIPTION; BINDING; UBF; GROWTH; LUNG	The chaperone protein and guanine nucleotide exchange factor SmgGDS (RAP1GDS1) is a key promoter of cancer cell proliferation and tumorigenesis. SmgGDS undergoes nucleocytoplasmic shuttling, suggesting that it has both cytoplasmic and nuclear functions that promote cancer. Previous studies indicate that SmgGDS binds cytoplasmic small GTPases and promotes their trafficking to the plasma membrane. In contrast, little is known about the functions of SmgGDS in the nucleus, or how these nuclear functions might benefit cancer cells. Here we show unique nuclear localization and regulation of gene transcription pathways by SmgGDS. Strikingly, SmgGDS depletion significantly reduces expression of over 600 gene products that are targets of the DREAM complex, which is a transcription factor complex that regulates expression of proteins controlling the cell cycle. The cell cycle regulators E2F1, MYC, MYBL2 (B-Myb) and FOXM1 are among the DREAM targets that are diminished by SmgGDS depletion. E2F1 is well known to promote G1 cell cycle progression, and the loss of E2F1 in SmgGDS-depleted cells provides an explanation for previous reports that SmgGDS depletion characteristically causes a G1 cell cycle arrest. We show that SmgGDS localizes in nucleoli, and that RNAimediated depletion of SmgGDS in cancer cells disrupts nucleolar morphology, signifying nucleolar stress. We show that nucleolar SmgGDS interacts with the RNA polymerase I transcription factor upstream binding factor (UBF). The RNAi-mediated depletion of UBF diminishes nucleolar localization of SmgGDS and promotes proteasome-mediated degradation of SmgGDS, indicating that nucleolar sequestration of SmgGDS by UBF stabilizes SmgGDS protein. The ability of SmgGDS to interact with UBF and localize in the nucleolus is diminished by expressing DiRas1 or DiRas2, which are small GTPases that bind SmgGDS and act as tumor suppressors. Taken together, our results support a novel nuclear role for SmgGDS in protecting malignant cells from nucleolar stress, thus promoting cell cycle progression and tumorigenesis.	[Gonyo, P.; Brandt, A. C.; Lorimer, E. L.; Williams, C. L.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA; [Gonyo, P.; Bergom, C.; Brandt, A. C.; Lorimer, E. L.; Rui, H.; Flister, M. J.; Williams, C. L.] Med Coll Wisconsin, Canc Ctr, Milwaukee, WI 53226 USA; [Bergom, C.] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA; [Tsaih, S-W; Flister, M. J.] Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Sun, Y.; Rui, H.] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA; [Bigley, T. M.; Terhune, S. S.; Long, R. M.] Med Coll Wisconsin, Dept Microbiol & Immunol, Milwaukee, WI 53226 USA; [Bigley, T. M.] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Terhune, S. S.] Med Coll Wisconsin, Biotechnol & Bioengn Ctr, Milwaukee, WI 53226 USA; [Flister, M. J.] Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53226 USA; [Flister, M. J.; Williams, C. L.] Med Coll Wisconsin, Cardiovasc Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA; [Long, R. M.] Med Coll Wisconsin, Cent Wisconsin Campus, Wausau, WI USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Washington University (WUSTL); Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Williams, CL (corresponding author), Med Coll Wisconsin, Cardiovasc Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.; Williams, CL (corresponding author), Med Coll Wisconsin, Dept Pharmacol & Toxicol, Canc Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	williams@mcw.edu		Rui, Hallgeir/0000-0002-8778-261X; Bigley, Tarin/0000-0001-7443-9436; Sun, Yunguang/0000-0003-4004-9514; Bergom, Carmen/0000-0002-0886-5055	NCI [R01 CA188871, R01 CA193343, R01 CA188575]; NIAID [R01 AI083281]; American Cancer Society [86-004-26]; Kathleen M Duffey Fogarty Eminent Scholar in Breast Cancer Research Award; Mary Kay Foundation [024.16]; Nancy Laning Sobczak, PhD, Breast Cancer Research Award; National Center for Research Resources; National Center for Advancing Translational Sciences; Office of the Director of the National Institutes of Health [8KL2TR000056]; NATIONAL CANCER INSTITUTE [R01CA188871, R01CA193343, R01CA188575] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI083281] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Cancer Society(American Cancer Society); Kathleen M Duffey Fogarty Eminent Scholar in Breast Cancer Research Award; Mary Kay Foundation; Nancy Laning Sobczak, PhD, Breast Cancer Research Award; National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Office of the Director of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Aniko Szabo (Medical College of Wisconsin) for assistance with statistical analysis. This work was supported by NCI R01 CA188871 (CLW), NCI R01 CA193343 (MJF), NIAID R01 AI083281 (SST), NCI R01 CA188575 (HR) and Institutional Research Grant 86-004-26 from the American Cancer Society (CB). Additional support was provided by the Kathleen M Duffey Fogarty Eminent Scholar in Breast Cancer Research Award (CLW), the Mary Kay Foundation Award Grant No. 024.16 (MJF), the Nancy Laning Sobczak, PhD, Breast Cancer Research Award (CB and CLW), and by the National Center for Research Resources, the National Center for Advancing Translational Sciences and the Office of the Director of the National Institutes of Health through Grant 8KL2TR000056 (CB).	Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Berg TJ, 2010, J BIOL CHEM, V285, P35255, DOI 10.1074/jbc.M110.129916; Bergom C, 2016, J BIOL CHEM, V291, P10948, DOI 10.1074/jbc.A115.696831; Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019; Chen DY, 2004, P NATL ACAD SCI USA, V101, P15106, DOI 10.1073/pnas.0404767101; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Derenzini M, 2004, J CLIN PATHOL, V57, P755, DOI 10.1136/jcp.2003.015917; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992; Donati G, 2011, J CELL SCI, V124, P3017, DOI 10.1242/jcs.086074; Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728; Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844; Ellis CA, 2002, P NATL ACAD SCI USA, V99, P9876, DOI 10.1073/pnas.142193799; Fields AP, 2010, ADV ENZYME REGUL, V50, P190, DOI 10.1016/j.advenzreg.2009.10.010; Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P164, DOI 10.1093/nar/gkv927; Goldenson B, 2015, ONCOGENE, V34, P537, DOI 10.1038/onc.2014.14; Grummt I, 2013, CHROMOSOMA, V122, P487, DOI 10.1007/s00412-013-0430-0; Hamdane N, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004505; Hauser AD, 2014, MOL CANCER RES, V12, P130, DOI 10.1158/1541-7786.MCR-13-0362; Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005; Holmberg Olausson Karl, 2012, Cells, V1, P774, DOI 10.3390/cells1040774; James A, 2014, NUCLEUS-PHILA, V5, P402, DOI 10.4161/nucl.32235; Justilien V, 2017, CANCER CELL, V31, P256, DOI 10.1016/j.ccell.2016.12.010; Kontani K, 2002, J BIOL CHEM, V277, P41070, DOI 10.1074/jbc.M202150200; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lanning CC, 2004, J BIOL CHEM, V279, P44197, DOI 10.1074/jbc.M404977200; Lanning CC, 2003, J BIOL CHEM, V278, P12495, DOI 10.1074/jbc.M211286200; Nguyen LXT, 2013, P NATL ACAD SCI USA, V110, P20681, DOI 10.1073/pnas.1313097110; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mais C, 2005, GENE DEV, V19, P50, DOI 10.1101/gad.310705; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259; McStay B, 2016, GENE DEV, V30, P1598, DOI 10.1101/gad.283838.116; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Muller GA, 2017, ONCOTARGET, V8, P97736, DOI 10.18632/oncotarget.10888; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Ntantie E, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003374; O'Sullivan AC, 2002, MOL CELL BIOL, V22, P657, DOI 10.1128/MCB.22.2.657-668.2002; Ogita Y, 2015, J BIOL CHEM, V290, P20245, DOI 10.1074/jbc.M115.637769; Panov KI, 2006, EMBO J, V25, P3310, DOI 10.1038/sj.emboj.7601221; Pich A, 2000, MICRON, V31, P133, DOI 10.1016/S0968-4328(99)00070-0; Portella G, 2011, CURR MED CHEM, V18, P482, DOI 10.2174/092986711794480203; Quaas M, 2012, CELL CYCLE, V11, P4661, DOI 10.4161/cc.22917; Quin JE, 2014, BBA-MOL BASIS DIS, V1842, P802, DOI 10.1016/j.bbadis.2013.12.009; Roberts A, 2013, NAT METHODS, V10, P71, DOI [10.1038/nmeth.2251, 10.1038/NMETH.2251]; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sanij E, 2009, EPIGENETICS-US, V4, P274, DOI 10.4161/epi.4.6.9449; Sanij E, 2008, J CELL BIOL, V183, P1259, DOI 10.1083/jcb.200805146; Schuld NJ, 2014, CELL CYCLE, V13, P941, DOI 10.4161/cc.27804; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Stefanovsky V, 2006, MOL CELL, V21, P629, DOI 10.1016/j.molcel.2006.01.023; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Sun XX, 2015, P NATL ACAD SCI USA, V112, P3734, DOI 10.1073/pnas.1411713112; Tew GW, 2008, J BIOL CHEM, V283, P963, DOI 10.1074/jbc.M707526200; Thoms HC, 2010, CANCER RES, V70, P139, DOI 10.1158/0008-5472.CAN-09-1397; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Woods SJ, 2015, BBA-GENE REGUL MECH, V1849, P821, DOI 10.1016/j.bbagrm.2014.10.007; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; Zhang YD, 2011, MOL CELL BIOL, V31, P4676, DOI 10.1128/MCB.05832-11; Zhi H, 2009, J PATHOL, V217, P389, DOI 10.1002/path.2456; Zhu YH, 2013, CANCER RES, V73, P2298, DOI 10.1158/0008-5472.CAN-12-2663	70	9	9	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6873	6883		10.1038/onc.2017.280	http://dx.doi.org/10.1038/onc.2017.280			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28806394	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000418041800004
J	Giebeler, N; Schonefuss, A; Landsberg, J; Tuting, T; Mauch, C; Zigrino, P				Giebeler, N.; Schoenefuss, A.; Landsberg, J.; Tuting, T.; Mauch, C.; Zigrino, P.			Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; INCREASED EXPRESSION; CELL-MIGRATION; CANCER-CELL; IN-VITRO; TUMOR; INVASION; METALLOPROTEINASES; PROLIFERATION; ABNORMALITIES	ADAM-9 is a metalloproteinase expressed in peritumoral areas by invading melanoma cells and by adjacent peritumoral stromal cells; however, its function in stromal and melanoma cells is not fully understood. To address this question in vivo in a spontaneous melanoma model, we deleted ADAM-9 in mice carrying the hepatocyte growth factor (Hgf) transgene and knock-in mutation Cdk4(R24C/R24C), demonstrated to spontaneously develop melanoma. Spontaneous melanoma arose less frequently in ADAM-9-deleted mice than in controls. Similarly reduced tumor numbers (although with faster growth kinetics) were detected upon induction of melanoma with 7,12-dimethylbenz[a]anthracene (DMBA). However, more lesions were induced at early time points in the absence of ADAM-9. Increased initial and decreased late tumor numbers were paralleled by altered tumor cell proliferation, but not apoptosis or inflammation. Importantly, significantly reduced lung metastases were detected upon ADAM-9 deletion. Using in vitro assays to address this effect mechanistically, we detected reduced adhesion and transmigration of ADAM-9-silenced melanoma cells to/through the endothelium. This implies that ADAM-9 functionally and cell autonomously mediates extravasation of melanoma cells. In vitro and in vivo we demonstrated that the basement membrane (BM) component laminin beta 3-chain is a direct substrate of ADAM-9, thus contributing to destabilization and disruption of the BM barrier during invasion. In in vitro invasion assays using human melanoma cells and skin equivalents, depletion of ADAM-9 resulted in decreased invasion of the BM, which remained almost completely intact, as shown by continuous staining for laminin beta 3-chain. Importantly, supplying soluble ADAM-9 to the system reversed this effect. Taken together, our data show that melanoma derived ADAM-9 autonomously contributes to melanoma progression by modulating cell adhesion to the endothelium and altering BM integrity by proteolytically processing the laminin-beta 3 chain. This newly described process and ADAM-9 itself may represent potential targets for anti-tumor therapies.	[Giebeler, N.; Schoenefuss, A.; Mauch, C.; Zigrino, P.] Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany; [Landsberg, J.] Univ Bonn, Dept Dermatol & Allergol, Bonn, Germany; [Tuting, T.] Univ Magdeburg, Dept Dermatol, Magdeburg, Germany	University of Cologne; University of Bonn; Otto von Guericke University	Zigrino, P (corresponding author), Univ Cologne, Dept Dermatol, NRW, Kerpener Str 62, D-50937 Cologne, Germany.	paola.zigrino@uni-koeln.de	Tüting, Thomas/AAJ-3610-2021; Landsberg, Jennifer/AAF-5113-2019; Landsberg, Jenny/AGI-0216-2022	Tüting, Thomas/0000-0001-7146-0934; Landsberg, Jenny/0000-0001-8029-3883; Zigrino, Paola/0000-0002-7470-0064	Melanoma Research Network of the Deutsche Krebshilfe (Melanoma Verbund); Deutsche Forschungsgemeinschaft [SFB829]; Koln Fortune Program of the University of Cologne	Melanoma Research Network of the Deutsche Krebshilfe (Melanoma Verbund); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Koln Fortune Program of the University of Cologne	We thank Prof Manuel Koch, Department of Biochemistry, University of Cologne for kindly providing the laminin beta 3 antibody and recombinant laminin beta 3-chain. We thank Jan Zamek, Claudia Coerper-Ochsman and Nina Ruers for excellent technical assistance. This work was supported by the Melanoma Research Network of the Deutsche Krebshilfe (Melanoma Verbund), by the Deutsche Forschungsgemeinschaft through the SFB829 (B4) and by Koln Fortune Program of the University of Cologne.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Abety AN, 2012, J INVEST DERMATOL, V132, P2451, DOI 10.1038/jid.2012.153; Bacac M, 2008, ANNU REV PATHOL-MECH, V3, P221, DOI 10.1146/annurev.pathmechdis.3.121806.151523; Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005; Chen CM, 2015, TUMOR BIOL, V36, P3407, DOI 10.1007/s13277-014-2975-9; Dennhofer R, 2003, INT J CANCER, V106, P316, DOI 10.1002/ijc.11255; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Felli N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056824; FIDLER IJ, 1976, JNCI-J NATL CANCER I, V57, P1199, DOI 10.1093/jnci/57.5.1199; Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-179; Guaiquil V, 2009, MOL CELL BIOL, V29, P2694, DOI 10.1128/MCB.01460-08; Landsberg J, 2010, PIGM CELL MELANOMA R, V23, P649, DOI 10.1111/j.1755-148X.2010.00744.x; Leiter U, 2004, J SURG ONCOL, V86, P172, DOI 10.1002/jso.20079; Lin CY, 2014, CANCER RES, V74, P5229, DOI 10.1158/0008-5472.CAN-13-2995; Mammadova-Bach E, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88245; McAteer MA, 2008, ARTERIOSCL THROM VAS, V28, P77, DOI 10.1161/ATVBAHA.107.145466; Micocci KC, 2016, BIOCHIMIE, V128, P174, DOI 10.1016/j.biochi.2016.08.006; Mongaret C, 2011, INT J CANCER, V129, P791, DOI 10.1002/ijc.25746; Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459; Nath D, 2000, J CELL SCI, V113, P2319; Parry DA, 2009, AM J HUM GENET, V84, P683, DOI 10.1016/j.ajhg.2009.04.005; Remy L, 2006, CANCER RES, V66, P11228, DOI 10.1158/0008-5472.CAN-06-1187; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Sarkar S, 2015, NEURO-ONCOLOGY, V17, P1095, DOI 10.1093/neuonc/nou362; SIKORSKI EE, 1993, J IMMUNOL, V151, P5239; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Strilic B, 2016, NATURE, V536, P215, DOI 10.1038/nature19076; Tao KS, 2010, JPN J CLIN ONCOL, V40, P645, DOI 10.1093/jjco/hyq030; Tormo D, 2006, AM J PATHOL, V169, P665, DOI 10.2353/ajpath.2006.060017; Tsuruta D, 2008, CURR MED CHEM, V15, P1968, DOI 10.2174/092986708785132834; Tzu J, 2008, INT J BIOCHEM CELL B, V40, P199, DOI 10.1016/j.biocel.2007.07.015; Udayakumar TS, 2003, CANCER RES, V63, P2292; Wan DW, 2016, ANTI-CANCER AGENT ME, V16, P414, DOI 10.2174/1871520615666150716105955; Wang CZ, 2015, INT J CLIN EXP PATHO, V8, P6547; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WILLIAMS RL, 1988, CELL, V52, P121; Xu Q, 2010, TUMOR BIOL, V31, P217, DOI 10.1007/s13277-010-0034-8; Yamada D, 2007, ANTICANCER RES, V27, P793; Zhang CZ, 2015, INVEST NEW DRUG, V33, P1, DOI 10.1007/s10637-014-0156-8; Zigrino P, 2005, INT J CANCER, V116, P853, DOI 10.1002/ijc.21087; Zigrino P, 2011, J BIOL CHEM, V286, P6801, DOI 10.1074/jbc.M110.168617	41	9	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2017	36	35					5058	5067		10.1038/onc.2017.162	http://dx.doi.org/10.1038/onc.2017.162			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF3AV	28553955				2022-12-17	WOS:000408768800010
J	Ouyang, H; Gore, J; Deitz, S; Korc, M				Ouyang, H.; Gore, J.; Deitz, S.; Korc, M.			microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-beta actions (vol 33, pg 4664, 2014)	ONCOGENE			English	Correction																		Ouyang H, 2014, ONCOGENE, V33, P4664, DOI 10.1038/onc.2013.405	1	9	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2017	36	34					4952	4952		10.1038/onc.2017.190	http://dx.doi.org/10.1038/onc.2017.190			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FE5EI	28604742	Green Published, hybrid			2022-12-17	WOS:000408234400012
J	Han, H; Yang, B; Wang, W				Han, H.; Yang, B.; Wang, W.			Angiomotin-like 2 interacts with and negatively regulates AKT	ONCOGENE			English	Article							ORGAN SIZE CONTROL; HIPPO PATHWAY; CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; HUMAN CANCER; TISSUE HOMEOSTASIS; FAMILY PROTEINS; YAP ONCOPROTEIN; ACTIN-BINDING	Angiomotin-like 2 (AMOTL2) is a member of Angiomotin family proteins, which are potent inhibitors for the Hippo pathway effector YAP. However, additional cellular functions of AMOTL2 besides YAP inhibition are largely unknown. Here, we reported that AMOTL2 associates with and negatively regulates AKT. Mechanistically, AMOTL2 binds to AKT pleckstrin homology domain and interrupts AKT's membrane localization. Liver-specific depletion of AMOTL2 enlarged mouse liver and activated both YAP and AKT. Downregulation of AMOTL2 is found in human liver cancers, correlating with the concomitant activation of YAP and AKT. Together, our results provide novel insights into a dual tumor suppressive function of AMOTL2 by targeting both YAP and AKT in liver size control and cancer prevention.	[Han, H.; Yang, B.; Wang, W.] Univ Calif Irvine, Dept Dev & Cell Biol, 3302A,Nat Sci 1, Irvine, CA 92697 USA	University of California System; University of California Irvine	Wang, W (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 3302A,Nat Sci 1, Irvine, CA 92697 USA.	wenqiw6@uci.edu	han, han/HDL-7807-2022; HAN, HAN/AAC-5464-2022	HAN, HAN/0000-0003-2222-5270; Wang, Wenqi/0000-0003-4053-5088	Breast Cancer Research Foundation [16-20-26-WANG]; American Cancer Society-Institutional Research Grant	Breast Cancer Research Foundation; American Cancer Society-Institutional Research Grant(American Cancer Society)	WW thanks Dr Junjie Chen at MD Anderson Cancer Center for his mentoring and continuous support. We also thank Kathryn E Aziz and My Kim Tran at MD Anderson Cancer Center for the technical help. WW is a recipient of American Association for Cancer Research Career Development Award for Translational Breast Cancer Research supported by the Breast Cancer Research Foundation (16-20-26-WANG). This work was also partially supported by the American Cancer Society-Institutional Research Grant to WW. WW is a member of Chao Family Comprehensive Cancer Center (P30 CA062203) and a member of Center for Complex Biological Systems at UC Irvine.	Aase K, 2007, GENE DEV, V21, P2055, DOI 10.1101/gad.432007; Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2013, J BIOL CHEM, V288, P37296, DOI 10.1074/jbc.M113.527598; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chan TO, 2015, BIOCHEM J, V471, P37, DOI 10.1042/BJ20150325; Dai XM, 2015, CELL RES, V25, P1175, DOI 10.1038/cr.2015.101; Dai XM, 2013, J BIOL CHEM, V288, P34041, DOI 10.1074/jbc.M113.518019; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189; Hirate Y, 2013, CURR BIOL, V23, P1181, DOI 10.1016/j.cub.2013.05.014; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kim MJ, 2016, EMBO REP, V17, P64, DOI 10.15252/embr.201540809; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Leung CY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3251; Li YJ, 2015, CELL RES, V25, P801, DOI 10.1038/cr.2015.69; Li Y, 2016, HEPATOLOGY, V63, P1928, DOI 10.1002/hep.28507; Liu PD, 2014, CELL CYCLE, V13, P2162, DOI 10.4161/cc.29584; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lv M, 2016, ONCOTARGET, V7, P12393, DOI 10.18632/oncotarget.7161; Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mojallal M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5557; Moleirinho S, 2014, FEBS LETT, V588, P2693, DOI 10.1016/j.febslet.2014.02.006; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Nishio M, 2016, P NATL ACAD SCI USA, V113, pE71, DOI 10.1073/pnas.1517188113; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Paramasivam M, 2011, MOL BIOL CELL, V22, P3725, DOI 10.1091/mbc.E11-04-0300; Troilo A, 2016, ONCOTARGET, V7, P28765, DOI 10.18632/oncotarget.9117; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang H, 2016, J BIOL CHEM, V291, P15256, DOI 10.1074/jbc.M116.722967; Wang WQ, 2008, J CELL SCI, V121, P1334, DOI 10.1242/jcs.018176; Wang WQ, 2015, CELL REP, V13, P524, DOI 10.1016/j.celrep.2015.09.014; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	45	9	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4662	4669		10.1038/onc.2017.101	http://dx.doi.org/10.1038/onc.2017.101			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368415				2022-12-17	WOS:000407246200013
J	Cristobal, I; Zazo, S; Torrejon, B; Pedregal, M; Madoz-Gurpide, J; Lluch, A; Eroles, P; Rovira, A; Albanell, J; Garcia-Foncillas, J; Rojo, F				Cristobal, I.; Zazo, S.; Torrejon, B.; Pedregal, M.; Madoz-Gurpide, J.; Lluch, A.; Eroles, P.; Rovira, A.; Albanell, J.; Garcia-Foncillas, J.; Rojo, F.			CIP2A confirms its prognostic value in triple-negative breast cancer	ONCOGENE			English	Letter							CELLS		[Cristobal, I.; Torrejon, B.; Pedregal, M.; Garcia-Foncillas, J.] Univ Hosp Fdn Jimenez Diaz, Oncohlth Inst, Hlth Res Inst FJD UAM, Dept Med Oncol,Translat Oncol Div, Madrid, Spain; [Zazo, S.; Madoz-Gurpide, J.; Rojo, F.] IIS Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain; [Rovira, A.; Albanell, J.] Hosp del Mar, Dept Med Oncol, Barcelona, Spain; [Lluch, A.; Eroles, P.] Inst Hlth Res INCLIVA, Dept Breast Canc Res, Valencia, Spain	Fundacion Jimenez Diaz; Fundacion Jimenez Diaz; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar	Cristobal, I (corresponding author), Univ Hosp Fdn Jimenez Diaz, Oncohlth Inst, Hlth Res Inst FJD UAM, Dept Med Oncol,Translat Oncol Div, Madrid, Spain.; Rojo, F (corresponding author), IIS Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain.	ion.cristobal@fjd.es; frojo@fjd.es	Rovira, Ana/ABH-5661-2020; Lluch, Ana/R-5493-2019; Albanell, Joan/R-9470-2019	Rovira, Ana/0000-0003-1301-2599; Lluch, Ana/0000-0003-2766-407X; J, Garcia-Foncillas/0000-0002-7591-8006; MADOZ-GURPIDE, JUAN/0000-0001-8094-4076; Rojo, Federico/0000-0001-9989-0290; Eroles, Pilar/0000-0003-2708-6206	Instituto de Salud Carlos III FEDER [PT13/0010/0012, PI13/02609, PI15/00934]; Fundacion Conchita Rabago de Jimenez Diaz	Instituto de Salud Carlos III FEDER(Instituto de Salud Carlos III); Fundacion Conchita Rabago de Jimenez Diaz	This work was supported by PT13/0010/0012, PI13/02609 and PI15/00934 grants from 'Instituto de Salud Carlos III FEDER'. BT is supported by 'Fundacion Conchita Rabago de Jimenez Diaz'.	Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Laine A, 2013, CANCER DISCOV, V3, P182, DOI 10.1158/2159-8290.CD-12-0292; Liu H, 2017, ONCOGENE, V36, P1952, DOI 10.1038/onc.2016.355; Rincon R, 2015, ONCOTARGET, V6, P4299, DOI 10.18632/oncotarget.3012	4	9	9	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3357	3358		10.1038/onc.2016.474	http://dx.doi.org/10.1038/onc.2016.474			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	28068327				2022-12-17	WOS:000402869800014
J	Ugale, A; Sawen, P; Dudenhoffer-Pfeifer, M; Wahlestedt, M; Norddahl, GL; Bryder, D				Ugale, A.; Sawen, P.; Dudenhoffer-Pfeifer, M.; Wahlestedt, M.; Norddahl, G. L.; Bryder, D.			MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment	ONCOGENE			English	Article							STEM-CELLS; B-CELL; RAS; PROGENITORS; MUTATIONS; TRANSDIFFERENTIATION; TRANSLOCATIONS; TRANSFORMATION; HEMATOPOIESIS; SPECIFICATION	Translocations involving the mixed lineage leukemia-1 are recurrent events in acute leukemia and associate with lymphoid (ALL), myeloid (AML) or mixed lineage (MLL) subtypes. Despite an association with ALL in humans, murine MLL fusion models are persistently restricted to AML. We here explored this issue using an inducible mixed lineage leukemia-eleven nineteen leukemia (MLL-ENL) mouse model. Although multiple progenitor cell types with myeloid potential are potent AML leukemia-initiating cells, also the earliest lymphoid progenitors were capable of initiating AML. This ability to evoke a latent myeloid potential in the earliest lymphoid progenitors was lost upon further lymphoid commitment. At the same time, more downstream/committed lymphoid precursors also failed to initiate lymphoid leukemia. Co-expression of MLL-ENL with a constitutively active RAS allele, the most common co-mutation in MLL fusion leukemias, could influence on both disease latency and lineage assignment of developing leukemia in what appears to be a mutation-order-dependent manner. Finally, CEBPB-mediated transdifferentation of committed and otherwise leukemia-incompetent B-cell progenitors imbued these cells with leukemic competence for AML. Therefore, apart from providing detailed insight into the differential responsiveness of candidate target cells to a first-hit MLL fusion event, our data warrants caution to therapeutic approaches based on the concept of transdifferentiation.	[Ugale, A.; Sawen, P.; Dudenhoffer-Pfeifer, M.; Wahlestedt, M.; Norddahl, G. L.; Bryder, D.] Lund Univ, Inst Lab Med, Mol Hematol, Klinikgatan 26, S-22184 Lund, Sweden	Lund University	Bryder, D (corresponding author), Lund Univ, Inst Lab Med, Mol Hematol, Klinikgatan 26, S-22184 Lund, Sweden.	David.Bryder@med.lu.se	Bryder, David/Q-6292-2019	Bryder, David/0000-0002-8761-4237	Knut and Alice Wallenberg Foundation; Gunnar Nilsson Cancer Foundation; Swedish Research Council; Swedish Cancer Society; Swedish Pediatric Leukemia Foundation; ERC Consolidator [615068]	Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Gunnar Nilsson Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Pediatric Leukemia Foundation; ERC Consolidator	We thank Gerd Sten and Eva Erlandsson for expert technical support. This work was supported by a joint project grant from Knut and Alice Wallenberg Foundation and grants from the Gunnar Nilsson Cancer Foundation, the Swedish Research Council, the Swedish Cancer Society, the Swedish Pediatric Leukemia Foundation and an ERC Consolidator grant 615068 to D.B.	Andersson AK, 2015, NAT GENET, V47, P330, DOI 10.1038/ng.3230; Bell JJ, 2008, NATURE, V452, P764, DOI 10.1038/nature06840; Cano F, 2008, ONCOGENE, V27, P1945, DOI 10.1038/sj.onc.1210818; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Driessen EMC, 2013, HAEMATOLOGICA, V98, P937, DOI 10.3324/haematol.2012.067983; Drynan LF, 2005, EMBO J, V24, P3136, DOI 10.1038/sj.emboj.7600760; Grossmann V, 2013, LEUKEMIA, V27, P1933, DOI 10.1038/leu.2013.90; Inlay MA, 2009, GENE DEV, V23, P2376, DOI 10.1101/gad.1836009; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; King PD, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003669; Krivtsov AV, 2013, LEUKEMIA, V27, P852, DOI 10.1038/leu.2012.363; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Lobry C, 2013, J EXP MED, V210, P301, DOI 10.1084/jem.20121484; Luc S, 2012, NAT IMMUNOL, V13, P412, DOI 10.1038/ni.2255; Mansson R, 2008, BLOOD, V112, P1048, DOI 10.1182/blood-2007-11-125385; Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Rapino F, 2013, CELL REP, V3, P1153, DOI 10.1016/j.celrep.2013.03.003; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sawen P, 2016, CELL REP, V14, P2809, DOI 10.1016/j.celrep.2016.02.073; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; Ugale A, 2014, CELL REP, V9, P1246, DOI 10.1016/j.celrep.2014.10.036; van Oevelen C, 2015, STEM CELL REP, V5, P232, DOI 10.1016/j.stemcr.2015.06.007; Velasco-Hernandez T, 2016, STEM CELL REP, V7, P21, DOI 10.1016/j.stemcr.2016.06.002; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2	27	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3207	3212		10.1038/onc.2016.470	http://dx.doi.org/10.1038/onc.2016.470			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28068328				2022-12-17	WOS:000402617900012
J	Burgess, M; Mapp, S; Mazzieri, R; Cheung, C; Chambers, L; Mattarollo, SR; Mollee, P; Gill, D; Saunders, NA				Burgess, M.; Mapp, S.; Mazzieri, R.; Cheung, C.; Chambers, L.; Mattarollo, S. R.; Mollee, P.; Gill, D.; Saunders, N. A.			Increased Fc gamma RIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients	ONCOGENE			English	Article							NURSE-LIKE CELLS; IN-VITRO; MACROPHAGES; RITUXIMAB; EXPRESSION; IDELALISIB; IBRUTINIB; CANCER; CLL; STRATEGIES	Resistance to therapeutic antibodies in chronic lymphocytic leukaemia (CLL) is common. In this study, we show that therapeutic antibodies against CD62L (CD62L-Ab) or CD20 (obinutuzumab) were able to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and phagocytosis (ADP) in primary cultures of CLL cells. CLL cells derived from patients with active disease requiring treatment displayed resistance to these antibodies, whereas patients with stable disease were sensitive. Using enrichment strategies and transcriptomic analyses, we show that antibody-dependent tumour cell killing was Fc gamma R-dependent and mediated by macrophages. Moreover, we show that resistance cannot be attributed to total numbers or established subtypes of monocytes/macrophages, or the efficiency with which they bind an immune complex. Rather, ADCC/ADP resistance was due to reduced signalling activity through the activating Fc gamma Rs resulting in the transfer of dominance to the inhibitory Fc gamma RIIb within macrophages. Most significantly, we show that resistance is an actionable event that could be reversed using inhibitors of Fc gamma RIIb signalling in primary cultures of CLL cells that were previously insensitive to obinutuzumab or CD62L-Ab.	[Burgess, M.; Mazzieri, R.; Mattarollo, S. R.; Gill, D.; Saunders, N. A.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia; [Burgess, M.; Mapp, S.; Cheung, C.; Chambers, L.; Mollee, P.; Gill, D.] Princess Alexandra Hosp, Dept Haematol, Canc Serv, Ipswich Rd, Woolloongabba, Qld 4102, Australia; [Mollee, P.] Univ Queensland, Sch Med, Translat Res Inst, Woolloongabba, Qld, Australia	University of Queensland; University of Queensland	Gill, D (corresponding author), Princess Alexandra Hosp, Dept Haematol, Canc Serv, Ipswich Rd, Woolloongabba, Qld 4102, Australia.; Saunders, NA (corresponding author), Univ Queensland, Diamantina Inst, Translat Res Inst, Ipswich Rd, Woolloongabba, Qld 4102, Australia.	Devinder.gill@health.qld.gov.au; nsaunders@uq.edu.au	saunders, nicholas/AAJ-6101-2020; Mollee, Peter/A-6677-2012; Mazzieri, Roberta/C-9773-2015	saunders, nicholas/0000-0002-2478-3420; Mollee, Peter/0000-0002-8537-1198; Mazzieri, Roberta/0000-0002-5172-0927	Australian NHMRC [APP1049182]; Cancer Council Queensland [APP1025479]; Senior Research Fellowship - Cancer Council Queensland	Australian NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council Queensland(Cancer Council Queensland); Senior Research Fellowship - Cancer Council Queensland(Cancer Council Queensland)	We gratefully acknowledge the patients who donated samples for this study. We also gratefully acknowledge the constructive comments of Professor Maher Gandhi before submission. NS is supported by grants from the Australian NHMRC (#APP1049182) and the Cancer Council Queensland (#APP1025479). NS is supported by a Senior Research Fellowship awarded by the Cancer Council Queensland.	ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Awan FT, 2014, CLIN CANCER RES, V20, P5869, DOI 10.1158/1078-0432.CCR-14-1889; Bhattacharya N, 2011, BRIT J HAEMATOL, V154, P349, DOI 10.1111/j.1365-2141.2011.08747.x; Boissard F, 2015, LEUKEMIA LYMPHOMA, V56, P1570, DOI 10.3109/10428194.2014.991731; Bournazos S, 2009, CLIN EXP IMMUNOL, V157, P244, DOI 10.1111/j.1365-2249.2009.03980.x; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 2014, LANCET ONCOL, V15, P1090, DOI 10.1016/S1470-2045(14)70335-3; Burger JA, 2014, NAT REV CLIN ONCOL, V11, P184, DOI 10.1038/nrclinonc.2014.42; Burgess M, 2016, GENOM DATA, V7, P4, DOI 10.1016/j.gdata.2015.11.010; Burgess M, 2013, CLIN CANCER RES, V19, P5675, DOI 10.1158/1078-0432.CCR-13-1037; Burgess M, 2012, LEUKEMIA LYMPHOMA, V53, P1988, DOI 10.3109/10428194.2012.672735; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; Filip AA, 2013, BLOOD CELL MOL DIS, V50, P263, DOI 10.1016/j.bcmd.2012.12.003; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Giannoni P, 2014, HAEMATOLOGICA, V99, P1078, DOI 10.3324/haematol.2013.091405; Gu  B, 2001, LEUKEMIA LYMPHOMA, V42, P5, DOI 10.3109/10428190109097671; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hallek M, 2013, BLOOD, V122, P3723, DOI 10.1182/blood-2013-05-498287; Herter S, 2014, J IMMUNOL, V192, P2252, DOI 10.4049/jimmunol.1301249; Jaglowski SM, 2015, BLOOD, V126, P842, DOI 10.1182/blood-2014-12-617522; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Mellor JD, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-1; Morabito F, 2015, LEUKEMIA LYMPHOMA, V56, P3250, DOI 10.3109/10428194.2015.1061193; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn F, 2007, CURR OPIN IMMUNOL, V19, P239, DOI 10.1016/j.coi.2007.01.005; Pallasch CP, 2014, CELL, V156, P590, DOI 10.1016/j.cell.2013.12.041; Patz M, 2011, BRIT J HAEMATOL, V152, P295, DOI 10.1111/j.1365-2141.2010.08428.x; Robak T, 2014, EXPERT REV HEMATOL, V7, P841, DOI 10.1586/17474086.2014.963048; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Tsukada N, 2002, BLOOD, V99, P1030, DOI 10.1182/blood.V99.3.1030; Ysebaert L, 2011, LEUKEMIA LYMPHOMA, V52, P1404, DOI 10.3109/10428194.2011.568078	32	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 27	2017	36	17					2366	2376		10.1038/onc.2016.387	http://dx.doi.org/10.1038/onc.2016.387			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET4QE	27748757				2022-12-17	WOS:000400268900004
J	Suh, Y; Yoon, CH; Kim, RK; Lim, EJ; Oh, YS; Hwang, SG; An, S; Yoon, G; Gye, MC; Yi, JM; Kim, MJ; Lee, SJ				Suh, Y.; Yoon, C-H; Kim, R-K; Lim, E-J; Oh, Y. S.; Hwang, S-G; An, S.; Yoon, G.; Gye, M. C.; Yi, J-M; Kim, M-J; Lee, S-J			Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells (vol 32, pg 4873, 2013)	ONCOGENE			English	Correction																		Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505	1	9	10	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2017	36	8					1167	1168		10.1038/onc.2016.294	http://dx.doi.org/10.1038/onc.2016.294			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EM5SA	27841864	Bronze			2022-12-17	WOS:000395371500014
J	Xi, G; Hayes, E; Lewis, R; Ichi, S; Mania-Farnell, B; Shim, K; Takao, T; Allender, E; Mayanil, CS; Tomita, T				Xi, G.; Hayes, E.; Lewis, R.; Ichi, S.; Mania-Farnell, B.; Shim, K.; Takao, T.; Allender, E.; Mayanil, C. S.; Tomita, T.			RETRACTION: CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-kappa B pathway in multidrug-resistant glioblastoma cells in vitro (Retraction of vol 35, pg 241, 2016)	ONCOGENE			English	Retraction																		Xi G, 2016, ONCOGENE, V35, P241, DOI 10.1038/onc.2015.78	1	9	12	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2016	35	42					5576	5576		10.1038/onc.2016.64	http://dx.doi.org/10.1038/onc.2016.64			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XO	27593924	Bronze			2022-12-17	WOS:000386998200011
J	Nowicka, AM; Hauselmann, I; Borsig, L; Bolduan, S; Schindler, M; Schraml, P; Heikenwalder, M; Moch, H				Nowicka, A. M.; Hauselmann, I.; Borsig, L.; Bolduan, S.; Schindler, M.; Schraml, P.; Heikenwalder, M.; Moch, H.			A novel pVHL-independent but NEMO-driven pathway in renal cancer promotes HIF stabilization	ONCOGENE			English	Article							NF-KAPPA-B; CELL-CARCINOMA; IKK COMPLEX; REGULATORY SUBUNIT; PROGNOSTIC VALUE; C-MYC; EXPRESSION; GAMMA; VHL; PHOSPHORYLATION	Activation of hypoxia-inducible factor (HIF) is due to loss of von Hippel-Lindau protein (pVHL) function in most clear cell renal cell carcinomas (ccRCCs). Here we describe a novel pVHL-independent mechanism of HIF regulation and identify nuclear factor (NF)-kappa B essential modulator (NEMO) as a hitherto unknown oncogenic factor influencing human ccRCC progression. Over 60% of human ccRCCs (n = 157) have negative or weak NEMO protein expression by immunohistochemistry. Moderate/strong NEMO protein expression is more frequent in VHL wild-type ccRCCs. We show that NEMO stabilizes HIFa via direct interaction and independently of NF-kappa B signaling in vitro. NEMO prolongs tumor cell survival via regulation of apoptosis and activation of epithelial-to-mesenchymal transition, facilitating tumor metastasis. Our findings suggest that NEMO-driven HIF activation is involved in progression of ccRCC. Therefore, NEMO may represent a clinically relevant link between NF-kappa B and the VHL/HIF pathways. Targeting NEMO with specific inhibitors in patients with metastatic ccRCC could be a novel treatment approach in patients with ccRCC expressing functional pVHL.	[Nowicka, A. M.; Schraml, P.; Heikenwalder, M.; Moch, H.] Univ Zurich Hosp, Inst Surg Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland; [Hauselmann, I.; Borsig, L.] Univ Zurich, Inst Physiol, Zurich Ctr Integrat Human Physiol, Zurich, Switzerland; [Bolduan, S.; Schindler, M.; Heikenwalder, M.] Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, Schneckenburgerstr 8, D-81675 Munich, Germany; [Heikenwalder, M.] German Canc Res Ctr DKFZ Heidelberg, Div Chron Inflammat & Canc, Heidelberg, Germany	University of Zurich; University Zurich Hospital; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Moch, H (corresponding author), Univ Zurich Hosp, Inst Surg Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.; Heikenwalder, M (corresponding author), Tech Univ Munich, Helmholtz Zentrum Munchen, Inst Virol, Schneckenburgerstr 8, D-81675 Munich, Germany.	heikenwaelder@helmholtz-muenchen.de; holger.moch@usz.ch	Schindler, Michael/C-1647-2015; Heikenwalder, Mathias/AAA-2269-2020	Schindler, Michael/0000-0001-8989-5813; Borsig, Lubor/0000-0003-2263-9545	Swiss National Science Foundation [3238BO-103145]; European Research Council (ERC) starting grant; Stiftung fur experimentelle Biomedizin (Peter-Hans Hofschneider foundation); pre-clinical comprehensive center (PCCC); Else Kroner-Fresenius Foundation; NCCR-Kidney.ch;  [SFB-TR36]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); European Research Council (ERC) starting grant(European Research Council (ERC)); Stiftung fur experimentelle Biomedizin (Peter-Hans Hofschneider foundation); pre-clinical comprehensive center (PCCC); Else Kroner-Fresenius Foundation; NCCR-Kidney.ch; 	We thank M Bieri from University Hospital Zurich for preparing the script and establishing a novel formula for TMA staining intensity measurement, M Storz and S Dettwiler from the tissue biobank, A Fitsche, O Buchi and C Mittmann from the University Hospital Zurich for the excellent technical support, Professor I Frew from the University of Zurich and Dr T O'Connor from the Technical University of Munich for their critical input and reading the manuscript. This work was supported by the Swiss National Science Foundation Grants (3238BO-103145 and Sinergia) to HM; European Research Council (ERC) starting grant, a grant by the Stiftung fur experimentelle Biomedizin (Peter-Hans Hofschneider foundation), the pre-clinical comprehensive center (PCCC), the SFB-TR36 and the Else Kroner-Fresenius Foundation to MH. AMN was supported by the NCCR-Kidney.ch.	Aigelsreiter A, 2012, HUM PATHOL, V43, P1012, DOI 10.1016/j.humpath.2011.08.009; An JB, 2005, MOL CELL BIOL, V25, P7546, DOI 10.1128/MCB.25.17.7546-7556.2005; [Anonymous], 2013, NATURE, V499, P43, DOI [10.1038/nature12222, DOI 10.1038/NATURE12222, DOI 10.1038/nature12222]; Banning C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009344; Beleut M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-310; Bettermann K, 2010, CANCER CELL, V17, P481, DOI 10.1016/j.ccr.2010.03.021; Bist P, 2011, ONCOGENE, V30, P3174, DOI 10.1038/onc.2011.28; Bracken CP, 2005, J BIOL CHEM, V280, P14240, DOI 10.1074/jbc.M409987200; Carvalho G, 2007, ONCOGENE, V26, P2299, DOI 10.1038/sj.onc.1210043; Dahinden C, 2010, CLIN CANCER RES, V16, P88, DOI 10.1158/1078-0432.CCR-09-0260; Fisher R, 2013, SEMIN CANCER BIOL, V23, P38, DOI 10.1016/j.semcancer.2012.06.004; Frew IJ, 2008, EMBO J, V27, P1747, DOI 10.1038/emboj.2008.96; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Gassenmaier M, 2013, STEM CELLS, V31, P1467, DOI 10.1002/stem.1407; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haybaeck J, 2009, CANCER CELL, V16, P295, DOI 10.1016/j.ccr.2009.08.021; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Irrinki KM, 2011, MOL CELL BIOL, V31, P3745, DOI 10.1128/MCB.05303-11; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim BY, 2010, FEBS LETT, V584, P4524, DOI 10.1016/j.febslet.2010.10.031; Konda R, 2008, J UROLOGY, V180, P481, DOI 10.1016/j.juro.2008.04.006; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Legarda-Addison D, 2009, CELL DEATH DIFFER, V16, P1279, DOI 10.1038/cdd.2009.41; Li GR, 2013, HISTOL HISTOPATHOL, V28, P1217, DOI 10.14670/HH-28.1217; Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025; Luedde T, 2007, CANCER CELL, V11, P119, DOI 10.1016/j.ccr.2006.12.016; Luu VD, 2009, CLIN CANCER RES, V15, P3297, DOI 10.1158/1078-0432.CCR-08-2779; Maher ER, 2013, SEMIN CANCER BIOL, V23, P10, DOI 10.1016/j.semcancer.2012.06.003; Maier HJ, 2013, ONCOGENE, V32, P2690, DOI 10.1038/onc.2012.272; Meteoglu I, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-53; Morais C, 2010, APOPTOSIS, V15, P412, DOI 10.1007/s10495-009-0414-y; Oya M, 2003, CARCINOGENESIS, V24, P377, DOI 10.1093/carcin/24.3.377; Palkowitsch L, 2008, J BIOL CHEM, V283, P76, DOI 10.1074/jbc.M708856200; Pawlowski R, 2013, INT J CANCER, V132, pE11, DOI 10.1002/ijc.27822; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Qi H, 2003, CANCER RES, V63, P7076; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Rechsteiner MP, 2011, CANCER RES, V71, P5500, DOI 10.1158/0008-5472.CAN-11-0757; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sakamoto K, 2013, ONCOGENE, V32, P1854, DOI 10.1038/onc.2012.192; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Schlesinger-Raab A, 2008, EUR J CANCER, V44, P2485, DOI 10.1016/j.ejca.2008.07.039; Schraml P, 2002, J PATHOL, V196, P186, DOI 10.1002/path.1034; Schultz L, 2011, AM J SURG PATHOL, V35, P1549, DOI 10.1097/PAS.0b013e31822895e5; Shen C, 2013, SEMIN CANCER BIOL, V23, P18, DOI 10.1016/j.semcancer.2012.06.001; Sourbier C, 2007, CANCER RES, V67, P11668, DOI 10.1158/0008-5472.CAN-07-0632; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tang SW, 2009, CANCER LETT, V273, P35, DOI 10.1016/j.canlet.2008.07.038; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029; Vogetseder A, 2013, INT J CANCER, V133, P2362, DOI 10.1002/ijc.28267; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wyler L, 2014, BRIT J CANCER, V110, P686, DOI 10.1038/bjc.2013.755; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Young AC, 2009, CLIN CANCER RES, V15, P7582, DOI 10.1158/1078-0432.CCR-09-2131	58	9	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3125	3138		10.1038/onc.2015.400	http://dx.doi.org/10.1038/onc.2015.400			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26500060				2022-12-17	WOS:000378092700005
J	Salas, E; Roy, S; Marsh, T; Rubin, B; Debnath, J				Salas, E.; Roy, S.; Marsh, T.; Rubin, B.; Debnath, J.			Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death	ONCOGENE			English	Article							ADVANCED SOLID TUMORS; PHASE-I TRIAL; AUTOPHAGY INHIBITION; BREAST-CANCER; HYDROXYCHLOROQUINE; P53; TEMOZOLOMIDE; COMBINATION; HOMEOSTASIS; PROGRESSION	Despite immense interest in using antimalarials as autophagy inhibitors to treat cancer, it remains unclear whether these agents act predominantly via autophagy inhibition or whether other pathways direct their anti-cancer properties. By comparing the treatment effects of the antimalarials chloroquine (CQ) and quinacrine (Q) on KRAS mutant lung cancer cells, we demonstrate that inhibition of the oxidative arm of the pentose phosphate pathway (oxPPP) is required for antimalarial induced apoptosis. Despite inhibiting autophagy, neither CQ treatment nor RNAi against autophagy regulators (ATGs) promote cell death. In contrast, Q triggers high levels of apoptosis, both in vitro and in vivo, and this phenotype requires both autophagy inhibition and p53-dependent inhibition of the oxPPP. Simultaneous genetic targeting of the oxPPP and autophagy is sufficient to trigger apoptosis in lung cancer cells, including cells lacking p53. Thus, in addition to reduced autophagy, oxPPP inhibition serves as an important determinant of antimalarial cytotoxicity in cancer cells.	[Salas, E.; Roy, S.; Marsh, T.; Debnath, J.] Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA; [Salas, E.; Roy, S.; Marsh, T.; Debnath, J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA; [Rubin, B.] Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA; [Rubin, B.] Cleveland Clin, Dept Mol Genet, Cleveland, OH 44106 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Debnath, J (corresponding author), Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA.; Debnath, J (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, 513 Parnassus Ave,HSW 450B Box 0502, San Francisco, CA 94143 USA.	Jayanta.Debnath@ucsf.edu		Marsh, Timothy/0000-0002-8772-7645; Debnath, Jayanta/0000-0002-8745-4069	NIH [R01CA126792, R01CA188404]; California Tobacco Related Diseases Research Program [18XT-0106]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA126792, R01CA188404] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Tobacco Related Diseases Research Program; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support to JD includes the NIH (R01CA126792 and R01CA188404), California Tobacco Related Diseases Research Program (18XT-0106) and Samuel Waxman Cancer Research Foundation.	Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165; Buchakjian MR, 2010, NAT REV MOL CELL BIO, V11, P715, DOI 10.1038/nrm2972; Ehsanian R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-13; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gallant JN, 2011, CANCER BIOL THER, V12, P239, DOI 10.4161/cbt.12.3.17034; Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048; Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172; Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700; Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025; Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231; Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470; Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554; McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109; Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918; Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119; Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118; Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111	35	9	9	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2016	35	22					2913	2922		10.1038/onc.2015.348	http://dx.doi.org/10.1038/onc.2015.348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MT	26434592	Green Accepted, Green Submitted			2022-12-17	WOS:000377473700011
J	Fadoukhair, Z; Zardavas, D; Chad, MA; Goulioti, T; Aftimos, P; Piccart, M				Fadoukhair, Z.; Zardavas, D.; Chad, M. A.; Goulioti, T.; Aftimos, P.; Piccart, M.			Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs	ONCOGENE			English	Review							FACTOR RECEPTOR 2; GENETIC-HETEROGENEITY; PROGESTERONE-RECEPTOR; MUTATIONAL EVOLUTION; FUTURE PERSPECTIVES; ESTROGEN-RECEPTOR; TUMOR DNA; METASTASES; EXPRESSION; MANAGEMENT	Breast cancer (BC) has been classified into four intrinsic subtypes through seminal studies employing gene expression profiling analysis of primary tumours, namely the luminal A and B subtypes, the human epidermal growth factor receptor 2-like subtype and the basal-like subtype. More recently, the emergence of high-throughput genomic sequencing techniques, such as next-generation or massive parallel sequencing has expanded our understanding of the complex genomic landscapes of BC, with marked intertumour heterogeneity seen among different patients. In addition, increasing evidence indicates intratumour heterogeneity, with molecular differences observed within one patient, both spatially and longitudinally. These phenomena have an impact on the clinical development of molecularly targeted agents, with the classical paradigm of population-based clinical trials being no longer efficient. In the era of genomically driven oncology, three complementary tools can accelerate the clinical development of targeted agents for advanced BC as follows: (i) the implementation of molecular profiling of metastatic tumour lesions, as exemplified by the AURORA (Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer) programme; (ii) serial assessments of circulating tumour DNA, allowing a more thorough molecular interrogation of metastatic tumour burden; and (iii) new innovative clinical trial designs able to address the challenges of the increasing molecular fragmentation of BC.	[Fadoukhair, Z.] Natl Inst Oncol, Dept Med Oncol, Rabat, Morocco; [Fadoukhair, Z.; Chad, M. A.; Aftimos, P.; Piccart, M.] Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, 1 Rrue Heger Bordet, B-1000 Brussels, Belgium; [Zardavas, D.] Breast Int Grp, Aisbl, Brussels, Belgium; [Chad, M. A.] Hassan II Univ Hosp, Dept Med Oncol, Fes, Morocco	Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; Institut Jules Bordet; Universite Libre de Bruxelles; Breast International Group; Hassan II University Hospital Center of Fez	Piccart, M (corresponding author), Univ Libre Bruxelles, Inst Jules Bordet, Dept Med, 1 Rrue Heger Bordet, B-1000 Brussels, Belgium.	martine.piccart@bordet.be						Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870; Ades F, 2014, CURR OPIN ONCOL, V26, P334, DOI 10.1097/CCO.0000000000000076; Andre F, 2014, LANCET ONCOL, V15, P267, DOI 10.1016/S1470-2045(13)70611-9; [Anonymous], 2014, Cancer Discov, V4, pOF2, DOI 10.1158/2159-8290.CD-NB2013-182; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Badve S, 2011, MODERN PATHOL, V24, P157, DOI 10.1038/modpathol.2010.200; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; Bjarnadottir O, 2013, BREAST CANCER RES TR, V138, P499, DOI 10.1007/s10549-013-2473-6; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Curigliano G, 2011, ANN ONCOL, V22, P2227, DOI 10.1093/annonc/mdq751; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Curtit E, 2013, ONCOLOGIST, V18, P667, DOI 10.1634/theoncologist.2012-0350; De Mattos-Arruda L, 2014, ANN ONCOL, V25, P1729, DOI 10.1093/annonc/mdu239; De Mattos-Arruda L, 2013, NAT REV CLIN ONCOL, V10, P377, DOI 10.1038/nrclinonc.2013.80; Desmedt C, 2014, UNRAVELING BREAST CA; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Duan NH, 2013, J CLIN EPIDEMIOL, V66, pS21, DOI 10.1016/j.jclinepi.2013.04.006; Duchnowska R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3244; Eirew P, 2015, NATURE, V518, P422, DOI 10.1038/nature13952; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Esserman LJ, 2012, J CLIN ONCOL, V30, P3242, DOI 10.1200/JCO.2011.39.2779; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gonzalez-Angulo AM, 2011, MOL CANCER THER, V10, P1093, DOI 10.1158/1535-7163.MCT-10-1089; Hadad S, 2011, BREAST CANCER RES TR, V128, P783, DOI 10.1007/s10549-011-1612-1; Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186; Hunsberger S, 2009, CLIN CANCER RES, V15, P5950, DOI 10.1158/1078-0432.CCR-08-3205; Jensen JD, 2011, CLIN CANCER RES, V17, P667, DOI 10.1158/1078-0432.CCR-10-1133; Kim ES, 2011, CANCER DISCOV, V1, P44, DOI 10.1158/2159-8274.CD-10-0010; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lindstrom LS, 2012, J CLIN ONCOL, V30, P2601, DOI 10.1200/JCO.2011.37.2482; Louly PG, 2009, CLIN THER, V31, P1007, DOI 10.1016/j.clinthera.2009.05.015; Macfarlane R, 2012, ONCOLOGIST, V17, P172, DOI 10.1634/theoncologist.2011-0127; Martinez de Duenas E, 2014, BREAST CANCER RES TR, V143, P507, DOI 10.1007/s10549-013-2825-2; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; NEDERGAARD L, 1995, APMIS, V103, P20, DOI 10.1111/j.1699-0463.1995.tb01074.x; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Printz C, 2013, CANCER-AM CANCER SOC, V119, P1925, DOI 10.1002/cncr.28172; Rodon J, 2012, NAT REV CLIN ONCOL, V9, P359, DOI 10.1038/nrclinonc.2012.48; Rothe F, 2014, ANN ONCOL, V25, P1959, DOI 10.1093/annonc/mdu288; Scudeller L, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d7653; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Simmons C, 2009, ANN ONCOL, V20, P1499, DOI 10.1093/annonc/mdp028; Sleijfer S, 2013, J CLIN ONCOL, V31, P1834, DOI 10.1200/JCO.2012.45.3639; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Von Hoff DD, 2010, J CLIN ONCOL, V28, P4877, DOI 10.1200/JCO.2009.26.5983; Wilking U, 2011, BREAST CANCER RES TR, V125, P553, DOI 10.1007/s10549-010-1029-2; Yan M, 2014, CANCER TREAT REV, V40, P770, DOI 10.1016/j.ctrv.2014.02.008; Zardavas D, 2014, BRIT J CANCER, V111, P1881, DOI 10.1038/bjc.2014.341; Zardavas D, 2013, AM SOC CLIN ONCOL ED, V2013, P2, DOI DOI 10.1200/EDB00K_; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73; Zardavas D, 2013, FUTURE ONCOL, V9, P1105, DOI [10.2217/fon.13.57, 10.2217/FON.13.57]; Zardavas D, 2013, NAT REV CLIN ONCOL, V10, P191, DOI 10.1038/nrclinonc.2013.29	58	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1743	1749		10.1038/onc.2015.249	http://dx.doi.org/10.1038/onc.2015.249			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119941				2022-12-17	WOS:000373610400001
J	Morrison, MM; Williams, MM; Vaught, DB; Hicks, D; Lim, J; McKernan, C; Aurisicchio, L; Ciliberto, G; Simion, C; Sweeney, C; Cook, RS				Morrison, M. M.; Williams, M. M.; Vaught, D. B.; Hicks, D.; Lim, J.; McKernan, C.; Aurisicchio, L.; Ciliberto, G.; Simion, C.; Sweeney, C.; Cook, R. S.			Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth	ONCOGENE			English	Article							FACTOR RECEPTOR FAMILY; ANTI-ERBB3 MONOCLONAL-ANTIBODIES; LEUCINE-RICH REPEAT; NEGATIVE REGULATOR; DOWN-REGULATION; RESISTANCE; OVEREXPRESSION; DEGRADATION; INHIBITION; ACTIVATION	ErbB3, a member of the ErbB family of receptor tyrosine kinases, is a potent activator of phosphatidyl inositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) signaling, driving tumor cell survival and therapeutic resistance in breast cancers. In luminal breast cancers, ErbB3 upregulation following treatment with the antiestrogen fulvestrant enhances PI3K/mTOR-mediated cell survival. However, the mechanism by which ErbB3 is upregulated in fulvestrant-treated cells is unknown. We found that ErbB3 protein levels and cell surface presentation were increased following fulvestrant treatment, focusing our attention on proteins that regulate ErbB3 at the cell surface, including Nrdp1, NEDD4 and LRIG1. Among these, only LRIG1 correlated positively with ER alpha, but inversely with ErbB3 in clinical breast cancer data sets. LRIG1, an estrogen-inducible ErbB downregulator, was decreased in a panel of fulvestrant-treated luminal breast cancer cells. Ectopic LRIG1 expression from an estrogen-independent promoter uncoupled LRIG1 from estrogen regulation, thus sustaining LRIG1 and maintaining low ErbB3 levels in fulvestrant-treated cells. An LRIG1 mutant lacking the ErbB3 interaction motif was insufficient to downregulate ErbB3. Importantly, LRIG1 overexpression improved fulvestrant-mediated growth inhibition, whereas cells expressing the LRIG1 mutant were poorly sensitive to fulvestrant, despite effective ER alpha downregulation. Consistent with these results, LRIG1 expression correlated positively with increased disease-free survival in antiestrogen-treated breast cancer patients. These data suggest that ER alpha-dependent expression of LRIG1 dampens ErbB3 signaling in luminal breast cancer cells, and by blocking ER alpha activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 accumulation, enhanced ErbB3 signaling to cell survival pathways and blunting therapeutic response to fulvestrant.	[Morrison, M. M.; Williams, M. M.; Vaught, D. B.; Hicks, D.; Lim, J.; McKernan, C.; Cook, R. S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, 2220 Pierce Ave,759 PRB, Nashville, TN USA; [Aurisicchio, L.] Takis Biotech, Via Castel Romano 100, I-00128 Rome, Italy; [Ciliberto, G.] IRCCS Natl Canc Inst G Pascale, Via Mariano Semmola, I-83131 Naples, Italy; [Simion, C.; Sweeney, C.] Univ Calif Davis, Ctr Canc, Basic Sci, Sacramento, CA 95817 USA; [Cook, R. S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA	Vanderbilt University; IRCCS Fondazione Pascale; University of California System; University of California Davis; Vanderbilt University	Cook, RS (corresponding author), Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, 2220 Pierce Ave,759 PRB, Nashville, TN 37232 USA.	rebecca.cook@vanderbilt.edu	Williams, Michelle/AAI-2839-2020; Ciliberto, Gennaro/J-4131-2017	Williams, Michelle/0000-0002-7063-9147; Ciliberto, Gennaro/0000-0003-2851-8605; Aurisicchio, Luigi/0000-0003-3110-4534	National Institutes of Health [R01CA143126]; Susan G. Komen for the Cure grant [KG100677]; NATIONAL CANCER INSTITUTE [R01CA118384, R01CA143126] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen for the Cure grant(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health R01CA143126 (RSC) and Susan G. Komen for the Cure grant KG100677 (RSC).	ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Aurisicchio L, 2012, J CELL PHYSIOL, V227, P3381, DOI 10.1002/jcp.24037; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Belleudi F, 2012, CELL CYCLE, V11, P1455, DOI 10.4161/cc.19861; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cook RS, 2011, CANCER RES, V71, P3941, DOI 10.1158/0008-5472.CAN-10-3775; Diamonti AJ, 2002, P NATL ACAD SCI USA, V99, P2866, DOI 10.1073/pnas.052709799; Fattore L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-180; Ghasimi S, 2012, J NEURO-ONCOL, V108, P435, DOI 10.1007/s11060-012-0856-x; Hamburger AW, 2008, J MAMMARY GLAND BIOL, V13, P225, DOI 10.1007/s10911-008-9077-5; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56; Hutcheson IR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2848; KIM HH, 1994, J BIOL CHEM, V269, P24747; Kim HH, 1998, BIOCHEM J, V334, P189, DOI 10.1042/bj3340189; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Krig SR, 2011, MOL CANCER RES, V9, P1406, DOI 10.1158/1541-7786.MCR-11-0227; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Liu BL, 2007, INT J CANCER, V120, P1874, DOI 10.1002/ijc.22423; Miller JK, 2008, CANCER RES, V68, P8286, DOI 10.1158/0008-5472.CAN-07-6316; Morrison MM, 2013, J CLIN INVEST, V123, P4329, DOI 10.1172/JCI66764; Noto A, 2013, ONCOTARGET, V4, P1253, DOI 10.18632/oncotarget.1141; Qiu XB, 2002, P NATL ACAD SCI USA, V99, P14843, DOI 10.1073/pnas.232580999; Rafidi H, 2013, J BIOL CHEM, V288, P21593, DOI 10.1074/jbc.M113.486050; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Stern DF, 2008, J MAMMARY GLAND BIOL, V13, P215, DOI 10.1007/s10911-008-9083-7; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Sutherland RL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2878; Tovey S, 2005, CLIN CANCER RES, V11, P4835, DOI 10.1158/1078-0432.CCR-05-0196; Wiseman SM, 2005, CANCER-AM CANCER SOC, V103, P1770, DOI 10.1002/cncr.20970; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464	36	9	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1143	1152		10.1038/onc.2015.169	http://dx.doi.org/10.1038/onc.2015.169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	26148232	Green Accepted			2022-12-17	WOS:000371351700008
J	Gaudette, BT; Dwivedi, B; Chitta, KS; Poulain, S; Powell, D; Vertino, P; Leleu, X; Lonial, S; Chanan-Khan, AA; Kowalski, J; Boise, LH				Gaudette, B. T.; Dwivedi, B.; Chitta, K. S.; Poulain, S.; Powell, D.; Vertino, P.; Leleu, X.; Lonial, S.; Chanan-Khan, A. A.; Kowalski, J.; Boise, L. H.			Low expression of pro-apoptotic Bcl-2 family proteins sets the apoptotic threshold in Waldenstrom macroglobulinemia	ONCOGENE			English	Article							CELL-DEATH; MITOCHONDRIAL DYSFUNCTION; MYELOMA; LINE; BIM; BAX; ESTABLISHMENT; ACTIVATION; BCL-X(L); SURVIVAL	Waldenstrom macroglobulinemia (WM) is a proliferative disorder of IgM-secreting, lymphoplasmacytoid cells that inhabit the lymph nodes and bone marrow. The disease carries a high prevalence of activating mutations in MyD88 (91%) and CXCR4 (28%). Because signaling through these pathways leads to Bcl-xL induction, we examined Bcl-2 family expression in WM patients and cell lines. Unlike other B-lymphocyte-derived malignancies, which become dependent on expression of anti-apoptotic proteins to counter expression of pro-apoptotic proteins, WM samples expressed both pro-and anti-apoptotic Bcl-2 proteins at low levels similar to their normal B-cell and plasma cell counterparts. Three WM cell lines expressed pro-apoptotic Bcl-2 family members Bim or Bax and Bak at low levels, which determined their sensitivity to inducers of intrinsic apoptosis. In two cell lines, miR-155 upregulation, which is common in WM, was responsible for the inhibition of FOXO3a and Bim expression. Both antagonizing miR-155 to induce Bim and proteasome inhibition increased the sensitivity to ABT-737 in these lines indicating a lowering of the apoptotic threshold. In this manner, treatments that increase pro-apoptotic protein expression increase the efficacy of agents treated in combination in addition to direct killing.	[Gaudette, B. T.; Lonial, S.; Boise, L. H.] Emory Univ, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Gaudette, B. T.; Dwivedi, B.; Powell, D.; Vertino, P.; Lonial, S.; Kowalski, J.; Boise, L. H.] Emory Univ, Winship Canc Inst, 1365C Clifton RD NE,Suite C4012, Atlanta, GA 30322 USA; [Gaudette, B. T.; Boise, L. H.] Emory Univ, Grad Program Immunol & Mol Pathogenesis, Atlanta, GA 30322 USA; [Chitta, K. S.] Mayo Clin, Canc Biol, Jacksonville, FL 32224 USA; [Poulain, S.] Hop Valenciennes, Serv Hematol Immunol Cytogenet, Valenciennes, France; [Vertino, P.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Leleu, X.] CHRU Lille, Hop Claude Huriez, Serv Malad Sang, F-59037 Lille, France; [Chanan-Khan, A. A.] Mayo Clin, Hematol & Oncol, Jacksonville, FL 32224 USA; [Boise, L. H.] Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Mayo Clinic; CH de Valenciennes; Emory University; Universite de Lille - ISITE; CHU Lille; Mayo Clinic; Emory University	Boise, LH (corresponding author), Emory Univ, Winship Canc Inst, 1365C Clifton RD NE,Suite C4012, Atlanta, GA 30322 USA.	lboise@emory.edu	Boise, Lawrence/AAD-2314-2019; Poulain, Stéphanie/T-9033-2018	Poulain, Stéphanie/0000-0002-1792-7270; Gaudette, Brian/0000-0001-6627-3085; Boise, Lawrence/0000-0001-9436-8815; Kowalski, Jeanne/0000-0003-3458-3024; Dwivedi, Bhakti/0000-0002-9029-3737	TJ Martell Foundation [R01 CA127910, R01 CA129968]; Leukemia & Lymphoma Society; International Waldenstrom Macroglobulinemia; Comite du Septentrion de la Ligue contre le Cancer; NATIONAL CANCER INSTITUTE [R01CA129968, R01CA127910, P30CA138292] Funding Source: NIH RePORTER	TJ Martell Foundation; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); International Waldenstrom Macroglobulinemia; Comite du Septentrion de la Ligue contre le Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Stephen Ansell and Kelvin Lee for cell lines and reagents. This work was supported by: R01 CA127910 and R01 CA129968 as well as funding from the TJ Martell Foundation (LHB), the Leukemia & Lymphoma Society (AAC), the International Waldenstrom Macroglobulinemia (AAC), and the Comite du Septentrion de la Ligue contre le Cancer (XL). LHB is a GRA Distinguished Cancer Scientist. ABT-737 and ABT-199 were a generous gift of Abbvie, (North Chicago, IL, USA).	Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466; Boise LH, 2010, BLOOD, V115, P4007, DOI 10.1182/blood-2010-02-270231; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chitta KS, 2013, LEUKEMIA LYMPHOMA, V54, P387, DOI 10.3109/10428194.2012.713481; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Gaudette BT, 2014, J BIOL CHEM, V289, P23629, DOI 10.1074/jbc.M114.569376; Gertz MA, 2013, AM J HEMATOL, V88, P703, DOI 10.1002/ajh.23472; Ghobrial IM, 2003, LANCET ONCOL, V4, P679, DOI 10.1016/S1470-2045(03)01246-4; Gutierrez NC, 2007, LEUKEMIA, V21, P541, DOI 10.1038/sj.leu.2404520; HERRINTON LJ, 1993, BLOOD, V82, P3148; Hodge LS, 2011, BLOOD, V117, pE190, DOI 10.1182/blood-2010-12-326868; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; Morales AA, 2011, BLOOD, V118, P1329, DOI 10.1182/blood-2011-01-327197; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Poulain S, 2013, BLOOD, V121, P4504, DOI 10.1182/blood-2012-06-436329; Premkumar DR, 2012, J PHARMACOL EXP THER, V341, P859, DOI 10.1124/jpet.112.191536; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Roccaro AM, 2010, BLOOD, V115, P4051, DOI 10.1182/blood-2009-09-243402; Roccaro AM, 2009, BLOOD, V113, P4391, DOI 10.1182/blood-2008-09-178228; Santos DD, 2007, EXP HEMATOL, V35, P1366, DOI 10.1016/j.exphem.2007.05.022; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Treon SP, 2014, BLOOD, V124, P503, DOI 10.1182/blood-2014-03-566273; Treon SP, 2012, NEW ENGL J MED, V367, P826, DOI 10.1056/NEJMoa1200710; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamanaka Y, 2009, BLOOD, V114, P3265, DOI 10.1182/blood-2009-06-222794; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647	31	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					479	490		10.1038/onc.2015.103	http://dx.doi.org/10.1038/onc.2015.103			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893290	Green Accepted			2022-12-17	WOS:000369056700008
J	Cao, LL; Wei, F; Du, Y; Song, B; Wang, D; Shen, C; Lu, X; Cao, Z; Yang, Q; Gao, Y; Wang, L; Zhao, Y; Wang, H; Yang, Y; Zhu, WG				Cao, L-L; Wei, F.; Du, Y.; Song, B.; Wang, D.; Shen, C.; Lu, X.; Cao, Z.; Yang, Q.; Gao, Y.; Wang, L.; Zhao, Y.; Wang, H.; Yang, Y.; Zhu, W-G			ATM-mediated KDM2A phosphorylation is required for the DNA damage repair (vol 35, pg 301, 2016)	ONCOGENE			English	Correction									[Cao, L-L; Wei, F.; Du, Y.; Song, B.; Wang, D.; Shen, C.; Lu, X.; Cao, Z.; Yang, Q.; Wang, L.; Zhao, Y.; Wang, H.; Yang, Y.; Zhu, W-G] Peking Univ, Hlth Sci Ctr,Key Lab Carcinogenesis & Translat Re, Sch Basic Med Sci,State Key Lab Nat & Biomimet Dr, Minist Educ,Dept Biochem & Mol Biol,Beijing Key L, Beijing, Peoples R China; [Gao, Y.] Tsinghua Univ, Sch Biol Sci, Protein Chem Facil, Beijing 100084, Peoples R China; [Zhu, W-G] Tsinghua Univ, Peking Univ, Joint Ctr Life Sci, Beijing 100084, Peoples R China	Peking University; Tsinghua University; Peking University; Tsinghua University	Zhu, WG (corresponding author), Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Xueyuan Rd 38, Beijing 100191, Peoples R China.	zhuweiguo@bjmu.edu.cn		Lu, Xiaopeng/0000-0001-7746-5322; Yang, Yang/0000-0002-8737-590X; Zhu, Wei-Guo/0000-0001-8385-6581				Cao LL, 2016, ONCOGENE, V35, P301, DOI 10.1038/onc.2015.81	1	9	11	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2016	35	3					402	402		10.1038/onc.2015.311	http://dx.doi.org/10.1038/onc.2015.311			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OF	26790816	Bronze			2022-12-17	WOS:000369055300013
J	de Laurentiis, A; Hiscott, J; Alcalay, M				de Laurentiis, A.; Hiscott, J.; Alcalay, M.			The TEL-AML1 fusion protein of acute lymphoblastic leukemia modulates IRF3 activity during early B-cell differentiation	ONCOGENE			English	Article							INTERFERON REGULATORY FACTOR-3; ORIGINS; EXPRESSION; RECEPTOR; TARGET; GENES	The t(12;21) translocation is the most common genetic rearrangement in childhood acute lymphoblastic leukemia (ALL) and gives rise to the TEL-AML1 fusion gene. Many studies on TEL-AML1 describe specific properties of the fusion protein, but a thorough understanding of its function is lacking. We exploited a pluripotent hematopoietic stem/progenitor cell line, EML1, and generated a cell line (EML-TA) stably expressing the TEL-AML1 fusion protein. EML1 cells differentiate to mature B-cells following treatment with IL7; whereas EML-TA display an impaired differentiation capacity and remain blocked at an early stage of maturation. Global gene expression profiling of EML1 cells at different stages of B-lymphoid differentiation, compared with EML-TA, identified the interferon (IFN)alpha/beta pathway as a primary target of repression by TEL-AML1. In particular, expression and phosphorylation of interferon-regulatory factor 3 (IRF3) was decreased in EML-TA cells; strikingly, stable expression of IRF3 restored the capacity of EML-TA cells to differentiate into mature B-cells. Similarly, IRF3 silencing in EML1 cells by siRNA was sufficient to block B-lymphoid differentiation. The ability of TEL-AML1 to block B-cell differentiation and downregulate the IRF3-IFN alpha/beta pathway was confirmed in mouse and human primary hematopoietic precursor cells (Lin- and CD34+ cells, respectively), and in a patient-derived cell line expressing TEL-AML1 (REH). Furthermore, treatment of TEL-AML1 expressing cells with IFN alpha/beta was sufficient to overcome the maturation block. Our data provide new insight on TEL-AML1 function and may offer a new therapeutic opportunity for B-ALL.	[de Laurentiis, A.; Alcalay, M.] Ist Europeo Oncol, Dept Expt Oncol, I-20139 Milan, Italy; [Hiscott, J.] Vaccine & Gene Therapy Inst Florida, Port St Lucie, FL USA; [Alcalay, M.] Univ Milan, Dipartimento Sci Salute, Milan, Italy	IRCCS European Institute of Oncology (IEO); Vaccine & Gene Therapy Institute of Florida; University of Milan	de Laurentiis, A (corresponding author), Ist Europeo Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	angela.delaurentiis@ieo.eu	Alcalay, Myriam/AAB-4300-2019; Alcalay, Myriam/B-3182-2016	Alcalay, Myriam/0000-0002-5558-4272; Alcalay, Myriam/0000-0002-5558-4272	Associazione Italiana per la Ricerca sul Cancro (AIRC); Fondazione Umberto Veronesi (FUV); Italian Ministry of Health [PO-RF08]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi (FUV)(Fondazione Umberto Veronesi); Italian Ministry of Health(Ministry of Health, Italy)	We are grateful to Giacomo Iros Barozzi and Stefano Casola for their support and advice, the cell culture staff of the IEO-DEO, the microarray and FACS facilities of the IFOM-IEO Campus for excellent technical assistance and to Elisa Barbieri, Alicja M Gruszka, Marco Saia and Rita de Molfetta for many helpful discussions. We are thankful to S Tsai for the EML1 cell line, A Zelent and AM Ford for TEL-AML1 expression vectors. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Fondazione Umberto Veronesi (FUV) and Italian Ministry of Health (PO-RF08) to MA.	Ardekani Ali M., 2011, Avicenna Journal of Medical Biotechnology, V3, P1; Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972; Caraglia M, 2013, PROTEIN PEPTIDE LETT, V20, P412, DOI 10.2174/092986613805290372; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chessells JM, 1998, BRIT J HAEMATOL, V102, P423, DOI 10.1046/j.1365-2141.1998.00776.x; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; de Lendonck LY, 2014, CELL MOL LIFE SCI, V71, P3873, DOI 10.1007/s00018-014-1653-9; Diakos C, 2007, BLOOD, V109, P2607, DOI 10.1182/blood-2006-04-019612; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Dupuis S, 2003, NAT GENET, V33, P388, DOI 10.1038/ng1097; Fan D, 2015, ONCOGENE, V34, P2083, DOI 10.1038/onc.2014.148; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Fuka G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026348; Gandemer V, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-385; George J, 2009, CLIN CANCER RES, V15, P7186, DOI 10.1158/1078-0432.CCR-09-1425; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Hong DL, 2008, SCIENCE, V319, P336, DOI 10.1126/science.1150648; Li M, 2013, LEUKEMIA, V27, P1570, DOI 10.1038/leu.2013.15; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Linka Y, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.48; Long LY, 2014, IMMUNITY, V40, P515, DOI 10.1016/j.immuni.2014.01.015; Moritz A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000998; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Nagasawa T, 2006, NAT REV IMMUNOL, V6, P107, DOI 10.1038/nri1780; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; ROSENFELD C, 1977, EUR J CANCER, V13, P377, DOI 10.1016/0014-2964(77)90085-8; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Tamassia N, 2012, J IMMUNOL, V189, P1500, DOI 10.4049/jimmunol.1102985; Taylor KE, 2013, IMMUNOLOGY, V138, P190, DOI 10.1111/imm.12038; Torrano V, 2011, BLOOD, V118, P4910, DOI 10.1182/blood-2011-05-354266; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; van Delft FW, 2011, BLOOD, V117, P6247, DOI 10.1182/blood-2010-10-314674; Zelent A, 2004, ONCOGENE, V23, P4275, DOI 10.1038/sj.onc.1207672; Zhao JW, 2010, MOL IMMUNOL, V48, P294, DOI 10.1016/j.molimm.2010.07.014	36	9	9	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					6018	6028		10.1038/onc.2015.50	http://dx.doi.org/10.1038/onc.2015.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25893288				2022-12-17	WOS:000366113500008
J	Lindsey, JC; Kawauchi, D; Schwalbe, EC; Solecki, DJ; Selby, MP; McKinnon, PJ; Olson, JM; Hayden, JT; Grundy, RG; Ellison, DW; Williamson, D; Bailey, S; Roussel, MF; Clifford, SC				Lindsey, J. C.; Kawauchi, D.; Schwalbe, E. C.; Solecki, D. J.; Selby, M. P.; McKinnon, P. J.; Olson, J. M.; Hayden, J. T.; Grundy, R. G.; Ellison, D. W.; Williamson, D.; Bailey, S.; Roussel, M. F.; Clifford, S. C.			Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance	ONCOGENE			English	Article							HEDGEHOG PATHWAY; METHYLATION; CANCER; MODEL; PROTOONCOGENE; TUMORIGENESIS; INACTIVATION; ORGANIZATION; CEREBELLUM; INHIBITION	The identification of key tumorigenic events in Sonic Hedgehog (SHH) subgroup medulloblastomas (MBSHH) will be essential for the development of individualized therapies and improved outcomes. However, beyond confirmation of characteristic SHH pathway mutations, recent genome-wide sequencing studies have not revealed commonly mutated genes with widespread relevance as potential therapeutic targets. We therefore examined any role for epigenetic DNA methylation events in MBSHH using a cross-species approach to candidate identification, prioritization and validation. MBSHH-associated DNA methylation events were first identified in 216 subgrouped human medulloblastomas (50 MBSHH, 28 Wnt/Wingless, 44 Group 3 and 94 Group 4) and their conservation then assessed in tumors arising from four independent murine models of Shh medulloblastoma, alongside any role in tumorigenesis using functional assessments in mouse and human models. This strategy identified widespread regional CpG hypomethylation of VAV1, leading to its elevated expression, as a conserved aberrant epigenetic event, which characterizes the majority of MBSHH tumors in both species, and is associated with a poor outcome in MBSHH patients. Moreover, direct modulation of VAV1 in mouse and human models revealed a critical role in tumor maintenance, and its abrogation markedly reduced medulloblastoma growth. Further, Vav1 activity regulated granule neuron precursor germinal zone exit and migration initiation in an ex vivo model of early postnatal cerebellar development. These findings establish VAV1 as a critical epigenetically regulated oncogene with a key role in MBSHH maintenance, and highlight its potential as a validated therapeutic target and prognostic biomarker for the improved therapy of medulloblastoma.	[Lindsey, J. C.; Schwalbe, E. C.; Selby, M. P.; Hayden, J. T.; Williamson, D.; Bailey, S.; Clifford, S. C.] Newcastle Univ, Royal Victoria Infirm, Northern Inst Canc Res, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Kawauchi, D.; Roussel, M. F.] St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; [Solecki, D. J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; [McKinnon, P. J.] St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA; [Olson, J. M.] Univ Washington, Mol & Cellular Biol Program, Seattle, WA 98195 USA; [Grundy, R. G.] Univ Nottingham, Childrens Brain Tumor Res Ctr, Nottingham NG7 2RD, England; [Ellison, D. W.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	Newcastle University - UK; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Washington; University of Washington Seattle; University of Nottingham; St Jude Children's Research Hospital	Clifford, SC (corresponding author), Newcastle Univ, Royal Victoria Infirm, Northern Inst Canc Res, Sir James Spence Inst Level 5, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	steve.clifford@ncl.ac.uk	Roussel, Martine F/F-1469-2016; Solecki, David/N-8080-2018	Roussel, Martine F/0000-0002-1740-8139; Lindsey, Janet/0000-0002-5043-7513; Clifford, Steve/0000-0003-4893-2184; Schwalbe, Ed/0000-0002-1190-9469	Brain Tumour Charity [16/46, 16/92]; NIH [CA-096832, CA-02165-29]; American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital; Mochida Foundation; Anderson fellowship; LoveOliver; Cancer Research UK [C8464/A13457]; Cancer Research UK [13457] Funding Source: researchfish; The Brain Tumour Charity [16/164, 16/193] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [R01CA114567, P30CA021765, P01CA096832, P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037956] Funding Source: NIH RePORTER	Brain Tumour Charity; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital(American Lebanese Syrian Associated Charities (ALSAC)); Mochida Foundation; Anderson fellowship; LoveOliver; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); The Brain Tumour Charity; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by grants from the Brain Tumour Charity (grants 16/46 (SCC and SB) and 16/92 (SCC, SB, DWE and JCL)), NIH CA-096832, CA-02165-29 (MFR), the American Lebanese Syrian Associated Charities of St Jude Children's Research Hospital (MFR, DK), the Mochida Foundation (DK), the Anderson fellowship (DK), LoveOliver (SCC and DW) and Cancer Research UK (grant C8464/A13457; SCC, SB and DWE). Cell lines D425Med and MEB-Med8A were gifts from Dr D Bigner (Duke University, Durham, USA) and Professor T Pietsch (University of Bonn Medical Centre, Bonn, Germany), respectively. Four normal cerebellar DNAs were gifts from Dr M Fruhwald (University of Munster, Munster, Germany). Vav1CA cDNA was a gift from Dr S Katzav (Hebrew University, Jerusalem, Israel). DAOY and D283Med cell lines were from the ATCC (Manassas, VA, USA). Approval from the Newcastle and North Tyneside Research Ethics Committee (study reference 07/Q0905/71) was obtained for the collection, storage, and biological study of all material described. Medulloblastomas investigated in this study include samples provided by the UK Children's Cancer and Leukaemia Group (CCLG) as part of CCLG-approved biological study BS-2007-04.	Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Anderton JA, 2008, NEURO-ONCOLOGY, V10, P981, DOI 10.1215/15228517-2008-048; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Denkinger DJ, 2000, BBA-GENE STRUCT EXPR, V1491, P253, DOI 10.1016/S0167-4781(00)00008-7; Ellison DW, 2011, J CLIN ONCOL, V29, P1400, DOI 10.1200/JCO.2010.30.2810; Famulski JK, 2010, SCIENCE, V330, P1834, DOI 10.1126/science.1198480; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hovestadt V, 2013, ACTA NEUROPATHOL, V125, P913, DOI 10.1007/s00401-013-1126-5; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; Katzav S, 2007, CANCER LETT, V255, P241, DOI 10.1016/j.canlet.2007.04.015; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kimura H, 2008, CANCER CELL, V13, P249, DOI 10.1016/j.ccr.2008.01.027; Kool M, 2014, CANCER CELL, V25, P393, DOI 10.1016/j.ccr.2014.02.004; Ladd-Acosta C, 2007, AM J HUM GENET, V81, P1304, DOI 10.1086/524110; Langdon JA, 2006, GENE CHROMOSOME CANC, V45, P47, DOI 10.1002/gcc.20262; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lindsey JC, 2014, ACTA NEUROPATHOL, V127, P307, DOI 10.1007/s00401-013-1225-3; Lusher ME, 2002, CANCER RES, V62, P5906; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Oberley MJ, 2012, AM J BLOOD RES, V2, P1; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pizer BL, 2009, BRIT J NEUROSURG, V23, P364, DOI 10.1080/02688690903121807; Quevedo C, 2010, MOL BIOL CELL, V21, P1125, DOI 10.1091/mbc.E09-04-0292; RDevelopmentCoreTeam, 2011, R FDN STAT COMP; Remke M, 2013, ACTA NEUROPATHOL, V126, P917, DOI 10.1007/s00401-013-1198-2; Roussel MF, 2011, CURR TOP DEV BIOL, V94, P235, DOI 10.1016/B978-0-12-380916-2.00008-5; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Schwalbe EC, 2011, CLIN CANCER RES, V17, P1883, DOI 10.1158/1078-0432.CCR-10-2210; Schwalbe EC, 2013, ACTA NEUROPATHOL, V125, P359, DOI 10.1007/s00401-012-1077-2; Sebban S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054321; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Taylor RE, 2003, J CLIN ONCOL, V21, P1581, DOI 10.1200/JCO.2003.05.116; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wells CM, 2005, EXP CELL RES, V310, P303, DOI 10.1016/j.yexcr.2005.07.015; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408; Zindy F, 2007, CANCER RES, V67, P2676, DOI 10.1158/0008-5472.CAN-06-3418	48	9	9	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4746	4757		10.1038/onc.2014.405	http://dx.doi.org/10.1038/onc.2014.405			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	25531316	Green Accepted			2022-12-17	WOS:000360931500008
J	Tsuchiya, M; Nakajima, Y; Waku, T; Hiyoshi, H; Morishita, T; Furumai, R; Hayashi, Y; Kishimoto, H; Kimura, K; Yanagisawa, J				Tsuchiya, M.; Nakajima, Y.; Waku, T.; Hiyoshi, H.; Morishita, T.; Furumai, R.; Hayashi, Y.; Kishimoto, H.; Kimura, K.; Yanagisawa, J.			CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population	ONCOGENE			English	Article							BREAST-CANCER CELLS; MORPHOLOGICAL EVOLUTION; UBIQUITIN LIGASE; PROTEINS; HSP90; IDENTIFICATION; CAPACITOR; MCF7; GENE; TRANSCRIPTION	Many types of cancer display heterogeneity in various features, including gene expression and malignant potential. This heterogeneity is associated with drug resistance and cancer progression. Recent studies have shown that the expression of a major protein quality control ubiquitin ligase, carboxyl terminus of Hsc70-interacting protein (CHIP), is negatively correlated with breast cancer clinicopathological stages and poor overall survival. Here we show that CHIP acts as a capacitor of heterogeneous Bcl-2 expression levels and prevents an increase in the anticancer drug-resistant population in breast cancer cells. CHIP knockdown in breast cancer cells increased variation in Bcl-2 expression levels, an antiapoptotic protein, among the cells. Our results also showed that CHIP knockdown increased the proportion of anticancer drug-resistant cells. These findings suggest that CHIP buffers variation in gene expression levels, affecting resistance to anticancer drugs. In single-cell clones derived from breast cancer cell lines, CHIP knockdown did not alter the variation in Bcl-2 expression levels and the proportion of anticancer drug-resistant cells. In contrast, when clonal cells were treated with a mutagen, the variation in Bcl-2 expression levels and proportion of anticancer drug-resistant cells were altered by CHIP knockdown. These results suggest that CHIP masks genetic variations to suppress heterogeneous Bcl-2 expression levels and prevents augmentation of the anticancer drug-resistant population of breast cancer cells. Because genetic variation is a major driver of heterogeneity, our results suggest that the degree of heterogeneity in expression levels is decided by a balance between genetic variation and the buffering capacity of CHIP.	[Tsuchiya, M.; Nakajima, Y.; Hiyoshi, H.; Morishita, T.; Hayashi, Y.; Kishimoto, H.; Kimura, K.; Yanagisawa, J.] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058577, Japan; [Nakajima, Y.; Hiyoshi, H.; Furumai, R.; Kishimoto, H.; Yanagisawa, J.] Univ Tsukuba, Life Sci Ctr, Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; [Waku, T.] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo, Japan	University of Tsukuba; University of Tsukuba; University of Tokyo	Kimura, K (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tenno Dai, Tsukuba, Ibaraki 3058577, Japan.	kekimura@tara.tsukuba.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan. We would like to thank Enago (www.enago.jp) for the English language review.	Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154; BUTLER WB, 1986, CANCER RES, V46, P6339; Coley HM, 2009, EJC SUPPL, V7, P3, DOI 10.1016/S1359-6349(09)70003-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Davis JM, 2003, CLIN CANCER RES, V9, P1161; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; DREWINKO B, 1973, CANCER RES, V33, P3091; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; HEWITT SM, 1995, CANCER RES, V55, P5386; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kampinga HH, 2003, MOL CELL BIOL, V23, P4948, DOI 10.1128/MCB.23.14.4948-4958.2003; Kurland JF, 2001, J BIOL CHEM, V276, P45380, DOI 10.1074/jbc.M108294200; Lambert G, 2011, NAT REV CANCER, V11, P375, DOI 10.1038/nrc3039; Lee JH, 2004, J BIOL CHEM, V279, P42758, DOI 10.1074/jbc.M407357200; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McDiarmid HM, 2001, MUTAT RES-GEN TOX EN, V497, P39, DOI 10.1016/S1383-5718(01)00245-5; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; PAPENDORP JT, 1985, J CELL PHYSIOL, V125, P591, DOI 10.1002/jcp.1041250331; Patani Neill, 2010, J Carcinog, V9, P9, DOI 10.4103/1477-3163.72505; Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295; Queitsch C, 2002, NATURE, V417, P618, DOI 10.1038/nature749; RESNICOFF M, 1987, P NATL ACAD SCI USA, V84, P7295, DOI 10.1073/pnas.84.20.7295; Rudin CM, 2003, CANCER RES, V63, P312; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sierra A, 1996, CLIN CANCER RES, V2, P1887; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Stevenson HS, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1766; Tabuchi Y, 2009, INT J ONCOL, V34, P313, DOI 10.3892/ijo_00000153; Theodoraki MA, 2012, BBA-MOL CELL RES, V1823, P683, DOI 10.1016/j.bbamcr.2011.08.006; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang JY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-388; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	43	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2015	34	35					4656	4663		10.1038/onc.2014.387	http://dx.doi.org/10.1038/onc.2014.387			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BS	25435366	Bronze			2022-12-17	WOS:000360189300011
J	Tomiatti, V; Istvanffy, R; Pietschmann, E; Kratzat, S; Hoellein, A; Quintanilla-Fend, L; von Bubnoff, N; Peschel, C; Oostendorp, RAJ; Keller, U				Tomiatti, V.; Istvanffy, R.; Pietschmann, E.; Kratzat, S.; Hoellein, A.; Quintanilla-Fend, L.; von Bubnoff, N.; Peschel, C.; Oostendorp, R. A. J.; Keller, U.			Cks1 is a critical regulator of hematopoietic stem cell quiescence and cycling, operating upstream of Cdk inhibitors	ONCOGENE			English	Article							POOL SIZE; BCR-ABL; SKP2; P27(KIP1); PROTEOLYSIS; MECHANISMS; PROLIFERATION; MAINTENANCE; HOMEOSTASIS; EXPRESSION	Cyclin-dependent kinase subunit 1 (Cks1) is a critical rate-limiting component of the Skp1-Cullin1-Skp2 (SCFSkp2) ubiquitin ligase that controls cell cycle inhibitor abundance. Cyclin-dependent kinase (Cdk) inhibitors (CKIs) regulate hematopoietic stem cell (HSC) self-renewal, regeneration after cytotoxic stress and tumor cell proliferation. We thus studied the role of Cks1 in HSC and in a prototypic stem cell disorder, chronic myeloid leukemia (CML). Cks1 transcript was highly expressed in Lin - Sca-1+Kit+ (LSK) HSC, and the loss resulted in accumulation of the SCFSkp2/Cks1 substrates p21, p27, p57 and p130 particularly in CD150+ LSK cells. This accumulation correlated with decreased proliferation and accumulation of Cks1(-/-)HSC, slower regeneration after stress and prolonged HSC quiescence. At the hematopoietic progenitor (HPC) level, loss of Cks1 sensitized towards apoptosis. In CML, Cks1 expression was increased, and treatment with the Abl kinase inhibitor, imatinib, reduced Cks1 expression. Also, we found that Cks1 is critical for Bcr-Abl-induced cytokine-independent clonogenic activity. In conclusion, our study presents a novel function of Cks1 in maintaining HSC/HPC homeostasis and shows that Cks1 is a possible target in therapies aimed at the SCFSkp2/Cks1 complex that controls CKI abundance and cancer cell proliferation.	[Tomiatti, V.; Istvanffy, R.; Pietschmann, E.; Kratzat, S.; Hoellein, A.; von Bubnoff, N.; Peschel, C.; Oostendorp, R. A. J.; Keller, U.] Tech Univ Munich, Dept Med 3, D-81675 Munich, Germany; [Quintanilla-Fend, L.] Univ Tubingen, Inst Pathol, Tubingen, Germany; [von Bubnoff, N.] Univ Freiburg, Dept Med 1, D-79106 Freiburg, Germany; [Peschel, C.; Keller, U.] German Canc Consortium DKTK, Heidelberg, Germany; [Peschel, C.; Keller, U.] German Canc Res Ctr, Heidelberg, Germany	Technical University of Munich; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Oostendorp, RAJ (corresponding author), Tech Univ Munich, Dept Med 3, Ismaninger Str 22, D-81675 Munich, Germany.	oostendorp@lrz.tu-muenchen.de; ulrich.keller@lrz.tum.de	von Bubnoff, Nikolas/AAG-1845-2021; von Bubnoff, Nikolas/F-2351-2017; Oostendorp, Robert A. J./K-9841-2018; Keller, Ulrich/L-1763-2016	von Bubnoff, Nikolas/0000-0001-9593-8947; Oostendorp, Robert A. J./0000-0002-4947-0412; Hollein, Alexander/0000-0002-9799-7809; Keller, Ulrich/0000-0002-8485-1958	Deutsche Forschungsgemeinschaft [KE 222/7-1, OO 8/2-3, OO 8/5-1, FOR 2033/1]; Deutsche Jose Carreras Leukamie Stiftung [R11/12, R11/18]; German Cancer Consortium (DKTK)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Jose Carreras Leukamie Stiftung; German Cancer Consortium (DKTK)	We thank Stephanie Schoffmann and Kerstin Behnke for excellent technical support, and the Flow Cytometry Core Facility and the Zentrum Praklinische Forschung (TU Munchen) for expert assistance. This work was supported by the Deutsche Forschungsgemeinschaft (KE 222/7-1, OO 8/2-3, OO 8/5-1 and FOR 2033/1), the Deutsche Jose Carreras Leukamie Stiftung (R11/12 and R11/18) and the German Cancer Consortium (DKTK).	Affer M, 2011, J ONCOL, V2011, DOI 10.1155/2011/798592; Bruennert D, 2009, LEUKEMIA, V23, P983, DOI 10.1038/leu.2008.337; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Cheng T, 2000, NAT MED, V6, P1235, DOI 10.1038/81335; Cheng T, 2004, ONCOGENE, V23, P7256, DOI 10.1038/sj.onc.1207945; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gomez-Casares MT, 2013, ONCOGENE, V32, P2239, DOI 10.1038/onc.2012.246; Hoellein A, 2012, MOL CELL BIOL, V32, P2416, DOI 10.1128/MCB.06771-11; Istvanffy R, 2011, BLOOD, V118, P2712, DOI 10.1182/blood-2010-05-287235; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Krek W, 1998, CURR OPIN GENET DEV, V8, P36, DOI 10.1016/S0959-437X(98)80059-2; Le Toriellec E, 2008, BLOOD, V111, P2321, DOI 10.1182/blood-2007-06-095570; LERNER C, 1990, EXP HEMATOL, V18, P114; Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463; Matsumoto A, 2013, BBA-GEN SUBJECTS, V1830, P2335, DOI 10.1016/j.bbagen.2012.07.004; Matsumoto A, 2011, CELL STEM CELL, V9, P262, DOI 10.1016/j.stem.2011.06.014; Miething C, 2006, LEUKEMIA, V20, P650, DOI 10.1038/sj.leu.2404151; Morita Y, 2010, J EXP MED, V207, P1173, DOI 10.1084/jem.20091318; Nagler RM, 2009, CANCER INVEST, V27, P512, DOI 10.1080/07357900802239116; Old JB, 2010, MOL CANCER RES, V8, P353, DOI 10.1158/1541-7786.MCR-09-0232; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 2010, J CLIN INVEST, V120, P2254, DOI 10.1172/JCI41246; Pietras EM, 2011, J CELL BIOL, V195, P709, DOI 10.1083/jcb.201102131; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Rodriguez S, 2011, BLOOD, V117, P6509, DOI 10.1182/blood-2010-11-321521; Rossi L, 2012, CELL STEM CELL, V11, P302, DOI 10.1016/j.stem.2012.08.006; Sattler M, 1996, ONCOGENE, V12, P839; Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tesio M, 2011, CELL STEM CELL, V9, P187, DOI 10.1016/j.stem.2011.08.005; Viatour P, 2008, CELL STEM CELL, V3, P416, DOI 10.1016/j.stem.2008.07.009; Wang J, 2011, BLOOD, V118, P5429, DOI 10.1182/blood-2010-10-312785; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Westbrook L, 2007, CANCER RES, V67, P11393, DOI 10.1158/0008-5472.CAN-06-4173; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhan FH, 2007, BLOOD, V109, P4995, DOI 10.1182/blood-2006-07-038703; Zhang HJ, 2012, NAT GENET, V44, P861, DOI 10.1038/ng.2350; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zou P, 2011, CELL STEM CELL, V9, P247, DOI 10.1016/j.stem.2011.07.003	45	9	10	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4347	4357		10.1038/onc.2014.364	http://dx.doi.org/10.1038/onc.2014.364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25417705				2022-12-17	WOS:000359494400006
J	Fernando, ATP; Andrabi, S; Cizmecioglu, O; Zhu, C; Livingston, DM; Higgins, JMG; Schaffhausen, BS; Roberts, TM				Fernando, A. T. Pores; Andrabi, S.; Cizmecioglu, O.; Zhu, C.; Livingston, D. M.; Higgins, J. M. G.; Schaffhausen, B. S.; Roberts, T. M.			Polyoma small T antigen triggers cell death via mitotic catastrophe	ONCOGENE			English	Article							PROTEIN PHOSPHATASE 2A; MIDDLE-T; KINETOCHORE LOCALIZATION; SPINDLE ORIENTATION; SIMIAN-VIRUS-40; PP2A; ARREST; COHESION; PHOSPHORYLATION; HOLOENZYMES	Polyoma small T antigen (PyST), an early gene product of the polyoma virus, has been shown to cause cell death in a number of mammalian cells in a protein phosphatase 2A (PP2A)-dependent manner. In the current study, using a cell line featuring regulated expression of PyST, we found that PyST arrests cells in mitosis. Live-cell and immunofluorescence studies showed that the majority of the PyST expressing cells were arrested in prometaphase with almost no cells progressing beyond metaphase. These cells exhibited defects in chromosomal congression, sister chromatid cohesion and spindle positioning, thereby resulting in the activation of the spindle assembly checkpoint. Prolonged mitotic arrest then led to cell death via mitotic catastrophe. Cell cycle inhibitors that block cells in G1/S prevented PyST-induced death. PyST-induced cell death that occurs during M is not dependent on p53 status. These data suggested, and our results confirmed, that PP2A inhibition could be used to preferentially kill cancer cells with p53 mutations that proliferate normally in the presence of cell cycle inhibitors.	[Fernando, A. T. Pores; Andrabi, S.; Cizmecioglu, O.; Livingston, D. M.; Roberts, T. M.] Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA; [Fernando, A. T. Pores; Cizmecioglu, O.; Roberts, T. M.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; [Zhu, C.; Higgins, J. M. G.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Higgins, J. M. G.] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Schaffhausen, B. S.] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Newcastle University - UK; Tufts University	Roberts, TM (corresponding author), Harvard Univ, Sch Med, Dept Canc Biol, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	shaida.andrabi@kashmiruniversity.ac.in; thomas_roberts@dfci.harvard.edu	Cizmecioglu, Onur/AAA-6289-2020; Cizmecioglu, Onur/AAF-5874-2020; Andrabi, Shaida/ABB-8795-2020	Cizmecioglu, Onur/0000-0002-7608-6950; Andrabi, Shaida/0000-0002-4114-4401; Higgins, Jonathan/0000-0001-6622-8268	National Institutes of Health PO1 grant [CA50661]; National Institutes of Health RO1 grant [CA30002, CA34722]; Ramalingaswami fellowship; CREST fellowship; Association for International Cancer Research; NATIONAL CANCER INSTITUTE [R37CA030002, R01CA034722, R37CA034722, P01CA050661, R01CA030002] Funding Source: NIH RePORTER; Worldwide Cancer Research [11-0775] Funding Source: researchfish	National Institutes of Health PO1 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health RO1 grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ramalingaswami fellowship; CREST fellowship; Association for International Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Worldwide Cancer Research	This work was supported by an National Institutes of Health PO1 grant CA50661 to TMR, BSS and DML; and an RO1 grant to TMR (CA30002) and BSS (CA34722); and a Ramalingaswami fellowship and a CREST fellowship to SA. JMGH is supported by the Association for International Cancer Research, and is a Scholar of the Leukemia and Lymphoma Society. We thank Drs Jennifer Spangle and Meera Bhanu for their helpful comments on this manuscript.	Andrabi S, 2007, P NATL ACAD SCI USA, V104, P19011, DOI 10.1073/pnas.0706696104; Andrabi S, 2011, J VIROL, V85, P10649, DOI 10.1128/JVI.05034-11; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Blagosklonny MV, 2002, CELL CYCLE, V1, P375, DOI 10.4161/cc.1.6.259; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen HH, 2003, CELL DEATH DIFFER, V10, P516, DOI 10.1038/sj.cdd.4401171; Cheng JW, 2009, SEMIN CANCER BIOL, V19, P218, DOI 10.1016/j.semcancer.2009.03.002; Dai J, 2006, DEV CELL, V11, P741, DOI 10.1016/j.devcel.2006.09.018; Dai J, 2009, J CELL SCI, V122, P4168, DOI 10.1242/jcs.054122; Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032; Foley EA, 2011, NAT CELL BIOL, V13, P1265, DOI 10.1038/ncb2327; Gaillard S, 2001, J VIROL, V75, P9799, DOI 10.1128/JVI.75.20.9799-9807.2001; Gjoerup O, 2001, J VIROL, V75, P9142, DOI 10.1128/JVI.75.19.9142-9155.2001; Honkanen RE, 2002, CURR MED CHEM, V9, P2055, DOI 10.2174/0929867023368836; Hwang JH, 2013, J BIOL CHEM, V288, P32064, DOI 10.1074/jbc.M113.497644; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2012, CURR MOL MED, V12, P268, DOI 10.2174/156652412799218930; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kitajima TS, 2006, NATURE, V441, P46, DOI 10.1038/nature04663; Kochupurakkal BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068509; Kwiatkowski N, 2010, NAT CHEM BIOL, V6, P359, DOI 10.1038/nchembio.345; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Li SY, 2009, J VIROL, V83, P8340, DOI 10.1128/JVI.00711-09; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Marusyk A, 2007, MOL CELL BIOL, V27, P5336, DOI 10.1128/MCB.01316-06; Moule MG, 2004, P NATL ACAD SCI USA, V101, P14063, DOI 10.1073/pnas.0405533101; Mullane KP, 1998, MOL CELL BIOL, V18, P7556, DOI 10.1128/MCB.18.12.7556; Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095; O'Shea CC, 2005, CELL CYCLE, V4, P449, DOI 10.4161/cc.4.3.1555; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Riedel CG, 2006, NATURE, V441, P53, DOI 10.1038/nature04664; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Schaffhausen BS, 2009, VIROLOGY, V384, P304, DOI 10.1016/j.virol.2008.09.042; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Sents W, 2013, FEBS J, V280, P644, DOI 10.1111/j.1742-4658.2012.08579.x; Seshacharyulu P, 2013, CANCER LETT, V335, P9, DOI 10.1016/j.canlet.2013.02.036; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; Swingle Mark, 2007, V365, P23; Tang ZY, 2006, DEV CELL, V10, P575, DOI 10.1016/j.devcel.2006.03.010; Taylor SS, 2001, J CELL SCI, V114, P4385; Toyoshima F, 2007, J CELL PHYSIOL, V213, P407, DOI 10.1002/jcp.21227; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yang CS, 2005, MOL CELL BIOL, V25, P1298, DOI 10.1128/MCB.25.4.1298-1308.2005; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; ZHENG B, 1991, J BIOL CHEM, V266, P10031; Zhou J, 2003, J BIOL CHEM, V278, P8617, DOI 10.1074/jbc.M211181200; Zhu M, 2013, J CELL BIOL, V200, P773, DOI 10.1083/jcb.201207050; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	52	9	9	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2015	34	19					2483	2492		10.1038/onc.2014.192	http://dx.doi.org/10.1038/onc.2014.192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CH7BK	24998850	Green Submitted, Green Accepted, Bronze			2022-12-17	WOS:000354190400007
J	Lo, D; Zhang, Y; Dai, MS; Sun, XX; Zeng, SX; Lu, H				Lo, D.; Zhang, Y.; Dai, M-S; Sun, X-X; Zeng, S. X.; Lu, H.			Nucleostemin stabilizes ARF by inhibiting the ubiquitin ligase ULF	ONCOGENE			English	Article							CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; RIBOSOME BIOGENESIS; TUMOR SUPPRESSION; ACTIVATES P53; P19(ARF); PROTEIN; MDM2; PROLIFERATION; DEGRADATION	Upregulated expression of nucleolar GTPase nucleostemin (NS) has been associated with increased cellular proliferation potential and tumor malignancy during cancer development. Recent reports attribute the growth regulatory effects of NS protein to its role in facilitating ribosome production. However, the oncogenic potential of NS remains unclear, as imbalanced levels of NS have been reported to exert growth inhibitory effect by modulating p53 tumor-suppressor activity. It also remains in questions if aberrant NS levels might have a p53-independent role in regulation of cell proliferation and growth. In this study, we performed affinity purification and mass spectrometry analysis to explore protein-protein interactions influencing NS growth regulatory properties independently of p53 tumor suppressor. We identified the alternative reading frame (ARF) protein as a key protein associating with NS and further verified the interaction through in vitro and in vivo assays. We demonstrated that NS is able to regulate cell cycle progression by regulating the stability of the ARF tumor suppressor. Furthermore, overexpression of NS suppressed ARF polyubiquitination by its E3 ligase Ubiquitin Ligase for ARF and elongated its half-life, whereas knockdown of NS led to the decrease of ARF levels. Also, we found that NS can enhance NPM stabilization of ARF. Thus, we propose that in the absence of p53, ARF can be stabilized by NS and nucleophosmin to serve as an alternative tumor-suppressor surveillance, preventing potential cellular transformation resulting from the growth-inducing effects of NS overexpression.	[Lo, D.; Zhang, Y.; Zeng, S. X.; Lu, H.] Tulane Univ, Tulane Canc Ctr, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; [Dai, M-S; Sun, X-X] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA	Tulane University; Oregon Health & Science University	Lu, H (corresponding author), Tulane Univ, Tulane Canc Ctr, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.	hlu2@tulane.edu			NIH-NCI grant [CA095441, CA079721, CA129828, CA172468]; NATIONAL CANCER INSTITUTE [R01CA129828, R01CA172468, R01CA095441, R01CA079721, R01CA160474] Funding Source: NIH RePORTER	NIH-NCI grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank L David at Oregon Health and Science University for conducting the mass spectrometry analysis in the affinity purification, W Gu at Columbia University for supplying the ULF reagents, and Y Dong at Tulane University School of Medicine for offering the lentivirus vector. This work was supported in part by NIH-NCI grants CA095441, CA079721, CA129828 and CA172468 to HL.	Beekman C, 2006, MOL CELL BIOL, V26, P9291, DOI 10.1128/MCB.01183-06; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang M, 2009, CANCER RES, V69, P3004, DOI 10.1158/0008-5472.CAN-08-3413; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Lin T, 2010, CANCER RES, V70, P9444, DOI 10.1158/0008-5472.CAN-10-2159; Lindstrom MS, 2006, CELL BIOCHEM BIOPHYS, V46, P79, DOI 10.1385/CBB:46:1:79; Lo D, 2012, J BIOL CHEM, V287, P10013, DOI 10.1074/jbc.M111.335141; Lo D, 2010, CELL CYCLE, V9, P3227, DOI 10.4161/cc.9.16.12605; Ma HH, 2008, MOL BIOL CELL, V19, P2870, DOI 10.1091/mbc.E08-02-0128; Ma HH, 2007, MOL BIOL CELL, V18, P2630, DOI 10.1091/mbc.E07-03-0244; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Nakajima TE, 2012, CANCER SCI, V103, P233, DOI 10.1111/j.1349-7006.2011.02142.x; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Romanova L, 2009, J BIOL CHEM, V284, P26685, DOI 10.1074/jbc.M109.013342; Romanova L, 2009, J BIOL CHEM, V284, P4968, DOI 10.1074/jbc.M804594200; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sijin L, 2004, J EXP CLIN CANC RES, V23, P529; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tamase A, 2009, P NATL ACAD SCI USA, V106, P17163, DOI 10.1073/pnas.0905016106; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tsai RYL, 2005, J CELL BIOL, V168, P179, DOI 10.1083/jcb.200409053; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhou Xiang, 2012, Genes Cancer, V3, P298, DOI 10.1177/1947601912455200; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424; Zwolinska AK, 2012, ONCOGENE, V31, P3311, DOI 10.1038/onc.2011.507	44	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1688	1697		10.1038/onc.2014.103	http://dx.doi.org/10.1038/onc.2014.103			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769896	Green Accepted			2022-12-17	WOS:000351848400009
J	Wu, TS; Tan, CT; Chang, CC; Lin, BR; Lai, WT; Chen, ST; Kuo, MYP; Rau, CL; Jaw, FS; Chang, HH				Wu, T-S; Tan, C-T; Chang, C-C; Lin, B-R; Lai, W-T; Chen, S-T; Kuo, M. Yen-Ping; Rau, C-L; Jaw, F-S; Chang, H-H			B-cell lymphoma/leukemia 10 promotes oral cancer progression through STAT1/ATF4/S100P signaling pathway	ONCOGENE			English	Article							NF-KAPPA-B; S100 PROTEINS; PANCREATIC-CANCER; EPITHELIAL-CELLS; GENE-EXPRESSION; NECK-CANCER; ACTIVATION; BCL10; BINDING; METASTASIS	B-cell lymphoma/leukemia 10 (BCL10) is an apoptotic regulatory protein related to advanced TNM stage and disease recurrence in oral squamous cell carcinoma (OSCC). However, the regulatory mechanism of BCL10 in OSCC progression is still unknown. Here, we showed that knockdown of endogenous BCL10 could significantly reduce cell migration and invasion abilities, retard cell proliferation by G(0)/G(1) phase accumulation and inhibit tumorigenicity in vivo. In molecular level, we identified S100P as a crucial downstream effector of BCL10-inhibited OSCC progression by high-throughput microarray analysis. S100P messenger RNA and protein expression levels were significantly diminished in silenced-BCL10 clones, and transfected S100P expression plasmids restored migration, invasion, proliferation abilities and tumorigenicity in shBCL10 transfectants. Furthermore, we provided evidence that BCL10 regulated S100P expression through signal transducers and activators of transcription 1 (STAT1) and activating transcription factor 4 (ATF4). Knockdown of BCL10 decreased S100P promoter activity, but showed no effect in truncated STAT1/ATF4 S100P promoter. In addition, we also found that the P50/P65 signaling pathway was involved in BCL10-enhanced OSCC progression. Restored S100P in silenced-BCL10 clones could markedly reverse P65 activation via outside-in signaling. Taken together, we discovered a novel axis of BCL10-regulated OSCC progression via STAT1/ATF4/S100P/P65 signaling, which could predict the prognosis of OSCC and will be beneficial for developing therapeutic strategy against advanced OSCC.	[Wu, T-S; Chang, C-C; Lai, W-T] Natl Taiwan Univ, Sch Dent, Grad Inst Oral Biol, Taipei 100, Taiwan; [Tan, C-T] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan; [Lin, B-R] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan; [Chen, S-T] Natl Taiwan Univ Hosp, Dept Pediat, YunLin Branch, Taipei 10016, Taiwan; [Kuo, M. Yen-Ping; Chang, H-H] Natl Taiwan Univ, Sch Dent, Dept Dent, Taipei 100, Taiwan; [Kuo, M. Yen-Ping; Chang, H-H] Natl Taiwan Univ, Sch Dent, Grad Inst Clin Dent, Taipei 100, Taiwan; [Rau, C-L; Jaw, F-S] Natl Taiwan Univ, Inst Biomed Engn, Taipei 100, Taiwan; [Rau, C-L] Taipei Med Univ, Shuang Ho Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; Taipei Medical University; Shuang Ho Hospital	Chang, HH (corresponding author), Natl Taiwan Univ, Sch Dent, Dept Dent, 1 Chang Te St, Taipei 100, Taiwan.	changhh@ntu.edu.tw		Tan, Ching-Ting/0000-0001-8317-2235; LIN, BEEN-REN/0000-0001-8354-1758; Chen, Szu-Ta/0000-0002-9715-1221	National Science Council, Taiwan [NSC-100-2314-B-002-097, NSC-101-2314-B-002-102]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from National Science Council, Taiwan NSC-100-2314-B-002-097 (to C-CC), NSC-101-2314-B-002-102 (to H-HC).	Arumugam T, 2004, J BIOL CHEM, V279, P5059, DOI 10.1074/jbc.M310124200; Austermann J, 2008, J BIOL CHEM, V283, P29331, DOI 10.1074/jbc.M806145200; Averboukh L, 1996, PROSTATE, V29, P350; Bertram J, 1998, ANTI-CANCER DRUG, V9, P311, DOI 10.1097/00001813-199804000-00004; Bhattacharyya S, 2008, J BIOL CHEM, V283, P10550, DOI 10.1074/jbc.M708833200; BOYLE P, 1995, EUR J CANCER, V31A, P1395, DOI 10.1016/0959-8049(95)00334-F; Cancemi P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-476; Chang HH, 2009, ORAL ONCOL, V45, P589, DOI 10.1016/j.oraloncology.2008.08.003; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; Diederichs S, 2004, CANCER RES, V64, P5564, DOI 10.1158/0008-5472.CAN-04-2004; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hacker Hans, 2006, Sci STKE, V2006, pre13, DOI 10.1126/stke.3572006re13; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Huttunen HJ, 2002, CANCER RES, V62, P4805; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Klemm S, 2007, P NATL ACAD SCI USA, V104, P134, DOI 10.1073/pnas.0608388103; Koltzscher M, 2003, MOL BIOL CELL, V14, P2372, DOI 10.1091/mbc.E02-09-0553; Lee SH, 1999, CANCER RES, V59, P5674; Logsdon CD, 2003, CANCER RES, V63, P2649; Martin D, 2009, J BIOL CHEM, V284, P6038, DOI 10.1074/jbc.C800207200; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; NEGRI E, 1993, CANCER EPIDEM BIOMAR, V2, P189; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parkkila S, 2008, BMC CLIN PATHOL, V8, DOI 10.1186/1472-6890-8-2; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Sato N, 2002, ANAT REC, V267, P60, DOI 10.1002/ar.10085; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shyu RY, 2003, J BIOMED SCI, V10, P313, DOI 10.1159/000070096; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Wang DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI 10.1073/pnas.0601894104; Whiteman HJ, 2007, CANCER RES, V67, P8633, DOI 10.1158/0008-5472.CAN-07-0545; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wutzl A, 2007, J ORAL MAXIL SURG, V65, P255, DOI 10.1016/j.joms.2006.09.007; Yao R, 2007, HISTOL HISTOPATHOL, V22, P1025, DOI 10.14670/HH-22.1025; Yeh PY, 2006, J BIOL CHEM, V281, P167, DOI 10.1074/jbc.M511014200	39	9	10	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1207	1219		10.1038/onc.2014.43	http://dx.doi.org/10.1038/onc.2014.43			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24681956				2022-12-17	WOS:000350687100001
J	Vallot, C; Herault, A; Boyle, S; Bickmore, WA; Radvanyi, F				Vallot, C.; Herault, A.; Boyle, S.; Bickmore, W. A.; Radvanyi, F.			PRC2-independent chromatin compaction and transcriptional repression in cancer	ONCOGENE			English	Article						cancer; chromatin compaction; gene cluster; histone deacetylase inhibitors; polycomb	TRANSITIONAL-CELL-CARCINOMA; GENE-EXPRESSION; NUCLEAR REORGANIZATION; HISTONE DEACETYLASE; EZH2; PROSTATE; COMPLEX; GENOME; DECONDENSATION; MUTATIONS	The silencing of large chromosomal regions by epigenetic mechanisms has been reported to occur frequently in cancer. Epigenetic marks, such as histone methylation and acetylation, are altered at these loci. However, the mechanisms of formation of such aberrant gene clusters remain largely unknown. Here, we show that, in cancer cells, the epigenetic remodeling of chromatin into hypoacetylated domains covered with histone H3K27 trimethylation is paralleled by changes in higher-order chromatin structures. Using fluorescence in situ hybridization, we demonstrate that regional epigenetic silencing corresponds to the establishment of compact chromatin domains. We show that gene repression is tightly correlated to the state of chromatin compaction and not to the levels of H3K27me3-its removal through the knockdown of EZH2 does not induce significant gene expression nor chromatin decompaction. Moreover, transcription can occur with intact high-H3K27me3 levels; treatment with histone deacetylase inhibitors can relieve chromatin compaction and gene repression, without altering H3K27me3 levels. Our findings imply that compaction and subsequent repression of large chromatin domains are not direct consequences of PRC2 deregulation in cancer cells. By challenging the role of EZH2 in aberrant gene silencing in cancer, these findings have therapeutical implications, notably for the choice of epigenetic drugs for tumors with multiple regional epigenetic alterations.	[Vallot, C.; Herault, A.; Radvanyi, F.] Inst Curie, CNRS, UMR 144, Dept Cell Biol, F-75231 Paris, France; [Vallot, C.; Herault, A.; Radvanyi, F.] Inst Curie, Ctr Rech, Paris, France; [Boyle, S.; Bickmore, W. A.] Univ Edinburgh, Inst Genet & Mol Med, MRC, Chromosome & Gene Express Sect,Human Genet Unit, Edinburgh EH8 9YL, Midlothian, Scotland; [Bickmore, W. A.] Univ Edinburgh, Breakthrough Breast Canc Res Unit, Edinburgh EH8 9YL, Midlothian, Scotland	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Edinburgh; University of Edinburgh	Vallot, C (corresponding author), Univ Paris Diderot, UMR7216, 35 Rue Helene Brion, F-75205 Paris, France.	celine.vallot@univ-paris-diderot.fr; francois.radvanyi@curie.fr	Bickmore, Wendy/C-7314-2013	Bickmore, Wendy/0000-0001-6660-7735; Radvanyi, Francois/0000-0002-5696-6424	Institut Curie; Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale; Institut National Contre le Cancer; Ligue Nationale Contre le Cancer; national program Cartes d'Identite des Tumeurs (CIT) - Ligue Nationale Contre le Cancer; UK Medical Research Council; Breakthrough Breast Cancer; MRC [MC_PC_U127527202] Funding Source: UKRI; Medical Research Council [MC_PC_U127527202] Funding Source: researchfish	Institut Curie; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut National Contre le Cancer; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); national program Cartes d'Identite des Tumeurs (CIT) - Ligue Nationale Contre le Cancer; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breakthrough Breast Cancer; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the Institut Curie; the Centre National de la Recherche Scientifique; the Institut National de la Sante et de la Recherche Medicale; the Institut National Contre le Cancer (program GepiG, program Tumult); the Ligue Nationale Contre le Cancer (CV, AH and FR, Equipe labellisee) and the national program Cartes d'Identite des Tumeurs (CIT), funded and developed by the Ligue Nationale Contre le Cancer. WAB and SB are supported by a unit program from the UK Medical Research Council and WAB is also supported by Breakthrough Breast Cancer. We thank Jennifer Southgate for providing us normal human urothelial (NHU) cells and Claire Rougeulle for critical reading of the manuscript.	Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Boumber Y, 2011, ONCOLOGY-NY, V25, P220; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Chambeyron S, 2005, DEVELOPMENT, V132, P2215, DOI 10.1242/dev.01813; Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Crawley JJ, 2002, GENOME BIOL, V3; DeBoer WI, 1997, INT J CANCER, V71, P284, DOI 10.1002/(SICI)1097-0215(19970410)71:2<284::AID-IJC25>3.0.CO;2-G; Eskeland R, 2011, COLD SPRING HARB SYM, V75, P71; Eskeland R, 2010, MOL CELL, V38, P452, DOI 10.1016/j.molcel.2010.02.032; Francis NJ, 2004, SCIENCE, V306, P1574, DOI 10.1126/science.1100576; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; Garrick D, 2008, BLOOD, V112, P3889, DOI 10.1182/blood-2008-06-161901; Gilbert N, 2004, CELL, V118, P555, DOI 10.1016/j.cell.2004.08.011; Illingworth RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034848; Karantzali E, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-4-r65; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lleres D, 2009, J CELL BIOL, V187, P481, DOI 10.1083/jcb.200907029; Margueron R, 2010, NAT REV GENET, V11, P285, DOI 10.1038/nrg2752; Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004; Morey C, 2007, DEVELOPMENT, V134, P909, DOI 10.1242/dev.02779; Morey L, 2013, CELL REP, V3, P60, DOI 10.1016/j.celrep.2012.11.026; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nagano T, 2008, SCIENCE, V322, P1717, DOI 10.1126/science.1163802; Nguyen CT, 2002, CANCER RES, V62, P6456; Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761; Nozawa RS, 2013, NAT STRUCT MOL BIOL; Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022; Pauler FM, 2009, GENOME RES, V19, P221, DOI 10.1101/gr.080861.108; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Soshnikova N, 2009, SCIENCE, V324, P1320, DOI 10.1126/science.1171468; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688; Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; Toth KF, 2004, J CELL SCI, V117, P4277, DOI 10.1242/jcs.01293; Vallot C, 2011, JNCI-J NATL CANCER I, V103, P47, DOI 10.1093/jnci/djq470; van Oers JMM, 2005, CLIN CANCER RES, V11, P7743, DOI 10.1158/1078-0432.CCR-05-1045; VANDENENGH G, 1992, SCIENCE, V257, P1410, DOI 10.1126/science.1388286; Wen B, 2009, NAT GENET, V41, P246, DOI 10.1038/ng.297; Wu XD, 2013, MOL CELL, V49, P1134, DOI 10.1016/j.molcel.2013.01.016; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004	59	9	9	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					741	751		10.1038/onc.2013.604	http://dx.doi.org/10.1038/onc.2013.604			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469045				2022-12-17	WOS:000348853800007
J	Pyne, NJ; Pyne, S				Pyne, N. J.; Pyne, S.			Sphingosine kinase 1 enables communication between melanoma cells and fibroblasts that provides a new link to metastasis	ONCOGENE			English	Editorial Material							1-PHOSPHATE; DIFFERENTIATION; GROWTH	In this issue of Oncogene, Albinet et al. have demonstrated a critical role of melanoma sphingosine kinase 1, which catalyses formation of sphingosine 1-phosphate (S1P), in promoting the differentiation of fibroblasts into myofibroblasts. The myofibroblast sphingosine kinase 1 then promotes the S1P-dependent dissemination (metastasis) of melanoma cells via a S1P receptor 3-mediated mechanism. These findings are of major significance because they provide a novel mechanism of interaction between melanoma and the microenvironment niche in promoting metastasis. These studies therefore identify S1P derived from myofibroblasts and melanoma cells as a novel target for therapeutic intervention.	[Pyne, N. J.; Pyne, S.] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Cell Biol Grp, Glasgow G4 0RE, Lanark, Scotland	University of Strathclyde	Pyne, NJ (corresponding author), Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Cell Biol Grp, Glasgow G4 0RE, Lanark, Scotland.	n.j.pyne@strath.ac.uk		Pyne, Nigel/0000-0002-5657-4578; Pyne, Susan/0000-0002-6608-9584				Albinet V, 2014, ONCOGENE, V33, P3364, DOI 10.1038/onc.2013.303; Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039; Gellings Lowe N, 2009, CARDIOVASC RES, V82, P303, DOI 10.1093/cvr/cvp056; Kono Y, 2007, AM J RESP CELL MOL, V37, P395, DOI 10.1165/rcmb.2007-0065OC; Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028; Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013; Long JS, 2010, MOL CELL BIOL, V30, P3827, DOI 10.1128/MCB.01133-09; Ponnusamy S, 2012, EMBO MOL MED, V4, P761, DOI 10.1002/emmm.201200244; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Pyne S, 2011, CANCER RES, V71, P6576, DOI 10.1158/0008-5472.CAN-11-2364; Schnute ME, 2012, BIOCHEM J, V444, P79, DOI 10.1042/BJ20111929; Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023	12	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3361	3363		10.1038/onc.2013.292	http://dx.doi.org/10.1038/onc.2013.292			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23873031	Green Accepted			2022-12-17	WOS:000338779300002
J	Yu, F; Gao, W; Yokochi, T; Suenaga, Y; Ando, K; Ohira, M; Nakamura, Y; Nakagawara, A				Yu, F.; Gao, W.; Yokochi, T.; Suenaga, Y.; Ando, K.; Ohira, M.; Nakamura, Y.; Nakagawara, A.			RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma	ONCOGENE			English	Article						RUNX3; MYCN; neuroblastoma; tumor suppressor	N-MYC; TUMOR-SUPPRESSOR; EXPRESSION; CANCER; GROWTH; GENE; IDENTIFICATION; PROGRESSION; INHIBITION; PROGNOSIS	RUNX3, a runt-related transcription factor, has a crucial role in dorsal root ganglion neurogenesis. Recent studies have suggested that RUNX3 acts as a tumor suppressor in stomach, colon and breast cancer. However, the biological role of RUNX3 in neuroblastoma remains elusive. Here we report that high levels of RUNX3 expression contribute to the favorable outcome in patients with neuroblastoma, whereas low levels of RUNX3 expression result in poor outcome. Array-based analysis suggested that the allelic loss at chromosome 1p36 is one of the reasons why expression of RUNX3 is downregulated in advanced neuroblastomas. Interestingly, the several patients survived from neuroblastoma with both high mRNA expressions of MYCN and RUNX3, suggesting that RUNX3 high expression might overcome the aggressive behavior of MYCN. Exogenous expression of RUNX3 strongly inhibits cell proliferation and migration in neuroblastoma cell lines. Furthermore, RUNX3 reduces the stability of MYCN protein in MYCN-amplified neuroblastoma cell lines, and this RUNX3-mediated MYCN degradation may depend on the physical interaction between RUNX3 and MYCN. Thus, our findings provide a tumor-suppressing mechanism by which RUNX3 inhibits the MYCN activity in neuroblastoma.	[Yu, F.; Gao, W.; Yokochi, T.; Suenaga, Y.; Ando, K.; Nakamura, Y.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem & Innovat Canc Therapeut, Chiba 2608717, Japan; [Yu, F.; Nakagawara, A.] Chiba Univ, Grad Sch Med, Dept Mol Biol & Oncol, Chiba, Japan; [Yu, F.] Hebei Med Univ, Forth Hosp, Dept Thorac Surg, Shijiazhuang, Hebei, Peoples R China; [Gao, W.] Hebei Med Univ, Forth Hosp, Dept Surg 1, Shijiazhuang, Hebei, Peoples R China; [Ohira, M.] Chiba Canc Ctr, Res Inst, Div Canc Genom, Chiba 2608717, Japan	Chiba Cancer Center; Chiba University; Hebei Medical University; Hebei Medical University; Chiba Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp		Suenaga, Yusuke/0000-0001-6902-5386	Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer; JSPS [24249061]; Takeda Science Foundation	Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Takeda Science Foundation(Takeda Science Foundation (TSF))	This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer, JSPS KAKENHI (Grant number 24249061) and a Grant from Takeda Science Foundation.	Akter J, 2011, CLIN CANCER RES, V17, P6681, DOI 10.1158/1078-0432.CCR-11-0313; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Chen L, 2008, CANCER RES, V70, P1377; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Cotterill SJ, 2000, EUR J CANCER, V36, P901, DOI 10.1016/S0959-8049(00)00058-7; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Inoue KI, 2007, J BIOL CHEM, V282, P24175, DOI 10.1074/jbc.M703746200; Inoue K, 2011, GENE, V487, P151, DOI 10.1016/j.gene.2011.05.016; Inoue KI, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-20; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee CWL, 2011, GYNECOL ONCOL, V122, P410, DOI 10.1016/j.ygyno.2011.04.044; Levanon D, 2004, ONCOGENE, V23, P4211, DOI 10.1038/sj.onc.1207670; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lin FC, 2012, ONCOGENE, V31, P4302, DOI 10.1038/onc.2011.596; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Nakagawara A, 1998, Hum Cell, V11, P115; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Park JR, 2010, HEMATOL ONCOL CLIN N, V24, P65, DOI 10.1016/j.hoc.2009.11.011; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; Suenaga Y, 2009, BIOCHEM BIOPH RES CO, V390, P21, DOI 10.1016/j.bbrc.2009.09.044; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; Tomioka N, 2008, ONCOGENE, V27, P441, DOI 10.1038/sj.onc.1210661; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Yamada C, 2010, J BIOL CHEM, V285, P16693, DOI 10.1074/jbc.M109.055525; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05	42	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2601	2609		10.1038/onc.2013.221	http://dx.doi.org/10.1038/onc.2013.221			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23851507				2022-12-17	WOS:000336502700006
J	Fang, M; Simeonova, I; Bardot, B; Lejour, V; Jaber, S; Bouarich-Bourimi, R; Morin, A; Toledo, F				Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.			Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival	ONCOGENE			English	Article						p53; Mdm4; p21; Plk1; Rb	PROLINE-RICH DOMAIN; THERAPEUTIC TARGET; PATHWAY; REPRESSION; MUTATION; LACKING; RB	The p53 pathway is inactivated in most human cancers, and its reactivation in tumors appears as a promising therapeutic strategy. Overexpression of Mdm4, a p53 negative regulator, occurs in a significant fraction of human cancers. Mouse models were used to evaluate the therapeutic potential of strategies against Mdm4, and encouraging results were obtained for tumor cells in which Mdm4 overexpression prevents wild-type p53 to exert its tumor suppressive functions. However, missense mutations in the p53 gene occur in about half of human cancers, and 15% of such mutations lead to the expression of a mutant protein that retains partial activity. In this report, we used mouse models to address the therapeutic potential of strategies against Mdm4 in tumors expressing an hypomorphic p53 mutant. We found that, in an Rb+/- background promoting pituitary and thyroid tumors, decreased Mdm4 levels improved the survival of mice expressing wild-type p53, but not that of mice expressing p53(Delta P), a p53 hypomorph lacking the proline-rich domain. Importantly, however, most Rb+/- p53(Delta P/Delta P) mice developped pituitary adenomas, but these tumors were rare in Rb+/- p53(Delta P/Delta P) mdm4(-/-) animals, because Mdm4 loss led to increased p21 levels, a suppressor of pituitary tumor growth. On the contrary, Rb+/- p53(Delta P/Delta P) and Rb+/- p53(Delta P/Delta P) Mdm4(-/-) mice developped anaplastic thyroid carcinomas at equal frequencies. Importantly, wild-type p53 represses the Plk1 gene, which encodes a promising therapeutic target in anaplastic thyroid carcinomas, and this repression is improved when Mdm4 levels are decreased. On the opposite, p53(Delta P) is a mediocre transcriptional repressor that is not improved by Mdm4 loss. In sum, depending on the tumor type, strategies against Mdm4 that work in cells expressing wild-type p53 may not work in cells expressing an hypomorphic p53. Furthermore, p53-mediated transcriptional repression should be considered when evaluating strategies to reactivate p53 in tumors.	[Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.] Inst Curie, Ctr Rech, F-75248 Paris 05, France; [Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.] Univ Paris 06, Paris, France; [Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.] CNRS, UMR 3244, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie; Universite Paris Cite	Toledo, F (corresponding author), Inst Curie, UMR 3244, Ctr Rech, 26 Rue Ulm, F-75248 Paris 05, France.	franck.toledo@curie.fr	Simeonova, Iva/Y-9412-2019	Jaber, Sara/0000-0002-3796-102X; Bardot, Boris/0000-0003-4976-9593; Toledo, Franck/0000-0003-3798-4106	Fondation de France; Association pour la Recherche sur le Cancer; Ligue Nationale contre le Cancer; Institut National du Cancer; Canceropole Ile de France; Ministere de l'Enseignement Superieur et de la Recherche	Fondation de France(Fondation de France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropole Ile de France(Region Ile-de-France); Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission)	We thank members of the Curie technological platforms for their contribution to this study: I Grandjean, C Daviaud and M Garcia from the Animal facility and M Richardson, M Huerre and A Nicolas from the Pathology service. We also thank L Plancke and L Charbonnier for their help with mouse dissections, and GM Wahl and M Debatisse for their support. Funding was provided from the Fondation de France (Comite Tumeurs), the Association pour la Recherche sur le Cancer, the Ligue Nationale contre le Cancer (Comite Ile de France) and the Institut National du Cancer. MF and IS received predoctoral fellowships from the Canceropole Ile de France, the Ministere de l'Enseignement Superieur et de la Recherche and the Ligue Nationale Contre le Cancer.	Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Chesnokova V, 2008, P NATL ACAD SCI USA, V105, P17498, DOI 10.1073/pnas.0804810105; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Leroy B, 2013, NUCLEIC ACIDS RES, V41, pD962, DOI 10.1093/nar/gks1033; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Marine JC, 2011, CURR TOP DEV BIOL, V94, P45, DOI 10.1016/B978-0-12-380916-2.00003-6; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nappi TC, 2009, CANCER RES, V69, P1916, DOI 10.1158/0008-5472.CAN-08-1693; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Prophet E, 1992, AFIP LAB METHODS HIS; Salvatore G, 2007, CANCER RES, V67, P10158; Simeonova I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002731; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vaseva AV, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.39; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	25	9	9	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1336	1339		10.1038/onc.2013.62	http://dx.doi.org/10.1038/onc.2013.62			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474762				2022-12-17	WOS:000332631100014
J	Walczynski, J; Lyons, S; Jones, N; Breitwieser, W				Walczynski, J.; Lyons, S.; Jones, N.; Breitwieser, W.			Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2	ONCOGENE			English	Article						ATF2; ATF7; JNK; c-MYC; B lymphoma; apoptosis	ACTIVATING TRANSCRIPTION FACTOR-2; JUN NH2-TERMINAL KINASE; JNK; SUPPRESSOR; INDUCTION; SURVIVAL; PROLIFERATION; PATHWAY; TARGET; ROLES	Transcription factors ATF2 (activating transcription factor 2) and ATF7 (activating transcription factor 7) are highly homologous members of the activator protein 1 (AP-1) family. Their activities are growth factor and stress stimulated and they strictly require phosphorylation by mitogen-activated protein (MAP) kinases for their transcriptional functions. In samples of human B-cell lymphomas as well as E mu-Myc-driven mouse B-cell lymphomas, we find that ATF2 as well as MAP kinase c-Jun N-terminal kinase (JNK) are significantly up-regulated compared with normal human B-cell lines and mouse B cells, respectively. The B cell-specific deletion of ATF2 and ATF7 in mice results in significantly accelerated onset of E mu-Myc-induced lymphoma. In addition, loss of ATF2/7 desensitises E mu-Myc lymphoma cells to spontaneous as well as stress-induced apoptosis. Our results therefore suggest that c-MYC induces stress-mediated activation of ATF2 and ATF7 and that these transcription factors regulate apoptosis in response to oncogenic transformation of B cells.	[Walczynski, J.; Lyons, S.; Jones, N.; Breitwieser, W.] Univ Manchester, Paterson Inst Canc Res, Dept Cell Regulat, Manchester, Lancs, England	Paterson Institute for Cancer Research; University of Manchester	Breitwieser, W (corresponding author), Paterson Inst Canc Res, Cell Regulat Lab, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	WBreitwieser@PICR.man.ac.uk			Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Professor Tim Illidge and members of the Targeted Therapy Group for useful discussions and suggestions, and Debby Burt for cell lines. We are grateful to the members of the Paterson Institute Biological Resource Unit, the Histology Department, the Molecular Biology Core Facility and the Flow Cytometry Department for their services and support. We also thank the members of the Cell Regulation Department for their discussions, encouragement and support. The project was entirely funded by a core grant provided by Cancer Research UK.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; Breitwieser W, 2007, GENE DEV, V21, P2069, DOI 10.1101/gad.430207; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; El Btaouri H, 2011, BBA-MOL CELL RES, V1813, P695, DOI 10.1016/j.bbamcr.2011.02.004; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gozdecka M, 2012, BIOCHEM SOC T, V40, P230, DOI 10.1042/BST20110630; Grassilli E, 2004, J BIOL CHEM, V279, P21318, DOI 10.1074/jbc.M313532200; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Klapproth K, 2010, BRIT J HAEMATOL, V149, P484, DOI 10.1111/j.1365-2141.2010.08159.x; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Sargent LM, 1996, CANCER RES, V56, P2137; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Ventura JJ, 2003, MOL CELL BIOL, V23, P2871, DOI 10.1128/MCB.23.8.2871-2882.2003; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang M, 2009, J PATHOL, V218, P95, DOI 10.1002/path.2521; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	9	11	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1027	1036		10.1038/onc.2013.28	http://dx.doi.org/10.1038/onc.2013.28			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23416976				2022-12-17	WOS:000331933200010
J	Bojovic, B; Ho, HY; Wu, J; Crowe, DL				Bojovic, B.; Ho, H-Y; Wu, J.; Crowe, D. L.			Stem cell expansion during carcinogenesis in stem cell-depleted conditional telomeric repeat factor 2 null mutant mice	ONCOGENE			English	Article						telomere; DNA damage; apoptosis; genomic instability	HAIR FOLLICLE BULGE; TRF2; CANCER; SKIN; EXPRESSION; PROTEIN; ATM; DEGRADATION; MAINTENANCE; EPIDERMIS	To examine the role of telomeric repeat-binding factor 2 (TRF2) in epithelial tumorigenesis, we characterized conditional loss of TRF2 expression in the basal layer of mouse epidermis. These mice exhibit some characteristics of dyskeratosis congenita, a human stem cell depletion syndrome caused by telomere dysfunction. The epidermis in conditional TRF2 null mice exhibited DNA damage response and apoptosis, which correlated with stem cell depletion. The stem cell population in conditional TRF2 null epidermis exhibited shorter telomeres than those in control mice. Squamous cell carcinomas induced in conditional TRF2 null mice developed with increased latency and slower growth due to reduced numbers of proliferating cells as the result of increased apoptosis. TRF2 null epidermal stem cells were found in both primary and metastatic tumors. Despite the low-grade phenotype of the conditional TRF2 null primary tumors, the number of metastatic lesions was similar to control cancers. Basal cells from TRF2 null tumors demonstrated extreme telomere shortening and dramatically increased numbers of telomeric signals by fluorescence in situ hybridization due to increased genomic instability and aneuploidy in these cancers. DNA damage response signals were detected at telomeres in TRF2 null tumor cells from these mice. The increased genomic instability in these tumors correlated with eightfold expansion of the transformed stem cell population compared with that in control cancers. We concluded that genomic instability resulting from loss of TRF2 expression provides biological advantages to the cancer stem cell population.	[Bojovic, B.; Ho, H-Y; Wu, J.; Crowe, D. L.] Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Crowe, DL (corresponding author), Univ Illinois, Ctr Canc, 801S Paulina St,Room 530C, Chicago, IL 60612 USA.	dlcrowe@uic.edu	Wu, Jianchun/AAX-3533-2020	Wu, Jianchun/0000-0002-8473-9368	National Institutes of Health [DE14283]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014283] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was supported by National Institutes of Health Grant No. DE14283.	Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Attwooll CL, 2009, MOL CELL BIOL, V29, P5540, DOI 10.1128/MCB.00479-09; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Blanco R, 2007, GENE DEV, V21, P206, DOI 10.1101/gad.406207; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Callicott RJ, 2006, COMPARATIVE MED, V56, P17; Capper R, 2007, GENE DEV, V21, P2495, DOI 10.1101/gad.439107; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Denchi EL, 2006, GENE DEV, V20, P2648, DOI 10.1101/gad.1453606; Deng YB, 2009, NATURE, V460, P914, DOI 10.1038/nature08196; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Dimitrova N, 2009, MOL CELL BIOL, V29, P5552, DOI 10.1128/MCB.00476-09; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Flores I, 2008, GENE DEV, V22, P654, DOI 10.1101/gad.451008; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Heath J, 2009, J INVEST DERMATOL, V129, P2358, DOI 10.1038/jid.2009.102; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Ku TKS, 2007, MOL CANCER RES, V5, P351, DOI 10.1158/1541-7786.MCR-06-0238; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Lantuejoul S, 2010, CLIN CANCER RES, V16, P2979, DOI 10.1158/1078-0432.CCR-10-0142; Liang Y, 2010, J BIOL CHEM, V285, P4931, DOI 10.1074/jbc.M109.048397; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; Matsutani N, 2001, INT J ONCOL, V19, P507; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Munoz P, 2006, CELL CYCLE, V5, P718, DOI 10.4161/cc.5.7.2636; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Savage SA, 2009, HEMATOL ONCOL CLIN N, V23, P215, DOI 10.1016/j.hoc.2009.01.003; Siegl-Cachedenier I, 2007, J CELL BIOL, V179, P277, DOI 10.1083/jcb.200704141; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Stout GJ, 2009, DIS MODEL MECH, V2, P139, DOI 10.1242/dmm.002121; Trempus CS, 2007, CANCER RES, V67, P4173, DOI 10.1158/0008-5472.CAN-06-3128; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011	50	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5156	5166		10.1038/onc.2012.555	http://dx.doi.org/10.1038/onc.2012.555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23178498	Green Accepted			2022-12-17	WOS:000326093200003
J	Amin, ARMR; Thakur, VS; Gupta, K; Agarwal, MK; Wald, DN; Shin, DM; Agarwal, ML				Amin, A. R. M. Ruhul; Thakur, V. S.; Gupta, K.; Agarwal, M. K.; Wald, D. N.; Shin, D. M.; Agarwal, M. L.			N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy	ONCOGENE			English	Article						DNA damage; apoptosis; signal transduction; aspartate transcarbamylase inhibitor; p53 family; replicative stress	PHASE-II TRIAL; KINASE C-ABL; DNA-DAMAGE; BH3-ONLY PROTEINS; P73 GENE; CHROMOSOME 1P36.3; UP-REGULATION; P53 HOMOLOG; MUTANT P53; CELL-DEATH	p53 is essential for the cellular responses to DNA damage that help to maintain genomic stability. However, the great majority of human cancers undergo disruption of the p53-network. Identification and characterization of molecular components important in both p53-dependent and -independent apoptosis might be useful in developing novel therapies for cancers. In the complete absence of p53, cells treated with N-(phosphonacetyl)-L-aspartate (PALA) continue to synthesize DNA slowly and eventually progress through S-phase, suffering severe DNA damage that in turn triggers apoptosis, whereas cells with functional p53 undergo growth arrest. In this study, we investigated apoptotic signaling in response to PALA and the role of p53 expression in this pathway. We found that treatment of cells lacking p53 with PALA induced TAp73, Noxa and Bim and inactivation of these proteins with dominant-negative plasmids or small interfering RNAs significantly inhibited apoptosis, suggesting that PALA-induced apoptosis was mediated via TAp73-dependent expression of Noxa and Binn. However, PALA treatment inhibited the expression of Delta Np73 only in cells lacking p53 but not in cells expressing p53. In addition, PALA treatment inhibited Bcl-2, and overexpression of Bcl-2 significantly inhibited PALA-induced apoptosis. Moreover, expression of p53 in these cells protected them from PALA-induced apoptosis by activating p21, sustaining the expression of Delta Np73 and inhibiting the induction of Noxa and Bim. Taken together, our study identifies novel but opposing roles for the p53 and TAp73 in the induction of Noxa and Bim and regulation of apoptosis. Our data will help to develop strategies to eliminate cancer cells lacking p53 while protecting normal cells with wild-type p53. Oncogene (2013) 32, 920-929; doi:10.1038/onc.2012.96; published online 19 March 2012	[Amin, A. R. M. Ruhul; Thakur, V. S.; Agarwal, M. L.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA; [Amin, A. R. M. Ruhul; Shin, D. M.] Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA; [Gupta, K.; Wald, D. N.] Case Western Reserve Univ, Dept Pathol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA; [Agarwal, M. K.] Invenio Therapeut, Cleveland, OH USA	Case Western Reserve University; Emory University; Case Western Reserve University	Amin, ARMR (corresponding author), Emory Univ, Dept Hematol & Med Oncol, Winship Canc Inst, Bldg C,Room 3074, Atlanta, GA 30322 USA.	aamin9@emory.edu; munnaagarwal@hotmail.com	Shin, Dong Moon/G-9649-2013; Ray, Dana M/C-3470-2013	Shin, Dong Moon/0000-0002-8245-4174; AMIN, ARM/0000-0001-9144-2960	National Institutes of Health [R01 CA98916, P50 CA128613]; Career Development Award; NATIONAL CANCER INSTITUTE [P50CA128613, R01CA098916] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Career Development Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are thankful to Dr George R Stark (Cleveland Clinic Foundation) for his continuous encouragement and criticism throughout the course of the work and critically reading and editing the manuscript, and to Dr Anthea Hammond (Emory University) for editorial assistance. We also thank Dr Rajib K Paul for screening SKp53 cells. This work was supported by National Institutes of Health Grants R01 CA98916 to MLA and P50 CA128613 to DMS and ARA. ARA is a recipient of Career Development Award.	Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1998, P NATL ACAD SCI USA, V95, P14775, DOI 10.1073/pnas.95.25.14775; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; Amin ARMR, 2007, P NATL ACAD SCI USA, V104, P5419, DOI 10.1073/pnas.0700642104; Amin ARMR, 2010, J BIOL CHEM, V285, P34557, DOI 10.1074/jbc.M110.141135; Amin ARMR, 2010, MOL CANCER THER, V9, P471, DOI 10.1158/1535-7163.MCT-09-0732; Amin ARMR, 2009, J CLIN ONCOL, V27, P2712, DOI 10.1200/JCO.2008.20.6235; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Chakraborty J, 2010, J BIOL CHEM, V285, P33104, DOI 10.1074/jbc.M110.122705; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Chung J, 2010, CURR DRUG TARGETS, V11, P667, DOI 10.2174/138945010791170833; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Faridoni-Laurens L, 2008, CELL CYCLE, V7, P1587, DOI 10.4161/cc.7.11.5894; Farnebo M, 2010, BIOCHEM BIOPH RES CO, V396, P85, DOI 10.1016/j.bbrc.2010.02.152; Ghiotto F, 2010, CYTOM PART A, V77A, P11, DOI 10.1002/cyto.a.20819; Gong JG, 1999, NATURE, V399, P806; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; Gottlieb E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001040; GREM JL, 1993, CANCER RES, V53, P4828; Hastak K, 2005, FASEB J, V19, P789, DOI 10.1096/fj.04-2226fje; Hastak K, 2008, P NATL ACAD SCI USA, V105, P6314, DOI 10.1073/pnas.0802080105; HEO DS, 1989, CANCER RES, V49, P5167; Ibrahim N, 2010, CANCER RES, V70, P7155, DOI 10.1158/0008-5472.CAN-10-0668; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Joerger AC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000919; John K, 2011, CELL DEATH DIFFER, V18, P874, DOI 10.1038/cdd.2010.153; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kirschnek S, 2011, CELL DEATH DIFFER, V18, P1805, DOI 10.1038/cdd.2011.69; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392; Leupin N, 2004, LEUKEMIA LYMPHOMA, V45, P1205, DOI 10.1080/10298190310001623829; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Lunghi P, 2009, CLIN CANCER RES, V15, P6495, DOI 10.1158/1078-0432.CCR-09-1229; Maisse C, 2004, CELL DEATH DIFFER, V11, P685, DOI 10.1038/sj.cdd.4401376; Malaguarnera R, 2007, ENDOCR-RELAT CANCER, V14, P43, DOI 10.1677/erc.1.01223; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Miyaguchi Y, 2009, CELL BIOL INT, V33, P853, DOI 10.1016/j.cellbi.2009.04.017; Moffitt KL, 2010, J PHARM PHARMACOL, V62, P547, DOI 10.1211/jpp.62.05.0001; Morales AA, 2008, BLOOD, V111, P5152, DOI 10.1182/blood-2007-10-116889; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Ozaki T, 2005, CANCER SCI, V96, P729, DOI 10.1111/j.1349-7006.2005.00116.x; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; REDEI I, 1994, INVEST NEW DRUG, V12, P319, DOI 10.1007/BF00873047; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Santidrian AF, 2010, BLOOD, V116, P3023, DOI 10.1182/blood-2010-05-283960; Sedletska Yuliya, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P251, DOI 10.2174/1568011053765967; Shats I, 2004, J BIOL CHEM, V279, P50976, DOI 10.1074/jbc.M402502200; Sunahara M, 1998, INT J ONCOL, V13, P319; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181; Tschan MP, 2000, BIOCHEM BIOPH RES CO, V277, P62, DOI 10.1006/bbrc.2000.3627; Vilgelm A, 2008, DRUG RESIST UPDATE, V11, P152, DOI 10.1016/j.drup.2008.08.001; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wadler S, 1996, EUR J CANCER, V32A, P1254, DOI 10.1016/0959-8049(96)00035-4; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yokomizo A, 1999, PROSTATE, V39, P94; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	79	9	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2013	32	7					920	929		10.1038/onc.2012.96	http://dx.doi.org/10.1038/onc.2012.96			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22430213	Green Accepted			2022-12-17	WOS:000316581100012
J	Stoddart, A; Tennant, TR; Fernald, AA; Anastasi, J; Brodsky, FM; Le Beau, MM				Stoddart, A.; Tennant, T. R.; Fernald, A. A.; Anastasi, J.; Brodsky, F. M.; Le Beau, M. M.			The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice	ONCOGENE			English	Article						AML; MPD; endocytosis; DOT1L; H3K79 methylation; oligomerization	ACUTE LYMPHOBLASTIC-LEUKEMIA; MLL FUSION PARTNER; TRANSGENIC MICE; CALM/AF10 FUSION; ASSEMBLY PROTEIN; CELL-LINE; T-ALL; GENE; CALM; AF10	The PICALM(CALM) gene, whose product is involved in clathrin-mediated endocytosis, has been identified in two recurring chromosomal translocations, involving either MLL or MLLT10 (AF10). We developed a mouse model of CALM-AF10(+) leukemia to examine the hypothesis that disruption of endocytosis contributes to leukemogenesis. Exclusion of the C-terminal portion of CALM from the fusion protein, which is required for optimal binding to clathrin, resulted in the development of a myeloproliferative disease, whereas inclusion of this domain led to the development of acute myeloid leukemia and changes in gene expression of several cancer-related genes, notably Pim1 and Crebbp. Nonetheless, the development of leukemia could not be attributed directly to interference with endocytosis or consequential changes in proliferation and signaling. In leukemia cells, full-length CALM-AF10 localized to the nucleus with no consistent effect on growth factor endocyctosis, and suppressed histone H3 lysine 79 methylation regardless of the presence of clathrin. Using fluorescence resonance energy transfer analysis, we show that CALM-AF10 has a propensity to homo-oligomerize, raising the possibility that the function of endocytic proteins involved in chimeric fusions may be to provide dimerization properties, a recognized mechanism for unleashing oncogenic properties of chimeric transcription factors, rather than disrupting the internalization of growth factor receptors. Oncogene (2012) 31, 494-506; doi: 10.1038/onc.2011.251; published online 27 June 2011	[Stoddart, A.; Tennant, T. R.; Fernald, A. A.; Le Beau, M. M.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA; [Anastasi, J.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Brodsky, F. M.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	University of Chicago; University of Chicago; University of California System; University of California San Francisco	Stoddart, A (corresponding author), Univ Chicago, Dept Med, Hematol Oncol Sect, 900 E,57th St,KCBD 7th Floor, Chicago, IL 60637 USA.	astoddar@bsd.uchicago.edu		Brodsky, Frances/0000-0002-1334-9258	Leukemia and Lymphoma Society [7015]; Special Fellow Award; Cancer Research Foundation; Lauri Strauss Leukemia Foundation; NIH [GM038093]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038093] Funding Source: NIH RePORTER	Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); Special Fellow Award; Cancer Research Foundation; Lauri Strauss Leukemia Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Vytas Bindokas and the University of Chicago Comprehensive Cancer Center Integrated Microscopy, and Flow Cytometry Facilities for their assistance. We also thank Scott Kogan for advice on classifying myeloid malignancies and Elizabeth Davis for technical assistance and members of the Le Beau laboratory for helpful discussions. This work was supported by a Special Fellow Award and SCOR (7015) from the Leukemia and Lymphoma Society, and grants from the Cancer Research Foundation, Lauri Strauss Leukemia Foundation and NIH (GM038093).	Archangelo LF, 2006, ONCOGENE, V25, P4099, DOI 10.1038/sj.onc.1209438; Asnafi V, 2003, BLOOD, V102, P1000, DOI 10.1182/blood-2002-09-2913; BERNARD OA, 1994, ONCOGENE, V9, P1039; Bhattacharya N, 2002, CHROMOSOMA, V111, P80, DOI 10.1007/s00412-002-0192-6; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Bradley SV, 2007, CANCER RES, V67, P8923, DOI 10.1158/0008-5472.CAN-07-2153; Broudy VC, 1999, BLOOD, V94, P1979; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; Caudell D, 2007, CANCER RES, V67, P8022, DOI 10.1158/0008-5472.CAN-06-3749; CHAKRABARTI R, 1993, J CELL BIOL, V123, P79, DOI 10.1083/jcb.123.1.79; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Chikatsu N, 2003, MODERN PATHOL, V16, P828, DOI 10.1097/01.MP.0000081729.40230.1F; Cho H, 2007, J CELL BIOL, V178, P245, DOI 10.1083/jcb.200604114; Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Dreyling MH, 1998, BLOOD, V91, P4662; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Forissier S, 2007, BIOL CELL, V99, P563, DOI 10.1042/BC20060131; Fu JF, 2003, GENE CHROMOSOME CANC, V37, P214, DOI 10.1002/gcc.10204; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; HOPKINS CR, 1985, CELL, V40, P199, DOI 10.1016/0092-8674(85)90323-X; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kung AL, 2000, GENE DEV, V14, P272; Lanzetti L, 2008, TRAFFIC, V9, P2011, DOI 10.1111/j.1600-0854.2008.00816.x; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; LEMMON SK, 1990, GENETICS, V124, P27; Lian Z, 2002, BLOOD, V100, P3209, DOI 10.1182/blood-2002-03-0850; Lin YH, 2009, BLOOD, V114, P651, DOI 10.1182/blood-2009-03-209395; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Meyerholz A, 2005, TRAFFIC, V6, P1225, DOI 10.1111/j.1600-0854.2005.00355.x; Muntau AC, 2003, EUR J CELL BIOL, V82, P333, DOI 10.1078/0171-9335-00325; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Royle SJ, 2005, NATURE, V434, P1152, DOI 10.1038/nature03502; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; So CW, 2003, CANCER CELL, V4, P99, DOI 10.1016/S1535-6108(03)00188-0; Tebar F, 1999, MOL BIOL CELL, V10, P2687, DOI 10.1091/mbc.10.8.2687; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511; Wechsler DS, 2003, GENE CHROMOSOME CANC, V36, P26, DOI 10.1002/gcc.10136	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					494	506		10.1038/onc.2011.251	http://dx.doi.org/10.1038/onc.2011.251			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706055	Green Accepted, Green Submitted			2022-12-17	WOS:000300219300008
J	Tanori, M; Pasquali, E; Leonardi, S; Giardullo, P; Di Majo, V; Taccioli, G; Essers, J; Kanaar, R; Mullenders, LH; Atkinson, MJ; Mancuso, M; Saran, A; Pazzaglia, S				Tanori, M.; Pasquali, E.; Leonardi, S.; Giardullo, P.; Di Majo, V.; Taccioli, G.; Essers, J.; Kanaar, R.; Mullenders, L. H.; Atkinson, M. J.; Mancuso, M.; Saran, A.; Pazzaglia, S.			Opposite modifying effects of HR and NHEJ deficiency on cancer risk in Ptc1 heterozygous mouse cerebellum	ONCOGENE			English	Article						radiation; Rad54; DNA-PKcs; LOH; medulloblastoma	DOUBLE-STRAND BREAKS; DNA-DAMAGE; SUPPRESS MEDULLOBLASTOMA; HOMOLOGOUS RECOMBINATION; GENETIC INSTABILITY; GENOME INSTABILITY; REPAIR; RAD54; DISRUPTION; DELETION	Heterozygous Patched1 (Ptc1(+/-)) mice are prone to medulloblastoma (MB), and exposure of newborn mice to ionizing radiation dramatically increases the frequency and shortens the latency of MB. In Ptc1(+/-) mice, MB is characterized by loss of the normal remaining Ptc1 allele, suggesting that genome rearrangements may be key events in MB development. Recent evidence indicates that brain tumors may be linked to defects in DNA-damage repair processes, as various combinations of targeted deletions in genes controlling cell-cycle checkpoints, apoptosis and DNA repair result in MB in mice. Non-homologous end joining (NHEJ) and homologous recombination (HR) contribute to genome stability, and deficiencies in either pathway predispose to genome rearrangements. To test the role of defective HR or NHEJ in tumorigenesis, control and irradiated Ptc1(+/-) mice with two, one or no functional Rad54 or DNA-protein kinase catalytic subunit (DNA-PKcs) alleles were monitored for MB development. We also examined the effect of Rad54 or DNA-PKcs deletion on the processing of endogenous and radiation-induced double-strand breaks (DSBs) in neural precursors of the developing cerebellum, the cells of origin of MB. We found that, although HR and NHEJ collaborate in protecting cells from DNA damage and apoptosis, they have opposite roles in MB tumorigenesis. In fact, although Rad54 deficiency increased both spontaneous and radiation-induced MB development, DNA-PKcs disruption suppressed MB tumorigenesis. Together, our data provide the first evidence that Rad54-mediated HR in vivo is important for suppressing tumorigenesis by maintaining genomic stability. Oncogene (2011) 30, 4740-4749; doi:10.1038/onc.2011.178; published online 23 May 2011	[Tanori, M.; Leonardi, S.; Di Majo, V.; Mancuso, M.; Saran, A.; Pazzaglia, S.] Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy; [Pasquali, E.; Giardullo, P.] Univ Guglielmo Marconi, Dept Radiat Phys, Rome, Italy; [Taccioli, G.] Boston Univ, Goldman Sch Dent Med, Dept Mol & Cellular Biol, Boston, MA 02215 USA; [Essers, J.; Kanaar, R.] Erasmus MC, Canc Genom Ctr, Dept Cell Biol & Genet, Rotterdam, Netherlands; [Essers, J.; Kanaar, R.] Erasmus MC, Dept Radiat Oncol, Rotterdam, Netherlands; [Mullenders, L. H.] Leiden Univ, Med Ctr, Dept Toxicogenet, Leiden, Netherlands; [Atkinson, M. J.] German Res Ctr Environm & Hlth, Helmholtz Zentrum Munchen, Inst Pathol, Neuherberg, Germany; [Essers, J.] Erasmus MC, Dept Vasc Surg, Rotterdam, Netherlands	Italian National Agency New Technical Energy & Sustainable Economics Development; Guglielmo Marconi University; Boston University; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Erasmus University Rotterdam; Erasmus MC	Saran, A (corresponding author), Agenzia Nazl Nuove Tecnol Energia & Sviluppo Econ, Lab Radiat Biol & Biomed, I-00123 Rome, Italy.	anna.saran@enea.it; simonetta.pazzaglia@enea.it	Pasquali, Emanuela/CAG-4451-2022; Atkinson, Michael/AAU-5127-2020; Atkinson, Michael J/E-5537-2011	Atkinson, Michael/0000-0003-3358-2089; Atkinson, Michael J/0000-0003-3358-2089; Saran, Anna/0000-0002-5587-064X	EU [FI6R-CT-2003-508842 RISC-RAD]; Associazione Italiana Ricerca sul Cancro (AIRC) [10357]; Netherlands Genomics Initiative/Netherlands Organization for Scientific Research	EU(European Commission); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Netherlands Genomics Initiative/Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	This work was supported by EU Contract FI6R-CT-2003-508842 RISC-RAD, by Grant 10357 from the Associazione Italiana Ricerca sul Cancro (AIRC) and the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research.	Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; Bakhshi S, 2003, J PEDIAT HEMATOL ONC, V25, P248, DOI 10.1097/00043426-200303000-00013; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Cahill D, 2006, FRONT BIOSCI-LANDMRK, V11, P1958, DOI 10.2741/1938; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Deans B, 2003, CANCER RES, V63, P8181; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frappart PO, 2007, EMBO J, V26, P2732, DOI 10.1038/sj.emboj.7601703; Frappart PO, 2009, P NATL ACAD SCI USA, V106, P1880, DOI 10.1073/pnas.0806882106; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Holcomb VB, 2006, ONCOGENE, V25, P7159, DOI 10.1038/sj.onc.1209704; Holcomb VB, 2008, CANCER RES, V68, P9497, DOI 10.1158/0008-5472.CAN-08-2085; Lee Y, 2002, CANCER RES, V62, P6395; Levanat S, 1996, NAT GENET, V12, P85, DOI 10.1038/ng0196-85; Li H, 2007, MOL CELL BIOL, V27, P8205, DOI 10.1128/MCB.00785-07; Li X, 2008, CELL RES, V18, P99, DOI 10.1038/cr.2008.1; Liu YH, 2010, CARCINOGENESIS, V31, P1762, DOI 10.1093/carcin/bgq141; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Marino S, 2005, TRENDS MOL MED, V11, P17, DOI 10.1016/j.molmed.2004.11.008; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; McKinnon PJ, 2009, NAT REV NEUROSCI, V10, P100, DOI 10.1038/nrn2559; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Moynahan ME, 1997, P NATL ACAD SCI USA, V19; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Pazzaglia S, 2006, ONCOGENE, V25, P5575, DOI 10.1038/sj.onc.1209544; Pazzaglia S, 2006, ONCOGENE, V25, P1165, DOI 10.1038/sj.onc.1209032; Pazzaglia S, 2000, MOL CARCINOGEN, V27, P219, DOI 10.1002/(SICI)1098-2744(200003)27:3<219::AID-MC9>3.0.CO;2-S; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Rooney S, 2004, P NATL ACAD SCI USA, V101, P2410, DOI 10.1073/pnas.0308757101; Schmuckli-Maurer J, 2003, NUCLEIC ACIDS RES, V31, P1013, DOI 10.1093/nar/gkg190; Smiraldo PG, 2005, CANCER RES, V65, P2089, DOI 10.1158/0008-5472.CAN-04-2079; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tanori M, 2008, CARCINOGENESIS, V29, P1911, DOI 10.1093/carcin/bgn174; Tischfield JA, 2003, NAT GENET, V33, P5, DOI 10.1038/ng0103-5; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Weinstock DM, 2006, MOL CELL BIOL, V26, P131, DOI 10.1128/MCB.26.1.131-139.2006; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yan CT, 2006, P NATL ACAD SCI USA, V103, P7378, DOI 10.1073/pnas.0601938103; Yoshihara T, 2004, EMBO J, V23, P670, DOI 10.1038/sj.emboj.7600087	49	9	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4740	4749		10.1038/onc.2011.178	http://dx.doi.org/10.1038/onc.2011.178			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602895				2022-12-17	WOS:000298033700006
J	Omori, E; Matsumoto, K; Ninomiya-Tsuji, J				Omori, E.; Matsumoto, K.; Ninomiya-Tsuji, J.			Non-canonical beta-catenin degradation mediates reactive oxygen species-induced epidermal cell death	ONCOGENE			English	Article						apoptosis; beta-catenin; caspase; epidermis; reactive oxygen species	TUMOR-NECROSIS-FACTOR; IL-1 SIGNALING PATHWAY; PROTEOLYTIC CLEAVAGE; FACTOR-ALPHA; KINASE TAK1; HELA-CELLS; TNF-ALPHA; KAPPA-B; ACTIVATION; APOPTOSIS	beta-Catenin is constantly degraded through the ubiquitin-proteasomal pathway. In this study, we report that a different type of beta-catenin degradation is causally involved in epidermal cell death. We observed that reactive oxygen species (ROS) caused beta-catenin degradation in the epidermal cells through a caspase-dependent mechanism, which results in disruption of cell adhesion. Disruption of cell adhesion increased ROS and activated caspases. Upregulation of the intact beta-catenin blocked ROS accumulation and caspase activation. These results indicate that a feed-forward loop consisting of ROS, caspases activation and beta-catenin degradation induces epidermal cell death. Oncogene (2011) 30, 3336-3344; doi:10.1038/onc.2011.49; published online 7 March 2011	[Omori, E.; Ninomiya-Tsuji, J.] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Matsumoto, K.] Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648601, Japan	University of North Carolina; North Carolina State University; Nagoya University	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Campus Box 7633, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu		Ninomiya-Tsuji, Jun/0000-0002-5584-0176	National Institutes of Health [GM068812, GM084406]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812, R01GM084406] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22020016] Funding Source: KAKEN	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank S Akira for tak1-floxed mice, ER Fearon for beta-catenin cDNAs, J Dow, BJ Welker and M Mattmuler for support. This work was supported by National Institutes of Health Grant GM068812 and GM084406 (to J N-T).	Abe K, 2007, NEURON, V53, P387, DOI 10.1016/j.neuron.2007.01.016; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200; Kitamura T, 1998, INT J HEMATOL, V67, P351; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Li G, 2002, P NATL ACAD SCI USA, V99, P13254, DOI 10.1073/pnas.202355799; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Omori E, 2008, J BIOL CHEM, V283, P26161, DOI 10.1074/jbc.M804513200; Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; Pasparakis M, 1996, J EXP MED, V184, P1397, DOI 10.1084/jem.184.4.1397; Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Tafani M, 2002, J BIOL CHEM, V277, P49569, DOI 10.1074/jbc.M208915200; Tafani M, 2001, CANCER RES, V61, P2459; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; Van de Craen M, 1999, FEBS LETT, V458, P167, DOI 10.1016/S0014-5793(99)01153-9; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771; Yang HP, 2005, BIOCHEM J, V391, P399, DOI 10.1042/BJ20050795	30	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2011	30	30					3336	3344		10.1038/onc.2011.49	http://dx.doi.org/10.1038/onc.2011.49			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	798NO	21383695	Green Accepted			2022-12-17	WOS:000293215700004
J	Kapoor, GS; O'Rourke, DM				Kapoor, G. S.; O'Rourke, D. M.			SIRP alpha 1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration	ONCOGENE			English	Article						SIRP alpha 1; EGFRvIII; SHP-2; glioblastoma; migration	GROWTH-FACTOR RECEPTOR; PROTEIN-TYROSINE-PHOSPHATASE; FOCAL ADHESION KINASE; ONCOGENIC TRANSFORMATION; LYSOPHOSPHATIDIC ACID; G(2)/M ARREST; IN-VIVO; SHP-2; ACTIVATION; PHOSPHORYLATION	EGFRvIII, a frequent genetic alteration of the epidermal growth factor receptor ( EGFR), has been shown to increase the migratory potential of tumor cells and normal fibroblasts. Previously, we showed that signal regulatory protein alpha 1 (SIRP alpha 1) receptors interact with SHP-2 to inhibit wild-type (wt) EGFR-mediated tumor migration, survival and cell transformation. However, the effects of SIRP alpha 1 inhibitory receptors on EGFRvIII-mediated phenotypes are unclear. The aim of this study was to investigate the effect of SIRP alpha 1 receptor on the EGFRvIII signalosome and phenotypes. Overexpression of SIRP alpha 1 in U87MG. EGFRvIII cells inhibited transformation and migration in a MAPK-dependent manner, and is independent of the phosphatidylinositol 3-kinase (PI3-K)/Akt pathway. We observed reduced EGFRvIII/SHP-2/Gab1/Grb2/Sos-1 interaction and enhanced SIRP/SHP-2 association in U87MG. EGFRvIII/SIRP alpha 1 cells when compared with empty vector control cells. Interestingly, SIRP alpha 1 overexpression differentially modulated SHP-2 phosphorylation at tyrosyl 542 and 580 residues, which may regulate Erk1/2 activity and the EGFRvIII phenotype. In addition, SIRP alpha 1-expressing cells exhibited reduced focal adhesion kinase (FAK) phosphorylation and its recruitment to the EGFRvIII/Grb2/Sos-1/Gab1/SHP-2 complex. Collectively, our data indicate that SIRP alpha 1 specifically affects the SHP-2/FAK/Grb2/Sos-1/MAPK activation loop to downmodulate EGFRvIII-mediated migration and transformation. Further understanding of the molecular interactions between the SIRP alpha 1 inhibitory receptor and the EGFRvIII signalosome may facilitate the identification of novel targets to inhibit the EGFRvIII glioblastoma phenotype. Oncogene (2010) 29, 4130-4144; doi: 10.1038/onc.2010.164; published online 17 May 2010	[Kapoor, G. S.; O'Rourke, D. M.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [O'Rourke, D. M.] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	O'Rourke, DM (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.	donald.orourke@uphs.upenn.edu	O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314	National Institutes of Health [R01 CA-90586, R01 2R56CA0905896-06A1]; Terri Ann for a Cure and For Pete's Sake Funds to the University of Pennsylvania; NATIONAL CANCER INSTITUTE [R01CA090586, T32CA009058] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Terri Ann for a Cure and For Pete's Sake Funds to the University of Pennsylvania; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants to DMO from the National Institutes of Health R01 CA-90586, R01 2R56CA0905896-06A1 and from the Terri Ann for a Cure and For Pete's Sake Funds to the University of Pennsylvania.	Aponte M, 2008, CANCER RES, V68, P5839, DOI 10.1158/0008-5472.CAN-07-5771; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Boockvar JA, 2003, MOL CELL NEUROSCI, V24, P1116, DOI 10.1016/j.mcn.2003.09.011; Boudot C, 2002, CELL SIGNAL, V14, P869, DOI 10.1016/S0898-6568(02)00036-0; Cetin S, 2007, AM J PHYSIOL-GASTR L, V292, pG1347, DOI 10.1152/ajpgi.00375.2006; Cui J, 2006, CANCER RES, V66, P10024, DOI 10.1158/0008-5472.CAN-06-0136; Dai HY, 2008, MOL CARCINOGEN, V47, P956, DOI 10.1002/mc.20448; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Dong LW, 2008, MOL IMMUNOL, V45, P3025, DOI 10.1016/j.molimm.2008.03.012; Eminaga S, 2008, J BIOL CHEM, V283, P15328, DOI 10.1074/jbc.M801382200; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; GARCIA DP, 1993, CANCER RES, V53, P3217; Guan JL, 1997, INT J BIOCHEM CELL B, V29, P1085, DOI 10.1016/S1357-2725(97)00051-4; Guo HB, 2007, J BIOL CHEM, V282, P22150, DOI 10.1074/jbc.M611518200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Kapoor GS, 2003, NEUROSURGERY, V52, P1425, DOI 10.1227/01.NEU.0000065135.28143.39; Kapoor GS, 2004, CANCER RES, V64, P6444, DOI 10.1158/0008-5472.CAN-04-0256; Kapoor GS, 2004, MOL CELL BIOL, V24, P823, DOI 10.1128/MCB.24.2.823-836.2004; Kapoor GS, 2007, CANCER BIOL THER, V6, P571, DOI 10.4161/cbt.6.4.3852; Keegan K, 1996, ONCOGENE, V12, P1537; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; Learn CA, 2004, CLIN CANCER RES, V10, P3216, DOI 10.1158/1078-0432.CCR-03-0521; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lorimer IAJ, 2001, BBA-MOL CELL RES, V1538, P1, DOI 10.1016/S0167-4889(00)00129-4; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Luo Y, 2009, BIOCHEMISTRY-US, V48, P1838, DOI 10.1021/bi8020789; Madan R, 2006, HUM PATHOL, V37, P9, DOI 10.1016/j.humpath.2005.09.024; Malchinkhuu E, 2005, ONCOGENE, V24, P6676, DOI 10.1038/sj.onc.1208805; Minoo P, 2003, CELL SIGNAL, V15, P319, DOI 10.1016/S0898-6568(02)00122-5; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Pedersen MW, 2004, INT J CANCER, V108, P643, DOI 10.1002/ijc.11566; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Qin Jian-Min, 2006, Hepatobiliary Pancreat Dis Int, V5, P246; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Sampaio C, 2008, MOL CELL BIOL, V28, P587, DOI 10.1128/MCB.01318-07; Sampson JH, 2008, SEMIN IMMUNOL, V20, P267, DOI 10.1016/j.smim.2008.04.001; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; Vogel W, 1996, CELL GROWTH DIFFER, V7, P1589; Wang FM, 2005, BREAST CANCER RES TR, V89, P5, DOI 10.1007/s10549-004-1002-z; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yan HX, 2004, HEPATOLOGY, V40, P618, DOI 10.1002/hep.20360; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; Yuan LP, 2005, J BIOL CHEM, V280, P42701, DOI 10.1074/jbc.M506768200; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zhan Y, 2004, CANCER RES, V64, P8292, DOI 10.1158/0008-5472.CAN-03-3143; Zhan Y, 2009, EXP CELL RES, V315, P2343, DOI 10.1016/j.yexcr.2009.05.001	64	9	10	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2010	29	29					4130	4144		10.1038/onc.2010.164	http://dx.doi.org/10.1038/onc.2010.164			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	628VL	20473329				2022-12-17	WOS:000280151500002
J	Osborne, LC; Duthie, KA; Seo, JH; Gascoyne, RD; Abraham, N				Osborne, L. C.; Duthie, K. A.; Seo, J. H.; Gascoyne, R. D.; Abraham, N.			Selective ablation of the YxxM motif of IL-7R alpha suppresses lymphomagenesis but maintains lymphocyte development	ONCOGENE			English	Article						lymphoma; haploinsufficiency; IL-7; c-myc; knock-in mouse models	ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL RECEPTOR; C-MYC; PHOSPHATIDYLINOSITOL 3-KINASE; INTERLEUKIN (IL)-7; IL-7; ACTIVATION; BCL-2; PROLIFERATION; EXPRESSION	Tumor progression is a multiple step process in which, in addition to oncogenic mutation, other supporting factors can contribute to transformation. The role these factors have in cancer is an open question. Using the E mu-myc model of B-cell transformation, we evaluated the contribution of the cytokine interleukin-7 (IL-7) in supporting lymphomagenesis. We have previously shown that disruption of the Y449xxM motif of the IL-7 receptor alpha (IL-7R alpha) in a knock-in mouse model (IL-7R alpha(449F)) has minor effects on lymphocyte production, but interferes with the activation of survival effectors. To address the hypothesis that targeted signal ablation would selectively affect lymphocyte transformation, IL-7R alpha(449F) mice were crossed with two lymphomagenesis models, transgenic (Tg) IL-7 and E mu-myc mice. We found that the loss of IL-7R alpha Y449 signaling prevented Tg IL-7-mediated T-and B-lymphocyte transformation and decreased the development of E mu-myc-induced B-cell tumors. We showed that the IL-7R alpha(449F) mutation prevented increased survival of Tg IL-7 CD8 T cells, and decreased viability of bone marrow progenitor B cells, as well as E mu-myc-induced proliferation. This study shows that IL-7R alpha Y449 is important for lymphocyte transformation, and that unlike deficiencies in pre-B cell receptor signaling, Myc overexpression cannot compensate for the loss of IL-7R alpha signals in early B-cell development. Oncogene (2010) 29, 3854-3864; doi: 10.1038/onc.2010.133; published online 3 May 2010	[Abraham, N.] Univ British Columbia, Dept Microbiol & Immunol, Dept Zool, Inst Life Sci, Vancouver, BC V5T 2L9, Canada; [Gascoyne, R. D.] Univ British Columbia, BC Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5T 2L9, Canada; [Abraham, N.] Univ British Columbia, Inst Life Sci, Dept Zool, Vancouver, BC V5T 2L9, Canada	University of British Columbia; British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Abraham, N (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, Dept Zool, Inst Life Sci, 3552-2350 Hlth Sci Mall, Vancouver, BC V5T 2L9, Canada.	ninan@interchange.ubc.ca	Osborne, Lisa/K-3027-2015; Gascoyne, Randy D/A-6009-2013; Abraham, Ninan/K-5572-2012	Osborne, Lisa/0000-0002-7170-3235; Gascoyne, Randy D/0000-0002-2610-5690; Abraham, Ninan/0000-0002-2747-1246	Canadian Institutes for Health Research (CIHR) [MOP-67005, MOP-84532]; Michael Smith Foundation for Health Research (MSFHR); Natural Sciences and Engineering Research Council (NSERC); CIHR/MSFHR	Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); Natural Sciences and Engineering Research Council (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); CIHR/MSFHR(Michael Smith Foundation for Health ResearchCanadian Institutes of Health Research (CIHR))	We thank Dr Robert Kay, Martin Richer and Caylib Durand for critical reading of the paper; Jill Miners, Eric Ma Asavee and Rachel Kim for animal colony maintenance and genotyping; Dr Sarah Gaffen for technical assistance; Nadia Gale and staff at the Centre for Translational and Applied Genomics; Dr Christine Eischen for providing C57BL/6 E mu-myc mice; Dr Bart Vanhaesebroeck for providing C57BL/6 p110 delta<SUP>D910A</SUP> mice; Dr Philippa Marrack for providing anti-Bim-producing Ham151 cells and the Wesbrook Animal Unit staff for animal husbandry. This work is supported by the Canadian Institutes for Health Research (CIHR) (MOP-67005 and MOP-84532 to N Abraham). LCO was supported by studentships from the Michael Smith Foundation for Health Research (MSFHR), the Natural Sciences and Engineering Research Council (NSERC) and the CIHR/MSFHR Strategic Training Program in Transplantation Research. KAD was supported by an NSERC Postgraduate scholarship. NA holds CIHR New Investigator and MSFHR Career Investigator awards.	Abraham N, 2005, ONCOGENE, V24, P5252, DOI 10.1038/sj.onc.1208726; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Cattaruzza L, 2009, INT J CANCER, V125, P1092, DOI 10.1002/ijc.24389; Duthie KA, 2007, MOL CELL PROTEOMICS, V6, P1700, DOI 10.1074/mcp.M600468-MCP200; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; El Kassar N, 2004, BLOOD, V104, P1419, DOI 10.1182/blood-2004-01-0201; Fleming HE, 2002, SEMIN IMMUNOL, V14, P423, DOI 10.1016/S1044532302000775; FOSS HD, 1995, AM J PATHOL, V146, P33; Habib T, 2007, J CELL BIOL, V179, P717, DOI 10.1083/jcb.200704173; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Juarez J, 2007, HAEMATOLOGICA, V92, P450, DOI 10.3324/haematol.10621; Keller U, 2005, ONCOGENE, V24, P6231, DOI 10.1038/sj.onc.1208779; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Kotani A, 2007, P NATL ACAD SCI USA, V104, P1616, DOI 10.1073/pnas.0610732104; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Lali FV, 2004, J IMMUNOL, V172, P3527, DOI 10.4049/jimmunol.172.6.3527; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LONG BW, 1995, P NATL ACAD SCI USA, V92, P1416, DOI 10.1073/pnas.92.5.1416; Marshall AJ, 1998, J IMMUNOL, V161, P6038; *NAT CANC I CAN CA, 2008, CAN CANC STAT; Nepal RM, 2008, ONCOGENE, V27, P4752, DOI 10.1038/onc.2008.111; Nilsson LM, 2007, ONCOGENE, V26, P2833, DOI 10.1038/sj.onc.1210104; Osborne LC, 2007, J EXP MED, V204, P619, DOI 10.1084/jem.20061871; Pallard C, 1999, IMMUNITY, V10, P525, DOI 10.1016/S1074-7613(00)80052-7; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; Sasson SC, 2010, CYTOKINE, V50, P58, DOI 10.1016/j.cyto.2009.12.001; Scott CL, 2004, J CELL BIOL, V164, P89, DOI 10.1083/jcb.200310041; Scupoli MT, 2007, HAEMATOLOGICA, V92, P264, DOI 10.3324/haematol.10356; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wei CJ, 2000, J IMMUNOL, V164, P1961, DOI 10.4049/jimmunol.164.4.1961; Wen RR, 2006, MOL CELL BIOL, V26, P9364, DOI 10.1128/MCB.00839-06; Wofford JA, 2008, BLOOD, V111, P2101, DOI 10.1182/blood-2007-06-096297; Yasuda T, 2008, IMMUNITY, V28, P499, DOI 10.1016/j.immuni.2008.02.015	40	9	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3854	3864		10.1038/onc.2010.133	http://dx.doi.org/10.1038/onc.2010.133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440272				2022-12-17	WOS:000279385200013
J	Ranjan, R; Thompson, EA; Yoon, K; Smart, RC				Ranjan, R.; Thompson, E. A.; Yoon, K.; Smart, R. C.			C/EBP alpha expression is partially regulated by C/EBP beta in response to DNA damage and C/EBP alpha-deficient fibroblasts display an impaired G(1) checkpoint	ONCOGENE			English	Article						C/EBP; DNA damage response; G(1)/S transition; p53	CCAAT/ENHANCER-BINDING-PROTEIN; TERMINAL ADIPOCYTE DIFFERENTIATION; CELL-CYCLE CHECKPOINTS; TRANSCRIPTION FACTORS; GENE PROMOTER; ONCOGENIC RAS; ANTIPROLIFERATIVE ROLE; DOWN-REGULATION; NUCLEAR FACTOR; PROLIFERATION	We observed that CCAAT/enhancer-binding protein (C/EBP)alpha is highly inducible in primary fibroblasts by DNA-damaging agents that induce strand breaks, alkylate and crosslink DNA as well as those that produce bulky DNA lesions. Fibroblasts deficient in C/EBP alpha (C/EBP alpha(-/-)) display an impaired G(1) checkpoint as evidenced by an inappropriate entry into the S-phase in response to DNA damage, and these cells also display an enhanced G(1)/S transition in response to mitogens. The induction of C/EBP alpha by DNA damage in fibroblasts does not require p53. Electrophoretic mobility shift assay (EMSA) analysis of nuclear extracts prepared from ultraviolet B (UVB)- and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-treated fibroblasts showed increased binding of C/EBP beta to a C/EBP consensus sequence and chromatin immunoprecipitation (ChIP) analysis also showed increased C/EBP beta binding to the C/EBP alpha promoter. To determine whether C/EBP beta has a function in the regulation of C/EBP alpha, we treated C/EBP beta(-/-) fibroblasts with UVB or MNNG. We observed that C/EBP alpha induction was impaired in both UVB- and MNNG-treated C/EBP beta(-/-) fibroblasts. Our study shows a novel function for C/EBP beta in the regulation of C/EBP alpha in response to DNA damage and provides definitive genetic evidence that C/EBP alpha has a critical role in the DNA damage G(1) checkpoint. Oncogene (2009) 28, 3235-3245; doi: 10.1038/onc.2009.176; published online 6 July 2009	[Ranjan, R.; Thompson, E. A.; Smart, R. C.] N Carolina State Univ, Cell Signaling & Canc Grp, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Yoon, K.] Natl Canc Ctr, Div Common Canc, Lung Canc Branch, Goyang Si, Gyeonggi Do, South Korea	University of North Carolina; North Carolina State University; National Cancer Center - Korea (NCC)	Smart, RC (corresponding author), N Carolina State Univ, Cell Signaling & Canc Grp, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA.	rcsmart@ncsu.edu		Smart, Robert/0000-0002-6767-6756	National Cancer Institute [CA46637]; National Institute of Environmental Health Sciences [ES12473]; NIEHS [ES007046]; NATIONAL CANCER INSTITUTE [R29CA046637, R01CA046637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012473, T32ES007046] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This research was supported by grants from the National Cancer Institute (CA46637), the National Institute of Environmental Health Sciences (ES12473), and a training grant from the NIEHS (ES007046). We thank Brian Sayers for his technical support with DNA-damaging agents.	AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Basseres DS, 2006, MOL CELL BIOL, V26, P1109, DOI 10.1128/MCB.26.3.1109-1123.2006; Bennett KL, 2007, CANCER RES, V67, P4657, DOI 10.1158/0008-5472.CAN-06-4793; Berberich-Siebelt F, 2006, J IMMUNOL, V176, P4843, DOI 10.4049/jimmunol.176.8.4843; Cesena TI, 2008, MOL CELL ENDOCRINOL, V289, P94, DOI 10.1016/j.mce.2008.03.009; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CHRISTY RJ, 1991, P NATL ACAD SCI USA, V88, P2593, DOI 10.1073/pnas.88.6.2593; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; DROUET C, 1991, J IMMUNOL, V147, P1694; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; Ewing SJ, 2008, CELL DEATH DIFFER, V15, P1734, DOI 10.1038/cdd.2008.105; Gery S, 2005, CLIN CANCER RES, V11, P3184, DOI 10.1158/1078-0432.CCR-04-2625; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Halmos B, 2002, CANCER RES, V62, P528; HENDRICKSTAYLOR LR, 1995, NUCLEIC ACIDS RES, V23, P4726, DOI 10.1093/nar/23.22.4726; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Hulla JE, 2001, CARCINOGENESIS, V22, P89, DOI 10.1093/carcin/22.1.89; Ishikawa K, 2006, DNA CELL BIOL, V25, P406, DOI 10.1089/dna.2006.25.406; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Loomis KD, 2007, CANCER RES, V67, P6768, DOI 10.1158/0008-5472.CAN-07-0139; Mo XM, 2004, MOL CELL, V13, P241, DOI 10.1016/S1097-2765(03)00521-5; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Osada S, 1996, J BIOL CHEM, V271, P3891; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Plachetka A, 2008, MOL CELL BIOL, V28, P2102, DOI 10.1128/MCB.01943-07; Pless O, 2008, J BIOL CHEM, V283, P26357, DOI 10.1074/jbc.M802132200; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shim M, 2005, CANCER RES, V65, P861; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tada T, 2006, JNCI-J NATL CANCER I, V98, P396, DOI 10.1093/jnci/djj093; Takai N, 2005, MOL CANCER RES, V3, P261, DOI 10.1158/1541-7786.MCR-04-0110; Tang QQ, 2004, BIOCHEM BIOPH RES CO, V319, P235, DOI 10.1016/j.bbrc.2004.04.176; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Watkins PJ, 1996, CANCER RES, V56, P1063; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xu L, 2001, CANCER RES, V61, P3176; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	65	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3235	3245		10.1038/onc.2009.176	http://dx.doi.org/10.1038/onc.2009.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19581927	Green Accepted			2022-12-17	WOS:000269673400006
J	Meyerkord, CL; Takahashi, Y; Araya, R; Takada, N; Weiss, RS; Wang, HG				Meyerkord, C. L.; Takahashi, Y.; Araya, R.; Takada, N.; Weiss, R. S.; Wang, H-G			Loss of Hus1 sensitizes cells to etoposide-induced apoptosis by regulating BH3-only proteins	ONCOGENE			English	Article						Hus1; Rad9; Bim; Puma; DNA damage; apoptosis	DNA-DAMAGE CHECKPOINT; HUMAN RAD9; GENOMIC INSTABILITY; IONIZING-RADIATION; CYCLE CHECKPOINT; BCL-2 FAMILY; MOUSE HUS1; COMPLEX; INTERACTS; RESPONSES	The Rad9-Rad1-Hus1 (9-1-1) cell cycle checkpoint complex plays a key role in the DNA damage response. Cells with a defective 9-1-1 complex have been shown to be sensitive to apoptosis induced by certain types of genotoxic stress. However, the mechanism linking the loss of a functional 9-1-1 complex to the cell death machinery has yet to be determined. Here, we report that etoposide treatment dramatically upregulates the BH3-only proteins, Bim and Puma, in Hus1-deficient cells. Inhibition of either Bim or Puma expression in Hus1-knockout cells confers significant resistance to etoposide-induced apoptosis, whereas knockdown of both proteins results in further resistance, suggesting that Bim and Puma cooperate in sensitizing Hus1-deficient cells to etoposide treatment. Moreover, we found that Rad9 collaborates with Bim and Puma to sensitize Hus1-deficient cells to etoposide-induced apoptosis. In response to DNA damage, Rad9 localizes to chromatin in Hus1-wild-type cells, whereas in Hus1-deficient cells, it is predominantly located in the cytoplasm where it binds to Bcl-2. Taken together, these results suggest that loss of Hus1 sensitizes cells to etoposide-induced apoptosis not only by inducing Bim and Puma expressions but also by releasing Rad9 into the cytosol to augment mitochondrial apoptosis.	[Meyerkord, C. L.; Takahashi, Y.; Araya, R.; Takada, N.; Wang, H-G] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; [Meyerkord, C. L.; Wang, H-G] Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Canc Biol PhD Program, Tampa, FL 33612 USA; [Weiss, R. S.] Cornell Univ, Dept Biomed Sci, Ithaca, NY USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Cornell University	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, SRB-2,12902 Magnolia Dr, Tampa, FL 33612 USA.	Hong-Gang.Wang@Moffitt.org	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Takahashi, Yoshinori/0000-0002-8004-4817	National Institutes of Health [CA90315, CA108773]; Department of Defense Breast Cancer [BC050563]; NATIONAL CANCER INSTITUTE [R01CA090315, R01CA108773] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Analytical Microscopy Core facility at the H Lee Moffitt Cancer Center and Research Institute for their technical assistance. This work was supported by grants from the National Institutes of Health (CA90315 to H-GW and CA108773 to RSW) and the Department of Defense Breast Cancer Research Program (BC050563 to CLM).	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Bao SL, 2004, ONCOGENE, V23, P5586, DOI 10.1038/sj.onc.1207753; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Brandt PD, 2006, BIOCHEM BIOPH RES CO, V347, P232, DOI 10.1016/j.bbrc.2006.06.064; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Dang TY, 2005, GENES CELLS, V10, P287, DOI 10.1111/j.1365-2443.2005.00840.x; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Galonek HL, 2006, NAT CELL BIOL, V8, P1317, DOI 10.1038/ncb1206-1317; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ishii H, 2005, P NATL ACAD SCI USA, V102, P9655, DOI 10.1073/pnas.0504222102; Kinzel B, 2002, CANCER, V94, P1808, DOI 10.1002/cncr.10383; Komatsu K, 2000, FEBS LETT, V481, P122, DOI 10.1016/S0014-5793(00)01975-X; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Lee MW, 2003, ONCOGENE, V22, P6340, DOI 10.1038/sj.onc.1206729; Lieberman HB, 2006, J CELL BIOCHEM, V97, P690, DOI 10.1002/jcb.20759; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Loegering D, 2004, J BIOL CHEM, V279, P18641, DOI 10.1074/jbc.M313536200; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Montecucco A, 2007, CANCER LETT, V252, P9, DOI 10.1016/j.canlet.2006.11.005; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Parrilla-Castellar ER, 2004, DNA REPAIR, V3, P1009, DOI 10.1016/j.dnarep.2004.03.032; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj/cdd/4400998; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Yang JY, 2006, INT J ONCOL, V29, P643; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	50	9	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	58					7248	7259		10.1038/onc.2008.336	http://dx.doi.org/10.1038/onc.2008.336			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382FI	18794804	Green Accepted			2022-12-17	WOS:000261590300003
J	Brellier, F; Bergoglio, V; Valin, A; Barnay, S; Chevallier-Lagente, O; Vielh, P; Spatz, A; Gorry, P; Avril, MF; Magnaldo, T				Brellier, F.; Bergoglio, V.; Valin, A.; Barnay, S.; Chevallier-Lagente, O.; Vielh, P.; Spatz, A.; Gorry, P.; Avril, M-F; Magnaldo, T.			Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures	ONCOGENE			English	Article						PATCHED; skin; keratinocyte; basal cell carcinoma; organotypic cultures; Gorlin syndrome	SONIC HEDGEHOG; CYCLE PROGRESSION; NEVUS SYNDROME; HUMAN HOMOLOG; MICE; GLI2; PTCH; KERATINOCYTES; ACTIVATION; SPECTRUM	Basal cell carcinoma of the skin is the most common type of cancer in humans. The majority of these tumors displays aberrant activation of the SONIC HEDGEHOG (SHH)/PATCHED pathway, triggered by mutations in the PATCHED tumor suppressor gene, which encodes a transmembrane receptor of SHH. In this study, we took advantage of the natural genotype (PATCHED(+/-)) of healthy keratinocytes expanded from patients with the nevoid basal cell carcinoma or Gorlin syndrome to mimic heterozygous somatic mutations thought to occur in the PATCHED gene early upon basal cell carcinoma development in the general population. PATCHED(+/-) epidermis developed on a dermal equivalent containing wild-type (WT) PATCHED(+/+). fibroblasts exhibited striking invasiveness and hyperproliferation, as well as marked differentiation impairment. Deciphering the phenotype of PATCHED(+/-) keratinocytes revealed slight increases of the transcriptional activators GLI1 and GLI2-the latter known to provoke basal cell carcinoma-like tumors when overexpressed in transgenic mice. PATCHED(+/-) keratinocytes also showed a substantial increase of the cell cycle regulator cyclin D1. These data show for the first time the physiological impact of constitutive heterozygous PATCHED mutations in primary human keratinocytes and strongly argue for a yet elusive mechanism of haploinsufficiency leading to cancer proneness.	[Bergoglio, V.; Valin, A.; Barnay, S.; Chevallier-Lagente, O.; Magnaldo, T.] Inst Gustave Roussy, FRE 2939, F-94805 Villejuif 05, France; [Brellier, F.] Friedrich Miescher Inst Biomed Res, Basel, Switzerland; [Vielh, P.; Spatz, A.] Inst Gustave Roussy, Dept Pathol, F-94805 Villejuif 05, France; [Gorry, P.] CHU Pellegrin Enfants, Serv Genet, Bordeaux, France; [Avril, M-F] Univ Paris 05, Serv Dermatol, Paris, France	UNICANCER; Gustave Roussy; Friedrich Miescher Institute for Biomedical Research; UNICANCER; Gustave Roussy; CHU Bordeaux; UDICE-French Research Universities; Universite Paris Cite	Magnaldo, T (corresponding author), Inst Gustave Roussy, FRE 2939, Rue Camille Desmoulins, F-94805 Villejuif 05, France.	marie-francoise.avril@cch.aphp.fr; magnaldo@igr.fr	SPATZ, ALAN/B-8645-2009; , GORRY/I-9725-2019; Bergoglio, Valérie VB/P-1624-2014	SPATZ, ALAN/0000-0003-3020-1420; , GORRY/0000-0002-5497-8069; Bergoglio, Valérie VB/0000-0003-2773-3178; Brellier, Florence/0000-0002-0143-472X; Barnay-Verdier, Stephanie/0000-0002-4615-3059	CNRS; ARC [9500]; Fondation de l'Avenir; SFD; AFM	CNRS(Centre National de la Recherche Scientifique (CNRS)); ARC(Australian Research Council); Fondation de l'Avenir; SFD; AFM(Association Francaise contre les Myopathies)	VB, AV, SB, have contributed equally to this work. FB and AV were recipients of PhD fellowships from the CNRS and Ligue Nationale contre le Cancer, and MESR, respectively. SB was an IGR post-doctoral fellow. We gratefully thank Dr Francoise Bernerd, Dr Howard Green, Ms Valerie Velasco, Virginie Marty, Dr Rune Toftgard, Dr Paule Opolon, and Marianne Brown-Luedi for their kind help. This work was supported by the CNRS, the ARC ( no. 9500), the Fondation de l'Avenir, the SFD and the AFM.	Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Bernerd F, 2001, P NATL ACAD SCI USA, V98, P7817, DOI 10.1073/pnas.141221998; Bigelow RLH, 2005, J INVEST DERMATOL, V124, P457, DOI 10.1111/j.0022-202X.2004.23590.x; Boutet N, 2003, J INVEST DERMATOL, V121, P478, DOI 10.1046/j.1523-1747.2003.12423.x; BRELLIER F, 2008, BR J DERMATOL   0528; Chidambaram A, 1996, ADV CANCER RES, V70, P49, DOI 10.1016/S0065-230X(08)60871-4; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Evans T, 2000, HUM MUTAT, V16, P43, DOI 10.1002/1098-1004(200007)16:1<43::AID-HUMU8>3.3.CO;2-Z; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pruvost-Balland C, 2006, ANN DERMATOL VENER, V133, P117, DOI 10.1016/S0151-9638(06)70861-4; Regl G, 2004, ONCOGENE, V23, P1263, DOI 10.1038/sj.onc.1207240; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Soufir N, 2006, BRIT J CANCER, V95, P548, DOI 10.1038/sj.bjc.6603303; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Teh MT, 2005, CANCER RES, V65, P8597, DOI 10.1158/0008-5472.CAN-05-0842; Unden AB, 1997, CANCER RES, V57, P2336	29	9	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2008	27	51					6601	6606		10.1038/onc.2008.260	http://dx.doi.org/10.1038/onc.2008.260			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RS	18679421				2022-12-17	WOS:000260501700008
J	Green, M; Panesar, NK; Loewenstein, PM				Green, M.; Panesar, N. K.; Loewenstein, P. M.			The transcription-repression domain of the adenovirus E1A oncoprotein targets p300 at the promoter	ONCOGENE			English	Article						adenovirus; Ad E1A; transcription repression; p300; promoter interaction	TATA-BINDING PROTEIN; MAJOR LATE PROMOTER; ACTIVATES TRANSCRIPTION; MAMMALIAN-CELLS; IN-VITRO; COACTIVATOR; DIFFERENTIATION; RECRUITMENT; CHROMATIN; CBP/P300	Extensive mutational/functional analysis of the transcription-repression domain encoded in the N-terminal 80 amino acids of the adenovirus E1A 243R oncoprotein suggests a model for the molecular mechanism of E1A repression: E1A accesses transcriptional co-activators such as p300 on specific promoters and then interacts with TBP to disrupt the TBP - TATA complex. In support of this model, as reported here, a basal core promoter activated by tethering p300 is repressible by E1A at the promoter level as shown by chromatin immunoprecipitation (ChIP) analysis. Sequestration of p300 by E1A does not play a significant role, as indicated by dose-response measurements. Furthermore, when the core promoter is transcriptionally activated by tethering activation domains of several transcription factors that can recruit p300 (p65, MyoD, cMyb and TFE3), transcription is repressible by E1A. However, when the core promoter is activated by factors not known to recruit p300 (USF1 and USF2), transcription is resistant to E1A repression. Finally, tethering p300 to the non-repressible adenovirus major late promoter (MLP) renders it repressible by E1A. ChIP analysis shows that E1A occupies the repressed MLP. These findings provide support for the hypothesis that p300 can serve as a scaffold for the E1A repression domain to access specific cellular gene promoters involved in growth regulation.	[Green, M.; Panesar, N. K.; Loewenstein, P. M.] St Louis Univ, Sch Med, Inst Mol Virol, EA Doisy Res Ctr, St Louis, MO 63104 USA	Saint Louis University	Green, M (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, EA Doisy Res Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	green@slu.edu			NCI NIH HHS [CA29561] Funding Source: Medline; NIAID NIH HHS [AI-04739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chan HM, 2001, J CELL SCI, V114, P2363; CHINNADURAI G, 2006, NUCLEUS; Chinnadurai G., 2006, CTBP FAMILY PROTEINS, P1; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Goodman RH, 2000, GENE DEV, V14, P1553; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Green M, 2008, VIROLOGY, V371, P1, DOI 10.1016/j.virol.2007.10.021; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Loewenstein PM, 2006, VIROLOGY, V351, P312, DOI 10.1016/j.virol.2006.03.041; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Parker SF, 1997, J VIROL, V71, P2004, DOI 10.1128/JVI.71.3.2004-2012.1997; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHENK T, 2001, FUNDAMENTAL VIROLOGY; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; SONG CZ, 1995, J BIOL CHEM, V40, P23263; Taatjes DJ, 2004, NAT REV MOL CELL BIO, V5, P403, DOI 10.1038/nrm1369; Takahashi Y, 2000, GENE DEV, V14, P804; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	38	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4446	4455		10.1038/onc.2008.85	http://dx.doi.org/10.1038/onc.2008.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18408753				2022-12-17	WOS:000257881700007
J	Schwab, R; Bussolari, R; Corvetta, D; Chayka, O; Santilli, G; Kwok, JMM; Amorotti, GF; Tonini, GP; Iacoviello, L; Bertorelle, R; Menin, C; Hubank, M; Calabretta, B; Sala, A				Schwab, R.; Bussolari, R.; Corvetta, D.; Chayka, O.; Santilli, G.; Kwok, J. M-M; Amorotti, G. F.; Tonini, G. P.; Iacoviello, L.; Bertorelle, R.; Menin, C.; Hubank, M.; Calabretta, B.; Sala, A.			Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk	ONCOGENE			English	Article						transcription; neuroblastoma; colon cancer; leukaemia; apoptosis	CHROMOSOMAL REGION; T-CELLS; APOPTOSIS; GENE; AMPLIFICATION	The B-MYB proto-oncogene is a transcription factor belonging to the MYB family that is frequently over-expressed or amplified in different types of human malignancies. While it is suspected that B-MYB plays a role in human cancer, there is still no direct evidence of its causative role. Looking for mutations of the B-MYB gene in human cell lines and primary cancer samples, we frequently isolated two nonsynonymous B-MYB polymorphic variants (rs2070235 and rs11556379). Compared to the wild-type protein, the B-MYB isoforms display altered conformation, impaired regulation of target genes and decreased antiapoptotic activity, suggesting that they are hypomorphic variants of the major allele. Importantly, the B-MYB polymorphisms are common; rs2070235 and rs11556379 are found, depending on the ethnic background, in 10-50% of human subjects. We postulated that, if B-MYB activity is important for transformation, the presence of common, hypomorphic variants might modify cancer risk. Indeed, the B-MYB polymorphisms are underrepresented in 419 cancer patients compared to 230 controls (odds ratio 0.53; (95%) confidence interval 0.385-0.755; P = 0.001). This data imply that a large fraction of the human population is carrier of B-MYB alleles that might be associated with a reduced risk of developing neoplastic disease.	[Schwab, R.; Corvetta, D.; Chayka, O.; Santilli, G.; Kwok, J. M-M; Hubank, M.; Sala, A.] UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; [Bussolari, R.; Amorotti, G. F.; Calabretta, B.] Univ Modena & Reggio Emilia, Dept Biomed Sci, Modena, Italy; [Corvetta, D.] Univ Parma, Dipartimento Med Sperimentale, Sezione Biochim, Biochem Clin & Biochim Esercizio Fis, I-43100 Parma, Italy; [Tonini, G. P.] Natl Inst Canc Res, IST, Genoa, Italy; [Iacoviello, L.] Catholic Univ, John Paul II Ctr High Technol Res & Educ Biomed S, Lab Genet & Environm Epidemiol, Campobasso, Italy; [Bertorelle, R.; Menin, C.] IRCCS, IOV, Padua, Italy	University of London; University College London; Universita di Modena e Reggio Emilia; University of Parma; University of Genoa; IRCCS AOU San Martino IST; Catholic University of the Sacred Heart; IRCCS Istituto Oncologico Veneto (IOV)	Sala, A (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, 30 Guilford St, London WC1N 1EH, England.	a.sala@ich.ucl.ac.uk	Iacoviello, Licia/AGX-7071-2022; Bertorelle, Roberta/AAC-2357-2022; Hubank, Michael JF/C-1837-2008; Siani, Alfonso/B-7925-2015; sala, arturo/C-4959-2008; Menin, Chiara/L-5770-2016; Iacoviello, Licia/K-4676-2016	Iacoviello, Licia/0000-0003-0514-5885; Bertorelle, Roberta/0000-0002-4235-3862; Hubank, Michael JF/0000-0002-2901-0742; Menin, Chiara/0000-0002-8907-772X; Iacoviello, Licia/0000-0003-0514-5885; Sala, Arturo/0000-0002-2841-7866				Ahlbory DR, 2005, ONCOGENE, V24, P7127, DOI 10.1038/sj.onc.1208869; Bar-Shira A, 2002, CANCER RES, V62, P6803; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Eckstein LA, 2005, INVEST OPHTH VIS SCI, V46, P782, DOI 10.1167/iovs.04-1022; Forozan F, 2000, CANCER RES, V60, P4519; Grassilli E, 1999, CANCER RES, V59, P2451; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; Imyanitov EN, 2004, CANCER LETT, V204, P3, DOI 10.1016/j.canlet.2003.09.026; Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308; Masselink H, 2001, CANCER LETT, V171, P87, DOI 10.1016/S0304-3835(01)00631-0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Raschella G, 1999, CANCER RES, V59, P3365; Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004; Shepard JL, 2005, P NATL ACAD SCI USA, V102, P13194, DOI 10.1073/pnas.0506583102; SUGIMURA H, 1990, CANCER RES, V50, P1857; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Tanner MM, 2000, CLIN CANCER RES, V6, P1833	19	9	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2929	2933		10.1038/sj.onc.1210947	http://dx.doi.org/10.1038/sj.onc.1210947			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026132				2022-12-17	WOS:000255502500014
J	Hasskarl, J; Mern, DS; Munger, K				Hasskarl, J.; Mern, D. S.; Muenger, K.			Interference of the dominant negative helix-loop-helix protein ID1 with the proteasomal subunit S5A causes centrosomal abnormalities	ONCOGENE			English	Article						ID1; centrosome; S5A; proteasome; cancer	CELL-CYCLE; RETINOBLASTOMA PROTEIN; MITOTIC DEFECTS; DNA-BINDING; DEGRADATION; ID-1; DUPLICATION; CANCER; DIFFERENTIATION; SENESCENCE	The inhibitor of DNA-binding (ID) proteins are dominant-negative inhibitors of basic helix-loop-helix transcription factors that have multiple functions d uring development and cellular differentiation. High-level expression of some ID family members has been observed in human malignancies, and in some cases was correlated with poor clinical prognosis. Ectopic ID1 expression extends the life span of primary human epithelial cells, inhibits cellular differentiation and induces centrosome duplication errors, thus suggesting that ID1 may have oncogenic activities. ID1 can bind to the proteasomal subunit S5A/Rpn10, but the biological consequences of the interaction have not been studied in detail. Here, we show that ID1' s ability to induce supernumerary centrosomes correlates with S5A binding. Similar to ID1, a fraction of the S5A protein localizes to centrosomal structures. Furthermore, partial depletion of S5A by RNA interference causes accumulation of cells with supernumerary centrosomes. These results are consistent with the model that ID1 dysregulates centrosome homeostasis at least in part by interfering with S5A activities at the centrosome.	[Hasskarl, J.; Mern, D. S.] Univ Freiburg, Med Ctr, Div Hematol & Oncol, D-79106 Freiburg, Freiburg Im Bre, Germany; [Muenger, K.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA	University of Freiburg; Harvard University; Brigham & Women's Hospital	Hasskarl, J (corresponding author), Univ Freiburg, Med Ctr, Div Hematol & Oncol, Hugstetter Str 55,Med 1, D-79106 Freiburg, Freiburg Im Bre, Germany.	jens.hasskarl@uniklinik-freiburg.de	Hasskarl, Jens/E-8980-2011	Shenegelegn Mern, Demissew/0000-0001-5893-981X; Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01 CA066980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Berse M, 2004, J MOL BIOL, V343, P361, DOI 10.1016/j.jmb.2004.08.043; Bloom J, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-5; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2001, CANCER RES, V61, P2356; Duensing Stefan, 2003, Mol Cancer, V2, P30, DOI 10.1186/1476-4598-2-30; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fajerman I, 2004, BIOCHEM BIOPH RES CO, V314, P505, DOI 10.1016/j.bbrc.2003.12.116; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Fraidenraich D, 2004, SCIENCE, V306, P247, DOI 10.1126/science.1102612; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HASSKARL J, 2004, ONCOGENE, V63, P476; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Stavropoulou V, 2005, CANCER RES, V65, P1361, DOI 10.1158/0008-5472.CAN-04-2085; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Szlanka T, 2003, J CELL SCI, V116, P1023, DOI 10.1242/jcs.00332; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Trausch-Azar JS, 2004, J BIOL CHEM, V279, P32614, DOI 10.1074/jbc.M403794200; Wigley WC, 1999, J CELL BIOL, V145, P481; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X	44	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1657	1664		10.1038/sj.onc.1210808	http://dx.doi.org/10.1038/sj.onc.1210808			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891176				2022-12-17	WOS:000253962100001
J	Denicourt, C; Legault, P; McNabb, FA; Rassart, E				Denicourt, C.; Legault, P.; McNabb, F-AC; Rassart, E.			Human and mouse cyclin D2 splice variants: transforming activity and subcellular localization	ONCOGENE			English	Article						truncated cyclin D2; transformation; splice variant	CELL-PROLIFERATION; KINASE ACTIVATION; DEPENDENT KINASE; PHASE ARREST; D1; EXPRESSION; PHOSPHORYLATION; GENE; OVEREXPRESSION; IDENTIFICATION	We have previously reported the identification of a novel 17 kDa truncated isoform of the cyclin D2 activated in 13% of the leukemias induced by the Graf. murine leukemia retrovirus. Retroviral integration in the Gris1 locus causes an alternative splicing of the mouse cyclin D2 gene and expression of a truncated protein of 159 amino acids that is detected at high levels in the Gris1 tumors and also in normal mouse tissues mainly the brain and ovaries. A truncated form of the cyclin D2 was also found in human. We show here that both mouse- and human-truncated cyclin D2 are able to transform primary mouse embryo fibroblasts (MEF) when co-expressed with an activated Ras protein. The truncated cyclin D2 localizes only to the cytoplasm of transfected cells. It has retained the ability to interact with cyclin-dependent kinases (CDKs), although it is a poor catalyst of pRb phosphorylation. Interestingly, the presence of a similar, alternatively spliced cyclin D2 mRNA was also detected in some human brain tumors.	[Denicourt, C.; Legault, P.; McNabb, F-AC; Rassart, E.] Univ Quebec, Dept Sci Biol, Mol Biol Lab, Montreal, PQ H3C 3P8, Canada	University of Quebec; University of Quebec Montreal	Rassart, E (corresponding author), Univ Quebec, Dept Sci Biol, Mol Biol Lab, Case Postale 8888, Montreal, PQ H3C 3P8, Canada.	Rassart.Eric@UQAM.ca		Denicourt, Catherine/0000-0001-8721-0163				Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Assoian Richard K., 1997, Cytokine and Growth Factor Reviews, V8, P165, DOI 10.1016/S1359-6101(97)00011-7; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1999, J PATHOL, V187, P573, DOI 10.1002/(SICI)1096-9896(199904)187:5<573::AID-PATH289>3.0.CO;2-H; Buschges R, 1999, BRAIN PATHOL, V9, P435; Denicourt C, 2003, J VIROL, V77, P37, DOI 10.1128/JVI.77.1.37-44.2003; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANNA Z, 1993, ONCOGENE, V8, P1661; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KERKHOFF E, 1995, EMBO J, V14, P1892, DOI 10.1002/j.1460-2075.1995.tb07181.x; Kim KK, 1996, NAT STRUCT BIOL, V3, P849, DOI 10.1038/nsb1096-849; Lu FM, 2003, CANCER RES, V63, P7056; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; Ortenblad A, 2002, INT J MANAG REV, V4, P87, DOI 10.1111/1468-2370.00078; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Resnitzky D, 1997, MOL CELL BIOL, V17, P5640, DOI 10.1128/MCB.17.9.5640; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Schwartz MA, 2001, J CELL SCI, V114, P2553; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Susaki E, 2007, MOL CELL BIOL, V27, P4626, DOI 10.1128/MCB.00862-06; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Taieb F, 1996, BIOL CELL, V88, P99, DOI 10.1016/S0248-4900(97)83525-3; Teramoto N, 1999, INT J CANCER, V81, P543, DOI 10.1002/(SICI)1097-0215(19990517)81:4<543::AID-IJC7>3.3.CO;2-V; TREMBLAY PJ, 1992, J VIROL, V66, P1344, DOI 10.1128/JVI.66.3.1344-1353.1992; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	38	9	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1253	1262		10.1038/sj.onc.1210750	http://dx.doi.org/10.1038/sj.onc.1210750			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17873913				2022-12-17	WOS:000253407000007
J	Bruton, RK; Rasti, M; Mapp, KL; Young, N; Carter, RZ; Abramowicz, IA; Sedgwick, GG; Onion, DF; Shuen, M; Mymryk, JS; Turnell, AS; Grand, RJA				Bruton, R. K.; Rasti, M.; Mapp, K. L.; Young, N.; Carter, R. Z.; Abramowicz, I. A.; Sedgwick, G. G.; Onion, D. F.; Shuen, M.; Mymryk, J. S.; Turnell, A. S.; Grand, R. J. A.			C-terminal-binding protein interacting protein binds directly to adenovirus early region 1A through its N-terminal region and conserved region 3	ONCOGENE			English	Article						adenovirus E1A; C-terminal-binding protein; interacting protein; CtIP; C-terminal-binding protein; CtBP	E1A PROTEIN; DNA-DAMAGE; ONCOGENIC TRANSFORMATION; STRUCTURAL DETERMINANTS; TRANSCRIPTIONAL ADAPTER; CELLULAR PHOSPHOPROTEIN; SIMIAN ADENOVIRUSES; NEGATIVE MODULATION; MOLECULAR-CLONING; SEQUENCE-ANALYSIS	C-terminal-binding protein interacting protein (CtIP) was first isolated as a binding partner of C-terminal-binding protein (CtBP). It is considered to contribute to the transcriptional repression and cell cycle regulatory properties of the retinoblastoma (Rb) family of proteins and to have a role in the cellular response to DNA damage. Here, we have shown that CtIP is a novel target for the adenovirus oncoprotein early region 1A (AdE1A). AdE1A associates with CtIP in both Ad5E1-transformed cells and Ad5-infected cells and binds directly in glutathione-S-transferase pull-down assays. Two binding sites have been mapped on Ad5E1A - the N-terminal alpha-helical region ( residues 1 - 30) and conserved region 3(CR3) - the transcriptional activation domain. CtIP can bind AdE1A and CtBP independently, raising the possibility that ternary complexes exist in Ad-transformed and - infected cells. Significantly, reduction of CtIP expression with small interfering RNAs results in reduction of the ability of a Gal4 DNA-binding domain-CR3 construct to transactivate a Gal 4-responsive luciferase reporter and this effect is reversed by reduction of CtBP expression. Therefore, in this model, CtIP acts as a transcriptional co-activator of AdE1A when dissociated from CtBP, through the action of AdE1A. These data are consistent with observations that CtIP expression is induced by AdE1A during viral infection and that reduction of CtIP expression with RNA interference can retard virus replication. In addition, AdE1A causes disruption of the CtIP/Rb complex during viral infection by its interaction with CtIP, possibly contributing to transcriptional derepression.	Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Univ Western Ontario, Dept Oncol & Microbiol & Immunol, London, ON N6A 3K7, Canada	Cancer Research UK; University of Birmingham; Western University (University of Western Ontario)	Grand, RJA (corresponding author), Univ Birmingham, Sch Med, Canc Res UK, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England.	R.J.A.Grand@bham.ac.uk		Onion, David/0000-0002-4522-2307	Breast Cancer Now [2001:218] Funding Source: Medline	Breast Cancer Now		ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2002, J VIROL, V76, P7968, DOI 10.1128/JVI.76.16.7968-7975.2002; Barral PM, 2005, FEBS LETT, V579, P2752, DOI 10.1016/j.febslet.2005.03.095; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Boyer TG, 1999, NATURE, V399, P276, DOI 10.1038/20466; Chen PL, 2005, MOL CELL BIOL, V25, P3535, DOI 10.1128/MCB.25.9.3535-3542.2005; Chinnadurai G, 2006, BBA-REV CANCER, V1765, P67, DOI 10.1016/j.bbcan.2005.09.002; Chinnadurai G, 2004, CURR TOP MICROBIOL, V273, P139; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; CHINNADURAI G, 2007, IN PRESS INT J BIOCH; Chinnadurai G., 2006, CTBP FAMILY PROTEINS, P1; CULP JS, 1988, P NATL ACAD SCI USA, V85, P6450, DOI 10.1073/pnas.85.17.6450; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GEISBERG JV, 1994, P NATL ACAD SCI USA, V91, P2488, DOI 10.1073/pnas.91.7.2488; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; GRAND RJA, 1984, J GEN VIROL, V65, P2149, DOI 10.1099/0022-1317-65-12-2149; GRAND RJA, 2006, LANDES BIOSCIENCE, P44; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELMSA TN, 1989, VIROLOGY, V171, P120; JONES N, 1995, CURR TOP MICROBIOL I, V199, P58; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Molloy DP, 2001, BBA-PROTEIN STRUCT M, V1546, P55, DOI 10.1016/S0167-4838(00)00071-6; Murakami P, 1999, ANAL BIOCHEM, V274, P283, DOI 10.1006/abio.1999.4282; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Wang G, 2002, J VIROL, V76, P9186, DOI 10.1128/JVI.76.18.9186-9193.2002; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WEBSTER LC, 1991, MOL CELL BIOL, V11, P4287, DOI 10.1128/MCB.11.9.4287; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006	50	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	2007	26	53					7467	7479		10.1038/sj.onc.1210551	http://dx.doi.org/10.1038/sj.onc.1210551			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546052				2022-12-17	WOS:000251282000008
J	Swaminathan, G; Feshchenko, EA; Tsygankov, AY				Swaminathan, G.; Feshchenko, E. A.; Tsygankov, A. Y.			c-Cbl-facilitated cytoskeletal effects in v-Abl-transformed. broblasts are regulated by membrane association of c-Cbl	ONCOGENE			English	Article						c-Cbl; SLAP; adaptor protein; membrane localization; cell spreading; cell migration	INTEGRIN SIGNALING PATHWAY; GROWTH-FACTOR RECEPTOR; ADAPTER PROTEIN SLAP; NIH 3T3 FIBROBLASTS; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; CELL MORPHOLOGY; LIPID RAFTS; SRC	The multi-functional protein c-Cbl is an important modulator of actin cytoskeletal dynamics in diverse biological systems. We had previously reported that c-Cbl facilitates cell spreading and adhesion and suppresses anchorage-independent growth of v-Abl-transformed fibroblasts. To assess the importance of membrane localization of c-Cbl for the observed effects of c-Cbl in v-Abl-3T3 cells, we. rst mapped the membrane interactive domain(s) of c-Cbl. Our studies indicate that localization of c-Cbl to the membrane is likely to be mediated by the tyrosine kinase binding (TKB) domain and the proline-rich region of c-Cbl, whereas C-terminal tyrosine phosphorylation does not play a role. The association of v-Cbl, which encompasses the TKB domain, with the membrane was unusual as it was not entirely dependent on SH2-phosphotyrosine interactions. Our studies further demonstrate that Src-like adaptor protein (SLAP), which binds to v-Cbl in a tyrosine phosphorylation-independent manner, facilitates membrane association of Cbl. The interaction between c-Cbl and SLAP in v-Abl-3T3 cells positively influenced c-Cbl-mediated spreading and adhesion of these cells. SLAP appears to exert its effects not simply by increasing the amount of c-Cbl in the membrane but by facilitating binding of p85-phosphatidylinositol-3-kinase (PI3K) with membrane-associated c-Cbl.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Tsygankov, Alexander Y/K-6205-2017		NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER; NCI NIH HHS [CA78499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abassi YA, 2002, EMBO J, V21, P4571, DOI 10.1093/emboj/cdf446; Arthur WT, 2004, J CELL BIOL, V167, P111, DOI 10.1083/jcb.200404068; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Haglund K, 2004, J CELL SCI, V117, P2557, DOI 10.1242/jcs.01148; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hasham MG, 2004, VIROLOGY, V320, P313, DOI 10.1016/j.virol.2003.11.032; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Klapper LN, 2000, CANCER RES, V60, P3384; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; MARAKOVA O, 2000, BIOTECHNIQUES, V29, P970; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Scaife RM, 2000, J CELL SCI, V113, P215; Scaife RM, 2003, MOL BIOL CELL, V14, P4605, DOI 10.1091/mbc.E02-11-0739; Scaife RM, 2003, J CELL SCI, V116, P463, DOI 10.1242/jcs.00244; Schmidt MHH, 2005, NAT REV MOL CELL BIO, V6, P907, DOI 10.1038/nrm1762; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Swaminathan G, 2006, J CELL PHYSIOL, V209, P21, DOI 10.1002/jcp.20694; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; Teckchandani AM, 2005, EXP CELL RES, V307, P247, DOI 10.1016/j.yexcr.2005.03.010; Teckchandani AM, 2005, EXP CELL RES, V306, P114, DOI 10.1016/j.yexcr.2005.02.014; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	38	9	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4095	4105		10.1038/sj.onc.1210184	http://dx.doi.org/10.1038/sj.onc.1210184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17237826				2022-12-17	WOS:000247252700005
J	Kweon, MH; Afaq, F; Bhat, KMR; Setaluri, V; Mukhtar, H				Kweon, M-H; Afaq, F.; Bhat, K. M. R.; Setaluri, V.; Mukhtar, H.			A novel antioxidant 3-O-Caffeoyl-1-methylquinic acid enhances ultraviolet A-mediated apoptosis in immortalized HaCaT keratinocytes via Sp1-dependent transcriptional activation of p21(WAF1/Cip1)	ONCOGENE			English	Article						MCGA3; UVA; p21; Sp1; iron chelation	SIGNAL-REGULATED KINASE; CELL-CYCLE ARREST; IRON CHELATION; GROWTH ARREST; HYPOXIA; UVA; EXPRESSION; INDUCTION; P53; PROLIFERATION	It has become clearthat ultraviolet A (UVA) radiation from the solar spectrum is a major environmental challenge to the skin. This necessitates developing novel mechanism- based agents capable of ameliorating UVAinduced effects in the skin. We recently described a novel antioxidant, 3-O-Caffeoyl-1-methylquinic acid (MCGA3) from leaves of bamboo. Here, we investigated the photochemopreventive effects of MCGA3 against UVA mediated apoptosis in immortalized HaCaT keratinocytes. Pretreatment of MCGA3 rendered cells more sensitive to subsequent UVA irradiation-induced apoptosis as well as completely reversed UVA-induced sustained phosphorylation of extracellular signal-regulated kinase 1/2 and protein kinase C alpha, downregulation of p21, and reactive oxygen species generation. Interestingly, MCGA3 itself effectively induced p21 protein and mRNA levels. Silencing of p21 by RNA interference revealed a pivotal role of p21 in generating G(1)-S arrest and in enhancing UVA-mediated apoptosis. Transcriptional activation of p21 by MCGA3 was mediated through the proximal region of multiple Sp1 sites regardless of p53-binding site in p21 promoter, and this effect was augmented by desferroioxamine, an iron chelating agent. Additional studies suggested that iron chelation-driven hypoxia by MCGA3 may function in activation of p21. MCGA3 could be a useful agent to prevent photocarcinogenesis via apoptotic elimination of p53 mutant and DNA- repair defective cells caused by UVA radiation.	Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	University of Wisconsin System; University of Wisconsin Madison; Korea University	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Bhat, Kumar/AAD-8831-2019	Bhat, Kumar/0000-0003-1805-3453; Bhat, Kumar MR/0000-0002-2346-6634	NCI NIH HHS [R01 CA78809, R01 CA101039] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078809, R01CA101039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abeysinghe RD, 2001, CARCINOGENESIS, V22, P1607, DOI 10.1093/carcin/22.10.1607; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Baby SM, 2003, HISTOCHEM CELL BIOL, V120, P343, DOI 10.1007/s00418-003-0588-2; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bossenmeyer-Pourie C, 2002, NEUROSCIENCE, V114, P869, DOI 10.1016/S0306-4522(02)00324-X; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Catalano A, 2005, EMBO J, V24, P170, DOI 10.1038/sj.emboj.7600502; Chung JH, 2003, FASEB J, V17, P1913, DOI 10.1096/fj.02-0914fje; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Fan LJ, 2001, CANCER RES, V61, P1073; FUKUCHI K, 1995, BIOL CHEM H-S, V376, P627; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; Jiao Y, 2006, FREE RADICAL BIO MED, V40, P1152, DOI 10.1016/j.freeradbiomed.2005.11.003; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Kweon MH, 2006, FREE RADICAL BIO MED, V40, P1349, DOI 10.1016/j.freeradbiomed.2005.12.002; Kweon MH, 2004, FREE RADICAL BIO MED, V36, P40, DOI 10.1016/j.freeradbiomed.2003.09.023; Kweon MH, 2001, J AGR FOOD CHEM, V49, P4646, DOI 10.1021/jf010514x; Martin BD, 1998, CHEM RES TOXICOL, V11, P1402, DOI 10.1021/tx9801559; Mukherjee S, 2005, J BIOL CHEM, V280, P17617, DOI 10.1074/jbc.M502278200; Patel V, 2002, CANCER RES, V62, P1401; Reagan-Shaw S, 2006, MOL CANCER THER, V5, P418, DOI 10.1158/1535-7163.MCT-05-0250; Song HJ, 2005, J PHARMACOL EXP THER, V312, P391, DOI 10.1124/jpet.104.074401; Valencia A, 2006, FREE RADICAL BIO MED, V40, P641, DOI 10.1016/j.freeradbiomed.2005.09.036; Wang SW, 2000, AM J PHYSIOL-CELL PH, V279, pC868, DOI 10.1152/ajpcell.2000.279.3.C868; Wanner R, 2002, J MOL MED, V80, P61, DOI 10.1007/s00109-001-0288-0	34	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3559	3571		10.1038/sj.onc.1210135	http://dx.doi.org/10.1038/sj.onc.1210135			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146435				2022-12-17	WOS:000246799200012
J	Nanjundan, M; Zhang, F; Schmandt, R; Smith-McCune, K; Mills, GB				Nanjundan, M.; Zhang, F.; Schmandt, R.; Smith-McCune, K.; Mills, G. B.			Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions	ONCOGENE			English	Article						AML1; splicing; ovarian cancers	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; E-CADHERIN; NUCLEAR-MATRIX; CELL-MIGRATION; BETA-CATENIN; EXPRESSION; GENE; TRANSACTIVATION; ASSOCIATION	Acute myeloid leukemia (AML) 1 is often disrupted by chromosomal translocations generating oncogenic fusions in human leukemias. However, its role in epithelial cancers has not been extensively investigated. Herein, we show a marked accumulation of AML1 transcripts including a high frequency of a novel alternatively spliced AML1b transcript lacking exon 6 (AML1b(Del179-242)) in ovarian cancer patients. The increases in RNA transcripts for total wild-type AML1 and AML1b(Del179-242) are associated with poor patient outcomes. We have shown that although both wild-type AML1b and AML1b(Del179-242) are localized to nuclear speckles, AML1b(Del179-242) was observed to have dramatically reduced transactivation potential with the plasminogen activator inhibitor-1 promoters and behaved as a weak dominant negative of wild-type AML1b. Wild-type AML1b was found to inhibit the growth of immortalized ovarian epithelial cells (T29) decreasing colony-forming ability. Moreover, we have identified a novel function of AML1b where it inhibits ovarian cell migration. In contrast, AML1b(Del179-242) has lost the ability to inhibit both ovarian cell proliferation and migration indicating that the functional effects observed with wild-type AML1b are dependent on amino acids 179-242. Collectively, these studies suggest that deregulated alternative splicing of AML1b transcripts may potentially contribute to the pathophysiology of ovarian cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77054 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco	Nanjundan, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 7435 Fannin St, Houston, TX 77054 USA.	mnanjund@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639, P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16672, P50 CA083639, P01 CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Berger R, 1997, CANCER GENET CYTOGEN, V94, P8, DOI 10.1016/S0165-4608(96)00351-2; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Faleiro-Rodrigues C, 2004, HUM PATHOL, V35, P663, DOI 10.1016/j.humpath.2004.01.024; Fowler M, 2006, J CELL BIOCHEM, V97, P1, DOI 10.1002/jcb.20664; Fujioka T, 2001, ONCOL REP, V8, P249; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Harrison S., 2002, SMALL SCALE EC MANAG, V1, P1, DOI [DOI 10.1007/S11842-002-0001-3, 10.1007/s11842-002-0001-3]; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; INOUE M, 1992, AM J CLIN PATHOL, V98, P76, DOI 10.1093/ajcp/98.1.76; Kirschnerova G, 2006, NEOPLASMA, V53, P150; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140; Sun LX, 2001, CANCER RES, V61, P4994; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Whitley BR, 2004, EXP CELL RES, V296, P151, DOI 10.1016/j.yexer.2004.02.022; Yamagata T, 2005, INT J HEMATOL, V82, P1, DOI 10.1532/IJH97.05075; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	28	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2574	2584		10.1038/sj.onc.1210067	http://dx.doi.org/10.1038/sj.onc.1210067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072347				2022-12-17	WOS:000245831200005
J	Deppert, W				Deppert, W.			Introduction - Mutant p53: from guardian to fallen angel?	ONCOGENE			English	Editorial Material							MUTATIONS; COMPLEX; GAIN		Tumor Virol, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute	Deppert, W (corresponding author), Tumor Virol, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.deppert@hpi.uni-hamburg.de						Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Kim E, 2004, J CELL BIOCHEM, V93, P878, DOI 10.1002/jcb.20271	5	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	2007	26	15					2142	2144		10.1038/sj.onc.1210276	http://dx.doi.org/10.1038/sj.onc.1210276			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401422				2022-12-17	WOS:000245394800002
J	Chen, E; Kwon, YT; Lim, MS; Dube, ID; Hough, MR				Chen, E.; Kwon, Y. T.; Lim, M. S.; Dube, I. D.; Hough, M. R.			Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice	ONCOGENE			English	Article						HOX11; homeobox; B cell lymphoma; aneuploidy; chromosome missegregation	END RULE PATHWAY; LINEAGE LYMPHOMAS; UBIQUITIN LIGASES; HOMEOBOX GENE; HOX11; DEGRADATION; INTERACTS; COMPONENT; ONCOGENE; SUBUNIT	The TLX1/HOX11 homeobox gene was originally identified at the recurrent t(10;14)(q24;q11) translocation breakpoint, a chromosomal abnormality observed in 5-7% of T-cell acute lymphoblastic leukemias (T-ALLs). Proviral insertional mutagenesis studies performed on transgenic mice ectopically expressing TLX1/HOX11 in B lymphocytes (IgH mu-HOX11(Tg) mice) revealed the Ubr1 gene locus as a frequent site of proviral insertion, concomitant with accelerated development of diffuse large B-cell lymphoma. Insertion into this genomic region was confirmed by Southern blotting and by the ability to generate a polymerase chain reaction (PCR) amplicon across the viral-genome junction. Western immunoblot and semiquantitative reverse transcriptase-PCR analysis revealed downregulated expression of the Ubr1 gene product subsequent to viral integration. Loss or reduced levels of Ubr1 expression was associated with 5/14 spontaneous B-cell lymphomas in IgH mu-HOX11(Tg) mice and one of nine primary human T-ALLs. To gain mechanistic insight into the cooperativity between TLX1/HOX11 and Ubr1, IgH(mu)-HOX11(Tg)/Ubr1(+/-) mice were generated. IgH mu-HOX11(Tg)/Ubr1(+/-) mice exhibited a modest but statistically significant acceleration of disease onset relative to IgH mu-HOX11(Tg)/Ubr1(+/-) mice. Moreover, micronucleus assays to detect for chromosome missegregation were conducted and revealed increased presence of micronuclei in IgH mu-HOX11(Tg)/Ubr1(-/-) primary B lymphocyte cultures, and in both TLX1/HOX11-overexpressing T cell lines and fibroblast cultures following transfection with short interfering RNAs (siRNAs) targeting Ubr1. Karyotyping of primary B lymphocyte cultures revealed increased incidences of hypodiploid karyotypes. Finally, mitotic figures analysed from Ubr1 siRNA-transfected fibroblast cultures revealed no defects in chromosome congression to the metaphase plate, but increased incidences of atypical anaphase figures, including the development of anaphase bridges and lagging chromosomes. Based on these findings, we identify a synergistic role between TLX1/HOX11 overexpression and Ubr1 inactivation in promoting chromosome missegregation, permitting the accrual of additional chromosome losses and cytogenic abnormalities en route to malignancy.	Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15260 USA; Univ Utah, Dept Pathol, Salt Lake City, UT USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; University of Utah; University of Toronto	Hough, MR (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, 2075 Bayview Ave,Room S232, Toronto, ON M4N 3M5, Canada.	margaret.hough@sw.ca	Hough, Margaret/AAA-1026-2019	Hough, Margaret/0000-0001-8539-6398; Lim, Megan/0000-0002-0415-2867; Chen, Edwin/0000-0003-0742-9734	NIGMS NIH HHS [GM69482] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069482] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen E, 2006, ONCOGENE, V25, P2575, DOI 10.1038/sj.onc.1209285; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; DUBE ID, 1986, BLOOD, V67, P1181; DUBE ID, 1991, BLOOD, V78, P2996; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; Yoshida S, 2002, PLANT J, V32, P129, DOI 10.1046/j.1365-313X.2002.01407.x	27	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5752	5763		10.1038/sj.onc.1209573	http://dx.doi.org/10.1038/sj.onc.1209573			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16862188				2022-12-17	WOS:000240765800006
J	Ling, X; Wang, Y; Dietrich, MF; Andreeff, M; Arlinghaus, RB				Ling, X.; Wang, Y.; Dietrich, M. F.; Andreeff, M.; Arlinghaus, R. B.			Vaccination with leukemia cells expressing cell-surface-associated GM-CSF blocks leukemia induction in immunocompetent mice	ONCOGENE			English	Article						vaccination; murine leukemia; membrane-bound GM-CSF; lentivirus	DENDRITIC CELLS; TUMOR-CELLS; BALB/C MICE; GENERATION; CANCER; PROGENITORS; VACCINES; IMMUNITY; EGFP; CML	The fundamental basis for immunotherapy of leukemia is that leukemic cells express specific antigens that are not expressed by normal hematopoietic cells. However, the host immune system appears to be tolerant to leukemia cells. To overcome this tolerance, we vaccinated immuno-competent mice with murine leukemia cells (WEHI-3B and BCR-ABL+ 32D cells) transduced with a specifically constructed transmembrane form of granulocyte macrophage colony-stimulating factor ( tmGM-CSF). The transduced cells expressed tmGM-CSF on the cell-surface. To determine whether tmGM-CSF-expressing WEHI-3B leukemia cells would prevent leukemia formation as a vaccine, immunocompetent mice ( BALB/c and C3H/HEJ) were immunized with lethally irradiated murine leukemia cells expressing cell-surface tmGM-CSF before challenging mice with murine leukemia cells. Two immunocompetent mouse models were investigated, either WEHI-3B cells in BALB/c mice or BCR-ABL+ 32D cells in C3H/HEJ mouse. The results showed that 100% of WEHI-3B/tmGM-CSF-vaccinated BALB/c mice and about 65% of 32D+ BCR-ABL/tmGM-CSF-vaccinated C3H/HEJ mice were protected from leukemia after leukemia cell challenge, whereas all non-vaccinated mice succumbed to leukemia. Spleen and marrow cell suspensions from vaccinated mice challenged with WEHI-3B cells lacked detectable GFP+ WEHI-3B cells at 82 days post-challenge. A significant delay of death was observed in C3H/HEJ mice challenged with the very aggressive DA-1 cell line expressing BCR-ABL. Vaccination of mice with WEHI-3B/CD40L cells protected 80% of the mice from the WEHI-3B challenge. Notably, 60% of the WEHI-3B/BALB/c mice were also protected from leukemia when WEHI-3B/tmGM-CSF vaccination was carried out after the leukemia challenge. In order to determine whether cellular immunity is involved in this vaccine-mediated protection, either CD4+ or CD8+ T cells were depleted from mice after the WEHI-3B/tmGM-CSF vaccination. The results indicate that CD8+ T-cells mediated the protective immune response provided by the irradiated tmGM-CSF-expressing WEHI-3B cells. In addition, vaccination of nude mice did not provide protection from WEHI-3B leukemia induction. Importantly, 80% of non-vaccinated mice were also protected from a WEHI-3B cell challenge after receiving spleen cells from vaccinated mice 1 day before challenge with leukemia cells. These results indicate that overexpression of tmGM-CSF on the leukemia cell-surface can enhance the recognition of leukemic cells by CD8+ T cells, and can either prevent or significantly delay leukemia induction. These findings suggest that injection of irradiated leukemia cells expressing cell-surface-bound GM-CSF has the potential as an immunological approach to treat leukemia.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Bone Marrow Transplant, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rarlingh@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [5P30 CA16672-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acres B, 2004, CURR OPIN MOL THER, V6, P40; BAHNSON AB, 1995, J VIROL METHODS, V54, P131, DOI 10.1016/0166-0934(95)00035-S; Bitton RJ, 2004, CURR OPIN MOL THER, V6, P17; Bleier JI, 2004, J IMMUNOL, V172, P7408, DOI 10.4049/jimmunol.172.12.7408; Butturini A, 1995, Cancer Treat Res, V76, P299; DALCY GQ, 1990, SCIENCE, V16, P824; de Vos S, 1998, LEUKEMIA, V12, P401, DOI 10.1038/sj.leu.2400940; Denaro M, 2001, GENE THER, V8, P1814, DOI 10.1038/sj.gt.3301601; Dong R, 2003, BLOOD, V101, P3560, DOI 10.1182/blood-2002-06-1841; Fujimura T, 2004, IMMUNOL LETT, V93, P17, DOI 10.1016/j.imlet.2004.01.013; Galea-Lauri J, 2002, IMMUNOLOGY, V107, P20, DOI 10.1046/j.1365-2567.2002.01497.x; Gambotto A, 2000, GENE THER, V7, P2036, DOI 10.1038/sj.gt.3301335; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Hoo WS, 1999, J IMMUNOL, V162, P7343; Larregina A, 1996, IMMUNOLOGY, V87, P317, DOI 10.1046/j.1365-2567.1996.451513.x; Ling XY, 2003, CANCER RES, V63, P298; MATULONIS UA, 1995, BLOOD, V85, P2507, DOI 10.1182/blood.V85.9.2507.bloodjournal8592507; Menetrier-Caux C, 1998, BLOOD, V92, P4778, DOI 10.1182/blood.V92.12.4778; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; O'Keefe Christine L, 2004, Hematology, V9, P189, DOI 10.1080/10245330410001701530; Platzbecker U, 2004, LEUKEMIA LYMPHOMA, V45, P447, DOI 10.1080/10428190310001615684; Pulendran B, 2004, EUR J IMMUNOL, V34, P66, DOI 10.1002/eji.200324567; Rojas R, 2003, LEUKEMIA RES, V27, P351, DOI 10.1016/S0145-2126(02)00180-7; Saudemont A, 2005, BLOOD, V105, P2428, DOI 10.1182/blood-2004-09-3458; Saudemont A, 2002, LEUKEMIA, V16, P1637, DOI 10.1038/sj.leu.2402590; STRIPECKE R, 2001, GENE THER, V6, P1305; Vereecque R, 1999, LEUKEMIA RES, V23, P415; Yei S, 2002, GENE THER, V9, P1302, DOI 10.1038/sj.gt.3301803; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	30	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	32					4483	4490		10.1038/sj.onc.1209477	http://dx.doi.org/10.1038/sj.onc.1209477			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547503				2022-12-17	WOS:000239326000011
J	Ndisang, D; Faulkes, DJ; Gascoyne, D; Lee, SA; Ripley, BJ; Sindos, M; Singer, A; Budhram-Mahadeo, V; Cason, J; Latchman, DS				Ndisang, D; Faulkes, DJ; Gascoyne, D; Lee, SA; Ripley, BJ; Sindos, M; Singer, A; Budhram-Mahadeo, V; Cason, J; Latchman, DS			Differential regulation of different human papilloma virus variants by the POU family transcription factor Brn-3a	ONCOGENE			English	Article						Brn-3a; HPV-16; cervical cancer; URR; E6	CERVICAL INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; ELEVATED EXPRESSION; BINDING-SITES; CANCER CELLS; FACTOR PLAYS; YOUNG-WOMEN; TYPE-16; PROMOTER; INFECTION	The Brn-3a POU family transcription factor is over-expressed in human cervical carcinoma biopsies and is able to activate expression of the human papilloma virus type 16 (HPV-16) upstream regulatory region ( URR), which drives the expression of the E6 and E7 oncoproteins. Inhibition of Brn-3a expression in human cervical cancer cells inhibits HPV gene expression and reduces cellular growth and anchorage independence in vitro as well as the ability to form tumours in vivo. Here, we show that Brn-3a differentially regulates different HPV-16 variants that have previously been shown to be associated with different risks of progression to cervical carcinoma. In human cervical material, Brn-3a levels correlate directly with HPV E6 levels in individuals infected with a high risk variant of HPV-16, whereas this is not the case for a low-risk variant. Moreover, the URRs of high- and intermediate-risk variants are activated by Brn-3a in transfection assays, whereas the URR of a low-risk variant is not. The change of one or two bases in a low-risk variant URR to their equivalent in a higher-risk URR can render the URR responsive to Brn-3a and vice versa. These results help explain why the specific interplay between viral and cellular factors necessary for the progression to cervical carcinoma only occurs in a minority of those infected with HPV-16.	UCL, Inst Child Hlth, Med Mol Biol Unit, London, England; Whittington Hosp, Dept Womens & Childrens Hlth, London N19 5NF, England; Kings Coll London, Sch Med, Richard Dimbelby Lab Canc Virol, GKT, London SE5 9PJ, England; Univ London Birkbeck Coll, London WC1E 7HX, England	University of London; University College London; University of London; University College London; University of London; King's College London; University of London; Birkbeck University London	Latchman, DS (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London, England.	d.latchman@ich.ucl.ac.uk						Bible JM, 2000, J GEN VIROL, V81, P1517, DOI 10.1099/0022-1317-81-6-1517; BURGHARDT E, 1984, CLIN OBSTET GYNAECOL, V11, P239; CHAN WK, 1990, NUCLEIC ACIDS RES, V18, P763, DOI 10.1093/nar/18.4.763; CHAN WK, 1989, J VIROL, V63, P3261, DOI 10.1128/JVI.63.8.3261-3269.1989; COX MF, 1986, LANCET, V2, P157; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DENT CL, 1991, NUCLEIC ACIDS RES, V19, P4531, DOI 10.1093/nar/19.16.4531; DEVILLIERS EM, 1987, LANCET, V2, P703; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; Gascoyne DM, 2004, ONCOGENE, V23, P3830, DOI 10.1038/sj.onc.1207497; GLOSS B, 1989, NUCLEIC ACIDS RES, V17, P3519, DOI 10.1093/nar/17.9.3519; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hudson CD, 2004, J NEUROSCI RES, V78, P803, DOI 10.1002/jnr.20299; Kammer C, 2000, J GEN VIROL, V81, P1975, DOI 10.1099/0022-1317-81-8-1975; Lee SA, 2005, CANCER RES, V65, P3072, DOI 10.1158/0008-5472.CAN-04-2865; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Miller AB, 2001, LANCET, V357, P1816, DOI 10.1016/S0140-6736(00)05008-X; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NAKSHATRI H, 1990, VIROLOGY, V178, P92, DOI 10.1016/0042-6822(90)90382-2; Ndisang D, 1999, J BIOL CHEM, V274, P28521, DOI 10.1074/jbc.274.40.28521; Ndisang D, 2000, CLIN SCI, V98, P601, DOI 10.1042/CS19990350; Ndisang D, 2001, ONCOGENE, V20, P4899, DOI 10.1038/sj.onc.1204634; Ndisdang D, 1998, J CLIN INVEST, V101, P1687, DOI 10.1172/JCI1089; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Ripley BJM, 2005, ARTHRITIS RHEUM-US, V52, P1171, DOI 10.1002/art.21000; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; Sindos M, 2003, GYNECOL ONCOL, V90, P366, DOI 10.1016/S0090-8258(03)00261-0; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Villa LL, 2000, J GEN VIROL, V81, P2959, DOI 10.1099/0022-1317-81-12-2959; VIVANCO MD, 1995, EMBO J, V14, P2217, DOI 10.1002/j.1460-2075.1995.tb07216.x; Woodman CBJ, 2001, LANCET, V357, P1831, DOI 10.1016/S0140-6736(00)04956-4; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	33	9	11	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					51	60		10.1038/sj.onc.1209006	http://dx.doi.org/10.1038/sj.onc.1209006			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247485	Green Accepted			2022-12-17	WOS:000234406400006
J	Debacq, C; Heraud, JM; Asquith, B; Bangham, C; Merien, F; Moules, V; Mortreux, F; Wattel, E; Burny, AN; Kettmann, R; Kazanji, M; Willems, L				Debacq, C; Heraud, JM; Asquith, B; Bangham, C; Merien, F; Moules, V; Mortreux, F; Wattel, E; Burny, AN; Kettmann, R; Kazanji, M; Willems, L			Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1	ONCOGENE			English	Article						HTLV-1; leukemia; BrdU; turnover	I-ASSOCIATED MYELOPATHY; LEUKEMIA-VIRUS; HTLV-I; ANIMAL-MODEL; SAIMIRI-SCIUREUS; HIV-1 INFECTION; TRANSGENIC RATS; VACCINIA VIRUS; TAX; DNA	Understanding cell dynamics in animal models have implications for therapeutic strategies elaborated against leukemia in human. Quanti. cation of the cell turnover in closely related primate systems is particularly important for rare and aggressive forms of human cancers, such as adult T-cell leukemia. For this purpose, we have measured the death and proliferation rates of the CD4(+) T lymphocyte population in squirrel monkeys (Saimiri sciureus) infected by human T-lymphotropic virus type 1 (HTLV-1). The kinetics of in vivo bromodeoxyuridine labeling revealed no modulation of the cell turnover in HTLV-1-infected monkeys with normal CD4 cell counts. In contrast, a substantial decrease in the proliferation rate of the CD4(+) T population was observed in lymphocytic monkeys (e.g. characterized by excessive proportions of CD4(+) T lymphocytes and by the presence of abnormal flower-like cells). Unexpectedly, onset of HTLV-associated leukemia thus occurs in the absence of increased CD4(+) T-cell proliferation. This dynamics significantly differs from the generalized activation of the T-cell turnover induced by other primate lymphotropic viruses like HIV and SIV.	FUSAG, Ctr Basic Biol, B-5030 Gembloux, Belgium; Inst Pasteur, Lab Retrovirol, Cayenne, French Guiana; Imperial Coll Sch Med, Dept Immunol, London, England; Ctr Leon Berard, CNRS UMR 5537, Unite Oncogenese Virale, F-69373 Lyon, France	Imperial College London; UNICANCER; Centre Leon Berard	Willems, L (corresponding author), FUSAG, Ctr Basic Biol, 13 Ave Marechal Juin, B-5030 Gembloux, Belgium.	willems.l@fsagx.ac.be	mortreux, franck/T-4564-2019; Heraud, Jean-Michel/O-1464-2013; mortreux, franck/M-5944-2014	mortreux, franck/0000-0002-4840-021X; Heraud, Jean-Michel/0000-0003-1107-0859; mortreux, franck/0000-0002-4840-021X; Asquith, Becca/0000-0002-5911-3160; Willems, Luc/0000-0002-0563-2213; Bangham, Charles/0000-0003-2624-3599				Akari H, 1998, AIDS RES HUM RETROV, V14, P367, DOI 10.1089/aid.1998.14.367; Asquith B, 2002, TRENDS IMMUNOL, V23, P596, DOI 10.1016/S1471-4906(02)02337-2; Bartoe JT, 2000, J VIROL, V74, P1094, DOI 10.1128/JVI.74.3.1094-1100.2000; BENVENISTY N, 1992, ONCOGENE, V7, P2399; Bomford R, 1996, AIDS RES HUM RETROV, V12, P403, DOI 10.1089/aid.1996.12.403; Collins ND, 1998, BLOOD, V91, P4701, DOI 10.1182/blood.V91.12.4701.412k23_4701_4707; Debacq C, 2003, J VIROL, V77, P13073, DOI 10.1128/JVI.77.24.13073-13083.2003; Debacq C, 2002, P NATL ACAD SCI USA, V99, P10048, DOI 10.1073/pnas.142100999; Delebecque F, 2002, J VIROL, V76, P7883, DOI 10.1128/JVI.76.15.7883-7889.2002; deThe G, 1996, J ACQ IMMUN DEF SYND, V13, pS191, DOI 10.1097/00042560-199600001-00029; Fang JH, 1998, J VIROL, V72, P3952, DOI 10.1128/JVI.72.5.3952-3957.1998; GESSAIN A, 1985, LANCET, V2, P407; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Hanabuchi S, 2001, J NATL CANCER I, V93, P1775, DOI 10.1093/jnci/93.23.1775; Hasegawa A, 2003, J VIROL, V77, P2956, DOI 10.1128/JVI.77.5.2956-2963.2003; Ibuki K, 1997, J GEN VIROL, V78, P147, DOI 10.1099/0022-1317-78-1-147; ICHIMARU M, 1991, CANCER DETECT PREV, V15, P177; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; Kazanji M, 1997, VIROLOGY, V231, P258, DOI 10.1006/viro.1997.8528; Kazanji M, 2001, J VIROL, V75, P5939, DOI 10.1128/JVI.75.13.5939-5948.2001; Kazanji M, 2000, AIDS RES HUM RETROV, V16, P1741, DOI 10.1089/08892220050193245; Kazanji M, 1997, INT J CANCER, V71, P300, DOI 10.1002/(SICI)1097-0215(19970410)71:2&lt;300::AID-IJC27&gt;3.0.CO;2-J; Kikuchi K, 2002, INT J EXP PATHOL, V83, P247, DOI 10.1046/j.1365-2613.2003.00233.x; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; LAIRMORE MD, 1992, INT J CANCER, V50, P124, DOI 10.1002/ijc.2910500125; LENO M, 1995, J EXP MED, V181, P1575, DOI 10.1084/jem.181.4.1575; MOCHIZUKI M, 1992, LANCET, V339, P1110, DOI 10.1016/0140-6736(92)90699-4; Mohri H, 2001, J EXP MED, V194, P1277, DOI 10.1084/jem.194.9.1277; Mohri H, 1998, SCIENCE, V279, P1223, DOI 10.1126/science.279.5354.1223; Mortreux F, 2001, J NATL CANCER I, V93, P367, DOI 10.1093/jnci/93.5.367; Mortreux F, 2001, J VIROL, V75, P1083, DOI 10.1128/JVI.75.2.1083-1089.2001; Nakamaru Y, 2001, PATHOBIOLOGY, V69, P11, DOI 10.1159/000048752; Ohashi T, 2002, J VIROL, V76, P7010, DOI 10.1128/JVI.76.14.7010-7019.2002; Ohashi T, 2000, J VIROL, V74, P9610, DOI 10.1128/JVI.74.20.9610-9616.2000; OSAME M, 1986, LANCET, V1, P1031; PAGLIUCA A, 1988, BRIT MED J, V297, P1456, DOI 10.1136/bmj.297.6661.1456; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Portis T, 2001, J VIROL, V75, P2185, DOI 10.1128/JVI.75.5.2185-2193.2001; Ribeiro RM, 2002, P NATL ACAD SCI USA, V99, P15572, DOI 10.1073/pnas.242358099; Rosenzweig M, 1998, P NATL ACAD SCI USA, V95, P6388, DOI 10.1073/pnas.95.11.6388; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Silic-Benussi M, 2004, P NATL ACAD SCI USA, V101, P6629, DOI 10.1073/pnas.0305502101; Simpson RM, 1998, AIDS RES HUM RETROV, V14, P711, DOI 10.1089/aid.1998.14.711; Sugaya T, 2002, EXP MOL PATHOL, V72, P56, DOI 10.1006/exmp.2001.2415; Willems L, 2000, AIDS RES HUM RETROV, V16, P1787, DOI 10.1089/08892220050193326; Yamaguchi K, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P770; YAMAGUCHI K, 1988, BRIT J HAEMATOL, V68, P169, DOI 10.1111/j.1365-2141.1988.tb06185.x; YAMANOUCHI K, 1985, JPN J CANCER RES, V76, P481; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	53	9	9	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7514	7523		10.1038/sj.onc.1208896	http://dx.doi.org/10.1038/sj.onc.1208896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16091751				2022-12-17	WOS:000233333800002
J	Romanov, VV; James, CH; Sherrington, PD; Pettitt, AR				Romanov, VV; James, CH; Sherrington, PD; Pettitt, AR			Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia	ONCOGENE			English	Article						p53; basic fibroblast growth factor (bFGF); chronic lymphocytic leukaemia (CLL); microenvironment; MDM2; ATM	SYNDECAN-1 CD138 EXPRESSION; PHOSPHORYLATION; MDM2; APOPTOSIS; KINASE; INTERNALIZATION; UBIQUITINATION; ANGIOGENESIS; DYSFUNCTION; RESISTANCE	p53 is the most frequently inactivated gene in human cancers, reflecting its pivotal role in maintaining genomic integrity. The present study was conducted to explore the possibility that tumour cells with no intrinsic defects of the p53 pathway might nevertheless acquire p53 dysfunction through extrinsic suppression of the pathway by microenvironmental factors. Neoplastic cells from patients with chronic lymphocytic leukaemia (CLL) were cultured in the presence or absence of basic fibroblast growth factor ( bFGF) and exposed to ionizing radiation (IR) to induce p53 accumulation. bFGF is greatly increased in the plasma of CLL patients and can suppress p53 activation in some experimental models. IR induced a marked increase in p53 levels in 28 samples from 24 patients. bFGF inhibited IR-induced p53 accumulation to some extent in most of these samples and by more than 50% in seven samples from seven patients. Suppression of p53 activation by bFGF was frequently but not always accompanied by upregulation of the p53-inhibitory protein MDM2 and/or phosphorylation of MDM2 at serine 166, and was associated with impaired transcriptional activation of the p53 target gene p21. These observations provide the first demonstration in human cancer cells that the p53 pathway can be suppressed by factors in the tumour-cell microenvironment.	Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Pettitt, AR (corresponding author), Royal Liverpool Univ Hosp, Dept Haematol, Level 2 Duncan Bldg,Prescot St, Liverpool L7 8XP, Merseyside, England.	andrew.pettitt@rlbuht.nhs.uk						Aguayo A, 2000, BLOOD, V96, P2240, DOI 10.1182/blood.V96.6.2240.h8002240_2240_2245; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Ashton AW, 2004, CIRC RES, V94, P735, DOI 10.1161/01.RES.0000122043.11286.57; Bairey O, 2001, BRIT J HAEMATOL, V113, P400, DOI 10.1046/j.1365-2141.2001.02731.x; Bourdon JC, 2003, CELL DEATH DIFFER, V10, P397, DOI 10.1038/sj.cdd.4401243; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Deguchi Y, 2002, J NEUROCHEM, V83, P381, DOI 10.1046/j.1471-4159.2002.01129.x; Dode C, 2003, NAT GENET, V33, P463, DOI 10.1038/ng1122; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gora-Tybor J, 2003, MEDIAT INFLAMM, V12, P167, DOI 10.1080/0962935031000134888; Gora-Tybor J, 2002, NEOPLASMA, V49, P145; Hosokawa K, 1998, ENDOCRINOLOGY, V139, P4688, DOI 10.1210/en.139.11.4688; Kay NE, 2002, LEUKEMIA, V16, P911, DOI 10.1038/sj.leu.2402467; Krejci P, 2001, LEUKEMIA, V15, P228, DOI 10.1038/sj.leu.2402012; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Molica S, 2002, BRIT J CANCER, V86, P31, DOI 10.1038/sj.bjc.6600022; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pardo OE, 2001, ONCOGENE, V20, P7658, DOI 10.1038/sj.onc.1204994; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Qiao DH, 2003, J BIOL CHEM, V278, P16045, DOI 10.1074/jbc.M211259200; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Sebestyen A, 1999, BRIT J HAEMATOL, V104, P412, DOI 10.1046/j.1365-2141.1999.01211.x; Sebestyen A, 1997, EUR J CANCER, V33, P2273, DOI 10.1016/S0959-8049(97)00248-7; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; She QB, 2002, ONCOGENE, V21, P1580, DOI 10.1038/sj.onc.1205239; She QB, 2001, CANCER RES, V61, P1604; Stankovic T, 2002, BLOOD, V99, P300, DOI 10.1182/blood.V99.1.300; Sutcliffe M, 2000, BRIT J HAEMATOL, V110, P239, DOI 10.1046/j.1365-2141.2000.02072-5.x; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Witzig TE, 1998, LEUKEMIA LYMPHOMA, V31, P167, DOI 10.3109/10428199809057596; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	41	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6855	6860		10.1038/sj.onc.1208895	http://dx.doi.org/10.1038/sj.onc.1208895			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16103882				2022-12-17	WOS:000232527800014
J	Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T				Sukezane, T; Oneyama, C; Kakumoto, K; Shibutani, K; Hanafusa, H; Akagi, T			Human diploid fibroblasts are resistant to MEK/ERK-mediated disruption of the actin cytoskeleton and invasiveness stimulated by Ras	ONCOGENE			English	Article						ras; ROCK/LIMK/Cofilin pathway; tropomyosin; morphological change; MEK/ERK pathway	ONCOGENIC RAS; DIFFERENTIAL EXPRESSION; TRANSFORMED FIBROBLASTS; TUMOR-SUPPRESSOR; DOWN-REGULATION; CANCER-CELLS; RHO GTPASES; LIM-KINASE; TROPOMYOSIN; PATHWAY	Ras-induced transformation is characterized not only by uncontrolled proliferation but also by drastic morphological changes accompanied by the disruption of the actin cytoskeleton. Previously, we reported that human fibroblasts are more resistant than rodent fibroblasts to Ras-induced transformation. To explore the molecular basis for the difference in susceptibility to Ras-induced transformation, we investigated the effect of activated H-Ras on the actin cytoskeleton in human diploid fibroblasts and in rat embryo fibroblasts, both of which are immortalized by SV40 early region. We demonstrate here that Ras-induced morphological changes, decreased expression of tropomyosin isoforms, and suppression of the ROCK/LIMK/Cofilin pathway observed in the rat fibroblasts were not detected in the human fibroblasts even with high expression levels of Ras. We also show that activation of the MEK/ERK pathway sufficed to induce all of these alterations in the rat fibroblasts, whereas the human fibroblasts were refractory to these MEK/ERKmediated changes. In addition to morphological changes, we demonstrated that the expression of activated Ras induced an invasive phenotype in the rat, but not in the human fibroblasts. These studies provide evidence for the existence of human-specific mechanisms that resist Ras/MEK/ERK-mediated transformation.	Osaka Biosci Inst, Mol Oncol Lab, Suita, Osaka 5650874, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan	Osaka University	Akagi, T (corresponding author), Osaka Biosci Inst, Mol Oncol Lab, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	takagi@obi.or.jp						Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GABBIANI G, 1976, AM J PATHOL, V83, P457; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hashimoto Y, 1996, CANCER RES, V56, P5266; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Janssen RAJ, 1998, J BIOL CHEM, V273, P32182, DOI 10.1074/jbc.273.48.32182; Janssen RAJ, 2003, MOL CELL BIOL, V23, P1786, DOI 10.1128/MCB.23.5.1786-1797.2003; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lee S, 2004, J BIOL CHEM, V279, P1885, DOI 10.1074/jbc.M306968200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Raval GN, 2003, ONCOGENE, V22, P6194, DOI 10.1038/sj.onc.1206719; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Shields JM, 2002, MOL CELL BIOL, V22, P2304, DOI 10.1128/MCB.22.7.2304-2317.2002; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; TAKENAGA K, 1988, MOL CELL BIOL, V8, P3934, DOI 10.1128/MCB.8.9.3934; TANAKA M, 1995, CANCER RES, V55, P3228; Wang FL, 1996, CANCER RES, V56, P3634; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	37	9	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5648	5655		10.1038/sj.onc.1208724	http://dx.doi.org/10.1038/sj.onc.1208724			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	16007212				2022-12-17	WOS:000231296100011
J	Bergamaschi, D; Samuels, Y; Zhong, S; Lu, X				Bergamaschi, D; Samuels, Y; Zhong, S; Lu, X			Mdm2 and mdmX prevent ASPP1 and ASPP2 from stimulating p53 without targeting p53 for degradation	ONCOGENE			English	Article						ASPP; p53; mdm2; mdmX; apoptosis; transactivation	EMBRYONIC LETHALITY; TRANSCRIPTIONAL ACTIVATION; MDM2-DEFICIENT MICE; APOPTOSIS; RESCUE; ONCOPROTEIN; PATHWAYS; PROTEINS; P300/CBP; BINDING	Using various mutants of p53 and mdm2, we demonstrate here that both the DNA binding and transactivation function of p53 are required for ASPP1 and ASPP2 to stimulate the apoptotic functions of p53. Mdm2 and mdmx prevent ASPP1 and ASPP2 from stimulating the apoptotic function of p53 by binding and inhibiting the transcriptional activity of p53. Importantly, mdm2 and mdmx can prevent the stimulatory effects of ASPP1 and ASPP2 without targeting p53 for degradation. These data provide a novel mechanism by which mdm2 and mdmx act as potent inhibitors of p53.	UCL, Ludwig Inst Canc Res, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London	Lu, X (corresponding author), UCL, Ludwig Inst Canc Res, Courtauld Bldg,91 Riding House St, London W1W 7BS, England.	x.lu@ludwig.ucl.ac.uk		Lu, Xin/0000-0002-6587-1152; Bergamaschi, Daniele/0000-0002-3955-1091; Samuels, Yardena/0000-0002-3349-7266				Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; CORDONCARDO C, 1994, CANCER RES, V54, P794; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LUNA RMD, 1995, NATURE, V378, P203; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moll UM, 2001, FEBS LETT, V493, P65, DOI 10.1016/S0014-5793(01)02284-0; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ramos YFM, 2001, CANCER RES, V61, P1839; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tang HJ, 2004, BRIT J CANCER, V90, P1285, DOI 10.1038/sj.bjc.6601653; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	26	9	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3836	3841		10.1038/sj.onc.1208535	http://dx.doi.org/10.1038/sj.onc.1208535			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782125				2022-12-17	WOS:000229346300014
J	Wang, M; Futamura, M; Wang, Y; You, M				Wang, M; Futamura, M; Wang, Y; You, M			Pas1c1 is a candidate for the mouse pulmonary adenoma susceptibility 1 locus	ONCOGENE			English	Article						mouse; Pas1 locus; lung tumor; susceptibility; alternative splicing	LUNG-TUMOR SUSCEPTIBILITY; LAMIN-A; MICE; LOCUS; GENES	Pas1 candidate 1 (Pas1c1) gene (also named Lmna-rs1) was found to encode two alternatively spliced mRNA transcripts (i.e. Pas1c1-Va and Pas1c1-Vb). In this study, we identified three additional mRNA transcripts encoded by the Pas1c1 gene, which were designated as Pas1c1-Vc, Pas1c1-Vd, and Pas1c1-Ve, respectively. Similar to Pas1c1-Vb, the newly identified transcripts were only expressed in mouse lung tissues from strains carrying the Pas1-susceptible (Pas1/s) allele. Pas1c1 transcripts were also detected in heart, testis, or brain but not in liver, spleen, or kidney. An 11-nucleotide polymorphism was found within the 3'-acceptor splice site of exon 8, which cosegregates with mouse strain Pas1 alleles and may underlie the strain-specific exon 8 skipping. We also found that ectopic expression of the Pas1c1-Va and Pas1c1-Vb in COS7 and NIH3T3 cells exhibited distinct intracellular distributions. These results support that Pas1c1 as a candidate for the Pas1 locus and the strain-specific isoforms may have differential effects on cell proliferation.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave,Campus Box 8109, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA058554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012063] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58554] Funding Source: Medline; NIEHS NIH HHS [R01ES012063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; Eriksson M, 2003, NATURE, V423, P293, DOI 10.1038/nature01629; Favreau C, 2004, MOL CELL BIOL, V24, P1481, DOI 10.1128/MCB.24.4.1481-1492.2004; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; Lammerding J, 2004, J CLIN INVEST, V113, P370, DOI 10.1172/JCI200419670; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Wang M, 2003, CANCER RES, V63, P3317; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	13	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1958	1963		10.1038/sj.onc.1208295	http://dx.doi.org/10.1038/sj.onc.1208295			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688036				2022-12-17	WOS:000227542000014
J	Vanhorne, JB; Andrew, SD; Harrison, KJ; Taylor, SAM; Thomas, B; McDonald, TJ; Ainsworth, PJ; Mulligan, LM				Vanhorne, JB; Andrew, SD; Harrison, KJ; Taylor, SAM; Thomas, B; McDonald, TJ; Ainsworth, PJ; Mulligan, LM			A model for GFR alpha 4 function and a potential modifying role in multiple endocrine neoplasia 2	ONCOGENE			English	Article						GFR alpha 4; GFRA family; thyroid tumours; multiple endocrine neoplasia type 2	MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE; TYROSINE KINASE; FAMILY LIGANDS; RECEPTOR; EXPRESSION; PERSEPHIN; MUTATION; GENE; ACTIVATION	Mutations of the RET proto-oncogene are found in the majority of patients with the inherited cancer syndrome multiple endocrine neoplasia type 2 ( MEN 2). A minority of cases, however, have no detectable RET mutation and there is considerable phenotypic variation within and among MEN 2 families with the same RET mutation, suggesting a role for other loci in this disease. A candidate for such a gene is glial cell line-derived neurotrophic factor receptor alpha 4 (GFRA4), which encodes a cell surface-bound co-receptor (GFRalpha4) required for interaction of RET with its ligand persephin. The GFRA4 gene has multiple alternative splices leading to three distinct protein isoforms that are prominently expressed in thyroid. We postulated that mutations of GFRA4 contribute to MEN 2 in the absence of RET mutations or modify the RET mutation phenotype. We screened patients with MEN 2 or MEN 2-like phenotypes, with and without RET mutations, for variants of GFRA4. We identified 10 variants, one of which was over represented in, and two of which were found exclusively in, our patient populations. One of these was a single-base substitution upstream of the GFRalpha4 coding region, where it may alter gene expression. The second was a 7 bp insertion, which results in a change in reading frame for all three GFRalpha4 isoforms. This would cause a relative shift in membrane bound and soluble forms of GFRalpha4, which would significantly alter the formation of RET signalling complexes. Our data suggest a model of wild-type GFRa4 isoform expression that includes both activating and inhibiting co-receptors for RET.	Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada	Queens University - Canada; Western University (University of Western Ontario); Western University (University of Western Ontario)	Mulligan, LM (corresponding author), Queens Univ, Dept Pathol, 20 Barrie St, Kingston, ON K7L 3N6, Canada.	mulligal@post.queensu.ca						Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BABU VR, 1984, P NATL ACAD SCI-BIOL, V81, P2525, DOI 10.1073/pnas.81.8.2525; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Enokido Y, 1998, CURR BIOL, V8, P1019, DOI 10.1016/S0960-9822(07)00422-8; Feldman GL, 2000, SURGERY, V128, P93, DOI 10.1067/msy.2000.107103; Frohnauer MK, 2000, SURGERY, V128, P1052, DOI 10.1067/msy.2000.11/6/111080; Gil L, 2002, INT J CANCER, V99, P299, DOI 10.1002/ijc.10298; Gimm O, 2001, ONCOGENE, V20, P2161, DOI 10.1038/sj.onc.1204289; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Hansford JR, 2001, AM J HUM GENET, V69, P366; Lindahl M, 2000, MOL CELL NEUROSCI, V15, P522, DOI 10.1006/mcne.2000.0845; Lindahl M, 2001, J BIOL CHEM, V276, P9344, DOI 10.1074/jbc.M008279200; Lombardo F, 2002, J CLIN ENDOCR METAB, V87, P1674, DOI 10.1210/jcem.87.4.8403; Masure S, 2000, J BIOL CHEM, V275, P39427, DOI 10.1074/jbc.M003867200; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; SHANNON KE, 1999, J ENDOCR GENET, V1, P39; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Van Dyke D L, 1984, Henry Ford Hosp Med J, V32, P266; Vanhorne JB, 2001, HUM GENET, V108, P409, DOI 10.1007/s004390100506; Wiench M, 2001, J CLIN ONCOL, V19, P1374, DOI 10.1200/JCO.2001.19.5.1374	24	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1091	1097		10.1038/sj.onc.1207826	http://dx.doi.org/10.1038/sj.onc.1207826			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592530				2022-12-17	WOS:000226749200015
J	Shively, JE				Shively, JE			CEACAM1 and hyperplastic polyps: new links in the chain of events leading to colon cancer	ONCOGENE			English	Editorial Material							CELL ADHESION MOLECULE; TUMORIGENESIS; MORPHOGENESIS; MODEL		City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	jshively@coh.org						BATTS KP, 2004, PATHOL CASE REV, V9, P173; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Huang J, 1999, J CELL SCI, V112, P4193; Kirshner J, 2004, J MOL HISTOL, V35, P287, DOI 10.1023/B:HIJO.0000032360.01976.81; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Phan D, 2004, CANCER RES, V64, P3072, DOI 10.1158/0008-5472.CAN-03-3730; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398	8	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9303	9305		10.1038/sj.onc.1208266	http://dx.doi.org/10.1038/sj.onc.1208266			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15602572				2022-12-17	WOS:000225764100001
J	Lachat, Y; Diserens, AC; Nozaki, M; Kobayashi, H; Hamou, MF; Godard, S; de Tribolet, N; Hegi, ME				Lachat, Y; Diserens, AC; Nozaki, M; Kobayashi, H; Hamou, MF; Godard, S; de Tribolet, N; Hegi, ME			INK4a/Arf is required for suppression of EGFR/Delta EGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma	ONCOGENE			English	Article						INK4a/Arf; EGFR; TP53; ERK; glioma	GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; EGF RECEPTOR; GENE AMPLIFICATION; HUMAN GLIOBLASTOMA; SIGNALING PATHWAY; TUMOR SUPPRESSION; P16(INK4A) GENE; CYCLE ARREST; P53	Amplification of the epidermal growth factor receptor ( EGFR) or expression of its constitutively activated mutant, DeltaEGFR(2-7), in association with the inactivation of the INK4a/Arf gene locus is a frequent alteration in human glioblastoma. The notion of a cooperative effect between these two alterations has been demonstrated in respective mouse brain tumor models including our own. Here, we investigated underlying molecular mechanisms in early passage cortical astrocytes deficient for p16(INK4a)/p19(Arf) or p53, respectively, with or without ectopic expression of DeltaEGFR(2-7). Targeting these cells with the specific EGFR inhibitor tyrphostin AG1478 revealed that phosphorylation of ERK was only abrogated in the presence of an intact INK4a/Arf gene locus. The sensitivity to inhibit ERK phosphorylation was independent of ectopic expression of DeltaEGFR(2-7) and independent of the TP53 status. This resistance to downregulate the MAPK pathway in the absence of INK4a/Arf was confirmed in cell lines derived from our mouse glioma models with the respective initial genetic alterations. Thus, deletion of INK4a/Arf appears to keep ERK in its active, phosphorylated state insensitive to an upstream inhibitor specifically targeting EGFR/DeltaEGFR(2-7). This resistance may contribute to the cooperative tumorigenic effect selected for in human glioblastoma that may be of crucial clinical relevance for treatments specifically targeting EGFR/DeltaEGFR( 2-7) in glioblastoma patients.	Univ Hosp CHUV, Dept Neurosurg, Lab Tumor Biol Genet, CH-1011 Lausanne, Switzerland; Natl Ctr Competence NCCR Mol Oncol, ISREC, CH-1066 Epalinges, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research	Hegi, ME (corresponding author), Univ Hosp CHUV, Dept Neurosurg, Lab Tumor Biol Genet, BH19-110, CH-1011 Lausanne, Switzerland.	Monika.Hegi@chuv.hospvd.ch	KOBAYASHI, Hiroyuki/G-8990-2012; Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; BOGLER O, 1995, CANCER RES, V55, P2746; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Cheng TL, 2004, EXP CELL RES, V295, P497, DOI 10.1016/j.yexcr.2004.02.002; Choe G, 2003, CANCER RES, V63, P2742; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; D'Amico M, 2003, CANCER RES, V63, P3395; Davies MA, 1998, CANCER RES, V58, P5285; DISERENS AC, 1981, ACTA NEUROPATHOL, V53, P21, DOI 10.1007/BF00697180; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gazzeri S, 1998, CANCER RES, V58, P3926; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Getz G, 2003, BIOINFORMATICS, V19, P1153, DOI 10.1093/bioinformatics/btg143; Godard S, 2003, CANCER RES, V63, P6613; Guha A, 1997, ONCOGENE, V15, P2755, DOI 10.1038/sj.onc.1201455; HAEDER M, 1988, CANCER RES, V48, P1132; Han YC, 1996, CANCER RES, V56, P3859; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; Hegi ME, 2000, CANCER RES, V60, P3019; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Ichimura K, 2000, CANCER RES, V60, P417; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kleihues P, 2000, PATHOLOGY GENETICS T; Koul D, 2001, ONCOGENE, V20, P6669, DOI 10.1038/sj.onc.1204799; Kuo ML, 2003, CANCER RES, V63, P1046; Labuhn M, 2001, ONCOGENE, V20, P1103, DOI 10.1038/sj.onc.1204197; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li B, 2003, CANCER RES, V63, P7443; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Nagane M, 2001, J NEUROSURG, V95, P472, DOI 10.3171/jns.2001.95.3.0472; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Okada Y, 2003, CANCER RES, V63, P413; Okamoto I, 2003, CANCER SCI, V94, P50, DOI 10.1111/j.1349-7006.2003.tb01351.x; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; QUELLE DE, 1995, CELL, V83, P993; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Reich A, 1999, DEVELOPMENT, V126, P4139; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; Steinbach JP, 2002, BRAIN PATHOL, V12, P12; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	62	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6854	6863		10.1038/sj.onc.1207872	http://dx.doi.org/10.1038/sj.onc.1207872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15273738				2022-12-17	WOS:000223750700002
J	Iacovoni, JS; Cohen, SB; Berg, T; Vogt, PK				Iacovoni, JS; Cohen, SB; Berg, T; Vogt, PK			v-Jun targets showing an expression pattern that correlates with the transformed cellular phenotype	ONCOGENE			English	Article						Jun; AP-1; target genes; coordinate expression; reversion; oncogenic transformation; DNA microarray	C-JUN; ONCOGENE JUN; IN-VIVO; PROTEIN; CELLS; AP-1; GENE; SRC; FIBROBLASTS; SEQUENCE	Targets of the oncogenic transcription factor v-Jun in the murine cell line C3H 10T1/2 cells have been identified using DNA microarrays. Two targets, Akap12 and Marcks, are downregulated in transformed cells and are known tumor suppressor genes. Overexpression of either Akap12 or Marcks in v-Jun-transformed cells reverses the transformed phenotype and leads to the re-expression of the other tumor suppressor gene, suggesting that these two genes cooperate in the establishment of the nontransformed state. Reverted cells continue to express v-Jun at high levels and also re-express c-Jun, which is normally repressed by v-Jun. A panel of six cell lines has been generated to evaluate the expression levels of other v-Jun targets in 10T1/2 cells. With these cells, we find that the upregulated target Sprr1a has an expression pattern that correlates with the transformed phenotype.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Novartis Res Fdn, Genom Inst, Dept Prot Sci, La Jolla, CA 92121 USA; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Scripps Research Institute; Novartis; Max Planck Society	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	pkvogt@scripps.edu	Berg, Thorsten/A-1306-2012; Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA79616, CA78230, CA78045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078230, P01CA078045, R01CA079616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GROVE BD, 1994, ANAT REC, V239, P231, DOI 10.1002/ar.1092390302; Hartl M, 2003, CURR CANCER DRUG TAR, V3, P41, DOI 10.2174/1568009033333781; Hussain S, 1998, CELL GROWTH DIFFER, V9, P677; Iacovoni JS, 2003, BIOINFORMATICS, V19, P2316, DOI 10.1093/bioinformatics/btg304; JOSEPH CK, 1992, J BIOL CHEM, V267, P1327; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; Kilbey A, 1996, ONCOGENE, V12, P2409; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; NISHIMURA T, 1988, ONCOGENE, V3, P659; REED JC, 1991, CELL SIGNAL, V3, P569, DOI 10.1016/0898-6568(91)90033-Q; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Wheeler DL, 2002, NUCLEIC ACIDS RES, V30, P13, DOI 10.1093/nar/30.1.13	24	9	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	2004	23	33					5703	5706		10.1038/sj.onc.1207737	http://dx.doi.org/10.1038/sj.onc.1207737			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15133497				2022-12-17	WOS:000222629500017
J	Hirai, I; Sasaki, T; Wang, HG				Hirai, I; Sasaki, T; Wang, HG			Human hRad1 but not hRad9 protects hHus1 from ubiquitin-proteasomal degradation	ONCOGENE			English	Article						Hus1; ubiquitination; proteasomal degradation; checkpoint	DNA-DAMAGE CHECKPOINT; HUMAN RAD9; DEPENDENT PHOSPHORYLATION; SLIDING CLAMP; FACTOR-C; COMPLEX; PROTEINS; ACTIVATION; RADIATION; RESPONSES	Three of the Rad family proteins, Rad9, Rad1, and Hus1, can interact with each other and form a heterotrimeric complex that is thought to play a role in the sensing step of the DNA integrity checkpoint pathways, but the nature of the Rad9 - Rad1 - Hus1 complex assembly remains enigmatic. Here, we demonstrate that the human hRad1 protein plays a significant role as molecular chaperone in the process of the hRad9 - hRad1 - hHus1 heterotrimeric complex formation. In contrast to hRad1, hHus1 is an unstable protein that is actively degraded via the ubiquitin - proteasome pathway. We show that treating cells with proteasome-specific inhibitors stabilizes hHus1 expression. Moreover, hRad1 can associate with hHus1 in the absence of hRad9 and protect hHus1 from ubiquitination and degradation in the cytoplasm. Importantly, genotoxic stress induces hRad1 expression and stabilizes the hHus1 protein. Taken together, these findings suggest a novel role of hRad1 as a potential intrinsic chaperone in the stabilization of hHus1 for the hRad9 - hRad1 - hHus1 checkpoint complex formation.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Sapporo Med Univ, Sch Med, Inst Canc, Dept Biochem, Sapporo, Hokkaido 0608556, Japan	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Sapporo Medical University	Wang, HG (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	wanghg@moffitt.usf.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571	NCI NIH HHS [CA90315] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bendjennat M, 2003, CELL, V114, P599, DOI 10.1016/j.cell.2003.08.001; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; Burtelow MA, 2001, J BIOL CHEM, V276, P25903, DOI 10.1074/jbc.M102946200; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316; Griffith JD, 2002, J BIOL CHEM, V277, P15233, DOI 10.1074/jbc.C200129200; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hirai I, 2002, J BIOL CHEM, V277, P25722, DOI 10.1074/jbc.M203079200; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Kaur R, 2001, MOL BIOL CELL, V12, P3744, DOI 10.1091/mbc.12.12.3744; Kondo T, 1999, MOL CELL BIOL, V19, P1136; Lee MW, 2003, ONCOGENE, V22, P6340, DOI 10.1038/sj.onc.1206729; Majka J, 2003, P NATL ACAD SCI USA, V100, P2249, DOI 10.1073/pnas.0437148100; McBride WH, 2003, ONCOGENE, V22, P5755, DOI 10.1038/sj.onc.1206676; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Post S, 2001, P NATL ACAD SCI USA, V98, P13102, DOI 10.1073/pnas.231364598; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; St Onge RP, 2003, J BIOL CHEM, V278, P26620, DOI 10.1074/jbc.M303134200; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Wang X, 2003, GENE DEV, V17, P965, DOI 10.1101/gad.1065103; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	32	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5124	5130		10.1038/sj.onc.1207658	http://dx.doi.org/10.1038/sj.onc.1207658			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15122316				2022-12-17	WOS:000222382500002
J	Hatakeyama, M; Yumoto, N; Yu, X; Shirouzu, M; Yokoyama, S; Konagaya, A				Hatakeyama, M; Yumoto, N; Yu, X; Shirouzu, M; Yokoyama, S; Konagaya, A			Transformation potency of ErbB heterodimer signaling is determined by B-Raf kinase	ONCOGENE			English	Article						ErbB; B-Raf; transformation; PP2A; PKA	EPIDERMAL-GROWTH-FACTOR; PROTEIN PHOSPHATASE 2A; PLECKSTRIN HOMOLOGY DOMAIN; MAP KINASE; ACTIVATION; PHOSPHORYLATION; DEPHOSPHORYLATION; DIFFERENTIATION; IDENTIFICATION; TRANSDUCTION	Cellular transformation occurs only in cells that express both ErbB1 and ErbB4 receptors, but not in cells expressing only one or the other of these receptors. However, when both receptors are coexpressed and ligand-stimulated, they interact with virtually the same adaptor/effector proteins as when expressed singly. To reveal the underlying regulatory mechanism of the kinase/phosphatase network in ErbB homo- and heterodimer receptor signaling, extracellular signal-regulated kinase (ERK) and Akt activities were evaluated in the presence of several enzyme inhibitors in ligand-induced cells expressing ErbB1 (E1), ErbB4 (E4), and ErbB1/ErbB4 (E1/4) receptor. The PP2A inhibitor okadaic acid showed receptor-specific inhibitory profiles for ERK and Akt activities. Moreover, B-Raf isolated only from E1/4 cells could induce in vitro phosphorylation for MEK; this B-Raf kinase activity was abolished by pretreatment of the cells with okadaic acid. Our study further showed that the E1/4 cell-specific B-Raf activity was stimulated by PLCgamma and subsequent Rap1 activation. The present study suggests that B-Raf kinase, which was specifically activated in the cells coexpressing ErbB1 and ErbB4 receptors, elevates total ERK activity within the cell and, therefore, can induce cellular transformation.	RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, Kanagawa 2300045, Japan; RIKEN Genom Sci Ctr, Prot Res Grp, Tsurumi Ku, Kanagawa 2300045, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; SPring8, RIKEN Harima Inst, Cellular Signaling Lab, Sayo, Hyogo 6795148, Japan; SPring8, RIKEN Harima Inst, Structurome Grp, Sayo, Hyogo 6795148, Japan	RIKEN; RIKEN; University of Tokyo; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN	Hatakeyama, M (corresponding author), RIKEN Genom Sci Ctr, Bioinformat Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Kanagawa 2300045, Japan.	marikoh@gsc.riken.jp	Okada, Mariko/N-6933-2015; Yokoyama, Shigeyuki/N-6911-2015; Konagaya, Akihiko/F-9302-2014; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Brose MS, 2002, CANCER RES, V62, P6997; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; Hatakeyama M, 2003, BIOCHEM J, V373, P451, DOI 10.1042/BJ20021824; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim JH, 2002, EUR J BIOCHEM, V269, P2323, DOI 10.1046/j.1432-1033.2002.02877.x; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; Oehrl W, 2003, J BIOL CHEM, V278, P17819, DOI 10.1074/jbc.M209951200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Shelly M, 1998, J BIOL CHEM, V273, P10496, DOI 10.1074/jbc.273.17.10496; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; Strack S, 2002, J BIOL CHEM, V277, P41525, DOI 10.1074/jbc.M203767200; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	45	9	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5023	5031		10.1038/sj.onc.1207664	http://dx.doi.org/10.1038/sj.onc.1207664			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15064721				2022-12-17	WOS:000222237300008
J	Adriaenssens, E; Mougel, A; Goormachtigh, G; Loing, E; Fafeur, V; Auriault, C; Coll, J				Adriaenssens, E; Mougel, A; Goormachtigh, G; Loing, E; Fafeur, V; Auriault, C; Coll, J			A novel dominant-negative mutant form of Epstein-Barr virus latent membrane protein-1 (LMP1) selectively and differentially impairs LMP1 and TNF signaling pathways	ONCOGENE			English	Article						EBV; LMP1; dominant-negative; signal; TNF; apoptosis	NF-KAPPA-B; LYMPHOCYTE GROWTH TRANSFORMATION; NECROSIS-FACTOR RECEPTOR; REED-STERNBERG CELLS; BINDING-SITE; HUMAN TRAF2; ACTIVATION; EXPRESSION; TRANSDUCTION; DOMAIN	The latent membrane protein-1 (LMP1) is an integral membrane molecule expressed by Epstein-Barr virus (EBV) during viral latency and displays properties of a constitutively activated member of the TNF receptor family. LMP1 is required for B-cell or monocyte immortalization induced by EBV and is sufficient to transform rodent fibroblasts. Transforming potential of LMP1 is mediated by its cytoplasmic C-terminal domain, which activates various cellular signaling pathways including NFkappaB and JNK. In this report, we constructed mutants of LMP1 with preserved membrane spanning domain but mutated in the C- terminal domain and a second truncated C- terminal LMP1 fused to the enhanced green fluorescent protein. This latter mutant, termed LMP1-CT, impairs signaling by ectopic LMP1 as well as endogenous EBV-expressed wild-type (wt) LMP1. In contrast to dominant-negative mutants of LMP1 with preserved membrane spanning domains, LMP1-CT was unable to bind wt LMP1 to form an inactive complex. Its dominant-negative effects were due to binding and sequestration of LMP1 adapters TRAF2 and TRADD as assessed by coimmunoprecipitation experiments and confocal analysis. The effect was selective since LMP1-CT did not inhibit IL-1beta-induced signaling, whereas it impaired TNF-triggered NFkappaB and JNK signals without affecting TNF-induced apoptosis. In addition and in contrast to LMP1 constructs with membrane localization, LMP-CT did not display cytostatic properties in noninfected cells. Importantly, LMP1-CT inhibited survival induced by LMP1 in an EBV-transformed T-cell line expressing the type II viral latency commonly found in the majority of EBV-associated human tumors. These data demonstrate that LMP1-CT is a new tool to explore the differences between LMP1 and TNF signaling and may facilitate the design of molecules with potential therapeutic roles.	Inst Biol Lille, CNRS, UMR 8527, F-59021 Lille, France; Sedac Therapeut, F-59120 Loos, France; Inst Biol Lille, CNRS, UMR 8117, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Coll, J (corresponding author), Inst Biol Lille, CNRS, UMR 8527, BP 447, F-59021 Lille, France.	jean.coll@ibl.fr	Fafeur, Veronique/L-9072-2018	Goormachtigh, Gautier/0000-0003-1736-8269				Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Brennan P, 2001, J BIOL CHEM, V276, P1195, DOI 10.1074/jbc.M005461200; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Coffin WF, 2003, J VIROL, V77, P3749, DOI 10.1128/JVI.77.6.3749-3758.2003; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; Groux H, 1997, BLOOD, V89, P4521, DOI 10.1182/blood.V89.12.4521; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Higuchi M, 2002, J VIROL, V76, P455, DOI 10.1128/JVI.76.1.455-459.2002; Horie R, 2002, AM J PATHOL, V160, P1647, DOI 10.1016/S0002-9440(10)61112-1; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Izumi KM, 1999, J VIROL, V73, P9908, DOI 10.1128/JVI.73.12.9908-9916.1999; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; Masy E, 2002, J VIROL, V76, P6460, DOI 10.1128/JVI.76.13.6460-6472.2002; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROWE M, 1995, EUR J IMMUNOL, V25, P1374, DOI 10.1002/eji.1830250536; Schultheiss U, 2001, EMBO J, V20, P5678, DOI 10.1093/emboj/20.20.5678; Tsao DHH, 2000, MOL CELL, V5, P1051, DOI 10.1016/S1097-2765(00)80270-1; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wang S, 1996, CANCER RES, V56, P4610; Werneburg BG, 2001, J BIOL CHEM, V276, P43334, DOI 10.1074/jbc.M104994200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	43	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	2004	23	15					2681	2693		10.1038/sj.onc.1207432	http://dx.doi.org/10.1038/sj.onc.1207432			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14767477	Green Published			2022-12-17	WOS:000220714900010
J	Baust, H; Schoke, A; Brey, A; Gern, U; Los, M; Schmid, RM; Rottinger, EM; Seufferlein, T				Baust, H; Schoke, A; Brey, A; Gern, U; Los, M; Schmid, RM; Rottinger, EM; Seufferlein, T			Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-kappa B independent mechanisms	ONCOGENE			English	Article						gliotoxin and radiosensitizing; NF-kappa B; XIAP; survivin; JNK	PROTEIN-KINASE PATHWAY; IONIZING-RADIATION; PERSISTENT ACTIVATION; 26S PROTEASOME; APOPTOSIS; INHIBITION; GENE; P53; SENSITIVITY; EXPRESSION	Radioresistance markedly impairs the efficacy of tumor radiotherapy and may involve antiapoptotic signal transduction pathways that prevent radiation-induced cell death. A common cellular response to genotoxic stress induced by radiation is the activation of the nuclear factor kappa B (NF-kappaB). NF-kappaB activation in turn can lead to an inhibition of radiation-induced apoptotic cell death. Thus, inhibition of NF-kappaB activation is commonly regarded as an important strategy to abolish radioresistance. Among other compounds, the fungal metabolite gliotoxin (GT) has been reported to be a highly selective inhibitor of NF-kappaB activation. Indeed, low doses of GT were sufficient to significantly enhance radiation-induced apoptosis in HL-60 cells. However, this effect turned out to be largely independent of NF-kappaB activation since radiation of HL-60 cells with clinically relevant doses of radiation induced only a marginal increase in NF-kappaB activity, and selective inhibition of NF-kappaB by SN50 did not result in a marked enhancement of GT-induced apoptosis. GT induced activation of JNKs, cytochrome c release from the mitochondria and potently stimulated the caspase cascade inducing cleavage of caspases -9, -8, -7 and -3. Furthermore, cleavage of the antiapoptotic protein X-linked IAP and downregulation of the G2/M-specific IAP-family member survivin were observed during GT-induced apoptosis. Finally, the radiation-induced G2/M arrest was markedly reduced in GT-treated cells most likely due to the rapid induction of apoptosis. Our data demonstrate that various other pathways apart from the NF-kappaB signaling complex can sensitize tumor cells to radiation and propose a novel mechanism for radio-sensitization by GT, the interference with the G2/M checkpoint that is important for repair of radiation-induced DNA damage in p53-deficient tumor cells.	Univ Ulm, Dept Radiat Oncol, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med, D-89081 Ulm, Germany; Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany	Ulm University; Ulm University; University of Munster; University of Munich	Baust, H (corresponding author), Univ Ulm, Dept Radiat Oncol, Robert Koch Str 6, D-89070 Ulm, Germany.	heinrich.baust@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018	Los, Marek/0000-0001-9518-1411				Aldridge DR, 1998, CANCER RES, V58, P2817; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bratton DL, 1999, J BIOL CHEM, V274, P28113, DOI 10.1074/jbc.274.40.28113; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; EICHNER RD, 1988, J BIOL CHEM, V263, P3772; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hida A, 2000, IMMUNOLOGY, V99, P553, DOI 10.1046/j.1365-2567.2000.00985.x; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(02)02075-5; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; KERR JFR, 1972, J PATHOL, V107, P217, DOI 10.1002/path.1711070309; Kroll M, 1999, CHEM BIOL, V6, P689, DOI 10.1016/S1074-5521(00)80016-2; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pajonk F, 2001, RADIOTHER ONCOL, V59, P203, DOI 10.1016/S0167-8140(01)00311-5; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; POWELL SN, 1995, CANCER RES, V55, P1643; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Waring P, 1996, GEN PHARMACOL, V27, P1311, DOI 10.1016/S0306-3623(96)00083-3; WARING P, 1990, J BIOL CHEM, V265, P14476; WILSON RE, 1993, ONCOGENE, V8, P3229; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	50	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8786	8796		10.1038/sj.onc.1206969	http://dx.doi.org/10.1038/sj.onc.1206969			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647473	Green Published			2022-12-17	WOS:000186844900016
J	Boerner, JL; Danielsen, AJ; Lovejoy, CA; Wang, Z; Juneja, SC; Faupel-Badger, JM; Darce, JR; Maihle, NJ				Boerner, JL; Danielsen, AJ; Lovejoy, CA; Wang, Z; Juneja, SC; Faupel-Badger, JM; Darce, JR; Maihle, NJ			Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis	ONCOGENE			English	Article						EGFR/ErbB; v-ErbB; Grb2; caldesmon	GROWTH-FACTOR RECEPTOR; GUANINE-NUCLEOTIDE EXCHANGE; HUMAN BREAST-CANCER; TYROSINE KINASES; V-ERBB; TRANSFORMED-CELLS; C-ERBB; ADAPTER PROTEINS; TUMOR-CELLS; SH3 DOMAINS	Mutations within members of the EGF/ErbB receptor family frequently release the oncogenic potential of these receptors, resulting in the activation of downstream signaling events independent of ligand regulatory constraints. We previously have demonstrated that the signal transduction events originating from S3-v-ErbB, a ligand-independent, oncogenic EGF receptor mutant, are qualitatively distinct from the ligand-dependent mitogenic signaling pathways associated with the wild-type EGF receptor. Specifically, expression of S3-v-ErbB in primary fibroblasts results in anchorage-independent growth, increased invasive potential, and the formation of a transformation-specific phosphoprotein signaling complex, all in a Ras-independent manner. Here we demonstrate the transformation-specific interaction between two components of this complex: the adaptor protein Grb2 and the cytoskeletal regulatory protein caldesmon. This interaction is mediated via both the amino-terminal SH3 and central SH2 domains of Grb2, and the aminoterminal (myosin-binding) domain of caldesmon. Expression of a dominant- negative Grb2 deletion mutant, which lacks the carboxy-terminal SH3 domain, in. broblasts expressing S3-v-ErbB results in a reduction in phosphoprotein complex formation, the loss of anchorage-independent growth, and a reduction in invasive potential. Together, these results demonstrate a Ras-independent role for Grb2 in modulating cytoskeletal function during ligand-independent EGF receptor-mediated transformation, and provide further support for the hypothesis that ligand-independent oncogenic signaling is qualitatively distinct from ligand-dependent mitogenic signaling by the EGF receptor.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Maihle, NJ (corresponding author), Yale Univ, Sch Med, Dept Obstet & Gynecol, 333 Cedar St, New Haven, CT 06520 USA.			Faupel-Badger, Jessica/0000-0001-9729-3660; Juneja, Subhash/0000-0002-8536-5724	NATIONAL CANCER INSTITUTE [R01CA079808] Funding Source: NIH RePORTER; NCI NIH HHS [CA79808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALBINI A, 1987, CANCER RES, V47, P3239; BELL SM, 1993, MOL CELL BIOL, V13, P5888, DOI 10.1128/MCB.13.9.5888; Boerner JL, 2003, EXP CELL RES, V284, P111, DOI 10.1016/S0014-4827(02)00096-4; Boerner JL, 2001, J BIOL CHEM, V276, P3691, DOI 10.1074/jbc.M003801200; Boerner JL, 2000, J CELL SCI, V113, P935; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; CONNOLLY DC, 1994, J VIROL, V68, P6804, DOI 10.1128/JVI.68.10.6804-6810.1994; DALY RJ, 1994, ONCOGENE, V9, P2723; DAmbrosio C, 1996, ONCOGENE, V12, P371; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gay B, 1999, J BIOL CHEM, V274, P23311, DOI 10.1074/jbc.274.33.23311; Goncharova EA, 2001, FEBS LETT, V497, P113, DOI 10.1016/S0014-5793(01)02445-0; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; Klapper LN, 2000, ADV CANCER RES, V77, P25; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIHLE NJ, 1989, BIOCHIM BIOPHYS ACTA, V948, P287, DOI 10.1016/0304-419X(89)90003-6; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MARSTON SB, 1991, BIOCHEM J, V279, P1; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; McManus MJ, 1997, P NATL ACAD SCI USA, V94, P11351, DOI 10.1073/pnas.94.21.11351; MCMANUS MJ, 1995, J VIROL, V69, P3631, DOI 10.1128/JVI.69.6.3631-3638.1995; McManus MJ, 2000, J BIOL CHEM, V275, P35328, DOI 10.1074/jbc.M005399200; NAIR N, 1992, MOL CELL BIOL, V12, P2010, DOI 10.1128/MCB.12.5.2010; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; Puto LA, 2003, J BIOL CHEM, V278, P9388, DOI 10.1074/jbc.M208414200; RAINES MA, 1988, J VIROL, V62, P2437, DOI 10.1128/JVI.62.7.2437-2443.1988; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Rochefort H, 1998, J STEROID BIOCHEM, V65, P163, DOI 10.1016/S0960-0760(98)00010-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; TANAKA J, 1993, J CELL SCI, V104, P595; Tari AM, 1999, ONCOGENE, V18, P1325, DOI 10.1038/sj.onc.1202422; Wang Z, 1999, J BIOL CHEM, V274, P33807, DOI 10.1074/jbc.274.47.33807; Xie YM, 1995, J BIOL CHEM, V270, P30717, DOI 10.1074/jbc.270.51.30717; YAMASHIRO S, 1994, ADV EXP MED BIOL, V358, P113	47	9	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 2	2003	22	43					6679	6689		10.1038/sj.onc.1206830	http://dx.doi.org/10.1038/sj.onc.1206830			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729XA	14555981				2022-12-17	WOS:000185799300003
J	Mao, ZB; Shan, S; Zhu, YY; Yi, X; Zhang, H; Shang, YF; Tong, TJ				Mao, ZB; Shan, S; Zhu, YY; Yi, X; Zhang, H; Shang, YF; Tong, TJ			Transcriptional regulation of A33 antigen expression by gut-enriched Kruppel-like factor	ONCOGENE			English	Article						A33 antigen; GKLF; gene regulation	MONOCLONAL-ANTIBODY A33; ADVANCED COLON-CANCER; COXSACKIE B VIRUSES; GENE-EXPRESSION; INTESTINAL EPITHELIUM; ENDOTHELIAL-CELLS; PHASE I/II; PROMOTER; GROWTH; DIFFERENTIATION	A33 antigen is a membrane-bound protein that is expressed only in intestinal epithelium and in most human colon cancers. Thus, A33 antigen has been explored as a potential therapeutic target for the treatment of colon cancers. However, little is known about the mechanism responsible for the tissue-specific pattern of its expression. In this report, we demonstrate that gut-enriched Kruppel-like factor (GKLF) binds to the promoter region of A33 antigen gene in colonic carcinoma cells and that mutations in the GKLF binding sequence in this region lead to diminished expression of A33 antigen. In addition, the expression of GKLF is linked to the expression of A33 antigen and blocking the expression of GKLF leads to the abolishment of A33 antigen expression. These results suggest that GKLF is a critical regulator in inducing the expression of A33 antigen in intestinal epithelium. While it has been suggested that GKLF is a regulator in inducing cell growth arrest and differentiation of the intestine, our observation that A33 antigen gene is a downstream target for GKLF suggests a more complex and diverse role for GKLF in the gut.	Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China	Peking University	Shang, YF (corresponding author), Peking Univ, Ctr Hlth Sci, Dept Biochem & Mol Biol, Beijing 100083, Peoples R China.							Abud HE, 2000, MECH DEVELOP, V98, P111, DOI 10.1016/S0925-4773(00)00438-X; Antoniw P, 1996, BRIT J CANCER, V74, P513, DOI 10.1038/bjc.1996.395; Barendswaard EC, 2001, J NUCL MED, V42, P1251; Behr R, 2002, MECH DEVELOP, V115, P167, DOI 10.1016/S0925-4773(02)00127-2; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Catimel B, 1996, J BIOL CHEM, V271, P25664, DOI 10.1074/jbc.271.41.25664; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Chretien I, 1996, EUR J IMMUNOL, V26, P780, DOI 10.1002/eji.1830260409; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Foster KW, 2000, CANCER RES, V60, P6488; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Gray S, 2002, J BIOL CHEM, V277, P34322, DOI 10.1074/jbc.M201304200; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Johnstone CN, 2002, J BIOL CHEM, V277, P34531, DOI 10.1074/jbc.M204865200; Katevuo K, 1999, J IMMUNOL, V162, P5685; Katz JP, 2002, DEVELOPMENT, V129, P2619; KING DJ, 1995, BRIT J CANCER, V72, P1364, DOI 10.1038/bjc.1995.516; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; Okano J, 2000, FEBS LETT, V473, P95, DOI 10.1016/S0014-5793(00)01468-X; Sakamoto J, 2000, CANCER CHEMOTH PHARM, V46, pS27, DOI 10.1007/PL00014045; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; WELT S, 1994, J CLIN ONCOL, V12, P1561, DOI 10.1200/JCO.1994.12.8.1561; Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917	38	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4434	4443		10.1038/sj.onc.1206508	http://dx.doi.org/10.1038/sj.onc.1206508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853980				2022-12-17	WOS:000183978900013
J	Settle, M; Gordon, MD; Nadella, M; Dankort, D; Muller, W; Jacobs, JR				Settle, M; Gordon, MD; Nadella, M; Dankort, D; Muller, W; Jacobs, JR			Genetic identification of effectors downstream of Neu (ErbB-2) autophosphorylation sites in a Drosophila model	ONCOGENE			English	Article						apoptosis; DEgft; Grb-2; Neu; SHC	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; PHOSPHOLIPASE C-GAMMA; EGF RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; SH3 DOMAINS; PTB DOMAIN; MAMMARY TUMORIGENESIS	The ErbB-2/Neu receptor tyrosine kinase plays a causal role in tumorigenesis in mammals. Neu's carboxyl terminus contains five phosphorylated tyrosines that mediate transformation through interaction with cytoplasmic SH2 or PTB containing adaptor proteins. We show that Drosophild adaptors signal from individual phosphotyrosine sites of rat Neu. Activated Neu expression in the midline glia suppressed apoptosis, similar to that seen with activated Drosophild EGF-R expression. Expression in eye and wing tissues generated graded phenotypes suitable for dos F-sensitive modifier genetics. Suppression of ErbB-2/Neu-induced phenotypes in tissues haplosufficient for genes encoding adaptor protein or second messengers suggests that pTyr 1227(YD) signals require Shc, and that pTyr 1253 (YE) signalling does not employ Ras, but does require Raf function. Signalling from pTyr (YB) was affected by a haplosufficiency in drk (Grb-2), and in genes thought to function downstream of Grb-2: dab, sos, csw (Shp-2), and dos (Gab-1). These data demonstrate the power of Drosophila genetics to unmask the molecules that signal from oncogenic ErbB-2/Neu.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada	McMaster University	Jacobs, JR (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	jacobsr@mcmaster.ca	Gordon, Michael D/H-9586-2012	Gordon, Michael D/0000-0002-5440-986X; jacobs, j roger/0000-0002-5878-5416; Dankort, David/0000-0002-5862-6829				BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BAUMANN P, 1993, DEVELOPMENT, P65; Bhandari P, 2001, ONCOGENE, V20, P6871, DOI 10.1038/sj.onc.1204849; BRAND AH, 1994, METHOD CELL BIOL, V44, P635, DOI 10.1016/S0091-679X(08)60936-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Dong R, 1997, DEV BIOL, V190, P165, DOI 10.1006/dbio.1997.8688; Dougall WC, 1996, DNA CELL BIOL, V15, P31, DOI 10.1089/dna.1996.15.31; Firth L, 2000, GENETICS, V156, P733; Gayko U, 1999, P NATL ACAD SCI USA, V96, P523, DOI 10.1073/pnas.96.2.523; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; Hamlet MRJ, 2001, GENETICS, V159, P1073; Hay BA, 1997, P NATL ACAD SCI USA, V94, P5195, DOI 10.1073/pnas.94.10.5195; Herbst R, 1999, EMBO J, V18, P6950, DOI 10.1093/emboj/18.24.6950; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jacobs JR, 2000, PROG NEUROBIOL, V62, P475, DOI 10.1016/S0301-0082(00)00016-2; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; Lanoue BR, 2000, GENOME, V43, P564, DOI 10.1139/gen-43-3-564; Lanoue BR, 1999, DEV GENET, V25, P321, DOI 10.1002/(SICI)1520-6408(1999)25:4<321::AID-DVG6>3.0.CO;2-Y; Le N, 1998, MOL CELL BIOL, V18, P4844, DOI 10.1128/MCB.18.8.4844; Lee T, 1996, DEVELOPMENT, V122, P409; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; Lesokhin AM, 1999, DEV BIOL, V205, P129, DOI 10.1006/dbio.1998.9121; Lock P, 1999, J BIOL CHEM, V274, P22775, DOI 10.1074/jbc.274.32.22775; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU XY, 1994, EMBO J, V13, P2592, DOI 10.1002/j.1460-2075.1994.tb06549.x; Ludlow C, 1996, DEV BIOL, V178, P149, DOI 10.1006/dbio.1996.0205; Maixner A, 1998, DEV GENET, V23, P347, DOI 10.1002/(SICI)1520-6408(1998)23:4<347::AID-DVG9>3.0.CO;2-C; Margolis B, 1999, KIDNEY INT, V56, P1230, DOI 10.1046/j.1523-1755.1999.00700.x; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1993, PHILOS T R SOC B, V340, P279, DOI 10.1098/rstb.1993.0069; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; RICCI A, 1995, ONCOGENE, V11, P1519; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHILO BZ, 1991, TRENDS GENET, V7, P388, DOI 10.1016/0168-9525(91)90261-N; SIMON JA, 1995, CHEM BIOL, V2, P53, DOI 10.1016/1074-5521(95)90080-2; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; Stewart BA, 2001, DEV BIOL, V234, P13, DOI 10.1006/dbio.2001.0228; STURTEVANT MA, 1995, DEVELOPMENT, V121, P785; STURTEVANT MA, 1993, GENE DEV, V7, P961, DOI 10.1101/gad.7.6.961; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	69	9	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1916	1926		10.1038/sj.onc.1206240	http://dx.doi.org/10.1038/sj.onc.1206240			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673197				2022-12-17	WOS:000181967700002
J	Tagliafico, E; Siena, M; Zanocco-Marani, T; Manfredini, R; Tenedini, E; Montanari, M; Grande, A; Ferrari, S				Tagliafico, E; Siena, M; Zanocco-Marani, T; Manfredini, R; Tenedini, E; Montanari, M; Grande, A; Ferrari, S			Requirement of the coiled-coil domains of p92(c-Fes) for nuclear localization in myeloid cells upon induction of differentiation	ONCOGENE			English	Article						c-Fes; oligomerization; myeloid differentiation; phosphorylation; nuclear localization; tyrosine kinase	FES TYROSINE KINASE; HUMAN C-FES; GREEN FLUORESCENT PROTEIN; HEMATOPOIETIC STEM-CELLS; VITAMIN-D-RECEPTOR; RETROVIRAL VECTORS; FPS FES; EXPRESSION; FPS/FES; GENE	The nonreceptor tyrosine kinase Fes is implicated in myeloid cells differentiation. It has been observed that its localization can be cytoplasmic, perinuclear, or nuclear. To further characterize this point, we studied Fes subcellular localization in myeloid cell lines (HL60 and K562) and in COS1 cells. Fes was observed in both the nucleus and the cytoplasm of HL60, K562 cells over-expressing Fes and only in the cytoplasm of COS1 cells, suggesting that nuclear localization is cell context dependent. Moreover, in myeloid cells, the treatment with differentiation-inducing agents such as retinoic acid, phorbol esters and vitamin D, is followed by an increase of the oligomeric form of Fes in the nucleus. In fact, oligomerization seems to be necessary for translocation to occur, since Fes mutants missing the coiled-coil domains are not able to form oligomers and fail to localize in the nucleus. The active form of Fes is tyrosine phosphorylated; however, phosphorylation is not required for Fes to localize in the nucleus, since tyrosine kinase inhibitors do not block the translocation process.	Univ Modena, Dipartimento Sci Biomed, Sez Chim Biol, I-41100 Modena, Italy	Universita di Modena e Reggio Emilia	Ferrari, S (corresponding author), Univ Modena, Dipartimento Sci Biomed, Sez Chim Biol, Via Campi 287, I-41100 Modena, Italy.		Manfredini, Rossella/C-5625-2015; Tagliafico, Enrico/C-9079-2009; Ferrari, Sergio/A-1110-2010; Zanocco Marani, Tommaso/D-5801-2015; tenedini, elena/ABB-3411-2020; Grande, Alexis/D-5816-2015	Manfredini, Rossella/0000-0003-0660-6110; Tagliafico, Enrico/0000-0003-0981-2542; Ferrari, Sergio/0000-0002-4822-2521; Zanocco Marani, Tommaso/0000-0002-9911-7078; Grande, Alexis/0000-0003-3319-1707; TENEDINI, Elena/0000-0003-0285-765X				ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARE A, 1994, ONCOGENE, V9, P739; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREXLER HG, 1987, LEUKEMIA, V1, P697; EMILIA G, 1986, BRIT J HAEMATOL, V62, P287, DOI 10.1111/j.1365-2141.1986.tb02931.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FERRARI S, 1994, LEUKEMIA, V8, pS91; FERRARI S, 1995, CELL DEATH DIFFER, V2, P155; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; Grande A, 1999, BLOOD, V93, P3276, DOI 10.1182/blood.V93.10.3276.410k08_3276_3285; Grande A, 1997, CELL DEATH DIFFER, V4, P497, DOI 10.1038/sj.cdd.4400270; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Greer P, 2002, NAT REV MOL CELL BIO, V3, P278, DOI 10.1038/nrm783; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; Hackenmiller R, 2002, DEV BIOL, V245, P255, DOI 10.1006/dbio.2002.0643; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HAZAN B, 1993, CELL GROWTH DIFFER, V4, P443; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; Hovland AR, 2001, J NEUROSCI RES, V64, P302; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JUCKER M, 1992, ONCOGENE, V7, P943; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; Manfredini R, 1999, CANCER RES, V59, P3803; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NELSON KL, 1998, J BIOL CHEM; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pendergast AM, 1996, CURR OPIN CELL BIOL, V8, P174, DOI 10.1016/S0955-0674(96)80063-9; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Read RD, 1997, J BIOL CHEM, V272, P18498, DOI 10.1074/jbc.272.29.18498; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; YATES KE, 1995, ONCOGENE, V10, P1239; YU G, 1989, J BIOL CHEM, V264, P10276; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217; Zirngibl RA, 2002, MOL CELL BIOL, V22, P2472, DOI 10.1128/MCB.22.8.2472-2486.2002	53	9	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1712	1723		10.1038/sj.onc.1206279	http://dx.doi.org/10.1038/sj.onc.1206279			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642874				2022-12-17	WOS:000181580500013
J	Mateos, S; Calothy, G; Lamballe, F				Mateos, S; Calothy, G; Lamballe, F			The noncatalytic TrkCNC2 receptor is cleaved by metalloproteases upon neurotrophin-3 stimulation	ONCOGENE			English	Article						neurotrophin; Trk receptor; metalloendoproteases	NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; EXTRACELLULAR DOMAIN; TRUNCATED RECEPTORS; ERBB-4 RECEPTOR; RAT TRKC; IDENTIFICATION; ENCODES; MEMBER; FAMILY	The trkC locus encodes catalytic and noneatalytic receptors, generated by alternative splicing. These primary high-affinity neurotrophin-3 (NT-3) receptors may act in concert to modulate responsiveness to NT-3. Signal modulation can also be achieved by receptors that are post-translationally processed. We report that the noncatalytic TrkC receptor, TrkCNC2, is cleaved at the membrane-proximal region of its extracellular domain. This generates a soluble ectodomain (gp90(TrkCNC2)) recovered in the cell culture medium and a membrane-bound fragment (p20(TrkCNC2)), which contains the transmembrane and intracellular regions including the juxtamembrane and the NC2-specific cytoplasmic domains. We also show that this processing, which does not occur in the TrkC catalytic counterpart, is upregulated by NT-3 and upon treatment with the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. Moreover, cleavage inhibition after EDTA or 1.10 phenanthroline treatment suggests involvement of a metalloprotease(s). Finally, this post-translational processing was observed not only in TrkCNC2-overexpressing NIH3T3 cells but also in primary cultures of cortical neurons and brain extracts. This study shows that, in addition to alternative splicing, ectodomain shedding represents a novel means of regulating TrkC receptor signaling, and consequently NT-3 biological effects on target cells.	Ctr Univ Orsay, Inst Curie, CNRS UMR 146, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Lamballe, F (corresponding author), IBDM, INSERM, U382, Campus Luminy,Case 907, F-13288 Marseille 09, France.	lamballe@ibdm.univ-mrs.fr	Lamballe, Fabienne/P-4293-2017; Lamballe, Fabienne/GLT-0820-2022	Lamballe, Fabienne/0000-0001-7631-942X				BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Benn B, 1998, J COMP NEUROL, V401, P47, DOI 10.1002/(SICI)1096-9861(19981109)401:1<47::AID-CNE4>3.0.CO;2-C; BIFFO S, 1995, DEVELOPMENT, V121, P2461; Butowt R, 2001, J NEUROSCI, V21, P8915, DOI 10.1523/JNEUROSCI.21-22-08915.2001; Cabrera N, 1996, J CELL BIOL, V132, P427, DOI 10.1083/jcb.132.3.427; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DISTEFANO PS, 1993, J NEUROSCI, V13, P2405, DOI 10.1523/JNEUROSCI.13-06-02405.1993; Donovan MJ, 1996, NAT GENET, V14, P210, DOI 10.1038/ng1096-210; Eide FF, 1996, J NEUROSCI, V16, P3123; GARNER AS, 1994, NEURON, V13, P457, DOI 10.1016/0896-6273(94)90360-3; GOTZ R, 1994, NATURE, V372, P266, DOI 10.1038/372266a0; Hapner SJ, 1998, DEV BIOL, V201, P90, DOI 10.1006/dbio.1998.8970; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; LAMBALLE F, 1993, EMBO J, V12, P3083, DOI 10.1002/j.1460-2075.1993.tb05977.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; Menn B, 2000, EUR J NEUROSCI, V12, P3211, DOI 10.1046/j.1460-9568.2000.00215.x; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; Nilsson AS, 1998, FEBS LETT, V424, P285, DOI 10.1016/S0014-5793(98)00192-6; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; PANDIELLAALONSO A, 1986, FEBS LETT, V208, P48, DOI 10.1016/0014-5793(86)81529-0; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YEE NS, 1993, J BIOL CHEM, V268, P14189; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	35	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					740	745		10.1038/sj.onc.1206213	http://dx.doi.org/10.1038/sj.onc.1206213			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569366				2022-12-17	WOS:000180642100011
J	Makris, C; Voisin, L; Giasson, E; Tudan, C; Kaplan, DR; Meloche, S				Makris, C; Voisin, L; Giasson, E; Tudan, C; Kaplan, DR; Meloche, S			The Rb-family protein p107 inhibits translation by a PDK1-dependent mechanism	ONCOGENE			English	Article						p107; cell growth; translation; PDK1; PI 3-kinase signaling	RNA-POLYMERASE-III; PHOSPHOINOSITIDE 3-KINASE; KINASE B; RETINOBLASTOMA PROTEIN; S6 KINASE; TARGET; PHOSPHORYLATION; GROWTH; SIZE; E2F	The Rb family of proteins, which consists of Rb, p107 and p130, are critical regulators of cell proliferation. In addition to their inhibitory effects on cell cycle progression, Rb-family proteins repress transcription by RNA polymerases I and 111, and may therefore restrain cell growth. However, it is not known if Rb, p107 or p130 have direct effects on protein synthesis. Here we report that ectopic expression of p107 in rat fibroblasts markedly attenuates the stimulation of mRNA translation and global protein synthesis by serum growth factors. This effect is associated with a reduction in the phosphorylation and activation of the serine-threonine kinases Akt1 and p70 S6 kinase (S6K1), two downstream targets of phosphoinositide-dependent kinase 1 (PDK1). We show that overexpression of p107 interferes with the recruitment of PDK1 to the plasma membrane in response to growth factors. Overexpression of PDK1 restores the defect in translation elicited by p107. These results suggest that p107 restricts cell growth by interfering with the phosphoinositide 3-kinase (PI3K) signaling pathway.	Univ Montreal, Inst Rech Clin, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; Montreal Neurol Inst, Brain Tumor Res Ctr, Montreal, PQ H3A 3B4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Meloche, S (corresponding author), Univ Montreal, Inst Rech Clin, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.	melochs@ircm.qc.ca						Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Coffer PJ, 1998, BIOCHEM J, V335, P1; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zini N, 2001, J CELL PHYSIOL, V189, P34, DOI 10.1002/jcp.1135	38	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7891	7896		10.1038/sj.onc.1205964	http://dx.doi.org/10.1038/sj.onc.1205964			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420226				2022-12-17	WOS:000178946000014
J	Gao, CF; Ren, S; Wang, JF; Zhang, SL; Jin, F; Nakajima, T; Ikeda, M; Tsuchida, N				Gao, CF; Ren, S; Wang, JF; Zhang, SL; Jin, F; Nakajima, T; Ikeda, M; Tsuchida, N			P130 and its truncated form mediate p53-induced cell cycle arrest in Rb-/- Saos2 cells	ONCOGENE			English	Article						p53; cell cycle arrest; p130; p53 binding sequence; E2F	RETINOBLASTOMA GENE-PRODUCT; GROWTH SUPPRESSION; KINASE INHIBITOR; CARCINOMA CELLS; E2F PROTEINS; TUMOR-CELLS; G(1) ARREST; DNA-DAMAGE; P53 GENES; IN-VIVO	In the present study, we investigate the mechanism of how p53 induces growth arrest in Rb-defective Saos2 cells that express temperature-sensitive mutant p53 (ts p53). The activation of p53 at a permissive temperature (32.5degreesC) induces the cell cycle arrest at both the G1 and G2 stages. The induction of several p53-responsive genes as well as a small form of p130 (S-p130) was detected upon p53 activation. S-p130 retained the functions as a pocket protein and was dominant over p130 at the protein level after 36 h at 32.5degreesC. A canonical p53 binding site was identified in intron 4 of p130. Furthermore, a novel p53-inducible transcript containing a partial intron 4 sequence downstream of the p53 binding site and exon 5 of p 130 was detected by RT - PCR, suggesting S-p 130 is induced by p53 at transcriptional level. The results from gel shift assay and immunoprecipitation showed that S-p130 as well as p130 formed complexes with both E2F1 and E2F4 at a permissive temperature. Moreover, the transient expression of E1A (12S) and E2F1 effectively abrogated p53-induced cell cycle arrest. These results strongly suggested that p130 and its truncated form might substitute Rb in mediating p53-induced cell cycle arrest in Rb-/- Saos2 cells.	Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Mol Craniofacial Embryol, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Tsuchida, N (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Mol Cellular Oncol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chan TA, 2000, GENE DEV, V14, P1584; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Cheng LY, 2000, J BIOL CHEM, V275, P30317, DOI 10.1074/jbc.M005707200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 1996, CANCER RES, V56, P2003; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DYNLACHT BD, 1997, MOL CELL BIOL, V17, P38677; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gao CF, 1999, BIOCHEM BIOPH RES CO, V264, P860, DOI 10.1006/bbrc.1999.1611; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARPER JW, 1993, CELL, V75, P805; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hauser PJ, 1997, J BIOL CHEM, V272, P22954, DOI 10.1074/jbc.272.36.22954; HERMEKING H, 1909, MOL CELL, V1, P3; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; KATO J, 1993, GENE DEV, V7, P333; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Mayol X, 1996, ONCOGENE, V13, P237; MAYOL X, 1995, ONCOGENE, V11, P801; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Robles SJ, 1998, DNA CELL BIOL, V17, P9, DOI 10.1089/dna.1998.17.9; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Stiegler P, 1998, CANCER RES, V58, P5049; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Terada Y, 1997, J AM SOC NEPHROL, V8, P51; Thomas NSB, 1998, J BIOL CHEM, V273, P23659, DOI 10.1074/jbc.273.37.23659; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG NP, 1993, ONCOGENE, V8, P279; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yageta M, 1999, ONCOGENE, V18, P4767, DOI 10.1038/sj.onc.1203063; YAMATO K, 1995, ONCOGENE, V11, P1; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z	70	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7569	7579		10.1038/sj.onc.1205933	http://dx.doi.org/10.1038/sj.onc.1205933			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386819				2022-12-17	WOS:000178618200012
J	Leder, A; Lebel, M; Zhou, F; Fontaine, K; Bishop, A; Leder, P				Leder, A; Lebel, M; Zhou, F; Fontaine, K; Bishop, A; Leder, P			Genetic interaction between the unstable v-Ha-RAS transgene (Tg.AC) and the murine Werner syndrome gene: transgene instability and tumorigenesis	ONCOGENE			English	Article						transgenic mouse; v-Ha-RAS; Werner syndrome; TPA; genome instability	X-CHROMOSOME INACTIVATION; MOUSE SKIN; SYNDROME PROTEIN; DNA HELICASE; MULTISTAGE CARCINOGENESIS; REPEAT HYPOTHESIS; LINE-1 ELEMENTS; MICE; RECOMBINATION; EXONUCLEASE	Tg.AC transgenic mice provide a sensitive assay for oncogenic agents and a convenient alternative to the two-stage initiation/promoter model of skin tumorigenesis. Although extensively used, this model has remained in part an enigma since mice that carry the Tg.AC transgene (consisting of v-Ha-Ras driven by an embryonic zeta-globin promoter) would not ordinarily be expected to develop skin and other adult tumors. Cloning and characterizing the inserted transgene has provided an insight into the Tg.AC phenotype. We find that the transgene is inserted into a Line-1 element in such a way as to create extended inverted repeats consisting of both transgene and Line-1 sequences. Such structures would be expected to contribute to the instability of the Tg.AC locus and we suggest that this instability is critical to the Tg.AC phenotype. Further, we strengthen this notion by introducing an inactivating mutation in the murine Wrn gene (a gene important in maintenance of genome stability) and showing that bigenic Tg.AC/ Wrn(Deltahel/Deltahel) mice experience an eightfold increase in inactivating germline mutations at the Tg.AC locus. Similarly, Tg.AC/ Wrn(Deltahel/Deltahel) mice that retain an intact and thus active Tg.AC locus experience a sharp increase in papillomas as compared to Tg.AC/Wrn(+/+), mice. This work demonstrates a genetic interaction between the instability of the multicopy transgene and the Werner Syndrome gene. From this, we conclude that genetic instability remains a key element in this tumor promoter model.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Univ Laval, Ctr Rech Cancerol, CHUQ, Quebec City, PQ G1R 2J6, Canada	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Laval University	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.			Bishop, Alexander/0000-0002-5742-4387				Akgun E, 1997, MOL CELL BIOL, V17, P5559, DOI 10.1128/MCB.17.9.5559; Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; Berenblum I, 1941, CANCER RES, V1, P807; Bestor TH, 1998, CIBA F SYMP, V214, P187; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Cannon RE, 2000, MOL CARCINOGEN, V29, P229, DOI 10.1002/1098-2744(200012)29:4<229::AID-MC1005>3.0.CO;2-9; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; DIGIOVANNI J, 1993, CARCINOGENESIS, V14, P1831, DOI 10.1093/carcin/14.9.1831; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Dunson DB, 2000, TOXICOL SCI, V55, P293, DOI 10.1093/toxsci/55.2.293; Eastin WC, 1998, TOXICOL PATHOL, V26, P461, DOI 10.1177/019262339802600401; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FUKUCHI K, 1990, HUM GENET, V84, P249; Gordenin DA, 1998, MUTAT RES-FUND MOL M, V400, P45, DOI 10.1016/S0027-5107(98)00047-5; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Gulezian D, 2000, TOXICOL PATHOL, V28, P482, DOI 10.1177/019262330002800320; Hansen LA, 1996, CARCINOGENESIS, V17, P1825, DOI 10.1093/carcin/17.9.1825; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; Honchel R, 2001, MOL CARCINOGEN, V30, P99, DOI 10.1002/1098-2744(200102)30:2<99::AID-MC1018>3.3.CO;2-Z; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Humble MC, 2000, GENOMICS, V70, P292, DOI 10.1006/geno.2000.6384; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lebel M, 2002, CARCINOGENESIS, V23, P213, DOI 10.1093/carcin/23.1.213; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Leder A, 1997, BLOOD, V90, P1275, DOI 10.1182/blood.V90.3.1275.1275_1275_1282; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Lyon MF, 2000, P NATL ACAD SCI USA, V97, P6248, DOI 10.1073/pnas.97.12.6248; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; MARASCHIO P, 1986, CLIN GENET, V30, P353; MELARAGNO MI, 1995, MECH AGEING DEV, V78, P117, DOI 10.1016/0047-6374(94)01530-Y; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ostertag EM, 2001, GENOME RES, V11, P2059, DOI 10.1101/gr.205701; OWENS DM, 1995, CANCER RES, V55, P3171; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Thompson KL, 2001, MOL CARCINOGEN, V32, P176, DOI 10.1002/mc.10009; Waldman AS, 1999, GENETICS, V153, P1873; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	56	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6657	6668		10.1038/sj.onc.1205795	http://dx.doi.org/10.1038/sj.onc.1205795			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242664				2022-12-17	WOS:000178202300012
J	Day, RM; Soon, L; Breckenridge, D; Bridges, B; Patel, BKR; Wang, LM; Corey, SJ; Bottaro, DP				Day, RM; Soon, L; Breckenridge, D; Bridges, B; Patel, BKR; Wang, LM; Corey, SJ; Bottaro, DP			Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways	ONCOGENE			English	Article						growth factor; cytokine; signal transduction; cell proliferation	FACTOR SCATTER FACTOR; C-MET; TYROSINE KINASE; FACTOR ISOFORMS; FACTOR-RECEPTOR; MAP KINASE; CELLS; TRANSDUCTION; ACTIVATION; HGF/SF	Hepatocyte growth factor (HGF) regulates various physiological and developmental processes in concerti with other growth factors, cytokines and hormones. We examined interactions between cell signaling events elicited by HGF and the cytokine interleukin (IL)-4, in the IL-3-dependent murine myeloid cell line 32D transfected with the human HGF receptor, c-Met. HGF was a potent mitogen in these cells, and prevented apoptosis in response to IL-3 withdrawal. IL-4 showed modest anti-apoptotic activity, but no significant mitogenic activity. IL-4 synergistically enhanced HGF-stimulated DNA synthesis, whereas only additive prevention of apoptosis was observed. IL-4 did not enhance HGF-dependent tyrosine phosphorylation of c-Met or She. In contrast, HGF-stimulated activation of MAP kinases was enhanced by IL-4, suggesting that the IL-4 and HGF signaling pathways converge upstream of these events. Although phosphatidylinositol 3-kinase (PI3K) inhibitors diminished HGF-induced mitogenesis, antiapoptosis, and MAP kinase activation, IL-4 enhanced HGF signaling persisted even in the presence of these inhibitors. IL-4 enhancement of HGF signaling was partially blocked in 32D/c-Met cells treated with inhibitors of MEK1 or c-Src kinases, completely blocked by expression of a catalytically inactive mutant of Janus kinase 3 (Jak3), and increased in 32D/c,Met cells overexpressing STAT6. Our results suggest that the IL-4 and HGF pathways converge at multiple levels, and that IL-4-dependent Jak3 and STAT6 activities modulate signaling events independent of PI3K to enhance, HGF-dependent mitogenesis in myeloid cells, and possibly other common cellular targets.	NCI, Cellular & Mol Biol Lab, Div Basic Sci, Natl Inst Hlth, Bethesda, MD USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bottaro, DP (corresponding author), EntreMed Inc, Dept Cell & Mol Biol, Rockville, MD 20850 USA.	donb@entremed.com	Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				ADAMS DH, 1994, P NATL ACAD SCI USA, V91, P7144, DOI 10.1073/pnas.91.15.7144; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Balkovetz DF, 1999, INT REV CYTOL, V186, P225; BARDELLI A, 1992, ONCOGENE, V7, P1973; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/0968-0004(96)10033-5; Borset M, 1999, LEUKEMIA LYMPHOMA, V32, P249, DOI 10.3109/10428199909167385; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Day RM, 1999, ONCOGENE, V18, P3399, DOI 10.1038/sj.onc.1202683; DELANEY B, 1993, LIFE SCI, V53, pPL89, DOI 10.1016/0024-3205(93)90654-L; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GOHDA E, 1995, LEUKEMIA LYMPHOMA, V19, P197; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hassuneh MR, 1997, BLOOD, V89, P610, DOI 10.1182/blood.V89.2.610; HOON DSB, 1991, CANCER RES, V51, P5687; Iguchi T, 1999, STEM CELLS, V17, P82, DOI 10.1002/stem.170082; Ikehara S, 1996, LEUKEMIA LYMPHOMA, V23, P297, DOI 10.3109/10428199609054832; IKIZAWA K, 1994, J ALLERGY CLIN IMMUN, V94, P620, DOI 10.1016/0091-6749(94)90138-4; Kaplan MH, 1998, MOL CELL BIOL, V18, P1996, DOI 10.1128/MCB.18.4.1996; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KMIECIK TE, 1992, BLOOD, V80, P2454; Machide M, 1998, J NEUROCHEM, V71, P592; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Montesano R, 1998, CELL GROWTH DIFFER, V9, P355; MORISAKI T, 1992, CANCER RES, V52, P6059; MORISAKI T, 1994, CANCER RES, V54, P1113; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; PAUL WE, 1991, BLOOD, V77, P1859; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Rahimi N, 1996, J BIOL CHEM, V271, P24850, DOI 10.1074/jbc.271.40.24850; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sakata H, 1997, J BIOL CHEM, V272, P9457; Schaper F, 1997, FEBS LETT, V405, P99, DOI 10.1016/S0014-5793(97)00167-1; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SOON L, 1999, MOL CELL BIOL, V38, P16; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Streit ACE, 1997, CIBA F SYMP, V212, P155; Sunitha I, 1999, EXP CELL RES, V250, P86, DOI 10.1006/excr.1999.4550; TORIGOE T, 1992, BLOOD, V80, P617; Uchiyama A, 1996, J CELL BIOCHEM, V62, P443, DOI 10.1002/(SICI)1097-4644(19960915)62:4<443::AID-JCB2>3.3.CO;2-H; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; vanDijk MCM, 1997, BIOCHEM J, V323, P693, DOI 10.1042/bj3230693; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; Weimar IS, 1998, EXP HEMATOL, V26, P885; Weimar IS, 1997, BLOOD, V89, P990, DOI 10.1182/blood.V89.3.990; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YANAGITA K, 1993, J BIOL CHEM, V268, P21212; Yashiro M, 1996, INT J CANCER, V67, P289, DOI 10.1002/(SICI)1097-0215(19960717)67:2<289::AID-IJC22>3.0.CO;2-5; Yu CZ, 1998, STEM CELLS, V16, P66, DOI 10.1002/stem.160066; Zamorano J, 1996, J IMMUNOL, V157, P4926; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	61	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2201	2211		10.1038/sj.onc.1205289	http://dx.doi.org/10.1038/sj.onc.1205289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948403				2022-12-17	WOS:000174555300009
J	Aouacheria, A; Ory, S; Schmitt, JR; Rigal, D; Jurdic, P; Gillet, G				Aouacheria, A; Ory, S; Schmitt, JR; Rigal, D; Jurdic, P; Gillet, G			p60(v-src) and serum control cell shape and apoptosis via distinct pathways in quail neuroretina cells	ONCOGENE			English	Article						v-src; cytoskeleton; apoptosis; MAP kinases; G-proteins; retina	FOCAL ADHESION KINASE; PP60C-SRC PROTEIN-KINASE; SRC TYROSINE KINASE; V-SRC; SUBSTRATUM ADHESIONS; SIGNALING PATHWAYS; TRANSFORMATION; RAS; ACTIVATION; RHO	We made use of QNR cells transformed by a thermosensitive (tsNY68) strain of the Rous sarcoma virus (RSV) to compare the effect of p60(v-src) and serum in cultured nerve cells. In this system, both p60(v-src) heat inactivation and serum removal resulted in growth arrest in G1. In both cases, growth arrest was reversible since cell proliferation was rapidly re-induced following respectively p60v-src renaturation or serum re-addition. However, cells did not fully recover their ability to grow in soft agar, suggesting that, in contrast to the cell cycle machinery, the transforming capacities of these cells have been irreversibly altered. We found that p60(v-src) kinase activity prevented detachment from the substratum and cell death following serum removal. Thermal inactivation of p60(v-src) at restrictive temperature (41.5degreesC), but not serum removal, resulted in dramatic morphological changes, which occured 4 h after temperature shift up to 41.5degreesC. Later on, typical features of apoptotic cells could be observed. Cell death was greatly reduced by the caspase-3 inhibitor ZVAD.FMK, but not by the caspase-1 inhibitor Ac-YVAD.CHO. Together, these results suggested that p60(v-src) and serum factors act on distinct pathways, at least in part. In an attempt to identify the signalling pathways involved in the cell response to p60(v-src) down regulation, we found that Erk and Rac were rapidly inactivated following temperature shift up to 41.5degreesC. Thus, the combined effects of p60(v-src) and serum factors on the cytoskeleton dynamics and the apoptosis machinery are essential for full neoplastic transformation of neuroretina cells.	Univ Lyon 1, CNRS, UMR 5086, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Ecole Normale Super Lyon, UMR 5665, Biol Cellulaire & Mol Lab, CNRS, F-69364 Lyon 07, France; Etab Transfus Sanguine, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Gillet, G (corresponding author), NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA.	g.gillet@ibcp.fr	Ory, Stéphane/G-9714-2019; gillet, germain/A-9095-2013; Ory, Stéphane/E-9947-2010	Ory, Stéphane/0000-0003-4359-1157; Ory, Stéphane/0000-0003-4359-1157; GILLET, Germain/0000-0002-1514-327X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Armstrong RC, 1997, J NEUROSCI, V17, P553; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; Carragher NO, 2001, J BIOL CHEM, V276, P4270, DOI 10.1074/jbc.M008972200; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Castellani L, 1996, J CELL SCI, V109, P1335; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; CHENG HC, 1992, J BIOL CHEM, V267, P9248; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; CRISANTICOMBES P, 1982, CELL DIFFER DEV, V11, P45, DOI 10.1016/0045-6039(82)90016-1; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVAZZI I, 1989, J CELL SCI, V94, P85; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; Gillet G, 1996, TRENDS MICROBIOL, V4, P312, DOI 10.1016/0966-842X(96)10047-0; GILLET G, 1993, ONCOGENE, V8, P565; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Meijne AML, 1997, EXP CELL RES, V234, P477, DOI 10.1006/excr.1997.3637; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Ory S, 2000, J CELL SCI, V113, P1177; PATCH LA, 1995, J CELL SCI, V108, P1371; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POIRIER F, 1982, J VIROL, V42, P780, DOI 10.1128/JVI.42.3.780-789.1982; Polte TR, 1997, J BIOL CHEM, V272, P5501, DOI 10.1074/jbc.272.9.5501; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Routes JM, 2000, J IMMUNOL, V165, P4522, DOI 10.4049/jimmunol.165.8.4522; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUDOL M, 1993, MOL BASIS HUMAN CANC, P203; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Webb BL, 2000, MOL CELL BIOL, V20, P9271, DOI 10.1128/MCB.20.24.9271-9280.2000; WU LW, 1995, ONCOGENE, V11, P1459; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	66	9	9	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1171	1186		10.1038/sj.onc.1205170	http://dx.doi.org/10.1038/sj.onc.1205170			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850837				2022-12-17	WOS:000173729400005
J	Deng, J; Zhang, HF; Kloosterboer, F; Liao, Y; Klostergaard, J; Levitt, ML; Hung, MC				Deng, J; Zhang, HF; Kloosterboer, F; Liao, Y; Klostergaard, J; Levitt, ML; Hung, MC			Ceramide does not act as a general second messenger for ultraviolet-induced apoptosis	ONCOGENE			English	Article						apoptosis; UV; second messenger; ceramide; E1A	STRESS-INDUCED APOPTOSIS; TUMOR-NECROSIS-FACTOR; IONIZING-RADIATION; CELL-DEATH; E1A; SPHINGOMYELIN; ACTIVATION; PRODUCT; PATHWAY; PROTEIN	Ceramide has been proposed as a second messenger for stress-induced apoptosis. By characterization of murine melanoma cells and their E1A transfectants, we found several tines of evidences against the role of ceramide as a second messenger for ultraviolet (UV)-induced apoptosis. First, although E1A transfected melanoma cells were more sensitive to UV-induced apoptosis than parental cells, the relative endogenous ceramide elevation induced by UV was greater in parental cells than in EI A transfectants. Second, UV-resistant melanoma cells were more sensitive to exogenous ceramide than UV-sensitive EIA transfectants. The differential responses to UV and ceramide by E1A require the same functional CR2 domain of E1A. Third, unlike the action of UV, transient exposure (up to 2 h) of lethal dose of ceramide was not sufficient to cause apoptosis in these cells, and persistent presence of ceramide was required for processing the apoptotic process. Finally, ceramide and UV do not share a common pathway in apoptosis induction. UV-induced apoptosis was blocked by interleukin-1 beta -converting enzyme (ICE) inhibitor z-VAD whereas ceramide-induced apoptosis was not. Therefore, we conclude that ceramide is not a general second messenger for UV-induced apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Allegheny Univ Hlth Sci, Lung Canc Program, Pittsburgh, PA 15212 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA058880, R01CA077858] Funding Source: NIH RePORTER; NCI NIH HHS [CA77858, R01 CA58880, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng AC, 1996, BIOPHYS J, V70, P2212, DOI 10.1016/S0006-3495(96)79787-4; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HUS SC, 1998, BLOOD, V91, P2658; Karasavvas N, 1999, CELL DEATH DIFFER, V6, P115, DOI 10.1038/sj.cdd.4400482; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KOLESNICK RN, 1994, BIOCHEM CELL BIOL, V72, P471, DOI 10.1139/o94-063; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; McConkey DJ, 1996, ONCOGENE, V13, P1693; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Pena LA, 1997, BIOCHEM PHARMACOL, V53, P615, DOI 10.1016/S0006-2952(96)00834-9; PIERCEALL WE, 1992, CANCER RES, V52, P3946; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Sillence DJ, 1997, BIOCHEM J, V324, P29, DOI 10.1042/bj3240029; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	34	9	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					44	52		10.1038/sj.onc.1204900	http://dx.doi.org/10.1038/sj.onc.1204900			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791175	Bronze			2022-12-17	WOS:000172887800005
J	Li, C; Ahlborn, TE; Tokita, K; Boxer, LM; Noda, A; Liu, JW				Li, C; Ahlborn, TE; Tokita, K; Boxer, LM; Noda, A; Liu, JW			The critical role of the PE21 element in oncostatin M-mediated transcriptional repression of the p53 tumor suppressor gene in breast cancer cells	ONCOGENE			English	Article						p53 tumor suppressor gene; transcriptional regulation; oncostatin M	NF-KAPPA-B; DOWN-REGULATION; SP1 SITES; NF1-LIKE PROTEIN; DNA-REPAIR; PROMOTER; EXPRESSION; ACTIVATION; GROWTH; IDENTIFICATION	Cytokine oncostatin M (OM) exerts growth-inhibitory and differentiative effects on breast cancer cells. Previously we showed that the transcription from the p53 gene in breast cancer cells was down regulated by OM. To elucidate the molecular mechanisms underlying the OM effect on p53 transcription, in this study, we dissected the p53 promoter region and analysed the p53 promoter activity in breast tumor cells. We showed that treatment of MCF-7 cells with OM induced a dose- and time-dependent suppression of p53 promoter activity. The p53 promoter activity was decreased to 35% of control at 24 h and further decreased to 20% at 48 h by OM at concentrations of 5 ng/ml and higher. Deletion of the F-flanking region of the p53 promoter from -426 to -97 did not affect the OM effect. However, further deletion to -40 completely abolished the repressive effect of OM. The p53 promoter region -96 to -41 contains NF-kappaB and c-myc binding sites, and a newly identified UV-inducible element PE21. Mutations to disrupt NF-KB binding or c-myc binding to the p53 promoter decreased the basal promoter activity without affecting the OM-mediated suppression, whereas mutation at the PE21 motif totally abolished the OM effect. We further demonstrated that insertion of PE21 element upstream of the thymidine kinase minimal promoter generated an OM response analogous to that of the p53 promoter. Finally, we detected the specific binding of a nuclear protein with a molecular mass of 87 kDa to the PE21 motif. Taken together, we demonstrate that OM inhibits the transcription of the p53 gene through the PE21 element. Thus, the PE21 element is functionally involved in p53 transcription regulated by UV-induction and OM suppression.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamigyo Ku, Kyoto 6028566, Japan; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, Kobe, Hyogo 6500017, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Kyoto Prefectural University of Medicine; Stanford University; Kobe University	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.			Noda, Asao/0000-0002-9029-9813	NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balint E, 1996, CANCER RES, V56, P1648; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; BRIGGS J, 1996, J BIOL CHEM, V271, P901; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; ESTROV Z, 1995, J INTERF CYTOK RES, V15, P905, DOI 10.1089/jir.1995.15.905; Hirose Y, 2001, CANCER RES, V61, P1957; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jeffy BD, 2000, NEOPLASIA, V2, P460, DOI 10.1038/sj.neo.7900104; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Lee M, 1999, BIOCHEM CELL BIOL, V77, P209, DOI 10.1139/bcb-77-3-209; Lee MY, 1998, BIOL CHEM, V379, P1333, DOI 10.1515/bchm.1998.379.11.1333; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Liu HF, 1999, WORLD J GASTROENTERO, V5, P15; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nayak BK, 1999, MOL BIOL REP, V26, P223, DOI 10.1023/A:1007006011253; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Phan SC, 1996, MOL CELL BIOL, V16, P2387; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; SOINI Y, 1992, VIRCHOWS ARCH A, V421, P415, DOI 10.1007/BF01606914; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Spence MJ, 1997, CANCER RES, V57, P2223; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Uberti D, 2000, AMINO ACIDS, V19, P253, DOI 10.1007/s007260070056; Wang JP, 2000, MOL CARCINOGEN, V29, P179, DOI 10.1002/1098-2744(200011)29:3<179::AID-MC7>3.0.CO;2-K; Wang XQ, 2001, CANCER RES, V61, P1598; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; Zeng XY, 2000, CANCER RES, V60, P6184; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215	43	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8193	8202		10.1038/sj.onc.1205046	http://dx.doi.org/10.1038/sj.onc.1205046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781835				2022-12-17	WOS:000172507800004
J	Wert, M; Kennedy, S; Palfrey, HC; Hay, N				Wert, M; Kennedy, S; Palfrey, HC; Hay, N			Myc drives apoptosis in PC12 cells in the absence of Max	ONCOGENE			English	Article						c-Myc; apoptosis; growth factors; Akt	NERVE GROWTH-FACTOR; C-MYC; MEDIATED APOPTOSIS; CYCLE PROGRESSION; DIFFERENTIATION; TRANSCRIPTION; FIBROBLASTS; PROTEIN; DIMERIZATION; MECHANISMS	A conditionally active chimeric form of the c-Myc protein fused to the ligand-binding domain of the estrogen receptor (MycER) was expressed in PC12 cells, Induction of Myc activity resulted in a threefold increase in apoptosis after 5 days when cells were maintained in 1% serum, The effect of Myc overexpression was dependent on its DNA-binding domain but not on its heterodimeric binding protein Max, which is absent in PC12 cells, Preincubation of the c-Myc overexpressing cells with either NGF or bFGF, but not EGF, prevented the Myc-mediated increase in apoptosis, although the signaling pathways used by NGF and bFGF to block cell death differed, NGF-mediated rescue was mediated by the phosphatidylinositol 3 ' -OH (P13) kinase/Akt pathway white rescue by bFGF was not affected by P13 kinase inhibitors, These results show that Myc can induce apoptosis in PC12 cells in a Max-independent manner and that alternate signaling pathways exist to mediate cell survival.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Hay, N (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Kennedy, Scott/0000-0002-7974-8155	NCI NIH HHS [CA71874] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Bao JX, 1996, ONCOGENE, V12, P2171; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Crowder RJ, 1998, J NEUROSCI, V18, P2933; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; MARUYAMA K, 1987, ONCOGENE, V1, P361; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RIBON V, 1994, MOL CELL NEUROSCI, V5, P277, DOI 10.1006/mcne.1994.1032; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SPANDIDOS DA, 1989, INT J DEV NEUROSCI, V7, P1, DOI 10.1016/0736-5748(89)90039-7; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Wert MM, 2000, BIOCHEM J, V352, P175, DOI 10.1042/0264-6021:3520175; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	27	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3746	3750		10.1038/sj.onc.1204466	http://dx.doi.org/10.1038/sj.onc.1204466			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439337				2022-12-17	WOS:000169400200015
J	Nielsen, KH; Gredsted, L; Broach, JR; Willumsen, BM				Nielsen, KH; Gredsted, L; Broach, JR; Willumsen, BM			Sensitivity of wild type and mutant ras alleles to Ras specific exchange factors: Identification of factor specific requirements	ONCOGENE			English	Article						Ras exchange; Ras V103E; Sos1; GRF; GRP; S. cerevisiae	MURINE SARCOMA-VIRUS; NUCLEOTIDE-RELEASING FACTOR; SACCHAROMYCES-CEREVISIAE CDC25; GTPASE ACTIVATING PROTEIN; P21 TRANSFORMING PROTEIN; MOLECULAR-CLONING; MAMMALIAN RAS; R-RAS; N-RAS; FUNCTIONAL INTERACTION	We have investigated the productive interaction between the four mammalian Ras proteins (H-, N-, KA- and KB-Ras) and their activators, the mammalian exchange factors mSos1, GRF1 and GRP, by using a modified Saccharomyces cerevisiae whose growth is dependent on activation of a mammalian Ras protein by its activator. All four mammalian Ras proteins were activated with similar efficiencies by the individual exchange factors. The H-Ras mutant V103E, which is competent for membrane localization, nucleotide binding, intrinsic and stimulated GTPase activity as well as intrinsic exchange, was defective for activation by all factors tested, suggesting that the integrity of this residue is necessary for catalyzed exchange. However, when other H-Ras mutants were studied, some distinct sensitivities to the exchange factors were observed. GRP-mediated, but not mSos1-mediated, exchange was blocked in additional mutants, suggesting different structural requirements for GRP, Analysis of Ras-mediated gene activation in murine fibroblasts confirmed these results.	Univ Copenhagen, Dept Mol Cell Biol, DK-1353 Copenhagen, Denmark; Princeton Univ, Lewis Thomas Lab 303, Princeton, NJ 08544 USA	University of Copenhagen; Princeton University	Willumsen, BM (corresponding author), Univ Copenhagen, Dept Mol Cell Biol, Oester Farimagsgade 2A, DK-1353 Copenhagen, Denmark.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Broach, James/0000-0003-1197-0312	NCI NIH HHS [CA41086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA041086] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COX AD, 1994, ONCOGENE, V9, P3281; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DEVENDITTIS E, 1986, EMBO J, V5, P3657, DOI 10.1002/j.1460-2075.1986.tb04696.x; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOWE LR, 1993, ONCOGENE, V8, P2583; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leonardsen L, 1996, ONCOGENE, V13, P2177; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Moreira JMA, 1998, EMBO J, V17, P6028, DOI 10.1093/emboj/17.20.6028; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; Nielsen KH, 1997, MOL CELL BIOL, V17, P7132, DOI 10.1128/MCB.17.12.7132; ORITA S, 1993, J BIOL CHEM, V268, P25542; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PILZ RB, 1984, J BIOL CHEM, V259, P2927; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROSE MD, 1990, METHODS YEAST GENETI; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1992, J BIOL CHEM, V267, P22747; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TATCHELL K, 1986, J BACTERIOL, V166, P364, DOI 10.1128/jb.166.2.364-367.1986; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269	61	9	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2091	2100		10.1038/sj.onc.1204306	http://dx.doi.org/10.1038/sj.onc.1204306			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360193	Bronze			2022-12-17	WOS:000168116700004
J	Weggen, S; Preuss, U; Pietsch, T; Hilger, N; Klawitz, I; Scheidtmann, KH; Wiestler, OD; Bayer, TA				Weggen, S; Preuss, U; Pietsch, T; Hilger, N; Klawitz, I; Scheidtmann, KH; Wiestler, OD; Bayer, TA			Identification of amplified genes from SV40 large T antigen-induced rat PNET cell lines by subtractive cDNA analysis and radiation hybrid mapping	ONCOGENE			English	Article						SV40 large T antigen; amplification; suppression subtractive hybridization; radiation hybrid mapping; cytosolic branched chain aminotransferase	PRIMITIVE NEUROECTODERMAL TUMORS; C-MYC; BINDING; IMMORTALIZATION; TUMORIGENESIS; EXPRESSION; MODELS; MAPS; UNR	Primitive neuroectodermal tumors (PNETs) such as human medulloblastomas are genetically heterogeneous and therefore poorly understood, In a rat model the SV40 large T antigen was used to induce neoplasms with characteristic features of PNETs, Tumor development requires a latency period of 8-11 months implicating secondary genetic alterations. To identify such secondary alterations we performed comparative analyses of two phenotypically identical PNET-derived eel lines. Indeed, these cell Lines displayed distinct high-level amplification sites. Using a combination of subtractive cDNA analysis and radiation hybrid mapping we have now identified genes in the amplicon regions of the two cell lines. Interestingly, one of these genes encodes the rat homolog of a cytosolic branched chain aminotransferase (BCAT(C)) previously shown to be amplified in a mouse teratocarcinoma cell line. We propose that this simple cloning strategy may serve as a powerful tool for the isolation of genes implicated in known chromosomal aberrations in primary tumors and tumor cell lines.	Univ Bonn, Genet Inst, D-53117 Bonn, Germany; Univ Bonn, Inst Psychol, D-53117 Bonn, Germany; Univ Bonn, Med Ctr, Dept Psychiat, D-53105 Bonn, Germany; Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany	University of Bonn; University of Bonn; University of Bonn; University of Bonn	Preuss, U (corresponding author), Univ Bonn, Genet Inst, Roemerstr 164, D-53117 Bonn, Germany.							Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; Bayer TA, 1999, ACTA NEUROPATHOL, V97, P607, DOI 10.1007/s004010051036; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BenYosef T, 1996, ONCOGENE, V13, P1859; BOEHNKE M, 1991, AM J HUM GENET, V49, P1174; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; DESTOPPELAAR JM, 1994, CYTOGENET CELL GENET, V67, P23, DOI 10.1159/000133718; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; EIBL RH, 1994, AM J PATHOL, V144, P556; Ferrer N, 1999, DNA CELL BIOL, V18, P209, DOI 10.1089/104454999315420; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; FUNG KM, 1995, J NEUROPATH EXP NEUR, V54, P285, DOI 10.1097/00005072-199505000-00001; Furth PA, 1998, DEV BIOL STAND, V94, P281; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HALL TR, 1993, J BIOL CHEM, V268, P3092; HELD WA, 1994, CANCER RES, V54, P6489; HELD WA, 1994, CANCER RES, V54, P6496; Hutson SM, 1995, J BIOL CHEM, V270, P30344, DOI 10.1074/jbc.270.51.30344; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; Kappler R, 1999, CARCINOGENESIS, V20, P1433, DOI 10.1093/carcin/20.8.1433; Kholodilov NG, 2000, MOL BRAIN RES, V75, P281, DOI 10.1016/S0169-328X(99)00318-6; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; MORIYAMA T, 1994, FEBS LETT, V353, P305, DOI 10.1016/0014-5793(94)01064-1; NIWA O, 1990, NUCLEIC ACIDS RES, V18, P6709, DOI 10.1093/nar/18.22.6709; Salewski H, 1999, CANCER RES, V59, P1980; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sargent LM, 1997, CANCER RES, V57, P3451; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Steen RG, 1999, GENOME RES, V9, pAP1; Weggen S, 1997, BRAIN PATHOL, V7, P731, DOI 10.1111/j.1750-3639.1997.tb01059.x	33	9	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2023	2031		10.1038/sj.onc.1204287	http://dx.doi.org/10.1038/sj.onc.1204287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360186				2022-12-17	WOS:000168043800010
J	Horstmann, S; Ferrari, S; Klempnauer, KH				Horstmann, S; Ferrari, S; Klempnauer, KH			An alternatively spliced isoform of B-Myb is a transcriptional inhibitor	ONCOGENE			English	Article						B-myb; cyclin; transactivation; cycle	CELL-CYCLE REGULATION; C-MYB; V-MYB; A-MYB; MESSENGER-RNA; PROTEIN TRUNCATION; MIM-1 GENE; S-PHASE; ACTIVATION; EXPRESSION	B-Myb is a highly conserved member of the Myb transcription factor family. The primary transcript of the B-myb gene is spliced alternatively in two mRNAs which either contain or lack a sequence corresponding to the so-called exon 9A of c-myb, Recent studies showed that full-length B-Myb containing the exon 9A encoded amino acids is a cell cycle regulated transcription factor whose activity is stimulated by cyclin A/Cdk 2-dependent phosphorylation at the carboxyl-terminus of B-Myb. We have now investigated in more detail the transactivation potential of the shorter isoform of B-Myb lacking exon 9A, Here, we show that B-Myb lacking exon 9A has no transactivation activity even in the presence of cyclin A. This inactivity of the shorter isoform of B-Myb is not due an improper subcelluar localization, Our work suggests that B-Myb lacking exon 9A may act as an inhibitor for full-length B-Myb mediated transactivation, Furthermore, by analysing the transactivation potential of Gal4/B-Myb fusion proteins we have identified the amino-terminal part of the exon 9A as the principal transactivation domain of full-length B-Myb, The results presented here demonstrate that B-myb encodes both an activator and an inhibitor of transcription and, thus, reveal an additional level of regulation of B-Myb activity beside the known cyclin dependent mechanisms.	Univ Munster, Inst Biochem, D-48149 Munster, Germany; Novartis Pharma AG, Dept Oncol, CH-4057 Basel, Switzerland	University of Munster; Novartis	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.		Ferrari, Stefano/I-7357-2016; Buchinger, Sebastian/M-3003-2013	Ferrari, Stefano/0000-0002-6607-215X; Buchinger, Sebastian/0000-0003-4859-8972				Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU YL, 1991, ONCOGENE, V6, P1549; Kamano H, 1995, ONCOGENE, V11, P2575; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Latchman DS, 1996, PHILOS T R SOC B, V351, P511, DOI 10.1098/rstb.1996.0049; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; METTUS RV, 1994, ONCOGENE, V9, P3077; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Robinson C, 1996, ONCOGENE, V12, P1855; ROSSON D, 1987, ANN NY ACAD SCI, V511, P219, DOI 10.1111/j.1749-6632.1987.tb36250.x; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Saville MK, 1998, ADV CANCER RES, V72, P109; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; Sitzmann J, 1996, ONCOGENE, V12, P1889; Tanabe M, 1999, J BIOL CHEM, V274, P27845, DOI 10.1074/jbc.274.39.27845; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Woo CH, 1998, J VIROL, V72, P6813, DOI 10.1128/JVI.72.8.6813-6821.1998; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	50	9	9	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2000	19	48					5428	5434		10.1038/sj.onc.1203937	http://dx.doi.org/10.1038/sj.onc.1203937			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114719				2022-12-17	WOS:000165396100002
J	Klein, MA; Ruedi, D; Nozaki, M; Dell, EW; Diserens, AC; Seelentag, W; Janzer, RC; Aguzzi, A; Hegi, ME				Klein, MA; Ruedi, D; Nozaki, M; Dell, EW; Diserens, AC; Seelentag, W; Janzer, RC; Aguzzi, A; Hegi, ME			Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant	ONCOGENE			English	Article						p53 germline mutation; transdominance; gain-of-function; turner penetrance; mouse brain tumor model	EPIDERMAL GROWTH-FACTOR; LI-FRAUMENI-SYNDROME; SRC TRANSGENIC MICE; MALIGNANT PROGRESSION; GERMLINE MUTATIONS; SUPPRESSOR GENE; FACTOR RECEPTOR; EGF RECEPTOR; FACTOR-ALPHA; V-SRC	p53-germline mutations located in the core DNA-binding domain have been associated with a more dominant tumor penetrance especially for breast cancer and brain tumors. We previously reported an unusual accumulation of CNS turners associated with a unique p53 germline mutation, Y236 Delta (deletion of codon 236). To test whether this tissue-specific tumor predisposition reflects a gain-of-function activity of Y236 Delta, we generated transgenic mice expressing Y236 Delta in astrocytes using the regulatory elements of the glial fibrillary acidic protein (G-FAP) gene. After transplacental exposure to N-ethyl-N-nitrosourea (25mg/kg BW) brain tumors developed in 18% (7/39) of GFAP-Y236 Delta transgenic p53(+/-) mice, while in p53(+/-) mice the incidence was 28% (11/40) (P > 0.3). However, the mean tumor latency for GFAP-Y236 Delta /p53(+/-) mice was significantly shorter than for p53(+/-) mice, with 19.9 weeks vs 31.6 weeks (P = 0.039), respectively. Taken together, cell specific expression of Y236 Delta results in an acceleration of tumor progression but does not confer a higher tumor penetrance. Conceivably, the transdominant effect of Y236 Delta provided a growth advantage early in the progression of neoplastic cells, since the endogenous p53 wild-type allele was lost in all brain tumors independent of the genotype. This reflects well observations from human astrocytic neoplasms with p53 mutations.	Univ Zurich Hosp, Inst Neuropathol, CH-8091 Zurich, Switzerland; Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Univ Hosp, Inst Pathol, CH-1011 Lausanne, Switzerland; Univ Hosp, Div Neuropathol, CH-1011 Lausanne, Switzerland	University of Zurich; University Zurich Hospital; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Hegi, ME (corresponding author), CHU Vaudois, Dept Neurosurg, Lab Tumor Biol & Genet, BH19-110, CH-1011 Lausanne, Switzerland.		Hegi, Monika/O-4796-2015; Aguzzi, Adriano/A-3351-2008	Hegi, Monika/0000-0003-0855-6495; Aguzzi, Adriano/0000-0002-0344-6708				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Chene P, 1999, INT J CANCER, V82, P17, DOI 10.1002/(SICI)1097-0215(19990702)82:1<17::AID-IJC4>3.0.CO;2-6; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENLINGER RH, 1974, INT J CANCER, V13, P559, DOI 10.1002/ijc.2910130416; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FORRESTER K, 1995, ONCOGENE, V10, P2103; FRASER H, 1971, J PATHOL, V103, P266, DOI 10.1002/path.1711030410; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GROOT PC, 1992, FASEB J, V6, P2826, DOI 10.1096/fasebj.6.10.1634045; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hegi ME, 2000, CANCER RES, V60, P3019; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Hermanson M, 1996, CANCER RES, V56, P164; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Ichimura K, 1996, ONCOGENE, V13, P1065; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; Kleihues P, 1997, AM J PATHOL, V150, P1; Kleihues P, 2000, PATHOLOGY GENETICS T; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1988, CANCER RES, V48, P5358; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; LUBBE J, 1995, BRAIN PATHOL, V5, P15, DOI 10.1111/j.1750-3639.1995.tb00572.x; LUONGO C, 1994, CANCER RES, V54, P5947; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marino S, 2000, GENE DEV, V14, P994; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; MUCKE L, 1991, NEW BIOL, V3, P465; Oda H, 1997, CANCER RES, V57, P646; Patel AC, 2000, CARCINOGENESIS, V21, P1691, DOI 10.1093/carcin/21.9.1691; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; Rosenberg JE, 1996, ONCOGENE, V13, P2483; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TIMME TL, 1994, BIOTECHNIQUES, V17, P461; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; VONDEIMLING A, 1992, CANCER RES, V52, P2897; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weissenberger J, 1997, ONCOGENE, V14, P2005, DOI 10.1038/sj.onc.1201168; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	55	9	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 9	2000	19	47					5329	5337		10.1038/sj.onc.1203941	http://dx.doi.org/10.1038/sj.onc.1203941			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103934				2022-12-17	WOS:000165302300004
J	Lagarkova, MA; Boitchenko, VE; Mescheryakov, AA; Kashkarova, UA; Nedospasov, SA				Lagarkova, MA; Boitchenko, VE; Mescheryakov, AA; Kashkarova, UA; Nedospasov, SA			Human cortactin as putative cancer antigen	ONCOGENE			English	Article						breast cancer; cortactin; cancer antigen; tumor marker	CHROMOSOME 11Q13 AMPLIFICATION; CYCLIN D1; EMS1 GENE; TUMOR-ANTIGENS; POOR-PROGNOSIS; BREAST-CANCER; CONTACT SITES; PHOSPHORYLATION; EMS1/CORTACTIN; OVEREXPRESSION	Humoral immune response against overexpressed oncogenic or tumor supressor proteins has been demonstrated for many types of cancer, In this study we report on the detection of the autologous antibody response to putative oncogene, human cortactin using serological analysis of breast carcinoma expression library. Cortactin maps to chromosome 11q13, the region amplified in about 15% of primary breast carcinomas and 30% of head and neck squamous cell carcinomas, Cortactin overexpression due to such amplification might affect adhesive properties of human cancer cells and is associated with poor disease prognosis, Accordingly, we detected overexpression of cortactin transcript in autologous tumor and amplification/overexpression of cortactin in tumors of breast cancer patients serologically positive for this marker, We demonstrate that 15% of breast cancer patients elicit humoral immune response against human cortactin.	Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Ctr Mol Med, Lab Mol Immunol, Moscow 119899, Russia; Russian Acad Med Sci, Oncol Sci Ctr, Moscow, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Lab Mol Immunol, Moscow 117984, Russia	Lomonosov Moscow State University; Russian Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Lagarkova, MA (corresponding author), Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Ctr Mol Med, Lab Mol Immunol, Moscow 119899, Russia.		Nedospasov, Sergei/Q-7319-2016; Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/L-1990-2015; Nedospasov, Sergei/C-3043-2018; Lagarkova, Maria/A-3296-2014	Meshcheryakov, Andrey/0000-0002-6009-653X; Lagarkova, Maria/0000-0001-9594-1134				BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brass N, 1999, BLOOD, V93, P2158, DOI 10.1182/blood.V93.7.2158.407a34_2158_2166; Bringuier PP, 1996, ONCOGENE, V12, P1747; Campbell DH, 1999, CANCER RES, V59, P5376; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schuuring E, 1998, CELL ADHES COMMUN, V6, P185, DOI 10.3109/15419069809004475; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	22	9	9	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5204	5207		10.1038/sj.onc.1203826	http://dx.doi.org/10.1038/sj.onc.1203826			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064458				2022-12-17	WOS:000090124100010
J	Awwad, R; Humphrey, LE; Periyasamy, B; Scovell, W; Li, WH; Coleman, K; Lynch, M; Carboni, J; Brattain, MG; Howell, GM				Awwad, R; Humphrey, LE; Periyasamy, B; Scovell, W; Li, WH; Coleman, K; Lynch, M; Carboni, J; Brattain, MG; Howell, GM			The EGF/TGF alpha response element within the TGF alpha promoter consists of a multi-complex regulatory element	ONCOGENE			English	Article						colon carcinoma; EGF-response element; TGF alpha promotor; transcription; transforming growth factor alpha	GROWTH-FACTOR-ALPHA; HUMAN-COLON CARCINOMA; PROTEIN-KINASE-C; FACTOR-RECEPTOR; MESSENGER-RNA; CELL-LINES; EPITHELIAL-CELLS; PHORBOL ESTER; CANCER-CELLS; EXPRESSION	Autocrine TGF alpha is an important growth effector in the transformed phenotype. Growth stimulation of some colon cancer cells as well as other types of cancer cells is effected by activation of the epidermal growth factor receptor. Importantly, this receptor activation leads to further stimulation of TGF alpha transcription and increased peptide synthesis. However, the molecular mechanism by which TGF alpha transcription is activated is poorly understood. In this paper, we describe the localization of a cis-sequence within the TGF alpha promoter which mediates this stimulation. This region contains parallel cis-acting elements which interact to regulate both basal and EGF-induced TGF alpha expression. The well differentiated colon carcinoma cell line designated FET was employed in these studies. It produces autocrine TGF alpha but requires exogenous EGF in the medium for optimal growth. Addition of EGF to FET cells maintained in the absence of EGF resulted in a 2-3-fold increase of both TGF promoter activity and endogenous TGF alpha mRNA at 4 h. This addition of EGF also stimulated protein synthesis. The use of deletion constructs of the TGF alpha promoter in chimeras with chloramphenicol acetyl transferase localized EGF-responsiveness to between -247 and -201 within the TGF alpha promoter. A 25 bp sequence within this region conferred EGF-responsiveness to heterologous promoter constructs. Further use of deletion/mutation chimeric constructs revealed the presence of at least two interacting cis-elements, one binding a repressor activity and the other, an activator. Gel shift studies indicate the presence of distinct complexes representing activator and repressor binding, which are positively modulated by EGF. The type and amount of complexes formed by these proteins interact to regulate both the basal activity and EGF-responsiveness of the TGF alpha promoter. The interaction of an activator protein with an EGF-responsive repressor may serve to regulate the level of this progression-associated, transforming protein within tight limits.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA; Bristol Myers Squibb Co, Oncol Drug Discovery, Dept Mol Genet, Princeton, NJ 08543 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	Bristol-Myers Squibb; Pfizer	Howell, GM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.				NATIONAL CANCER INSTITUTE [R01CA034432, R01CA054807] Funding Source: NIH RePORTER; NCI NIH HHS [CA54807, CA34432] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOYD DD, 1988, CANCER RES, V48, P2469; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHANTRET I, 1988, CANCER RES, V48, P1936; CHEN XR, 1992, ONCOGENE, V7, P1805; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DALTON S, 1993, PHILOS T ROY SOC B, V340, P325, DOI 10.1098/rstb.1993.0074; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMANISHI K, 1989, J NATL CANCER I, V81, P220, DOI 10.1093/jnci/81.3.220; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; Kudlow J E, 1990, Semin Cancer Biol, V1, P293; LEE LW, 1991, CANCER RES, V51, P5238; LEWIS EJ, 1987, MOL CELL BIOL, V7, P3332, DOI 10.1128/MCB.7.9.3332; LEWIS JJ, 1990, SURGERY, V108, P220; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MALDEN LT, 1989, INT J CANCER, V43, P380, DOI 10.1002/ijc.2910430305; Maniatis T, 1982, MOL CLONING LABORATO; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MERCHANT JL, 1991, MOL CELL BIOL, V11, P2686, DOI 10.1128/MCB.11.5.2686; Mulder K. M., 1989, CELL MOL BIOL COLON, P45; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; SAEKI T, 1991, MOL ENDOCRINOL, V5, P1955, DOI 10.1210/mend-5-12-1955; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SIZELAND AM, 1991, MOL CELL BIOL, V11, P4005, DOI 10.1128/MCB.11.8.4005; SIZELAND AM, 1992, MOL BIOL CELL, V3, P1235, DOI 10.1091/mbc.3.11.1235; SUKHATME VP, 1991, AM J KIDNEY DIS, V17, P615, DOI 10.1016/S0272-6386(12)80333-7; Todaro G J, 1990, Semin Cancer Biol, V1, P257; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WAN CW, 1988, CANCER LETT, V43, P139, DOI 10.1016/0304-3835(88)90226-1; WATKINS LF, 1988, CANCER LETT, V40, P59, DOI 10.1016/0304-3835(88)90262-5; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	57	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5923	5935		10.1038/sj.onc.1202982	http://dx.doi.org/10.1038/sj.onc.1202982			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557079				2022-12-17	WOS:000083270700009
J	Mori, N; Yamate, J; Stassen, APM; Oka, S; Okumoto, H; Tsubura, A; Akamatsu, T; Sakuma, S; Demant, P				Mori, N; Yamate, J; Stassen, APM; Oka, S; Okumoto, H; Tsubura, A; Akamatsu, T; Sakuma, S; Demant, P			Modulations of glucocorticoid-induced apoptosis linked to the p53 deletion and to the apoptosis susceptibility gene Rapop1 (Radiation-induced apoptosis 1)	ONCOGENE			English	Article						p53; glucocorticoid-induced apoptosis; apoptosis susceptibility genes; genetic analysis; mouse	RECOMBINANT CONGENIC STRAINS; INDUCED THYMOCYTE APOPTOSIS; POSITIVE SELECTION; INHIBITION; RECEPTOR; IMMUNOSUPPRESSION; IDENTIFICATION; ACTIVATION; INVITRO; TUMORS	We have analysed the effects of p53 and of the apoptosis susceptibility gene Rapop1 (Radiation-induced apoptosis 1) located on chromosome 16 on glucocorticoid- and radiation-induced in vivo apoptosis of thymocytes. For those analyses, we used Rapop1 semicongenic mice heterozygous for the STS and BALB/cHeA alleles in the chromosomal segment containing Rapop1 in the. BALB/cHeA background, mice bearing a p53 deficient allele in the BALB/cHeA background and the genetic crosses between these mice. The p53 wild type mice with a STS/A allele at the Rapop1 locus were less susceptible to both radiation- and glucocorticoid-induced apoptosis than those with homozygous BALB/cHeA alleles at this locus. Surprisingly, glucocorticoid-induced apoptosis was enhanced in the p53 hemizygous mice and considerably increased in the p53 nullizygous mice. In contrast, a sizable reduction of radiation-induced apoptosis was seen in tbe p53 hemizygous mice, The low susceptibility to glucocortocoid-induced apoptosis linked to the STS allele of Rapop1 was less pronounced in the p53 hemizygous mice and a diminished effect of Rapop1 on radiation-induced apoptosis was seen in these mice. Although it remains to be established whether the genes modulating glucocortocoid-induced apoptosis are identical to g53 and Rapop1, our data suggest that p53 and Rapop1 may participate in glucocorticoid-induced apoptosis of thymocytes.	Univ Osaka Prefecture, Dept Appl Biosci, Res Inst Adv Sci & Technol, Sakai, Osaka 5998570, Japan; Univ Osaka Prefecture, Coll Agr, Dept Vet Pathol, Sakai, Osaka 5998531, Japan; Univ Osaka Prefecture, Coll Agr, Dept Vet Radiol, Sakai, Osaka 5998531, Japan; Kansai Med Univ, Dept Pathol, Moriguchi, Osaka 5700074, Japan; Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Kansai Medical University; Netherlands Cancer Institute	Mori, N (corresponding author), Univ Osaka Prefecture, Dept Appl Biosci, Res Inst Adv Sci & Technol, 1-2 Gakuen Cho, Sakai, Osaka 5998570, Japan.							AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEMANT P, 1986, IMMUNOGENETICS, V24, P416, DOI 10.1007/BF00377961; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODROW TL, 1992, MOL CARCINOGEN, V5, P9; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; IWATA M, 1991, EUR J IMMUNOL, V21, P643, DOI 10.1002/eji.1830210316; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mori N, 1995, GENOMICS, V30, P553, DOI 10.1006/geno.1995.1276; MORI N, 1995, GENOMICS, V25, P609, DOI 10.1016/0888-7543(95)80001-3; MORI N, 1992, INT J RADIAT BIOL, V62, P53; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Shimizu S, 1996, ONCOGENE, V13, P21; Stassen APM, 1996, MAMM GENOME, V7, P55, DOI 10.1007/s003359900013; Vacchio MS, 1997, J EXP MED, V185, P2033, DOI 10.1084/jem.185.11.2033; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468; Weil MM, 1997, GENOMICS, V45, P626, DOI 10.1006/geno.1997.4999; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yu CL, 1997, CANCER LETT, V116, P191, DOI 10.1016/S0304-3835(97)00186-9	24	9	9	2	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4282	4285		10.1038/sj.onc.1202719	http://dx.doi.org/10.1038/sj.onc.1202719			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435642				2022-12-17	WOS:000081542400013
J	March, KL; Sandusky, G; Fan, L				March, KL; Sandusky, G; Fan, L			Hyperplasia in multiple smooth muscle tissues in transgenic mice expressing a temperature-sensitive SV40 T-antigen under the control of smooth muscle alpha-actin regulatory sequences	ONCOGENE			English	Article						transgenic mouse; smooth muscle; cellular proliferation; T antigen; temperature-sensitive mutant	CELL-LINES; GEL-ELECTROPHORESIS; MOUSE; PROMOTER; GENE; IMMORTALIZATION; CARDIOMYOCYTES; NEURONS; RAT	Control of smooth muscle cell (SMC) proliferation is of fundamental importance in the development and pathology of the vasculature. To derive vascular SMC with conditional inactivation of negative cell cycle regulatory proteins in the context of smooth muscle protein expression, a 3.4 kb fragment of the mouse SMC alpha-actin promoter was used to target a temperature-sensitive mutant SV40 T antigen (tsA58) to smooth in transgenic mice. Mice with this genotype display heritable phenotype of abnormal SMC proliferation in the central tail artery, vasa deferentia, seminal vesicles, prostate, and uterus, with the latter resembling uterine leiomyomatosis and prostatic hypertrophy. Neither the aorta nor other viscera manifested abnormal proliferation, Cultures from aorta, vas deferens, seminal vesicle, and kidney tissue were characterized with regard to protein expression, stability, and matrix remodelling capacity. The a-actin content/cell was up to 3-4-fold higher, as well as more stable than in primary SMC cultures, suggesting successful selection for propagation of cells expressing this differentiation marker, All cells displayed enhanced growth at the permissive temperature, As an initial functional assessment, the cells were compared to non-transformed mouse aortic SMC with respect to the ability to remodel collagen gel matrices, and demonstrated conservation of this physiologic function. This in vivo analysis of the SMC alpha-actin promoter supports a broader range of smooth muscle-directed expression activity than previously recognized, and establishes the feasibility of its use to direct transgene expression to vascular as well as genito-urinary smooth muscle. The targeted expression of the tsA58 T antigen has yielded transgenic animals with several manifestations of smooth muscle hyperplasia; these animals have in turn permitted the derivation of several murine SMC lines with phenotypic stability and conditionally-modulated proliferation. These cells will allow expansion of derivative transfected smooth muscle cell lines under permissive conditions, as well as oncogene inactivation at the restrictive temperature when desired for functional studies.	Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Richard L Roudebush Vet Adm Med Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center	March, KL (corresponding author), Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA.			March, Keith/0000-0001-5677-0379				BABAI F, 1990, DIFFERENTIATION, V44, P132, DOI 10.1111/j.1432-0436.1990.tb00546.x; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; DELCARPIO JB, 1991, CIRC RES, V69, P1591, DOI 10.1161/01.RES.69.6.1591; DELEON JR, 1994, P NATL ACAD SCI USA, V91, P519, DOI 10.1073/pnas.91.2.519; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GORDON C, 1992, CAMBRIDGE U PRESS, V4, P73; HAMMANG JP, 1990, NEURON, V4, P775, DOI 10.1016/0896-6273(90)90204-S; HARATS D, 1995, J CLIN INVEST, V95, P1335, DOI 10.1172/JCI117784; KERSHAW TR, 1994, NEUROREPORT, V5, P2197, DOI 10.1097/00001756-199410270-00052; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; LOEBER G, 1989, J VIROL, V63, P4426, DOI 10.1128/JVI.63.10.4426-4430.1989; Maniatis T, 1989, DECONTAMINATION DILU; MARCH KL, 1995, J AM COLL CARDIOL, V25, pA365; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; MIN BH, 1990, J BIOL CHEM, V265, P16667; MOGHAL N, 1995, LAB INVEST, V72, P291; MORGAN JE, 1994, DEV BIOL, V162, P486, DOI 10.1006/dbio.1994.1103; NOBLE M, 1995, TRANSGENIC RES, V4, P15; PARADIS K, 1995, GASTROENTEROLOGY, V109, P1308, DOI 10.1016/0016-5085(95)90593-6; PAUL D, 1988, EXP CELL RES, V175, P354, DOI 10.1016/0014-4827(88)90199-1; PEREZREYES N, 1992, P NATL ACAD SCI USA, V89, P1224, DOI 10.1073/pnas.89.4.1224; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; REILLY CF, 1990, J CELL PHYSIOL, V142, P342, DOI 10.1002/jcp.1041420217; Sambrook J, 1989, MOL CLONING LAB MANU, V1; SKALLI O, 1986, J CELL BIOL, V103, P2787, DOI 10.1083/jcb.103.6.2787; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEINHELPER ME, 1990, AM J PHYSIOL, V259, pH1826, DOI 10.1152/ajpheart.1990.259.6.H1826; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P6450; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587	32	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3773	3782		10.1038/sj.onc.1202994	http://dx.doi.org/10.1038/sj.onc.1202994			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391686				2022-12-17	WOS:000081140200012
J	Comegys, MM; Carreiro, MP; Brown, JF; Mazzacua, A; Flanagan, DL; Makarovskiy, A; Lin, SH; Hixson, DC				Comegys, MM; Carreiro, MP; Brown, JF; Mazzacua, A; Flanagan, DL; Makarovskiy, A; Lin, SH; Hixson, DC			C-CAM1 expression: Differential effects on morphology, differentiation state and suppression of human PC-3 prostate carcinoma cells	ONCOGENE			English	Article						C-CAM; tumor suppression; morphometric analysis; prostate carcinoma; cytokeratin expression; TGF-beta	RAT HEPATOCELLULAR CARCINOMAS; ANTIGEN GENE FAMILY; MOLECULE C-CAM; ADHESION MOLECULE; BILIARY GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; COLORECTAL CARCINOMAS; MEDIATED CYTOLYSIS; LIVER DEVELOPMENT; GROWTH INHIBITOR	Studies in rat prostate and liver have suggested that C-CAM1 is involved in the formation and maintenance of histotypic associations in tissues and possibly tumors. Most recently, C-CAM1 has been shown to suppress tumorigenicity of prostate and colon carcinoma cells. However, the mechanisms whereby C-CAM1 suppresses growth and the relationship of this activity to its proposed role in histotypic interactions remain largely unknown. In the present study, we have analysed the growth, phenotypic, morphological and ultrastructural characteristics of four human PC-3 prostate carcinoma cell lines transduced with C-CAM1 retrovirus. We report that three of four lines regained their tumorigenic phenotype in vivo while maintaining high levels of C-CAM1 expression and a growth retarded phenotype in vitro. These findings suggested that high levels of C-CAM1 expression were negatively influencing recovery during reconstitution after freezing or during the latency period after subcutaneous injection and that loss of suppression resulted from changes in expression of other molecules required for full disclosure of C-CAM1 mediated growth inhibition. Results from Northern blot and immunofluorescence analyses of tumor nodules demonstrated that C-CAM1 decreased rather than enhanced phenotypic differentiation and induced ultrastructural and morphological changes that occurred independently of tumor suppression.	Brown Univ, Rhode Isl Hosp, Dept Med Oncol, Providence, RI 02903 USA; Brown Univ, Rhode Isl Hosp, Dept Urol, Providence, RI 02903 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital; University of Texas System; UTMD Anderson Cancer Center	Hixson, DC (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Med Oncol, 593 Eddy St, Providence, RI 02903 USA.				NCI NIH HHS [CA42714] Funding Source: Medline; NIEHS NIH HHS [T32 ESO7272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barrack ER, 1997, PROSTATE, V31, P61; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BECK BN, 1982, TRANSPLANTATION, V33, P118, DOI 10.1097/00007890-198202000-00003; BECKER A, 1986, EUR J CELL BIOL, V39, P417; BRUMMER J, 1995, ONCOGENE, V11, P1649; BUDZYNSKI W, 1994, IMMUNOPHARM IMMUNOT, V16, P319, DOI 10.3109/08923979409007097; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; Denhez F, 1990, GROWTH FACTORS, V3, P139, DOI 10.3109/08977199009108276; DUNSFORD HA, 1989, CANCER RES, V49, P4887; DUPREY P, 1985, P NATL ACAD SCI USA, V82, P8535, DOI 10.1073/pnas.82.24.8535; FARIS RA, 1991, CANCER RES, V51, P1308; Foty RA, 1997, CANCER RES, V57, P5033; Goldman R. D., 1990, CELLULAR MOL BIOL IN, P3; GREEN KJ, 1990, CELLULAR MOL BIOL IN, P147; HANKS SK, 1988, P NATL ACAD SCI USA, V85, P79, DOI 10.1073/pnas.85.1.79; HIXSON DC, 1989, CANCER RES, V49, P6788; HIXSON DC, 1983, CANCER RES, V43, P3874; HIXSON DC, 1984, EXP CELL RES, V152, P402, DOI 10.1016/0014-4827(84)90641-4; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1994, J BIOL CHEM, V269, P3711; HSIEH JT, 1995, CANCER RES, V55, P190; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kunath T, 1995, ONCOGENE, V11, P2375; KUNG JT, 1988, J IMMUNOL, V140, P3727; LAKE JP, 1991, J IMMUNOL, V147, P1121; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; LEO O, 1988, J IMMUNOL, V141, P37; LIEBERMAN M, ANDERSONS PATHOLOGY; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Marceau N, 1995, BIOCHEM CELL BIOL, V73, P619, DOI 10.1139/o95-068; MARCEL M, 1992, B CANC, V79, P347; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Miyaki M, 1995, ONCOGENE, V11, P2547; MOWERY J, 1991, HEPATOLOGY, V13, P47; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nollau P, 1997, CANCER RES, V57, P2354; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Perry KT, 1997, UROLOGY, V49, P151, DOI 10.1016/S0090-4295(96)00426-8; QIAN SW, 1990, NUCLEIC ACIDS RES, V18, P3059, DOI 10.1093/nar/18.10.3059; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANG J, 1993, CANCER RES, V55, P1152; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SARMIENTO M, 1982, IMMUNOL REV, V68, P135, DOI 10.1111/j.1600-065X.1982.tb01063.x; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; STITZ L, 1986, J IMMUNOL, V136, P4674; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON NL, 1994, PATHOBIOLOGY, V62, P209, DOI 10.1159/000163912; THOMPSON NL, 1993, CELL GROWTH DIFFER, V4, P257; THOMPSON NL, 1990, J CELL BIOL, V11, pA156; Turbide C, 1997, CANCER RES, V57, P2781; WILLIAMS MA, 1997, QUANTITATIVE METHODS, V6, P5; Yang YM, 1997, AM J PATHOL, V150, P693	65	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	1999	18	21					3261	3276		10.1038/sj.onc.1202666	http://dx.doi.org/10.1038/sj.onc.1202666			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200DF	10359532				2022-12-17	WOS:000080523800009
J	Elliott, J; Jones, MD; Griffin, BE; Krauzewicz, N				Elliott, J; Jones, MD; Griffin, BE; Krauzewicz, N			Regulation of cytoskeletal association by a basic amino acid motif in polyoma virus middle T antigen	ONCOGENE			English	Article						CaaX box; cytoskeleton; green fluorescent protein; middle T antigen	MEDIUM TUMOR-ANTIGEN; SRC GENE-PRODUCT; PLASMA-MEMBRANE; PHOSPHATIDYLINOSITOL KINASE; ONCOGENIC TRANSFORMATION; SIGNAL-TRANSDUCTION; STRUCTURAL PROTEINS; COMPLEX-FORMATION; CELL-MEMBRANES; EARLY REGION	The subcellular localization of many oncogenic proteins is thought to be important for their function. In the case of the middle T antigen of the DNA tumour virus, polyoma, localization to membranes in a specific manner is essential for its cellular transforming activity. To investigate factors that influence this localization, heterologous membrane targetting sequences were substituted for the middle T antigen transmembrane domain and the properties of the resulting proteins studied. Whereas G-terminal lipid modification derived from the H-ras CaaX box restored oncogenic activity to nontransforming truncated middle T antigen species, N-terminal myristylation from pp60c-src did not. Furthermore, a region, rich in basic amino acids and adjacent to the middle T transmembrane domain, was found to mediate association with detergent-insoluble cytoskeleton. Go-operation between the basic motif and neighbouring membrane binding domains resulted in specific localization of proteins to particular membrane sites, characterized by the association with subcellular structures, likely to be cytoskeletal in nature. These results demonstrate that the cellular localization of MT is regulated by at least two determinants, a transmembrane sequence which confers membrane binding and a basic motif which specifies a particular site within the membrane.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, London W12 0NN, England	Imperial College London	Krauzewicz, N (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, 7th Floor,Du Cane Rd, London W12 0NN, England.							ANDREWS DW, 1993, MOL CELL BIOL, V13, P4703, DOI 10.1128/MCB.13.8.4703; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BALLMERHOFER K, 1987, VIRUS RES, V6, P345, DOI 10.1016/0168-1702(87)90066-9; BOLEN JB, 1984, J BIOL CHEM, V259, P1686; Brewster CEP, 1997, J VIROL, V71, P5512, DOI 10.1128/JVI.71.7.5512-5520.1997; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARMICHAEL GG, 1982, P NATL ACAD SCI-BIOL, V79, P3579, DOI 10.1073/pnas.79.11.3579; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHENG SH, 1988, EMBO J, V7, P3845, DOI 10.1002/j.1460-2075.1988.tb03270.x; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1989, ONCOGENE RES, V4, P75; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAHL J, 1992, MOL CELL BIOL, V12, P5050, DOI 10.1128/MCB.12.11.5050; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DILWORTH SM, 1982, P NATL ACAD SCI-BIOL, V79, P1059, DOI 10.1073/pnas.79.4.1059; DILWORTH SM, 1986, EMBO J, V5, P491, DOI 10.1002/j.1460-2075.1986.tb04238.x; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; Doherty J, 1997, ONCOGENE, V14, P1923, DOI 10.1038/sj.onc.1201025; FORSTOVA J, 1993, J VIROL, V67, P1405; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRIFFIN BE, 1979, J VIROL, V31, P645, DOI 10.1128/JVI.31.3.645-656.1979; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; ITO Y, 1977, P NATL ACAD SCI USA, V74, P4666, DOI 10.1073/pnas.74.10.4666; JANIAK F, 1994, J BIOL CHEM, V269, P9842; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KRAUZEWICZ N, 1994, ONCOGENE, V9, P2283; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; MARKLAND W, 1986, J VIROL, V59, P82, DOI 10.1128/JVI.59.1.82-89.1986; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Messerschmitt A, 1996, J GEN VIROL, V77, P17, DOI 10.1099/0022-1317-77-1-17; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TEMPLETON D, 1984, MOL CELL BIOL, V4, P282, DOI 10.1128/MCB.4.2.282; Topp WC, 1981, DNA TUMOR VIRUSES 2, P205; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1987, J VIROL, V61, P405, DOI 10.1128/JVI.61.2.405-410.1987; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WYSS A, 1990, J VIROL, V64, P5163, DOI 10.1128/JVI.64.10.5163-5166.1990; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	61	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 8	1998	17	14					1797	1806		10.1038/sj.onc.1202083	http://dx.doi.org/10.1038/sj.onc.1202083			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126PX	9778045				2022-12-17	WOS:000076303300005
J	Zurovec, M; Petrenko, O; Roll, R; Enrietto, PJ				Zurovec, M; Petrenko, O; Roll, R; Enrietto, PJ			A chicken c-Rel-estrogen receptor chimeric protein shows conditional nuclear localization, DNA binding, transformation and transcriptional activation	ONCOGENE			English	Article						c-Rel; NF-kappa B; transformation; apoptosis	NF-KAPPA-B; V-REL; EXHIBIT DEFECTS; FUSION PROTEIN; IN-VITRO; EXPRESSION; CELLS; ALPHA; INHIBITOR; VIRUS	In this report, we characterize the biological and biochemical properties of a conditional protein containing chicken c-Rel fused to the hormone-binding domain of the human estrogen receptor. This chimeric c-RelER protein causes estrogen-dependent, but otherwise c-Rel-specific, transformation of avian fibroblasts in vitro. Our results demonstrate that c-RelER heterodimerizes with wild-type c-Rel and forms specific complexes with I kappa B-alpha. Estrogen causes translocation of c-RelER to the nucleus and stabilizes its binding to DNA. Hormone-activated c-RelER induces transcription of at least four cellular genes that are constitutively active in wild-type c-Rel-transformed fibroblasts. Two distinct cell populations were examined that differed with respect to their growth phenotypes. The growth of fibroblasts with moderate expression levels of c-RelER was stimulated by estrogen. In contrast, the addition of estrogen to cells with high c-RelER expression levels resulted in inhibition of cytokinesis and the arrest of growth. The carboxy terminal transactivation domain of c-Rel was required for the induction of these effects since neither v-Rel nor c-Rel deletion mutants were able to induce similar changes. Taken together, our results demonstrate that high levels of c-Rel expression can affect cell cycle control and/or cytokinesis. Furthermore, they also indicate that the biological properties of c-Rel in cell growth and differentiation will potentially differ depending on the level of expression.	SUNY Stony Brook, Dept Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Zurovec, M (corresponding author), Univ S Bohemia, Fac Biol, Branisovska 31, Ceske Budejovice 37005, Czech Republic.		Zurovec, Michal/H-2562-2014; Zurovec, Michal/AAE-8185-2021	Zurovec, Michal/0000-0002-0913-166X; Zurovec, Michal/0000-0002-0913-166X	FIC NIH HHS [1FO TW04933-01] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004933] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Gilmore TD, 1996, ONCOGENE, V13, P1367; GREEN S, 1991, OESTROGEN RECEPTOR P, P15; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KUMAR V, 1986, EMBO J, V5, P2331; METZ T, 1991, EMBO J, V10, P837, DOI 10.1002/j.1460-2075.1991.tb08016.x; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P667; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; PETRENKO O, 1995, GENE, V160, P305, DOI 10.1016/0378-1119(95)00210-W; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WAKELING AE, 1988, J STEROID BIOCHEM, V31, P645, DOI 10.1016/0022-4731(88)90014-3; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	44	9	9	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3133	3142		10.1038/sj.onc.1201860	http://dx.doi.org/10.1038/sj.onc.1201860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671392				2022-12-17	WOS:000074261300006
J	Hadman, M; Lin, W; Bush, L; Bos, TJ				Hadman, M; Lin, W; Bush, L; Bos, TJ			Apolipoprotein A-1 is a negative target of v-Jun overexpression	ONCOGENE			English	Article						Jun; apolipoprotein A-1; regulation	A-I-GENE; HIGH-DENSITY LIPOPROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; C-JUN; GLUCOCORTICOID RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL REGULATION; FUNCTIONAL ANTAGONISM; EMBRYO FIBROBLASTS; COLLAGENASE GENE	The product of the Jun oncogene influences a variety of processes including cell proliferation and differentiation. Jun exerts its influence by binding to the promoter and enhancer regions of a number of different target genes resulting in their activation or repression. We describe here the isolation and characterization of a gene differentially downregulated upon overexpression of v-Jun but not c-Jun. DNA and amino acid homology search analysis revealed this gene to be identical to chicken apolipoprotein A-1, the major component of high density lipoprotein (HDL). The half life of apolipoprotein A-1 RNA remains constant in the presence or absence of v-Jun overexpression suggesting downregulation by v-Jun is at the level of promoter-activity. Consistent with this hypothesis, apolipoprotein A-1 upstream promoter fragments active in normal and c-Jun expressing CEF are inactive in v-Jun transformed CEF. Analysis of expression of apolipoprotein A-1 in CEF overexpressing other oncogenes revealed a similar downregulation by Myc and v-Src but not c-Fos, v-Ha-Ras, c-Src or c-Ski. Our findings point to a potential regulatory affect on cholesterol metabolism by v-Jun, as a result of altered levels of apolipoprotein A-1 message expression.	Eastern Virginia Med Sch, Dept Microbiol & Immunol, Norfolk, VA 23501 USA	Eastern Virginia Medical School	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Immunol, POB 1980, Norfolk, VA 23501 USA.				NCI NIH HHS [R29 CA 51982, R01 CA 51982] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051982, R01CA051982] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BARONI S, 1994, LEUKEMIA RES, V18, P643, DOI 10.1016/0145-2126(94)90047-7; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BHATTACHARYYA N, 1993, DNA CELL BIOL, V12, P597, DOI 10.1089/dna.1993.12.597; BHATTACHARYYA N, 1991, GENE, V104, P163, DOI 10.1016/0378-1119(91)90246-8; BHATTACHARYYA N, 1993, GENE, V137, P315, DOI 10.1016/0378-1119(93)90027-Z; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; EISENBERG S, 1984, J LIPID RES, V25, P1017; FOLIN M, 1993, HAEMATOLOGICA, V78, P277; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; GAUDET F, 1995, J BIOL CHEM, V270, P29916; GE RW, 1994, J BIOL CHEM, V269, P13185; GIZANGGINSBERG E, 1990, GENE DEV, V4, P447; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hadman M, 1996, ONCOGENE, V12, P135; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAMONFAVA S, 1992, J LIPID RES, V33, P831; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MILNER JN, 1992, GENE DEV, V6, P2491; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; RAJAVASHISTH TB, 1987, J BIOL CHEM, V262, P7058; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROBINSON GLWG, 1995, MOL CELL BIOL, V15, P1398; RONNEMAA T, 1989, AM J EPIDEMIOL, V130, P632, DOI 10.1093/oxfordjournals.aje.a115385; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Scribano D, 1996, HAEMATOLOGICA, V81, P343; SPIEGEL RJ, 1982, AM J MED, V72, P775, DOI 10.1016/0002-9343(82)90543-5; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Taylor AH, 1996, J LIPID RES, V37, P2232; TOURAY M, 1991, ONCOGENE, V6, P1227; VARMA VK, 1992, METABOLISM, V41, P1075, DOI 10.1016/0026-0495(92)90288-L; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; VOGT PK, 1990, CANCER BIOL, V1, P27; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WONG WY, 1992, ONCOGENE, V7, P2077; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	55	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					655	660		10.1038/sj.onc.1201574	http://dx.doi.org/10.1038/sj.onc.1201574			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482111				2022-12-17	WOS:000071816600010
J	Kiyokawa, N; Karunagaran, D; Lee, EK; Xie, YM; Yan, DH; Hung, MC				Kiyokawa, N; Karunagaran, D; Lee, EK; Xie, YM; Yan, DH; Hung, MC			Involvement of cdc2-mediated phosphorylation in the cell cycle-dependent regulation of p185(neu)	ONCOGENE			English	Article						cdc2; cell cycle; p185(neu); phosphoamino acid analysis; peptide mapping; serine/threonine kinases	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NEU ONCOGENE; POINT MUTATION; PROTEIN-KINASE; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; EGF RECEPTOR; GENE-PRODUCT; CDC2 KINASE	We previously reported cell cycle-dependent negative regulation of p185(neu) (decreased tyrosine phosphorylation and kinase activity, with electrophoretic mobility retarded by serine/threonine phosphorylation) in M phase and the escape of mutation-activated p185(neu*) from this regulation. Our present results showed that retardation of electrophoretic mobility occurs independently of the cells' transformed status. We found that normal p185(neu) lost its ability to dimerize in the M phase. We demonstrated a physical association between cdc2 (a serine/threonine kinase, active in NI phase) and p185(neu). We showed that the carboxy terminal portion of p185(neu) is phosphorylated in vitro by cdc2. Many phosphopeptides (at least three phosphoserine residues) unique to the M phase were identified, and the in vivo and irt vitro phosphopeptide patterns were superimposable. In contrast, mutation-activated p185(neu*) dimerized in the M phase with no changes in electrophoretic mobility, failed to associate with cdc2 and no unique phosphoserine residues could be identified in the M phase (data not shown), consistent with the escape of p185(neu*) from cell cycle-dependent regulation. Our results suggest that this escape is an intrinsic property of the mutation-activated p185(neu*) independent of its ability to transform cells. Our results also suggest the involvement of serine/threonine kinases such as cdc2 in the cell cycle-dependent negative regulation of p185(neu).	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT TUMOR BIOL,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Karunagaran, Devarajan/A-8148-2010; Hung, Mien-Chie/ABD-5911-2021	Karunagaran, Devarajan/0000-0001-9331-8947; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [CA60856, CA58880, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060856, R01CA058880, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; CAO HN, 1991, ONCOGENE, V6, P705; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; COCHET C, 1984, J BIOL CHEM, V259, P2553; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; FEINMESSER RL, 1986, ONCOGENE, V12, P2725; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; MATIN A, 1994, ONCOGENE, V9, P1333; MORRISON P, 1993, J BIOL CHEM, V268, P15536; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; Stock J, 1996, CURR BIOL, V6, P825, DOI 10.1016/S0960-9822(02)00605-X; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	49	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2633	2641		10.1038/sj.onc.1201442	http://dx.doi.org/10.1038/sj.onc.1201442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400990				2022-12-17	WOS:A1997YH46800001
J	FitzerAttas, CJ; Do, MS; Feigelson, S; Vadai, E; Feldman, M; Eisenbach, L				FitzerAttas, CJ; Do, MS; Feigelson, S; Vadai, E; Feldman, M; Eisenbach, L			Modification of PDGF alpha receptor expression or function alters the metastatic phenotype of 3LL cells	ONCOGENE			English	Article						3LL cells; dominant negative; paracrine loop; PDGF alpha receptors; tumor metastases	GROWTH-FACTOR PDGF; LUNG-CARCINOMA CELLS; BETA-RECEPTOR; TUMOR-CELLS; DIFFERENTIAL EXPRESSION; SIGNAL TRANSDUCTION; NEGATIVE MUTATIONS; CANCER METASTASIS; PROTEIN PRODUCTS; TYROSINE KINASES	Functional PDGF alpha receptors are selectively expressed on highly lung-metastasizing clones of the 3LL Lewis lung carcinoma, but not on low-mestastatic clones. The highly metastatic clones are also growth induced in vitro by PDGF and lung conditioned medium. To investigate whether modification of PDGF alpha receptor expression or function can affect metastatic capability, we transfected cells of a low-metastatic 3LL clone with a full length PDGF alpha receptor gene and cells of a highly-metastatic clone with a truncated kinase domain PDGF alpha receptor gene. Introduction of the full length PDGF alpha receptor conferred upon low-metastatic cells the ability to grow in vitro in the presence of PDGF-AA and to colonize the lung in experimental and spontaneous metastases assays. Conversely, introduction of a truncated version of the PDGF alpha receptor into highly metastatic cells reduced their metastatic load to control levels. Accordingly, their responses to PDGF-AA, including growth stimulation and receptor autophosphorylation, were reduced. These results demonstrate that PDGF alpha receptor expression and function can control the capacity of tumor cells to generate metastases in the lung. The response of this receptor to lung-derived PDGF-like factors may define a paracrine mode of metastatic cell growth in the target organ.	WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Fitzer-Attas, Cheryl/0000-0002-8709-1384; Eisenbach, Lea R/0000-0002-4816-1968				ANTONIADES HN, 1992, P NATL ACAD SCI USA, V89, P3942, DOI 10.1073/pnas.89.9.3942; Bostrom H, 1996, CELL, V85, P863, DOI 10.1016/S0092-8674(00)81270-2; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DEBAETSELIER P, 1980, NATURE, V288, P179; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DO MS, 1992, ONCOGENE, V7, P1567; EISENBACH L, 1983, INT J CANCER, V32, P113, DOI 10.1002/ijc.2910320118; EISENBACH L, 1984, INT J CANCER, V34, P567, DOI 10.1002/ijc.2910340421; FIDLER IJ, 1989, CYTOMETRY, V10, P673, DOI 10.1002/cyto.990100602; FIDLER IJ, 1990, CANCER RES, V50, P6130; FITZERATTAS C, 1993, INT J CANCER, V53, P315, DOI 10.1002/ijc.2910530224; FITZERATTAS CJ, 1993, THESIS WEIZMANN I SC; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; Hall A, 1996, DEVELOPMENT, V122, P4085; HARSH GR, 1990, J NEURO-ONCOL, V8, P1; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART IR, 1981, CANCER RES, V41, P1281; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; HENRIKSEN R, 1993, CANCER RES, V53, P4550; HERMANSON M, 1992, CANCER RES, V52, P3213; IIDA H, 1991, P NATL ACAD SCI USA, V88, P6560, DOI 10.1073/pnas.88.15.6560; KEMP PR, 1993, FEBS LETT, V336, P119, DOI 10.1016/0014-5793(93)81623-8; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIU M, 1995, AM J PHYSIOL, V269, P178; MALIK R, 1991, CANCER RES, V51, P5626; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1990, INT J CANCER, V46, P16, DOI 10.1002/ijc.2910460106; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; PLAKSIN D, 1988, P NATL ACAD SCI USA, V85, P4463, DOI 10.1073/pnas.85.12.4463; PONTEN F, 1994, J INVEST DERMATOL, V102, P304, DOI 10.1111/1523-1747.ep12371787; PORGADOR A, 1993, J IMMUNOL, V150, P1458; RADINSKY R, 1992, In Vivo (Attiki), V6, P325; RUSCIANO D, 1992, BIOESSAYS, V14, P185, DOI 10.1002/bies.950140309; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAMAH SM, 1995, METHOD ENZYMOL, V254, P565; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SMITS A, 1992, AM J PATHOL, V140, P639; SOUZA P, 1995, DEVELOPMENT, V121, P2559; STRAWN LM, 1994, J BIOL CHEM, V269, P21215; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; TARIN D, 1984, CANCER RES, V44, P3584; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; Van Furth R, 1980, MONONUCLEAR PHAGOCYT; VIGNAUD JM, 1994, CANCER RES, V54, P5455; WANG JL, 1990, INT J CANCER, V46, P772, DOI 10.1002/ijc.2910460504; WESTERMARK B, 1993, ACTA ONCOL, V32, P101, DOI 10.3109/02841869309083897; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	58	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1545	1554		10.1038/sj.onc.1201321	http://dx.doi.org/10.1038/sj.onc.1201321			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380406				2022-12-17	WOS:A1997XX36900005
J	Acton, D; Jacobs, H; Domen, J; Berns, A				Acton, D; Jacobs, H; Domen, J; Berns, A			Bcl2 reduces lymphomagenesis in Delta V-TCR beta transgenic mice	ONCOGENE			English	Article						Bcl-2; T-cell receptor; T-cell development; lymphomagenesis; tumor suppression	CELLS; INHIBITION; EXPRESSION; CLONING; GROWTH; IL-7	Overexpression of the bcl-2 oncogene in the lymphoid compartment of transgenic mice prolongs the lifespan of lymphocytes and leads to a low incidence of lymphomas at later age. Transgenic mice carrying a mutated T-cell receptor lacking the variable domain (Delta V-TCR beta) suffer from lymphocyte depletion and are highly predisposed to lymphoma development. We intercrossed Bcl-2-Ig and Delta V-TCR beta transgenic mice to assess whether Bcl-2 could synergize with Delta V-TCR beta in tumorigenesis as reported previously for other oncogenes. Surprisingly, bitransgenic Delta V-TCR beta; bcl-2-Ig mice showed a reduction in the incidence of lymphomas. Analyses of prelymphomatous mice showed that Bcl-2 restored some of the phenotypic aberrations caused by the Delta V-TCR beta transgene in the lymphoid compartment. The inhibitory activity of Bcl-2 on Delta VTCR beta-induced lymphomagenesis was not observed when both transgenes were crossed into the RAG-1(-/-) background suggesting an important role for more mature lymphocytes in this phenomenon. These results show that, depending on the specific conditions, overexpression of Bcl-2 can both promote as well as impair lymphoma development.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850				Acton D, 1992, Curr Top Microbiol Immunol, V182, P293; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; CARROZZA ML, IN PRESS ONCOGENE; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Jacobs H, 1996, ONCOGENE, V12, P2089; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; LEE G, 1989, J IMMUNOL, V142, P3875; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; SMETS LA, 1994, BLOOD, V84, P1613; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vairo G, 1996, ONCOGENE, V13, P1511	25	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2497	2501		10.1038/sj.onc.1201089	http://dx.doi.org/10.1038/sj.onc.1201089			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191049				2022-12-17	WOS:A1997XA94900001
J	Park, WM; Mosteller, RD; Broek, D				Park, WM; Mosteller, RD; Broek, D			Identification of a dominant-negative mutation in the yeast CDC25 guanine nucleotide exchange factor for Ras	ONCOGENE			English	Article						Ras; CDC25 dominant-negative mutant; yeast; signal transduction	ADENYLYL CYCLASE GENE; SACCHAROMYCES-CEREVISIAE; WILD-TYPE; PROTEINS; ACTIVATION; MUTANT; RESIDUES; TRANSFORMATION; COMPLEX; CELLS	In previous studies we changed five conserved amino acid residues in the catalytic domain of the yeast Ras-specific guanine nucleotide exchange factor CDC25(GEF) (Park et al., 1994). One of the substitutions (R1489E) resulted in a molecule which could bind Ras but was catalytically inactive. These observations suggested that CDC25(R1489E) might be a dominant-negative mutant. Here we report further experiments which confirm the dominant-negative phenotype of CDC25(R1489E). Two lines of evidence indicate that the CDC25(R1489E) mutant exhibits Ras-specific binding in vivo. First, expression of CDC25(R1489E) in a wild-type yeast strain caused a partial inhibition of growth which was reversed by overexpression of the wildtype yeast RAS2 protein. Second, expression of CDC25(R1489E) in yeast strain containing a temperature-sensitive, dominant-negative RAS2 mutation (RAS2(vall9ala22)) suppressed the temperature-sensitive phenotype. The latter findings suggest that the CDC25(R1489E) protein bound the mutant RAS2 protein thereby releasing the wild-type CDC25 protein for activation of the wild-type RAS1 protein. Further, using a protein-protein binding assay and guanine nucleotide exchange assay (release of [H-3]-GDP) in vitro, we demonstrate that the CDC25(R1489E) protein can bind wild-type Ras protein but is unable to catalyze GDP-GTP exchange. Thus, the results of genetic and biochemical experiments demonstrate that CDC25(R1489E) encodes a dominant-negative GEF which blocks the Ras signaling pathway by binding wild-type Ras in a catalytically inactive complex.	UNIV SO CALIF, KENNETH NORRIS JR COMPREHENS CANC CTR, DEPT BIOCHEM & MOL BIOL, LOS ANGELES, CA 90033 USA	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER; NCI NIH HHS [CA50261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CHEN SY, 1994, ONCOGENE, V9, P2691; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; HANEY SA, 1994, J BIOL CHEM, V269, P16541; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JUNG V, 1994, MOL CELL BIOL, V14, P3707, DOI 10.1128/MCB.14.6.3707; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MACARA IG, 1996, FASEB J, V10, P624; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sherman F, 1986, LAB COURSE MANUAL ME; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	26	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					831	836		10.1038/sj.onc.1200893	http://dx.doi.org/10.1038/sj.onc.1200893			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047390				2022-12-17	WOS:A1997WJ11200009
J	Zenklusen, JC; Hodges, LC; Conti, CJ				Zenklusen, JC; Hodges, LC; Conti, CJ			Loss of heterozygosity on murine chromosome 6 in two-stage carcinogenesis: Evidence for a conserved tumor suppressor gene	ONCOGENE			English	Article						human chromosome 7; mitotic recombination; skin tumors; tumor suppressor gene; trisomy	POLYMERASE CHAIN-REACTION; MOUSE SKIN TUMORS; SQUAMOUS-CELL; MICROSATELLITE INSTABILITY; MITOTIC RECOMBINATION; ALLELOTYPE ANALYSIS; MALIGNANT-TUMORS; FREQUENT LOSS; CARCINOMAS; CANCER	We have recently demonstrated that loss of heterozygosity (LOH) at 7q31 is frequent in many kinds of human primary tumors and that introducing a single human chromosome (hchr) 7 into a murine squamous cell carcinoma (SCC)-derived cell line suppresses the malignant phenotype. To investigate whether the putative tumor suppressor gene on hchr 7 is conserved in mice, we studied LOH on mouse chromosome (mchr) 6 in chemically induced SCCs in (C57BL x DBA2) F1 (B6D2F1) females. LOH analysis was performed by polymerase chain reaction amplification of 17 (CA), microsatellite repeats in mchr 6 A1-C3. As expected, all the B6D2F1-derived tumors were informative for all the locus assayed. The highest percentage of LOH in the hchr 7q-homologous segment was found at D6Mit50 (60.0%) and the other markers in this segment had LOH incidences normally distributed around the peak. The high incidence of LOH in the tumors studied suggests that a tumor suppressor gene relevant to the development of epithelial cancers is present on mchr 6 A2. As this segment is homologous with hchr 7q31, these data suggest that the putative tumor suppressor gene is conserved in the two species and explains the suppression of tumorigenicity when a single hchr 7 is introduced to a murine SCC cell line.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT CARCINOGENESIS, DIV SCI PK RES, SMITHVILLE, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA53123] Funding Source: Medline; PHS HHS [PP 57596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053123] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON GM, 1993, AM J HEMATOL, V42, P171, DOI 10.1002/ajh.2830420206; ALDAZ CM, 1986, CANCER GENET CYTOGEN, V20, P223, DOI 10.1016/0165-4608(86)90077-4; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; AN HX, 1995, INT J CANCER, V64, P291, DOI 10.1002/ijc.2910640502; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; ATKIN NB, 1991, CANCER GENET CYTOGEN, V52, P113, DOI 10.1016/0165-4608(91)90061-X; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Boyd J A, 1991, Basic Life Sci, V57, P183; CANZIAN F, 1994, CANCER RES, V54, P6315; Conti C. J, 1994, HDB MOUSE MUTATIONS, P39; CONTI CJ, 1992, PROG CLIN BIOL RES, V376, P85; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DIGIOVANNI J, 1991, PROG EXP TUMOR RES, V33, P192; EMERIT I, 1989, MUTAT RES, V214, P97, DOI 10.1016/0027-5107(89)90202-9; HEGI ME, 1994, CANCER RES, V54, P6257; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; KEMP CJ, 1993, CANCER RES, V53, P6022; KERE J, 1989, BLOOD, V73, P230; KIBBELAAR RE, 1993, BLOOD, V82, P904; LEHMAN TA, 1991, ENVIRON HEALTH PERSP, V93, P133, DOI 10.2307/3431181; LOEB LA, 1994, CANCER RES, V54, P5059; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; MILLER DR, 1987, CANCER RES, V47, P1935; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; MORI N, 1989, CANCER RES, V49, P5130; NEUBAUER A, 1992, ONCOGENE, V7, P1019; OHSUMI T, 1995, BIOCHEM BIOPH RES CO, V212, P632, DOI 10.1006/bbrc.1995.2016; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; SASAKI K, 1995, CANCER RES, V55, P3513; SCHREIBER G, 1990, AM J PATHOL, V137, P653; SHIRAISHI Y, 1985, EMBO J, V4, P2553, DOI 10.1002/j.1460-2075.1985.tb03970.x; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; *WHIT I MIT CTR GE, 1994, GEN MAP MOUS; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YUSPA SH, 1994, INVEST DERMATOL S, V103, pS90; ZAR JH, 1991, BIOSTAT ANAL, P102; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	1997	14	1					109	114		10.1038/sj.onc.1200806	http://dx.doi.org/10.1038/sj.onc.1200806			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010237				2022-12-17	WOS:A1997WB76000010
J	Ou, XL; Campau, S; Slusher, R; Jasti, RK; Mabry, M; Kalemkerian, GP				Ou, XL; Campau, S; Slusher, R; Jasti, RK; Mabry, M; Kalemkerian, GP			Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer	ONCOGENE			English	Article						retinoic acid; myc; lung cancer; transcription	N-MYC; CARCINOMA-CELLS; HIGH-FREQUENCY; RECEPTOR-BETA; C-MYC; EXPRESSION; FAMILY; LINES; ONCOGENES; DIFFERENTIATION	The L-myc oncogene is commonly expressed in small cell lung cancer (SCLC) cells and is associated with SCLC cells with a high level of neuroendocrine differentiation and a relatively low proliferative index, We have previously reported that all-trans-retinoic acid (RA) inhibits the growth of NCI-H82 SCLC cells in association with increased neuroendocrine differentiation, increased L-myc gene expression and decreased c-myc gene expression, In the present report, the mechanism of RA-mediated L-myc up-regulation in NCI-H82 SCLC cells was determined by analysing transcriptional and post-transcriptional control of L-myc gene expression, Increases in steady-state levels of L-myc mRNA occurred in a dose-dependent manner after exposure to RA at a time-point prior to discernible changes in cellular morphology or growth, By nuclear run-on analysis, there was a clear increase in L-myc transcript initiation in NCI-H82 cells treated with 1 mu M RA, but no alteration was noted in the baseline degree of transcript attenuation when compared to control cells, L-myc transcript half-life remained unchanged after exposure to 1 mu M RA, indicating that post-transcriptional regulation is not a major factor in the control of L-myc gene expression, A marked dose-dependent increase in RAR beta expression was also demonstrated in RA-treated NCI-H82 cells, We conclude that RA-mediated up-regulation of L-myc gene expression occurs through stimulation of transcript initiation and that the biological effects of RA in SCLC cells may be mediated through RAR beta-dependent pathways.	WAYNE STATE UNIV, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA; KARMANOS CANC INST, DETROIT, MI 48201 USA; JOHNS HOPKINS ONCOL CTR, DEPT RADIAT ONCOL, BALTIMORE, MD 21287 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL CANCER INSTITUTE [R01CA048081, R01CA058974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007076] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58974-03, R01CA48081-06] Funding Source: Medline; NIEHS NIH HHS [R01ES07076-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1992, NEURON, V9, P1217, DOI 10.1016/0896-6273(92)90079-S; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BRENNAN J, 1991, CANCER RES, V51, P1708; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CELANO P, 1989, BIOTECHNIQUES, V7, P942; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DOYLE LA, 1989, CANCER RES, V49, P6745; GAZZERI S, 1991, CANCER RES, V51, P2566; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gudas Lorraine J., 1994, P443; HONG WK, 1993, RETINOIDS ONCOLOGY; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; INGVARSSON S, 1988, ONCOGENE, V3, P679; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; KALEMKERIAN G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P370; KALEMKERIAN GP, 1994, CELL GROWTH DIFFER, V5, P55; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KIM YH, 1995, CANCER RES, V55, P5603; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; MILLER WH, 1990, ONCOGENE, V5, P511; MOROY T, 1991, ONCOGENE, V6, P1941; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PRINS J, 1993, ANTICANCER RES, V13, P1373; RYGAARD K, 1993, INT J CANCER, V54, P144, DOI 10.1002/ijc.2910540123; SAKSELA K, 1990, J CELL BIOCHEM, V42, P153, DOI 10.1002/jcb.240420306; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sporn M B, 1984, J Natl Cancer Inst, V73, P1381; TAKAHASHI T, 1989, CANCER RES, V49, P2683; THIELE CJ, 1988, ONCOGENE, V3, P281; WADA RK, 1992, ONCOGENE, V7, P711; Weber E., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P503; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	41	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1893	1899						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934535				2022-12-17	WOS:A1996VR79500008
J	Dalley, BK; Cannon, JF				Dalley, BK; Cannon, JF			Novel, activated RAS mutations alter protein-protein interactions	ONCOGENE			English	Article						RAS; RAF; NF1; GTPase activating proteins; yeast; genetics	SITE-DIRECTED MUTAGENESIS; ADENYLATE-CYCLASE PATHWAY; SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDES; SIGNAL TRANSDUCTION; EFFECTOR RESIDUES; TERMINAL DOMAIN; GTP HYDROLYSIS; YEAST-CELLS; GENE	Random RAS2 mutants of Saccharmoyces cerevisiae were screened for activating traits, A total of 69 distinct mutations were identified, affecting 44 different amino acid residues, Many activated alleles do not bypass the requirement for the nucleotide exchange factor, CDC25, nor is the severity of RAS2 phenotypic traits strictly correlated with the capacity to bypass CDC25, In vivo interactions of mutant RAS2 proteins with RAS effecters (adenylate cyclase and RAF), CDC25 and GTPase activating proteins (IRA2 and NF1) mere assayed to assess how the various amino acid substitutions influence interactions with regulatory and target proteins of RAS, Nearly all activated RAS2 proteins mere observed to interact better with adenylate cyclase and RaF, although some distinct differences were found, Several amino acid substitutions that reduce the affinity of RAS2 for guanine nucleotides apparently elevate the fraction of nucleotide-free RAS2, which has greater CDC25 affinity. Amino acid alterations that reduce the affinity of RAS2 for GTPase activating proteins included substitutions both within the switch I/switch II domain and distinctly outside it, One mutant, RAS2-Y78F, bound a lower fraction of GTP in vivo than the wild-type protein, The Y78F substitution is localized to the switch II domain, a region of the RAS protein that undergoes guanine nucleotide-dependent conformational changes.	UNIV MISSOURI, DEPT MOL MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia				Cannon, John/0000-0001-6698-176X				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barnard D, 1995, ONCOGENE, V10, P1283; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CANNON JF, 1994, GENETICS, V136, P485; CASPERSON GF, 1985, P NATL ACAD SCI USA, V82, P5060, DOI 10.1073/pnas.82.15.5060; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eckert K A, 1991, PCR Methods Appl, V1, P17; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HU JS, 1993, BIOCHEMISTRY-US, V32, P6763, DOI 10.1021/bi00077a031; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1993, ONCOGENE, V8, P425; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PETITJEAN A, 1990, GENETICS, V124, P797; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIKORSKI RS, 1989, GENETICS, V122, P19; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILSON BA, 1993, ONCOGENE, V8, P3441; WOOD DR, 1994, J BIOL CHEM, V269, P5322; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	60	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1209	1220						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808695				2022-12-17	WOS:A1996VJ20200012
J	Gunning, KB; Cohn, SL; Tomlinson, GE; Strong, LC; Huff, V				Gunning, KB; Cohn, SL; Tomlinson, GE; Strong, LC; Huff, V			Analysis of possible abnormal WT1 RNA processing in primary Wilms tumors	ONCOGENE			English	Article						WT1; RNA; editing; aberrant splicing; Wilms tumor	GENE; EXPRESSION; DELETION; MUTATIONS; CELLS	WT1 RNA processing abnormalities have been suggested to play a role in the development of Wilms tumor by reports of editing at codon 280 in the rat WT1 transcript (codon 281 in humans) and aberrant splicing of exon 2 in WT1 transcripts from Wilms tumor xenograft cell lines, Both events result in a functionally changed WT1 protein and are potential mechanisms of altering normal protein function in the absence of WT1 DNA mutations, To determine whether either of these RNA processing events occurs in primary Wilms tumors, we analysed WT1 mRNA from 15 primary tumors, There was no evidence of WT1 RNA editing at codon 281, and only one primary tumor displayed aberrant splicing of exon 2, Sequence and Southern analysis of DNA from this tumor did not reveal any alteration in or around exon 2, These results suggest that neither RNA editing at codon 281 nor abberant exon 2 splicing is a frequent mechanism of WT1 alteration during tumorigenesis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPT PEDIAT,HOUSTON,TX 77030; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611; CHILDRENS MEM HOSP,CHICAGO,IL 60614; UNIV TEXAS,SW MED SCH,DEPT PEDIAT HEMATOL ONCOL & FAMILY GENET,DALLAS,TX	University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [P01CA034936, U01CA060114] Funding Source: NIH RePORTER; NCI NIH HHS [CA34936, CA60114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BROWN KW, 1993, GENE CHROMOSOME CANC, V8, P74, DOI 10.1002/gcc.2870080203; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1990, HUM GENET, V84, P253; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; NICHOLS KE, 1995, CANCER RES, V55, P4540; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	17	9	10	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1179	1185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808692				2022-12-17	WOS:A1996VJ20200009
J	LeNaour, F; Prenant, M; Francastel, C; Rubinstein, E; Uzan, G; Boucheix, C				LeNaour, F; Prenant, M; Francastel, C; Rubinstein, E; Uzan, G; Boucheix, C			Transcriptional regulation of the human CD9 gene: Characterization of the 5'-flanking region	ONCOGENE			English	Article						CD9 antigen; tetraspan; promoter; leukemia; platelets	ACUTE LYMPHOBLASTIC-LEUKEMIA; DIPHTHERIA-TOXIN RECEPTOR; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; CELL-LINE; MEMBRANE-PROTEIN; TRANSMEMBRANE-4 SUPERFAMILY; ENCODING METALLOTHIONEIN; IMMUNOGLOBULIN GENES; MOLECULAR-CLONING	The CD9 antigen, initially discovered on B lineage leukemic cells, belongs to the tetraspan superfamily of surface molecules. If no precise function has been assigned to any of these molecules, there are some indications that they could be involved in cell adhesion and cell migration, as well as malignant progression. The CD9 antigen is associated with surface proteins such as VLA integrins or HB-EGF precursor. Transfection of CD9 in melanoma cells reduces tumor growth and metastasis. The heterogenous distribution of the CD9 antigen suggests a complex regulation of its expression. We have previously characterized the CD9 gene and shown that transcription could be initiated at several sites in the TATA-less 5 '-flanking region. We show here, using as a model two human leukemic cell lines with erythromegakaryocytic potential, HEL and K562, that the [-205,-154] region supports a promoter activity when cloned ahead of a CAT reporter gene. Mutagenesis analysis suggested the presence of a positive element located within the [-170,-154] region. Gel shift experiments using HEL extracts were compatible with the binding of the transcriptional factor Spl to the [-237,-205] region and indicated that a non-identified protein binds to the 3 ' end of the [-205,-154] region.	CENG,INSERM,U217,HEMATOL LAB,F-38054 GRENOBLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	LeNaour, F (corresponding author), HOP PAUL BROUSSE,INSERM,U268,F-94807 VILLEJUIF,FRANCE.		Francastel, Claire/AAI-4798-2021; Rubinstein, Eric/B-4650-2019; Uzan, Georges/M-8199-2018	Rubinstein, Eric/0000-0001-7623-9665; Uzan, Georges/0000-0002-0178-5386; Francastel, Claire/0000-0002-6353-4320; Boucheix, Claude/0000-0003-4184-7008				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANTON ES, 1995, J NEUROSCI, V15, P584; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BOUCHEIX C, 1985, LEUKEMIA RES, V9, P597, DOI 10.1016/0145-2126(85)90139-0; BRACH MA, 1992, BLOOD, V79, P728; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HOTTA H, 1988, CANCER RES, V48, P2955; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KADONAGA JT, 1986, TIBS, V11, P21; KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LABBE S, 1993, NUCLEIC ACIDS RES, V21, P1549, DOI 10.1093/nar/21.7.1549; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RIECKMANN P, 1991, J IMMUNOL, V147, P3994; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; RUBINSTEIN E, 1993, GENOMICS, V16, P132, DOI 10.1006/geno.1993.1150; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT AF, 1994, GENOMICS, V20, P227, DOI 10.1006/geno.1994.1157; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SHAW S, 1994, LEUCOCYTE TYPING, V5, P16; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; TROUCHE D, 1991, BLOOD, V77, P55; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; UZAN G, 1991, J BIOL CHEM, V266, P8932; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	66	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					481	486						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760289				2022-12-17	WOS:A1996VB32800005
J	Akagi, T; Ono, H; Shimotohno, K				Akagi, T; Ono, H; Shimotohno, K			Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells	ONCOGENE			English	Article						tyrosine kinase; cell cycle; herbimycin A; cdk6; stability; T-cell	RETINOBLASTOMA SUSCEPTIBILITY GENE; PHOSPHORYLATION; EXPRESSION; PRODUCT; REQUIREMENTS; SPECIFICITY; ACTIVATION; LEUKOCYTES; MUTATIONS; FAMILY	The Cdk6 protein level rapidly decreased after treatment with the tyrosine kinase inhibitor herbimycin A in human T-cell lines. This decrease is fairly specific, because the level of other Cdks such as Cdk2 and Cdk4 and cyclins such as cyclin D2, cyclin E and cyclin A, did not change significantly even after 24 h treatment with herbimycin A. Pulse-chase analysis revealed that the decrease in the Cdk6 protein level results from reduced stability of the protein. Our results suggest that herbimycin A-sensitive protein tyrosine kinase(s) are involved in the regulation of the Cdk6 protein level.	NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan								AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; BATES S, 1994, ONCOGENE, V9, P1633; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GAZDAR AF, 1980, BLOOD, V55, P409; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MODIANO JF, 1994, J BIOL CHEM, V269, P32972; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UMEZAWA K, 1991, METHOD ENZYMOL, V201, P379; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; XU HJ, 1991, ONCOGENE, V6, P1139; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467	35	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					399	405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710379				2022-12-17	WOS:A1996VA25200019
J	Walker, AK; Enrietto, PJ				Walker, AK; Enrietto, PJ			Analysis of the role of v-rel in transcriptional regulation of high mobility group protein 14	ONCOGENE			English	Article						v-rel; oncogenes; gene expression; HMG proteins; chromatin	NF-KAPPA-B; PHENOL-CHLOROFORM EXTRACTION; ENHANCER-BINDING-PROTEIN; RECEPTOR FUSION PROTEIN; SINGLE-STEP METHOD; HUMAN C-REL; CHROMOSOMAL-PROTEINS; NUCLEAR FACTORS; RNA ISOLATION; PROMOTER	The oncogene v-rel is a member of the rel/NF-kappa B family of transcription factors. It causes a rapidly fatal lymphoma in young chicks and is capable of transforming both fibroblasts and primitive hematopoietic cells in culture. To understand the role of v-rel in transformation we constructed an inducible form of v-rel and used it to identify potential cellular target genes for v-rel regulation. In this paper we show that High Mobility Group Protein 14 (HMG 14) is expressed in a wide variety of v-rel transformed cell types. In addition we show that v-rel participates in the transcriptional regulation of HMG 14 and that extracts from v-relER cells interact with the HMG 14 promoter. These experiments suggest a role for v-rel in the regulation of a unique gene whose protein product may influence gene transcription in a global fashion.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA051792, T32CA009176] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 51792, CA 09176] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUG H, 1982, CELL, V39, P5479; BLANAR MA, 1989, MOL CELL BIOL, V9, P844, DOI 10.1128/MCB.9.2.844; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; BUSTIN M, 1991, NUCLEIC ACIDS RES, V19, P3115, DOI 10.1093/nar/19.11.3115; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CRIPPA MP, 1991, J BIOL CHEM, V266, P2712; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; Enrietto P J, 1990, Semin Cancer Biol, V1, P399; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1992, CANCER SURV, V15, P69; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE JH, 1991, ONCOGENE, V6, P665; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LU D, 1991, ONCOGENE, V6, P1235; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; PASH JM, 1993, J BIOL CHEM, V268, P13632; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; SAMBROOK PL, 1989, MOL CLONING LAB MANU; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKOORI AR, 1993, J CELL BIOCHEM, V51, P479, DOI 10.1002/jcb.2400510413; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SRIKANTHA T, 1990, J MOL BIOL, V211, P49, DOI 10.1016/0022-2836(90)90010-J; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	61	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2515	2525						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700510				2022-12-17	WOS:A1996UW48700005
J	Gao, C; Arlinghaus, RB; Singh, B				Gao, C; Arlinghaus, RB; Singh, B			Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells	ONCOGENE			English	Article						c-mos expression; transcriptional regulation; cell cycle control	PROTO-ONCOGENE; SARCOMA-VIRUS; MEIOTIC MATURATION; MOUSE-TISSUES; IDENTIFICATION; SEQUENCES; RNA; UPSTREAM; PRODUCT; CLONING	The mouse c-mos proto-oncogene is primarily expressed in germ cells. Our previous studies demonstrated c-mos RNA expression in mouse somatic cells, with the highest level present in the G(2) phase of the cell cycle (Tsui et al., 1993). We have identified the transcription start site of this G(2) specific c-mos transcript to be located about 1580 bp upstream from the open reading frame based on RT-PCR and RNase protection experiments. Upstream sequences containing this transcription start site directed highest expression of the luciferase reporter gene in M phase of the cell cycle. These results suggest that c-mos transcripts are produced in G, phase and that c-Mos protein albeit at extremely low levels would accumulate in M phase.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; JANG SK, 1990, GENE DEV, V4, P1560, DOI 10.1101/gad.4.9.1560; JONES M, 1980, P NATL ACAD SCI-BIOL, V77, P2651, DOI 10.1073/pnas.77.5.2651; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MCGEADY ML, 1986, DNA-J MOLEC CELL BIO, V5, P289, DOI 10.1089/dna.1986.5.289; NASH M, 1984, J VIROL, V50, P478, DOI 10.1128/JVI.50.2.478-488.1984; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PROPST F, 1984, NUCLEIC ACIDS RES, V12, P8381, DOI 10.1093/nar/12.22.8381; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; TOBEY RA, 1990, P NATL ACAD SCI USA, V87, P5104, DOI 10.1073/pnas.87.13.5104; TSUI L, 1993, THESIS U TEXAS GRADU; TSUI LV, 1993, INT J ONCOL, V2, P493; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43; ZINKEL SS, 1992, MOL CELL BIOL, V12, P2029, DOI 10.1128/MCB.12.5.2029	23	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1571	1576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622874				2022-12-17	WOS:A1996UF07600022
J	Zubiaur, M; Forman, LW; Stice, LL; Faller, DV				Zubiaur, M; Forman, LW; Stice, LL; Faller, DV			A role for activated p21(ras) in inhibition regulation of platelet-derived growth factor (PDGF) type-beta receptor activation	ONCOGENE			English	Article						Ras; signal transduction; tyrosine phosphorylation; EGF; grb-2; syp	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; EJ-RAS ONCOGENE; SIGNAL TRANSDUCTION; CDNA CLONING; TRANSFORMED CELLS; PHOSPHORYLATION; EXPRESSION; BINDING	Ligand-stimulated Platelet-Derived Growth Factor [PDGF] type-beta receptor autophosphorylation, and tyrosine phosphorylation of receptor-associated signalling proteins, is blocked in cells expressing activated Ras genes. A factor present in membrane fractions of v-ras-expressing fibroblasts (Kbalb cells) dominantly inhibits the autophosphorylation of the PDGF type-beta receptor. Purification of this factor, via ion exchange, reveals that the inhibitor can be physically separated from the PDGF type-beta receptor, with reconstitution of PDGF type-beta receptor kinase activity in response to ligand binding. The inhibitor exhibited specificity for the PDGF type-beta receptor, and consistently co-purified with activated p21(ras), with Syp/PTP-2, and with Grb2. Neutralization of the p21(ras) protein from the Kbalb cell membranes by p21(ras)-specific monoclonal antibodies, however, completely removed the inhibition of PDGF type-beta receptor, rendering the PDGF type-beta receptor molecule capable of autophosphorylation in response to ligand. These results indicate that activated p21(ras) either interacts directly with the PDGF type-beta receptor to inhibit autokinase activity, or complexes with different molecules such as Syp and/or Grb2 at the cell membrane to act on another effector which then inhibits PDGF type-beta receptor function.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University			Zubiaur, Mercedes/AAC-5792-2021; Zubiaur, Mercedes/K-9390-2014	Zubiaur, Mercedes/0000-0002-4127-3027; Zubiaur, Mercedes/0000-0002-4127-3027				BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN S, 1980, J BIOL CHEM, V255, P4834; DOWNING JR, 1991, ONCOGENE, V6, P607; EGAN SE, 1993, NATURE, V363, P15; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIN AH, 1988, MOL CELL BIOL, V18, P5052; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIAO S, 1994, J BIOL CHEM, V269, P21244; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	49	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1213	1222						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649823				2022-12-17	WOS:A1996UC06700006
J	Kim, S; Brown, PH; Birrer, MJ				Kim, S; Brown, PH; Birrer, MJ			The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor	ONCOGENE			English	Article						transcription factor; jun; fos; AP-1; dominant negative mutant; estrogen receptor	FUSION PROTEIN; TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; GENE FAMILY; TRANSFORMATION; CELLS; DIFFERENTIATION; ONCOPROTEIN; SUPPRESSION; EXPRESSION	Tam-67 is an amino-terminal deletion mutant of c-Jun (Delta 3-122) lacking most of the c-Jun transactivation domain, which has been shown previously to function in a transdominant fashion to inhibit c-Jun-induced transactivation and cellular transformation. In order to create a ligand-dependent dominant negative repressor of AP-1, we have constructed a fusion of the TAM-67 gene with the ligand binding domain of the estrogen receptor. Fusion of TAM-67 with the ligand binding domain of the estrogen receptor produced a 68 kD protein (TAM-67ER) which was immunoprecipitated by c-Jun-specific and estrogen receptor-specific antisera and shown by gel retardation assay to bind oligonucleotides containing an AP-1 sequence. Cotransfection of TAM-67ER and an AP-1-dependent reporter construct into rat embryo cells demonstrated ligand specific inhibition of AP-1 transactivation. In the absence of hormone, TAM-67ER produced complete inhibition of cJun-induced AP-1 transactivation. This inhibition was relieved by treatment with estradiol but not by treatment with tamoxifen. In addition, TAM-67ER inhibited activated c-Ha-ras- or c- raf-induced transformation of NTH3T3 cells. However, this inhibition of transformation was not relieved by the addition of estrogen. Thus, TAM-67ER inhibits transactivation in a ligand-dependent manner, but inhibits transformation in a ligand-independent manner. The results suggest that the ligand-dependent transactivation domain of the estrogen receptor (TAF-2) can substitute for the cJun transactivation domain absent in TAM-67 to stimulate transactivation. However, TAF-2 cannot substitute for the missing c-Jun transactivation domain to induce cellular transformation.	NCI,DIV CLIN SCI,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANCIS MK, 1995, J BIOL CHEM, V270, P11502, DOI 10.1074/jbc.270.19.11502; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILBERT DM, 1993, MOL CELL BIOL, V13, P462, DOI 10.1128/MCB.13.1.462; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; MATSUI M, 1990, ONCOGENE, V5, P249; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; RAPP UR, 1994, ONCOGENE, V9, P3493; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TOMMASINO M, 1994, J VIROL, V68, P2206; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	35	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1043	1053						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649795				2022-12-17	WOS:A1996UA88400012
J	DAmbrosio, C; Hongo, A; Li, S; Baserga, R				DAmbrosio, C; Hongo, A; Li, S; Baserga, R			The role of Grb2 in the growth and transformation of mouse embryo cells	ONCOGENE			English	Article						Grb2; IGF-I receptor; transformation; T-antigen	INSULIN-RECEPTOR SUBSTRATE-1; MITOGENIC SIGNAL TRANSDUCTION; FACTOR-I; TYROSINE KINASES; SH3 DOMAIN; RAS; PROTEIN; EXPRESSION; IRS-1; GENE	An overexpressed insulin-like growth factor I receptor (IGF-IR) allows cells to grow in IGF-I only and to form colonies in soft agar. Conversely, cells with a targeted disruption of the IGF-IR genes, R(-) cells, are refractory to transformation by several oncoproteins and growth factor receptors, that readily transform their wild type counterparts, W cells. Grb2 is an SH2-SH3 domains protein that links tyrosine kinase receptors to ras signalling. In order to determine its role in mitogenesis and transformation, we have transfected a plasmid expressing Grb2 into R(-) and W cells, and their derivatives already expressing the SV40 large T antigen. In addition, we have used loss-of-function mutants of Grb2 to inquire whether they would act as dominant negatives. Our results show that: (1) an overexpressed Grb2 cannot replace the IGF-IR in IGF-I-mediated mitogenesis; (2) Grb2 also fails to transform either W or R(-) cells; (3) Grb2 and SV40 T antigen, singly transfected, cannot transform R(-) cells, but can do so when combined; and (4) SH3 domain mutants of Grb2 act as dominant negatives, causing reversion of the transformed phenotype. We conclude that Grb2 is necessary but not sufficient for transformation.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIA NIH HHS [AG 00378] Funding Source: Medline; NIGMS NIH HHS [GM 33694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000378] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BASERGA R, 1985, BIOL CELL REPRODUCTI; BASU T, 1994, ONCOGENE, V9, P3483; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOK JR, 1993, LIFE SCI, V53, P803, DOI 10.1016/0024-3205(93)90502-T; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DEANGELIS T, 1995, IN PRESS J CELL PHYS; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; LI FZ, 1995, MOL CELL BIOL, V15, P4232; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORJAN J, 1993, SCIENCE, V256, P94; ULLRICH A, 1986, EMBO J, V5, P503; VALENTINIS B, 1994, ONCOGENE, V9, P825; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	71	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570214				2022-12-17	WOS:A1996TR53800016
J	FRANKLIN, GC; ADAM, GIR; MILLER, SJ; MONCRIEFF, CL; ULLERAS, E; OHLSSON, R				FRANKLIN, GC; ADAM, GIR; MILLER, SJ; MONCRIEFF, CL; ULLERAS, E; OHLSSON, R			AN INR-CONTAINING SEQUENCE FLANKING THE TATA BOX OF THE HUMAN C-SIS (PDGF-B) PROTOONCOGENE PROMOTER FUNCTIONS IN CIS AS A COACTIVATOR FOR ITS INTRONIC ENHANCER	ONCOGENE			English	Article						PDGF-B; C-SIS; INR; ENHANCER PROMOTER INTERACTIONS	GROWTH-FACTOR; CELL-LINES; TRANSCRIPTION INITIATION; REGULATORY ELEMENTS; MESSENGER-RNAS; 1ST INTRON; GENE; EXPRESSION; REGION; IDENTIFICATION	High-level activity of the human PDGF-B promoter in choriocarcinoma cell lines depends upon an atypical, intronic enhancer-like element which does not function with heterologous promoters tested. An extensive series of mutant PDGF-B promoter-driven constructs identified a sequence flanking the TATA box which is required specifically for enhancer-mediated transcription in human choriocarcinoma cell lines. This element, which we here term an enhancer-dependent cis co-activator (EDC) contains an Inr (initiator) consensus sequence upstream of the TATA box which is required, but not sufficient for its function. Requirement for the EDC is cell type-specific, since it was dispensable for enhancer-mediated transcription in a human breast cancer cell line. Although it lies within the region defined, the TATA box itself is not required for EDC function, or for basal promoter function which may derive from a second Inr-like sequence situated at the transcriptional start site. These observations indicate that interactions between some promoter and enhancer elements may be more complex than that generally described for 'classical' enhancer systems and may suggest an additional function for the initiator motif.			FRANKLIN, GC (corresponding author), UPPSALA UNIV,DEPT ANIM DEV & GENET,NORBYVAGEN 18A,S-75236 UPPSALA,SWEDEN.							BEHL C, 1993, NEUROSURGERY, V33, P697; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; FEN Z, 1991, ONCOGENE, V6, P953; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GARCIA JV, 1986, NATURE, V322, P383, DOI 10.1038/322383a0; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HELDIN CH, 1990, CELL REGUL, V1, P555, DOI 10.1091/mbc.1.8.555; HOLMGREN L, 1993, CANCER RES, V53, P2927; HOLMGREN L, 1991, DEVELOPMENT, V113, P749; Holmgren L, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026929; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; JIN HM, 1994, J BIOL CHEM, V269, P28648; KANEDA S, 1992, SOMAT CELL MOLEC GEN, V18, P409, DOI 10.1007/BF01233080; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KERMEKCHIEV M, 1991, GENE EXPRESSION, V1, P71; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LI H, 1994, EMBO J, V13, P3580, DOI 10.1002/j.1460-2075.1994.tb06665.x; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; MATSUOKA S, 1993, EUR J BIOCHEM, V218, P173, DOI 10.1111/j.1432-1033.1993.tb18363.x; NISTER M, 1988, CANCER RES, V48, P3910; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; OSHIMA RG, 1990, GENE DEV, V4, P835, DOI 10.1101/gad.4.5.835; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PERES R, 1987, CANCER RES, V47, P3425; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; TIJAN R, 1994, CELL, V77, P5; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0	44	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1873	1884						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478617				2022-12-17	WOS:A1995TD09400024
J	RONDINELLI, RH; HASLAM, SZ; FLUCK, MM				RONDINELLI, RH; HASLAM, SZ; FLUCK, MM			THE ROLE OF OVARIAN HORMONES, AGE AND MAMMARY-GLAND DEVELOPMENT IN POLYOMAVIRUS MAMMARY TUMORIGENESIS	ONCOGENE			English	Article						MAMMARY TUMOR DEVELOPMENT; OVARIAN HORMONES; AGE; POLYOMAVIRUS	VIRUS ONCOGENICITY; BREAST-CANCER; NUDE-MICE; CARCINOGENESIS; INDUCTION; ESTROGEN; DISEASE; TISSUE; TUMORS; RATS	Polyomavirus infection of adolescent athmyic female mice causes a high incidence of mammary adenocarcinomas, We have examined the role of ovarian hormones, age and mammary gland developmental stage at infection on subsequent tumor induction, viral replication and gene expression, Ovariectomy (OVX) of adolescent mice 1 week before infection decreased mammary tumor incidence and number, and significantly increased tumor latency. Reduction in tumorigenesis mas observed to a lesser degree if mice mere OVX at the time of or after infection, indicating that ovarian hormones are mainly required for tumor initiation. Tumor incidence was also reduced with increasing age; OVX prior to infection at older ages drastically reduced tumor development. Treatment of OVX adult mice with estrogen + progesterone for 1-3 weeks prior to infection was unable to restore tumorigenesis to the level observed in intact mice. Thus, in contrast to adolescent mice, the continued presence of ovarian hormones after infection was required for maximal tumorigenesis in adult mice. The decreased tumorigenesis observed in older animals is not likely due to increased differentiation since late pregnant mice with well differentiated mammary glands remained highly susceptible to tumorigenesis. At 10 days post infection, the levels of viral genomes were moderately high and similar in all experimental groups. Early viral protein and middle T-associated kinase levels were undetectable in infected tissues in all experimental conditions. However, high levels were found in tumors, perhaps reflecting a high dosage requirement for oncogenesis.	MICHIGAN STATE UNIV,DEPT MICROBIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PHYSIOL,CELL & MOLEC BIOL PROGRAM,E LANSING,MI 48824	Michigan State University; Michigan State University					NCI NIH HHS [5R01 CA58763, 5R01 CA40104] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058763, R01CA040104] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUZZI A, 1990, New Biologist, V2, P533; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BANERJEE M R, 1976, TCA (Tissue Culture Association) Manual, V2, P457, DOI 10.1007/BF00918341; BEREBBI M, 1988, ONCOGENE, V2, P149; BEREBBI M, 1990, ONCOGENE, V5, P505; BODIAN CA, 1993, CANCER, V71, P3896, DOI 10.1002/1097-0142(19930615)71:12<3896::AID-CNCR2820711217>3.0.CO;2-I; BOICE JD, 1977, J NATL CANCER I, V59, P823, DOI 10.1093/jnci/59.3.823; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHEN MC, 1995, J VIROL, V69, P326, DOI 10.1128/JVI.69.1.326-333.1995; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAO TL, 1959, JNCI-J NATL CANCER I, V23, P567; DAO TL, 1962, CANCER RES, V22, P973; DAO TL, 1969, SCIENCE, V165, P810, DOI 10.1126/science.165.3895.810; DAO TL, 1960, J NATL CANCER I, V25, P991; DAWE CJ, 1987, AM J PATHOL, V127, P243; DIFRONZO G, 1990, ANTICANCER RES, V10, P1699; GRUBBS CJ, 1983, J NATL CANCER I, V70, P209; GRUBBS CJ, 1983, J NATL CANCER I, V71, P625; GULLINO PM, 1975, J NATL CANCER I, V54, P401; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HASLAM SZ, 1988, ENDOCRINOLOGY, V122, P464, DOI 10.1210/endo-122-2-464; HASLAM SZ, 1992, ONCOGENE, V7, P1295; HASLAM SZ, 1992, J STEROID BIOCHEM, V42, P589, DOI 10.1016/0960-0760(92)90449-S; HASLAM SZ, 1989, ENDOCRINOLOGY, V125, P2766, DOI 10.1210/endo-125-5-2766; HASLAM SZ, 1980, INT J CANCER, V26, P349, DOI 10.1002/ijc.2910260315; HASLAM SZ, 1993, J CELL PHYSIOL, V155, P72, DOI 10.1002/jcp.1041550110; HUGGINS C, 1959, J EXP MED, V109, P25, DOI 10.1084/jem.109.1.25; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KORFSMEIER KH, 1979, ANAT ANZEIGER, V145, P313; MERANZE DR, 1969, INT J CANCER, V4, P480, DOI 10.1002/ijc.2910040413; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NAGASAWA H, 1977, ACTA ENDOCRINOL-COP, V86, P794, DOI 10.1530/acta.0.0860794; NANDI S, 1958, J NATL CANCER I, V21, P1039; NERI C, 1990, CANCER RES, V50, P5892; RUSSO IH, 1990, BRIT J CANCER, V62, P243, DOI 10.1038/bjc.1990.268; RUSSO J, 1977, J NATL CANCER I, V59, P435, DOI 10.1093/jnci/59.2.435; RUSSO J, 1987, J NATL CANCER I, V78, P413; RUSSO J, 1979, AM J PATHOL, V96, P721; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; RUSSO J, 1978, J NATL CANCER I, V61, P1451; SHARKEY SM, 1986, CARCINOGENESIS, V7, P1991, DOI 10.1093/carcin/7.12.1991; SINHA DK, 1983, INT J CANCER, V31, P321, DOI 10.1002/ijc.2910310312; Swanson G M, 1994, J Natl Cancer Inst Monogr, P69; TOKUNAGA M, 1979, J NATL CANCER I, V62, P1347; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; VONDERHAAR BK, 1985, CONTROL CELL GROWTH, P11; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183; WIRTH JJ, 1992, J VIROL, V66, P3278, DOI 10.1128/JVI.66.6.3278-3286.1992	50	9	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1817	1827						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478610				2022-12-17	WOS:A1995TD09400017
J	PASTEAU, S; LOISEAU, L; AMAUD, L; TREMBLEAU, A; BRUN, G				PASTEAU, S; LOISEAU, L; AMAUD, L; TREMBLEAU, A; BRUN, G			ISOLATION AND CHARACTERIZATION OF A CHICKEN HOMOLOG OF THE E2F-1 TRANSCRIPTION FACTOR	ONCOGENE			English	Article						CHICKEN E2F-1; CELL CYCLE; TRANSCRIPTION FACTOR; NEURORETINA; ONCOGENIC PROPERTIES	DIHYDROFOLATE-REDUCTASE PROMOTER; RETINOBLASTOMA PROTEIN; EMBRYO FIBROBLASTS; BINDING PROTEIN; C-JUN; CLONING; ACTIVATION; EXPRESSION; GENE; MYC	In higher eukaryotes, the E2F-1 transcription factor is an essential and limiting component of cell cycle progression in late G1. E2F-1 heterodimerizes with members of the DP gene family and the resulting heterodimer regulates the expression of several protooncogenes and the genetic machinery of DNA replication. Cell cycle regulation of E2F activity is mediated through its association with the tumor suppressor Rb gene product. To examine the evolutionary conservation of the E2F-1 protein sequence and its developmental expression pattern we have isolated and sequenced the chick E2F-1 gene (chE2F-1) cDNA. The chicken protein is 34 amino acids (a.a) shorter than its human counterpart (403/437 a.a.) but has extremely web conserved bHLH and pRb binding domains, with respectively 94% and 83% identity. The position of the leucine zipper is also strictly conserved thereby accounting for ability of E2F-1 to form heterodimers with human and chicken DP-1. E2F-1 expression was analysed in synchronized cells as well as in embryonic or newborn chick tissues and appears to be closely correlated to the cell proliferation rate. In situ hybridization studies have shown very high expression levels in the neuroretina during the early stages of embryonic development when active nenroblast division occurs. Tn contrast, a sharp down-regulation is observed when cells become postmitotic. Overexpression of the chE2F-1 protein leads to oncogenic transformation only when a truncated version of the transgene lacking the pRb binding domain is used; the full length protein either has no effect or may be deleterious for cell survival.			PASTEAU, S (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,ENS,UMR49,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.			Trembleau, Alain/0000-0002-8290-0795				BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CRESS WD, 1994, J VIROL, V68, P4212, DOI 10.1128/JVI.68.7.4213-4219.1994; DOBROWOLSKI SF, 1994, ONCOGENE, V9, P2605; DOU QP, 1994, J BIOL CHEM, V269, P1306; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAYES TE, 1991, NEW BIOL, V3, P259; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V9, P1529; JORDAN KL, 1994, ONCOGENE, V9, P1177; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sambrook J., 1989, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; WU CL, 1995, MOL CELL BIOL, V15, P2536; WU X, 1994, P NATL ACAD SCI USA, V91, P36602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	48	9	10	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 19	1995	11	8					1475	1486						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478572				2022-12-17	WOS:A1995TC53500006
J	GAJEWSKI, KM; SCHULZ, RA				GAJEWSKI, KM; SCHULZ, RA			REQUIREMENT OF THE ETS DOMAIN TRANSCRIPTION FACTOR D-ELG FOR EGG CHAMBER PATTERNING AND DEVELOPMENT DURING DROSOPHILA OOGENESIS	ONCOGENE			English	Article						CELL MIGRATION; DROSOPHILA OOGENESIS; MUTANT PHENOTYPE; TRANSCRIPTION FACTOR	BINDING-PROTEIN; GENE; RNA; LOCALIZATION; EMBRYO; DIFFERENTIATION; EMBRYOGENESIS; MELANOGASTER; CHROMOSOME; POLARITY	The D-elg gene encodes an ETS domain transcription factor that functions in Drosophila oogenesis. D-elg belongs to a small group of genes that are required for the formation of both the anteroposterior and dorsoventral axes of the egg chamber. During oogenesis in D-elg mutant females, the spatial localization of oskar and gurken mRNAs in the oocyte is disrupted and a follicle cell enhancer trap marker identifies dorsoventral polarity defects. Also, specialized follicle cells, called border cells, fail to migrate from their anterior location to a position adjacent to the developing oocyte. Consistent with these phenotypes, D-elg shows genetic interactions with two genes required for normal egg chamber differentiation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NICHD NIH HHS [T32 HD 07324] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007324] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BROWN T, 1992, GENE DEV, V6, P502; CHRISTERSON LB, 1994, GENE DEV, V8, P614, DOI 10.1101/gad.8.5.614; CUPP MB, 1962, MOUSE NEWS LETT, V26, P51; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FORLANI S, 1993, MECH DEVELOP, V41, P109, DOI 10.1016/0925-4773(93)90041-U; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KIMBLE M, 1990, GENETICS, V126, P991; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; LANTZ V, 1994, GENE DEV, V8, P598, DOI 10.1101/gad.8.5.598; LEPTIN M, 1989, CELL, V56, P401, DOI 10.1016/0092-8674(89)90243-2; LU XY, 1993, DEVELOPMENT, P47; MANSEAU L, 1994, 35TH ANN DROS RES C; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; NEUMANSILBERBER.FS, 1993, CELL, V75, P165; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PEIFER M, 1993, DEVELOPMENT, V118, P1191; ROTH S, 1994, DEVELOPMENT, V120, P2245; SCHULZ RA, 1993, P NATL ACAD SCI USA, V90, P10076, DOI 10.1073/pnas.90.21.10076; SCHULZ RA, 1993, ONCOGENE, V8, P3369; SCHUPBACH T, 1991, GENETICS, V129, P1119; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SPRADLING A, 1909, DEV DROSOPHILA MELAN, P1; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; STJOHNSTON D, 1989, CELL, P13; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1994, SCIENCE, V265, P2093, DOI 10.1126/science.8091233; THEURKAUF WE, 1992, DEVELOPMENT, V115, P923; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644	36	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1033	1040						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566961				2022-12-17	WOS:A1995RX18000004
J	MEDEMA, JP; DEVRIESSMITS, AMM; BOS, JL				MEDEMA, JP; DEVRIESSMITS, AMM; BOS, JL			CALCIUM INDUCES TYROSINE PHOSPHORYLATION OF A NOVEL P120GAP-ASSOCIATED PROTEIN OF 65 KDA	ONCOGENE			English	Article						KERATINOCYTES; SIGNAL TRANSDUCTION; P2LRAS	GTPASE-ACTIVATING PROTEIN; INDUCED KERATINOCYTE DIFFERENTIATION; MOUSE EPIDERMAL-CELLS; MOLECULAR-CLONING; KINASE-ACTIVITY; GAP; ASSOCIATION; RECEPTOR; SRC; RAS	Several tyrosine-phosphorylated proteins have been identified that associate with p120GAP, the GTPase activating protein of p21ras. In keratinocytes, calcium induced the tyrosine phosphorylation of a 65 kDa p120GAP-associated protein (p65Ca). This protein did not comigrate with two previously reported p120GAP-associated proteins, i.e. a 68 kDa protein from src-transformed cells (p68) and an insulin-induced protein of 60 kDa (p60(2C4)). P65Ca was neither recognized by poly(U)-sepharose, which efficiently precipitates p68, nor did it crossreact with antibodies against p68. In addition, a monoclonal antibody directed to p60(2C4) did not recognize p65Ca. From these results we conclude that p65Ca is different from p68 and p60(2C4) and thus, a novel p120GAP-associated protein. Since calcium has an important, tyrosine kinase dependent, role in the differentiation of keratinocytes, phosphorylation of p65Ca may be important for this differentiation process. However, surprisingly, calcium induced the phosphorylation of a similar-sized p120GAP-associated 65 kDa protein in fibroblast cell lines.	UNIV UTRECHT, PHYSIOL CHEM LAB, 3584 CG UTRECHT, NETHERLANDS	Utrecht University				Medema, Jan Paul/0000-0003-3045-2924				BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Buxton R S, 1992, Semin Cell Biol, V3, P157; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FILVAROFF E, 1994, J BIOL CHEM, V269, P21735; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HENNINGS H, 1983, EXP CELL RES, V143, P127, DOI 10.1016/0014-4827(83)90115-5; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; MEDEMA JP, 1994, MOL CELL BIOL, V14, P7078, DOI 10.1128/MCB.14.11.7078; MENON GK, 1991, ARCH DERMATOL, V127, P57, DOI 10.1001/archderm.127.1.57; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; OGAWA W, 1994, J BIOL CHEM, V269, P29602; PRONK GJ, 1992, J BIOL CHEM, V267, P24058; PRONK GJ, 1992, ONCOGENE, V7, P389; SCHERUBL H, 1990, FEBS LETT, V273, P51, DOI 10.1016/0014-5793(90)81048-S; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; STROOP SD, 1993, J BIOL CHEM, V268, P19927; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298	36	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					757	762						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7544452				2022-12-17	WOS:A1995RQ46900018
J	VASTRIK, I; MAKELA, TP; KOSKINEN, PJ; ALITALO, K				VASTRIK, I; MAKELA, TP; KOSKINEN, PJ; ALITALO, K			DETERMINATION OF SEQUENCES RESPONSIBLE FOR THE DIFFERENTIAL REGULATION OF MYC FUNCTION BY DELTA-MAX AND MAX	ONCOGENE			English	Article						MYC; MAX; DELTA-MAX; TRANSFORMATION; TRANSACTIVATION	MAMMALIAN EXPRESSION VECTOR; C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; PROTEIN; FORMS; COTRANSFORMATION; DIMERIZATION; DOMAINS; COMPLEX	The DNA-binding, transcriptional activation and transforming activities of the Myc protein require dimerization with Max. Max can form also homodimers which are able to bind the same DNA sequence as Myc/Max heterodimers and suppress Myc-induced transcription and transformation. We have recently identified naturally occurring truncated form of Max, Delta Max, which in a rat embryo fibroblast enhances transformation by Myc and Ras, Like Max, this Delta Max protein contains a b-HLH-Zip domain, except that the end of the leucine zipper is replaced by five Delta Max-specific amino acid residues. Delta Max also lacks the C-terminal sequences of Max including a nuclear localisation signal. Here we have dissected the regions responsible for the specific effects of Max and Delta Max in Ras-Myc cotransformation of rat embryo fibroblasts, Our results indicate that the suppressive activity of Max requires C-terminal acidic and basic regions and an intact leucine zipper. Replacement of the end of the leucine zipper with the Delta Max-specific sequence is responsible for the enhancement of transformation by Delta Max. Surprisingly, Delta Max does not require the DNA-binding basic region for enhancement of transformation and has no effect on Myc-induced transcription activation from Myc/Max-binding site-containing promoter construct.	UNIV HELSINKI,HAARTMAN INST,MOLEC CANC BIOL LAB,SF-00014 HELSINKI,FINLAND	University of Helsinki			makela, tomi/B-3734-2009; Vastrik, Imre/C-2690-2009; Alitalo, Kari K/J-5013-2014; Koskinen, Päivi J/G-8939-2014	makela, tomi/0000-0002-4869-8044; Alitalo, Kari K/0000-0002-7331-0902; Vastrik, Imre/0000-0001-6658-9311				ALITALO K, 1992, GENE AMPLIFICATION M, P371; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P1; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KATAGIRI F, 1992, MOL CELL BIOL, V12, P809; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOSKINEN PJ, 1994, CELL GROWTH DIFFER, V5, P313; KOSKINEN PJ, 1993, SEMIN CANCER BIOL, V4, P3; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MCCLUTCHAN JH, 1968, J NATL CANCER I, V41, P351; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; Sambrook J., 1989, MOL CLONING LAB MANU; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; STACEY A, 1990, NUCLEIC ACIDS RES, V18, P2829, DOI 10.1093/nar/18.9.2829; VASTRIK I, 1993, ONCOGENE, V8, P503; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	32	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					553	560						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630640				2022-12-17	WOS:A1995RN53000016
J	BUCKLE, RS; MECHALI, M				BUCKLE, RS; MECHALI, M			ANALYSIS OF C-MYC AND MAX BINDING TO THE C-MYC PROMOTER - EVIDENCE THAT AUTOSUPPRESSION OCCURS VIA AN INDIRECT MECHANISM	ONCOGENE			English	Note						C-MYC/MAX; AUTOSUPPRESSION; DNA BINDING PROTEINS; XENOPUS; DNA REPLICATION	DNA-BINDING; REPLICATION ORIGIN; PROTEIN; GENE; SEQUENCE; AUTOREGULATION; TRANSCRIPTION; ONCOPROTEIN; ASSOCIATION; ACTIVATION	c-myc negatively autoregulates its expression at the level of transcriptional initiation, although the precise mechanism remains debated. While conclusive evidence for c-Myc binding in its own promoter has not been found, it has been proposed that c-Myc binds to a site upstream of the human c-myc gene which may also be a component of a replication origin (Ariga et al., 1989). In an attempt to clarify this issue, sequences flanking the c-myc gene were screened for c-Myc or Max binding sites using a novel procedure to facilitate the detection of DNA binding dependent upon long distance interactions or DNA secondary structure, Since the sequence specificity of DNA binding proteins may also be mediated by interaction with other proteins or by protein modification, this affinity capture assay was used in conjunction with nuclear extracts, potentially allowing the selection of novel in vivo DNA binding spcificities. Using conditions that gave strong binding to an internal control sequence, c-Myc or Max binding elements were not detected in genomic sequences extending 5.4 kb upstream of the Xenopus c-myc gene. Identical results were obtained using both purified proteins and a variety of nuclear extracts, suggesting c-myc autosuppression most likely involves an indirect pathway.	INST JACQUES MONOD,MOLEC EMBRYOL UNIT,F-75251 PARIS 05,FRANCE	UDICE-French Research Universities; Universite Paris Cite								AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; Cleveland J L, 1988, Oncogene Res, V3, P357; CROUCH DH, 1990, ONCOGENE, V5, P683; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V5, P1475; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUSSE M, 1989, MOL CELL BIOL, V9, P5395, DOI 10.1128/MCB.9.12.5395; HALZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6612; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KATO GJ, 1992, GENE DEV, V6, P85; KITAURA H, 1991, FEBS LETT, V290, P147, DOI 10.1016/0014-5793(91)81246-5; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; NEGISHI Y, 1992, ONCOGENE, V7, P543; PAPOULAS O, 1992, J BIOL CHEM, V267, P10470; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4916; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WRIGHT WE, 1993, TRENDS BIOCHEM SCI, V18, P77, DOI 10.1016/0968-0004(93)90156-H; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	40	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1249	1255						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700652				2022-12-17	WOS:A1995QN35300029
J	PULS, A; PROIKASCEZANNE, T; MARQUARDT, B; PROPST, F; STABEL, S				PULS, A; PROIKASCEZANNE, T; MARQUARDT, B; PROPST, F; STABEL, S			KINASE-ACTIVITIES OF C-MOS AND V-MOS PROTEINS - A SINGLE AMINO-ACID EXCHANGE IS RESPONSIBLE FOR CONSTITUTIVE ACTIVATION OF THE 124-V-MOS KINASE	ONCOGENE			English	Article						PROTEIN KINASE ACTIVITY; C-MOS; V-MOS; MAP KINASE ACTIVATION; PHOSPHORYLATION; ONCOGENE; ATP BINDING MUTATION	MURINE SARCOMA-VIRUS; MAMMALIAN SOMATIC-CELLS; PROTO-ONCOGENE PRODUCT; XENOPUS OOCYTES; CYTOSTATIC FACTOR; MAP KINASE; NUCLEOTIDE-SEQUENCE; MEIOTIC MATURATION; CRYSTAL-STRUCTURE; FROG OOCYTES	The Mos protein kinase is a serine-/threonine-specific protein kinase with a crucial role in meiotic cell divisions in vertebrates. Several oncogenic derivatives of the c-Mos protein have been discovered in murine retroviruses. These proteins have acquired mutations and exhibit different degrees of protein kinase activity in vitro. In an attempt to understand the factors governing Mos protein kinase activity we have compared the kinase activities of the wild-type c-Mos protein and of two v-Mos proteins (strain HT1 and MSV124) after expression in insect cells. Only the 124 v-Mos protein showed kinase activity in vitro as measured by autophosphorylation, vimentin phosphorylation or by phosphorylation and activation of MAP kinase kinase. By domain swapping and site-directed mutagenesis we identified a single point mutation in the 124 v-Mos protein (Arg(145)-->Gly) which is responsible for its constitutive activity. This residue is located in the alpha-helix C of the kinase domain close to the ATP binding fold and is conserved in all known c-Mos proteins. Introduction of the corresponding mutation into HT1 v-Mos and into murine c-Mos activated bath proteins for autophosphorylation, vimentin phosphorylation and for signalling via MAP kinase kinase in vitro. We hypothesize that the Arg(145)-->Gly mutation found in 124 v-Mos mimicks a conformational change which might be an obligatory step in the activation of c-Mos in vivo.	MAX PLANCK GESELL, MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY; UNIV VIENNA, BIOZENTRUM, INST BIOCHEM & MOLEK ZELLBIOL, A-1030 VIENNA, AUSTRIA	Max Planck Society; University of Vienna				Proikas-Cezanne, Prof. Dr. Tassula/0000-0001-6934-132X				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLAIR DG, 1984, CANCER CELLS ONCOGEN, P281; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HASHIMOTO N, 1994, NATURE, V370, P58; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MARQUARDT B, 1992, GENE, V120, P297, DOI 10.1016/0378-1119(92)90109-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NEBREDA AR, 1993, FEBS LETT, V333, P183, DOI 10.1016/0014-5793(93)80401-F; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAULES RS, 1992, ONCOGENE, V7, P2489; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1992, J NEUROPATH EXP NEUR, V51, P499, DOI 10.1097/00005072-199209000-00004; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P23933	45	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					623	630						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862439				2022-12-17	WOS:A1995QH61200001
J	VENNSTROM, B; RAYNOSCHECK, C; JANSSON, L; DOEDERLEIN, G; LHOTAK, V; JOHNSSON, A; BEUG, H				VENNSTROM, B; RAYNOSCHECK, C; JANSSON, L; DOEDERLEIN, G; LHOTAK, V; JOHNSSON, A; BEUG, H			RETROVIRAL CAPTURE OF C-ERBB PROTOONCOGENE SEQUENCES - RAPID EVOLUTION OF DISTINCT VIRAL GENOMES CARRYING MUTANT V-ERBB GENES WITH DIFFERENT TRANSFORMING CAPACITIES	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; ROUS-SARCOMA VIRUS; TISSUE-SPECIFIC TRANSFORMATION; SINGLE REPLICATION CYCLE; LARGE DELETION MUTANTS; LEUKOSIS VIRUS; EGF RECEPTOR; NUCLEOTIDE-SEQUENCE; CELL-TRANSFORMATION	The evolution of oncogene-transducing retorviruses was followed by studying the genomes of five new, erbB carrying retroviruses. These viruses, isolated from cells of one chicken infected with Rous Associated virus 1 (RAV-1), had captured c-erbB sequences as a consequence of RAV-1 integration into the host genome. Their genome structures were distinct; however, their v-erbB genes had sustained identical 5' and 3' deletions and the v-erbB-env junctions were identical at the nucleotide level. The results therefore strongly suggest that all five viruses originate from the same capture event. Sequence analyses of the v-erbB genes from three of these viruses revealed that one of them had undergone no further mutation and lacked detectable capacity to transform cells, therefore probably representing an 'early' form of transducing virus. The two other v-erbB genes contained distinct mutations and differed in their potential to induce fibroblast- and erythroblast transformation; they therefore probably represent later derivatives of the virus that captured the erbB oncogene. The data suggest that the initial retrovirus rapidly underwent many alterations after capture of c-erbB sequences, already in the RAV-1 infected bird as well as during subsequent in vitro isolation procedures. The changes involve both major rearrangements of the genome as well as point mutations that activated the erbB oncogene.	KAROLINSKA INST,DEPT MED CELL BIOL,S-10401 STOCKHOLM,SWEDEN; SQUIBB FORRESTRAL GREENS,DEPT MOLEC BIOL,PLAINSBORO,NJ 08536; EMBL,HEIDELBERG,GERMANY; MT SINAI HOSP,TORONTO M5G 1X5,ON,CANADA; INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Karolinska Institutet; European Molecular Biology Laboratory (EMBL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	VENNSTROM, B (corresponding author), KAROLINSKA INST,DEPT MOLEC BIOL,S-10401 STOCKHOLM,SWEDEN.			Sanchez-Pardo Echevarria, Jesus/0000-0002-3683-5371				BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1981, VIROLOGY, V111, P201, DOI 10.1016/0042-6822(81)90665-6; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; FUNG YKT, 1983, CELL, V33, P357, DOI 10.1016/0092-8674(83)90417-8; GAMETT DC, 1986, P NATL ACAD SCI USA, V83, P6053, DOI 10.1073/pnas.83.16.6053; GLINEUR C, 1990, GENE DEV, V4, P1663, DOI 10.1101/gad.4.10.1663; GOODWIN RG, 1986, MOL CELL BIOL, V6, P3128, DOI 10.1128/MCB.6.9.3128; GRAF T, 1973, VIROLOGY, V54, P398, DOI 10.1016/0042-6822(73)90152-9; GRAF T, 1980, P NATL ACAD SCI-BIOL, V77, P389, DOI 10.1073/pnas.77.1.389; HAYMAN MJ, 1984, NATURE, V309, P460, DOI 10.1038/309460a0; HAYMAN MJ, 1983, CELL, V32, P579, DOI 10.1016/0092-8674(83)90477-4; HIHARA H, 1983, J NATL CANCER I, V70, P891; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HUANG CC, 1986, CELL, V44, P935, DOI 10.1016/0092-8674(86)90016-4; HUANG CC, 1985, J MOL BIOL, V181, P175, DOI 10.1016/0022-2836(85)90083-X; JANSSON M, 1987, ONCOGENE, V1, P167; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KAWAI S, 1987, J VIROL, V61, P1665, DOI 10.1128/JVI.61.5.1665-1669.1987; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KILLISCH I, 1992, J CELL SCI, V103, P211; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LEE EB, 1990, ONCOGENE, V5, P1165; LEE EB, 1993, ONCOGENE, V8, P1317; LEUTZ A, 1988, J BIOL CHEM, V263, P3905; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MAIHLE NJ, 1988, MOL CELL BIOL, V8, P4868, DOI 10.1128/MCB.8.11.4868; MILES BD, 1985, J VIROL, V54, P295, DOI 10.1128/JVI.54.2.295-303.1985; NILSEN TW, 1985, CELL, V41, P719, DOI 10.1016/S0092-8674(85)80052-0; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6024, DOI 10.1073/pnas.87.16.6024; PELLEY RJ, 1989, P NATL ACAD SCI USA, V86, P7164, DOI 10.1073/pnas.86.18.7164; PELLEY RJ, 1988, J VIROL, V62, P1840, DOI 10.1128/JVI.62.5.1840-1844.1988; PRIVALSKY ML, 1984, VIROLOGY, V135, P356, DOI 10.1016/0042-6822(84)90192-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAINES MA, 1988, J VIROL, V62, P2444, DOI 10.1128/JVI.62.7.2444-2452.1988; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2127; ROBINSON HL, 1985, J VIROL, V55, P617, DOI 10.1128/JVI.55.3.617-622.1985; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SCOTTING P, 1987, ONCOGENE RES, V1, P265; SHU HKG, 1991, J VIROL, V65, P6173, DOI 10.1128/JVI.65.11.6173-6180.1991; SHU HKG, 1990, P NATL ACAD SCI USA, V87, P9103, DOI 10.1073/pnas.87.23.9103; SORGE J, 1982, Journal of Molecular and Applied Genetics, V1, P547; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; UHL E., 1936, Acta Pathologica et Microbiologica Scandinavica, V13, P434; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X; VOYNOW SL, 1985, J VIROL, V55, P79, DOI 10.1128/JVI.55.1.79-85.1985; VOYNOW SL, 1985, J VIROL, V55, P67, DOI 10.1128/JVI.55.1.67-78.1985; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1	62	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1307	1320						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152791				2022-12-17	WOS:A1994NH40100001
J	CHOI, KH; WALL, C; HANRATTY, R; KELLER, G				CHOI, KH; WALL, C; HANRATTY, R; KELLER, G			ISOLATION OF A GENE ENCODING A NOVEL RECEPTOR TYROSINE KINASE FROM DIFFERENTIATED EMBRYONIC STEM-CELLS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; C-KIT; SIGNAL TRANSDUCTION; ENZYMATIC AMPLIFICATION; MESSENGER-RNAS; SEQUENCES; IDENTIFICATION; ANGIOGENESIS; EXPRESSION; MUTATIONS	A mouse gene encoding a receptor tyrosine kinase, designated Embryonic receptor kinase (EmRK2), was isolated from embryoid bodies (EBs) generated by differentiating embryonic stem (ES) cells in culture for 6 days. Sequence analysis of EmRK2 cDNA clones predicts a receptor with a 755 amino acid extracellular region with seven immunoglobulin-like domains, a transmembrane region, and a 552 amino acid cytoplasmic region containing the kinase domain. The kinase domain is interrupted by a stretch of hydrophilic amino acids, the kinase insert. EmRK2 is expressed in embryoid bodies, in whole embryos at day 10 and 12 of gestation, and in the embryonic yolk sac and the fetal liver. On the basis of sequence homology, EmRK2 is likely to be the mouse homologue of human flt, a receptor for vascular endothelial growth factor, and as such, could encode an endothelial cell specific receptor tyrosine kinase.	UNIV COLORADO,HLTH SCI CTR,DEPT BIOCHEM BIOPHYS & GENET,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	CHOI, KH (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.			Keller, Gordon/0000-0001-9309-9297				BREIER G, 1992, DEVELOPMENT, V114, P521; CHOI KG, 1993, P NATL ACAD SCI USA, V90, P5747, DOI 10.1073/pnas.90.12.5747; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; EVANS M, NATURE, V292, P154; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEN Z, 1991, ONCOGENE, V6, P953; GALLAND F, 1993, ONCOGENE, V8, P1233; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; REITH AD, 1990, GENE DEV, V4, P3900; RISAU W, 1988, DEVELOPMENT, V102, P471; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SHIBUYA M, 1990, ONCOGENE, V5, P519; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER RC, 1980, ADV MICROCIRCULAT, V9, P45; WANG R, 1992, DEVELOPMENT, V114, P303; WILES MV, 1991, DEVELOPMENT, V111, P259; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1	39	9	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1261	1266						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134130				2022-12-17	WOS:A1994NC04800032
J	KIVINEN, L; PITKANEN, K; LAIHO, M				KIVINEN, L; PITKANEN, K; LAIHO, M			HUMAN RETINOBLASTOMA GENE-PRODUCT PREVENTS C-HA-RAS ONCOGENE-MEDIATED CELLULAR-TRANSFORMATION OF MOUSE FIBROBLASTS	ONCOGENE			English	Article								Suppression of tumor formation and restoration of normal growth of cells has been an insignia that the retinoblastoma gene (RB1) functions as a tumor suppressor gene. The tumor suppressive functions of RB are suggested to associate with regulation of cell cycle events or gene transcription. We have analysed here the interactions of RB and c-Ha-ras oncogene by gene transfection studies. Mouse fibroblasts stably expressing high levels human wild type (wt) pRB or mutant pRB were transfected with genomic or LTR promoter driven c-Ha-ras(Val-12) expression vectors. We find that expression of normal, but not mutant RB protein in the cells prevents c-Ha-ras oncogene mediated cellular transformation and colony formation in soft agar. Analysis of stable RB and genomic c-Ha-ras cell transfectants for expression of pRB and p21ras by immunoblotting indicates a strong correlation with the presence of high levels of RB protein and inhibition of ras-transformation. Moreover, during culturing the RB and genomic c-Ha-ras expressing clones a progressive transformation of phenotypically normal clones was observed which paralleled loss or decrease of RB expression and concomitant increase in p21ras production. These findings suggest a functional cross-talk between RB protein and p21ras, which balances the cell phenotype between normal and transformed states.	UNIV HELSINKI, DEPT VIROL, SF-00014 HELSINKI, FINLAND	University of Helsinki								BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEVINS JR, 1992, SCIENCE, V258, P424; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SISTONEN L, 1990, ONCOGENE, V5, P815; STIRDIVANT SM, 1992, J BIOL CHEM, V267, P14846; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	55	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2703	2711						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378082				2022-12-17	WOS:A1993LX34300011
J	BENIT, L; CHARON, M; COCAULT, L; WENDLING, F; GISSELBRECHT, S				BENIT, L; CHARON, M; COCAULT, L; WENDLING, F; GISSELBRECHT, S			THE WS-MOTIF COMMON TO V-MPL AND MEMBERS OF THE CYTOKINE RECEPTOR SUPERFAMILY IS DISPENSABLE FOR MYELOPROLIFERATIVE LEUKEMIA-VIRUS PATHOGENICITY	ONCOGENE			English	Note							MURINE SARCOMA-VIRUS; MOLECULAR-CLONING; PROGENITOR CELLS; ONCOGENICITY; EXPRESSION; RETROVIRUS; SEQUENCES; INVITRO	Several motifs are conserved in the extracellular domain of the cloned chains of the recently described cytokine receptor superfamily. One of them, usually close to the transmembrane region, is the 'WS motif'. Its function remains unknown, but it has been recently shown that the integrity of this motif is essential for interleukin 2 receptor beta-chain and erythropoietin receptor activity [Miyazaki, T., Maruyama, M., Yamada, G., Hatakeyama, M. & Taniguchi, T. (1991). EMBO J., 10, 3191-3197; Watowich, S.S., Yoshimura, A., Longmore, G.D., Hilton, D.J., Hoshimura, Y. & Lodish, H.R. (1992). Proc. Natl. Acad. Sci. USA, 89, 2140-21441. This WS motif is present in the v-mpl oncogene, which has been transduced in the myeloproliferative leukemia virus (MPLV). v-mpl encodes a truncated transmembrane protein that belongs to this growth factor receptor family. We demonstrate that determinants of MPLV pathogenesis are encoded by the env-mpl fusion gene and that the complete deletion of the WS motif does not abolish MPLV oncogenic properties.	HOP COCHIN,ICGM,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75674 PARIS 14,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier				PETIT, Laurence/0000-0002-2475-9367				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CHIBA T, 1992, BIOCHEM BIOPH RES CO, V184, P485, DOI 10.1016/0006-291X(92)91220-K; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HANAFUSA H, 1977, J EXP MED, V146, P1735, DOI 10.1084/jem.146.6.1735; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; PENCIOLELLI JF, 1987, J VIROL, V61, P579, DOI 10.1128/JVI.61.2.579-583.1987; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; VIGON I, 1992, IN PRESS P NATL ACAD; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WENDLING F, 1989, BLOOD, V73, P1161	25	9	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					787	790						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382360				2022-12-17	WOS:A1993KN00800032
J	ROUER, E; BENAROUS, R				ROUER, E; BENAROUS, R			ALTERNATIVE SPLICING IN THE HUMAN LCK GENE LEADS TO THE DELETION OF EXON-1' AND RESULTS IN A NEW TYPE-II LCK TRANSCRIPT	ONCOGENE			English	Note							TYROSINE-PROTEIN-KINASE; MESSENGER-RNAS; CELL-LINES; EXPRESSION; P56LCK; ACID; CD4	In this study we describe a new lck mRNA transcribed from the type II promoter, resulting from alternative splicing, in the deletion of exon 1' which comprises the AUG initiation codon. In this type IIB lck transcript, as a consequence of exon 1' deletion, a new AUG codon in exon 1, located 35 nt upstream from the regular initiation codon in exon 1', and normally out of frame, is now in frame with exon 2 and the following lck coding sequence. In this type IIB lck transcript, 10 residues encoded by exon 1 from the new AUG codon replace the first 35 residues encoded by exon 1'. Strikingly, in this new N-terminal amino acid sequence, a glycine residue, needed for myristylation and anchorage in the plasma membrane, is present at position 2. This alternative splicing has been observed in T-cell lines, normal mature T cells and in peripheral blood lymphocytes from different leukemic patients. Different ratios of regular type IIA lck mRNA (with exon 1') to spliced type IIB lck mRNA (without exon 1') have been observed depending on the patient.			ROUER, E (corresponding author), ICGM,INSERM,U332,22 RUE MECHAIN,F-75014 PARIS,FRANCE.							CHEUNG RK, 1991, J BIOL CHEM, V266, P8667; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; MARCHILDON GA, 1984, P NATL ACAD SCI-BIOL, V81, P7679, DOI 10.1073/pnas.81.24.7679; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357	17	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2535	2538						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461657				2022-12-17	WOS:A1992KA85600021
J	BAUNOCH, DA; XU, M; TEWARI, A; CHRISTMAN, JK; LANE, MA				BAUNOCH, DA; XU, M; TEWARI, A; CHRISTMAN, JK; LANE, MA			INSITU DEPHOSPHORYLATION OF P53 PROTEIN BY CALF INTESTINAL ALKALINE-PHOSPHATASE TREATMENT	ONCOGENE			English	Note							BREAST	The monoclonal antibody (mAb) 1801 has been reported to identify an N-terminal determinant within the tumor-suppressor protein p53 located between amino acids 32 and 79. This region contains two potential sites for serine phosphorylation at amino acids 33 and 46. Using a novel technique which dephosphorylates proteins in situ in fixed permeabilized cells, we have unmasked determinants in p53 recognized by mAb 1801, allowing additional sites of p53 protein to be detected in immunohistochemically reacted cells. This result indicates that phosphorylation at one or both sites within the determinant recognized by mAb 1801 previously blocked antibody-ligand interaction. It further suggests that in situ dephosphorylation may be of more general use in identifying antibodies which can only bind to epitopes in a particular phosphorylation state.	MICHIGAN CANC FDN,MOLEC GENET LAB,110 E WARREN AVE,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; MICHIGAN CANC FDN,MOLEC BIOL PROGRAM,DETROIT,MI 48201	Wayne State University					NATIONAL CANCER INSTITUTE [P30CA022453, T32CA009531] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-22453, T32 CA09531] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, ONCOGENE, V6, P1699; BUCHKOVICH K, 1989, CELL, V58, P1079; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; TAIT L, 1990, CANCER RES, V50, P6087	6	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2351	2353						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437159				2022-12-17	WOS:A1992JW66500031
J	FALCONE, G; PROVENZANO, C; ALEMA, S; TATO, F				FALCONE, G; PROVENZANO, C; ALEMA, S; TATO, F			TRANSFORMATION OF NIH3T3 CELLS BY ROUS-SARCOMA VIRUS OCCURS WITH HIGH-EFFICIENCY IN THE ABSENCE OF PROVIRAL REARRANGEMENTS OR AMPLIFICATION	ONCOGENE			English	Article							RAT-CELLS; INTEGRATION SITES; RETROVIRUS INTEGRATION; GENE AMPLIFICATION; DNA; EXPRESSION; CHROMATIN; REGIONS; MAP	NIH3T3 cells could be transformed by a mammaltropic strain of Rous sarcoma virus (RSV) with an efficiency 10(3) times greater than that observed in Balb/c 3T3 cells or other mammalian cell lines and almost identical to that of chick embryo fibroblasts. In infected NIH3T3 cells a single, properly integrated, provirus was sufficient to induce focus formation; moreover, kinase activity of pp60v-src and tyrosine phosphorylation of cellular proteins could be detected very soon after infection in the majority of cells. On the other hand, in transformed foci from RSV-infected Balb/c 3T3 cells both rearrangements and amplification of proviral sequences were frequently detected. Accordingly, expression of pp60v-src and ensuing tyrosine phosphorylation of cellular proteins occurred, at high levels, only in a minority of the infected cells. Furthermore, by using a murine retrovirus carrying the v-src oncogene and an independent selectable marker, we found that Balb/c 3T3 cells were transformed with a 100-fold lower efficiency than NIH3T3 cells, yet the majority of infected untransformed Balb/c 3T3 cells expressed active pp60v-src. These findings are consistent with the existence in most mammalian cell lines of a major restriction to v-src-induced transformation, operating at the level of proviral expression, that is apparently absent in NIH3T3 cells.	UNIV ROME LA SAPIENZA,DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-00185 ROME,ITALY	Sapienza University Rome	FALCONE, G (corresponding author), CNR,IST BIOL CELLULARE,VIALE MARX 43,I-00137 ROME,ITALY.		Falcone, Germana/A-3735-2016	Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				AKROYD J, 1987, ONCOGENE, V1, P347; ALTANER C, 1970, VIROLOGY, V70, P118; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOETTIGER D, 1975, J VIROL, V15, P108, DOI 10.1128/JVI.15.1.108-114.1975; BOETTIGER D, 1974, VIROLOGY, V62, P522, DOI 10.1016/0042-6822(74)90412-7; BOULTER CA, 1988, ONCOGENE, V2, P207; CHISWELL DJ, 1982, NUCLEIC ACIDS RES, V10, P3967, DOI 10.1093/nar/10.13.3967; CHISWELL DJ, 1982, VIROLOGY, V116, P428, DOI 10.1016/0042-6822(82)90137-4; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; DENG CT, 1977, VIROLOGY, V76, P313, DOI 10.1016/0042-6822(77)90305-1; FEINSTEIN SC, 1982, J MOL BIOL, V156, P549, DOI 10.1016/0022-2836(82)90266-2; FINCHAM VJ, 1991, J VIROL, V65, P461, DOI 10.1128/JVI.65.1.461-463.1991; GILLESPIE DAF, 1985, CELL, V41, P279, DOI 10.1016/0092-8674(85)90081-9; GILMER TM, 1987, CANCER RES, V47, P4663; GREEN AR, 1986, EMBO J, V5, P707, DOI 10.1002/j.1460-2075.1986.tb04271.x; HJELLE B, 1988, P NATL ACAD SCI USA, V85, P4355, DOI 10.1073/pnas.85.12.4355; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Maniatis T, 1989, DECONTAMINATION DILU; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARIANI BD, 1984, J BIOL CHEM, V259, P1901; MOOSLEHNER K, 1990, J VIROL, V64, P3056, DOI 10.1128/JVI.64.6.3056-3058.1990; ROGUEL N, 1986, BIOCHIM BIOPHYS ACTA, V908, P12; ROHDEWOHLD H, 1987, J VIROL, V61, P336, DOI 10.1128/JVI.61.2.336-343.1987; RYNDITCH A, 1991, GENE, V106, P165, DOI 10.1016/0378-1119(91)90196-I; SCHERDIN U, 1990, J VIROL, V64, P907, DOI 10.1128/JVI.64.2.907-912.1990; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; TATO F, 1978, VIROLOGY, V88, P71, DOI 10.1016/0042-6822(78)90111-3; VARMUS HE, 1975, SPR COLD HARB S QUAN, V39, P118; WEISS R, 1985, RNA TUMOR VIRUSES MO; Wyke J A, 1975, Cold Spring Harb Symp Quant Biol, V39 Pt 2, P897; WYKE JA, 1980, VIROLOGY, V106, P217, DOI 10.1016/0042-6822(80)90246-9	31	9	9	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1992	7	10					1913	1920						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP424	1328985				2022-12-17	WOS:A1992JP42400003
J	LALLEMAND, C; KAHAN, A; TELVI, L; JORET, AM; GERFAUX, J				LALLEMAND, C; KAHAN, A; TELVI, L; JORET, AM; GERFAUX, J			AN ANTISENSE INTERFERON-BETA RNA ABOLISHES REPRESSION OF C-FOS GENE-EXPRESSION	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; PROTO-ONCOGENE FOS; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; RAT FIBROBLASTS; PHORBOL ESTER; 3T3 CELLS; KINASE-C	To determine the cellular functions which are modified when interferon-beta (IFN-beta) gene expression is inhibited, a plasmid allowing the constitutive expression of RNA complementary to IFN-beta mRNA was constructed and stably introduced into L929 cells. Some of the selected clones expressing this antisense IFN-beta mRNA, named L-ASI, were unable to produce IFN-beta and lost the ability to arrest in the G0 phase of the cell cycle. Indeed, the usual transrepression of the c-fos gene observed in quiescent cells was blocked in IFN-beta antisense L-ASI clones and the c-fos gene was permanently stimulated. This overexpression of c-fos was not modified in response to protein kinase C agonists such as phorbol esters, but increased in response to the adenylate cyclase activator forskolin. In addition, the ability to induce major histocompatibility class I genes following recombinant IFN-beta treatment was impaired in antisense IFN-beta L-ASI clones, suggesting an important alteration of this cell with regard to the interferon system. Unexpectedly, the tumorigenicity of the clones was significantly diminished. We postulate that IFN-beta antisense RNA blocks the repression of the c-fos gene and thus prevents the arrest of cells in the G0 phase of the cycle.	INSERM, U153, 17 RUE FER MOULIN, F-75005 PARIS, FRANCE; HOP COCHIN, INSERM, U283, F-75674 PARIS 14, FRANCE; HOP ST VINCENT DE PAUL, SERV HISTOL EMBRYOL CYTOGENET & ANAT PATHOL, F-75674 PARIS 14, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite				lallemand, christophe/0000-0001-5965-2482				BARBER JR, 1987, ANN NY ACAD SCI, V511, P117, DOI 10.1111/j.1749-6632.1987.tb36242.x; BARLOW DP, 1984, DIFFERENTIATION, V27, P229, DOI 10.1111/j.1432-0436.1984.tb01433.x; BRANCA AA, 1988, IN VITRO CELL DEV B, V24, P155; BRAVO R, 1987, CELL, V48, P251, DOI 10.1016/0092-8674(87)90428-4; BUSCHER M, 1988, ONCOGENE, V3, P301; CHRISTOFINIS GJ, 1981, J GEN VIROL, V52, P169, DOI 10.1099/0022-1317-52-1-169; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COSMAN D, 1982, NATURE, V295, P73, DOI 10.1038/295073a0; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DOHERTY PJ, 1989, ANAL BIOCHEM, V177, P7, DOI 10.1016/0003-2697(89)90003-1; EINAT M, 1985, P NATL ACAD SCI USA, V82, P7608, DOI 10.1073/pnas.82.22.7608; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FELLOUS M, 1982, P NATL ACAD SCI-BIOL, V79, P3082, DOI 10.1073/pnas.79.10.3082; FISHER PB, 1983, P NATL ACAD SCI-BIOL, V80, P2961, DOI 10.1073/pnas.80.10.2961; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; FRANCIS MK, 1989, MOL CELL BIOL, V9, P3553, DOI 10.1128/MCB.9.8.3553; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GERFAUX J, 1989, CANCER RES, V49, P1241; GEWERT DR, 1984, EUR J BIOCHEM, V139, P619, DOI 10.1111/j.1432-1033.1984.tb08049.x; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GREEN DA, 1984, MON NOT R ASTRON SOC, V211, P433, DOI 10.1093/mnras/211.2.433; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GREENE JJ, 1984, J INTERFERON RES, V4, P517, DOI 10.1089/jir.1984.4.517; GROSSBERG SE, 1989, EXPERIENTIA, V45, P508, DOI 10.1007/BF01990499; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIGASHI Y, 1983, J BIOL CHEM, V258, P9522; ISAACS A, 1957, PROC R SOC SER B-BIO, V147, P258, DOI 10.1098/rspb.1957.0048; JOKLIK WK, 1990, INTERFERONS VIROLOGY, P383; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KEAY S, 1980, P NATL ACAD SCI-BIOL, V77, P4099, DOI 10.1073/pnas.77.7.4099; KOHASE M, 1987, MOL CELL BIOL, V7, P273, DOI 10.1128/MCB.7.1.273; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LANGER JA, 1988, IMMUNOL TODAY, V9, P393, DOI 10.1016/0167-5699(88)91241-8; LEVI BZ, 1988, GENE DEV, V2, P554, DOI 10.1101/gad.2.5.554; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MINTY AJ, 1982, CELL, V30, P185, DOI 10.1016/0092-8674(82)90024-1; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OLDBERG A, 1983, J BIOL CHEM, V258, P193; OLESZAK E, 1980, J INTERFERON RES, V1, P37, DOI 10.1089/jir.1980.1.37; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SANFORD KK, 1948, J NATL CANCER I, V9, P229; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SCHONTHAL A, 1989, ONCOGENE, V4, P629; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; TOMINAGA S, 1985, J BIOL CHEM, V260, P1975; TOVEY MG, 1987, P NATL ACAD SCI USA, V84, P5038, DOI 10.1073/pnas.84.14.5038; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WAN YJY, 1988, J INTERFERON RES, V8, P105, DOI 10.1089/jir.1988.8.105; ZULLO JN, 1985, CELL, V43, P793, DOI 10.1016/0092-8674(85)90252-1	69	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1992	7	6					1109	1118						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594242				2022-12-17	WOS:A1992HU64200008
J	WERGE, TM; BRADBURY, A; DILUZIO, A; CATTANEO, A				WERGE, TM; BRADBURY, A; DILUZIO, A; CATTANEO, A			A RECOMBINANT CELL-LINE EXPRESSING A FORM OF THE Y13-259 ANTI-P21RAS ANTIBODY WHICH BINDS PROTEIN-A AND MAY BE PRODUCED AS ASCITES	ONCOGENE			English	Note							ENCODED P21; RAS P21; MICROINJECTION; CLONING; GENE	We have recently reported the molecular cloning of the immunoglobulin genes encoding the variable regions of the rat anti-p21ras antibody, Y13-259. These genes were reassembled into expression vectors supplying DNA sequences encoding human gamma 1 and kappa constant domains, as well as the leader sequence for antibody secretion, thus yielding Hu-Y13-259, a secretory anti-p21ras antibody containing human constant regions. We now report the creation of a recombinant cell line, NSO/Hu-Y13-259/B6, secreting high levels of the Hu-Y13-259 Ig. The antigen specificity of this recombinant antibody was demonstrated to be identical to that of the parental Y13-259, i.e. the amino acid sequence 60-76 of the p21ras protein. Unlike the parental cell line, the recombinant cells could be grown as ascites in mice, allowing the production of large quantities of the protein A-binding Hu-Y13-259 antibody.	CNR,INST NEUROBIOL,VIALE KARL MARX 15,I-00156 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)			Cattaneo, Antonino/AAA-7252-2019; CATTANEO, ANTONINO/K-4471-2016	CATTANEO, ANTONINO/0000-0002-6975-8923				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIOCCA S, 1990, EMBO J, V9, P101, DOI 10.1002/j.1460-2075.1990.tb08085.x; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; CHARBIT A, 1991, J BACTERIOL, V173, P262, DOI 10.1128/jb.173.1.262-275.1991; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; JURNAK F, 1990, CELL, V60, P525, DOI 10.1016/0092-8674(90)90652-U; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; WERGE TM, 1990, FEBS LETT, V274, P193, DOI 10.1016/0014-5793(90)81362-R	13	9	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					1033	1035						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1570149				2022-12-17	WOS:A1992HP64200027
J	FLYNN, DC; SCHALLER, MD; PARSONS, JT				FLYNN, DC; SCHALLER, MD; PARSONS, JT			TYROSINE PHOSPHORYLATION OF A 120000 DALTON MEMBRANE-ASSOCIATED PROTEIN BY THE NEURAL FORM OF PP60C-SRC, PP60C-SRC+	ONCOGENE			English	Note							CELLULAR SRC GENE; C-SRC; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; CARBOXY TERMINUS; PHOSPHOLIPASE-C; KINASE-ACTIVITY; MESSENGER-RNA; CELLS; PRODUCT	The c-src proto-oncogene encodes a 60000 dalton tyrosine kinase, pp60c-src, which is the prototype member of the family of non-receptor tyrosine kinases. A neural-specific form of pp60c-src, pp60c-src+, is detected only in neurons of the central nervous system. pp60c-src+ contains a six amino acid insert (neural insert) in the SH3 region that is generated by alternative splicing. Previous reports indicate that the profiles of proteins phosphorylated on tyrosine in chick embryo fibroblast (CEF) cells by pp60c-sec+ or pp60c-src are equivalent. In this report, the activities of pp60c-src+ and pp60c-src, as well as the activated variants, pp60(527F+) and pp60(527F), were compared in CEF cells by examining the steady-state levels of tyrosine phosphorylation of several known pp60src substrates. Most substrates examined were phosphorylated on tyrosine to equivalent levels in CEF cells expressing either the neural- or fibroblast-specific src gene products. However, the relative extent of tyrosine phosphorylation of a 120 kDa protein (p120) was increased in cells expressing the neuronal forms of either c-src or c-src527F. The increased tyrosine phosphorylation of p120 did not appear to be caused by the neural insert facilitating a specific interaction between pp60c-src+ and p120. These data indicate that preferential phosphorylation of p120 in neural cells may contribute to the specialized function of pp60c-src+ in neural cells.	UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,BOX 441,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,CTR CANC,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia					NCI NIH HHS [CA29243, CA40042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029243, R37CA029243, P01CA040042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COLLETT MS, 1978, CELL, V15, P1363, DOI 10.1016/0092-8674(78)90061-2; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DOWNING JR, 1991, ONCOGENE, V6, P607; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; GOULD KL, 1989, MOL ENDOCRINOL, V3, P79, DOI 10.1210/mend-3-1-79; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; OPPERMANN H, 1979, P NATL ACAD SCI USA, V76, P1804, DOI 10.1073/pnas.76.4.1804; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; RAULF F, 1989, ONCOGENE RES, V5, P39; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; ROHRSCHNEIDER LR, 1979, P NATL ACAD SCI USA, V76, P4479, DOI 10.1073/pnas.76.9.4479; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WASENIUS VM, 1989, J CELL BIOL, V108, P79, DOI 10.1083/jcb.108.1.79; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; YANG XM, 1988, ONCOGENE, V3, P237	44	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1992	7	3					579	583						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HK005	1372401				2022-12-17	WOS:A1992HK00500027
J	ZAK, NB; SHILO, BZ				ZAK, NB; SHILO, BZ			BIOCHEMICAL-PROPERTIES OF THE DROSOPHILA EGF RECEPTOR HOMOLOG (DER) PROTEIN	ONCOGENE			English	Note									WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Shilo, Ben Zion/0000-0003-4903-8889	NIGMS NIH HHS [GM35998] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035998] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; CLIFFORD RJ, 1990, GENETICS, V123, P771; DECKER S, 1984, ARCH BIOCHEM BIOPHYS, V228, P621, DOI 10.1016/0003-9861(84)90031-6; DECKER SJ, 1984, MOL CELL BIOL, V4, P571, DOI 10.1128/MCB.4.4.571; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1988, CELL, V54, P593, DOI 10.1016/S0092-8674(88)80001-1; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FESSLER LI, 1987, J CELL BIOL, V105, P2383, DOI 10.1083/jcb.105.5.2383; GRAY A, 1983, NATURE, V303, P722, DOI 10.1038/303722a0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; KAMPS MP, 1988, ONCOGENE, V2, P305; LAUB O, 1983, J VIROL, V48, P271, DOI 10.1128/JVI.48.1.271-280.1983; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHEJTER ED, 1986, CELL, V46, P1091, DOI 10.1016/0092-8674(86)90709-9; SCHUPBACH T, 1987, CELL, V49, P699, DOI 10.1016/0092-8674(87)90546-0; SCOTT J, 1983, SCIENCE, V221, P236, DOI 10.1126/science.6602382; SHILO BZ, 1987, TRENDS GENET, V3, P69, DOI 10.1016/0168-9525(87)90178-8; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZAK NB, 1990, DEVELOPMENT, V109, P865	34	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1990	5	10					1589	1593						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK502	2250916				2022-12-17	WOS:A1990EK50200021
J	GARSON, K; KANG, CY				GARSON, K; KANG, CY			MAPPING OF THE FUNCTIONAL DOMAINS OF THE V-REL ONCOGENE	ONCOGENE			English	Note									UNIV OTTAWA,FAC MED,DEPT MICROBIOL & IMMUNOL,OTTAWA K1H 8M5,ONTARIO,CANADA	University of Ottawa								ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BROWNELL E, 1989, ONCOGENE, V4, P935; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN HR, 1986, NUCLEIC ACIDS RES, V14, P3977, DOI 10.1093/nar/14.9.3977; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GARSON K, 1986, BIOCHEM BIOPH RES CO, V134, P716, DOI 10.1016/S0006-291X(86)80479-X; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HERZOG NK, 1986, P NATL ACAD SCI USA, V83, P812, DOI 10.1073/pnas.83.3.812; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORRISON LE, 1989, ONCOGENE, V4, P677; PARKER RC, 1977, P NATL ACAD SCI USA, V74, P851, DOI 10.1073/pnas.74.3.851; RICE NR, 1986, VIROLOGY, V149, P217, DOI 10.1016/0042-6822(86)90123-6; SHAW DJ, 1982, NUCLEIC ACIDS RES, V10, P6119, DOI 10.1093/nar/10.19.6119; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THEILEN GH, 1966, J NATL CANCER I, V37, P731; TUNG HYL, 1988, P NATL ACAD SCI USA, V85, P2479, DOI 10.1073/pnas.85.8.2479; TUNG HYL, 1988, BIOCHEM BIOPH RES CO, V152, P441; WALRO DS, 1987, VIROLOGY, V160, P433, DOI 10.1016/0042-6822(87)90015-8; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	31	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1431	1434						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216467				2022-12-17	WOS:A1990EC24100025
J	GRAY, GM; MACARA, IG				GRAY, GM; MACARA, IG			SERUM-STIMULATED PHOSPHATIDYLINOSITOL TURNOVER IS ENHANCED IN 3T3 CELLS WITH ACTIVE PP60V-SRC	ONCOGENE			English	Article											GRAY, GM (corresponding author), UNIV ROCHESTER,MED CTR,CTR ENVIRONM HLTH SCI,DIV TOXICOL,ROCHESTER,NY 14642, USA.							ARZONIA R, 1984, J MEMBRANE BIOL, V82, P191; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; DIRINGER H, 1977, CANCER RES, V37, P2979; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; GRAY GM, 1988, J BIOL CHEM, V263, P10714; HESLOP JP, 1986, CELL, V47, P703, DOI 10.1016/0092-8674(86)90513-1; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KATO M, 1987, J BIOL CHEM, V262, P5696; MACARA IG, 1985, AM J PHYSIOL, V248, pC3, DOI 10.1152/ajpcell.1985.248.1.C3; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; PANET R, 1985, J BIOL CHEM, V260, P5752; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0	20	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1213	1217						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2507998				2022-12-17	WOS:A1989AU50800008
J	TOURKINE, N; MECHTI, N; PIECHACZYK, M; JEANTEUR, P; BLANCHARD, JM				TOURKINE, N; MECHTI, N; PIECHACZYK, M; JEANTEUR, P; BLANCHARD, JM			INSITU AND INVITRO EVIDENCE FOR INTRAGENIC BINDING OF NUCLEAR FACTORS AT THE MURINE C-MYC LOCUS	ONCOGENE			English	Article									UNIV MONTPELLIER 2,CNRS,URA 1191,BIOL MOLEC LAB,F-34060 MONTPELLIER,FRANCE; UNIV MONTPELLIER 2,CNRS,URA 1191,BIOCHIM PROT LAB,F-34060 MONTPELLIER,FRANCE; CTR PAUL LAMARQUE,BIOCHIM LAB,F-34094 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier			PIECHACZYK, Marc/E-7896-2013	PIECHACZYK, Marc/0000-0003-1367-2597				BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BLANCHARD JM, 1988, BIOCHIMIE, V70, P877, DOI 10.1016/0300-9084(88)90228-3; BLANCHARD JM, 1988, LYMPHOCYTE ACTIVATIO, P339; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DANI C, 1985, P NATL ACAD SCI USA, V82, P4896, DOI 10.1073/pnas.82.15.4896; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FAHRLANDER PD, 1985, EMBO J, V4, P3195, DOI 10.1002/j.1460-2075.1985.tb04065.x; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JULIUS MA, 1988, ONCOGENE, V2, P469; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; MARCU KB, 1987, BIOESSAYS, V6, P28, DOI 10.1002/bies.950060108; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; PIECHACZYK M, 1988, GENE, V72, P287, DOI 10.1016/0378-1119(88)90154-0; PIECHACZYK M, 1987, TRENDS GENET, V3, P47, DOI 10.1016/0168-9525(87)90166-1; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RIFKIND RA, 1983, ANN NY ACAD SCI, V411, P141, DOI 10.1111/j.1749-6632.1983.tb47296.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; WU C, 1984, NATURE, V309, P229, DOI 10.1038/309229a0; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	33	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					973	978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2548146				2022-12-17	WOS:A1989AJ29700004
J	MILLIGAN, G; DAVIES, SA; HOUSLAY, MD; WAKELAM, MJO				MILLIGAN, G; DAVIES, SA; HOUSLAY, MD; WAKELAM, MJO			IDENTIFICATION OF THE PERTUSSIS AND CHOLERA-TOXIN SUBSTRATES IN NORMAL AND N-RAS TRANSFORMED NIH3T3 FIBROBLASTS AND AN ASSESSMENT OF THEIR INVOLVEMENT IN BOMBESIN-STIMULATION OF INOSITOL PHOSPHOLIPID-METABOLISM	ONCOGENE			English	Note									UNIV GLASGOW,DEPT BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND; UNIV GLASGOW,DEPT MED BIOCHEM,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,SCOTLAND	University of Glasgow; University of Glasgow			Houslay, Miles/AAM-5281-2020; Milligan, Graeme/F-9426-2011; Houslay, Miles D/A-6825-2011	Milligan, Graeme/0000-0002-6946-3519; Wakelam, Michael/0000-0003-4059-9276; Houslay, Miles/0000-0002-3826-8091				BACKLUND PS, 1988, BIOCHEMISTRY-US, V27, P2040, DOI 10.1021/bi00406a034; COCKCROFT S, 1987, TRENDS BIOCHEM SCI, V12, P75, DOI 10.1016/0968-0004(87)90035-1; DOWNES CP, 1985, MOL ASPECTS CELL REG, V4, P2; FONG KHW, 1988, P NATL ACAD SCI USA, V85, P3066; GARDNER SD, 1989, IN PRESS BIOCH J; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HANCOCK JF, 1988, ONCOGENE, V3, P187; JONES DT, 1987, J BIOL CHEM, V262, P14241; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MILLIGAN G, 1987, BIOCHEM J, V245, P501, DOI 10.1042/bj2450501; MILLIGAN G, 1988, BIOCHEM J, V254, P391, DOI 10.1042/bj2540391; MILLIGAN G, 1988, BIOCHEM J, V255, P1; MULLANEY I, 1988, BIOCHEM J, V256, P649, DOI 10.1042/bj2560649; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; WAKELAM MJO, 1988, FEBS LETT, V228, P182, DOI 10.1016/0014-5793(88)80613-6; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0	17	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					659	663						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2498808				2022-12-17	WOS:A1989U768800018
J	LUTTRELL, LM; LUTTRELL, DK; PARSONS, SJ; ROGOL, AD				LUTTRELL, LM; LUTTRELL, DK; PARSONS, SJ; ROGOL, AD			INSULIN AND PHORBOL ESTER INDUCE DISTINCT PHOSPHORYLATIONS OF PP60C-SRC IN THE BC3H-1 MURINE MYOCYTE CELL-LINE	ONCOGENE			English	Article									UNIV VIRGINIA,SCH MED,DEPT PEDIAT,BOX 386,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia			Rogol, A.D./H-5871-2019	Rogol, A.D./0000-0002-7526-3142; Luttrell, Louis/0000-0003-2805-6949	NCI NIH HHS [CA 29243, CA 39438] Funding Source: Medline; NIADDK NIH HHS [AM 22125] Funding Source: Medline; NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [P60AM022125] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA039438, R37CA029243, R01CA029243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beavo J A, 1974, Methods Enzymol, V38, P299; BESTERMAN JM, 1986, J BIOL CHEM, V261, P723; BLACKSHEAR PJ, 1987, MOL ENDOCRINOL, V1, P44, DOI 10.1210/mend-1-1-44; BLACKSHEAR PJ, 1985, J BIOL CHEM, V260, P3304; BLACKSHEAR PJ, 1986, MECHANISMS INSULIN A, P211; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHAKALAPARAMPIL I, 1988, CELL, V52, P801; CHERQUI G, 1986, ENDOCRINOLOGY, V118, P1759, DOI 10.1210/endo-118-5-1759; CHU DTW, 1987, MOL ENDOCRINOL, V1, P53, DOI 10.1210/mend-1-1-53; CHU DTW, 1986, J BIOL CHEM, V261, P6848; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLETT MS, 1979, J VIROL, V29, P770, DOI 10.1128/JVI.29.2.770-781.1979; COLLETT MS, 1978, CELL, V15, P1363, DOI 10.1016/0092-8674(78)90061-2; COOPER DR, 1987, FEBS LETT, V214, P122, DOI 10.1016/0014-5793(87)80025-X; COOPER DR, 1987, J BIOL CHEM, V262, P3633; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; FARESE RV, 1987, SCIENCE, V236, P586, DOI 10.1126/science.3107122; FARESE RV, 1985, ENDOCRINOLOGY, V116, P2650, DOI 10.1210/endo-116-6-2650; FARESE RV, 1985, BIOCHEM J, V231, P269, DOI 10.1042/bj2310269; FARESE RV, 1986, J BIOL CHEM, V261, P8589; FARESE RV, 1984, J BIOL CHEM, V259, P7094; FOX JA, 1987, P NATL ACAD SCI USA, V84, P2663, DOI 10.1073/pnas.84.9.2663; GENTRY LE, 1986, MOL CELL BIOL, V6, P735, DOI 10.1128/MCB.6.2.735; GESCHWENDT M, 1986, BIOCHEM BIOPH RES CO, V137, P766; GLYNN BP, 1986, BIOCHEM BIOPH RES CO, V135, P1119, DOI 10.1016/0006-291X(86)91044-2; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GRANNER DK, 1986, MECHANISMS INSULIN A, P365; GRAVES CB, 1985, J BIOL CHEM, V260, P1286; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HERSHKO A, 1971, NATURE-NEW BIOL, V232, P206, DOI 10.1038/newbio232206a0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KANNER SB, 1988, ONCOGENE, V2, P327; KIKKAWA U, 1986, BIOCHEM BIOPH RES CO, V135, P636, DOI 10.1016/0006-291X(86)90040-9; KURET J, 1985, EUR J BIOCHEM, V151, P39, DOI 10.1111/j.1432-1033.1985.tb09066.x; LALLEMAIN G, 1986, FEBS LETT, V197, P344, DOI 10.1016/0014-5793(86)80354-4; LARNER J, 1982, RECENT PROG HORM RES, V38, P511; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LUTTRELL L, 1986, ENDOCRINOLOGY, V119, P331, DOI 10.1210/endo-119-1-331; LUTTRELL LM, 1988, J BIOL CHEM, V263, P6134; LUTTRELL LM, 1986, MOL PHARMACOL, V30, P624; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PATSCHINSKY T, 1986, J VIROL, V59, P73, DOI 10.1128/JVI.59.1.73-81.1986; POTTER VR, 1984, IN VITRO CELL DEV B, V20, P723; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; ROZENGURT E, 1983, P NATL ACAD SCI USA, V81, P2975; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SALTIEL AR, 1987, ENDOCRINOLOGY, V120, P967, DOI 10.1210/endo-120-3-967; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SPACH DH, 1986, J BIOL CHEM, V261, P2750; STANDAERT ML, 1988, J BIOL CHEM, V263, P8696; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TAMURA T, 1984, FEBS LETT, V177, P151, DOI 10.1016/0014-5793(84)81001-7; TAYLOR D, 1985, J BIOL CHEM, V260, P2011; TREVILLYAN JM, 1985, J BIOL CHEM, V260, P3041; WU VS, 1981, LIFE SCI, V29, P1855, DOI 10.1016/0024-3205(81)90516-6; YONEMOTO W, 1985, P NATL ACAD SCI USA, V82, P4568, DOI 10.1073/pnas.82.14.4568	68	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					317	324						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2468125				2022-12-17	WOS:A1989U567600007
J	MONTENARH, M; QUAISER, A				MONTENARH, M; QUAISER, A			2 DIFFERENT PROTEIN-PROTEIN INTERACTIONS IN OLIGOMERIC COMPLEXES OF SV40 LARGE T-ANTIGEN WITH THE CELLULAR ONCOPROTEIN-P53	ONCOGENE			English	Note											MONTENARH, M (corresponding author), UNIV ULM,DEPT BIOCHEM,POB 4066,D-7900 ULM,FED REP GER.		Montenarh, Mathias/AAB-6689-2020					BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; CRAWFORD LV, 1983, INT REV EXP PATHOL, V35, P1; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FANNING E, 1981, J VIROL, V37, P92, DOI 10.1128/JVI.37.1.92-102.1981; Flint S. J, 1981, DNA TUMOR VIRUSES; GIDONI D, 1982, J VIROL, V42, P456, DOI 10.1128/JVI.42.2.456-466.1982; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MONTENARH M, 1987, FEBS LETT, V221, P199, DOI 10.1016/0014-5793(87)80925-0; MONTENARH M, 1987, J VIROL, V61, P940, DOI 10.1128/JVI.61.3.940-944.1987; MONTENARH M, 1984, J VIROL, V49, P658, DOI 10.1128/JVI.49.3.658-664.1984; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; MONTENARH M, 1983, J VIROL, V45, P531, DOI 10.1128/JVI.45.2.531-538.1983; MONTENARH M, 1986, J VIROL, V60, P761, DOI 10.1128/JVI.60.2.761-764.1986; MONTENARH M, 1986, FEBS LETT, V204, P51, DOI 10.1016/0014-5793(86)81386-2; MONTENARH M, 1983, J GEN VIROL, V64, P241, DOI 10.1099/0022-1317-64-1-241; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHURMANN C, 1985, VIROLOGY, V146, P1, DOI 10.1016/0042-6822(85)90047-9; TODARO GJ, 1966, SCIENCE, V153, P1252, DOI 10.1126/science.153.3741.1252; WACHTER M, 1985, J VIROL, V56, P520, DOI 10.1128/JVI.56.2.520-526.1985	37	9	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1989	4	3					379	382						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5676	2495505				2022-12-17	WOS:A1989U567600015
J	SIRCAR, S; RODRIGUES, M; WEBER, JM				SIRCAR, S; RODRIGUES, M; WEBER, JM			RESISTANCE TO RETRANSFORMATION BY ADENOVIRUS BUT NOT BY HETEROLOGOUS ONCOGENES IN AN E1-POSITIVE TRANSFORMATION REVERTANT CELL-LINE MAY BE MEDIATED BY A CELLULAR FUNCTION	ONCOGENE			English	Article									CHU SHERBROOKE,FAC MED,DEPT MICROBIOL,SHERBROOKE J1H 5N4,QUEBEC,CANADA	University of Sherbrooke								BABISS LE, 1983, J VIROL, V46, P454, DOI 10.1128/JVI.46.2.454-465.1983; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BOUCHARD L, 1986, VIROLOGY, V155, P1, DOI 10.1016/0042-6822(86)90162-5; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; FLINT SJ, 1981, DNA TUMOR VIRUSES, P383; GALLIMORE PH, 1977, CELL, V10, P669, DOI 10.1016/0092-8674(77)90100-3; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRODZICKER T, 1980, CELL, V21, P453, DOI 10.1016/0092-8674(80)90482-1; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; KNUDSON AG, 1985, CANCER RES, V45, P1437; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEOF EB, 1987, MOL CELL BIOL, V7, P2649, DOI 10.1128/MCB.7.7.2649; MAK I, 1986, BIOCHEM CELL BIOL, V64, P256, DOI 10.1139/o86-036; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHARA BM, 1987, MOL CELL BIOL, V7, P2941, DOI 10.1128/MCB.7.8.2941; OWEN RD, 1987, MOL CELL BIOL, V7, P2512, DOI 10.1128/MCB.7.7.2512; RODRIGUES MT, 1987, BIOCHEM BIOPH RES CO, V147, P675, DOI 10.1016/0006-291X(87)90983-1; RYAN KW, 1985, MOL CELL BIOL, V5, P3577, DOI 10.1128/MCB.5.12.3577; SAGER R, 1986, CANCER RES, V46, P1573; SAMID D, 1987, MOL CELL BIOL, V7, P2196, DOI 10.1128/MCB.7.6.2196; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; SIRCAR S, 1988, J CELL PHYSIOL, V134, P467, DOI 10.1002/jcp.1041340319; SIRCAR S, 1987, CANCER RES, V47, P1339; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P9099, DOI 10.1073/pnas.84.24.9099; STOW ND, 1982, NUCLEIC ACIDS RES, V10, P5105, DOI 10.1093/nar/10.17.5105; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	31	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					725	728						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577877				2022-12-17	WOS:A1988R646000017
J	PATSCHINSKY, T; BISTER, K				PATSCHINSKY, T; BISTER, K			STRUCTURAL-ANALYSIS OF NORMAL AND TRANSFORMING MIL(RAF) PROTEINS - EFFECT OF 5'-TRUNCATION ON PHOSPHORYLATION INVIVO OR INVITRO	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-1000 BERLIN 33,FED REP GER	Max Planck Society			Bister, Klaus/AFA-9400-2022	Bister, Klaus/0000-0001-6545-5653				BECHADE C, 1988, J VIROL, V62, P1211; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BIEGALKE B, 1987, J VIROL, V61, P1949, DOI 10.1128/JVI.61.6.1949-1956.1987; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1987, ONCOGENE, V1, P97; BISTER K, 1987, ADV VIRAL ONCOL, V6, P45; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DOZIER C, 1987, MOL CELL BIOL, V7, P1995, DOI 10.1128/MCB.7.5.1995; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FUKUI M, 1987, MOL CELL BIOL, V7, P1776, DOI 10.1128/MCB.7.5.1776; GALIBERT F, 1984, EMBO J, V3, P1333, DOI 10.1002/j.1460-2075.1984.tb01972.x; HU SSF, 1978, VIROLOGY, V89, P162, DOI 10.1016/0042-6822(78)90049-1; HUANG KP, 1986, J BIOL CHEM, V261, P2134; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; INOUE M, 1977, J BIOL CHEM, V252, P7610; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1985, MODERN TRENDS HUMAN, V6, P280; KAN NC, 1984, SCIENCE, V223, P813, DOI 10.1126/science.6320371; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOENEN M, 1988, ONCOGENE, V2, P179; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLDERS H, 1985, EMBO J, V4, P693, DOI 10.1002/j.1460-2075.1985.tb03685.x; PALMIERI S, 1987, J VIROL, V61, P1717, DOI 10.1128/JVI.61.5.1717-1721.1987; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; PATSCHINSKY T, 1986, MOL CELL BIOL, V6, P739, DOI 10.1128/MCB.6.2.739; PATSCHINSKY T, 1984, VIROLOGY, V136, P348, DOI 10.1016/0042-6822(84)90171-5; RAMSAY G, 1982, EMBO J, V1, P1111, DOI 10.1002/j.1460-2075.1982.tb01305.x; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; RAPP UR, 1983, J VIROL, V45, P914, DOI 10.1128/JVI.45.3.914-924.1983; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; SCHULTZ AM, 1988, ONCOGENE, V2, P187; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; VANBEVEREN C, 1986, CURR TOP MICROBIOL, V123, P73; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	44	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					357	364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3274084				2022-12-17	WOS:A1988Q773900002
J	PODELL, SB; SEFTON, BM				PODELL, SB; SEFTON, BM			CHICKEN PROTO-ONCOGENE C-ROS CDNA CLONES - IDENTIFICATION OF A C-ROS RNA TRANSCRIPT AND DEDUCTION OF THE AMINO-ACID SEQUENCE OF THE CARBOXYL TERMINUS OF THE C-ROS PRODUCT	ONCOGENE			English	Article											PODELL, SB (corresponding author), SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92138, USA.				NCI NIH HHS [CA-14195, CA-17289] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017289, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BALDUZZI PC, 1981, J VIROL, V40, P268, DOI 10.1128/JVI.40.1.268-275.1981; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P3109, DOI 10.1128/MCB.6.9.3109; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DENTE L, 1985, DNA CLONING PRACTICA, V1, P101; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; MAYTIN EV, 1984, J BIOL CHEM, V259, P2135; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PARKER RC, 1985, MOL CELL BIOL, V5, P831, DOI 10.1128/MCB.5.4.831; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0	25	9	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	2	1					9	14						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	L4813	3325887				2022-12-17	WOS:A1987L481300002
J	Cen, B; Wei, J; Wang, DZ; Xiong, Y; Shay, JW; DuBois, RN				Cen, Bo; Wei, Jie; Wang, Dingzhi; Xiong, Ying; Shay, Jerry W.; DuBois, Raymond N.			Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer	ONCOGENE			English	Article							EXPRESSION; IMMUNOTHERAPY; MUTATIONS; MECHANISM; LIGAND-1; BLOCKADE; RECEPTOR; ESCAPE	PD-L1 expression is elevated in various human cancers, including colorectal cancer. High levels of PD-L1 expressed on tumor epithelial cells are one of the potential mechanisms by which tumor cells become resistant to immune attack. However, PD-L1 regulation in tumor cells is not fully understood. Here we demonstrate that mutations in the adenomatous polyposis coli (APC) gene lead to colonic epithelial cell resistance to CD8(+) T cell cytotoxicity by induction of PD-L1 expression. Mechanistically, this occurs as a result of the beta-catenin/TCF4 complex binding to the PD-L1 promoter, leading to increased transcription. Our findings not only reveal a novel mechanism by which APC mutations induce tumor immune evasion via an immune checkpoint pathway but also pave the way for developing beta-catenin or TCF4 inhibitors as possible new options for immune checkpoint inhibition.	[Cen, Bo; Wei, Jie; Wang, Dingzhi; Xiong, Ying; DuBois, Raymond N.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Shay, Jerry W.] Univ Texas Southwestern Med Ctr Dallas, Div Digest & Liver Dis, Dept Cell Biol, Dallas, TX 75390 USA	Medical University of South Carolina; University of Texas System; University of Texas Southwestern Medical Center Dallas	DuBois, RN (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	duboisrn@musc.edu		DuBois, Raymond/0000-0002-6385-7154; Shay, Jerry W./0000-0001-5052-0627	Flow Cytometry & Cell Sorting Unit, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]	Flow Cytometry & Cell Sorting Unit, Hollings Cancer Center, Medical University of South Carolina	This work was supported in part by Flow Cytometry & Cell Sorting Unit, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).	Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Du LY, 2020, J EXP MED, V217, DOI 10.1084/jem.20191115; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; McIntyre RE, 2015, BIOESSAYS, V37, P909, DOI 10.1002/bies.201500032; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Peng J, 2015, CANCER RES, V75, P5034, DOI 10.1158/0008-5472.CAN-14-3098; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; Salvatore L, 2019, CANCERS, V11, DOI 10.3390/cancers11111765; Song MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065821; Strome SE, 2003, CANCER RES, V63, P6501; TARMIN L, 1995, CANCER RES, V55, P2035; Thompson RH, 2005, UROLOGY, V66, P10, DOI 10.1016/j.urology.2005.06.010; Zhu JJ, 2014, HUM IMMUNOL, V75, P348, DOI 10.1016/j.humimm.2014.01.006	23	8	8	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2021	40	41					5984	5992		10.1038/s41388-021-01972-6	http://dx.doi.org/10.1038/s41388-021-01972-6		AUG 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WH0WV	34385594	Green Accepted			2022-12-17	WOS:000684526700002
J	Rugolo, F; Bazan, NG; Calandria, J; Jun, BK; Raschella, G; Melino, G; Agostini, M				Rugolo, Francesco; Bazan, Nicolas G.; Calandria, Jorgelina; Jun, Bokkyoo; Raschella, Giuseppe; Melino, Gerry; Agostini, Massimiliano			The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome	ONCOGENE			English	Article							FATTY-ACID SYNTHESIS; LIPID-METABOLISM; RETINOIC ACID; INHIBITION; CELLS	Cancer cells exhibit dysregulation of critical genes including those involved in lipid biosynthesis, with subsequent defects in metabolism. Here, we show that ELOngation of Very Long chain fatty acids protein 4 (ELOVL4), a rate-limiting enzyme in the biosynthesis of very-long polyunsaturated fatty acids (n-3, >= 28 C), is expressed and transcriptionally repressed by the oncogene MYCN in neuroblastoma cells. In keeping, ELOVL4 positively regulates neuronal differentiation and lipids droplets accumulation in neuroblastoma cells. At the molecular level we found that MYCN binds to the promoter of ELOVL4 in close proximity to the histone deacetylases HDAC1, HDAC2, and the transcription factor Sp1 that can cooperate in the repression of ELOVL4 expression. Accordingly, in vitro differentiation results in an increase of fatty acid with 34 carbons with 6 double bonds (FA34:6); and when MYCN is silenced, FA34:6 metabolite is increased compared with the scrambled. In addition, analysis of large neuroblastoma datasets revealed that ELOVL4 expression is highly expressed in localized clinical stages 1 and 2, and low in high-risk stages 3 and 4. More importantly, high expression of ELOVL4 stratifies a subsets of neuroblastoma patients with good prognosis. Indeed, ELOVL4 expression is a marker of better overall clinical survival also in MYCN not amplified patients and in those with neuroblastoma-associated mutations. In summary, our findings indicate that MYCN, by repressing the expression of ELOVL4 and lipid metabolism, contributes to the progression of neuroblastoma.	[Rugolo, Francesco; Melino, Gerry; Agostini, Massimiliano] Univ Roma Tor Vergata, Dept Expt Med, TOR, Rome, Italy; [Bazan, Nicolas G.; Calandria, Jorgelina; Jun, Bokkyoo] Louisiana State Univ Hlth New Orleans, Sch Med, Neurosci Ctr Excellence, New Orleans, LA USA; [Raschella, Giuseppe] Italian Natl Agcy New Technol, Lab Hlth & Environm, Energy & Sustainable Econ Dev ENEA, Rome, Italy	University of Rome Tor Vergata; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Italian National Agency New Technical Energy & Sustainable Economics Development	Melino, G; Agostini, M (corresponding author), Univ Roma Tor Vergata, Dept Expt Med, TOR, Rome, Italy.	melino@uniroma2.it; m.agostini@med.uniroma2.it	; Agostini, Massimiliano/G-9579-2014	Rugolo, Francesco/0000-0002-3174-100X; MELINO, GERRY/0000-0001-9428-5972; Bazan, Nicolas/0000-0002-9243-5444; Agostini, Massimiliano/0000-0003-3124-2072	Associazione Italiana per la Ricerca contro il Cancro (AIRC) [20473]; Ministry of Health and MAECI Italy-China Science and Technology Cooperation [PGR00961]; Regione Lazio through LazioInnova Progetto Gruppo di Ricerca [85-2017-14986]	Associazione Italiana per la Ricerca contro il Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministry of Health and MAECI Italy-China Science and Technology Cooperation; Regione Lazio through LazioInnova Progetto Gruppo di Ricerca	This research was funded by Associazione Italiana per la Ricerca contro il Cancro (AIRC) to GM (IG#20473; 2018-2022), Ministry of Health and MAECI Italy-China Science and Technology Cooperation (#PGR00961) to GM. Work has been also supported by Regione Lazio through LazioInnova Progetto Gruppo di Ricerca n 85-2017-14986.	Agbaga MP, 2008, P NATL ACAD SCI USA, V105, P12843, DOI 10.1073/pnas.0802607105; Agostini M, 2016, CELL DEATH DIFFER, V23, P1502, DOI 10.1038/cdd.2016.36; Amelio I, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00373-0; Amelio I, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-00274-3; Bazan NG, 2018, MOL ASPECTS MED, V64, P18, DOI 10.1016/j.mam.2018.09.003; Bellomaria A, 2012, CELL CYCLE, V11, P3638, DOI 10.4161/cc.21918; Bhattacharjee S, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700735; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Carroll PA, 2015, CANCER CELL, V27, P271, DOI 10.1016/j.ccell.2014.11.024; Chen JCY, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-00287-y; Chierici M, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-0259-4; Ciocci M, 2016, ONCOTARGET, V7, P84338, DOI 10.18632/oncotarget.12609; DeBose-Boyd RA, 2018, TRENDS BIOCHEM SCI, V43, P358, DOI 10.1016/j.tibs.2018.01.005; Depuydt P, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.240; Dickerman BA, 2019, NAT MED, V25, P1601, DOI 10.1038/s41591-019-0597-x; Han YT, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-019-0244-y; Han YT, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-018-0229-2; Harris ZN, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-019-0242-0; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Iraci N, 2011, CANCER RES, V71, P404, DOI 10.1158/0008-5472.CAN-10-2627; Jun B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05433-7; Lamastra FR, 2014, RSC ADV, V4, P61809, DOI 10.1039/c4ra12519c; Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807; Liu L, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-020-00264-5; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.78; McGregor GH, 2020, CANCER RES, V80, P175, DOI 10.1158/0008-5472.CAN-19-0644; Mihaylov I, 2019, BIOL DIRECT, V14, DOI 10.1186/s13062-019-0249-6; Mizutani Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067317; Nicolai S, 2020, MOL ONCOL, V14, P294, DOI 10.1002/1878-0261.12605; Nohturfft A, 2009, ANNU REV CELL DEV BI, V25, P539, DOI 10.1146/annurev.cellbio.24.110707.175344; Pallucca R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090764; Petroni A, 1996, J LIPID MEDIAT CELL, V14, P39, DOI 10.1016/0929-7855(96)00506-8; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; Pieraccioli M, 2018, P NATL ACAD SCI USA, V115, P7356, DOI 10.1073/pnas.1801435115; Riscal R, 2019, MOL CELL, V76, P220, DOI 10.1016/j.molcel.2019.09.008; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; ROSS RA, 1983, J NATL CANCER I, V71, P741; Snaebjornsson MT, 2020, CELL METAB, V31, P62, DOI 10.1016/j.cmet.2019.11.010; Snaebjornsson MT, 2019, NATURE, V566, P333, DOI 10.1038/d41586-019-00352-1; Sulciner ML, 2018, CANCER METAST REV, V37, P557, DOI 10.1007/s10555-018-9754-9; Sumsion GR, 2020, BIOL DIRECT, V15, DOI 10.1186/s13062-019-0257-6; Teo W, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2016897118; Thiam AR, 2017, J CELL SCI, V130, P315, DOI 10.1242/jcs.192021; THIELE CJ, 1991, CANCER METAST REV, V10, P311, DOI 10.1007/BF00554793; Ruiz-Perez MV, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102128; Yao L, 2015, CANCER RES, V75, P1388, DOI 10.1158/0008-5472.CAN-14-2561; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817; Zirath H, 2013, P NATL ACAD SCI USA, V110, P10258, DOI 10.1073/pnas.1222404110	50	8	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5741	5751		10.1038/s41388-021-01959-3	http://dx.doi.org/10.1038/s41388-021-01959-3		JUL 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34333551				2022-12-17	WOS:000679771600001
J	Zhang, MX; Zhang, LZ; Fu, LM; Yao, HH; Tan, L; Feng, ZH; Li, JY; Lu, J; Pan, YH; Shu, GN; Li, PJ; Tang, YM; Liao, ZY; Wei, JH; Chen, W; Guo, JP; Luo, JH; Chen, ZH				Zhang, Ming-xiao; Zhang, Li-zhen; Fu, Liang-min; Yao, Hao-hua; Tan, Lei; Feng, Zi-hao; Li, Jia-ying; Lu, Jun; Pan, Yi-hui; Shu, Guan-nan; Li, Peng-ju; Tang, Yi-ming; Liao, Zhuang-yao; Wei, Jin-huan; Chen, Wei; Guo, Jian-ping; Luo, Jun-hang; Chen, Zhen-hua			Positive feedback regulation of lncRNA PVT1 and HIF2 alpha contributes to clear cell renal cell carcinoma tumorigenesis and metastasis	ONCOGENE			English	Article							LONG NONCODING RNAS; PROMOTES PROLIFERATION; CANCER; HSP90; BINDING; DOMAIN; ALPHA; ANTAGONIST; GROWTH; HIF-2	Long noncoding RNAs (lncRNAs) have been reported to exert important roles in tumors, including clear cell renal cell carcinoma (ccRCC). PVT1 is an important oncogenic lncRNA which has critical effects on onset and development of various cancers, however, the underlying mechanism of PVT1 functioning in ccRCC remains largely unknown. VHL deficiency-induced HIF2 alpha accumulation is one of the major factors for ccRCC. Here, we identified the potential molecular mechanism of PVT1 in promoting ccRCC development by stabilizing HIF2 alpha. PVT1 was significantly upregulated in ccRCC tissues and high PVT1 expression was associated with poor prognosis of ccRCC patients. Both gain-of-function and loss-of function experiments revealed that PVT1 enhanced ccRCC cells proliferation, migration, and invasion and induced tumor angiogenesis in vitro and in vivo. Mechanistically, PVT1 interacted with HIF2 alpha protein and enhanced its stability by protecting it from ubiquitination-dependent degradation, thereby exerting its biological significance. Meanwhile, HIF2 alpha bound to the enhancer of PVT1 to transactivate its expression. Furthermore, HIF2 alpha specific inhibitor could repress PVT1 expression and its oncogenic functions. Therefore, our study demonstrates that the PVT1/ HIF2 alpha positive feedback loop involves in tumorigenesis and progression of ccRCC, which may be exploited for anticancer therapy.	[Zhang, Ming-xiao; Zhang, Li-zhen; Fu, Liang-min; Yao, Hao-hua; Tan, Lei; Feng, Zi-hao; Li, Jia-ying; Lu, Jun; Pan, Yi-hui; Shu, Guan-nan; Li, Peng-ju; Tang, Yi-ming; Liao, Zhuang-yao; Wei, Jin-huan; Chen, Wei; Luo, Jun-hang; Chen, Zhen-hua] Sun Yat Sen Univ, Dept Urol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Tan, Lei] Southern Med Univ, Nanfang Hosp, Dept Urol, Guangzhou, Peoples R China; [Guo, Jian-ping; Luo, Jun-hang] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China; [Luo, Jun-hang] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China	Sun Yat Sen University; Southern Medical University - China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University	Luo, JH; Chen, ZH (corresponding author), Sun Yat Sen Univ, Dept Urol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Guo, JP; Luo, JH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China.; Luo, JH (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Peoples R China.	guojp6@mail.sysu.edu.cn; luojunh@mail.sysu.edu.cn; chenzhh75@mail.sysu.edu.cn		Zhang, Li-Zhen/0000-0002-3106-6825	National Natural Science Foundation of China [81902576, 81725016, 81872094, 82002684]; Natural Science Foundation of Guangdong Province, China [2017B020227004, 2017A030313538, 2018A030310327]; Medical Scientific Research Foundation of Guangdong Province, China [A2018051]; Guangdong Basic and Applied Basic Research Foundation [2020A1515111077]; China Postdoctoral Science Foundation [236464]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province, China(National Natural Science Foundation of Guangdong Province); Medical Scientific Research Foundation of Guangdong Province, China; Guangdong Basic and Applied Basic Research Foundation; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (No.81902576, No.81725016, No. 81872094 and No. 82002684), the Natural Science Foundation of Guangdong Province, China (2017B020227004, 2017A030313538, 2018A030310327), the Medical Scientific Research Foundation of Guangdong Province, China (A2018051), Guangdong Basic and Applied Basic Research Foundation (2020A1515111077), and China Postdoctoral Science Foundation Funded Project (No. 236464).	Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Chen WF, 2016, NATURE, V539, P112, DOI 10.1038/nature19796; Clark PE, 2009, KIDNEY INT, V76, P939, DOI 10.1038/ki.2009.296; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Courtney KD, 2018, J CLIN ONCOL, V36, P867, DOI 10.1200/JCO.2017.74.2627; Ehrlich ES, 2009, P NATL ACAD SCI USA, V106, P20330, DOI 10.1073/pnas.0810571106; Escudier B, 2007, DRUGS, V67, P1257, DOI 10.2165/00003495-200767090-00002; Frank I, 2003, J UROLOGY, V170, P2225, DOI 10.1097/01.ju.0000095541.10333.a7; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Grampp S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13183; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Katschinski DM, 2004, CELL PHYSIOL BIOCHEM, V14, P351, DOI 10.1159/000080345; Li MY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00787; Li WC, 2018, ONCOL LETT, V15, P7855, DOI 10.3892/ol.2018.8315; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Ljungberg B, 2019, EUR UROL, V75, P799, DOI 10.1016/j.eururo.2019.02.011; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Oudard S, 2007, ANN ONCOL, V18, P25, DOI 10.1093/annonc/mdm411; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ren Y, 2019, ONCOTARGETS THER, V12, P2563, DOI 10.2147/OTT.S190239; Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098; Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034; Takeda N, 2004, CIRC RES, V95, P146, DOI 10.1161/01.RES.0000134920.10128.b4; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473; Wang F, 2014, HEPATOLOGY, V60, P1278, DOI 10.1002/hep.27239; Wang H, 2020, J CANCER, V11, P2737, DOI 10.7150/jca.36822; Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y; Wu QJ, 2017, ONCOTARGET, V8, P101865, DOI 10.18632/oncotarget.21706; Xu MD, 2017, CLIN CANCER RES, V23, P2071, DOI 10.1158/1078-0432.CCR-16-0742; Xu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1064-5; Yang T, 2017, ONCOTARGET, V8, P85353, DOI 10.18632/oncotarget.19743; Yu XG, 2018, J BUON, V23, P48; Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z; Zhao L, 2018, J CELL PHYSIOL, V233, P4044, DOI 10.1002/jcp.26072	41	8	8	2	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5639	5650		10.1038/s41388-021-01971-7	http://dx.doi.org/10.1038/s41388-021-01971-7		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34321604	Green Published, hybrid			2022-12-17	WOS:000678443300001
J	Zhang, YJ; Shi, G; Zhang, HT; Xiong, Q; Cheng, FY; Wang, HL; Luo, JY; Zhang, Y; Shi, PY; Xu, J; Fu, JM; Chen, N; Cheng, L; Li, YM; Dai, L; Yang, Y; Yu, DC; Zhang, S; Deng, HX				Zhang, Yujing; Shi, Gang; Zhang, Hantao; Xiong, Qi; Cheng, Fuyi; Wang, Huiling; Luo, Jieyan; Zhang, Yong; Shi, Pengyi; Xu, Jia; Fu, Jiamei; Chen, Na; Cheng, Lin; Li, Yiming; Dai, Lei; Yang, Yang; Yu, Dechao; Zhang, Shuang; Deng, Hongxin			Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway	ONCOGENE			English	Article							TISSUE GROWTH-FACTOR; IMMUNE SURVEILLANCE; CELL-PROLIFERATION; SIGNALING PATHWAY; ACTIVATES SGK1; MECHANISMS; GENE; PHARMACOKINETICS; CHEMOTHERAPY; CARBOPLATIN	Dexamethasone (Dex), as a pretreatment agent, is widely used to attenuate the side effects of chemotherapy in breast cancer treatment. However, whether and how Dex affects breast cancer metastasis remain to be furtherly understood. In this study, we established several mouse breast cancer metastatic models to study the effect of Dex in vitro and in vivo. Transwell, Western Blot and RNA interference were applied to study the molecular mechanism of Dex in promoting breast cancer cell migration. Meanwhile, the effect of Dex on lung metastasis of breast cancer in Dex combined with PTX chemotherapy was discussed. Our results confirmed that Dex could promote breast cancer cell metastasis both in vitro and in vivo. Mechanistic studies revealed that this pro-metastatic effect of Dex was mediated by the GR-PI3K-SGK1-CTGF pathway in tumor cells. Ligation of Dex and glucocorticoid receptor (GR) on tumor cells activated the PI3K signaling pathway and upregulated serum glucocorticoid-inducible kinase 1 (SGK1) expression, and then increased the expression of connective tissue growth factor (CTGF) through Nedd4l-Smad2. Moreover, Dex was the leading factor for lung metastasis in a standard regimen for breast cancer treatment with paclitaxel and Dex. Importantly, targeting SGK1 with the inhibitor GSK650394 remarkably reduced lung metastasis in this regimen. Our present data provide new insights into Dex-induced breast cancer metastasis and indicate that SGK1 could be a candidate target for the treatment of breast cancer metastasis.	[Zhang, Yujing; Shi, Gang; Zhang, Hantao; Xiong, Qi; Cheng, Fuyi; Wang, Huiling; Shi, Pengyi; Xu, Jia; Fu, Jiamei; Chen, Na; Cheng, Lin; Li, Yiming; Dai, Lei; Yang, Yang; Yu, Dechao; Zhang, Shuang; Deng, Hongxin] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu, Peoples R China; [Luo, Jieyan; Zhang, Yong; Zhang, Shuang] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China; [Yu, Dechao] Innovent Biol Inc, Suzhou, Jiangsu, Peoples R China; [Deng, Hongxin] Chinese Acad Med Sci, Res Unit Gene & Immunotherapy, Beijing, Peoples R China	Sichuan University; Sichuan University; Chinese Academy of Medical Sciences - Peking Union Medical College	Zhang, S; Deng, HX (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu, Peoples R China.; Zhang, S (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Sichuan, Peoples R China.; Deng, HX (corresponding author), Chinese Acad Med Sci, Res Unit Gene & Immunotherapy, Beijing, Peoples R China.	shuang.zhang@scu.edu.cn; denghongx@scu.edu.cn			National Key R&D Program of China [2017YFA0105702]; National Natural Science Foundation of China [81672577, 81772939, 81902918, 81972607]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYGD20003]; CAMS Innovation Fund for Medical Science [2019-I2M-5-075]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; CAMS Innovation Fund for Medical Science	This study was supported by the National Key R&D Program of China grant (no. 2017YFA0105702) and the National Natural Science Foundation of China Program grant (81672577, 81772939, 81902918, 81972607), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYGD20003), and CAMS Innovation Fund for Medical Science (2019-I2M-5-075).	Aguiar DP, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-61; Bill R, 2015, FEBS LETT, V589, P1577, DOI 10.1016/j.febslet.2015.05.002; Blomberg OS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.036236; Borsig L, 2018, GLYCOBIOLOGY, V28, P648, DOI 10.1093/glycob/cwx105; Cantrell W, 2018, MOLECULES, V23, DOI 10.3390/molecules23071791; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Chang YS, 2017, P NATL ACAD SCI USA, V114, pE7159, DOI 10.1073/pnas.1700455114; Chaudhary LN, 2018, SURG ONCOL CLIN N AM, V27, P141, DOI 10.1016/j.soc.2017.08.004; Chen PS, 2007, J CELL SCI, V120, P2053, DOI 10.1242/jcs.03460; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Crean JK, 2004, FASEB J, V18, P1541, DOI 10.1096/fj.04-1546fje; Creed TJ, 2009, J IMMUNOL, V183, P164, DOI 10.4049/jimmunol.0801998; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Giles AJ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0371-5; Gonzalez H, 2018, FEBS J, V285, P654, DOI 10.1111/febs.14325; Gupte R, 2013, P NATL ACAD SCI USA, V110, P14616, DOI 10.1073/pnas.1309898110; Guy R, 2002, CELL IMMUNOL, V216, P82, DOI 10.1016/S0008-8749(02)00505-1; Hamidi Hellyeh, 2018, Nat Rev Cancer, V18, P533, DOI 10.1038/s41568-018-0038-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/S0140-6736(16)31891-8, 10.1016/s0140-6736(16)31891-8]; Karagiannis GS, 2019, CANCER RES, V79, P4567, DOI 10.1158/0008-5472.CAN-19-1147; Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026; Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041; Lauby-Secretan B, 2015, NEW ENGL J MED, V372, P2353, DOI 10.1056/NEJMsr1504363; Liu XY, 2018, FUTURE ONCOL, V14, P665, DOI 10.2217/fon-2017-0588; Liu Y, 2016, J MOL MED, V94, P509, DOI 10.1007/s00109-015-1376-x; Lyons TG, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0682-x; Ma XQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08154-1; Manzoni D, 2016, LEUKEMIA RES, V47, P1, DOI 10.1016/j.leukres.2016.05.003; Marinella MA, 2020, J ONCOL PHARM PRACT, V26, P1482, DOI 10.1177/1078155220931921; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200; Mohme M, 2017, NAT REV CLIN ONCOL, V14, P155, DOI 10.1038/nrclinonc.2016.144; Morrison BL, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-35; Obradovic MMS, 2019, NATURE, V567, P540, DOI 10.1038/s41586-019-1019-4; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Pi LY, 2015, HEPATOLOGY, V61, P678, DOI 10.1002/hep.27425; Picard M, 2017, IMMUNOL ALLERGY CLIN, V37, P679, DOI 10.1016/j.iac.2017.07.004; Ramazani Y, 2018, MATRIX BIOL, V68-69, P44, DOI 10.1016/j.matbio.2018.03.007; Ratman D, 2013, MOL CELL ENDOCRINOL, V380, P41, DOI 10.1016/j.mce.2012.12.014; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Saitoh M, 2018, J BIOCHEM, V164, P257, DOI 10.1093/jb/mvy047; Schwartz RS, 2017, NEW ENGL J MED, V376, P2486, DOI 10.1056/NEJMcibr1701388; Singh PP, 2014, BRIT J ANAESTH, V113, P68, DOI 10.1093/bja/aet577; Stavreva DA, 2009, NAT CELL BIOL, V11, P1093, DOI 10.1038/ncb1922; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Toska E, 2019, CELL REP, V27, P294, DOI 10.1016/j.celrep.2019.02.111; Wang H, 2004, CANCER CHEMOTH PHARM, V53, P459, DOI 10.1007/s00280-003-0759-9; Wang H, 2004, CLIN CANCER RES, V10, P1633, DOI 10.1158/1078-0432.CCR-0829-3; Wang HX, 2017, BIOPHARM DRUG DISPOS, V38, P449, DOI 10.1002/bdd.2085; Wu W, 2005, J BIOL CHEM, V280, P4117, DOI 10.1074/jbc.M411200200; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Yousefi M, 2018, CELL ONCOL, V41, P123, DOI 10.1007/s13402-018-0376-6; Zheng YC, 2012, MOL CANCER THER, V11, P2621, DOI 10.1158/1535-7163.MCT-12-0621	57	8	8	3	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2021	40	35					5367	5378		10.1038/s41388-021-01944-w	http://dx.doi.org/10.1038/s41388-021-01944-w		JUL 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO0SJ	34272474	hybrid, Green Published			2022-12-17	WOS:000673332300002
J	Sun, HY; Zhou, R; Zheng, YN; Wen, ZW; Zhang, DL; Zeng, DQ; Wu, JH; Huang, ZH; Rong, XX; Huang, N; Sun, L; Bin, JP; Liao, YL; Shi, M; Liao, WJ				Sun, Huiying; Zhou, Rui; Zheng, Yannan; Wen, Zhaowei; Zhang, Dingling; Zeng, Dongqiang; Wu, Jianhua; Huang, Zhenhua; Rong, Xiaoxiang; Huang, Na; Sun, Li; Bin, Jianping; Liao, Yulin; Shi, Min; Liao, Wangjun			CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy	ONCOGENE			English	Article							ADVANCED GASTRIC-CANCER; GASTROESOPHAGEAL JUNCTION CANCER; DOUBLE-BLIND; COLORECTAL-CANCER; 1ST-LINE THERAPY; INTESTINAL-TYPE; CAPECITABINE; OVEREXPRESSION; EXPRESSION; PROTEIN-1	Homologous recombination (HR) repair is an important determinant of chemosensitivity. However, the mechanisms underlying HR regulation remain largely unknown. Cysteine-rich intestinal protein 1 (CRIP1) is a member of the LIM/double-zinc finger protein family and is overexpressed and associated with prognosis in several tumor types. However, to date, the functional role of CRIP1 in cancer biology is poorly understood. Here we found that CRIP1 downregulation causes HR repair deficiency with concomitant increase in cell sensitivity to cisplatin, epirubicin, and the poly ADP-ribose polymerase (PARP) inhibitor olaparib in gastric cancer cells. Mechanistically, upon DNA damage, CRIP1 is deubiquitinated and upregulated by activated AKT signaling. CRIP1, in turn, promotes nuclear enrichment of RAD51, which is a prerequisite step for HR commencement, by stabilizing BRCA2 to counteract FBXO5-targeted RAD51 degradation and by binding to the core domain of RAD51 (RAD51(184-257)) in coordination with BRCA2, to facilitate nuclear export signal masking interactions between BRCA2 and RAD51. Moreover, through mass spectrometry screening, we found that KPNA4 is at least one of the carriers controlling the nucleo-cytoplasmic distribution of the CRIP1-BRCA2-RAD51 complex in response to chemotherapy. Consistent with these findings, RAD51 inhibitors block the CRIP1-mediated HR process, thereby restoring chemotherapy sensitivity of gastric cancer cells with high CRIP1 expression. Analysis of patient specimens revealed an abnormally high level of CRIP1 expression in GC tissues compared to that in the adjacent normal mucosa and a significant negative association between CRIP1 expression and survival time in patient cohorts with different types of solid tumors undergoing genotoxic treatments. In conclusion, our study suggests an essential function of CRIP1 in promoting HR repair and facilitating gastric cancer cell adaptation to genotoxic therapy.	[Sun, Huiying; Zhou, Rui; Zheng, Yannan; Wen, Zhaowei; Zhang, Dingling; Zeng, Dongqiang; Wu, Jianhua; Huang, Zhenhua; Rong, Xiaoxiang; Huang, Na; Sun, Li; Shi, Min; Liao, Wangjun] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China; [Bin, Jianping; Liao, Yulin] Southern Med Univ, Nanfang Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China	Zhou, R; Liao, WJ (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Guangdong, Peoples R China.	dr.zhourui@qq.com; nfyyliaowj@163.com	Zeng, Dongqiang/C-3828-2019	Zeng, Dongqiang/0000-0001-9724-8325	National Natural Science Foundation of China [81772580]; Natural Science Foundation of Guangdong Province of China [2020A1515110686]; President Foundation of Nanfang Hospital, Southern Medical University [2020C020]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); President Foundation of Nanfang Hospital, Southern Medical University	We thank Lei Li for technical support with liquid chromatography-tandem mass spectrometry. We also thank the members of WL's Laboratory for advice and discussion. This work was supported by the National Natural Science Foundation of China (number 82073303 to WL), National Natural Science Foundation of China (number 81772580 to WL), Natural Science Foundation of Guangdong Province of China (2020A1515110686 to RZ), and President Foundation of Nanfang Hospital, Southern Medical University (2020C020 to RZ).	Balluff B, 2011, AM J PATHOL, V179, P2720, DOI 10.1016/j.ajpath.2011.08.032; Bang YJ, 2017, LANCET ONCOL, V18, P1637, DOI 10.1016/S1470-2045(17)30682-4; Baumhoer D, 2011, ONCOTARGET, V2, P970; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; Ghezraoui H, 2014, MOL CELL, V55, P829, DOI 10.1016/j.molcel.2014.08.002; Han Z, 2008, DIGEST DIS SCI, V53, P1801, DOI 10.1007/s10620-007-9824-2; He GY, 2019, AM J TRANSL RES, V11, P3578; Hecht JR, 2016, J CLIN ONCOL, V34, P443, DOI 10.1200/JCO.2015.62.6598; Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jeyasekharan AD, 2013, NAT STRUCT MOL BIOL, V20, P1191, DOI 10.1038/nsmb.2666; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Klein HL, 2008, DNA REPAIR, V7, P686, DOI 10.1016/j.dnarep.2007.12.008; Latonen L, 2010, PHOTODERMATOL PHOTO, V26, P70, DOI 10.1111/j.1600-0781.2010.00488.x; Li HG, 2017, CELL PHYSIOL BIOCHEM, V43, P2037, DOI 10.1159/000484184; Liu W, 2012, J CLIN GASTROENTEROL, V46, pE31, DOI 10.1097/MCG.0b013e31823457ea; Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5; Ludyga N, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-28; Luo KT, 2016, GENE DEV, V30, P2581, DOI 10.1101/gad.289439.116; Ma HR, 2018, INT J CANCER, V142, P2578, DOI 10.1002/ijc.31274; Marzio A, 2019, MOL CELL, V73, P224, DOI 10.1016/j.molcel.2018.11.003; Motegi A, 2019, SEMIN CANCER BIOL, V58, P29, DOI 10.1016/j.semcancer.2019.02.005; Ohtsu A, 2013, J CLIN ONCOL, V31, P3935, DOI 10.1200/JCO.2012.48.3552; Pannunzio NR, 2018, J BIOL CHEM, V293, P10512, DOI 10.1074/jbc.TM117.000374; Ramanathan RK, 2015, CANCER-AM CANCER SOC, V121, P2193, DOI 10.1002/cncr.29363; Schild D, 2010, NUCLEIC ACIDS RES, V38, P1061, DOI 10.1093/nar/gkp1063; Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580; Smith MA, 2014, TRENDS CELL BIOL, V24, P575, DOI [10.1016/j.tcb.2014.04.009, 10.1016/J.tcb.2014.04.009]; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2; Wang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147613; Wiegmans AP, 2015, MOL CANCER THER, V14, P2321, DOI 10.1158/1535-7163.MCT-15-0374; Wright WD, 2018, J BIOL CHEM, V293, P10524, DOI 10.1074/jbc.TM118.000372; Xu L, 2017, CANCER LETT, V393, P76, DOI 10.1016/j.canlet.2017.02.014; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Yan SY, 2011, WORLD J GASTROENTERO, V17, P1501, DOI 10.3748/wjg.v17.i11.1501; Zhang LZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1117-z; Zhang W, 2017, J PROTEOMICS, V152, P172, DOI 10.1016/j.jprot.2016.11.002; Zhao WX, 2017, NATURE, V550, P360, DOI 10.1038/nature24060	42	8	8	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2021	40	34					5342	5355		10.1038/s41388-021-01932-0	http://dx.doi.org/10.1038/s41388-021-01932-0		JUL 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UJ0LG	34262130	Green Published, hybrid			2022-12-17	WOS:000673426400001
J	Li, JJ; Chen, XL; Zhu, LQ; Lao, ZH; Zhou, TH; Zang, LJ; Ge, WY; Jiang, MY; Xu, JX; Cao, Y; Du, SQ; Yu, Y; Fan, GJ; Wang, HX				Li, Junjian; Chen, Xiaoliang; Zhu, Liqun; Lao, Zhenghong; Zhou, Tianhao; Zang, Lijuan; Ge, Weiyu; Jiang, Mengyi; Xu, Jingxuan; Cao, Yuan; Du, Shaoqian; Yu, Yue; Fan, Guangjian; Wang, Hongxia			SOX9 is a critical regulator of TSPAN8-mediated metastasis in pancreatic cancer	ONCOGENE			English	Article							STEM-CELLS; TUMOR; TETRASPANINS; EXPRESSION; INVASION; TSPAN8; CO-029; EGFR; TRANSCRIPTION; INDUCTION	Pancreatic ductal adenocarcinoma (PDAC) is the deadliest cancer mainly owing to its proclivity to early metastasis and the lack of effective targeted therapeutic drugs. Hence, understanding the molecular mechanisms underlying early invasion and metastasis by PDAC is imperative for improving patient outcomes. The present study identified that upregulation of TSPAN8 expression in PDAC facilitates metastasis in vivo and in vitro. We found SOX9 as a key transcriptional regulator of TSPAN8 expression in response to EGF stimulation. SOX9 modulation was sufficient to positively regulate endogenous expression of TSPAN8, with concomitant in vitro phenotypic changes such as loss of cell-matrix adherence and increased invasion. Moreover, increased SOX9 and TSPAN8 levels were shown to correlate in human pancreatic cancer specimens and downregulated in vitro by EGFR tyrosine kinase inhibitors. High expression of SOX9 and TSPAN8 has been associated with tumor stage, poor prognosis and poor patient survival in PDAC. In conclusion, this study highlights the importance of the EGF-SOX9-TSPAN8 signaling cascade in the control of PDAC invasion and implies that TSPAN8 may be a promising novel therapeutic target for the treatment of PDAC.	[Li, Junjian] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai, Peoples R China; [Li, Junjian; Zhou, Tianhao; Ge, Weiyu; Xu, Jingxuan; Cao, Yuan; Du, Shaoqian; Wang, Hongxia] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China; [Chen, Xiaoliang] Shenzhen Guangming Dist Ctr Dis Control & Prevent, Ctr Chron Dis Control & Prevent, Shenzhen, Peoples R China; [Zhu, Liqun] Liyang Peoples Hosp, Dept Oncol, Liyang, Peoples R China; [Lao, Zhenghong] Deqing Peoples Hosp, Dept Oncol, Huzhou, Peoples R China; [Zang, Lijuan] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Pathol Ctr, Sch Med, Shanghai, Peoples R China; [Jiang, Mengyi] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Med Oncol, East Campus, Shanghai, Peoples R China; [Yu, Yue] Shanghai Expt Sch, Shanghai, Peoples R China; [Fan, Guangjian] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Translat Med Ctr, Sch Med, Shanghai, Peoples R China	Shanghai University of Medicine & Health Sciences; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Wang, HX (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Oncol, State Key Lab Oncogenes & Related Genes,Sch Med, Shanghai, Peoples R China.; Fan, GJ (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Translat Med Ctr, Sch Med, Shanghai, Peoples R China.	gjfan@shsmu.edu.cn; whx365@126.com	Li, Junjian/GSN-5570-2022	Li, Junjian/0000-0001-7970-4163; Xu, Jingxuan/0000-0002-9678-7906	National Natural Science Funds [82073269, 81772802]; Shanghai Science and Technology Innovation Action Plan [20XD1402800]; Clinical Research Plan of SHDC [SHDC2020CR2065B]; Construction Project of Shanghai Key Laboratory of Molecular Imaging [18DZ2260400]; Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS); Huzhou Natural Science Funds [2017YZ11]	National Natural Science Funds(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Innovation Action Plan; Clinical Research Plan of SHDC; Construction Project of Shanghai Key Laboratory of Molecular Imaging; Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS); Huzhou Natural Science Funds	This work was supported by the National Natural Science Funds (grant number 82073269 and 81772802), Shanghai Science and Technology Innovation Action Plan (grant number 20XD1402800) and Clinical Research Plan of SHDC (grant number SHDC2020CR2065B) to H.X.W., the Construction Project of Shanghai Key Laboratory of Molecular Imaging (grant number 18DZ2260400) and Shanghai Municipal Education Commission (Class II Plateau Disciplinary Construction Program of Medical Technology of SUMHS, 2018-2020) to J.J.L. and the Huzhou Natural Science Funds (grant number 2017YZ11) to Z.H.L.	Agaesse G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.11; Anami K, 2016, GASTRIC CANCER, V19, P370, DOI 10.1007/s10120-015-0478-z; Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086; Charrin S, 2014, J CELL SCI, V127, P3641, DOI 10.1242/jcs.154906; Chen NM, 2015, GASTROENTEROLOGY, V148, P1024, DOI 10.1053/j.gastro.2015.01.033; Chen T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01024-2; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Dellle Cave D, 2020, ONCOGENE, V39, P4271, DOI 10.1038/s41388-020-1289-1; El Kharbili M, 2019, ONCOGENE, V38, P3781, DOI 10.1038/s41388-019-0691-z; Fang TT, 2016, ONCOTARGET, V7, P40630, DOI 10.18632/oncotarget.9769; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Giampieri R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215990; Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482; Grimont A, 2015, GUT, V64, P1790, DOI 10.1136/gutjnl-2014-307075; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; Hessmann E, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5272498; Higashihara T, 2017, PANCREAS, V46, P1296, DOI 10.1097/MPA.0000000000000945; Hu B, 2017, ONCOL LETT, V14, P7583, DOI 10.3892/ol.2017.7160; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kaushik G, 2021, ONCOGENE, V40, P848, DOI 10.1038/s41388-020-01564-w; Kawaguchi Y, 2013, J CLIN INVEST, V123, P1881, DOI 10.1172/JCI66022; Kim TK, 2015, BIOCHEM BIOPH RES CO, V468, P774, DOI 10.1016/j.bbrc.2015.11.031; Kopp JL, 2012, CANCER CELL, V22, P737, DOI 10.1016/j.ccr.2012.10.025; Kyuno D, 2019, TRANSL ONCOL, V12, P191, DOI 10.1016/j.tranon.2018.08.021; Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Liu HW, 2015, CELL BIOCHEM BIOPHYS, V73, P205, DOI 10.1007/s12013-015-0647-z; Luanpitpong S, 2016, ONCOGENE, V35, P2824, DOI 10.1038/onc.2015.351; Mu W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020319; Mu W, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01359; Nedaeinia R, 2014, CURR DRUG TARGETS, V15, P1293, DOI 10.2174/1389450115666141125123003; Park CS, 2016, ONCOGENE, V35, P4540, DOI 10.1038/onc.2015.520; Park SJ, 2015, INT J CLIN EXP PATHO, V8, P8298; Pishvaian MJ, 2020, LANCET ONCOL, V21, P508, DOI 10.1016/S1470-2045(20)30074-7; Pritchett J, 2011, TRENDS MOL MED, V17, P166, DOI 10.1016/j.molmed.2010.12.001; Rana S, 2011, INT J BIOCHEM CELL B, V43, P106, DOI 10.1016/j.biocel.2010.10.002; Shi JG, 2018, INT J ONCOL, V52, P179, DOI 10.3892/ijo.2017.4201; Shi ZC, 2015, NUCLEIC ACIDS RES, V43, P6257, DOI 10.1093/nar/gkv568; Shih HP, 2012, DEVELOPMENT, V139, P2488, DOI 10.1242/dev.078634; Si JL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-92; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; Tang L, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0232-1; Blasco MT, 2019, CANCER CELL, V35, P573, DOI 10.1016/j.ccell.2019.03.002; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Voglstaetter M, 2019, J PATHOL, V248, P421, DOI 10.1002/path.5281; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wang HB, 2013, INT J CANCER, V133, P416, DOI 10.1002/ijc.28044; Wang LD, 2019, GENE DEV, V33, P641, DOI 10.1101/gad.323303.118; Yan SY, 2018, GENE, V679, P138, DOI 10.1016/j.gene.2018.08.038; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yue GGL, 2015, AM J CANCER RES, V5, P3570; Yue SJ, 2015, ONCOTARGET, V6, P2366, DOI 10.18632/oncotarget.2958; Zhou H, 2018, ONCOGENE, V37, P912, DOI 10.1038/onc.2017.393; Zhu RX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10739-3	58	8	9	7	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4884	4893		10.1038/s41388-021-01864-9	http://dx.doi.org/10.1038/s41388-021-01864-9		JUN 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163029	Green Published, hybrid			2022-12-17	WOS:000664853000005
J	Zhao, L; Jiang, LY; Zhang, M; Zhang, Q; Guan, QT; Li, YL; He, M; Zhang, JD; Wei, MJ				Zhao, Lin; Jiang, Longyang; Zhang, Ming; Zhang, Qiang; Guan, Qiutong; Li, Yalun; He, Miao; Zhang, Jingdong; Wei, Minjie			NF-kappa B-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay	ONCOGENE			English	Article							UP-REGULATION; ADENOCARCINOMA; STAUFEN1	Previous study demonstrated that most long non-coding RNAs (lncRNAs) function as competing endogenous RNAs or molecular sponges to negatively modulate miRNA and regulate tumor development. However, the molecular mechanisms of lncRNAs in cancer are not fully understood. Our study describes the role of the lncRNA SPRY4 intronic transcript 1 (SPRY4-IT1) in cancer metastasis by mechanisms related to Staufen1 (STAU1)-mediated mRNA decay (SMD). Briefly, we found that, high SPRY4-IT1 expression was associated with aggressiveness and poor outcome in human colorectal, breast and ovarian cancer tissues. In addition, functional assays revealed that SPRY4-IT1 significantly promoted colorectal, breast and ovarian cancer metastasis in vitro and in vivo. Mechanistically, microarray analyses identified several differentially-expressed genes upon SPRY4-IT1 overexpression in HCT 116 colorectal cancer cells. Among them, the 3 '-UTR of transcription elongation factor B subunit 1 (TCEB1) mRNA can base-pair with the Alu element in the 3 '-UTR of SPRY4-IT1. Moreover, SPRY4-IT1 was found to bind STAU1, promote STAU1 recruitment to the 3 '-UTR of TCEB1 mRNA, and affect TCEB1 mRNA stability and expression, resulting in hypoxia-inducible factor 1 alpha (HIF-1 alpha) upregulation, and thereby affecting cancer cell metastasis. In addition, STAU1 depletion abrogated TCEB1 SMD and alleviated the pro-metastatic effect of SPRY4-IT1 overexpression. Significantly, we revealed that SPRY4-IT1 is also transactivated by NF-kappa B/p65, which activates SPRY4-IT1 to inhibit TCEB1 expression, and subsequently upregulate HIF-1 alpha. In conclusion, our results highlight a novel mechanism of cytoplasmic lncRNA SPRY4-IT1 in which SPRY4-IT1 affecting TCEB1 mRNA stability via STAU1-mediated degradation during cancer metastasis.	[Zhao, Lin; Jiang, Longyang; Zhang, Ming; Zhang, Qiang; Guan, Qiutong; He, Miao; Wei, Minjie] China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China; [Zhao, Lin; Jiang, Longyang; Zhang, Ming; Zhang, Qiang; Guan, Qiutong; He, Miao; Wei, Minjie] China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China; [Li, Yalun] China Med Univ, Hosp 1, Dept Anorectal Surg, Shenyang, Peoples R China; [Zhang, Jingdong] China Med Univ, Med Oncol Dept Gastrointestinal Canc, Liaoning Canc Hosp & Inst, Canc Hosp, Shenyang, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University	Wei, MJ (corresponding author), China Med Univ, Sch Pharm, Dept Pharmacol, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China.; Wei, MJ (corresponding author), China Med Univ, Liaoning Key Lab Mol Targeted Antitumor Drug Dev, Shenyang North New Area, 77 Puhe Rd, Shenyang 110122, Liaoning, Peoples R China.; Zhang, JD (corresponding author), China Med Univ, Med Oncol Dept Gastrointestinal Canc, Liaoning Canc Hosp & Inst, Canc Hosp, Shenyang, Peoples R China.	jdzhang@cancerhosp-ln-cmu.com; weiminjiecmu@163.com	Zhang, Jing/GWZ-7332-2022		Shengjing Hospital of China Medical University; National Natural Science Foundation of China [82073884, 82073281, 81673475, U1608281, 81573462, 31828005]; Key R&D Guidance Plan Projects in Liaoning Province [2019JH8/10300011]; Liaoning Province Doctoral Scientific Research Foundation [20180540036]; Liaoning Revitalization Talents Program [XLYC1807201]; Shenyang ST Projects [Z18-4-020]	Shengjing Hospital of China Medical University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key R&D Guidance Plan Projects in Liaoning Province; Liaoning Province Doctoral Scientific Research Foundation; Liaoning Revitalization Talents Program; Shenyang ST Projects	This study was supported by the First Hospital and the Shengjing Hospital of China Medical University. The authors thank all the doctors and nurses for their great help in collecting tissue samples. This work was supported by grants from National Natural Science Foundation of China (No. 82073884, 82073281, 81673475, U1608281, 81573462, 31828005), Key R&D Guidance Plan Projects in Liaoning Province (2019JH8/10300011), Liaoning Province Doctoral Scientific Research Foundation (No 20180540036), Liaoning Revitalization Talents Program (No. XLYC1807201), Shenyang S&T Projects (Z18-4-020).	Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bulatov E, 2015, J BIOL CHEM, V290, P4178, DOI 10.1074/jbc.M114.616664; Cao SG, 2019, MOL THER-NUCL ACIDS, V17, P455, DOI 10.1016/j.omtn.2019.04.030; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cho H, 2012, MOL CELL, V46, P495, DOI 10.1016/j.molcel.2012.03.009; Cong ZZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1361-3; Damas ND, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13875; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gong CG, 2009, GENE DEV, V23, P54, DOI 10.1101/gad.1717309; Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887; Han QR, 2019, ONCOGENE, V38, P3019, DOI 10.1038/s41388-018-0614-4; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460; Kim MY, 2014, NUCLEIC ACIDS RES, V42, P6999, DOI 10.1093/nar/gku388; Kim YK, 2005, CELL, V120, P195, DOI 10.1016/j.cell.2004.11.050; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lee B, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602505; Li WY, 2014, CANCER CELL, V25, P557, DOI 10.1016/j.ccr.2014.04.014; Liang HH, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0870-5; Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004; Liu JY, 2018, BRIT J CANCER, V118, P1617, DOI 10.1038/s41416-018-0116-8; Ma WJ, 2020, J CELL PHYSIOL, V235, P7849, DOI 10.1002/jcp.29438; Moon BS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02720-9; Okumura F, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00010; Park E, 2013, WIRES RNA, V4, P423, DOI 10.1002/wrna.1168; Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002; Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4; Sato Y, 2013, NAT GENET, V45, P860, DOI 10.1038/ng.2699; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sun M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.256; Tan XC, 2018, J CLIN INVEST, V128, P3198, DOI 10.1172/JCI122740; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang YQ, 2017, CELL DEATH DIFFER, V24, P2089, DOI 10.1038/cdd.2017.129; Wu TY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0354-y; Xie M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0595-9; Xu TP, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.205; Xu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0747-x; Yamaki Y, 2016, MOL CELL BIOCHEM, V414, P1, DOI 10.1007/s11010-015-2643-4; Yang CQ, 2020, MOL THER-NUCL ACIDS, V20, P866, DOI 10.1016/j.omtn.2020.05.004; Yang Q, 2013, MOL CANCER RES, V11, P1497, DOI 10.1158/1541-7786.MCR-13-0214; Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1; Yao Y, 2018, GENE, V659, P52, DOI 10.1016/j.gene.2018.03.048; Ye TB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1074-6; Yu GF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16781-9	45	8	8	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4919	4929		10.1038/s41388-021-01900-8	http://dx.doi.org/10.1038/s41388-021-01900-8		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163032	Green Published, hybrid			2022-12-17	WOS:000664853000001
J	O'Connor, MJ; Thakar, T; Nicolae, CM; Moldovan, GL				O'Connor, Michael J.; Thakar, Tanay; Nicolae, Claudia M.; Moldovan, George-Lucian			PARP14 regulates cyclin D1 expression to promote cell-cycle progression	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; FAMILY; CANCER; GENE; P21; P53; PROLIFERATION; INHIBITION; DYNAMICS; PARP-14	Cyclin D1 is an essential regulator of the G1-S cell-cycle transition and is overexpressed in many cancers. Expression of cyclin D1 is under tight cellular regulation that is controlled by many signaling pathways. Here we report that PARP14, a member of the poly(ADP-ribose) polymerase (PARP) family, is a regulator of cyclin D1 expression. Depletion of PARP14 leads to decreased cyclin D1 protein levels. In cells with a functional retinoblastoma (RB) protein pathway, this results in G1 cell-cycle arrest and reduced proliferation. Mechanistically, we found that PARP14 controls cyclin D1 mRNA levels. Using luciferase assays, we show that PARP14 specifically regulates cyclin D1 3 ' UTR mRNA stability. Finally, we also provide evidence that G1 arrest in PARP14-depleted cells is dependent on an intact p53-p21 pathway. Our work uncovers a new role for PARP14 in promoting cell-cycle progression through both cyclin D1 and the p53 pathway.	[O'Connor, Michael J.; Thakar, Tanay; Nicolae, Claudia M.; Moldovan, George-Lucian] Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Moldovan, GL (corresponding author), Penn State Univ, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.	glm29@psu.edu	Thakar, Tanay/AGX-3854-2022	Thakar, Tanay/0000-0001-5261-458X; Nicolae, Claudia/0000-0003-4933-5496	NIH [R01ES026184]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Drs James Broach, Gregory Yochum, Lisa Shantz, Hein Te Riele, Titia de Lange, Nicholas Dyson, Hong-Gang Wang, Raymond Hohl, Myriam Gorospe, Khandan Keyomarsi, and Peter Sicinski for materials and advice, as well as the Penn State College of Medicine Flow Cytometry core for their assistance with flow cytometry experiments. This work was supported by NIH R01ES026184 (to G-LM).	Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; Barbarulo A, 2013, ONCOGENE, V32, P4231, DOI 10.1038/onc.2012.448; Benedict B, 2018, ELIFE, V7, DOI 10.7554/eLife.37868; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Carbone M, 2008, ONCOGENE, V27, P6083, DOI 10.1038/onc.2008.221; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Cho SH, 2009, BLOOD, V113, P2416, DOI 10.1182/blood-2008-03-144121; DeFilippis RA, 2003, J VIROL, V77, P1551, DOI 10.1128/JVI.77.2.1551-1563.2003; Dyson NJ, 2016, GENE DEV, V30, P1492, DOI 10.1101/gad.282145.116; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Goenka S, 2006, P NATL ACAD SCI USA, V103, P4210, DOI 10.1073/pnas.0506981103; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Guiley KZ, 2019, SCIENCE, V366, P1330, DOI 10.1126/science.aaw2106; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Hydbring P, 2017, CANCER CELL, V31, P576, DOI 10.1016/j.ccell.2017.03.004; Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882; Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765; Iqbal MB, 2014, BLOOD, V124, P3646, DOI 10.1182/blood-2014-07-588046; Kettner NM, 2019, CLIN CANCER RES, V25, P3996, DOI 10.1158/1078-0432.CCR-18-3274; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee MS, 2016, ONCOTARGET, V7, P39595, DOI 10.18632/oncotarget.9153; Mayr C, 2017, ANNU REV GENET, V51, P171, DOI 10.1146/annurev-genet-120116-024704; Milek M, 2017, GENOME RES, V27, P1344, DOI 10.1101/gr.218438.116; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Narasimha AM, 2014, ELIFE, V3, DOI 10.7554/eLife.02872; Nicolae CM, 2018, ONCOGENE, V37, P3647, DOI 10.1038/s41388-018-0219-y; Nicolae CM, 2015, NUCLEIC ACIDS RES, V43, P3143, DOI 10.1093/nar/gkv147; Nicolae CM, 2014, J BIOL CHEM, V289, P13627, DOI 10.1074/jbc.M114.556340; Nicolay BN, 2015, GENE DEV, V29, P1875, DOI 10.1101/gad.264127.115; Riley JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083127; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Stengel KR, 2009, J BIOL CHEM, V284, P19265, DOI 10.1074/jbc.M808740200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Velez-Cruz R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081776; Viatour P, 2011, DIS MODEL MECH, V4, P581, DOI 10.1242/dmm.008060; Vyas S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5426; Vyas S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3240; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; Yang Z, 2017, MOL CANCER RES, V15, P1579, DOI 10.1158/1541-7786.MCR-17-0084; Yao N, 2019, MOL CARCINOGEN, V58, P1291, DOI 10.1002/mc.23011; Zhang JF, 2016, MOL CELL, V62, P929, DOI 10.1016/j.molcel.2016.04.023	47	8	8	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4872	4883		10.1038/s41388-021-01881-8	http://dx.doi.org/10.1038/s41388-021-01881-8		JUN 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34158578	Green Accepted			2022-12-17	WOS:000664429900001
J	Li, BR; Pei, GS; Yao, J; Ding, QQ; Jia, PL; Zhao, ZM				Li, Bingrui; Pei, Guangsheng; Yao, Jun; Ding, Qingqing; Jia, Peilin; Zhao, Zhongming			Cell-type deconvolution analysis identifies cancer-associated myofibroblast component as a poor prognostic factor in multiple cancer types	ONCOGENE			English	Article							STROMAL CELLS; TUMOR-CELLS; MITOMYCIN-C; FIBROBLASTS; FIBROSIS	Cancer-associated fibroblasts (CAFs) constitute a prominent component of the tumor microenvironment and play critical roles in cancer progression and drug resistance. Although recent studies indicate CAFs may consist of several CAF subtypes, the breadth of CAF heterogeneity and functional roles of CAF subtypes in cancer progression remain unclear. In this study, we implemented a cell-type deconvolutional approach to comprehensively characterize cell-type alternations across 18 cancer types from The Cancer Genome Atlas (TCGA). Pan-cancer survival analysis using deconvoluted CAF subtypes revealed myofibroblastic CAF (myCAF) composition as a poor prognostic factor in nine cancer types. Patients with higher myCAF compositions tend to have worse response to six antineoplastic drugs predicted by a lncRNA-based Elastic Net prediction model (LENP). In addition, integrative mutational analysis identified 14 and 413 genes associated with the differentiation degree of myCAF and inflammatory CAF (iCAF), respectively, with significant enrichment of genes involved in fibroblast and extracellular matrix (ECM)-related pathways. In summary, our findings systematically illustrated the complex roles of CAF subtypes in patient prognosis and drug response, and identified putative driver genes in CAF-subtype differentiation. These results provided novel therapeutic perspectives for targeting CAF subtypes in tumor microenvironment and arranging treatment scheme based on the CAF compositions in different cancer types.	[Li, Bingrui; Pei, Guangsheng; Jia, Peilin; Zhao, Zhongming] Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Ctr Precis Hlth, Houston, TX 77030 USA; [Yao, Jun] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Ding, Qingqing] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Zhao, Zhongming] Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA; [Zhao, Zhongming] MD Anderson Canc Ctr, UT Hlth Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Texas System; UTMD Anderson Cancer Center	Jia, PL; Zhao, ZM (corresponding author), Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Ctr Precis Hlth, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), Univ Texas Hlth Sci Ctr, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.; Zhao, ZM (corresponding author), MD Anderson Canc Ctr, UT Hlth Grad Sch Biomed Sci, Houston, TX 77030 USA.	peilin.jia@gmail.com; zhongming.zhao@uth.tmc.edu		Li, Bingrui/0000-0002-4807-1452; Pei, Guangsheng/0000-0003-1804-7598	National Institutes of Health [R01LM012806]; Cancer Prevention and Research Institute of Texas grant (CPRIT) [RP180734, RP170668]; CPRIT [RP180734]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas grant (CPRIT); CPRIT	This work was partially supported by National Institutes of Health grant (R01LM012806) and the Cancer Prevention and Research Institute of Texas grant (CPRIT RP180734 and RP170668). Publication charges for this article have been funded by CPRIT RP180734.	Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427; Cho JG, 2018, EUR ARCH OTO-RHINO-L, V275, P2355, DOI 10.1007/s00405-018-5061-x; COBOS FA, 2020, NAT COMMUN, V11; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fox NG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09989-y; Glastonbury CA, 2019, AM J HUM GENET, V104, P1013, DOI 10.1016/j.ajhg.2019.03.025; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Kadel D, 2019, CELL BIOL TOXICOL, V35, P407, DOI 10.1007/s10565-019-09461-z; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Mukaida N, 2016, WORLD J GASTROENTERO, V22, P5301, DOI 10.3748/wjg.v22.i23.5301; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Pei GS, 2021, GENOME RES, V31, P146, DOI 10.1101/gr.265769.120; Pei GS, 2019, BIOINFORMATICS, V35, P3842, DOI 10.1093/bioinformatics/btz138; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Ricard-Blum S, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004978; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; SAPPINO AP, 1988, INT J CANCER, V41, P707, DOI 10.1002/ijc.2910410512; Shi YF, 2017, NAT REV DRUG DISCOV, V16, P35, DOI 10.1038/nrd.2016.193; Singh M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11049-4; Stunnenberg HG, 2016, CELL, V167, P1897, DOI 10.1016/j.cell.2016.12.002; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Sun Y, 2015, EUR J PHARMACOL, V765, P198, DOI 10.1016/j.ejphar.2015.08.002; Tlsty TD, 2001, CURR OPIN GENET DEV, V11, P54, DOI 10.1016/S0959-437X(00)00156-8; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang X, 1999, BRIT J CANCER, V80, P1223, DOI 10.1038/sj.bjc.6690489; Wang YQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02951-4; Yoav Benjamini, 2001, Behavioural Brain Research, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Zheng J, 2019, QUANT BIOL, V7, P247, DOI 10.1007/s40484-019-0189-2	44	8	8	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4686	4694		10.1038/s41388-021-01870-x	http://dx.doi.org/10.1038/s41388-021-01870-x		JUN 2021	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140640				2022-12-17	WOS:000662838900002
J	Wang, HY; Wang, X; Zhang, HY; Deng, T; Liu, R; Liu, Y; Li, HL; Bai, M; Ning, T; Wang, JY; Ge, SH; Ba, Y				Wang, Huiya; Wang, Xia; Zhang, Haiyang; Deng, Ting; Liu, Rui; Liu, Ying; Li, Hongli; Bai, Ming; Ning, Tao; Wang, Junyi; Ge, Shaohua; Ba, Yi			The HSF1/miR-135b-5p axis induces protective autophagy to promote oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal cancer	ONCOGENE			English	Article							ADJUVANT CHEMOTHERAPY; OPEN-LABEL; CELLS; CHEMORESISTANCE; MIR-135B-5P; MICRORNAS; TUMORIGENESIS; FLUOROURACIL; LEUCOVORIN; MECHANISM	Oxaliplatin (oxa) is widely used in the treatment of colorectal cancer (CRC), but the development of oxaliplatin resistance is a major obstacle to the therapeutic efficacy in patients. MicroRNAs (miRNAs), endogenous noncoding RNAs measuring between 22 and 24 nucleotides, have been shown to be involved in the development of CRC drug resistance. However, the mechanism by which differentially expressed miRNAs induce chemotherapy resistance in CRC has not been fully elucidated to date. Here, we showed the differentially expressed miRNAs in oxaliplatin-sensitive and oxaliplatin-resistant CRC cells through miRNA microarray technology and found that miR-135b-5p was significantly increased in oxaliplatin-resistant cells. And miR-135b-5p was increased in the serum of colorectal cancer patients. More importantly, the miR-135b-5p level in the serum of oxaliplatin-resistant patients was further increased compared to that of oxaliplatin-sensitive patients. Recent studies have shown that protective autophagy is an important mechanism that promotes drug resistance in tumors. The potential role of miR-135b-5p in inducing protective autophagy and promoting oxaliplatin resistance was evaluated in two stable oxaliplatin-resistant CRC cell lines and their parental cells. We further identified MUL1 as a direct downstream target of miR-135b-5p and showed that MUL1 could degrade the key molecule of autophagy, ULK1, through ubiquitination. Mouse xenograft models were adopted to evaluate the correlation between miR-135b-5p and oxaliplatin-induced autophagy in vivo. Furthermore, we also investigated the regulatory factors for the upregulation of miR-135b-5p in CRC cells under oxaliplatin chemotoxicity. These results indicated that miR-135b-5p upregulation in colorectal cancer could induce protective autophagy through the MUL1/ULK1 signaling pathway and promote oxaliplatin resistance. Targeting miR-135b-5p may provide a new treatment strategy for reversing oxaliplatin resistance in CRC.	[Wang, Huiya; Wang, Xia; Zhang, Haiyang; Deng, Ting; Liu, Rui; Liu, Ying; Li, Hongli; Bai, Ming; Ning, Tao; Wang, Junyi; Ge, Shaohua; Ba, Yi] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China	Tianjin Medical University	Ba, Y (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.	bayi@tjmuch.com	wang, junyi/GYA-3213-2022		National Natural Science Foundation of China [82072664, 81772629, 81802363, 81702431, 81772843, 81974374]; Demonstrative Research Platform of Clinical Evaluation Technology for New Anticancer Drugs [2018ZX09201015]; Tianjin Science Foundation [18JCQNJC81900, 18JCYBJC92000, 18JCYBJC25400, 18JCYBJC92900, 20JCYBJC00100]; Science & Technology Development Fund of the Tianjin Education Commission for Higher Education [2018KJ046, 2017KJ227]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Demonstrative Research Platform of Clinical Evaluation Technology for New Anticancer Drugs; Tianjin Science Foundation(Natural Science Foundation of Tianjin); Science & Technology Development Fund of the Tianjin Education Commission for Higher Education	This work was supported by grants from the National Natural Science Foundation of China (Nos. 82072664, 81772629, 81802363, 81702431, 81772843, 81974374) and the Demonstrative Research Platform of Clinical Evaluation Technology for New Anticancer Drugs (No. 2018ZX09201015). This work was also supported by the Tianjin Science Foundation (Nos. 18JCQNJC81900, 18JCYBJC92000, 18JCYBJC25400, 18JCYBJC92900, 20JCYBJC00100) and the Science & Technology Development Fund of the Tianjin Education Commission for Higher Education (2018KJ046, 2017KJ227). The funders had no role in the study design, the data collection and analysis, the interpretation of the data, the writing of the report, and the decision to submit this article for publication.	Andre T, 2018, J CLIN ONCOL, V36, P1469, DOI 10.1200/JCO.2017.76.0355; Bai M, 2019, MOL THER, V27, P1772, DOI 10.1016/j.ymthe.2019.06.018; Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543; Chen H, 2019, ONCOTARGETS THER, V12, P3869, DOI 10.2147/OTT.S207938; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI 10.1016/S1470-2045(14)70377-8; Iqbal MA, 2019, MOL ASPECTS MED, V70, P3, DOI 10.1016/j.mam.2018.07.003; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li J, 2015, AUTOPHAGY, V11, P1216, DOI 10.1080/15548627.2015.1017180; Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu B, 2017, MOL CARCINOGEN, V56, P2669, DOI 10.1002/mc.22710; Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7; Lorente J, 2018, BIOL REV, V93, P152, DOI 10.1111/brv.12337; Lv ZD, 2019, J CELL PHYSIOL, V234, P10819, DOI 10.1002/jcp.27906; Magalhaes L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4980-7; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Mishra S, 2016, CRIT REV ONCOL HEMAT, V98, P12, DOI 10.1016/j.critrevonc.2015.10.003; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Neuspiel M, 2008, CURR BIOL, V18, P102, DOI 10.1016/j.cub.2007.12.038; Pan XF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1660-8; Poultsides GA, 2009, J CLIN ONCOL, V27, P3379, DOI 10.1200/JCO.2008.20.9817; Puri R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11636-5; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Seo HA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010029; Shao LL, 2019, FASEB J, V33, P264, DOI 10.1096/fj.201701456RR; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; Su WM, 2016, BIOMED PHARMACOTHER, V84, P123, DOI 10.1016/j.biopha.2016.09.027; Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621; Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood-2014-05-576116; Vihervaara A, 2014, J CELL SCI, V127, P261, DOI 10.1242/jcs.132605; Wang N, 2016, ONCOL LETT, V11, P543, DOI 10.3892/ol.2015.3970; Wang Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00308; Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014; Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021; Zhang BC, 2008, CELL RES, V18, P900, DOI 10.1038/cr.2008.75; Zhang Y, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1024-3; Zhang ZL, 2017, BIOMED PHARMACOTHER, V96, P1341, DOI 10.1016/j.biopha.2017.11.074; Zhou CF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01237-y	45	8	8	4	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4695	4708		10.1038/s41388-021-01898-z	http://dx.doi.org/10.1038/s41388-021-01898-z		JUN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140641				2022-12-17	WOS:000662838900005
J	Zhao, ZX; Guo, YY; Liu, YY; Sun, LC; Chen, B; Wang, CY; Chen, TT; Wang, YQ; Li, YW; Dong, Q; Ai, LQ; Wang, R; Gu, YY; Li, X				Zhao, Zhangxiang; Guo, YingYing; Liu, Yaoyao; Sun, Lichun; Chen, Bo; Wang, Chengyu; Chen, Tingting; Wang, Yuquan; Li, Yawei; Dong, Qi; Ai, Liqiang; Wang, Ran; Gu, Yunyan; Li, Xia			Individualized lncRNA differential expression profile reveals heterogeneity of breast cancer	ONCOGENE			English	Article							LONG NONCODING RNAS; SUBTYPES; REPAIR	Long non-coding RNAs (lncRNAs) play key regulatory roles in breast cancer. However, population-level differential expression analysis methods disregard the heterogeneous expression of lncRNAs in individual patients. Therefore, we individualized lncRNA expression profiles for breast invasive carcinoma (BRCA) using the method of LncRNA Individualization (LncRIndiv). After evaluating the robustness of LncRIndiv, we constructed an individualized differentially expressed lncRNA (IDElncRNA) profile for BRCA and investigated the subtype-specific IDElncRNAs. The breast cancer subtype-specific IDElncRNA showed frequent co-occurrence with alterations of protein-coding genes, including mutations, copy number variation and differential methylation. We performed hierarchical clustering to subdivide TNBC and revealed mesenchymal subtype and immune subtype for TNBC. The TNBC immune subtype showed a better prognosis than the TNBC mesenchymal subtype. LncRNA PTOV1-AS1 was the top differentially expressed lncRNA in the mesenchymal subtype. And biological experiments validated that the upregulation of PTOV1-AS1 could downregulate TJP1 (ZO-1) and E-Cadherin, and upregulate Vimentin, which suggests PTOV1-AS1 may promote epithelial-mesenchymal transition and lead to migration and invasion of TNBC cells. The mesenchymal subtype showed a higher fraction of M2 macrophages, whereas the immune subtype was more associated with CD4 + T cells. The immune subtype is characterized by genomic instability and upregulation of immune checkpoint genes, thereby suggesting a potential response to immunosuppressive drugs. Last, drug response analysis revealed lncRNA ENSG00000230082 (PRRT3-AS1) is a potential resistance biomarker for paclitaxel in BRCA treatment. Our analysis highlights that IDElncRNAs can characterize inter-tumor heterogeneity in BRCA and the new TNBC subtypes indicate novel insights into TNBC immunotherapy.	[Zhao, Zhangxiang; Liu, Yaoyao; Chen, Bo; Wang, Chengyu; Chen, Tingting; Wang, Yuquan; Li, Yawei; Dong, Qi; Ai, Liqiang; Gu, Yunyan] Harbin Med Univ, Dept Syst Biol, Coll Bioinformat Sci & Technol, Harbin, Peoples R China; [Guo, YingYing] Harbin Med Univ, Coll Pharm, Minist Educ, China Key Lab Cardiovasc Res,Dept Pharmacol,State, Harbin, Peoples R China; [Guo, YingYing] Harbin Med Univ, Heilongjiang Acad Med Sci, Northern Translat Med Res & Cooperat, Harbin, Peoples R China; [Sun, Lichun] Harbin Med Univ, Dept Breast Med Oncol, Canc Hosp, Harbin, Peoples R China; [Wang, Ran] Harbin Med Univ, Dept Physiol, Harbin, Peoples R China; [Li, Xia] Harbin Med Univ, Dept Bioinformat, Coll Bioinformat Sci & Technol, Harbin, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University	Gu, YY (corresponding author), Harbin Med Univ, Dept Syst Biol, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.; Li, X (corresponding author), Harbin Med Univ, Dept Bioinformat, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.	guyunyan@ems.hrbmu.edu.cn; lixia@hrbmu.edu.cn		Gu, Yunyan/0000-0001-5693-4126; Zhao, Zhangxiang/0000-0001-7467-7223; Chen, Tingting/0000-0002-3918-5132; Wang, Chengyu/0000-0003-2384-0822	National Natural Science Foundation of China [61673143, 61873075]; National Key R&D Program of China [2018YFC2000100]; Postdoctoral Scientific Research Developmental Fund [LBH-Q16166]; Fundamental Research Funds for the Heilongjiang Provincial Universities [31041180010]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; Postdoctoral Scientific Research Developmental Fund; Fundamental Research Funds for the Heilongjiang Provincial Universities	This work was supported by the National Natural Science Foundation of China [grant number: 61673143, 61873075], the National Key R&D Program of China [grant number: 2018YFC2000100], the Postdoctoral Scientific Research Developmental Fund [no. LBH-Q16166] and the Fundamental Research Funds for the Heilongjiang Provincial Universities [grant number: 31041180010].	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Bareche Y, 2018, ANN ONCOL, V29, P895, DOI 10.1093/annonc/mdy024; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Bhan A, 2015, BBA-REV CANCER, V1856, P151, DOI 10.1016/j.bbcan.2015.07.001; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457; Ding JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9554; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Goldhirsch A, 2013, BREAST, V22, pS3, DOI 10.1016/j.breast.2013.07.001; Huang X, 2018, Zhonghua Yi Xue Za Zhi, V98, P1213, DOI 10.3760/cma.j.issn.0376-2491.2018.16.005; Jiang YZ, 2019, CANCER CELL, V35, P428, DOI 10.1016/j.ccell.2019.02.001; Knijnenburg TA, 2018, CELL REP, V23, P239, DOI 10.1016/j.celrep.2018.03.076; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Li YY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15095-1; Luo J, 2010, PHARMACOGENOMICS J, V10, P278, DOI 10.1038/tpj.2010.57; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Nath A, 2019, P NATL ACAD SCI USA, V116, P22020, DOI 10.1073/pnas.1909998116; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Peng FD, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0666-z; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Pusztai L, 2015, CLIN CANCER RES, V21, P3575, DOI 10.1158/1078-0432.CCR-14-3121; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z; Schmitt AM, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026492; Senkus E, 2015, ANN ONCOL, V26, pV8, DOI 10.1093/annonc/mdv298; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Sun BY, 2020, ONCOL LETT, V19, P595, DOI 10.3892/ol.2019.11182; Tang JM, 2018, ONCOGENE, V37, P4723, DOI 10.1038/s41388-018-0310-4; Thapar R, 2018, MOLECULES, V23, DOI 10.3390/molecules23112789; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Wang HW, 2015, BIOINFORMATICS, V31, P62, DOI 10.1093/bioinformatics/btu522; Wu SC, 2010, CELL RES, V20, P1109, DOI 10.1038/cr.2010.114; Xing F, 2018, CANCER RES, V78, P4316, DOI 10.1158/0008-5472.CAN-18-1102; Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006; Youness RA, 2019, NON-CODING RNA RES, V4, P36, DOI 10.1016/j.ncrna.2019.01.003; Zhang TZ, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819843889; Zheng RN, 2018, BIOCHEM BIOPH RES CO, V498, P1002, DOI 10.1016/j.bbrc.2018.03.104	38	8	8	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4604	4614		10.1038/s41388-021-01883-6	http://dx.doi.org/10.1038/s41388-021-01883-6		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34131286	Green Published, hybrid			2022-12-17	WOS:000661812800001
J	Liu, X; Li, LY; Si, FS; Huang, L; Zhao, YJ; Zhang, CC; Hoft, DF; Peng, GY				Liu, Xia; Li, Lingyun; Si, Fusheng; Huang, Lan; Zhao, Yangjing; Zhang, Chenchen; Hoft, Daniel F.; Peng, Guangyong			NK and NKT cells have distinct properties and functions in cancer	ONCOGENE			English	Article							KILLER T-CELLS; BREAST-CANCER; TUMOR MICROENVIRONMENT; ANTITUMOR-ACTIVITY; SELF-TOLERANCE; ACTIVATION; EXPRESSION; EXHAUSTION; IMMUNITY; DYSFUNCTION	Natural killer (NK) and natural killer T (NKT) cells are two important cell subsets of the innate immune system. NK and NKT cells share many phenotypes and functions for anti-tumor immunity; however, the dynamic changes in phenotypes and functional interactions within the tumor microenvironment during tumor development and progression are unknown. Here we report that NK and NKT cells have distinct properties, metabolic profiles, and functions during tumor development. Using the mouse E0771 breast cancer and B16 melanoma models, we found that both NK and NKT cells are dynamically involved in the immune responses to cancer but have distinct distributions and phenotypic profiles in tumor sites and other peripheral organs during the course of tumor development and progression. In the early stages of tumor development, both NK and NKT cells exhibit effector properties. In the later cancer stages, NK and NKT cells have impaired cytotoxic capacities and dysfunctional states. NK cells become senescent cells, while NKT cells, other than invariant NKT (iNKT) cells, are exhausted in the advanced cancers. In contrast, iNKT cells develop increases in activation and effector function within the breast tumor microenvironment. In addition, senescent NK cells have heightened glucose and lipid metabolism, but exhausted NKT cells display unbalanced metabolism in tumor microenvironments of both breast cancer and melanoma tumor models. These studies provide a better understanding of the dynamic and distinct functional roles of NK and NKT cells in anti-tumor immunity, which may facilitate the development of novel immunotherapies targeting NK and NKT cells for cancer treatment.	[Liu, Xia; Li, Lingyun; Si, Fusheng; Huang, Lan; Zhao, Yangjing; Zhang, Chenchen; Hoft, Daniel F.; Peng, Guangyong] St Louis Univ, Sch Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63104 USA; [Liu, Xia; Li, Lingyun; Si, Fusheng; Huang, Lan; Zhao, Yangjing; Zhang, Chenchen; Hoft, Daniel F.; Peng, Guangyong] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA; [Hoft, Daniel F.; Peng, Guangyong] St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University; Saint Louis University	Peng, GY (corresponding author), St Louis Univ, Sch Med, Div Infect Dis Allergy & Immunol, St Louis, MO 63104 USA.; Peng, GY (corresponding author), St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA.; Peng, GY (corresponding author), St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA.	guangyong.peng@health.slu.edu	Zhang, Chenchen/GPW-7947-2022	Zhang, Chenchen/0000-0003-4519-3435	American Cancer Society [RSG10-160-01-LIB]; Melanoma Research Alliance; NIH [CA184379, CA242188, CA237149, AG067441]	American Cancer Society(American Cancer Society); Melanoma Research Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was partially supported by grants from the American Cancer Society (RSG10-160-01-LIB, to GP), Melanoma Research Alliance (to GP), and the NIH (CA184379, CA242188, CA237149, and AG067441 to GP).	Ardolino M, 2014, J CLIN INVEST, V124, P4781, DOI 10.1172/JCI74337; Baitsch L, 2012, TRENDS IMMUNOL, V33, P364, DOI 10.1016/j.it.2012.02.006; Baitsch L, 2011, J CLIN INVEST, V121, P2350, DOI 10.1172/JCI46102; Bates JP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4441-3; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179; Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Fu BQ, 2011, IMMUNOLOGY, V133, P350, DOI 10.1111/j.1365-2567.2011.03446.x; Gajewski TF, 2011, CURR OPIN IMMUNOL, V23, P286, DOI 10.1016/j.coi.2010.11.013; Gardiner CM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00367; Gill S, 2012, BLOOD, V119, P5758, DOI 10.1182/blood-2012-03-415364; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Hasmim M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00482; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Hu ZSI, 2018, CURR BREAST CANCER R, V10, P35, DOI 10.1007/s12609-018-0274-y; Huang Y, 2015, ONCOTARGET, V6, P17462, DOI 10.18632/oncotarget.3958; Izhak L, 2013, CANCER RES, V73, P1514, DOI 10.1158/0008-5472.CAN-12-2567; Keppel MP, 2015, J IMMUNOL, V194, P1954, DOI 10.4049/jimmunol.1402099; Kim YH, 2017, J IMMUNOL, V199, P3478, DOI 10.4049/jimmunol.1700567; Kobayashi T, 2019, MOL IMMUNOL, V115, P3, DOI [10.1016/J.molimm.2017.11.021, 10.1016/j.molimm.2017.11.021]; Krneta T, 2016, CELL MOL IMMUNOL, V13, P628, DOI 10.1038/cmi.2015.42; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Liu X, 2020, J CLIN INVEST, V130, P1073, DOI 10.1172/JCI133679; Liu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02689-5; Liu Y, 2017, ONCOGENE, V36, P6143, DOI 10.1038/onc.2017.209; Lyons TG, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0701-2; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; Mah AY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95128; Mah AY, 2016, CRIT REV IMMUNOL, V36, P131, DOI 10.1615/CritRevImmunol.2016017387; Mamessier E, 2011, J CLIN INVEST, V121, P3609, DOI 10.1172/JCI45816; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; McEwen-Smith RM, 2015, CANCER IMMUNOL RES, V3, P425, DOI 10.1158/2326-6066.CIR-15-0062; Moretta L, 2014, INT ARCH ALLERGY IMM, V164, P253, DOI 10.1159/000365632; Motohashi S, 2009, J IMMUNOL, V182, P2492, DOI 10.4049/jimmunol.0800126; Muller-Durovic B, 2016, J IMMUNOL, V197, P2891, DOI 10.4049/jimmunol.1600590; O'Konek JJ, 2013, CLIN CANCER RES, V19, P4404, DOI 10.1158/1078-0432.CCR-12-2169; Parekh VV, 2005, J CLIN INVEST, V115, P2572, DOI 10.1172/JCI24762; Pietra G, 2012, CANCER RES, V72, P1407, DOI 10.1158/0008-5472.CAN-11-2544; Polk A, 2018, CANCER TREAT REV, V63, P122, DOI 10.1016/j.ctrv.2017.12.008; Sag D, 2014, J CLIN INVEST, V124, P3725, DOI 10.1172/JCI72308; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schule Jana M, 2004, J Transl Med, V2, P45, DOI 10.1186/1479-5876-2-45; Shifrin N, 2014, SEMIN IMMUNOL, V26, P138, DOI 10.1016/j.smim.2014.02.007; Shin JH, 2013, P NATL ACAD SCI USA, V110, P12391, DOI 10.1073/pnas.1302856110; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; Stojanovic A, 2014, J IMMUNOL, V192, P4184, DOI 10.4049/jimmunol.1302091; Terabe M, 2008, ADV CANCER RES, V101, P277, DOI 10.1016/S0065-230X(08)00408-9; Thommen DS, 2018, CANCER CELL, V33, P547, DOI 10.1016/j.ccell.2018.03.012; Ververs FA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01192; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Webb JR, 2010, GYNECOL ONCOL, V118, P228, DOI 10.1016/j.ygyno.2010.05.016; Webb TJ, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw055; Xia LY, 2019, CELL METAB, V29, P103, DOI 10.1016/j.cmet.2018.09.020; Yamasaki K, 2011, CLIN IMMUNOL, V138, P255, DOI 10.1016/j.clim.2010.11.014; Ye J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.994398; Ye J, 2014, EMBO MOL MED, V6, P1294, DOI 10.15252/emmm.201403918; Ye J, 2013, J IMMUNOL, V190, P2403, DOI 10.4049/jimmunol.1202369; Ye J, 2012, BLOOD, V120, P2021, DOI 10.1182/blood-2012-03-416040; Yu JH, 2013, TRENDS IMMUNOL, V34, P573, DOI 10.1016/j.it.2013.07.005; Zhao YJ, 2020, CELL MOL IMMUNOL, V17, P27, DOI 10.1038/s41423-019-0344-8	63	8	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2021	40	27					4521	4537		10.1038/s41388-021-01880-9	http://dx.doi.org/10.1038/s41388-021-01880-9		JUN 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TG4PV	34120141				2022-12-17	WOS:000660811300002
J	Atashrazm, F; Ellis, S				Atashrazm, Farzaneh; Ellis, Sarah			The polarity protein PARD3 and cancer	ONCOGENE			English	Review							ASYMMETRIC CELL-DIVISION; EPITHELIAL TIGHT JUNCTION; C-ELEGANS; DEFECTIVE EXPRESSION; BINDING-PARTNERS; MAMMALIAN PAR3; MUTATION-RATE; COMPLEX; ADHESION; GENE	Tissue disorganisation is one of the main hallmarks of cancer. Polarity proteins are responsible for the arrangement of cells within epithelial tissues through the asymmetric organisation of cellular components. Partition defective 3 (PARD3) is a master regulator of the Par polarity complex primarily due to its ability to form large complexes via its self-homologous binding domain. In addition to its role in polarity, PARD3 is a scaffolding protein that binds to intracellular signalling molecules, many of which are frequently deregulated in cancer. The role of PARD3 has been implicated in multiple solid cancers as either a tumour suppressor or promoter. This dual functionality is both physiologically and cell context dependent. In this review, we will discuss PARD3's role in tumourigenesis in both laboratory and clinical settings. We will also review several of the mechanisms underpinning PARD3's function including its association with intracellular signalling pathways and its role in the regulation of asymmetric cell division.	[Atashrazm, Farzaneh] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3000, Australia; [Atashrazm, Farzaneh] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Ellis, Sarah] La Trobe Univ, Olivia Newton John Canc Res Inst, Victoria, Vic, Australia; [Ellis, Sarah] La Trobe Univ, Sch Canc Med, Victoria, Vic, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; La Trobe University; Olivia Newton-John Cancer Research Institute; La Trobe University	Atashrazm, F (corresponding author), Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3000, Australia.; Atashrazm, F (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia.; Ellis, S (corresponding author), La Trobe Univ, Olivia Newton John Canc Res Inst, Victoria, Vic, Australia.; Ellis, S (corresponding author), La Trobe Univ, Sch Canc Med, Victoria, Vic, Australia.	f.atashrazm@gmail.com; sarah.ellis@onjcri.org.au		Ellis, Sarah/0000-0002-5772-6051; Atashrazm, Farzaneh/0000-0003-3471-8160				Ahmed SM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14867; Alberti S, 2019, CELL, V176, P419, DOI 10.1016/j.cell.2018.12.035; Ali NJA, 2016, J INVEST DERMATOL, V136, P2406, DOI 10.1016/j.jid.2016.07.011; Archibald A, 2015, ONCOGENE, V34, P3199, DOI 10.1038/onc.2014.242; Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; Brown S, 2017, NATURE, V548, P334, DOI 10.1038/nature23304; Bultje RS, 2009, NEURON, V63, P189, DOI 10.1016/j.neuron.2009.07.004; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Catterall R, 2020, INT J CANCER, V146, P1578, DOI 10.1002/ijc.32691; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Chen S, 2013, DEV CELL, V24, P26, DOI 10.1016/j.devcel.2012.11.014; Chen XY, 2006, J CELL BIOL, V172, P671, DOI 10.1083/jcb.200510061; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cowan CR, 2004, ANNU REV CELL DEV BI, V20, P427, DOI 10.1146/annurev.cellbio.19.111301.113823; Das S, 2015, P NATL ACAD SCI USA, V112, pE267, DOI 10.1073/pnas.1409667112; De P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050382; Diamantopoulou Z, 2017, CANCER CELL, V31, P621, DOI 10.1016/j.ccell.2017.03.007; Djiane A, 2005, CELL, V121, P621, DOI 10.1016/j.cell.2005.03.014; Dong ZQ, 2012, NEURON, V74, P65, DOI 10.1016/j.neuron.2012.01.031; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Dziengelewski C, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201805122; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Ebnet K, 2003, J CELL SCI, V116, P3879, DOI 10.1242/jcs.00704; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Facciuto F, 2014, MOL ONCOL, V8, P533, DOI 10.1016/j.molonc.2014.01.002; Fang CM, 2001, CELL RES, V11, P223, DOI 10.1038/sj.cr.7290090; Fang LH, 2007, CELL RES, V17, P100, DOI 10.1038/sj.cr.7310145; Feldman JL, 2012, CURR BIOL, V22, P575, DOI 10.1016/j.cub.2012.02.044; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Funahashi Y, 2013, J NEUROSCI, V33, P13270, DOI 10.1523/JNEUROSCI.4210-12.2013; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gao L, 2002, GENE, V294, P99, DOI 10.1016/S0378-1119(02)00681-9; Gomes MD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11325-3; Gont A, 2014, ONCOTARGET, V5, P11541, DOI 10.18632/oncotarget.2580; Grill SW, 2001, NATURE, V409, P630, DOI 10.1038/35054572; Guo XJ, 2016, CLIN EXP MED, V16, P357, DOI 10.1007/s10238-015-0365-2; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Halaoui R, 2017, GENE DEV, V31, P1573, DOI 10.1101/gad.300566.117; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Hapak SM, 2018, CELL MOL LIFE SCI, V75, P2735, DOI 10.1007/s00018-018-2828-6; Harris TJC, 2005, J CELL BIOL, V170, P813, DOI 10.1083/jcb.200505127; Hawkins ED, 2008, ONCOGENE, V27, P7003, DOI 10.1038/onc.2008.350; HEDDLE JA, 1975, NATURE, V258, P359, DOI 10.1038/258359a0; HOLLIDAY R, 1993, MUTAT RES, V285, P61, DOI 10.1016/0027-5107(93)90052-H; Holly RW, 2020, CURR BIOL, V30, P893, DOI 10.1016/j.cub.2019.12.055; Hong E, 2010, DEV BIOL, V341, P335, DOI 10.1016/j.ydbio.2010.01.034; Horikoshi Y, 2011, CELL STRUCT FUNCT, V36, P97, DOI 10.1247/csf.11005; Horikoshi Y, 2009, J CELL SCI, V122, P1595, DOI 10.1242/jcs.043174; Huebner RJ, 2014, DEVELOPMENT, V141, P1085, DOI 10.1242/dev.103333; Huo YL, 2014, NAT CELL BIOL, V16, P526, DOI 10.1038/ncb2969; Hurd TW, 2003, CURR BIOL, V13, P2082, DOI 10.1016/j.cub.2003.11.020; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Inaba M, 2015, ELIFE, V4, DOI 10.7554/eLife.04960; Itoh M, 2001, J CELL BIOL, V154, P491, DOI 10.1083/jcb.200103047; Itoh N, 2010, CYTOSKELETON, V67, P297, DOI 10.1002/cm.20444; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jha HC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005801; Kelsom C, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-38; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; Kim MK, 2018, BMB REP, V51, P126, DOI 10.5483/BMBRep.2018.51.3.015; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kohjima M, 2002, BIOCHEM BIOPH RES CO, V299, P641, DOI 10.1016/S0006-291X(02)02698-0; Kono K, 2019, ELIFE, V8, DOI 10.7554/eLife.45559; Krahn MP, 2010, CURR BIOL, V20, P636, DOI 10.1016/j.cub.2010.01.065; Lang CF, 2017, DEVELOPMENT, V144, P3405, DOI 10.1242/dev.139063; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Li JJ, 2019, CANCER MED-US, V8, P2288, DOI 10.1002/cam4.2063; Li TY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698393; Li TY, 2017, BIOCHEM BIOPH RES CO, V482, P1037, DOI 10.1016/j.bbrc.2016.11.154; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Ling J, 2020, J CELL SCI, V133, DOI 10.1242/jcs.249102; Liu ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17462-4; Loeffler D, 2019, NATURE, V573, P426, DOI 10.1038/s41586-019-1531-6; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Lv XB, 2015, EMBO REP, V16, P975, DOI 10.15252/embr.201439951; Mangeol P, 2020, SUPER RESOLUTION IMA, DOI 10.1101/2020.08.12.248674; Martin E, 2021, FEBS J, V288, P7073, DOI 10.1111/febs.15710; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Matsuzawa K, 2016, MOL BIOL CELL, V27, P1511, DOI 10.1091/mbc.E15-09-0670; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCaffrey LM, 2009, GENE DEV, V23, P1450, DOI 10.1101/gad.1795909; Mescher M, 2017, J EXP MED, V214, P339, DOI 10.1084/jem.20160596; Mishima M, 2002, DEV CELL, V2, P41, DOI 10.1016/S1534-5807(01)00110-1; Mizuno K, 2003, J BIOL CHEM, V278, P31240, DOI 10.1074/jbc.M303593200; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Morais-de-Sa E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040; Morrow A, 2019, ELIFE, V8, DOI 10.7554/eLife.48482; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; NAKAMURA H, 2016, BMC CANCER, V16; Nam SC, 2003, DEVELOPMENT, V130, P4363, DOI 10.1242/dev.00648; Neumuller RA, 2009, GENE DEV, V23, P2675, DOI 10.1101/gad.1850809; Nishant KT, 2009, BIOESSAYS, V31, P912, DOI 10.1002/bies.200900017; Nishimura T, 2005, NAT CELL BIOL, V7, P270, DOI 10.1038/ncb1227; Nishimura T, 2004, NAT CELL BIOL, V6, P328, DOI 10.1038/ncb1118; Oliaro J, 2010, J IMMUNOL, V185, P367, DOI 10.4049/jimmunol.0903627; Piraino SW, 2019, ENCY CANC, P551, DOI DOI 10.1016/B978-0-12-801238-3.65045-6; Poulson ND, 2010, J CELL BIOL, V191, P915, DOI 10.1083/jcb.201008001; Ravid S, 2014, CELL ADHES MIGR, V8, P378, DOI 10.4161/cam.29387; ROCHE J, 2018, CANCERS, V10; Romero G, 2011, ADV PHARMACOL, V62, P279, DOI 10.1016/B978-0-12-385952-5.00003-8; Rothenberg SM, 2010, CANCER RES, V70, P2158, DOI 10.1158/0008-5472.CAN-09-3458; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Simoes SD, 2010, DEV CELL, V19, P377, DOI 10.1016/j.devcel.2010.08.011; Slater M, 2005, HISTOPATHOLOGY, V47, P170, DOI 10.1111/j.1365-2559.2005.02155.x; Supek F, 2015, NATURE, V521, P81, DOI 10.1038/nature14173; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Takekuni K, 2003, J BIOL CHEM, V278, P5497, DOI 10.1074/jbc.C200707200; Tan B, 2020, CURR BIOL, V30, P2791, DOI 10.1016/j.cub.2020.05.032; Terawaki S, 2010, EMBO J, V29, P236, DOI 10.1038/emboj.2009.323; Tong S, 2016, ONCOTARGET, V7, P64260, DOI 10.18632/oncotarget.11728; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanlandewijck Michael, 2018, Oncotarget, V9, P5716, DOI 10.18632/oncotarget.23788; Vorhagen S, 2018, ONCOGENE, V37, P5136, DOI 10.1038/s41388-018-0313-1; Wang F, 2002, NAT CELL BIOL, V4, P513, DOI 10.1038/ncb810; Wang L, 2017, MED SCI MONITOR, V23, P2382, DOI 10.12659/MSM.903380; Wang YG, 2006, EMBO J, V25, P5058, DOI 10.1038/sj.emboj.7601384; Wang ZZ, 2009, EMBO J, V28, P2360, DOI 10.1038/emboj.2009.190; Watts JL, 1996, DEVELOPMENT, V122, P3133; Wen WY, 2018, J MOL BIOL, V430, P3504, DOI 10.1016/j.jmb.2017.09.013; WIESCHAUS E, 1986, ROUX ARCH DEV BIOL, V195, P63, DOI 10.1007/BF00444042; Williams E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189081; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Ying Z, 2018, NAT CELL BIOL, V20, P1256, DOI 10.1038/s41556-018-0218-9; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368; Zhang P, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.21; Zhang XP, 2019, ONCOGENE, V38, P699, DOI 10.1038/s41388-018-0447-1; Zhang Y, 2013, STRUCTURE, V21, P997, DOI 10.1016/j.str.2013.04.004; Zheng JH, 2017, EUR J GYNAECOL ONCOL, V38, P199, DOI 10.12892/ejgo3440.2017; Zhou PJ, 2019, ONCOGENE, V38, P2192, DOI 10.1038/s41388-018-0580-x; Zhou PJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0609-y; Zhou QY, 2017, CELL SIGNAL, V38, P49, DOI 10.1016/j.cellsig.2017.06.016; Zhou Y, 2008, ACTA BIOCH BIOPH SIN, V40, P729, DOI 10.1111/j.1745-7270.2008.00452.x; Zitzelsberger H, 2004, GENE CHROMOSOME CANC, V40, P55, DOI 10.1002/gcc.20024	145	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2021	40	25					4245	4262		10.1038/s41388-021-01813-6	http://dx.doi.org/10.1038/s41388-021-01813-6		JUN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SY4AZ	34099863				2022-12-17	WOS:000658593300001
J	Lodillinsky, C; Fuhrmann, L; Irondelle, M; Pylypenko, O; Li, XY; Bonsang-Kitzis, H; Reyal, F; Vacher, S; Calmel, C; De Wever, O; Bieche, I; Lacombe, ML; Eijan, AM; Houdusse, A; Vincent-Salomon, A; Weiss, SJ; Chavrier, P; Boissan, M				Lodillinsky, Catalina; Fuhrmann, Laetitia; Irondelle, Marie; Pylypenko, Olena; Li, Xiao-Yan; Bonsang-Kitzis, Helene; Reyal, Fabien; Vacher, Sophie; Calmel, Claire; De Wever, Olivier; Bieche, Ivan; Lacombe, Marie-Lise; Eijan, Ana Maria; Houdusse, Anne; Vincent-Salomon, Anne; Weiss, Stephen J.; Chavrier, Philippe; Boissan, Mathieu			Metastasis-suppressor NME1 controls the invasive switch of breast cancer by regulating MT1-MMP surface clearance	ONCOGENE			English	Article							CARCINOMA IN-SITU; TUMOR-CELLS; DYNAMIN; TRAFFICKING; MICROINVASION; PROGRESSION; TRANSITION; MIGRATION	Membrane Type 1 Matrix Metalloprotease (MT1-MMP) contributes to the invasive progression of breast cancers by degrading extracellular matrix tissues. Nucleoside diphosphate kinase, NME1/NM23-H1, has been identified as a metastasis suppressor; however, its contribution to local invasion in breast cancer is not known. Here, we report that NME1 is up-regulated in ductal carcinoma in situ (DCIS) as compared to normal breast epithelial tissues. NME1 levels drop in microinvasive and invasive components of breast tumor cells relative to synchronous DCIS foci. We find a strong anti-correlation between NME1 and plasma membrane MT1-MMP levels in the invasive components of breast tumors, particularly in aggressive histological grade III and triple-negative breast cancers. Knockout of NME1 accelerates the invasive transition of breast tumors in the intraductal xenograft model. At the mechanistic level, we find that MT1-MMP, NME1 and dynamin-2, a GTPase known to require GTP production by NME1 for its membrane fission activity in the endocytic pathway, interact in clathrin-coated vesicles at the plasma membrane. Loss of NME1 function increases MT1-MMP surface levels by inhibiting endocytic clearance. As a consequence, the ECM degradation and invasive potentials of breast cancer cells are enhanced. This study identifies the down-modulation of NME1 as a potent driver of the in situ-to invasive transition during breast cancer progression.	[Lodillinsky, Catalina; Eijan, Ana Maria] Univ Buenos Aires, Inst Oncol Angel H Roffo, Res Area, Buenos Aires, DF, Argentina; [Lodillinsky, Catalina; Eijan, Ana Maria] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina; [Fuhrmann, Laetitia; Vincent-Salomon, Anne] PSL Res Univ, Inst Curie, Diagnost & Theranost Med Div, Paris, France; [Irondelle, Marie; Pylypenko, Olena; Houdusse, Anne; Chavrier, Philippe] PSL Res Univ, Inst Curie, UMR144, CNRS, Paris, France; [Li, Xiao-Yan; Weiss, Stephen J.] Univ Michigan, Life Sci Inst, Dept Internal Med, Div Med Genet, Ann Arbor, MI 48109 USA; [Bonsang-Kitzis, Helene; Reyal, Fabien] Inst Curie, Dept Surg, Paris, France; [Bonsang-Kitzis, Helene; Reyal, Fabien] Inst Curie, Translat Res Dept, RT2Lab Team, Immun & Canc,INSERM,U932, Paris, France; [Vacher, Sophie; Bieche, Ivan] Inst Curie, Pharmacogen Unit, Paris, France; [Calmel, Claire; Lacombe, Marie-Lise; Boissan, Mathieu] Univ Sorbonne, CRSA, St Antoine Res Ctr, INSERM,UMR S 938, Paris, France; [De Wever, Olivier] Univ Ghent, Canc Res Inst Ghent CRIG, Dept Human Struct & Repair, Lab Expt Canc Res, Ghent, Belgium; [Boissan, Mathieu] Tenon Hosp, AP HP, Lab Biochem & Hormonol, Paris, France; [Bonsang-Kitzis, Helene] Hop Prive Peupliers, RAMSAY Gen Sante, Gynecol & Breast Surg & Cancerol Ctr, Paris, France	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; University of Michigan System; University of Michigan; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Boissan, M (corresponding author), Univ Sorbonne, CRSA, St Antoine Res Ctr, INSERM,UMR S 938, Paris, France.; Boissan, M (corresponding author), Tenon Hosp, AP HP, Lab Biochem & Hormonol, Paris, France.	mathieu.boissan@inserm.fr	EIJAN, ANA MARIA/AAC-8849-2022; de wever, olivier/J-3094-2013; CHAVRIER, Philippe/B-4707-2010	de wever, olivier/0000-0002-5453-760X; CHAVRIER, Philippe/0000-0002-7351-733X; CALMEL, Claire/0000-0001-7215-7910; Pylypenko, Olena/0000-0001-7073-5238	NIH/NCI [R01 CA071699]; Breast Cancer Research Foundation; Margolies Family Discovery Fund for Cancer Research; University of Michigan Rogel Cancer Center Support Grant [P30 CA046592]; Fondation ARC pour la Recherche sur le Cancer [PGA1 RF20170205408]; Fondation Ruban Rose (Prix Avenir 2018); Groupement des Entreprises Francaises contre le Cancer (GEFLUC); Canceropole-Ile de France [2015-1-EMERG-25-INSERM 6-1]; PLAN CANCER [C19048DS];  [ANR-10-INBS-04]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Breast Cancer Research Foundation; Margolies Family Discovery Fund for Cancer Research; University of Michigan Rogel Cancer Center Support Grant; Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Fondation Ruban Rose (Prix Avenir 2018); Groupement des Entreprises Francaises contre le Cancer (GEFLUC); Canceropole-Ile de France(Region Ile-de-France); PLAN CANCER; 	The authors acknowledge the Breast Cancer Study Group and the Incentive and Cooperative Research Program "Breast cancer: Cell Invasion and Motility" and patients of Institut Curie for the breast tumor samples, Drs. C. Tomasetto, P. De camilli, P. S. Steeg and E. Smythe for kindly providing reagents, cell lines and samples for this study, the Nikon Imaging Centre @ Institut Curie-CNRS and Cell and Tissue Imaging Facility of Institut Curie, member of the France Bio Imaging national research infrastructure (ANR-10-INBS-04) for help with image acquisition, F. Guillonneau from the Proteomic Facility 3P5, Paris-Descartes University for MALDI-MS analysis, Sandra Antoine from Institut Curie for help with the collagenolysis assay, and C. Kikuti from Institut Curie for help with SEC-MALS analysis. This work was supported by grants from the NIH/NCI to S.J.W and X.Y.L. (R01 CA071699) as well as the Breast Cancer Research Foundation and the Margolies Family Discovery Fund for Cancer Research to S.J.W and X.Y.L. Additional support was provided by the University of Michigan Rogel Cancer Center Support Grant (P30 CA046592). Funding for this work was provided by Fondation ARC pour la Recherche sur le Cancer (PGA1 RF20170205408) and Fondation Ruban Rose (Prix Avenir 2018) to PC, the Groupement des Entreprises Francaises contre le Cancer (GEFLUC), Canceropole-Ile de France (no 2015-1-EMERG-25-INSERM 6-1) and PLAN CANCER (Project C19048DS) to MB.	Baldassarre M, 2003, MOL BIOL CELL, V14, P1074, DOI 10.1091/mbc.E02-05-0308; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Boissan M, 2005, JNCI-J NATL CANCER I, V97, P836, DOI 10.1093/jnci/dji143; Boissan M, 2018, LAB INVEST, V98, P164, DOI 10.1038/labinvest.2017.137; Boissan M, 2014, SCIENCE, V344, P1510, DOI 10.1126/science.1253768; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Casasent AK, 2017, J PATHOL, V241, P208, DOI 10.1002/path.4840; Castro-Castro A, 2016, ANNU REV CELL DEV BI, V32, P555, DOI 10.1146/annurev-cellbio-111315-125227; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Dammai V, 2003, GENE DEV, V17, P2812, DOI 10.1101/gad.1096903; de Mascarel I, 2002, CANCER, V94, P2134, DOI 10.1002/cncr.10451; Eppinga RD, 2012, ONCOGENE, V31, P1228, DOI 10.1038/onc.2011.329; Feinberg TY, 2018, DEV CELL, V47, P145, DOI 10.1016/j.devcel.2018.08.025; Gifford V, 2019, BIOCHEM SOC T, V47, P811, DOI 10.1042/BST20180363; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Khan I, 2019, CANCER RES, V79, P4689, DOI 10.1158/0008-5472.CAN-19-0492; Kushner MH, 2020, EMBO REP, V21, DOI 10.15252/embr.201948741; Lee S, 2012, CANCER RES, V72, P4574, DOI 10.1158/0008-5472.CAN-12-0636; Li XY, 2008, MOL BIOL CELL, V19, P3221, DOI 10.1091/mbc.E08-01-0016; Lodillinsky C, 2016, ONCOGENE, V35, P344, DOI 10.1038/onc.2015.87; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Meister M, 2014, FEBS J, V281, P2956, DOI 10.1111/febs.12834; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162; Nicoziani P, 2000, MOL BIOL CELL, V11, P481, DOI 10.1091/mbc.11.2.481; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Ouatas T, 2003, J BIOENERG BIOMEMBR, V35, P73, DOI 10.1023/A:1023497924277; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Planchon D, 2018, J CELL SCI, V131, DOI 10.1242/jcs.218925; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Razidlo GL, 2013, DEV CELL, V24, P573, DOI 10.1016/j.devcel.2013.02.010; Rosse C, 2014, P NATL ACAD SCI USA, V111, pE1872, DOI 10.1073/pnas.1400749111; Rowe RG, 2008, TRENDS CELL BIOL, V18, P560, DOI 10.1016/j.tcb.2008.08.007; Sopik V, 2018, BREAST CANCER RES TR, V167, P787, DOI 10.1007/s10549-017-4572-2; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Szabova L, 2008, ONCOGENE, V27, P3274, DOI 10.1038/sj.onc.1210982; Tan CY, 2018, LAB INVEST, V98, P219, DOI 10.1038/labinvest.2017.105; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; van Seijen M, 2019, BRIT J CANCER, V121, P285, DOI 10.1038/s41416-019-0478-6; Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616; Zala Diana, 2017, F1000Res, V6, P724, DOI 10.12688/f1000research.11561.2	42	8	8	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					4019	4032		10.1038/s41388-021-01826-1	http://dx.doi.org/10.1038/s41388-021-01826-1		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	34012098	Green Published, hybrid			2022-12-17	WOS:000652080600001
J	Kamada, S; Namekawa, T; Ikeda, K; Suzuki, T; Kagawa, M; Takeshita, H; Yano, A; Okamoto, K; Ichikawa, T; Horie-Inoue, K; Kawakami, S; Inoue, S				Kamada, Shuhei; Namekawa, Takeshi; Ikeda, Kazuhiro; Suzuki, Takashi; Kagawa, Makoto; Takeshita, Hideki; Yano, Akihiro; Okamoto, Koji; Ichikawa, Tomohiko; Horie-Inoue, Kuniko; Kawakami, Satoru; Inoue, Satoshi			Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma	ONCOGENE			English	Article							HORMONE-RELATED PROTEIN; HUMORAL HYPERCALCEMIA; SUNITINIB RESISTANCE; GENE-EXPRESSION; RETINOIC ACID; IN-VITRO; ANTIBODY; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION	Tyrosine kinase inhibitors (TKIs) are used as targeted drugs for advanced renal cell carcinoma (RCC), although most cases eventually progress by acquiring resistance. Cancer stemness plays critical roles in tumor aggressiveness and therapeutic resistance, and dipeptidyl peptidase IV (DPP4) has been recently identified as a cancer stemness-related protein. A question arises whether DPP4 contributes to TKI efficacy in RCC. We established patient-derived RCC spheroids and showed that DPP4 expression is associated with stemness-related gene expression. TKI sunitinib resistance was rescued by DPP4 inhibition using sitagliptin or specific siRNAs in RCC cells and tumors. DPP4 expression can be inducible by retinoic acid and repressed by ALDH1A inhibition. Among type 2 diabetes patients with clinical RCC tumors, higher TKI efficacy is observed in those bearing DPP4(high) tumors treated with DPP4 inhibitors. This study provides new insights into TKI resistance and drug repositioning of DPP4 inhibitor as a promising strategy for advanced RCC.	[Kamada, Shuhei; Namekawa, Takeshi; Ikeda, Kazuhiro; Horie-Inoue, Kuniko; Inoue, Satoshi] Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan; [Kamada, Shuhei; Namekawa, Takeshi; Ichikawa, Tomohiko] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan; [Suzuki, Takashi] Tohoku Univ, Grad Sch Med, Dept Pathol & Histotechnol, Sendai, Miyagi, Japan; [Kagawa, Makoto; Takeshita, Hideki; Yano, Akihiro; Kawakami, Satoru] Saitama Med Univ, Dept Urol, Saitama Med Ctr, Saitama, Japan; [Okamoto, Koji] Natl Canc Ctr, Res Inst, Div Canc Differentiat, Tokyo, Japan; [Inoue, Satoshi] Tokyo Metropolitan Inst Gerontol, Dept Syst Aging Sci & Med, Tokyo, Japan	Saitama Medical University; Chiba University; Tohoku University; Saitama Medical University; National Cancer Center - Japan; Tokyo Metropolitan Institute of Gerontology	Inoue, S (corresponding author), Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan.; Inoue, S (corresponding author), Tokyo Metropolitan Inst Gerontol, Dept Syst Aging Sci & Med, Tokyo, Japan.	sinoue@tmig.or.jp	TAKESHITA, Hideki/AFN-5038-2022	TAKESHITA, Hideki/0000-0002-1512-6904; Ichikawa, Tomohiko/0000-0002-8637-4163; Kagawa, Makoto/0000-0002-4294-438X; Suzuki, Takashi/0000-0003-0195-815X; Kamada, Shuhei/0000-0002-9024-0176	Support Project of Strategic Research Center in Private Universities from the MEXT; Practical Research for Innovative Cancer Control [JP18ck0106194]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and Development (AMED) [JP18cm0106144]; Japan Society for the Promotion of Science [15K15353, 20K21667, 17H04205]; Vehicle Racing Commemorative Foundation	Support Project of Strategic Research Center in Private Universities from the MEXT; Practical Research for Innovative Cancer Control; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Vehicle Racing Commemorative Foundation	We thank S. Kitayama, W. Sato, S. Shiba, Y. Okada, and S. Aoki for their technical support and valuable comments. This study was supported by the Support Project of Strategic Research Center in Private Universities from the MEXT (to SI), the Practical Research for Innovative Cancer Control (JP18ck0106194 to KI) and the Project for Cancer Research and Therapeutic Evolution (P-CREATE, JP18cm0106144 to SI) from Japan Agency for Medical Research and Development (AMED), and grants from the Japan Society for the Promotion of Science (15K15353 and 20K21667 to SI, and 17H04205 to K-HI) and the Vehicle Racing Commemorative Foundation (to K-HI).	Adelaiye-Ogala R, 2017, CANCER RES, V77, P6651, DOI 10.1158/0008-5472.CAN-17-0899; Angevin E, 2017, BRIT J CANCER, V116, P1126, DOI 10.1038/bjc.2017.62; Bauvois B, 2000, ONCOGENE, V19, P265, DOI 10.1038/sj.onc.1203292; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; BULENS F, 1995, J BIOL CHEM, V270, P7167, DOI 10.1074/jbc.270.13.7167; Christopherson KW, 2002, J IMMUNOL, V169, P7000, DOI 10.4049/jimmunol.169.12.7000; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Corro C, 2018, J PATHOL CLIN RES, V4, P3, DOI 10.1002/cjp2.91; da Silva RB, 2015, NAT IMMUNOL, V16, P850, DOI 10.1038/ni.3201; Decalf J, 2016, EMBO MOL MED, V8, P679, DOI 10.15252/emmm.201506145; Diaz-Montero CM, 2016, BRIT J CANCER, V115, P920, DOI 10.1038/bjc.2016.263; Dong, 2017, NAT COMMUN, V8; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Enz N, 2019, PHARMACOL THERAPEUT, V198, P135, DOI 10.1016/j.pharmthera.2019.02.015; FAHN HJ, 1991, J UROLOGY, V145, P248, DOI 10.1016/S0022-5347(17)38305-2; Fendler A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14700-7; Ghani FI, 2011, BIOCHEM BIOPH RES CO, V404, P735, DOI 10.1016/j.bbrc.2010.12.054; Ghatalia P, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0458-0; Guo FJ, 2014, CELL SIGNAL, V26, P1998, DOI 10.1016/j.cellsig.2014.05.008; Hatipoglu G, 2015, CANCER SCI, V106, P160, DOI 10.1111/cas.12580; Holst JJ, 2009, MOL CELL ENDOCRINOL, V297, P127, DOI 10.1016/j.mce.2008.08.012; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Inamoto T, 2006, CLIN CANCER RES, V12, P3470, DOI 10.1158/1078-0432.CCR-06-0361; Ishibashi K, 2017, ONCOTARGET, V8, P55230, DOI 10.18632/oncotarget.19420; Ishiguro T, 2016, CANCER RES, V76, P150, DOI 10.1158/0008-5472.CAN-15-0361; Joeckel E, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-42; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Larrinaga G, 2012, AM J PHYSIOL-RENAL, V303, pF1584, DOI 10.1152/ajprenal.00477.2012; Long Z, 2017, FREE RADICAL BIO MED, V113, P71, DOI 10.1016/j.freeradbiomed.2017.09.016; Luo L, 2019, ONCOL LETT, V18, P1442, DOI 10.3892/ol.2019.10442; Makhov P, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0388-1; Mehta RJ, 2012, BREAST CANCER RES TR, V131, P881, DOI 10.1007/s10549-011-1482-6; Miyake M, 2012, ONCOL LETT, V3, P1195, DOI 10.3892/ol.2012.662; Namekawa T, 2020, INT J CANCER, V146, P1099, DOI 10.1002/ijc.32505; Oguro T, 2013, EUR J CANCER, V49, P1715, DOI 10.1016/j.ejca.2012.11.038; Onuma E, 2005, CLIN CANCER RES, V11, P4198, DOI 10.1158/1078-0432.CCR-04-2531; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Papworth K, 2005, TUMOR BIOL, V26, P201, DOI 10.1159/000086953; Pinheiro MM, 2017, EUR J PHARM SCI, V100, P17, DOI 10.1016/j.ejps.2016.12.040; Pujadas G, 2017, ENDOCRINE, V56, P509, DOI 10.1007/s12020-016-1052-0; Qin CJ, 2018, CANCER LETT, V420, P26, DOI 10.1016/j.canlet.2018.01.064; Rohrborn D, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00386; Sakai I, 2013, BJU INT, V112, pE211, DOI 10.1111/j.1464-410X.2012.11655.x; Shiba S, 2019, ENDOCRINOLOGY, V160, P1895, DOI 10.1210/en.2019-00362; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Stany MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021121; Sun CK, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt181; Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507; Varna M, 2015, CLIN CANCER RES, V21, P916, DOI 10.1158/1078-0432.CCR-14-0666; Varona A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-193; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Wronkowitz N, 2014, BBA-MOL BASIS DIS, V1842, P1613, DOI 10.1016/j.bbadis.2014.06.004; Xin H, 2009, CANCER RES, V69, P2506, DOI 10.1158/0008-5472.CAN-08-4323; Xu J, 2018, LAB INVEST, V98, P1333, DOI 10.1038/s41374-018-0080-1	55	8	8	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3899	3913		10.1038/s41388-021-01822-5	http://dx.doi.org/10.1038/s41388-021-01822-5		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972682				2022-12-17	WOS:000648930100005
J	Li, M; Shi, MK; Hu, CY; Chen, BJ; Li, SF				Li, Ming; Shi, Minke; Hu, Chaoyue; Chen, Baojun; Li, Shufeng			MALAT1 modulated FOXP3 ubiquitination then affected GINS1 transcription and drived NSCLC proliferation	ONCOGENE			English	Article							LONG NONCODING RNA; DNA-REPLICATION; SUPPRESSIVE ACTIVITY; EXPRESSION; PROMOTES; PSF1; INHIBITION; CDC45; ASSOCIATION; METASTASIS	An increasing number of studies have shown that long-noncoding RNAs (lncRNAs) are involved in the post-translational modifications (PTMs) of protein in a variety of tumors. However, little is known about the exact regulation mechanism of lncRNAs in regulating PTMs in non-small-cell lung carcinoma (NSCLC) proliferation. Metastasis-associated lung adenocarcinoma transcript1 (MALAT1) and GINS complex subunit 1(GINS1) both were upregulated and promoted proliferation progression in NSCLC. In this study, the clinicopathologic significance of MALAT1 and GINS1 in NSCLC was investigated, a positive correlation in their expression was found. The silencing of MALAT1 decreased GINS1 expression and inhibited NSCLC proliferation in vitro and in vivo. The upregulation of GINS1 reversed NSCLC proliferation inhibited by MALAT1 knockdown. FOXP3 (forkhead box protein 3) was identified as the critical transcription factor for GINS1 transcription. In addition, MALAT1 could stabilize FOXP3 by binding to zinc finger (ZF) domain and leucine zipper (LZ) domain of FOXP3. Interestingly, these two domains were also interaction domains for FOXP3 binding with E3 ligase STUB1 (STIP1 homology and U-box containing protein 1). In this way, MALAT1 masked the protein-interacting domain, and inhibited FOXP3 ubiquitination by STUB1. Together, our results identified a novel regulatory axis of MALAT1-FOXP3-GINS1, and demonstrated that MALAT1 played an important modulatory role in PTM of FOXP3 which affects GINS1 transcription and drives proliferation character in NSCLC.	[Li, Ming; Li, Shufeng] Southeast Univ, Key Lab Dev Genes & Human Dis, Minist Educ, Dept Biochem & Mol Biol,Med Sch, Nanjing, Peoples R China; [Shi, Minke; Hu, Chaoyue; Chen, Baojun] Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Thorac & Cardiovasc Surg, Nanjing, Peoples R China	Southeast University - China; Nanjing University	Li, SF (corresponding author), Southeast Univ, Key Lab Dev Genes & Human Dis, Minist Educ, Dept Biochem & Mol Biol,Med Sch, Nanjing, Peoples R China.	shufengli@seu.edu.cn		hu, chaoyue/0000-0002-3284-5636; Li, Shufeng/0000-0003-4857-4532; Li, Ming/0000-0001-9637-1030				Amodio N, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0606-4; Brown JA, 2016, P NATL ACAD SCI USA, V113, P14013, DOI 10.1073/pnas.1614759113; Chen L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0196-9; Chen RB, 2017, NUCLEIC ACIDS RES, V45, P9947, DOI 10.1093/nar/gkx600; Chen ZJ, 2013, IMMUNITY, V39, P272, DOI 10.1016/j.immuni.2013.08.006; Colamatteo A, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03136; Cottineau J, 2017, J CLIN INVEST, V127, P1991, DOI 10.1172/JCI90727; Cunha LL, 2012, CLINICS, V67, P483, DOI 10.6061/clinics/2012(05)13; Gambus A, 2006, NAT CELL BIOL, V8, P358, DOI 10.1038/ncb1382; Ilves I, 2010, MOL CELL, V37, P247, DOI 10.1016/j.molcel.2009.12.030; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Jia H, 2019, BBA-REV CANCER, V1871, P170, DOI 10.1016/j.bbcan.2018.12.004; Jiang RQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15129; Jin D, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0830-6; Kwon HS, 2012, J IMMUNOL, V188, P2712, DOI 10.4049/jimmunol.1100903; Li M, 2015, FEBS LETT, V589, P1018, DOI 10.1016/j.febslet.2015.03.004; Li SF, 2018, CANCER SCI, V109, P1346, DOI 10.1111/cas.13587; Li SF, 2015, J CANCER RES CLIN, V141, P1909, DOI 10.1007/s00432-015-1951-0; Li ZY, 2015, CELL MOL IMMUNOL, V12, P558, DOI 10.1038/cmi.2015.10; Lian YF, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181178; Liu NA, 2017, NUCLEIC ACIDS RES, V45, P6051, DOI 10.1093/nar/gkx141; Liu YJ, 2013, NAT MED, V19, P1173, DOI 10.1038/nm.3286; Loo CS, 2020, IMMUNITY, V53, P143, DOI 10.1016/j.immuni.2020.06.011; Ma HL, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6985031; Ma XD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122997; Malakar P, 2019, CANCER RES, V79, P2480, DOI 10.1158/0008-5472.CAN-18-1432; Masai H, 2010, ANNU REV BIOCHEM, V79, P89, DOI 10.1146/annurev.biochem.052308.103205; Nakahara I, 2010, GENES CELLS, V15, P1015, DOI 10.1111/j.1365-2443.2010.01442.x; Song XM, 2012, CELL REPORTS, V1, P665, DOI 10.1016/j.celrep.2012.04.012; Srinivasan SV, 2013, CELL REP, V3, P1629, DOI 10.1016/j.celrep.2013.04.002; Stamato MA, 2017, ONCOTARGET, V8, P106527, DOI 10.18632/oncotarget.22507; Szylberg L, 2016, ANTICANCER RES, V36, P3789; Tahara H, 2015, PROSTATE CANCER P D, V18, P56, DOI 10.1038/pcan.2014.46; Takayama Y, 2003, GENE DEV, V17, P1153, DOI 10.1101/gad.1065903; Tang L, 2019, CLIN TRANSL ONCOL, V21, P1624, DOI 10.1007/s12094-019-02090-2; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Ueno M, 2005, MOL CELL BIOL, V25, P10528, DOI 10.1128/MCB.25.23.10528-10532.2005; van Loosdregt J, 2010, BLOOD, V115, P965, DOI 10.1182/blood-2009-02-207118; Wang W, 2016, ONCOTARGET, V7, P25668, DOI 10.18632/oncotarget.8257; Wang XC, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0144-8; Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1; Yu T, 2017, CANCER RES, V77, P5782, DOI 10.1158/0008-5472.CAN-17-0671; Yu WW, 2019, ONCOGENE, V38, P1225, DOI 10.1038/s41388-018-0463-1; Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069; Zhang JY, 2015, TUMOR BIOL, V36, P2163, DOI 10.1007/s13277-014-2826-8; Zhang XJ, 2017, RNA BIOL, V14, P1705, DOI 10.1080/15476286.2017.1358347	46	8	8	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3870	3884		10.1038/s41388-021-01816-3	http://dx.doi.org/10.1038/s41388-021-01816-3		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33972684				2022-12-17	WOS:000648930100001
J	Liu, LX; Zhang, XL; Ding, HY; Liu, X; Cao, DH; Liu, YQ; Liu, JW; Lin, C; Zhang, N; Wang, GN; Hou, JY; Huang, BQ; Zhang, Y; Lu, J				Liu, Lingxia; Zhang, Xiliu; Ding, Huayi; Liu, Xin; Cao, Donghui; Liu, Yingqi; Liu, Jiwei; Lin, Cong; Zhang, Na; Wang, Guannan; Hou, Jingyao; Huang, Baiqu; Zhang, Yu; Lu, Jun			Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS	ONCOGENE			English	Article								Mitochondrial oxidative phosphorylation (OXPHOS) is a vital regulator of tumor metastasis. However, the mechanisms governing OXPHOS to facilitate tumor metastasis remain unclear. In this study, we discovered that arginine 21(R21) and lysine 108 (K108) of mitochondrial ribosomal protein S23 (MRPS23) was methylated by the protein arginine methyltransferase 7 (PRMT7) and SET-domain-containing protein 6 (SETD6), respectively. R21 methylation accelerated the poly-ubiquitin-dependent degradation of MRPS23 to a low level. The MRPS23 degradation inhibited OXPHOS with elevated mtROS level, which consequently increased breast cancer cell invasion and metastasis. In contrast, K108 methylation increased MRPS23 stability, and K108 methylation coordinated with R21 methylation to maintain a low level of MRPS23, which was in favor of supporting breast cancer cell survival through regulating OXPHOS. Consistently, R21 and K108 methylation was correlated with malignant breast carcinoma. Significantly, our findings unveil a unique mechanism of controlling OXPHOS by arginine and lysine methylation and point to the impact of the PRMT7-SETD6-MRPS23 axis during breast cancer metastasis.	[Liu, Lingxia; Zhang, Xiliu; Liu, Xin; Liu, Jiwei; Lin, Cong; Huang, Baiqu; Lu, Jun] Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, Changchun, Peoples R China; [Ding, Huayi; Liu, Yingqi; Zhang, Na; Hou, Jingyao; Zhang, Yu] Northeast Normal Univ, Inst Genet & Cytol, Changchun, Peoples R China; [Cao, Donghui] First Hosp Jilin Univ, Div Clin Res, Changchun, Peoples R China; [Wang, Guannan] Northeast Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun, Peoples R China	Northeast Normal University - China; Northeast Normal University - China; Jilin University; Northeast Normal University - China	Lu, J (corresponding author), Northeast Normal Univ, Minist Educ MOE, Key Lab Mol Epigenet, Changchun, Peoples R China.; Zhang, Y (corresponding author), Northeast Normal Univ, Inst Genet & Cytol, Changchun, Peoples R China.	zhangy288@nenu.edu.cn; luj809@nenu.edu.cn			National Natural Science Foundation of China [31770825, 31571317, 31570718, 31771335, 31870765]; Science and Technology Development Project of Jilin province [20180101232JC, 20180101234JC, 20200404106YY]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Development Project of Jilin province	This work was supported by the grants from the National Natural Science Foundation of China (grant numbers: 31770825, 31571317, 31570718, 31771335, and 31870765) and the Science and Technology Development Project of Jilin province (grant number: 20180101232JC, 20180101234JC, and 20200404106YY).	AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Baldwin RM, 2015, ONCOTARGET, V6, P3013, DOI 10.18632/oncotarget.3072; Bedford MT, 2007, J CELL SCI, V120, P4243, DOI 10.1242/jcs.019885; Biggar KK, 2015, NAT REV MOL CELL BIO, V16, P5, DOI 10.1038/nrm3915; Binda O, 2020, EPIGENETICS-US, V15, P26, DOI 10.1080/15592294.2019.1649529; Binda O, 2013, EPIGENETICS-US, V8, P177, DOI 10.4161/epi.23416; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Boisvert Francois-Michel, 2005, Sci STKE, V2005, pre2, DOI 10.1126/stke.2712005re2; Chen GY, 2014, ACTA BIOCH BIOPH SIN, V46, P512, DOI 10.1093/abbs/gmu029; Dan L., 2011, NAT IMMUNOL, V12, P29, DOI DOI 10.1038/NI.1968; Del Rizzo PA, 2014, BBA-GENE REGUL MECH, V1839, P1404, DOI 10.1016/j.bbagrm.2014.06.008; Dewhirst MW, 2009, RADIAT RES, V172, P653, DOI 10.1667/RR1926.1; Feldman M, 2019, P NATL ACAD SCI USA, V116, P1235, DOI 10.1073/pnas.1804407116; Feng J, 2017, ONCOGENE, V36, P2775, DOI 10.1038/onc.2016.432; Ferreira TR, 2020, NUCLEIC ACIDS RES, V48, P5511, DOI 10.1093/nar/gkaa211; Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gao Y, 2017, ONCOTARGET, V8, P71772, DOI 10.18632/oncotarget.17888; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Geng PY, 2017, FASEB J, V31, P2287, DOI 10.1096/fj.201601196R; Gopisetty G, 2016, GENE, V589, P27, DOI 10.1016/j.gene.2016.05.008; Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414; Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249; Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906; Jain K, 2017, P NATL ACAD SCI USA, V114, P10101, DOI 10.1073/pnas.1706978114; Kenmochi N, 2001, GENOMICS, V77, P65, DOI 10.1006/geno.2001.6622; Kim HJ, 2017, SEMIN CANCER BIOL, V47, P67, DOI 10.1016/j.semcancer.2017.04.004; Klaestad E, 2020, BREAST CANCER RES TR, V180, P73, DOI 10.1007/s10549-020-05532-6; Kohda M, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005679; Le DD, 2012, CURR OPIN CHEM BIOL, V16, P507, DOI 10.1016/j.cbpa.2012.09.014; Liu FB, 2017, NAT CELL BIOL, V19, P1358, DOI 10.1038/ncb3630; O'Neill DJ., 2014, EPIGENETICS-US, V9, P9; Piao L, 2015, ONCOTARGET, V6, P16939, DOI 10.18632/oncotarget.4760; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Pu M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317709127; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Sullivan LB, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-17; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vershinin Z, 2016, J BIOL CHEM, V291, P6786, DOI 10.1074/jbc.M115.697292; Wang YP, 2016, MOL CELL, V64, P673, DOI 10.1016/j.molcel.2016.09.028; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wong TL, 2020, HEPATOLOGY, V71, P1279, DOI 10.1002/hep.30923; Wu WC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0961-7; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800; Zempel KEC, 2016, J PROTEOME RES, V15, P4436, DOI 10.1021/acs.jproteome.6b00521; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045; Zhang ZL, 2003, GENOMICS, V81, P468, DOI 10.1016/S0888-7543(03)00004-1; Zhao L, 2015, CELL DEATH DIFFER, V22, P1630, DOI 10.1038/cdd.2015.6; Zhou C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0196-z; Zielonka J, 2010, FREE RADICAL BIO MED, V48, P983, DOI 10.1016/j.freeradbiomed.2010.01.028; Zurita-Lopez CI, 2012, J BIOL CHEM, V287, P7859, DOI 10.1074/jbc.M111.336271	55	8	8	7	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3548	3563		10.1038/s41388-021-01785-7	http://dx.doi.org/10.1038/s41388-021-01785-7		APR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33927350				2022-12-17	WOS:000645517200001
J	Zhang, G; Yang, Y; Hu, H; Liu, KY; Li, BY; Zhu, Y; Wang, ZY; Wu, QF; Mei, YD				Zhang, Guang; Yang, Yang; Hu, Hao; Liu, Kaiyue; Li, Bingyan; Zhu, Yu; Wang, Zhongyu; Wu, Qingfa; Mei, Yide			Energy stress-induced linc01564 activates the serine synthesis pathway and facilitates hepatocellular carcinogenesis	ONCOGENE			English	Article								Cancer cells undergo metabolic adaption to sustain their survival and growth under metabolic stress conditions, yet the underlying mechanism remains largely unclear. It is also not known if lncRNAs contribute to this metabolic adaption of cancer cells. Here we show that linc01564 is induced in response to glucose deprivation by the transcription factor ATF4. Linc01564 functions to facilitate hepatocellular carcinoma cell survival under glucose deprivation by activating the serine synthesis pathway. Mechanistically, linc01564 acts as a competing endogenous RNA for miR-107/103a-3p and attenuates the inhibitory effect of miR-107/103a-3p on PHGDH, the rate-limiting enzyme of the serine synthesis pathway, thereafter leading to increased PHGDH expression. Furthermore, linc01564 is able to promote hepatocellular carcinogenesis via PHGDH. Together, these findings suggest that linc01564 is an important player in the regulation of metabolic adaption of cancer cells and also implicate linc01564 as a potential therapeutic target for cancer.	[Zhang, Guang; Yang, Yang; Hu, Hao; Liu, Kaiyue; Li, Bingyan; Zhu, Yu; Wang, Zhongyu; Wu, Qingfa; Mei, Yide] Univ Sci & Technol China, Sch Basic Med Sci, Div Life Sci & Med,CAS Key Lab Innate Immun & Chr, Affiliated Hosp 1,USTC,Hefei Natl Lab Phys Sci Mi, Hefei, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Mei, YD (corresponding author), Univ Sci & Technol China, Sch Basic Med Sci, Div Life Sci & Med,CAS Key Lab Innate Immun & Chr, Affiliated Hosp 1,USTC,Hefei Natl Lab Phys Sci Mi, Hefei, Anhui, Peoples R China.	meiyide@ustc.edu.cn			Ministry of Science and Technology of China [2019YFA0802600]; National Natural Science Foundation of China [91957108, 31671487, 31871440]; Collaborative Innovation Programs of Hefei Science Center, CAS [2019HSC-CIP010]; Fundamental Research Funds For Central Universities [WK9110000007, YD2070002007]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Collaborative Innovation Programs of Hefei Science Center, CAS; Fundamental Research Funds For Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by grants from the Ministry of Science and Technology of China (2019YFA0802600), National Natural Science Foundation of China (91957108, 31671487, and 31871440), Collaborative Innovation Programs of Hefei Science Center, CAS (2019HSC-CIP010), and the Fundamental Research Funds For Central Universities (WK9110000007 and YD2070002007).	Adams CM, 2007, J BIOL CHEM, V282, P16744, DOI 10.1074/jbc.M610510200; Ala U, 2013, P NATL ACAD SCI USA, V110, P7154, DOI 10.1073/pnas.1222509110; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667; Chen PS, 2011, J CLIN INVEST, V121, P3442, DOI 10.1172/JCI45390; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Deng SJ, 2019, CANCER RES, V79, P1398, DOI 10.1158/0008-5472.CAN-18-0419; DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Finnerty JR, 2010, J MOL BIOL, V402, P491, DOI 10.1016/j.jmb.2010.07.051; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang YA, 2018, BIOINFORMATICS, V34, P812, DOI 10.1093/bioinformatics/btx672; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kartha RV, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00008; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li XX, 2018, MOL CELL, V69, P480, DOI 10.1016/j.molcel.2018.01.001; Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008; Liu J, 2020, J CLIN INVEST, V130, P3253, DOI 10.1172/JCI132876; Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Ma ML, 2019, HEPATOLOGY, V70, P215, DOI 10.1002/hep.30602; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176; Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mullarky E, 2016, P NATL ACAD SCI USA, V113, P1778, DOI 10.1073/pnas.1521548113; Mullarky E, 2011, PIGM CELL MELANOMA R, V24, P1112, DOI 10.1111/j.1755-148X.2011.00919.x; Nilsson LM, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002573; Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Reid MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07868-6; Samanta D, 2016, CANCER RES, V76, P4430, DOI 10.1158/0008-5472.CAN-16-0530; Silva-Fisher JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15547-8; SNELL K, 1986, TRENDS BIOCHEM SCI, V11, P241, DOI 10.1016/0968-0004(86)90184-2; Su XY, 2017, ANAL CHEM, V89, P5941, DOI 10.1021/acs.analchem.7b00396; Sullivan MR, 2019, CELL METAB, V29, P1410, DOI 10.1016/j.cmet.2019.02.015; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Sun M, 2015, ENDOCR REV, V36, P25, DOI 10.1210/er.2014-1034; Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Townsend DM, 2003, BIOMED PHARMACOTHER, V57, P145, DOI 10.1016/S0753-3322(03)00043-X; Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112; Turco C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00427; VAUPEL P, 1989, CANCER RES, V49, P6449; Wang CF, 2019, P NATL ACAD SCI USA, V116, P14620, DOI 10.1073/pnas.1903432116; Wang Y, 2016, BIOCHEM BIOPH RES CO, V480, P455, DOI 10.1016/j.bbrc.2016.10.070; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12606-7; Wortel IMN, 2017, TRENDS ENDOCRIN MET, V28, P794, DOI 10.1016/j.tem.2017.07.003; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81; Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zhang BX, 2017, CELL REP, V19, P2289, DOI 10.1016/j.celrep.2017.05.067; Zhu JH, 2016, TRANSL ONCOL, V9, P592, DOI 10.1016/j.tranon.2016.08.003	73	8	8	5	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2936	2951		10.1038/s41388-021-01749-x	http://dx.doi.org/10.1038/s41388-021-01749-x		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33742121				2022-12-17	WOS:000630655600002
J	Bencomo-Alvarez, AE; Rubio, AJ; Olivas, IM; Gonzalez, MA; Ellwood, R; Fiol, CR; Eide, CA; Lara, JJ; Barreto-Vargas, C; Jave-Suarez, LF; Nteliopoulos, G; Reid, AG; Milojkovic, D; Druker, BJ; Apperley, J; Khorashad, JS; Eiring, AM				Bencomo-Alvarez, Alfonso E.; Rubio, Andres J.; Olivas, Idaly M.; Gonzalez, Mayra A.; Ellwood, Rebecca; Fiol, Carme Ripoll; Eide, Christopher A.; Lara, Joshua J.; Barreto-Vargas, Christian; Jave-Suarez, Luis F.; Nteliopoulos, Georgios; Reid, Alistair G.; Milojkovic, Dragana; Druker, Brian J.; Apperley, Jane; Khorashad, Jamshid S.; Eiring, Anna M.			Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; STEM-CELLS; CML STEM; IMATINIB; THERAPY; INHIBITION; GENE; RESISTANT; STAT3; TRANSCRIPTION	Tyrosine kinase inhibitors (TKIs) targeting BCR-ABL1 have revolutionized therapy for chronic myeloid leukemia (CML), paving the way for clinical development in other diseases. Despite success, targeting leukemic stem cells and overcoming drug resistance remain challenges for curative cancer therapy. To identify drivers of kinase-independent TKI resistance in CML, we performed genome-wide expression analyses on TKI-resistant versus sensitive CML cell lines, revealing a nuclear factor-kappa B (NF-kappa B) expression signature. Nucleocytoplasmic fractionation and luciferase reporter assays confirmed increased NF-kappa B activity in the nucleus of TKI-resistant versus sensitive CML cell lines and CD34(+) patient samples. Two genes that were upregulated in TKI-resistant CML cells were proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), both members of the 19S regulatory complex in the 26S proteasome. PSMD1 and PSMD3 were also identified as survival-critical genes in a published small hairpin RNA library screen of TKI resistance. We observed markedly higher levels of PSMD1 and PSMD3 mRNA in CML patients who had progressed to the blast phase compared with the chronic phase of the disease. Knockdown of PSMD1 or PSMD3 protein correlated with reduced survival and increased apoptosis in CML cells, but not in normal cord blood CD34(+) progenitors. Luciferase reporter assays and immunoblot analyses demonstrated that PSMD1 and PSMD3 promote NF-kappa B protein expression in CML, and that signal transducer and activator of transcription 3 (STAT3) further activates NF-kappa B in scenarios of TKI resistance. Our data identify NF-kappa B as a transcriptional driver in TKI resistance, and implicate PSMD1 and PSMD3 as plausible therapeutic targets worthy of future investigation in CML and possibly other malignancies.	[Bencomo-Alvarez, Alfonso E.; Rubio, Andres J.; Gonzalez, Mayra A.; Lara, Joshua J.; Eiring, Anna M.] Texas Tech Univ, Hlth Sci Ctr El Paso, Ctr Emphasis Canc, Dept Mol & Translat Med,Paul L Foster Sch Med, El Paso, TX 79905 USA; [Olivas, Idaly M.; Eiring, Anna M.] Texas Tech Univ, Grad Sch Biomed Sci, Hlth Sci Ctr El Paso, El Paso, TX USA; [Ellwood, Rebecca; Fiol, Carme Ripoll; Nteliopoulos, Georgios; Milojkovic, Dragana; Apperley, Jane; Khorashad, Jamshid S.] Imperial Coll London, Ctr Haematol, Dept Med, London, England; [Eide, Christopher A.; Druker, Brian J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol Med Oncol, Portland, OR 97201 USA; [Barreto-Vargas, Christian] Univ Guadalajara, Guadalajara, Jalisco, Mexico; [Jave-Suarez, Luis F.] Ctr Invest Biomed Occidente, Inst Mexicano Seguro Social, Guadalajara, Jalisco, Mexico; [Nteliopoulos, Georgios] Imperial Coll London, Dept Surg & Canc, London, England; [Reid, Alistair G.] Royal Liverpool Univ Hosp, Mol Pathol Unit, Liverpool Clin Labs, Liverpool, Merseyside, England	Texas Tech University System; Texas Tech University; Texas Tech University System; Texas Tech University; Imperial College London; Oregon Health & Science University; Universidad de Guadalajara; Instituto Mexicano del Seguro Social; Imperial College London; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Eiring, AM (corresponding author), Texas Tech Univ, Hlth Sci Ctr El Paso, Ctr Emphasis Canc, Dept Mol & Translat Med,Paul L Foster Sch Med, El Paso, TX 79905 USA.	anna.eiring@ttuhsc.edu	Jave-Suarez, Luis Felipe/T-7036-2018; Eiring, Anna M./ABA-8673-2020	Jave-Suarez, Luis Felipe/0000-0001-6209-5031; Eiring, Anna M./0000-0001-6533-9150; Bencomo-Alvarez, Alfonso Enrique/0000-0002-1771-8532; Apperley, Jane/0000-0002-1710-1794; Ellwood, Rebecca/0000-0002-0412-7530	Imperial BRC Genomics Facility, Imperial College London; National Institute for Health Research (NIHR); National Cancer Institute of the National Institutes of Health [K22CA216008-04, R01CA065823-21]; Consejo Nacional de Ciencia y Tecnologia (CONACyT)	Imperial BRC Genomics Facility, Imperial College London; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Consejo Nacional de Ciencia y Tecnologia (CONACyT)(Consejo Nacional de Ciencia y Tecnologia (CONACyT))	The authors would like to thank the Imperial BRC Genomics Facility, Imperial College London for providing resources and support that have contributed to the results reported within this paper. The Imperial BRC Genomics Facility is supported by the National Institute for Health Research (NIHR) to the Imperial Biomedical Research Centre. Research reported in this publication was supported in part by the National Cancer Institute of the National Institutes of Health under award numbers K22CA216008-04 (AME) and R01CA065823-21 (BJD). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CBV is grateful for scholarship obtained through support from Consejo Nacional de Ciencia y Tecnologia (CONACyT). We also wish to thank Michael Deininger, MD, PhD, from the University of Utah Huntsman Cancer Institute, for providing the cell lines used in this study. We thank Jessica M. Hernando, MT, ASCP (CM) and her team at the University Medical Center of El Paso (El Paso, TX, USA) for graciously donating the discarded cord blood used in this study. The authors are thankful to Shrikanth Gadad, PhD and Rajkumar Lakshmanaswamy, PhD for critical review of the paper.	Aichberger KJ, 2011, AM J HEMATOL, V86, P533, DOI 10.1002/ajh.22037; Baba T, 2013, J EXP MED, V210, P2661, DOI 10.1084/jem.20130112; Bencomo-Alvarez AE, 2019, BRIT J HAEMATOL, V186, P524, DOI 10.1111/bjh.16074; Bocchia M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00194; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Breccia M, 2010, EXPERT OPIN THER TAR, V14, P1157, DOI 10.1517/14728222.2010.522570; Caocci G, 2019, HEMATOL ONCOL, V37, P296, DOI 10.1002/hon.2606; Carra G, 2016, ONCOTARGET, V7, P66287, DOI 10.18632/oncotarget.11507; Chen JQ, 2013, CURR OPIN IMMUNOL, V25, P4, DOI 10.1016/j.coi.2012.12.005; Chen YM, 2013, LEUKEMIA LYMPHOMA, V54, P1411, DOI 10.3109/10428194.2012.745525; Chiu CF, 2016, P NATL ACAD SCI USA, V113, pE2526, DOI 10.1073/pnas.1522612113; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; Chorzalska A, 2018, MOL ONCOL, V12, P630, DOI 10.1002/1878-0261.12186; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Cilloni D, 2006, LEUKEMIA, V20, P61, DOI 10.1038/sj.leu.2403998; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Dai YJ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.143; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eiring A M, 2014, Leuk Suppl, V3, pS5, DOI 10.1038/leusup.2014.3; Eiring AM, 2015, LEUKEMIA, V29, P2328, DOI 10.1038/leu.2015.196; Eiring AM, 2015, LEUKEMIA, V29, P586, DOI 10.1038/leu.2014.245; Fararjeh AS, 2019, CANCERS, V11, DOI 10.3390/cancers11040527; Fisher DAC, 2017, LEUKEMIA, V31, P1962, DOI 10.1038/leu.2016.377; Fukuoka M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201796; Gallipoli P, 2013, BLOOD, V122, P3335, DOI 10.1182/blood-2013-02-485607; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Han SH, 2017, LEUKEMIA, V31, P1659, DOI 10.1038/leu.2017.107; Han SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-97; Heaney NB, 2010, BLOOD, V115, P2241, DOI 10.1182/blood-2008-06-164582; Im E, 2016, BMB REP, V49, P459, DOI 10.5483/BMBRep.2016.49.9.094; Jain P, 2019, BLOOD ADV, V3, P851, DOI 10.1182/bloodadvances.2018025874; Janssen L, 2019, LEUKEMIA, V33, P2116, DOI 10.1038/s41375-019-0443-7; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kagoya Y, 2014, J CLIN INVEST, V124, P528, DOI 10.1172/JCI68101; Khorashad JS, 2015, BLOOD, V125, P1772, DOI 10.1182/blood-2014-08-588855; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lounnas N, 2009, INT J CANCER, V125, P308, DOI 10.1002/ijc.24294; Lu ZZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-112; Mahon FX, 2010, LANCET ONCOL, V11, P1029, DOI 10.1016/S1470-2045(10)70233-3; McWeeney SK, 2010, BLOOD, V115, P315, DOI 10.1182/blood-2009-03-210732; Mendez-Ferrer S, 2020, NAT REV CANCER, V20, P285, DOI 10.1038/s41568-020-0245-2; Minson AG, 2019, BLOOD ADV, V3, P1084, DOI 10.1182/bloodadvances.2018028035; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; Oh B, 2013, ANTI-CANCER DRUG, V24, P20, DOI 10.1097/CAD.0b013e32835a0fbd; Okumura T, 2018, J BIOCHEM, V163, P19, DOI 10.1093/jb/mvx053; Orlova A, 2019, CANCERS, V11, DOI 10.3390/cancers11121930; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Rousselot P, 2014, J CLIN ONCOL, V32, P424, DOI 10.1200/JCO.2012.48.5797; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Santos FPS, 2011, CL LYMPH MYELOM LEUK, V11, P355, DOI 10.1016/j.clml.2011.06.004; Shen N, 2019, ONCOTARGETS THER, V12, P2355, DOI 10.2147/OTT.S197535; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Styczynski J, 2012, WSPOLCZESNA ONKOL, V16, P210, DOI 10.5114/wo.2012.29286; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Traer E, 2012, LEUKEMIA, V26, P1140, DOI 10.1038/leu.2011.325; Tsvetkov P, 2017, P NATL ACAD SCI USA, V114, P382, DOI 10.1073/pnas.1619067114; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wei W, 2013, APOPTOSIS, V18, P1060, DOI 10.1007/s10495-013-0854-2; Welner RS, 2015, CANCER CELL, V27, P671, DOI 10.1016/j.ccell.2015.04.004; Yamada T, 2014, LEUKEMIA RES, V38, P210, DOI 10.1016/j.leukres.2013.10.006; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yu ZY, 2002, BIOCHEM J, V367, P97, DOI 10.1042/BJ20020588; Zhang B, 2016, BLOOD, V128, P2671, DOI 10.1182/blood-2015-11-679928; Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018; Zhang TQ, 2019, CELL BIOL INT, V43, P98, DOI 10.1002/cbin.11026; Zhang XD, 2016, CANCER CELL, V29, P639, DOI 10.1016/j.ccell.2016.03.026	76	8	8	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2697	2710		10.1038/s41388-021-01732-6	http://dx.doi.org/10.1038/s41388-021-01732-6		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33712704	Green Published, hybrid			2022-12-17	WOS:000628201500001
J	Zhou, JF; Wang, YL; Wu, DL; Wang, SS; Chen, ZQ; Xiang, ST; Chan, FL				Zhou, Jianfu; Wang, Yuliang; Wu, Dinglan; Wang, Shusheng; Chen, Zhiqiang; Xiang, Songtao; Chan, Franky Leung			Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer	ONCOGENE			English	Review							STEROIDOGENIC FACTOR-I; TRANSCRIPTIONAL REGULATION; ERR-ALPHA; INCREASED SURVIVAL; EMERGING ROLES; COUP-TFII; HOMOLOG 1; EXPRESSION; LRH-1; METABOLISM	Castration-resistant prostate cancer (CRPC) almost invariably occurs after androgen-deprivation therapy (ADT) for the advanced metastatic disease. It is generally believed that among multiple mechanisms and signaling pathways, CRPC is significantly driven by the reactivation of androgen receptor (AR) signaling in ADT-treated patients with castrate levels of androgen, partially at least mediated by the androgen biosynthesis within the tumor, also known as intratumoral or intraprostatic androgen biosynthesis. Steroidogenic enzymes, such as CYP11A1, CYP17A1, HSD3B1, AKR1C3 and SRD5A, are essential to catalyze the conversion of the initial substrate cholesterol into potent androgens that confers the CRPC progression. Accumulating evidences indicate that many steroidogenic enzymes are upregulated in the progression setting; however, little is known about the dysregulation of these enzymes in CRPC. Orphan nuclear receptors (ONRs) are members of the nuclear receptor superfamily, of which endogenous physiological ligands are unknown and which are constitutively active independent of any physiological ligands. Studies have validated that besides AR, ONRs could be the potential therapeutic targets for prostate cancer, particularly the lethal CRPC progression. Early studies reveal that ONRs play crucial roles in the transcriptional regulation of steroidogenic enzyme genes. Notably, we and others show that three distinct ONRs, including liver receptor homolog-1 (LRH-1, NR5A2), steroidogenic factor 1 (SF-1, AD4BP, NR5A1) and estrogen-related receptor alpha (ERR alpha, NR3B1), can contribute to the CRPC progression by promotion of the intratumoral androgen synthesis via their direct transcriptional regulation on multiple steroidogenic enzymes. This review presents an overview of the current understanding on the intratumoral androgen biosynthesis in CRPC, with a special focus on the emerging roles of ONRs in this process.	[Zhou, Jianfu; Wang, Shusheng; Chen, Zhiqiang; Xiang, Songtao] Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Urol, Guangzhou, Peoples R China; [Zhou, Jianfu] Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Peoples R China; [Zhou, Jianfu; Wang, Yuliang; Chan, Franky Leung] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China; [Wu, Dinglan] Southern Med Univ, Shenzhen Hosp, Clin Innovat & Res Ctr, Shenzhen Key Lab Viral Oncol, Shenzhen, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Chinese University of Hong Kong; Southern Medical University - China	Xiang, ST (corresponding author), Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Urol, Guangzhou, Peoples R China.; Chan, FL (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.	tonyxst@gzucm.edu.cn; franky-chan@cuhk.edu.hk	Chan, Franky/M-1043-2018	Chan, Franky/0000-0003-0567-2052	National Natural Science Foundation of China [81774067, 81802575, 82072830, 81872283]; Medical Science and Technology Research Fund of Guangdong Province [A2020239]; Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine [YN2016MJ03]; Guangdong-Hong Kong collaborative innovation projects from the Department of Science and Technology of Guangdong Province [2017A050506042]; Guangdong Provincial Hospital of Chinese Medicine [YN2018HK02]; General Research Fund, Research Grants Council of Hong Kong [461009, 2140789, 14100914, 14107116, 14110918]; Health and Medical Research Fund [02130066]; Food and Health Bureau of Hong Kong; Eternal Flame Scholar Programme of Guangzhou University of Chinese Medicine	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science and Technology Research Fund of Guangdong Province; Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine; Guangdong-Hong Kong collaborative innovation projects from the Department of Science and Technology of Guangdong Province; Guangdong Provincial Hospital of Chinese Medicine; General Research Fund, Research Grants Council of Hong Kong(Hong Kong Research Grants Council); Health and Medical Research Fund; Food and Health Bureau of Hong Kong; Eternal Flame Scholar Programme of Guangzhou University of Chinese Medicine	The work described in this article was partially supported by the National Natural Science Foundation of China (No. 81774067, 81802575, 82072830, 81872283), Medical Science and Technology Research Fund of Guangdong Province (No. A2020239), Specific Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine (No. YN2016MJ03), Guangdong-Hong Kong collaborative innovation projects from the Department of Science and Technology of Guangdong Province (No. 2017A050506042) and Guangdong Provincial Hospital of Chinese Medicine (No. YN2018HK02); and also by grants from the General Research Fund (project numbers: 461009, 2140789, 14100914, 14107116, 14110918), Research Grants Council of Hong Kong; a grant from the Health and Medical Research Fund (project number: 02130066), Food and Health Bureau of Hong Kong (to FLC). JZ was awarded by the Eternal Flame Scholar Programme of Guangzhou University of Chinese Medicine.	Armandari I, 2014, PROSTATE INT, V2, P105, DOI 10.12954/PI.14063; Attard G, 2016, LANCET, V387, P70, DOI 10.1016/S0140-6736(14)61947-4; Baek SH, 2014, ANNU REV PHYSIOL, V76, P177, DOI 10.1146/annurev-physiol-030212-183758; BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016/0960-0760(94)90131-7; Benod C, 2011, P NATL ACAD SCI USA, V108, P16927, DOI 10.1073/pnas.1112047108; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buholzer CF, 2005, MOL ENDOCRINOL, V19, P65, DOI 10.1210/me.2004-0061; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Chand AL, 2013, STEROIDS, V78, P700, DOI 10.1016/j.steroids.2013.03.001; Chandrasekar T, 2015, TRANSL ANDROL UROL, V4, P365, DOI 10.3978/j.issn.2223-4683.2015.05.02; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen B, 2014, CANCER GENE THER, V21, P411, DOI 10.1038/cgt.2014.41; Cheung CP, 2005, J CLIN ENDOCR METAB, V90, P1830, DOI 10.1210/jc.2004-1421; Clyne CD, 2004, MOL CELL ENDOCRINOL, V215, P39, DOI 10.1016/j.mce.2003.11.001; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Del Tredici AL, 2008, MOL PHARMACOL, V73, P900, DOI 10.1124/mol.107.040089; Ehrlund A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032080; Eichner LJ, 2011, MITOCHONDRION, V11, P544, DOI 10.1016/j.mito.2011.03.121; Evans RM, 2005, MOL ENDOCRINOL, V19, P1429, DOI 10.1210/me.2005-0046; Evans RM, 2014, CELL, V157, P255, DOI 10.1016/j.cell.2014.03.012; Fayard E, 2004, TRENDS CELL BIOL, V14, P250, DOI 10.1016/j.tcb.2004.03.008; Fontana F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020460; Fujimura T, 2007, INT J CANCER, V120, P2325, DOI 10.1002/ijc.22363; GELLER J, 1984, J UROLOGY, V132, P693, DOI 10.1016/S0022-5347(17)49829-6; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; Grist E, 2015, J STEROID BIOCHEM, V145, P157, DOI 10.1016/j.jsbmb.2014.09.006; Hanley NA, 2001, MOL ENDOCRINOL, V15, P57, DOI 10.1210/me.15.1.57; Hofland J, 2010, CANCER RES, V70, P1256, DOI 10.1158/0008-5472.CAN-09-2092; HUM DW, 1993, CLIN CHEM, V39, P333; Jia L, 2018, ONCOGENE, V37, P3340, DOI 10.1038/s41388-018-0198-z; Jimenez P, 2003, ENDOCRINOLOGY, V144, P4285, DOI 10.1210/en.2003-0472; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lewis SR, 2014, ENDOCRINOLOGY, V155, P358, DOI 10.1210/en.2013-1583; Lin SQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10287; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Madoux F, 2008, MOL PHARMACOL, V73, P1776, DOI 10.1124/mol.108.045963; Martin LJ, 2008, MOL ENDOCRINOL, V22, P2021, DOI 10.1210/me.2007-0370; Martin LJ, 2009, J MOL ENDOCRINOL, V42, P119, DOI 10.1677/JME-08-0095; Mathieu R, 2013, PROSTATE, V73, P1103, DOI 10.1002/pros.22659; Mei L, 2010, MOL CELL ENDOCRINOL, V319, P39, DOI 10.1016/j.mce.2010.01.014; Meinsohn MC, 2019, PHYSIOL REV, V99, P1249, DOI 10.1152/physrev.00019.2018; Mendoza-Villarroel RE, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.113.115790; Miao L, 2010, MOL ENDOCRINOL, V24, P1175, DOI 10.1210/me.2009-0470; Miki Y, 2006, CANCER LETT, V244, P24, DOI 10.1016/j.canlet.2005.11.038; Miller S, 2013, INT J ONCOL, V42, P627, DOI 10.3892/ijo.2012.1758; Milona A, 2019, MOL METAB, V30, P221, DOI 10.1016/j.molmet.2019.09.007; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; MOORE CCD, 1991, J STEROID BIOCHEM, V40, P517, DOI 10.1016/0960-0760(91)90271-6; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Parakh TN, 2006, P NATL ACAD SCI USA, V103, P12435, DOI 10.1073/pnas.0603006103; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Peng N, 2003, J CLIN ENDOCR METAB, V88, P6020, DOI 10.1210/jc.2003-030880; Penning TM, 2014, ENDOCR-RELAT CANCER, V21, pT67, DOI 10.1530/ERC-14-0109; Qin J, 2013, NATURE, V493, P236, DOI 10.1038/nature11674; Reichert ZR, 2016, CANCER J, V22, P326, DOI 10.1097/PPO.0000000000000214; Saxena D, 2007, ENDOCRINOLOGY, V148, P726, DOI 10.1210/en.2006-0108; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Seely J, 2005, ENDOCRINOLOGY, V146, P3605, DOI 10.1210/en.2004-1619; Sharifi N, 2013, MOL ENDOCRINOL, V27, P708, DOI 10.1210/me.2013-1007; Shi YH, 2007, DRUG DISCOV TODAY, V12, P440, DOI 10.1016/j.drudis.2007.04.006; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sirianni R, 2002, J ENDOCRINOL, V174, pR13, DOI 10.1677/joe.0.174R013; Stuchbery R, 2017, NAT REV UROL, V14, P49, DOI 10.1038/nrurol.2016.221; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Volle DH, 2007, GENE DEV, V21, P303, DOI 10.1101/gad.409307; Wang JJ, 2016, NAT MED, V22, P488, DOI 10.1038/nm.4070; Wang LM, 2016, ONCOTARGET, V7, P14673, DOI 10.18632/oncotarget.7405; Wang Z, 2018, ENDOCR-RELAT CANCER, V25, P35, DOI 10.1530/ERC-17-0280; Wright AS, 1999, ENDOCRINOLOGY, V140, P4509, DOI 10.1210/en.140.10.4509; Wu C, 2018, ONCOL LETT, V16, P2833, DOI 10.3892/ol.2018.8988; Wu DL, 2016, BBA-REV CANCER, V1866, P23, DOI 10.1016/j.bbcan.2016.06.001; Wu J, 2018, CLIN TRANSL ONCOL, V20, P1302, DOI 10.1007/s12094-018-1862-z; Xiao LJ, 2018, CANCER MANAG RES, V10, P2389, DOI 10.2147/CMAR.S162887; Xiao LJ, 2018, CANCER RES, V78, P2205, DOI 10.1158/0008-5472.CAN-17-2341; Xu ZY, 2020, THERANOSTICS, V10, P4201, DOI 10.7150/thno.35589; Xu ZY, 2018, ONCOGENE, V37, P6259, DOI 10.1038/s41388-018-0409-7; Zhao LJ, 2019, ENDOCR REV, V40, P1207, DOI 10.1210/er.2018-00222; Zhou J, 2005, CANCER RES, V65, P657; Zou C, 2014, J PATHOL, V233, P61, DOI 10.1002/path.4329	82	8	8	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2625	2634		10.1038/s41388-021-01737-1	http://dx.doi.org/10.1038/s41388-021-01737-1		MAR 2021	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33750894	Green Published, hybrid			2022-12-17	WOS:000626816500001
J	Li, Y; Liu, M; Yang, ST; Fuller, AM; Eisinger-Mathason, TSK; Yang, SY				Li, Yang; Liu, Min; Yang, Shuting; Fuller, Ashley M.; Karin Eisinger-Mathason, T. S.; Yang, Shuying			RGS12 is a novel tumor suppressor in osteosarcoma that inhibits YAP-TEAD1-Ezrin signaling	ONCOGENE			English	Article								Osteosarcoma (OS) is the most common primary malignancy of the bone that predominantly affects children and adolescents. Hippo pathway is a crucial regulator of organ size and tumorigenesis. However, how Hippo pathway regulates the occurrence of osteosarcoma is largely unknown. Here, we reported the regulator of G protein signaling protein 12 (RGS12) is a novel Hippo pathway regulator and tumor suppressor of osteosarcoma. Depletion of Rgs12 promotes osteosarcoma progression and lung metastasis in an orthotopic xenograft mouse model. Our data showed that the knockdown of RGS12 upregulates Ezrin expression through promoting the GNA12/13-RhoA-YAP pathway. Moreover, RGS12 negatively regulates the transcriptional activity of YAP/TEAD1 complex through its PDZ domain function to inhibit the expression and function of the osteosarcoma marker Ezrin. PDZ domain peptides of RGS12 can inhibit the development of intratibial tumor and lung metastases. Collectively, this study identifies that the RGS12 is a novel tumor suppressor in osteosarcoma through inhibiting YAP-TEAD1-Ezrin signaling pathway and provides a proof of principle that targeting RGS12 may be a therapeutic strategy for osteosarcoma.	[Li, Yang; Liu, Min; Yang, Shuting; Yang, Shuying] Univ Penn, Sch Dent Med, Dept Basic & Translat Sci, Philadelphia, PA 19104 USA; [Fuller, Ashley M.; Karin Eisinger-Mathason, T. S.] Univ Penn, Abramson Family Canc Res Inst, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA; [Yang, Shuying] Univ Penn, Sch Dent Med, Sch Engn & Appl Sci, Ctr Innovat & Precis Dent, Philadelphia, PA 19104 USA; [Yang, Shuying] Univ Penn, Sch Med, Penn Ctr Musculoskeletal Disorders, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania	Yang, SY (corresponding author), Univ Penn, Sch Dent Med, Dept Basic & Translat Sci, Philadelphia, PA 19104 USA.; Yang, SY (corresponding author), Univ Penn, Sch Dent Med, Sch Engn & Appl Sci, Ctr Innovat & Precis Dent, Philadelphia, PA 19104 USA.; Yang, SY (corresponding author), Univ Penn, Sch Med, Penn Ctr Musculoskeletal Disorders, Philadelphia, PA 19104 USA.	shuyingy@upenn.edu		Yang, Shuying/0000-0002-7126-6901; Li, Yang/0000-0002-7375-3025	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [AR061052]; National Institute on Aging (NIA) [AG048388]	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS, AR061052), the National Institute on Aging (NIA, AG048388) awarded to SY.	Abramow-Newerly M, 2006, CELL SIGNAL, V18, P579, DOI 10.1016/j.cellsig.2005.08.010; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bouvier C, 2016, ONCOTARGET, V7, P64702, DOI 10.18632/oncotarget.11876; Bradley SJ, 2016, P NATL ACAD SCI USA, V113, P4524, DOI 10.1073/pnas.1521706113; Brusgard JL, 2015, ONCOTARGET, V6, P28132, DOI 10.18632/oncotarget.4654; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; Chai JW, 2017, BIOCHEM BIOPH RES CO, V488, P297, DOI 10.1016/j.bbrc.2017.05.032; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Cho H., 2004, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V4, P107, DOI 10.2174/1568008043339938; Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343; Fukuda H, 2016, BIOCHEM BIOPH RES CO, V471, P63, DOI 10.1016/j.bbrc.2016.01.179; Gross JD, 2018, J PSYCHOPHARMACOL, V32, P191, DOI 10.1177/0269881117742100; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Holden JK, 2018, CANCERS, V10, DOI 10.3390/cancers10030081; Hurst JH, 2009, BIOCHEM PHARMACOL, V78, P1289, DOI 10.1016/j.bcp.2009.06.028; Igarashi K, 2020, CANCER LETT, V469, P332, DOI 10.1016/j.canlet.2019.10.028; Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266; Jules J, 2015, PROG MOL BIOL TRANSL, V133, P47, DOI 10.1016/bs.pmbts.2015.02.002; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Keinan D, 2014, FRONT BIOSCI-LANDMRK, V19, P634, DOI 10.2741/4232; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109; Lee HJ, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-8; Li Y, 2017, FEBS J, V284, P948, DOI 10.1111/febs.14026; Li ZQ, 2019, J BONE MINER RES, V34, P752, DOI 10.1002/jbmr.3645; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Mohri Z, 2017, J THORAC DIS, V9, pE507, DOI 10.21037/jtd.2017.03.179; Ng AYH, 2019, ELIFE, V8, DOI 10.7554/eLife.42951; Ren L, 2014, ADV EXP MED BIOL, V804, P181, DOI 10.1007/978-3-319-04843-7_10; Rozengurt E, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0005-2; Sabile AA, 2012, J BONE MINER RES, V27, P58, DOI 10.1002/jbmr.535; Stewart A, 2015, PROG MOL BIOL TRANSL, V133, P1, DOI 10.1016/bs.pmbts.2015.03.002; Tang QL, 2018, ONCOGENE, V37, P3617, DOI 10.1038/s41388-018-0231-2; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang DY, 2016, CHIN J CANCER, V35, P1, DOI 10.1186/s40880-016-0109-z; Wang GY, 2005, J BONE MINER RES, V20, P1022, DOI 10.1359/JBMR.050113; Wang YQ, 2017, CANCER RES, V77, P4247, DOI 10.1158/0008-5472.CAN-17-0669; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yang SY, 2013, GENESIS, V51, P201, DOI 10.1002/dvg.22373; Yang SY, 2007, J BONE MINER RES, V22, P45, DOI 10.1359/JBMR.061007; Yang Z, 2014, ONCOL REP, V32, P1265, DOI 10.3892/or.2014.3305; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yuan X, 2015, CELL DEATH DIFFER, V22, P2046, DOI 10.1038/cdd.2015.45; Yuan X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11024; Zhang L, 2009, FLY, V3, P68, DOI 10.4161/fly.3.1.7788; Zhang WQ, 2017, J CELL MOL MED, V21, P2663, DOI 10.1111/jcmm.13182; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhang YC, 2014, CELL SIGNAL, V26, P2504, DOI 10.1016/j.cellsig.2014.07.031; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2008, CURR OPIN CELL BIOL, V20, P638, DOI 10.1016/j.ceb.2008.10.001	56	8	9	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2021	40	14					2553	2566		10.1038/s41388-020-01599-z	http://dx.doi.org/10.1038/s41388-020-01599-z		MAR 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK3YE	33686240	Green Accepted			2022-12-17	WOS:000626396000003
J	Reinsborough, CW; Ipas, H; Abell, NS; Gouws, EB; Williams, JP; Mercado, M; Van den Berg, C; Xhemalce, B				Reinsborough, Calder W.; Ipas, Helene; Abell, Nathan S.; Gouws, Ellen B.; Williams, J. Paige; Mercado, Marvin; Van den Berg, Carla; Xhemalce, Blerta			BCDIN3D RNA methyltransferase stimulates Aldolase C expression and glycolysis through let-7 microRNA in breast cancer cells	ONCOGENE			English	Article							MAMMALIAN PROTEIN; PRE-MICRORNA; URIDYLATION; IDENTIFICATION; ZCCHC11; BIOGENESIS; RECRUITS; FAMILY; TUMORS; LOCI	Type II diabetes (T2D) and specific cancers share many risk factors, however, the molecular mechanisms underlying these connections are often not well-understood. BCDIN3D is an RNA modifying enzyme that methylates specific precursor microRNAs and tRNA(His). In addition to breast cancer, BCDIN3D may also be linked to metabolism, as its gene locus is associated with obesity and T2D. In order to uncover metabolic pathways regulated by BCDIN3D in cancer, we performed an unbiased analysis of the metabolome, transcriptome, and proteome of breast cancer cells depleted for BCDIN3D. Intersection of these analyses showed that BCDIN3D-depleted cells have increased levels of Fructose 1,6 Bisphosphate (F1,6-BP), the last six-carbon glycolytic intermediate accompanied by reduced glycolytic capacity. We further show that elevated F1,6-BP is due to downregulation of Aldolase C (ALDOC), an enzyme that cleaves F1,6-BP mainly in the brain, but whose high expression/amplification is associated with poor prognosis in breast cancer. BCDIN3D regulates ALDOC through a non-canonical mechanism involving the crucial let-7 microRNA family and its target site on the 3 ' UTR of ALDOC. Overall, our results reveal an important connection between BCDIN3D, let-7 and glycolysis that may be relevant to breast cancer, obesity, and T2D.	[Reinsborough, Calder W.; Ipas, Helene; Abell, Nathan S.; Gouws, Ellen B.; Williams, J. Paige; Mercado, Marvin; Xhemalce, Blerta] Univ Texas Austin, LiveStrong Canc Inst, Dept Mol Biosci, Dell Med Sch, 2500 Speedway, Austin, TX 78712 USA; [Abell, Nathan S.] Stanford Univ, Sch Med, Dept Genet, 300 Pasteur Dr, Stanford, CA 94305 USA; [Van den Berg, Carla] Univ Texas Austin, Dell Med Sch, Coll Pharm, Div Pharmacol & Toxicol, Austin, TX 78723 USA; [Van den Berg, Carla] Univ Texas Austin, Dell Med Sch, Dept Oncol, Austin, TX 78723 USA	University of Texas System; University of Texas Austin; Stanford University; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Xhemalce, B (corresponding author), Univ Texas Austin, LiveStrong Canc Inst, Dept Mol Biosci, Dell Med Sch, 2500 Speedway, Austin, TX 78712 USA.	b.xhemalce@austin.utexas.edu		Xhemalce, Blerta/0000-0002-0517-9607	NIH [R01-GM127802]; DOD-CDMRP-BCRP [W81XWH-16-1-0352]; Welch Foundation [F1859]; STORM Therapeutics; CPRIT [RR160093]; CPRIT Core Facility Support Grants [RP120348, RP170002]; DHHS/NCI Cancer Center Support Grant (CCSG) [P30 CA16672]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD-CDMRP-BCRP(United States Department of Defense); Welch Foundation(The Welch Foundation); STORM Therapeutics; CPRIT; CPRIT Core Facility Support Grants; DHHS/NCI Cancer Center Support Grant (CCSG)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	BX was supported by NIH (R01-GM127802, DOD-CDMRP-BCRP (W81XWH-16-1-0352), Welch Foundation (F1859), STORM Therapeutics, and start-up funds. CVDB was partly supported by CPRIT (RR160093). This study made use of the MD Anderson Science Park facilities supported by CPRIT Core Facility Support Grants RP120348 and RP170002 and P30 CA16672 DHHS/NCI Cancer Center Support Grant (CCSG).	Auyeung VC, 2013, CELL, V152, P844, DOI 10.1016/j.cell.2013.01.031; Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006; Berndt SI, 2013, NAT GENET, V45, P501, DOI 10.1038/ng.2606; Blazer LL, 2017, SLAS DISCOV, V22, P32, DOI 10.1177/1087057116666276; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Faehnle CR, 2014, NATURE, V514, P252, DOI 10.1038/nature13553; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Heo I, 2012, CELL, V151, P521, DOI 10.1016/j.cell.2012.09.022; Heo I, 2009, CELL, V138, P696, DOI 10.1016/j.cell.2009.08.002; Huangyang PW, 2020, CELL METAB, V31, P174, DOI 10.1016/j.cmet.2019.10.012; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026; Jones MR, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003105; Jones MR, 2009, NAT CELL BIOL, V11, P1157, DOI 10.1038/ncb1931; Kim B, 2015, EMBO J, V34, P1801, DOI 10.15252/embj.201590931; Kim K, 2018, RNA, V24, P892, DOI 10.1261/rna.065862.118; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li MQ, 2019, CELL METAB, V30, P508, DOI 10.1016/j.cmet.2019.05.018; Lin SC, 2020, NAT REV MOL CELL BIO, V21, P714, DOI 10.1038/s41580-020-00305-x; Lin SB, 2015, RNA BIOL, V12, P792, DOI 10.1080/15476286.2015.1058478; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Martinez A, 2017, NUCLEIC ACIDS RES, V45, P5423, DOI 10.1093/nar/gkx051; McCall MN, 2017, GENOME RES, V27, P1769, DOI 10.1101/gr.222067.117; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Reinsborough CW, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008273; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Schapira M, 2016, ACS CHEM BIOL, V11, P575, DOI 10.1021/acschembio.5b00781; Schwartz MW, 2013, NATURE, V503, P59, DOI 10.1038/nature12709; Shelton SB, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006139; Shi DS, 2015, INT J MOL SCI, V16, P13004, DOI 10.3390/ijms160613004; Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274; Thornton JE, 2014, NUCLEIC ACIDS RES, V42, P11777, DOI 10.1093/nar/gku805; Walley AJ, 2009, NAT REV GENET, V10, P431, DOI 10.1038/nrg2594; Xhemalce B, 2012, CELL, V151, P278, DOI 10.1016/j.cell.2012.08.041; Yao L, 2016, ONCOTARGET, V7, P53895, DOI 10.18632/oncotarget.9656; Zhang CS, 2017, NATURE, V548, P112, DOI 10.1038/nature23275; Zhu L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217603; Zhu WC, 2000, GENE, V245, P329, DOI 10.1016/S0378-1119(00)00048-2	42	8	8	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2395	2406		10.1038/s41388-021-01702-y	http://dx.doi.org/10.1038/s41388-021-01702-y		MAR 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664453	Green Accepted			2022-12-17	WOS:000625833000004
J	Wu, RF; Li, KK; Yuan, MH; Luo, KQ				Wu, Renfei; Li, Koukou; Yuan, Mingheng; Luo, Kathy Qian			Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells	ONCOGENE			English	Article							INDUCED APOPTOSIS; EXPRESSION; TRK; SURVIVAL; PATHWAY	Cellular heterogeneity and the lack of metastatic biomarkers limit the diagnosis of and development of therapies for metastatic triple-negative breast cancer (TNBC). Thus, development of new clinically relevant markers is urgently needed. By using RNA-seq analysis, we found that nerve growth factor receptor (NGFR) was highly expressed in metastatic lung clones of MDA-MB-231 cells. This high level of NGFR expression was necessary for TNBC cells to grow into tumor spheres under nonadhesive conditions, resist anoikis, promote primary tumor growth and increase metastasis in mice. NGFR was also expressed at a high level in a greater number of TNBC patients (45%) than non-TNBC patients (23%), enriched in higher grade tumors, and negatively correlated with the overall survival of TNBC patients. Mechanistic analysis indicated that NGFR exerted its prometastatic effects by binding with neurotrophic receptor tyrosine kinase 3 (TrkC) mainly through a ligand-independent manner, which activated the MEK-ERK1-ZEB1 and PI3K-AKT signaling pathways, increased the level of fibronectin, and decreased the expression of PUMA. Notably, we observed that NGFR expression in TrkC-positive metastatic clones reduced cellular sensitivity to anti-Trk therapy. Moreover, WNT family member 5a (WNT5A) and TrkC activated NGFR transcription in a ZEB1-dependent manner. Taken together, this study identified NGFR as a novel driver for transforming TNBC into higher grade metastatic tumors. Our findings provide the basis for the future development of NGFR as a diagnostic and prognostic marker for determining the metastatic potential of TNBC and as a therapeutic target for treating TNBC patients.	[Wu, Renfei; Li, Koukou; Yuan, Mingheng; Luo, Kathy Qian] Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China	University of Macau	Luo, KQ (corresponding author), Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.	kluo@um.edu.mo		Luo, Kathy Qian/0000-0001-7454-9547; Wu, Renfei/0000-0002-8847-7254	Science and Technology Development Fund (FDCT), Macao SAR, China [083/2016/A2, 068/2017/A2]	Science and Technology Development Fund (FDCT), Macao SAR, China	This project was funded by The Science and Technology Development Fund (FDCT), Macao SAR, China (File no. 083/2016/A2 and 068/2017/A2).	Anand P, 2015, BIOTECHNOL BIOENG, V112, P1673, DOI 10.1002/bit.25572; Ardini E, 2016, MOL CANCER THER, V15, P628, DOI 10.1158/1535-7163.MCT-15-0758; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161; Brewster AM, 2014, LANCET ONCOL, V15, pE625, DOI 10.1016/S1470-2045(14)70364-X; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chang JL, 2019, J CELL BIOL, V218, P2456, DOI 10.1083/jcb.201903066; Chiu LY, 2017, ONCOGENE, V36, P242, DOI 10.1038/onc.2016.195; Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0; Contreras-Zarate MJ, 2019, ONCOGENE, V38, P4685, DOI 10.1038/s41388-019-0756-z; Deng XF, 2017, INT J CLIN EXP PATHO, V10, P11685; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Faulkner S, 2018, AM J PATHOL, V188, P229, DOI 10.1016/j.ajpath.2017.09.008; Fu A, 2016, ONCOTARGET, V7, P50239, DOI 10.18632/oncotarget.10360; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Hondermarck H, 2012, CYTOKINE GROWTH F R, V23, P357, DOI 10.1016/j.cytogfr.2012.06.004; Howlader N., 2021, SEER CANC STAT REV 1; Jin W, 2010, CARCINOGENESIS, V31, P1939, DOI 10.1093/carcin/bgq180; Katsura A, 2017, MOL ONCOL, V11, P1241, DOI 10.1002/1878-0261.12098; Koren S, 2015, MOL CELL, V60, P537, DOI 10.1016/j.molcel.2015.10.031; Lagadec C, 2009, ONCOGENE, V28, P1960, DOI 10.1038/onc.2009.61; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lee S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182666; Luo KQ, 2001, BIOCHEM BIOPH RES CO, V283, P1054, DOI 10.1006/bbrc.2001.4896; Ma SJ, 2017, CANCER LETT, V388, P239, DOI 10.1016/j.canlet.2016.12.001; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Restivo G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01573-6; Saadipour K, 2017, J BIOL CHEM, V292, P16594, DOI 10.1074/jbc.M117.788729; Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Verbeke S, 2010, CELL SIGNAL, V22, P1864, DOI 10.1016/j.cellsig.2010.07.014; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; Wang JP, 2017, J CANCER, V8, P674, DOI 10.7150/jca.16901	38	8	8	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2165	2181		10.1038/s41388-021-01691-y	http://dx.doi.org/10.1038/s41388-021-01691-y		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33627781				2022-12-17	WOS:000621289100002
J	Ye, ZD; Wang, DW; Lu, YY; He, YJ; Yu, JT; Wei, WJ; Chen, C; Wang, R; Zhang, L; Zhang, LR; Le, MTN; Cho, WC; Yang, MS; Zhang, HM; Yue, JB				Ye, Zuodong; Wang, Dawei; Lu, Yingying; He, Yunjiao; Yu, Jingting; Wei, Wenjie; Chen, Chang; Wang, Rui; Zhang, Liang; Zhang, Liangren; Le, Minh T. N.; Cho, William C.; Yang, Mengsu; Zhang, Hongmin; Yue, Jianbo			Vacuolin-1 inhibits endosomal trafficking and metastasis via CapZ beta	ONCOGENE			English	Article							ENDOCYTIC TRAFFICKING; VESICLE TRAFFICKING; CELL; INTEGRIN; GEFS; EXOCYTOSIS; EXPRESSION; REGULATORS; MORPHOLOGY; MIGRATION	Metastasis is the fundamental cause of cancer mortality, but there are still very few anti-metastatic drugs available. Endosomal trafficking has been implicated in tumor metastasis, and we have previously found that small chemical vacuolin-1 (V1) potently inhibits autophagosome-lysosome fusion and general endosomal-lysosomal degradation. Here, we assessed the anti-metastatic activity of V1 both in vitro and in vivo. V1 significantly inhibits colony formation, migration, and invasion of various cancer cells in vitro. It also compromises the assembly-disassembly dynamics of focal adhesions (FAs) by inhibiting the recycling and degradation of integrins. In various experimental or transgenic mouse models, V1 significantly suppresses the metastasis and/or tumor growth of breast cancer or melanoma. We further identified capping protein Z beta (CapZ beta) as a V1 binding protein and showed that it is required for the V1-mediated inhibition of migration and metastasis of cancer cells. Collectively, our results indicate that V1 targets CapZ beta to inhibit endosomal trafficking and metastasis.	[Ye, Zuodong; Wang, Dawei; Lu, Yingying; Yu, Jingting; Wang, Rui; Zhang, Liang; Yang, Mengsu; Yue, Jianbo] City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China; [Ye, Zuodong; Wang, Dawei; Lu, Yingying; Wang, Rui; Zhang, Liang; Yang, Mengsu; Yue, Jianbo] City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China; [He, Yunjiao; Zhang, Hongmin] Southern Univ Sci & Technol, Dept Biol, Guangdong Prov Key Lab Cell Microenvironm & Dis R, Shenzhen 518055, Peoples R China; [He, Yunjiao; Zhang, Hongmin] Southern Univ Sci & Technol, Shenzhen Key Lab Cell Microenvironm, Shenzhen 518055, Peoples R China; [Wei, Wenjie] South Univ Sci & Technol China, Res Core Facil, Shenzhen 518052, Peoples R China; [Chen, Chang; Zhang, Liangren] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China; [Le, Minh T. N.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore; [Cho, William C.] Queen Elizabeth Hosp, Dept Clin Oncol, 30 Gascoigne Rd, Hong Kong, Peoples R China; [Yue, Jianbo] City Univ Hong Kong, Chengdu Res Inst, Chengdu, Peoples R China	City University of Hong Kong; City University of Hong Kong; Southern University of Science & Technology; Southern University of Science & Technology; Southern University of Science & Technology; Peking University; National University of Singapore; City University of Hong Kong	Yue, JB (corresponding author), City Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Peoples R China.; Yue, JB (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.; Yue, JB (corresponding author), City Univ Hong Kong, Chengdu Res Inst, Chengdu, Peoples R China.	jianbyue@cityu.edu.hk	Zhang, Liang/GWM-6088-2022; Yue, Jianbo/K-8002-2015; Zhang, Hongmin/S-9953-2017	Lu, Yingying/0000-0002-5423-9522; ZHANG, Liang/0000-0003-3100-8593; WANG, Rui/0000-0003-3830-4133; Ye, zuodong/0000-0002-9575-6198; Yue, Jianbo/0000-0001-6384-5447; Zhang, Hongmin/0000-0003-4356-3615	Hong Kong Research Grant Council (RGC) [11101717, 11103620]; NSFC [21778045, 32070702, 31670753, 31501116]; Guangdong Science and Technology Program [2017B030301018]; Shenzhen Science and Technology Innovation Committee [JCYJ201602291652 35739, JCYJ20170413141331470, JCYJ20160608140912962, SYS20140509142721429]; Sichuan Provincial Science and Technology Research Grant [2019YJ0633]; CASCroucher Funding Scheme	Hong Kong Research Grant Council (RGC)(Hong Kong Research Grants Council); NSFC(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Program; Shenzhen Science and Technology Innovation Committee; Sichuan Provincial Science and Technology Research Grant; CASCroucher Funding Scheme	This work was supported by Hong Kong Research Grant Council (RGC) grants (11101717 and 11103620), NSFC (21778045, 32070702, 31670753, 31501116), CASCroucher Funding Scheme, Guangdong Science and Technology Program (2017B030301018), research grants from Shenzhen Science and Technology Innovation Committee (JCYJ201602291652 35739, JCYJ20170413141331470, JCYJ20160608140912962, ZD SYS20140509142721429), Sichuan Provincial Science and Technology Research Grant (2019YJ0633).	Alanko J, 2016, TRENDS CELL BIOL, V26, P391, DOI 10.1016/j.tcb.2016.02.001; Alday-Parejo B, 2019, CANCERS, V11, DOI 10.3390/cancers11070978; Alizadeh AM, 2014, TUMOR BIOL, V35, P8483, DOI 10.1007/s13277-014-2421-z; Anderson RL, 2019, NAT REV CLIN ONCOL, V16, P185, DOI 10.1038/s41571-018-0134-8; Barr F, 2010, CURR OPIN CELL BIOL, V22, P461, DOI 10.1016/j.ceb.2010.04.007; Bhuin T, 2014, EXP CELL RES, V328, P1, DOI 10.1016/j.yexcr.2014.07.027; Burridge K, 2017, FEBS J, V284, P3355, DOI 10.1111/febs.14195; Cerny J, 2004, EMBO REP, V5, P883, DOI 10.1038/sj.embor.7400243; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen C, 2017, MOLECULES, V22, DOI 10.3390/molecules22060891; Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279; Derivery E, 2009, DEV CELL, V17, P712, DOI 10.1016/j.devcel.2009.09.010; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; di Pietro F, 2017, CURR BIOL, V27, P2452, DOI 10.1016/j.cub.2017.06.055; Dubey, STATPEARLS, P2020; Edwards M, 2014, NAT REV MOL CELL BIO, V15, P677, DOI 10.1038/nrm3869; Elkin M, 2001, CURR PROTOC CELL BIO, V12; Fletcher SJ, 2010, TRENDS CELL BIOL, V20, P71, DOI 10.1016/j.tcb.2009.11.006; Fontebasso Yari, 2015, Critical Reviews in Oncogenesis, V20, P449, DOI 10.1615/CritRevOncog.v20.i5-6.150; Gandalovicova A, 2017, TRENDS CANCER, V3, P391, DOI 10.1016/j.trecan.2017.04.008; Goldenring JR, 2013, NAT REV CANCER, V13, P813, DOI 10.1038/nrc3601; Gomez-Cuadrado L, 2017, DIS MODEL MECH, V10, P1061, DOI 10.1242/dmm.030403; Guerra F, 2019, CANCERS, V11, DOI 10.3390/cancers11081096; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamidi Hellyeh, 2018, Nat Rev Cancer, V18, P533, DOI 10.1038/s41568-018-0038-z; Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286; Huynh C, 2005, EMBO REP, V6, P843, DOI 10.1038/sj.embor.7400495; Ishida M, 2016, CELL STRUCT FUNCT, V41, P61, DOI 10.1247/csf.16008; Johannes L, 2020, CANCER METAST REV, V39, P375, DOI 10.1007/s10555-020-09880-z; Kinch LN, 2006, PROTEIN SCI, V15, P2669, DOI 10.1110/ps.062419006; Lamber EP, 2019, CURR OPIN CELL BIOL, V59, P34, DOI 10.1016/j.ceb.2019.03.004; Langemeyer L, 2018, TRENDS CELL BIOL, V28, P957, DOI 10.1016/j.tcb.2018.06.007; Levine Timothy P, 2013, Small GTPases, V4, P62, DOI 10.4161/sgtp.24262; Liu J, 2007, MOL BIOL CELL, V18, P1375, DOI 10.1091/mbc.E06-08-0725; Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200; MacDonald E, 2018, J CELL BIOL, V217, P2549, DOI 10.1083/jcb.201710051; Mellman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016949; Mendoza P, 2014, CURR MOL MED, V14, P235, DOI 10.2174/1566524014666140128111347; Mendoza Pablo, 2014, Small GTPases, V5, pe28195, DOI 10.4161/sgtp.28195; Mukherjee K, 2016, HUM MOL GENET, V25, P1255, DOI 10.1093/hmg/ddw006; Muller Matthias P, 2018, Small GTPases, V9, P5, DOI 10.1080/21541248.2016.1276999; Naslavsky N, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216499; Novick Peter, 2016, Small GTPases, V7, P252; Palamidessi A, 2008, CELL, V134, P135, DOI 10.1016/j.cell.2008.05.034; Parachoniak CA, 2012, TRENDS CELL BIOL, V22, P231, DOI 10.1016/j.tcb.2012.02.002; Park, 2019, SEMIN CANCER BIOL; Paul NR, 2015, CURR BIOL, V25, pR1092, DOI 10.1016/j.cub.2015.09.049; Pfeffer SR, 2017, MOL BIOL CELL, V28, P712, DOI 10.1091/mbc.E16-10-0737; Poteryaev D, 2010, CELL, V141, P497, DOI 10.1016/j.cell.2010.03.011; Powelka AM, 2004, TRAFFIC, V5, P20, DOI 10.1111/j.1600-0854.2004.00150.x; Rajendran V, 2018, METHODS MOL BIOL, V1692, P89, DOI 10.1007/978-1-4939-7401-6_8; Rashid OM, 2013, J THORAC DIS, V5, P385, DOI 10.3978/j.issn.2072-1439.2013.06.17; Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043; Roberts M, 2001, CURR BIOL, V11, P1392, DOI 10.1016/S0960-9822(01)00442-0; Rosel D, 2019, TRENDS CANCER, V5, P755, DOI 10.1016/j.trecan.2019.10.011; Schmid SL, 2017, J CELL BIOL, V216, P2623, DOI 10.1083/jcb.201705017; Scott CC, 2014, SEMIN CELL DEV BIOL, V31, P2, DOI 10.1016/j.semcdb.2014.03.034; Shaik GM, 2009, CELL SIGNAL, V21, P1337, DOI 10.1016/j.cellsig.2009.04.001; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Teckchandani A, 2009, J CELL BIOL, V186, P98, DOI 10.1083/jcb.200812160; Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391; Yao F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138213; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	63	8	8	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1775	1791		10.1038/s41388-021-01662-3	http://dx.doi.org/10.1038/s41388-021-01662-3		FEB 2021	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564074	Green Published, hybrid			2022-12-17	WOS:000616489100007
J	Yoshida, K; Yokoi, A; Sugiyama, M; Oda, S; Kitami, K; Tamauchi, S; Ikeda, Y; Yoshikawa, N; Nishino, K; Niimi, K; Suzuki, S; Kikkawa, F; Yokoi, T; Kajiyama, H				Yoshida, Kosuke; Yokoi, Akira; Sugiyama, Mai; Oda, Shingo; Kitami, Kazuhisa; Tamauchi, Satoshi; Ikeda, Yoshiki; Yoshikawa, Nobuhisa; Nishino, Kimihiro; Niimi, Kaoru; Suzuki, Shiro; Kikkawa, Fumitaka; Yokoi, Tsuyoshi; Kajiyama, Hiroaki			Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistance	ONCOGENE			English	Article							CANCER CELLS; IDENTIFICATION; MIR-509-3P; SENSITIVITY; MICRORNAS; APOPTOSIS; GENES	Ovarian clear cell carcinoma (OCCC) is a histological subtype of epithelial ovarian cancer and exhibits dismal prognosis due to chemoresistance. Moreover, only few effective therapeutic options exist for patients with recurrent OCCC, and an understanding of its molecular characteristics is essential for the development of novel therapeutic approaches. In the present study, we investigated unique MicroRNAs (miRNA) profiles in recurrent/metastatic OCCC and the role of miRNAs in cisplatin resistance. Comprehensive miRNA sequencing revealed that expression of several miRNAs, including miR-508-3p, miR-509-3p, miR-509-3-5p, and miR-514a-3p was remarkably less in recurrent cancer tissues when compared with that in paired primary cancer tissues. These miRNAs are located in the chrXq27.3 region on the genome. Moreover, its expression was negative in omental metastases in two patients with advanced OCCC. In vitro analyses revealed that overexpression of miR-509-3p and miR-509-3-5p reversed cisplatin resistance and yes-associated protein 1 (YAP1) was partially responsible for the resistance. Immunohistochemistry revealed that YAP1 expression was inversely correlated with the chrXq27.3 miRNA cluster expression. In conclusion, these findings suggest that alteration of the chrXq27.3 miRNA cluster could play a critical role in chemoresistance and miRNAs in the cluster and their target genes can be potential therapeutic targets.	[Yoshida, Kosuke; Yokoi, Akira; Kitami, Kazuhisa; Tamauchi, Satoshi; Ikeda, Yoshiki; Yoshikawa, Nobuhisa; Nishino, Kimihiro; Niimi, Kaoru; Suzuki, Shiro; Kikkawa, Fumitaka; Kajiyama, Hiroaki] Nagoya Univ, Dept Obstet & Gynecol, Grad Sch Med, Nagoya, Aichi, Japan; [Yoshida, Kosuke; Yokoi, Akira] Nagoya Univ, Inst Adv Res, Nagoya, Aichi, Japan; [Yoshida, Kosuke; Oda, Shingo; Yokoi, Tsuyoshi] Nagoya Univ, Div Clin Pharmacol, Dept Drug Safety Sci, Grad Sch Med, Nagoya, Aichi, Japan; [Sugiyama, Mai] Nagoya Univ, Dept Obstet & Gynecol Collaborat Res, Bell Res Ctr, Grad Sch Med, Nagoya, Aichi, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University	Yokoi, A (corresponding author), Nagoya Univ, Dept Obstet & Gynecol, Grad Sch Med, Nagoya, Aichi, Japan.; Yokoi, A (corresponding author), Nagoya Univ, Inst Adv Res, Nagoya, Aichi, Japan.	ayokoi@med.nagoya-u.ac.jp	YOSHIKAWA, NOBUHISA/AAE-5967-2021; YOSHIDA, Kosuke/AAM-6507-2020	YOSHIDA, Kosuke/0000-0003-1484-4872; Ikeda, Yoshiki/0000-0002-9456-0468; Yoshikawa, Nobuhisa/0000-0001-8662-9421	Japan Society for the Promotion of Science [16K15704, 16H02616, 17H04338, 19H03797, 20K22806]; Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) [20ck0106630h0001]; Aichi Cancer Research Foundation; Program for Promoting the Enhancement of Research Universities at Nagoya University	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED); Aichi Cancer Research Foundation(Aichi Cancer Research Foundation); Program for Promoting the Enhancement of Research Universities at Nagoya University	We express our highest appreciation to all members of the Department of Drug Safety Sciences, Division of Clinical Pharmacology, and Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine. Moreover, we received technical support from the Division for Medical Research Engineering, Nagoya University Graduate School of Medicine. Furthermore, we thank Enago (https://www.enago.jp/) for English editing of this manuscript. This study was supported by a Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research: Grant Numbers 16K15704, 16H02616, 17H04338, 19H03797, and 20K22806, and Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED): Grant Number 20ck0106630h0001. Aichi Cancer Research Foundation supported as well. Moreover, research reported in this publication was supported by the Program for Promoting the Enhancement of Research Universities as young researcher units for the advancement of new and undeveloped fields at Nagoya University.	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Anglesio MS, 2011, GYNECOL ONCOL, V121, P407, DOI 10.1016/j.ygyno.2011.01.005; Bagnoli M, 2011, ONCOTARGET, V2, P1265, DOI 10.18632/oncotarget.401; Boone JD, 2015, GYNECOL ONCOL, V138, P486, DOI 10.1016/j.ygyno.2015.05.022; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chan CK, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160275; Chen W, 2017, PHARMACOGENOMICS, V18, P1671, DOI 10.2217/pgs-2017-0115; Chen W, 2016, PHARMACOGENOMICS, V17, P187, DOI 10.2217/pgs.15.166; Chorn G, 2012, RNA, V18, P1796, DOI 10.1261/rna.031278.111; Damia G, 2019, CANCERS, V11, DOI 10.3390/cancers11010119; Das MK, 2016, CANCER GENOM PROTEOM, V13, P63; Elgaaen BV, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-80; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Ghafouri-Fard S, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104381; Ghosh S, 2019, BIOORG CHEM, V88, DOI 10.1016/j.bioorg.2019.102925; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kabekkodu SP, 2020, WIRES RNA, V11, DOI 10.1002/wrna.1563; Li J, 2016, ONCOGENE, V35, P5501, DOI 10.1038/onc.2016.90; Matsui M, 2016, MOL THER, V24, P946, DOI 10.1038/mt.2016.39; Mendes ND, 2009, NUCLEIC ACIDS RES, V37, P2419, DOI 10.1093/nar/gkp145; Mihanfar A, 2019, J CELL PHYSIOL, V234, P3180, DOI 10.1002/jcp.26060; Nam EJ, 2016, ONCOTARGET, V7, P70524, DOI 10.18632/oncotarget.12045; Niu LL, 2019, GENE, V686, P63, DOI 10.1016/j.gene.2018.11.011; Ozata DM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.464; Pan YH, 2016, ONCOTARGET, V7, P25930, DOI 10.18632/oncotarget.8412; Ramaiah M, 2019, EMBO REP, V20, DOI 10.15252/embr.201846566; Reggiani F, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2020.188341; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Song J, 2018, ONCOL LETT, V16, P3949, DOI 10.3892/ol.2018.9141; Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Wang J, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-199; Wang XH, 2016, BIOCHEM BIOPH RES CO, V478, P676, DOI 10.1016/j.bbrc.2016.08.006; Wei X, 2019, ONCOL REP, V42, P2768, DOI 10.3892/or.2019.7370; Xia Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109575; Yan TT, 2018, CANCER RES, V78, P1751, DOI 10.1158/0008-5472.CAN-17-2101; Yoshida K, 2019, CARCINOGENESIS, V40, P1435, DOI 10.1093/carcin/bgz135; Yoshida K, 2018, ONCOL LETT, V16, P515, DOI 10.3892/ol.2018.8610; Zanconato F, 2019, NAT REV CANCER, V19, P454, DOI 10.1038/s41568-019-0168-y; Zhai QN, 2012, BIOCHEM BIOPH RES CO, V419, P621, DOI 10.1016/j.bbrc.2012.02.060; Zhao LJ, 2019, ONCOGENE, V38, P2305, DOI 10.1038/s41388-018-0577-5; Zhou YF, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00139	44	8	8	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1255	1268		10.1038/s41388-020-01595-3	http://dx.doi.org/10.1038/s41388-020-01595-3		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420363	Green Published, hybrid			2022-12-17	WOS:000607346000011
J	Periyasamy, M; Singh, AK; Gemma, C; Farzan, R; Allsopp, RC; Shaw, JA; Charmsaz, S; Young, LS; Cunnea, P; Coombes, RC; Gyorffy, B; Buluwela, L; Ali, S				Periyasamy, Manikandan; Singh, Anup K.; Gemma, Carolina; Farzan, Raed; Allsopp, Rebecca C.; Shaw, Jacqueline A.; Charmsaz, Sara; Young, Leonie S.; Cunnea, Paula; Coombes, R. Charles; Gyorffy, Balazs; Buluwela, Lakjaya; Ali, Simak			Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-kappa B	ONCOGENE			English	Article							SMALL-MOLECULE INHIBITOR; SIGNALING PATHWAY; DEAMINASE APOBEC3B; CATALYTIC SUBUNIT; MUTAGENESIS; EVOLUTION; FAMILY; DEFICIENCY; PROTEINS; REVEALS	The mutagenic APOBEC3B (A3B) cytosine deaminase is frequently over-expressed in cancer and promotes tumour heterogeneity and therapy resistance. Hence, understanding the mechanisms that underlie A3B over-expression is important, especially for developing therapeutic approaches to reducing A3B levels, and consequently limiting cancer mutagenesis. We previously demonstrated that A3B is repressed by p53 and p53 mutation increases A3B expression. Here, we investigate A3B expression upon treatment with chemotherapeutic drugs that activate p53, including 5-fluorouracil, etoposide and cisplatin. Contrary to expectation, these drugs induced A3B expression and concomitant cellular cytosine deaminase activity. A3B induction was p53-independent, as chemotherapy drugs stimulated A3B expression in p53 mutant cells. These drugs commonly activate ATM, ATR and DNA-PKcs. Using specific inhibitors and gene knockdowns, we show that activation of DNA-PKcs and ATM by chemotherapeutic drugs promotes NF-kappa B activity, with consequent recruitment of NF-kappa B to the A3B gene promoter to drive A3B expression. Further, we find that A3B knockdown re-sensitises resistant cells to cisplatin, and A3B knockout enhances sensitivity to chemotherapy drugs. Our data highlight a role for A3B in resistance to chemotherapy and indicate that stimulation of A3B expression by activation of DNA repair and NF-kappa B pathways could promote cancer mutations and expedite chemoresistance.	[Periyasamy, Manikandan; Singh, Anup K.; Gemma, Carolina; Farzan, Raed; Cunnea, Paula; Coombes, R. Charles; Buluwela, Lakjaya; Ali, Simak] Imperial Coll London, Dept Surg & Canc, London W12 0NN, England; [Allsopp, Rebecca C.; Shaw, Jacqueline A.] Univ Leicester, Dept Canc Studies & Canc Res UK, Leicester Ctr, Leicester, Leics, England; [Charmsaz, Sara; Young, Leonie S.] Royal Coll Surgeons Ireland, Dept Surg, Endocrine Oncol Res Grp, Dublin, Ireland; [Gyorffy, Balazs] Semmelweis Univ, Dept Bioinformat, Budapest, Hungary; [Gyorffy, Balazs] Semmelweis Univ, Dept Pediat 2, Budapest, Hungary; [Gyorffy, Balazs] Inst Enzymol, MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary; [Farzan, Raed] King Saud Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Riyadh, Saudi Arabia	Imperial College London; University of Leicester; Royal College of Surgeons - Ireland; Semmelweis University; Semmelweis University; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; King Saud University	Ali, S (corresponding author), Imperial Coll London, Dept Surg & Canc, London W12 0NN, England.	simak.ali@imperial.ac.uk	Gyorffy, Balazs/AAA-9135-2021; Farzan, Raed/AAD-2486-2020; Ali, Simak/M-6912-2018	Gyorffy, Balazs/0000-0002-5772-3766; Farzan, Raed/0000-0003-1189-6319; Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816; Cunnea, Paula/0000-0002-3699-4911; Gemma, Carolina/0000-0002-4890-9972; Shaw, Jacqui/0000-0003-4227-503X; Periyasamy, Manikandan/0000-0001-7626-2531	Cancer Research UK [C37/A18784]; LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre; Cancer Research UK Imperial Centre	Cancer Research UK(Cancer Research UK); LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility; Imperial Experimental Cancer Medicine Centre; Imperial NIHR Biomedical Research Centre(National Institute for Health Research (NIHR)); Cancer Research UK Imperial Centre	We thank Dr B Vogelstein for p53-null HCT116 cells. We are grateful to Dr S Langdon for the PEA1 and PEA2 lines. Our thanks also go to Drs. S Hong and L Magnani for their kind gift of PEOO3 cells. This study was supported by Cancer Research UK grant C37/A18784. We thank the LMS/NIHR Imperial Biomedical Research Centre Flow Cytometry Facility for support. Additional support was provided by the Imperial Experimental Cancer Medicine Centre, Imperial NIHR Biomedical Research Centre, and the Cancer Research UK Imperial Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.	Andrysik Z, 2017, GENOME RES, V27, P1645, DOI 10.1101/gr.220533.117; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Ding QR, 2013, CELL STEM CELL, V12, P393, DOI 10.1016/j.stem.2013.03.006; Faltas BM, 2016, NAT GENET, V48, P1490, DOI 10.1038/ng.3692; Fang Y, 2015, MOL CELL BIOCHEM, V399, P269, DOI 10.1007/s11010-014-2253-6; Gadducci A, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0484-6; Gavande NS, 2016, PHARMACOL THERAPEUT, V160, P65, DOI 10.1016/j.pharmthera.2016.02.003; Green AM, 2019, DNA REPAIR, V83, DOI 10.1016/j.dnarep.2019.102700; Hadian K, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001712; Hong SP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11721-9; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; KUBO K, 1992, BIOCHEMISTRY-US, V31, P3703, DOI 10.1021/bi00129a020; LANGDON SP, 1988, CANCER RES, V48, P6166; Law EK, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601737; Leonard B, 2016, CLIN CANCER RES, V22, P4746, DOI 10.1158/1078-0432.CCR-15-2910; Leonard B, 2015, CANCER RES, V75, P4538, DOI 10.1158/0008-5472.CAN-15-2171-T; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Maruyama W, 2016, BIOCHEM BIOPH RES CO, V478, P1466, DOI 10.1016/j.bbrc.2016.08.148; McDaniel YZ, 2020, NUCLEIC ACIDS RES, V48, P1353, DOI 10.1093/nar/gkz1164; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Menendez D, 2017, MOL CANCER RES, V15, P735, DOI 10.1158/1541-7786.MCR-17-0019; Nik-Zainal S, 2014, NAT GENET, V46, P487, DOI 10.1038/ng.2955; Nowarski R, 2012, BLOOD, V120, P366, DOI 10.1182/blood-2012-01-402123; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Peng YL, 2005, CANCER RES, V65, P1670, DOI 10.1158/0008-5472.CAN-04-3451; Periyasamy M, 2017, NUCLEIC ACIDS RES, V45, P11056, DOI 10.1093/nar/gkx721; Periyasamy M, 2015, CELL REP, V13, P108, DOI 10.1016/j.celrep.2015.08.066; Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484; Pommier Y, 2014, DNA REPAIR, V19, P114, DOI 10.1016/j.dnarep.2014.03.020; Poulos RC, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007779; Rajagopalan S, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000467; Refsland EW, 2010, NUCLEIC ACIDS RES, V38, P4274, DOI 10.1093/nar/gkq174; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Roper N, 2019, CELL REP, V26, P2651, DOI 10.1016/j.celrep.2019.02.028; Sabatel H, 2011, BIOCHEM PHARMACOL, V82, P1371, DOI 10.1016/j.bcp.2011.07.105; Salter JD, 2016, TRENDS BIOCHEM SCI, V41, P578, DOI 10.1016/j.tibs.2016.05.001; Schmitt C, 2018, ONCOL REP, V40, P2742, DOI 10.3892/or.2018.6698; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Serebrenik AA, 2020, CLIN CANCER RES, V26, P3397, DOI 10.1158/1078-0432.CCR-19-2786; Stenglein MD, 2010, NAT STRUCT MOL BIOL, V17, P222, DOI 10.1038/nsmb.1744; Strickson S, 2013, BIOCHEM J, V451, P427, DOI 10.1042/BJ20121651; Stronach EA, 2011, NEOPLASIA, V13, P1069, DOI 10.1593/neo.111032; Sur S, 2009, P NATL ACAD SCI USA, V106, P3964, DOI 10.1073/pnas.0813333106; Taylor BJM, 2013, ELIFE, V2, DOI 10.7554/eLife.00534; Treiber T, 2017, MOL CELL, V66, P270, DOI 10.1016/j.molcel.2017.03.014; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Venkatesan S, 2018, ANN ONCOL, V29, P563, DOI 10.1093/annonc/mdy003; Wilson DM, 2010, TRENDS BIOCHEM SCI, V35, P247, DOI 10.1016/j.tibs.2010.01.003; Wyatt MD, 2009, CELL MOL LIFE SCI, V66, P788, DOI 10.1007/s00018-008-8557-5; Zaky A, 2008, NUCLEIC ACIDS RES, V36, P1555, DOI 10.1093/nar/gkm1173	58	8	8	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1077	1090		10.1038/s41388-020-01583-7	http://dx.doi.org/10.1038/s41388-020-01583-7		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323971	Green Submitted, Green Accepted			2022-12-17	WOS:000599126500005
J	Shi, CX; Yang, EJ; Liu, YF; Mou, PK; Ren, GW; Shim, JS				Shi, Changxiang; Yang, Eun Ju; Liu, Yifan; Mou, Pui Kei; Ren, Guowen; Shim, Joong Sup			Bromodomain and extra-terminal motif (BET) inhibition is synthetic lethal with loss of SMAD4 in colorectal cancer cells via restoring the loss of MYC repression	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; TUMOR-SUPPRESSOR; C-MYC; DOSE-ESCALATION; DNA-BINDING; DPC4; EXPRESSION; DOMAIN; GENE	The tumor suppressor SMAD4 is frequently mutated in colorectal cancer (CRC). However, no effective targeted therapies exist for CRC with SMAD4 loss. Here, we employed a synthetic lethality drug screening in isogenic SMAD4(+/+) and SMAD4(-/-) HCT116 CRC cells and found that bromodomain and extra-terminal motif (BET) inhibitors, as selective drugs for the growth of SMAD4(-/-) HCT116 cells. BET inhibition selectively induced G1 cell cycle arrest in SMAD4(-/-) cells and this effect was accompanied by the reprogramming of the MYC-p21 axis. Mechanistically, SMAD4 is a transcription repressor of MYC, and MYC in turn represses p21 transcription. SMAD4(-/-) cells lost MYC repression ability, thereby causing the cells addicted to the MYC oncogenic signaling. BET inhibition significantly reduced MYC level and restored p21 expression in SMAD4(-/-) cells, inducing the selective growth arrest. The ectopic overexpression of MYC or the silencing of p21 could rescue the BET inhibitor-induced growth arrest in SMAD4(-/-) cells, verifying this model. Tumor xenograft mouse experiments further demonstrated the synthetic lethality interaction between BET and SMAD4 in vivo. Taken together, our data suggest that BET could be a potential drug target for the treatment of SMAD4-deficient CRC.	[Shi, Changxiang; Yang, Eun Ju; Liu, Yifan; Mou, Pui Kei; Ren, Guowen; Shim, Joong Sup] Univ Macau, Fac Hlth Sci, Canc Ctr, Ave Univ, Taipa, Macau, Peoples R China	University of Macau	Shim, JS (corresponding author), Univ Macau, Fac Hlth Sci, Canc Ctr, Ave Univ, Taipa, Macau, Peoples R China.	jsshim@um.edu.mo	Shim, Joong Sup/G-8383-2011	Shim, Joong Sup/0000-0003-0167-7307	University of Macau [MYRG2019-00116-FHS, MYRG2017-00176-FHS]	University of Macau	We thank to the members of the FHS Animal Facility, Biological Imaging and Stem Cell Core, and Genomics, Bioinformatics and Single Cell Core at the University of Macau for experimental and technical supports. This study was supported by the Multi-Year Research Grants (MYRG2019-00116-FHS and MYRG2017-00176-FHS) to JSS from the University of Macau.	Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Alazzouzi H, 2005, CLIN CANCER RES, V11, P2606, DOI 10.1158/1078-0432.CCR-04-1458; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Alqahtani A, 2019, FUTUR SCI OA, V5, DOI 10.4155/fsoa-2018-0115; Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Choi PS, 2014, P NATL ACAD SCI USA, V111, pE3316, DOI 10.1073/pnas.1406123111; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; deCaestecker MP, 1997, J BIOL CHEM, V272, P13690, DOI 10.1074/jbc.272.21.13690; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dong XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0181-6; Doroshow DB, 2017, ANN ONCOL, V28, P1776, DOI 10.1093/annonc/mdx157; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241; Gadir N, 2008, ONCOGENE, V27, P1055, DOI 10.1038/sj.onc.1210721; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garcia-Gutierrez L, 2019, GENES-BASEL, V10, DOI 10.3390/genes10030244; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Jones JB, 2000, NUCLEIC ACIDS RES, V28, P2363, DOI 10.1093/nar/28.12.2363; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]; Lewin J, 2018, J CLIN ONCOL, V36, P3007, DOI 10.1200/JCO.2018.78.2292; Li Y, 2014, J INTERN MED, V276, P52, DOI 10.1111/joim.12237; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyaki M, 2003, BIOCHEM BIOPH RES CO, V306, P799, DOI 10.1016/S0006-291X(03)01066-0; Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269; Peterfia B, 2017, J CANCER, V8, P162, DOI 10.7150/jca.16037; Picaud S, 2013, CANCER RES, V73, P3336, DOI 10.1158/0008-5472.CAN-12-3292; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090; Wang H, 2006, CANCER RES, V66, P9722, DOI 10.1158/0008-5472.CAN-05-4602; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939; Zhang BY, 2018, ONCOGENE, V37, P6341, DOI 10.1038/s41388-018-0408-8	61	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2021	40	5					937	950		10.1038/s41388-020-01580-w	http://dx.doi.org/10.1038/s41388-020-01580-w		DEC 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC5NB	33293694				2022-12-17	WOS:000599053400001
J	Bala, P; Singh, AK; Kavadipula, P; Kotapalli, V; Sabarinathan, R; Bashyam, MD				Bala, Pratyusha; Singh, Anurag Kumar; Kavadipula, Padmavathi; Kotapalli, Viswakalyan; Sabarinathan, Radhakrishnan; Bashyam, Murali Dharan			Exome sequencing identifies ARID2 as a novel tumor suppressor in early-onset sporadic rectal cancer	ONCOGENE			English	Article							CHROMATIN-REMODELING COMPLEX; INACTIVATING MUTATIONS; GENOME; GENE; REQUIRES; SUBUNIT; BAF200; CELLS; APC	Early-onset sporadic rectal cancer (EOSRC) is a unique and predominant colorectal cancer (CRC) subtype in India. In order to understand the tumorigenic process in EOSRC, we performed whole-exome sequencing of 47 microsatellite stable EOSRC samples. Signature 1 was the predominant mutational signature in EOSRC, as previously shown in other CRC exome studies. More importantly, we identified TP53, KRAS, APC, PIK3R1, SMAD4 and ZNF880 as significantly mutated (q < 0.1) and ARID1A and ARID2 as near-significantly mutated (restricted hypothesis testing; q < 0.1) candidate drivers. Unlike the other candidates, the tumorigenic potential of ARID2, encoding a component of the SWI/SNF chromatin remodeling complex, is largely unexplored in CRC. shRNA-mediated ARID2 knockdown performed in different CRC cell lines resulted in significant alterations in transcript levels of cancer-related target genes. More importantly, ARID2 knockdown promoted several tumorigenic features including cell viability, proliferation, ability to override contact inhibition of growth, and migration besides significantly increasing tumor formation ability in nude mice. The observed gain in tumorigenic features was rescued upon ectopic expression of wild type but not mutant ARID2. Analyses of the TCGA pan-cancer dataset revealed several modes of ARID2 inactivation and of the CRC dataset revealed poorer survival in patients with ARID2 alterations. We therefore propose ARID2 as a novel tumor suppressor in CRC.	[Bala, Pratyusha; Kavadipula, Padmavathi; Kotapalli, Viswakalyan; Bashyam, Murali Dharan] Ctr DNA Fingerprinting & Diagnost, Lab Mol Oncol, Hyderabad 500039, India; [Bala, Pratyusha] Manipal Acad Higher Educ, Grad Studies, Manipal 576104, India; [Singh, Anurag Kumar; Sabarinathan, Radhakrishnan] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India	Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Manipal Academy of Higher Education (MAHE); Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Bashyam, MD (corresponding author), Ctr DNA Fingerprinting & Diagnost, Lab Mol Oncol, Hyderabad 500039, India.	bashyam@cdfd.org.in		Bashyam, M D/0000-0002-1967-5249	Department of Science and Technology, Government of India [SB/SO/HS-007/2013]; University Grants Commission, Government of India; NCBS-TIFR; Ramanujan fellowship (SERB) [SB/S2/RJN-071/2018]; Department of Atomic Energy, Government of India [12-RD-TFR-5.04-0800]	Department of Science and Technology, Government of India(Department of Science & Technology (India)); University Grants Commission, Government of India(University Grants Commission, India); NCBS-TIFR; Ramanujan fellowship (SERB); Department of Atomic Energy, Government of India(Department of Atomic Energy (DAE))	We thank the patients for kindly agreeing to be a part of the study. We are grateful to Dr Swarnalata Gowrishankar, Apollo Hospitals, Hyderabad and Dr Satish Rao, Krishna Institute of Medical Sciences, Hyderabad for evaluation of ARID2 IHC stains on CRC TMA. We also thank Dr Asmita Gupta, Department of Science and Technology National Postdoctoral Fellow, Laboratory of Molecular Oncology, CDFD, Hyderabad, for help in generating Fig. S4a. The work was supported by a grant (SB/SO/HS-007/2013) from the Department of Science and Technology, Government of India to MDB. PB, a registered PhD student of Manipal Academy of Higher Education, is grateful to the University Grants Commission, Government of India for junior and senior research fellowships. We acknowledge CDFD's Sophisticated Equipment Facility for fluorescence microscopy and Sanger sequencing and the Experimental Animal Facility, for nude mice experiments. RS acknowledges funding support from NCBS-TIFR, and Ramanujan fellowship (SERB, SB/S2/RJN-071/2018). RS and AKS acknowledge support of the Department of Atomic Energy, Government of India, under project no. 12-R&D-TFR-5.04-0800.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2013, CLIN TRANSL GASTROEN, V4, pe39, DOI DOI 10.1038/ncomms3873; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Bracken AP, 2019, GENE DEV, V33, P936, DOI 10.1101/gad.326066.119; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cajuso T, 2014, INT J CANCER, V135, P611, DOI 10.1002/ijc.28705; Carlson RV, 2004, BRIT J CLIN PHARMACO, V57, P695, DOI 10.1111/j.1365-2125.2004.02103.x; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; de Castro RO, 2017, J BIOL CHEM, V292, P8459, DOI 10.1074/jbc.M117.778183; de la Chapelle A, 2010, J CLIN ONCOL, V28, P3380, DOI 10.1200/JCO.2009.27.0652; Duan YJ, 2016, ONCOTARGET, V7, P45863, DOI 10.18632/oncotarget.10244; Ellrott K, 2018, CELL SYST, V6, P271, DOI 10.1016/j.cels.2018.03.002; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Gaedcke J, 2010, RADIOTHER ONCOL, V94, P76, DOI 10.1016/j.radonc.2009.10.001; Garcia M, 2018, BIORXIV, DOI [10.1101/316976, DOI 10.1101/316976]; Gori K., 2018, SIGFIT FLEXIBLE BAYE, DOI [10.1101/372896, DOI 10.1101/372896]; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hofseth LJ, 2020, NAT REV GASTRO HEPAT, V17, P352, DOI 10.1038/s41575-019-0253-4; Jones RP, 2017, BRIT J CANCER, V116, P923, DOI 10.1038/bjc.2017.37; Kadoch C, 2013, NAT GENET, V45, P592, DOI 10.1038/ng.2628; Karczewski K.J., 2019, GENOMICS, DOI [10.1101/531210, DOI 10.1101/531210]; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Kumar R, 2018, GENE CHROMOSOME CANC, V57, P304, DOI 10.1002/gcc.22531; Kumar R, 2018, J MOL MED, V96, P135, DOI 10.1007/s00109-017-1607-4; Kurosaki T, 2019, NAT REV MOL CELL BIO, V20, P406, DOI 10.1038/s41580-019-0126-2; Laskar RS, 2015, MOL CARCINOGEN, V54, P1786, DOI 10.1002/mc.22250; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Martincorena I, 2018, CELL, V173, P1823, DOI 10.1016/j.cell.2018.06.001; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Meisenberg C, 2019, MOL CELL, V73, P212, DOI 10.1016/j.molcel.2018.11.001; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mularoni L, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0994-0; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neumann J, 2009, PATHOL RES PRACT, V205, P858, DOI 10.1016/j.prp.2009.07.010; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Raman R, 2014, MOL CARCINOGEN, V53, pE181, DOI 10.1002/mc.21976; Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929; Schell MJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11743; Shorstova T, 2019, CANCER RES, V79, P2761, DOI 10.1158/0008-5472.CAN-18-1545; Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1; Tamborero D, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0531-8; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Wall JD, 2019, NATURE, V576, P106, DOI 10.1038/s41586-019-1793-z; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Wang JY, 2007, HEPATO-GASTROENTEROL, V54, P2259; Xu FH, 2012, J BIOL CHEM, V287, P5033, DOI 10.1074/jbc.M111.279968; Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805	54	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					863	874		10.1038/s41388-020-01537-z	http://dx.doi.org/10.1038/s41388-020-01537-z		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33262464	Green Submitted			2022-12-17	WOS:000595928700004
J	Guha, P; Gardell, J; Rabinowitz, B; Lopes, M; DaSilva, NA; Rowley, D; Katz, SC				Guha, Prajna; Gardell, Jillian; Rabinowitz, Benjamin; Lopes, Mikayla; DaSilva, Nicholas A.; Rowley, David; Katz, Steven C.			Monocytic and granulocytic myeloid-derived suppressor cell plasticity and differentiation are organ-specific	ONCOGENE			English	Article							LIVER METASTASES; CANCER; ANERGY; MICE	Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that proliferate in the setting of cancer and have potent immunosuppressive functions hindering anti-tumor immunity. Here we establish that the immunologic landscape and tumor microenvironments (TME) vary between different organs which discretely shape MDSC repertoires. We found that pSTAT3 signaling exerts a dominant effect on MDSC programming in liver metastasis (LM). In contrast, in lung metastasis (LuM), MDSC programming is driven mainly by pSTAT5. Adoptive transfer of LM-MDSC into LuM resulted in a shift from pSTAT3 signaling to pSTAT5, in association with an overall shift toward lung MDSC programming. A shift from more immunosuppressive M-MDSC to G-MDSC, along with enhanced differentiation of MDSCs into pro-inflammatory M1 macrophages in LuM, indicated that MDSC plasticity and differentiation patterns are environmentally dependent. Using mass spectroscopy, we confirmed that LM-MDSCs showed enhanced expression of key proliferation pathway markers. This confirmed that liver-specific MDSC programing was comprehensive but reversible, implying that therapeutic targeting of LM-MDSC could prime the TME in a favorable manner. Our data suggest that MDSC programming in response to malignancy is highly dependent on organ-specific conditions and is modifiable.	[Guha, Prajna; Gardell, Jillian; Rabinowitz, Benjamin; Lopes, Mikayla; Katz, Steven C.] Roger Williams Med Ctr, Immunooncol Inst, Providence, RI 02908 USA; [Guha, Prajna; Gardell, Jillian; Rabinowitz, Benjamin; Lopes, Mikayla; Katz, Steven C.] Roger Williams Med Ctr, Dept Med, Immunotherapy Serv, Providence, RI 02908 USA; [Guha, Prajna; Katz, Steven C.] Boston Univ, Dept Surg, Sch Med, Boston, MA 02215 USA; [Guha, Prajna; DaSilva, Nicholas A.; Rowley, David; Katz, Steven C.] Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA	Roger Williams Medical Center; Roger Williams Medical Center; Boston University; University of Rhode Island	Katz, SC (corresponding author), Roger Williams Med Ctr, Immunooncol Inst, Providence, RI 02908 USA.; Katz, SC (corresponding author), Roger Williams Med Ctr, Dept Med, Immunotherapy Serv, Providence, RI 02908 USA.; Katz, SC (corresponding author), Boston Univ, Dept Surg, Sch Med, Boston, MA 02215 USA.; Katz, SC (corresponding author), Univ Rhode Isl, Dept Biomed & Pharmaceut Sci, Kingston, RI 02881 USA.	skatz@chartercare.org	Lopes, Mikayla C/GRO-2554-2022	Rowley, David/0000-0001-7808-1312				Amici SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01593; Bronte V, 2005, NAT REV IMMUNOL, V5, P641, DOI 10.1038/nri1668; Burga RA, 2015, CANCER IMMUNOL IMMUN, V64, P817, DOI 10.1007/s00262-015-1692-6; Centuori SM, 2012, J LEUKOCYTE BIOL, V92, P987, DOI 10.1189/jlb.0911465; Chan T, 2011, INT IMMUNOPHARMACOL, V11, P879, DOI 10.1016/j.intimp.2010.12.024; Cheng HY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00421; Chiu DKC, 2016, HEPATOLOGY, V64, P797, DOI 10.1002/hep.28655; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Guha P, 2017, CANCER GENE THER, V24, P114, DOI 10.1038/cgt.2016.54; Guha P, 2019, ONCOGENE, V38, P533, DOI 10.1038/s41388-018-0449-z; Hardy LL, 2008, J IMMUNOL, V180, P5956, DOI 10.4049/jimmunol.180.9.5956; Hawila E, 2017, CELL REP, V21, P2212, DOI 10.1016/j.celrep.2017.10.104; Horst AK, 2016, CELL MOL IMMUNOL, V13, P277, DOI 10.1038/cmi.2015.112; Huang B, 2006, CANCER RES, V66, P1123, DOI 10.1158/0008-5472.CAN-05-1299; Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342; Jones RP, 2017, LIVER CANCER, V6, P66, DOI 10.1159/000449348; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Kolahian S, 2016, EUR RESPIR J, V47, P967, DOI 10.1183/13993003.01572-2015; Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240; Lin A, 2010, IMMUNOL LETT, V127, P77, DOI 10.1016/j.imlet.2009.09.003; Nefedova Y, 2005, CANCER RES, V65, P9525, DOI 10.1158/0008-5472.CAN-05-0529; Oliver AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00070; Perez-Soler R, 2004, CLIN CANCER RES, V10, p4238S, DOI 10.1158/1078-0432.CCR-040017; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Qin SG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00307; Rodriguez PC, 2008, IMMUNOL REV, V222, P180, DOI 10.1111/j.1600-065X.2008.00608.x; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; Thorn M, 2016, CANCER GENE THER, V23, P188, DOI 10.1038/cgt.2016.19; Thorn M, 2014, J LEUKOCYTE BIOL, V96, P883, DOI 10.1189/jlb.3A0114-012RR; Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611; Waight JD, 2013, J CLIN INVEST, V123, P4464, DOI 10.1172/JCI68189; Zheng PP, 2018, DRUG DISCOV TODAY, V23, P1175, DOI 10.1016/j.drudis.2018.02.012	33	8	8	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					693	704		10.1038/s41388-020-01559-7	http://dx.doi.org/10.1038/s41388-020-01559-7		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33230244				2022-12-17	WOS:000591948700001
J	Hu, ZH; Wang, XH; Li, D; Cao, LD; Cui, HX; Xu, GQ				Hu, Zhanhong; Wang, Xiaohui; Li, Dan; Cao, Lindong; Cui, Hongxia; Xu, Guoqiang			UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2	ONCOGENE			English	Article							CANCER CELLS; INHIBITION; EXPRESSION; RESISTANCE; UFM1	The key component in the UFM1 conjugation system, UFM1-binding and PCI domain-containing protein 1 (UFBP1), regulates many biological processes. Recently it has been shown that low UFBP1 protein level is associated with the worse outcome of gastric cancer patients. However, how it responses to the sensitivity of gastric cancer to chemotherapy drugs and the underlying molecular mechanism remain elusive. Here, we discovered that high UFBP1 expression increases the progression-free survival of advanced gastric cancer patients treated with platinum-based chemotherapy. Cell-line based studies unveiled that UFBP1 expression enhances while UFBP1 knockdown attenuates the sensitivity of gastric cancer cells to cisplatin. High-throughput SILAC-based quantitative proteomic analysis revealed that the protein level of aldo-keto reductase 1Cs (AKR1Cs) is significantly downregulated by UFBP1. Flow cytometry analysis showed that UFBP1 expression increases while UFBP1 knockdown reduces reactive oxygen species upon cisplatin treatment. We further disclosed that UFBP1 attenuates the gene expression of AKR1Cs and the transcription activity of the master oxidative stress-response transcription factor Nrf2 (nuclear factor erythroid-2-related factor 2). Detailed mechanistic studies manifested that UFBP1 promotes the formation of K48-linked polyubiquitin chains on Nrf2 and thus augments its proteasome-mediated degradation. Experiments using genetic depletion and pharmacological activation in vitro and in vivo demonstrated that UFBP1 enhances the sensitivity of gastric cancer cells to cisplatin through the Nrf2/AKR1C axis. Overall, this work discovered a novel prognostic biomarker for gastric cancer patients treated with platinum-based chemotherapy and elucidated the underlying molecular mechanism, which may benefit to future personalized chemotherapy.	[Hu, Zhanhong; Wang, Xiaohui; Li, Dan; Cao, Lindong; Xu, Guoqiang] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215123, Jiangsu, Peoples R China; [Hu, Zhanhong; Wang, Xiaohui; Li, Dan; Cao, Lindong; Xu, Guoqiang] Soochow Univ, Coll Pharmaceut Sci, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Suzhou 215123, Jiangsu, Peoples R China; [Hu, Zhanhong] Soochow Univ, Dept Pharm, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China; [Cui, Hongxia] Soochow Univ, Dept Pathol, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Soochow University - China	Xu, GQ (corresponding author), Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou 215123, Jiangsu, Peoples R China.; Xu, GQ (corresponding author), Soochow Univ, Coll Pharmaceut Sci, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Suzhou 215123, Jiangsu, Peoples R China.	gux2002@suda.edu.cn	Xiaohui, Wang/AFS-7746-2022	Xu, Guoqiang/0000-0002-4753-4769	National Key R&D Program of China [2019YFA0802400]; National Natural Science Foundation of China [31700722, 31971353]; Suzhou Bureau of Science and Technology (Basic Research in Medical and Health Sciences) [SYS201718]; Talent Program in Six Major Disciplines in Jiangsu Province [SWYY-080]; Open Project of Jiangsu Key Laboratory of Neuropsychiatric Diseases [KIS1722]; Open Project Program of the State Key Laboratory of Proteomics [SKLP-O201905]; Postgraduate Research & Practice Innovation Program of Jiangsu Province [KYCX17_2040]; Natural Science Foundation of Jiangsu Higher Education Institutes of China [17KJA180010]; National Center for International Research [2017B01012]; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Suzhou Bureau of Science and Technology (Basic Research in Medical and Health Sciences); Talent Program in Six Major Disciplines in Jiangsu Province; Open Project of Jiangsu Key Laboratory of Neuropsychiatric Diseases; Open Project Program of the State Key Laboratory of Proteomics; Postgraduate Research & Practice Innovation Program of Jiangsu Province; Natural Science Foundation of Jiangsu Higher Education Institutes of China; National Center for International Research; Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions	We are grateful to Drs. Xinliang Mao (Soochow University) and Siwang Yu (Peking University) for kindly providing plasmids and to Dr. Guanghui Wang (Soochow University) for fruitful discussion. MS analyses were performed at the Mass Spectrometry core facility of the Medical School of Soochow University. This work was supported by the National Key R&D Program of China (2019YFA0802400), the National Natural Science Foundation of China (31700722 & 31971353), Suzhou Bureau of Science and Technology (Basic Research in Medical and Health Sciences, SYS201718), Talent Program in Six Major Disciplines in Jiangsu Province (SWYY-080), Open Project of Jiangsu Key Laboratory of Neuropsychiatric Diseases (KIS1722), Open Project Program of the State Key Laboratory of Proteomics (SKLP-O201905), Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX17_2040), Natural Science Foundation of Jiangsu Higher Education Institutes of China (17KJA180010), National Center for International Research (2017B01012), a project funded by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions.	Bortolozzi R, 2018, BRIT J CANCER, V118, P985, DOI 10.1038/s41416-018-0014-0; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cai YF, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-018-0070-x; Cai YF, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005643; Chen CC, 2013, BIOCHEM PHARMACOL, V86, P872, DOI 10.1016/j.bcp.2013.07.025; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Duan QQ, 2019, J PROTEOME RES, V18, P2903, DOI 10.1021/acs.jproteome.9b00208; Egunsola AT, 2017, J CLIN INVEST, V127, P1475, DOI 10.1172/JCI90193; Gambardella V, 2019, CLIN CANCER RES, V25, P1639, DOI 10.1158/1078-0432.CCR-18-2421; Guo DK, 2019, ACTA PHARMACOL SIN, V40, P26, DOI 10.1038/s41401-018-0064-0; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Hou XO, 2015, ACTA PHARMACOL SIN, V36, P1300, DOI 10.1038/aps.2015.54; Hu SQ, 2015, CNS NEUROSCI THER, V21, P953, DOI 10.1111/cns.12472; Ivanova T, 2013, GUT, V62, P22, DOI 10.1136/gutjnl-2011-301113; Jung KA, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/423965; Lee JY, 2017, J GENET, V96, P1041, DOI 10.1007/s12041-017-0854-z; Liang JR, 2020, CELL, V180, P1160, DOI 10.1016/j.cell.2020.02.017; Lin JX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1416-4; Lin JX, 2018, WORLD J GASTROENTERO, V24, P3898, DOI 10.3748/wjg.v24.i34.3898; Liu J, 2020, NAT CELL BIOL, V22, P1056, DOI 10.1038/s41556-020-0559-z; Neziri Dashurie, 2016, J Nephropathol, V5, P65, DOI 10.15171/jnp.2016.13; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Qin B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09175-0; Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010; Rukova B, 2014, BIOTECHNOL BIOTEC EQ, V28, P518, DOI 10.1080/13102818.2014.933501; Tanaka Y, 2011, HUM MOL GENET, V20, P3507, DOI 10.1093/hmg/ddr249; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Walczak CP, 2019, P NATL ACAD SCI USA, V116, P1299, DOI 10.1073/pnas.1816202116; Wang LH, 2020, CELL RES, V30, DOI 10.1038/s41422-019-0236-6; Wang SY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.450; Wang XJ, 2006, CANCER RES, V66, P10983, DOI 10.1158/0008-5472.CAN-06-2298; Wang ZF, 2019, NUCLEIC ACIDS RES, V47, P4124, DOI 10.1093/nar/gkz110; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Wu TD, 2014, GENE DEV, V28, P708, DOI 10.1101/gad.238246.114; Xi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064231; Xu GQ, 2013, J BIOL CHEM, V288, P29573, DOI 10.1074/jbc.M113.472092; Yakirevich E, 2016, CLIN CANCER RES, V22, P3831, DOI 10.1158/1078-0432.CCR-15-3000; Yoo HM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00036; Yoo HM, 2014, MOL CELL, V56, P261, DOI 10.1016/j.molcel.2014.08.007; Zhao Y, 2016, CHEM BIODIVERS, V13, P1186, DOI 10.1002/cbdv.201600012; Zhu Y, 2018, J PROTEOME RES, V17, P1509, DOI 10.1021/acs.jproteome.7b00843	43	8	8	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					647	662		10.1038/s41388-020-01551-1	http://dx.doi.org/10.1038/s41388-020-01551-1		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33219317				2022-12-17	WOS:000591146100002
J	Guan, XW; Deng, HL; Choi, UL; Li, ZF; Yang, YQ; Zeng, JM; Liu, YZ; Zhang, XJ; Li, G				Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang			EZH2 overexpression dampens tumor-suppressive signals via anEGR1silencer to drive breast tumorigenesis	ONCOGENE			English	Article							HISTONE METHYLTRANSFERASE EZH2; GROUP PROTEIN EZH2; TRANSCRIPTION FACTOR; DEVELOPMENTAL REGULATORS; CHIP-SEQ; POLYCOMB; EXPRESSION; GENE; CANCER; GROWTH	The mechanism underlying EZH2 overexpression in breast cancer and its involvement in tumorigenesis remain poorly understood. In this study, we developed an approach to systematically identify the trans-acting factors regulating the EZH2 expression, and identified more than 20 such factors. We revealed reciprocal regulation of early growth response 1 (EGR1) and EZH2: EGR1 activates the expression of EZH2, and EZH2 represses EGR1 expression. Using CRISPR-mediated genome/epigenome editing, we demonstrated that EHZ2 represses EGR1 expression through a silencer downstream of theEGR1gene. Deletion of theEGR1silencer resulted in reduced cell growth, invasion, tumorigenicity of breast cancer cells, and extensive changes in gene expression, such as upregulation of GADD45, DDIT3, and RND1; and downregulation of genes encoding cholesterol biosynthesis pathway enzymes. We hypothesize that EZH2/PRC2 acts as a "brake" for EGR1 expression by targeting theEGR1silencer, and EZH2 overexpression dampens tumor-suppressive signals mediated by EGR1 to drive breast tumorigenesis.	[Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang] Univ Macau, Fac Hlth Sci, Macau, Peoples R China; [Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang] Univ Macau, Fac Hlth Sci, Ctr Canc, Macau, Peoples R China; [Guan, Xiaowen; Deng, Houliang; Choi, Un Lam; Li, Zhengfeng; Yang, Yiqi; Zeng, Jianming; Liu, Yunze; Zhang, Xuanjun; Li, Gang] Univ Macau, Fac Hlth Sci, Inst Translat Med, Ctr Reprod Dev & Aging, Macau, Peoples R China	University of Macau; University of Macau; University of Macau	Li, G (corresponding author), Univ Macau, Fac Hlth Sci, Macau, Peoples R China.; Li, G (corresponding author), Univ Macau, Fac Hlth Sci, Ctr Canc, Macau, Peoples R China.; Li, G (corresponding author), Univ Macau, Fac Hlth Sci, Inst Translat Med, Ctr Reprod Dev & Aging, Macau, Peoples R China.	gangli@um.edu.mo		deng, houliang/0000-0002-7217-0063; Liu, Yunze/0000-0002-7414-8556	Science and Technology Development Fund, Macau SAR [137/2014/A3, 095/2015/A3]; Science and Technology Program of Guangzhou, China [201807010101]; Research & Development Administration Office of the University of Macau [MYRG201700099, MYRG2018-00022]	Science and Technology Development Fund, Macau SAR; Science and Technology Program of Guangzhou, China; Research & Development Administration Office of the University of Macau	This work was funded by the Science and Technology Development Fund, Macau SAR (File no. 137/2014/A3 and 095/2015/A3), the Science and Technology Program of Guangzhou, China (201807010101), and the Research & Development Administration Office of the University of Macau (MYRG201700099, MYRG2018-00022) awarded to GL.	Alajez NM, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.64; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Bahrami Shahram, 2016, Advances in Biological Regulation, V62, P37, DOI 10.1016/j.jbior.2016.05.001; Barbieri E, 2018, MOL CELL, V71, P103, DOI 10.1016/j.molcel.2018.05.031; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Bhattacharyya S, 2013, J PATHOL, V229, P286, DOI 10.1002/path.4131; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Breuer RHJ, 2004, NEOPLASIA, V6, P736, DOI 10.1593/neo.04160; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118; Gibbs J, 2008, ONCOGENE, V27, P98, DOI 10.1038/sj.onc.1210627; Gnad F, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S8-S5; Gokey NG, 2011, J BIOL CHEM, V286, P29501, DOI 10.1074/jbc.M111.263509; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Kalashnikova EV, 2010, CANCER RES, V70, P9402, DOI 10.1158/0008-5472.CAN-10-1199; Keilwagen J, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1614-y; Khan A, 2018, NUCLEIC ACIDS RES, V46, pD1284, DOI 10.1093/nar/gkx1188; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327; Koppens M, 2016, ONCOGENE, V35, P1341, DOI 10.1038/onc.2015.195; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lejard V, 2011, J BIOL CHEM, V286, P5855, DOI 10.1074/jbc.M110.153106; Lin YW, 2013, J PATHOL, V230, P277, DOI 10.1002/path.4179; Liu CT, 1998, CANCER GENE THER, V5, P3; Mahara S, 2016, P NATL ACAD SCI USA, V113, pE3735, DOI 10.1073/pnas.1602079113; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; McCabe MT, 2014, EPIGENOMICS-UK, V6, P341, DOI [10.2217/EPI.14.23, 10.2217/epi.14.23]; Mei SL, 2017, NUCLEIC ACIDS RES, V45, pD658, DOI 10.1093/nar/gkw983; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Okada T, 2015, NAT CELL BIOL, V17, P81, DOI 10.1038/ncb3082; Pagel JI, 2011, INDIAN J BIOCHEM BIO, V48, P226; Pietrasik S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030870; Salvador JM, 2013, ADV EXP MED BIOL, V793, P1, DOI 10.1007/978-1-4614-8289-5_1; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; Shafarenko M, 2005, BLOOD, V106, P871, DOI 10.1182/blood-2004-08-3056; Silvente-Poirot S, 2014, SCIENCE, V343, P1445, DOI 10.1126/science.1252787; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Spaapen F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058083; Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Tamura RE, 2012, CURR MOL MED, V12, P634; Tanaka S, 2012, BLOOD, V120, P1107, DOI 10.1182/blood-2011-11-394932; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thyss R, 2005, EMBO J, V24, P128, DOI 10.1038/sj.emboj.7600501; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang GG, 2015, BLOOD, V125, P1217, DOI 10.1182/blood-2014-10-606822; Wassef M, 2017, J MOL BIOL, V429, P1978, DOI 10.1016/j.jmb.2016.10.012; Weikert S, 2005, INT J MOL MED, V16, P349; Worringer KA, 2014, CELL STEM CELL, V14, P40, DOI 10.1016/j.stem.2013.11.001; Yamaguchi H, 2014, CANCER RES TREAT, V46, P209, DOI 10.4143/crt.2014.46.3.209; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029; Zeng JM, 2018, INT J BIOL SCI, V14, P1724, DOI 10.7150/ijbs.28850; Zheng RB, 2019, NUCLEIC ACIDS RES, V47, pD729, DOI 10.1093/nar/gky1094	70	8	8	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7127	7141		10.1038/s41388-020-01484-9	http://dx.doi.org/10.1038/s41388-020-01484-9		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33009487				2022-12-17	WOS:000574731000002
J	Angom, RS; Mondal, SK; Wang, F; Madamsetty, VS; Wang, EF; Dutta, SK; Gulani, Y; Sarabia-Estrada, R; Sarkaria, JN; Quinones-Hinojosa, A; Mukhopadhyay, D				Angom, Ramcharan Singh; Mondal, Sujan Kumar; Wang, Fei; Madamsetty, Vijay Sagar; Wang, Enfeng; Dutta, Shamit K.; Gulani, Yash; Sarabia-Estrada, Rachel; Sarkaria, Jann N.; Quinones-Hinojosa, Alfredo; Mukhopadhyay, Debabrata			Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme	ONCOGENE			English	Article							ENDOTHELIAL GROWTH-FACTOR; N-CADHERIN EXPRESSION; CANCER STEM-CELLS; GLIOMA PROGRESSION; C-MET; SURVIVAL; OVEREXPRESSION; ANGIOGENESIS; TUMORS; TUMORIGENICITY	Glioblastoma multiforme (GBM) is a highly proliferative and locally invasive cancer with poor prognosis and a high recurrence rate. Although anti-VEGF (vascular endothelial growth factor) therapy offers short-term benefit to GBM patients, this approach fails as the tumor develops into a more invasive and drug-resistant phenotype and ultimately recurs. Recently, both glioma stemlike cells (GSCs) and brain tumor-initiating cells (BTICs) have been implicated in GBM recurrence and its resistance to therapy. We observed that patient-derived GBM cells expressing shRNAs of VEGF or neuropilin-1 (NRP-1) attenuate cancer stem cell markers, inhibit the tumor-initiating cell's neurosphere-forming capacity, and migration. Furthermore, both VEGF and NRP-1 knockdown inhibit the growth of patient-derived GBM xenografts in both zebrafish and mouse models. Interestingly, NRP-1-depleted patient-derived GBM xenografts substantially prolonged survival in mice compared to that of VEGF depletion. Our results also demonstrate that NRP-1 ablation of patient-derived GBM cells improves the sensitivity of TMZ and enhances the overall survival of the respective tumor-bearing mice. This improved outcome may provide insight into the inhibition of GBM progression and effective treatment strategies by targeting NRP-1 in addition to chemotherapy and radiotherapy.	[Angom, Ramcharan Singh; Wang, Fei; Madamsetty, Vijay Sagar; Wang, Enfeng; Dutta, Shamit K.; Gulani, Yash; Mukhopadhyay, Debabrata] Mayo Clin, Coll Med & Sci, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA; [Mondal, Sujan Kumar; Sarabia-Estrada, Rachel; Quinones-Hinojosa, Alfredo] Mayo Clin, Coll Med & Sci, Dept Neurosurg, Jacksonville, FL 32224 USA; [Sarkaria, Jann N.] Mayo Clin, Coll Med & Sci, Dept Radiat Oncol, Rochester, MN USA; [Mondal, Sujan Kumar] Univ Pittsburgh, Med Ctr, Dept Pathol, UPMC Hillman Ctr, Pittsburgh, PA USA; [Wang, Fei] Inner Mongolia Med Univ, Affiliated Hosp, Dept Neurosurg, Hohhot 010050, Inner Mongolia, Peoples R China	Mayo Clinic; Mayo Clinic; Mayo Clinic; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Inner Mongolia Medical University	Mukhopadhyay, D (corresponding author), Mayo Clin, Coll Med & Sci, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA.; Quinones-Hinojosa, A (corresponding author), Mayo Clin, Coll Med & Sci, Dept Neurosurg, Jacksonville, FL 32224 USA.	Quinones-Hinojosa.Alfredo@mayo.edu; Mukhopadhyay.Debabrata@mayo.edu	Madamsetty, Vijay Sagar/AAF-4804-2019; Mondal, Sujan K./AAI-3850-2020; Angom, Ramcharan/ABH-2691-2021	Madamsetty, Vijay Sagar/0000-0001-9883-190X; Mondal, Sujan K./0000-0003-3241-2504; ANGOM, RAMCHARAN/0000-0002-5894-1108; Gulani, Yash/0000-0002-8053-8702	NIH [DM R01CA 78383, RO1HL140411, R01CA150190, R43CA221490, R01CA200399, R01CA195503, R01CA216855]; Florida Department of Health Cancer Research Chair Fund Florida [3J]; Mayo Clinic Professorship; Florida Department of Health Cancer Research Chair Fund	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Department of Health Cancer Research Chair Fund Florida; Mayo Clinic Professorship; Florida Department of Health Cancer Research Chair Fund	The authors thank Dr Leonard Zon, Children's Hospital, Boston, Massachusetts, for providing the Casper zebrafish strain, and Dr Ying Wang, Mayo Clinic, Jacksonville, for assistance with lentiviral preparation. The work was supported by the NIH Grant to DM R01CA 78383, RO1HL140411, R01CA150190, Florida Department of Health Cancer Research Chair Fund Florida #3J. AQH was supported by the Mayo Clinic Professorship and a Clinician Investigator award, the Florida Department of Health Cancer Research Chair Fund, and the NIH (R43CA221490, R01CA200399, R01CA195503, and R01CA216855).	An ZY, 2018, ONCOGENE, V37, P1561, DOI 10.1038/s41388-017-0045-7; Andaloussi-Saghir K, 2011, N AM J MED SCI, V3, P527, DOI 10.4297/najms.2011.3527; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Cantanhede IG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15045-w; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Cao Y, 2012, CANCER RES, V72, P3912, DOI 10.1158/0008-5472.CAN-11-4058; Chaichana KL, 2014, NEURO-ONCOLOGY, V16, P113, DOI 10.1093/neuonc/not137; Chaichana KL, 2011, J NEUROSURG, V114, P587, DOI 10.3171/2010.8.JNS1081; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Chen WJ, 2015, INT J CLIN EXP MED, V8, P8709; Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002; Dirkse A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09853-z; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gamble JT, 2018, BIOCHEM BIOPH RES CO, V506, P833, DOI 10.1016/j.bbrc.2018.10.076; Gong CF, 2018, NEURO-ONCOLOGY, V20, P131; Grun D, 2016, ONCOGENE, V35, P4379, DOI 10.1038/onc.2015.507; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Han JF, 2015, AM J CANCER RES, V5, P945; Hattermann K, 2016, INT J ONCOL, V49, P1899, DOI 10.3892/ijo.2016.3682; Her NG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0825-1; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Hou HL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0937-4; Hu B, 2007, ONCOGENE, V26, P5577, DOI 10.1038/sj.onc.1210348; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kim YJ, 2017, ONCOGENE, V36, P2543, DOI 10.1038/onc.2016.407; Kitange GJ, 2012, CLIN CANCER RES, V18, P4070, DOI 10.1158/1078-0432.CCR-12-0560; Kwak Y, 2015, INT J CLIN EXP PATHO, V8, P14932; Kwiatkowski SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185065; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Liu TR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05982-z; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maire CL, 2014, NEURO-ONCOLOGY, V16, pviii1, DOI 10.1093/neuonc/nou294; McCarty JH, 2013, CLIN CANCER RES, V19, P1631, DOI 10.1158/1078-0432.CCR-13-0051; Mercurio AM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030490; Mukhopadhyay D, 2004, SEMIN CANCER BIOL, V14, P123, DOI 10.1016/j.semcancer.2003.09.019; Noh MG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3591-z; Oka N, 2007, BIOCHEM BIOPH RES CO, V360, P553, DOI 10.1016/j.bbrc.2007.06.094; Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223; Peglion F, 2012, CELL ADHES MIGR, V6, P327, DOI 10.4161/cam.20855; Peng KW, 2019, DRUG DISCOV TODAY, V24, P656, DOI 10.1016/j.drudis.2018.10.004; Petterson SA, 2015, J NEURO-ONCOL, V122, P517, DOI 10.1007/s11060-015-1723-3; Rizzolio S, 2018, J CLIN INVEST, V128, P3976, DOI 10.1172/JCI99257; Ruffini F, 2017, ONCOTARGET, V8, P66833, DOI 10.18632/oncotarget.18706; Seymour T, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00159; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Singh SK, 2003, CANCER RES, V63, P5821; Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140; Song WS, 2016, J CHIN MED ASSOC, V79, P538, DOI 10.1016/j.jcma.2016.03.010; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Tilghman J, 2014, CANCER RES, V74, P3168, DOI 10.1158/0008-5472.CAN-13-2103; Tomida C, 2018, INT J ONCOL, V52, P1350, DOI 10.3892/ijo.2018.4291; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang P, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.105; Xu CS, 2013, SCI WORLD J, DOI 10.1155/2013/417413; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257; Zhao JX, 2018, APPL IMMUNOHISTO M M, V26, P337, DOI 10.1097/PAI.0000000000000420	62	8	8	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7114	7126		10.1038/s41388-020-01462-1	http://dx.doi.org/10.1038/s41388-020-01462-1		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33005016				2022-12-17	WOS:000574356500001
J	Mehner, C; Miller, E; Hockla, A; Coban, M; Weroha, SJ; Radisky, DC; Radisky, ES				Mehner, Christine; Miller, Erin; Hockla, Alexandra; Coban, Mathew; Weroha, S. John; Radisky, Derek C.; Radisky, Evette S.			Targeting an autocrine IL-6-SPINK1 signaling axis to suppress metastatic spread in ovarian clear cell carcinoma	ONCOGENE			English	Article							INHIBITOR KAZAL TYPE-1; TRYPSIN-INHIBITOR; MONOCLONAL-ANTIBODY; ANOIKIS RESISTANCE; INTERLEUKIN-6; SPINK1; CANCER; EXPRESSION; PROGNOSIS; IL-6	A major clinical challenge of ovarian cancer is the development of malignant ascites accompanied by widespread peritoneal metastasis. In ovarian clear cell carcinoma (OCCC), a challenging subtype of ovarian cancer, this problem is compounded by near-universal primary chemoresistance; patients with advanced stage OCCC thus lack effective therapies and face extremely poor survival rates. Here we show that tumor-cell-expressed serine protease inhibitor Kazal type 1 (SPINK1) is a key driver of OCCC progression and metastasis. Using cell culture models of human OCCC, we find that shRNA silencing of SPINK1 sensitizes tumor cells to anoikis and inhibits proliferation. Knockdown of SPINK1 in OCCC cells also profoundly suppresses peritoneal metastasis in mouse implantation models of human OCCC. We next identify a novel autocrine signaling axis in OCCC cells whereby tumor-cell-produced interleukin-6 (IL-6) regulates SPINK1 expression to stimulate a common protumorigenic gene expression pattern leading to anoikis resistance and proliferation of OCCC cells. We further demonstrate that this signaling pathway can be successfully interrupted with the IL-6R alpha inhibitor tocilizumab, sensitizing cells to anoikis in vitro and reducing metastasis in vivo. These results suggest that clinical trials of IL-6 pathway inhibitors in OCCC may be warranted, and that SPINK1 might offer a candidate predictive biomarker in this population.	[Mehner, Christine] Mayo Clin, Grad Sch Biomed Sci, Rochester, MN USA; [Mehner, Christine; Miller, Erin; Hockla, Alexandra; Coban, Mathew; Radisky, Derek C.; Radisky, Evette S.] Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 32224 USA; [Weroha, S. John] Mayo Clin, Div Med Oncol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Radisky, ES (corresponding author), Mayo Clin, Dept Canc Biol, Ctr Comprehens Canc, Jacksonville, FL 32224 USA.	radisky.evette@mayo.edu	Coban, Matt/AAH-7053-2019	Coban, Matt/0000-0001-6396-6759; Radisky, Evette/0000-0003-3121-109X	NCI NIH HHS [P50 CA136393, R01 CA154387, R21 CA177865, R21 CA226302] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI) [R01CA154387, P50CA136393, R21CA177865] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)		Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Al-Quteimat OM, 2014, J ONCOL PHARM PRACT, V20, P369, DOI 10.1177/1078155213506244; Angevin E, 2014, CLIN CANCER RES, V20, P2192, DOI 10.1158/1078-0432.CCR-13-2200; Anglesio MS, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0072162, 10.1371/annotation/ffcaf179-872f-470b-8bb6-f06d8ba6d03a]; Anglesio MS, 2011, CLIN CANCER RES, V17, P2538, DOI 10.1158/1078-0432.CCR-10-3314; Ateeq B, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001498; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006; Chandler RL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7118; Chen F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06860-4; Cichon MA, 2015, CANCER INFORM, V14, P1, DOI 10.4137/CIN.S18965; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; del Carmen MG, 2012, GYNECOL ONCOL, V126, P481, DOI 10.1016/j.ygyno.2012.04.021; Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309; du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036; HALILA H, 1987, BRIT J CANCER, V56, P153, DOI 10.1038/bjc.1987.175; Hirano G, 2011, INT J ONCOL, V38, P893, DOI 10.3892/ijo.2011.938; Howlader N, 2017, SEER CANC STAT REV 1; HUHTALA ML, 1982, J BIOL CHEM, V257, P13713; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Itkonen O, 2014, CLIN CHIM ACTA, V431, P260, DOI 10.1016/j.cca.2014.02.014; Kawabata A, 2017, GYNECOL ONCOL, V146, P609, DOI 10.1016/j.ygyno.2017.06.027; Kereszturi E, 2009, GUT, V58, P545, DOI 10.1136/gut.2008.164947; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Lamontagne J, 2010, J VIROL, V84, P907, DOI 10.1128/JVI.01249-09; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Lu XY, 2008, APOPTOSIS, V13, P483, DOI 10.1007/s10495-008-0193-x; Ma H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38362-0; Marzec K, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00162; Mehner C, 2015, ONCOTARGET, V6, P35737, DOI 10.18632/oncotarget.5927; Mitra AK, 2016, TUMOR METASTASIS, P43, DOI 10.5772/64700; Nilsson MB, 2005, CANCER RES, V65, P10794, DOI 10.1158/0008-5472.CAN-05-0623; Paju A, 2004, CLIN CANCER RES, V10, P4761, DOI 10.1158/1078-0432.CCR-0204-03; Pectasides D, 2006, ONCOLOGIST, V11, P1089, DOI 10.1634/theoncologist.11-10-1089; Portolano N, 2014, JOVE-J VIS EXP, DOI 10.3791/51897; Rasanen K, 2016, MOL CARCINOGEN, V55, P2010, DOI 10.1002/mc.22447; Rasanen K, 2016, CLIN CHEM, V62, P449, DOI 10.1373/clinchem.2015.241513; RINDERKNECHT H, 1986, DIGEST DIS SCI, V31, P314, DOI 10.1007/BF01318124; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Soon WW, 2011, EMBO MOL MED, V3, P451, DOI 10.1002/emmm.201100150; Stany MP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021121; Stenman UH, 2002, CLIN CHEM, V48, P1206; Stenman UH, 2011, ASIAN J ANDROL, V13, P628, DOI 10.1038/aja.2011.45; Sugiyama T, 1998, CANCER LETT, V128, P211, DOI 10.1016/S0304-3835(98)00065-2; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X; Takano M, 2006, BRIT J CANCER, V94, P1369, DOI 10.1038/sj.bjc.6603116; Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001; Tomlins SA, 2008, CANCER CELL, V13, P519, DOI 10.1016/j.ccr.2008.04.016; WATSON JM, 1990, CANCER RES, V50, P6959; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Yanaihara N, 2016, MOL CARCINOGEN, V55, P832, DOI 10.1002/mc.22325; YASUDA T, 1993, GENE, V131, P275; YASUDA T, 1990, BIOL CHEM H-S, V371, P95; Yuniati L, 2019, J CELL PHYSIOL, V234, P5379, DOI 10.1002/jcp.27407	54	8	8	2	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6606	6618		10.1038/s41388-020-01451-4	http://dx.doi.org/10.1038/s41388-020-01451-4		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32929152	Green Accepted			2022-12-17	WOS:000569499000001
J	Azad, AK; Zhabyeyev, P; Vanhaesebroeck, B; Eitzen, G; Oudit, GY; Moore, RB; Murray, AG				Azad, Abul K.; Zhabyeyev, Pavel; Vanhaesebroeck, Bart; Eitzen, Gary; Oudit, Gavin Y.; Moore, Ronald B.; Murray, Allan G.			Inactivation of endothelial cell phosphoinositide 3-kinase beta inhibits tumor angiogenesis and tumor growth	ONCOGENE			English	Article							ANTIANGIOGENIC AGENT SUNITINIB; VASCULAR DEVELOPMENT; MEDIATES RESISTANCE; P110-ALPHA ISOFORM; THERAPY; CARCINOMA; PATHWAY; OXYGENATION; METASTASIS; EXPRESSION	Angiogenesis inhibitors, such as the receptor tyrosine kinase (RTK) inhibitor sunitinib, target vascular endothelial growth factor (VEGF) signaling in cancers. However, only a fraction of patients respond, and most ultimately develop resistance to current angiogenesis inhibitor therapies. Activity of alternative pro-angiogenic growth factors, acting via RTK or G-protein coupled receptors (GPCR), may mediate VEGF inhibitor resistance. The phosphoinositide 3-kinase (PI3K)beta isoform is uniquely coupled to both RTK and GPCRs. We investigated the role of endothelial cell (EC) PI3K beta in tumor angiogenesis. Pro-angiogenic GPCR ligands were expressed by patient-derived renal cell carcinomas (PD-RCC), and selective inactivation of PI3K beta reduced PD-RCC-stimulated EC spheroid sprouting. EC-specific PI3K beta knockout (Epsilon C-beta KO) in mice potentiated the sunitinib-induced reduction in subcutaneous growth of LLC1 and B16F10, and lung metastasis of B16F10 tumors. Compared to single-agent sunitinib treatment, tumors in sunitinib-treated Epsilon C-beta KO mice showed a marked decrease in microvessel density, and reduced new vessel formation. The fraction of perfused mature tumor microvessels was increased in Epsilon C-beta KO mice suggesting immature microvessels were most sensitive to combined sunitinib and PI3K beta inactivation. Taken together, EC PI3K beta inactivation with sunitinib inhibition reduces microvessel turnover and decreases heterogeneity of the tumor microenvironment, hence PI3K beta inhibition may be a useful adjuvant antiangiogenesis therapy with sunitinib.	[Azad, Abul K.; Zhabyeyev, Pavel; Oudit, Gavin Y.; Murray, Allan G.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Zhabyeyev, Pavel; Oudit, Gavin Y.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada; [Vanhaesebroeck, Bart] UCL, UCL Canc Inst, London, England; [Eitzen, Gary] Univ Alberta, Dept Cell Biol, Edmonton, AB, Canada; [Moore, Ronald B.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of London; University College London; University of Alberta; University of Alberta	Murray, AG (corresponding author), Univ Alberta, Dept Med, Edmonton, AB, Canada.	allan.murray@ualberta.ca	Moore, Ronald Brian/AET-3015-2022		Translational Research Fellowship award from the Department of Medicine at the University of Alberta; Canadian Cancer Society Research Institute	Translational Research Fellowship award from the Department of Medicine at the University of Alberta; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	AKA was supported by a Translational Research Fellowship award from the Department of Medicine at the University of Alberta. Operating funding was provided by the Canadian Cancer Society Research Institute to AGM. The authors acknowledge the technical assistance of Jessica DesAulniers.	Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Nieto MA, 2017, NAT CELL BIOL, V19, P416, DOI 10.1038/ncb3520; Bergerot P, 2019, MOL CANCER THER, V18, P2185, DOI 10.1158/1535-7163.MCT-18-1399; Bilanges B, 2019, NAT REV MOL CELL BIO, V20, P515, DOI 10.1038/s41580-019-0129-z; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Bridgeman VL, 2017, J PATHOL, V241, P362, DOI 10.1002/path.4845; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Charo DN, 2009, AM J PHYSIOL-HEART C, V297, pH1904, DOI 10.1152/ajpheart.00686.2009; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gougis P, 2017, CRIT REV ONCOL HEMAT, V119, P75, DOI 10.1016/j.critrevonc.2017.08.010; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Grepin R, 2012, ONCOGENE, V31, P1683, DOI 10.1038/onc.2011.360; Grepin R, 2014, CANCER RES, V74, P873, DOI 10.1158/0008-5472.CAN-13-1267; Grunstein J, 1999, CANCER RES, V59, P1592; Haddad G, 2014, BLOOD, V124, P2142, DOI 10.1182/blood-2014-02-557975; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Jimenez-Valerio G, 2016, CURR DRUG TARGETS, V17, P1728, DOI 10.2174/1389450117666160301101425; Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402; Kryczek I, 2005, CANCER RES, V65, P465; Lyons YA, 2017, ONCOTARGET, V8, P96496, DOI [10.19632/oncotarget.20410, 10.18632/oncotarget.20410]; Ma Shaolin, 2018, F1000Res, V7, P326, DOI 10.12688/f1000research.11771.1; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mastrella G, 2019, CANCER RES, V79, P2298, DOI 10.1158/0008-5472.CAN-18-0881; Mateo J, 2017, CLIN CANCER RES, V23, P5981, DOI 10.1158/1078-0432.CCR-17-0725; Matsumoto S, 2011, CANCER RES, V71, P6350, DOI 10.1158/0008-5472.CAN-11-2025; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Nowak-Sliwinska P, 2018, ANGIOGENESIS, V21, P425, DOI 10.1007/s10456-018-9613-x; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soler A, 2013, J EXP MED, V210, P1937, DOI 10.1084/jem.20121571; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Strasser GA, 2010, BLOOD, V115, P5102, DOI 10.1182/blood-2009-07-230284; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Terry S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103044; Thomas JS, 2015, CRIT REV ONCOL HEMAT, V96, P527, DOI 10.1016/j.critrevonc.2015.07.009; Vanhaesebroeck B, 2016, J MOL MED, V94, P5, DOI 10.1007/s00109-015-1352-5; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	57	8	8	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6480	6492		10.1038/s41388-020-01444-3	http://dx.doi.org/10.1038/s41388-020-01444-3		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879446	Green Submitted			2022-12-17	WOS:000565482600001
J	Shin, SH; Kim, I; Lee, JE; Lee, M; Park, JW				Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan			Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; POOR-PROGNOSIS; GROWTH; EXPRESSION; PTEN; IDENTIFICATION; INFLAMMATION; GADD45-BETA; MECHANISMS; CARCINOMA	Identification of pro-metastatic genomic alterations is urgently needed to help understand and prevent the fatal course of prostate cancer. Here, we found that the transcription factorEGR3, located at chromosome 8p21.3, is a critical metastasis suppressor. Aberrant deletion ofEGR3was found in up to 59.76% (deep deletions, 16.87%; shallow deletions, 42.89%) of prostate cancer patients. In informatics analysis,EGR3loss was associated with prostate cancer progression and low survival rates.EGR3expression inversely correlated with the expressions of epithelial-to-mesenchymal transition (EMT) and metastasis-related gene sets in prostate cancer tissues. In prostate cancer cells, EGR3 blocked the EMT process and suppressed cell migration and invasion. In a mouse model for cancer metastasis, EGR3 overexpression significantly suppressed bone metastases of PC3 and 22Rv1 prostate cancer cells. Mechanistically, EGR3 transcriptionally activatedZFP36,GADD45B, andSOCS3genes by directly binding to their promoter regions. The EMT-inhibitory and tumor-suppressive roles of the EGR3 downstream genes were identified through in vitro and in silico analyses. Together, our results showed that EGR3 may be a biomarker to predict clinical outcomes and that it plays an important role in the metastatic progression of prostate cancer.	[Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea; [Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Dept Pharmacol, Coll Med, Seoul, South Korea; [Shin, Seung-Hyun; Kim, Iljin; Lee, Jae Eun; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea; [Kim, Iljin; Lee, Mingyu; Park, Jong-Wan] Seoul Natl Univ, Ischem Hypox Dis Inst, Coll Med, Seoul, South Korea; [Lee, Mingyu] Seoul Natl Univ, Obstruct Upper Airway Res OUaR Lab, Coll Med, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU)	Park, JW (corresponding author), Seoul Natl Univ, Dept Biomed Sci, Coll Med, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Dept Pharmacol, Coll Med, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea.; Park, JW (corresponding author), Seoul Natl Univ, Ischem Hypox Dis Inst, Coll Med, Seoul, South Korea.	parkjw@snu.ac.kr		Park, Jong-Wan/0000-0003-4676-5191	National Research Foundation of Korea [2019R1A2B5B03069677, 2020R1A4A2002903]	National Research Foundation of Korea(National Research Foundation of Korea)	The authors acknowledge the contribution of all the investigators at the participating study sites. This work was supported by the National Research Foundation of Korea (2019R1A2B5B03069677 and 2020R1A4A2002903).	Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Baron VT, 2015, BRIT J CANCER, V112, P755, DOI 10.1038/bjc.2014.622; BOVA GS, 1993, CANCER RES, V53, P3869; Brawley OW, 2012, WORLD J UROL, V30, P195, DOI 10.1007/s00345-012-0824-2; Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003; Buttigliero C, 2015, CANCER TREAT REV, V41, P884, DOI 10.1016/j.ctrv.2015.08.002; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Choi YJ, 2019, SCI REP, V9; Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186; Demichelis F, 2013, NAT MED, V19, P966, DOI 10.1038/nm.3285; El Gammal AT, 2010, CLIN CANCER RES, V16, P56, DOI 10.1158/1078-0432.CCR-09-1423; Eldredge LC, 2008, DEVELOPMENT, V135, P2949, DOI 10.1242/dev.023960; Gandhi J, 2018, PROSTATE CANCER P D, V21, P22, DOI 10.1038/s41391-017-0023-8; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI [10.2217/fon.09.67, 10.2217/FON.09.67]; Gomez-Martin D, 2010, AUTOIMMUN REV, V9, P454, DOI 10.1016/j.autrev.2009.12.006; Huang H, 2018, PROSTATE, V78, P327, DOI 10.1002/pros.23469; Jamaspishvili T, 2018, NAT REV UROL, V15, P222, DOI 10.1038/nrurol.2018.9; Kim SH, 2015, PLOS ONE, V10; Kirby M, 2011, INT J CLIN PRACT, V65, P1180, DOI 10.1111/j.1742-1241.2011.02799.x; Kluth M, 2017, ONCOTARGET, V8, P108923, DOI 10.18632/oncotarget.22408; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Li SL, 2012, IMMUNITY, V37, P685, DOI 10.1016/j.immuni.2012.08.001; Liao F, 2013, J MOL HISTOL, V44, P463, DOI 10.1007/s10735-013-9493-8; Logothetis CJ, 2013, CANCER DISCOV, V3, P849, DOI 10.1158/2159-8290.CD-12-0460; Michaelis KA, 2011, ENDOCRINOLOGY, V152, P3603, DOI 10.1210/en.2011-0109; O'Donovan KJ, 2000, J NEUROCHEM, V75, P1352, DOI 10.1046/j.1471-4159.2000.0751352.x; Ou DL, 2010, CANCER RES, V70, P9309, DOI 10.1158/0008-5472.CAN-10-1033; Park JM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113384; Parker C, 2015, ANN ONCOL, V26, pV69, DOI 10.1093/annonc/mdv222; Pio R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054096; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Safford M, 2005, NAT IMMUNOL, V6, P472, DOI 10.1038/ni1193; Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Suzuki T, 2007, ENDOCR-RELAT CANCER, V14, P279, DOI 10.1677/ERC-06-0005; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tourtellotte WG, 1998, NAT GENET, V20, P87, DOI 10.1038/1757; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang GC, 2018, GENE DEV, V32, P1105, DOI 10.1101/gad.315739.118; Wendt MK, 2014, JAK STAT, V3; Yoon NA, 2016, ONCOTARGET, V7, P8931, DOI 10.18632/oncotarget.7094; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	44	8	8	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5839	5854		10.1038/s41388-020-01418-5	http://dx.doi.org/10.1038/s41388-020-01418-5		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32796959				2022-12-17	WOS:000559718800002
J	Reischmann, N; Andrieux, G; Griffin, R; Reinheckel, T; Boerries, M; Brummer, T				Reischmann, Nadine; Andrieux, Geoffroy; Griffin, Ricarda; Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman			BRAF(V600E) drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation	ONCOGENE			English	Article							COLORECTAL-CANCER; STEM-CELLS; MOLECULAR SUBTYPES; ECTOPIC EXPRESSION; BRAF MUTATION; MOUSE MODELS; GENE; DIFFERENTIATION; PROGRESSION; CAVEOLIN-1	BRAF(V600E)confers poor prognosis and is associated with a distinct subtype of colorectal cancer (CRC). Little is known, however, about the genetic events driving the initiation and progression of BRAF(V600E)mutant CRCs. Recent genetic analyses of CRCs indicate that BRAF(V600E)often coexists with alterations in the WNT- and p53 pathways, but their cooperation remains ill-defined. Therefore, we systematically compared small and large intestinal organoids from mice harboring conditionalBraf(floxV600E),Trp53(LSL-R172H), and/orApc(flox/flox)alleles. Using these isogenic models, we observe tissue-specific differences toward sudden BRAF(V600E)expression, which can be attributed to different ERK-pathway ground states in small and large intestinal crypts. BRAF(V600E)alone causes transient proliferation and suppresses epithelial organization, followed by organoid disintegration. Moreover, BRAF(V600E)induces a fetal-like dedifferentiation transcriptional program in colonic organoids, which resembles human BRAF(V600E)-driven CRC. Co-expression of p53(R172H)delays organoid disintegration, confers anchorage-independent growth, and induces invasive properties. Interestingly, p53(R172H)cooperates with BRAF(V600E)to modulate the abundance of transcripts linked to carcinogenesis, in particular within colonic organoids. Remarkably, WNT-pathway activation byApcdeletion fully protects organoids against BRAF(V600E)-induced disintegration and confers growth/niche factor independence. Still,Apc-deficient BRAF(V600E)-mutant organoids remain sensitive toward the MEK inhibitor trametinib, albeit p53(R172H)confers partial resistance against this clinically relevant compound. In summary, our systematic comparison of the response of small and large intestinal organoids to oncogenic alterations suggests colonic organoids to be better suited to model the human situation. In addition, our work on BRAF-, p53-, and WNT-pathway mutations provides new insights into their cooperation and for the design of targeted therapies.	[Reischmann, Nadine; Griffin, Ricarda; Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Freiburg, Germany; [Reischmann, Nadine] Univ Freiburg, Spemann Grad Sch Biol & Med SGBM, Freiburg, Germany; [Reischmann, Nadine] Univ Freiburg, Fac Biol, Freiburg, Germany; [Andrieux, Geoffroy; Boerries, Melanie] Univ Freiburg, Med Ctr, Inst Med Bioinformat & Syst Med, Freiburg, Germany; [Andrieux, Geoffroy; Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman] German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany; [Andrieux, Geoffroy; Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman] German Canc Res Ctr, Heidelberg, Germany; [Reinheckel, Thomas; Boerries, Melanie; Brummer, Tilman] Univ Freiburg, Univ Med Ctr Freiburg, Comprehens Canc Ctr Freiburg CCCF, Freiburg, Germany; [Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Brummer, T (corresponding author), Univ Freiburg, Inst Mol Med & Cell Res IMMZ, Freiburg, Germany.; Brummer, T (corresponding author), German Canc Consortium DKTK, Partner Site Freiburg, Heidelberg, Germany.; Brummer, T (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Univ Med Ctr Freiburg, Comprehens Canc Ctr Freiburg CCCF, Freiburg, Germany.; Brummer, T (corresponding author), Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany.	tilman.brummer@mol-med.uni-freiburg.de	Brummer, Tilman/AAA-9428-2020; Reinheckel, Thomas/AAL-9761-2021; Brummer, Tilman/B-6218-2016; Boerries, Melanie/AAM-2602-2021	Brummer, Tilman/0000-0003-4387-7905; Reinheckel, Thomas/0000-0001-9866-9105; Brummer, Tilman/0000-0003-4387-7905; ANDRIEUX, GEOFFROY/0000-0002-5389-9481; Griffin, Ricarda/0000-0003-1368-2832	German Research Foundation (DFG) [SFB 850, BR 3662/5-1, EXC 294 BIOSS]; German Cancer Consortium DKTK [L627]; DFG [GSC-4]; German Federal Ministry of Education and Research (BMBF) [FKZ 01ZX1708F]; MIRACUM within the Medical Informatics Funding Scheme [FKZ 01ZZ1801B]; Projekt DEAL	German Research Foundation (DFG)(German Research Foundation (DFG)); German Cancer Consortium DKTK; DFG(German Research Foundation (DFG)); German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); MIRACUM within the Medical Informatics Funding Scheme; Projekt DEAL	We thank the Genomics and Proteomics Core Facility team, German Cancer Research Center/DKFZ, for its sequencing service. This work was supported by the German Research Foundation (DFG) through SFB 850, projects B4 (TB), B7 (TR), and Z1 (MB), a Heisenberg professorship to TB (BR 3662/5-1) and EXC 294 BIOSS, and the German Cancer Consortium DKTK (L627 to TR, MB, and TB). NR was supported in part by the DFG funded SGBM (GSC-4). MB is supported by the German Federal Ministry of Education and Research (BMBF) within the framework of the e:Med research and funding concept to CoNfirm (FKZ 01ZX1708F) and by MIRACUM within the Medical Informatics Funding Scheme (FKZ 01ZZ1801B). Open access funding provided by Projekt DEAL.	Aguirre-Portoles C, 2018, MOL ONCOL, V12, P1735, DOI 10.1002/1878-0261.12367; Bender FC, 2000, CANCER RES, V60, P5870; Bond CE, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/9250757; Bond CE, 2018, EPIGENETICS-US, V13, P40, DOI 10.1080/15592294.2017.1411446; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brandt R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10954-y; Campos A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080314; Carragher LAS, 2010, EMBO MOL MED, V2, P458, DOI 10.1002/emmm.201000099; Caruso M, 2009, VIRCHOWS ARCH, V454, P291, DOI 10.1007/s00428-009-0731-0; Chanvorachote P, 2015, MOL CELL BIOCHEM, V399, P291, DOI 10.1007/s11010-014-2255-4; Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077; Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407; Datta J, 2020, CLIN CANCER RES, V26, P1077, DOI 10.1158/1078-0432.CCR-19-2390; Dawson H, 2014, INT J CANCER, V134, P2342, DOI 10.1002/ijc.28564; Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713; Delker DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088367; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Dorard C, 2017, BIOCHEM SOC T, V45, P27, DOI 10.1042/BST20160135; Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033; DUDA P, 2020, CELLS-BASEL, V9, DOI DOI 10.3390/CELLS9051110; Dunne PD, 2016, CLIN CANCER RES, V22, P230, DOI 10.1158/1078-0432.CCR-15-0603; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fennell LJ, 2020, CANCERS, V12, DOI 10.3390/cancers12051171; Gillies TE, 2017, CELL SYST, V5, P549, DOI 10.1016/j.cels.2017.10.019; Halim H, 2012, CELL BIOL INT, V36, P1055, DOI 10.1042/CBI20120111; Han T, 2020, CANCER DISCOV, V10, P1590, DOI 10.1158/2159-8290.CD-19-1536; Hashimoto T, 2019, AM J SURG PATHOL, V43, P132, DOI 10.1097/PAS.0000000000001149; Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5; Herr R, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2014.1002709; Herr R, 2015, CANCER RES, V75, P216, DOI 10.1158/0008-5472.CAN-13-3686; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Jackstadt R, 2016, J PATHOL, V238, P141, DOI 10.1002/path.4645; Kane AM, 2020, NEOPLASIA, V22, P120, DOI 10.1016/j.neo.2019.12.002; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Kawasaki K, 2020, GASTROENTEROLOGY, V158, P638, DOI 10.1053/j.gastro.2019.10.009; Kawazoe T, 2019, CANCER SCI, V110, P1525, DOI 10.1111/cas.13999; Khanal T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11106-2; Kidger AM, 2016, SEMIN CELL DEV BIOL, V50, P125, DOI 10.1016/j.semcdb.2016.01.009; Kitowska A, 2015, J SURG ONCOL, V112, P408, DOI 10.1002/jso.23995; Laforest A, 2014, EUR J CANCER, V50, P1740, DOI 10.1016/j.ejca.2014.04.007; Lannagan TRM, 2019, GUT, V68, P684, DOI 10.1136/gutjnl-2017-315920; Lavoie H, 2018, NATURE, V554, P549, DOI 10.1038/nature25478; Li S, 2019, J CELL PHYSIOL, V234, P3730, DOI 10.1002/jcp.27149; Liu QZ, 2015, INT J CLIN EXP PATHO, V8, P12802; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Matsuda M, 2010, PATHOL INT, V60, P673, DOI 10.1111/j.1440-1827.2010.02587.x; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Mi L, 2017, ONCOGENE, V36, P4323, DOI 10.1038/onc.2017.74; Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Mustata RC, 2013, CELL REP, V5, P421, DOI 10.1016/j.celrep.2013.09.005; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187; Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038; Popovici V, 2012, J CLIN ONCOL, V30, P1288, DOI 10.1200/JCO.2011.39.5814; Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014; Rademaker G, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0130-6; Riemer P, 2015, ONCOGENE, V34, P3164, DOI 10.1038/onc.2014.247; Riemer P, 2017, J CELL BIOL, V216, P1567, DOI 10.1083/jcb.201610058; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Sakamoto N, 2017, ELIFE, V6, DOI 10.7554/eLife.20331; Sato Toshiro, 2013, Methods Mol Biol, V945, P319, DOI 10.1007/978-1-62703-125-7_19; Sekine S, 2020, J GASTROENTEROL, V55, P418, DOI 10.1007/s00535-020-01673-z; Sentani K, 2013, HISTOPATHOLOGY, V62, P1018, DOI 10.1111/his.12099; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Sundar R, 2017, CANCER DISCOV, V7, P558, DOI 10.1158/2159-8290.CD-17-0087; Tan BS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.191; Tao Y, 2019, CANCER CELL, V35, P315, DOI 10.1016/j.ccell.2019.01.005; Tong K, 2017, CELL REP, V21, P3833, DOI 10.1016/j.celrep.2017.11.104; Torrejon B, 2017, WORLD J SURG, V41, P2625, DOI 10.1007/s00268-017-4065-9; Verzi MP, 2011, MOL CELL BIOL, V31, P2026, DOI 10.1128/MCB.01250-10; Wang DY, 2019, DIGEST DIS, V37, P214, DOI 10.1159/000494454; Wang YM, 2018, CELL REP, V25, P1304, DOI 10.1016/j.celrep.2018.10.001; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yui SR, 2012, NAT MED, V18, P618, DOI 10.1038/nm.2695; Zhou X, 2019, J MOL CELL BIOL, V11, P293, DOI 10.1093/jmcb/mjy072	83	8	8	5	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6053	6070		10.1038/s41388-020-01414-9	http://dx.doi.org/10.1038/s41388-020-01414-9		AUG 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32792685	Green Published, hybrid			2022-12-17	WOS:000559422800001
J	Li, H; Jiang, W; Liu, XN; Yuan, LY; Li, TJ; Li, S; Xu, SS; Zhang, WH; Gao, HL; Han, X; Wang, WQ; Wu, CT; Yu, XJ; Xu, HX; Liu, L				Li, Hao; Jiang, Wang; Liu, Xue-Ni; Yuan, Li-Yun; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang			TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway	ONCOGENE			English	Article							GEMCITABINE; METASTASIS; PROMOTER; METHYLATION; GROWTH	Chemoresistance is a major obstacle to prolonging pancreatic ductal adenocarcinoma (PDAC) patient survival. TET1 is identified as the most important epigenetic modification enzyme that facilitates chemoresistance in cancers. However, the chemoresistance mechanism of TET1 in PDAC is unknown. This study aimed to determine the role of TET1 in the chemoresistance of PDAC. TET1-associated chemoresistance in PDAC was investigated in vitro and in vivo. The clinical significance of TET1 was analyzed in 228 PDAC patients by tissue microarray profiling. We identified that TET1 downregulation is caused by its promoter hypermethylation and correlates with poor survival in PDAC patients. In vitro and in vivo functional studies performed by silencing or overexpressing TET1 suggested that TET1 is able to suppress epithelial-mesenchymal transition (EMT) and sensitize PDAC cells to 5FU and gemcitabine. Then RNA-seq, whole genome bisulfite sequencing (WGBS) and ChIP-seq were used to explore the TET1-associated pathway, and showed that TET1 promotes the transcription of CHL1 by binding and demethylating the CHL1 promoter, which consequently inhibits the Hedgehog pathway. Additionally, inhibiting Hedgehog signaling by CHL1 overexpression or the Hedgehog pathway inhibitor, GDC-0449, reversed the chemoresistance induced by TET1 silencing. Regarding clinical significance, we found that high TET1 and high CHL1 expression predicted a better prognosis in resectable PDAC patients. In summary, we demonstrated that TET1 reverses chemoresistance in PDAC by downregulating the CHL1-associated Hedgehog signaling pathway. PDAC patients with a high expression levels of TET1 and CHL1 have a better prognosis.	[Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai, Peoples R China; [Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Shanghai Pancreat Canc Inst, Shanghai, Peoples R China; [Li, Hao; Jiang, Wang; Li, Tian-Jiao; Li, Shuo; Xu, Shuai-Shuai; Zhang, Wu-Hu; Gao, He-Li; Han, Xuan; Wang, Wen-Quan; Wu, Chun-Tao; Yu, Xian-Jun; Xu, Hua-Xiang; Liu, Liang] Fudan Univ, Pancreat Canc Inst, Shanghai, Peoples R China; [Liu, Xue-Ni] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai, Peoples R China; [Yuan, Li-Yun] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Biomed Big Data Ctr, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Max Planck Society	Yu, XJ; Xu, HX; Liu, L (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Pancreat Surg, Shanghai, Peoples R China.; Yu, XJ; Xu, HX; Liu, L (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Yu, XJ; Xu, HX; Liu, L (corresponding author), Shanghai Pancreat Canc Inst, Shanghai, Peoples R China.; Yu, XJ; Xu, HX; Liu, L (corresponding author), Fudan Univ, Pancreat Canc Inst, Shanghai, Peoples R China.	yuxianjun@fudanpci.org; xuhuaxiang@fudanpci.org; liuliang@fudanpci.org	Li, Shuo/GXV-6545-2022	Jiang, Wang/0000-0003-4546-3466; wuhu, Zhang/0000-0002-5182-9850; Liu, Liang/0000-0002-7826-3877	National Science Foundation for Distinguished Young Scholars of China [81625016]; National Natural Science Foundation of China [81871941, 81872366, 81827807, 81802675, 81702341, 81802380]; Outstanding Academic Leader Program of the "Technological Innovation Action Plan" in Shanghai Science and Technology Commission [18XD1401200]; Scientific Innovation Project of Shanghai Education Committee [2019-01-07-00-07-E00057]; Young Talented Specialist Training Program of Shanghai	National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Outstanding Academic Leader Program of the "Technological Innovation Action Plan" in Shanghai Science and Technology Commission; Scientific Innovation Project of Shanghai Education Committee; Young Talented Specialist Training Program of Shanghai	This work was supported by grants from the National Science Foundation for Distinguished Young Scholars of China [81625016]; the National Natural Science Foundation of China [81871941, 81872366, 81827807, 81802675, 81702341, and 81802380]; the Outstanding Academic Leader Program of the "Technological Innovation Action Plan" in Shanghai Science and Technology Commission [18XD1401200]; Scientific Innovation Project of Shanghai Education Committee (2019-01-07-00-07-E00057) and the Young Talented Specialist Training Program of Shanghai. The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamska A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071338; Baharudin R, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00047; Bhateja P, 2019, CANCERS, V11, DOI 10.3390/cancers11081126; Chen J, 2019, INT J BIOL SCI, V15, P1802, DOI 10.7150/ijbs.34785; Dahl JA, 2008, NAT PROTOC, V3, P1032, DOI 10.1038/nprot.2008.68; De Jesus-Acosta A, 2020, BRIT J CANCER, V122, P498, DOI 10.1038/s41416-019-0683-3; Eto K, 2013, BRIT J CANCER, V108, P1488, DOI 10.1038/bjc.2013.108; Feng JH, 2015, INT J CLIN EXP MED, V8, P203; Fu HL, 2014, J BIOMED NANOTECHNOL, V10, P1217, DOI 10.1166/jbn.2014.1861; Gaianigo N, 2017, CANCERS, V9, DOI 10.3390/cancers9090122; Han X, 2017, CELL BIOL INT, V41, P405, DOI 10.1002/cbin.10734; Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030; Infante P, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.195; Kang KA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.149; Kumar V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01942-7; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Li H, 2017, HEPATOLOGY, V66, P136, DOI 10.1002/hep.29116; Martin-Sanchez E, 2017, ONCOTARGET, V8, P15789, DOI 10.18632/oncotarget.15004; Ognibene Marzia, 2018, Oncotarget, V9, P25903, DOI 10.18632/oncotarget.25403; Pei YF, 2016, ONCOTARGET, V7, P31322, DOI 10.18632/oncotarget.8900; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Tang H, 2019, ONCOGENE, V38, P3119, DOI 10.1038/s41388-018-0648-7; Thomson JP, 2016, CANCER RES, V76, P3097, DOI 10.1158/0008-5472.CAN-15-1910; Voutsadakis IA, 2011, WORLD J GASTRO ONCOL, V3, P153, DOI 10.4251/wjgo.v3.i11.153; Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003; Wang CX, 2019, CANCER MED-US, V8, P990, DOI 10.1002/cam4.1983; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wu J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1334-5; Zhang JF, 2018, CELL PHYSIOL BIOCHEM, V45, P692, DOI 10.1159/000487162; Zhang SR, 2019, EJSO-EUR J SURG ONC, V45, P769, DOI 10.1016/j.ejso.2018.10.539; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zhou PT, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0624-9	32	8	9	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5825	5838		10.1038/s41388-020-01407-8	http://dx.doi.org/10.1038/s41388-020-01407-8		AUG 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32753651				2022-12-17	WOS:000555747100003
J	Whitlock, NC; Trostel, SY; Wilkinson, S; Terrigino, NT; Hennigan, ST; Lake, R; Carrabba, NV; Atway, R; Walton, ED; Gryder, BE; Capaldo, BJ; Ye, HH; Sowalsky, AG				Whitlock, Nichelle C.; Trostel, Shana Y.; Wilkinson, Scott; Terrigino, Nicholas T.; Hennigan, S. Thomas; Lake, Ross; Carrabba, Nicole, V; Atway, Rayann; Walton, Elizabeth D.; Gryder, Berkley E.; Capaldo, Brian J.; Ye, Huihui; Sowalsky, Adam G.			MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity	ONCOGENE			English	Article							GENE-EXPRESSION; C-MYC; ANDROGEN RECEPTOR; OVEREXPRESSION; CELL; DIFFERENTIATION; PROLIFERATION; ONCOGENE; PREDICTS; PROGRAMS	Localized prostate cancer develops very slowly in most men, with the androgen receptor (AR) and MYC transcription factors amongst the most well-characterized drivers of prostate tumorigenesis. Canonically, MYC up-regulation in luminal prostate cancer cells functions to oppose the terminally differentiating effects of AR. However, the effects of MYC up-regulation are pleiotropic and inconsistent with a poorly proliferative phenotype. Here we show that increased MYC expression and activity are associated with the down-regulation ofMEIS1, a HOX-family transcription factor. Using RNA-seq to profile a series of human prostate cancer specimens laser capture microdissected on the basis of MYC immunohistochemistry, MYC activity, andMEIS1expression were inversely correlated. Knockdown ofMYCexpression in prostate cancer cells increased the expression ofMEIS1and increased the occupancy of MYC at theMEIS1locus. Finally, we show in laser capture microdissected human prostate cancer samples and the prostate TCGA cohort thatMEIS1expression is inversely proportional to AR activity as well asHOXB13, a known interacting protein of both AR and MEIS1. Collectively, our data demonstrate that elevated MYC in a subset of primary prostate cancers functions in a negative role in regulatingMEIS1expression, and that this down-regulation may contribute to MYC-driven development and progression.	[Whitlock, Nichelle C.; Trostel, Shana Y.; Wilkinson, Scott; Terrigino, Nicholas T.; Hennigan, S. Thomas; Lake, Ross; Carrabba, Nicole, V; Atway, Rayann; Walton, Elizabeth D.; Capaldo, Brian J.; Sowalsky, Adam G.] NCI, Lab Genitourinary Canc Pathogenesis, NIH, Bethesda, MD 20892 USA; [Gryder, Berkley E.] NCI, Genet Branch, NIH, Bethesda, MD 20892 USA; [Ye, Huihui] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA; [Ye, Huihui] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California Los Angeles	Sowalsky, AG (corresponding author), NCI, Lab Genitourinary Canc Pathogenesis, NIH, Bethesda, MD 20892 USA.	adam.sowalsky@nih.gov	Sowalsky, Adam/K-1485-2013	Sowalsky, Adam/0000-0003-2760-1853; Terrigino, Nicholas T./0000-0002-0829-8433; Carrabba, Nicole/0000-0003-4118-9690; Wilkinson, Scott/0000-0002-2613-8425	Prostate Cancer Foundation; Intramural Research Program of the NIH, National Cancer Institute	Prostate Cancer Foundation; Intramural Research Program of the NIH, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Prostate Cancer Foundation (Young Investigator Awards to SW, HY and AGS) and the Intramural Research Program of the NIH, National Cancer Institute.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Baena-Del Valle JA, 2018, J PATHOL, V244, P11, DOI 10.1002/path.4980; Bai SS, 2019, ONCOGENE, V38, P4977, DOI 10.1038/s41388-019-0768-8; Barfeld SJ, 2017, EBIOMEDICINE, V18, P83, DOI 10.1016/j.ebiom.2017.04.006; Barfeld SJ, 2015, ONCOTARGET, V6, P12587, DOI 10.18632/oncotarget.3494; Bhanvadia RR, 2018, CLIN CANCER RES, V24, P3668, DOI 10.1158/1078-0432.CCR-17-3673; Brechka H, 2017, GENES DIS, V4, P75, DOI 10.1016/j.gendis.2017.01.003; Calvo KR, 2002, ONCOGENE, V21, P4247, DOI 10.1038/sj.onc.1205516; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Collins CT, 2016, CURR OPIN HEMATOL, V23, P354, DOI 10.1097/MOH.0000000000000245; Cui L, 2014, EXP CELL RES, V328, P58, DOI 10.1016/j.yexcr.2014.08.023; Cunningham D, 2015, J BIOL METHODS, V2; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dang CV, 1999, MOL CELL BIOL, V19, P1; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Gallenne T, 2017, ONCOTARGET, V8, P20572, DOI 10.18632/oncotarget.16244; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Hammarsten P, 2019, MODERN PATHOL, V32, P1310, DOI 10.1038/s41379-019-0260-6; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Johng D, 2019, PROSTATE, V79, P414, DOI 10.1002/pros.23747; Junttila MR, 2008, CELL CYCLE, V7, P592, DOI 10.4161/cc.7.5.5492; Koh CM, 2011, AM J PATHOL, V178, P1824, DOI 10.1016/j.ajpath.2010.12.040; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Marcos S, 2015, DEVELOPMENT, V142, P3009, DOI 10.1242/dev.122176; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Norris JD, 2009, MOL CELL, V36, P405, DOI 10.1016/j.molcel.2009.10.020; Packer JR, 2016, BBA-MOL CELL RES, V1863, P1238, DOI 10.1016/j.bbamcr.2016.02.016; Park JW, 2016, P NATL ACAD SCI USA, V113, P4482, DOI 10.1073/pnas.1603645113; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Shaffer AL, 2006, IMMUNOL REV, V210, P67, DOI 10.1111/j.0105-2896.2006.00373.x; Sowalsky AG, 2018, CANCER RES, V78, P4716, DOI 10.1158/0008-5472.CAN-18-0610; Sowalsky AG, 2017, CLIN CANCER RES, V23, P3823, DOI 10.1158/1078-0432.CCR-16-2414; Takeda A, 2006, CANCER RES, V66, P6628, DOI 10.1158/0008-5472.CAN-06-0458; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tretiakova MS, 2016, PROSTATE CANCER P D, V19, P264, DOI 10.1038/pcan.2016.12; Trock BJ, 2016, MODERN PATHOL, V29, P764, DOI 10.1038/modpathol.2016.63; Varlakhanova N, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-20; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Yang YA, 2015, GENES DIS, V2, P144, DOI 10.1016/j.gendis.2015.01.003; Yohe ME, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan4470	44	8	10	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2020	39	34					5663	5674		10.1038/s41388-020-01389-7	http://dx.doi.org/10.1038/s41388-020-01389-7		JUL 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NE9FK	32681068	Green Submitted, Green Published, hybrid			2022-12-17	WOS:000549696500001
J	Lin, CC; Yao, CY; Hsu, YW; Hou, HA; Yuan, CS; Li, YH; Kao, HJ; Chuang, PH; Chiu, YC; Chen, YD; Chou, WC; Tien, WF				Lin, Chien-Chin; Yao, Chi-Yuan; Hsu, Yueh-Chwen; Hou, Hsin-An; Yuan, Chang-Tsu; Li, Yi-Hung; Kao, Chein-Jun; Chuang, Po-Han; Chiu, Yu-Chiao; Chen, Yidong; Chou, Wen-Chien; Tien, Hwei-Fang			Knock-out ofHopxdisrupts stemness and quiescence of hematopoietic stem cells in mice	ONCOGENE			English	Article							LABEL-RETAINING CELLS; HOMEOBOX GENE; HOPX EXPRESSION; CXCR4; PROLIFERATION; METHYLATION; POPULATION; SUBSET; CANCER	HOPX is a stem cell marker in hair follicles and intestines. It was shown critical for primitive hematopoiesis. We previously showed an association between higherHOPXexpression and clinical characteristics related to stemness and quiescence of leukemic cells in acute myeloid leukemia (AML) patients. To further explore its physiologic functions in hematopoietic system, we generated a mouse model with hematopoietic cell-specific knockout ofHopx(Hopx(-/-)). In youngHopx(-/-)mice, the hematopoietic stem cells (HSC) showed decreased reconstitution ability after serial transplantation. Further transcriptomic study revealed decreased HSC signatures in long-term HSCs from theHopx(-/-)mice. At 18 months of age, half of theHopx(-/-)mice developed cytopenia and splenomegaly. Bone marrow (BM) from the sick mice showed myeloid hyperplasia with predominant mature neutrophils, and decreased progenitor cells and lymphocytes. These phenotypes suggested critical functions of Hopx in maintaining HSC quiescence. Transcriptomic study of theHopx(-/-)marrow cells showed significant downregulation of theCxcl12-Cxcr4axis, which is critical for maintenance of HSC quiescence. We next examined the role of Hopx in AML by using theMN1overexpression murine leukemia model. Mice transplanted withMN1-overexpressedHopx(-/-)BM cells developed AML with more aggressive phenotypes compared with those transplanted withMN1-overexpressedHopx-wild cells.Hopx(-/-)MN1-overexpressed leukemia cells showed higher proliferation rate and downregulation ofCxcl12andCxcr4. Furthermore, in human AML, BM plasma CXCL12 levels were lower in patients with lowerHOPXexpression. In conclusion, our study highlights the roles of Hopx in maintenance of quiescence of the hematopoietic stem cells through CXCL12 pathway in vivo and provides implication of this protein in normal and malignant hematopoiesis.	[Lin, Chien-Chin; Yao, Chi-Yuan; Hsu, Yueh-Chwen; Chou, Wen-Chien] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan; [Lin, Chien-Chin; Yao, Chi-Yuan; Hou, Hsin-An; Kao, Chein-Jun; Chuang, Po-Han; Chou, Wen-Chien; Tien, Hwei-Fang] Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan; [Lin, Chien-Chin; Yuan, Chang-Tsu] Natl Taiwan Univ, Grad Inst Clin Med, Taipei, Taiwan; [Yuan, Chang-Tsu] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Dept Pathol, Taipei, Taiwan; [Li, Yi-Hung] Chinese Culture Univ, Dept Anim Sci, Taipei, Taiwan; [Chiu, Yu-Chiao; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; Chinese Culture University; University of Texas System; University of Texas Health San Antonio	Chou, WC (corresponding author), Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.; Chou, WC; Tien, WF (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan.	wchou@ntu.edu.tw; hftien@ntu.edu.tw		HOU, HSIN-AN/0000-0003-2780-4845; TIEN, HWEI-FANG/0000-0002-1384-5593; Yuan, Chang-Tsu/0000-0003-1438-9187; Yao, Chi-Yuan/0000-0001-5052-9445; Chiu, Yu-Chiao/0000-0003-1647-8634; LIN, CHIEN-CHIN/0000-0001-7160-2285; CHOU, WEN-CHIEN/0000-0003-2967-698X				Agarwal P, 2019, CELL STEM CELL, V24, P769, DOI 10.1016/j.stem.2019.02.018; Basak O, 2017, CELL STEM CELL, V20, P177, DOI 10.1016/j.stem.2016.11.001; Beck TC, 2014, J EXP MED, V211, P2567, DOI 10.1084/jem.20140457; Berg DA, 2019, CELL, V177, P654, DOI 10.1016/j.cell.2019.02.010; Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chakkalakal JV, 2012, NATURE, V490, P355, DOI 10.1038/nature11438; Chen F, 2002, CELL, V110, P713, DOI 10.1016/S0092-8674(02)00932-7; Chen Y, 2007, INT J CANCER, V121, P1021, DOI 10.1002/ijc.22753; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Codega P, 2014, NEURON, V82, P545, DOI 10.1016/j.neuron.2014.02.039; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Greenbaum A, 2013, NATURE, V495, P227, DOI 10.1038/nature11926; Harada Y, 2011, ANTICANCER RES, V31, P2889; Heuser M, 2011, CANCER CELL, V20, P39, DOI 10.1016/j.ccr.2011.06.020; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Hsu YC, 2019, BLOOD ADV, V3, P2355, DOI 10.1182/bloodadvances.2019000391; Jain R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7727; Katoh H, 2012, NEOPLASIA, V14, P559, DOI 10.1593/neo.12330; Kook H, 2006, BIOCHEMISTRY-US, V45, P10584, DOI 10.1021/bi060641s; Lin CC, 2017, HAEMATOLOGICA, V102, P1044, DOI 10.3324/haematol.2016.161257; Mendelson A, 2014, NAT MED, V20, P833, DOI 10.1038/nm.3647; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Munoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166; Ni F, 2019, CELL STEM CELL, V24, P608, DOI 10.1016/j.stem.2019.02.009; Nie YC, 2008, J EXP MED, V205, P777, DOI 10.1084/jem.20072513; Ooki A, 2010, ONCOGENE, V29, P3263, DOI 10.1038/onc.2010.76; Palpant NJ, 2017, CELL REP, V20, P1597, DOI 10.1016/j.celrep.2017.07.067; Pitt LA, 2015, CANCER CELL, V27, P755, DOI 10.1016/j.ccell.2015.05.002; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Scadden DT, 2014, CELL, V157, P41, DOI 10.1016/j.cell.2014.02.013; Shin CH, 2002, CELL, V110, P725, DOI 10.1016/S0092-8674(02)00933-9; Takeda N, 2013, DEVELOPMENT, V140, P1655, DOI 10.1242/dev.093005; Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214; Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408; Tumpel S, 2019, TRENDS CELL BIOL, V29, P672, DOI 10.1016/j.tcb.2019.05.002; Tzeng YS, 2011, BLOOD, V117, P429, DOI 10.1182/blood-2010-01-266833; Waraya M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-397; Yamaguchi S, 2009, INT J CANCER, V124, P2577, DOI 10.1002/ijc.24217; Yamashita K, 2008, MOL CANCER RES, V6, P31, DOI 10.1158/1541-7786.MCR-07-0213; Zhou XY, 2015, STEM CELL REP, V5, P125, DOI 10.1016/j.stemcr.2015.05.008	41	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5112	5123		10.1038/s41388-020-1340-2	http://dx.doi.org/10.1038/s41388-020-1340-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32533098				2022-12-17	WOS:000546718100003
J	Lorenzo-Martin, LF; Rodriguez-Fdez, S; Fabbiano, S; Abad, A; Garcia-Macias, MC; Dosil, M; Cuadrado, M; Robles-Valero, J; Bustelo, XR				Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Fabbiano, Salvatore; Abad, Antonio; Garcia-Macias, Maria C.; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.			Vav2pharmaco-mimetic mice reveal the therapeutic value and caveats of the catalytic inactivation of a Rho exchange factor	ONCOGENE			English	Article							GTP-BINDING PROTEINS; SKIN TUMOR-FORMATION; RAC ACTIVATOR TIAM1; VAV FAMILY; PATHWAY; GTPASES; CANCER; INHIBITION; TARGETS; DOMAIN	The current paradigm holds that the inhibition of Rho guanosine nucleotide exchange factors (GEFs), the enzymes that stimulate Rho GTPases, can be a valuable therapeutic strategy to treat Rho-dependent tumors. However, formal validation of this idea using in vivo models is still missing. In this context, it is worth remembering that many Rho GEFs can mediate both catalysis-dependent and independent responses, thus raising the possibility that the inhibition of their catalytic activities might not be sufficient per se to block tumorigenic processes. On the other hand, the inhibition of these enzymes can trigger collateral side effects that could preclude the practical implementation of anti-GEF therapies. To address those issues, we have generated mouse models to mimic the effect of the systemic application of an inhibitor for the catalytic activity of the Rho GEF Vav2 at the organismal level. Our results indicate that lowering the catalytic activity of Vav2 below specific thresholds is sufficient to block skin tumor initiation, promotion, and progression. They also reveal that the negative side effects typically induced by the loss of Vav2 can be bypassed depending on the overall level of Vav2 inhibition achieved in vivo. These data underscore the pros and cons of anti-Rho GEF therapies for cancer treatment. They also support the idea that Vav2 could represent a viable drug target.	[Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Fabbiano, Salvatore; Abad, Antonio; Garcia-Macias, Maria C.; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.] Univ Salamanca, Ctr Invest Canc, CSIC, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Fabbiano, Salvatore; Abad, Antonio; Garcia-Macias, Maria C.; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Rodriguez-Fdez, Sonia; Abad, Antonio; Dosil, Mercedes; Cuadrado, Myriam; Robles-Valero, Javier; Bustelo, Xose R.] Univ Salamanca, Ctr Invest Biomed Red Canc CIBERONC, CSIC, Salamanca 37007, Spain; [Dosil, Mercedes] Univ Salamanca, Sch Pharm, Dept Bioquim & Biol Mol, Salamanca 37007, Spain; [Fabbiano, Salvatore] Cell Press Editorial Off, Cambridge, MA 02139 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; University of Salamanca	Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, Ctr Invest Biomed Red Canc CIBERONC, CSIC, Salamanca 37007, Spain.	xbustelo@usal.es	Rodriguez-Fdez, Sonia/AAD-9317-2021; Bustelo, Xose R./AAD-2081-2022; Robles-Valero, Javier/J-4069-2017; Dosil, Mercedes/A-9536-2016	Bustelo, Xose R./0000-0001-9398-6072; Abad de Blas, Antonio Luis/0000-0001-8019-2775; Fabbiano, Salvatore/0000-0003-0768-6028; Robles-Valero, Javier/0000-0001-5218-0187; Cuadrado, Myriam/0000-0001-9410-1205; Dosil, Mercedes/0000-0001-8119-8263; Lorenzo-Martin, L. Francisco/0000-0003-4717-9338; Rodriguez-Fdez, Sonia/0000-0001-5369-2969	Worldwide Cancer Research [14-1248]; Castilla-Leon Government [CSI252P18, CLC-2017-01]; Spanish Ministry of Science and Innovation (MSI) [RTI2018-096481-B-I00]; Spanish Association against Cancer [GC16173472GARC]; Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government [CLC-2017-01]; MSI [BES-2010-031386, BES-2013-063573]; Spanish Ministry of Universities [CLC-2017-01, FPU13/02923]; CIBERONC; Spanish Association against Cancer; European Regional Development Fund	Worldwide Cancer Research; Castilla-Leon Government; Spanish Ministry of Science and Innovation (MSI)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Association against Cancer; Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government; MSI; Spanish Ministry of Universities(Spanish Government); CIBERONC; Spanish Association against Cancer; European Regional Development Fund(European Commission)	We thank M. Blazquez for lab work and CIC facilities' personnel for technical assistance. XRB is supported by grants from Worldwide Cancer Research (14-1248), the Castilla-Leon Government (CSI252P18, CLC-2017-01), the Spanish Ministry of Science and Innovation (MSI) (RTI2018-096481-B-I00), and the Spanish Association against Cancer (GC16173472GARC). XRB's institution is supported by the Programa de Apoyo a Planes Estrategicos de Investigacion de Estructuras de Investigacion de Excelencia of the Castilla-Leon autonomous government (CLC-2017-01). SF, SR-F, and LFL-M contracts have been supported by funding from the MSI (SF, BES-2010-031386; SR-F, BES-2013-063573), the Spanish Ministry of Universities (LFL-M, FPU13/02923), and the CLC-2017-01 grant (SR-F and LFL-M). JR-V has been supported by the CIBERONC and, currently, by the Spanish Association against Cancer. Both Spanish and Castilla-Leon government-associated funding is partially supported by the European Regional Development Fund.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Amado-Azevedo J, 2014, CELL TISSUE RES, V355, P557, DOI 10.1007/s00441-014-1828-6; Arash EH, 2014, EMBO J, V33, P2997, DOI 10.15252/embj.201490230; Barreira M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004993; Bouquier N, 2009, CHEM BIOL, V16, P391, DOI 10.1016/j.chembiol.2009.02.006; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2018, BIOCHEM SOC T, V46, P741, DOI 10.1042/BST20170531; Bustelo Xose R, 2014, Small GTPases, V5, P9, DOI 10.4161/21541248.2014.973757; Chrencik JE, 2008, J MOL BIOL, V380, P828, DOI 10.1016/j.jmb.2008.05.024; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Cullis J, 2014, CANCER CELL, V25, P181, DOI 10.1016/j.ccr.2014.01.025; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Dutting S, 2015, J THROMB HAEMOST, V13, P827, DOI 10.1111/jth.12861; Fabbiano S, 2014, MOL CELL BIOL, V34, P4404, DOI 10.1128/MCB.01066-14; Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569; Lorenzo-Martin LF, 2019, ONCOGENE, V38, P209, DOI 10.1038/s41388-018-0433-7; Fujikawa K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009050; Garcia-Mariscal A, 2018, ONCOGENE, V37, P847, DOI 10.1038/onc.2017.333; Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Huang YP, 2019, CELL DISCOV, V5, DOI 10.1038/s41421-019-0126-6; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; Kawasaki Y, 2009, EMBO REP, V10, P1355, DOI 10.1038/embor.2009.233; Khanna N, 2013, P NATL ACAD SCI USA, V110, P15979, DOI 10.1073/pnas.1310434110; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Luch A, 2005, NAT REV CANCER, V5, P113, DOI 10.1038/nrc1546; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Niebel B, 2013, BIOORGAN MED CHEM, V21, P6239, DOI 10.1016/j.bmc.2013.05.021; Que SKT, 2018, J AM ACAD DERMATOL, V78, P237, DOI 10.1016/j.jaad.2017.08.059; Rapley J, 2008, EMBO REP, V9, P655, DOI 10.1038/embor.2008.80; Robles-Valero Javier, 2020, Small GTPases, V11, P233, DOI 10.1080/21541248.2018.1423851; Robles-Valero J, 2017, CANCER CELL, V32, P608, DOI 10.1016/j.ccell.2017.10.004; Rodriguez-Fdez S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050465; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Ruggiero C, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal2464; Sauzeau V, 2006, NAT MED, V12, P841, DOI 10.1038/nm1426; Sauzeau V, 2007, MOL BIOL CELL, V18, P943, DOI 10.1091/mbc.E06-09-0877; Sauzeau V, 2010, J CLIN INVEST, V120, P315, DOI 10.1172/JCI38356; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Svensmark JH, 2019, ONCOGENE, V38, P7447, DOI 10.1038/s41388-019-0963-7; Thomas EK, 2007, CANCER CELL, V12, P467, DOI 10.1016/j.ccr.2007.10.015; Verma R, 2020, MOL CELL, V77, P446, DOI 10.1016/j.molcel.2020.01.010; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; Wang Z, 2010, ONCOGENE, V29, P3362, DOI 10.1038/onc.2010.95; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zugaza JL, 2002, J BIOL CHEM, V277, P45377, DOI 10.1074/jbc.M208039200	55	8	8	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5098	5111		10.1038/s41388-020-1353-x	http://dx.doi.org/10.1038/s41388-020-1353-x		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32528129	Green Accepted			2022-12-17	WOS:000539817600001
J	Portney, BA; Arad, M; Gupta, A; Brown, RA; Khatri, R; Lin, PN; Hebert, AM; Angster, KH; Silipino, LE; Meltzer, WA; Taylor, RJ; Zalzman, M				Portney, Benjamin A.; Arad, Michal; Gupta, Aditi; Brown, Robert A.; Khatri, Raju; Lin, Phyo Nay; Hebert, Andrea M.; Angster, Kristen H.; Silipino, Lorna E.; Meltzer, W. Alex; Taylor, Rodney J.; Zalzman, Michal			ZSCAN4 facilitates chromatin remodeling and promotes the cancer stem cell phenotype	ONCOGENE			English	Article							DEVELOPMENTAL REGULATORS; TELOMERE ELONGATION; GENOMIC STABILITY; NECK-CANCER; HEAD; PLURIPOTENCY; NANOG; EXPRESSION; CARCINOMA; POLYCOMB	Cancer stem cells (CSCs) are cells within tumors that maintain the ability to self-renew, drive tumor growth, and contribute to therapeutic resistance and cancer recurrence. In this study, we investigate the role of Zinc finger and SCAN domain containing 4 (ZSCAN4) in human head and neck squamous cell carcinoma (HNSCC). The murine Zscan4 is involved in telomere maintenance and genomic stability of mouse embryonic stem cells. Our data indicate that the human ZSCAN4 is enriched for, marks and is co-expressed with CSC markers in HNSCC. We show that transient ZSCAN4 induction for just 2 days increases CSC frequency both in vitro and in vivo and leads to upregulation of pluripotency and CSC factors. Importantly, we define for the first time the role of ZSCAN4 in altering the epigenetic profile and regulating the chromatin state. Our data show that ZSCAN4 leads to a functional histone 3 hyperacetylation at the promoters of OCT3/4 and NANOG, leading to an upregulation of CSC factors. Consistently, ZSCAN4 depletion leads to downregulation of CSC markers, decreased ability to form tumorspheres and severely affects tumor growth. Our study suggests that ZSCAN4 plays an important role in the maintenance of the CSC phenotype, indicating it is a potential therapeutic target in HNSCC.	[Portney, Benjamin A.; Arad, Michal; Gupta, Aditi; Brown, Robert A.; Khatri, Raju; Lin, Phyo Nay; Hebert, Andrea M.; Angster, Kristen H.; Meltzer, W. Alex; Zalzman, Michal] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Hebert, Andrea M.; Angster, Kristen H.; Silipino, Lorna E.; Taylor, Rodney J.; Zalzman, Michal] Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA; [Taylor, Rodney J.; Zalzman, Michal] Univ Maryland, Sch Med, Marlene & Stewart Greenbaum Canc Ctr, Baltimore, MD 21201 USA; [Zalzman, Michal] Univ Maryland, Sch Med, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Zalzman, M (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA.; Zalzman, M (corresponding author), Univ Maryland, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Baltimore, MD 21201 USA.; Zalzman, M (corresponding author), Univ Maryland, Sch Med, Marlene & Stewart Greenbaum Canc Ctr, Baltimore, MD 21201 USA.; Zalzman, M (corresponding author), Univ Maryland, Sch Med, Ctr Stem Cell Biol & Regenerat Med, Baltimore, MD 21201 USA.	MZalzman@som.umaryland.edu	Gupta, Aditi/HGD-9632-2022	Khatri, Raju/0000-0002-1381-8560; Zalzman, Michal/0000-0002-4689-2951; Lin, Phyo Nay/0000-0003-4041-629X	National Institutes of Health/NINDS grant [1R21 NS095088-01A1]; NIH/NIAMS [R01 AR070819]; National Institutes of Health/NIH/NIAMS grant [R01 AR070819]	National Institutes of Health/NINDS grant; NIH/NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); National Institutes of Health/NIH/NIAMS grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The molecular studies of ZSCAN4 were partially supported by the National Institutes of Health/NINDS grant number 1R21 NS095088-01A1 and NIH/NIAMS grant number R01 AR070819. MZ, RJT, BAP, were partially supported by the National Institutes of Health/NIH/NIAMS grant number R01 AR070819.	Adhikary G, 2015, CARCINOGENESIS, V36, P800, DOI 10.1093/carcin/bgv064; Adhikary G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084324; Ailles L, 2009, METHODS MOL BIOL, V568, P175, DOI 10.1007/978-1-59745-280-9_11; Akiyama T, 2015, DNA RES, V22, P307, DOI 10.1093/dnares/dsv013; Allegra E, 2014, ONCOLOGY-BASEL, V86, P199, DOI 10.1159/000358598; Allegra E, 2012, ONCOTARGETS THER, V5, P375, DOI 10.2147/OTT.S38694; Amano T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2966; Azuara V, 2006, NAT CELL BIOL, V8, P532, DOI 10.1038/ncb1403; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037; Chinn SB, 2015, HEAD NECK-J SCI SPEC, V37, P317, DOI 10.1002/hed.23600; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Dan JM, 2017, CELL REP, V20, P1936, DOI 10.1016/j.celrep.2017.07.070; Falco G, 2007, DEV BIOL, V307, P539, DOI 10.1016/j.ydbio.2007.05.003; Gaspar-Maia A, 2011, NAT REV MOL CELL BIO, V12, P36, DOI 10.1038/nrm3036; Hirata T, 2012, SCI REP-UK, V2, DOI 10.1038/srep00208; Jiang J, 2013, CELL RES, V23, P92, DOI 10.1038/cr.2012.157; Joshi P, 2014, RAMBAM MAIMONIDES ME, V5, DOI 10.5041/RMMJ.10143; Joshua B, 2012, HEAD NECK-J SCI SPEC, V34, P42, DOI 10.1002/hed.21699; Lee K, 2014, CANCER BIOL THER, V15, P1094, DOI 10.4161/cbt.29220; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu AF, 2013, CHIN J CANCER, V32, P483, DOI 10.5732/cjc.012.10282; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Lu YH, 2013, CANCER LETT, V340, P113, DOI 10.1016/j.canlet.2013.07.009; Marur S, 2016, MAYO CLIN PROC, V91, P386, DOI 10.1016/j.mayocp.2015.12.017; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938; Nakai-Futatsugi Y, 2016, STEM CELL REP, V6, P483, DOI 10.1016/j.stemcr.2016.02.010; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Okamoto A, 2009, ORAL ONCOL, V45, P633, DOI 10.1016/j.oraloncology.2008.10.003; Orkin SH, 2011, CELL, V145, P835, DOI 10.1016/j.cell.2011.05.019; Plimack ER, 2007, J CLIN ONCOL, V25, P4519, DOI 10.1200/JCO.2007.12.6029; Portney BA, 2018, BIOCHEM BIOPH RES CO, V498, P72, DOI 10.1016/j.bbrc.2018.02.155; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Prince MEP, 2008, J CLIN ONCOL, V26, P2871, DOI 10.1200/JCO.2007.15.1613; Proctor E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055820; Sano D, 2007, CANCER METAST REV, V26, P645, DOI 10.1007/s10555-007-9082-y; Seiwert TY, 2005, BRIT J CANCER, V92, P1341, DOI 10.1038/sj.bjc.6602510; Sharov AA, 2003, PLOS BIOL, V1, P410, DOI 10.1371/journal.pbio.0000074; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Spafford MF, 1996, ARCH OTOLARYNGOL, V122, P627; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; van Vlerken LE, 2013, STEM CELL TRANSL MED, V2, P43, DOI 10.5966/sctm.2012-0036; Zalzman M, 2010, NATURE, V464, P858, DOI 10.1038/nature08882	51	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4970	4982		10.1038/s41388-020-1333-1	http://dx.doi.org/10.1038/s41388-020-1333-1		JUN 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32507861	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000538701900001
J	Li, W; Wang, QX; Qi, XY; Guo, YY; Lu, HM; Chen, YH; Lu, ZM; Yan, Q; Zhu, XF; Jung, JU; Tosato, OAN; Gao, SJ; Lu, C				Li, Wan; Wang, Qingxia; Qi, Xiaoyu; Guo, Yuanyuan; Lu, Hongmei; Chen, Yuheng; Lu, Zhongmou; Yan, Qin; Zhu, Xiaofei; Jung, Jae U.; Tosato, Giovanna; Gao, Shou-Jiang; Lu, Chun			Viral interleukin-6 encoded by an oncogenic virus promotes angiogenesis and cellular transformation by enhancing STAT3-mediated epigenetic silencing of caveolin 1	ONCOGENE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; HIV-1 NEF; STAT3; GENE; ACTIVATION; TRANSCRIPTION; PROTEIN; VIL-6; IL-6	Kaposi's sarcoma (KS) caused by oncogenic Kaposi's sarcoma-associated herpesvirus (KSHV) is a highly angiogenic and invasive vascular tumor and the most common AIDS-associated cancer. KSHV-encoded viral interleukin-6 (vIL-6) is implicated in the development of KSHV-induced malignancies; however, the mechanisms underlying vIL-6-induced angiogenesis and tumorigenesis remain undefined. Here, we show that vIL-6 promotes angiogenesis, cell proliferation, and invasion by downregulating caveolin 1 (CAV1) that plays a pivotal and versatile role in multiple cancer-associated processes. Mechanistically, vIL-6 signaling led to the phosphorylation and acetylation of STAT3 that targeted DNA methyltransferase 1 (DNMT1) in a sequential manner. Specifically, the vIL-6-induced phosphorylated form of STAT3 transcriptionally activated DNMT1 expression. Furthermore, vIL-6-induced acetylated form of STAT3 interacted with DNMT1 to form a transcription factor complex that bound to and methylated the CAV1 promoter, leading to CAV1 expression silencing. In fact, downregulation of CAV1 expression resulted in the activation of AKT signaling, promoting cell invasion, and growth transformation induced by KSHV. Finally, genetic deletion of vIL-6 from the KSHV genome abolished KSHV-induced cellular transformation and impaired angiogenesis. Our results reveal that vIL-6 epigenetically silences CAV1 expression to promote angiogenesis and tumorigenesis by regulating the formation of STAT3-DNMT1 complex. These novel findings define a mechanism by which KSHV inhibits the CAV1 pathway and establish the scientific basis for targeting this pathway to treat KSHV-associated cancers.	[Li, Wan; Wang, Qingxia; Qi, Xiaoyu; Chen, Yuheng; Lu, Zhongmou; Yan, Qin; Lu, Chun] Nanjing Med Univ, Dept Microbiol, Nanjing 211166, Peoples R China; [Li, Wan; Lu, Chun] Nanjing Med Univ, Womens Hosp, Nanjing Matern & Child Hlth Hosp, Dept Gynecol, Nanjing 210029, Peoples R China; [Li, Wan; Lu, Chun] Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing 211166, Peoples R China; [Guo, Yuanyuan] Nanjing Univ Chinese Med, Coll Med & Life Sci, Nanjing 210023, Peoples R China; [Lu, Hongmei] Nanjing Med Univ, Dept Obstet, Affiliated Hosp 1, Nanjing 210036, Peoples R China; [Zhu, Xiaofei] Nanjing Univ Chinese Med, Dept Lab Med, Affiliated Hosp, Nanjing 210029, Peoples R China; [Jung, Jae U.] Univ Southern Calif, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; [Tosato, Giovanna] NCI, Ctr Canc Res, Bethesda, MD 20892 USA; [Gao, Shou-Jiang] Univ Pittsburgh, UPMC Hillman Canc Ctr, Dept Microbiol & Mol Genet, Pittsburgh, PA 15232 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing University of Chinese Medicine; Nanjing Medical University; Nanjing University of Chinese Medicine; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lu, C (corresponding author), Nanjing Med Univ, Dept Microbiol, Nanjing 211166, Peoples R China.; Lu, C (corresponding author), Nanjing Med Univ, Womens Hosp, Nanjing Matern & Child Hlth Hosp, Dept Gynecol, Nanjing 210029, Peoples R China.; Lu, C (corresponding author), Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing 211166, Peoples R China.; Zhu, XF (corresponding author), Nanjing Univ Chinese Med, Dept Lab Med, Affiliated Hosp, Nanjing 210029, Peoples R China.	zxfyxjy@163.com; clu@njmu.edu.cn		Gao, Shou-Jiang/0000-0001-6194-1742; Tosato, Giovanna/0000-0003-1663-3227; Lu, Chun/0000-0002-6078-9352	National Natural Science Foundation of China [81730062, 81761128003, 31800148, 81503368]; Natural Science Foundation of Jiangsu Province [BK20180681]; Nanjing Medical University [KY101RC1710]; NIH [R01CA213275, CA200422, AI073099, AI116585, AI129496, AI140718, AI140705, DE023926, DE027888, DE028521]; Fletcher Jones Foundation	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Nanjing Medical University; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Fletcher Jones Foundation	This work was supported by grants from National Natural Science Foundation of China (81730062, 81761128003, 31800148, and 81503368), Natural Science Foundation of Jiangsu Province (BK20180681), Nanjing Medical University (KY101RC1710), a grant from NIH (R01CA213275), and grants (CA200422, AI073099, AI116585, AI129496, AI140718, AI140705, DE023926, DE027888, DE028521 and Fletcher Jones Foundation).	Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoki Y, 2001, BLOOD, V97, P2173, DOI 10.1182/blood.V97.7.2173; Belo Y, 2019, BBA-GEN SUBJECTS, V1863, P1343, DOI 10.1016/j.bbagen.2019.05.019; Bhatt AP, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00401; Boshoff C, 2001, ANNU REV MED, V52, P453, DOI 10.1146/annurev.med.52.1.453; Brulois KF, 2012, J VIROL, V86, P9708, DOI 10.1128/JVI.01019-12; Chandriani S, 2010, J VIROL, V84, P5565, DOI 10.1128/JVI.02723-09; Cousins E, 2013, J VIROL, V87, P10816, DOI 10.1128/JVI.02047-13; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Ding XY, 2019, CELL DEATH DIFFER, V26, P1970, DOI 10.1038/s41418-018-0268-3; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Fullwood RA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204947; Giffin L, 2015, MBIO, V6, DOI 10.1128/mBio.01499-15; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Gruffaz M, 2017, CANCER RES, V77, P7094, DOI 10.1158/0008-5472.CAN-17-2321; Gu XW, 2017, PROG RETIN EYE RES, V56, P84, DOI 10.1016/j.preteyeres.2016.09.005; Hu F, 2006, J VIROL, V80, P10874, DOI 10.1128/JVI.00767-06; Hu MM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005171; Jones T, 2014, CELL CYCLE, V13, P845, DOI 10.4161/cc.27758; Jones T, 2012, J CLIN INVEST, V122, P1076, DOI 10.1172/JCI58530; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lamaze C, 2017, CURR OPIN CELL BIOL, V47, P117, DOI 10.1016/j.ceb.2017.02.014; Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109; Lee MS, 2016, MBIO, V7, DOI 10.1128/mBio.02109-15; Lee MS, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004412; Li TT, 2019, J VIROL, V93, DOI 10.1128/JVI.01599-18; Li W, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007578; Li W, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005605; Magnaudeix A, 2016, ACTA BIOMATER, V38, P179, DOI 10.1016/j.actbio.2016.04.039; Mergia A, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060129; Molden J, 1997, J BIOL CHEM, V272, P19625, DOI 10.1074/jbc.272.31.19625; Moody R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003857; Morris VA, 2008, J VIROL, V82, P8771, DOI 10.1128/JVI.00766-08; Morris VA, 2012, VIROLOGY, V428, P112, DOI 10.1016/j.virol.2012.03.013; Nwosu ZC, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0558-7; Punjabi AS, 2007, J VIROL, V81, P2449, DOI 10.1128/JVI.01769-06; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Senetta R, 2013, J CELL MOL MED, V17, P325, DOI 10.1111/jcmm.12030; Stary CM, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00393; Suthaus J, 2012, BLOOD, V119, P5173, DOI 10.1182/blood-2011-09-377705; Syeed N, 2012, ASIAN PAC J CANCER P, V13, P371, DOI 10.7314/APJCP.2012.13.1.371; Tischer BK, 2010, METHODS MOL BIOL, V634, P421, DOI 10.1007/978-1-60761-652-8_30; Tischer BK, 2006, BIOTECHNIQUES, V40, P191, DOI 10.2144/000112096; Uldrick TS, 2010, CLIN INFECT DIS, V51, P350, DOI 10.1086/654798; Wake MS, 2015, FEBS J, V282, P2600, DOI 10.1111/febs.13285; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; Wen KW, 2010, CANCER LETT, V289, P140, DOI 10.1016/j.canlet.2009.07.004; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093478; Xia H, 2010, AM J PATHOL, V176, P2626, DOI 10.2353/ajpath.2010.091117; Xu HP, 2017, ONCOTARGET, V8, P76165, DOI 10.18632/oncotarget.19191; Xue M, 2014, NUCLEIC ACIDS RES, V42, P9862, DOI 10.1093/nar/gku583; Yao SH, 2015, NUCLEIC ACIDS RES, V43, P9362, DOI 10.1093/nar/gkv988; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang Q, 2006, BLOOD, V108, P1058, DOI 10.1182/blood-2005-08-007377; Zhou F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053145; Zhu X, 2014, ONCOGENE, V33, P1986, DOI 10.1038/onc.2013.136; Zhu Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005648	59	8	9	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2020	39	23					4603	4618		10.1038/s41388-020-1317-1	http://dx.doi.org/10.1038/s41388-020-1317-1		MAY 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LU5ZF	32393833	Green Accepted			2022-12-17	WOS:000531771800002
J	Li, WJ; Dai, Y; Shi, BY; Yue, F; Zou, J; Xu, GB; Jiang, XH; Wang, F; Zhou, XK; Liu, LY				Li, Wenjiao; Dai, Yuan; Shi, Boyun; Yue, Fei; Zou, Jing; Xu, Guibin; Jiang, Xianhan; Wang, Fen; Zhou, Xinke; Liu, Leyuan			LRPPRC sustains Yap-P27-mediated cell ploidy and P62-HDAC6-mediated autophagy maturation and suppresses genome instability and hepatocellular carcinomas	ONCOGENE			English	Article							MITOCHONDRIAL; PROTEIN; TUMORIGENESIS; MICROTUBULE; PATHWAY; RASSF1; LIVER; ASSOCIATION; ACTIVATION; ANEUPLOIDY	Mutants in the gene encoding mitochondrion-associated protein LRPPRC were found to be associated with French Canadian Type Leigh syndrome, a human disorder characterized with neurodegeneration and cytochrome c oxidase deficiency. LRPPRC interacts with one of microtubule-associated protein family MAP1S that promotes autophagy initiation and maturation to suppress genomic instability and tumorigenesis. Previously, although various studies have attributed LRPPRC nuclear acid-associated functions, we characterized that LRPPRC acted as an inhibitor of autophagy in human cancer cells. Here we show that liver-specific deletion of LRPPRC causes liver-specific increases of YAP and P27 and decreases of P62, leading to an increase of cell polyploidy and an impairment of autophagy maturation. The blockade of autophagy maturation and promotion of polyploidy caused by LRPPRC depletion synergistically enhances diethylnitrosamine-induced DNA damage, genome instability, and further tumorigenesis so that LRPPRC knockout mice develop more and larger hepatocellular carcinomas and survive a shorter lifespan. Therefore, LRPPRC suppresses genome instability and hepatocellular carcinomas and promotes survivals in mice by sustaining Yap-P27-mediated cell ploidy and P62-HDAC6-controlled autophagy maturation.	[Li, Wenjiao; Shi, Boyun; Xu, Guibin; Jiang, Xianhan; Zhou, Xinke; Liu, Leyuan] Guangzhou Med Univ, Affiliated Hosp 5, 621 Gangwan Rd, Guangzhou 710700, Guangdong, Peoples R China; [Li, Wenjiao; Dai, Yuan; Shi, Boyun; Yue, Fei; Zou, Jing; Xu, Guibin; Jiang, Xianhan; Wang, Fen; Liu, Leyuan] Texas A&M Univ, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA; [Liu, Leyuan] Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA	Guangzhou Medical University; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station	Liu, LY (corresponding author), Guangzhou Med Univ, Affiliated Hosp 5, 621 Gangwan Rd, Guangzhou 710700, Guangdong, Peoples R China.; Liu, LY (corresponding author), Texas A&M Univ, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.; Liu, LY (corresponding author), Texas A&M Univ, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77843 USA.	liuleyuan@hotmail.com	Yue, Fei/N-1891-2018	Zou, Jing/0000-0002-0976-7078; Li, Wenjiao/0000-0003-1308-8489	National Natural Science Foundation of China [81772931]; NCI [R01CA142862]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nils-Goran Larsson, Department of Mitochondrial Genetics, Max Planck Institute for Biology of Ageing, Cologne, Germany, for providing LRPPRCloxP/loxP mice to us as a gift. This work was supported by National Natural Science Foundation of China (81772931) and NCI R01CA142862 to Leyuan Liu.	Chen Q, 2015, J BIOL CHEM, V290, P26051, DOI 10.1074/jbc.M115.653568; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8; Cuillerier A, 2017, HUM MOL GENET, V26, P3186, DOI 10.1093/hmg/ddx202; Hergovich A, 2012, BIOCHEM SOC T, V40, P124, DOI 10.1042/BST20110619; Jiang XH, 2018, PROSTATE, V78, P426, DOI 10.1002/pros.23487; Jiang XH, 2015, MOL CARCINOGEN, V54, P1194, DOI 10.1002/mc.22193; Jiang XH, 2014, CANCER-AM CANCER SOC, V120, P1228, DOI 10.1002/cncr.28551; Jimenez-Martinez M, 2019, CANCERS, V11, DOI 10.3390/cancers11111767; Johansen T, 2020, J MOL BIOL, V432, P80, DOI 10.1016/j.jmb.2019.07.016; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007; Lee YA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07338-z; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li WJ, 2019, CELL DEATH DIFFER, V26, P1379, DOI 10.1038/s41418-018-0211-7; Li WJ, 2016, AGING CELL, V15, P370, DOI 10.1111/acel.12441; Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537; Liu LY, 2012, AUTOPHAGY, V8, P278, DOI 10.4161/auto.8.2.18939; Liu LJ, 2011, J BIOL CHEM, V286, P41253, DOI 10.1074/jbc.M111.276121; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P4191, DOI 10.1158/0008-5472.CAN-04-3865; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Liu LY, 2002, IN VITRO CELL DEV-AN, V38, P582; Liu LY, 2002, GENOMICS, V79, P124, DOI 10.1006/geno.2001.6679; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Mili S, 2003, MOL CELL BIOL, V23, P4972, DOI 10.1128/MCB.23.14.4972-4982.2003; Mishra PK, 2009, FREE RADICAL RES, V43, P718, DOI 10.1080/10715760903037699; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; Nam M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01879-x; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Refolo G, 2019, HEPATOLOGY, V69, P34, DOI 10.1002/hep.30149; Ruzzenente B, 2012, EMBO J, V31, P443, DOI 10.1038/emboj.2011.392; Ryter Stefan W, 2014, Int J Cell Biol, V2014, P502676, DOI 10.1155/2014/502676; Schweitzer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040537; Siira SJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01221-z; Singh S, 2014, NAT REV GASTRO HEPAT, V11, P45, DOI 10.1038/nrgastro.2013.143; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211; Terman A, 2006, CHEM-BIOL INTERACT, V163, P29, DOI 10.1016/j.cbi.2006.04.013; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vandin F, 2012, BIOCOMPUT-PAC SYM, P55; Xie R, 2011, CANCER RES, V71, P7537, DOI 10.1158/0008-5472.CAN-11-2170; Xie R, 2011, J BIOL CHEM, V286, P10367, DOI 10.1074/jbc.M110.206532; Xie R, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-89; Xu FH, 2012, BIOCHEM J, V441, P275, DOI 10.1042/BJ20110985; Xu GB, 2016, ONCOTARGET, V7, P6255, DOI 10.18632/oncotarget.6669; Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111; Yue F, 2017, CANCER RES, V77, P2938, DOI 10.1158/0008-5472.CAN-16-3462; Yue F, 2015, AGING-US, V7, P839, DOI 10.18632/aging.100818; Zhang SH, 2017, CANCER CELL, V31, P669, DOI 10.1016/j.ccell.2017.04.004; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zou J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094903; Zou J, 2013, BIOCHEM J, V454, P447, DOI 10.1042/BJ20130306	56	8	8	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3879	3892		10.1038/s41388-020-1257-9	http://dx.doi.org/10.1038/s41388-020-1257-9		MAR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32203162				2022-12-17	WOS:000519841000001
J	Park, SM; Hwang, CY; Choi, J; Joung, CY; Cho, KH				Park, Sang-Min; Hwang, Chae Young; Choi, Jihye; Joung, Chang Young; Cho, Kwang-Hyun			Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy	ONCOGENE			English	Article							MEK INHIBITION; SYSTEMS BIOLOGY; NETWORKS; DYNAMICS; BRAF; PATHWAY; SRC; KINOME; ENCYCLOPEDIA; ACTIVATION	Targeted drugs aim to treat cancer by directly inhibiting oncogene activity or oncogenic pathways, but drug resistance frequently emerges. Due to the intricate dynamics of cancer signaling networks, which contain complex feedback regulations, cancer cells can rewire these networks to adapt to and counter the cytotoxic effects of a drug, thereby limiting the efficacy of targeted therapies. To identify a combinatorial drug target that can overcome such a limitation, we developed a Boolean network simulation and analysis framework and applied this approach to a large-scale signaling network of colorectal cancer with integrated genomic information. We discovered Src as a critical combination drug target that can overcome the adaptive resistance to the targeted inhibition of mitogen-activated protein kinase pathway by blocking the essential feedback regulation responsible for resistance. The proposed framework is generic and can be widely used to identify drug targets that can overcome adaptive resistance to targeted therapies.	[Park, Sang-Min; Hwang, Chae Young; Choi, Jihye; Joung, Chang Young; Cho, Kwang-Hyun] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Lab Syst Biol & Bioinspired Engn, Daejeon 34141, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Cho, KH (corresponding author), Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Lab Syst Biol & Bioinspired Engn, Daejeon 34141, South Korea.	ckh@kaist.ac.kr	Cho, Kwang-Hyun/C-1684-2011	Park, Sang-Min/0000-0003-2915-0742	National Research Foundation of Korea (NRF) - Korea Government; Ministry of Science and ICT [2017R1A2A1A17069642, 2015M3A9A7067220]	National Research Foundation of Korea (NRF) - Korea Government(National Research Foundation of Korea); Ministry of Science and ICT(Ministry of Science, ICT & Future Planning, Republic of Korea)	We thank Dr Ki-Sun Kwon (Korea Research Institute of Bioscience and Biotechnology) for the rabbit polyclonal anti-GAPDH antibody, Nancy R. Gough (BioSerendipity, LLC) for editorial assistance, and Sea Choi for her editorial assistance during revision. This work was supported by the National Research Foundation of Korea (NRF) grants funded by the Korea Government, the Ministry of Science and ICT (2017R1A2A1A17069642 and 2015M3A9A7067220).	Abdi A, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000008; Aldridge BB, 2006, NAT CELL BIOL, V8, P1195, DOI 10.1038/ncb1497; Anderson GR, 2017, CELL REP, V20, P999, DOI 10.1016/j.celrep.2017.07.006; Assmus HE, 2006, EXPERT REV MOL DIAGN, V6, P891, DOI 10.1586/14737159.6.6.891; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011; Chen SH, 2016, CURR OPIN STRUC BIOL, V41, P145, DOI 10.1016/j.sbi.2016.07.020; Cho SH, 2016, BMC SYST BIOL, V10, DOI 10.1186/s12918-016-0341-9; Choi M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02160-5; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Creixell P, 2015, CELL, V163, P202, DOI 10.1016/j.cell.2015.08.056; Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430; Eshaghi M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011620; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Gargalionis AN, 2014, INT J CANCER, V134, P2019, DOI 10.1002/ijc.28299; Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012; Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Helikar T, 2008, P NATL ACAD SCI USA, V105, P1913, DOI 10.1073/pnas.0705088105; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Imperial R, 2019, SEMIN CANCER BIOL, V54, P14, DOI 10.1016/j.semcancer.2017.11.016; Jeong WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0049-y; Johnson GL, 2014, CLIN CANCER RES, V20, P2516, DOI 10.1158/1078-0432.CCR-13-1081; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim JR, 2006, COMPUT BIOL CHEM, V30, P438, DOI 10.1016/j.compbiolchem.2006.09.004; Kim JR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001390; Kim J, 2013, SCI REP-UK, V3, DOI 10.1038/srep02223; Kim S, 2007, COMPUT BIOL CHEM, V31, P239, DOI 10.1016/j.compbiolchem.2007.03.013; Kirouac DC, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0016-1; Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29; Kolch W, 2015, NAT REV CANCER, V15, P515, DOI 10.1038/nrc3983; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534; Kwon YK, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-430; Kwon YK, 2007, BIOPHYS J, V92, P2975, DOI 10.1529/biophysj.106.097097; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Lee HS, 2015, SCI REP-UK, V5, DOI 10.1038/srep10305; Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392; Murray PJ, 2010, BIOPHYS J, V99, P716, DOI 10.1016/j.bpj.2010.05.016; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ornes S, 2016, P NATL ACAD SCI USA, V113, P7007, DOI 10.1073/pnas.1608277113; Park D, 2018, J MOL CELL BIOL, V10, P180, DOI 10.1093/jmcb/mjy019; Park SM, 2019, FEBS J, V286, P1305, DOI 10.1111/febs.14773; Park SG, 2006, FEBS LETT, V580, P822, DOI 10.1016/j.febslet.2006.01.004; Parseghian CM, 2017, CLIN CANCER RES, V23, P4146, DOI 10.1158/1078-0432.CCR-16-3138; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Saez-Rodriguez J, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.87; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Scaltriti J, 2017, CANC CONVERG, V1, P5, DOI DOI 10.1186/s41236-017-0007-6; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Schmidt H, 2005, FEBS J, V272, P2141, DOI 10.1111/j.1742-4658.2005.04605.x; Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907; Shin D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01171-6; Shmulevich I, 2002, BIOINFORMATICS, V18, P261, DOI 10.1093/bioinformatics/18.2.261; Sontag ED, 2008, ESSAYS BIOCHEM, V45, P161, DOI 10.1042/BSE0450161; Sreenath SN, 2008, ESSAYS BIOCHEM, V45, P1, DOI 10.1042/BSE0450001; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010; Thieffry D, 1999, BIOSYSTEMS, V50, P49, DOI 10.1016/S0303-2647(98)00087-2; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	68	8	8	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	19					3803	3820		10.1038/s41388-020-1255-y	http://dx.doi.org/10.1038/s41388-020-1255-y		MAR 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LK4OF	32157217				2022-12-17	WOS:000518886000008
J	Zhou, S; Liu, SL; Lin, CY; Li, Y; Ye, LP; Wu, XQ; Jian, YT; Dai, YH; Ouyang, Y; Zhao, L; Liu, MZ; Song, LB; Xi, M				Zhou, Sha; Liu, Shiliang; Lin, Chuyong; Li, Yue; Ye, Liping; Wu, Xianqiu; Jian, Yunting; Dai, Yuhu; Ouyang, Ying; Zhao, Lei; Liu, Mengzhong; Song, Libing; Xi, Mian			TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZ	ONCOGENE			English	Article							CANCER STATISTICS; TRB3 INTERACTS; C/EBP-ALPHA; STEM-CELLS; PROLIFERATION; PROGRESSION; ACTIVATION; EXPRESSION; DROSOPHILA; MIGRATION	Radioresistance becomes the major obstacle to reduce tumor recurrence and improve prognosis in the treatment of esophageal squamous cell carcinoma (ESCC). Thus new strategies for radioresistant ESCC are urgently needed. Herein, we reported that tribbles pseudokinase 3 (TRIB3) serves as a key regulator of radioresistance in ESCC. TRIB3 is overexpressed in ESCC tissues and cell lines. High expression of TRIB3 significantly correlates with poor radiotherapy response and prognosis in ESCC patients. Upregulation of TRIB3 in ESCC cells conferred radioresistance in vitro and in vivo by interacting with TAZ thus impeding beta-TrCP-mediated TAZ ubiquitination and degradation. Conversely, silencing TRIB3 sensitized ESCC cells to ionizing radiation. More importantly, TRIB3 was significantly correlated with TAZ activation in ESCC biopsies, and patients with high expression of both TRIB3 and TAZ suffered the worst radiotherapy response and survival. Our study uncovers the critical mechanism of ESCC resistance to radiotherapy, and provides a new pharmacological opportunity for developing a mechanism-based strategy to eliminate radioresistant ESCC in clinical practice.	[Zhou, Sha; Liu, Shiliang; Zhao, Lei; Liu, Mengzhong; Xi, Mian] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Lin, Chuyong; Li, Yue; Ye, Liping; Wu, Xianqiu; Jian, Yunting; Ouyang, Ying; Song, Libing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China; [Dai, Yuhu] Sun Yat Sen Univ, Dept Orthpaed Surg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Xi, M (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Radiat Oncol, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.; Song, LB (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, Canc Ctr,State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.	songlb@sysucc.org.cn; ximian@sysucc.org.cn	Lin, Chuyong/AAA-9931-2020; Song, LB/AAL-1968-2020	Lin, Chuyong/0000-0003-4887-5386; 	Natural Science Foundation of China [81272487, 81874220, 81530082, 81672854, 81773106, 91740118]; Science and Technology of Guangdong Province [2016A030308002, 2017A030306019, 2018B030311060]; Guangdong Esophageal Cancer Institute Science and Technology Program [M201715]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology of Guangdong Province; Guangdong Esophageal Cancer Institute Science and Technology Program	This work was supported by Natural Science Foundation of China (Nos. 81272487, 81874220, 81530082, 81672854, 81773106, 91740118); The Science and Technology of Guangdong Province (Nos. 2016A030308002, 2017A030306019, 2018B030311060); Guangdong Esophageal Cancer Institute Science and Technology Program (M201715).	Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003; Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Ando T, 2018, ONCOGENE, V37, P263, DOI 10.1038/onc.2017.321; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Bhat KPL, 2011, GENE DEV, V25, P2594, DOI 10.1101/gad.176800.111; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Che SM, 2011, DIS ESOPHAGUS, V24, P265, DOI 10.1111/j.1442-2050.2010.01138.x; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chen YA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00060; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004-1013.2003; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Hou ZL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0922-x; Hua F, 2019, GASTROENTEROLOGY, V156, P708, DOI 10.1053/j.gastro.2018.10.031; Hua F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8951; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Hwang CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105676; Jin GA, 2007, BLOOD, V109, P3998, DOI 10.1182/blood-2006-08-041202; Kim MH, 2017, CELL MOL LIFE SCI, V74, P1457, DOI 10.1007/s00018-016-2412-x; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lee YC, 2019, CANCERS, V11, DOI 10.3390/cancers11020127; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li J, 2008, CLIN CANCER RES, V14, P6996, DOI 10.1158/1078-0432.CCR-08-0754; Li K, 2018, ONCOGENE, V37, P2967, DOI 10.1038/s41388-018-0172-9; Li K, 2017, CANCER CELL, V31, P697, DOI 10.1016/j.ccell.2017.04.006; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C; Mata J, 2000, CELL, V101, P511, DOI 10.1016/S0092-8674(00)80861-2; Miyoshi N, 2009, BRIT J CANCER, V101, P1664, DOI 10.1038/sj.bjc.6605361; O'Connor C, 2016, ONCOGENE, V35, P5272, DOI 10.1038/onc.2016.66; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Salome M, 2018, EXP HEMATOL, V66, P63, DOI 10.1016/j.exphem.2018.07.005; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Tian T, 2015, BIOCHEM BIOPH RES CO, V463, P638, DOI 10.1016/j.bbrc.2015.05.115; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Wang JY, 2013, MOL CELL, V51, P211, DOI 10.1016/j.molcel.2013.05.013; Wennemers M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2934; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200; Xi M, 2019, ANN SURG, V269, P663, DOI 10.1097/SLA.0000000000002670; Xu JM, 2007, BBA-GEN SUBJECTS, V1770, P273, DOI 10.1016/j.bbagen.2006.09.025; Xu W, 2015, CELL BIOSCI, V5, DOI 10.1186/2045-3701-5-7; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhang J, 2011, ORAL ONCOL, V47, P934, DOI 10.1016/j.oraloncology.2011.06.512; Zhang L, 2019, ONCOGENE, V38, P2788, DOI 10.1038/s41388-018-0626-0; Zhang XC, 2008, CLIN CANCER RES, V14, P2813, DOI 10.1158/1078-0432.CCR-07-1528; Zhang ZK, 2019, MOL CELL, V73, P7, DOI 10.1016/j.molcel.2018.10.030; Zhao YY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0466-4; Zhou S, 2018, ANN SURG ONCOL, V25, P3639, DOI 10.1245/s10434-018-6736-7	52	8	10	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3710	3725		10.1038/s41388-020-1245-0	http://dx.doi.org/10.1038/s41388-020-1245-0		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157210				2022-12-17	WOS:000518886000004
J	Zhang, ML; Lin, X; Zhang, JP; Su, L; Ma, MM; Ea, VL; Liu, X; Wang, LM; Chang, J; Li, XR; Zhang, XM				Zhang, Mingliang; Lin, Xiao; Zhang, Jinping; Su, Lin; Ma, Mingming; Ea, Vicki L.; Liu, Xun; Wang, Liming; Chang, Jin; Li, Xiaorong; Zhang, Xiaomin			Blue light-triggered optogenetic system for treating uveal melanoma	ONCOGENE			English	Article							PHOTODYNAMIC THERAPY; EXPRESSION	Uveal melanoma is the most common intraocular primary malignancy in adults and has been considered a fatal disease for decades. Optogenetics is an emerging technique that can control the activation of signaling components via irradiation with visible light. The clinical translation of optogenetics has been limited because of the need for surgical implantation of electrodes and relatively shallow tissue penetration. As visible light easily penetrates the eyes, we hypothesized that an optogenetics approach can be an effective treatment of uveal melanoma without surgery. In this study, we evaluated the feasibility of this strategy by using a genetically encoded optogenetic system based on reversible blue light-induced binding pairs between Fas-CIB1-EGFP and CRY2-mCherry-FADD. Subretinal injection of B16 cells was performed to create a uveal melanoma model. Plasmids pairs were co-transfected into B16 cells. We found that blue light irradiation dynamically controlled the translocation of FADD to Fas on the plasma membrane and induced the apoptosis of B16 cells transfected with the optogenetic nanosystem in vitro. Moreover, the blue light-controlled optogenetic nanosystem suppressed the growth of uveal melanoma in vivo by inducing apoptosis. These results suggest that light-controlled optogenetic therapy can be used as a potential novel therapeutic strategy for uveal melanoma.	[Zhang, Mingliang; Lin, Xiao; Zhang, Jinping; Su, Lin; Ma, Mingming; Ea, Vicki L.; Liu, Xun; Wang, Liming; Li, Xiaorong; Zhang, Xiaomin] Tianjin Med Univ, Tianjin Key Lab Retinal Funct & Dis, Inst Eye, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China; [Zhang, Mingliang; Lin, Xiao; Zhang, Jinping; Su, Lin; Ma, Mingming; Ea, Vicki L.; Liu, Xun; Wang, Liming; Li, Xiaorong; Zhang, Xiaomin] Tianjin Med Univ, Sch Optometry, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China; [Chang, Jin] Tianjin Univ, Sch Life Sci, 92 Weijin Rd, Tianjin 300072, Peoples R China	Tianjin Medical University; Tianjin Medical University; Tianjin University	Li, XR; Zhang, XM (corresponding author), Tianjin Med Univ, Tianjin Key Lab Retinal Funct & Dis, Inst Eye, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China.; Li, XR; Zhang, XM (corresponding author), Tianjin Med Univ, Sch Optometry, Hosp Eye, 251 Fukang Rd, Tianjin 300384, Peoples R China.	lixiaorong@tmu.edu.cn; xzhang08@tmu.edu.cn	Chang, Jin/B-1413-2016; zhang, jin/GXV-9154-2022	Zhang, Xiaomin/0000-0003-4898-4152; Ea, Vicki/0000-0002-5450-6264; Zhang, Mingliang/0000-0003-2285-3592	National Natural Science Foundation of China [81900894, 81671642, 81870651]; Natural Science Foundation of Tianjin [18JCQNJC11300]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin)	We thank Prof. Colin J. Barnstable for his contribution in revising this manuscript. This work was supported by grants from the National Natural Science Foundation of China (81900894, 81671642, 81870651) and Natural Science Foundation of Tianjin (18JCQNJC11300).	Alvarez-Rodriguez B, 2017, MED RES REV, V37, P1350, DOI 10.1002/med.21460; Amaro A, 2017, CANCER METAST REV, V36, P109, DOI 10.1007/s10555-017-9663-3; Blasi MA, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010017; Canal-Fontcuberta I, 2012, RETINA-J RET VIT DIS, V32, P942, DOI 10.1097/IAE.0b013e31825097c1; Chen LX, 2009, ONCOL REP, V21, P917, DOI 10.3892/or_00000304; Chen S, 2018, SCIENCE, V359, P679, DOI 10.1126/science.aaq1144; Chen XY, 2013, INVEST OPHTH VIS SCI, V54, P2248, DOI 10.1167/iovs.12-10977; Damato BE, 2012, DEV OPHTHALMOL, V49, P16, DOI 10.1159/000328251; Deisseroth K, 2011, NAT METHODS, V8, P26, DOI 10.1038/NMETH.F.324; He L, 2015, ELIFE, V4, DOI 10.7554/eLife.10024; Jiang C, 2018, EUROPACE, V20, P1741, DOI 10.1093/europace/eux345; Jmor F, 2017, PHOTODIAGN PHOTODYN, V20, P175, DOI 10.1016/j.pdpdt.2017.10.018; Kennedy MJ, 2010, NAT METHODS, V7, P973, DOI [10.1038/nmeth.1524, 10.1038/NMETH.1524]; Kim CK, 2017, NAT REV NEUROSCI, V18, P222, DOI 10.1038/nrn.2017.15; Konermann S, 2013, NATURE, V500, P472, DOI 10.1038/nature12466; Konig K, 1996, OPT LETT, V21, P1090, DOI 10.1364/OL.21.001090; Luo C, 2017, CANCER LETT, V397, P120, DOI 10.1016/j.canlet.2017.03.037; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Oliva M, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.05.04; Sagoo MS, 2014, ONCOGENE, V33, P4722, DOI 10.1038/onc.2013.555; Shain AH, 2019, NAT GENET, V51, P1123, DOI 10.1038/s41588-019-0440-9; Shao JW, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2298; Tanaka, 2012, WORLD J DERMATOL, V1, P30, DOI DOI 10.5314/WJD.V1.I3.30; Venza I, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0156-3; Xu YX, 2014, P NATL ACAD SCI USA, V111, P6371, DOI 10.1073/pnas.1319296111; Ye HF, 2019, CSH PERSPECT MED, V9, DOI 10.1101/cshperspect.a034371; Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017; Yu LL, 2017, J AM COLL CARDIOL, V70, P2778, DOI 10.1016/j.jacc.2017.09.1107; Zhang K, 2015, TRENDS BIOTECHNOL, V33, P92, DOI 10.1016/j.tibtech.2014.11.007; Zhang KW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098215; Zhang Y, 2009, J NEUROSCI, V29, P9186, DOI 10.1523/JNEUROSCI.0184-09.2009; Zheng B, 2018, BIOMATER SCI-UK, V6, P1379, DOI 10.1039/c8bm00218e; Zheng B, 2017, ACS NANO, V11, P11898, DOI 10.1021/acsnano.7b06395; Zhou YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116095	34	8	8	3	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2118	2124		10.1038/s41388-019-1119-5	http://dx.doi.org/10.1038/s41388-019-1119-5			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31811271				2022-12-17	WOS:000518584000007
J	Kasiri, S; Chen, BZ; Wilson, AN; Reczek, A; Mazambani, S; Gadhvi, J; Noel, E; Marriam, U; Mino, B; Lu, W; Girard, L; Solis, LM; Luby-Phelps, K; Bishop, J; Kim, JW; Kim, J				Kasiri, Sahba; Chen, Baozhi; Wilson, Alexandra N.; Reczek, Annika; Mazambani, Simbarashe; Gadhvi, Jashkaran; Noel, Evan; Marriam, Ummay; Mino, Barbara; Lu, Wei; Girard, Luc; Solis, Luisa M.; Luby-Phelps, Katherine; Bishop, Justin; Kim, Jung-Whan; Kim, James			Stromal Hedgehog pathway activation by IHH suppresses lung adenocarcinoma growth and metastasis by limiting reactive oxygen species	ONCOGENE			English	Article							MITOCHONDRIAL COMPLEX-III; MOTOR-NEURON INDUCTION; SONIC-HEDGEHOG; OXIDATIVE STRESS; FLOOR PLATE; MOUSE MODEL; CANCER; ANGIOGENESIS; PROGRESSION; MUTATIONS	Activation of the Hedgehog (Hh) signaling pathway by mutations within its components drives the growth of several cancers. However, the role of Hh pathway activation in lung cancers has been controversial. Here, we demonstrate that the canonical Hh signaling pathway is activated in lung stroma by Hh ligands secreted from transformed lung epithelia. Genetic deletion of Shh, the primary Hh ligand expressed in the lung, in Kras(G12D/+);Trp53(fl/fl) autochthonous murine lung adenocarcinoma had no effect on survival. Early abrogation of the pathway by an anti-SHH/IHH antibody 5E1 led to significantly worse survival with increased tumor and metastatic burden. Loss of IHH, another Hh ligand, by in vivo CRISPR led to more aggressive tumor growth suggesting that IHH, rather than SHH, activates the pathway in stroma to drive its tumor suppressive effects-a novel role for IHH in the lung. Tumors from mice treated with 5E1 had decreased blood vessel density and increased DNA damage suggestive of reactive oxygen species (ROS) activity. Treatment of Kras(G12D/+);Trp53(fl/fl) mice with 5E1 and N-acetylcysteine, as a ROS scavenger, decreased tumor DNA damage, inhibited tumor growth and prolonged mouse survival. Thus, IHH induces stromal activation of the canonical Hh signaling pathway to suppress tumor growth and metastases, in part, by limiting ROS activity.	[Kasiri, Sahba; Chen, Baozhi; Wilson, Alexandra N.; Reczek, Annika; Noel, Evan; Marriam, Ummay; Girard, Luc; Kim, James] Nancy B & Jake L Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [Kasiri, Sahba; Chen, Baozhi; Wilson, Alexandra N.; Reczek, Annika; Noel, Evan; Marriam, Ummay; Girard, Luc; Kim, James] Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA; [Mazambani, Simbarashe; Gadhvi, Jashkaran; Kim, Jung-Whan] Univ Texas Dallas, Dept Biol Sci, Richardson, TX 75080 USA; [Mino, Barbara; Lu, Wei; Solis, Luisa M.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Luby-Phelps, Katherine] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, Dallas, TX 75390 USA; [Bishop, Justin] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Kim, James] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Kim, J (corresponding author), Nancy B & Jake L Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.; Kim, J (corresponding author), Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA.; Kim, J (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.	james.kim@utsouthwestern.edu		Luby-Phelps, Katherine/0000-0002-8378-1409; Gadhvi, Jashkaran/0000-0002-9522-8053; Mazambani, Simbarashe/0000-0002-6554-7889	National Cancer Institute [P50CA70907, R01CA196851, R21 CA208746]; National Heart, Lung, and Blood Institute [5T32HL098040]; American Cancer Society [RSG-16-090-01-TBG]; American Lung Association [LCD-400239]; Sidney Kimmel Foundation for Cancer Research [SKF-14-057]; Lung Cancer Research Foundation; Bonnie J. Addario Lung Cancer Foundation	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Cancer Society(American Cancer Society); American Lung Association; Sidney Kimmel Foundation for Cancer Research; Lung Cancer Research Foundation; Bonnie J. Addario Lung Cancer Foundation	We thank Dr John D. Minna for valuable discussions, Drs Rolf Brekken and David Wang for their helpful comments on the manuscript, Nicolas Loof, Kim Nguyen, and Terry Shih of the Moody Foundation Flow Cytometry Core Facility for assistance with FACS, and Denise Ramirez of the Whole Brain Microscopy Facility. We also thank John Shelton at UTSW HistoPathology Core and Dr Cheryl Lewis at UTSW Tissue Management Core for assistance with tissue processing and embedding. This work was supported in part by the National Cancer Institute (P50CA70907: JK; R01CA196851: JK; R21 CA208746: J-WK), National Heart, Lung, and Blood Institute (5T32HL098040 to SK), American Cancer Society (RSG-16-090-01-TBG: JK), American Lung Association (LCD-400239: J-WK), Sidney Kimmel Foundation for Cancer Research (SKF-14-057: JK), Lung Cancer Research Foundation (JK) and Bonnie J. Addario Lung Cancer Foundation (J.K.).	Aavikko M, 2012, AM J HUM GENET, V91, P520, DOI 10.1016/j.ajhg.2012.07.015; Administration USFaD, 2015, SON; Administration USFaD, 2018, FDA APPR NEW TREATM; Axelson M, 2013, CLIN CANCER RES, V19, P2289, DOI 10.1158/1078-0432.CCR-12-1956; Bai CB, 2002, DEVELOPMENT, V129, P4753; Barreto DC, 2000, J DENT RES, V79, P1418, DOI 10.1177/00220345000790061101; Belani CP, 2013, J CLIN ONCOL S, V31, P7508, DOI DOI 10.1200/JCO.2013.31.15_SUPPL.7508; Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074; Bermudez O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063226; Brastianos PK, 2013, NAT GENET, V45, P285, DOI 10.1038/ng.2526; Buglino JA, 2008, J BIOL CHEM, V283, P22076, DOI 10.1074/jbc.M803901200; Byrd N, 2002, DEVELOPMENT, V129, P361; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Cha YJ, 2017, TRANSL LUNG CANCER R, V6, P508, DOI 10.21037/tlcr.2017.06.10; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009; Colnot C, 2005, DEVELOPMENT, V132, P1057, DOI 10.1242/dev.01649; Di Mauro C, 2017, BRIT J CANCER, V116, P1425, DOI 10.1038/bjc.2017.116; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023; Gerling M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12321; Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kasiri S, 2017, CANCER RES, V77, P4448, DOI 10.1158/0008-5472.CAN-16-3315; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kugler MC, 2015, AM J RESP CELL MOL, V52, P1, DOI 10.1165/rcmb.2014-0132TR; Lauth M, 2010, NAT STRUCT MOL BIOL, V17, P718, DOI 10.1038/nsmb.1833; Lee JJ, 2016, P NATL ACAD SCI USA, V113, pE7545, DOI 10.1073/pnas.1616447113; Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111; Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Li W, 2016, CANCER INVEST, V34, P424, DOI 10.1080/07357907.2016.1227442; Li ZX, 2006, FEBS LETT, V580, P6161, DOI 10.1016/j.febslet.2006.10.016; Liou GY, 2016, CELL REP, V14, P2325, DOI 10.1016/j.celrep.2016.02.029; Maity T, 2005, P NATL ACAD SCI USA, V102, P17026, DOI 10.1073/pnas.0507848102; MARTI E, 1995, DEVELOPMENT, V121, P2537; Mathew E, 2014, CELL REP, V9, P484, DOI 10.1016/j.celrep.2014.09.010; Maun HR, 2010, J BIOL CHEM, V285, P26570, DOI 10.1074/jbc.M110.112284; Morrisey EE, 2010, DEV CELL, V18, P8, DOI 10.1016/j.devcel.2009.12.010; Munchhof MJ, 2012, ACS MED CHEM LETT, V3, P106, DOI 10.1021/ml2002423; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; National Cancer Institute Surveillance E and End Results Program, CANC STAT FACTS LUNG; Paladini RD, 2005, J INVEST DERMATOL, V125, P638, DOI 10.1111/j.0022-202X.2005.23867.x; Pan SF, 2010, ACS MED CHEM LETT, V1, P130, DOI 10.1021/ml1000307; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Po A, 2017, ONCOGENE, V36, P4641, DOI 10.1038/onc.2017.91; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Reczek CR, 2017, ANNU REV CANC BIOL, V1, P79, DOI 10.1146/annurev-cancerbio-041916-065808; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Robarge KD, 2009, BIOORG MED CHEM LETT, V19, P5576, DOI 10.1016/j.bmcl.2009.08.049; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803; SAFFORD SE, 1994, CANCER RES, V54, P4261; Samudrala P, 2017, PROC SPIE, V10147, DOI 10.1117/12.2258137; Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shimada Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070995; Shin K, 2014, CANCER CELL, V26, P521, DOI 10.1016/j.ccell.2014.09.001; Shin K, 2014, NAT CELL BIOL, V16, P469, DOI 10.1038/ncb2956; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; STCLAIR DK, 1992, MOL CARCINOGEN, V6, P238, DOI 10.1002/mc.2940060404; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Szczepny A, 2017, ONCOGENE, V36, P5544, DOI 10.1038/onc.2017.173; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tanaka T, 2006, CELL CYCLE, V5, P2671, DOI 10.4161/cc.5.22.3472; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Wang LC, 2000, J INVEST DERMATOL, V114, P901, DOI 10.1046/j.1523-1747.2000.00951.x; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005; Yang ZH, 2017, DIS MODEL MECH, V10, P39, DOI 10.1242/dmm.027417	83	8	8	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3258	3275		10.1038/s41388-020-1224-5	http://dx.doi.org/10.1038/s41388-020-1224-5		FEB 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32108165	hybrid, Green Submitted, Green Published, Green Accepted			2022-12-17	WOS:000516891300002
J	Cluzet, V; Devillers, MM; Petit, F; Chauvin, S; Francois, CM; Giton, F; Genestie, C; di Clemente, N; Cohen-Tannoudji, J; Guigon, CJ				Cluzet, Victoria; Devillers, Marie M.; Petit, Florence; Chauvin, Stephanie; Francois, Charlotte M.; Giton, Frank; Genestie, Catherine; di Clemente, Nathalie; Cohen-Tannoudji, Joelle; Guigon, Celine J.			Aberrant granulosa cell-fate related to inactivated p53/Rb signaling contributes to granulosa cell tumors and to FOXL2 downregulation in the mouse ovary	ONCOGENE			English	Article							ANTI-MULLERIAN HORMONE; FOLLICULAR DEVELOPMENT; EXPRESSION; GENE; MUTATIONS; PROTEIN; PROLIFERATION; RECEPTOR; LOCALIZATION; INHIBITION	Ovarian granulosa cell tumors (GCTs) are indolent tumors of the ovary affecting women at all ages and potentially displaying late recurrence. Even if there is still little information regarding the mechanisms involved in GCT development and progression, FOXL2 would be a major tumor suppressor gene in granulosa cells. We analyzed the mechanisms underlying GCT initiation and progression by using mice with targeted expression of SV40 large T-antigen in granulosa cells (AT mouse), which develop GCTs. Consistent with patients, AT mice with developing GCTs displayed increased levels in circulating anti-Mullerian hormone (AMH), estradiol and androgens, as well as decreased FOXL2 protein abundance. Very few mice developed metastases (1 out of 30). In situ analyses revealed that GCT initiation resulted from both increased granulosa cell survival and proliferation in large antral follicles. Tumorigenesis was associated with the combined inactivation of p53 and Rb pathways, as shown by the impaired expression of respective downstream targets regulating cell apoptosis and proliferation, i.e., Bax, Bak, Gadd45a, Ccna2, Ccne1, E2f1, and Orc1. Importantly, the expression of FOXL2 was still present in newly developed GCTs and its downregulation only started during GCT growth. Collectively, our experiments provide evidence that disrupted p53/Rb signaling can drive tumor initiation and growth. This model challenges the current paradigm that impaired FOXL2 signaling is a major switch of granulosa cell tumorigenesis, albeit possibly contributing to tumor growth.	[Cluzet, Victoria; Devillers, Marie M.; Petit, Florence; Chauvin, Stephanie; Francois, Charlotte M.; Cohen-Tannoudji, Joelle; Guigon, Celine J.] Univ Paris Diderot, Physiol Axe Gonadotrope U1133, Biol Fonct & Adaptat UMR 8251, INSERM,Sorbonne Paris Cite, Paris, France; [Giton, Frank] Inserm IMRB U955 Eq07, Pole Biol Pathol Henri Mondor, AP HP, Creteil, France; [Genestie, Catherine] Inst Gustave Roussy, Dept Pathol, Villejuif, France; [di Clemente, Nathalie] Sorbonne Univ, CRSA, IHU ICAN, INSERM, Paris, France; [Guigon, Celine J.] Unite Biol Fonct & Adaptat, 4 Rue MA Lagroua Weill Halle,Case Courrier 7007, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite	Guigon, CJ (corresponding author), Univ Paris Diderot, Physiol Axe Gonadotrope U1133, Biol Fonct & Adaptat UMR 8251, INSERM,Sorbonne Paris Cite, Paris, France.; Guigon, CJ (corresponding author), Unite Biol Fonct & Adaptat, 4 Rue MA Lagroua Weill Halle,Case Courrier 7007, F-75013 Paris, France.	celine.guigon@univ-paris-diderot.fr	; guigon, celine/L-3518-2017	Chauvin, Stephanie/0000-0002-8439-1453; GITON, Frank/0000-0002-4959-1214; guigon, celine/0000-0002-4489-4304; di Clemente, Nathalie/0000-0001-9087-3486; PETIT, Florence/0000-0002-0363-280X	Ligue contre le Cancer Ile-de-France; Projet Fondation ARC [PJA 20151203391]; GEFLUC Paris-Ile de France; "Institut National de la Sante & de la Recherche Medicale" (Inserm), "Center National de la Recherche Scientifique" (CNRS), University Paris Diderot; Ecole Doctorale Bio-SPC	Ligue contre le Cancer Ile-de-France; Projet Fondation ARC; GEFLUC Paris-Ile de France; "Institut National de la Sante & de la Recherche Medicale" (Inserm), "Center National de la Recherche Scientifique" (CNRS), University Paris Diderot; Ecole Doctorale Bio-SPC	We wish to thank Pr. R Veitia, Dr. AL Todeschini (Institut Jacques Monod, Paris, France), and Dr. S Bouret (Institut du Cerveau et de la Moelle, Paris, France) for valuable discussions regarding this work. They acknowledge the technical assistance of M. Surenaud for gonadotropin assays (IMRB-INSERM U955, Hopital Henri Mondor, France), and Dr. B. Querat and Dr. D. L'hote (University Paris 7, BFA unit, France) for providing p53 antibody and Foxl2 primers. They also thank the technical help of Dr. M. Pannetier (INRA, Jouy en Josas, France) for the detection of FOXL2 by Western blots. They thank O. Trassard (UMS-32 INSERM, Hopital du Kremlin Bicetre, France) for his kind help in scanning histological slides. They acknowledge the great help of the technicians of the Buffon Animal Facility (University Paris Diderot, France). This work was supported by Ligue contre le Cancer Ile-de-France (attributed to NC), Projet Fondation ARC (PJA 20151203391, attributed to CJG) and GEFLUC Paris-Ile de France (CJG). It was also funded by "Institut National de la Sante & de la Recherche Medicale" (Inserm), "Center National de la Recherche Scientifique" (CNRS), University Paris Diderot, and by fellowships from Ecole Doctorale Bio-SPC (VC, MMD, CMF).	Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Alexander BM, 2007, ANAT REC, V290, P59, DOI 10.1002/ar.20409; Alexiadis M, 2019, MOL CANCER RES, V17, P177, DOI 10.1158/1541-7786.MCR-18-0359; Andreu-Vieyra C, 2008, MOL ENDOCRINOL, V22, P2141, DOI 10.1210/me.2008-0033; Anttonen M, 2011, LAB INVEST, V91, P1605, DOI 10.1038/labinvest.2011.116; Arcellana-Panlilio MY, 2002, GENE CHROMOSOME CANC, V35, P176, DOI 10.1002/gcc.10108; Auguste A, 2015, HUM MOL GENET, V24, P6687, DOI 10.1093/hmg/ddv373; Batisse-Lignier M, 2017, ONCOGENE, V36, P4445, DOI 10.1038/onc.2017.54; Batista F, 2007, P NATL ACAD SCI USA, V104, P3330, DOI 10.1073/pnas.0611326104; Benayoun BA, 2011, HUM MOL GENET, V20, P1673, DOI 10.1093/hmg/ddr042; Benayoun BA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008789; Bessiere L, 2015, EBIOMEDICINE, V2, P421, DOI 10.1016/j.ebiom.2015.03.002; BUKOVSKY A, 1995, BIOL REPROD, V52, P776, DOI 10.1095/biolreprod52.4.776; Caburet S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1283-0; Chu S, 2002, MOL HUM REPROD, V8, P426, DOI 10.1093/molehr/8.5.426; De Cian MC, 2017, ONCOGENE, V36, P208, DOI 10.1038/onc.2016.191; Devillers MM, 2019, J ENDOCRINOL, V240, P215, DOI 10.1530/JOE-18-0313; Dutertre M, 2001, ENDOCRINOLOGY, V142, P4040, DOI 10.1210/en.142.9.4040; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502; Fleming NI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014389; Francois CM, 2017, SCI REP-UK, V7, DOI 10.1038/srep46222; Francois CM, 2015, CARCINOGENESIS, V36, P564, DOI 10.1093/carcin/bgv041; Fuller PJ, 2017, CLIN GENET, V91, P285, DOI 10.1111/cge.12917; Georges A, 2014, J MOL ENDOCRINOL, V52, pR17, DOI 10.1530/JME-13-0159; Georges A, 2014, ELIFE, V3, DOI 10.7554/eLife.04207; Gershon R, 2011, GYNECOL ONCOL, V122, P580, DOI 10.1016/j.ygyno.2011.05.008; Goulvent T, 2016, HISTOPATHOLOGY, V68, P279, DOI 10.1111/his.12747; Guigon CJ, 2010, CARCINOGENESIS, V31, P1284, DOI 10.1093/carcin/bgq059; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hillman RT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04950-x; Jamieson S, 2012, ENDOCR REV, V33, P109, DOI 10.1210/er.2011-0014; Kalfa N, 2006, J CLIN ENDOCR METAB, V91, P1842, DOI 10.1210/jc.2005-2710; Kalfa N, 2007, FERTIL STERIL, V87, P896, DOI 10.1016/j.fertnstert.2006.11.016; Kalfa N, 2009, GYNECOL ENDOCRINOL, V25, P299, DOI 10.1080/09513590802630153; Kim JH, 2011, ONCOGENE, V30, P1653, DOI 10.1038/onc.2010.541; L'Hote D, 2012, HUM MOL GENET, V21, P3264, DOI 10.1093/hmg/dds170; Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186; Ligtenberg MJ, 1999, J CLIN ENDOCR METAB, V84, P2233, DOI 10.1210/jc.84.6.2233; Liu ZL, 2015, MOL ENDOCRINOL, V29, P1006, DOI 10.1210/me.2015-1103; Makrigiannakis A, 2000, J CLIN ENDOCR METAB, V85, P449, DOI 10.1210/jc.85.1.449; Mayr D, 2002, MODERN PATHOL, V15, P951, DOI 10.1097/01.MP.0000024290.55261.14; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; Merras-Salmio L, 2002, PEDIATR HEMAT ONCOL, V19, P145, DOI 10.1080/088800102753541297; Nogales FF, 2004, MODERN PATHOL, V17, P868, DOI 10.1038/modpathol.3800133; Ogawa T, 2003, MOL CELL ENDOCRINOL, V210, P31, DOI 10.1016/j.mce.2003.08.008; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; Pannetier M, 2016, SEX DEV, V10, P167, DOI 10.1159/000448667; Pectasides D, 2008, CANCER TREAT REV, V34, P1, DOI 10.1016/j.ctrv.2007.08.007; Rey RA, 1996, AM J OBSTET GYNECOL, V174, P958, DOI 10.1016/S0002-9378(96)70333-2; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Sirotkin AV, 2008, REPRODUCTION, V136, P611, DOI 10.1530/REP-08-0229; TILLY KI, 1995, ENDOCRINOLOGY, V136, P1394, DOI 10.1210/en.136.4.1394; Uhlenhaut NH, 2009, CELL, V139, P1130, DOI 10.1016/j.cell.2009.11.021; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021	57	8	9	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1875	1890		10.1038/s41388-019-1109-7	http://dx.doi.org/10.1038/s41388-019-1109-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31745296				2022-12-17	WOS:000516579800004
J	Joseph, J; Radulovich, N; Wang, T; Raghavan, V; Zhu, CQ; Tsao, MS				Joseph, Joella; Radulovich, Nikolina; Wang, Tao; Raghavan, Vibha; Zhu, Chang-Qi; Tsao, Ming-Sound			Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							UP-REGULATION; LUNG-CANCER; EXPRESSION; KINASE; CELLS; SRC; INHIBITION; GENE; VAV1; OVEREXPRESSION	Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human cancers, with 5-year patient survival rates of KRAS are the predominant oncogenic drivers of PDAC but are accompanied by additional lower frequency genetic alterations. Our group previously identified the guanine nucleotide exchange factor ARHGEF10 in a genomic screen for genes with copy number alterations that may synergize with oncogenic KRAS to promote PDAC carcinogenesis. In the present study we show that ARHGEF10 possesses putative tumor suppressor function in PDAC. ARHGEF10 expression is reduced in over 70% of PDAC cell lines, and copy number loss is documented in more than 30% of PDAC patient-derived xenografts. Loss of ARHGEF10 expression enhanced subcutaneous tumor growth in mouse models, while its exogenous expression greatly impaired tumorigenesis. Loss of ARHGEF10 expression also increased in vitro proliferation, invasion, and motility of PDAC cell lines, and enhanced their metastatic spread in orthotopic mouse models. Treatment of ARHGEF10-depleted cells with the inhibitor dasatinib reduced levels of phospho Src kinase and attenuated motility and invasion in vitro. Together, our data indicate that ARHGEF10 may function as a tumor suppressor in PDAC.	[Joseph, Joella; Radulovich, Nikolina; Wang, Tao; Raghavan, Vibha; Zhu, Chang-Qi; Tsao, Ming-Sound] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Joseph, Joella; Tsao, Ming-Sound] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Wang, Tao; Tsao, Ming-Sound] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Tsao, MS (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.; Tsao, MS (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.; Tsao, MS (corresponding author), Univ Hlth Network, Dept Pathol, Toronto, ON, Canada.	ming.tsao@uhn.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405	Canadian Cancer Society [700809]; Canadian Institutes of Health Research Foundation Scheme grant [FDN-148395]; Ontario Ministry of Health and Long Term Care; Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR [STP 53912]	Canadian Cancer Society(Canadian Cancer Society (CCS)); Canadian Institutes of Health Research Foundation Scheme grant(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR(Canadian Institutes of Health Research (CIHR))	We thank Ming Li for his assistance with orthotopic implantation, Jing Xu for her assistance with immunohistochemistry, and Quan Li for his assistance with the analysis of gene expression data. This work was supported by the Canadian Cancer Society grant #700809, the Canadian Institutes of Health Research Foundation Scheme grant FDN-148395, and the Ontario Ministry of Health and Long Term Care. TW was supported by the Terry Fox Foundation Training Program in Molecular Pathology of Cancer at CIHR (STP 53912). Dr Tsao is the M. Qasim Choksi Chair in Lung Cancer Translational Research. The microarray data reported in this paper have been deposited into the Gene Expression Omnibus (GEO) database (accession number GSE131859).	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Adnane J, 2002, CLIN CANCER RES, V8, P2225; Aoki T, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-56; Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Cai YY, 2016, CANCER CELL, V29, P751, DOI 10.1016/j.ccell.2016.04.003; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288; Furukawa T, 1996, AM J PATHOL, V148, P1763; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Harada T, 2009, PANCREATOLOGY, V9, P13, DOI 10.1159/000178871; Horiuchi A, 2003, LAB INVEST, V83, P861, DOI 10.1097/01.LAB.0000073128.16098.31; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jin H, 2011, HUM PATHOL, V42, P541, DOI 10.1016/j.humpath.2010.08.013; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kazerounian S, 2013, CANCER RES, V73, P50, DOI 10.1158/0008-5472.CAN-11-3055; Konstantinidou G, 2013, CANCER DISCOV, V3, P444, DOI 10.1158/2159-8290.CD-12-0388; Lazer G, 2009, J PATHOL, V219, P25, DOI 10.1002/path.2579; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Lohse I, 2014, CANCERS, V6, P459, DOI 10.3390/cancers6010459; Lopez J, 2012, CELL DEATH DIFFER, V19, P1459, DOI 10.1038/cdd.2012.21; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Mak AB, 2010, MOL CELL PROTEOMICS, V9, P811, DOI 10.1074/mcp.M000002-MCP201; Marlow LA, 2009, CANCER RES, V69, P1536, DOI 10.1158/0008-5472.CAN-08-3718; Mazieres J, 2004, CLIN CANCER RES, V10, P2742, DOI 10.1158/1078-0432.CCR-03-0149; Mohl M, 2006, N-S ARCH PHARMACOL, V373, P333, DOI 10.1007/s00210-006-0083-0; Morton JP, 2010, GASTROENTEROLOGY, V139, P292, DOI 10.1053/j.gastro.2010.03.034; Nagaraj NS, 2010, MOL CANCER THER, V9, P2322, DOI 10.1158/1535-7163.MCT-09-1212; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Radulovich N, 2015, ONCOGENE, V34, P4238, DOI 10.1038/onc.2014.357; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Razidlo GL, 2015, CANCER RES, V75, P2907, DOI 10.1158/0008-5472.CAN-14-3103; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Robles-Valero J, 2017, CANCER CELL, V32, P608, DOI 10.1016/j.ccell.2017.10.004; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Shi HB, 2012, J AM CHEM SOC, V134, P3001, DOI 10.1021/ja208518u; Shields DJ, 2011, ONCOGENE, V30, P2123, DOI 10.1038/onc.2010.589; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Tan YG, 2015, ONCOTARGET, V6, P17391, DOI 10.18632/oncotarget.3975; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105570; Williams SV, 2010, GENE CHROMOSOME CANC, V49, P642, DOI 10.1002/gcc.20775; Witkiewicz AK, 2016, CELL REP, V16, P2017, DOI 10.1016/j.celrep.2016.07.023; Xue W, 2012, P NATL ACAD SCI USA, V109, P8212, DOI 10.1073/pnas.1206062109; Zandvakili I, 2017, ONCOGENE, V36, P3213, DOI 10.1038/onc.2016.473; Zhou JT, 2011, INT J CANCER, V128, P1057, DOI 10.1002/ijc.25445	50	8	8	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					308	321		10.1038/s41388-019-0985-1	http://dx.doi.org/10.1038/s41388-019-0985-1			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477830				2022-12-17	WOS:000507766400005
J	Pataer, A; Ozpolat, B; Shao, RP; Cashman, NR; Plotkin, SS; Samuel, CE; Lin, SH; Kabil, NN; Wang, J; Majidi, M; Fang, BL; Roth, JA; Vaporciyan, AA; Wistuba, II; Hung, MC; Swisher, SG				Pataer, Apar; Ozpolat, Bulent; Shao, RuPing; Cashman, Neil R.; Plotkin, Steven S.; Samuel, Charles E.; Lin, Steven H.; Kabil, Nashwa N.; Wang, Jing; Majidi, Mourad; Fang, Bingliang; Roth, Jack A.; Vaporciyan, Ara A.; Wistuba, Ignacio I.; Hung, Mien-Chie; Swisher, Stephen G.			Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells	ONCOGENE			English	Article							KINASE PKR; PI4KII-ALPHA; MECHANISM; PHOSPHORYLATION; DEGRADATION; INITIATION; VIRUSES; IMPACT; GROWTH; DEATH	The role of RNA-dependent protein kinase R (PKR) and its association with misfolded protein expression in cancer cells are unclear. Herein we report that PKR regulates misfolded protein clearance by preventing it release through exosomes and promoting lysosomal degradation of misfolded prion proteins in cancer cells. We demonstrated that PKR contributes to the lysosome function and regulates misfolded prion protein clearance. We hypothesized that PKR-associated lysosome function is critical for cancer but not normal cell survival, representing an effective approach for highly targeted cancer therapy. In screening a compound library, we identified two PKR-associated compounds 1 and 2 (Pac 1 and 2) did not affect normal cells but selectively induced cell death in cancer cells depending on their PKR expression status. Pac 1 significantly inhibited the growth of human lung and breast xenograft tumors in mice with no toxicity. Pac 1 binds to PI4K2A and disrupts the PKR/PI4K2A-associated lysosome complex, contributing to destabilization of cancer cell lysosomes and triggering cell death. We observed that PKR and PI4K2A play significant prognostic roles in breast cancer patients. These results demonstrate that targeting of a PI4K2A/PKR lysosome complex may be an effective approach for cancer therapy.	[Pataer, Apar; Shao, RuPing; Majidi, Mourad; Fang, Bingliang; Roth, Jack A.; Vaporciyan, Ara A.; Swisher, Stephen G.] Univ Texas MD Anderson Canc Ctr, Dept Thorac, Houston, TX 77030 USA; [Pataer, Apar; Shao, RuPing; Majidi, Mourad; Fang, Bingliang; Roth, Jack A.; Vaporciyan, Ara A.; Swisher, Stephen G.] Univ Texas MD Anderson Canc Ctr, Dept Cardiovasc Surg, Houston, TX 77030 USA; [Ozpolat, Bulent; Kabil, Nashwa N.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Cashman, Neil R.] Univ British Columbia, Dept Med Neurol, Vancouver, BC, Canada; [Cashman, Neil R.] Brain Res Ctr, Vancouver Coastal Hlth Res Inst, Vancouver, BC, Canada; [Cashman, Neil R.] Amorfix Life Sci Ltd, Mississauga, ON, Canada; [Plotkin, Steven S.] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada; [Samuel, Charles E.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Lin, Steven H.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA; [Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat, Houston, TX 77030 USA; [Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of British Columbia; Vancouver Coastal Health Research Institute; University of British Columbia; University of California System; University of California Santa Barbara; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Pataer, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac, Houston, TX 77030 USA.; Pataer, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Cardiovasc Surg, Houston, TX 77030 USA.	apataer@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Plotkin, Steven/AAO-3257-2020	Hung, Mien-Chie/0000-0003-4317-4740; Plotkin, Steven/0000-0001-8998-877X; Ozpolat, Bulent/0000-0001-8602-7463; Pataer, Apar/0000-0002-1960-3579	NIH/NCI [P30CA016672]; Homer Flower Gene Therapy Fund; Charles Rogers Gene Therapy Fund; Margaret W. Elkins Endowed Research Fund; Flora and Stuart Mason Lung Cancer Research Fund; Phalan Thoracic Gene Therapy Fund; George P. Sweeney Esophageal Research Fund	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Homer Flower Gene Therapy Fund; Charles Rogers Gene Therapy Fund; Margaret W. Elkins Endowed Research Fund; Flora and Stuart Mason Lung Cancer Research Fund; Phalan Thoracic Gene Therapy Fund; George P. Sweeney Esophageal Research Fund	This work was supported in part by the NIH/NCI under award number P30CA016672 and used and by the Homer Flower Gene Therapy Fund, the Charles Rogers Gene Therapy Fund, the Margaret W. Elkins Endowed Research Fund, the Flora and Stuart Mason Lung Cancer Research Fund, the Phalan Thoracic Gene Therapy Fund, and the George P. Sweeney Esophageal Research Fund (S.G. Swisher).	ALI A, 2011, PLOS ONE, V0006; Aronson LI, 2012, HAEMATOL-HEMATOL J, V97, P1119, DOI 10.3324/haematol.2012.064923; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Balachandran Siddharth, 2007, V383, P277, DOI 10.1007/978-1-59745-335-6_18; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Baumlova A, 2014, EMBO REP, V15, P1085, DOI 10.15252/embr.201438841; Boya P, 2012, ANTIOXID REDOX SIGN, V17, P766, DOI 10.1089/ars.2011.4405; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Cortes Constanza J, 2013, Int J Cell Biol, V2013, P560421, DOI 10.1155/2013/560421; Craige B, 2008, MOL BIOL CELL, V19, P1415, DOI 10.1091/mbc.E07-12-1239; Davidson SM, 2017, ANNU REV PHARMACOL, V57, P481, DOI 10.1146/annurev-pharmtox-010715-103101; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fasen K, 2008, TRAFFIC, V9, P251, DOI 10.1111/j.1600-0854.2007.00679.x; Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476; Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463; Galluzzi L, 2014, NAT CELL BIOL, V16, P728, DOI 10.1038/ncb3005; Garcia MA, 2006, MICROBIOL MOL BIOL R, V70, P1032, DOI 10.1128/MMBR.00027-06; Gregersen N, 2006, ANNU REV GENOM HUM G, V7, P103, DOI 10.1146/annurev.genom.7.080505.115737; Guo CC, 2015, ONCOTARGET, V6, P11114, DOI 10.18632/oncotarget.3573; Hamouda MA, 2014, ONCOTARGET, V5, P6252, DOI 10.18632/oncotarget.2193; Hugon J, 2009, EXPERT REV NEUROTHER, V9, P1455, DOI [10.1586/ern.09.92, 10.1586/ERN.09.92]; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710; Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008; Li J, 2010, ONCOGENE, V29, P2550, DOI 10.1038/onc.2010.14; Li JM, 2017, CANCER RES, V77, P6253, DOI 10.1158/0008-5472.CAN-17-0484; Marchal JA, 2014, FASEB J, V28, P1965, DOI 10.1096/fj.13-248294; Minogue Shane, 2012, Subcell Biochem, V58, P1, DOI 10.1007/978-94-007-3012-0_1; Morel M, 2009, J CELL MOL MED, V13, P1476, DOI 10.1111/j.1582-4934.2009.00849.x; Moreno-Gonzalez I, 2011, SEMIN CELL DEV BIOL, V22, P482, DOI 10.1016/j.semcdb.2011.04.002; Mouton-Liger F, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.552; Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001; Pataer A, 2008, MOL CANCER THER, V7, P2528, DOI 10.1158/1535-7163.MCT-08-0083; Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953; Robinson JW, 2014, BIOCHEM J, V464, P145, DOI 10.1042/BJ20140497; Rochet Jean-Christophe, 2007, Expert Reviews in Molecular Medicine, V9, DOI 10.1017/S1462399407000385; Samuel CE, 2012, CURR TOP MICROBIOL, V353, P163, DOI 10.1007/82_2011_148; Savina A, 2003, J BIOL CHEM, V278, P20083, DOI 10.1074/jbc.M301642200; Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565; Silva JL, 2013, BIOSCI REP, V33; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Soto C, 2018, NAT NEUROSCI, V21, P1332, DOI 10.1038/s41593-018-0235-9; Sukhai MA, 2013, J CLIN INVEST, V123, P315, DOI 10.1172/JCI64180; Vilchez D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6659; Waugh MG, 2012, CANCER LETT, V325, P125, DOI 10.1016/j.canlet.2012.06.009; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Zhang P, 2008, J VIROL, V82, P840, DOI 10.1128/JVI.01891-07; Zhang P, 2007, J VIROL, V81, P8192, DOI 10.1128/JVI.00426-07	49	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					801	813		10.1038/s41388-019-1010-4	http://dx.doi.org/10.1038/s41388-019-1010-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31554935	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000509197200005
J	Williams, CB; Phelps-Polirer, K; Dingle, IP; Williams, CJ; Rhett, MJ; Eblen, ST; Armeson, K; Hill, EG; Yeh, ES				Williams, Carly B.; Phelps-Polirer, Kendall; Dingle, Ivan P.; Williams, Christina J.; Rhett, Matthew J.; Eblen, Scott T.; Armeson, Kent; Hill, Elizabeth G.; Yeh, Elizabeth S.			HUNK phosphorylates EGFR to regulate breast cancer metastasis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTORS; MAMMARY-TUMOR; EXPRESSION; KINASE; SNAIL; OVEREXPRESSION; SUBPOPULATIONS; INTRAVASATION; HETEROGENEITY; SURVIVAL	Epidermal growth factor receptor (EGFR) is commonly over-expressed in metastatic breast cancer yet metastatic breast cancer is generally resistant to anti-EGFR therapies, and the mechanism for resistance to EGFR inhibitors in this setting is not fully understood. Hormonally up-regulated neu-associated kinase (HUNK) kinase is up-regulated in aggressive breast cancers and is thought to play a role in breast cancer metastasis. However, no studies have been conducted to examine a relationship between EGFR and HUNK in breast cancer metastasis. We performed a kinase substrate screen and identified that EGFR is phosphorylated by HUNK. Our studies show that HUNK phosphorylates EGFR at T654, enhancing receptor stability and downstream signaling. We found that increased phosphorylation of T654 EGFR correlates with increased epithelial to mesenchymal, migration and invasion, and metastasis. In addition, we found that HUNK expression correlates with overall survival and distant metastasis free survival. This study shows that HUNK directly phosphorylates EGFR at T654 to promote metastasis and is the first study to show that the phosphorylation of this site in EGFR regulates metastasis.	[Williams, Carly B.; Phelps-Polirer, Kendall; Dingle, Ivan P.; Williams, Christina J.; Rhett, Matthew J.; Eblen, Scott T.; Yeh, Elizabeth S.] Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,BSB 358,MSC509, Charleston, SC 29425 USA; [Armeson, Kent; Hill, Elizabeth G.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA; [Yeh, Elizabeth S.] Indiana Univ Sch Med, Simon Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN 46220 USA	Medical University of South Carolina; Medical University of South Carolina; Indiana University System; Indiana University Bloomington	Yeh, ES (corresponding author), Med Univ South Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 173 Ashley Ave,BSB 358,MSC509, Charleston, SC 29425 USA.; Yeh, ES (corresponding author), Indiana Univ Sch Med, Simon Canc Ctr, Dept Pharmacol & Toxicol, Indianapolis, IN 46220 USA.	esyeh@iu.edu	Williams-Scalise, Carly Bess/D-7095-2016	Williams-Scalise, Carly Bess/0000-0002-7612-7791	South Carolina Clinical and Translational Research (SCTR) Institute [TL1 TR001451, UL1 TR001450]; Concern Foundation Conquer Cancer Now Award; American Cancer Society Institutional Research Grant at Hollings Cancer Center [IRG-97-219-14]; Department of Defense BRIDGE Award at Hollings Cancer Center [W81XWH-11-2-0229]; Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina [P30 CA138313]; Medical University of South Carolina;  [R01CA187304]	South Carolina Clinical and Translational Research (SCTR) Institute; Concern Foundation Conquer Cancer Now Award; American Cancer Society Institutional Research Grant at Hollings Cancer Center(American Cancer Society); Department of Defense BRIDGE Award at Hollings Cancer Center(United States Department of Defense); Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina; Medical University of South Carolina; 	This work was supported by TL1 TR001451 and UL1 TR001450 through the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina (CBW). This work was also supported by R01CA187304 (ESY) as well as past funding from a Concern Foundation Conquer Cancer Now Award (ESY), American Cancer Society Institutional Research Grant (IRG-97-219-14) at Hollings Cancer Center, and a Department of Defense BRIDGE Award (W81XWH-11-2-0229) at Hollings Cancer Center. These studies were also supported by the Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).	Ali R, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2016.42; Appert-Collin A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00283; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Buchanan BW, 2016, JOVE-J VIS EXP, DOI 10.3791/53975; Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579; Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990; Dickler MN, 2009, BREAST CANCER RES TR, V115, P115, DOI 10.1007/s10549-008-0055-9; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Feigin ME, 2009, EXP CELL RES, V315, P707, DOI 10.1016/j.yexcr.2008.10.034; Hauck CR, 2001, CANCER RES, V61, P7079; HEPPNER GH, 1978, CANCER RES, V38, P3758; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hipp S, 2009, J CELL MOL MED, V13, P3858, DOI 10.1111/j.1582-4934.2008.00526.x; Lanczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7; Liu SV, 2014, EXPERT OPIN EMERG DR, V19, P51, DOI 10.1517/14728214.2014.873403; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; MILLER FR, 1983, INVAS METAST, V3, P22; Park HS, 2014, MODERN PATHOL, V27, P1212, DOI 10.1038/modpathol.2013.251; Phelps-Polirer K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153025; Pulaski B A, 2001, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2002s39; Quintela-Fandino M, 2010, P NATL ACAD SCI USA, V107, P2622, DOI 10.1073/pnas.0914492107; Reed KR, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1087-2; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tischkowitz M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-134; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Wertheim GBW, 2009, P NATL ACAD SCI USA, V106, P15855, DOI 10.1073/pnas.0906993106; Williams CB, 2015, ADV CANCER RES, V127, P253, DOI 10.1016/bs.acr.2015.04.008; Xue CS, 2006, CANCER RES, V66, P1418, DOI 10.1158/0008-5472.CAN-05-0550; Xue CS, 2006, CANCER RES, V66, P192, DOI 10.1158/0008-5472.CAN-05-1242; Yeh ES, 2015, BREAST CANCER RES TR, V149, P91, DOI 10.1007/s10549-014-3227-9; Yeh ES, 2011, J CLIN INVEST, V121, P866, DOI 10.1172/JCI42928; Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409; Zambrano Joelle N, 2018, Oncotarget, V9, P35962, DOI 10.18632/oncotarget.26311	43	8	9	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1112	1124		10.1038/s41388-019-1046-5	http://dx.doi.org/10.1038/s41388-019-1046-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31597954	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000511209700012
J	Zhou, Y; Liu, HY; Wang, J; Wang, XL; Qian, LL; Xu, F; Song, WG; Wu, DB; Shen, Z; Feng, DQ; Ling, B; Xiao, WH; Shan, G; Chen, L				Zhou, Ying; Liu, Hanyuan; Wang, Juan; Wang, Xiaolin; Qian, Lili; Xu, Fei; Song, Weiguo; Wu, Dabao; Shen, Zhen; Feng, Dingqing; Ling, Bin; Xiao, Weihua; Shan, Ge; Chen, Liang			Delta Np63 alpha exerts antitumor functions in cervical squamous cell carcinoma	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; REGENERATIVE PROLIFERATION; BREAST-CANCER; DNA-BINDING; P63; EXPRESSION; CISPLATIN; PROTEIN; ACTIVATION; TARGET	The molecular basis underlying the aggressive nature and excessive proliferation of cervical squamous cancer cell remains unclear. Delta Np63 alpha is the predominant isotype of p63 expressed in the epithelia and regulates epithelial cell differentiation. The pro-/anti-tumor role of Delta Np63 alpha in different kinds of solid tumors remains controversial and the precise molecular mechanisms are still elusive. In this study, we uncovered the molecular functions of Delta Np63 alpha in cervical squamous cell carcinoma to clarify its roles as a tumor suppressor. We demonstrated that Delta Np63 alpha suppressed cell migration, invasiveness, and tumor growth in SiHa and ME-180 cells with both in vivo and in vitro assays. Mechanistic investigation via RNA-sequencing and chromatin immunoprecipitation-sequencing revealed that Delta Np63 alpha exerted its antitumor capacity via regulating the expression of a cohort of cell junction genes. Further, we showed that ZNF385B and CLDN1 were two direct Delta Np63 alpha targets with significant relevance to cervical squamous cell carcinoma examined in cell cultures, tumor xenografts, and clinic tumors. We also demonstrated that Delta Np63 alpha downregulated NFATC1 to reduce cisplatin resistance. These findings shed new lights on functions of Delta Np63 alpha in tumors and providing novel insights in targeted therapy of cervical cancers.	[Zhou, Ying; Qian, Lili; Wu, Dabao; Shen, Zhen; Chen, Liang] Univ Sci & Technol China, Anhui Prov Hosp, Affiliated Hosp 1, Dept Obstet & Gynecol, Hefei 230001, Anhui, Peoples R China; [Liu, Hanyuan; Wang, Juan; Xu, Fei; Song, Weiguo] Anhui Med Univ, Hefei 230001, Anhui, Peoples R China; [Wang, Xiaolin; Xiao, Weihua; Shan, Ge; Chen, Liang] Univ Sci & Technol China, Sch Life Sci, Div Mol Med, CAS Key Lab Innate Immun & Chron Dis,Hefei Natl L, Hefei 230027, Peoples R China; [Feng, Dingqing; Ling, Bin] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing 100730, Peoples R China; [Shan, Ge] Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Chen, L (corresponding author), Univ Sci & Technol China, Anhui Prov Hosp, Affiliated Hosp 1, Dept Obstet & Gynecol, Hefei 230001, Anhui, Peoples R China.; Shan, G; Chen, L (corresponding author), Univ Sci & Technol China, Sch Life Sci, Div Mol Med, CAS Key Lab Innate Immun & Chron Dis,Hefei Natl L, Hefei 230027, Peoples R China.; Shan, G (corresponding author), Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.	shange@ustc.edu.cn; anqingcl@ustc.edu.cn	钱, 钱丽丽/GWV-8162-2022	Zhou, Ying/0000-0001-8992-7897	National Natural Science Foundation of China [81872110, 31600657, 81272881, 8137277"9, 81372777, 31725016, 81902632]; National Key Research and Development Program [2018YFC1003903]; Anhui Provincial Key Research and Development Projects [1704a0802151]; Strategic Priority Research Program (Pilot study): "Biological basis of aging and therapeutic strategies" of the Chinese Academy of Sciences [XDPB10]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program; Anhui Provincial Key Research and Development Projects; Strategic Priority Research Program (Pilot study): "Biological basis of aging and therapeutic strategies" of the Chinese Academy of Sciences	We would like to thank Yuhui Miao, Huimin Liu, Lu Qi, Xu Liu, Shuai Wei, Jingxin Li in University of Science and Technology of China for their valuable comments during the preparation of the manuscript. This work was supported by the National Natural Science Foundation of China (No. 81872110, 31600657, 81272881, 8137277"9, 81372777, 31725016, and 81902632); National Key Research and Development Program (2018YFC1003903); Anhui Provincial Key Research and Development Projects (1704a0802151); the Strategic Priority Research Program (Pilot study): "Biological basis of aging and therapeutic strategies" of the Chinese Academy of Sciences (grant XDPB10).	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC; Chen L, 2015, P NATL ACAD SCI USA, V112, P10002, DOI 10.1073/pnas.1502159112; Chen YL, 2018, CELL MOL LIFE SCI, V75, P965, DOI 10.1007/s00018-017-2666-y; Chung J, 2010, EMBO REP, V11, P777, DOI 10.1038/embor.2010.125; Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012; Dang TT, 2015, CANCER RES, V75, P3925, DOI 10.1158/0008-5472.CAN-14-3363; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Eftang LL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-586; Fisher ML, 2016, CANCER RES, V76, P7265, DOI 10.1158/0008-5472.CAN-16-2032; Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793; Gerald RC, 2002, CELL, V109, P67; Hoevel T, 2002, J CELL PHYSIOL, V191, P60, DOI 10.1002/jcp.10076; Hu SS, 2016, NAT STRUCT MOL BIOL, V23, P1011, DOI 10.1038/nsmb.3302; Im JY, 2016, BBA-MOL CELL RES, V1863, P40, DOI 10.1016/j.bbamcr.2015.10.011; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Katayama A, 2017, PATHOL INT, V67, P404, DOI 10.1111/pin.12560; Ko E, 2013, CLIN CANCER RES, V19, P1204, DOI 10.1158/1078-0432.CCR-12-2848; Koster MI, 2004, DIFFERENTIATION, V72, P364, DOI 10.1111/j.1432-0436.2004.07208002.x; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Le Bras GF, 2012, CELL ADHES MIGR, V6, P365, DOI 10.4161/cam.21326; Lee M, 2006, MOL CELLS, V22, P1; Lopardo T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002715; Lv J, 2017, MOL CELL BIOCHEM, V432, P91, DOI 10.1007/s11010-017-3000-6; Machado-Silva A, 2010, SEMIN CANCER BIOL, V20, P57, DOI 10.1016/j.semcancer.2010.02.005; Mangiulli M, 2009, NUCLEIC ACIDS RES, V37, P6092, DOI 10.1093/nar/gkp674; Martin TA, 2001, HISTOL HISTOPATHOL, V16, P1183, DOI 10.14670/HH-16.1183; Mills AA, 2006, CURR OPIN GENET DEV, V16, P38, DOI 10.1016/j.gde.2005.12.001; Minion LE, 2018, GYNECOL ONCOL, V148, P609, DOI 10.1016/j.ygyno.2018.01.009; National Research Council, 2011, GUIDE CARE USE LAB A; Ortt K, 2006, FEBS LETT, V580, P4544, DOI 10.1016/j.febslet.2006.07.004; Pflaumf J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00285; Qian LL, 2017, CYTOKINE, V96, P114, DOI 10.1016/j.cyto.2017.04.001; Qian X, 2015, CRIT REV ONCOL HEMAT, V95, P337, DOI 10.1016/j.critrevonc.2015.03.009; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Ratovitski EA, 2013, FEBS LETT, V587, P3581, DOI 10.1016/j.febslet.2013.09.023; Rizzo JM, 2016, CELL DEATH DIFFER, V23, P1073, DOI 10.1038/cdd.2015.162; Rodriguez-Carunchio L, 2015, BJOG-INT J OBSTET GY, V122, P119, DOI 10.1111/1471-0528.13071; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Rusan M, 2015, CLIN CANCER RES, V21, P2009, DOI 10.1158/1078-0432.CCR-14-1101; Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001; Salah Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.6; Sen T, 2011, CANCER RES, V71, P1167, DOI 10.1158/0008-5472.CAN-10-1481; Si H, 2016, ONCOGENE, V35, P5781, DOI 10.1038/onc.2016.112; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sol ES, 2009, J GYNECOL ONCOL, V20, P28, DOI 10.3802/jgo.2009.20.1.28; Szymborska A, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029223; Tran MN, 2013, J BIOL CHEM, V288, P3275, DOI 10.1074/jbc.M112.408104; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005; Zhou Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022065; Zhou Y, 2011, CLIN INVEST MED, V34, pE184; Zhou Y, 2009, J INTERF CYTOK RES, V29, P695, DOI 10.1089/jir.2009.0003	57	8	8	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					905	921		10.1038/s41388-019-1033-x	http://dx.doi.org/10.1038/s41388-019-1033-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31576015				2022-12-17	WOS:000509197200012
J	Hwang, BJ; Zhang, Y; Brozowski, JM; Liu, Z; Burette, S; Lough, K; Smith, CC; Shan, Y; Chen, JB; Li, N; Williams, S; Su, M; Googe, P; Thomas, NE; Liu, Z				Hwang, Bin-Jin; Zhang, Yang; Brozowski, Jaime M.; Liu, Zhen; Burette, Susan; Lough, Kendall; Smith, Christof C.; Shan, Yue; Chen, Jinbo; Li, Ning; Williams, Scott; Su, Maureen; Googe, Paul; Thomas, Nancy E.; Liu, Zhi			The dysfunction of BP180/collagen XVII in keratinocytes promotes melanoma progression	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMA; SUPPRESSOR-CELLS; EPIDERMOLYSIS-BULLOSA; COLLAGEN-XVII; MYELOID CELLS; BP180; INFLAMMATION; EXPRESSION; METASTASIS; CHEMOKINE	BP180, also termed collagen XVII, is a hemidesmosomal transmembrane glycoprotein expressed in basal keratinocytes, and functions as a cell-matrix adhesion molecule in the dermal-epidermal junction of the skin. Its function, other than cell-matrix adhesion, remains unclear. We generated a mouse strain with BP180 dysfunction (termed Delta NC16A), which develops spontaneous skin inflammation accompanied by an influx of myeloid derived suppressor cells (MDSCs). We used the B16 mouse melanoma model to demonstrate that BP180 dysfunction in either skin or basal keratinocytes promotes MDSC influx into skin and tumor progression. MDSC depletion reduced tumor progression in Delta NC16A mice, demonstrating a critical role for BP180 dysfunction-driven MDSCs in melanoma progression. This study provides the first direct evidence that BP180, a cell-cell matrix adhesion molecule, possesses antitumor function through modulating infiltration of MDSCs. Basal keratinocytes actively participate in skin microenvironment changes caused by BP180 dysfunction. Delta NC16A mice could be a new animal model to study the melanoma microenvironment.	[Hwang, Bin-Jin; Brozowski, Jaime M.; Smith, Christof C.; Liu, Zhi] Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27515 USA; [Zhang, Yang; Liu, Zhen; Burette, Susan; Li, Ning; Googe, Paul; Thomas, Nancy E.; Liu, Zhi] Univ N Carolina, Dept Dermatol, Sch Med, Chapel Hill, NC 27515 USA; [Zhang, Yang] Xi An Jiao Tong Univ, Hosp 2, Sch Med, Dept Dermatol, Xian, Shaanxi, Peoples R China; [Brozowski, Jaime M.] Duke Univ, Sch Med, Dept Med Rheumatol & Immunol, Durham, NC USA; [Liu, Zhen] Guangdong Ctr Adverse Drug React Monitoring, Guangzhou, Guangdong, Peoples R China; [Lough, Kendall; Williams, Scott] Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27515 USA; [Shan, Yue] Univ N Carolina, Dept Biostat, Sch Publ Hlth, Chapel Hill, NC 27515 USA; [Chen, Jinbo] Huazhong Univ Sci & Technol, Wuhan 1 Hosp, Tongji Med Coll, Dept Dermatol, Wuhan, Hubei, Peoples R China; [Su, Maureen] Univ N Carolina, Dept Pediat, Sch Med, Chapel Hill, NC 27515 USA; [Su, Maureen; Thomas, Nancy E.; Liu, Zhi] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Xi'an Jiaotong University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Huazhong University of Science & Technology; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Liu, Z (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Sch Med, Chapel Hill, NC 27515 USA.; Liu, Z (corresponding author), Univ N Carolina, Dept Dermatol, Sch Med, Chapel Hill, NC 27515 USA.; Liu, Z (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA.	zhi_liu@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022	Su, Maureen/0000-0002-3680-9982; Chen, Jinbo/0000-0002-9665-8506; Williams, Scott/0000-0001-9975-7334	Cancer Center Core Support Grant [P30 CA016086]; NIH [R01 AI40768, R01 AR072694]; 15 UNC Cancer Center Research Award; UNC Graduate School Dissertation 16 Completion Fellowship;  [P01CA206980]; NATIONAL CANCER INSTITUTE [P01CA206980, P30CA016086] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR072694] Funding Source: NIH RePORTER	Cancer Center Core Support Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); 15 UNC Cancer Center Research Award; UNC Graduate School Dissertation 16 Completion Fellowship; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Dr. Dennis Loop for providing the Krt-14 promoter driven Cre mice. We thank Dr. Donna Culton and Susan McCray for assistance in Flow Cytometry. We thank Dr. Yisong Wan and Dr. Jenny PY Ting for their assistance. We thank the UNC Flow Cytometry Core Facility, which is supported in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger Comprehensive Cancer Center, for their assistance in flow cytometry analyses. This work was supported by the NIH (R01 AI40768 and R01 AR072694 to ZL), the 15 UNC Cancer Center Research Award (to ZL) and UNC Graduate School Dissertation 16 Completion Fellowship (to BJH) and P01CA206980 (to NT).	Aho S, 1999, 180 KD BULLOUS PEMPH, V367, P356; Bangert C, 2011, CLIN DERMATOL, V29, P360, DOI 10.1016/j.clindermatol.2011.01.006; Bleehen S., 1998, TXB DERMATOLOGY, P1765; Bobek V, 2010, ANTICANCER RES, V30, P4799; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bruce DW, 2017, J CLIN INVEST, V127, P1813, DOI 10.1172/JCI91816; Bubier JA, 2010, J INVEST DERMATOL, V130, P1819, DOI 10.1038/jid.2010.46; Chen RY, 2002, J IMMUNOL, V169, P3987, DOI 10.4049/jimmunol.169.7.3987; Chen RY, 2001, J CLIN INVEST, V108, P1151, DOI 10.1172/jci11494; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Di Meglio P, 2011, IMMUNITY, V35, P857, DOI 10.1016/j.immuni.2011.12.003; Fine JD, 2012, J AM ACAD DERMATOL, V66, P856, DOI 10.1016/j.jaad.2012.01.045; Fine JD, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-12; Fine JD, 2010, ANN NY ACAD SCI, V1194, P213, DOI 10.1111/j.1749-6632.2010.05463.x; Fine JD, 2009, J AM ACAD DERMATOL, V60, P203, DOI 10.1016/j.jaad.2008.09.035; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; Golan T, 2015, MOL CELL, V59, P664, DOI 10.1016/j.molcel.2015.06.028; Hammers CM, 2016, ANNU REV PATHOL-MECH, V11, P175, DOI 10.1146/annurev-pathol-012615-044313; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hopkinson SB, 2000, MOL BIOL CELL, V11, P277, DOI 10.1091/mbc.11.1.277; Hurskainen T, 2014, J INVEST DERMATOL, P1; Hurskainen T, 2012, CELL TISSUE RES, V348, P579, DOI 10.1007/s00441-012-1368-x; Jonkman MF, 1982, 180 KD BULLOUS PEMPH, P1345; Kiritsi D, 2011, J MED GENET, V48, P450, DOI 10.1136/jmg.2010.086751; Koster J, 2003, J CELL SCI, V116, P387, DOI 10.1242/jcs.00241; Krenacs T, 2012, HISTOCHEM CELL BIOL, V138, P653, DOI 10.1007/s00418-012-0981-9; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Leighty L, 2007, ARCH DERMATOL RES, V299, P417, DOI 10.1007/s00403-007-0790-5; Liu Z, 2008, J AUTOIMMUN, V31, P331, DOI 10.1016/j.jaut.2008.08.009; Lund AW, 2016, CANCER DISCOV, V6, P22, DOI 10.1158/2159-8290.CD-15-0023; Mabuchi E, 2007, BRIT J DERMATOL, V157, P596, DOI 10.1111/j.1365-2133.2007.08046.x; Mallipeddi R, 2002, CLIN EXP DERMATOL, V27, P616, DOI 10.1046/j.1365-2230.2002.01130.x; Margadant C, 2008, CURR OPIN CELL BIOL, V20, P589, DOI 10.1016/j.ceb.2008.05.001; Matsumura H, 2016, SCIENCE, V351, DOI 10.1126/science.aad4395; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nishie W, 2007, NAT MED, V13, P378, DOI 10.1038/nm1496; Ortiz ML, 2015, J EXP MED, V212, P351, DOI 10.1084/jem.20140835; Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740; Parikka M, 2006, EXP CELL RES, V312, P1431, DOI 10.1016/j.yexcr.2006.01.015; Parikka M, 2003, J HISTOCHEM CYTOCHEM, V51, P921, DOI 10.1177/002215540305100707; Parikka M, 2001, J ORAL PATHOL MED, V30, P589, DOI 10.1034/j.1600-0714.2001.301003.x; Rozenberg GI, 2010, MELANOMA RES, V20, P361, DOI 10.1097/CMR.0b013e328336ee17; Sawanobori Y, 2008, BLOOD, V111, P5457, DOI 10.1182/blood-2008-01-136895; Silvers WK, 1979, INBRED GENETICALLY 1, P1979; Stelkovics E, 2008, APPL IMMUNOHISTO M M, V16, P433, DOI 10.1097/PAI.0b013e318162f8aa; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Tang L., 2016, J MOL SIGNAL, V11, P1; Tanimura S, 2011, CELL STEM CELL, V8, P177, DOI 10.1016/j.stem.2010.11.029; Van den Bergh F, 2012, EXP DERMATOL, V21, P605, DOI 10.1111/j.1600-0625.2012.01529.x; van Deventer HW, 2010, CANCER RES, V70, P10161, DOI 10.1158/0008-5472.CAN-10-1921; Van Kilsdonk JWJ, 2010, MELANOMA RES, V20, P372, DOI 10.1097/CMR.0b013e32833d8d70; Williams SE, 2011, NATURE, V470, P353, DOI 10.1038/nature09793; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Youn JI, 2010, EUR J IMMUNOL, V40, P2969, DOI 10.1002/eji.201040895; Zhang Y, 2018, P NATL ACAD SCI USA, V115, P6434, DOI 10.1073/pnas.1721805115	57	8	8	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7491	7503		10.1038/s41388-019-0961-9	http://dx.doi.org/10.1038/s41388-019-0961-9			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31435021	Green Accepted			2022-12-17	WOS:000502530500004
J	Ko, YS; Bae, JA; Kim, KY; Kim, SJ; Sun, EG; Lee, KH; Kim, N; Kang, H; Seo, YW; Kim, H; Chung, IJ; Kim, KK				Ko, Yoo-Seung; Bae, Jeong A.; Kim, Keon Young; Kim, Sung Jin; Sun, Eun Gene; Lee, Kyung Hwa; Kim, Nacksung; Kang, Hyuno; Seo, Young-Woo; Kim, Hangun; Chung, Ik Joo; Kim, Kyung Keun			MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis	ONCOGENE			English	Article							NONMUSCLE MYOSIN-II; UNCONVENTIONAL MYOSINS; NEGATIVE REGULATION; CARGO RECOGNITION; RECEPTOR; MOTOR; RESISTANCE; KITENIN; SIGNAL; INVASIVENESS	The cell surface receptor tyrosine kinase (RTK) exists in a dynamic state, however, it remains unknown how single membrane-spanning RTK proteins are retained in the plasma membrane before their activation. This study was undertaken to investigate how RTK proteins are anchored in the plasma membrane before they bind with their respective extracellular ligands for activation through protein-protein interaction, co-localization, and functional phenotype studies. Here we show that unconventional myosin-I MYO1D functions to hold members of the EGFR family (except ErbB3) at the plasma membrane. MYO1D binds only with unphosphorylated EGFRs and anchors them to underlying actin cytoskeleton at the plasma membrane. The C-terminal end region of the MYO1D tail domain containing a beta-meander motif is critical for direct binding with kinase domain of the EGFR family, and expression of the tail domain alone suppresses the oncogenic action of full-length MYO1D. Overexpressed MYO1D increases colorectal and breast cancer cell motility and viability through upregulating EGFR level, and thereby promotes colorectal tumor progression in a syngeneic mouse model. MYO1D is upregulated in human colorectal cancer tissues from advanced stages. Collectively, molecular motor MYO1D plays a distinct role in the dynamic regulation of EGFR family levels by holding them at the plasma membrane before their activation. Overexpressed MYO1D contributes to colorectal carcinogenesis possibly as a novel oncogene and thus may serve as an additional target for suppression of RTK signaling in cancer treatment.	[Ko, Yoo-Seung; Bae, Jeong A.; Kim, Keon Young; Kim, Sung Jin; Kim, Nacksung; Kim, Kyung Keun] Chonnam Natl Univ, Dept Pharmacol, Med Sch, Gwangju 61469, South Korea; [Sun, Eun Gene; Chung, Ik Joo] Chonnam Natl Univ, Dept Hematol Oncol, Med Sch, Gwangju 61469, South Korea; [Lee, Kyung Hwa] Chonnam Natl Univ, Dept Pathol, Med Sch, Gwangju 61469, South Korea; [Kang, Hyuno; Seo, Young-Woo] Korea Basic Sci Inst, Gwangju Ctr, Gwangju 61186, South Korea; [Kim, Hangun] Sunchon Natl Univ, Coll Pharm, Sunchon 57922, North Korea	Chonnam National University; Chonnam National University; Chonnam National University; Korea Basic Science Institute (KBSI)	Kim, KK (corresponding author), Chonnam Natl Univ, Dept Pharmacol, Med Sch, Gwangju 61469, South Korea.	kimkk@chonnam.ac.kr		Kim, Keon Young/0000-0001-9703-9195; , Eun-Gene Sun/0000-0002-3396-6966	National Research Foundation of Korea - Korea government (MSIP) [NRF-2018R1A5A2024181, NRF-2017R1A2B2002040]; National Research Foundation of Korea [NRF-2017R1A6A3A11031332, NRF-2015R1C1A2A01052689]	National Research Foundation of Korea - Korea government (MSIP); National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea grant (NRF-2018R1A5A2024181, NRF-2017R1A2B2002040) funded by the Korea government (MSIP). KYS (NRF-2017R1A6A3A11031332) and JAB (NRF-2015R1C1A2A01052689) were partly supported by the by the National Research Foundation of Korea grant.	ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; Almeida CG, 2011, NAT CELL BIOL, V13, P779, DOI 10.1038/ncb2262; Arif E, 2011, MOL CELL BIOL, V31, P2134, DOI 10.1128/MCB.05051-11; Bae JA, 2014, CLIN CANCER RES, V20, P4115, DOI 10.1158/1078-0432.CCR-13-2863; BAHLER M, 1994, J CELL BIOL, V126, P375, DOI 10.1083/jcb.126.2.375; Barylko B, 2005, ACTA BIOCHIM POL, V52, P373; Barylko B, 2000, BBA-MOL CELL RES, V1496, P23, DOI 10.1016/S0167-4889(00)00006-9; Bergeron JJM, 2016, ANNU REV BIOCHEM, V85, P573, DOI 10.1146/annurev-biochem-060815-014659; Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246; Casaletto JB, 2012, NAT REV CANCER, V12, P386, DOI 10.1038/nrc3277; Chandrasekar I, 2014, TRAFFIC, V15, P418, DOI 10.1111/tra.12152; Dutta Dipannita, 2012, Cell Logist, V2, P203; Fang Y, 2015, BIOSENSORS-BASEL, V5, P223, DOI 10.3390/bios5020223; Fry WHD, 2009, EXP CELL RES, V315, P697, DOI 10.1016/j.yexcr.2008.07.022; Gillespie PG, 2001, J CELL BIOL, V155, P703, DOI 10.1083/jcb.200110032; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Hegan PS, 2015, CYTOSKELETON, V72, P503, DOI 10.1002/cm.21259; Hokanson DE, 2006, MOL BIOL CELL, V17, P4856, DOI 10.1091/mbc.e06-05-0449; Huber LA, 2000, TRAFFIC, V1, P494, DOI 10.1034/j.1600-0854.2000.010607.x; Kho DH, 2009, GUT, V58, P509, DOI 10.1136/gut.2008.150938; Kim JH, 2012, J BIOL CHEM, V287, P27345, DOI 10.1074/jbc.M111.304824; Komaba S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138012; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Lee JH, 2005, CANCER RES, V65, P8993, DOI 10.1158/0008-5472.CAN-05-0590; Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275; Li JC, 2016, TRAFFIC, V17, P822, DOI 10.1111/tra.12383; Lu Q, 2014, ACCOUNTS CHEM RES, V47, P3061, DOI 10.1021/ar500216z; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Maina F, 2014, CURR MED CHEM, V21, P1607, DOI 10.2174/09298673113209990222; Mazerik JN, 2014, BIOPHYS J, V106, P649, DOI 10.1016/j.bpj.2013.12.038; McConnell RE, 2010, TRENDS CELL BIOL, V20, P418, DOI 10.1016/j.tcb.2010.04.004; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Ouderkirk JL, 2014, CYTOSKELETON, V71, P447, DOI 10.1002/cm.21187; Ouyang XM, 1999, J CELL PHYSIOL, V179, P52, DOI 10.1002/(SICI)1097-4652(199904)179:1<52::AID-JCP7>3.0.CO;2-M; Patino-Lopez G, 2010, J BIOL CHEM, V285, P8675, DOI 10.1074/jbc.M109.086959; Rosenzweig SA, 2012, BIOCHEM PHARMACOL, V83, P1041, DOI 10.1016/j.bcp.2011.12.025; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; Tiwari A, 2013, AM J PHYSIOL-HEART C, V304, pH687, DOI 10.1152/ajpheart.00744.2012; Valley CC, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020735; Visuttijai K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164063; Vouri M, 2017, CANCER RES, V77, P2775, DOI 10.1158/0008-5472.CAN-16-2675; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Xu AM, 2010, CANCER RES, V70, P3857, DOI 10.1158/0008-5472.CAN-10-0163; Yamazaki R, 2016, ASN NEURO, V8, DOI 10.1177/1759091416669609; Zeng FH, 2009, FASEB J, V23, P1935, DOI 10.1096/fj.08-121947; Zinchuk V, 2013, SCI REP-UK, V3, DOI 10.1038/srep01365	47	8	8	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7416	7432		10.1038/s41388-019-0954-8	http://dx.doi.org/10.1038/s41388-019-0954-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31420606				2022-12-17	WOS:000500936600004
J	Liu, HJ; Lam, HC; Baglini, CV; Nijmeh, J; Cottrill, AA; Chan, SY; Henske, EP				Liu, Heng-Jia; Lam, Hilaire C.; Baglini, Christian, V; Nijmeh, Julie; Cottrill, Alischer A.; Chan, Stephen Y.; Henske, Elizabeth P.			Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor beta (RAR beta)	ONCOGENE			English	Article							TUBEROUS SCLEROSIS COMPLEX; MICRORNA-29 FAMILY; HUMAN-MELANOMA; CANCER; MIGRATION; INVASION; MULTICENTER; EXPRESSION; EVEROLIMUS; INHIBITOR	miR-29b has been identified as a rapamycin-induced microRNA (miRNA) in Tsc2-deficient, mTORC1-hyperactive cells. The biological significance of this induction of miR-29b is unknown. We have found that miR-29b acts as an oncogenic miRNA in Tsc2-deficient cells: inhibition of miR-29b suppressed cell proliferation, anchorage-independent cell growth, cell migration, invasion, and the growth of Tsc2-deficient tumors in vivo. Importantly, the combination of miR-29b inhibition with rapamycin treatment further inhibited these tumor-associated cellular processes. To gain insight into the molecular mechanisms by which miR-29b promotes tumorigenesis, we used RNA sequencing to identify the tumor suppressor retinoid receptor beta (RAR beta) as a target gene of miR-29b. We found that miR-29b directly targeted the 3'UTR of RAR beta. Forced expression of RAR beta reversed the effects of miR-29b overexpression in proliferation, migration, and invasion, indicating that it is a critical target. miR-29b expression correlated with low RAR beta expression in renal clear cell carcinomas and bladder urothelial carcinomas, tumors associated with TSC gene mutations. We further identified growth family member 4 (ING4) as a novel interacting partner of RAR beta. Overexpression of ING4 inhibited the migration and invasion of Tsc2-deficient cells while silencing of ING4 reversed the RAR beta-mediated suppression of cell migration and invasion. Taken together, our findings reveal a novel miR-29b/RAR beta/ING4 pathway that regulates tumorigenic properties of Tsc2-deficient cells, and that may serve as a potential therapeutic target for TSC, lymphangioleiomyomatosis (LAM), and other mTORC1-hyperactive tumors.	[Liu, Heng-Jia; Lam, Hilaire C.; Baglini, Christian, V; Nijmeh, Julie; Henske, Elizabeth P.] Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA; [Liu, Heng-Jia; Lam, Hilaire C.; Baglini, Christian, V; Nijmeh, Julie; Henske, Elizabeth P.] Harvard Med Sch, Boston, MA 02115 USA; [Cottrill, Alischer A.; Chan, Stephen Y.] Univ Pittsburgh, Sch Med, Dept Med, Div Cardiol,Ctr Pulm Vasc Biol & Med,Pittsburgh H, Pittsburgh, PA 15213 USA; [Cottrill, Alischer A.; Chan, Stephen Y.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Henske, EP (corresponding author), Brigham & Womens Hosp, Dept Med, Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.; Henske, EP (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	EHENSKE@BWH.HARVARD.EDU			Engles Program in TSC and LAM research, Department of Defense [W81XWH-15-1-0263 TS14003]; Tuberous Sclerosis Alliance; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL138437, R01HL122596, R01HL124021] Funding Source: NIH RePORTER	Engles Program in TSC and LAM research, Department of Defense; Tuberous Sclerosis Alliance; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Lorena Pantano of the Harvard Chan Bioinformatics Core for assistance with RNAseq analysis. This work was supported by the Engles Program in TSC and LAM research, Department of Defense grant W81XWH-15-1-0263 TS14003 (EPH) and a postdoctoral Fellowship from Tuberous Sclerosis Alliance (HJL).	Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012; Bertolini F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199371; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Bissler JJ, 2013, LANCET, V381, P817, DOI 10.1016/S0140-6736(12)61767-X; Byron SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046823; Carsillo T, 2000, P NATL ACAD SCI USA, V97, P6085, DOI 10.1073/pnas.97.11.6085; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Cheng JJ, 2013, CELL REP, V5, P471, DOI 10.1016/j.celrep.2013.08.050; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Cui SY, 2015, CELL PHYSIOL BIOCHEM, V36, P409, DOI 10.1159/000430108; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133; Henske EP, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.35; Henske EP, 2003, GENE CHROMOSOME CANC, V38, P376, DOI 10.1002/gcc.10252; Hou Y, 2014, ONCOGENE, V33, P1997, DOI 10.1038/onc.2013.135; Jiang HS, 2014, ONCOL REP, V31, P1509, DOI 10.3892/or.2014.3036; Kinoshita T, 2013, BRIT J CANCER, V109, P2636, DOI 10.1038/bjc.2013.607; Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671; Lam HC, 2017, ONCOTARGET, V8, P64714, DOI 10.18632/oncotarget.19947; Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086; McCormack FX, 2012, AM J RESP CRIT CARE, V186, P1210, DOI 10.1164/rccm.201205-0848OE; Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Ogorek B, 2018, HUM MOL GENET, V27, P1654, DOI 10.1093/hmg/ddy073; Palacios A, 2008, J BIOL CHEM, V283, P15956, DOI 10.1074/jbc.M710020200; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Poudyal D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075034; Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044; Ren MQ, 2005, MOL CELL BIOL, V25, P10591, DOI 10.1128/MCB.25.23.10591-10603.2005; Rosset C, 2017, GENET MOL BIOL, V40, P69, DOI [10.1590/1678-4685-GMB-2015-0321, 10.1590/1678-4685-gmb-2015-0321]; Rossi M, 2013, J CELL PHYSIOL, V228, P1506, DOI 10.1002/jcp.24306; Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Song SM, 2005, ONCOGENE, V24, P8268, DOI 10.1038/sj.onc.1208992; Sun SY, 2000, J BIOL CHEM, V275, P17149, DOI 10.1074/jbc.M000527200; Tang Y, 2014, CARCINOGENESIS, V35, P86, DOI 10.1093/carcin/bgt346; Trindade AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060014; Wang C, 2012, J CANCER RES CLIN, V138, P2127, DOI 10.1007/s00432-012-1288-x; Wang C, 2011, MOL CELL BIOCHEM, V352, P197, DOI 10.1007/s11010-011-0755-z; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Xu F, 2013, J INT MED RES, V41, P1803, DOI 10.1177/0300060513505266; Yan B, 2015, ONCOTARGETS THER, V8, P539, DOI 10.2147/OTT.S75899; Ye PY, 2015, MOL CELL, V57, P708, DOI 10.1016/j.molcel.2014.12.034; Young LR, 2013, LANCET RESP MED, V1, P445, DOI 10.1016/S2213-2600(13)70090-0; ZIMMER A, 1992, DEVELOPMENT, V116, P977	51	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7367	7383		10.1038/s41388-019-0957-5	http://dx.doi.org/10.1038/s41388-019-0957-5			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31420607	Green Accepted			2022-12-17	WOS:000500936600001
J	Raimondi, F; Inoue, A; Kadji, FMN; Shuai, N; Gonzalez, JC; Singh, G; de la Vega, AA; Sotillo, R; Fischer, B; Aoki, J; Gutkind, JS; Russell, RB				Raimondi, Francesco; Inoue, Asuka; Kadji, Francois M. N.; Shuai, Ni; Gonzalez, Juan-Carlos; Singh, Gurdeep; de la Vega, Alicia Alonso; Sotillo, Rocio; Fischer, Bernd; Aoki, Junken; Gutkind, J. Silvio; Russell, Robert B.			Rare, functional, somatic variants in gene families linked to cancer genes: GPCR signaling as a paradigm	ONCOGENE			English	Article							PROTEIN-COUPLED RECEPTORS; MUTATIONAL LANDSCAPE; ADENOSINE RECEPTOR; TUMOR-SUPPRESSOR; PATHWAY; PROLIFERATION; ACTIVATION; EXPRESSION; MECHANISM; DATABASE	Oncodriver genes are usually identified when mutations recur in multiple tumours. Different drivers often converge in the activation or repression of key cancer-relevant pathways. However, as many pathways contain multiple members of the same gene family, individual mutations might be overlooked, as each family member would necessarily have a lower mutation frequency and thus not identified as significant in any one-gene-at-a-time analysis. Here, we looked for mutated, functional sequence positions in gene families that were mutually exclusive (in patients) with another gene in the same pathway, which identified both known and new candidate oncodrivers. For instance, many inactivating mutations in multiple G-protein (particularly G(i/o)) coupled receptors, are mutually exclusive with G alpha(s) oncogenic activating mutations, both of which ultimately enhance cAMP signalling. By integrating transcriptomics and interaction data, we show that the G(s) pathway is upregulated in multiple cancer types, even those lacking known GNAS activating mutations. This suggests that cancer cells may develop alternative strategies to activate adenylate cyclase signalling in multiple cancer types. Our study provides a mechanistic interpretation for several rare somatic mutations in multi-gene oncodrivers, and offers possible explanations for known and potential off-label cancer treatments, suggesting new therapeutic opportunities.	[Raimondi, Francesco; Gonzalez, Juan-Carlos; Singh, Gurdeep; Russell, Robert B.] Heidelberg Univ, BioQuant, Neuenheimer Feld 267, D-69120 Heidelberg, Germany; [Raimondi, Francesco; Gonzalez, Juan-Carlos; Singh, Gurdeep; Russell, Robert B.] Heidelberg Univ, Biochem Ctr BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany; [Inoue, Asuka; Kadji, Francois M. N.; Aoki, Junken] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan; [Inoue, Asuka; Kadji, Francois M. N.; Aoki, Junken] Japan Agcy Med Res & Dev AMED, Adv Res & Dev Programs Med Innovat PRIME, Chiyoda Ku, Tokyo 1000004, Japan; [Shuai, Ni; Fischer, Bernd] German Canc Res Ctr, Computat Genome Biol, D-69120 Heidelberg, Germany; [de la Vega, Alicia Alonso; Sotillo, Rocio] German Canc Res Ctr, TLRC, Div Mol Thorac Oncol, D-69120 Heidelberg, Germany; [de la Vega, Alicia Alonso; Sotillo, Rocio] German Ctr Lung Res DZL, D-69120 Heidelberg, Germany; [Gutkind, J. Silvio] Univ San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Tohoku University; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of San Diego	Raimondi, F; Russell, RB (corresponding author), Heidelberg Univ, BioQuant, Neuenheimer Feld 267, D-69120 Heidelberg, Germany.; Raimondi, F; Russell, RB (corresponding author), Heidelberg Univ, Biochem Ctr BZH, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	francesco.raimondi@bioquant.uni-heidelberg.de; robert.russell@bioquant.uni-heidelberg.de	Gutkind, J. Silvio/J-1201-2016; Russell, Robert/GWU-6389-2022; Russell, Rob/AAH-9145-2019; Francois, Kadji/ABF-2484-2021; Ngako KADJI, Francois Marie/ABF-8093-2021; Raimondi, Francesco/AAB-8586-2019	Gutkind, J. Silvio/0000-0002-5150-4482; Russell, Robert/0000-0002-7213-1398; Russell, Rob/0000-0002-1905-4717; Francois, Kadji/0000-0002-9187-4584; RAIMONDI, Francesco/0000-0002-6891-3178; Gonzalez-Sanchez, Juan Carlos/0000-0002-7493-3669; Alonso de la Vega, Alicia/0000-0002-4898-6871; Sotillo, Rocio/0000-0002-0855-7917	Cell Networks Excellence initiative of the Germany Research Foundation (DFG); Alexander Von Humboldt post-doctoral fellowship; Michael J. Fox Foundation; Japan Science and Technology Agency (JST) [JPMJPR1331]; Japan Agency for Medical Research and Development (AMED) [JP17gm5910013]; Japan Society for the Promotion of Science (JSPS) KAKENHI [17K08264]; AMED [JP17gm0710001]	Cell Networks Excellence initiative of the Germany Research Foundation (DFG)(German Research Foundation (DFG)); Alexander Von Humboldt post-doctoral fellowship(Alexander von Humboldt Foundation); Michael J. Fox Foundation; Japan Science and Technology Agency (JST)(Japan Science & Technology Agency (JST)); Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED)); Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED	FR, JCG, GS and RBR are supported by the Cell Networks Excellence initiative of the Germany Research Foundation (DFG). FR was supported by an Alexander Von Humboldt post-doctoral fellowship and a Michael J. Fox Foundation research grant. RBR is part of the DFG SFB/TPR186 Molecular Switches in the Spatio-Temporal Control of Cellular Signal Transmission, and a member of the BMBF German Network for Bioinfomatics Infrastructure (de. NBI). AI was funded by Japan Science and Technology Agency (JST) Grant Number JPMJPR1331, Japan Agency for Medical Research and Development (AMED) Grant Number JP17gm5910013 and Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 17K08264. JA received funding from AMED Grant Number JP17gm0710001. The authors thank Ayumi Inoue, Naoko Kuroda and Yuko Sugamura (Tohoku University) for plasmid construction and cell culture experiments. We also thank a reviewer for the helpful suggestion to explore the wider set of genes potentially affecting cAMP in cancer.	Audet M, 2012, CELL, V151, P14, DOI 10.1016/j.cell.2012.09.003; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Ballesteros J. A., 1995, METH NEUROSCI, V25, P366, DOI DOI 10.1016/S1043-9471(05)80049-7; Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Betts MJ, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1094; Choy C, 2016, ONCOL REP, V35, P3135, DOI 10.3892/or.2016.4710; Cives M, 2015, ENDOCR-RELAT CANCER, V22, P1, DOI 10.1530/ERC-14-0360; Cohen S, 2011, J CELL PHYSIOL, V226, P2438, DOI 10.1002/jcp.22593; De Giorgi V, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.2908; Demir H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109897; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eddy Sean R, 2009, Genome Inform, V23, P205; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Finn RD, 2016, NUCLEIC ACIDS RES, V44, pD279, DOI 10.1093/nar/gkv1344; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Flock T, 2015, NATURE, V524, P173, DOI 10.1038/nature14663; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gelis L, 2017, EXP DERMATOL, V26, P569, DOI 10.1111/exd.13316; Gelis L, 2016, J BIOL CHEM, V291, P17772, DOI 10.1074/jbc.M116.734517; Gonzalez-Sanchez JC, 2018, FEBS LETT, V592, P463, DOI 10.1002/1873-3468.12988; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gussow AB, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0869-4; Han H, 2015, SCI REP-UK, V5, DOI 10.1038/srep11432; Ideno N, 2018, GASTROENTEROLOGY, V155, P1593, DOI 10.1053/j.gastro.2018.08.006; Inoue A, 2012, NAT METHODS, V9, P1021, DOI [10.1038/NMETH.2172, 10.1038/nmeth.2172]; Jiang C, 2007, NUCLEIC ACIDS RES, V35, pD137, DOI 10.1093/nar/gkl1041; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Jose J, 2017, ACS MED CHEM LETT, V8, P1072, DOI 10.1021/acsmedchemlett.7b00282; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kucuk C, 2011, P NATL ACAD SCI USA, V108, P20119, DOI 10.1073/pnas.1115128108; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marbach D, 2016, NAT METHODS, V13, P366, DOI [10.1038/NMETH.3799, 10.1038/nmeth.3799]; Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042; Marx V, 2016, NAT METHODS, V134, P2016; Menigatti M, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.21; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Miller ML, 2015, CELL SYST, V1, P197, DOI 10.1016/j.cels.2015.08.014; Moore AR, 2016, NAT GENET, V48, P675, DOI 10.1038/ng.3549; Mu JS, 2017, ONCOL LETT, V13, P1223, DOI 10.3892/ol.2017.5573; Muppidi JR, 2014, NATURE, V516, P254, DOI 10.1038/nature13765; Nairismagi ML, 2016, LEUKEMIA, V30, P1311, DOI 10.1038/leu.2016.13; Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040; Neuhaus EM, 2009, J BIOL CHEM, V284, P16218, DOI 10.1074/jbc.M109.012096; Nilsson MB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4307; O'Hayre M, 2016, ONCOGENE, V35, P3771, DOI 10.1038/onc.2015.442; O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521; Patra KC, 2018, NAT CELL BIOL, V20, P811, DOI 10.1038/s41556-018-0122-3; Petrovski S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003709; Porta-Pardo E, 2017, NAT METHODS, V14, P782, DOI [10.1038/NMETH.4364, 10.1038/nmeth.4364]; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Raimondi F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12971-7; Raimondi F, 2016, SCI REP-UK, V6, DOI 10.1038/srep34490; Reimand J, 2016, NUCLEIC ACIDS RES, V44, pW83, DOI 10.1093/nar/gkw199; Rochdi MD, 2010, MOL PHARMACOL, V77, P836, DOI 10.1124/mol.109.061804; Rosenbaum DM, 2009, NATURE, V459, P356, DOI 10.1038/nature08144; Rovati GE, 2007, MOL PHARMACOL, V71, P959, DOI 10.1124/mol.106.029470; Samyn B, 2015, NAT METHODS, V2, P1; Sarnataro D, 2006, MOL PHARMACOL, V70, P1298, DOI 10.1124/mol.106.025601; Scheer A, 2000, MOL PHARMACOL, V57, P219; Southan C, 2016, NUCLEIC ACIDS RES, V44, pD1054, DOI 10.1093/nar/gkv1037; Tuominen I, 2015, ONCOGENE, V34, P1174, DOI 10.1038/onc.2014.50; Turan S, 2015, CURR OSTEOPOROS REP, V13, P146, DOI 10.1007/s11914-015-0268-x; Velazquez EF, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-2; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Wang YM, 2015, MOL MED REP, V11, P1925, DOI 10.3892/mmr.2014.2944; White C, 2016, ONCOTARGET, V7, P23106, DOI 10.18632/oncotarget.7145; Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Zatelli MC, 2007, ENDOCR-RELAT CANCER, V14, P91, DOI 10.1677/ERC-06-0026; Zhang D, 2010, CANCER BIOL THER, V10, P19, DOI 10.4161/cbt.10.1.11944; Zheng GY, 2008, BIOINFORMATICS, V24, P2416, DOI 10.1093/bioinformatics/btn439	78	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2019	38	38					6491	6506		10.1038/s41388-019-0895-2	http://dx.doi.org/10.1038/s41388-019-0895-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IY7XR	31337866	Green Published, hybrid			2022-12-17	WOS:000486609000002
J	Kim, SJ; Garcia-Recio, S; Creighton, CJ; Perou, CM; Rosen, JM				Kim, S. J.; Garcia-Recio, S.; Creighton, C. J.; Perou, C. M.; Rosen, J. M.			Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression	ONCOGENE			English	Article							REGULATORY T-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER CELLS; TUMOR-INITIATING CELLS; STEM-CELLS; WNT/BETA-CATENIN; PROMOTES; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION	Metastatic breast cancer is an extremely complex disease with limited treatment options due to the lack of information about the major characteristics of metastatic disease. There is an urgent need, therefore, to understand the changes in cellular complexity and dynamics that occur during metastatic progression. In the current study, we analyzed the cellular and molecular differences between primary tumors and paired lung metastases using a syngeneic p53-null mammary tumor model of basal-like breast cancer. Distinct subpopulations driven by the Wnt- and/or STAT3 signaling pathways were detected in vivo using a lentiviral Wnt- and STAT3 signaling reporter system. A significant increase in the overlapping populations driven by both the Wnt- and STAT3 signaling pathways was observed in the lung metastases as compared to the primary tumors. Furthermore, the overlapping populations showed a higher metastatic potential relative to the other populations and pharmacological inhibition of both signaling pathways was shown to markedly reduce the metastatic lesions in established lung metastases. An analysis of the unique molecular features of the lung metastases revealed a significant association with immune response signatures. Specifically, Foxp3 gene expression was markedly increased and elevated levels of Foxp3 + Treg cells were detected in close proximity to lung metastases. Collectively, these studies illustrate the importance of analyzing intratumoral heterogeneity, changes in population dynamics, and the immune microenvironment during metastatic progression.	[Kim, S. J.; Rosen, J. M.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Garcia-Recio, S.; Perou, C. M.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27515 USA; [Garcia-Recio, S.; Perou, C. M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA; [Creighton, C. J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Creighton, C. J.] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Baylor College of Medicine; Baylor College of Medicine	Rosen, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	jrosen@bcm.edu	Recio, Susana Garcia/M-4723-2019; Perou, Charles M/H-9934-2014	Recio, Susana Garcia/0000-0003-3820-1679; Perou, Charles M/0000-0001-9827-2247; Rosen, Jeffrey/0000-0002-6637-844X	NIH [RO1 CA148761]; Susan G. Komen [PDF17479425]; Cytometry and Cell Sorting Core [NIH CA125123, RR024574]; NATIONAL CANCER INSTITUTE [P30CA125123, R01CA148761, R01CA195754, R01CA016303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen(Susan G. Komen Breast Cancer Foundation); Cytometry and Cell Sorting Core; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	;This work was supported by NIH RO1 CA148761 (to JMR and CMP) and by the Susan G. Komen to SGR (PDF17479425). We would like to thank to Dr. Michael T. Lewis for generously providing us with the STAT3-GFP and EFS-GFP reporters. This project was conducted with technical support from the Cytometry and Cell Sorting Core (NIH CA125123 and RR024574) and the expert assistance of Joel M. Sederstrom, the Integrated Microscopy core (NCI CA125123, NIDDK56338, CPRIT RP150578 and John S. Dunn Gulf Coast Consortium for Chemical Genomics), the Lester and Sue Smith Breast Center Pathology Core, and Human Genome Sequencing Center at Baylor College of Medicine. We thank Yiqun Zhang for technical assistance with the gene expression analyses. We would also like to thank to the IHC laboratory at University of Texas MD Anderson Cancer Center for scanning of IHC images. We specially thank Drs. Michael T. Lewis and Kevin P. Roarty for critically reading and editing the manuscript.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Ansari AM, 2016, STEM CELL REV REP, V12, P553, DOI 10.1007/s12015-016-9670-8; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Bockhorn J, 2014, CANCER RES, V74, P7406, DOI 10.1158/0008-5472.CAN-14-1188; Bos PD, 2013, J EXP MED, V210, P2435, DOI 10.1084/jem.20130762; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Chang CH, 2015, STEM CELL REP, V5, P378, DOI 10.1016/j.stemcr.2015.07.009; Chen MW, 2017, CANCER RES, V77, P1955, DOI 10.1158/0008-5472.CAN-16-1115; Chen Q, 2011, CANCER CELL, V20, P538, DOI 10.1016/j.ccr.2011.08.025; Chuang CH, 2017, NAT MED, V23, P291, DOI 10.1038/nm.4285; Dalotto-Moreno T, 2013, CANCER RES, V73, P1107, DOI 10.1158/0008-5472.CAN-12-2418; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Fan C, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-3; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Feuerer M, 2009, NAT IMMUNOL, V10, P689, DOI 10.1038/ni.1760; Follenzi A, 2004, BLOOD, V103, P3700, DOI 10.1182/blood-2003-09-3217; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032; Halvorsen EC, 2014, CANCER METAST REV, V33, P1025, DOI 10.1007/s10555-014-9529-x; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Jacob LS, 2015, CANCER RES, V75, P3713, DOI 10.1158/0008-5472.CAN-15-0562; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Jones LM, 2016, CANCER RES, V76, P1416, DOI 10.1158/0008-5472.CAN-15-2770; Jung KH, 2017, CLIN CANCER RES, V23, P5537, DOI 10.1158/1078-0432.CCR-16-2253; Khramtsov AI, 2010, AM J PATHOL, V176, P2911, DOI 10.2353/ajpath.2010.091125; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim MJ, 2014, CANCER LETT, V354, P33, DOI 10.1016/j.canlet.2014.06.023; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lee-Chang C, 2013, J IMMUNOL, V191, P4141, DOI 10.4049/jimmunol.1300606; Linde N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02481-5; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015; Medina D, 2002, FASEB J, V16, P881, DOI 10.1096/fj.01-0885fje; Moon SH, 2013, INT J ONCOL, V42, P921, DOI 10.3892/ijo.2013.1765; Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Naxerova K, 2015, NAT REV CLIN ONCOL, V12, P258, DOI 10.1038/nrclinonc.2014.238; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Perry JM, 2011, GENE DEV, V25, P1928, DOI 10.1101/gad.17421911; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123; Roarty K, 2017, ONCOGENE, V36, P5958, DOI 10.1038/onc.2017.206; Roarty K, 2015, J CELL BIOL, V208, P351, DOI 10.1083/jcb.201408058; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Pereira LMS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00605; Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707; ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang RF, 2008, HUM IMMUNOL, V69, P811, DOI 10.1016/j.humimm.2008.08.276; Wei W, 2014, STEM CELLS, V32, P2571, DOI 10.1002/stem.1752; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Wu JQ, 2016, CELL REP, V14, P1979, DOI 10.1016/j.celrep.2016.01.074; Xu L, 2010, CLIN IMMUNOL, V135, P466, DOI 10.1016/j.clim.2010.01.014; Xu XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004783; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2869; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang CH, 2015, ONCOL REP, V33, P1872, DOI 10.3892/or.2015.3783; Zhang M, 2010, P NATL ACAD SCI USA, V107, P3522, DOI 10.1073/pnas.0910179107; Zhu L, 2019, BIORXIV, DOI [10.1101/525071, DOI 10.1101/525071]	86	8	8	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5942	5958		10.1038/s41388-019-0852-0	http://dx.doi.org/10.1038/s41388-019-0852-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31289359	Green Accepted			2022-12-17	WOS:000482740000003
J	Scalia, P; Pandini, G; Carnevale, V; Giordano, A; Williams, SJ				Scalia, Pierluigi; Pandini, Giuseppe; Carnevale, Vincenzo; Giordano, Antonio; Williams, Stephen J.			Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma	ONCOGENE			English	Article							GROWTH-FACTOR-II; INSULIN-RECEPTOR ISOFORM; IGF-II; TYROSINE-KINASE; BIOLOGICAL SIGNIFICANCE; VASCULAR MORPHOGENESIS; BREAST CANCERS; CELL MIGRATION; MELANOMA-CELLS; EXPRESSION	Malignant mesothelioma is a deadly disease with limited therapeutic options. EphB4 is an oncogenic tyrosine kinase receptor expressed in malignant mesothelioma as well as in a variety of cancers. It is involved in tumor microenvironment mediating angiogenesis and invasive cellular effects via both EphrinB2 ligand-dependent and independent mechanisms. The molecular network underlying EphB4 oncogenic effects is still unclear. Here we show that EphB4 expression in malignant mesothelioma cells is markedly decreased upon neutralization of cancer-secreted IGF-II. In particular, we demonstrate that EphB4 protein expression in malignant mesothelioma cells depend upon a degradation rescue mechanism controlled by the autocrine IGF-II-insulin receptor-A specific signaling axis. We show that the regulation of EphB4 expression is linked to a competing post-translational modification of its carboxy-terminal tail via phosphorylation of its tyrosine 987 by the Insulin receptor isoform-A kinase-associated activity in response to the autocrine IGF-II stimuli. Neutralization of this autocrine-induced EphB4-phosphorylation by IGF-II associates with the increased ubiquitination of EphB4 carboxy-terminal tail and with its rapid degradation. We also describe a novel Ubiquitin binding motif in the targeted region as part of the identified EphB4 phosphodegron and provide 3D modeling data supporting a possible model for the acute EphB4 PTM-driven regulation by IGF-II. Altogether, these findings disclose a novel molecular mechanism for the maintenance of EphB4-expression in malignant mesothelioma cells and other IGF-II-secreting cancers (IGF2omas).	[Scalia, Pierluigi; Giordano, Antonio; Williams, Stephen J.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Scalia, Pierluigi; Giordano, Antonio; Williams, Stephen J.] Temple Univ, Ctr Biotechnol, Biol Dept, Philadelphia, PA 19122 USA; [Scalia, Pierluigi; Williams, Stephen J.] ISOPROG, Ist Somatogene Ric Oncogenom, I-93100 Caltanissetta, Italy; [Scalia, Pierluigi; Williams, Stephen J.] Somatolink Res Fdn, Philadelphia, PA 19102 USA; [Pandini, Giuseppe] Univ Catania, Garibaldi Nesima Med Ctr, Dept Clin & Expt Med, Endocrinol, I-95122 Catania, Italy; [Carnevale, Vincenzo] Temple Univ, Coll Sci & Technol, Inst Computat Mol Sci, Philadelphia, PA 19122 USA; [Giordano, Antonio] Univ Siena, Dept Med Biotechnol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Presidio Ospedaliero Garibaldi-Nesima; University of Catania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Scalia, P (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.; Scalia, P (corresponding author), Temple Univ, Ctr Biotechnol, Biol Dept, Philadelphia, PA 19122 USA.; Scalia, P (corresponding author), ISOPROG, Ist Somatogene Ric Oncogenom, I-93100 Caltanissetta, Italy.; Scalia, P (corresponding author), Somatolink Res Fdn, Philadelphia, PA 19102 USA.	pscalia@isoprog.org	Scalia, Pierluigi/AAH-8443-2019; Pandini, Giuseppe/AAB-9650-2019; Giordano, Antonio/F-1927-2010	Scalia, Pierluigi/0000-0002-5911-1640; Pandini, Giuseppe/0000-0003-3747-7649; Giordano, Antonio/0000-0002-5959-016X	ASEM srl (Treviso, Italy); GianAmico Alessandrini Family	ASEM srl (Treviso, Italy); GianAmico Alessandrini Family	We thank Dr. Steven Albelda (University of Pennsylvania, USA) for providing the MSTO211H cell line and his constructive criticism during the manuscript preparation; Dr Veronica Vella (University of Catania, Italy) for IR system expression data in colorectal cancer cell lines; Dr Parkash S Gill (USC, Los Angeles, CA) for critical insights in manuscript revision. We also thank ASEM srl (Treviso, Italy) and the GianAmico Alessandrini Family for supporting PS research.	Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Atapattu L, 2014, CELL ADHES MIGR, V8, P294, DOI 10.4161/19336918.2014.970026; Baserga R, 2013, J CELL PHYSIOL, V228, P675, DOI 10.1002/jcp.24217; Becerikli M, 2015, INT J CANCER, V136, P1781, DOI 10.1002/ijc.29244; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420; Chen T, 2013, TUMOR BIOL, V34, P379, DOI 10.1007/s13277-012-0560-7; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; DAUGHADAY WH, 1993, P NATL ACAD SCI USA, V90, P5823, DOI 10.1073/pnas.90.12.5823; Dynkevich Y, 2013, ENDOCR REV, V34, P798, DOI 10.1210/er.2012-1033; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Erber R, 2006, EMBO J, V25, P628, DOI 10.1038/sj.emboj.7600949; Ferguson BD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10641; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Greenall SA, 2018, TRANSL ONCOL, V11, P971, DOI 10.1016/j.tranon.2018.05.011; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Huang X, 2007, CANCER RES, V67, P9800, DOI 10.1158/0008-5472.CAN-07-0531; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kim KW, 1998, CANCER RES, V58, P348; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Liu R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-269; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Marks AG, 2011, ENDOCRINOLOGY, V152, P922, DOI 10.1210/en.2010-0784; Martiny-Baron G, 2010, ANGIOGENESIS, V13, P259, DOI 10.1007/s10456-010-9183-z; Morcavallo A, 2011, MOL ENDOCRINOL, V25, P1456, DOI 10.1210/me.2010-0484; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Noren NK, 2009, BIOCHEM J, V422, P433, DOI 10.1042/BJ20090014; Nussbaum T, 2008, HEPATOLOGY, V48, P146, DOI 10.1002/hep.22297; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Pundir S, 2017, METHODS MOL BIOL, V1558, P41, DOI 10.1007/978-1-4939-6783-4_2; Ritter MR, 2002, P NATL ACAD SCI USA, V99, P7455, DOI 10.1073/pnas.102185799; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rutkowski R, 2012, INT J CANCER, V131, pE614, DOI 10.1002/ijc.27392; RUTTEN AAJJL, 1995, CANCER RES, V55, P3634; Salgia R, 2018, BBA-REV CANCER, V1869, P128, DOI 10.1016/j.bbcan.2018.01.003; Scalia P, 2001, J CELL BIOCHEM, V82, P610, DOI 10.1002/jcb.1196; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; SINHA UK, 2003, ENT-EAR NOSE THROAT, V82, P887; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tawo R, 2017, CELL, V169, P470, DOI 10.1016/j.cell.2017.04.003; Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Xia GB, 2005, CLIN CANCER RES, V11, P4305, DOI 10.1158/1078-0432.CCR-04-2109; Xia GB, 2005, CANCER RES, V65, P4623, DOI 10.1158/0008-5472.CAN-04-2667; Xu WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14399; Yang NY, 2006, J BIOL CHEM, V281, P32574, DOI 10.1074/jbc.M604338200; Zhao SK, 2010, P NATL ACAD SCI USA, V107, P7704, DOI 10.1073/pnas.0908764107	55	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2019	38	31					5987	6001		10.1038/s41388-019-0854-y	http://dx.doi.org/10.1038/s41388-019-0854-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IT3GE	31270394	Green Published, hybrid			2022-12-17	WOS:000482740000006
J	Casado-Medrano, V; Barrio-Real, L; Wang, A; Cooke, M; Lopez-Haber, C; Kazanietz, MG				Casado-Medrano, Victoria; Barrio-Real, Laura; Wang, Anita; Cooke, Mariana; Lopez-Haber, Cynthia; Kazanietz, Marcelo G.			Distinctive requirement of PKC epsilon in the control of Rho GTPases in epithelial and mesenchymally transformed lung cancer cells	ONCOGENE			English	Article							PROTEIN-KINASE-C; DOWN-REGULATION; PROSTATE-CANCER; BREAST-CANCER; CONSTITUTIVE ACTIVATION; ESSENTIAL MEDIATOR; EXPRESSION; GEF; PHOSPHORYLATION; DIFFERENTIATION	Diacylglycerol (DAG)/phorbol ester-regulated protein kinase C (PKC) isozymes have been widely linked to tumor promotion and the development of a metastatic phenotype. PKC epsilon, an oncogenic member of the PKC family, is abnormally overexpressed in lung cancer and other cancer types. This kinase plays significant roles in proliferation, survival, and migration; however, its role in epithelial-to-mesenchymal transition (EMT) has been scarcely studied. Silencing experiments in non-small lung cancer (NSCLC) cells revealed that PKC epsilon or other DAG-regulated PKCs (PKC alpha and PKC delta) were dispensable for the acquisition of a mesenchymal phenotype induced by transforming growth factor beta (TGF-beta. Unexpectedly, we found a nearly complete down-regulation of PKC epsilon expression in TGF-beta-mesenchymally transformed NSCLC cells. PMA and AJH-836 (a DAG-mimetic that preferentially activates PKC epsilon) promote ruffle formation in NSCLC cells via Racl, however they fail to induce these morphological changes in TGF-beta-mesenchymally transformed cells despite their elevated Racl activity. Several Rac guanine nucleotide exchange-factors (Rac-GEFs) were also up-regulated in TGF-beta-treated NSCLC cells, including Trio and Tiam2, which were required for cell motility. Lastly, we found that silencing or inhibiting PKC epsilon enhances RhoA activity and stress fiber formation, a phenotype also observed in TGF-beta-transformed cells. Our studies established a distinctive involvement of PKC in epithelial and mesenchymal NSCLC cells, and identified a complex interplay between PKC epsilon and small GTPases that contributes to regulation of NSCLC cell morphology and motile activity.	[Casado-Medrano, Victoria; Barrio-Real, Laura; Wang, Anita; Cooke, Mariana; Lopez-Haber, Cynthia; Kazanietz, Marcelo G.] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Kazanietz, MG (corresponding author), Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.	marcelog@upenn.edu	Casado-Medrano, Victoria/ABE-6429-2021; Cooke, Mariana/ABD-5051-2021	Casado-Medrano, Victoria/0000-0002-6929-4559; Cooke, Mariana/0000-0001-9300-8447; Lopez Haber, Cynthia/0000-0001-9106-543X	National Institutes of Health [R01-ES026023, R01-ES026023-S1]; NATIONAL CANCER INSTITUTE [R01CA196232] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES026023] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by grant R01-ES026023 and R01-ES026023-S1 from the National Institutes of Health to M.G.K.	Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037; Barrio-Real Laura, 2018, Oncotarget, V9, P28612, DOI 10.18632/oncotarget.25584; Bassini A, 1999, BLOOD, V93, P1178, DOI 10.1182/blood.V93.4.1178.404k28_1178_1188; Basu A, 2007, CELL SIGNAL, V19, P1633, DOI 10.1016/j.cellsig.2007.04.008; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bin Hafeez B, 2011, CANCER RES, V71, P2318, DOI 10.1158/0008-5472.CAN-10-4170; Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778; Burgos M, 2007, GLIA, V55, P1437, DOI 10.1002/glia.20555; Bustelo XR, 2018, BIOCHEM SOC T, V46, P741, DOI 10.1042/BST20170531; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Caino MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031714; Chang MT, 2016, NAT BIOTECHNOL, V34, P155, DOI 10.1038/nbt.3391; Cook Danielle R, 2011, Genes Cancer, V2, P932, DOI 10.1177/1947601912437035; Cooke M, 2018, J BIOL CHEM, V293, P8330, DOI 10.1074/jbc.RA117.000235; David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009; Di Marcantonio D, 2015, EXP CELL RES, V339, P10, DOI 10.1016/j.yexcr.2015.09.017; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Gaboardi GC, 2010, CELL SIGNAL, V22, P629, DOI 10.1016/j.cellsig.2009.11.017; Galli D, 2015, EXP CELL RES, V330, P277, DOI 10.1016/j.yexcr.2014.11.011; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Garg R, 2018, ONCOGENE, V37, P4735, DOI 10.1038/s41388-018-0318-9; Garg R, 2017, CELL REP, V19, P375, DOI 10.1016/j.celrep.2017.03.042; Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925; Garofalo M, 2011, ANNU REV PHARMACOL, V51, P25, DOI 10.1146/annurev-pharmtox-010510-100517; Gobbi G, 2007, STEM CELLS, V25, P2322, DOI 10.1634/stemcells.2006-0839; Gobbi G, 2013, BLOOD, V122, P1305, DOI 10.1182/blood-2013-04-490599; Gobbi G, 2012, J CELL PHYSIOL, V227, P630, DOI 10.1002/jcp.22765; Gobbi G, 2010, INT J ONCOL, V37, P719, DOI 10.3892/ijo_00000721; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Gorshkova I, 2008, J BIOL CHEM, V283, P11794, DOI 10.1074/jbc.M800250200; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Griner EM, 2010, J BIOL CHEM, V285, P16931, DOI 10.1074/jbc.M109.099036; Guilluy C, 2011, NAT PROTOC, V6, P2050, DOI 10.1038/nprot.2011.411; Gutierrez-Uzquiza A, 2015, MOL CANCER RES, V13, P1336, DOI 10.1158/1541-7786.MCR-15-0111; Hafeez Bilal Bin, 2015, Cancer Prev Res (Phila), V8, P375, DOI 10.1158/1940-6207.CAPR-14-0231; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147; Isakov N, 2018, SEMIN CANCER BIOL, V48, P36, DOI 10.1016/j.semcancer.2017.04.012; Iyengar PV, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040877; Jain K, 2014, CANCERS, V6, P860, DOI 10.3390/cancers6020860; Jain K, 2014, BREAST CANCER-BASIC, V8, P61, DOI 10.4137/BCBCR.S13640; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Leask A, 2008, J CELL SCI, V121, P3459, DOI 10.1242/jcs.029215; Leontieva OV, 2004, J BIOL CHEM, V279, P5788, DOI 10.1074/jbc.M308375200; Levay M, 2009, BIOCHEMISTRY-US, V48, P8615, DOI 10.1021/bi900667y; Lopez-Haber C, 2016, MOL CELL BIOL, V36, P2011, DOI 10.1128/MCB.00180-16; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Meshki J, 2010, J BIOL CHEM, V285, P26033, DOI 10.1074/jbc.M110.128371; Mochly-Rosen D, 2012, NAT REV DRUG DISCOV, V11, P937, DOI 10.1038/nrd3871; Montero JC, 2016, ONCOTARGET, V7, P77937, DOI 10.18632/oncotarget.12846; Newton AC, 2017, TRENDS PHARMACOL SCI, V38, P438, DOI 10.1016/j.tips.2017.02.002; Ong ST, 2014, J BIOL CHEM, V289, P19420, DOI 10.1074/jbc.M113.545863; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Pardo OE, 2006, EMBO J, V25, P3078, DOI 10.1038/sj.emboj.7601198; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Shankar E, 2008, ONCOGENE, V27, P3957, DOI 10.1038/onc.2008.39; Slupsky JR, 2007, AM J PATHOL, V170, P745, DOI 10.2353/ajpath.2007.060557; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Sun XW, 2018, J CELL PHYSIOL, V233, P596, DOI 10.1002/jcp.25920; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Ungefroren H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061568; Ungefroren H, 2018, DEV DYNAM, V247, P451, DOI 10.1002/dvdy.24505; Wang HB, 2014, J BIOL CHEM, V289, P19823, DOI 10.1074/jbc.M114.548446; Wang LY, 2017, PEPTIDES, V96, P44, DOI 10.1016/j.peptides.2017.08.006; Wang YY, 2015, CELL PHYSIOL BIOCHEM, V36, P179, DOI 10.1159/000374062; Yu JR, 2015, GENE DEV, V29, P250, DOI 10.1101/gad.248963.114; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; Zhang HT, 2009, BIOL REPROD, V80, P440, DOI 10.1095/biolreprod.108.072983; Zhang XP, 2014, INT J CANCER, V134, P257, DOI 10.1002/ijc.28141; Zhao W, 2015, MOL BIOL CELL, V26, P1786, DOI 10.1091/mbc.E14-10-1474	81	8	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5396	5412		10.1038/s41388-019-0796-4	http://dx.doi.org/10.1038/s41388-019-0796-4			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30923343	Green Accepted			2022-12-17	WOS:000473842500005
J	Rataj, F; Planel, S; Denis, J; Roelants, C; Filhol, O; Guyon, L; Feige, JJ; Cherradi, N				Rataj, Felicitas; Planel, Severine; Denis, Josiane; Roelants, Caroline; Filhol, Odile; Guyon, Laurent; Feige, Jean-Jacques; Cherradi, Nadia			Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis	ONCOGENE			English	Article							BREAST-CANCER; BINDING PROTEIN; CXCR4/CXCL12 AXIS; TRISTETRAPROLIN; EXPRESSION; TTP; DESTABILIZATION; SEQUENCE; TIMP-1; GROWTH	Altered expression of regulatory RNA-binding proteins (RBPs) in cancer leads to abnormal expression of mRNAs encoding many factors involved in cancer hallmarks. While conventional anticancer therapies usually target one pathway at a time, targeting key RBP would affect multiple genes and thus overcome drug resistance. Among the Tristetraprolin family of RBP, TIS11b/BRF1/ZFP36L1 mediates mRNA decay through binding to Adenylate/Uridylate (AU-rich elements) in mRNA 3'-untranslated region and recruitment of mRNA degradation enzymes. Here, we show that TIS11b is markedly underexpressed in three breast cancer cell lines, as well as in breast tumor samples. We hypothesized that restoring intracellular TIS11b levels could impair cancer cell phenotypic traits. We thus generated a derivative of TIS11b called R9-ZnCS334D, by combining N-terminal domain deletion, serine-to-aspartate substitution at position 334 to enhance the function of the protein and fusion to the cell-penetrating peptide polyarginine R9. R9-ZnCS334D not only blunted secretion of vascular endothelial growth factor (VEGF) but also inhibited proliferation, migration, invasion, and anchorage-independent growth of murine 4T1 or human MDA-MB-231 breast cancer cells. Moreover, R9-ZnCS334D prevented endothelial cell organization into vessel-like structures, suggesting that it could potentially target various cell types within the tumor microenvironment. In vivo, injection of R9-ZnCS334D in 4T1 tumors impaired tumor growth, decreased tumor hypoxia, and expression of the epithelial-to-mesenchymal transition (EMT) markers Snail, Vimentin, and N-cadherin. R9-ZnCS334D also hindered the expression of chemokines and proteins involved in cancer-related inflammation and invasion including Fractalkine (CX3CL1), SDF-1 (CXCL12), MCP-1 (CCL2), NOV (CCN3), and Pentraxin-3 (PTX3). Collectively, our data indicate that R9-ZnCS334D counteracts multiple traits of breast cancer cell aggressiveness and suggest that this novel protein could serve as the basis for innovative multi-target therapies in cancer.	[Rataj, Felicitas; Planel, Severine; Denis, Josiane; Filhol, Odile; Guyon, Laurent; Feige, Jean-Jacques; Cherradi, Nadia] Univ Grenoble Alpes, INSERM, Biosci & Biotechnol Inst Grenoble, CEA,Biol Canc & Infect UMR S 1036, F-38000 Grenoble, France; [Roelants, Caroline] Inovarion, Paris, France	CEA; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm)	Cherradi, N (corresponding author), Univ Grenoble Alpes, INSERM, Biosci & Biotechnol Inst Grenoble, CEA,Biol Canc & Infect UMR S 1036, F-38000 Grenoble, France.	nadia.cherradi@cea.fr	Cherradi, Nadia/K-9695-2016; Filhol-Cochet, Odile/I-3962-2016; Feige, Jean-Jacques/F-5534-2013	Cherradi, Nadia/0000-0002-4292-774X; Guyon, Laurent/0000-0002-7674-2348; Feige, Jean-Jacques/0000-0002-1354-7692; Filhol, Odile/0000-0003-1964-7958	Institut National de la Sante et de la Recherche Medicale [INSERM U1036]; Commissariat a l'Energie Atomique; University Grenoble Alpes (UGA); Labex GRAL [ANR-10-LABX-49-01]; Fondation ARC; Fondation pour la Recherche Medicale	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Commissariat a l'Energie Atomique(French Atomic Energy Commission); University Grenoble Alpes (UGA); Labex GRAL; Fondation ARC; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by the Institut National de la Sante et de la Recherche Medicale (INSERM U1036), the Commissariat a l'Energie Atomique (to FR), The University Grenoble Alpes (UGA), the Labex GRAL (ANR-10-LABX-49-01), the Fondation ARC and the Fondation pour la Recherche Medicale (to SP). We thank Dr. Jean-Luc Coll (Institute for Advanced Biosciences, Grenoble, France) and Dr. Olivier Peyruchaud (INSERM U1033, Faculte de Medecine Laennec, Lyon, France) for providing the 4T1-luc and 4T1 cell lines, respectively. We thank the animal facility staff at Biosciences and Biotechnology Institute of Grenoble (BIG) for animal care.	Al-Souhibani N, 2010, ONCOGENE, V29, P4205, DOI 10.1038/onc.2010.168; Al-Souhibani N, 2014, CARCINOGENESIS, V35, P1983, DOI 10.1093/carcin/bgu080; Baklaushev VP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07851-z; Barcellos-Hoff MH, 2013, NAT REV CANCER, V13, P511, DOI 10.1038/nrc3536; Bell SE, 2006, DEV DYNAM, V235, P3144, DOI 10.1002/dvdy.20949; Benjamin D, 2007, EXPERT OPIN BIOL TH, V7, P1515, DOI 10.1517/14712598.7.10.1515; Bisogno LS, 2018, CURR OPIN GENET DEV, V48, P97, DOI 10.1016/j.gde.2017.11.004; Bleau AM, 2005, FRONT BIOSCI-LANDMRK, V10, P998, DOI 10.2741/1594; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Brooks SA, 2013, BBA-GENE REGUL MECH, V1829, P666, DOI 10.1016/j.bbagrm.2013.02.003; Carrick DM, 2007, ARCH BIOCHEM BIOPHYS, V462, P278, DOI 10.1016/j.abb.2007.04.011; Chamboredon S, 2011, MOL BIOL CELL, V22, P3366, DOI 10.1091/mbc.E10-07-0617; Chen PC, 2014, ONCOTARGET, V5, P1595, DOI 10.18632/oncotarget.1570; Cherradi N, 2006, MOL ENDOCRINOL, V20, P916, DOI 10.1210/me.2005-0121; Choi B, 2014, ONCOTARGET, V5, P481, DOI 10.18632/oncotarget.1664; Ciais D, 2004, ONCOGENE, V23, P8673, DOI 10.1038/sj.onc.1207939; Ciais D, 2013, CELL MOL LIFE SCI, V70, P2031, DOI 10.1007/s00018-012-1150-y; D'Angelo RC, 2014, MOL CANCER RES, V12, P1324, DOI 10.1158/1541-7786.MCR-14-0105; Diamandis EP, 2011, CLIN CANCER RES, V17, P2395, DOI 10.1158/1078-0432.CCR-10-3024; Domanska UM, 2013, EUR J CANCER, V49, P219, DOI 10.1016/j.ejca.2012.05.005; Duan H, 2009, MOL ENDOCRINOL, V23, P497, DOI 10.1210/me.2008-0296; Galloway A, 2016, SCIENCE, V352, P453, DOI 10.1126/science.aad5978; Griseri P, 2011, HUM MOL GENET, V20, P4556, DOI 10.1093/hmg/ddr390; Gruber AR, 2011, NUCLEIC ACIDS RES, V39, pD66, DOI 10.1093/nar/gkq990; Guidotti G, 2017, TRENDS PHARMACOL SCI, V38, P406, DOI 10.1016/j.tips.2017.01.003; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hekmat O, 2013, J PROTEOME RES, V12, P4136, DOI 10.1021/pr400457u; Jamieson-Gladney WL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3016; Johnson BA, 2002, ONCOGENE, V21, P4237, DOI 10.1038/sj.onc.1205526; Khabar KS, 2017, WILEY INTERDISCIP RE, V8, P1; Kondo S, 2013, BRIT J CANCER, V109, P739, DOI 10.1038/bjc.2013.348; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lee HH, 2014, J MICROBIOL BIOTECHN, V24, P287, DOI 10.4014/jmb.1309.09070; Lee SK, 2005, INT J CANCER, V117, P32, DOI 10.1002/ijc.21133; Liang Z, 2007, BIOCHEM BIOPH RES CO, V359, P716, DOI 10.1016/j.bbrc.2007.05.182; Locatelli M, 2013, J NEUROIMMUNOL, V260, P99, DOI 10.1016/j.jneuroim.2013.04.009; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Milke L, 2013, CARCINOGENESIS, V34, P850, DOI 10.1093/carcin/bgs387; Nagel S, 2017, LEUKEMIA LYMPHOMA, V58, P2196, DOI 10.1080/10428194.2017.1283029; Ouellet V, 2011, AM J PATHOL, V178, P2377, DOI 10.1016/j.ajpath.2011.01.033; Planel S, 2010, ONCOGENE, V29, P5989, DOI 10.1038/onc.2010.341; Planel S, 2014, MOL MECH ANGIOGENESI, P353, DOI 10.1007/978-2-8178-0466-8; Presta M, 2007, J CELL MOL MED, V11, P723, DOI 10.1111/j.1582-4934.2007.00061.x; Rataj F, 2016, MOL BIOL CELL, V27, P3841, DOI 10.1091/mbc.E16-06-0379; Reed JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045877; Sanduja S, 2012, FRONT BIOSCI-LANDMRK, V17, P174, DOI 10.2741/3920; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018; Tao K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-228; Wurtz SO, 2008, ACTA ONCOL, V47, P580, DOI 10.1080/02841860802022976; Yoshimura T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058791	51	8	8	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5174	5190		10.1038/s41388-019-0784-8	http://dx.doi.org/10.1038/s41388-019-0784-8			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30914800				2022-12-17	WOS:000473025300005
J	Tsai, FJ; Lai, MT; Cheng, J; Chao, SCC; Korla, PK; Chen, HJ; Lin, CM; Tsai, MH; Hua, CH; Jan, CI; Jinawath, N; Wu, CC; Chen, CM; Kuo, BYT; Chen, LW; Yang, J; Hwang, T; Sheu, JJC				Tsai, Fuu-Jen; Lai, Ming-Tsung; Cheng, Jack; Chao, Stev Chun-Chin; Korla, Praveen Kumar; Chen, Hui-Jye; Lin, Chung-Ming; Tsai, Ming-Hsui; Hua, Chun-Hung; Jan, Chia-Ing; Jinawath, Natini; Wu, Chia-Chen; Chen, Chih-Mei; Kuo, Brian Yu-Ting; Chen, Li-Wen; Yang, Jacky; Hwang, Tritium; Sheu, Jim Jinn-Chyuan			Novel K6-K14 keratin fusion enhances cancer sternness and aggressiveness in oral squamous cell carcinoma	ONCOGENE			English	Article							GENOMIC CHARACTERIZATION; RHABDOID FEATURES; STEM-CELLS; HEAD; ORGANIZATION; EXPRESSION; INVASION; METASTASIS; RESISTANCE; MIGRATION	Keratin intermediate filament (IF) is one component of cellular architectures, which provides necessary mechanical support to conquer environmental stresses. Recent findings reveal its involvement in mechano-transduction and the associated stem cell reprogramming, suggesting the possible roles in cancer development. Here, we report t(12;17)(q13.13;q21.2) chromosomal rearrangement as the most common fusion event in OSCC, resulting in a variety of inter-keratin fusions. Junction site mapping verified 9 in-frame K6-K14 variants, three of which were correlated with lymph node invasion, late tumor stages (T3/T4) and shorter disease-free survival times. When expressed in OSCC cells, those fusion variants disturbed wild-type K14 organization through direct interaction or aggregate formation, leading to perinuclear structure loss and nuclear deformation. Protein array analyses showed the ability of K6-K14 variant 7 (K6-K14/V7) to upregulate TGF-beta and G-CSF signaling, which contributed to cell stemness, drug tolerance, and cell aggressiveness. Notably, K6-K14/V7-expressing cells easily adapted to a soft 3-D culture condition in vitro and formed larger, less differentiated tumors in vivo. In addition to the anti-mechanical-stress activity, our data uncover oncogenic functionality of novel keratin filaments caused by gene fusions during OSCC development.	[Tsai, Fuu-Jen; Cheng, Jack; Chao, Stev Chun-Chin; Chen, Chih-Mei; Sheu, Jim Jinn-Chyuan] China Med Univ Hosp, Human Genet Ctr, Taichung 40447, Taiwan; [Tsai, Fuu-Jen; Sheu, Jim Jinn-Chyuan] China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan; [Lai, Ming-Tsung] Taichung Hosp, Minist Hlth & Welf, Dept Pathol, Taichung 40343, Taiwan; [Korla, Praveen Kumar; Wu, Chia-Chen; Kuo, Brian Yu-Ting; Chen, Li-Wen; Yang, Jacky; Hwang, Tritium; Sheu, Jim Jinn-Chyuan] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan; [Chen, Hui-Jye] China Med Univ, Sch Med, Taichung 40402, Taiwan; [Lin, Chung-Ming] Ming Chuan Univ, Dept Biotechnol, Taoyuan 33348, Taiwan; [Tsai, Ming-Hsui; Hua, Chun-Hung] China Med Univ Hosp, Dept Otolaryngol, Taichung 40447, Taiwan; [Jan, Chia-Ing] China Med Univ Hosp, Dept Pathol, Taichung 40447, Taiwan; [Jinawath, Natini] Mahidol Univ, Ramathibodi Hosp, Fac Med, Program Translat Med, Bangkok 10400, Thailand; [Sheu, Jim Jinn-Chyuan] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; National Sun Yat Sen University; China Medical University Taiwan; Ming Chuan University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Mahidol University; Asia University Taiwan	Sheu, JJC (corresponding author), China Med Univ Hosp, Human Genet Ctr, Taichung 40447, Taiwan.; Sheu, JJC (corresponding author), China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan.; Sheu, JJC (corresponding author), Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.; Sheu, JJC (corresponding author), Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.	jimsheu@mail.nsysu.edu.tw	Korla, Praveen Kumar/AAZ-4949-2020	Korla, Praveen Kumar/0000-0003-1655-625X	Ministry of Science and Technology (MOST), Taiwan [NSC-102-2628-B-039-001-MY3, MOST 103-2314-B-039-009-MY3, MOST 106-2314-B-110-001-MY3]; NSYSU-KMU joint research projects [107-P012, 105-P021]	Ministry of Science and Technology (MOST), Taiwan; NSYSU-KMU joint research projects	The authors thank technical assistance from Ms. Lesley Lin at China Medical University Hospital and Mr. Ming-Der Pong at National Sun Yatsen University. The authors also thank critical comments from Prof. Mien-Chie Hung at MD Anderson Cancer Center/U.S., Prof. Chung Chang at National Sun Yatsen University/Taiwan, Prof. Ming-Jer Tang at National Cheng Kung University/Taiwan, and Prof. Ka-Lok Ng at Asia University/Taiwan. This study was supported by grants from Ministry of Science and Technology (MOST), Taiwan with numbers: NSC-102-2628-B-039-001-MY3, MOST 103-2314-B-039-009-MY3, and MOST 106-2314-B-110-001-MY3, and the NSYSU-KMU joint research projects: 107-P012 and 105-P021.	Agarwal S, 2015, CANCER RES, V75, P2566, DOI 10.1158/0008-5472.CAN-14-2946; Baillie R, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00112; Beil M, 2003, NAT CELL BIOL, V5, P803, DOI 10.1038/ncb1037; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Chen JL, 2006, J CELL SCI, V119, P5067, DOI 10.1242/jcs.03298; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chu PG, 2002, HISTOPATHOLOGY, V40, P403, DOI 10.1046/j.1365-2559.2002.01387.x; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Feng X, 2015, J BIOL CHEM, V290, P22507, DOI 10.1074/jbc.M115.654749; Feng X, 2015, J CELL BIOL, V209, P59, DOI 10.1083/jcb.201408079; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Foty R, 2011, JOVE-J VIS EXP, DOI 10.3791/2720; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Gemenetzidis E, 2015, ONCOTARGET, V6, P43964, DOI 10.18632/oncotarget.6268; Guo T, 2016, INT J CANCER, V139, P373, DOI 10.1002/ijc.30081; Hsu DM, 2013, CANCER RES, V73, P4134, DOI 10.1158/0008-5472.CAN-12-4056; Iwaya K, 2005, SEMIN CANCER BIOL, V15, P309, DOI 10.1016/j.semcancer.2005.04.006; Joosse SA, 2012, CLIN CANCER RES, V18, P993, DOI 10.1158/1078-0432.CCR-11-2100; Kang NY, 2011, NAT PROTOC, V6, P1044, DOI 10.1038/nprot.2011.350; Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456; Kawai T, 2015, CLIN CANCER RES, V21, P3081, DOI 10.1158/1078-0432.CCR-14-1936; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kuroiwa K, 2002, HISTOPATHOLOGY, V41, P538, DOI 10.1046/j.1365-2559.2002.01427.x; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Li R, 2015, HEAD NECK-J SCI SPEC, V37, P1642, DOI 10.1002/hed.23807; Loschke F, 2015, CURR OPIN CELL BIOL, V32, P56, DOI 10.1016/j.ceb.2014.12.006; McGregor AL, 2016, CURR OPIN CELL BIOL, V40, P32, DOI 10.1016/j.ceb.2016.01.011; Moll R, 2008, HISTOCHEM CELL BIOL, V129, P705, DOI 10.1007/s00418-008-0435-6; Ohmoto T, 2015, PATHOL INT, V65, P264, DOI 10.1111/pin.12283; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Przybycin CG, 2014, AM J SURG PATHOL, V38, P1260, DOI 10.1097/PAS.0000000000000251; Reinholz MM, 2011, CLIN CANCER RES, V17, P7183, DOI 10.1158/1078-0432.CCR-11-0981; Rudland SD, 2011, AM J PATHOL, V179, P1061, DOI 10.1016/j.ajpath.2011.04.022; Sawant MS, 2017, INT REV CEL MOL BIO, V330, P171, DOI 10.1016/bs.ircmb.2016.09.005; Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310; Seltmann K, 2013, P NATL ACAD SCI USA, V110, P18507, DOI 10.1073/pnas.1310493110; Sewell A, 2014, CLIN CANCER RES, V20, P2300, DOI 10.1158/1078-0432.CCR-13-2585; Sheu JJC, 2014, ONCOGENE, V33, P1375, DOI 10.1038/onc.2013.98; Sheu JJC, 2009, CANCER RES, V69, P2568, DOI 10.1158/0008-5472.CAN-08-3199; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Snider NT, 2014, NAT REV MOL CELL BIO, V15, P163, DOI 10.1038/nrm3753; Souto GR, 2010, J ORAL PATHOL MED, V39, P605, DOI 10.1111/j.1600-0714.2010.00907.x; Sugimoto K, 2016, BRAIN TUMOR PATHOL, V33, P137, DOI 10.1007/s10014-015-0243-3; Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104; van Helvert S, 2018, NAT CELL BIOL, V20, P8, DOI 10.1038/s41556-017-0012-0; Wang GY, 2011, CANCER CELL, V19, P114, DOI 10.1016/j.ccr.2010.11.007; Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632; Yoshihara K, 2015, ONCOGENE, V34, P4845, DOI 10.1038/onc.2014.406; Zaphiropoulos Peter G., 2011, Frontiers in Genetics, V2, P92, DOI 10.3389/fgene.2011.00092	50	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5113	5126		10.1038/s41388-019-0781-y	http://dx.doi.org/10.1038/s41388-019-0781-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30867567				2022-12-17	WOS:000473025300001
J	Rossa, C; D'Silva, NJ				Rossa, Carlos, Jr.; D'Silva, Nisha J.			Non-murine models to investigate tumor-immune interactions in head and neck cancer	ONCOGENE			English	Review							SQUAMOUS-CELL CARCINOMA; FUNCTIONAL-CHARACTERIZATION; KNOCKOUT PIGS; EXPRESSION; SURVIVAL; SYSTEM; GENOME; CATS; DOG; IMMUNOTHERAPY	The immune response has important roles in the biology of solid tumors, including oncogenesis, tumor growth, invasion and metastasis, and response to treatment. Improved understanding of tumor-immune system interactions has provided promising therapeutic options that are based on the rescue and enhancement of the anti-tumoral host response. Immunebased treatments have been approved for clinical use in various types of cancer, including head and neck cancer (HNC); other strategies involving combination therapies are currently in development. These novel therapies were developed based on knowledge derived from in vitro, in silico, and in vivo pre-clinical studies. However, clinical trials seldom replicate the efficacy observed in pre-clinical animal studies. This lack of correlation between pre-clinical studies and clinical trials may be related to limitations of the models used; which highlights the relevance of considering immune-related aspects of different pre-clinical models. Murine models are the most frequently used pre-clinical models of HNC and are discussed elsewhere. Non-murine models have characteristics that offer unique opportunities for the study of HNC etiology, therapeutic strategies, and tumor-immune system interactions. The current review focuses on immune-related aspects of nonmurine models, including dog, cat, pig, zebrafish, and frog, that could be used to investigate tumor-immune interactions in HNC.	[Rossa, Carlos, Jr.] State Univ Sao Paulo, UNESP, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil; [Rossa, Carlos, Jr.; D'Silva, Nisha J.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [D'Silva, Nisha J.] Univ Michigan, Dept Pathol, Med Sch, Ann Arbor, MI 48109 USA	Universidade Estadual Paulista; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Rossa, C (corresponding author), State Univ Sao Paulo, UNESP, Sch Dent Araraquara, Dept Diag & Surg, Araraquara, SP, Brazil.; Rossa, C; D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.; D'Silva, NJ (corresponding author), Univ Michigan, Dept Pathol, Med Sch, Ann Arbor, MI 48109 USA.	c.rossa@unesp.br; njdsilva@umich.edu	Rossa, Carlos/D-8328-2012	Rossa, Carlos/0000-0003-1705-5481; D'Silva, Nisha/0000-0001-7030-3187	NIH/NIDCR [DE027551, DE022567]; University of Michigan; FAPESP [2017/14283-5, 2014/50312-4]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022567, R35DE027551] Funding Source: NIH RePORTER	NIH/NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); University of Michigan(University of Michigan System); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by grants from NIH/NIDCR DE027551 (NJD), DE022567 (NJD), FAPESP 2017/14283-5 (CRJ), and University of Michigan and FAPESP 2014/50312-4 (NJD and CRJ)	Adam SJ, 2007, ONCOGENE, V26, P1038, DOI 10.1038/sj.onc.1209892; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Alves AM, 2018, J ORAL PATHOL MED, V47, P460, DOI 10.1111/jop.12643; Arnold CR, 2017, OR SURG OR MED OR PA, V123, P536, DOI 10.1016/j.oooo.2016.11.017; Bergeron LM, 2014, VET IMMUNOL IMMUNOP, V157, P31, DOI 10.1016/j.vetimm.2013.10.018; Bergkvist GT, 2011, VET COMP ONCOL, V9, P106, DOI 10.1111/j.1476-5829.2010.00239.x; Bordignon V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064613; Borovansky J, 2003, MELANOMA RES, V13, P543, DOI 10.1097/01.cmr.0000056276.15046.21; Callesen MM, 2017, MOL ONCOL, V11, P1616, DOI 10.1002/1878-0261.12136; Cannon Claire M, 2015, Vet Sci, V2, P111, DOI 10.3390/vetsci2030111; Choi YJ, 2017, ONCOTARGET, V8, P69398, DOI 10.18632/oncotarget.20626; Curry JM, 2007, OTOLARYNG HEAD NECK, V137, P735, DOI 10.1016/j.otohns.2007.07.019; Day M.J., 2014, VET IMMUNOLOGY PRINC; Day MJ, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1798-5; de Almeida EMP, 2001, J HISTOCHEM CYTOCHEM, V49, P867, DOI 10.1177/002215540104900707; De Pelsmaeker S, 2018, J LEUKOCYTE BIOL, V103, P129, DOI 10.1002/JLB.4A0417-163RR; de Ruiter EJ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356148; Dobson J. M., 2013, ISRN VET SCI, V2013, DOI DOI 10.1155/2013/941275); Ferris RL, 2018, ORAL ONCOL, V81, P45, DOI 10.1016/j.oraloncology.2018.04.008; Ferris RL, 2015, J CLIN ONCOL, V33, P3293, DOI 10.1200/JCO.2015.61.1509; Fulton AJ, 2013, JAVMA-J AM VET MED A, V243, P696, DOI 10.2460/javma.243.5.696; Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189; Groenen MAM, 2012, NATURE, V491, P393, DOI 10.1038/nature11622; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanna GJ, 2017, ORAL ONCOL, V67, P61, DOI 10.1016/j.oraloncology.2017.02.005; Harley R, 2011, J COMP PATHOL, V144, P239, DOI 10.1016/j.jcpa.2010.09.173; Hassan BB, 2017, VET PATHOL, V54, P32, DOI 10.1177/0300985816650243; Hayes A, 2006, J COMP PATHOL, V135, P93, DOI 10.1016/j.jcpa.2006.06.001; Hirano F, 2005, CANCER RES, V65, P1089; Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111; Hu L, 2017, ORAL DIS, V23, P801, DOI 10.1111/odi.12667; Huang J, 2014, J IMMUNOL, V193, P1496, DOI 10.4049/jimmunol.1400915; Ito T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113833; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Kamb A, 2005, NAT REV DRUG DISCOV, V4, P161, DOI 10.1038/nrd1635; Karo JM, 2014, CELL, V159, P94, DOI 10.1016/j.cell.2014.08.026; Khanna C, 2006, NAT BIOTECHNOL, V24, P1065, DOI 10.1038/nbt0906-1065b; Khoshnevis M, 2017, J NEUROSCI METH, V282, P61, DOI 10.1016/j.jneumeth.2017.03.007; Klobukowska HJ, 2016, VET PATHOL, V53, P1124, DOI 10.1177/0300985816629713; Lam SH, 2004, DEV COMP IMMUNOL, V28, P9, DOI 10.1016/S0145-305X(03)00103-4; Lei SH, 2016, SCI REP-UK, V6, DOI 10.1038/srep25222; Leroy G, 2009, ANIM GENET, V40, P333, DOI 10.1111/j.1365-2052.2008.01843.x; Li S, 2015, TRANSGENIC RES, V24, P509, DOI 10.1007/s11248-015-9866-8; Li X, 2006, CARDIOVASC INTER RAD, V29, P420, DOI 10.1007/s00270-005-0099-8; Li YJ, 2017, CELL MOL IMMUNOL, V14, P80, DOI 10.1038/cmi.2016.50; Lieschke GJ, 2001, BLOOD, V98, P3087, DOI 10.1182/blood.V98.10.3087; Lillico SG, 2013, SCI REP-UK, V3, DOI 10.1038/srep02847; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Liu DL, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005277; Lunney JK, 2009, DEV COMP IMMUNOL, V33, P362, DOI 10.1016/j.dci.2008.07.002; Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022; Martano M, 2016, ONCOL LETT, V11, P399, DOI 10.3892/ol.2015.3847; Martin CK, 2011, VET PATHOL, V48, P302, DOI 10.1177/0300985810384414; Mas A, 2011, J SMALL ANIM PRACT, V52, P359, DOI 10.1111/j.1748-5827.2011.01075.x; McAnulty PA, 2012, MINIPIG IN BIOMEDICAL RESEARCH, P1; Mestrinho LA, 2017, J VET DENT, V34, P92, DOI 10.1177/0898756417713979; Meurens F, 2012, TRENDS MICROBIOL, V20, P50, DOI 10.1016/j.tim.2011.11.002; Miyazawa J, 2004, CANCER RES, V64, P2024, DOI 10.1158/0008-5472.CAN-03-1855; Mochizuki H, 2017, VET COMP ONCOL, V15, P1598, DOI 10.1111/vco.12275; Montague MJ, 2014, P NATL ACAD SCI USA, V111, P17230, DOI 10.1073/pnas.1410083111; Munday JS, 2015, VET J, V204, P223, DOI 10.1016/j.tvjl.2015.03.002; Munday JS, 2011, RES VET SCI, V90, P280, DOI 10.1016/j.rvsc.2010.06.014; Nemec A, 2012, J COMP PATHOL, V147, P111, DOI 10.1016/j.jcpa.2011.11.198; Popovic A, 2018, J CLIN INVEST, V128, P3209, DOI 10.1172/JCI120775; Rathore K, 2014, TRANSL RES, V164, P158, DOI 10.1016/j.trsl.2014.02.002; Reymond MA, 2000, EUR J SURG ONCOL, V26, P393, DOI 10.1053/ejso.1999.0905; Rossa C, 2019, ONCOGENE, V38, P3973, DOI 10.1038/s41388-019-0686-9; Rothkotter HJ, 2009, DEV COMP IMMUNOL, V33, P267, DOI 10.1016/j.dci.2008.06.016; Sanz R, 2017, EUR J PHARM BIOPHARM, V117, P203, DOI 10.1016/j.ejpb.2017.04.019; Schachtschneider KM, 2017, ONCOTARGET, V8, P63620, DOI 10.18632/oncotarget.18872; Schachtschneider KM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02912-9; Schook LB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128864; Schook LB, 2015, ANNU REV ANIM BIOSCI, V3, P219, DOI 10.1146/annurev-animal-022114-110815; Seoane J, 2013, MED ORAL PATOL ORAL, V18, pE246, DOI 10.4317/medoral.17998; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Sieren JC, 2014, J CLIN INVEST, V124, P4052, DOI 10.1172/JCI75447; Sinkora M, 2009, DEV COMP IMMUNOL, V33, P273, DOI 10.1016/j.dci.2008.07.011; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Snyder LA, 2004, VET PATHOL, V41, P209, DOI 10.1354/vp.41-3-209; Soltero-Rivera MM, 2014, J FELINE MED SURG, V16, P164, DOI 10.1177/1098612X13502975; STEBBINS KE, 1989, VET PATHOL, V26, P121, DOI 10.1177/030098588902600204; Sterenczak KA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-694; Stramandinoli-Zanicotti RT, 2013, INT ARCH OTORHINOLAR, V17, P163, DOI 10.7162/S1809-97772013000200008; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Strietzel CJ, 2014, VET IMMUNOL IMMUNOP, V158, P214, DOI 10.1016/j.vetimm.2014.01.012; Supsavhad Wachiraphan, 2016, Vet Sci, V3, DOI 10.3390/vetsci3030018; Supsavhad W, 2016, VET J, V210, P7, DOI 10.1016/j.tvjl.2015.11.006; Suzuki S, 2016, VET IMMUNOL IMMUNOP, V178, P37, DOI 10.1016/j.vetimm.2016.06.011; Suzuki S, 2012, CELL STEM CELL, V10, P753, DOI 10.1016/j.stem.2012.04.021; TODOROFF RJ, 1979, J AM VET MED ASSOC, V175, P567; Wakshlag JJ, 2011, AM J VET RES, V72, P1369, DOI 10.2460/ajvr.72.10.1369; Walters Eric M, 2013, Mo Med, V110, P212; Watson AL, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00078; Wiles V, 2017, J FELINE MED SURG, V19, P185, DOI 10.1177/1098612X15622237; Wypij J. M., 2013, PATHOL RES INT, V2013, DOI DOI 10.1155/2013/502197; Yamakawa Hirohito, 1999, Journal of Reproduction and Development, V45, P111, DOI 10.1262/jrd.45.111; Yoshikawa H, 2012, AM J VET RES, V73, P1801, DOI 10.2460/ajvr.73.11.1801; Yuhki N, 2007, J HERED, V98, P390, DOI 10.1093/jhered/esm056; Zhang C, 2008, CYTOTHERAPY, V10, P711, DOI 10.1080/14653240802320237; 2011, GENETICS PIG, P1	100	8	8	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4902	4914		10.1038/s41388-019-0776-8	http://dx.doi.org/10.1038/s41388-019-0776-8			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30872793	Green Accepted			2022-12-17	WOS:000472145900002
J	Short, SP; Barrett, CW; Stengel, KR; Revetta, FL; Choksi, YA; Coburn, LA; Lintel, MK; McDonough, EM; Washington, MK; Wilson, KT; Prokhortchouk, E; Chen, X; Hiebert, SW; Reynolds, AB; Williams, CS				Short, Sarah P.; Barrett, Caitlyn W.; Stengel, Kristy R.; Revetta, Frank L.; Choksi, Yash A.; Coburn, Lori A.; Lintel, Mary K.; McDonough, Elizabeth M.; Washington, M. Kay; Wilson, Keith T.; Prokhortchouk, Egor; Chen, Xi; Hiebert, Scott W.; Reynolds, Albert B.; Williams, Christopher S.			Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma	ONCOGENE			English	Article							HUMAN BREAST; STEM-CELLS; IN-VITRO; GENE; DNA; CANCER; EXPRESSION; COLON; MTG16; BETA	The myeloid translocation gene family member MTG16 is a transcriptional corepressor that relies on the DNA-binding ability of other proteins to determine specificity. One such protein is the ZBTB family member Kaiso, and the MTG16:Kaiso interaction is necessary for repression of Kaiso target genes, such as matrix metalloproteinase-7. Using the azoxymethane and dextran sodium sulfate (AOM/DSS) murine model of colitis-associated carcinoma, we previously determined that MTG16 loss accelerates tumorigenesis and inflammation. However, it was unknown whether this effect was modified by Kaiso-dependent transcriptional repression. To test for a genetic interaction between MTG16 and Kaiso in inflammatory carcinogenesis, we subjected single and double knockout (DKO) mice to the AOM/DSS protocol. Mtg16(-/-) mice demonstrated increased colitis and tumor burden; in contrast, disease severity in Kaiso(-/-) mice was equivalent to wild-type controls. Surprisingly, Kaiso deficiency in the context of MTG16 loss reversed injury and pro-tumorigenic responses in the intestinal epithelium following AOM/DSS treatment, and tumor numbers were returned to near to wild-type levels. Transcriptomic analysis of non-tumor colon tissue demonstrated that changes induced by MTG16 loss were widely mitigated by concurrent Kaiso loss, and DKO mice demonstrated downregulation of metabolism and cytokine-associated gene sets with concurrent activation of DNA damage checkpoint pathways as compared with Mtg16(-/-). Further, Kaiso knockdown in intestinal enteroids reduced stem- and WNT-associated phenotypes, thus abrogating the induction of these pathways observed in Mtg16(-/-) samples. Together, these data suggest that Kaiso modifies MTG16-driven inflammation and tumorigenesis and suggests that Kaiso deregulation contributes to MTG16-dependent colitis and CAC phenotypes.	[Short, Sarah P.; Barrett, Caitlyn W.; Choksi, Yash A.; Coburn, Lori A.; Lintel, Mary K.; McDonough, Elizabeth M.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA; [Short, Sarah P.; Barrett, Caitlyn W.; Choksi, Yash A.; Wilson, Keith T.; Reynolds, Albert B.; Williams, Christopher S.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA; [Stengel, Kristy R.; Hiebert, Scott W.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; [Revetta, Frank L.; Washington, M. Kay; Wilson, Keith T.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, Med Ctr, Nashville, TN 37232 USA; [Choksi, Yash A.; Coburn, Lori A.; Wilson, Keith T.; Williams, Christopher S.] Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN 37232 USA; [Coburn, Lori A.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Ctr Mucosal Inflammat & Canc, Med Ctr, Nashville, TN 37232 USA; [McDonough, Elizabeth M.] Our Lady Lake Childrens Hosp, Dept Pediat, Div Gastroenterol, Baton Rouge, TN 70808 USA; [Wilson, Keith T.; Hiebert, Scott W.; Reynolds, Albert B.; Williams, Christopher S.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Prokhortchouk, Egor] Russian Acad Sci, Inst Bioengn, Res Ctr Biotechnol, Moscow, Russia; [Chen, Xi] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA; [Chen, Xi] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University; Research Center of Biotechnology RAS; Russian Academy of Sciences; University of Miami; University of Miami	Williams, CS (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Ctr Mucosal Inflammat & Canc, Med Ctr, Nashville, TN 37232 USA.; Williams, CS (corresponding author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.	Christopher.williams@vanderbilt.edu	Prokhortchouk, Egor/I-9108-2014; Williams, Christopher/W-3524-2019	Williams, Christopher/0000-0002-1541-579X; Coburn, Lori/0000-0003-3249-9806; Wilson, Keith/0000-0003-4421-1830; Short, Sarah/0000-0001-9606-7370; Stengel, Kristy/0000-0002-8330-5744	National Institutes of Health [R01DK099204, R01AT004821, R01CA178030, 1F31CA167920, F32DK108492]; Federal Research Center "Fundamentals of Biotechnology" budget [01201371085]; Office of Medical Research, Department of Veterans Affairs [1I01BX001426, 1I01BX001453, 1IK2BX002126]; NIH [P30DK058404]; NATIONAL CANCER INSTITUTE [R01CA164605, R01CA178030] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK099204, P30DK058404, F32DK108492] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001426, IK2BX002126, I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Federal Research Center "Fundamentals of Biotechnology" budget; Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	National Institutes of Health (R01DK099204 to CSW; R01AT004821 to KTW; R01CA178030 to SWH; 1F31CA167920 to CWB; F32DK108492 to SPS); the Federal Research Center "Fundamentals of Biotechnology" budget (No. 01201371085 to EP); Office of Medical Research, Department of Veterans Affairs (1I01BX001426 to CSW; 1I01BX001453 to KTW; 1IK2BX002126 to LAC). Additional support was provided by the NIH grant P30DK058404 (Vanderbilt Digestive Disease Research Center).	Barrett CW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051205; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Becker C, 2006, NAT PROTOC, V1, P2900, DOI 10.1038/nprot.2006.446; Becker C, 2005, GUT, V54, P950, DOI 10.1136/gut.2004.061283; Bergstrom KSB, 2008, INFECT IMMUN, V76, P796, DOI 10.1128/IAI.00093-07; Blattler A, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-13; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brown JJ, 2018, J VIROL, V92, DOI 10.1128/JVI.02062-17; Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816; Buck-Koehntop BA, 2012, FEBS LETT, V586, P734, DOI 10.1016/j.febslet.2012.01.045; Chaudhary R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074160; Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Donaldson IJ, 2012, NUCLEIC ACIDS RES, V40, P3990, DOI 10.1093/nar/gkr1240; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031; Kim SW, 2004, NAT CELL BIOL, V6, P1212, DOI 10.1038/ncb1191; Koch S, 2011, GASTROENTEROLOGY, V141, P259, DOI 10.1053/j.gastro.2011.03.043; Kochetkova M, 2002, CANCER RES, V62, P4599; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lopes EC, 2008, CANCER RES, V68, P7258, DOI 10.1158/0008-5472.CAN-08-0344; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Martinez JA, 2006, GASTROENTEROLOGY, V131, P579, DOI 10.1053/j.gastro.2006.06.009; MCCORMICK DA, 1990, J CLIN PATHOL, V43, P143, DOI 10.1136/jcp.43.2.143; McDonough EM, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.78210; Miyoshi H, 2013, NAT PROTOC, V8, P2471, DOI 10.1038/nprot.2013.153; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nowarski R, 2015, CELL, V163, P1444, DOI 10.1016/j.cell.2015.10.072; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Pierre CC, 2015, BBA-MOL BASIS DIS, V1852, P1846, DOI 10.1016/j.bbadis.2015.06.011; Poindexter SV, 2015, AM J PHYSIOL-GASTR L, V308, pG562, DOI 10.1152/ajpgi.00253.2014; Pozner A, 2016, J BIOL CHEM, V291, P24538, DOI 10.1074/jbc.M116.746370; Prokhortchouk A, 2006, MOL CELL BIOL, V26, P199, DOI 10.1128/MCB.26.1.199-208.2006; Raghav SK, 2012, MOL CELL, V46, P335, DOI 10.1016/j.molcel.2012.03.017; Reddy VK, 2016, STEM CELLS, V34, P1626, DOI 10.1002/stem.2307; Rudolph KL, 2009, GASTROENTEROLOGY, V137, P754, DOI 10.1053/j.gastro.2009.07.037; Ruzov A, 2009, DEVELOPMENT, V136, P729, DOI 10.1242/dev.025569; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Syljuasen RG, 1999, CANCER RES, V59, P1008; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Williams CS, 2013, GUT, V62, P1446, DOI 10.1136/gutjnl-2011-301439; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441	51	8	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5091	5106		10.1038/s41388-019-0777-7	http://dx.doi.org/10.1038/s41388-019-0777-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858547	Green Accepted			2022-12-17	WOS:000472145900015
J	Block, I; Muller, C; Sdogati, D; Pedersen, H; List, M; Jaskot, AM; Syse, SD; Hansen, PL; Schmidt, S; Christiansen, H; Casella, C; Olsen, SB; Blomstrom, MM; Riedel, A; Thomassen, M; Kruse, TA; Hansen, SWK; Kioschis, P; Mollenhauer, J				Block, Ines; Mueller, Carolin; Sdogati, Daniel; Pedersen, Henriette; List, Markus; Jaskot, Aleksandra M.; Syse, Silje Damkjaer; Hansen, Pernille Lund; Schmidt, Steffen; Christiansen, Helle; Casella, Cinzia; Olsen, Sidsel Bering; Blomstrom, Monica M.; Riedel, Angela; Thomassen, Mads; Kruse, Torben A.; Hansen, Soren W. Karlskov; Kioschis, Petra; Mollenhauer, Jan			CFP suppresses breast cancer cell growth by TES-mediated upregulation of the transcription factor DDIT3	ONCOGENE			English	Article							UNFOLDED PROTEIN RESPONSE; SOMATIC MUTATIONS; PROPERDIN BINDS; LARGE-SCALE; INHIBITION; EXPRESSION; PROLIFERATION; DEFICIENCY; LANDSCAPE; MORTALITY	Breast cancer is a heterogeneous genetic disease driven by the accumulation of individual mutations per tumor. Whole-genome sequencing approaches have identified numerous genes with recurrent mutations in primary tumors. Although mutations in well characterized tumor suppressors and oncogenes are overrepresented in these sets, the majority of the genetically altered genes have so far unknown roles in breast cancer progression. To improve the basic understanding of the complex disease breast cancer and to potentially identify novel drug targets or regulators of known cancer-driving pathways, we analyzed 86 wild-type genes and 94 mutated variants for their effect on cell growth using a serially constructed panel of MCF7 cell lines. We demonstrate in subsequent experiments that the metal cation transporter CNNM4 regulates growth by induction of apoptosis and identified a tumor suppressive role of complement factor properdin (CFP) in vitro and in vivo. CFP appears to induce the intracellular upregulation of the pro-apoptotic transcription factor DDIT3 which is associated with endoplasmic reticulum-stress response.	[Block, Ines; Mueller, Carolin; Sdogati, Daniel; Pedersen, Henriette; List, Markus; Jaskot, Aleksandra M.; Syse, Silje Damkjaer; Hansen, Pernille Lund; Schmidt, Steffen; Christiansen, Helle; Casella, Cinzia; Olsen, Sidsel Bering; Blomstrom, Monica M.; Riedel, Angela; Mollenhauer, Jan] Univ Southern Denmark, Inst Mol Med, Lundbeckfonden Ctr Excellence NanoCAN, Odense, Denmark; [Block, Ines; Mueller, Carolin; Sdogati, Daniel; Pedersen, Henriette; List, Markus; Jaskot, Aleksandra M.; Syse, Silje Damkjaer; Hansen, Pernille Lund; Schmidt, Steffen; Christiansen, Helle; Casella, Cinzia; Olsen, Sidsel Bering; Blomstrom, Monica M.; Riedel, Angela; Mollenhauer, Jan] Univ Southern Denmark, Inst Mol Med, Mol Oncol, Odense, Denmark; [Block, Ines; Thomassen, Mads; Kruse, Torben A.] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark; [Hansen, Pernille Lund; Olsen, Sidsel Bering; Hansen, Soren W. Karlskov] Univ Southern Denmark, Dept Canc & Inflammat Res, Odense, Denmark; [Thomassen, Mads; Kruse, Torben A.] Univ Southern Denmark, Dept Human Genet, Odense, Denmark; [Kioschis, Petra] Mannheim Univ Appl Sci, Dept Biotechnol, Mannheim, Germany; [Block, Ines] Martin Luther Univ Halle Wittenberg, Inst Physiol Chem, Halle, Saale, Germany; [Mueller, Carolin] Univ Southern Denmark, Dept Biochem & Mol Biol, Odense, Denmark; [Pedersen, Henriette; Blomstrom, Monica M.] Danish Canc Soc Res Ctr, Brain Tumor Biol Grp, Copenhagen, Denmark; [List, Markus] Tech Univ Munich, TUM Sch Life Sci, Chair Expt Bioinformat, Big Data BioMed Grp, D-85354 Freising Weihenstephan, Germany; [Riedel, Angela] HI STEM gGmbH, Heidelberg Inst Stem Cell Technol & Expt Med, Heidelberg, Germany; [Riedel, Angela] German Canc Res Ctr, Cell Biol & Tumor Biol Program, Heidelberg, Germany	Lundbeckfonden; University of Southern Denmark; University of Southern Denmark; University of Southern Denmark; Odense University Hospital; University of Southern Denmark; University of Southern Denmark; Martin Luther University Halle Wittenberg; University of Southern Denmark; Danish Cancer Society; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Block, I (corresponding author), Univ Southern Denmark, Inst Mol Med, Lundbeckfonden Ctr Excellence NanoCAN, Odense, Denmark.; Block, I (corresponding author), Univ Southern Denmark, Inst Mol Med, Mol Oncol, Odense, Denmark.; Block, I (corresponding author), Odense Univ Hosp, Dept Clin Genet, Odense, Denmark.; Block, I (corresponding author), Martin Luther Univ Halle Wittenberg, Inst Physiol Chem, Halle, Saale, Germany.	Ines.Block@uk-halle.de	Block, Ines/Q-5507-2016; Riedel, Angela/ABC-7207-2020; Hansen, Pernille Lund/F-3919-2016; Pedersen, Henriette/S-6231-2017	Block, Ines/0000-0003-1964-6031; Hansen, Soren/0000-0002-8186-4630; Bering Olsen, Sidsel/0000-0001-8465-6629; Hansen, Pernille Lund/0000-0001-8284-4917; Pedersen, Henriette/0000-0002-6872-0405; List, Markus/0000-0002-0941-4168	Lundbeck Foundation (Grant NanoCAN); Rektorspuljen SDU2020 Program [DAWN-2020]; Region Syddanmarks Ph.D.- and Forskningspulje; Fonden Til Laegevidenskabens Fremme; MIO project of the OUH Frontlinjepuljen; Aase og Ejnar Danielsens Fond; Torben og Alice Frimodts Fond; Kong Christian den Tiendes Fond; Brodrene Hartmanns Fond; Fru Astrid Thaysens Legat for Laegevidenskabelig Grundforskning; Grosserer A. V. Lykfeldt og Hustrus Legat; Familien Hede Nielsens Fond; Oda og Hans Svenningsens Fond; Lippmann Fonden; Gangsted Fonden; Kraeftens Bekaempelse; INTERREG 4A-program Syddanmark-Schleswig-K.E.R.N.; European Regional Development Fund	Lundbeck Foundation (Grant NanoCAN); Rektorspuljen SDU2020 Program; Region Syddanmarks Ph.D.- and Forskningspulje; Fonden Til Laegevidenskabens Fremme; MIO project of the OUH Frontlinjepuljen; Aase og Ejnar Danielsens Fond; Torben og Alice Frimodts Fond; Kong Christian den Tiendes Fond; Brodrene Hartmanns Fond; Fru Astrid Thaysens Legat for Laegevidenskabelig Grundforskning; Grosserer A. V. Lykfeldt og Hustrus Legat; Familien Hede Nielsens Fond; Oda og Hans Svenningsens Fond; Lippmann Fonden; Gangsted Fonden; Kraeftens Bekaempelse; INTERREG 4A-program Syddanmark-Schleswig-K.E.R.N.; European Regional Development Fund(European Commission)	The work was supported by the Lundbeck Foundation (Grant NanoCAN), and the Rektorspuljen SDU2020 Program (Grant: DAWN-2020); Region Syddanmarks Ph.D.- and Forskningspulje; Fonden Til Laegevidenskabens Fremme; MIO project of the OUH Frontlinjepuljen; Aase og Ejnar Danielsens Fond; Torben og Alice Frimodts Fond, Kong Christian den Tiendes Fond, Brodrene Hartmanns Fond, Fru Astrid Thaysens Legat for Laegevidenskabelig Grundforskning, Grosserer A. V. Lykfeldt og Hustrus Legat, Familien Hede Nielsens Fond, Oda og Hans Svenningsens Fond, Lippmann Fonden and Gangsted Fonden. The work was further support by scholarships granted by Kraeftens Bekaempelse and was co-financed by the INTERREG 4A-program Syddanmark-Schleswig-K.E.R.N. with funds from The European Regional Development Fund. The funding sources had no role in study design, collection of data and analysis, nor in the decision to publish, or preparation of the article.	Al-Rayahi IAM, 2017, IMMUN INFLAMM DIS, V5, P68, DOI 10.1002/iid3.142; Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Bathum L, 2006, MOL IMMUNOL, V43, P473, DOI 10.1016/j.molimm.2005.02.017; Biunno I, 2006, J CELL PHYSIOL, V208, P23, DOI 10.1002/jcp.20574; Chittenden TW, 2008, GENOMICS, V91, P508, DOI 10.1016/j.ygeno.2008.03.002; End C, 2009, EUR J IMMUNOL, V39, P833, DOI 10.1002/eji.200838689; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fijen CAP, 1999, MOL IMMUNOL, V36, P863, DOI 10.1016/S0161-5890(99)00107-8; Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Funato Y, 2014, J CLIN INVEST, V124, P5398, DOI 10.1172/JCI76614; Gulerez I, 2016, EMBO REP, V17, P1890, DOI 10.15252/embr.201643393; Guo DH, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-15; Guo J, 2015, ONCOL REP, V33, P3124, DOI 10.3892/or.2015.3902; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jiao X, 2012, GENE CHROMOSOME CANC, V51, P480, DOI 10.1002/gcc.21935; Kemper C, 2008, P NATL ACAD SCI USA, V105, P9023, DOI 10.1073/pnas.0801015105; Kemper C, 2010, ANNU REV IMMUNOL, V28, P131, DOI 10.1146/annurev-immunol-030409-101250; Kostantin E, 2016, J BIOL CHEM, V291, P10716, DOI 10.1074/jbc.M115.705863; Kretowski R, 2016, MOL CELL BIOCHEM, V417, P35, DOI 10.1007/s11010-016-2711-4; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Laurberg T, 2017, ACTA ONCOL, V56, P59, DOI 10.1080/0284186X.2016.1246803; List M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04278; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Marcotte R, 2016, CELL, V164, P293, DOI 10.1016/j.cell.2015.11.062; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092; Mollenhauer J, 2000, CANCER RES, V60, P1704; Muller H, 2008, CLIN EXP IMMUNOL, V151, P123, DOI 10.1111/j.1365-2249.2007.03528.x; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Orlandi R, 2002, CANCER RES, V62, P567; Park SH, 2012, J BIOL CHEM, V287, P19841, DOI 10.1074/jbc.M111.330639; Parry DA, 2009, AM J HUM GENET, V84, P266, DOI 10.1016/j.ajhg.2009.01.009; PILLEMER L, 1954, SCIENCE, V120, P279, DOI 10.1126/science.120.3112.279; Pio R, 2013, SEMIN IMMUNOL, V25, P54, DOI 10.1016/j.smim.2013.04.001; Pluquet O, 2015, AM J PHYSIOL-CELL PH, V308, pC415, DOI 10.1152/ajpcell.00334.2014; Schlesinger M, 1996, LEUKEMIA, V10, P1509; Schroder M, 2008, CELL MOL LIFE SCI, V65, P862, DOI 10.1007/s00018-007-7383-5; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Vivian J, 2017, NAT BIOTECHNOL, V35, P314, DOI 10.1038/nbt.3772; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wittig-Blaich S, 2017, ONCOTARGET, V8, P23760, DOI 10.18632/oncotarget.15863; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xu W, 2008, J IMMUNOL, V180, P7613, DOI 10.4049/jimmunol.180.11.7613; Yamazaki D, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003983; Zhu J, 2012, CANCER SCI, V103, P2092, DOI 10.1111/cas.12020	52	8	8	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4560	4573		10.1038/s41388-019-0739-0	http://dx.doi.org/10.1038/s41388-019-0739-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755730				2022-12-17	WOS:000470240300009
J	Zang, GX; Mu, YB; Gao, LL; Bergh, A; Landstrom, M				Zang, Guangxiang; Mu, Yabing; Gao, Linlin; Bergh, Anders; Landstrom, Marene			PKC sigma facilitates lymphatic metastatic spread of prostate cancer cells in a mice xenograft model	ONCOGENE			English	Article							KINASE-C-ZETA; TUMOR-ASSOCIATED MACROPHAGES; NODE METASTASIS; GROWTH; LYMPHANGIOGENESIS; MECHANISMS; MIGRATION; INVASION; HYALURONAN; PHOSPHORYLATION	Prostate cancer disseminates primarily into the adjacent lymph nodes, which is related to a poor outcome. Atypical protein kinase C sigma (PKC sigma) is highly expressed in aggressive prostate cancer and correlates with Gleason score, clinical stage, and poor prognosis. Here, we report the molecular mechanisms of PKC sigma in lymphatic metastasis during prostate cancer progression. Using zinc-finger nuclease technology or PKC shRNA lentiviral particles, and orthotopic mouse xenografts, we show that PKC sigma-knockout or knockdown from aggressive prostate cancer (PC3 and PC3U) cells, decreasesd tumor growth and lymphatic metastasis in vivo. Intriguingly, PKC sigma-knockout or knockdown impaired the activation of AKT, ERK, and NF-kappa B signaling in prostate cancer cells, thereby impairing the expression of lymphangiogenic factors and macrophage recruitment, resulting in aberrant lymphangiogenesis. Moreover, PKC sigma regulated the expression of hyaluronan synthase enzymes, which is important for hyaluronan-mediated lymphatic drainage and tumor dissemination. Thus, PKC sigma plays a crucial oncogenic role in the lymphatic metastasis of prostate cancer and is predicted to be a novel therapeutic target for prostate cancer.	[Zang, Guangxiang; Mu, Yabing; Gao, Linlin; Bergh, Anders; Landstrom, Marene] Umea Univ, Dept Med Biosci, Bldg 6M,2nd Floor, SE-90185 Umea, Sweden; [Gao, Linlin] Natl Inst Biol Sci, 7 Sci Pk Rd ZGC Life Sci Pk, Beijing 102206, Peoples R China	Umea University; National Institute of Biological Sciences, Beijing	Landstrom, M (corresponding author), Umea Univ, Dept Med Biosci, Bldg 6M,2nd Floor, SE-90185 Umea, Sweden.	Marene.Landstrom@umu.se		Landstrom, Marene/0000-0001-6737-7230	RFI/VR and Science for Life Laboratory, Sweden; Bioinformatics Infrastructure for Life Sciences (BILS); Swedish Medical Research Council [K2016-02513]; Swedish Cancer Society [CAN 2017/544, 2016/387]; Knut and Alice Wallenberg Foundation [2012.0090]; Cancer Research Foundation in Northern Sweden; Lion's Cancer Research Foundation; Umea University;  [ALF-VLL464591];  [ALF-VLL-738911]	RFI/VR and Science for Life Laboratory, Sweden; Bioinformatics Infrastructure for Life Sciences (BILS); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Swedish Cancer Society(Swedish Cancer Society); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Cancer Research Foundation in Northern Sweden; Lion's Cancer Research Foundation; Umea University; ; 	We would like to acknowledge the National Genomics Infrastructure (NGI)/Uppsala Genome Center and UPPMAX for providing assistance in massive parallel sequencing and computational infrastructure. Work performed at the NGI/Uppsala Genome Center was funded by the RFI/VR and Science for Life Laboratory, Sweden. We would like to thank Dr. Jeanette Tangrot for the exome sequencing analysis and support from the Bioinformatics Infrastructure for Life Sciences (BILS) and Dr. Xiaolian Gu for valuable advices on data achieved from whole genome sequencing of PC3 and PC3U cells. We acknowledge the skillful technical assistance performed by Pernilla Andersson and Susanne Gidlund at Department of Medical Bioscience, Umea University. This work was supported by grants from the Swedish Medical Research Council (K2016-02513), the Swedish Cancer Society (CAN 2017/544; 2016/387), ALF-VLL464591 and ALF-VLL-738911, the Knut and Alice Wallenberg Foundation (2012.0090), the Cancer Research Foundation in Northern Sweden, Lion's Cancer Research Foundation, and Umea University.	Avraamides CJ, 2008, NAT REV CANCER, V8, P604, DOI 10.1038/nrc2353; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Brown AJ, 2013, NAT METHODS, V10, P638, DOI 10.1038/nmeth.2516; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dadras SS, 2003, AM J PATHOL, V162, P1951, DOI 10.1016/S0002-9440(10)64328-3; Daneshmand S, 2004, J UROLOGY, V172, P2252, DOI 10.1097/01.ju.0000143448.04161.cc; Datta K, 2010, FUTURE ONCOL, V6, P823, DOI 10.2217/FON.10.33; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Esteve PO, 2002, J BIOL CHEM, V277, P35150, DOI 10.1074/jbc.M108600200; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; Guo H, 2009, J NEUROCHEM, V109, P203, DOI 10.1111/j.1471-4159.2009.05946.x; Hagemann T, 2009, BLOOD, V113, P3139, DOI 10.1182/blood-2008-12-172825; Halin S, 2009, NEOPLASIA, V11, P177, DOI 10.1593/neo.81338; Hamidi A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal4186; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Izumi K, 2016, ONCOTARGET, V7, P8389, DOI 10.18632/oncotarget.6690; Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337; Josefsson A, 2011, AM J PATHOL, V179, P1961, DOI 10.1016/j.ajpath.2011.06.005; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim JY, 2013, P NATL ACAD SCI USA, V110, P6418, DOI 10.1073/pnas.1221799110; Kyzas PA, 2005, J PATHOL, V206, P170, DOI 10.1002/path.1776; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033; Monslow J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00231; Mu Y, 2015, BRIT J CANCER, V112, P1223, DOI 10.1038/bjc.2015.71; Nguyen DP, 2013, BJU INT, V111, pE143, DOI [10.1111/j.1464-410X.2013.11397_10.x, 10.1111/bju.12488]; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Pang MF, 2016, ONCOGENE, V35, P748, DOI 10.1038/onc.2015.133; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Sato K, 2016, CELL STEM CELL, V19, P127, DOI 10.1016/j.stem.2016.06.003; Shayan R, 2006, CARCINOGENESIS, V27, P1729, DOI 10.1093/carcin/bgl031; Shiao SL, 2016, CANCER LETT, V380, P340, DOI 10.1016/j.canlet.2015.12.022; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Stacker SA, 2014, NAT REV CANCER, V14, P159, DOI 10.1038/nrc3677; Sun RH, 2005, CANCER RES, V65, P1433, DOI 10.1158/0008-5472.CAN-04-1163; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Vigetti D, 2010, J BIOL CHEM, V285, P24639, DOI 10.1074/jbc.M110.134536; Yang MJ, 2011, J EXP MED, V208, P2099, DOI 10.1084/jem.20102667; Yao Sheng, 2010, Genes Cancer, V1, P444, DOI 10.1177/1947601910376079; Yokoyama Y, 2003, BRIT J CANCER, V88, P237, DOI 10.1038/sj.bjc.6600701; Zeng YP, 2005, PROSTATE, V65, P222, DOI 10.1002/pros.20288; Zheng W, 2014, J CLIN INVEST, V124, P878, DOI 10.1172/JCI71603	45	8	8	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4215	4231		10.1038/s41388-019-0722-9	http://dx.doi.org/10.1038/s41388-019-0722-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30705401	Green Published, hybrid			2022-12-17	WOS:000469339100002
J	Lin, T; Lin, TC; McGrail, DJ; Bhupal, PK; Ku, YH; Zhang, W; Meng, LJ; Lin, SY; Peng, G; Tsai, RYL				Lin, Tao; Lin, Tsung-Chin; McGrail, Daniel J.; Bhupal, Parnit K.; Ku, Yi-Hsuan; Zhang, Wen; Meng, Lingjun; Lin, Shiaw-Yih; Peng, Guang; Tsai, Robert Y. L.			Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression	ONCOGENE			English	Article							STEM-CELLS; SOMATIC MUTATIONS; SELF-RENEWAL; REPAIR; DAMAGE; REPLICATION; INHIBITION; EXPRESSION; LANDSCAPE; MAINTAINS	A defective homologous recombination (HR) repair program increases tumor incidence as well as providing a survival advantage in patients with breast and ovarian cancers. Here we hypothesize that the tumor-promoting side of genome maintenance programs may be contributed by a self-renewal protein, nucleostemin (NS). To address this issue, we established its functional importance in mammary tumor progression in mice and showed that mammary tumor cells become highly susceptible to replicative DNA damage following NS depletion and are protected from hydroxyurea-induced damage by NS overexpression. Breast cancer cells with basal-like characters display more reliance on NS for genome maintenance than those with luminal characters. Mechanistically, NS-deficient cells demonstrate a significantly reduced HR repair activity. TCGA analyses of human breast cancers revealed that NS is co-enriched positively with HR repair proteins and that high NS expression correlates with low HR defects and predicts poor progression-free survival and resistance to knockdown of cell-cycle checkpoint genes in triple-negative/basal-like breast cancers. This work indicates that NS constitutes a tumor-promoting genome maintenance program required for mammary tumor progression.	[Lin, Tao; Lin, Tsung-Chin; Bhupal, Parnit K.; Ku, Yi-Hsuan; Zhang, Wen; Meng, Lingjun; Tsai, Robert Y. L.] Texas A&M Univ, Inst Biosci & Technol, Houston, TX 77030 USA; [McGrail, Daniel J.; Lin, Shiaw-Yih] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Peng, Guang] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Tsai, Robert Y. L.] Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA	Texas A&M University System; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Texas A&M University System; Texas A&M University College Station	Tsai, RYL (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Houston, TX 77030 USA.; Tsai, RYL (corresponding author), Texas A&M Univ, Dept Mol & Cellular Med, College Stn, TX 77843 USA.	rtsai@ibt.tamhsc.edu	McGrail, Daniel/F-3967-2014	McGrail, Daniel/0000-0002-6669-6069; Tsai, Robert/0000-0002-8357-0812	NCI-PHS grants [R01 CA113750, R03 CA201988, R21AG052006]; National Science Council Postdoctoral Fellowship (ROC); G. Komen [PDF17483544]; CPRIT [RP140456]; NATIONAL CANCER INSTITUTE [R03CA201988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG052006] Funding Source: NIH RePORTER	NCI-PHS grants; National Science Council Postdoctoral Fellowship (ROC); G. Komen; CPRIT; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Margie Moczygemba at the IBT Flow Cytometry Core for her help in cell cycle analysis. This work was supported by NCI-PHS grants (R01 CA113750, R03 CA201988, R21AG052006) to RYT, National Science Council Postdoctoral Fellowship (ROC) to TCL, G. Komen PDF17483544 to DJM, and CPRIT RP140456 to GP.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Baddoo M, 2003, J CELL BIOCHEM, V89, P1235, DOI 10.1002/jcb.10594; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dai MS, 2008, MOL CELL BIOL, V28, P4365, DOI 10.1128/MCB.01662-07; ETIENNE MC, 1989, BRIT J CANCER, V60, P30, DOI 10.1038/bjc.1989.214; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Gunn Amanda, 2012, Methods Mol Biol, V920, P379, DOI 10.1007/978-1-61779-998-3_27; Gunn A, 2011, J BIOL CHEM, V286, P42470, DOI 10.1074/jbc.M111.309252; Hsu JK, 2012, J CELL BIOL, V197, P613, DOI 10.1083/jcb.201109038; Huang G, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.60; Knijnenburg TA, 2018, CELL REP, V23, P239, DOI 10.1016/j.celrep.2018.03.076; Kobayashi T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-215; Konstantinopoulos PA, 2015, CANCER DISCOV, V5, P1137, DOI 10.1158/2159-8290.CD-15-0714; Lin T, 2014, J CELL SCI, V127, P2302, DOI 10.1242/jcs.143842; Lin T, 2013, HEPATOLOGY, V58, P2176, DOI 10.1002/hep.26600; Lin T, 2010, CANCER RES, V70, P9444, DOI 10.1158/0008-5472.CAN-10-2159; Lindahl T, 2000, COLD SPRING HARB SYM, V65, P127, DOI 10.1101/sqb.2000.65.127; LOEB LA, 1974, CANCER RES, V34, P2311; Meng LJ, 2013, P NATL ACAD SCI USA, V110, P11415, DOI 10.1073/pnas.1301672110; Meng LJ, 2008, J CELL SCI, V121, P4037, DOI 10.1242/jcs.037952; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; Michel B, 2004, P NATL ACAD SCI USA, V101, P12783, DOI 10.1073/pnas.0401586101; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Peng G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4361; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Pritchard CC, 2016, NEW ENGL J MED, V375, P443, DOI 10.1056/NEJMoa1603144; Qu J, 2012, J CELL BIOL, V197, P731, DOI 10.1083/jcb.201103071; Seashore-Ludlow B, 2015, CANCER DISCOV, V5, P1210, DOI 10.1158/2159-8290.CD-15-0235; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Tsai RYL, 2016, CELL MOL LIFE SCI, V73, P1803, DOI 10.1007/s00018-016-2152-y; Tsai RYL, 2014, J CELL SCI, V127, P3885, DOI 10.1242/jcs.154054; Tsai RYL, 2011, PROTEIN REV, V15, P301, DOI 10.1007/978-1-4614-0514-6_13; Tsai RYL, 2009, INT J BIOCHEM CELL B, V41, P2122, DOI 10.1016/j.biocel.2009.05.020; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002; Watkins JA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3670; Wiedemeyer WR, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00034; Zhu QB, 2006, MOL CELL BIOL, V26, P9279, DOI 10.1128/MCB.00724-06; Zwolinska AK, 2012, ONCOGENE, V31, P3311, DOI 10.1038/onc.2011.507; 2010, CELL CYCLE, V9, P3227, DOI DOI 10.4161/CC.9.16.12605	47	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3919	3931		10.1038/s41388-019-0710-0	http://dx.doi.org/10.1038/s41388-019-0710-0			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30692636	Green Accepted			2022-12-17	WOS:000468035600011
J	Huang, JJ; Corona, AL; Dunn, BP; Cai, EM; Prakken, JN; Blobe, GC				Huang, Jennifer J.; Corona, Armando L.; Dunn, Brian P.; Cai, Elise M.; Prakken, Jesse N.; Blobe, Gerard C.			Increased type III TGF-beta receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition	ONCOGENE			English	Article							SIGNALING PATHWAY; PEPTIDE INHIBITORS; CANCER; BETAGLYCAN; ACTIVATION; METASTASIS; MECHANISMS; APOPTOSIS; RIII; ERK	The type III TGF-beta receptor (T beta RIII) is a TGF-beta co-receptor that presents ligand to the type II TGF-beta receptor to initiate signaling. T beta RIII also undergoes ectodomain shedding to release a soluble form (sT beta RIII) that can bind ligand, sequestering it away from cell surface receptors. We have previously identified a T beta RIII extracellular mutant that has enhanced ectodomain shedding ("super shedding (SS)"-T beta RIII-SS). Here, we utilize T beta RIII-SS to study the balance of cell surface and soluble T beta RIII in the context of lung cancer. We demonstrate that expressing T beta RIII-SS in lung cancer cell models induces epithelial-to-mesenchymal transition (EMT) and that these T beta RIII-SS (EMT) cells are less migratory, invasive and adhesive and more resistant to gemcitabine. Moreover, T beta RIII-SS (EMT) cells exhibit decreased tumorigenicity but increased growth rate in vitro and in vivo. These studies suggest that the balance of cell surface and soluble T beta RIII may regulate a dichotomous role for T beta RIII during cancer progression.	[Huang, Jennifer J.; Corona, Armando L.; Blobe, Gerard C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA; [Dunn, Brian P.; Cai, Elise M.; Prakken, Jesse N.; Blobe, Gerard C.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA	Duke University; Duke University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA.; Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA.	gerard.blobe@duke.edu	Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901; Cai, Elise/0000-0002-6650-8208	National Institutes of Health/National Cancer Institute [F30CA196162, T32-GM007171, R01CA135006]; NATIONAL CANCER INSTITUTE [F30CA196162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER	National Institutes of Health/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the following grants from the National Institutes of Health/National Cancer Institute: F30CA196162 (J.J.H.), T32-GM007171 (Medical Scientist Training Program; J.J.H), and R01CA135006 (G.C.B).	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chambard JC, 2007, BBA-MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Dotor J, 2007, CYTOKINE, V39, P106, DOI 10.1016/j.cyto.2007.06.004; Elderbroom JL, 2014, MOL BIOL CELL, V25, P2320, DOI 10.1091/mbc.E13-09-0524; Finger EC, 2008, CARCINOGENESIS, V29, P528, DOI 10.1093/carcin/bgm289; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gallo-Oller G, 2016, CANCER LETT, V381, P67, DOI 10.1016/j.canlet.2016.07.029; Gatza CE, 2010, CELL SIGNAL, V22, P1163, DOI 10.1016/j.cellsig.2010.01.016; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005; Hanks BA, 2013, J CLIN INVEST, V123, P3925, DOI 10.1172/JCI65745; Hempel N, 2007, CANCER RES, V67, P5231, DOI 10.1158/0008-5472.CAN-07-0035; Huang JJ, 2016, BIOCHEM SOC T, V44, P1441, DOI 10.1042/BST20160065; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Jurisic D, 2015, GROWTH FACTORS, V33, P200, DOI 10.3109/08977194.2015.1055740; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Llopiz D, 2009, INT J CANCER, V125, P2614, DOI 10.1002/ijc.24656; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Treffers LW, 2016, IMMUNOL REV, V273, P312, DOI 10.1111/imr.12444; Turley RS, 2007, CANCER RES, V67, P1090, DOI 10.1158/0008-5472.CAN-06-3117; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Velasco-Loyden G, 2004, J BIOL CHEM, V279, P7721, DOI 10.1074/jbc.M306499200; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	40	8	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3402	3414		10.1038/s41388-018-0672-7	http://dx.doi.org/10.1038/s41388-018-0672-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30643193	Green Accepted			2022-12-17	WOS:000466610000006
J	Claeys, S; Denecker, G; Durinck, K; Decaesteker, B; Mus, LM; Loontiens, S; Vanhauwaert, S; Althoff, K; Wigerup, C; Bexell, D; Dolman, E; Henrich, KO; Wehrmann, L; Westerhout, EM; Demoulin, JB; Kumps, C; Van Maerken, T; Laureys, G; Van Neste, C; De Wilde, B; De Wever, O; Westermann, F; Versteeg, R; Molenaar, JJ; Pahlman, S; Schulte, JH; De Preter, K; Speleman, F				Claeys, Shana; Denecker, Geertrui; Durinck, Kaat; Decaesteker, Bieke; Mus, Liselot M.; Loontiens, Siebe; Vanhauwaert, Suzanne; Althoff, Kristina; Wigerup, Caroline; Bexell, Daniel; Dolman, Emmy; Henrich, Kai-Oliver; Wehrmann, Lea; Westerhout, Ellen M.; Demoulin, Jean-Baptiste; Kumps, Candy; Van Maerken, Tom; Laureys, Genevieve; Van Neste, Christophe; De Wilde, Bram; De Wever, Olivier; Westermann, Frank; Versteeg, Rogier; Molenaar, Jan J.; Pahlman, Sven; Schulte, Johannes H.; De Preter, Katleen; Speleman, Frank			ALK positively regulates MYCN activity through repression of HBP1 expression	ONCOGENE			English	Article							LARGE-CELL LYMPHOMA; TRANSCRIPTIONAL REPRESSOR; NEURONAL DIFFERENTIATION; ACTIVATING MUTATIONS; BET INHIBITORS; TARGET GENES; CANCER CELLS; NEUROBLASTOMA; KINASE; RESISTANCE	ALK mutations occur in 10% of primary neuroblastomas and represent a major target for precision treatment. In combination with MYCN amplification, ALK mutations infer an ultra-high-risk phenotype resulting in very poor patient prognosis. To open up opportunities for future precision drugging, a deeper understanding of the molecular consequences of constitutive ALK signaling and its relationship to MYCN activity in this aggressive pediatric tumor entity will be essential. We show that mutant ALK downregulates the 'HMG-box transcription factor 1' (HBP1) through the PI3K-AKT-FOXO3a signaling axis. HBP1 inhibits both the transcriptional activating and repressing activity of MYCN, the latter being mediated through PRC2 activity. HBP1 itself is under negative control of MYCN through miR-17 similar to 92. Combined targeting of HBP1 by PI3K antagonists and MYCN signaling by BET- or HDAC-inhibitors blocks MYCN activity and significantly reduces tumor growth, suggesting a novel targeted therapy option for high-risk neuroblastoma.	[Claeys, Shana; Denecker, Geertrui; Durinck, Kaat; Decaesteker, Bieke; Mus, Liselot M.; Loontiens, Siebe; Vanhauwaert, Suzanne; Kumps, Candy; Van Maerken, Tom; Van Neste, Christophe; De Wilde, Bram; De Preter, Katleen; Speleman, Frank] Univ Ghent, CMGG, Ghent, Belgium; [Claeys, Shana; Denecker, Geertrui; Durinck, Kaat; Decaesteker, Bieke; Mus, Liselot M.; Loontiens, Siebe; Vanhauwaert, Suzanne; Van Maerken, Tom; Laureys, Genevieve; Van Neste, Christophe; De Wilde, Bram; De Wever, Olivier; De Preter, Katleen; Speleman, Frank] Univ Ghent, CRIG, Ghent, Belgium; [Althoff, Kristina] Univ Childrens Hosp Essen, Dept Pediat Oncol & Hematol, Essen, Germany; [Wigerup, Caroline; Bexell, Daniel; Pahlman, Sven] Lund Univ, Translat Canc Res, Canc Ctr Medicon Village, Lund, Sweden; [Dolman, Emmy; Molenaar, Jan J.] Princess Maxima Ctr Pediat Canc, Utrecht, Netherlands; [Henrich, Kai-Oliver; Wehrmann, Lea; Westermann, Frank] German Canc Res Ctr, Neuroblastoma Genom B087, Heidelberg, Germany; [Westerhout, Ellen M.; Versteeg, Rogier] Acad Med Ctr, Dept Oncogen, Amsterdam, Netherlands; [Demoulin, Jean-Baptiste] Catholic Univ Louvain, De Duve Inst, Brussels, Belgium; [Kumps, Candy] Ghent Univ Hosp, Dept Urogynaecol, Ghent, Belgium; [Laureys, Genevieve; De Wilde, Bram] Ghent Univ Hosp, Dept Pediat Oncol & Hematol, Ghent, Belgium; [De Wever, Olivier] Univ Ghent, LECR, Ghent, Belgium; [Schulte, Johannes H.] Charite, Dept Pediat Oncol Hematol, Berlin, Germany; [Schulte, Johannes H.] BIH, Berlin, Germany; [Schulte, Johannes H.] German Translat Canc Res Consortium DKTK, Berlin, Germany; [Schulte, Johannes H.] German Translat Canc Res Consortium DKFZ, Heidelberg, Germany	Ghent University; Ghent University; University of Duisburg Essen; Lund University; Helmholtz Association; German Cancer Research Center (DKFZ); University of Amsterdam; Academic Medical Center Amsterdam; Universite Catholique Louvain; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital; Ghent University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health	Speleman, F (corresponding author), Univ Ghent, CMGG, Ghent, Belgium.; Speleman, F (corresponding author), Univ Ghent, CRIG, Ghent, Belgium.	franki.speleman@ugent.be	Van Neste, Christophe/AAE-5505-2020; Westermann, Frank/F-7509-2013; Versteeg, Rogier/AAQ-1765-2020; Mus, Liselot/FCB-1557-2022; speleman, frank/AAR-5184-2020; de wever, olivier/J-3094-2013; laureys, genevieve/AAG-2390-2021; Durinck, Kaat/AFN-5192-2022	Mus, Liselot/0000-0001-5738-0639; speleman, frank/0000-0002-6628-8559; de wever, olivier/0000-0002-5453-760X; Bexell, Daniel/0000-0001-9426-9550; Dolman, Emmy/0000-0002-0567-5918; Durinck, Kaat/0000-0003-1762-5739; Decaesteker, Bieke/0000-0003-2264-781X; De Wilde, Bram/0000-0003-0213-1322; Schulte, Johannes Hubertus/0000-0003-0671-1201; Vanhauwaert, Suzanne/0000-0002-7768-4549; Loontiens, Siebe/0000-0002-4602-4580	Research Foundation-Flanders (FWO) [11J8313N, 18B1716N, 12N6917N, 1803115 N]; Emmanuel van der Schueren grant ('Kom op tegen Kanker'); VLK (Flemish League against cancer); FWO Research Foundation-Flanders (FWO); Ghent University (BOF) [BOF16/PDO/043]; Belgian Foundation against Cancer [2014-175]; Ghent University [BOF10/GOA/019, BOF16/GOA/23]; Belgian Program of Interuniversity Poles of Attraction (IUAP) [VII-P7/03]; fund for Scientific Research Flanders [G053012N, G050712N, G051516N]; Stichting Villa Joep	Research Foundation-Flanders (FWO)(FWO); Emmanuel van der Schueren grant ('Kom op tegen Kanker'); VLK (Flemish League against cancer); FWO Research Foundation-Flanders (FWO)(FWO); Ghent University (BOF)(Ghent University); Belgian Foundation against Cancer; Ghent University(Ghent University); Belgian Program of Interuniversity Poles of Attraction (IUAP); fund for Scientific Research Flanders(FWO); Stichting Villa Joep	S.C. is supported by a pre-doctoral fellowship of the Research Foundation-Flanders (FWO; 11J8313N) and an Emmanuel van der Schueren grant ('Kom op tegen Kanker'). S.V. is funded by the VLK (Flemish League against cancer) and 'Stichting Villa Joep'. B.D. and S.L. are supported by a pre-doctoral fellowship of the FWO Research Foundation-Flanders (FWO). K.D. is supported by Ghent University (BOF; BOF16/PDO/043). C.V., B.D.W. and T.V.M. are senior clinical investigators of the Research Foundation-Flanders (FWO; 18B1716N (B.D.W.), 12N6917N (C.V.), 1803115 N (T.V.M.)). We would further like to thank the following funding agencies: the Belgian Foundation against Cancer (project 2014-175) to F.S., Ghent University (BOF10/GOA/019, BOF16/GOA/23) to F.S., the Belgian Program of Interuniversity Poles of Attraction (IUAP Phase VII-P7/03) to F.S., the fund for Scientific Research Flanders (Research projects G053012N, G050712N, G051516N to F.S) and 'Stichting Villa Joep' to F.S.	Althoff K, 2015, ONCOGENE, V34, P3357, DOI 10.1038/onc.2014.269; Amin AD, 2016, ONCOTARGET, V7, P23715, DOI 10.18632/oncotarget.8173; Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001; Bollaert E, 2018, CELL SIGNAL, V44, P158, DOI 10.1016/j.cellsig.2018.01.014; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Braekeveldt N, 2015, INT J CANCER, V136, pE252, DOI 10.1002/ijc.29217; Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019; Bresler SC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002950; Cage TA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00111; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Cheung NKV, 2013, NAT REV CANCER, V13, P397, DOI 10.1038/nrc3526; CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cortes C, 2015, CELL ONCOL, V38, P341, DOI 10.1007/s13402-015-0233-9; Corvetta D, 2013, J BIOL CHEM, V288, P8332, DOI 10.1074/jbc.M113.454280; de Brachene AC, 2014, BIOCHEM J, V460, P25, DOI 10.1042/BJ20131467; De Brouwer S, 2010, CLIN CANCER RES, V16, P4353, DOI 10.1158/1078-0432.CCR-09-2660; Debruyne DN, 2016, ONCOGENE, V35, P3681, DOI 10.1038/onc.2015.434; Ferreira ACD, 2016, J LEUKOCYTE BIOL, V99, P569, DOI 10.1189/jlb.2A0415-162R; Duffy DJ, 2014, MOL CANCER THER, V13, P454, DOI 10.1158/1535-7163.MCT-13-0560-T; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Escamilla-Powers JR, 2010, J BIOL CHEM, V285, P4847, DOI 10.1074/jbc.M109.074856; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; Frumm SM, 2013, CHEM BIOL, V20, P713, DOI 10.1016/j.chembiol.2013.03.020; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Gu TL, 2004, BLOOD, V103, P4622, DOI 10.1182/blood-2003-03-0820; Guan J, 2016, DIS MODEL MECH, V9, P941, DOI 10.1242/dmm.024448; Hasan MK, 2013, SCI REP-UK, V3, DOI 10.1038/srep03450; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Henrich KO, 2016, CANCER RES, V76, P5523, DOI 10.1158/0008-5472.CAN-15-2507; Heuckmann JM, 2011, CLIN CANCER RES, V17, P7394, DOI 10.1158/1078-0432.CCR-11-1648; Heukamp LC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003967; Isozaki H, 2016, CANCER RES, V76, P1506, DOI 10.1158/0008-5472.CAN-15-1010; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Lambertz I, 2015, CLIN CANCER RES, V21, P3327, DOI 10.1158/1078-0432.CCR-14-2024; Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4; Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014; Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121; Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Moore NF, 2014, ONCOTARGET, V5, P8737, DOI 10.18632/oncotarget.2372; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2013, LANCET ONCOL, V14, P472, DOI 10.1016/S1470-2045(13)70095-0; Pall G, 2015, CURR OPIN ONCOL, V27, P118, DOI 10.1097/CCO.0000000000000165; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Pei YX, 2016, CANCER CELL, V29, P311, DOI 10.1016/j.ccell.2016.02.011; Persson CU, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09662-8; Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418; Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004; Santo EE, 2013, CANCER RES, V73, P2189, DOI 10.1158/0008-5472.CAN-12-3767; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Schubbert S, 2014, CANCER RES, V74, P7048, DOI 10.1158/0008-5472.CAN-14-1470; Stratikopoulos EE, 2016, CLIN CANCER RES, V22, P2605, DOI 10.1158/1078-0432.CCR-15-2389; Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Toyokawa G, 2015, ONCOL RES TREAT, V38, P291, DOI 10.1159/000430852; Umapathy G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005470; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Vaughan L, 2016, ONCOTARGET, V7, P57525, DOI 10.18632/oncotarget.10544; Watanabe N, 2015, DEVELOPMENT, V142, P2278, DOI 10.1242/dev.120477; Yan Xiaocai, 2011, Genes Cancer, V2, P538, DOI 10.1177/1947601911416003; Yao CJ, 2005, LEUKEMIA, V19, P1958, DOI 10.1038/sj.leu.2403918; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047; Zeller K, 2003, GENOME BIOL, V4, P1; Zhu SZ, 2012, CANCER CELL, V21, P362, DOI 10.1016/j.ccr.2012.02.010	73	8	9	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2690	2705		10.1038/s41388-018-0595-3	http://dx.doi.org/10.1038/s41388-018-0595-3			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30538293				2022-12-17	WOS:000464121600002
J	Klug, LR; Bannon, AE; Javidi-Sharifi, N; Town, A; Fleming, WH; VanSlyke, JK; Musil, LS; Fletcher, JA; Tyner, JW; Heinrich, MC				Klug, Lillian R.; Bannon, Amber E.; Javidi-Sharifi, Nathalie; Town, Ajia; Fleming, William H.; VanSlyke, Judy K.; Musil, Linda S.; Fletcher, Jonathan A.; Tyner, Jeffrey W.; Heinrich, Michael C.			LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma	ONCOGENE			English	Article							GASTROINTESTINAL STROMAL TUMORS; IMATINIB MESYLATE; TYROSINE KINASE; C-KIT; THERAPEUTIC TARGET; MOUSE MODEL; PHASE-II; PROTEIN PHOSPHATASE-1; GENE-MUTATIONS; DOSE IMATINIB	Certain cancers, including gastrointestinal stromal tumor (GIST) and subsets of melanoma, are caused by somatic KIT mutations that result in KIT receptor tyrosine kinase constitutive activity, which drives proliferation. The treatment of KIT-mutant GIST has been revolutionized with the advent of KIT-directed cancer therapies. KIT tyrosine kinase inhibitors (TKI) are superior to conventional chemotherapy in their ability to control advanced KIT-mutant disease. However, these therapies have a limited duration of activity due to drug-resistant secondary KIT mutations that arise (or that are selected for) during KIT TKI treatment. To overcome the problem of KIT TKI resistance, we sought to identify novel therapeutic targets in KIT-mutant GIST and melanoma cells using a human tyrosine kinome siRNA screen. From this screen, we identified lemur tyrosine kinase 3 (LMTK3) and herein describe its role as a novel KIT regulator in KIT-mutant GIST and melanoma cells. We find that LMTK3 regulated the translation rate of KIT, such that loss of LMTK3 reduced total KIT, and thus KIT downstream signaling in cancer cells. Silencing of LMTK3 decreased cell viability and increased cell death in KIT-dependent, but not KIT-independent GIST and melanoma cell lines. Notably, LMTK3 silencing reduced viability of all KIT-mutant cell lines tested, even those with drug-resistant KIT secondary mutations. Furthermore, targeting of LMTK3 with siRNA delayed KIT-dependent GIST growth in a xenograft model. Our data suggest the potential of LMTK3 as a target for treatment of patients with KIT-mutant cancer, particularly after failure of KIT TKIs.	[Klug, Lillian R.; Bannon, Amber E.; Town, Ajia; Heinrich, Michael C.] Portland VA Hlth Care Syst, Portland, OR 97239 USA; [Klug, Lillian R.; Bannon, Amber E.; Javidi-Sharifi, Nathalie; Town, Ajia; Fleming, William H.; Tyner, Jeffrey W.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA; [Klug, Lillian R.; Bannon, Amber E.; Javidi-Sharifi, Nathalie; Town, Ajia; Fleming, William H.; Tyner, Jeffrey W.; Heinrich, Michael C.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA; [Fleming, William H.] Oregon Hlth & Sci Univ, Dept Pediat, Oregon Stem Cell Ctr, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA; [VanSlyke, Judy K.; Musil, Linda S.] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; [Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Fletcher, Jonathan A.] Brigham & Womens Hosp, Dept Pediat, 75 Francis St, Boston, MA 02115 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Klug, LR (corresponding author), Portland VA Hlth Care Syst, Portland, OR 97239 USA.; Klug, LR (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.; Klug, LR (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97201 USA.	klugl@ohsu.edu	Heinrich, Michael/AAC-6745-2019	Heinrich, Michael/0000-0003-3790-0478	VA Merit Review Grants [1I01BX000338-01, 2I01BX000338-05]; GIST Cancer Research Fund; Life Raft Group; V Foundation for Cancer Research; Leukemia & Lymphoma Society; Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute [5R00CA151457-04, 1R01CA183947-01]; Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH [TL1 RR024159]; NIH Roadmap for Medical Research; NATIONAL CANCER INSTITUTE [R00CA151457, R01CA183974] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [TL1RR024159] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000338] Funding Source: NIH RePORTER	VA Merit Review Grants(US Department of Veterans Affairs); GIST Cancer Research Fund; Life Raft Group; V Foundation for Cancer Research; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); Gabrielle's Angel Foundation for Cancer Research; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH; NIH Roadmap for Medical Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Veterans Affairs(US Department of Veterans Affairs)	L.R. Klug, A. Town, A.E. Bannon, and M.C. Heinrich were supported by VA Merit Review Grants 1I01BX000338-01 and 2I01BX000338-05. M.C. Heinrich was also supported by the GIST Cancer Research Fund and the Life Raft Group. L.R. Klug, W.H. Fleming, J.W. Tyner, and M.C. Heinrich were supported by the V Foundation for Cancer Research. J.W. Tyner was supported by the Leukemia & Lymphoma Society, Gabrielle's Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01). N. Javidi-Sharifi was supported by the Oregon Clinical and Translational Research Institute (OCTRI), grant number TL1 RR024159 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH, and NIH Roadmap for Medical Research.	Agarwal A, 2016, METHODS MOL BIOL, V1470, P85, DOI 10.1007/978-1-4939-6337-9_7; An NF, 2016, EXP HEMATOL ONCOL, V5, P1, DOI 10.1186/s40164-016-0060-3; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Bannon AE, 2017, EXPERT REV MOL DIAGN, V17, P445, DOI 10.1080/14737159.2017.1308826; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Blanke CD, 2008, J CLIN ONCOL, V26, P620, DOI 10.1200/JCO.2007.13.4403; Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452; Carvajal RD, 2015, CLIN CANCER RES, V21, P2289, DOI 10.1158/1078-0432.CCR-14-1630; Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143; DeMatteo RP, 2002, HUM PATHOL, V33, P466, DOI 10.1053/hupa.2002.124122; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Edmonson JH, 2002, CANCER INVEST, V20, P605, DOI 10.1081/CNV-120002485; Gagnon KBE, 2007, AM J PHYSIOL-CELL PH, V292, pC1809, DOI 10.1152/ajpcell.00580.2006; Garner AP, 2014, CLIN CANCER RES, V20, P5745, DOI 10.1158/1078-0432.CCR-14-1397; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Gramza AW, 2009, CLIN CANCER RES, V15, P7510, DOI 10.1158/1078-0432.CCR-09-0190; Grzmil M, 2012, CANCER RES, V72, P3891, DOI 10.1158/0008-5472.CAN-12-0026; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836; Jacob J, 2016, CANCER LETT, V372, P137, DOI 10.1016/j.canlet.2015.12.026; Javidi-Sharifi N, 2015, CANCER RES, V75, P880, DOI 10.1158/0008-5472.CAN-14-0573; Kajimoto N, 2015, INT J CLIN EXP PATHO, V8, P11970; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Larizza L, 2005, LEUKEMIA LYMPHOMA, V46, P247, DOI 10.1080/10428190400007565; LEV S, 1992, J BIOL CHEM, V267, P15970; LEV S, 1991, EMBO J, V10, P647, DOI 10.1002/j.1460-2075.1991.tb07993.x; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakai N, 2008, J PATHOL, V214, P302, DOI 10.1002/path.2296; Roberts KG, 2007, MOL CANCER THER, V6, P1159, DOI 10.1158/1535-7163.MCT-06-0641; Rossi F, 2010, MOL CANCER RES, V8, P1271, DOI 10.1158/1541-7786.MCR-10-0065; Rubin BP, 2005, CANCER RES, V65, P6631, DOI 10.1158/0008-5472.CAN-05-0891; Sakurama K, 2009, MOL CANCER THER, V8, P127, DOI 10.1158/1535-7163.MCT-08-0884; Spencer KR, 2016, CANCER TREAT RES, V167, P295, DOI 10.1007/978-3-319-22539-5_13; Stebbing J, 2013, ONCOGENE, V32, P3371, DOI 10.1038/onc.2012.343; Taguchi T, 2002, LAB INVEST, V82, P663, DOI 10.1038/labinvest.3780461; Takahashi T, 2013, INT J CANCER, V133, P2737, DOI 10.1002/ijc.28282; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Tomomura M, 2007, NEUROSCIENCE, V148, P510, DOI 10.1016/j.neuroscience.2007.05.048; Tyner JW, 2008, BLOOD, V111, P2238, DOI 10.1182/blood-2007-06-097253; Tyner JW, 2009, P NATL ACAD SCI USA, V106, P8695, DOI 10.1073/pnas.0903233106; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; Weisberg E, 2003, DRUG RESIST UPDATE, V6, P231, DOI 10.1016/S1368-7646(03)00062-1; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; Xu YC, 2015, CELL REP, V12, P837, DOI 10.1016/j.celrep.2015.06.073; Xu YC, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005170	48	8	10	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1200	1210		10.1038/s41388-018-0508-5	http://dx.doi.org/10.1038/s41388-018-0508-5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30242244	Green Accepted			2022-12-17	WOS:000459249800004
J	Kohler, M; Ehrenfeld, S; Halbach, S; Lauinger, M; Burk, U; Reischmannl, N; Cheng, SF; Spohr, C; Uhl, FM; Kohler, N; Ringwald, K; Braun, S; Peters, C; Zeiser, R; Reinheckel, T; Brummer, T				Koehler, Martin; Ehrenfeld, Sophia; Halbach, Sebastian; Lauinger, Manuel; Burk, Ulrike; Reischmannl, Nadine; Cheng, Shuofei; Spohr, Corinna; Uhl, Franziska Maria; Koehler, Natalie; Ringwald, Kathrin; Braun, Sandra; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman			B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model	ONCOGENE			English	Article							ERK ACTIVATION; MAPK PATHWAY; CATHEPSIN-B; BRAF; INHIBITORS; PHOSPHORYLATION; METASTASIS; EXPRESSION; CELLS; GENE	Copy number gains, point mutations and epigenetic silencing events are increasingly observed in genes encoding elements of the Ras/Raf/MEK/ERK signaling axis in human breast cancer. The three Raf kinases A-Raf, B-Raf, and Raf-1 have an important role as gatekeepers in ERK pathway activation and are often dysregulated by somatic alterations of their genes or by the aberrant activity of receptor tyrosine kinases (RTKs) and Ras-GTPases. B-Raf represents the most potent Raf isoform and a critical effector downstream of RTKs and RAS proteins. Aberrant RTK signaling is mimicked by the polyoma middle T antigen (PyMT), which activates various oncogenic signaling pathways, incl. the RAS/ERK axis, in a similar manner as RTKs in human breast cancer. Mammary epithelial cell directed expression of PyMT in mice by the MMTV-PyMT transgene induces mammary hyperplasia progressing over adenoma to metastatic breast cancer with an almost complete penetrance. To understand the functional role of B-Raf in this model for luminal type B breast cancer, we crossed MMTV-PyMT mice with animals that either lack B-Raf expression in the mammary gland or express the signaling impaired B-Raf(AVKA) mutant. The AVKA mutation prevents phosphorylation of T599 and S602 in the B-Raf activation loop and thereby activation of the kinase by upstream signals. We demonstrate for the first time that B-Raf expression and activation is important for tumor initiation in vivo as well as for lung metastasis. Isogenic tumor cell lines generated from conditional Braf knock-out or knock-in mice displayed a reduction in EGF-induced ERK pathway activity as well as in proliferation and invasive growth in three-dimensional matrigel cultures. Our results suggest that B-Raf, which has been hardly studied in the context of breast cancer, represents a critical effector of the PyMT oncoprotein and invite for an assessment of its functional role in human breast cancer.	[Koehler, Martin; Ehrenfeld, Sophia; Halbach, Sebastian; Lauinger, Manuel; Burk, Ulrike; Reischmannl, Nadine; Cheng, Shuofei; Spohr, Corinna; Ringwald, Kathrin; Braun, Sandra; Peters, Christoph; Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany; [Koehler, Martin; Halbach, Sebastian; Reischmannl, Nadine; Spohr, Corinna; Koehler, Natalie] Univ Freiburg, Spemann Grad Sch Biol & Med, Freiburg, Germany; [Koehler, Martin; Ehrenfeld, Sophia; Halbach, Sebastian; Lauinger, Manuel; Reischmannl, Nadine; Spohr, Corinna; Uhl, Franziska Maria; Koehler, Natalie; Ringwald, Kathrin] Univ Freiburg, Fac Biol, Freiburg, Germany; [Ehrenfeld, Sophia; Lauinger, Manuel; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] German Consortium Translat Canc Res DKTK, Partner Site Freiburg, Heidelberg, Germany; [Ehrenfeld, Sophia; Lauinger, Manuel; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] German Canc Res Ctr, Heidelberg, Germany; [Burk, Ulrike; Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany; [Uhl, Franziska Maria; Koehler, Natalie; Zeiser, Robert] Univ Freiburg, Univ Med Ctr, Fac Med, Dept Hematol & Oncol, Freiburg, Germany; [Peters, Christoph; Zeiser, Robert; Reinheckel, Thomas; Brummer, Tilman] Comprehens Canc Ctr Freiburg, Freiburg, Germany	University of Freiburg; University of Freiburg; University of Freiburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg; University of Freiburg	Reinheckel, T; Brummer, T (corresponding author), Univ Freiburg, Fac Med, Inst Mol Med & Cell Res, Freiburg, Germany.; Reinheckel, T; Brummer, T (corresponding author), German Consortium Translat Canc Res DKTK, Partner Site Freiburg, Heidelberg, Germany.; Reinheckel, T; Brummer, T (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Reinheckel, T; Brummer, T (corresponding author), Univ Freiburg, Ctr Biol Signalling Studies BIOSS, Freiburg, Germany.; Reinheckel, T; Brummer, T (corresponding author), Comprehens Canc Ctr Freiburg, Freiburg, Germany.	thomas.reinheckel@mol-med.uni-freiburg.de; tilman.brummer@mol-med.uni-freiburg.de	Halbach, Sebastian/G-4021-2012; Brummer, Tilman/B-6218-2016; Köhler, Natalie/AAG-1712-2019; Brummer, Tilman/AAA-9428-2020; Reinheckel, Thomas/AAL-9761-2021	Halbach, Sebastian/0000-0002-6827-8178; Brummer, Tilman/0000-0003-4387-7905; Köhler, Natalie/0000-0002-7502-0431; Brummer, Tilman/0000-0003-4387-7905; Reinheckel, Thomas/0000-0001-9866-9105; Kohler, Martin/0000-0002-7248-6084; Zeiser, Robert/0000-0001-6565-3393	Deutsche Forschungsgemeinschaft (DFG) via the Collaborative Research Centre 850; Excellence Initiative of the German Federal and State Governments [EXC 294 BIOSS]; German Cancer Consortium (DKTK) [L627]; Spemann Graduate School for Biology and Medicine (SGBM) [GSC-4]; Emmy-Noether program of the DFG; Heisenberg program of the DFG	Deutsche Forschungsgemeinschaft (DFG) via the Collaborative Research Centre 850(German Research Foundation (DFG)); Excellence Initiative of the German Federal and State Governments; German Cancer Consortium (DKTK); Spemann Graduate School for Biology and Medicine (SGBM); Emmy-Noether program of the DFG(German Research Foundation (DFG)); Heisenberg program of the DFG	This work was funded by the Deutsche Forschungsgemeinschaft (DFG) via the Collaborative Research Centre 850 (projects B4; B7, and C6), the Excellence Initiative of the German Federal and State Governments (EXC 294 BIOSS), the German Cancer Consortium (DKTK, L627) and the Spemann Graduate School for Biology and Medicine (GSC-4; SGBM) via fellowships to MK, SH, NK, CK. and NR. TB was also supported by the Emmy-Noether and Heisenberg programs of the DFG. We would also like to thank Chris Ormandy for helpful discussions, Ricarda Herr for advice, and Nicole Klemm and Ulrike Reif for expert technical assistance.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Ali NA, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0437-3; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Beliveau A, 2010, GENE DEV, V24, P2800, DOI 10.1101/gad.1990410; Ben-David U, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12160; Bengsch F, 2014, ONCOGENE, V33, P4474, DOI 10.1038/onc.2013.395; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095; Chen AP, 2006, J NEUROSCI RES, V83, P28, DOI 10.1002/jnr.20703; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Desideri E, 2015, CELL, V161, P967, DOI 10.1016/j.cell.2015.04.045; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Dow LE, 2012, NAT PROTOC, V7, P374, DOI 10.1038/nprot.2011.446; Fantozzi A, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1530; Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009-09; Galabova-Kovacs G, 2006, P NATL ACAD SCI USA, V103, P1325, DOI 10.1073/pnas.0507399103; Galabova-Kovacs G, 2008, J CELL BIOL, V180, P947, DOI 10.1083/jcb.200709069; Gillies TE, 2017, CELL SYST, V5, P549, DOI 10.1016/j.cels.2017.10.019; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Ha JR, 2016, J CELL BIOCHEM, V117, P1971, DOI 10.1002/jcb.25561; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Haug S, 2015, INT J CANCER, V136, P2328, DOI 10.1002/ijc.29289; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Herr R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-17; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hillebrand LE, 2016, ONCOTARGET, V7, P58244, DOI 10.18632/oncotarget.11309; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Hu JC, 2013, CELL, V154, P1036, DOI 10.1016/j.cell.2013.07.046; Jacob LS, 2015, CANCER RES, V75, P3713, DOI 10.1158/0008-5472.CAN-15-0562; Kamata T, 2010, CANCER RES, V70, P8475, DOI 10.1158/0008-5472.CAN-10-0603; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kohler M, 2016, CELL CYCLE, V15, P1171, DOI 10.1080/15384101.2016.1159111; Kohler M, 2016, EMBO J, V35, P143, DOI 10.15252/embj.201592097; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lan LX, 2015, EMBO J, V34, P1493, DOI 10.15252/embj.201489004; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Liu H, 2018, CANCER DISCOV, V8, P354, DOI 10.1158/2159-8290.CD-17-0679; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; McLaughlin SK, 2013, CANCER CELL, V24, P365, DOI 10.1016/j.ccr.2013.08.004; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Nieto P, 2017, NATURE, V548, P239, DOI 10.1038/nature23297; O'Toole SA, 2013, J CLIN PATHOL, V66, P530, DOI 10.1136/jclinpath-2012-201361; Olsen SN, 2017, CANCER DISCOV, V7, P202, DOI 10.1158/2159-8290.CD-16-0520; Pearson GW, 2007, J CELL BIOL, V179, P1555, DOI 10.1083/jcb.200706099; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Roring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100; Roering Michael, 2012, Critical Reviews in Oncogenesis, V17, P97; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Santarpia L, 2012, BREAST CANCER RES TR, V134, P333, DOI 10.1007/s10549-012-2035-3; Sears R, 2017, CANCER DISCOV, V7, P131, DOI 10.1158/2159-8290.CD-16-1423; Sevenich L, 2011, ONCOGENE, V30, P54, DOI 10.1038/onc.2010.387; Sevenich L, 2010, P NATL ACAD SCI USA, V107, P2497, DOI 10.1073/pnas.0907240107; Smith Brittni A, 2012, Genes Cancer, V3, P550, DOI 10.1177/1947601913475359; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Thevakumaran N, 2015, NAT STRUCT MOL BIOL, V22, P37, DOI 10.1038/nsmb.2924; Tilch E, 2014, BREAST CANCER RES TR, V143, P385, DOI 10.1007/s10549-013-2798-1; Varga A, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8482; Wagner KU, 2002, DEVELOPMENT, V129, P1377; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Yaktapour N, 2014, J CLIN INVEST, V124, P5074, DOI 10.1172/JCI76539; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982; Zhong J, 2007, NAT NEUROSCI, V10, P598, DOI 10.1038/nn1898; Zuber J, 2011, NAT BIOTECHNOL, V29, P79, DOI 10.1038/nbt.1720	71	8	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1324	1339		10.1038/s41388-018-0663-8	http://dx.doi.org/10.1038/s41388-018-0663-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30659267				2022-12-17	WOS:000459249800013
J	Wustenhagen, E; Boukhallouk, F; Negwer, I; Rajalingam, K; Stubenrauch, F; Florin, L				Wuestenhagen, Elena; Boukhallouk, Fatima; Negwer, Inka; Rajalingam, Krishnaraj; Stubenrauch, Frank; Florin, Luise			The Myb-related protein MYPOP is a novel intrinsic host restriction factor of oncogenic human papillomaviruses	ONCOGENE			English	Article							MINOR CAPSID PROTEIN; TRANSCRIPTION FACTORS; HPV INFECTION; REPLICATION; L2; EXPRESSION; BINDING; E6; EPIDEMIOLOGY; ONCOPROTEINS	The skin represents a physical and chemical barrier against invading pathogens, which is additionally supported by restriction factors that provide intrinsic cellular immunity. These factors detect viruses to block their replication cycle. Here, we uncover the Myb-related transcription factor, partner of profilin (MYPOP) as a novel antiviral protein. It is highly expressed in the epithelium and binds to the minor capsid protein L2 and the DNA of human papillomaviruses (HPV), which are the primary causative agents of cervical cancer and other tumors. The early promoter activity and early gene expression of the oncogenic HPV types 16 and 18 is potently silenced by MYPOP. Cellular MYPOP-depletion relieves the restriction of HPV16 infection, demonstrating that MYPOP acts as a restriction factor. Interestingly, we found that MYPOP protein levels are significantly reduced in diverse HPV-transformed cell lines and in HPV-induced cervical cancer. Decades ago it became clear that the early oncoproteins E6 and E7 cooperate to immortalize keratinocytes by promoting degradation of tumor suppressor proteins. Our findings suggest that E7 stimulates MYPOP degradation. Moreover, overexpression of MYPOP blocks colony formation of HPV and non-virally transformed keratinocytes, suggesting that MYPOP exhibits tumor suppressor properties.	[Wuestenhagen, Elena; Boukhallouk, Fatima; Florin, Luise] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med Microbiol & Hyg, Obere Zahlbacher Str 67, D-55131 Mainz, Germany; [Negwer, Inka] Max Planck Inst Polymer Res, Ackermannweg 10, D-55128 Mainz, Germany; [Rajalingam, Krishnaraj] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Mol Signaling Unit, Mainz, Germany; [Stubenrauch, Frank] Univ Hosp, Inst Med Virol & Epidemiol Viral Dis, Div Expt Virol, Tubingen, Germany	Johannes Gutenberg University of Mainz; Max Planck Society; Johannes Gutenberg University of Mainz; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Florin, L (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med Microbiol & Hyg, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	lflorin@uni-mainz.de		Florin, Luise/0000-0003-4310-7329	Max Planck Graduate Center; Johannes Gutenberg-University Mainz (MPGC); Deutsche Forschungsgemeinschaft (DFG) [FL 696/2-1]	Max Planck Graduate Center(Max Planck Society); Johannes Gutenberg-University Mainz (MPGC); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	We thank Dr. Hans-Jurgen Butt, Dr. Kaloian Koynov, and Dr. Ulrike Wieland for helpful discussion. We are grateful to Marc A. Schneider and Gilles Spoden for initial experiments (Y2H screening), Karl Sotlar for CIS sections, Claudia Simon for providing the E6 plasmid, Caroline Manicam and Monika Wied-mann for proofreading this manuscript. The skillful technical assistance in lentiviral RNAi system of Aleksandra Dimitrijevic is gratefully acknowledged. This work, including the efforts of Elena Wustenhagen and Inka Negwer, was funded by the Max Planck Graduate Center together with the Johannes Gutenberg-University Mainz (MPGC). Luise Florin receives research support from the Deutsche Forschungsgemeinschaft (DFG; FL 696/2-1).	Akgul B, 2003, VIROLOGY, V308, P279, DOI 10.1016/S0042-6822(02)00133-2; Baldwin Amy, 2007, Open Virol J, V1, P33, DOI 10.2174/1874357900701010033; Bernard HU, 2013, VIROLOGY, V445, P197, DOI 10.1016/j.virol.2013.04.035; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bund T, 2014, CELL MICROBIOL, V16, P1179, DOI 10.1111/cmi.12271; Calton CM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006200; Campos SK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9120370; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Digiuseppe S, 2017, VIRUS RES, V231, P1, DOI 10.1016/j.virusres.2016.10.015; DiGiuseppe S, 2015, J VIROL, V89, P10442, DOI 10.1128/JVI.01588-15; DOLLARD SC, 1993, J VIROL, V67, P1721, DOI 10.1128/JVI.67.3.1721-1726.1993; Doorbar J, 2015, REV MED VIROL, V25, P2, DOI 10.1002/rmv.1822; Doorbar J, 2012, VACCINE, V30, pF55, DOI 10.1016/j.vaccine.2012.06.083; Dreer M, 2017, VIRUS RES, V231, P96, DOI 10.1016/j.virusres.2016.11.005; Duggal NK, 2012, NAT REV IMMUNOL, V12, P687, DOI 10.1038/nri3295; Fast LA, 2017, BIOCHEM SOC T, V45, P489, DOI 10.1042/BST20160295; Florin L, 2012, MED MICROBIOL IMMUN, V201, P437, DOI 10.1007/s00430-012-0270-1; Grassel L, 2016, SCI REP-UK, V6, DOI 10.1038/srep32337; HOPPESEYLER F, 1994, MOL CARCINOGEN, V10, P134, DOI 10.1002/mc.2940100304; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; Jackson J, 2001, BLOOD CELL MOL DIS, V27, P446, DOI 10.1006/bcmd.2001.0403; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Kawamura T, 2014, J DERMATOL SCI, V75, P159, DOI 10.1016/j.jdermsci.2014.05.004; Lederer M, 2005, J CELL SCI, V118, P331, DOI 10.1242/jcs.01618; Leitz J, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003957; Maglennon Gareth Adam, 2012, Open Virol J, V6, P190, DOI 10.2174/1874357901206010190; McBride AA, 2017, BIOL CHEM, V398, P919, DOI 10.1515/hsz-2017-0113; McBride AA, 2013, VIROLOGY, V445, P57, DOI 10.1016/j.virol.2013.06.006; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; MUNGER K, 1992, CANCER SURV, V12, P197; NURNBERG W, 1995, CANCER RES, V55, P4432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Organista Nava J., 2016, J MOL GENET MED, V10, P1; Porter SS, 2017, VIRUS RES, V231, P10, DOI 10.1016/j.virusres.2016.11.014; Prouse MB, 2012, BBA-GENE REGUL MECH, V1819, P67, DOI 10.1016/j.bbagrm.2011.10.010; Raff AB, 2013, J VIROL, V87, P6062, DOI 10.1128/JVI.00330-13; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Scheffer KD, 2014, VIRUSES-BASEL, V6, P893, DOI 10.3390/v6020893; Schiffman M, 2007, LANCET, V370, P890, DOI 10.1016/S0140-6736(13)60022-7; Schneider MA, 2011, IDENTIFIZIERUNG CHAR, V16, P1; Schneider MA, 2013, J VIROL, V87, P4461, DOI 10.1128/JVI.01803-12; Schneider MA, 2011, CELL MICROBIOL, V13, P32, DOI 10.1111/j.1462-5822.2010.01515.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; Soeda E, 2006, VIROLOGY, V351, P29, DOI 10.1016/j.virol.2006.03.016; Stanley M, 2010, GYNECOL ONCOL, V117, pS5, DOI [10.1016/j.ygyno.2010.01.024, 10.1016/j.ygyno.2010.04.002]; Stepp WH, 2013, MBIO, V4, DOI 10.1128/mBio.00845-13; Straub E, 2014, J VIROL, V88, P937, DOI 10.1128/JVI.02296-13; Thierry F, 2009, VIROLOGY, V384, P375, DOI 10.1016/j.virol.2008.11.014; Tomaic V, 2016, CANCERS, V8, DOI 10.3390/cancers8100095; Tota JE, 2011, PREV MED, V53, pS12, DOI 10.1016/j.ypmed.2011.08.017; Van Doorslaer K, 2017, MBIO, V8, DOI 10.1128/mBio.01758-17; Wang JW, 2013, VIROLOGY, V445, P175, DOI 10.1016/j.virol.2013.04.017; White EA, 2016, MBIO, V7, DOI 10.1128/mBio.01530-16; Wustenhagen E, 2016, J VIROL, V90, P10629, DOI 10.1128/JVI.01222-16; YEE C, 1985, AM J PATHOL, V119, P361; Yim Eun-Kyoung, 2005, Cancer Res Treat, V37, P319, DOI 10.4143/crt.2005.37.6.319; Zhou Y, 2011, FRONT BIOSCI-LANDMRK, V16, P1109, DOI 10.2741/3738	58	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6275	6284		10.1038/s41388-018-0398-6	http://dx.doi.org/10.1038/s41388-018-0398-6			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30018400	hybrid, Green Published			2022-12-17	WOS:000451622100006
J	Johnson, CE; Dunlop, EA; Seifan, S; McCann, HD; Hay, T; Parfitt, GJ; Jones, AT; Giles, PJ; Shen, MH; Sampson, JR; Errington, RJ; Davies, DM; Tee, AR				Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Hay, Trevor; Parfitt, Geraint J.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.			Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavir - bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death	ONCOGENE			English	Article							HIV PROTEASE INHIBITOR; RENAL ANGIOMYOLIPOMA; ER STRESS; AUTOPHAGY; MTOR	Cancer cells lose homeostatic flexibility because of mutations and dysregulated signaling pathways involved in maintaining homeostasis. Tuberous Sclerosis Complex 1 (TSC1) and TSC2 play a fundamental role in cell homeostasis, where signal transduction through TSC1/TSC2 is often compromised in cancer, leading to aberrant activation of mechanistic target of rapamycin complex 1 (mTORC1). mTORC1 hyperactivation increases the basal level of endoplasmic reticulum (ER) stress via an accumulation of unfolded protein, due to heightened de novo protein translation and repression of autophagy. We exploit this intrinsic vulnerability of tumor cells lacking TSC2, by treating with nelvinavir to further enhance ER stress while inhibiting the proteasome with bortezomib to prevent effective protein removal. We show that TSC2-deficient cells are highly dependent on the proteosomal degradation pathway for survival. Combined treatment with nelfinavir and bortezomib at clinically relevant drug concentrations show synergy in selectively killing TSC2-deficient cells with limited toxicity in control cells. This drug combination inhibited tumor formation in xenograft mouse models and patient-derived cell models of TSC and caused tumor spheroid death in 3D culture. Importantly, 3D culture assays differentiated between the cytostatic effects of the mTORC1 inhibitor, rapamycin, and the cytotoxic effects of the nelfinavir/bortezomib combination. Through RNA sequencing, we determined that nelfinavir and bortezomib tip the balance of ER protein homeostasis of the already ER-stressed TSC2-deficient cells in favor of cell death. These findings have clinical relevance in stratified medicine to treat tumors that have compromised signaling through TSC and are inflexible in their capacity to restore ER homeostasis.	[Johnson, Charlotte E.; Dunlop, Elaine A.; Seifan, Sara; McCann, Henry D.; Jones, Ashley T.; Giles, Peter J.; Shen, Ming H.; Sampson, Julian R.; Errington, Rachel J.; Davies, D. Mark; Tee, Andrew R.] Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales; [Hay, Trevor; Parfitt, Geraint J.] Cardiff Univ, European Canc Stem Cell Res Inst, Hadyn Ellis Bldg,Maindy Rd, Cardiff CF24 4HQ, S Glam, Wales; [Davies, D. Mark] Singleton Hosp, South West Wales Canc Ctr, Dept Oncol, Swansea SA2 8QA, W Glam, Wales	Cardiff University; Cardiff University; Singleton Hospital	Tee, AR (corresponding author), Cardiff Univ, Div Canc & Genet, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	teea@cardiff.ac.uk	/J-6218-2019; Parfitt, Geraint/J-2778-2018	/0000-0002-9209-7561; Davies, Mark/0000-0002-0688-3129; Parfitt, Geraint/0000-0002-8704-7906	Health and Care Research Wales (Wales Cancer Research Centre); Tuberous Sclerosis Association; Cancer Research Wales; Tuberous Sclerosis Alliance; BBSRC; Hospital Saturday Fund	Health and Care Research Wales (Wales Cancer Research Centre); Tuberous Sclerosis Association; Cancer Research Wales; Tuberous Sclerosis Alliance; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Hospital Saturday Fund	This work was supported by Health and Care Research Wales (the Wales Cancer Research Centre) (to EAD, ART, PJG and TH), the Tuberous Sclerosis Association (to EAD, ART, and MHS), Cancer Research Wales (to CEJ, RJE, and ART), the Tuberous Sclerosis Alliance (to EAD and ART), the Hospital Saturday Fund (to ART) and BBSRC (to RJE). We would like to thank the Wales Gene Park for their contribution to this study.	Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006; Astrinidis A, 2002, ONCOGENE, V21, P8470, DOI 10.1038/sj.onc.1205962; Auricchio N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031900; Babcock JT, 2013, J BIOL CHEM, V288, P15687, DOI 10.1074/jbc.M112.431056; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Crawford LJA, 2006, CANCER RES, V66, P6379, DOI 10.1158/0008-5472.CAN-06-0605; Dabora SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023379; Driessen C, 2016, HAEMATOLOGICA, V101, P346, DOI 10.3324/haematol.2015.135780; Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006; Dunlop EA, 2017, ONCOTARGET, V8, P48711, DOI 10.18632/oncotarget.16232; Dunlop EA, 2011, AUTOPHAGY, V7, P737, DOI 10.4161/auto.7.7.15491; Gandolfi S, 2017, CANCER METAST REV, V36, P561, DOI 10.1007/s10555-017-9707-8; Gills J, 2007, CLIN CANCER RES, V13, P5183, DOI 10.1158/1078-0432.CCR-07-0161; Johnson CE, 2015, MOL ONCOL, V9, P675, DOI 10.1016/j.molonc.2014.11.005; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kawabata S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.87; Kraus M, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.2; Kraus M, 2014, LEUKEMIA RES, V38, P383, DOI 10.1016/j.leukres.2013.12.017; Lam HC, 2017, J PATHOL, V241, P219, DOI 10.1002/path.4827; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Peng ZF, 2014, J UROLOGY, V192, P1424, DOI 10.1016/j.juro.2014.04.096; Shim JS, 2012, JNCI-J NATL CANCER I, V104, P1576, DOI 10.1093/jnci/djs396; Siroky BJ, 2012, AM J PHYSIOL-RENAL, V303, pF831, DOI 10.1152/ajprenal.00441.2011; Stengel S, 2017, BBA-MOL CELL RES, V1864, P2183, DOI 10.1016/j.bbamcr.2017.07.008; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang YN, 2014, NATURE, V513, P440, DOI 10.1038/nature13492	27	8	8	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5913	5925		10.1038/s41388-018-0381-2	http://dx.doi.org/10.1038/s41388-018-0381-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29980790	hybrid, Green Accepted			2022-12-17	WOS:000449562500001
J	Tao, Y; Liu, ZJ; Hou, YY; Wang, SL; Liu, SH; Jiang, YH; Tan, D; Ge, QL; Li, CF; Hu, YM; Liu, Z; Chen, X; Wang, Q; Wang, ML; Zhang, XR				Tao, Yu; Liu, Zhanjie; Hou, Yingyong; Wang, Shouli; Liu, Sanhong; Jiang, Yuhang; Tan, Dan; Ge, Qiulin; Li, Cuifeng; Hu, Yiming; Liu, Zhi; Chen, Xi; Wang, Qi; Wang, Mingliang; Zhang, Xiaoren			Alternative NF-kappa B signaling promotes colorectal tumorigenesis through transcriptionally upregulating Bcl-3	ONCOGENE			English	Article							FAMILY-MEMBER BCL-3; C-MYC; CANCER STATISTICS; PROSTATE-CANCER; ACTIVATION; INFLAMMATION; ANGIOGENESIS; EXPRESSION; BINDING; KINASE	Multiple studies have shown that chronic inflammation is closely related to the occurrence and development of colorectal cancer (CRC). Classical NF-kappa B signaling, the key factor in controlling inflammation, has been found to be of great importance to CRC development. However, the role of alternative NF-kappa B signaling in CRC is still elusive. Here, we found aberrant constitutive activation of alternative NF-kappa B signaling both in CRC tissue and CRC cells. Knockdown of RelB downregulates c-Myc and upregulates p27(Kip1) protein level, which inhibits CRC cell proliferation and retards CRC xenograft growth. Conversely, overexpression of RelB increases proliferation of CRC cells. In addition, we revealed a significant correlation between Bcl-3 and RelB in CRC tissues. The expression of RelB was consistent with the expression of Bcl-3 and the phosphorylation of Bcl-3 downstream proteins p-Akt (S473) and p-GSK3 beta (S9). Bcl-3 overexpression can restore the phenotype changes caused by RelB knockdown. Importantly, we demonstrated that alternative NF-kappa B transcriptional factor (p52:RelB) can directly bind to the promoter region of Bcl-3 gene and upregulate its transcription. Moreover, the expression of RelB, NF-kappa B2 p52, and Bcl-3 was associated with poor survival of CRC patients. Taken together, these results represent that alternative NF-kappa B signaling may function as an oncogenic driver in CRC, and also provide new ideas and research directions for the pathogenesis, prevention, and treatment of other inflammatory-related diseases.	[Tao, Yu; Liu, Zhanjie; Liu, Sanhong; Jiang, Yuhang; Li, Cuifeng; Hu, Yiming; Liu, Zhi; Chen, Xi; Wang, Qi; Zhang, Xiaoren] Shanghai Jiao Tong Univ, Inst Hlth Sci, Key Lab Stem Cell Biol, Sch Med, Shanghai 200025, Peoples R China; [Tao, Yu; Liu, Zhanjie; Liu, Sanhong; Jiang, Yuhang; Li, Cuifeng; Hu, Yiming; Liu, Zhi; Chen, Xi; Wang, Qi; Zhang, Xiaoren] Chinese Acad Sci, SIBS, Shanghai 200025, Peoples R China; [Hou, Yingyong] Fudan Univ, Zhongshan Hosp, Dept Pathol, 180 Fenglin Rd, Shanghai 200032, Peoples R China; [Wang, Shouli] Soochow Univ, Dept Pathol, Sch Med, Suzhou 215123, Peoples R China; [Liu, Sanhong] Shanghai Tech Univ, Shanghai Inst Adv Immunochem Studies, Shanghai, Peoples R China; [Tan, Dan; Wang, Mingliang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China; [Ge, Qiulin] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Zhang, Xiaoren] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510000, Guangdong, Peoples R China	Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University; Soochow University - China; ShanghaiTech University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Guangzhou Medical University	Zhang, XR (corresponding author), Shanghai Jiao Tong Univ, Inst Hlth Sci, Key Lab Stem Cell Biol, Sch Med, Shanghai 200025, Peoples R China.; Zhang, XR (corresponding author), Chinese Acad Sci, SIBS, Shanghai 200025, Peoples R China.; Wang, ML (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gen Surg, Shanghai 200025, Peoples R China.; Zhang, XR (corresponding author), Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou 510000, Guangdong, Peoples R China.	mingliang-99@hotmail.com; xrzhang@sibs.ac.cn	wang, mingliang/GXF-2439-2022	Liu, Sanhong/0000-0002-8695-0343; zhang, xiaoren/0000-0003-4080-433X	National Program on Key Research [2016YFC1302400]; National Basic Research Program [2014CB541904, 2014CB943600]; National Natural Science Foundation of China [91742113, 31570902, 31370881]; Natural Science Foundation of Shanghai [14ZR1426300, 18ZR1424400, 18ZR1446400]	National Program on Key Research; National Basic Research Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Shanghai(Natural Science Foundation of Shanghai)	This work was supported by the National Program on Key Research (2016YFC1302400), the National Basic Research Program (2014CB541904, 2014CB943600), National Natural Science Foundation of China (91742113, 31570902, 31370881), and Natural Science Foundation of Shanghai (14ZR1426300, 18ZR1424400, 18ZR1446400).	Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; Brasier AR, 2001, J BIOL CHEM, V276, P32080, DOI 10.1074/jbc.M102949200; Bretones G, 2011, J BIOL CHEM, V286, P9815, DOI 10.1074/jbc.M110.165977; Chandramohan V, 2008, J CELL BIOCHEM, V104, P2091, DOI 10.1002/jcb.21765; Chen C, 2013, BIOCHEM BIOPH RES CO, V430, P505, DOI 10.1016/j.bbrc.2012.12.006; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; Ge QL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.309; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jacque E, 2013, ONCOGENE, V32, P2661, DOI 10.1038/onc.2012.282; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Liu SH, 2014, GASTROENTEROLOGY, V147, P847, DOI 10.1053/j.gastro.2014.06.006; Liu ZJ, 2013, J MOL CELL BIOL, V5, P280, DOI 10.1093/jmcb/mjt020; Maldonado V, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-152; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Nottingham LK, 2014, ONCOGENE, V33, P1135, DOI 10.1038/onc.2013.49; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Poljak L, 1999, J IMMUNOL, V163, P6581; Saamarthy K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1342-6; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; TANAKA S, 1990, CANCER GENET CYTOGEN, V49, P219, DOI 10.1016/0165-4608(90)90144-Y; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Urban BC, 2016, GUT, V65, P1151, DOI 10.1136/gutjnl-2014-308270; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Vallabhapurapu SD, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9428; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; Wang Y, 2016, ONCOGENE, V35, P4080, DOI 10.1038/onc.2015.470; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Wen DY, 2006, J PHARMACOL EXP THER, V317, P989, DOI 10.1124/jpet.105.097584; Wharry CE, 2009, CANCER BIOL THER, V8, P1567, DOI 10.4161/cbt.8.16.8961; Xu Y, 2009, CANCER RES, V69, P3267, DOI 10.1158/0008-5472.CAN-08-4635; Xue G, 2015, ONCOGENE, V34, P1393, DOI 10.1038/onc.2014.82; Zhang JP, 2007, ENDOCRINOLOGY, V148, P268, DOI 10.1210/en.2006-0500; Zhang XR, 2007, IMMUNITY, V27, P438, DOI 10.1016/j.immuni.2007.07.017	51	8	8	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5887	5900		10.1038/s41388-018-0363-4	http://dx.doi.org/10.1038/s41388-018-0363-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973688				2022-12-17	WOS:000448943100006
J	Lee, H; Kim, N; Yoo, YJ; Kim, H; Jeong, E; Choi, S; Moon, SU; Oh, SH; Mills, GB; Yoon, S; Kim, WY				Lee, Hani; Kim, Nayoung; Yoo, Young Ji; Kim, Hyejin; Jeong, Euna; Choi, SeokGyeong; Moon, Sung Un; Oh, Seung Hyun; Mills, Gordon B.; Yoon, Sukjoon; Kim, Woo-Young			beta-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer	ONCOGENE			English	Article							GROWTH-FACTOR-I; RAS SIGNALING PATHWAYS; ADVANCED SOLID TUMORS; COLORECTAL-CANCER; PLASMA-LEVELS; PHASE-I; TRANSCRIPTIONAL ACTIVITY; NUCLEAR-LOCALIZATION; BINDING PROTEIN-3; INSULIN-RECEPTORS	The availability of large-scale drug screening data on cell line panels provides a unique opportunity to identify predictive biomarkers for targeted drug efficacy. Analysis of diverse drug data on similar to 990 cancer cell lines revealed enhanced sensitivity of insulin-like growth factor 1 receptor/Insulin Receptor (IGF-1R/IR) tyrosine kinase inhibitors (TKIs) in colon cancer cells. Interestingly, beta-catenin/TCF(T cell factor)-responsive promoter activity exhibited a significant positive association with IGF-1R/IR TM response, while the mutational status of direct upstream genes, such as CTNNB1 and APC, was not significantly associated with the response. The beta-catenin/TCF activity high cell lines express components of IGF-1R/IR signaling more than the low cell lines explaining their enhanced sensitivity against IGF-1R/IR TKI. Reinforcing beta-catenin/TCF responsive promoter activity by introducing CTNNB1 gain-of-function mutations into IGF-1R/IR TM-resistant cells increased the expression and activity of IGF-1R/IR signaling components and also sensitized the cells to IGF-1R/IR TKIs in vitro and in vivo. Analysis of TCGA data revealed that the stronger beta-catenin/TCF responsive promoter activity was associated with higher IGF-1R and IGF2 transcription in human colon cancer specimens as well. Collectively, compared to the mutational status of upstream genes, beta-catenin/TCF responsive promoter activity has potential to be a stronger predictive positive biomarker for IGF-1R/IR TM responses in colon cancer cells. The present study highlights the potential of transcriptional activity as therapeutic biomarkers for targeted therapies, overcoming the limited ability of upstream genetic mutations to predict responses.	[Lee, Hani; Yoo, Young Ji; Kim, Hyejin; Choi, SeokGyeong; Kim, Woo-Young] Sookmyung Womens Univ, Res Ctr Cell Fate Control, Coll Pharm, Seoul 04310, South Korea; [Lee, Hani; Kim, Nayoung; Yoo, Young Ji; Kim, Hyejin; Jeong, Euna; Choi, SeokGyeong; Moon, Sung Un; Yoon, Sukjoon; Kim, Woo-Young] Sookmyung Womens Univ, Ctr Adv Bioinformat & Syst Med, Seoul 04310, South Korea; [Kim, Nayoung; Yoon, Sukjoon] Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea; [Oh, Seung Hyun] Gachon Univ, Coll Pharm, Incheon 21936, South Korea; [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Syst Biol, Houston, TX 77030 USA	Sookmyung Women's University; Sookmyung Women's University; Sookmyung Women's University; Gachon University; University of Texas System; UTMD Anderson Cancer Center	Kim, WY (corresponding author), Sookmyung Womens Univ, Res Ctr Cell Fate Control, Coll Pharm, Seoul 04310, South Korea.; Yoon, S; Kim, WY (corresponding author), Sookmyung Womens Univ, Ctr Adv Bioinformat & Syst Med, Seoul 04310, South Korea.; Yoon, S (corresponding author), Sookmyung Womens Univ, Dept Biol Sci, Seoul 04310, South Korea.	yoonsj@sookmyung.ac.kr; wykim@sookmyung.ac.kr		Mills, Gordon/0000-0002-0144-9614	National Research Foundation of Korea [NRF-2018R1A2B6009313, NRF-2017R1A2B2007745, NRF-2016R1A5A1011974, NRF-2012M3A9B6055466, NRF-2015R1D1A1A01056594, NRF-2011-0030074]	National Research Foundation of Korea(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea, [NRF-2018R1A2B6009313 to EJ], [NRF-2017R1A2B2007745, and NRF-2016R1A5A1011974 to SY] and [NRF-2012M3A9B6055466, NRF-2015R1D1A1A01056594, and NRF-2011-0030074 to W-YK].	Agaram NP, 2008, GENE CHROMOSOME CANC, V47, P853, DOI 10.1002/gcc.20589; Beneit N, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0477-3; Bommer GT, 2010, J BIOL CHEM, V285, P1928, DOI 10.1074/jbc.M109.060319; Cai J, 2015, GENE DEV, V29, P1493, DOI 10.1101/gad.264515.115; Califano A, 2017, NAT REV CANCER, V17, P116, DOI 10.1038/nrc.2016.124; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Di Cosimo S, 2015, CLIN CANCER RES, V21, P49, DOI 10.1158/1078-0432.CCR-14-0940; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Fassnacht M, 2015, LANCET ONCOL, V16, P426, DOI 10.1016/S1470-2045(15)70081-1; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Greshock J, 2010, CANCER RES, V70, P3677, DOI 10.1158/0008-5472.CAN-09-3788; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Hlubek F, 2007, INT J CANCER, V121, P1941, DOI 10.1002/ijc.22916; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79; Jones RL, 2015, CLIN CANCER RES, V21, P693, DOI 10.1158/1078-0432.CCR-14-0265; Kim N, 2012, INT J CANCER, V131, P2456, DOI 10.1002/ijc.27529; Kubo T, 2009, INT J CANCER, V124, P1778, DOI 10.1002/ijc.24150; Ma J, 1999, JNCI-J NATL CANCER I, V91, P2052, DOI 10.1093/jnci/91.23.2052; Ma J, 2000, GROWTH HORM IGF RES, V10, pS28, DOI 10.1016/S1096-6374(00)90013-3; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; Michor F, 2004, NAT REV CANCER, V4, P197, DOI 10.1038/nrc1295; Min HY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0392-3; Najdi R, 2009, ONCOGENE, V28, P4133, DOI 10.1038/onc.2009.271; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Ormanns S, 2014, ONCOTARGET, V5, P2999, DOI 10.18632/oncotarget.1626; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pollak M, 2008, BEST PRACT RES CL EN, V22, P625, DOI 10.1016/j.beem.2008.08.004; Pollak MN, 2007, AM J CLIN NUTR, V86, p820S, DOI 10.1093/ajcn/86.3.820S; Puzanov I, 2015, CLIN CANCER RES, V21, P701, DOI 10.1158/1078-0432.CCR-14-0303; Qu X, 2017, ONCOTARGET, V8, P29501, DOI 10.18632/oncotarget.15704; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Sabbatini P, 2009, MOL CANCER THER, V8, P2811, DOI 10.1158/1535-7163.MCT-09-0423; Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131; Sclafani F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv258; Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057; Sparks AB, 1998, CANCER RES, V58, P1130; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Takayama T, 2001, GASTROENTEROLOGY, V121, P599, DOI 10.1053/gast.2001.27203; Tap WD, 2012, J CLIN ONCOL, V30, P1849, DOI 10.1200/JCO.2011.37.2359; Tatematsu T, 2014, MOL CLIN ONCOL, V2, P725, DOI 10.3892/mco.2014.318; Tognon CE, 2012, EXPERT OPIN THER TAR, V16, P33, DOI 10.1517/14728222.2011.638626; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088291; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; Wu YP, 2002, CANCER RES, V62, P1030; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zenonos K, 2013, WORLD J GASTRO ONCOL, V5, P97, DOI 10.4251/wjgo.v5.i5.97; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhong H, 2017, ONCOGENE, V36, P797, DOI 10.1038/onc.2016.248	55	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 4	2018	37	40					5466	5475		10.1038/s41388-018-0362-5	http://dx.doi.org/10.1038/s41388-018-0362-5			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV7MY	29895971				2022-12-17	WOS:000446312900007
J	Oda, T; Yamazumi, Y; Hiroko, T; Kamiya, A; Kiriya, S; Suyama, S; Shiozaki-Sato, Y; Akiyama, T				Oda, Takeaki; Yamazumi, Yusuke; Hiroko, Takatoshi; Kamiya, Atsushi; Kiriya, Saori; Suyama, Saki; Shiozaki-Sato, Yumi; Akiyama, Tetsu			Mex-3B induces apoptosis by inhibiting miR-92a access to the Bim-3 ' UTR	ONCOGENE			English	Article							RNA-BINDING PROTEIN; COLORECTAL-CANCER CELLS; AU-RICH ELEMENT; MESSENGER-RNA; P53; EXPRESSION; MICRORNAS; GENE; IDENTIFICATION; DISEASE	Cells respond to a variety of cellular stresses, including DNA damage, by regulating genes whose expression modulates cell cycle arrest, DNA repair, senescence, and/or apoptosis. MicroRNAs (miRNAs) play essential roles in both normal development and disease pathogenesis by destabilizing mRNAs and inhibiting translation. In turn, miRNA biogenesis, turnover, and activity can be regulated by specific RNA-binding proteins. Here we show that Mex-3B, an hnRNP K homology (KH) domain-containing RNA-binding protein, critically modulates DNA stress-induced apoptosis by posttranscriptionally upregulating the pro-apoptotic BH3 (Bcl-2 homology region 3)-only family member Bim. Furthermore, our data indicate that binding of Mex-3B to the 3'-untranslated region (3'UTR) of Bim interferes with the interaction of an Argonaute (Ago)-miR-92a complex with a miR-92a target site present in the Bim RNA. Our results provide novel insights into the posttranscriptional mechanisms that are critical for cellular stress responses.	[Oda, Takeaki; Yamazumi, Yusuke; Hiroko, Takatoshi; Kamiya, Atsushi; Kiriya, Saori; Suyama, Saki; Shiozaki-Sato, Yumi; Akiyama, Tetsu] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan	University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp			P-CREATE (Project for Cancer Research and Therapeutic Evolution) from the Japan Agency for Medical Research and Development [17cm0106103h0002]; P-DIRECT (Project for Development of Innovative Research on Cancer Therapeutics) from the Japan Agency for Medical Research and Development [15cm0106016h0005]; MEXT, Japan [17H06325]	P-CREATE (Project for Cancer Research and Therapeutic Evolution) from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); P-DIRECT (Project for Development of Innovative Research on Cancer Therapeutics) from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We are grateful to Y Nakamura for adenovirus expressing p53. This work was supported by P-CREATE (Project for Cancer Research and Therapeutic Evolution: Grant No. 17cm0106103h0002) and P-DIRECT (Project for Development of Innovative Research on Cancer Therapeutics: Grant No. 15cm0106016h0005) grants from the Japan Agency for Medical Research and Development, and Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Analysis and Regulation of Cellular Diversity: Grant No. 17H06325) from MEXT, Japan.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Buchet-Poyau K, 2007, NUCLEIC ACIDS RES, V35, P1289, DOI 10.1093/nar/gkm016; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Cano F, 2013, MOL IMMUNOL, V55, P135, DOI 10.1016/j.molimm.2012.10.015; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kedde M, 2007, CELL, V131, P1273, DOI 10.1016/j.cell.2007.11.034; Kedde M, 2010, NAT CELL BIOL, V12, P1014, DOI 10.1038/ncb2105; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Le Borgne M, 2014, DEVELOPMENT, V141, P2096, DOI 10.1242/dev.108514; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lewis HA, 2000, CELL, V100, P323, DOI 10.1016/S0092-8674(00)80668-6; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pereira B, 2013, NUCLEIC ACIDS RES, V41, P3986, DOI 10.1093/nar/gkt087; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Ray PS, 2009, NATURE, V457, P915, DOI 10.1038/nature07598; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Siomi H, 2010, MOL CELL, V38, P323, DOI 10.1016/j.molcel.2010.03.013; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Ule J, 2003, SCIENCE, V302, P1212, DOI 10.1126/science.1090095; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Vilborg A, 2009, P NATL ACAD SCI USA, V106, P15756, DOI 10.1073/pnas.0900862106; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yamazumi Y, 2016, CELL REP, V16, P2456, DOI 10.1016/j.celrep.2016.07.062; Yang Y, 2016, CELL RES, V26, P288, DOI 10.1038/cr.2016.16; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhao Y, 2007, TRENDS BIOCHEM SCI, V32, P189, DOI 10.1016/j.tibs.2007.02.006	48	8	8	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5233	5247		10.1038/s41388-018-0336-7	http://dx.doi.org/10.1038/s41388-018-0336-7			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849121				2022-12-17	WOS:000445093100007
J	Sirtl, S; Knoll, G; Trinh, DT; Lang, I; Siegmund, D; Gross, S; Schuler-Thurner, B; Neubert, P; Jantsch, J; Wajant, H; Ehrenschwender, M				Sirtl, Simon; Knoll, Gertrud; Dieu Thuy Trinh; Lang, Isabell; Siegmund, Daniela; Gross, Stefanie; Schuler-Thurner, Beatrice; Neubert, Patrick; Jantsch, Jonathan; Wajant, Harald; Ehrenschwender, Martin			Hypertonicity-enforced BCL-2 addiction unleashes the cytotoxic potential of death receptors	ONCOGENE			English	Article							APOPTOSIS-INDUCING LIGAND; CELL-SURFACE ANTIGEN; MITOCHONDRIAL-MEMBRANE; TUMORICIDAL ACTIVITY; ANTITUMOR-ACTIVITY; DENDRITIC CELLS; HIGH-SALT; CASPASE 8; TRAIL; BAX	Attempts to exploit the cytotoxic activity of death receptors (DR) for treating cancer have thus far been disappointing. DR activation in most malignant cells fails to trigger cell death and may even promote tumor growth by activating cell death-independent DR-associated signaling pathways. Overcoming apoptosis resistance is consequently a prerequisite for successful clinical exploitation of DR stimulation. Here we show that hyperosmotic stress in the tumor microenvironment unleashes the deadly potential of DRs by enforcing BCL-2 addiction of cancer cells. Hypertonicity robustly enhanced cytotoxicity of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and other DR ligands in various cancer entities. Initial events in TRAIL DR signaling remained unaffected, but hypertonic conditions unlocked activation of the mitochondrial death pathway and thus amplified the apoptotic signal. Mechanistically, we demonstrate that hyperosmotic stress imposed a BCL-2-addiction on cancer cells to safeguard the integrity of the outer mitochondrial membrane (OMM), essentially exhausting the protective capacity of BCL-2-like pro-survival proteins. Deprivation of these mitochondrial safeguards licensed DR-generated truncated BH3-interacting domain death agonist (tBID) to activate BCL-2-associated X protein (BAX) and initiated mitochondrial outer membrane permeabilization (MOMP). Our work highlights that hyperosmotic stress in the tumor environment primes mitochondria for death and lowers the threshold for DR-induced apoptosis. Beyond TRAIL-based therapies, our findings could help to strengthen the efficacy of other apoptosis-inducing cancer treatment regimens.	[Sirtl, Simon; Knoll, Gertrud; Dieu Thuy Trinh; Neubert, Patrick; Jantsch, Jonathan; Ehrenschwender, Martin] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany; [Lang, Isabell; Siegmund, Daniela; Wajant, Harald] Univ Hosp Wurzburg, Div Mol Internal Med Med Clin & Polyclin 2, Rontgenring 11, D-97070 Wurzburg, Germany; [Gross, Stefanie; Schuler-Thurner, Beatrice] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Dermatol, Ulmenweg 18, D-91054 Erlangen, Germany	University of Regensburg; University of Wurzburg; University of Erlangen Nuremberg	Ehrenschwender, M (corresponding author), Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	martin.ehrenschwender@ukr.de		Ehrenschwender, Martin/0000-0003-4681-8628; Lang, Isabell/0000-0002-6369-4973; Gross, Stefanie/0000-0002-5406-1736	Deutsche Forschungsgemeinschaft (DFG) [EH 465/2-1, JA 1993/4-1, WA 1025/24-1]; Roggenbuck Stiftung; Universitatsstiftung Angela Schotz-Keilholz; Medical Faculty of the University of Regensburg (ReForM-B-program); Deutsche Krebshilfe [111703]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Roggenbuck Stiftung; Universitatsstiftung Angela Schotz-Keilholz; Medical Faculty of the University of Regensburg (ReForM-B-program); Deutsche Krebshilfe(Deutsche Krebshilfe)	ME is supported by grants from Deutsche Forschungsgemeinschaft (DFG Grant EH 465/2-1), the Roggenbuck Stiftung, the Universitatsstiftung Angela Schotz-Keilholz, and the Medical Faculty of the University of Regensburg (ReForM-B-program). JJ is supported by grants from Deutsche Forschungsgemeinschaft (DFG Grant JA 1993/4-1). HW is supported by grants from Deutsche Forschungsgemeinschaft (DFG Grant WA 1025/24-1) and Deutsche Krebshilfe (Grant 111703).	Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019; Bittner S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.355; Callus BA, 2008, J MOL BIOL, V384, P313, DOI 10.1016/j.jmb.2008.09.041; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chonghaile TN, 2011, SCIENCE, V334, P1129, DOI 10.1126/science.1206727; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; de Miguel D, 2016, CELL DEATH DIFFER, V23, P733, DOI 10.1038/cdd.2015.174; Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Dewson Grant, 2015, Cold Spring Harb Protoc, V2015, P477, DOI 10.1101/pdb.prot086462; Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034; Ehrenschwender M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.534; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fick A, 2012, J BIOL CHEM, V287, P484, DOI 10.1074/jbc.M111.287656; Fischereder M, 2017, AM J PHYSIOL-RENAL, V313, pF319, DOI 10.1152/ajprenal.00703.2016; Franco D, 2002, CELL DEATH DIFFER, V9, P1090, DOI 10.1038/sj.cdd.4401074; Galvez A, 2001, CELL TISSUE RES, V304, P279, DOI 10.1007/s004410100358; Ganesan V, 2012, BIOPHYS J, V103, P483, DOI 10.1016/j.bpj.2012.06.047; Gillissen B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.67; Graves JD, 2014, CANCER CELL, V26, P177, DOI 10.1016/j.ccr.2014.04.028; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Huang K, 2016, J BIOL CHEM, V291, P11843, DOI 10.1074/jbc.M115.711051; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jantsch J, 2015, CELL METAB, V21, P493, DOI 10.1016/j.cmet.2015.02.003; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Knoll G, 2016, ONCOTARGET, V7, P41488, DOI 10.18632/oncotarget.9206; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Kums J, 2017, MABS-AUSTIN, V9, P506, DOI 10.1080/19420862.2016.1274844; Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; MacFarlane M, 2005, CANCER RES, V65, P11265, DOI 10.1158/0008-5472.CAN-05-2801; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Michea L, 2000, AM J PHYSIOL-RENAL, V278, pF209, DOI 10.1152/ajprenal.2000.278.2.F209; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nikpey E, 2017, HYPERTENSION, V69, P660, DOI 10.1161/HYPERTENSIONAHA.116.08539; O'Neill KL, 2016, GENE DEV, V30, P973, DOI 10.1101/gad.276725.115; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pecot J, 2016, CELL REP, V17, P3347, DOI 10.1016/j.celrep.2016.11.064; Reis CR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.61; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schug ZT, 2011, CELL DEATH DIFFER, V18, P538, DOI 10.1038/cdd.2010.135; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Telford W, 2016, CURR PROTOC CYTOM, V77; Thomann S, 2015, IMMUNOLOGY, V146, P327, DOI 10.1111/imm.12509; Todt F, 2015, EMBO J, V34, P67, DOI 10.15252/embj.201488806; Trebing J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.555; Tuthill MH, 2015, ONCOGENE, V34, P2138, DOI 10.1038/onc.2014.156; von Karstedt S, 2017, NAT REV CANCER, V17, P352, DOI 10.1038/nrc.2017.28; Wajant H, 2015, CELL DEATH DIFFER, V22, P1727, DOI 10.1038/cdd.2015.109; Wajant H, 2001, ONCOGENE, V20, P4101, DOI 10.1038/sj.onc.1204558; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang C, 2012, ONCOGENE, V31, P3177, DOI 10.1038/onc.2011.497; Westphal D, 2014, CELL DEATH DIFFER, V21, P196, DOI 10.1038/cdd.2013.139; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yaacoub K, 2016, CANCER LETT, V378, P150, DOI 10.1016/j.canlet.2016.05.012; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	60	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 26	2018	37	30					4122	4136		10.1038/s41388-018-0265-5	http://dx.doi.org/10.1038/s41388-018-0265-5			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GO2YI	29706657	hybrid, Green Published			2022-12-17	WOS:000439847000006
J	Ikink, GJ; Boer, M; Bakker, ERM; Vendel-Zwaagstra, A; Klijn, C; ten Hoeve, J; Jonkers, J; Wessels, LF; Hilkens, J				Ikink, Gerjon J.; Boer, Mandy; Bakker, Elvira R. M.; Vendel-Zwaagstra, Annabel; Klijn, Chris; ten Hoeve, Jelle; Jonkers, Jos; Wessels, Lodewyk F.; Hilkens, John			Insertional mutagenesis in a HER2-positive breast cancer model reveals ERAS as a driver of cancer and therapy resistance	ONCOGENE			English	Article							TRANSGENIC MAMMARY-TUMORS; EXPRESSED RAS ERAS; TRASTUZUMAB RESISTANCE; GASTRIC-CANCER; PI3K PATHWAY; NEU ONCOGENE; MICE; GENE; ACTIVATION; LAPATINIB	Personalized medicine for cancer patients requires a deep understanding of the underlying genetics that drive cancer and the subsequent identification of predictive biomarkers. To discover new genes and pathways contributing to oncogenesis and therapy resistance in HER2+ breast cancer, we performed Mouse Mammary Tumor Virus (MMTV)-induced insertional mutagenesis screens in ErbB2/cNeu-transgenic mouse models. The screens revealed 34 common integration sites (CIS) in mammary tumors of MMTV-infected mice, highlighting loci with multiple independent MMTV integrations in which potential oncogenes are activated, most of which had never been reported as MMTV CIS. The CIS most strongly associated with the ErbB2-transgenic genotype was the locus containing Eras (ES cell-expressed Ras), a constitutively active RAS-family GTPase. We show that upon expression, Eras acts as a potent oncogenic driver through hyperactivation of the PI3K/AKT pathway, in contrast to other RAS proteins that signal primarily via the MAPK/ERK pathway and require upstream activation or activating mutations to induce signaling. We additionally show that ERAS synergistically enhances HER2-induced tumorigenesis and, in this role, can functionally replace ERBB3/HER3 by acting as a more powerful activator of PI3K/AKT signaling. Although previously reported as pseudogene in humans, we observed ERAS RNA and protein expression in a substantial subset of human primary breast carcinomas. Importantly, we show that ERAS induces primary resistance to the widely used HER2-targeting drugs Trastuzumab (Herceptin) and Lapatinib (Tykerb/Tyverb) in vivo, and is involved in acquired resistance via selective upregulation during treatment in vitro, indicating that ERAS may serve as a novel clinical biomarker for PI3K/AKT pathway hyperactivation and HER2-targeted therapy resistance.	[Ikink, Gerjon J.; Boer, Mandy; Bakker, Elvira R. M.; Vendel-Zwaagstra, Annabel; Hilkens, John] Netherlands Canc Inst, Div Mol Genet, Amsterdam, Netherlands; [Klijn, Chris; Jonkers, Jos] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands; [ten Hoeve, Jelle; Wessels, Lodewyk F.] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute	Hilkens, J (corresponding author), Netherlands Canc Inst, Div Mol Genet, Amsterdam, Netherlands.	j.hilkens@nki.nl	Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792; Hilkens, John/0000-0002-0932-7793; Ikink, Gerjon/0000-0002-7482-9298				Akagi K, 2004, NUCLEIC ACIDS RES, V32, pD523, DOI 10.1093/nar/gkh013; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Andrechek ER, 2003, CANCER RES, V63, P4920; Aoyama M, 2010, INT J ONCOL, V37, P1011, DOI 10.3892/ijo_00000752; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Blackwell KL, 2010, J CLIN ONCOL, V28, P1124, DOI 10.1200/JCO.2008.21.4437; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Callahan R, 2008, J MAMMARY GLAND BIOL, V13, P309, DOI 10.1007/s10911-008-9092-6; Callahan R, 2012, ONCOTARGET, V3, P1320, DOI 10.18632/oncotarget.682; Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Dawood S, 2010, J CLIN ONCOL, V28, P92, DOI 10.1200/JCO.2008.19.9844; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462; Engstrom MJ, 2013, BREAST CANC RES TREA, V140, P1; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Gagliato DD, 2016, ONCOTARGET, V7, P64431, DOI 10.18632/oncotarget.7043; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanker AB, 2013, P NATL ACAD SCI USA, V110, P14372, DOI 10.1073/pnas.1303204110; Hilkens J, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1376; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Ikink GJ, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1279722; Ikink GJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13567; Kaizaki R, 2009, ANTICANCER RES, V29, P2189; Kameda T, 2005, STEM CELLS, V23, P1535, DOI 10.1634/stemcells.2005-0054; Kim HH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027425; Klijn C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062113; Knutson KL, 2004, CANCER RES, V64, P1146, DOI 10.1158/0008-5472.CAN-03-0173; Koudijs MJ, 2011, GENOME RES, V21, P2181, DOI 10.1101/gr.112763.110; Kubota E, 2011, ANTICANCER RES, V31, P3353; Kubota E, 2010, AM J PATHOL, V177, P955, DOI 10.2353/ajpath.2010.091056; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Mah W, 2010, J NEUROSCI, V30, P5559, DOI 10.1523/JNEUROSCI.4839-09.2010; Majewski IJ, 2015, J CLIN ONCOL, V33, P1334, DOI 10.1200/JCO.2014.55.2158; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Takahashi K, 2003, NATURE, V423, P541, DOI 10.1038/nature01646; Theodorou V, 2007, NAT GENET, V39, P759, DOI 10.1038/ng2034; Vyazunova I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113489; Wang LP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-248; Wang PY, 2008, MOL CELL NEUROSCI, V39, P83, DOI 10.1016/j.mcn.2008.05.019; Yu Y, 2014, STEM CELLS, V32, P349, DOI 10.1002/stem.1447; Zhao ZA, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150092	50	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1594	1609		10.1038/s41388-017-0031-0	http://dx.doi.org/10.1038/s41388-017-0031-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29326437	Green Published, hybrid			2022-12-17	WOS:000428626700004
J	Velmurugan, KR; Varghese, RT; Fonville, NC; Garner, HR				Velmurugan, K. R.; Varghese, R. T.; Fonville, N. C.; Garner, H. R.			High-depth, high-accuracy microsatellite genotyping enables precision lung cancer risk classification	ONCOGENE			English	Article							BREAST-CANCER; INSTABILITY; VARIANTS; REVEALS; ACTIVATION; SIGNATURE; LYMPHOMA; PATTERNS; GAINS; GENES	There remains a large discrepancy between the known genetic contributions to cancer and that which can be explained by genomic variants, both inherited and somatic. Recently, understudied repetitive DNA regions called microsatellites have been identified as genetic risk markers for a number of diseases including various cancers (breast, ovarian and brain). In this study, we demonstrate an integrated process for identifying and further evaluating microsatellite-based risk markers for lung cancer using data from the cancer genome atlas and the 1000 genomes project. Comparing whole-exome germline sequencing data from 488 TCGA lung cancer samples to germline exome data from 390 control samples from the 1000 genomes project, we identified 119 potentially informative microsatellite loci. These loci were found to be able to distinguish between cancer and control samples with sensitivity and specificity ratios over 0.8. Then these loci, supplemented with additional loci from other cancers and controls, were evaluated using a target enrichment kit and sample-multiplexed nextgen sequencing. Thirteen of the 119 risk markers were found to be informative in a well powered study (40.99 for a 0.95 confidence interval) using high-depth (579x +/- 315) nextgen sequencing of 30 lung cancer and 89 control samples, resulting in sensitivity and specificity ratios of 0.90 and 0.94, respectively. When 8 loci harvested from the bioinformatic analysis of other cancers are added to the classifier, then the sensitivity and specificity rise to 0.93 and 0.97, respectively. Analysis of the genes harboring these loci revealed two genes (ARID1B and REL) and two significantly enriched pathways (chromatin organization and cellular stress response) suggesting that the process of lung carcinogenesis is linked to chromatin remodeling, inflammation, and tumor microenvironment restructuring. We illustrate that high-depth sequencing enables a high-precision microsatellite-based risk classifier analysis approach. This microsatellite-based platform confirms the potential to create clinically actionable diagnostics for lung cancer.	[Velmurugan, K. R.; Varghese, R. T.; Garner, H. R.] Edward Via Coll Osteopath Med, Dept Biol Sci, Ctr Bioinformat & Genet, Blacksburg, VA 24060 USA; [Velmurugan, K. R.; Varghese, R. T.; Garner, H. R.] Edward Via Coll Osteopath Med, Primary Care Res Network, 2265 Kraft Dr, Blacksburg, VA 24060 USA; [Velmurugan, K. R.; Varghese, R. T.; Garner, H. R.] Gibbs Canc Ctr & Res Inst, Dept Biol Sci, Spartanburg, SC USA; [Fonville, N. C.] Riverside Law LLP, Glenhardie Corp Ctr, Dept Biol Sci, Wayne, PA USA		Garner, HR (corresponding author), Edward Via Coll Osteopath Med, Primary Care Res Network, 2265 Kraft Dr, Blacksburg, VA 24060 USA.; Garner, HR (corresponding author), Edward Via Coll Osteopath Med, Ctr Bioinformat & Genet, 2265 Kraft Dr, Blacksburg, VA 24060 USA.	skipgarner@gmail.com			Bradley Engineering Foundation; National Science Foundation [OCI-1124123]	Bradley Engineering Foundation; National Science Foundation(National Science Foundation (NSF))	This work was funded by a grant from the Bradley Engineering Foundation to the Edward Via College of Osteopathic Medicine, and computing was supported by a grant from the National Science Foundation (OCI-1124123). We wish to thank Zalman Vaksman and Lauren J. McIver for programming assistance. We also wish to thank Nicholas Kinney for assistance with statistical computations and manuscript preparation, and Ramu Anandakrishnan for manuscript review.	[Anonymous], 2016, CANC FACTS FIG 2016; Bavarva JH, 2014, ONCOTARGET, V5, P4788, DOI 10.18632/oncotarget.2033; Bavarva JH, 2014, AGING-US, V6, P511, DOI 10.18632/aging.100674; Biegel JA, 2014, AM J MED GENET C, V166, P350, DOI 10.1002/ajmg.c.31410; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Budworth Helen, 2013, Methods Mol Biol, V1010, P3, DOI 10.1007/978-1-62703-411-1_1; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fonville NC, 2015, ONCOTARGET, V6, P11407, DOI 10.18632/oncotarget.2933; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Freimer NB, 1996, CIBA F SYMP, V197, P51; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Geismann C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.417; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Guilmatre A, 2013, HUM MUTAT, V34, P1304, DOI 10.1002/humu.22359; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191; Hasnis E, 2007, J PHYSIOL PHARMACOL, V58, P275; Huang HT, 2015, ONCOL REP, V33, P283, DOI 10.3892/or.2014.3584; Hunter JE, 2016, BRIT J CANCER, V114, P1, DOI 10.1038/bjc.2015.410; Institute NC, 2016, SEER STAT FACT SHEET; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Karunasena E, 2015, ONCOTARGET, V6, P22038, DOI 10.18632/oncotarget.4194; Karunasena E, 2014, ONCOTARGET, V5, P6003, DOI 10.18632/oncotarget.2076; Khursheed M, 2013, BRIT J CANCER, V108, P2056, DOI 10.1038/bjc.2013.200; Kultz D, 2005, ANNU REV PHYSIOL, V67, P225, DOI 10.1146/annurev.physiol.67.040403.103635; Li YF, 2010, LANCET ONCOL, V11, P321, DOI 10.1016/S1470-2045(10)70042-5; Lian Y, 2005, BIOINFORMATICS, V21, P1358, DOI 10.1093/bioinformatics/bti180; Lu H, 2011, CANCER RES, V71, P6867, DOI 10.1158/0008-5472.CAN-11-2460; McIver LJ, 2014, BREAST CANCER RES TR, V145, P791, DOI 10.1007/s10549-014-2908-8; McIver LJ, 2013, GENE, V516, P328, DOI 10.1016/j.gene.2012.12.068; McIver LJ, 2011, GENOMICS, V97, P193, DOI 10.1016/j.ygeno.2011.01.001; Rivera GA, 2016, ADV EXP MED BIOL, V893, P43, DOI 10.1007/978-3-319-24223-1_3; Sing T, 2005, BIOINFORMATICS, V21, P3940, DOI 10.1093/bioinformatics/bti623; Society AC, 2016, NONSM CELL LUNG CANC; Society AC, 2016, WHAT IS NONSM CELL L; Team RDC, 2010, R LANG ENV STAT COMP; Vaksman Z, 2015, ONCOTARGET, V6, P5760, DOI 10.18632/oncotarget.3306; Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56; Wagner AH, 2016, NUCLEIC ACIDS RES, V44, pD1036, DOI 10.1093/nar/gkv1165; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007; Weniger MA, 2007, GENE CHROMOSOME CANC, V46, P406, DOI 10.1002/gcc.20420; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760	49	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6383	6390		10.1038/onc.2017.256	http://dx.doi.org/10.1038/onc.2017.256			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28759038	hybrid, Green Published			2022-12-17	WOS:000415622900003
J	Senturk, JC; Bohlman, S; Manfredi, JJ				Senturk, J. C.; Bohlman, S.; Manfredi, J. J.			Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53	ONCOGENE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISM; GENE AMPLIFICATION; CATALYTIC-ACTIVITY; P-GLYCOPROTEIN; CELL-LINES; CANCER; OVEREXPRESSION; ALPHA; MANAGEMENT; LEUKEMIA	Mdm2 is often overexpressed in tumors that retain wild-type TP53 but may affect therapeutic response independently of p53. Herein is shown that tumor cells with MDM2 amplification are selectively resistant to treatment with topoisomerase II poisons but not other DNA damaging agents. Tumor cells that overexpress Mdm2 have reduced DNA double-strand breaks in response to doxorubicin or etoposide. This latter result is not due to altered drug uptake. The selective attenuation of DNA damage in response to these agents is dependent on both Mdm2 levels and an intact ubiquitin ligase function. These findings reveal a novel, p53-independent activity of Mdm2 and have important implications for the choice of chemotherapeutic agents in the treatment of Mdm2-overexpressing tumors.	[Manfredi, J. J.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10021 USA; Icahn Sch Med Mt Sinai, Grad Sch Biol Sci, New York, NY 10021 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Manfredi, JJ (corresponding author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl,Box 1130, New York, NY 10021 USA.	james.manfredi@mssm.edu			National Cancer Institute [T32CA078207, R03CA216466, P30CA196521]; NATIONAL CANCER INSTITUTE [R03CA216466, T32CA078207, P30CA196521] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank the members of the Manfredi laboratory-Lois Resnick-Silverman, Luis Carvajal, Pierre-Jacques Hamard, Crystal Tonnessen and Nicolas Bartelery-as well as Matthew O'Connell, Miguel Gama-Sosa, Stuart Aaronson and Robert Maki for helpful discussions. We also wish to thank Jonathan Fletcher (Brigham and Women's Hospital) for the LS141 liposarcoma cell line, Ze'ev Ronai (Sanford-Burnham Medical Research Institute) for the expression vector for Flag-tagged Mdm2WT and Shohreh Varmeh for the recombinant Adeno-Mdm2-GFP adenovirus. We wish to thank Carol Prives (Columbia University) for Trp53<SUP>-/-</SUP> MDM2<SUP>+/+</SUP> and Trp53<SUP>-/-</SUP>Mdm2<SUP>-/-</SUP> MEFs. Joseph Tripodi and Vesna Najfeld are gratefully thanked for performing the FISH analysis. These studies were supported by National Cancer Institute grants T32CA078207 to JCS and R03CA216466 to JJM and developmental support from P30CA196521.	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Ambrosini G, 2007, ONCOGENE, V26, P3473, DOI 10.1038/sj.onc.1210136; Binaschi M, 1998, CANCER RES, V58, P1886; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bouska A, 2008, MOL CELL BIOL, V28, P4862, DOI 10.1128/MCB.01584-07; Bouska A, 2009, TRENDS BIOCHEM SCI, V34, P279, DOI 10.1016/j.tibs.2009.02.006; Chen W, 2012, DRUG DISCOV THER, V6, P230, DOI 10.5582/ddt.2012.v6.5.230; Cheng QA, 2011, CELL CYCLE, V10, P1162, DOI 10.4161/cc.10.7.15249; Chikamori K, 2003, J BIOL CHEM, V278, P12696, DOI 10.1074/jbc.M300837200; Chikamori K, 2010, CURR CANCER DRUG TAR, V10, P758, DOI 10.2174/156800910793605785; Conradt L, 2013, INT J CANCER, V132, P2248, DOI 10.1002/ijc.27916; CORDONCARDO C, 1994, CANCER RES, V54, P794; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; Dimitriadi M, 2008, BRIT J CANCER, V99, P1144, DOI 10.1038/sj.bjc.6604643; Duhamel LAE, 2012, HISTOPATHOLOGY, V60, P357, DOI 10.1111/j.1365-2559.2011.04023.x; DURAND RE, 1981, CANCER RES, V41, P3489; FRICHE E, 1991, CANCER RES, V51, P4213; Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Gomez-Herreros F, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003226; Grozav AG, 2009, NUCLEIC ACIDS RES, V37, P382, DOI 10.1093/nar/gkn934; Hamard PJ, 2012, J BIOL CHEM, V287, P22397, DOI 10.1074/jbc.M111.331298; HE J, 1994, GENE CHROMOSOME CANC, V11, P91, DOI 10.1002/gcc.2870110205; ISHIDA R, 1995, CANCER RES, V55, P2299; ISSELL BF, 1979, CANCER TREAT REV, V6, P239, DOI 10.1016/S0305-7372(79)80040-7; Ivashkevich A, 2012, CANCER LETT, V327, P123, DOI 10.1016/j.canlet.2011.12.025; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Kondo S, 1996, BRIT J CANCER, V74, P1263, DOI 10.1038/bjc.1996.527; LADANYI M, 1993, CANCER RES, V53, P16; Lamoureux F, 2007, EXPERT REV ANTICANC, V7, P169, DOI 10.1586/14737140.7.2.169; Ledesma FC, 2009, NATURE, V461, P674, DOI 10.1038/nature08444; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LUK CK, 1989, JNCI-J NATL CANCER I, V81, P55, DOI 10.1093/jnci/81.1.55; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Miller CW, 1996, J CANCER RES CLIN, V122, P559, DOI 10.1007/BF01213553; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Movva S, 2011, DRUGS, V71, P2115, DOI 10.2165/11594500-000000000-00000; Nayak MS, 2007, CANCER RES, V67, P5831, DOI 10.1158/0008-5472.CAN-06-4533; Neal JW, 2011, CLIN CHEST MED, V32, P853, DOI 10.1016/j.ccm.2011.07.002; Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607; Ohnstad HO, 2013, CANCER-AM CANCER SOC, V119, P1013, DOI 10.1002/cncr.27837; Onel K, 2004, MOL CANCER RES, V2, P1; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Plo I, 2002, J BIOL CHEM, V277, P31407, DOI 10.1074/jbc.M204654200; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636; Reis C, 2005, MOL CANCER THER, V4, P1457, DOI 10.1158/1535-7163.MCT-05-0156; RITKE MK, 1995, MOL PHARMACOL, V48, P798; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Vos SM, 2011, NAT REV MOL CELL BIO, V12, P827, DOI 10.1038/nrm3228; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; WATANABE T, 1994, BLOOD, V84, P3158; Wunder JS, 1999, ONCOGENE, V18, P783, DOI 10.1038/sj.onc.1202346; Yamazaki K, 1997, CANCER CHEMOTH PHARM, V39, P192; Yeo CQX, 2016, CELL REP, V15, P132, DOI 10.1016/j.celrep.2016.03.011; Zeng ZH, 2011, J BIOL CHEM, V286, P403, DOI 10.1074/jbc.M110.181016	60	8	8	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6085	6096		10.1038/onc.2017.229	http://dx.doi.org/10.1038/onc.2017.229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28692049	Green Accepted			2022-12-17	WOS:000414249800003
J	Marzook, H; Deivendran, S; George, B; Reshmi, G; Santhoshkumar, TR; Kumar, R; Pillai, MR				Marzook, H.; Deivendran, S.; George, B.; Reshmi, G.; Santhoshkumar, T. R.; Kumar, R.; Pillai, M. R.			Cytoplasmic translocation of MTA1 coregulator promotes de-repression of SGK1 transcription in hypoxic cancer cells	ONCOGENE			English	Article							GLUCOCORTICOID-INDUCIBLE KINASE; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; STEM-CELLS; METASTASIS; SERUM; ACTIVATION; SURVIVAL; PROTEIN	Chromatin remodeling factor metastatic tumor protein 1 (MTA1), one of the most upregulated oncogene in human cancer, has an important role in gene expression, cell survival and promoting hypoxic response. Successful cancer progression is dependent on the ability of cells to utilize its survival pathways for adapting to hypoxic microenvironment. Although MTA1 is a stress-responsive gene, but whether hypoxia modulates its function and its role in engaging other core stress-responsive survival pathway(s) remains unknown. Here we have discovered that MTA1 is a novel corepressor of serum and glucocorticoid-inducible kinase 1 (SGK1). Surprisingly, this regulatory corepressive function of MTA1 is lost under hypoxia, allowing upregulation of SGK1 expression and engaging the MTA1-SGK1 axis for the benefit of the cell survival. The underlying mechanism of the noticed stimulation of SGK1 expression by hypoxia includes de-repression of SGK1 transcription because of hypoxia-triggered nucleus-to-cytoplasmic translocation of MTA1. In addition, the newly recognized cytoplasmic translocation of MTA1 was dependent on the chaperoning function of heat shock protein 90 (HSP90) and co-accompanied by the formation of MTA1, HSP90 and HIF1 alpha complex under hypoxic condition but not under normoxic condition. Hypoxia-triggered redistribution of MTA1, SGK1 upregulation and cell survival functions were compromised by a pharmacological SGK1 inhibitor. In summary, for the first time, we report MTA1 regulation of SGK1 expression, hypoxia-dependent MTA1 translocation to the cytoplasm and de-repression of SGK1 transcription. These findings illustrate how cancer cells utilize a chromatin remodeling factor to engage a core survival pathway to support its cancerous phenotypes, and reveal new facets of MTA1-SGK1 axis by a physiologic signal in cancer progression.	[Marzook, H.; Deivendran, S.; George, B.; Reshmi, G.; Santhoshkumar, T. R.; Kumar, R.; Pillai, M. R.] Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India; [Kumar, R.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); George Washington University	Kumar, R; Pillai, MR (corresponding author), Rajiv Gandhi Ctr Biotechnol, Canc Res Program, Thiruvananthapuram 695014, Kerala, India.; Kumar, R (corresponding author), Sch Med & Hlth Sci, 530 Ross Hall,2300 Eye St NW, Washington, DC 20037 USA.	bcmrxk@gwu.edu; mrpillai@rgcb.res.in	Kumar, Rakesh/ABD-1065-2020; Sankaran, Deivendran/X-8009-2019	Kumar, Rakesh/0000-0001-7664-0803; 	NIH [CA098823]; Department of Biotechnology, Government of India; Council of Science and Industrial Research [09/716(0142)/2010-EMR-1]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); Council of Science and Industrial Research	We thank Christie P Thomas, University of Iowa for the promoter construct pGL3bas_hsgkF4R4, Nirmalya Sen from Kumar's laboratory for identifying SGK1 as a MTA1 target from an in-house, microarray data set generated using NIH grant CA098823. Assistance from Vipin Mohan Dan for MTT analyses, Indu Ramachandran (Core facility for FACS), Confocal Microscopy facility, as well as Prakash R and Ishaque P (Central Cell Line Repository) for hypoxia standardization. This work was supported by Department of Biotechnology, Government of India and Hezlin Marzook is supported by a Senior Research Fellowship from the Council of Science and Industrial Research (09/716(0142)/2010-EMR-1).	Amato R, 2013, ONCOGENE, V32, P4572, DOI 10.1038/onc.2012.470; Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110; Azeez JM, 2015, DRUG DES DEV THER, V9, P5987, DOI 10.2147/DDDT.S89390; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cong BH, 2014, CAN J CARDIOL, V30, P687, DOI 10.1016/j.cjca.2014.03.024; Dickmanns A, 2015, CELLS-BASEL, V4, P538, DOI 10.3390/cells4030538; Ellen TP, 2008, CARCINOGENESIS, V29, P2, DOI 10.1093/carcin/bgm200; Feng XH, 2014, MOL CELLS, V37, P699, DOI 10.14348/molcells.2014.0029; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Gluck S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7; Guo XF, 2013, THORAC CANCER, V4, P312, DOI 10.1111/1759-7714.12024; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hall BA, 2012, BREAST CANCER RES TR, V135, P469, DOI 10.1007/s10549-012-2161-y; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Itani OA, 2002, AM J PHYSIOL-ENDOC M, V283, pE971, DOI 10.1152/ajpendo.00021.2002; Johnson AB, 2008, MUTAT RES-FUND MOL M, V640, P174, DOI 10.1016/j.mrfmmm.2008.01.001; Kumar R, 2016, GENE, V582, P112, DOI 10.1016/j.gene.2016.02.012; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lang F, 2013, HORM-INT J ENDOCRINO, V12, P160, DOI 10.14310/horm.2002.1401; Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016; Li DQ, 2015, ADV CANCER RES, V127, P1, DOI 10.1016/bs.acr.2015.04.005; Liu J, 2014, CANCER METAST REV, V33, P843, DOI 10.1007/s10555-014-9511-7; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Matschke J, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0647-1; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18; Moon HE, 2006, ONCOL REP, V16, P929; Murakami Y, 2010, BIOCHEM BIOPH RES CO, V396, P376, DOI 10.1016/j.bbrc.2010.04.100; Newman B, 2012, CANCER RES, V72, P4551, DOI 10.1158/0008-5472.CAN-11-3600; Pakala SB, 2013, CANCER RES, V73, P3761, DOI 10.1158/0008-5472.CAN-12-3998; Rusai K, 2009, CELL PHYSIOL BIOCHEM, V24, P577, DOI 10.1159/000257527; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577; Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111; Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3; Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Talarico C, 2015, ONCOTARGET, V6, P37520, DOI 10.18632/oncotarget.5527; Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190; Wang K, 2013, ISRN HEPATOL, V2013, P1; Wang RA, 2014, CANCER METAST REV, V33, P1001, DOI 10.1007/s10555-014-9525-1; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yu L, 2013, FEBS LETT, V587, P2542, DOI 10.1016/j.febslet.2013.06.029; Zhang C, 2015, INT J CANCER, V136, P2001, DOI 10.1002/ijc.28975	50	8	8	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5263	5273		10.1038/onc.2017.19	http://dx.doi.org/10.1038/onc.2017.19			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504714				2022-12-17	WOS:000410671700005
J	D'Brot, A; Kurtz, P; Regan, E; Jakubowski, B; Abrams, JM				D'Brot, A.; Kurtz, P.; Regan, E.; Jakubowski, B.; Abrams, J. M.			A platform for interrogating cancer-associated p53 alleles This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue	ONCOGENE			English	Article							MUTANT P53; DROSOPHILA-MELANOGASTER; NUCLEAR-BODIES; MOUSE MODELS; CELL-DEATH; GAIN; PROTEIN; ACTIVATION; APOPTOSIS; NETWORK	p53 is the most frequently mutated gene in human cancer. Compelling evidence argues that full transformation involves loss of growth suppression encoded by wild-type p53 together with poorly understood oncogenic activity encoded by missense mutations. Furthermore, distinguishing disease alleles from natural polymorphisms is an important clinical challenge. To interrogate the genetic activity of human p53 variants, we leveraged the Drosophila model as an in vivo platform. We engineered strains that replace the fly p53 gene with human alleles, producing a collection of stocks that are, in effect, 'humanized' for p53 variants. Like the fly counterpart, human p53 transcriptionally activated a biosensor and induced apoptosis after DNA damage. However, all humanized strains representing common alleles found in cancer patients failed to complement in these assays. Surprisingly, stimulus-dependent activation of hp53 occurred without stabilization, demonstrating that these two processes can be uncoupled. Like its fly counterpart, hp53 formed prominent nuclear foci in germline cells but cancer-associated p53 variants did not. Moreover, these same mutant alleles disrupted hp53 foci and inhibited biosensor activity, suggesting that these properties are functionally linked. Together these findings establish a functional platform for interrogating human p53 alleles and suggest that simple phenotypes could be used to stratify disease variants.	[D'Brot, A.; Kurtz, P.; Abrams, J. M.] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA; [Regan, E.] Univ Texas Southwestern Med Ctr Dallas, Dept Phys Therapy, Dallas, TX 75390 USA; [Jakubowski, B.] Univ Texas Southwestern Med Ctr Dallas, Southwestern Med Sch, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Abrams, JM (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	john.abrams@utsouthwestern.edu		D'Brot, Alejandro/0000-0002-9885-0702	NIH [GM072124, GM115682, S10 RR029731-01]; Welch Foundation [1-1865]; Ellison Medical Foundation; CPRIT [RP110076]; NRSA [F31 GM108472-03]; NATIONAL CANCER INSTITUTE [P30CA142543] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR029731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM108472, R01GM072124, R56GM072124, R01GM115682] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); Ellison Medical Foundation(Lawrence Ellison Foundation); CPRIT; NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge Melissa O'neal for help cloning constructs for humanized lines and Akash Patel for help with crosses to make humanized lines. We are grateful to Anne Dejean for the dSmt3/dSUMO antibody and to Michael Buszczak for the coilin and Ism11 antibodies. We thank Kate Luby-Phelps, Abhijit Bugde and the Live Cell Imaging Facility at UT Southwestern for help with confocal imaging, deconvolution and Imaris. We also thank Po Chen, Nichole Link, Annika Wylie, Gianella Garcia-Hughes, Mike Buszczak, Robin Hiesinger and Helmut Kramer for discussion, advice and comments. This work was supported by the NIH (GM072124) and (GM115682), the Welch Foundation (1-1865), the Ellison Medical Foundation and CPRIT (RP110076) as well as NRSA (F31 GM108472-03) to Paula Kurtz and NIH (S10 RR029731-01) to Kate Luby-Phelps.	ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Abrams JM, 2002, CELL, V110, P403, DOI 10.1016/S0092-8674(02)00904-2; Akdemir F, 2007, ONCOGENE, V26, P5184, DOI 10.1038/sj.onc.1210328; Attrill H, 2016, NUCLEIC ACIDS RES, V44, pD786, DOI 10.1093/nar/gkv1046; Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brooks CL, 2010, CELL RES, V20, P614, DOI 10.1038/cr.2010.53; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Godfrey AC, 2009, RNA, V15, P1661, DOI 10.1261/rna.1518009; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Joerger AC, 2007, ONCOGENE, V26, P2226, DOI 10.1038/sj.onc.1210291; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Liu JL, 2009, MOL BIOL CELL, V20, P1661, DOI 10.1091/mbc.E08-05-0525; Lu WJ, 2010, SCIENCE, V328, P1278, DOI 10.1126/science.1185640; Lu WJ, 2009, NAT REV CANCER, V9, P758, DOI 10.1038/nrc2732; Lubin R, 1995, CLIN CANCER RES, V1, P1463; Mauri F, 2008, J BIOL CHEM, V283, P20848, DOI 10.1074/jbc.M710186200; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Monk AC, 2012, CELL TISSUE RES, V350, P385, DOI 10.1007/s00441-012-1479-4; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Schoborg T, 2013, J CELL BIOL, V202, P261, DOI 10.1083/jcb.201304181; Schumacher B, 2005, CELL, V120, P357, DOI 10.1016/j.cell.2004.12.009; Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Venken KJT, 2009, NAT METHODS, V6, P431, DOI [10.1038/nmeth.1331, 10.1038/NMETH.1331]; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wei QX, 2012, NAT PROTOC, V7, P1145, DOI 10.1038/nprot.2012.042; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wylie A, 2014, ELIFE, V3, DOI 10.7554/eLife.01530; Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546; Yamaguchi M, 1999, ONCOGENE, V18, P6767, DOI 10.1038/sj.onc.1203113	42	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 12	2017	36	2					286	291		10.1038/onc.2016.48	http://dx.doi.org/10.1038/onc.2016.48			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK5AA	26996664	Green Accepted			2022-12-17	WOS:000393938100013
J	Liu, Z; Lam, N; Wang, E; Virden, RA; Pawel, B; Attiyeh, EF; Maris, JM; Thiele, CJ				Liu, Z.; Lam, N.; Wang, E.; Virden, R. A.; Pawel, B.; Attiyeh, E. F.; Maris, J. M.; Thiele, C. J.			Identification of CASZ1 NES reveals potential mechanisms for loss of CASZ1 tumor suppressor activity in neuroblastoma	ONCOGENE			English	Article							NUCLEAR EXPORT SIGNALS; TRANSCRIPTION FACTOR; P53 TETRAMERIZATION; GENE-EXPRESSION; CRM1 INHIBITOR; DNA-DAMAGE; IN-VIVO; PROTEIN; LOCALIZATION; PHOSPHORYLATION	As a transcription factor, localization to the nucleus and the recruitment of cofactors to regulate gene transcription is essential. Nuclear localization and nucleosome remodeling and histone deacetylase (NuRD) complex binding are required for the zinc-finger transcription factor CASZ1 to function as a neuroblastoma (NB) tumor suppressor. However, the critical amino acids (AAs) that are required for CASZ1 interaction with NuRD complex and the regulation of CASZ1 subcellular localization have not been characterized. Through alanine scanning, immunofluorescence cell staining and co-immunoprecipitation, we define a critical region at the CASZ1 N terminus (AAs 23-40) that mediates the CASZ1b nuclear localization and NuRD interaction. Furthermore, we identified a nuclear export signal (NES) at the N terminus (AAs 176-192) that contributes to CASZ1 nuclear-cytoplasmic shuttling in a chromosomal maintenance 1 -dependent manner. An analysis of CASZ1 protein expression in a primary NB tissue microarray shows that high nuclear CASZ1 staining is detected in tumor samples from NB patients with good prognosis. In contrast, cytoplasmic-restricted CASZ1 staining or low nuclear CASZ1 staining is found in tumor samples from patients with poor prognosis. These findings provide insight into mechanisms by which CASZ1 regulates transcription, and suggests that regulation of CASZ1 subcellular localization may impact its function in normal development and pathologic conditions such as NB tumorigenesis.	[Liu, Z.; Lam, N.; Wang, E.; Virden, R. A.; Thiele, C. J.] NCI, Pediat Oncol Branch, 9000 Rockville Pike,Bldg 10,Room 1W-3940,MSC 1105, Bethesda, MD 20892 USA; [Pawel, B.; Attiyeh, E. F.; Maris, J. M.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Thiele, CJ (corresponding author), NCI, Pediat Oncol Branch, 9000 Rockville Pike,Bldg 10,Room 1W-3940,MSC 1105, Bethesda, MD 20892 USA.	thielec@mail.nih.gov			Intramural Research Program of the NIH; National Cancer Institute; Center for Cancer Research; NATIONAL CANCER INSTITUTE [ZIABC010788] Funding Source: NIH RePORTER	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Gregory Wray from the Institute for Genome Sciences and Policy, Duke University for generously providing the tyrosine hydroxylase promoter-pGL4.1-luc (TH-Luc) construct; Nisha Pawer and Neeraj Prasad of the POB, NCI for making the CASZ1b and mutant-EGFP constructs. We appreciate the insightful discussions with Drs Dinah Singer and David Levens of the CCR, NCI on this study. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute and Center for Cancer Research.	Bottardi S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004827; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Charpentier MS, 2013, DEV CELL, V25, P132, DOI 10.1016/j.devcel.2013.03.003; Chayka O, 2009, JNCI-J NATL CANCER I, V101, P663, DOI 10.1093/jnci/djp063; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; CUI X, 1992, DEVELOPMENT, V116, P943; Denslow SA, 2007, ONCOGENE, V26, P5433, DOI 10.1038/sj.onc.1210611; Foo RSY, 2007, P NATL ACAD SCI USA, V104, P20826, DOI 10.1073/pnas.0710017104; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gerecitano J, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0067-3; Henrich KO, 2012, CANCER RES, V72, P6079, DOI 10.1158/0008-5472.CAN-12-2230; Hoff AM, 2015, ONCOTARGET, V6, P36587, DOI 10.18632/oncotarget.5500; Ishizawa J, 2015, PHARMACOL THERAPEUT, V153, P25, DOI 10.1016/j.pharmthera.2015.06.001; Jiang JH, 2011, CANCER RES, V71, P5546, DOI 10.1158/0008-5472.CAN-10-3423; Jiao W, 2006, J BIOL CHEM, V281, P38098, DOI 10.1074/jbc.M605271200; Jordan VK, 2015, APPL CLIN GENET, V8, P189, DOI 10.2147/TACG.S65698; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kulisz A, 2008, MOL CELL BIOL, V28, P1553, DOI 10.1128/MCB.00935-07; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liu Z, 2011, CELL DEATH DIFFER, V18, P1174, DOI 10.1038/cdd.2010.187; Liu ZT, 2011, EURASIP J ADV SIG PR, DOI 10.1155/2011/490289; Liu ZZ, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00001; Liu ZH, 2006, BIOCHEM BIOPH RES CO, V344, P834, DOI 10.1016/j.bbrc.2006.03.207; Liu ZH, 2014, J BIOL CHEM, V289, P29801, DOI 10.1074/jbc.M114.570416; Malki S, 2010, INT J BIOCHEM CELL B, V42, P411, DOI 10.1016/j.biocel.2009.09.020; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; Mattar P, 2015, NEURON, V85, P497, DOI 10.1016/j.neuron.2014.12.052; MELLERICK DM, 1992, NEURON, V9, P789, DOI 10.1016/0896-6273(92)90234-5; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mutka SC, 2009, CANCER RES, V69, P510, DOI 10.1158/0008-5472.CAN-08-0858; Nguyen Kevin T, 2012, Int J Biochem Mol Biol, V3, P137; Nie LH, 2007, J BIOL CHEM, V282, P14616, DOI 10.1074/jbc.M610515200; Prieto G, 2014, BIOINFORMATICS, V30, P1220, DOI 10.1093/bioinformatics/btu016; Ranganathan P, 2012, BLOOD, V120, P1765, DOI 10.1182/blood-2012-04-423160; Rehberg S, 2002, MOL CELL BIOL, V22, P5826, DOI 10.1128/MCB.22.16.5826-5834.2002; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Sakakibara K, 2011, BLOOD, V118, P3922, DOI 10.1182/blood-2011-01-333138; Schmitz M, 2012, INT J CANCER, V131, pE593, DOI 10.1002/ijc.27433; Schulte JH, 2009, INT J CANCER, V124, P2488, DOI 10.1002/ijc.24204; Seibel NM, 2007, ANAL BIOCHEM, V368, P95, DOI 10.1016/j.ab.2007.05.025; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Takeuchi F, 2010, CIRCULATION, V121, P2302, DOI 10.1161/CIRCULATIONAHA.109.904664; Vacalla CMH, 2002, MECH DEVELOP, V118, P265, DOI 10.1016/S0925-4773(02)00282-4; Virden RA, 2012, MOL CELL BIOL, V32, P1518, DOI 10.1128/MCB.06039-11; Wang C, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001564; Warner LR, 2009, BRAIN RES, V1288, P1, DOI 10.1016/j.brainres.2009.06.086; Winter C, 2008, PEDIATR BLOOD CANCER, V51, P10, DOI 10.1002/pbc.21475; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	52	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					97	109		10.1038/onc.2016.179	http://dx.doi.org/10.1038/onc.2016.179			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270431	Green Accepted			2022-12-17	WOS:000394069100009
J	Parang, B; Bradley, AM; Mittal, MK; Short, SP; Thompson, JJ; Barrett, CW; Naik, RD; Bilotta, AJ; Washington, MK; Revetta, FL; Smith, JJ; Chen, X; Wilson, KT; Hiebert, SW; Williams, CS				Parang, B.; Bradley, A. M.; Mittal, M. K.; Short, S. P.; Thompson, J. J.; Barrett, C. W.; Naik, R. D.; Bilotta, A. J.; Washington, M. K.; Revetta, F. L.; Smith, J. J.; Chen, X.; Wilson, K. T.; Hiebert, S. W.; Williams, C. S.			Myeloid translocation genes differentially regulate colorectal cancer programs	ONCOGENE			English	Article							INTESTINAL TUMORIGENESIS; COLON-CANCER; CELL-PROLIFERATION; APC(MIN/+) MICE; NOTCH; COLITIS; APC; ACTIVATION; NEOPLASIA; CARCINOMA	Myeloid translocation genes (MTGs), originally identified as chromosomal translocations in acute myelogenous leukemia, are transcriptional corepressors that regulate hematopoietic stem cell programs. Analysis of The Cancer Genome Atlas (TCGA) database revealed that MTGs were mutated in epithelial malignancy and suggested that loss of function might promote tumorigenesis. Genetic deletion of MTGR1 and MTG16 in the mouse has revealed unexpected and unique roles within the intestinal epithelium. Mtgr1(-/-) mice have progressive depletion of all intestinal secretory cells, and Mtg16(-/-) mice have a decrease in goblet cells. Furthermore, both Mtgr1(-/-) and Mtg16(-/-) mice have increased intestinal epithelial cell proliferation. We thus hypothesized that loss of MTGR1 or MTG16 would modify Apc(1638/+)-dependent intestinal tumorigenesis. Mtgr1(-/-) mice, but not Mtg16(-/-) mice, had a 10-fold increase in tumor multiplicity. This was associated with more advanced dysplasia, including progression to invasive adenocarcinoma, and augmented intratumoral proliferation. Analysis of chromatin immunoprecipitation sequencing data sets for MTGR1 and MTG16 targets indicated that MTGR1 can regulate Wnt and Notch signaling. In support of this, immunohistochemistry and gene expression analysis revealed that both Wnt and Notch signaling pathways were hyperactive in Mtgr1(-/-) tumors. Furthermore, in human colorectal cancer (CRC) samples MTGR1 was downregulated at both the transcript and protein level. Overall our data indicates that MTGR1 has a contextdependent effect on intestinal tumorigenesis.	[Parang, B.; Bradley, A. M.; Mittal, M. K.; Short, S. P.; Thompson, J. J.; Barrett, C. W.; Naik, R. D.; Bilotta, A. J.; Wilson, K. T.; Williams, C. S.] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA; [Parang, B.; Bradley, A. M.; Mittal, M. K.; Short, S. P.; Thompson, J. J.; Barrett, C. W.; Wilson, K. T.; Williams, C. S.] Vanderbilt Univ, Sch Med, Dept Canc Biol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA; [Washington, M. K.; Revetta, F. L.] Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Smith, J. J.] Div Surg Oncol, Dept Surg, Nashville, TN USA; [Chen, X.] Dept Biostat, Nashville, TN USA; [Wilson, K. T.; Hiebert, S. W.; Williams, C. S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Wilson, K. T.; Williams, C. S.] Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN USA; [Hiebert, S. W.] Dept Biochem, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Williams, CS (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA.; Williams, CS (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 2231 Garland Ave,1065D MRB-IV, Nashville, TN 37235 USA.	christopher.williams@vanderbilt.edu	Williams, Christopher/W-3524-2019; Smith, Jesse Joshua/AAN-5440-2020	Williams, Christopher/0000-0002-1541-579X; Smith, Jesse Joshua/0000-0003-2538-5456; Short, Sarah/0000-0001-9606-7370	National Institutes of Health [K08DK080221, R01DK099204, P50CA095103, 1F30DK096718, 1F31 CA167920, T32 GM07347]; Office of Medical Research, Department of Veterans Affairs [1I01BX001426]; ACS-RSG [116552]; NIH [UL1TR000445];  [R01AT004821];  [P30DK058404]; NATIONAL CANCER INSTITUTE [R01CA178030, P01CA116087, F31CA167920, R01CA190612, P50CA095103] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, F30DK096718, K08DK080221, R01DK099204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001426, I01BX001453] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Medical Research, Department of Veterans Affairs(US Department of Veterans Affairs); ACS-RSG(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Veterans Affairs(US Department of Veterans Affairs)	We thank the members of the Williams lab, and Karie Ballard for help in revising and proofreading the manuscript. We also thank Dr R Daniel Beauchamp, David Bader and Barbara Fingleton for their advice and counsel in preparing the manuscript. This work was supported by the National Institutes of Health Grants K08DK080221, R01DK099204 (to CSW), P50CA095103 (to MKW), 1F30DK096718 (to BP), 1F31 CA167920 (to CWB), T32 GM07347 (NIH/NIGMS) (to BP), Merit Review Grant from the Office of Medical Research, Department of Veterans Affairs 1I01BX001426 (to CSW), ACS-RSG 116552 (to CSW), R01AT004821 (to KTW), P30DK058404 (Vanderbilt Digestive Disease Research Center), NIH Grant UL1TR000445 (Vanderbilt CTSA). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	American Cancer Society, 2010, CANC FACTS FIG 2010; Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Barrett CW, 2011, CANCER RES, V71, P1302, DOI 10.1158/0008-5472.CAN-10-3317; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chyla BJ, 2008, MOL CELL BIOL, V28, P6234, DOI 10.1128/MCB.00404-08; Dahl JA, 2007, FRONT BIOSCI-LANDMRK, V12, P4925, DOI 10.2741/2438; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Garg P, 2010, CANCER RES, V70, P792, DOI 10.1158/0008-5472.CAN-09-3166; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Katoh M, 2007, INT J ONCOL, V30, P247; Kazanjian A, 2010, GASTROENTEROLOGY, V139, P918, DOI 10.1053/j.gastro.2010.05.081; Kochetkova M, 2002, CANCER RES, V62, P4599; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Lee SH, 2010, NAT MED, V16, P665, DOI 10.1038/nm.2143; Li Y, 2014, ONCOGENE, V33, P369, DOI 10.1038/onc.2012.581; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Martinez JA, 2006, GASTROENTEROLOGY, V131, P579, DOI 10.1053/j.gastro.2006.06.009; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Moore AC, 2008, MOL CELL BIOL, V28, P977, DOI 10.1128/MCB.01242-07; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Parang B, 2015, FASEB J, V29, P786, DOI 10.1096/fj.14-254284; Peignon G, 2011, GUT, V60, P166, DOI 10.1136/gut.2009.204719; Poindexter SV, 2015, AM J PHYSIOL-GASTR L, V308, pG562, DOI 10.1152/ajpgi.00253.2014; Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Silverman KA, 2002, GENOME RES, V12, P88, DOI 10.1101/gr.206002; Sinnamon MJ, 2008, INT J EXP PATHOL, V89, P466, DOI 10.1111/j.1365-2613.2008.00621.x; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Soler E, 2010, GENE DEV, V24, P277, DOI 10.1101/gad.551810; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Weyden L, 2008, ONCOGENE, V27, P4503; Williams CS, 2013, GUT, V62, P1446, DOI 10.1136/gutjnl-2011-301439; Williams CS, 2011, J CLIN INVEST, V121, P4056, DOI 10.1172/JCI44228; Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598; Zecchini V, 2005, GENE DEV, V19, P1686, DOI 10.1101/gad.341705	48	8	9	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2016	35	49					6341	6349		10.1038/onc.2016.167	http://dx.doi.org/10.1038/onc.2016.167			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EF3TJ	27270437	Green Accepted			2022-12-17	WOS:000390247000007
J	Lee-Sherick, AB; Eisenman, KM; Sather, S; McGranahan, A; Armistead, PM; McGary, CS; Hunsucker, SA; Schlegel, J; Martinson, H; Cannon, C; Keating, AK; Earp, HS; Liang, X; DeRyckere, D; Graham, DK				Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; McGranahan, A.; Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Schlegel, J.; Martinson, H.; Cannon, C.; Keating, A. K.; Earp, H. S.; Liang, X.; DeRyckere, D.; Graham, D. K.			Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia (vol 32, pg 5359, 2013)	ONCOGENE			English	Correction														Martinson, Holly/0000-0003-2745-2755				Lee-Sherick AB, 2013, ONCOGENE, V32, P5359, DOI 10.1038/onc.2013.40	1	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6270	6270		10.1038/onc.2016.295	http://dx.doi.org/10.1038/onc.2016.295			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27593932	hybrid, Green Published			2022-12-17	WOS:000388857700011
J	Wang, F; Gao, C; Lu, J; Tatetsu, H; Williams, DA; Muller, LU; Cui, W; Chai, L				Wang, F.; Gao, C.; Lu, J.; Tatetsu, H.; Williams, D. A.; Mueller, L. U.; Cui, W.; Chai, L.			Leukemic survival factor SALL4 contributes to defective DNA damage repair	ONCOGENE			English	Article							EARLY EMBRYONIC-DEVELOPMENT; FANCONI-ANEMIA PATHWAY; STEM-CELL FACTOR; HEMATOPOIETIC STEM; OKIHIRO-SYNDROME; HOMOLOGOUS RECOMBINATION; MUTATIONS; GENE; FANCD2; MONOUBIQUITINATION	SALL4 is aberrantly expressed in human myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We have generated a SALL4 transgenic (SALL4B Tg) mouse model with pre-leukemic MDS-like symptoms that transform to AML over time. This makes our mouse model applicable for studying human MDS/AML diseases. Characterization of the leukemic initiation population in this model leads to the discovery that Fancl (Fanconi anemia, complementation group L) is downregulated in SALL4B Tg leukemic and pre-leukemic cells. Similar to the reported Fanconi anemia (FA) mouse model, chromosomal instability with radial changes can be detected in pre-leukemic SALL4B Tg bone marrow (BM) cells after DNA damage challenge. Results from additional studies using DNA damage repair reporter assays support a role of SALL4 in inhibiting the homologous recombination pathway. Intriguingly, unlike the FA mouse model, after DNA damage challenge, SALL4B Tg BM cells can survive and generate hematopoietic colonies. We further elucidated that the mechanism by which SALL4 promotes cell survival is through Bcl2 activation. Overall, our studies demonstrate for the first time that SALL4 has a negative impact in DNA damage repair, and support the model of dual functional properties of SALL4 in leukemogenesis through inhibiting DNA damage repair and promoting cell survival.	[Wang, F.; Gao, C.; Lu, J.; Tatetsu, H.; Chai, L.] Harvard Med Sch, Brigham & Womens Hosp, Joint Program Transfus Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Wang, F.; Cui, W.] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China; [Wang, F.; Cui, W.] Chinese Acad Med Sci, Beijing, Peoples R China; [Williams, D. A.; Mueller, L. U.] Harvard Med Sch, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA USA; [Mueller, L. U.] Genentech Inc, San Francisco, CA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Harvard University; Boston Children's Hospital; Harvard Medical School; Roche Holding; Genentech	Chai, L (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Joint Program Transfus Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.; Cui, W (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Clin Lab, Beijing 100730, Peoples R China.	cuiw@pumch.cn; lchai@partners.org		Chai, Li/0000-0003-1937-4750	NIH [R03CA184531, PO1HL095489]; Lymphoma and Leukemia Society [SLP-8004-14, TRP-6482-16]; V cancer research Foundation; National Natural Science Foundation of China (NSFC) [81071418, 81472029]; China Scholarship Council [201206210154]; NATIONAL CANCER INSTITUTE [R03CA184531] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL095489] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lymphoma and Leukemia Society(Leukemia and Lymphoma Society); V cancer research Foundation; National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China Scholarship Council(China Scholarship Council); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	L Chai and W Cui designed the research, analyzed data and wrote the paper. F Wang and C Gao performed the research experiments, analyzed data and wrote the paper. J Lu and H Tatetsu performed the research experiments and analyzed the data. D Williams provided Fanca - / - mice and edited the paper. L Muller performed Fanca - / - mice related experiments. We also want to thank Dr S Xiao for providing DNA repair reporter plasmids, X Yao, and D Neuberg for statistic analysis, X Tian in assisting animal work, and N Kong in editing of the manuscript. This work was supported in part through NIH R03CA184531 and PO1HL095489, funding from Lymphoma and Leukemia Society (No. SLP-8004-14 and TRP-6482-16) and V cancer research Foundation (to L Chai), by the National Natural Science Foundation of China (NSFC) - 81071418 and 81472029 (to W Cui), and China Scholarship Council (No. 201206210154) (to F Wang).	Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Al-Baradie R, 2002, AM J HUM GENET, V71, P1195, DOI 10.1086/343821; Alpi AF, 2008, MOL CELL, V32, P767, DOI 10.1016/j.molcel.2008.12.003; Alsner J, 2008, ACTA ONCOL, V47, P600, DOI 10.1080/02841860802047411; Bejar R, 2014, J CLIN ONCOL, V32, P2691, DOI 10.1200/JCO.2013.52.3381; Borozdin W, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019505; Cui W, 2006, MODERN PATHOL, V19, P1585, DOI 10.1038/modpathol.3800694; D'Andrea AD, 2010, NEW ENGL J MED, V362, P1909, DOI 10.1056/NEJMra0809889; Gao C, 1999, INT J MOL MED, V4, P291; Gao C, 2013, TRANSFUSION, V53, P1037, DOI 10.1111/j.1537-2995.2012.03888.x; Gurtan AM, 2006, J BIOL CHEM, V281, P10896, DOI 10.1074/jbc.M511411200; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hess CJ, 2008, CELL ONCOL, V30, P299, DOI 10.3233/CLO-2008-0426; Huard CC, 2014, P NATL ACAD SCI USA, V111, P2152, DOI 10.1073/pnas.1314226111; Kohlhase J, 2002, HUM MOL GENET, V11, P2979, DOI 10.1093/hmg/11.23.2979; Kohlhase J, 2003, J MED GENET, V40, P473, DOI 10.1136/jmg.40.7.473; Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Li AL, 2013, J CLIN INVEST, V123, P4195, DOI 10.1172/JCI62891; Lu J, 2011, LEUKEMIA, V25, P1211, DOI 10.1038/leu.2011.65; Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594; Mao ZY, 2008, CELL CYCLE, V7, P2902, DOI 10.4161/cc.7.18.6679; Mao ZY, 2007, P NATL ACAD SCI USA, V104, P13068, DOI 10.1073/pnas.0702410104; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Milsom MD, 2009, BLOOD, V113, P5111, DOI 10.1182/blood-2008-09-180224; Muller LUW, 2008, MOL THER, V16, P1154, DOI 10.1038/mt.2008.67; Oostra AB, 2012, ANEMIA, V2012, DOI 10.1155/2012/238731; Paradisi I, 2007, AM J MED GENET A, V143A, P326, DOI 10.1002/ajmg.a.31603; Rego MA, 2012, BLOOD, V120, P2109, DOI 10.1182/blood-2012-02-410472; Rio P, 2002, BLOOD, V100, P2032; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Seluanov A., 2010, J VIS EXP; Singh TR, 2009, BLOOD, V114, P174, DOI 10.1182/blood-2009-02-207811; Wang F, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-73; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; Warren M, 2007, GENESIS, V45, P51, DOI 10.1002/dvg.20264; Will B, 2010, BLOOD, V115, P2901, DOI 10.1182/blood-2009-03-209544; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Yang JC, 2008, BLOOD, V112, P805, DOI 10.1182/blood-2007-11-126326; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang Y, 2001, BLOOD, V98, P3435, DOI 10.1182/blood.V98.12.3435; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	42	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2016	35	47					6087	6095		10.1038/onc.2016.146	http://dx.doi.org/10.1038/onc.2016.146			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CE	27132514	Green Accepted, Green Submitted			2022-12-17	WOS:000388509800005
J	Visone, R; Pallante, P; Vecchione, A; Cirombella, R; Ferracin, M; Ferraro, A; Volinia, S; Coluzzi, S; Leone, V; Borbone, E; Liu, CG; Petrocca, F; Troncone, G; Calin, GA; Scarpa, A; Colato, C; Tallini, G; Santoro, M; Croce, CM; Fusco, A				Visone, R.; Pallante, P.; Vecchione, A.; Cirombella, R.; Ferracin, M.; Ferraro, A.; Volinia, S.; Coluzzi, S.; Leone, V.; Borbone, E.; Liu, C-G; Petrocca, F.; Troncone, G.; Calin, G. A.; Scarpa, A.; Colato, C.; Tallini, G.; Santoro, M.; Croce, C. M.; Fusco, A.			Specific microRNAs are downregulated in human thyroid anaplastic carcinomas (vol 26, pg 7590, 2007)	ONCOGENE			English	Correction													Pallante, Pierlorenzo/AAX-8758-2020; Volinia, Stefano/AAA-9264-2019; Ferracin, Manuela/K-2097-2016; Tallini, Giovanni/F-7850-2013; Volinia, Stefano/A-3029-2010; scarpa, aldo/K-6832-2016	Volinia, Stefano/0000-0003-0910-3893; Ferracin, Manuela/0000-0002-1595-6887; Tallini, Giovanni/0000-0003-0113-6682; Volinia, Stefano/0000-0003-0910-3893; scarpa, aldo/0000-0003-1678-739X; Coluzzi, Sabrina/0000-0003-4483-6232				Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564	1	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2016	35	39					5214	5214		10.1038/onc.2016.139	http://dx.doi.org/10.1038/onc.2016.139			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX5PI	27345412	Bronze			2022-12-17	WOS:000384433000012
J	Zhou, X; Zhang, CZ; Lu, SX; Chen, GG; Li, LZ; Liu, LL; Yi, C; Fu, J; Hu, W; Wen, JM; Yun, JP				Zhou, X.; Zhang, C. Z.; Lu, S-X; Chen, G. G.; Li, L-Z; Liu, L-L; Yi, C.; Fu, J.; Hu, W.; Wen, J-M; Yun, J-P			miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma (vol 34, pg 965, 2015)	ONCOGENE			English	Correction																		Zhou X, 2015, ONCOGENE, V34, P965, DOI 10.1038/onc.2014.35	1	8	9	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2016	35	38					5078	5078		10.1038/onc.2016.61	http://dx.doi.org/10.1038/onc.2016.61			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW9GT	27499093	Bronze			2022-12-17	WOS:000383965300011
J	Schulze, M; Fedorchenko, O; Zink, TG; Knobbe-Thomsen, CB; Kraus, S; Schwinn, S; Beilhack, A; Reifenberger, G; Monoranu, CM; Siren, AL; Jeanclos, E; Gohla, A				Schulze, M.; Fedorchenko, O.; Zink, T. G.; Knobbe-Thomsen, C. B.; Kraus, S.; Schwinn, S.; Beilhack, A.; Reifenberger, G.; Monoranu, C. M.; Siren, A-L; Jeanclos, E.; Gohla, A.			Chronophin is a glial tumor modifier involved in the regulation of glioblastoma growth and invasiveness	ONCOGENE			English	Article							MALIGNANT GLIOMA; CELL-LINE; COFILIN; INVASION; BRAIN; ADF/COFILIN; INHIBITION; LANDSCAPE; DELETION; MOTILITY	Glioblastoma is the most aggressive primary brain tumor in adults. Although the rapid recurrence of glioblastomas after treatment is a major clinical challenge, the relationships between tumor growth and intracerebral spread remain poorly understood. We have identified the cofilin phosphatase chronophin (gene name: pyridoxal phosphatase, PDXP) as a glial tumor modifier. Monoallelic PDXP loss was frequent in four independent human astrocytic tumor cohorts and increased with tumor grade. We found that aberrant PDXP promoter methylation can be a mechanism leading to further chronophin downregulation in glioblastomas, which correlated with shorter glioblastoma patient survival. Moreover, we observed an inverse association between chronophin protein expression and cofilin phosphorylation levels in glioma tissue samples. Chronophin-deficient glioblastoma cells showed elevated cofilin phosphorylation, an increase in polymerized actin, a higher directionality of cell migration, and elevated in vitro invasiveness. Tumor growth of chronophin-depleted glioblastoma cells xenografted into the immunodeficient mouse brain was strongly impaired. Our study suggests a mechanism whereby the genetic and epigenetic alterations of PDXP resulting in altered chronophin expression may regulate the interplay between glioma cell proliferation and invasion.	[Schulze, M.; Zink, T. G.; Jeanclos, E.; Gohla, A.] Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Bavaria, Germany; [Schulze, M.; Jeanclos, E.; Gohla, A.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, D-97078 Wurzburg, Bavaria, Germany; [Fedorchenko, O.] Univ Dusseldorf, Inst Biochem & Mol Biol 2, Dusseldorf, Germany; [Knobbe-Thomsen, C. B.; Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany; [Knobbe-Thomsen, C. B.; Reifenberger, G.] German Canc Res Ctr, German Canc Consortium DKTK, Heidelberg, Germany; [Kraus, S.; Schwinn, S.; Beilhack, A.] Univ Wurzburg, Dept Internal Med 2, D-97078 Wurzburg, Bavaria, Germany; [Kraus, S.; Schwinn, S.; Beilhack, A.] Univ Wurzburg, Ctr Interdisciplinary Clin Res, D-97078 Wurzburg, Bavaria, Germany; [Monoranu, C. M.] Univ Wurzburg, Inst Pathol, Dept Neuropathol, D-97078 Wurzburg, Bavaria, Germany; [Monoranu, C. M.] Univ Wurzburg, Comprehens Canc Ctr Mainfranken, D-97078 Wurzburg, Bavaria, Germany; [Siren, A-L] Univ Wurzburg, Dept Neurosurg, D-97078 Wurzburg, Bavaria, Germany; [Schulze, M.] Univ Regensburg, Dept Neuropathol, D-93053 Regensburg, Germany; [Fedorchenko, O.] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany	University of Wurzburg; University of Wurzburg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Helmholtz Association; German Cancer Research Center (DKFZ); University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Wurzburg; University of Regensburg; University of Cologne	Gohla, A (corresponding author), Univ Wurzburg, Dept Pharmacol, Versbacher Str 9, D-97078 Wurzburg, Germany.	antje.gohla@uni-wuerzburg.de	Reifenberger, Guido/AAE-3599-2019; Knobbe-Thomsen, Christiane B/D-3116-2019; Sirén, Anna-Leena/AAE-1374-2019; Fedorchenko, Oleg/AAA-6533-2021	Sirén, Anna-Leena/0000-0002-2217-0081; Knobbe-Thomsen, Christiane/0000-0003-1231-0076; Gohla, Antje/0000-0002-7442-1487; Jeanclos, Elisabeth/0000-0001-5934-5490	Deutsche Forschungsgemeinschaft [SFB728, SFB688, FZ82, TR17]; Forschungskommission of the Medical Faculty of Heinrich Heine University Dusseldorf; IZKF Wurzburg research grant; Medical Faculty of the University of Wurzburg (Graduate School of Life Sciences); Else Kroner-Fresenius-Stiftung; Max Eder Program of the German Cancer Aid (Deutsche Krebshilfe)	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Forschungskommission of the Medical Faculty of Heinrich Heine University Dusseldorf; IZKF Wurzburg research grant; Medical Faculty of the University of Wurzburg (Graduate School of Life Sciences); Else Kroner-Fresenius-Stiftung; Max Eder Program of the German Cancer Aid (Deutsche Krebshilfe)	We thank Andrea Odersky and Beate Vogt for excellent technical assistance and Miriam Ritz, Carolin Graf, Thorsten Winter and Katja Ottmuller for help with bioluminescence imaging. We also thank Stephan Kissler for the gift of viral vectors, Christian Linden for FACS sorting and Michael Krause and Lukas Rycak, Marburg University, for microarray analysis. This work was supported by grants from the Deutsche Forschungsgemeinschaft (SFB728 to AG and GR; SFB688 and FZ82 to AG), the Forschungskommission of the Medical Faculty of Heinrich Heine University Dusseldorf (to AG) and by an IZKF Wurzburg research grant (to AB). TGZ was supported by a predoctoral fellowship from the Medical Faculty of the University of Wurzburg (Graduate School of Life Sciences) and by the Deutsche Forschungsgemeinschaft TR17. SK was supported by a fellowship of the Else Kroner-Fresenius-Stiftung, and CBKT is supported by the Max Eder Program of the German Cancer Aid (Deutsche Krebshilfe).	Bellail AC, 2004, INT J BIOCHEM CELL B, V36, P1046, DOI 10.1016/j.biocel.2004.01.013; Bernstein BW, 2006, AM J PHYSIOL-CELL PH, V291, pC828, DOI 10.1152/ajpcell.00066.2006; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Bugyi B, 2010, ANNU REV BIOPHYS, V39, P449, DOI 10.1146/annurev-biophys-051309-103849; Carlsson SK, 2014, EMBO MOL MED, V6, P1359, DOI 10.15252/emmm.201302627; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chopra M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081320; Clark MJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000832; Collazo J, 2014, CANCER RES, V74, P2362, DOI 10.1158/0008-5472.CAN-13-3058; de Stahl TD, 2005, GENE CHROMOSOME CANC, V44, P161, DOI 10.1002/gcc.20226; Di Tomaso E, 2000, NEUROPATH APPL NEURO, V26, P22, DOI 10.1046/j.1365-2990.2000.00214.x; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Floyd D, 2014, NEURO-ONCOLOGY, V16, P622, DOI 10.1093/neuonc/nou049; Frattini V, 2013, NAT GENET, V45, P1141, DOI 10.1038/ng.2734; Galluzzi L, 2012, CELL REP, V2, P257, DOI 10.1016/j.celrep.2012.06.017; Gohla A, 2005, NAT CELL BIOL, V7, P21, DOI 10.1038/ncb1201; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hartmann C, 2004, INT J CANCER, V108, P839, DOI 10.1002/ijc.11638; Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x; Huang TY, 2008, DEV CELL, V15, P691, DOI 10.1016/j.devcel.2008.09.017; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Ino Y, 1999, J NEUROPATH EXP NEUR, V58, P881, DOI 10.1097/00005072-199908000-00010; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; KRUSE CA, 1992, IN VITRO CELL DEV-AN, V28A, P609; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mizuno K, 2013, CELL SIGNAL, V25, P457, DOI 10.1016/j.cellsig.2012.11.001; Muhammad A K, 1997, Neurol Med Chir (Tokyo), V37, P606, DOI 10.2176/nmc.37.606; Muhammad AK, 1997, NEUROL MEDICOCHIRURG, V37, P611; Nagai Shoichi, 2011, Genes Cancer, V2, P859, DOI 10.1177/1947601911431839; Oskam NT, 2000, INT J CANCER, V85, P336, DOI 10.1002/(SICI)1097-0215(20000201)85:3<336::AID-IJC7>3.0.CO;2-9; Park JY, 2014, J KOREAN RELIG, V5, P5, DOI 10.1353/jkr.2014.0003; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Pollard TD, 2003, CELL, V112, P453, DOI 10.1016/S0092-8674(03)00120-X; Ren S, 2012, CANCER CHEMOTH PHARM, V70, P415, DOI 10.1007/s00280-012-1921-z; Ridley AJ, 2011, CELL, V145, P1012, DOI 10.1016/j.cell.2011.06.010; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Sauzeau V, 2010, ONCOGENE, V29, P3781, DOI 10.1038/onc.2010.134; Seifried A, 2014, J BIOL CHEM, V289, P3416, DOI 10.1074/jbc.M113.503359; Seifried A, 2013, FEBS J, V280, P549, DOI 10.1111/j.1742-4658.2012.08633.x; Seng TJ, 2005, GENE CHROMOSOME CANC, V43, P181, DOI 10.1002/gcc.20181; Sturm D, 2014, NAT REV CANCER, V14, P92, DOI 10.1038/nrc3655; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang W, 2006, J CELL BIOL, V173, P395, DOI 10.1083/jcb.200510115; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Wiggan O, 2012, DEV CELL, V22, P530, DOI 10.1016/j.devcel.2011.12.026; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100	53	8	8	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2016	35	24					3163	3177		10.1038/onc.2015.376	http://dx.doi.org/10.1038/onc.2015.376			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO9GI	26549022				2022-12-17	WOS:000378092700008
J	Chen, Y; Guo, Y; Zhao, W; Ho, WTT; Fu, X; Zhao, ZJ				Chen, Y.; Guo, Y.; Zhao, W.; Ho, W-T Tina; Fu, X.; Zhao, Z. J.			Identification of an orally available compound with potent and broad FLT3 inhibition activity	ONCOGENE			English	Article							TYROSINE KINASE INHIBITOR; ACUTE MYELOID-LEUKEMIA; EFFECTIVE PROTEIN SUBSTRATE; DRUG-RESISTANCE; MUTANT FLT3; AMG 925; MUTATIONS; EXPRESSION; GENERATION; CRENOLANIB	FLT3 internal tandem duplication (FLT3-ITD) is an activating mutation found in 20-30% of patients with acute myeloid leukemia (AML), which makes FLT3 an attractive target for the treatment of AML. Although FLT3-mutant patients respond to current FLT3 inhibitors, relapse usually happens because of the acquisition of resistant secondary mutations at the FLT3 catalytic domain, which is mainly on D835. In the search for compounds with broad FLT3 inhibition activities, we screened a kinase inhibitor library by using our unique FLT3 substrate and identified JAK3 inhibitor VI (designated JI6 hereafter) as a novel FLT3 inhibitor, which selectively targets FLT3 D835 mutants as well as FLT3-ITD. JI6 effectively inhibited FLT3-ITD-containing MV4-11 cells and HCD-57 cells transformed with FLT3-ITD and D835 mutants. Furthermore, administration of JI6 effectively targeted FLT3 signaling in vivo and suppressed the myeloproliferative phenotypes in FLT3-ITD knock-in mice, and significantly prolonged the survival of immunodeficient mice implanted with the transformed HCD-57 cells. Therefore, JI6 is a promising candidate for the development of next-generation anti-AML drugs.	[Chen, Y.; Zhao, W.; Ho, W-T Tina; Zhao, Z. J.] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA; [Guo, Y.; Fu, X.; Zhao, Z. J.] Jilin Univ, Coll Life Sci, Edmond H Fischer Signal Transduct Lab, Changchun 130023, Peoples R China	University of Oklahoma System; University of Oklahoma Health Sciences Center; Jilin University	Zhao, ZJ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	joe-zhao@ouhsc.edu			National Institutes of Health [HL079441]; Oklahoma Center for the Advancement of Science and Technology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079441] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Oklahoma Center for the Advancement of Science and Technology; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by Grant HL079441 from the National Institutes of Health and a grant from Oklahoma Center for the Advancement of Science and Technology.	Adams C, 2003, BIOORG MED CHEM LETT, V13, P3105, DOI 10.1016/S0960-894X(03)00657-7; Annesley CE, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00263; Bramson HN, 2001, J MED CHEM, V44, P4339, DOI 10.1021/jm010117d; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Chen Y, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-39; Cools J, 2004, CANCER RES, V64, P6385, DOI 10.1158/0008-5472.CAN-04-2148; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Estey EH, 2014, AM J HEMATOL, V89, P1063, DOI 10.1002/ajh.23834; Farkas T, 2011, J BIOL CHEM, V286, P38904, DOI 10.1074/jbc.M111.269134; Gregory TK, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-23; Guo Y, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-72; Hofmann M, 2012, LEUKEMIA, V26, P1228, DOI 10.1038/leu.2011.372; Hsu FYY, 2006, CANCER RES, V66, P9002, DOI 10.1158/0008-5472.CAN-05-4101; Lee BH, 2007, CANCER CELL, V12, P367, DOI 10.1016/j.ccr.2007.08.031; Lee HK, 2014, BLOOD, V123, P2209, DOI 10.1182/blood-2013-04-493916; Leung AYH, 2013, LEUKEMIA, V27, P260, DOI 10.1038/leu.2012.195; Levis M, 2014, FUTURE ONCOL, V10, P1571, DOI [10.2217/FON.14.105, 10.2217/fon.14.105]; Li C, 2015, MOL CANCER THER, V14, P375, DOI 10.1158/1535-7163.MCT-14-0388; Li Z, 2007, EXP HEMATOL, V35, P1624, DOI 10.1016/j.exphem.2007.07.003; Li Z, 2007, J BIOL CHEM, V282, P3428, DOI 10.1074/jbc.C600277200; Li ZH, 2014, J MED CHEM, V57, P3430, DOI 10.1021/jm500118j; Lockman JW, 2011, BIOORG MED CHEM LETT, V21, P1724, DOI 10.1016/j.bmcl.2011.01.077; Ma HS, 2014, CANCER RES, V74, P5206, DOI 10.1158/0008-5472.CAN-14-1028; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Moreno-Miralles I, 2005, J BIOL CHEM, V280, P40097, DOI 10.1074/jbc.M506855200; Papaetis GS, 2009, BIODRUGS, V23, P377, DOI 10.2165/11318860-000000000-00000; Schlenk RF, 2014, BLOOD, V124, P3441, DOI 10.1182/blood-2014-05-578070; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Smith CC, 2012, NATURE, V485, P260, DOI 10.1038/nature11016; Smith CC, 2014, P NATL ACAD SCI USA, V111, P5319, DOI 10.1073/pnas.1320661111; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Swords R, 2012, LEUKEMIA, V26, P2176, DOI 10.1038/leu.2012.114; Takahashi S, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-36; Weisberg E, 2002, CANCER CELL, V1, P433, DOI 10.1016/S1535-6108(02)00069-7; WEN DY, 1994, J BIOL CHEM, V269, P22839; Williams AB, 2013, LEUKEMIA, V27, P48, DOI 10.1038/leu.2012.191; Wodicka LM, 2010, CHEM BIOL, V17, P1241, DOI 10.1016/j.chembiol.2010.09.010; Wood ER, 2004, BIOORG MED CHEM LETT, V14, P953, DOI 10.1016/j.bmcl.2003.12.002; Xing S, 2008, BLOOD, V111, P5109, DOI 10.1182/blood-2007-05-091579; Xu MJ, 2003, BLOOD, V102, P4354, DOI 10.1182/blood-2003-04-1308; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034; Zhang WG, 2008, JNCI-J NATL CANCER I, V100, P184, DOI 10.1093/jnci/djm328; Zhao W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099017; Zhao WK, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-15; Zimmerman EI, 2013, BLOOD, V122, P3607, DOI 10.1182/blood-2013-07-513044	46	8	8	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2016	35	23					2971	2978		10.1038/onc.2015.362	http://dx.doi.org/10.1038/onc.2015.362			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0NB	26411368	Green Accepted			2022-12-17	WOS:000377474500003
J	Schreck, I; Grico, N; Hansjosten, I; Marquardt, C; Bormann, S; Seidel, A; Kvietkova, DL; Pieniazek, D; Segerback, D; Diabate, S; van der Horst, GTJ; Oesch-Bartlomowicz, B; Oesch, F; Weiss, C				Schreck, I.; Grico, N.; Hansjosten, I.; Marquardt, C.; Bormann, S.; Seidel, A.; Kvietkova, D. L.; Pieniazek, D.; Segerback, D.; Diabate, S.; van der Horst, G. T. J.; Oesch-Bartlomowicz, B.; Oesch, F.; Weiss, C.			The nucleotide excision repair protein XPC is essential for bulky DNA adducts to promote interleukin-6 expression via the activation of p38-SAPK	ONCOGENE			English	Article							XERODERMA-PIGMENTOSUM; HUMAN-LUNG; 7,8-DIOL 9,10-EPOXIDES; ULTRAVIOLET-RADIATION; INDUCED APOPTOSIS; AH RECEPTOR; P38; KINASE; CELLS; GENE	Polycyclic aromatic hydrocarbons (PAHs) are environmental pollutants, and many are potent carcinogens. Benzo[a]pyrene (B[a]P), one of the best-studied PAHs, is metabolized ultimately to the genotoxin anti-B[a]P-7,8-dihydrodiol-9,10-epoxide (BPDE). BPDE triggers stress responses linked to gene expression, cell death and survival. So far, the underlying mechanisms that initiate these signal transduction cascades are unknown. Here we show that BPDE-induced DNA damage is recognized by DNA damage sensor proteins to induce activation of the stress-activated protein kinase (SAPK) p38. Surprisingly, the classical DNA damage response, which involves the kinases ATM and ATR, is not involved in p38-SAPK activation by BPDE. Moreover, the induction of p38-SAPK phosphorylation also occurs in the absence of DNA strand breaks. Instead, increased phosphorylation of p38-SAPK requires the nucleotide excision repair (NER) and DNA damage sensor proteins XPC and mHR23B. Interestingly, other genotoxins such as cisplatin (CDDP), hydrogen peroxide and ultraviolet radiation also enhance XPC-dependent p38-SAPK phosphorylation. In contrast, anti-benzo[c]phenanthrene-3,4-dihydrodiol-1,2-epoxide, the DNA adducts of which are not properly recognized by NER, does not trigger p38-SAPK activation. As a downstream consequence, expression and secretion of the pro-inflammatory cytokine interleukin-6 is induced by BPDE and CDDP in vitro and by CDDP in the murine lung, and depends on XPC. In conclusion, we describe a novel pathway in which DNA damage recognition by NER proteins specifically leads to activation of p38-SAPK to promote inflammatory gene expression.	[Schreck, I.; Grico, N.; Hansjosten, I.; Marquardt, C.; Bormann, S.; Diabate, S.; Weiss, C.] Inst Toxicol & Genet, KIT Campus North,Hermann von Helmholtzpl 1, D-76344 Eggenstein Leopoldshafen, Germany; [Grico, N.; Oesch-Bartlomowicz, B.; Oesch, F.] Johannes Gutenberg Univ Mainz, Inst Toxicol, D-55122 Mainz, Germany; [Seidel, A.] Biochem Inst Environm Carcinogens, Lurup 4, Grosshansdorf, Germany; [Kvietkova, D. L.; Pieniazek, D.; Segerback, D.] Novum, Karolinska Inst, Dept Biosci & Nutr, S-14183 Huddinge, Sweden; [van der Horst, G. T. J.] Erasmus Univ, Med Ctr, Dept Genet, MGC, Rotterdam, Netherlands	Helmholtz Association; Karlsruhe Institute of Technology; Johannes Gutenberg University of Mainz; Karolinska Institutet; Erasmus University Rotterdam; Erasmus MC	Weiss, C (corresponding author), Inst Toxicol & Genet, KIT Campus North,Hermann von Helmholtzpl 1, D-76344 Eggenstein Leopoldshafen, Germany.	carsten.weiss@kit.edu	Oesch, Franz/AAA-8746-2020; van der Horst, Gijsbertus TJ/E-3661-2015; Weiss, Carsten/I-1811-2013	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Weiss, Carsten/0000-0002-5380-3208; Marquardt, Clarissa/0000-0001-5872-0164	ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: 'Food Quality and Safety' [513943]	ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: 'Food Quality and Safety'	This work was supported by ECNIS (Environmental Cancer Risk, Nutrition and Individual Susceptibility), a network of excellence operating within the European Union 6th Framework Program, Priority 5: 'Food Quality and Safety' (Contract No 513943). We thank Dorit Mattern for technical assistance; Jonathan Sleeman for critical reading and editing, Selma Huber, Simone Maier, Tobias Stoger and Barbel Ritter for supervision and performance of the animal experiments. Heinz Frank is greatly acknowledged for his contribution to the synthesis of PAHs and sadly passed away.	[Anonymous], 1985, BIOACTIVATION FOREIG; Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Boehme KA, 2008, P NATL ACAD SCI USA, V105, P7785, DOI 10.1073/pnas.0703423105; Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024; BROUGHTON BC, 1995, AM J HUM GENET, V56, P167; Brown RH, 1999, J APPL PHYSIOL, V87, P2362, DOI 10.1152/jappl.1999.87.6.2362; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Buterin T, 2000, CANCER RES, V60, P1849; Callizot N, 2008, CANCER CHEMOTH PHARM, V62, P995, DOI 10.1007/s00280-008-0689-7; Chen SJ, 2003, J BIOL CHEM, V278, P19526, DOI 10.1074/jbc.M300780200; Chen WS, 2012, CARCINOGENESIS, V33, P1368, DOI 10.1093/carcin/bgs159; Chen YM, 1996, JPN J CLIN ONCOL, V26, P18, DOI 10.1093/oxfordjournals.jjco.a023173; Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8; Coussens LM, 2013, SCIENCE, V339, P286, DOI 10.1126/science.1232227; DIPPLE A, 1987, NATURE, V327, P535, DOI 10.1038/327535a0; Donauer J, 2012, ARCH TOXICOL, V86, P329, DOI 10.1007/s00204-011-0757-3; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Gaestel M, 2009, NAT REV DRUG DISCOV, V8, P480, DOI 10.1038/nrd2829; Gehrke H, 2013, NANOTOXICOLOGY, V7, P274, DOI 10.3109/17435390.2011.652207; Graham JM, 2001, AM J HUM GENET, V69, P291, DOI 10.1086/321295; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herrlich P, 2008, MOL CELL, V29, P279, DOI 10.1016/j.molcel.2008.01.001; Hollander MC, 2005, P NATL ACAD SCI USA, V102, P13200, DOI 10.1073/pnas.0503133102; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; Kumar S, 1997, J ORG CHEM, V62, P8535, DOI 10.1021/jo9712355; Lagerqvist A, 2008, DNA REPAIR, V7, P1202, DOI 10.1016/j.dnarep.2008.03.022; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li JX, 2004, J CELL BIOL, V165, P77, DOI 10.1083/jcb.200401004; Lloyd DR, 2000, CANCER RES, V60, P517; Lubin A, 2014, INT J MOL SCI, V15, P141, DOI 10.3390/ijms15010141; Maillard O, 2008, MUTAT RES-REV MUTAT, V658, P271, DOI 10.1016/j.mrrev.2008.01.007; Maillard O, 2007, PLOS BIOL, V5, P717, DOI 10.1371/journal.pbio.0050079; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MCCAUSTLAND DJ, 1975, TETRAHEDRON LETT, P2549; Mitazaki S, 2009, TOXICOLOGY, V265, P115, DOI 10.1016/j.tox.2009.10.005; Naugler WE, 2008, TRENDS MOL MED, V14, P109, DOI 10.1016/j.molmed.2007.12.007; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Oh KS, 2006, HUM MUTAT, V27, P1092, DOI 10.1002/humu.20392; PELKONEN O, 1982, PHARMACOL REV, V34, P189; Pereira L, 2013, EMBO MOL MED, V5, P1759, DOI 10.1002/emmm.201302732; Petit-Frere C, 1998, J INVEST DERMATOL, V111, P354, DOI 10.1038/sj.jid.5602962; Phillips DH, 1999, MUTAGENESIS, V14, P301, DOI 10.1093/mutage/14.3.301; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; Porras A, 2004, MOL BIOL CELL, V15, P922, DOI 10.1091/mbc.E03-08-0592; Raman M, 2007, EMBO J, V26, P2005, DOI 10.1038/sj.emboj.7601668; RANDERATH K, 1989, CARCINOGENESIS, V10, P1231, DOI 10.1093/carcin/10.7.1231; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; SAYER JM, 1981, J AM CHEM SOC, V103, P4970, DOI 10.1021/ja00406a063; Schafer ZT, 2007, J CLIN INVEST, V117, P3660, DOI 10.1172/JCI34237; Schreck I, 2009, TOXICOLOGY, V259, P91, DOI 10.1016/j.tox.2009.02.006; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stoeger T, 2004, INTERPRETATIONS MOL, P75; Straif K, 2005, LANCET ONCOL, V6, P931, DOI 10.1016/S1470-2045(05)70458-7; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Ulrich-Pur H, 2000, ONCOLOGY-BASEL, V59, P187, DOI 10.1159/000012159; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Weiss C, 2003, EMBO J, V22, P3686, DOI 10.1093/emboj/cdg364; Weston CR, 2007, CURR OPIN CELL BIOL, V19, P142, DOI 10.1016/j.ceb.2007.02.001; YAGI H, 1977, J AM CHEM SOC, V99, P1604, DOI 10.1021/ja00447a053; Zhao Q, 2008, J BIOL CHEM, V283, P32553, DOI 10.1074/jbc.M803963200	67	8	8	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					908	918		10.1038/onc.2015.145	http://dx.doi.org/10.1038/onc.2015.145			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25982271				2022-12-17	WOS:000370332200011
J	Trono, P; Di Modugno, F; Circo, R; Spada, S; Di Benedetto, A; Melchionna, R; Palermo, B; Matteoni, S; Soddu, S; Mottolese, M; De Maria, R; Nistio, P				Trono, P.; Di Modugno, F.; Circo, R.; Spada, S.; Di Benedetto, A.; Melchionna, R.; Palermo, B.; Matteoni, S.; Soddu, S.; Mottolese, M.; De Maria, R.; Nistio, P.			hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells	ONCOGENE			English	Article							UP-REGULATION; TUMOR CELLS; MENA; GROWTH; PROTEIN; EXPRESSION; 3-KINASE; ACTIN; ENAH; BIM	Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 overexpression and an activated status of AKT and MAPK. The concomitant overexpression of hMENA and HER2 in breast cancer patients is indicative of a worse prognosis. hMENA is expressed along with alternatively expressed isoforms, hMENA(11a) and hMENA Delta v6 with opposite functions. A novel role for the epithelial-associated hMENA(11a) isoform in sustaining HER3 activation and pro-survival pathways in HER2-overexpressing breast cancer cells has been identified by reverse phase protein array and validated in vivo in a series of breast cancer tissues. As HER3 activation is crucial in mechanisms of cell resistance to PI3K inhibitors, we explored whether hMENA(11a) is involved in these resistance mechanisms. The specific hMENA(11a) depletion switched off the HER3r-elated pathway activated by PI3K inhibitors and impaired the nuclear accumulation of HER3 transcription factor FOXO3a induced by PI3K inhibitors, whereas PI3K inhibitors activated hMENA(11a) phosphorylation and affected its localization. At the functional level, we found that hMENA(11a) sustains cell proliferation and survival in response to PI3K inhibitor treatment, whereas hMENA(11a) silencing increases molecules involved in cancer cell apoptosis. As shown in three-dimensional cultures, hMENA(11a) contributes to resistance to PI3K inhibition because its depletion drastically reduced cell viability upon treatment with PI3K inhibitor BEZ235. Altogether, these results indicate that hMENA(11a) in HER2-overexpressing breast cancer cells sustains HER3/AKT axis activation and contributes to HER3-mediated resistance mechanisms to PI3K inhibitors. Thus, hMENA(11a) expression can be proposed as a marker of HER3 activation and resistance to PI3K inhibition therapies, to select patients who may benefit from these combined targeted treatments. hMENA(11a) activity could represent a new target for antiproliferative therapies in breast cancer.	[Trono, P.; Di Modugno, F.; Spada, S.; Melchionna, R.; Palermo, B.; Nistio, P.] Regina Elena Inst Canc Res, Lab Immunol, Expt Oncol, Rome, Italy; [Circo, R.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy; [Spada, S.; Palermo, B.] Univ Rome, Dept Mol Med, Rome, Italy; [Di Benedetto, A.; Mottolese, M.] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Matteoni, S.; Soddu, S.] Regina Elena Inst Canc Res, Expt Oncol, Rome, Italy; [De Maria, R.] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Nistio, P (corresponding author), Regina Elena Inst Canc Res, Immunol Lab, Via Elio Chianesi 53, I-00144 Rome, Italy.	nistico@ifo.it	Spada, Sheila/AAN-1520-2020; Nisticò, Paola/B-2862-2018; Matteoni, Silvia/U-7578-2017; Melchionna, Roberta/AAZ-4111-2021; De Maria, Ruggero/S-6385-2019; Di Modugno, Francesca/B-2865-2018; Di Modugno, Francesca/ABH-9406-2020; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020	Nisticò, Paola/0000-0003-4409-2261; Matteoni, Silvia/0000-0001-6926-6593; Melchionna, Roberta/0000-0002-8410-9681; De Maria, Ruggero/0000-0003-2255-0583; Di Modugno, Francesca/0000-0003-1427-1883; Di Modugno, Francesca/0000-0003-1427-1883; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Palermo, Belinda/0000-0001-6293-0113; Trono, Paola/0000-0002-2053-6334; Di Benedetto, Anna/0000-0002-9853-8671	Associazione Italiana per la Ricerca sul Cancro (AIRC) [12182, 9979]; IG [11631]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); IG	We thank Dr C Rinaldo for her helpful suggestions, Dr M Panetta for her support, Dr I Terrenato for statistical analysis of data, Mrs G Falasca for technical support and Mrs MV Sarcone for secretarial assistance. This work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) 5x1000 Grants 12182 and 9979 and IG 11631 (to PN).	Amin DN, 2012, BIOCHEM J, V447, P417, DOI 10.1042/BJ20120724; Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Andersen JN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001065; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Bean GR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003483; Bear JE, 2000, CELL, V101, P717, DOI 10.1016/S0092-8674(00)80884-3; Boudreau A, 2013, P NATL ACAD SCI USA, V110, pE3937, DOI 10.1073/pnas.1315022110; Chakrabarty A, 2012, P NATL ACAD SCI USA, V109, P2718, DOI 10.1073/pnas.1018001108; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Desouza Melissa, 2012, Bioarchitecture, V2, P75; Di Modugno F, 2006, CLIN CANCER RES, V12, P1470, DOI 10.1158/1078-0432.CCR-05-2027; Di Modugno F, 2004, INT J CANCER, V109, P909, DOI 10.1002/ijc.20094; Di Modugno F, 2007, CANCER RES, V67, P2657, DOI 10.1158/0008-5472.CAN-06-1997; Di Modugno F, 2012, P NATL ACAD SCI USA, V109, P19280, DOI 10.1073/pnas.1214394109; Di Modugno F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015852; Dinkel H, 2012, NUCLEIC ACIDS RES, V40, pD242, DOI 10.1093/nar/gkr1064; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Federici G, 2013, MOL CANCER RES, V11, P676, DOI 10.1158/1541-7786.MCR-12-0690; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Howes AL, 2007, MOL CANCER THER, V6, P2505, DOI 10.1158/1535-7163.MCT-06-0698; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Knowlden JM, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3018; Polo ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010786; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Morrison MM, 2013, J CLIN INVEST, V123, P4329, DOI 10.1172/JCI66764; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; NISTICO P, 1994, J CLIN INVEST, V94, P1426, DOI 10.1172/JCI117479; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Pinto Mauricio P, 2011, Front Endocrinol (Lausanne), V2, P15, DOI 10.3389/fendo.2011.00015; Rexer BN, 2013, CANCER RES, V73, P3817, DOI 10.1158/0008-5472.CAN-13-0687; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shapiro GI, 2014, CLIN CANCER RES, V20, P233, DOI 10.1158/1078-0432.CCR-13-1777; Singh A, 2010, MOL BIOL CELL, V21, P1140, DOI 10.1091/mbc.E09-09-0795; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tani K, 2003, J BIOL CHEM, V278, P21685, DOI 10.1074/jbc.M301447200; Urbanelli L, 2006, BBA-GENE STRUCT EXPR, V1759, P99, DOI 10.1016/j.bbaexp.2006.01.001; Vehlow A, 2013, EMBO J, V32, P2722, DOI 10.1038/emboj.2013.212; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weigelt B, 2014, ADV DRUG DELIVER REV, V69, P42, DOI 10.1016/j.addr.2014.01.001	50	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					887	896		10.1038/onc.2015.143	http://dx.doi.org/10.1038/onc.2015.143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25961924	Green Published			2022-12-17	WOS:000370332200009
J	Seviour, EG; Sehgal, V; Lu, Y; Luo, Z; Moss, T; Zhang, F; Hill, SM; Liu, W; Maiti, SN; Cooper, L; Azencot, R; Lopez-Berestein, G; Rodriguez-Aguayo, C; Roopaimoole, R; Pecot, CV; Sood, AK; Mukherjee, S; Gray, JW; Mills, GB; Ram, PT				Seviour, E. G.; Sehgal, V.; Lu, Y.; Luo, Z.; Moss, T.; Zhang, F.; Hill, S. M.; Liu, W.; Maiti, S. N.; Cooper, L.; Azencot, R.; Lopez-Berestein, G.; Rodriguez-Aguayo, C.; Roopaimoole, R.; Pecot, C. V.; Sood, A. K.; Mukherjee, S.; Gray, J. W.; Mills, G. B.; Ram, P. T.			Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer (vol 35, pg 691, 2016)	ONCOGENE			English	Correction													Sood, Anoop Kumar/A-7344-2013; , Pathology Services Core/CEZ-2246-2022	Sood, Anoop Kumar/0000-0001-5702-4108; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Ram, Prahlad/0000-0003-4739-3166				Seviourig EG, 2016, ONCOGENE, V35, P691, DOI 10.1038/onc.2014.469	1	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					801	801		10.1038/onc.2015.177	http://dx.doi.org/10.1038/onc.2015.177			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	26865225	Green Published, Bronze			2022-12-17	WOS:000370331300014
J	Balmus, G; Lim, PX; Oswald, A; Hume, KR; Cassano, A; Pierre, J; Hill, A; Huang, W; August, A; Stokol, T; Southard, T; Weiss, RS				Balmus, G.; Lim, P. X.; Oswald, A.; Hume, K. R.; Cassano, A.; Pierre, J.; Hill, A.; Huang, W.; August, A.; Stokol, T.; Southard, T.; Weiss, R. S.			HUS1 regulates in vivo responses to genotoxic chemotherapies	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; CELL-CYCLE CHECKPOINT; LUNG-CARCINOMA CELLS; STRAND BREAK REPAIR; ATAXIA-TELANGIECTASIA; GENOMIC INSTABILITY; MOUSE HUS1; CHROMOSOMAL FRAGMENTATION; TRANSLESION SYNTHESIS; SYNTHETIC LETHALITY	Cells are under constant attack from genotoxins and rely on a multifaceted DNA damage response (DDR) network to maintain genomic integrity. Central to the DDR are the ATM and ATR kinases, which respond primarily to double-strand DNA breaks (DSBs) and replication stress, respectively. Optimal ATR signaling requires the RAD9A-RAD1-HUS1 (9-1-1) complex, a toroidal clamp that is loaded at damage sites and scaffolds signaling and repair factors. Whereas complete ATR pathway inactivation causes embryonic lethality, partial Hus1 impairment has been accomplished in adult mice using hypomorphic (Hus1(neo)) and null (Hus1(Delta 1)) Hus1 alleles, and here we use this system to define the tissue- and cell type-specific actions of the HUS1-mediated DDR in vivo. Hus1(neo/Delta 1) mice showed hypersensitivity to agents that cause replication stress, including the crosslinking agent mitomycin C (MMC) and the replication inhibitor hydroxyurea, but not the DSB inducer ionizing radiation. Analysis of tissue morphology, genomic instability, cell proliferation and apoptosis revealed that MMC treatment caused severe damage in highly replicating tissues of mice with partial Hus1 inactivation. The role of the 9-1-1 complex in responding to MMC was partially ATR-independent, as a HUS1 mutant that was proficient for ATR-induced checkpoint kinase 1 phosphorylation nevertheless conferred MMC hypersensitivity. To assess the interplay between the ATM and ATR pathways in responding to replication stress in vivo, we used Hus1/Atm double mutant mice. Whereas Hus1(neo/neo) and Atm(-/-) single mutant mice survived low-dose MMC similar to wild-type controls, Hus1(neo/neo) Atm(-/-) double mutants showed striking MMC hypersensitivity, consistent with a model in which MMC exposure in the context of Hus1 dysfunction results in DSBs to which the ATM pathway normally responds. This improved understanding of the inter-dependency between two major DDR mechanisms during the response to a conventional chemotherapeutic illustrates how inhibition of checkpoint factors such as HUS1 may be effective for the treatment of ATM-deficient and other cancers.	[Balmus, G.; Lim, P. X.; Oswald, A.; Hume, K. R.; Cassano, A.; Pierre, J.; Hill, A.; Southard, T.; Weiss, R. S.] Cornell Univ, Dept Biomed Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA; [Hume, K. R.] Cornell Univ, Dept Clin Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA; [Huang, W.; August, A.] Cornell Univ, Dept Microbiol & Immunol, T2-006C Vet Res Tower, Ithaca, NY 14853 USA; [Stokol, T.] Cornell Univ, Dept Populat Med & Diagnost Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University; Cornell University	Weiss, RS (corresponding author), Cornell Univ, Dept Biomed Sci, T2-006C Vet Res Tower, Ithaca, NY 14853 USA.	rsw26@cornell.edu	Huang, Weishan/J-3127-2014; Balmus, Gabriel/GZM-2145-2022; Balmus, Gabriel/G-3497-2017	Huang, Weishan/0000-0002-1330-1131; Balmus, Gabriel/0000-0003-2872-4468; Balmus, Gabriel/0000-0003-2872-4468; Lim, Pei Xin/0000-0001-5742-3539	National Institutes of Health [R01 CA108773]; Cornell University College of Veterinary Medicine Graduate Research Assistantship; Cornell University College of Veterinary Medicine Clinical Fellowship; National Center for Research Resources grant [S10RR023781]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cornell University College of Veterinary Medicine Graduate Research Assistantship; Cornell University College of Veterinary Medicine Clinical Fellowship; National Center for Research Resources grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Amy Lyndaker, Steve Jackson and Yaron Galanti for helpful discussions and comments on the manuscript; Natasha Karp for help with statistical analysis and the staff of the Cornell Lab Animal Services and CARE programs for excellent animal care. This work was supported by a National Institutes of Health grant R01 CA108773 to RSW; a Cornell University College of Veterinary Medicine Graduate Research Assistantship to GB; a Cornell University College of Veterinary Medicine Clinical Fellowship to KRH; and a National Center for Research Resources grant (S10RR023781) for instrumentation.	Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Bai HB, 2010, DNA REPAIR, V9, P478, DOI 10.1016/j.dnarep.2010.01.011; Balmus G, 2012, HUM MOL GENET, V21, P3408, DOI 10.1093/hmg/dds173; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartek J, 2012, NAT STRUCT MOL BIOL, V19, P5, DOI 10.1038/nsmb.2220; Brooks K, 2013, ONCOGENE, V32, P788, DOI 10.1038/onc.2012.72; Broustas CG, 2014, RADIAT RES, V181, P111, DOI 10.1667/RR13515.1; Broustas CG, 2012, J BIOL CHEM, V287, P41324, DOI 10.1074/jbc.M112.402784; Brown EJ, 2000, GENE DEV, V14, P397; Church D, 2014, NAT REV CANCER, V14, P440, DOI 10.1038/nrc3729; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cotta-Ramusino C, 2011, SCIENCE, V332, P1313, DOI 10.1126/science.1203430; De la Torre J, 2008, INT J GYNECOL PATHOL, V27, P24, DOI 10.1097/pgp.0b013e31812dfaef; Delacroix S, 2007, GENE DEV, V21, P1472, DOI 10.1101/gad.1547007; Ellisen LW, 2011, CANCER CELL, V19, P165, DOI 10.1016/j.ccr.2011.01.047; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Fokas E, 2014, CANCER TREAT REV, V40, P109, DOI 10.1016/j.ctrv.2013.03.002; Friedrich-Heineken F, 2005, J MOL BIOL, V353, P980, DOI 10.1016/j.jmb.2005.09.018; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Goodship J, 2000, AM J HUM GENET, V67, P498, DOI 10.1086/303023; Hall AB, 2014, ONCOTARGET, V5, P5674, DOI 10.18632/oncotarget.2158; Han L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-67; Helt CE, 2005, CELL CYCLE, V4, P529, DOI 10.4161/cc.4.4.1598; Hopkins KM, 2004, MOL CELL BIOL, V24, P7235, DOI 10.1128/MCB.24.16.7235-7248.2004; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jansen JG, 2007, MOL CELL, V28, P522, DOI 10.1016/j.molcel.2007.11.005; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jeon Y, 2011, J BIOL CHEM, V286, P5414, DOI 10.1074/jbc.M110.189704; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kass EM, 2013, P NATL ACAD SCI USA, V110, P5564, DOI 10.1073/pnas.1216824110; Kawasumi M, 2011, P NATL ACAD SCI USA, V108, P13716, DOI 10.1073/pnas.1111378108; Kinzel B, 2005, CANCER, V94, P1808; Kottemann MC, 2013, NATURE, V493, P356, DOI 10.1038/nature11863; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levitt PS, 2007, MOL CELL BIOL, V27, P2189, DOI 10.1128/MCB.01763-06; Levitt PS, 2005, GENOMICS, V86, P212, DOI 10.1016/j.ygeno.2005.04.007; Liu QH, 2000, GENE DEV, V14, P1448; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Lyndaker AM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003320; Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765; Maniwa Y, 2005, CANCER-AM CANCER SOC, V103, P126, DOI 10.1002/cncr.20740; Marechal A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012716; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; McKinnon PJ, 2007, ANNU REV GENOM HUM G, V8, P37, DOI 10.1146/annurev.genom.7.080505.115648; McKinnon PJ, 2012, ANNU REV PATHOL-MECH, V7, P303, DOI 10.1146/annurev-pathol-011811-132509; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Driscoll M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012773; Origanti S, 2013, ONCOGENE, V32, P577, DOI 10.1038/onc.2012.84; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Ruzankina Y, 2007, CELL STEM CELL, V1, P113, DOI 10.1016/j.stem.2007.03.002; Schoppy DW, 2012, J CLIN INVEST, V122, P241, DOI 10.1172/JCI58928; Shiotani B, 2009, J CELL SCI, V122, P301, DOI 10.1242/jcs.035105; Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4; Tang Y, 2012, CANCER BIOL THER, V13, P379, DOI 10.4161/cbt.19240; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang WS, 2006, J BIOL CHEM, V281, P20865, DOI 10.1074/jbc.M602289200; Weiss RS, 2000, GENE DEV, V14, P1886; Weiss RS, 2003, MOL CELL BIOL, V23, P791, DOI 10.1128/MCB.23.3.791-803.2003; Weiss RS, 2002, CURR BIOL, V12, P73, DOI 10.1016/S0960-9822(01)00626-1; Xu XJ, 2013, NUCLEIC ACIDS RES, V41, P10020, DOI 10.1093/nar/gkt810; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yazinski SA, 2009, P NATL ACAD SCI USA, V106, P21282, DOI 10.1073/pnas.0904965106; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353; Zhu A, 2008, CANCER RES, V68, P1267, DOI 10.1158/0008-5472.CAN-07-2304	68	8	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2016	35	5					662	669		10.1038/onc.2015.118	http://dx.doi.org/10.1038/onc.2015.118			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC9NR	25915840				2022-12-17	WOS:000369548800013
J	Castillo-Lluva, S; Hontecillas-Prieto, L; Blanco-Gomez, A; Saez-Freire, MD; Garcia-Cenador, B; Garcia-Criado, J; Perez-Andres, M; Orfao, A; Canamero, M; Mao, JH; Gridley, T; Castellanos-Martin, A; Perez-Losada, J				Castillo-Lluva, S.; Hontecillas-Prieto, L.; Blanco-Gomez, A.; del Mar Saez-Freire, M.; Garcia-Cenador, B.; Garcia-Criado, J.; Perez-Andres, M.; Orfao, A.; Canamero, M.; Mao, J. H.; Gridley, T.; Castellanos-Martin, A.; Perez-Losada, J.			A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development	ONCOGENE			English	Article							TUMOR-INITIATING CELLS; PROGENITOR CELLS; MESENCHYMAL TRANSITION; KINASE-ACTIVITY; PROTO-ONCOGENE; SELF-RENEWAL; SLUG GENE; STEM; EXPRESSION; CYCLIN	Breast cancer is a major cause of mortality in women. The transcription factor SNAI2 has been implicated in the pathogenesis of several types of cancer, including breast cancer of basal origin. Here we show that SNAI2 is also important in the development of breast cancer of luminal origin in MMTV-ErbB2 mice. SNAI2 deficiency leads to longer latency and fewer luminal tumors, both of these being characteristics of pretumoral origin. These effects were associated with reduced proliferation and a decreased ability to generate mammospheres in normal mammary glands. However, the capacity to metastasize was not modified. Under conditions of increased ERBB2 oncogenic activity after pregnancy plus SNAI2 deficiency, both pretumoral defects-latency and tumor load-were compensated. However, the incidence of lung metastases was dramatically reduced. Furthermore, SNAI2 was required for proper postlactational involution of the breast. At 3 days post lactational involution, the mammary glands of Snai2-deficient mice exhibited lower levels of pSTAT3 and higher levels of pAKT1, resulting in decreased apoptosis. Abundant noninvoluted ducts were still present at 30 days post lactation, with a greater number of residual ERBB2+ cells. These results suggest that this defect in involution leads to an increase in the number of susceptible target cells for transformation, to the recovery of the capacity to generate mammospheres and to an increase in the number of tumors. Our work demonstrates the participation of SNAI2 in the pathogenesis of luminal breast cancer, and reveals an unexpected connection between the processes of postlactational involution and breast tumorigenesis in Snai2-null mutant mice.	[Castillo-Lluva, S.; Hontecillas-Prieto, L.; Blanco-Gomez, A.; del Mar Saez-Freire, M.; Perez-Andres, M.; Orfao, A.; Castellanos-Martin, A.; Perez-Losada, J.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc IBMCC, Salamanca 37007, Spain; [Castillo-Lluva, S.; Hontecillas-Prieto, L.; Blanco-Gomez, A.; del Mar Saez-Freire, M.; Garcia-Cenador, B.; Garcia-Criado, J.; Perez-Andres, M.; Orfao, A.; Castellanos-Martin, A.; Perez-Losada, J.] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Garcia-Cenador, B.; Garcia-Criado, J.] Univ Salamanca, Dept Cirugia, Salamanca 37007, Spain; [Perez-Andres, M.; Orfao, A.] Univ Salamanca, IBSAL, Unidad Citometria Flujo, Salamanca, Spain; [Canamero, M.] Ctr Nacl Invest Oncol CNIO, Madrid, Spain; [Mao, J. H.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Life Sci Div, Berkeley, CA 94720 USA; [Gridley, T.] Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Maine Medical Center	Castellanos-Martin, A (corresponding author), Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Ctr Invest Canc, Campus Miguel de Unamuno Sn, Salamanca 37007, Spain.	andres.castellanos@irbbarcelona.org; jperezlosada@usal.es	CASTILLO-LLUVA, SONIA/AAA-1776-2020; Cenador, Begoña García/Q-9417-2018; Pérez-Losada, Jesús/A-5883-2019; Blanco-Gomez, Adrian/GPK-8337-2022; Cenador, María Begoña García/CAI-2603-2022; Mao, Jian-Hua/EIZ-8595-2022; Castellanos, Andres/F-3302-2016; Perez-Andres, Martin/B-3692-2019; /AAI-3238-2021; Orfao, Alberto/B-5801-2017	Cenador, Begoña García/0000-0002-8950-8542; Pérez-Losada, Jesús/0000-0003-2400-624X; Cenador, María Begoña García/0000-0002-8950-8542; Mao, Jian-Hua/0000-0001-9320-6021; Castellanos, Andres/0000-0003-2864-7271; Perez-Andres, Martin/0000-0003-4599-0776; Castillo-LLuva, Sonia/0000-0001-5357-7178; Blanco Gomez, Adrian/0000-0002-1956-088X	FEDER; MICINN [PLE2009-119, SAF2014-56989-R]; Instituto de Salud Carlos III [PI07/0057, PI10/00328, PIE14/00066]; Junta de Castilla y Leon [SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13]; Fundacion Eugenio Rodriguez Pascual; 'Fundacion Inbiomed' (Instituto Oncologico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa); Fundacion Sandra Ibarra de Solidaridad frente al Cancer; FIS [PI07/0057]; JAEdoc Fellowship (CSIC)/FSE; Junta de Castilla y Leon; National Institutes of Health; National Cancer Institute [R01 CA116481]; Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy [DE-AC02-05CH11231]; NATIONAL CANCER INSTITUTE [R01CA116481] Funding Source: NIH RePORTER	FEDER(European Commission); MICINN(Ministry of Science and Innovation, Spain (MICINN)Spanish GovernmentEuropean Commission); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Junta de Castilla y Leon(Junta de Castilla y Leon); Fundacion Eugenio Rodriguez Pascual; 'Fundacion Inbiomed' (Instituto Oncologico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa); Fundacion Sandra Ibarra de Solidaridad frente al Cancer; FIS(Instituto de Salud Carlos III); JAEdoc Fellowship (CSIC)/FSE; Junta de Castilla y Leon(Junta de Castilla y Leon); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy(United States Department of Energy (DOE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	JP-L was partially supported by FEDER and MICINN (PLE2009-119, SAF2014-56989-R), Instituto de Salud Carlos III (PI07/0057, PI10/00328, PIE14/00066), Junta de Castilla y Leon (SAN673/SA26/08, SAN126/SA66/09, SA078A09, CSI034U13), the 'Fundacion Eugenio Rodriguez Pascual', the 'Fundacion Inbiomed' (Instituto Oncologico Obra Social de la Caja Guipozcoa-San Sebastian, Kutxa) and the 'Fundacion Sandra Ibarra de Solidaridad frente al Cancer'. AC-M was supported by FIS (PI07/0057) and MICINN (PLE2009-119). SC-L was funded by a JAEdoc Fellowship (CSIC)/FSE. MMS-F and AB-G are funded by fellowships from the Junta de Castilla y Leon. J-HM was supported by the National Institutes of Health, a National Cancer Institute Grant (R01 CA116481) and the Low-Dose Scientific Focus Area, Office of Biological and Environmental Research, US Department of Energy (DE-AC02-05CH11231). We thank Dr Montoliu for HC11 cells, Dr Garcia Macias and the Comparative Pathology Core Facility of the 'Centro de Investigacion del Cancer (CIC) de la Universidad de Salamanca' for Pathology support, Maria Luz Hernandez Mulas and Isabel Ramos for technical assistance, Dr Sanchez-Garcia and Dr Martin-Zanca for useful comments along this project, Dr Balmain and Dr Lazo for comments about the manuscript and Nicholas Skinner for his useful help in English editing.	Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bowe DB, 2002, ONCOGENE, V21, P291, DOI 10.1038/sj/onc/1205025; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Carpenter RL, 2014, ONCOGENE, V34, P546; Castellanos-Martin A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0599-z; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Cobaleda C, 2007, ANNU REV GENET, V41, P41, DOI 10.1146/annurev.genet.41.110306.130146; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; Deugnier MA, 2006, DEV BIOL, V293, P414, DOI 10.1016/j.ydbio.2006.02.007; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; Dillon RL, 2010, CANCER RES, V70, P4260, DOI 10.1158/0008-5472.CAN-10-0266; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; GUNZBURG WH, 1992, BIOCHEM J, V283, P625; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hajra KM, 2002, CANCER RES, V62, P1613; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hinohara K, 2012, P NATL ACAD SCI USA, V109, P6584, DOI 10.1073/pnas.1113271109; Hudson LG, 2007, MOL CARCINOGEN, V46, P257, DOI 10.1002/mc.20257; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1006/dbio.1998.8909; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Landis MD, 2006, ONCOGENE, V25, P3325, DOI 10.1038/sj.onc.1209365; Little JL, 2014, ONCOGENE, V33, P411, DOI 10.1038/onc.2012.607; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Mittal MK, 2011, J BIOL CHEM, V286, P469, DOI 10.1074/jbc.M110.164384; Mukherjee S, 2000, ONCOGENE, V19, P5982, DOI 10.1038/sj.onc.1203964; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nassour M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053498; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phillips S, 2014, STEM CELL REP, V2, P633, DOI 10.1016/j.stemcr.2014.03.008; Prater MD, 2014, NAT CELL BIOL, V16, P942, DOI 10.1038/ncb3025; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Rowse GJ, 1998, CANCER RES, V58, P2675; Sanchez-Garcia I, 2009, NEW ENGL J MED, V360, P297, DOI 10.1056/NEJMcibr0808031; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Storci G, 2008, J PATHOL, V214, P25, DOI 10.1002/path.2254; Ullrich RL, 1996, RADIAT RES, V146, P353, DOI 10.2307/3579468; VANDUUREN BL, 1975, CANCER RES, V35, P502; Ventura A, 2004, P NATL ACAD SCI USA, V101, P10380, DOI 10.1073/pnas.0403954101; Villarejo A, 2015, CARCINOGENESIS, V36, P585, DOI 10.1093/carcin/bgv021; Wang GH, 2014, MOL CANCER THER, V13, P1837, DOI 10.1158/1535-7163.MCT-14-0049; Watson CJ, 2011, INT J DEV BIOL, V55, P757, DOI 10.1387/ijdb.113414cw; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012	67	8	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2015	34	36					4777	4790		10.1038/onc.2015.224	http://dx.doi.org/10.1038/onc.2015.224			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CQ9JU	26096931	Green Accepted, Green Submitted			2022-12-17	WOS:000360931500011
J	Mapelli, P; Aboagye, EO; Stebbing, J; Sharma, R				Mapelli, P.; Aboagye, E. O.; Stebbing, J.; Sharma, R.			Epigenetic changes in gastroenteropancreatic neuroendocrine tumours	ONCOGENE			English	Review							HISTONE DEACETYLASE INHIBITORS; PANCREATIC ENDOCRINE; DNA METHYLTRANSFERASE; SOMATOSTATIN ANALOGS; METHYLATION PATTERN; MICRORNA EXPRESSION; SUPPRESSOR GENES; DOWN-REGULATION; VALPROIC ACID; BETA-CATENIN	An understanding of epigenetic drivers of tumorigenesis has developed rapidly during the last years. The identification of these changes including DNA methylation and histone modifications in gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is a step forward in trying to define underlying biologic processes in this heterogeneous disease. The reversible nature of these changes represents a potential therapeutic target. We present an overview of the current knowledge of epigenetic alterations related to GEP-NETs, focusing on the influence and impact these changes have on pathogenesis and prognosis. The potential role of demethylating agents in the management of this patient population is discussed.	[Mapelli, P.; Aboagye, E. O.; Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Surg & Canc, London, England; [Sharma, R.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Expt Med, London, England	Imperial College London; Imperial College London	Mapelli, P (corresponding author), Ist Sci San Raffaele, Dept Nucl Med, Via Olgettina 60, I-20132 Milan, Italy.	mapelli.paola@imperial.ac.uk	Mapelli, Paola/AAC-8990-2022	Mapelli, Paola/0000-0002-8780-5690; Stebbing, Justin/0000-0002-1117-6947; ABOAGYE, Eric/0000-0003-2276-6771	Cancer Research UK [16584] Funding Source: researchfish; National Institute for Health Research [NIHR/CS/009/009, NIHR-RP-011-053] Funding Source: researchfish; MRC [MR/J007986/1] Funding Source: UKRI; Cancer Research UK [10337, 12011, 14549] Funding Source: Medline; Medical Research Council [MR/J007986/1, G0700915] Funding Source: Medline; Department of Health [NIHR/CS/009/009, NIHR-RP-011-053, EME/13/122/01] Funding Source: Medline	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Adler JT, 2009, ANN SURG ONCOL, V16, P481, DOI 10.1245/s10434-008-0194-6; Alexander VM, 2010, INT J CLIN EXP MED, V3, P95; Arnold CN, 2008, INT J CANCER, V123, P1556, DOI 10.1002/ijc.23690; Arnold CN, 2007, INT J CANCER, V120, P2157, DOI 10.1002/ijc.22569; Baradari V, 2006, ENDOCR-RELAT CANCER, V13, P1237, DOI 10.1677/erc.1.01249; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chen SF, 2013, HUM PATHOL, V44, P2199, DOI 10.1016/j.humpath.2013.04.025; Choi IS, 2007, MODERN PATHOL, V20, P802, DOI 10.1038/modpathol.3800825; Chu SH, 2012, MOL MED REP, V5, P138, DOI 10.3892/mmr.2011.620; de Wilde RF, 2012, MODERN PATHOL, V25, P1033, DOI 10.1038/modpathol.2012.53; Dejeux E, 2009, ENDOCR-RELAT CANCER, V16, P939, DOI 10.1677/ERC-08-0331; Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329; Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530; Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547; Fialova B, 2013, ONCOL REP, V29, P2039, DOI 10.3892/or.2013.2344; Fontaniere S, 2006, ENDOCR-RELAT CANCER, V13, P1223, DOI 10.1677/erc.1.01294; Fotouhi O, 2014, EPIGENETICS, V9, P7; Furlan D, 2013, VIRCHOWS ARCH, V462, P47, DOI 10.1007/s00428-012-1348-2; Geli J, 2008, CLIN CANCER RES, V14, P2551, DOI 10.1158/1078-0432.CCR-07-1867; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; Gordon Marilyn, 2012, Mol Biol Int, V2012, P365213, DOI 10.1155/2012/365213; Graham JS, 2009, EUR J CANCER, V45, P1129, DOI 10.1016/j.ejca.2009.01.003; Greenblatt DY, 2007, ONCOLOGIST, V12, P942, DOI 10.1634/theoncologist.12-8-942; Habbe N, 2007, PANCREATOLOGY, V7, P352, DOI 10.1159/000107270; Hagelgans A, 2013, EXP MOL PATHOL, V94, P458, DOI 10.1016/j.yexmp.2013.03.006; Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313; House MG, 2003, ANN SURG, V238, P423, DOI 10.1097/01.sla.0000086659.49569.9e; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Karahoca M, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-3; Kazazian HH, 2002, CELL, V110, P277, DOI 10.1016/S0092-8674(02)00868-1; Kim JT, 2013, CARCINOGENESIS, V34, P953, DOI 10.1093/carcin/bgt018; Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476; La Rosa S, 2012, AM J SURG PATHOL, V36, P601, DOI 10.1097/PAS.0b013e318242e21c; Larsson C, 2013, NEUROENDOCRINOLOGY, V97, P19, DOI 10.1159/000336087; Li SC, 2013, MODERN PATHOL, V26, P685, DOI 10.1038/modpathol.2012.216; Liu LL, 2006, CLIN CANCER RES, V12, P328, DOI 10.1158/1078-0432.CCR-05-2543; Lubomierski N, 2001, CANCER RES, V61, P5905; Magerl C, 2010, HUM PATHOL, V41, P181, DOI 10.1016/j.humpath.2009.08.007; Malpeli G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-351; Masramon L, 2006, J CELL SCI, V119, P1477, DOI 10.1242/jcs.02871; Meeker A, 2014, MOL CELL ENDOCRINOL, V386, P101, DOI 10.1016/j.mce.2013.07.015; Mei M, 2009, J CLIN ENDOCR METAB, V94, P3448, DOI 10.1210/jc.2009-0173; Modlin IM, 2010, ALIMENT PHARM THER, V31, P169, DOI 10.1111/j.1365-2036.2009.04174.x; Modlin IM, 2008, LANCET ONCOL, V9, P61, DOI 10.1016/S1470-2045(07)70410-2; Mohammed TA, 2011, ONCOLOGIST, V16, P835, DOI 10.1634/theoncologist.2011-0031; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366; Muscarella P, 1998, CANCER RES, V58, P237; Naldi I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098101; Oberg K, 2004, ANN ONCOL, V15, P966, DOI 10.1093/annonc/mdh216; Oberg K, 2012, ANN ONCOL, V23, P120, DOI 10.1093/annonc/mds267; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Pavlicek A, 2001, GENE, V276, P39, DOI 10.1016/S0378-1119(01)00645-X; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Pizzi S, 2005, J PATHOL, V206, P409, DOI 10.1002/path.1784; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Rahman MM, 2010, HUM PATHOL, V41, P1069, DOI 10.1016/j.humpath.2010.01.011; Rius M, 2012, ONCOGENE, V31, P4257, DOI 10.1038/onc.2011.601; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Ruebel K, 2010, MODERN PATHOL, V23, P367, DOI 10.1038/modpathol.2009.161; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Serrano J, 2000, J CLIN ENDOCR METAB, V85, P4146, DOI 10.1210/jc.85.11.4146; Shah MH, 2006, CLIN CANCER RES, V12, P3997, DOI 10.1158/1078-0432.CCR-05-2689; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Stricker I, 2012, ANTICANCER RES, V32, P3699; Strosberg JR, 2011, CANCER-AM CANCER SOC, V117, P268, DOI 10.1002/cncr.25425; Thibault A, 1998, TUMORI, V84, P87, DOI 10.1177/030089169808400120; Tian J, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395574; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353; Verdugo AD, 2014, ENDOCR-RELAT CANCER, V21, pL5, DOI 10.1530/ERC-13-0481; Vijayaraghavalu S, 2013, CANCER LETT, V331, P122, DOI 10.1016/j.canlet.2012.12.009; Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4; Warneboldt J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-388; Wild A, 2003, J CLIN ENDOCR METAB, V88, P1367, DOI 10.1210/jc.2002-021027; Yachida S, 2012, AM J SURG PATHOL, V36, P173, DOI 10.1097/PAS.0b013e3182417d36; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Zhang HY, 2006, ENDOCRINE, V30, P299, DOI 10.1007/s12020-006-0008-1	83	8	8	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4439	4447		10.1038/onc.2014.379	http://dx.doi.org/10.1038/onc.2014.379			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25435371				2022-12-17	WOS:000360189200003
J	Yang, HW; Kim, TM; Song, SS; Menon, L; Jiang, X; Huang, W; Black, PM; Park, PJ; Carroll, RS; Johnson, MD				Yang, H. W.; Kim, T-M; Song, S. S.; Menon, L.; Jiang, X.; Huang, W.; Black, P. M.; Park, P. J.; Carroll, R. S.; Johnson, M. D.			A small subunit processome protein promotes cancer by altering translation	ONCOGENE			English	Article							INTERNAL RIBOSOME ENTRY; MESSENGER-RNA; CHILDHOOD MEDULLOBLASTOMA; C-MYC; NEUROBLASTOMA; REVEALS; PROGRESSION; INHIBITION; BIOGENESIS; DEFECTS	Dysregulation of ribosome biogenesis or translation can promote cancer, but the underlying mechanisms remain unclear. UTP18 is a component of the small subunit processome, a nucleolar multi-protein complex whose only known function is to cleave pre-ribosomal RNA to yield the 18S ribosomal RNA component of 40S ribosomal subunits. Here, we show that UTP18 also alters translation to promote stress resistance and growth, and that UTP18 is frequently gained and overexpressed in cancer. We observed that UTP18 localizes to the cytoplasm in a subset of cells, and that serum withdrawal increases cytoplasmic UTP18 localization. Cytoplasmic UTP18 associates with the translation complex and Hsp90 to upregulate the translation of IRES-containing transcripts such as HIF1a, Myc and VEGF, thereby inducing stress resistance. Hsp90 inhibition decreases cytoplasmic UTP18 and UTP18-induced increases in translation. Importantly, elevated UTP18 expression correlates with increased aggressiveness and decreased survival in numerous cancers. Enforced UTP18 overexpression promotes transformation and tumorigenesis, whereas UTP18 knockdown inhibits these processes. This stress adaptation mechanism is thus co-opted for growth by cancers, and its inhibition may represent a promising new therapeutic target.	[Yang, H. W.; Song, S. S.; Menon, L.; Jiang, X.; Huang, W.; Black, P. M.; Carroll, R. S.; Johnson, M. D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; [Kim, T-M; Park, P. J.] Harvard Univ, Ctr Biomed Informat, Sch Med, Boston, MA 02115 USA; [Johnson, M. D.] Dana Farber Brigham & Womens Canc Ctr, Program Neurooncol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Johnson, MD (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.	mjohnson27@partners.org			Brain Science Foundation; Santos Family Foundation; National Institute of Neurological Disorders and Stroke [R01 NS062219]; NIH [DP2 OD002319]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062219] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002319] Funding Source: NIH RePORTER	Brain Science Foundation; Santos Family Foundation; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a Brain Science Foundation Research Award, the Santos Family Foundation, a Hagerty Fund Research Award, R01 NS062219 from the National Institute of Neurological Disorders and Stroke and an NIH Director's New Innovator Award (DP2 OD002319) to MDJ.	Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147; Bernstein KA, 2004, EUKARYOT CELL, V3, P1619, DOI 10.1128/EC.3.6.1619-1626.2004; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; Calabrese C, 2003, J BIOL CHEM, V278, P24951, DOI 10.1074/jbc.M211600200; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; De Preter K, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-9-r84; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Del Prete MJ, 2007, RNA, V13, P414, DOI 10.1261/rna.79407; Fichelson P, 2009, NAT CELL BIOL, V11, P685, DOI 10.1038/ncb1874; Goda N, 2012, INT J HEMATOL, V95, P457, DOI 10.1007/s12185-012-1069-y; Goutagny S, 2010, CLIN CANCER RES, V16, P4155, DOI 10.1158/1078-0432.CCR-10-0891; Holzel M, 2010, J BIOL CHEM, V285, P6364, DOI 10.1074/jbc.M109.054734; Jackson SE, 2013, TOP CURR CHEM, V328, P155, DOI 10.1007/128_2012_356; Kang J, 2006, ANTICANCER RES, V26, P1903; Kim H, 2010, P NATL ACAD SCI USA, V107, P2183, DOI 10.1073/pnas.0909896107; Kim TM, 2013, GENOME RES, V23, P217, DOI 10.1101/gr.140301.112; Kim TM, 2011, CANCER RES, V71, P3387, DOI 10.1158/0008-5472.CAN-10-4117; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Pan E, 2005, CLIN CANCER RES, V11, P4733; Pisa V, 2009, GENE, V432, P67, DOI 10.1016/j.gene.2008.11.025; Reardon DA, 1997, CANCER RES, V57, P4042; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Schleiermacher G, 2007, BRIT J CANCER, V97, P238, DOI 10.1038/sj.bjc.6603820; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Spriggs KA, 2008, BIOL CELL, V100, P27, DOI 10.1042/BC20070098; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Suzuki Y, 2009, J BIOL CHEM, V284, P35597, DOI 10.1074/jbc.M109.036285; Ujino S, 2012, VIRUS RES, V163, P390, DOI 10.1016/j.virusres.2011.10.003; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Willimott S, 2010, BIOCHEM SOC T, V38, P1571, DOI 10.1042/BST0381571	35	8	8	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4471	4481		10.1038/onc.2014.376	http://dx.doi.org/10.1038/onc.2014.376			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25435373				2022-12-17	WOS:000360189200006
J	Sriram, G; Jankowski, W; Kasikara, C; Reichman, C; Saleh, T; Nguyen, KQ; Li, J; Hornbeck, P; Machida, K; Liu, T; Li, H; Kalodimos, CG; Birge, RB				Sriram, G.; Jankowski, W.; Kasikara, C.; Reichman, C.; Saleh, T.; Nguyen, K-Q; Li, J.; Hornbeck, P.; Machida, K.; Liu, T.; Li, H.; Kalodimos, C. G.; Birge, R. B.			Iterative tyrosine phosphorylation controls non-canonical domain utilization in Crk	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; MEDIATED CELL-ADHESION; SH3 DOMAIN; APOPTOTIC CELLS; ADAPTER PROTEIN; C-ABL; SIGNALING PROTEIN; STRUCTURAL BASIS; FACTOR RECEPTOR; FACTOR C3G	Crk, the prototypical member of a class of Src homology-2 (SH2) and Src homology-3 (SH3) domain containing proteins that controls the coordinated assembly of signaling complexes, is regulated by phosphorylation of Y221 in the linker region, which forms an intramolecular SH2-pY221 auto-clamp to interrupt SH2-N-terminal SH3 domain (SH3N) signaling. Here, we show using LC-MS/MS and by generating phospho-specific antibodies that, iteratively with Y221, the Crk C-terminal SH3 domain (SH3C) is routinely phosphorylated on Y239 and/or Y251 by several extracellular stimuli known to engage Crk. Although phosphorylation at Y221 auto-inhibits the Crk SH2, phosphorylation of the SH3C generates an unconventional phosphoSH3C-SH3N unit in which the SH3N is fully functional to bind polyproline type II ligands and the phosphoSH3C binds de novo to other SH2 domains. Using high-throughput SH2 domain profiling, artificial neural network and position-specific scoring matrix-based bioinformatics approaches, and unbiased mass spectometry, we found that the phosphoSH3C binds several SH2 domain containing proteins, including specific non-receptor tyrosine kinases-Abl via pY251 and C-terminal Src kinase via pY239. Functionally, we show that the phosphoSH3C modulates the Abl-mediated phenotypes of cell spreading and motility. Together, these studies describe a versatile mechanism wherein phosphorylation of Crk at Y221 is not an off switch but redirects signaling from the SH2-SH3N axis to a phosphoSH3C-SH3N axis, with the SH3N as a common denominator.	[Sriram, G.; Kasikara, C.; Reichman, C.; Nguyen, K-Q; Birge, R. B.] Rutgers Biomed & Hlth Sci, Dept Biochem & Mol Biol, Newark, NJ USA; [Jankowski, W.; Saleh, T.; Kalodimos, C. G.] Rutgers State Univ, Dept Chem & Chem Biol, Piscataway, NJ USA; [Li, J.; Hornbeck, P.] Cell Signaling Technol, Danvers, MA USA; [Machida, K.] Univ Connecticut Hlth Ctr, Dept Genet & Dev Biol, Raymond & Beverly Sackler Lab Genet & Mol Med, Farmington, CT USA; [Liu, T.; Li, H.] Rutgers Biomed & Hlth Sci, Ctr Adv Prote Res, Newark, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; University of Connecticut; Rutgers State University New Brunswick; Rutgers State University Medical Center	Birge, RB (corresponding author), Rutgers Biomed & Hlth Sci Canc Ctr H121, Dept Biochem & Mol Biol, 205 South Orange Ave, Newark, NJ 07103 USA.	birgera@njms.rutgers.edu	Kalodimos, Charalampos/Q-9846-2018; Hornbeck, Peter V/K-2226-2017; Saleh, Tamjeed/M-8698-2016	Kalodimos, Charalampos/0000-0001-6354-2796; Hornbeck, Peter V/0000-0002-1126-5149; Li, Hong/0000-0001-5731-5335; Saleh, Tamjeed/0000-0002-7539-7300	NIH [CA165077, GM080308, NS046593]; Rutgers Foundation; NATIONAL CANCER INSTITUTE [R01CA165077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM080308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS046593] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rutgers Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the NIH grant CA165077 to RBB and Rutgers Foundation grant to RBB and in part by NIH grant to CGK and RBB GM080308. The LC-MS/MS work was funded in part by an NIH grant NS046593, for the support of the Rutgers Neuroproteomics Core Facility. We thank Chingiz Underbayev, WenI Tsou and Anita Antes for technical support; Sushil Kumar and Stanley Kimani for discussion.	Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Antoku S, 2008, J CELL SCI, V121, P3071, DOI 10.1242/jcs.031575; Antoku S, 2009, J CELL SCI, V122, P4228, DOI 10.1242/jcs.054627; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Chen S, 2008, J MOL BIOL, V383, P414, DOI 10.1016/j.jmb.2008.08.040; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; HEDGECOCK EM, 1983, SCIENCE, V220, P1277, DOI 10.1126/science.6857247; Huang HM, 2008, MOL CELL PROTEOMICS, V7, P768, DOI 10.1074/mcp.M700312-MCP200; Jankowski W, 2012, NAT CHEM BIOL, V8, P590, DOI [10.1038/NCHEMBIO.954, 10.1038/nchembio.954]; Janostiak R, 2011, MOL BIOL CELL, V22, P4256, DOI 10.1091/mbc.E11-03-0207; Jin H, 2007, MOL BIOL CELL, V18, P4143, DOI 10.1091/mbc.E07-01-0085; Kardinal C, 1999, ANN NY ACAD SCI, V886, P289, DOI 10.1111/j.1749-6632.1999.tb09439.x; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kobashigawa Y, 2007, J BIOTECHNOL, V131, P458, DOI 10.1016/j.jbiotec.2007.07.956; Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lamorte L, 2002, J BIOL CHEM, V277, P37904, DOI 10.1074/jbc.M201743200; Li L, 2008, NUCLEIC ACIDS RES, V36, P3263, DOI 10.1093/nar/gkn161; Machida K, 2007, MOL CELL, V26, P899, DOI 10.1016/j.molcel.2007.05.031; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Morrogh LM, 1999, EUR J IMMUNOL, V29, P2269; Muralidharan V, 2006, BIOCHEMISTRY-US, V45, P8874, DOI 10.1021/bi060590z; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Reichman C, 2005, ONCOGENE, V24, P8187, DOI 10.1038/sj.onc.1208988; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; Sarkar P, 2007, MOL CELL, V25, P413, DOI 10.1016/j.molcel.2007.01.004; Sarkar P, 2011, NAT CHEM BIOL, V7, P51, DOI 10.1038/NCHEMBIO.494; Seeliger MA, 2005, PROTEIN SCI, V14, P3135, DOI 10.1110/ps.051750905; Tinti M, 2013, CELL REP, V3, P1293, DOI 10.1016/j.celrep.2013.03.001; Tosello-Trampont AC, 2001, J BIOL CHEM, V276, P13797, DOI 10.1074/jbc.M011238200; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632	42	8	8	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4260	4269		10.1038/onc.2014.361	http://dx.doi.org/10.1038/onc.2014.361			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25381819	Green Accepted			2022-12-17	WOS:000359199800012
J	Agarwal, A; MacKenzie, RJ; Eide, CA; Davare, MA; Watanabe-Smith, K; Tognon, CE; Mongoue-Tchokote, S; Park, B; Braziel, RM; Tyner, JW; Druker, BJ				Agarwal, A.; MacKenzie, R. J.; Eide, C. A.; Davare, M. A.; Watanabe-Smith, K.; Tognon, C. E.; Mongoue-Tchokote, S.; Park, B.; Braziel, R. M.; Tyner, J. W.; Druker, B. J.			Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE MEGAKARYOBLASTIC LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; JAK3 MUTATIONS; DOWN-SYNDROME; SOMATIC MUTATIONS; JAK/STAT PATHWAY; FERM DOMAIN; STEM-CELLS; EXPRESSION	To understand the role of cytokine and growth factor receptor-mediated signaling in leukemia pathogenesis, we designed a functional RNA interference (RNAi) screen targeting 188 cytokine and growth factor receptors that we found highly expressed in primary leukemia specimens. Using this screen, we identified interleukin-2 gamma receptor (IL2R gamma) as a critical growth determinant for a JAK3A572V mutation-positive acute myeloid leukemia cell line. We observed that knockdown of IL2R. abrogates phosphorylation of JAK3 and downstream signaling molecules, JAK1, STAT5, MAPK and pS6 ribosomal protein. Overexpression of IL2R gamma in murine cells increased the transforming potential of activating JAK3 mutations, whereas absence of IL2R. completely abrogated the clonogenic potential of JAK3A572V, as well as the transforming potential of additional JAK3-activating mutations such as JAK3M511I. In addition, mutation at the IL2R gamma interaction site in the FERM domain of JAK3 (Y100C) completely abrogated JAK3mediated leukemic transformation. Mechanistically, we found IL2R gamma contributes to constitutive JAK3 mutant signaling by increasing JAK3 expression and phosphorylation. Conversely, we found that mutant, but not wild-type JAK3, increased the expression of IL2R gamma, indicating IL2R gamma and JAK3 contribute to constitutive JAK/STAT signaling through their reciprocal regulation. Overall, we demonstrate a novel role for IL2R gamma in potentiating oncogenesis in the setting of JAK3-mutation-positive leukemia. In addition, our study highlights an RNAi-based functional assay that can be used to facilitate the identification of non-kinase cytokine and growth factor receptor targets for inhibiting leukemic cell growth.	[Agarwal, A.; MacKenzie, R. J.; Eide, C. A.; Watanabe-Smith, K.; Druker, B. J.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA; [Agarwal, A.; MacKenzie, R. J.; Eide, C. A.; Watanabe-Smith, K.; Tognon, C. E.; Mongoue-Tchokote, S.; Park, B.; Tyner, J. W.; Druker, B. J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA; [Eide, C. A.; Tognon, C. E.; Druker, B. J.] Howard Hughes Med Inst, Portland, OR USA; [Davare, M. A.] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA; [Mongoue-Tchokote, S.; Park, B.] Oregon Hlth & Sci Univ, Biostat Shared Resource, Portland, OR 97239 USA; [Braziel, R. M.] Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97239 USA; [Tyner, J. W.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Agarwal, A (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd,Mailcode L592-BRB553, Portland, OR 97239 USA.	agarwala@ohsu.edu		Davare, Monika/0000-0003-1802-7597; Druker, Brian/0000-0001-8331-8206; Eide, Christopher/0000-0001-8835-8928; Watanabe-Smith, Kevin/0000-0003-4231-8562	National Cancer Institute [5 K99 CA151670-02, 5R00CA151457-04, 1R01CA183947-01]; Collins Foundation; Knight Pilot Project and Friends of Doernbecher grants; V-Foundation; Gabrielle's Angel Foundation; Leukemia & Lymphoma Society; NATIONAL CANCER INSTITUTE [K99CA151670, R00CA151670, R00CA151457, P30CA069533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM071338] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Collins Foundation; Knight Pilot Project and Friends of Doernbecher grants; V-Foundation; Gabrielle's Angel Foundation; Leukemia & Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Sarah Bowden for administrative support. AA is supported by a National Cancer Institute Career Development Award (5 K99 CA151670-02), Collins Foundation, Knight Pilot Project and Friends of Doernbecher grants. JWT is supported by grants from the V-Foundation, Gabrielle's Angel Foundation and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01). BJD is a Howard Hughes Medical Institute investigator. This work is also supported by The Leukemia & Lymphoma Society. We thank Dr. Jamie Keck (Dr. Brian Druker's Laboratory, OHSU) for providing her technical assistance in creating Gateway compatible pMXs-IRES-Puromycin vector.	Bains T, 2012, LEUKEMIA, V26, P2144, DOI 10.1038/leu.2012.74; Baird AM, 1998, J LEUKOCYTE BIOL, V63, P669, DOI 10.1002/jlb.63.6.669; Bellanger D, 2014, LEUKEMIA, V28, P417, DOI 10.1038/leu.2013.271; Blink M, 2011, LEUKEMIA, V25, P1365, DOI 10.1038/leu.2011.86; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Candotti F, 1996, J EXP MED, V183, P2687, DOI 10.1084/jem.183.6.2687; Constantinescu SN, 2008, TRENDS BIOCHEM SCI, V33, P122, DOI 10.1016/j.tibs.2007.12.002; Cornejo MG, 2009, INT J BIOCHEM CELL B, V41, P2376, DOI 10.1016/j.biocel.2009.09.004; De Vita S, 2007, BRIT J HAEMATOL, V137, P337, DOI 10.1111/j.1365-2141.2007.06574.x; Ferretti E, 2012, J LEUKOCYTE BIOL, V92, P567, DOI 10.1189/jlb.0112036; Funakoshi-Tago M, 2008, MOL CELL BIOL, V28, P1792, DOI 10.1128/MCB.01447-07; Graf M, 2004, EUR J HAEMATOL, V72, P89, DOI 10.1046/j.0902-4441.2003.00184.x; Hercus TR, 2013, CYTOKINE GROWTH F R, V24, P189, DOI 10.1016/j.cytogfr.2013.03.002; Hofmann SR, 2004, MOL CELL BIOL, V24, P5039, DOI 10.1128/MCB.24.11.5039-5049.2004; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Ju W, 2011, BLOOD, V117, P1938, DOI 10.1182/blood-2010-09-305425; Kiss C, 2004, PEDIATR BLOOD CANCER, V42, P113, DOI 10.1002/pbc.10436; Kiyoi H, 2007, LEUKEMIA, V21, P574, DOI 10.1038/sj.leu.2404527; Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Murphy JM, 2006, VITAM HORM, V74, P1, DOI 10.1016/S0083-6729(06)74001-8; O'Shea JJ, 2004, NAT REV DRUG DISCOV, V3, P555, DOI 10.1038/nrd1441; O'Shea JJ, 2005, CURR OPIN RHEUMATOL, V17, P305, DOI 10.1097/01.bor.0000160781.07174.db; Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270; Rubin JB, 2009, SEMIN CANCER BIOL, V19, P116, DOI 10.1016/j.semcancer.2008.10.001; Russell LJ, 2009, BLOOD, V114, P2688, DOI 10.1182/blood-2009-03-208397; Sakaguchi H, 2013, NAT GENET, V45, P937, DOI 10.1038/ng.2698; Sato T, 2008, BRIT J HAEMATOL, V141, P681, DOI 10.1111/j.1365-2141.2008.07081.x; Spivak JL, 2012, AM SOC HEMATOL BLOOD, V120, P427; Tang W, 2001, BIOCHEM BIOPH RES CO, V283, P598, DOI 10.1006/bbrc.2001.4824; Tefferi A, 2010, LEUKEMIA, V24, P1128, DOI 10.1038/leu.2010.69; Tefferi A, 2008, LEUKEMIA LYMPHOMA, V49, P388, DOI 10.1080/10428190801895360; Tyner JW, 2008, BLOOD, V111, P2238, DOI 10.1182/blood-2007-06-097253; Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347; Van Etten RA, 2007, ONCOGENE, V26, P6738, DOI 10.1038/sj.onc.1210758; Vijayakrishnan L, 2011, TRENDS PHARMACOL SCI, V32, P25, DOI 10.1016/j.tips.2010.10.004; Walters DK, 2006, CANCER CELL, V10, P65, DOI 10.1016/j.ccr.2006.06.002; Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186	40	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 4	2015	34	23					2991	2999		10.1038/onc.2014.243	http://dx.doi.org/10.1038/onc.2014.243			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3EX	25109334	Green Accepted			2022-12-17	WOS:000356100500005
J	Orticello, M; Fiore, M; Totta, P; Desideri, M; Barisic, M; Passeri, D; Lenzi, J; Rosa, A; Orlandi, A; Maiato, H; Del Bufalo, D; Degrassi, F				Orticello, M.; Fiore, M.; Totta, P.; Desideri, M.; Barisic, M.; Passeri, D.; Lenzi, J.; Rosa, A.; Orlandi, A.; Maiato, H.; Del Bufalo, D.; Degrassi, F.			N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochore-microtubule dynamics	ONCOGENE			English	Article							CANCER-CELLS; CHROMOSOME SEGREGATION; MITOTIC PROGRESSION; GENE DELIVERY; IN-VIVO; CHECKPOINT; PROTEIN; EXPRESSION; INSTABILITY; ATTACHMENT	Mitotic proteins are attractive targets to develop molecular cancer therapeutics due to the intimate interdependence between cell proliferation and mitosis. In this work, we have explored the therapeutic potential of the kinetochore (KT) protein Hec1 (Highly Expressed in Cancer protein 1) as a molecular target to produce massive chromosome missegregation and cell death in cancer cells. Hec1 is a constituent of the Ndc80 complex, which mediates KT-microtubule (MT) attachments at mitosis and is upregulated in various cancer types. We expressed Hec1 fused with enhanced green fluorescent protein (EGFP) at its N-terminus MT-interaction domain in HeLa cells and showed that expression of this modified Hec1, which localized at KTs, blocked cell proliferation and promoted apoptosis in tumour cells. EGFP-Hec1 was extremely potent in tumour cell killing and more efficient than siRNA-induced Hec1 depletion. In striking contrast, normal cells showed no apparent cell proliferation defects or cell death following EGFP-Hec1 expression. Live-cell imaging demonstrated that cancer cell death was associated with massive chromosome missegregation within multipolar spindles after a prolonged mitotic arrest. Moreover, EGFP-Hec1 expression was found to increase KT-MT attachment stability, providing a molecular explanation for the abnormal spindle architecture and the cytotoxic activity of this modified protein. Consistent with cell culture data, EGFP-Hec1 expression was found to strongly inhibit tumour growth in a mouse xenograft model by disrupting mitosis and inducing multipolar spindles. Taken together, these findings demonstrate that stimulation of massive chromosome segregation defects can be used as an anti-cancer strategy through the activation of mitotic catastrophe after a multipolar mitosis. Importantly, this study represents a clear proof of concept that targeting KT proteins required for proper KT-MT attachment dynamics constitutes a powerful approach in cancer therapy.	[Orticello, M.; Fiore, M.; Totta, P.; Degrassi, F.] CNR, Inst Biol Mol Med & Nanobiotechnol, Rome, Italy; [Desideri, M.; Del Bufalo, D.] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy; [Barisic, M.; Maiato, H.] Univ Porto, Inst Biol Mol & Celular, Chromosome Instabil & Dynam Lab, P-4100 Oporto, Portugal; [Passeri, D.; Orlandi, A.] Univ Roma Tor Vergata, Anat Pathol Inst, Rome, Italy; [Lenzi, J.; Rosa, A.] Univ Roma La Sapienza, Dept Biol & Biotechnol Charles Darwin, I-00185 Rome, Italy; [Maiato, H.] Univ Porto, Fac Med, Dept Expt Biol, Cell Div Unit, P-4100 Oporto, Portugal	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universidade do Porto; University of Rome Tor Vergata; Sapienza University Rome; Universidade do Porto	Degrassi, F (corresponding author), CNR, Inst Biol Mol Med & Nanobiotechnol, Rome, Italy.	francesca.degrassi@uniroma1.it	Alessandro, Rosa/A-3860-2012; Del Bufalo, Donatella/AAC-1594-2021; Del Bufalo, Donatella/K-8673-2016; desideri, marianna/K-5771-2016; Totta, Pierangela/I-3251-2018; Orlandi, Augusto/AHE-8753-2022; Barisic, Marin/K-2301-2013; Maiato, Helder/J-9466-2013	Alessandro, Rosa/0000-0001-9999-7223; Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; desideri, marianna/0000-0002-4311-9656; Totta, Pierangela/0000-0001-7826-4733; Barisic, Marin/0000-0001-7587-3867; Maiato, Helder/0000-0002-6200-9997; orlandi, augusto/0000-0001-7202-5854	Italian Association for Cancer Research [IG 14100]; COMPETE [FCOMP-01-0124-FEDER-015941 (PTDC/SAU-ONC/112917/2009)]; Fundacao para a Ciencia e a Tecnologia of Portugal, Human Frontier Science Program; European Research Council	Italian Association for Cancer Research(Fondazione AIRC per la ricerca sul cancro); COMPETE; Fundacao para a Ciencia e a Tecnologia of Portugal, Human Frontier Science Program; European Research Council(European Research Council (ERC)European Commission)	Live-cell imaging experiments were performed at the Nikon Reference Centre, CNR Institute of Biology, Molecular Medicine and Nanobiotechnology. We thank Giulia Guarguaglini and Patrizia Lavia for advice and support with live cell analysis. We also thank Giulia Vargiu for her contribution in the initial phases of the work, Enrico Cundari for helpful comments and suggestions, Antonio Pereira for expert advice and software update in the statistical analysis of MT dynamics data and Stephan Geley for mEOS-tubulin vector. This work was partially supported by a grant from the Italian Association for Cancer Research to DDB (IG 14100). Work in HM's laboratory is funded by FCOMP-01-0124-FEDER-015941 (PTDC/SAU-ONC/112917/2009) through COMPETE and Fundacao para a Ciencia e a Tecnologia of Portugal, the Human Frontier Science Program and PRECISE grant from the European Research Council.	Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Bieche I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-23; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Ciferri C, 2008, CELL, V133, P427, DOI 10.1016/j.cell.2008.03.020; Cimini D, 2006, CURR BIOL, V16, P1711, DOI 10.1016/j.cub.2006.07.022; Daum JR, 2011, CURR BIOL, V21, P1018, DOI 10.1016/j.cub.2011.05.032; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; Degenhardt Y, 2010, CLIN CANCER RES, V16, P384, DOI 10.1158/1078-0432.CCR-09-1380; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; DeLuca JG, 2012, CURR OPIN CELL BIOL, V24, P48, DOI 10.1016/j.ceb.2011.11.003; DeLuca JG, 2003, CURR BIOL, V13, P2103, DOI 10.1016/j.cub.2003.10.056; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Duijf PHG, 2013, ONCOGENE, V32, P4727, DOI 10.1038/onc.2012.616; Ferretti C, 2010, CELL CYCLE, V9, P4174, DOI 10.4161/cc.9.20.13457; Frecha C, 2008, CURR GENE THER, V8, P449, DOI 10.2174/156652308786848003; Galimberti F, 2010, CLIN CANCER RES, V16, P109, DOI 10.1158/1078-0432.CCR-09-2151; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Guimaraes GJ, 2008, CURR BIOL, V18, P1778, DOI 10.1016/j.cub.2008.08.012; Gurzov EN, 2006, GENE THER, V13, P1, DOI 10.1038/sj.gt.3302595; Hayama S, 2006, CANCER RES, V66, P10339, DOI 10.1158/0008-5472.CAN-06-2137; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Janssen A, 2013, ONCOGENE, V32, P4459, DOI 10.1038/onc.2012.576; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Kabeche L, 2013, NATURE, V502, P110, DOI 10.1038/nature12507; Kaneko N, 2009, BIOCHEM BIOPH RES CO, V390, P1235, DOI 10.1016/j.bbrc.2009.10.127; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lacoste A, 2009, CELL STEM CELL, V5, P332, DOI 10.1016/j.stem.2009.07.011; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Li L, 2007, GENE THER, V14, P814, DOI 10.1038/sj.gt.3302933; Logarinho E, 2012, NAT CELL BIOL, V14, P295, DOI 10.1038/ncb2423; Maiato H, 2014, NAT CELL BIOL, V16, P386, DOI 10.1038/ncb2958; Manning AL, 2007, CURR BIOL, V17, P260, DOI 10.1016/j.cub.2006.11.071; Manning AL, 2010, EMBO J, V29, P3531, DOI 10.1038/emboj.2010.230; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Mattiuzzo M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016307; McKinney SA, 2009, NAT METHODS, V6, P131, DOI [10.1038/nmeth.1296, 10.1038/NMETH.1296]; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Miller SA, 2008, CURR BIOL, V18, P1785, DOI 10.1016/j.cub.2008.11.007; Morlando M, 2012, EMBO J, V31, P4502, DOI 10.1038/emboj.2012.319; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; Orlandi A, 2006, MODERN PATHOL, V19, P797, DOI 10.1038/modpathol.3800586; Rosa A, 2011, EMBO J, V30, P237, DOI 10.1038/emboj.2010.319; Schafer J, 2010, BIOMATERIALS, V31, P6892, DOI 10.1016/j.biomaterials.2010.05.043; Senzer N, 2013, MOL THER, V21, P1096, DOI 10.1038/mt.2013.32; Sethi G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047086; Singh J, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-7; Stevens D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022969; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wandke C, 2012, J CELL BIOL, V198, P847, DOI 10.1083/jcb.201110060; Wang YQ, 2012, INT J NANOMED, V7, P693, DOI 10.2147/IJN.S27849; Welburn JPI, 2010, MOL CELL, V38, P383, DOI 10.1016/j.molcel.2010.02.034; Zasadil LM, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007965; ZHAI Y, 1995, J CELL BIOL, V131, P721, DOI 10.1083/jcb.131.3.721; Zhou Q, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22566	57	8	8	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3325	3335		10.1038/onc.2014.265	http://dx.doi.org/10.1038/onc.2014.265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132262				2022-12-17	WOS:000356592300011
J	Cunnick, JM; Kim, S; Hadsell, J; Collins, S; Cerra, C; Reiser, P; Flynn, DC; Cho, Y				Cunnick, J. M.; Kim, S.; Hadsell, J.; Collins, S.; Cerra, C.; Reiser, P.; Flynn, D. C.; Cho, Y.			Actin filament-associated protein 1 is required for cSrc activity and secretory activation in the lactating mammary gland	ONCOGENE			English	Article							SRC FAMILY KINASES; C-SRC; PROLACTIN RECEPTOR; AFAP-110; CANCER; PHOSPHORYLATION; EXPRESSION; INTEGRITY; ABILITY; IDENTIFICATION	Actin filament-associated protein 1 (AFAP1) is an adaptor protein of cSrc that binds to filamentous actin and regulates the activity of this tyrosine kinase to affect changes to the organization of the actin cytoskeleton. In breast and prostate cancer cells, AFAP1 has been shown to regulate cellular responses requiring actin cytoskeletal changes such as adhesion, invadopodia formation and invasion. However, a normal physiologic role for AFAP1 has remained elusive. In this study, we generated an AFAP1 knockout mouse model that establishes a novel physiologic role for AFAP1 in lactation. Specifically, these animals displayed a defect in lactation that resulted in an inability to nurse efficiently. Histologically, the mammary glands of the lactating knockout mice were distinguished by the accumulation of large cytoplasmic lipid droplets in the alveolar epithelial cells. There was a reduction in lipid synthesis and the expression of lipogenic genes without a corresponding reduction in the production of beta-casein, a milk protein. Furthermore, these defects were associated with histologic and biochemical signs of precocious involution. This study also demonstrated that AFAP1 responds to prolactin, a lactogenic hormone, by forming a complex with cSrc and becoming tyrosine phosphorylated. Taken together, these observations pointed to a defect in secretory activation. Certain characteristics of this phenotype mirrored the defect in secretory activation in the cSrc knockout mouse, but most importantly, the activity of cSrc in the mammary gland was reduced during early lactation in the AFAP1-null mouse and the localization of active cSrc at the apical surface of luminal epithelial cells during lactation was selectively lost in the absence of AFAP1. These data define, for the first time, the requirement of AFAP1 for the spatial and temporal regulation of cSrc activity in the normal breast, specifically for milk production.	[Cunnick, J. M.; Cho, Y.] Commonwealth Med Coll, Dept Basic Sci, Scranton, PA 18509 USA; [Kim, S.] Commonwealth Med Coll, Grad Sch Med, Scranton, PA 18509 USA; [Hadsell, J.] Fortis Inst Scranton, Scranton, PA USA; [Cerra, C.; Reiser, P.] Pocono Hlth Syst, Dept Pathol, East Stroudsburg, PA USA; [Flynn, D. C.] Univ Delaware, Coll Hlth Sci, Newark, DE USA	Geisinger Commonwealth School of Medicine; Geisinger Commonwealth School of Medicine; University of Delaware	Cho, Y (corresponding author), Commonwealth Med Coll, Dept Basic Sci, 525 Pine St, Scranton, PA 18509 USA.	ycho@tcmedc.org	Cunnick, Jess/F-1715-2018	Collins, Stephen/0000-0003-4515-5412	NIH [R01CA060731-15A1]; NATIONAL CANCER INSTITUTE [R01CA060731] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by NIH Grant R01CA060731-15A1. We thank Victor Malloy for his care of the mice and Wafa Atamna for cell sorting. We also thank Raj Kumar and John Arnott for the careful reading of our manuscript.	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Aksamitiene E, 2011, CELL SIGNAL, V23, P1794, DOI 10.1016/j.cellsig.2011.06.014; AMATO PA, 1981, CELL MOTIL CYTOSKEL, V1, P329, DOI 10.1002/cm.970010305; Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653; Baisden JM, 2001, ONCOGENE, V20, P6607, DOI 10.1038/sj.onc.1204802; Baisden JM, 2001, ONCOGENE, V20, P6435, DOI 10.1038/sj.onc.1204784; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Bourguignon LYW, 2011, CYTOSKELETON, V68, P671, DOI 10.1002/cm.20544; Clump DA, 2010, TRANSL ONCOL, V3, P276, DOI 10.1593/tlo.10106; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dimri M, 2007, CANCER RES, V67, P4164, DOI 10.1158/0008-5472.CAN-06-2580; Dorfleutner A, 2008, J CELL SCI, V121, P2394, DOI 10.1242/jcs.026187; Dorfleutner A, 2007, J CELL PHYSIOL, V213, P740, DOI 10.1002/jcp.21143; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FRANKE WW, 1981, J CELL BIOL, V89, P485, DOI 10.1083/jcb.89.3.485; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; Guappone AC, 1998, MOL CARCINOGEN, V22, P110, DOI 10.1002/(SICI)1098-2744(199806)22:2<110::AID-MC6>3.0.CO;2-Q; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Hughes K, 2012, J PATHOL, V227, P106, DOI 10.1002/path.3961; Kabotyanski EB, 2003, J BIOL CHEM, V278, P17218, DOI 10.1074/jbc.M301578200; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390; Liu Y, 2002, ARTERIOSCL THROM VAS, V22, P76, DOI 10.1161/hq0102.101822; Garcia-Martinez JM, 2010, CELL SIGNAL, V22, P415, DOI 10.1016/j.cellsig.2009.10.013; Marcotte R, 2012, P NATL ACAD SCI USA, V109, P2808, DOI 10.1073/pnas.1018861108; McManaman JL, 2004, ADV EXP MED BIOL, V554, P263; Mirmohammadsadegh A, 2006, J INVEST DERMATOL, V126, P2272, DOI 10.1038/sj.jid.5700385; Naylor MJ, 2005, MOL ENDOCRINOL, V19, P1868, DOI 10.1210/me.2004-0254; Naylor MJ, 2005, J CELL BIOL, V171, P717, DOI 10.1083/jcb.200503144; Ogg SL, 2004, P NATL ACAD SCI USA, V101, P10084, DOI 10.1073/pnas.0402930101; Palmer CA, 2006, J MAMMARY GLAND BIOL, V11, P269, DOI 10.1007/s10911-006-9023-3; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Piazza TM, 2009, MOL ENDOCRINOL, V23, P202, DOI 10.1210/me.2008-0341; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Qian Y, 2002, MOL BIOL CELL, V13, P2311, DOI 10.1091/mbc.E01-12-0148; Reynolds AB, 2014, ONCOGENE, V33, P4537, DOI 10.1038/onc.2013.416; Richert MM, 2000, J MAMMARY GLAND BIOL, V5, P227, DOI 10.1023/A:1026499523505; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sandilands E, 2007, J CELL SCI, V120, P2555, DOI 10.1242/jcs.003657; Scott KEN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029761; Shackleford TJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2902; Shimizu A, 2005, BIOL REPROD, V73, P1219, DOI 10.1095/biolreprod.105.041616; Snyder BN, 2011, EUR J CELL BIOL, V90, P376, DOI 10.1016/j.ejcb.2010.11.016; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Vara JAF, 2000, BIOCHEM J, V345, P17, DOI 10.1042/0264-6021:3450017; Vorbach C, 2002, GENE DEV, V16, P3223, DOI 10.1101/gad.1032702; Watkin H, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-6; Watson CJ, 2011, INT J DEV BIOL, V55, P757, DOI 10.1387/ijdb.113414cw; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710	53	8	8	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2640	2649		10.1038/onc.2014.205	http://dx.doi.org/10.1038/onc.2014.205			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043309	Green Accepted			2022-12-17	WOS:000354541300010
J	Miyagawa, S; Sato, M; Sudo, T; Yamada, G; Iguchi, T				Miyagawa, S.; Sato, M.; Sudo, T.; Yamada, G.; Iguchi, T.			Unique roles of estrogen-dependent Pten control in epithelial cell homeostasis of mouse vagina	ONCOGENE			English	Article							GROWTH-FACTOR-I; NF-KAPPA-B; RECEPTOR-ALPHA; ENDOMETRIAL CANCER; UTERINE EPITHELIUM; SIGNALING PATHWAYS; MTOR INHIBITION; PTEN(+/-) MICE; ACTIVATION; DIETHYLSTILBESTROL	Numerous studies support a role of phosphatase and tensin homolog deleted from chromosome 10 (Pten) as a tumor suppressor gene that controls epithelial cell homeostasis to prevent tumor formation. Mouse vaginal epithelium cyclically exhibits cell proliferation and differentiation in response to estrogen and provides a unique model for analyzing homeostasis of stratified squamous epithelia. We analyzed vaginal epithelium-specific Pten conditional knockout (CKO) mice to provide new insights into Pten/phosphoinositide-3-kinase (PI3K)/Akt function. The vaginal epithelium of ovariectomized (OVX) mice ( control) was composed of 1-2 layers of cuboidal cells, whereas OVX CKO mice exhibited epithelial hyperplasia in the suprabasal cells with increased cell mass and mucin production. This is possibly due to misactivation of mammalian target of rapamycin and mitogen-activated protein kinase. Intriguingly, estrogen administration to OVX Pten CKO mice induced stratification and keratinized differentiation in the vaginal epithelium, as in estrogen-treated controls. We found that Pten is exclusively expressed in the suprabasal cells in the absence of estrogens, whereas estrogen administration induced Pten expression in the basal cells. This suggests that Pten acts to prevent excessive cell proliferation as in the case of other squamous tissues. Thus, Pten exhibits a dual role on the control of vaginal homeostasis, depending on whether estrogens are present or absent. Our results provide new insights into how Pten functions in tissue homeostasis.	[Miyagawa, S.; Sato, M.; Iguchi, T.] Grad Univ Adv Studies, Okazaki Inst Integrat Biosci, Natl Inst Basic Biol, Natl Inst Nat Sci, Okazaki, Aichi 4448787, Japan; [Miyagawa, S.; Sato, M.; Iguchi, T.] Grad Univ Adv Studies, Dept Basic Biol, Okazaki, Aichi 4448787, Japan; [Sudo, T.] Hyogo Canc Ctr, Sect Translat Res, Akashi, Hyogo, Japan; [Sudo, T.] Hyogo Canc Ctr, Dept Gynecol Oncol, Akashi, Hyogo, Japan; [Yamada, G.] Wakayama Med Univ, Inst Adv Med, Dept Dev Genet, Wakayama, Wakayama, Japan; [Yamada, G.] Wakayama Med Univ, Inst Adv Med, Lab Anim Ctr, Wakayama, Wakayama, Japan	Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Hyogo Cancer Center; Hyogo Cancer Center; Wakayama Medical University; Wakayama Medical University	Iguchi, T (corresponding author), Grad Univ Adv Studies, Okazaki Inst Integrat Biosci, Natl Inst Basic Biol, Natl Inst Nat Sci, Okazaki, Aichi 4448787, Japan.	taisen@nibb.ac.jp	Iguchi, Taisen/AAL-4225-2021		Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour and Welfare, Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan)	We thank Dr J Takeda, Osaka University, Suita, Japan, for providing K5-Cre mice. We also thank Dr Y Mikami, Kyoto University, Kyoto, Japan, and Dr Bruce Blumberg, University of California, Irvine, CA, USA, for their support. This study was supported by Grant-in-Aid for Young Scientists B, Grant-in-Aid for Scientific Research B from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Health Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan.	Blanco Veronica, 2006, Med Oral Patol Oral Cir Bucal, V11, pE12; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Buckanan DL, 1998, ENDOCRINOLOGY, V139, P4345, DOI 10.1210/en.139.10.4345; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Cooke PS, 1997, P NATL ACAD SCI USA, V94, P6535, DOI 10.1073/pnas.94.12.6535; Daikoku T, 2008, CANCER RES, V68, P5619, DOI 10.1158/0008-5472.CAN-08-1274; Ebrahim S, 2001, GYNECOL ONCOL, V80, P89, DOI 10.1006/gyno.2000.5963; GHAHARY A, 1990, MOL ENDOCRINOL, V4, P191, DOI 10.1210/mend-4-2-191; GIMENEZCONTI IB, 1994, DIFFERENTIATION, V56, P143, DOI 10.1007/s002580050031; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; Joshi A, 2012, AM J PATHOL, V180, P2536, DOI 10.1016/j.ajpath.2012.03.006; Joshi A, 2011, EXP CELL RES, V317, P1580, DOI 10.1016/j.yexcr.2011.03.006; Kim TH, 2010, ONCOGENE, V29, P3770, DOI 10.1038/onc.2010.126; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Kurita T, 2004, DEVELOPMENT, V131, P4955, DOI 10.1242/dev.01384; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Leao JC, 2005, ORAL SURG ORAL MED O, V99, P569, DOI 10.1016/j.tripleo.2004.08.032; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; McCluggage WG, 2001, INT J GYNECOL PATHOL, V20, P399, DOI 10.1097/00004347-200110000-00015; Memarzadeh S, 2010, P NATL ACAD SCI USA, V107, P17298, DOI 10.1073/pnas.1012548107; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Miyagawa S, 2004, J MOL ENDOCRINOL, V32, P663, DOI 10.1677/jme.0.0320663; Miyagawa S, 2004, ONCOGENE, V23, P340, DOI 10.1038/sj.onc.1207207; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Mudhar HS, 2001, INT J GYNECOL PATHOL, V20, P204, DOI 10.1097/00004347-200104000-00016; NELSON KG, 1994, CELL GROWTH DIFFER, V5, P595; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; OZAWA S, 1991, CANCER LETT, V58, P167, DOI 10.1016/0304-3835(91)90096-Z; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; PLATZ CE, 1995, CANCER, V75, P270, DOI 10.1002/1097-0142(19950101)75:1+<270::AID-CNCR2820751312>3.0.CO;2-D; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Segrelles C, 2006, ONCOGENE, V25, P1174, DOI 10.1038/sj.onc.1209155; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Squarize CH, 2008, CANCER RES, V68, P7066, DOI 10.1158/0008-5472.CAN-08-0922; Suzuki A, 2003, CANCER RES, V63, P674; Tarutani M, 1997, P NATL ACAD SCI USA, V94, P7400, DOI 10.1073/pnas.94.14.7400; Vilgelm A, 2006, CANCER RES, V66, P3375, DOI 10.1158/0008-5472.CAN-05-4019; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986	45	8	9	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2015	34	8					1035	1043		10.1038/onc.2014.62	http://dx.doi.org/10.1038/onc.2014.62			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RT	24632614				2022-12-17	WOS:000350121300009
J	Lu, X; Boora, U; Seabra, L; Rabai, EM; Fenton, J; Reiman, A; Nagy, Z; Maher, ER				Lu, X.; Boora, U.; Seabra, L.; Rabai, E. M.; Fenton, J.; Reiman, A.; Nagy, Z.; Maher, E. R.			Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dube tumour suppressor gene (FLCN)	ONCOGENE			English	Article						Birt-Hogg-Dube; folicullin; Slingshot phosphatases; synthetic lethality; caspase; therapeutic target	POLYCYSTIC KIDNEYS; RENAL-CARCINOMA; CANCER-THERAPY; MUTATIONS; PATHWAY; INHIBITION; FAMILIES; PROTEIN; MODEL	Birt-Hogg-Dube (BHD) syndrome, is a dominantly inherited familial cancer syndrome associated with susceptibility to renal cell carcinoma (RCC) caused by inactivating mutations in the folliculin (FLCN) gene. The precise functions of the FLCN gene product are still under investigation but RCC from BHD patients show loss of the wild-type allele consistent with a tumor suppressor gene function. In a search for potential synthetic-lethal targets for FLCN using a phosphatase siRNA library screening approach, we found that knockdown of SSH2 serine phosphatase (one of the three members of Slingshot family and previously implicated in actin reorganization) specifically induced Caspase3/7 activity in a dose-dependent manner (up to six-fold increase, 10 nM, 72 h) in two human FLCN-deficient cell lines (BHD-origin renal cell carcinoma UOK257 and thyroid carcinoma FTC133) but not in their folliculin expressing isogenic cell lines. SSH2 siRNA-induced knockdown was accompanied by increased expression of SSH1 and SSH3 (suggesting a compensatory regulatory mechanism among members of SSH family). FLCN-null cells exhibited evidence of dysregulated cofilin de/phosphorylation pathways. Knockdown of SSH2 in FLCN-null cells was associated with an alteration in cell cycle kinetics (20% increase in G1, 30% and 40% decrease in S and G2M, respectively). Combination treatment of multiple SSH family (SSH2 plus SSH1 and/or SSH3) siRNAs potentiated induction of Caspase3/7 activity and changes in the cell cycle kinetics. These data indicate that: (a) apoptotic cell death in FLCN-null cells can be triggered by SSH2 knockdown through cell cycle arrest; (b) SSH2 represents a potential therapeutic target for the development of agents for the treatment of BHD syndrome and, possibly, related tumors.	[Lu, X.; Boora, U.; Seabra, L.; Fenton, J.; Reiman, A.; Maher, E. R.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Ctr Rare Dis & Personalised Med, Birmingham B15 2TT, W Midlands, England; [Rabai, E. M.; Nagy, Z.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Maher, ER (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Ctr Rare Dis & Personalised Med, Birmingham B15 2TT, W Midlands, England.	E.R.MAHER@bham.ac.uk	MAHER, EAMONN R/A-9507-2008; Nagy, Zsuzsanna/L-8446-2013	MAHER, EAMONN R/0000-0002-6226-6918; Nagy, Zsuzsanna/0000-0002-6700-4829	Myrovlytis Trust	Myrovlytis Trust	We thank the Myrovlytis Trust for financial support.	Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Chen JD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003581; da Silva NF, 2003, J MED GENET, V40, P820; Dedes KJ, 2011, CELL CYCLE, V10, P1192, DOI 10.4161/cc.10.8.15273; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Kaelin WG, 2005, COLD SH Q B, V70, P159, DOI 10.1101/sqb.2005.70.001; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lim DHK, 2010, HUM MUTAT, V31, pE1043, DOI 10.1002/humu.21130; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Lu XH, 2011, MOL CANCER THER, V10, P80, DOI 10.1158/1535-7163.MCT-10-0628; Menko FH, 2009, LANCET ONCOL, V10, P1199, DOI 10.1016/S1470-2045(09)70188-3; Mizuno K, 2013, CELL SIGNAL, V25, P457, DOI 10.1016/j.cellsig.2012.11.001; Motzer RJ, 2009, CLIN GENITOURIN CANC, V7, P28, DOI 10.3816/CGC.2009.n.005; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Patel PH, 2006, CLIN CANCER RES, V12, P7215, DOI 10.1158/1078-0432.CCR-06-2254; Plastino J, 2005, CURR OPIN CELL BIOL, V17, P62, DOI 10.1016/j.ceb.2004.12.001; Posadas I, 2012, J NEUROCHEM, V120, P515, DOI 10.1111/j.1471-4159.2011.07599.x; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2009, CELL CYCLE, V8, P3112, DOI 10.4161/cc.8.19.9626; Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842; Toro JR, 2008, J MED GENET, V45, P321, DOI 10.1136/jmg.2007.054304; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Yang Y, 2008, CANCER GENET CYTOGEN, V180, P100, DOI 10.1016/j.cancergencyto.2007.10.010	30	8	9	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					956	965		10.1038/onc.2013.27	http://dx.doi.org/10.1038/onc.2013.27			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23416984				2022-12-17	WOS:000331933200003
J	Jin, L; Craven, RJ				Jin, L.; Craven, R. J.			The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor	ONCOGENE			English	Article						signaling; tyrosine kinase; Rak; Frk; EGFR; SH2; SH3	CELL LUNG-CANCER; CLINICAL-RESPONSE; BREAST-CANCER; PROTEIN; EGFR; MUTATIONS; FAMILY; RAK; ENDOCYTOSIS; ACTIVATION	Src is the founding member of a diverse family of intracellular tyrosine kinases, and Src has a key role in promoting cancer growth, in part, through its association with receptor tyrosine kinases. However, some Src-related proteins have widely divergent physiological roles, and these proteins include the Rak/Frk tyrosine kinase (Frk stands for Fyn-related kinase), which inhibits cancer cell growth and suppresses tumorigenesis. Rak/Frk phosphorylates and stabilizes the Pten tumor suppressor, protecting it from degradation, and Rak/Frk associates with the retinoblastoma (Rb) tumor suppressor. However, the role of Rak/Frk in receptor-mediated signaling is largely unknown. Here, we demonstrate that Rak/Frk associates with epidermal growth factor receptor (EGFR), increasing in activity and EGFR binding after EGF stimulation, when it decreases the pool of EGFR present at the plasma membrane. EGFR-Rak binding is direct, requires the SH2 and SH3 domains of Rak/Frk for efficient complex formation and is not dependent on the Grb2 adaptor protein. EGFR mutations are associated with increased EGFR activity and tumorigenicity, and we found that Rak/Frk associates preferentially with an EGFR exon 19 mutant, EGFR Delta 747-749/A750P, compared with wild-type EGFR. Furthermore, Rak/Frk inhibited mutant EGFR phosphorylation at an activating site and dramatically decreased the levels of EGFR Delta 747-749/A750P from the plasma membrane. Taken together, the results suggest that Rak/Frk inhibits EGFR signaling in cancer cells and has elevated activity against EGFR exon 19 mutants.	[Jin, L.; Craven, R. J.] Univ Kentucky, Lucille P Markey Canc Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Craven, RJ (corresponding author), Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA.	rolf.craven@uky.edu			Kentucky Lung Cancer Research Program, cycle 9	Kentucky Lung Cancer Research Program, cycle 9	This work was supported by the Kentucky Lung Cancer Research Program, cycle 9. We thank Drs Gengxian Shi and Doug Andres for advice and reagents, Mary Gail Engle of the University of Kentucky Imaging Core Facility for expertise in microscopy and Woodrow Friend for reading of the manuscript.	Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Berclaz G, 2000, INT J CANCER, V85, P889; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Brauer PM, 2010, BBA-REV CANCER, V1806, P66, DOI 10.1016/j.bbcan.2010.02.003; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; Chandrasekharan S, 2002, MOL CELL BIOL, V22, P5235, DOI 10.1128/MCB.22.14.5235-5247.2002; CRAVEN RJ, 1995, CANCER RES, V55, P3969; Crudden G, 2005, TUMOR BIOL, V26, P142, DOI 10.1159/000086485; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Furukawa M, 2007, DNA CELL BIOL, V26, P178, DOI 10.1089/dna.2006.0573; Ganti AK, 2010, CANCER INVEST, V28, P515, DOI 10.3109/07357900903476760; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325; Giubellino A, 2008, EXPERT OPIN THER TAR, V12, P1021, DOI [10.1517/14728222.12.8.1021, 10.1517/14728222.12.8.1021 ]; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Haegebarth A, 2006, MOL CELL BIOL, V26, P4949, DOI 10.1128/MCB.01901-05; Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158; Jin GA, 2011, LUNG CANCER, V71, P115, DOI 10.1016/j.lungcan.2010.10.002; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li X, 2012, ONCOGENE, V31, P4372, DOI 10.1038/onc.2011.608; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Meyer T, 2003, INT J CANCER, V104, P139, DOI 10.1002/ijc.10925; Oberg-Welsh C, 1998, GROWTH FACTORS, V16, P111; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Padron D, 2007, CANCER RES, V67, P7695, DOI 10.1158/0008-5472.CAN-07-0484; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palka-Hamblin HL, 2010, J CELL SCI, V123, P236, DOI 10.1242/jcs.053264; Rivera F, 2008, ANTI-CANCER DRUG, V19, P99, DOI 10.1097/CAD.0b013e3282f23287; Sequist LV, 2008, ANNU REV MED, V59, P429, DOI 10.1146/annurev.med.59.090506.202405; Serfas MS, 2003, ONCOL RES, V13, P409; SMITHGALL TE, 1995, J PHARMACOL TOX MET, V34, P125, DOI 10.1016/1056-8719(95)00082-7; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; THUVESON M, 1995, BIOCHEM BIOPH RES CO, V209, P582, DOI 10.1006/bbrc.1995.1540; Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012; Zheng Y, 2012, J BIOL CHEM, V287, P148, DOI 10.1074/jbc.M111.298117; Zheng Y, 2010, MOL CELL BIOL, V30, P4280, DOI 10.1128/MCB.00024-10	45	8	8	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					326	335		10.1038/onc.2012.589	http://dx.doi.org/10.1038/onc.2012.589			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318459	Green Submitted			2022-12-17	WOS:000330214000007
J	Wu, J; Mukherjee, A; Lebman, DA; Fang, X				Wu, J.; Mukherjee, A.; Lebman, D. A.; Fang, X.			Gene expression of the lysophosphatidic acid receptor 1 is a target of transforming growth factor beta	ONCOGENE			English	Article						cancer; LPA; TGF beta; LPA1; migration; invasion	BREAST-CANCER CELLS; PROTEIN-COUPLED RECEPTOR; SMAD-BINDING-ELEMENT; TGF-BETA; OVARIAN-CANCER; EPITHELIAL-CELLS; LPA RECEPTORS; C-MYC; MOTILITY; METASTASIS	The lysophosphatidic acid (LPA) receptor LPA(1)/Edg2 is the first identified LPA receptor. Although its wide tissue distribution and biological functions have been well studied, little is known about how LPA(1) is transcriptionally regulated. In the current study, we showed that LPA(1) is a physiological target of transforming growth factor beta (TGF beta)-mediated repression. In both normal and neoplastic cells, TGF beta inhibits LPA(1) promoter activity, LPA(1) mRNA expression and LPA(1)-dependent chemotaxis and tumor cell invasion. Knockdown of the TGF beta intracellular effector Smad3 or Smad4 with lentivirally transduced short hairpin RNA relieved these inhibitory effects of TGF beta. Interestingly, the LPA(1) promoter contains two potential TGF beta inhibitory elements (TIEs), each consisting of a Smad-binding site and an adjacent E2F4/5 element, structurally similar to the TIE found on the promoter of the well-defined TGF beta target gene c-myc. Deletion and point mutation analyses indicate that the distal TIE located at 401 bp from the transcription initiation site, is required for TGF beta repression of the LPA(1) promoter. A DNA pull-down assay showed that the -401 TIE was capable of binding Samd3 and E2F4 in TGF beta-treated cells. TGF beta-induced binding of the Smad complex to the native -401 TIE sequence of the LPA(1) gene promoter was further verified by chromatin immunoprecipitation assays. We therefore identified a novel role of TGF beta in the control of LPA(1) expression and LPA(1)-coupled biological functions, adding LPA(1) to the list of TGF beta-repressed target genes.	[Wu, J.; Mukherjee, A.; Fang, X.] Virginia Commonwealth Univ, Dept Biochem, Sch Med, Richmond, VA 23298 USA; [Wu, J.; Mukherjee, A.; Fang, X.] Virginia Commonwealth Univ, Dept Mol Biol, Sch Med, Richmond, VA 23298 USA; [Lebman, D. A.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Sch Med, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Fang, X (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, POB 980614,Sanger Hall,1101 E Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu			NIH/NCI [2R01CA102196]; Department of Defense [W81XWH-11-1-0541]; Jeffress Memorial Fund award; NIH [P30 CA16059]; NATIONAL CANCER INSTITUTE [P30CA016059, R01CA102196] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Jeffress Memorial Fund award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work was supported in part by the NIH/NCI grant 2R01CA102196 (XF), the Department of Defense ovarian cancer research program grant W81XWH-11-1-0541 (XF), the Jeffress Memorial Fund award (XF), and the NIH grant P30 CA16059 to Massey Cancer Center of Virginia Commonwealth University School of Medicine.	AUERSPERG N, 1994, LAB INVEST, V71, P510; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blount AL, 2008, J BIOL CHEM, V283, P7016, DOI 10.1074/jbc.M709502200; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen HJ, 2010, CANCER RES, V70, P9979, DOI 10.1158/0008-5472.CAN-10-2394; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Horak CE, 2007, CANCER RES, V67, P11751, DOI 10.1158/0008-5472.CAN-07-3175; Horak CE, 2007, CANCER RES, V67, P7238, DOI 10.1158/0008-5472.CAN-07-0962; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Jeon ES, 2008, STEM CELLS, V26, P789, DOI 10.1634/stemcells.2007-0742; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Lee Z, 2008, MOL BIOL CELL, V19, P5435, DOI 10.1091/mbc.E08-03-0316; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; Lin SB, 2009, GASTROENTEROLOGY, V136, P1711, DOI 10.1053/j.gastro.2009.01.002; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marshall JC, 2010, EUR J CANCER, V46, P1278, DOI 10.1016/j.ejca.2010.02.042; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Murph MM, 2008, BBA-MOL CELL BIOL L, V1781, P547, DOI 10.1016/j.bbalip.2008.04.007; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Panupinthu N, 2010, BRIT J CANCER, V102, P941, DOI 10.1038/sj.bjc.6605588; Pasternack SM, 2008, NAT GENET, V40, P329, DOI 10.1038/ng.84; Pradere JP, 2007, J AM SOC NEPHROL, V18, P3110, DOI 10.1681/ASN.2007020196; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Sauer B, 2004, J INVEST DERMATOL, V123, P840, DOI 10.1111/j.0022-202X.2004.23458.x; Seoane J, 2006, CARCINOGENESIS, V27, P2148, DOI 10.1093/carcin/bgl068; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Shida D, 2003, CANCER RES, V63, P1706; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Stadler CR, 2006, CELL SIGNAL, V18, P783, DOI 10.1016/j.cellsig.2005.07.002; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Sugiyama N, 2010, P NATL ACAD SCI USA, V107, P15786, DOI 10.1073/pnas.0914459107; Tager AM, 2008, NAT MED, V14, P45, DOI 10.1038/nm1685; van Leeuwen FN, 2003, J BIOL CHEM, V278, P400, DOI 10.1074/jbc.M210151200; Wu JH, 2011, MOL CANCER RES, V9, P1562, DOI 10.1158/1541-7786.MCR-11-0340; Xu MY, 2009, AM J PATHOL, V174, P1264, DOI 10.2353/ajpath.2009.080160; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378	51	8	8	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 27	2013	32	26					3198	3206		10.1038/onc.2012.325	http://dx.doi.org/10.1038/onc.2012.325			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172LL	22824789	Green Accepted			2022-12-17	WOS:000321004600010
J	Xie, Z; Jiang, Y; Liao, EY; Chen, Y; Pennypacker, SD; Peng, J; Chang, SM				Xie, Z.; Jiang, Y.; Liao, E-Y; Chen, Y.; Pennypacker, S. D.; Peng, J.; Chang, S. M.			PIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells	ONCOGENE			English	Article						SCC; EGFR; PLC-gamma 1; PIKE; proliferation	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; HUMAN KERATINOCYTE DIFFERENTIATION; GENE COPY NUMBER; PHOSPHOLIPASE C-GAMMA-1; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; COLORECTAL-CANCER; ACTIVATES RAF-1; POOR-PROGNOSIS	One of the key drivers for squamous cell carcinoma (SCC) proliferation is activation of the epidermal growth factor receptor (EGFR), a known proto-oncogene. However, the mechanism of EGFR-dependent SCC proliferation remains unclear. Our previous studies indicate that epidermal growth factor (EGF)-induced SCC cell proliferation requires the SH3 domain of phospholipase C-gamma 1 (PLC-gamma 1), but not its catalytic activity. The SH3 domain of PLC-gamma 1 is known to activate the short form of nuclear phosphatidylinositol 3-kinase enhancer (PIKE) that enhances the activity of nuclear class Ia phosphatidylinositol 3-kinase (PI3K) required for proliferation. However, PIKE has been described for more than a decade to be present exclusively in neuronal cells. In the present study, we found that PIKE was highly expressed in malignant human keratinocytes (SCC4 and SCC12B2) but had low expression in normal human keratinocytes. Immunohistochemical analysis showed strong nuclear staining of PIKE in human epidermal and tongue SCC specimens but little staining in the adjacent non-cancerous epithelium. Treatment of SCC4 cells with EGF-induced translocation of PLC-gamma 1 to the nucleus and binding of PLC-gamma 1 to the nuclear PIKE. Knockdown of PLC-gamma 1 or PIKE blocked EGF-induced activation of class Ia PI3K and protein kinase C-zeta and phosphorylation of nucleolin in the nucleus as well as EGF-induced SCC cell proliferation. However, inhibition of the catalytic activity of PLC-gamma 1 had little effect. These data suggest that PIKE has a critical role in EGF-induced SCC cell proliferation and may function as a proto-oncogene in SCC. Oncogene (2012) 31, 5090-5098; doi:10.1038/onc.2012.10; published online 20 February 2012	[Xie, Z.; Liao, E-Y; Peng, J.] Cent S Univ, Xiangya Hosp 2, Inst Metab & Endocrinol, Changsha 410011, Hunan, Peoples R China; [Xie, Z.; Pennypacker, S. D.; Chang, S. M.] Vet Affairs Med Ctr, No Calif Inst Res & Educ, Endocrine Unit, San Francisco, CA 94121 USA; [Xie, Z.; Pennypacker, S. D.; Chang, S. M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Jiang, Y.] Cent S Univ, Xiang Ya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China; [Chen, Y.] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing, Peoples R China	Central South University; Northern California Institute for Research & Education; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Central South University; China Academy of Chinese Medical Sciences; Institute of Chinese Materia Medica, CACMS	Xie, Z (corresponding author), Cent S Univ, Xiangya Hosp 2, Inst Metab & Endocrinol, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.	Zhongjian.Xie@gmail.com		Yi, Jiang/0000-0002-7877-0561	National Natural Science Foundation of China [81072219]; US National Institutes of Health [1R03DE01800, 1R21DE019529]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE018001, R21DE019529] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the grant 81072219 from the National Natural Science Foundation of China and grants 1R03DE018001 and 1R21DE019529 from the US National Institutes of Health. We thank Drs Daniel D Bikle, Chia-Ling Tu and Yongmei Wang for helpful discussions. We also thank Dr Larry L Wang (Department of Pathology, Children Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles) for reviewing pathological slides.	Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Cacace AM, 1996, ONCOGENE, V13, P2517; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Destro A, 2006, LUNG CANCER, V51, P207, DOI 10.1016/j.lungcan.2005.10.016; Ettl T, 2008, HISTOPATHOLOGY, V53, P567, DOI 10.1111/j.1365-2559.2008.03159.x; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Galizia G, 2007, WORLD J SURG, V31, P1458, DOI 10.1007/s00268-007-9016-4; Ginisty H, 1999, J CELL SCI, V112, P761; Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Hiraishi Y, 2006, PATHOL ONCOL RES, V12, P87, DOI 10.1007/BF02893450; HUANG PS, 1995, FEBS LETT, V358, P287, DOI 10.1016/0014-5793(94)01453-8; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Kim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x; Kim MJ, 2000, EXP MOL MED, V32, P101, DOI 10.1038/emm.2000.18; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Liu X, 2007, ONCOGENE, V26, P4918, DOI 10.1038/sj.onc.1210290; Livasy CA, 2006, GYNECOL ONCOL, V100, P101, DOI 10.1016/j.ygyno.2005.07.124; Lurje G, 2009, ONCOLOGY-BASEL, V77, P400, DOI 10.1159/000279388; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; PILLAI S, 1988, J CELL PHYSIOL, V134, P229, DOI 10.1002/jcp.1041340208; Rakosy Z, 2007, INT J CANCER, V121, P1729, DOI 10.1002/ijc.22928; ROTIN D, 1992, J BIOL CHEM, V267, P9678; Schiff BA, 2004, CLIN CANCER RES, V10, P8594, DOI 10.1158/1078-0432.CCR-04-0690; Smith MR, 1996, BIOCHEM BIOPH RES CO, V222, P186, DOI 10.1006/bbrc.1996.0719; Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006; Speake G, 2005, CURR OPIN PHARMACOL, V5, P343, DOI 10.1016/j.coph.2005.02.007; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Storck S, 2009, BIOL CELL, V101, P153, DOI 10.1042/BC20080054; Tajrishi Marjan M, 2011, Commun Integr Biol, V4, P267, DOI 10.4161/cib.4.3.14884; Thomas SM, 2003, CANCER RES, V63, P5629; TOKER A, 1994, J BIOL CHEM, V269, P32358; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Xie ZJ, 2007, J BIOL CHEM, V282, P8695, DOI 10.1074/jbc.M609135200; Xie ZJ, 2010, BIOCHEM BIOPH RES CO, V398, P719, DOI 10.1016/j.bbrc.2010.07.007; Xie ZJ, 2010, BIOCHEM BIOPH RES CO, V397, P296, DOI 10.1016/j.bbrc.2010.05.103; Xie ZJ, 2009, MOL BIOL CELL, V20, P1695, DOI 10.1091/mbc.E08-07-0756; Xie ZJ, 2005, MOL BIOL CELL, V16, P3236, DOI 10.1091/mbc.E05-02-0109; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130; Zlobec I, 2007, BRIT J CANCER, V96, P793, DOI 10.1038/sj.bjc.6603619; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	51	8	9	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5090	5098		10.1038/onc.2012.10	http://dx.doi.org/10.1038/onc.2012.10			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22349826				2022-12-17	WOS:000312000900005
J	Kurasawa, Y; Kozaki, K; Pimkhaokham, A; Muramatsu, T; Ono, H; Ishihara, T; Uzawa, N; Imoto, I; Amagasa, T; Inazawa, J				Kurasawa, Y.; Kozaki, K.; Pimkhaokham, A.; Muramatsu, T.; Ono, H.; Ishihara, T.; Uzawa, N.; Imoto, I.; Amagasa, T.; Inazawa, J.			Stabilization of phenotypic plasticity through mesenchymal-specific DNA hypermethylation in cancer cells	ONCOGENE			English	Article						EMT; DNA hypermethylation; WNT7A; WNT10A; oral squamous cell carcinoma	MIR-200 FAMILY; E-CADHERIN; TRANSITION; METHYLATION; ZEB1; ASSOCIATION; STATISTICS; EXPRESSION; GENES	The epithelial-mesenchymal transition (EMT) has a crucial role in normal and disease processes including tumor progression. In this study, we first classified epithelial-like and mesenchymal-like oral squamous cell carcinoma (OSCC) cell lines based on expression profiles of typical EMT-related genes using a panel of 18 OSCC cell lines. Then, we performed methylation-based and expression-based analyses of components of the Wnt signaling pathway, and identified WNT7A and WNT10A as genes silenced by mesenchymal-specific DNA hypermethylation in OSCCs. A significant association was revealed between some clinicopathological findings and the DNA methylation status of WNT7A (normal vs tumor, P = 0.007; T1-2 vs T3-4, P = 0.040; I-III vs IV, P = 0.016) and WNT10A (N0-N1 vs N2-N3, P = 0.046) in the advanced stages of OSCC. Moreover, we found that E-cadherin expression in cancer cells may be positively regulated by WNT7A, whose expression is negatively regulated by mesenchymal-specific DNA hypermethylation or ZEB1 in mesenchymal-like OSCC cells. Our findings indicate that epithelial-specific gene silencing through mesenchymal-specific DNA hypermethylation may stabilize the phenotypic plasticity of cancer cells during EMT/MET. Oncogene (2012) 31, 1963-1974; doi:10.1038/onc.2011.373; published online 29 August 2011	[Kurasawa, Y.; Kozaki, K.; Pimkhaokham, A.; Muramatsu, T.; Ono, H.; Ishihara, T.; Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Kurasawa, Y.; Kozaki, K.; Pimkhaokham, A.; Muramatsu, T.; Ono, H.; Ishihara, T.; Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Sch Biomed Sci, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Kurasawa, Y.; Uzawa, N.; Amagasa, T.] Tokyo Med & Dent Univ, Dept Maxillofacial Surg, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Kozaki, K.; Inazawa, J.] Tokyo Med & Dent Univ, Dept Genome Med, Hard Tissue Genome Res Ctr, Yushima Bunkyo Ku, Tokyo 1138510, Japan; [Pimkhaokham, A.] Chulalongkorn Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Bangkok, Thailand; [Inazawa, J.] Tokyo Med & Dent Univ, Program Int Res, Ctr Mol Sci Tooth & Bone Dis, GCOE, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Chulalongkorn University; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Yushima Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	Kozaki, Ken-ichi/M-6281-2014; imoto, Issei/D-8065-2012; Pimkhaokham, Atiphan/AAQ-4177-2021; Imoto, Issei/AAD-5799-2020	Kozaki, Ken-ichi/0000-0003-3286-819X; Pimkhaokham, Atiphan/0000-0002-0170-243X	Ministry of Education, Culture, Sports, Science and Technology, Japan; Ministry of Health, Labour and Welfare, Japan; Core Research for Evolutional Science and Technology of the Japan Science and Technology Corporation; New Energy and Industrial Technology Development Organization; Grants-in-Aid for Scientific Research [23390077, 22134002] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labour and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Core Research for Evolutional Science and Technology of the Japan Science and Technology Corporation(Core Research for Evolutional Science and Technology (CREST)); New Energy and Industrial Technology Development Organization(New Energy and Industrial Technology Development Organization (NEDO)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ayako Takahashi and Rumi Mori for technical assistance. This study was supported in part by Grant-in-Aid for Scientific Research (A), (B) and (C), and Scientific Research on Priority Areas and Innovative Areas, and the Global Center of Excellence Program for International Research Center for Molecular Science in Tooth and Bone Diseases from the Ministry of Education, Culture, Sports, Science and Technology, Japan; a Health and Labour Sciences Research Grant by the Ministry of Health, Labour and Welfare, Japan; a grant from Core Research for Evolutional Science and Technology of the Japan Science and Technology Corporation; and a grant from the New Energy and Industrial Technology Development Organization.	Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227; McNeill H, 2010, NAT REV MOL CELL BIO, V11, P404, DOI 10.1038/nrm2902; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nomura K, 2005, CANC STAT JAPAN 2005, P36; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161; Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Sato N, 2003, CANCER RES, V63, P3735; Scully C, 2000, ORAL ONCOL, V36, P256, DOI 10.1016/S1368-8375(00)00007-5; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Suzuki E, 2007, ONCOGENE, V26, P7921, DOI 10.1038/sj.onc.1210589; Taki M, 2003, CANCER SCI, V94, P593, DOI 10.1111/j.1349-7006.2003.tb01488.x; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Winn RA, 2005, J BIOL CHEM, V280, P19625, DOI 10.1074/jbc.M409392200; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	30	8	8	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1963	1974		10.1038/onc.2011.373	http://dx.doi.org/10.1038/onc.2011.373			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874048				2022-12-17	WOS:000302809900008
J	Krishnamurthy, N; Ngam, CR; Berdis, AJ; Montano, MM				Krishnamurthy, N.; Ngam, C. R.; Berdis, A. J.; Montano, M. M.			The exonuclease activity of hPMC2 is required for transcriptional regulation of the QR gene and repair of estrogen-induced abasic sites	ONCOGENE			English	Article						EpRE; hPMC2; quninone reductase; tamoxifen	QUINONE REDUCTASE GENE; DNA-BINDING; RECEPTOR; BREAST; TAMOXIFEN; MECHANISM; IDENTIFICATION; ACTIVATION; CANCER; RNA	We have previously reported that the expression of antioxidative stress enzymes is upregulated by trans-hydroxytamoxifen (TOT) in breast epithelial cell lines providing protection against estrogen-induced DNA damage. This regulation involves Estrogen Receptor beta (ER beta) recruitment to the Electrophile Response Element (EpRE) and a novel protein, human homolog of Xenopus gene which Prevents Mitotic Catastrophe (hPMC2). We have also demonstrated that ER beta and hPMC2 are required for TOT-dependent recruitment of poly (ADP-ribose) polymerase 1 (PARP-1) and Topoisomerase II beta (Topo II beta) to the EpRE. Sequence analysis reveals that the C-terminus of hPMC2 encodes a putative exonuclease domain. Using in vitro kinetic assays, we found that hPMC2 is a 3'-5' non-processive exonuclease that degrades both single-stranded and double-stranded substrates. Mutation of two conserved carboxylate residues drastically reduced the exonuclease activity of hPMC2, indicating the relative importance of the catalytic residues. Western blot analysis of breast cancer cell lines for Quinone Reductase (QR) levels revealed that the intrinsic exonuclease activity of hPMC2 was required for TOT-induced QR upregulation. Chromatin immunoprecipitation (ChIP) assays also indicated that hPMC2 was involved in the formation of strand breaks observed with TOT treatment and is specific for the EpRE-containing region of the QR gene. We also determined that the transcription factor NF-E2-related factor-2 (Nrf2) is involved in the specificity of hPMC2 for the EpRE. In addition, we determined that the catalytic activity of hPMC2 is required for repair of abasic sites that result from estrogen-induced DNA damage. Thus, our study provides a mechanistic basis for transcriptional regulation by hPMC2 and provides novel insights into its role in cancer prevention. Oncogene (2011) 30, 4731-4739; doi:10.1038/onc.2011.186; published online 23 May 2011	[Montano, M. M.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W305,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@case.edu			Department of Defense [BC087610]; NIH [CA92240]; NATIONAL CANCER INSTITUTE [R01CA092240, R01CA092440] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Defense Breast Cancer Postdoctoral award (BC087610) to NK and NIH Grant (CA92240) to MMM.	Ando K, 2008, NUCLEIC ACIDS RES, V36, P4327, DOI 10.1093/nar/gkn416; Berdis AJ, 2001, BIOCHEMISTRY-US, V40, P7180, DOI 10.1021/bi0101594; Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Bolton JL, 2008, CHEM RES TOXICOL, V21, P93, DOI 10.1021/tx700191p; Cavalieri E, 2006, BBA-REV CANCER, V1766, P63, DOI 10.1016/j.bbcan.2006.03.001; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Gaikwad NW, 2007, FREE RADICAL BIO MED, V43, P1289, DOI 10.1016/j.freeradbiomed.2007.07.021; Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; HSIEH JC, 1993, J BIOL CHEM, V268, P24607; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Jordan VC, 1998, J NATL CANCER I, V90, P967, DOI 10.1093/jnci/90.13.967; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Marti TM, 2004, CELL MOL LIFE SCI, V61, P336, DOI 10.1007/s00018-003-3223-4; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Montano MM, 2007, ONCOGENE, V26, P3587, DOI 10.1038/sj.onc.1210144; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Nakamura T, 2008, STROKE, V39, P463, DOI 10.1161/STROKEAHA.107.486654; Nakopoulou L, 2004, J CLIN PATHOL, V57, P523, DOI 10.1136/jcp.2003.008599; Nguyen LH, 2001, BIOCHEMISTRY-US, V40, P7174, DOI 10.1021/bi010141t; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Saji S, 2005, CANCER CHEMOTH PHARM, V56, pS21, DOI 10.1007/s0028-005-0107-3; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; Sripathy SP, 2008, ONCOGENE, V27, P6376, DOI 10.1038/onc.2008.235; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776	33	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2011	30	47					4731	4739		10.1038/onc.2011.186	http://dx.doi.org/10.1038/onc.2011.186			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	861QG	21602889	Green Accepted, Green Submitted			2022-12-17	WOS:000298033700005
J	Osei-Sarfo, K; Martello, L; Ibrahim, S; Pellicer, A				Osei-Sarfo, K.; Martello, L.; Ibrahim, S.; Pellicer, A.			The human Rgr oncogene is overexpressed in T-cell malignancies and induces transformation by acting as a GEF for Ras and Ral	ONCOGENE			English	Article						Rgr; GEFs; Ras GTPases; Ral GTPases; T-cell lymphoma	GUANINE-NUCLEOTIDE EXCHANGE; DISSOCIATION STIMULATOR; HUMAN CANCER; KAPPA-B; ACTIVATION; GENE; GTPASE; PATHWAY; EFFECTOR; SOS	The Ras superfamily of GTPases is involved in the modification of many cellular processes including cellular motility, proliferation and differentiation. Our laboratory has previously identified the RalGDS-related (Rgr) oncogene in a DMBA (7,12-dimethylbenz[alpha]anthracene)-induced rabbit squamous cell carcinoma and its human orthologue, hRgr. In this study, we analyzed the expression levels of the human hRgr transcript in a panel of human hematopoietic malignancies and found that a truncated form (diseased-truncated (Dtr-hrgr)) was significantly overexpressed in many T-cell-derived neoplasms. Although the Rgr proto-oncogene belongs to the RalGDS family of guanine nucleotide exchange factors (GEFs), we show that upon the introduction of hRgr into fibroblast cell lines, it is able to elicit the activation of both Ral and Ras GTPases. Moreover, in vitro guanine nucleotide exchange assays confirm that hRgr promotes Ral and Ras activation through GDP dissociation, which is a critical characteristic of GEF proteins. hRgr has guanine nucleotide exchange activity for both small GTPases and this activity was reduced when a point mutation within the catalytic domain (CDC25) of the protein, (cd) Dtr-hRgr, was utilized. These observations prompted the analysis of the biological effects of hRgr and (cd) hRgr expression in cultured cells. Here, we show that hRgr increases proliferation in low serum, increases invasion, reduces anchorage dependence and promotes the progression into the S phase of the cell cycle; properties that are abolished or severely reduced in the presence of the catalytic dead mutant. We conclude that the ability of hRgr to activate both Ral and Ras is responsible for its transformation-inducing phenotype and it could be an important contributor in the development of some T-cell malignancies. Oncogene (2011) 30, 3661-3671; doi:10.1038/onc.2011.93; published online 28 March 2011	[Osei-Sarfo, K.; Martello, L.; Pellicer, A.] New York Univ, Langone Med Ctr, Dept Pathol, New York, NY 10016 USA; [Ibrahim, S.] New York Univ, Langone Med Ctr, Dept Hematopathol, New York, NY 10016 USA	New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center	Pellicer, A (corresponding author), New York Univ, Langone Med Ctr, Dept Pathol, 550 1st Ave,MSB 594, New York, NY 10016 USA.	Angel.Pellicer@nyumc.org	MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NIH [CA50434, CA36327]; NATIONAL CANCER INSTITUTE [R01CA036327, R37CA036327, R01CA050434] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Drs M Philips, D Bar-Sagi and J Bos for the gift of expression plasmids. We thank Kamlesh Yadav and Pamela Sung for their assistance with the mant-guanine nucleotide exchange and cellular proliferation assays, respectively, and Dr M Liu for her assistance with the statistical analysis for the cellular proliferation assay. These studies were supported by NIH Grants CA50434 and CA36327 to AP.	ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; BOS JL, 1989, CANCER RES, V49, P4682; Boykevisch S, 2006, CURR BIOL, V16, P2173, DOI 10.1016/j.cub.2006.09.033; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; Cascone I, 2008, EMBO J, V27, P2375, DOI 10.1038/emboj.2008.166; Ceriani M, 2007, EXP CELL RES, V313, P2293, DOI 10.1016/j.yexcr.2007.03.016; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; COROMINAS M, 1989, P NATL ACAD SCI USA, V86, P6372, DOI 10.1073/pnas.86.16.6372; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Das J, 2009, CELL, V136, P337, DOI 10.1016/j.cell.2008.11.051; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; Hernandez-Munoz I, 2003, CANCER RES, V63, P4188; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010; Leonardi P, 2002, ONCOGENE, V21, P5108, DOI 10.1038/sj.onc.1205694; Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030; Lim KH, 2006, CURR BIOL, V16, P2385, DOI 10.1016/j.cub.2006.10.023; Linnemann T, 2002, J BIOL CHEM, V277, P7831, DOI 10.1074/jbc.M110800200; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Mittar D, 2004, BIOCHEM BIOPH RES CO, V322, P203, DOI 10.1016/j.bbrc.2004.07.107; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; Paulsson K, 2008, P NATL ACAD SCI USA, V105, P6708, DOI 10.1073/pnas.0800408105; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; Roose JP, 2007, MOL CELL BIOL, V27, P2732, DOI 10.1128/MCB.01882-06; Rosse C, 2006, MOL CELL BIOL, V26, P727, DOI 10.1128/MCB.26.2.727-734.2006; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SEKIDO Y, 1995, CANCER RES, V55, P1227; Senga T, 2001, J BIOL CHEM, V276, P32678, DOI 10.1074/jbc.M105749200; Shao HP, 2000, J BIOL CHEM, V275, P26914; Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855; Sondermann H, 2004, CELL, V119, P393, DOI 10.1016/j.cell.2004.10.005; Sood R, 2000, BBA-GENE STRUCT EXPR, V1491, P285, DOI 10.1016/S0167-4781(00)00031-2; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takaya A, 2007, MOL BIOL CELL, V18, P1850, DOI 10.1091/mbc.E06-08-0765; Tazmini G, 2009, BBA-MOL CELL RES, V1793, P447, DOI 10.1016/j.bbamcr.2008.12.019; Tchevkina E, 2005, ONCOGENE, V24, P329, DOI 10.1038/sj.onc.1208094; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023	52	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	34					3661	3671		10.1038/onc.2011.93	http://dx.doi.org/10.1038/onc.2011.93			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	811VO	21441953	Green Accepted			2022-12-17	WOS:000294244500002
J	Birts, CN; Bergman, LM; Blaydes, JP				Birts, C. N.; Bergman, L. M.; Blaydes, J. P.			CtBPs promote mitotic fidelity through their activities in the cell nucleus	ONCOGENE			English	Article						aurora B; CtBP proteins; BARS; mitosis; transcriptional repressor	HISTONE DEACETYLASE INHIBITORS; NEGATIVE MODULATION; GENE-EXPRESSION; BINDING CLEFT; PROTEIN; COREPRESSOR; PHOSPHOPROTEIN; SURVIVAL; FISSION; REGION	CtBPs form NADH-sensitive chromatin-modifying complexes, which link cellular metabolism to gene transcription. They also function in the cytoplasm to regulate Golgi fissioning; their inhibition can consequently cause a Golgi-dependent checkpoint in G(2). We have recently identified a novel role of CtBPs in the maintenance of mitotic fidelity; inhibition of CtBP synthesis resulting in reduced association of aurora B with mitotic chromatin and aberrant segregation of chromosomes. Here, we demonstrate that it is the interaction of CtBPs with transcriptional regulators and/or chromatin-modifying enzymes in the cell nucleus, rather than their role in Golgi fission, which is critical for the maintenance of mitotic fidelity. Oncogene (2011) 30, 1272-1280; doi:10.1038/onc.2010.507; published online 8 November 2010	[Birts, C. N.; Blaydes, J. P.] Univ Southampton, Sch Med, Southampton Canc Res UK Ctr, Southampton SO16 6YD, Hants, England; [Bergman, L. M.] Therapeut Goods Adm, Med Toxicol Evaluat Sect, Off Prescript Med, Woden, ACT, Australia	University of Southampton	Blaydes, JP (corresponding author), Univ Southampton, Sch Med, Southampton Gen Hosp, Southampton Canc Res UK Ctr, MP 824, Southampton SO16 6YD, Hants, England.	j.p.blaydes@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019; Birts, Charles N/N-9845-2013	Blaydes, Jeremy/0000-0001-8525-0209; Bergman, Lee/0000-0002-0111-411X; Birts, Charles/0000-0002-0368-8766	UK Breast Cancer Campaign	UK Breast Cancer Campaign	We are grateful to Matthew Darley for the generation of plasmid reagents, Patrick Duriez for the preparation of GST fusion proteins for microinjection, and the Southampton School of Medicine Bioimaging Unit for assistance with live cell imaging. Funding for the work was from the UK Breast Cancer Campaign.	Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; Bergman LM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-35; Bergman LM, 2009, MOL CELL BIOL, V29, P4539, DOI 10.1128/MCB.00439-09; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Carcedo CH, 2004, SCIENCE, V305, P93, DOI 10.1126/science.1097775; Chen YW, 2008, CANCER RES, V68, P476, DOI 10.1158/0008-5472.CAN-07-1960; Cheok CF, 2010, CELL DEATH DIFFER, V17, P1486, DOI 10.1038/cdd.2010.18; Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Colanzi A, 2007, EMBO J, V26, P2465, DOI 10.1038/sj.emboj.7601686; Ditchfield Claire, 2004, V296, P371; Eot-Houllier G, 2009, CANCER LETT, V274, P169, DOI 10.1016/j.canlet.2008.06.005; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Kovi RC, 2010, CELL DEATH DIFFER, V17, P513, DOI 10.1038/cdd.2009.140; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Mirnezami AH, 2003, CURR BIOL, V13, P1234, DOI 10.1016/S0960-9822(03)00454-8; Mroz EA, 2008, CANCER RES, V68, P6049, DOI 10.1158/0008-5472.CAN-08-1279; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8202, DOI 10.1128/MCB.00445-06; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Stevens FE, 2008, ONCOGENE, V27, P1345, DOI 10.1038/sj.onc.1210779; Warrener R, 2003, FASEB J, V17, P1550, DOI 10.1096/fj.02-1003fje; Yang JS, 2008, NAT CELL BIOL, V10, P1146, DOI 10.1038/ncb1774; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2002, SCIENCE, V295, P1895	29	8	8	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1272	1280		10.1038/onc.2010.507	http://dx.doi.org/10.1038/onc.2010.507			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057548				2022-12-17	WOS:000288492100002
J	Kim, MKH; Min, DJ; Rabin, M; Licht, JD				Kim, M. K-H; Min, D. J.; Rabin, M.; Licht, J. D.			Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants	ONCOGENE			English	Article						WTX; WT1; microarray; tumor suppressor; G(0)/G(1) arrest; p21	BECKWITH-WIEDEMANN SYNDROME; KIDNEY DEVELOPMENT; BETA-CATENIN; BONE MASS; GENE; MUTATIONS; INDUCTION; FREQUENT; EVENT; TUMORIGENESIS	The WTX, Wilms tumor-associated tumor-suppressor gene, is present on the X chromosome and a single WTX mutation may be sufficient to promote carcinogenesis. Unlike the WT1 tumor suppressor, a transcription factor, WTX lacks conserved functional protein domains. To study the function of WTX, we constructed inducible cell lines expressing WTX and tumor-associated WTX mutants. Induction of WTX inhibited cell growth and caused G(1)/G(0) arrest. In contrast, a short, tumor-associated truncation mutant of WTX358 only slightly inhibited cell growth without a significant cell-cycle arrest, although expression of a longer truncation mutant WTX565 led to the growth inhibition and cell-cycle arrest to a similar extent as wild-type WTX. Like WT1, WTX slowed growth and caused cell-cycle arrest through p21 induction. Gene expression profiling showed that these two tumor-suppressors regulated genes in similar pathways, including those implicated in control of the cellular growth, cell cycle, cell death, cancer and cardiovascular system development. When gene expression changes mediated by wild-type WTX were compared with those affected by mutant forms, WTX565 showed a 55% overlap (228 genes) in differentially regulated genes, whereas WTX358 regulated only two genes affected by wild-type WTX, implying that amino-acid residues 358-561 are critical for WTX function. Oncogene (2011) 30, 832-842; doi:10.1038/onc.2010.452; published online 18 October 2010	[Kim, M. K-H; Min, D. J.; Rabin, M.; Licht, J. D.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr,Dept Med, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Licht, JD (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr,Dept Med, Lurie 5-123,303 E Super St, Chicago, IL 60611 USA.	j-licht@northwestern.edu	Licht, Jonathan/L-4239-2019; Licht, Jonathan/AAL-9184-2020	Licht, Jonathan/0000-0002-3942-1369	Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE [R01CA059998] Funding Source: NIH RePORTER	Northwestern Memorial Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by a grant from the Northwestern Memorial Foundation.	BARDEESY N, 1995, CANCER RES, V55, P215; Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102; Chung NG, 2008, LEUKEMIA LYMPHOMA, V49, P1616, DOI 10.1080/10428190802105082; Englert C, 1997, CANCER RES, V57, P1429; Grohmann A, 2007, J CELL SCI, V120, P3738, DOI 10.1242/jcs.011320; Huff V, 1998, AM J MED GENET, V79, P260, DOI 10.1002/(SICI)1096-8628(19981002)79:4<260::AID-AJMG6>3.0.CO;2-Q; Jenkins ZA, 2009, NAT GENET, V41, P95, DOI 10.1038/ng.270; Kim MKH, 2009, P NATL ACAD SCI USA, V106, P11154, DOI 10.1073/pnas.0901591106; Koesters R, 1999, CANCER RES, V59, P3880; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Licht JD, 2008, NEOPLASIA, V10, P69, DOI 10.1593/neo.07869; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Morrison DJ, 2008, MOL CANCER RES, V6, P1225, DOI 10.1158/1541-7786.MCR-08-0078; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Owen C, 2008, HAEMATOLOGICA, V93, P947, DOI 10.3324/haematol.12509; Park JS, 2007, DEVELOPMENT, V134, P2533, DOI 10.1242/dev.006155; Perotti D, 2008, ONCOGENE, V27, P4625, DOI 10.1038/onc.2008.93; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; Rivera MN, 2009, P NATL ACAD SCI USA, V106, P8338, DOI 10.1073/pnas.0811349106; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Ruteshouser EC, 2008, GENE CHROMOSOME CANC, V47, P461, DOI 10.1002/gcc.20553; Schmidt-Ott KM, 2007, DEVELOPMENT, V134, P3177, DOI 10.1242/dev.006544; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Wegert J, 2009, GENE CHROMOSOME CANC, V48, P1102, DOI 10.1002/gcc.20712; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; Yoo NJ, 2009, DIGEST DIS SCI, V54, P1011, DOI 10.1007/s10620-008-0458-9	30	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					832	842		10.1038/onc.2010.452	http://dx.doi.org/10.1038/onc.2010.452			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20956941				2022-12-17	WOS:000287444600007
J	Al-Reefy, S; Osman, H; Jiang, W; Mokbel, K				Al-Reefy, S.; Osman, H.; Jiang, W.; Mokbel, K.			Evidence for a pro-apoptotic function of RACK1 in human breast cancer	ONCOGENE			English	Letter									[Al-Reefy, S.; Osman, H.; Jiang, W.; Mokbel, K.] Princess Grace Hosp, London Breast Inst, London, England		Al-Reefy, S (corresponding author), Princess Grace Hosp, London Breast Inst, London, England.	saraalreefy@hotmail.com	jiang, wen/GYI-9662-2022; Jiang, Wen G./AAF-1876-2020; Jiang, Wen G/B-1293-2010	Jiang, Wen G./0000-0002-3283-1111; Jiang, Wen G/0000-0002-3283-1111				Al Sarakbi W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-290; Cao XX, 2010, INT J CANCER, V127, P1172, DOI 10.1002/ijc.25120; Mamidipudi V, 2009, ONCOGENE, V28, P4421, DOI 10.1038/onc.2009.293	3	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2010	29	41					5651	5651		10.1038/onc.2010.291	http://dx.doi.org/10.1038/onc.2010.291			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664FX	20697360				2022-12-17	WOS:000282946900011
J	Liss, AS; Tiwari, R; Kralova, J; Bose, HR				Liss, A. S.; Tiwari, R.; Kralova, J.; Bose, H. R., Jr.			Cell transformation by v-Rel reveals distinct roles of AP-1 family members in Rel/NF-kappa B oncogenesis	ONCOGENE			English	Article						v-Rel; Rel/NF-kappa B; oncogenesis; AP-1; Ras; MAPK	DNA-BINDING; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTORS; TRANSDUCTION PATHWAY; HUMAN CANCER; ATF-2; PHOSPHORYLATION; EXPRESSION; KINASE	Cell transformation by the v-rel oncogene is mediated by the aberrant expression of genes that are normally tightly regulated by other Rel/NF-kappa B family members. Although a number of genes inappropriately activated or suppressed by v-Rel have been identified, their contributions to the v-Rel transformation process have been poorly characterized. Here, we examine the role of individual AP-1 proteins in v-Rel-mediated transformation. v-Rel-transformed cells exhibit elevated RNA and protein expression of c-Fos, c-Jun and ATF2 and sustained repression of Fra-2. c-Fos and c-Jun are essential in both the initiation and maintenance of v-Rel-mediated transformation, whereas Fra-2 is dispensable. By employing a c-Jun dimerization mutant, we further identified Fos/Jun heterodimers as major contributors to the v-Rel transformation process. The inability of c-Rel to induce the expression of c-Fos and c-Jun contributes to its weaker oncogenic potential relative to v-Rel. Our studies also demonstrate that v-Rel may induce AP-1 members by directly upregulating gene expression (c-fos and ATF2) and by activating pathways that stimulate AP-1 activity. Although elevated expression of ATF2 is also required for v-Rel-mediated transformation, its ectopic overexpression is inhibitory. Investigating the mode of ATF2 regulation revealed a positive feedback mechanism whereby ATF2 induces p38 MAPK phosphorylation to further induce its own activity. In addition, these studies identified Ha-Ras as an effector of v-Rel-mediated transformation and reveal a novel role for ATF2 in the inhibition of the Ras-Raf-MEK-ERK signaling pathway. Overall, these studies reveal distinct and complex roles of AP-1 proteins in Rel/NF-kappa B oncogenesis. Oncogene (2010) 29, 4925-4937; doi: 10.1038/onc.2010.239; published online 21 June 2010	[Liss, A. S.; Tiwari, R.; Kralova, J.; Bose, H. R., Jr.] Univ Texas Austin, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Bose, HR (corresponding author), Univ Texas Austin, Sect Mol Genet & Microbiol, Inst Cellular & Mol Biol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	National Cancer Institute [CA33192, CA098151]; NATIONAL CANCER INSTITUTE [R01CA033192, R01CA098151] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ashley Sims for her technical assistance and Marc Castellazzi for providing the Coll and Jun2 luciferase reporter vectors. This study was supported by Public Health Service Grants CA33192 and CA098151 from the National Cancer Institute.	Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bhoumik A, 2008, P NATL ACAD SCI USA, V105, P1674, DOI 10.1073/pnas.0706057105; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Breitwieser W, 2007, GENE DEV, V21, P2069, DOI 10.1101/gad.430207; Chaudhary A, 2000, CURR BIOL, V10, P551, DOI 10.1016/S0960-9822(00)00475-9; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chin M, 2009, ONCOGENE, V28, P2100, DOI 10.1038/onc.2009.74; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Das RM, 2006, DEV BIOL, V294, P554, DOI 10.1016/j.ydbio.2006.02.020; DYER RB, 1995, BIOTECHNIQUES, V19, P192; Ewert D, 1999, ACTA VIROL, V43, P133; Fujii Masahiro, 1997, Leukemia (Basingstoke), V11, P402; Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; HOWE LR, 1993, ONCOGENE, V8, P2583; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Lewis JS, 2005, ONCOL RES, V15, P113, DOI 10.3727/096504005776367924; Liss AS, 2002, J VIROL, V76, P4928, DOI 10.1128/JVI.76.10.4928-4939.2002; LISS AS, 2008, ENCY VIROLOGY, P412; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Majid SM, 2006, ONCOGENE, V25, P756, DOI 10.1038/sj.onc.1209107; Mathas S, 2005, BLOOD, V106, P4287, DOI 10.1182/blood-2004-09-3620; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Morton S, 2004, FEBS LETT, V572, P177, DOI 10.1016/j.febslet.2004.07.031; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ricote M, 2006, J PATHOL, V208, P401, DOI 10.1002/path.1910; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Shaulian E, 2010, CELL SIGNAL, V22, P894, DOI 10.1016/j.cellsig.2009.12.008; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vlahopoulos SA, 2008, BIOESSAYS, V30, P314, DOI 10.1002/bies.20734; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	46	8	8	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	35					4925	4937		10.1038/onc.2010.239	http://dx.doi.org/10.1038/onc.2010.239			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	646XP	20562914	Green Accepted			2022-12-17	WOS:000281578700007
J	Staub, E; Buhr, HJ; Grone, J				Staub, E.; Buhr, H-J; Groene, J.			Predicting the site of origin of tumors by a gene expression signature derived from normal tissues	ONCOGENE			English	Article						gene expression signature; CUP; cancer type; expression profiling; microarray	CHAIN-REACTION ASSAY; UNKNOWN PRIMARY; MOLECULAR CLASSIFICATION; MICROARRAY; CANCER; CARCINOMA; IDENTIFICATION; DIAGNOSIS; IDENTIFY; MARKERS	Multiple expression signatures for the prediction of the site of origin of metastatic cancer of unknown primary origin (CUP) have been developed. Owing to their limited coverage of tumor types and suboptimal prediction accuracy on distinct tumors, there is still room for alternative CUP gene expression signatures. Whereas in past studies, CUP classifiers were trained solely on data from tumor samples, we now use expression patterns from normal tissues for classifier training. This approach potentially avoids pitfalls related to the representation of genetically heterogeneous tumor subtypes during classifier training. Two expression data sets of normal human tissues have been reanalyzed to derive an expression signature for liver, prostate, kidney, ovarian and lung tissues. In reciprocal validation, classifiers trained on either data set achieved overall accuracies greater than 97%. Classifiers trained on combined expression data from both normal tissue data sets were able to predict the site of origin in a cohort of 652 primary tumors with similar to 90% accuracy. Prediction accuracies of primary cancer-based classifiers were in the same range, as determined by cross-validation on this cohort. For individual tumor types, normal tissue-based classifiers achieved sensitivities in the range of 64-99% and specificities in the range of 92-100%. Primary origins for 12 of 20 metastases were predicted correctly, with false predictions highlighting the need for accurate sample preparation to avoid contaminations by metastases-surrounding tissue. We conclude that gene expression patterns of normal tissues harbor phenotypic information that is retained in tumors and can be sufficient to recover the type of primary tumor from expression patterns alone. Oncogene (2010) 29, 4485-4492; doi: 10.1038/onc.2010.196; published online 31 May 2010	[Staub, E.] Merck KGaA, Merck Serono, Drug Discovery Informat, Darmstadt, Germany; [Buhr, H-J; Groene, J.] Charite, Dept Gen Vasc & Thorac Surg, Berlin, Germany	Merck KGaA; EMD Serono Inc.; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Staub, E (corresponding author), Merck KGaA, Merck Serono, Drug Discovery Informat, Darmstadt, Germany.	eike.staub@merck.de	Staub, Eike/B-9801-2009	Staub, Eike/0000-0002-5039-3098				ABBRUZZESE JL, 1994, J CLIN ONCOL, V12, P1272, DOI 10.1200/JCO.1994.12.6.1272; Bloom G, 2004, AM J PATHOL, V164, P9, DOI 10.1016/S0002-9440(10)63090-8; Bridgewater J, 2008, BRIT J CANCER, V98, P1425, DOI 10.1038/sj.bjc.6604315; Canales RD, 2006, NAT BIOTECHNOL, V24, P1115, DOI 10.1038/nbt1236; Dennis JL, 2005, CLIN CANCER RES, V11, P3766, DOI 10.1158/1078-0432.CCR-04-2236; Dennis JL, 2002, CANCER RES, V62, P5999; Dumur CI, 2008, J MOL DIAGN, V10, P67, DOI 10.2353/jmoldx.2008.070099; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; Horlings HM, 2008, J CLIN ONCOL, V26, P4435, DOI 10.1200/JCO.2007.14.6969; Ma XJ, 2006, ARCH PATHOL LAB MED, V130, P465; Monzon FA, 2009, J CLIN ONCOL, V27, P2503, DOI 10.1200/JCO.2008.17.9762; Oien KA, 2008, J CLIN ONCOL, V26, P4373, DOI 10.1200/JCO.2008.17.6156; Pentheroudakis G, 2007, EUR J CANCER, V43, P2026, DOI 10.1016/j.ejca.2007.06.023; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Su AI, 2001, CANCER RES, V61, P7388; Talantov D, 2006, J MOL DIAGN, V8, P320, DOI 10.2353/jmoldx.2006.050136; Tothill RW, 2005, CANCER RES, V65, P4031, DOI 10.1158/0008-5472.CAN-04-3617; van de Wouw AJ, 2002, EUR J CANCER, V38, P409, DOI 10.1016/S0959-8049(01)00378-1; van Laar RK, 2009, INT J CANCER, V125, P1390, DOI 10.1002/ijc.24504; Varadhachary GR, 2008, J CLIN ONCOL, V26, P4442, DOI 10.1200/JCO.2007.14.4378; YEANG CH, 2001, BIOINFORMATICS, V17, P316	24	8	9	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	2010	29	31					4485	4492		10.1038/onc.2010.196	http://dx.doi.org/10.1038/onc.2010.196			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634DG	20514016				2022-12-17	WOS:000280559100011
J	Watari, A; Iwabe, N; Masuda, H; Okada, M				Watari, A.; Iwabe, N.; Masuda, H.; Okada, M.			Functional transition of Pak proto-oncogene during early evolution of metazoans	ONCOGENE			English	Article						evolution; metazoans; Pak; proto-oncogene	PROTEIN-TYROSINE KINASE; P21-ACTIVATED KINASES; MONOSIGA-BREVICOLLIS; SRC; ACTIVATION; CANCER; ONCOGENES; ANIMALS; PATHWAY; CELLS	Proto-oncogenes encode signaling molecular switches regulating cellular homeostasis in metazoans, and can be converted to oncogenes by gain-of-function mutations. To address the molecular basis for development of the regulatory system of proto-oncogenes during evolution, we screened for ancestral proto-oncogenes from the unicellular choanoflagellate Monosiga ovata by monitoring their transforming activities, and isolated a Pak gene ortholog encoding a serine/threonine kinase as a 'primitive oncogene'. We also cloned Pak orthologs from fungi and the multicellular sponge Ephydatia fluviatilis, and compared their regulatory features with that of M. ovata Pak (MoPak). MoPak is constitutively active and induces cell transformation in mammalian fibroblasts, although the Pak orthologs from multicellular animals are strictly regulated. Analyses of Pak mutants revealed that structural alteration of the auto-inhibitory domain (AID) of MoPak confers higher constitutive kinase activity, as well as greater binding ability to Rho family GTPases than the multicellular Paks, and this structural alteration is responsible for cell transformation and disruption of multicellular tissue organization. These results show that maturation of AID function was required for the development of the strict regulatory system of the Pak proto-oncogene, and suggest a potential link between the establishment of the regulatory system of proto-oncogenes and metazoan evolution. Oncogene (2010) 29, 3815-3826; doi: 10.1038/onc.2010.148; published online 10 May 2010	[Watari, A.; Masuda, H.; Okada, M.] Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; [Iwabe, N.] Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto, Japan	Osaka University; Kyoto University	Okada, M (corresponding author), Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, 3-1 Yamada Oka, Suita, Osaka 5650871, Japan.	okadam@biken.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Drs M Matsuda, T Akagi, T Hishida, M Yutsudo and S Morita for their generous gifts of reagents. This work was supported by Grants-in-Aids for Scientific Research on Priority Areas 'Cancer' and 'Comparative Genomics', from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BISHOP JM, 1981, CELL, V23, P5; Bokoch GM, 2003, ANNU REV BIOCHEM, V72, P743, DOI 10.1146/annurev.biochem.72.121801.161742; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chung CY, 1999, J CELL BIOL, V147, P559, DOI 10.1083/jcb.147.3.559; Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; HIBBERD DJ, 1975, J CELL SCI, V17, P191; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hofmann C, 2004, J CELL SCI, V117, P4343, DOI 10.1242/jcs.01392; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOHNSTON RN, 1992, BIOCHEM CELL BIOL, V70, P831, DOI 10.1139/o92-130; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lang BF, 2002, CURR BIOL, V12, P1773, DOI 10.1016/S0960-9822(02)01187-9; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li WQ, 2008, J BIOL CHEM, V283, P15491, DOI 10.1074/jbc.M800002200; Lozano E, 2008, J CELL SCI, V121, P933, DOI 10.1242/jcs.016121; Manning G, 2008, P NATL ACAD SCI USA, V105, P9674, DOI 10.1073/pnas.0801314105; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; O'Sullivan GC, 2007, INT J CANCER, V121, P1930, DOI 10.1002/ijc.22893; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Philippe H, 2004, MOL BIOL EVOL, V21, P1740, DOI 10.1093/molbev/msh182; Reeder MK, 2001, J BIOL CHEM, V276, P40606, DOI 10.1074/jbc.M103925200; Segawa Y, 2006, P NATL ACAD SCI USA, V103, P12021, DOI 10.1073/pnas.0600021103; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Suga H, 2001, GENE, V280, P195, DOI 10.1016/S0378-1119(01)00784-3; Suga H, 2008, FEBS LETT, V582, P815, DOI 10.1016/j.febslet.2008.02.002; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Todd R, 1999, ANTICANCER RES, V19, P4729; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200	38	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 1	2010	29	26					3815	3826		10.1038/onc.2010.148	http://dx.doi.org/10.1038/onc.2010.148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20453877				2022-12-17	WOS:000279385200009
J	Iejima, D; Minegishi, Y; Takenaka, K; Siswanto, A; Watanabe, M; Huang, L; Watanabe, T; Tanaka, F; Kuroda, M; Gotoh, N				Iejima, D.; Minegishi, Y.; Takenaka, K.; Siswanto, A.; Watanabe, M.; Huang, L.; Watanabe, T.; Tanaka, F.; Kuroda, M.; Gotoh, N.			FRS2 beta, a potential prognostic gene for non-small cell lung cancer, encodes a feedback inhibitor of EGF receptor family members by ERK binding	ONCOGENE			English	Article						FRS2; SNT2; FRS3; HER; NSCLC; prognosis	DOCKING-PROTEIN FRS2-ALPHA; FRS2 FAMILY; MAP KINASE; ACTIVATION; MUTATIONS; EXPRESSION; SITES; MOTIF	An adaptor protein FRS2b inhibits epidermal growth factor-receptor (EGFR) tyrosine kinase without being phosphorylated at tyrosine residues after EGF stimulation. Although binding to ERK appears to be important for this inhibition, the precise molecular mechanisms and the role of FRS2b in signal transduction mediated by other EGFR family members, as well as its role in human cancer, remain unclear. In this study, we demonstrate that FRS2b inhibits anchorage-independent cell growth induced by oncogenic ErbB2, another member of EGFR family, and that it inhibits heterodimer formation between EGFR and ErbB2. We mapped the residues important for the FRS2b and ERK interaction to two docking (D) domain-like sequences on FRS2b and two aspartic acid residues in the common docking (CD) domain of ERK. Moreover, in response to EGF, ERK translocated to the plasma membrane in cells expressing FRS2b but not an FRS2b mutant in which four arginine residues in the D domains were replaced with alanines, suggesting that FRS2b serves as a plasma membrane anchor for activated ERK. Finally, a low mRNA expression level of FRS2b was significantly correlated with poor prognosis in a cohort of 60 non-small cell lung cancer patients. Therefore, we have identified the molecular mechanisms by which FRS2b acts as a feedback inhibitor of EGFR family members and suggest a role for FRS2b as a tumor suppressor. Oncogene (2010) 29, 3087-3099; doi: 10.1038/onc.2010.69; published online 15 March 2010	[Iejima, D.; Minegishi, Y.; Siswanto, A.; Watanabe, M.; Gotoh, N.] Univ Tokyo, Inst Med Sci, Dept Syst Biomed Technol, Minato Ku, Tokyo 1088639, Japan; [Takenaka, K.; Tanaka, F.] Kyoto Univ, Sch Med, Dept Thorac Surg, Kyoto 606, Japan; [Takenaka, K.] Koseikai Takeda Hosp, Dept Thorac Surg, Kyoto, Japan; [Siswanto, A.; Watanabe, T.] Univ Tokyo, Grad Sch Frontier Sci, Dept Med Genome Sci, Minato Ku, Tokyo 1088639, Japan; [Huang, L.] RIKEN, Cellular Biochem Lab, Wako, Saitama, Japan; [Tanaka, F.] Hyogo Coll Med, Dept Thorac Surg, Nishinomiya, Hyogo, Japan; [Kuroda, M.] Tokyo Med Univ, Dept Pathol, Tokyo, Japan	University of Tokyo; Kyoto University; University of Tokyo; RIKEN; Hyogo College of Medicine; Tokyo Medical University	Gotoh, N (corresponding author), Univ Tokyo, Inst Med Sci, Dept Syst Biomed Technol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	ngotoh@ims.u-tokyo.ac.jp	Huang, Lin/AAI-5740-2020		Ministry of Health, Labor and Welfare of Japan; Naito Foundation; Cell Science Research Foundation	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Naito Foundation(Naito Memorial Foundation); Cell Science Research Foundation(Cell Science Research Foundation, Japan)	We are grateful to Dr Toshio Kitamura for valuable reagents for retrovirus expression system and Dr Tadashi Yamamoto for NIH3T3 cells expressing oncogenic ErbB2 and for expression vectors for ErbB2 and VE mutant. This work was supported by grants from the Ministry of Health, Labor and Welfare of Japan for the 3rd-term Comprehensive 10-year Strategy for Cancer Control; from the Naito Foundation; and Cell Science Research Foundation to NG.	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Butch ER, 1996, J BIOL CHEM, V271, P4230; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Gotoh N, 2005, MOL CELL BIOL, V25, P4105, DOI 10.1128/MCB.25.10.4105-4116.2005; Gotoh N, 2004, P NATL ACAD SCI USA, V101, P17144, DOI 10.1073/pnas.0407577101; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Gotoh N, 2008, CANCER SCI, V99, P1319, DOI 10.1111/j.1349-7006.2008.00840.x; Gotoh N, 2009, INT J BIOCHEM CELL B, V41, P511, DOI 10.1016/j.biocel.2008.06.019; Hadari YR, 2001, P NATL ACAD SCI USA, V98, P8578, DOI 10.1073/pnas.161259898; Huang L, 2006, ONCOGENE, V25, P6457, DOI 10.1038/sj.onc.1209656; Huang L, 2004, BIOCHEM BIOPH RES CO, V324, P1011, DOI 10.1016/j.bbrc.2004.09.152; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kawamura-Tsuzuku J, 2004, ONCOGENE, V23, P6630, DOI 10.1038/sj.onc.1207890; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Lee T, 2004, MOL CELL, V14, P43, DOI 10.1016/S1097-2765(04)00161-3; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Sato T, 2009, EXPERT OPIN THER TAR, V13, P689, DOI 10.1517/14728220902942330; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sonobe M, 2005, BRIT J CANCER, V93, P355, DOI 10.1038/sj.bjc.6602707; Sonobe M, 2006, J MOL DIAGN, V8, P351, DOI 10.2353/jmoldx.2006.050132; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Yamamoto S, 2005, P NATL ACAD SCI USA, V102, P15983, DOI 10.1073/pnas.0507961102; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	30	8	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3087	3099		10.1038/onc.2010.69	http://dx.doi.org/10.1038/onc.2010.69			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20228838				2022-12-17	WOS:000278133100006
J	Neel, BD; Lopez, J; Chabadel, A; Gillet, G				Neel, B. D.; Lopez, J.; Chabadel, A.; Gillet, G.			Lithium suppresses motility and invasivity of v-src-transformed cells by glutathione-dependent activation of phosphotyrosine phosphatases	ONCOGENE			English	Article						lithium; Src tyrosine kinase; PTPases; cell migration; glutathione	GLYCOGEN-SYNTHASE KINASE-3; ROUS-SARCOMA VIRUS; GENE-EXPRESSION; TYROSINE KINASE; NEURORETINAL CELLS; ENDOTHELIAL-CELLS; BIPOLAR DISORDER; FAMILY KINASES; CANCER CELLS; IN-VIVO	Lithium has long been used for the treatment and prophylaxis of bipolar mood disorder. However, nerve cells are not the sole targets of lithium. Indeed, lithium was reported to target numerous cell types, and affect cell proliferation, differentiation and death. Thus, the idea has been raised that lithium may act on signaling pathways involved in neoplastic transformation. Indeed, the effect of lithium on tumor progression is currently being tested in a limited number of clinical trials. However, the molecular mechanisms by which lithium affects neoplastic transformation remain to be characterized. Here, using mouse fibroblasts transformed by the v-src oncogene as a model, we show that lithium drastically inhibits cell motility and compromises the invasive phenotype of v-src-transformed cells. In addition, we show that this effect is mediated by the activation of phosphotyrosine phosphatases, but not by the direct inhibition of the v-Src tyrosine kinase. Finally, we show that lithium activates phosphotyrosine phosphatases by the modulation of the redox status of the cell, independently of the Wnt and the inositol phosphate canonical pathways. Thus, this study supports the idea that lithium, acting similar to an antioxydizer, may have antimetastatic properties in vivo. Oncogene (2009) 28, 3246-3260; doi: 10.1038/onc.2009.190; published online 13 July 2009	[Neel, B. D.; Lopez, J.; Gillet, G.] Univ Lyon 1, Inst Biol & Chim Prot, UMR 5086, CNRS,IFR 128, F-69367 Lyon 07, France; [Chabadel, A.] Univ Lyon, Lab Biol Mol Cellule, UMR 5239, CNRS,Ecole Normale Super Lyon,IFR 128, Lyon 07, France; [Lopez, J.] Hop Croix Rousse, Hosp Civils Lyon, F-69317 Lyon 04, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet; CHU Lyon	Gillet, G (corresponding author), Univ Lyon 1, Inst Biol & Chim Prot, UMR 5086, CNRS,IFR 128, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	gillet, germain/A-9095-2013	LOPEZ, Jonathan/0000-0003-3768-2378; GILLET, Germain/0000-0002-1514-327X	Association pour la Recherche sur le Cancer (ARC); the Ligue Nationale contre le Cancer; Region Rhone Alpes; Ministere de la Recherche; ARC	Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); the Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Region Rhone Alpes(Region Auvergne-Rhone-Alpes); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); ARC(Australian Research Council)	We thank Pierre Jurdic and Philippe Gonzalo for helpfull discussions and critical reading of the paper. We acknowledge Aurelie Cornut for skillfull technical assistance. This work was supported by the Association pour la Recherche sur le Cancer (ARC), the Ligue Nationale contre le Cancer and the Region Rhone Alpes. BDN is a recipient of fellowships from the Ministere de la Recherche and the ARC.	Aghdam SY, 2007, CURR ALZHEIMER RES, V4, P21; Almeida CG, 2003, NEUROSCI LETT, V339, P127, DOI 10.1016/S0304-3940(02)01478-7; Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200; Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Beaulieu JM, 2008, CELL, V132, P125, DOI 10.1016/j.cell.2007.11.041; Benati D, 2008, CURR MED CHEM, V15, P1154, DOI 10.2174/092986708784310404; CAMPAGNE MMV, 1988, DEV GENET, V9, P589, DOI 10.1002/dvg.1020090435; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Clement-Lacroix P, 2005, P NATL ACAD SCI USA, V102, P17406, DOI 10.1073/pnas.0505259102; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; Cui J, 2007, NEUROSCIENCE, V144, P1447, DOI 10.1016/j.neuroscience.2006.11.010; D'Alessio M, 2004, FASEB J, V18, P1609, DOI 10.1096/fj.04-1813fje; Edwards CM, 2008, BLOOD, V111, P2833, DOI 10.1182/blood-2007-03-077685; GILLET G, 1993, ONCOGENE, V8, P565; Gould TD, 2005, NEUROPSYCHOPHARMACOL, V30, P1223, DOI 10.1038/sj.npp.1300731; Gould TD, 2004, MOL PSYCHIATR, V9, P734, DOI 10.1038/sj.mp.4001518; Hashimoto R, 2003, FEBS LETT, V538, P145, DOI 10.1016/S0014-5793(03)00167-4; Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012; Johnson FM, 2007, ANTI-CANCER AGENT ME, V7, P651, DOI 10.2174/187152007784111278; JOVE R, 1986, J VIROL, V60, P840, DOI 10.1128/JVI.60.3.840-848.1986; KAO KR, 1989, DEV BIOL, V132, P81, DOI 10.1016/0012-1606(89)90207-8; Karlovic D, 2007, CELL BIOL TOXICOL, V23, P83, DOI 10.1007/s10565-006-0126-9; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; Linder S, 2005, J CELL SCI, V118, P2079, DOI 10.1242/jcs.02390; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Markova B, 2005, METHODS, V35, P22, DOI 10.1016/j.ymeth.2004.07.004; MARONEY AC, 1992, ONCOGENE, V7, P1207; Mathew S, 2008, J BIOL CHEM, V283, P22709, DOI 10.1074/jbc.M801319200; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Moldovan L, 2006, CARDIOVASC RES, V71, P236, DOI 10.1016/j.cardiores.2006.05.003; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; Pao LI, 2007, ANNU REV IMMUNOL, V25, P473, DOI 10.1146/annurev.immunol.23.021704.115647; Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; PIZARRO JG, 2008, J CELL MOL MED; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Ronziere MC, 2003, BIOMATERIALS, V24, P851, DOI 10.1016/S0142-9612(02)00418-0; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V324, P1155, DOI 10.1016/j.bbrc.2004.09.171; Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Seelan RS, 2008, NEUROSCIENCE, V151, P1184, DOI 10.1016/j.neuroscience.2007.10.045; Severus WE, 2008, BIPOLAR DISORD, V10, P231, DOI 10.1111/j.1399-5618.2007.00475.x; Smits VAJ, 1999, FEBS LETT, V457, P23, DOI 10.1016/S0014-5793(99)01002-9; Song L, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-20; Stump RJW, 2006, J PATHOL, V210, P249, DOI 10.1002/path.2049; Sun AJ, 2007, PROSTATE, V67, P976, DOI 10.1002/pros.20586; Wada A, 2005, J PHARMACOL SCI, V99, P307, DOI 10.1254/jphs.CRJ05009X; WELSHONS WV, 1995, J CELL PHYSIOL, V165, P134, DOI 10.1002/jcp.1041650116; Yang B, 2003, CANCER RES, V63, P1520; Zhang WV, 2005, APOPTOSIS, V10, P75, DOI 10.1007/s10495-005-6063-x; Zhen XC, 2002, PSYCHOPHARMACOLOGY, V162, P379, DOI 10.1007/s00213-002-1126-y	52	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3246	3260		10.1038/onc.2009.190	http://dx.doi.org/10.1038/onc.2009.190			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19597466				2022-12-17	WOS:000269673400007
J	Steinmann, S; Schulte, K; Beck, K; Chachra, S; Bujnicki, T; Klempnauer, KH				Steinmann, S.; Schulte, K.; Beck, K.; Chachra, S.; Bujnicki, T.; Klempnauer, K-H			v-Myc inhibits C/EBP beta activity by preventing C/EBP beta-induced phosphorylation of the co-activator p300	ONCOGENE			English	Article						Myc; C/EBP beta; p300; HIPK2; phosphorylation	BINDING-PROTEIN-BETA; ACUTE MYELOID LEUKEMIAS; C-MYC; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; ALPHA; CELLS; PROLIFERATION; ASSOCIATION	Myc, a key regulator of cellular proliferation, differentiation and apoptosis, exerts its biological functions by activating or suppressing the transcription of specific sets of target genes. C/EBP transcription factors play important roles during differentiation of various cell types and have been identified as critical targets for v-Myc- and c-Myc-dependent suppression of myeloid and fat cell differentiation. Here, we have addressed the mechanism by which v-Myc suppresses the activity of C/EBP beta. We show that v-Myc is recruited to the aminoterminal domain of C/EBP beta and interferes with the cooperation of C/EBP beta and the co-activator p300 by preventing C/EBP beta-induced phosphorylation of p300. We have identified the protein kinase responsible for C/EBP beta-induced phosphorylation of p300 as homeo-domain interacting protein kinase 2 (HIPK2) and show that v-Myc displaces the kinase from the C/EBP beta-p300 complex. Overall, our findings that the modulation of the C/EBP beta-induced phosphorylation of p300 as a new mechanism of transcriptional suppression by v-Myc. Oncogene (2009) 28, 2446-2455; doi:10.1038/onc.2009.90;published online 18 May 2009	[Steinmann, S.; Schulte, K.; Beck, K.; Chachra, S.; Bujnicki, T.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de		Bujnicki, Tuyen/0000-0002-7191-8455; Schachtrup, Kristina/0000-0002-9385-8254				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Calkhoven CF, 2000, GENE DEV, V14, P1920; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Di Stefano V, 2004, EXP CELL RES, V293, P311, DOI 10.1016/j.yexcr.2003.09.032; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Heath VJ, 2000, EXP CELL RES, V254, P91, DOI 10.1006/excr.1999.4736; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Izumi H, 2001, J CELL SCI, V114, P1533; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Joo M, 2004, J BIOL CHEM, V279, P6658, DOI 10.1074/jbc.M306267200; Kleine-Kohlbrecher D, 2006, CURR TOP MICROBIOL, V302, P51; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lee CM, 1999, ONCOGENE, V18, P2997, DOI 10.1038/sj.onc.1202786; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nerlov C, 2004, NAT REV CANCER, V4, P394, DOI 10.1038/nrc1363; Nerlov C, 2007, TRENDS CELL BIOL, V17, P318, DOI 10.1016/j.tcb.2007.07.004; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Reiter F, 2007, ONCOGENE, V26, P1769, DOI 10.1038/sj.onc.1209975; Rinaldo C, 2007, BIOCHEM CELL BIOL, V85, P411, DOI 10.1139/O07-071; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; SYMONDS G, 1986, MOL CELL BIOL, V6, P1796, DOI 10.1128/MCB.6.5.1796; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tinel M, 2003, J HEPATOL, V39, P171, DOI 10.1016/S0168-8278(03)00238-1; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Xu M, 2003, EMBO J, V22, P893, DOI 10.1093/emboj/cdg094; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zahnow CA, 2001, CANCER RES, V61, P261; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569	57	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	26					2446	2455		10.1038/onc.2009.90	http://dx.doi.org/10.1038/onc.2009.90			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465QH	19448669				2022-12-17	WOS:000267601400003
J	Komori, K; Takagi, Y; Sanada, M; Lim, TH; Nakatsu, Y; Tsuzuki, T; Sekiguchi, M; Hidaka, M				Komori, K.; Takagi, Y.; Sanada, M.; Lim, T-H; Nakatsu, Y.; Tsuzuki, T.; Sekiguchi, M.; Hidaka, M.			A novel protein, MAPO1, that functions in apoptosis triggered by O-6-methylguanine mispair in DNA	ONCOGENE			English	Article						apoptosis; gene-trap mutagenesis; Mapo1; MGMT; O-6-methylguanine	EMBRYONIC STEM-CELLS; ALKYLATION-INDUCED APOPTOSIS; MISMATCH REPAIR; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ANTINEOPLASTIC DRUGS; ESCHERICHIA-COLI; INDUCE APOPTOSIS; KNOCKOUT MICE; MUTL-ALPHA; ATR KINASE	O-6-Methylguanine produced in DNA induces mutation due to its ambiguous base-pairing properties during DNA replication. To suppress such an outcome, organisms possess a mechanism to eliminate cells carrying O-6-methylguanine by inducing apoptosis that requires the function of mismatch repair proteins. To identify other factors involved in this apoptotic process, we performed retrovirus-mediated gene-trap mutagenesis and isolated a mutant that acquired resistance to a simple alkylating agent, N-methyl-N-nitrosourea (MNU). However, it was still sensitive to methyl methanesulfonate, 1-(4-amino-2methyl- 5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea, etoposide and ultraviolet irradiation. Moreover, the mutant exhibited an increased mutant frequency after exposure to MNU. The gene responsible was identified and designated Mapo1 (O-6-methylguanine- induced apoptosis 1). When the expression of the gene was inhibited by small interfering RNA, MNU-induced apoptosis was significantly suppressed. In the Mapo1-defective mutant cells treated with MNU, the mitochondrial membrane depolarization and caspase-3 activation were severely suppressed, although phosphorylation of p53, CHK1 and histone H2AX was observed. The orthologs of the Mapo1 gene are present in various organisms from nematode to humans. Both mouse and human MAPO1 proteins expressed in cells localize in the cytoplasm. We therefore propose that MAPO1 may play a role in the signaltransduction pathway of apoptosis induced by O-6-methyl-guanine-mispaired lesions.	[Hidaka, M.] Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, Fukuoka 8140193, Japan; [Komori, K.; Sekiguchi, M.; Hidaka, M.] Biomol Engn Res Inst, Dept Mol Biol, Suita, Osaka, Japan; [Takagi, Y.; Sekiguchi, M.] Fukuoka Dent Coll, Frontier Res Ctr, Fukuoka 8140193, Japan; [Lim, T-H; Nakatsu, Y.; Tsuzuki, T.; Hidaka, M.] Kyushu Univ, Fac Med Sci, Dept Med Biophys & Radiat Biol, Fukuoka 812, Japan	Fukuoka Dental College (FDC); Fukuoka Dental College (FDC); Kyushu University	Hidaka, M (corresponding author), Fukuoka Dent Coll, Dept Physiol Sci & Mol Biol, Sawara Ku, 2-15-1 Tamura, Fukuoka 8140193, Japan.	hidaka@college.fdcnet.ac.jp		Nakatsu, Yoshimichi/0000-0001-7408-7071	Kazusa DNA Research Institute [hKIAA1450cDNA]; Ministry of Education, Culture, Sports, Science and Technology of Japan	Kazusa DNA Research Institute; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank the Kazusa DNA Research Institute for providing hKIAA1450cDNA. This study was supported by grants (including a Frontier Research Grant) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Caporali S, 2004, MOL PHARMACOL, V66, P478; Cejka P, 2003, EMBO J, V22, P2245, DOI 10.1093/emboj/cdg216; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Glaab WE, 1998, MUTAT RES-FUND MOL M, V398, P197, DOI 10.1016/S0027-5107(98)00004-9; Glassner BJ, 1999, MUTAGENESIS, V14, P339, DOI 10.1093/mutage/14.3.339; Guo G, 2004, NATURE, V429, P891, DOI 10.1038/nature02653; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; Hickman MJ, 2004, MOL CELL, V14, P105, DOI 10.1016/S1097-2765(04)00162-5; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hidaka M, 2005, NUCLEIC ACIDS RES, V33, P5703, DOI 10.1093/nar/gki878; Ishida Y, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.24.e35; ITO T, 1994, MUTAT RES, V314, P273, DOI 10.1016/0921-8777(94)90071-X; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Ochs K, 2000, CANCER RES, V60, P5815; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; Peng M, 2007, EMBO J, V26, P3238, DOI 10.1038/sj.emboj.7601754; Pepponi R, 2003, J PHARMACOL EXP THER, V304, P661, DOI 10.1124/jpet.102.043950; Sakumi K, 1997, CANCER RES, V57, P2415; Sanada M, 2007, CARCINOGENESIS, V28, P2657, DOI 10.1093/carcin/bgm188; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; Stojic L, 2004, GENE DEV, V18, P1331, DOI 10.1101/gad.294404; Takagi Y, 2003, DNA REPAIR, V2, P1135, DOI 10.1016/S1568-7864(03)00134-4; Takagi Y, 2008, BIOCHEM PHARMACOL, V76, P303, DOI 10.1016/j.bcp.2008.05.008; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Tsuzuki T, 1996, CARCINOGENESIS, V17, P1215, DOI 10.1093/carcin/17.6.1215; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; Yoshioka K, 2006, MOL CELL, V22, P501, DOI 10.1016/j.molcel.2006.04.023	41	8	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2009	28	8					1142	1150		10.1038/onc.2008.462	http://dx.doi.org/10.1038/onc.2008.462			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412KE	19137017				2022-12-17	WOS:000263722900009
J	Petrie, K; Guidez, F; Zhu, J; Howell, L; Owen, G; Chew, YP; Parks, S; Waxman, S; Licht, J; Mittnacht, S; Zelent, A				Petrie, K.; Guidez, F.; Zhu, J.; Howell, L.; Owen, G.; Chew, Y. P.; Parks, S.; Waxman, S.; Licht, J.; Mittnacht, S.; Zelent, A.			Retinoblastoma protein and the leukemia-associated PLZF transcription factor interact to repress target gene promoters	ONCOGENE			English	Article						PLZF; Rb; E2F1	ACUTE PROMYELOCYTIC LEUKEMIA; ZINC-FINGER PROTEIN; PML-RAR-ALPHA; HISTONE DEACETYLASE; PROGENITOR CELLS; FUSION PROTEINS; SELF-RENEWAL; E2F FUNCTION; DNA-BINDING; STEM-CELLS	Translocations of the retinoic acid receptor-alpha (RAR alpha) locus with the promyelocytic leukemia zinc-finger (PLZF) or PML genes lead to expression of oncogenic PLZF RAR alpha or PML-RAR alpha fusion proteins, respectively. These fusion oncoproteins constitutively repress RAR alpha target genes, in large part through aberrant recruitment of multiprotein co-repressor complexes. PML and PML RAR alpha have previously been shown to associate with the retinoblastoma (Rb) tumour suppressor protein in its hypophosphorylated state. Here, we demonstrate that PLZF also interacts with Rb in vitro and in vivo. The interaction between PLZF and Rb is mediated through the Rb pocket and the region of PLZF that lies between its transcriptional repression (poxvirus and zinc-finger, POZ) and DNA-binding (zinc-finger) domains. In addition, Rb can simultaneously interact with PLZF and the E2F1 S phase-inducing transcription factor, suggesting that these proteins can exist in the same multiprotein complex. In contrast to the interaction of Rb with PML or E2F1, the PLZF-Rb interaction is not dependent on hypophosphorylation of Rb. These data are supported by chromatin immunoprecipitation analysis, which indicates that PLZF associates with the promoter region of CDC6, a known E2F/Rb target gene. Co-expression of PLZF and Rb results in enhancement of transcriptional repression of PLZF and E2F/Rb target genes, indicating functional co-operation between the two proteins. Both PLZF and Rb have been shown to function in stem cells and taken together these data suggest that interactions between PLZF and Rb could be important in stem cell biology.	[Petrie, K.; Howell, L.; Zelent, A.] Inst Canc Res, Sect Haemato Oncol, Sutton SM2 5NG, Surrey, England; [Guidez, F.; Parks, S.] Kings Coll London, Dept Med & Mol Genet, London WC2R 2LS, England; [Zhu, J.] Shanghai Med Univ 2, Ruijin Hosp, Shanghai Inst Hematol, Shanghai, Peoples R China; [Owen, G.] Catholic Univ Chile, Fac Biol Sci, Dept Physiol, Santiago, Chile; [Chew, Y. P.; Mittnacht, S.] Inst Canc Res, Canc Res UK Ctr Cell & Mol Biol, London, England; [Waxman, S.] Mt Sinai Sch Med, Div Hematol & Med Oncol, New York, NY 10029 USA; [Licht, J.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	University of London; Institute of Cancer Research - UK; University of London; King's College London; Shanghai Jiao Tong University; Pontificia Universidad Catolica de Chile; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai; Northwestern University; Feinberg School of Medicine	Zelent, A (corresponding author), Inst Canc Res, Sect Haemato Oncol, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	arthur.zelent@icr.ac.uk	Zelent, Arthur/B-3532-2009; Petrie, Kevin/I-7115-2015; Guidez, Fabien/P-4220-2019; Licht, Jonathan/L-4239-2019; Owen, Gareth Ivor/A-5100-2013; Licht, Jonathan/AAL-9184-2020; Guidez, Fabien/B-3750-2009	Petrie, Kevin/0000-0002-9805-9152; Guidez, Fabien/0000-0003-1380-4473; Licht, Jonathan/0000-0002-3942-1369; Zelent, Arthur/0000-0002-7968-9888	Leukaemia Research Fund of Great Britain; Samuel Waxman Cancer Research Foundation; Kay Kendall Leukaemia Fund; Cancer Research UK; National Institute of Health [CA59936]; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER	Leukaemia Research Fund of Great Britain; Samuel Waxman Cancer Research Foundation; Kay Kendall Leukaemia Fund; Cancer Research UK(Cancer Research UK); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge support from the Leukaemia Research Fund of Great Britain (AZ and FG), the Samuel Waxman Cancer Research Foundation, the Kay Kendall Leukaemia Fund (KP), Cancer Research UK (SM) and the National Institute of Health (CA59936, AZ, JL and SW). We also thank Drs Angela Barrett and Manuel Boix-Chornet for critical reading of the article.	Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bergh G, 1999, BLOOD, V94, P1971; Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; CROOK T, 1991, ONCOGENE, V6, P873; Dai MS, 2002, J BIOL CHEM, V277, P26327, DOI 10.1074/jbc.M201834200; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Galderisi U, 2006, ONCOGENE, V25, P5250, DOI 10.1038/sj.onc.1209736; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 2005, MOL CELL BIOL, V25, P5552, DOI 10.1128/MCB.25.13.5552-5566.2005; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Ivins S, 2003, ONCOGENE, V22, P3685, DOI 10.1038/sj.onc.1206328; Kelly KF, 2006, TRENDS CELL BIOL, V16, P578, DOI 10.1016/j.tcb.2006.09.003; Khan MM, 2001, J BIOL CHEM, V276, P43491, DOI 10.1074/jbc.C100532200; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Piazza F, 2004, MOL CELL BIOL, V24, P10456, DOI 10.1128/MCB.24.23.10456-10469.2004; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sivertsen EA, 2006, BRIT J HAEMATOL, V135, P117, DOI 10.1111/j.1365-2141.2006.06252.x; Walkley CR, 2006, P NATL ACAD SCI USA, V103, P9057, DOI 10.1073/pnas.0603389103; Warrell RP, 1997, INT J CANCER, V70, P496, DOI 10.1002/(SICI)1097-0215(19970207)70:4<496::AID-IJC25>3.3.CO;2-P; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; YAVUZER U, 1995, ONCOGENE, V10, P123; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Yoshimoto T, 2006, EXP CELL RES, V312, P2040, DOI 10.1016/j.yexcr.2006.03.001; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	47	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5260	5266		10.1038/onc.2008.159	http://dx.doi.org/10.1038/onc.2008.159			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18504436				2022-12-17	WOS:000258915100010
J	Talukder, AH; Li, DQ; Manavathi, B; Kumar, R				Talukder, A. H.; Li, D-Q; Manavathi, B.; Kumar, R.			Serine 28 phosphorylation of NRIF3 confers its co-activator function for estrogen receptor-alpha transactivation	ONCOGENE			English	Article						NRIF3; Pak1; ER alpha; phosphorylation	ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TRANSCRIPTIONAL ACTIVATION; IN-VITRO; INDEPENDENT GROWTH; NUCLEAR RECEPTORS; TYROSINE KINASE; DNA-BINDING; ESTRADIOL; INSULIN	NRIF3 is an estrogen-inducible nuclear receptor coregulator that stimulates estrogen receptor-alpha (ER alpha) transactivation functions and associates with the endogenous ER and its target gene promoter. p21-activated protein kinase 1 (Pak1) phosphorylates ER alpha at Ser305 and this modification is important in ER alpha transactivation function. Although ERa transactivation functions are regulated by co-activator activity of NRIF3, it remains unclear whether Pak1 could impact ER functions via a posttranslational modi. cation of NRIF3. Here, we report that Pak1 phosphorylates NRIF3 at Serine28 and that NRIF3 binds to Pak1 in vitro and in vivo. We found that NRIF3 phosphorylation, co-activator activity and association with ER alpha increased following Pak1 phosphorylation of NRIF3's Ser28 and that activated ER alpha-Ser305 and NRIF3-Ser28 cooperatively support transactivation of ER alpha. NRIF3 expression increased significantly in cells with inducible Pak1 expression. We found that NRIF3 and ER alpha interaction, subcellular localization and ER alpha transactivation activity all increased in cells expressing the Pak1 phosphorylation-mimicking mutant NRIF3-Ser28Glu. Consistently, the NRIF3-Ser28Glu mutant exhibited an enhanced recruitment to the endogenous ER target genes and increased expression following estrogen stimulation. Finally, breast cancer cells with stable overexpression of NRIF3 showed increased proliferation and enhanced anchorage-independent growth. These findings suggest that NRIF3-Ser28 is a physiologic target of Pak1 signaling and contributes to the enhanced NRIF3 co-activator activity, leading to coordinated potentiation of ER alpha transactivation, its target gene expression and estrogen responsiveness of breast cancer cells.	[Talukder, A. H.; Li, D-Q; Manavathi, B.; Kumar, R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Kumar, R.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Kumar, R (corresponding author), Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.	rkumar@mdanderson.org		Manavathi, Bramanandam/0000-0002-1797-398X	NIH [CA90970, CA098823]; NATIONAL CANCER INSTITUTE [R01CA090970, R01CA098823] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Christopher J Barnes and Suresh Rayala for the confocal microscopy and western blotting, respectively. This study was supported by the NIH grants CA90970 and CA098823 to RK.	ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARNOLD SF, 1995, J STEROID BIOCHEM, V55, P163, DOI 10.1016/0960-0760(95)00177-2; ARNOLD SF, 1995, J STEROID BIOCHEM, V52, P159, DOI 10.1016/0960-0760(94)00166-J; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Glass CK, 2000, GENE DEV, V14, P121; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; Li DS, 1999, MOL CELL BIOL, V19, P7191; Li DS, 2001, MOL CELL BIOL, V21, P8371, DOI 10.1128/MCB.21.24.8371-8384.2001; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; ONATE SA, 1995, SCIENCE, V270, P1354; Patrone C, 1996, MOL ENDOCRINOL, V10, P499, DOI 10.1210/me.10.5.499; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Talukder AH, 2004, MOL CELL BIOL, V24, P6581, DOI 10.1128/mcb.24.15.6581-6591.2004; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019	37	8	9	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	39					5233	5242		10.1038/onc.2008.151	http://dx.doi.org/10.1038/onc.2008.151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GO	18521086	Green Accepted			2022-12-17	WOS:000258915100007
J	Milliken, EL; Lozada, KL; Johnson, E; Landis, MD; Seachrist, DD; Whitten, I; Sutton, ALM; Abdul-Karim, FW; Keri, RA				Milliken, E. L.; Lozada, K. L.; Johnson, E.; Landis, M. D.; Seachrist, D. D.; Whitten, I.; Sutton, A. L. M.; Abdul-Karim, F. W.; Keri, R. A.			Ovarian hyperstimulation induces centrosome amplification and aneuploid mammary tumors independently of alterations in p53 in a transgenic mouse model of breast cancer	ONCOGENE			English	Article						breast cancer; mammary gland; ovarian steroids; p53; centrosome; aneuploidy	ELEVATED LUTEINIZING-HORMONE; CHROMOSOMAL INSTABILITY; GENOMIC INSTABILITY; RANDOMIZED-TRIALS; MENSTRUAL FACTORS; EPITHELIAL-CELLS; MICE DEFICIENT; TAMOXIFEN; RECEPTOR; RISK	Aneuploidy and genomic instability are common features of human cancers, including breast cancer; however, mechanisms by which such abnormalities develop are not understood. The exquisite dependence of the mammary gland on hormones for growth and development as well as hormonal contributions to breast cancer risk and progression suggest that tumorigenic mechanisms in the breast should be considered in the context of hormonal stimulation. We used transgenic mice that overexpress luteinizing hormone with subsequent ovarian hyperstimulation as a model to identify mechanisms involved in hormone-induced mammary cancer. Tumor pathology in these mice is highly variable, suggesting individual tumors undergo distinct initiating or promoting events. Supporting this notion, hormone-induced tumors display considerable chromosomal instability and aneuploidy, despite the presence of functional p53. The presence of extensive centrosome amplification in tumors and hyperplastic glands prior to tumor formation suggests that alterations in the ovarian hormonal milieu dysregulate the centrosome cycle in mammary epithelial cells, leading to aneuploidy and cancer.	[Milliken, E. L.; Lozada, K. L.; Johnson, E.; Landis, M. D.; Seachrist, D. D.; Whitten, I.; Sutton, A. L. M.; Keri, R. A.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; [Abdul-Karim, F. W.] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; [Abdul-Karim, F. W.] Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA; [Keri, R. A.] Case Western Reserve Univ, Sch Med, Div Gen Med Sci Oncol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Keri, RA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 2109 Adelbert Rd,10900 Euclid Ave, Cleveland, OH 44106 USA.	keri@case.edu	Keri, Ruth/ABF-2209-2021	Keri, Ruth/0000-0002-1640-3088; Sutton, Amelia/0000-0003-0493-0670	NCI NIH HHS [R01 CA090398, R01 CA090398-06A1, T32CA059366, CA090398, P30 CA043703, T32 CA059366, R01 CA090398-07] Funding Source: Medline; NIGMS NIH HHS [T32GM08056, T32 GM008803, T32 GM008056, T32GM08803, T32 GM007250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA059366, R01CA090398, P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250, T32GM008056, T32GM008803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Backlund MG, 2001, CANCER RES, V61, P6577; Baum M, 2002, LANCET, V359, P2131; Bonneterre J, 2001, CANCER, V92, P2247, DOI 10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y; Braakhuis BJM, 2003, CANCER RES, V63, P1727; BRINTON LA, 1988, CANCER INVEST, V6, P245, DOI 10.3109/07357908809080645; Buzdar AU, 2006, CANCER-AM CANCER SOC, V107, P472, DOI 10.1002/cncr.22042; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; CHENG KC, 1993, ADV CANCER RES, V60, P121; Clarke M, 1998, LANCET, V351, P1451; Clarke RB, 2005, DEV BIOL, V277, P443, DOI 10.1016/j.ydbio.2004.07.044; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; Duesberg P, 2005, CELL ONCOL, V27, P293; Ewan KB, 2002, CANCER RES, V62, P5627; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Goepfert TM, 2002, CANCER RES, V62, P4115; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HSIEH CC, 1990, INT J CANCER, V46, P796, DOI 10.1002/ijc.2910460508; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; IRWIN KL, 1988, AM J EPIDEMIOL, V127, P1192, DOI 10.1093/oxfordjournals.aje.a114912; Jerry DJ, 2000, ONCOGENE, V19, P1052, DOI 10.1038/sj.onc.1203270; Kero J, 2000, J CLIN INVEST, V105, P633, DOI 10.1172/JCI7716; Kinyamu HK, 2003, MOL CELL BIOL, V23, P5867, DOI 10.1128/MCB.23.16.5867-5881.2003; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; KVALE G, 1988, CANCER-AM CANCER SOC, V62, P1625, DOI 10.1002/1097-0142(19881015)62:8<1625::AID-CNCR2820620828>3.0.CO;2-K; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li BL, 1998, ONCOGENE, V16, P997, DOI 10.1038/sj.onc.1201621; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mann RJ, 1999, ENDOCRINOLOGY, V140, P2592, DOI 10.1210/en.140.6.2592; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; MILLER CW, 1993, ONCOGENE, V8, P1815; Milliken EL, 2002, ENDOCRINOLOGY, V143, P3671, DOI 10.1210/en.2002-220228; Mohammad HP, 2003, ENDOCRINOLOGY, V144, P4626, DOI 10.1210/en.2003-0357; Pati D, 2004, CANCER RES, V64, P5608, DOI 10.1158/0008-5472.CAN-03-0629; Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Pihan GA, 2003, CANCER RES, V63, P1398; Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200; Zell JA, 2002, LIFE SCI, V71, P2331, DOI 10.1016/S0024-3205(02)02045-3	47	8	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1759	1766		10.1038/sj.onc.1210815	http://dx.doi.org/10.1038/sj.onc.1210815			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891171	Green Accepted			2022-12-17	WOS:000253962100011
J	Chaigne-Delalande, B; Anies, G; Kramer, I; Genot, E				Chaigne-Delalande, B.; Anies, G.; Kramer, I.; Genot, E.			Nonadherent cells switch to a Rac-mediated, SHIP regulated, Akt activation mode for survival	ONCOGENE			English	Article						adhesion; anoikis; akt; rac; SHIP; survival	PROTEIN-KINASE B; INTEGRINS; PATHWAYS; MOTILITY; ADHESION; 3-KINASE; PHOSPHORYLATION; PI-3-KINASE; P130(CAS); ANOIKIS	Constitutively active Rac stimulates Akt activity in T lymphocytes cultured in suspension. This regulation contrasts with findings obtained in fibroblasts, endothelial or neuronal cells grown on substrate, where Akt stimulation occurs independently of Rac. We now show that V12Rac-mediated stimulation of Akt is not restricted to the hematopoietic lineage but is dependent on the adherence status of the cell. V12Rac-mediated stimulation of Akt as well as molecular association between Rac and Akt occurred exclusively in cells kept in suspension. Stimulation and complex formation are dependent on SHIP but in a manner that differs from its role in dephosphorylation of phosphoinositide lipids. Adherent cells lacking SHIP, but not those lacking PTEN, are able to activate Akt through the Rac pathway. Our data reveal the existence of a bona. de Rac to Akt signaling pathway, tightly regulated by SHIP and operational in suspended cells only. This pathway may point to an alternative survival signal that is called into action when cells lose contact with the substrate and/or with other cells.	[Chaigne-Delalande, B.; Anies, G.; Kramer, I.; Genot, E.] Univ Bordeaux 1, European Inst Chem & Biol, Pessac, France; [Chaigne-Delalande, B.; Anies, G.; Kramer, I.; Genot, E.] INSERM, U889, Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm)	Chaigne-Delalande, B (corresponding author), IECB, INSERT U441, 2 Rue Robert Escapit, F-33600 Pessac, France.	e.genot@iecb.u-bordeaux.fr	Genot, Elisabeth/G-8031-2014					Astoul E, 2001, TRENDS IMMUNOL, V22, P490, DOI 10.1016/S1471-4906(01)01973-1; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Genot E, 1998, ONCOGENE, V17, P1731, DOI 10.1038/sj.onc.1202101; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Grodzki ACG, 2003, BRAZ J MED BIOL RES, V36, P1101, DOI 10.1590/S0100-879X2003000800017; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Krystal G, 2000, SEMIN IMMUNOL, V12, P397, DOI 10.1006/smim.2000.0222; MARTE BM, 1997, CURR BIOL, V63, P3; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128/MCB.23.19.6809-6822.2003; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Prasad N, 2001, MOL CELL BIOL, V21, P1416, DOI 10.1128/MCB.21.4.1416-1428.2001; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Snyder JT, 2003, J BIOL CHEM, V278, P21099, DOI 10.1074/jbc.M301418200; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Song JX, 2004, NAT IMMUNOL, V5, P150, DOI 10.1038/ni1030; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; WARD SG, 1992, EUR J IMMUNOL, V22, P45, DOI 10.1002/eji.1830220108; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7	33	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2008	27	13					1876	1885		10.1038/sj.onc.1210830	http://dx.doi.org/10.1038/sj.onc.1210830			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276NZ	17906692				2022-12-17	WOS:000254150600007
J	Radhakrishnan, SK; Bhat, UG; Halasi, M; Gartel, AL				Radhakrishnan, S. K.; Bhat, U. G.; Halasi, M.; Gartel, A. L.			P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents	ONCOGENE			English	Article						P-TEFb; ARC; flavopiridol; p53; phosphorylation; DNA-damaging agents	DEPENDENT PROTEIN-KINASE; TUMOR-CELLS; PHOSPHORYLATION; APOPTOSIS; DOXORUBICIN	Tumor suppressor p53 is stabilized in response to c-irradiation or treatment with DNA-damaging agents, and as a result p53 transcriptionally activates its targets leading to cell-cycle arrest or apoptosis. P-TEFb (positive transcription elongation factor b) inhibitors such as flavopiridol or 4-amino-6-hydrazino-7-b-d-ribofuranosyl-7H- pyrrolo[2,3-d]-pyrimidine-5-carboxamide (ARC) upregulate p53 protein levels, but inhibit the expression of its targets p21 and hdm2. DNA-damaging agents, doxorubicin and cisplatin are being used in combination with P-TEFb inhibitor flavopiridol in clinical trials for the treatment of some cancer patients. In this study, we found that P-TEFb inhibitors block the phosphorylation of p53 induced by doxorubicin. Furthermore, treatment of cells with P-TEFb inhibitors together with doxorubicin inhibits doxorubicin-induced binding of p53 to DNA and p53 transcriptional activity. These data suggest that P-TEFb inhibitors may antagonize the activation of p53 by DNA-damaging agents in tumors with wild-type p53.	[Radhakrishnan, S. K.; Bhat, U. G.; Halasi, M.; Gartel, A. L.] Univ Illinois, Dept Med, Coll Med, Chicago, IL 60612 USA; [Radhakrishnan, S. K.; Gartel, A. L.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA; [Halasi, M.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Med, Coll Med, 840 S Wood St,Room 1041, Chicago, IL 60612 USA.	agartel@uic.edu		Radhakrishnan, Senthil/0000-0002-5211-9498				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Bible KC, 2005, CLIN CANCER RES, V11, P5935, DOI 10.1158/1078-0432.CCR-04-2566; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Dunkern TR, 2003, DNA REPAIR, V2, P49, DOI 10.1016/S1568-7864(02)00185-4; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Radhakrishnan SK, 2006, CELL CYCLE, V5, P519, DOI 10.4161/cc.5.5.2514; Radhakrishnan SK, 2006, CANCER RES, V66, P3264, DOI 10.1158/0008-5472.CAN-05-3940; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, NAT CELL BIOL, V2, pE178, DOI 10.1038/35036427; Wang SW, 2004, J BIOL CHEM, V279, P25535, DOI 10.1074/jbc.M400944200; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	19	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1306	1309		10.1038/sj.onc.1210737	http://dx.doi.org/10.1038/sj.onc.1210737			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724473				2022-12-17	WOS:000253407000013
J	Sun, J; Blaskovich, MA; Jove, R; Livingston, SK; Coppola, D; Sebti, SM				Sun, J.; Blaskovich, M. A.; Jove, R.; Livingston, S. K.; Coppola, D.; Sebti, S. M.			Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity (vol 24, pg 3236, 2005)	ONCOGENE			English	Correction																		Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470	1	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1344	1344		10.1038/sj.onc.1211028	http://dx.doi.org/10.1038/sj.onc.1211028			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT		Bronze			2022-12-17	WOS:000253407000021
J	O'Neill, LAJ				O'Neill, L. A. J.			Toll-like receptors in cancer - Introduction	ONCOGENE			English	Editorial Material							INNATE IMMUNITY; ACTIVATION		Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland	Trinity College Dublin	O'Neill, LAJ (corresponding author), Trinity Coll Dublin, Sch Biochem & Immunol, Dublin, Ireland.	laoneill@tcd.ie						ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010; Hicks AM, 2006, P NATL ACAD SCI USA, V103, P7753, DOI 10.1073/pnas.0602382103; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; O'Neill LAJ, 2006, NAT REV DRUG DISCOV, V5, P549, DOI 10.1038/nrd2070; Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003	8	8	8	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2008	27	2					158	160		10.1038/sj.onc.1210903	http://dx.doi.org/10.1038/sj.onc.1210903			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248OO					2022-12-17	WOS:000252163600001
J	Borges, HL; Hunton, IC; Wang, JYJ				Borges, H. L.; Hunton, I. C.; Wang, J. Y. J.			Reduction of apoptosis in Rb-deficient embryos via Abl knockout	ONCOGENE			English	Article						central nervous system; fetal live; haploid insufficiency; knockout mice; tumor suppressor	RETINOBLASTOMA TUMOR-SUPPRESSOR; KINASE C-ABL; TYROSINE KINASE; NERVOUS-SYSTEM; DNA-DAMAGE; NUCLEAR ENTRAPMENT; MICE DEFICIENT; MOUSE EMBRYOS; CELL-DEATH; PROTEIN	The retinoblastoma protein RB regulates cell proliferation, differentiation and apoptosis. Homozygous knockout of Rb in mice causes embryonic lethality owing to placental defects that result in excessive apoptosis. RB binds to a number of cellular proteins including the nuclear Abl protein and inhibits its tyrosine kinase activity. Ex vivo experiments have shown that genotoxic or inflammatory stress can activate Abl kinase to stimulate apoptosis. Employing the Rb-null embryos as an in vivo model of apoptosis, we have shown that the genetic ablation of Abl can reduce apoptosis in the developing central nervous system and the embryonic liver. These results are consistent with the inhibitory interaction between RB and Abl, and provide in vivo evidence for the proapoptotic function of Abl.	Univ Calif San Diego, Sch Med, Moores Canc Ctr, Div Hematol Oncol,Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Sch Med, Moores Canc Ctr, Div Hematol Oncol,Dept Med, 4328,3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Borges, Helena/W-7533-2019; Borges, Helena/AAG-3701-2020; Borges, Helena L/E-5044-2013	Borges, Helena/0000-0003-2866-4223; Borges, Helena L/0000-0003-2866-4223	NATIONAL CANCER INSTITUTE [R37CA043054, R01CA058320, R01CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA043054, R01 CA043054, R01 CA058320, CA58320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams PD, 1999, MOL CELL BIOL, V19, P1068; Agami R, 1999, NATURE, V399, P809; Aloisi A, 2006, BLOOD, V107, P1591, DOI 10.1182/blood-2005-05-2123; Alvarez AR, 2004, NEUROBIOL DIS, V17, P326, DOI 10.1016/j.nbd.2004.06.007; Borges HL, 2004, CELL DEATH DIFFER, V11, P494, DOI 10.1038/sj.cdd.4401366; Chau BN, 2004, MOL CELL BIOL, V24, P4438, DOI 10.1128/MCB.24.10.4438-4447.2004; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; GOGA A, 1995, ONCOGENE, V11, P791; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gong JG, 1999, NATURE, V399, P806; Guo Z, 2001, CANCER RES, V61, P8395; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kaufman M.H., 1992, ATLAS MOUSE DEV; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Levinson NM, 2006, PLOS BIOL, V4, P753, DOI 10.1371/journal.pbio.0040144; Li BJ, 2000, NAT GENET, V24, P304, DOI 10.1038/73542; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Liu X, 2006, J BIOL CHEM, V281, P578, DOI 10.1074/jbc.M508455200; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Takao N, 2000, J BIOL CHEM, V275, P725, DOI 10.1074/jbc.275.2.725; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Vella V, 2003, J BIOL CHEM, V278, P25151, DOI 10.1074/jbc.M301962200; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	50	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3868	3877		10.1038/sj.onc.1210157	http://dx.doi.org/10.1038/sj.onc.1210157			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17173068				2022-12-17	WOS:000247026400010
J	Xu, J; Gao, M; Fan, S; Meng, Q; Goldberg, ID; Abounader, R; Ressom, H; Laterra, JJ; Rosen, EM				Xu, J.; Gao, M.; Fan, S.; Meng, Q.; Goldberg, I. D.; Abounader, R.; Ressom, H.; Laterra, J. J.; Rosen, E. M.			Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells	ONCOGENE			English	Article						scatter factor (SF); hepatocyte growth factor (HGF); c-Akt; dominant-negative; gene expression; DU-145	GROWTH FACTOR/SCATTER FACTOR; C-MET RECEPTOR; FACTOR PROTECTS; INDUCED APOPTOSIS; PATHWAY; IDENTIFICATION; PROGRESSION; ACTIVATION; TARGETS; GAB1	The cytokine scatter factor (SF) (hepatocyte growth factor) transduces various biologic actions, including cell motility, invasion, angiogenesis and apoptosis inhibition. The latter is relevant to understanding the role of SF in promoting tumor cell survival in different contexts, for example, detachment from basement membrane, growth in metastatic sites and responses to chemo- and radiotherapy. Previously, we showed that SF protects cells against apoptosis owing to DNA damage, by a mechanism involving phosphoinositol-3-kinase/c-Akt signaling. Here, we used DNA microarray assays to identify c-Akt-regulated genes that might contribute to cell protection. DU-145 human prostate cancer cells were transfected+/-a dominant-negative mutant Akt, treated+/-SF and analysed for gene expression using Affymetrix arrays. These studies identified SF-regulated genes for which induction was c-Akt-dependent vs -independent. Selected microarray findings were confirmed by semiquantitative and quantitative reverse transcription-polymerase chain reaction. We tested the contribution of four SF-inducible/c-Akt-dependent genes (AMPD3, EPHB2, MX1 and WNT4) to protection against adriamycin (a DNA topoisomerase II alpha inhibitor) using RNA interference. Knockdown of each gene except EPHB2 caused a small but significant reduction in the SF cell protection. The lack of effect of EPHB2 knockdown may be due to the fact that DU-145 cells contain a single-mutant EPHB2 allele. A combination of three small interfering RNAs blocked most of the protection by SF in both DU-145 and T47D cells. These findings identify novel c-Akt-regulated genes, some of which contribute to SF-mediated cytoprotection.	Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Dept Neurooncol, Baltimore, MD USA	Georgetown University; Northwell Health; Yeshiva University; Johns Hopkins University; Kennedy Krieger Institute	Rosen, EM (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, 3970 Reservoir Rd,NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; ALLEY MC, 1988, CANCER RES, V48, P589; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Barry CP, 2000, CANCER RES, V60, P1887; Beppu K, 2000, ANTICANCER RES, V20, P1263; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carter TH, 2002, J NUTR, V132, P3314, DOI 10.1093/jn/132.11.3314; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Cutforth T, 2002, TRENDS NEUROSCI, V25, P332, DOI 10.1016/S0166-2236(02)02187-2; Dworkin LD, 2004, KIDNEY INT, V65, P409, DOI 10.1111/j.1523-1755.2004.00417.x; Engelhardt OG, 2004, J GEN VIROL, V85, P2315, DOI 10.1099/vir.0.79795-0; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Futamatsu H, 2005, CIRC RES, V96, P823, DOI 10.1161/01.RES.0000163016.52653.2e; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011; Kim HS, 2005, FASEB J, V19, P1042, DOI 10.1096/fj.04-2841fje; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; Kuhn I, 2001, PHYSIOL GENOMICS, V7, P105, DOI 10.1152/physiolgenomics.00052.2001; Leiriao P, 2005, CELL MICROBIOL, V7, P603, DOI 10.1111/j.1462-5822.2004.00490.x; Mahnke-Zizelman DK, 2001, BIOCHEM BIOPH RES CO, V285, P489, DOI 10.1006/bbrc.2001.5180; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Rosen EM, 1997, CIBA F SYMP, V212, P215; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Wang X, 2004, J BIOL CHEM, V279, P5237, DOI 10.1074/jbc.M309271200; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yao HHC, 2004, DEV DYNAM, V230, P210, DOI 10.1002/dvdy.20042; Yuan RQ, 2001, CANCER RES, V61, P8022; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	42	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2925	2938		10.1038/sj.onc.1210088	http://dx.doi.org/10.1038/sj.onc.1210088			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17099727				2022-12-17	WOS:000246210800012
J	Brenet, F; Dussault, N; Delfino, C; Boudouresque, F; Chinot, O; Martin, PM; Ouafik, LH				Brenet, F.; Dussault, N.; Delfino, C.; Boudouresque, F.; Chinot, O.; Martin, P-M; Ouafik, L. H.			Identification of secondary structure in the 5 '-untranslated region of the human adrenomedullin mRNA with implications for the regulation of mRNA translation	ONCOGENE			English	Article						adrenomedullin mRNA; 5 ' UTR; translational control; stem-loop structure; RNA-binding proteins	INTERNAL RIBOSOME ENTRY; TUMOR-CELL LINES; GROWTH-FACTOR; 3'-UNTRANSLATED REGION; DELETION MUTAGENESIS; UNTRANSLATED REGION; PROTEIN BINDS; MICE LACKING; EXPRESSION; SEQUENCES	Adrenomedullin (AM) is a multifunctional regulatory peptide with important angiogenic and mitogenic properties. Here we identify a region of stable secondary structure in the 5'-untranslated region ( 50 UTR) of human AM mRNA. Reverse transcriptase-polymerase chain reaction of the 50 UTR consistently resulted, in addition to the product with the expected size of 155 base pair ( bp), in a second product with an similar to 65-bp deletion from the central region of the 50 UTR, suggesting the presence of a secondary structure. The presence of a stem-loop structure was confirmed by probing the 50 UTR with RNases with selectivity for single- or double-stranded RNA. We investigated the role of this stem-loop structure in expression of luciferase reporter gene in cultured cell lines. Reporter assays using a chimeric mRNA that combined luciferase and the 50 UTR of AM mRNA demonstrated a dramatic decrease of the reporter activity owing to a decreased translation, whereas the deletion of the stem-loop structure localized between nt + 31 and + 95 from the capsite led to the recovery of activity. Gel migration shift assays using cytosolic extracts from mammalian cell lines demonstrate a specific binding of a cytosolic protein to riboprobes containing the 50 UTR of AM but not to riboprobes either corresponding to other areas of the message or containing the 50 UTR but lacking the region of secondary structure. Although we conclude that the 50 UTR of the human AM mRNA can modulate the translation of AM mRNA in vivo, and that the predicted stem-loop structure is necessary for this inhibition, the functional consequences of the cis element-binding activity remain to be determined.	Univ Aix Marseille 2, Expt Cancerol Lab, INSERM, EMI 0359, Marseille 20, France; Univ Mediterranee, Lab Transfert Oncol Biol, Fac Med Secteur Nord, IFR Jean Roche, F-13916 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Ouafik, LH (corresponding author), Univ Aix Marseille 2, Expt Cancerol Lab, INSERM, EMI 0359, Marseille 20, France.	ouafik.h@jean-roche.univ-mrs.fr	Brenet, Fabienne/R-1881-2016; CHINOT, Olivier/M-9196-2018	Brenet, Fabienne/0000-0003-4098-1096; CHINOT, Olivier/0000-0001-6317-9691; Ouafik, L'Houcine/0000-0002-4848-1232				Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; Bernstein J, 1997, J BIOL CHEM, V272, P9356; Brenet F, 2005, MOL CELL BIOL, V25, P7505, DOI 10.1128/MCB.25.17.7505-7521.2005; Canceill D, 1996, P NATL ACAD SCI USA, V93, P6647, DOI 10.1073/pnas.93.13.6647; CARIELLO NF, 1991, GENE, V99, P105, DOI 10.1016/0378-1119(91)90040-I; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; ElMeskini R, 1997, ENDOCRINOLOGY, V138, P5256, DOI 10.1210/en.138.12.5256; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; Fernandez-Sauze S, 2004, INT J CANCER, V108, P797, DOI 10.1002/ijc.11663; Fraboulet S, 1998, ENDOCRINOLOGY, V139, P894, DOI 10.1210/en.139.3.894; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; GLICKMAN BW, 1984, P NATL ACAD SCI-BIOL, V81, P512, DOI 10.1073/pnas.81.2.512; Hata K, 2000, MOL HUM REPROD, V6, P867, DOI 10.1093/molehr/6.10.867; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Ishikawa T, 2003, ONCOGENE, V22, P1238, DOI 10.1038/sj.onc.1206207; ISHIMITSU T, 1994, BIOCHEM BIOPH RES CO, V203, P631, DOI 10.1006/bbrc.1994.2229; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V194, P720, DOI 10.1006/bbrc.1993.1881; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAING LG, 1994, J MOL BIOL, V237, P577, DOI 10.1006/jmbi.1994.1256; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Letizia C, 1998, CLIN ENDOCRINOL, V48, P145, DOI 10.1046/j.1365-2265.1998.3531170.x; Miller MJ, 1996, J BIOL CHEM, V271, P23345; Morrisey K, 2001, AM J PATHOL, V159, P1905, DOI 10.1016/S0002-9440(10)63037-4; Murakami Y, 1998, LIFE SCI, V63, pPL337, DOI 10.1016/S0024-3205(98)00503-7; ODELBERG SJ, 1995, NUCLEIC ACIDS RES, V23, P2049, DOI 10.1093/nar/23.11.2049; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ouafik L, 2002, AM J PATHOL, V160, P1279, DOI 10.1016/S0002-9440(10)62555-2; Paraskeva E, 1999, MOL CELL BIOL, V19, P807; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; Pewitt EB, 1999, ENDOCRINOLOGY, V140, P2382, DOI 10.1210/en.140.5.2382; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Rocchi P, 2001, CANCER RES, V61, P1196; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111; SONENBERG N, 1994, CURR OPIN GENET DEV, V4, P310, DOI 10.1016/S0959-437X(05)80059-0; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2; WILUSZ J, 1988, CELL, V52, P221, DOI 10.1016/0092-8674(88)90510-7; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	51	8	9	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6510	6519		10.1038/sj.onc.1209672	http://dx.doi.org/10.1038/sj.onc.1209672			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16715138	Green Submitted			2022-12-17	WOS:000241395100007
J	Ishimura, A; Lee, HS; Bong, YS; Saucier, C; Mood, K; Park, E; Daar, IO				Ishimura, A.; Lee, H-S; Bong, Y-S; Saucier, C.; Mood, K.; Park, E. K.; Daar, I. O.			Oncogenic Met receptor induces ectopic structures in Xenopus embryos	ONCOGENE			English	Article						Met receptor; Xenopus; tyrosine kinase signaling	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; EPITHELIAL-MESENCHYMAL TRANSITIONS; GRB2 BINDING-SITE; TYROSINE KINASE; MESODERM INDUCTION; C-MET; NEURAL CREST; MAP KINASE; CELL-TRANSFORMATION	When aberrantly expressed or activated, the Met receptor tyrosine kinase is involved in tumor invasiveness and metastasis. In this study, we have used the Xenopus embryonic system to de. ne the role of various Met proximal-binding partners and downstream signaling pathways in regulating an induced morphogenetic event. We show that expression of an oncogenic derivative of the Met receptor (Tpr-Met) induces ectopic morphogenetic structures during Xenopus embryogenesis. Using variant forms of Tpr-Met that are engineered to recruit a specific signaling molecule of choice, we demonstrate that the sole recruitment of either the Grb2 or the Shc adaptor protein is sufficient to induce ectopic structures and anterior reduction, while the recruitment of PI-3Kinase (PI-3K) is necessary but not sufficient for this effect. In contrast, the recruitment of PLC gamma can initiate the induction, but fails to maintain or elongate supernumerary structures. Finally, evidence indicates that the Ras/Raf/MAPK pathway is necessary, but not sufficient to induce these structures. This study also emphasizes the importance of examining signaling molecules in the regulatory context that is provided by receptor/effector interactions when assessing a role in cell growth and differentiation.	NCI, Frederick Canc Res & Dev Ctr, Lab Prot Dynam & Signaling, Frederick, MD 21702 USA; McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; McGill University	Daar, IO (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Lab Prot Dynam & Signaling, Bldg 560,Room 22-3, Frederick, MD 21702 USA.	daar@ncifcrf.gov	Saucier, Caroline/Q-9250-2019; Lee, Hyun-Shik/G-3555-2011	Saucier, Caroline/0000-0001-7678-9886; Daar, Ira/0000-0003-2657-526X	NATIONAL CANCER INSTITUTE [Z01BC010006, ZIABC010006] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aoki S, 1997, BIOCHEM BIOPH RES CO, V234, P8, DOI 10.1006/bbrc.1997.6567; Atabey N, 2001, J BIOL CHEM, V276, P14308, DOI 10.1074/jbc.M010202200; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Berthou S, 2004, ONCOGENE, V23, P5387, DOI 10.1038/sj.onc.1207691; Brewster R, 2000, DEVELOPMENT, V127, P4395; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Carballada R, 2001, DEVELOPMENT, V128, P35; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; Chen YL, 1999, MECH DEVELOP, V80, P67, DOI 10.1016/S0925-4773(98)00194-4; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Chong LD, 2000, MOL CELL BIOL, V20, P724, DOI 10.1128/MCB.20.2.724-734.2000; Christen B, 2003, DEV DYNAM, V226, P349, DOI 10.1002/dvdy.10231; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Christensen JG, 2003, CANCER RES, V63, P7345; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Coltella N, 2003, FASEB J, V17, P1162, DOI 10.1096/fj.02-0576fje; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Dupont H, 1999, EUR J BIOCHEM, V265, P530, DOI 10.1046/j.1432-1327.1999.00689.x; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gao CF, 2005, CELL RES, V15, P49, DOI 10.1038/sj.cr.7290264; Gupta RW, 1998, ONCOGENE, V17, P2155, DOI 10.1038/sj.onc.1202158; GURDON JB, 1984, CELL, V38, P691, DOI 10.1016/0092-8674(84)90264-2; Hama J, 2001, MECH DEVELOP, V109, P195, DOI 10.1016/S0925-4773(01)00524-X; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; JACOBSON M, 1986, DEV BIOL, V116, P524, DOI 10.1016/0012-1606(86)90153-3; Jeffers M, 1998, ONCOGENE, V17, P2691, DOI 10.1038/sj.onc.1202209; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, ONCOGENE, V13, P853; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim P, 1997, DEV BIOL, V187, P1, DOI 10.1006/dbio.1997.8572; Koibuchi N, 2004, BLOOD, V103, P3320, DOI 10.1182/blood-2003-02-0352; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; LIU C, 1992, ONCOGENE, V7, P181; Lock LS, 2003, J BIOL CHEM, V278, P30083, DOI 10.1074/jbc.M302675200; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lombardo A, 2001, MECH DEVELOP, V106, P191, DOI 10.1016/S0925-4773(01)00438-5; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; Maeda R, 2001, ONCOGENE, V20, P1329, DOI 10.1038/sj.onc.1204250; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maulik G, 2002, CLIN CANCER RES, V8, P620; MAYOR R, 1995, DEVELOPMENT, V121, P767; Mood K, 2006, J CELL PHYSIOL, V207, P271, DOI 10.1002/jcp.20564; Nakata K, 1997, P NATL ACAD SCI USA, V94, P11980, DOI 10.1073/pnas.94.22.11980; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Park EK, 2004, MOL BIOL CELL, V15, P1647, DOI 10.1091/mbc.E03-09-0674; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Pownall ME, 1996, DEVELOPMENT, V122, P3881; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RONG S, 1994, COLD SPRING HARB SYM, V59, P629, DOI 10.1101/SQB.1994.059.01.072; RONG S, 1993, CANCER RES, V53, P5355; SATO SM, 1991, DEVELOPMENT, V112, P747; Sattler M, 2003, CANCER RES, V63, P5462; Saucier C, 2002, ONCOGENE, V21, P1800, DOI 10.1038/sj.onc.1205261; Schmidt L, 1998, CANCER RES, V58, P1719; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; SIVE HL, 2000, EARLY DEV XENOPUS LA, P143; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; STERN CD, 1990, DEVELOPMENT, V110, P1271; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Tada M, 1997, DEVELOPMENT, V124, P2225; Takayama H, 1996, P NATL ACAD SCI USA, V93, P5866, DOI 10.1073/pnas.93.12.5866; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; To CTT, 1998, ONCOL REP, V5, P1013; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; Tsarfaty I, 1999, ANAL QUANT CYTOL, V21, P397; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weinstein DC, 1998, NATURE, V394, P904, DOI 10.1038/29808; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yasuo H, 2001, INT J DEV BIOL, V45, P229; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	93	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4286	4299		10.1038/sj.onc.1209463	http://dx.doi.org/10.1038/sj.onc.1209463			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518409				2022-12-17	WOS:000239240100004
J	Gianni-Barrera, R; Gariboldi, M; De Cecco, L; Manenti, G; Dragani, TA				Gianni-Barrera, R.; Gariboldi, M.; De Cecco, L.; Manenti, G.; Dragani, T. A.			Specific gene expression profiles distinguish among functional allelic variants of the mouse Pthlh gene in transfected human cancer cells	ONCOGENE			English	Article						parathyroid hormone-like hormone; parathyroid hormone-related protein; PTHrP; NCI-H520; cancer modifiers	HORMONE-RELATED PROTEIN; MODIFIER LOCI; GROWTH-FACTOR; MIGRATION; ADENOCARCINOMA; INFLAMMATION; CARCINOMA; PEPTIDES; PATTERNS	The mouse parathyroid hormone-like hormone (Pthlh) gene encodes three allelic variants characterized by amino acid substitutions that are associated with susceptibility (Pthlh(Pro)) or resistance (Pthlh(Thr) and Pthlh(SerAspTyr)) to two-stage skin carcinogenesis and to modulation of cell migration in vitro in transfected human cancer cells. cDNA microarray hybridization analysis of 8473 transcript clones revealed a similar gene expression profile for the PthlhThr and PthlhSerAspTyr alleles but a distinct pattern for the PthlhPro allele, suggesting an association between a specific gene expression profile and biological function of the Pthlh alleles. Some of the genes modulated by the Pthlh alleles, e.g., ANXA1, CCL2, FN1 and TFF3, play a role in cell migration and may represent candidate targets for this Pthlh function. Our study demonstrates the potential usefulness of gene expression profiling of genetic variants for the functional characterization of candidate cancer modifier genes.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Tumori, Expt Oncol Lab, Milan, Italy; IFOM Fdn, Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Gianni-Barrera, Roberto/ACU-4280-2022; De Cecco, Loris/K-7036-2016; Dragani, Tommaso A./K-4493-2016; Manenti, Giacomo/J-3339-2017; Gariboldi, Manuela/K-4744-2016	Gianni-Barrera, Roberto/0000-0001-6303-4513; De Cecco, Loris/0000-0002-7066-473X; Dragani, Tommaso A./0000-0001-5915-4598; Manenti, Giacomo/0000-0002-4887-4482; Gariboldi, Manuela/0000-0001-8406-165X				Benelli R, 2003, ONCOGENE, V22, P7711, DOI 10.1038/sj.onc.1207088; Cambien B, 2001, BLOOD, V97, P359, DOI 10.1182/blood.V97.2.359; De Cecco L, 2004, ONCOGENE, V23, P8171, DOI 10.1038/sj.onc.1207979; Deans C, 2005, CANCER-AM CANCER SOC, V103, P1810, DOI 10.1002/cncr.20972; Dragani TA, 2003, CANCER RES, V63, P3011; Duxbury MS, 2005, ANN SURG, V241, P491, DOI 10.1097/01.sla.0000154455.86404.e9; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Funk JL, 2001, INT IMMUNOPHARMACOL, V1, P1101, DOI 10.1016/S1567-5769(01)00040-6; Hiraki A, 2002, CANCER, V95, P1706, DOI 10.1002/cncr.10828; Hoffmann W, 2001, HISTOL HISTOPATHOL, V16, P319, DOI 10.14670/HH-16.319; Leeb SN, 2004, AM J GASTROENTEROL, V99, P335, DOI 10.1111/j.1572-0241.2004.04044.x; Manenti G, 2000, ONCOGENE, V19, P5324, DOI 10.1038/sj.onc.1203916; Maus UA, 2003, J IMMUNOL, V170, P3273, DOI 10.4049/jimmunol.170.6.3273; Nagase H, 2001, CANCER RES, V61, P1305; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Parente L, 2004, INFLAMM RES, V53, P125, DOI 10.1007/s00011-003-1235-z; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Yio XY, 2005, CLIN EXP METASTAS, V22, P157, DOI 10.1007/s10585-005-6615-z; Zhang ZW, 2004, CANCER CAUSE CONTROL, V15, P211, DOI 10.1023/B:CACO.0000019510.96285.e9	20	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2006	25	32					4501	4504		10.1038/sj.onc.1209478	http://dx.doi.org/10.1038/sj.onc.1209478			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	067TR	16547502				2022-12-17	WOS:000239326000014
J	Lahne, HU; Kloster, MM; Lefdal, S; Blomhoff, HK; Naderi, S				Lahne, HU; Kloster, MM; Lefdal, S; Blomhoff, HK; Naderi, S			Degradation of cyclin D3 independent of Thr-283 phosphorylation	ONCOGENE			English	Article						okadaic acid; cyclin D3; degradation; phosphorylation	PHOSPHATIDYLINOSITOL 3-KINASE; RETINOBLASTOMA PROTEIN; DEPENDENT DEGRADATION; DOWN-REGULATION; CDK INHIBITORS; D1 EXPRESSION; OKADAIC ACID; PROGRESSION; PATHWAY; ARREST	Cyclin D3 has been shown to play a major role in the regulation of cell cycle progression in lymphocytes. It is therefore important to understand the mechanisms involved in the regulation of this protein. We have previously shown that both basal and cAMP-induced degradation of cyclin D3 in Reh cells is dependent on Thr-283 phosphorylation by glycogen synthase kinase-3 beta (GSK-3 beta). We now provide evidence of an alternative mechanism being involved in the regulation of cyclin D3 degradation. Treatment of lymphoid cells with okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A (PP1 and PP2A), induces rapid phosphorylation and proteasomal degradation of cyclin D3. This degradation is not inhibited by the GSK-3 beta inhibitors lithium or Kenpaullone, or by substitution of Thr-283 with Ala on cyclin D3, indicating that cyclin D3 can be degraded independently of Thr-283 phosphorylation and GSK-3 beta activity. Interestingly, in vitro experiments revealed that PP1, but not PP2A, was able to dephosphorylate cyclin D3 efficiently, and PP1 was found to associate with His-tagged cyclin D3. These results support the hypothesis that PP1 constitutively keeps cyclin D3 in a stable, dephosphorylated state, and that treatment of cells with OA leads to phosphorylation and degradation of cyclin D3 through inhibition of PP1.	Univ Oslo, Inst Basic Med Sci, Dept Biochem, N-0317 Oslo, Norway	University of Oslo	Naderi, S (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Biochem, POB 1112, N-0317 Oslo, Norway.	soheil.naderi@basalmed.uio.no						Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Bergsagel PL, 2005, BLOOD, V106, P296, DOI 10.1182/blood-2005-01-0034; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bollen M, 2002, TRENDS CELL BIOL, V12, P138, DOI 10.1016/S0962-8924(01)02247-4; Boonen GJJC, 1999, J BIOL CHEM, V274, P34676, DOI 10.1074/jbc.274.49.34676; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Casanovas O, 2004, ONCOGENE, V23, P7537, DOI 10.1038/sj.onc.1208040; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Deng XB, 2003, J BIOL CHEM, V278, P41347, DOI 10.1074/jbc.M306780200; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Filipits M, 2002, CLIN CANCER RES, V8, P729; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gutzkow KB, 2003, CELL SIGNAL, V15, P871, DOI 10.1016/S0898-6568(03)00038-X; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hu XT, 2002, J BIOL CHEM, V277, P16528, DOI 10.1074/jbc.M109929200; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIYATAKE S, 1995, J EXP MED, V182, P401, DOI 10.1084/jem.182.2.401; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; Naderi S, 2004, J CELL SCI, V117, P3769, DOI 10.1242/jcs.01210; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Singer JD, 1999, GENE DEV, V13, P2375, DOI 10.1101/gad.13.18.2375; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tao GZ, 2002, J BIOL CHEM, V277, P19295, DOI 10.1074/jbc.M109654200; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	42	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2468	2476		10.1038/sj.onc.1209278	http://dx.doi.org/10.1038/sj.onc.1209278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331257				2022-12-17	WOS:000236948000005
J	O'Shea, CC				O'Shea, CC			Viruses: tools for tumor target discovery, and agents for oncolytic therapies - an introduction	ONCOGENE			English	Editorial Material						oncolytic; virus; cancer therapy; transformation	REPLICATION		Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	O'Shea, CC (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St,N315, San Francisco, CA 94115 USA.	coshea@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Barber GN, 2005, ONCOGENE, V24, P7710, DOI 10.1038/sj.onc.1209042; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Freeman-Cook LL, 2005, ONCOGENE, V24, P7756, DOI 10.1038/sj.onc.1209039; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; Mohr I, 2005, ONCOGENE, V24, P7697, DOI 10.1038/sj.onc.1209053; O'Shea CC, 2005, ONCOGENE, V24, P7640, DOI 10.1038/sj.onc.1209047; Shmulevitz M, 2005, ONCOGENE, V24, P7720, DOI 10.1038/sj.onc.1209041; Uren AG, 2005, ONCOGENE, V24, P7656, DOI 10.1038/sj.onc.1209043; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Working PK, 2005, ONCOGENE, V24, P7792, DOI 10.1038/sj.onc.1209045	15	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7636	7639		10.1038/sj.onc.1209035	http://dx.doi.org/10.1038/sj.onc.1209035			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299525				2022-12-17	WOS:000233372600001
J	Sander, S; Bullinger, L; Karlsson, A; Giuriato, S; Hernandez-Boussard, T; Felsher, DW; Pollack, JR				Sander, S; Bullinger, L; Karlsson, A; Giuriato, S; Hernandez-Boussard, T; Felsher, DW; Pollack, JR			Comparative genomic hybridization on mouse cDNA microarrays and its application to a murine lymphoma model	ONCOGENE			English	Article						array CGH; microarray; mouse model; lymphoma; expression profiling	COPY-NUMBER CHANGES; CYTOGENETIC ANALYSIS; RESOLUTION; CANCER; TUMOR; EXPRESSION; ONCOGENES; SURVIVAL; REVEALS; MCL-1	Microarray-based formats offer a high-resolution alternative to conventional, chromosome-based comparative genomic hybridization (CGH) methods for assessing DNA copy number alteration (CNA) genome-wide in human cancer. For murine tumors, array CGH should provide even greater advantage, since murine chromosomes are more difficult to individually discern. We report here the adaptation and evaluation of a cDNA microarray-based CGH method for the routine characterization of CNAs in murine tumors, using mouse cDNA microarrays representing similar to 14 000 different genes, thereby providing an average mapping resolution of 109 kb. As a first application, we have characterized CNAs in a set of 10 primary and recurrent lymphomas derived from a Myc-induced murine lymphoma model. In primary lymphomas and more commonly in Myc- independent relapses, we identified a recurrent genomic DNA loss at chromosome 3G3-3H4, and recurrent amplifications at chromosome 3F2.1-3G3 and chromosome 15E1/ E2 - 15F3, the boundaries of which we defined with high resolution. Further, by pro. ling gene expression using the same microarray platform, we identifed within CNAs the relevant subset of candidate cancer genes displaying comparably altered expression, including Mcl1 ( myeloid cell leukemia sequence 1), a highly expressed antiapoptotic gene residing within the chr 3 amplicon peak. CGH on mouse cDNA microarrays therefore represents a reliable method for the high-resolution characterization of CNAs in murine tumors, and a powerful approach for elucidating the molecular events in tumor development and progression in murine models.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Stanford Univ, Dept Med Oncol, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; Univ Ulm, Dept Internal Med 3, D-89069 Ulm, Germany	Stanford University; Stanford University; Stanford University; Ulm University	Pollack, JR (corresponding author), Stanford Univ, Sch Med, Dept Pathol, CCSR Bldg,Room 3245Am 269 Campus Dr, Stanford, CA 94305 USA.	pollack1@stanford.edu	Bullinger, Lars/AAL-7965-2020; Giuriato, Sylvie/A-9113-2010	Giuriato, Sylvie/0000-0003-3274-3397; Bullinger, Lars/0000-0002-5890-5510; Sander, Sandrine/0000-0003-4645-3366	NCI NIH HHS [CA97139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2003, HUM MOL GENET, V12, pR145, DOI 10.1093/hmg/ddg261; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Barrett MT, 2004, P NATL ACAD SCI USA, V101, P17765, DOI 10.1073/pnas.0407979101; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Cho-Vega JH, 2004, HUM PATHOL, V35, P1095, DOI 10.1016/j.humpath.2004.04.018; Chung YJ, 2004, GENOME RES, V14, P188, DOI 10.1101/gr.1878804; Coleman AE, 1999, LEUKEMIA, V13, P1592, DOI 10.1038/sj.leu.2401518; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Felsher DW, 2003, NAT REV CANCER, V3, P375, DOI 10.1038/nrc1070; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Giuriato S, 2004, SEMIN CANCER BIOL, V14, P3, DOI 10.1016/j.semcancer.2003.11.002; Gollub J, 2003, NUCLEIC ACIDS RES, V31, P94, DOI 10.1093/nar/gkg078; Hackett CS, 2003, CANCER RES, V63, P5266; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Jackson-Grusby L, 2002, ONCOGENE, V21, P5504, DOI 10.1038/sj.onc.1205603; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li JZ, 2004, NAT GENET, V36, P952, DOI 10.1038/ng1417; Lichter P, 2000, SEMIN HEMATOL, V37, P348, DOI 10.1053/shem.2000.16594; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; O'Hagan RC, 2003, CANCER RES, V63, P5352; O'Hagan RC, 2002, CANCER CELL, V2, P149, DOI 10.1016/S1535-6108(02)00094-6; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pollack JR, 2002, NAT GENET, V32, P515, DOI 10.1038/ng1035; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Vrana JA, 2002, CANCER RES, V62, P892; Wang P, 2005, BIOSTATISTICS, V6, P45, DOI 10.1093/biostatistics/kxh017; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	36	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6101	6107		10.1038/sj.onc.1208751	http://dx.doi.org/10.1038/sj.onc.1208751			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	16007205				2022-12-17	WOS:000231718100004
J	Helmrich, A; Lee, S; O'Brien, P; Dorken, B; Lowe, SW; Schrock, E; Schmitt, CA				Helmrich, A; Lee, S; O'Brien, P; Dorken, B; Lowe, SW; Schrock, E; Schmitt, CA			Recurrent chromosomal aberrations in INK4a/ARF defective primary lymphomas predict drug responses in vivo	ONCOGENE			English	Article						cytogenetic analysis; chemoresistance; INK4a/ARF; lymphoma; mouse model	ACUTE LYMPHOBLASTIC-LEUKEMIA; GENOMIC ABERRATIONS; C-MYC; P16(INK4A); APOPTOSIS; CANCER; SENESCENCE; RELAPSE; P53	Predicting responsiveness to anticancer therapy based on molecular findings at diagnosis is important to optimize treatment decisions. Although clinical outcome correlates with distinct mutations in some cancer entities, treatment responses within these lesion-stratified subgroups still remain heterogeneous, underscoring the need for additional prognosticators. We previously demonstrated that defined genetic defects at the INK4a/ARF locus, which encodes the tumor suppressors p16(INK4a) and ARF, not only accelerated lymphomagenesis in the E mu-myc transgenic mouse but also interfered with treatment sensitivity. In this study, we take a nonbiased genome-wide approach to examine whether the responsiveness of these lymphomas can be further stratified based on cytogenetic information at diagnosis. Indeed, using spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization in 38 primary lymphomas, we find recurrent cytogenetic alterations that re. ne the predictive value of INK4a/ARF lesions on drug responses in vivo: gain of chromosome 14, which was never detected in INK4a/ ARFnull lymphomas, defined an ARFnull subgroup with superior treatment outcome. Gain of chromosome 6 was identified as a recurrent chromosomal aberration that predisposed ARFnull tumors to their subsequent INK4a loss during therapy. These data illustrate how cytogenetic information from cancer specimens might complement established prognostic markers and may improve anticancer treatment strategies.	Max Delbruck Ctr Mol Med, D-13353 Berlin, Germany; Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Clin Genet, D-01307 Dresden, Germany; Charite Univ Med Berlin, D-13353 Berlin, Germany; Univ Cambridge, Dept Clin Vet Med, Cambridge CB3 0ES, England; Watson Sch Biol Sci, Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Cambridge; Cold Spring Harbor Laboratory	Schmitt, CA (corresponding author), Max Delbruck Ctr Mol Med, Campus Virchow,Augustenburger Pl 1, D-13353 Berlin, Germany.	clemens.schmitt@charite.de	Schmitt, Clemens A/S-9479-2017; Lee, Soyoung/T-6669-2019; Lee, Soyoung/AHC-5032-2022	Schmitt, Clemens A/0000-0002-4731-2226; Lee, Soyoung/0000-0002-4614-2931	NATIONAL CANCER INSTITUTE [P30CA008748, P01CA087497] Funding Source: NIH RePORTER; NCI NIH HHS [CA87497, P30 CA008748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Carter TL, 2001, BRIT J HAEMATOL, V113, P323, DOI 10.1046/j.1365-2141.2001.02729.x; Carter TL, 2001, BLOOD, V97, P572, DOI 10.1182/blood.V97.2.572; DAVISSON MT, 1996, COMMITTEE STANDARDIZ; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eischen CM, 2004, ONCOGENE, V23, P8931, DOI 10.1038/sj.onc.1208052; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Maloney KW, 1999, BLOOD, V93, P2380, DOI 10.1182/blood.V93.7.2380.407k27_2380_2385; Moorman AV, 2003, BLOOD, V102, P2756, DOI 10.1182/blood-2003-04-1128; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, COLD SPRING HARB SYM, V65, P499, DOI 10.1101/sqb.2000.65.499; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; SCHROCK E, 1999, SPECTRAL KARYOTYPING; SCHROCK E, 2001, COMP GENOMIC HYBRIDI; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; TELENIUS H, 1992, GENE CHROMOSOME CANC, V4, P257, DOI 10.1002/gcc.2870040311; Wei G, 1999, INT J CANCER, V80, P199, DOI 10.1002/(SICI)1097-0215(19990118)80:2<199::AID-IJC7>3.0.CO;2-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	29	8	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 16	2005	24	26					4174	4182		10.1038/sj.onc.1208600	http://dx.doi.org/10.1038/sj.onc.1208600			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	935WY	15824738				2022-12-17	WOS:000229815300002
J	Tikhomirov, O; Dikov, M; Carpenter, G				Tikhomirov, O; Dikov, M; Carpenter, G			Identification of proteolytic fragments from ErbB-2 that induce apoptosis	ONCOGENE			English	Article						ErbB-2; apoptosis; proteolytic fragmentation; kinase domain	CASPASE-MEDIATED ACTIVATION; KINASE DOMAIN; KAPPA-B; CLEAVAGE; GELDANAMYCIN; SENSITIVITY; MECHANISM; MEMBRANE; PROTEASE; CELLS	The receptor tyrosine kinase ErbB-2 plays an important role in cell proliferation and differentiation as well as oncogenesis. We have found that ErbB-2 kinase domain fragmentation is important for the induction of apoptosis. Exogenous expression of peptides derived from the ErbB-2 kinase domain induces cells death with the hallmarks of apoptosis. In contrast, transfection of the ErbB-2 carboxy-terminal domain did not induce apoptosis. We have identified a 37-residue segment from the ErbB-2 kinase N-terminal lobe that can strongly induce apoptosis in transfected cells. Cell death was not blocked by the pan-caspase inhibitor z-VAD-FMK. Similar fragments derived from several other receptor tyrosine kinases also induce cell death. These data imply that proteolytic fragmentation of tyrosine kinases liberates apoptotic fragments that can accelerate cell death.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Hematol Oncol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 647 Light Hall,23rd Ave & Garland, Nashville, TN 37232 USA.	graham.carpenter@vanderbilt.edu	Dikov, Mikhail/E-5593-2010		NCI NIH HHS [P30 CA 68485] Funding Source: Medline; NIDDK NIH HHS [P30 DK 20593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Bonvin C, 2002, CELL SIGNAL, V14, P123, DOI 10.1016/S0898-6568(01)00219-4; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Cuello M, 2001, CANCER RES, V61, P4892; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Kim JW, 2000, ONCOGENE, V19, P4491, DOI 10.1038/sj.onc.1203796; Kogel D, 1999, ONCOGENE, V18, P7212, DOI 10.1038/sj.onc.1203169; Lin Y, 2000, MOL CELL BIOL, V20, P6638, DOI 10.1128/MCB.20.18.6638-6645.2000; MUNSTER P, 2002, CANCER RES, V61, P2945; Neve RM, 2001, ANN ONCOL, V12, P9, DOI 10.1023/A:1011199404516; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Smith V, 2002, ANTICANCER RES, V22, P1993; Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; Tikhomirov O, 2003, CANCER RES, V63, P39; Tikhomirov O, 2001, J BIOL CHEM, V276, P33675, DOI 10.1074/jbc.M101394200; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	27	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3906	3913		10.1038/sj.onc.1208534	http://dx.doi.org/10.1038/sj.onc.1208534			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782126				2022-12-17	WOS:000229435300006
J	Janz, S				Janz, S			Uncovering MYC's full oncogenic potential in the hematopoietic system	ONCOGENE			English	Editorial Material						transgenic mice; hematopoietic stem and early progenitor cells; T-cell lymphomas; Vav promoter	TRANSGENIC MICE; COMPARTMENT; VAV	MYC is an important oncogene in hematopoietic neoplasms in humans, yet the mechanism by which MYC induces the malignant transformation of blood cells has remained elusive. Postulating that mouse models of deregulated MYC expression may be helpful for advancing our understanding of MYC-induced hematopoietic malignancies, Suzanne Cory and her associates took advantage of the Vav promoter to express MYC throughout the hematopoietic system in transgenic mice. In this issue of Oncogene, they report ( Smith et al.) that the newly developed strain, referred to as VavP-MYC17, is prone to mature T-cell lymphomas ( for which few good mouse models exist). They further show that VavP-MYC17 mice that are devoid of mature T cells ( and B cells) because of genetic deficiency in Rag1 recombinase develop neoplasms of three distinct blood cell lineages: pre-T cells, pro-B cells, and macrophages. These findings establish that VavP-driven MYC has broad oncogenic potential in the hematopoietic compartment and prompts new views of the cellular assaults of deregulated MYC on hematopoietic stem and early progenitor cells.	NCI, Ctr Canc Res, Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Ctr Canc Res, Genet Lab, NIH, Bldg 37,Room 3140A, Bethesda, MD 20892 USA.	sj4s@nih.gov						ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Egle A, 2004, BLOOD, V103, P2276, DOI 10.1182/blood-2003-07-2469; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; Ogilvy S, 1999, BLOOD, V94, P1855; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0	5	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3541	3543		10.1038/sj.onc.1208473	http://dx.doi.org/10.1038/sj.onc.1208473			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782131				2022-12-17	WOS:000229221800001
J	Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR				Sansom, OJ; Bishop, SM; Bird, A; Clarke, AR			MBD2 deficiency does not accelerate p53 mediated lymphomagenesis	ONCOGENE			English	Article						MBD2; p53; DNA methylation; tumorigenesis; chemoprevention; genomic instability	DNA HYPOMETHYLATION; TUMORIGENESIS; MICE; SUPPRESSION; INSTABILITY; TUMORS	Recent studies using hypomorphic DNA methyltransferase 1 (DNMT1) alleles have suggested that strategies aiming to reduce DNA methylation may increase genomic instability and lymphomagenesis. Given our recent finding that loss of methyl-binding domain protein 2 (Mbd2) suppresses intestinal tumorigenesis, we have tested whether loss of Mbd2 increases lymphomagenesis by intercrossing Mbd2 deficient mice with p53 deficient and p53 heterozygous mice. Unlike DNMT1, loss of Mbd2 does not accelerate lymphomagenesis, arguing that MBD2 may represent a better potential therapeutic target than DNMT1.	Univ Cardiff, Cardiff Sci Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Inst Cell & Mol Biol, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Univ Cardiff, Cardiff Sci Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.	clarkear@cardiff.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Bird, Adrian/0000-0002-8600-0372; Sansom, Owen J./0000-0001-9540-3010				Campbell PM, 2004, CARCINOGENESIS, V25, P499, DOI 10.1093/carcin/bgh045; Eads CA, 2002, CANCER RES, V62, P1296; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Hendrich B, 2001, GENE DEV, V15, P710, DOI 10.1101/gad.194101; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lengauer C, 2003, SCIENCE, V300, P442, DOI 10.1126/science.1084468; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; Yang AS, 2003, SCIENCE, V302	13	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2430	2432		10.1038/sj.onc.1208166	http://dx.doi.org/10.1038/sj.onc.1208166			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735763				2022-12-17	WOS:000227877400015
J	Seitz, S; Frege, R; Jacobsen, A; Weimer, R; Arnold, W; von Haefen, C; Niederacher, D; Schmutzler, R; Arnold, N; Scherneck, S				Seitz, S; Frege, R; Jacobsen, A; Weimer, R; Arnold, W; von Haefen, C; Niederacher, D; Schmutzler, R; Arnold, N; Scherneck, S			A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8	ONCOGENE			English	Article						breast tumorigenesis; microcell-mediated chromosome transfer; expression difference analysis	CLUSTERIN EXPRESSION; SUPPRESSOR GENE; ALLELIC LOSS; REGION; HETEROZYGOSITY; IDENTIFICATION; CHROMOSOME-8; ASSOCIATION; METASTASIS; PROGNOSIS	Several investigations have supposed that tumor suppressor genes might be located on human chromosome 8. We used microcell-mediated transfer of chromosome 8 into MDA-MB-231 breast cancer cells and generated independent hybrids with strongly reduced tumorigenic potential. Loss of the transferred chromosome results in reappearance of the malignant phenotype. Expression analysis identified a set of 109 genes (CT8-ps) differentially expressed in microcell hybrids as compared to the tumorigenic MDA-MB-231 and rerevertant cells. Of these, 44.9% are differentially expressed in human breast tumors. The expression pattern of CT8-ps was associated with prognostic factors such as tumor size and grading as well as loss of heterozygosity at the short arm of chromosome 8. We identified CT8-ps networks suggesting that these genes act cooperatively to cause reversion of tumorigenicity in MDA-MB-231 cells. Our findings provide a conceptual basis and experimental system to identify and evaluate genes and gene networks involved in the development and/or progression of breast cancer.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13125 Berlin, Germany; Gynecol & Obstet Clin, Oncol Lab, D-24105 Kiel, Germany; Atugen AG, D-13125 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Dept Obstet & Gynecol, D-40225 Dusseldorf, Germany; Gynecol & Obstet Clin, Dept Mol Gynecol & Oncol, D-50931 Cologne, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Heinrich Heine University Dusseldorf	Seitz, S (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, Robert Roessle Str 10, D-13125 Berlin, Germany.	sseitz@mdc-berlin.de	Arnold, Norbert/E-3012-2010; Weimer, Jörg Paul/E-3472-2010	Arnold, Norbert/0000-0003-4523-8808; Weimer, Jörg Paul/0000-0002-4528-8509				Arnold N, 1996, GENE CHROMOSOME CANC, V16, P46, DOI 10.1002/(SICI)1098-2264(199605)16:1<46::AID-GCC7>3.0.CO;2-3; Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Borg A, 2003, NAT MED, V9, P16, DOI 10.1038/nm0103-16; Goldberg EK, 2000, AM J HUM GENET, V67, P417, DOI 10.1086/302999; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Gustafson CE, 1996, CANCER RES, V56, P5238; HOGUE DA, 1996, AM J HUM GENET, V56, pA15; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Jenssen TK, 2001, NAT GENET, V28, P21, DOI 10.1038/ng0501-21; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kugoh H, 2002, MOL CARCINOGEN, V35, P148, DOI 10.1002/mc.10080; Lerebours F, 2002, CRIT REV ONCOL HEMAT, V44, P121, DOI 10.1016/S1040-8428(01)00191-3; LOGAN GJ, 2002, IMMUNOLOGY, V28; Murakami Y, 2002, ONCOGENE, V21, P6936, DOI 10.1038/sj.onc.1205825; Nihei N, 2002, CANCER RES, V62, P367; Payton M, 2002, ONCOGENE, V21, P8529, DOI 10.1038/sj.onc.1206035; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Rennstam K, 2003, CANCER RES, V63, P8861; Saffer H, 2002, MODERN PATHOL, V15, P1221, DOI 10.1097/01.MP.0000036386.87517.AA; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Schlitt T, 2003, GENOME RES, V13, P2568, DOI 10.1101/gr.1111403; Seitz S, 2000, EUR J CANCER, V36, P1507, DOI 10.1016/S0959-8049(00)00135-0; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Seitz S, 2003, GENE CHROMOSOME CANC, V37, P29, DOI 10.1002/gcc.10196; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Suzuki A, 1999, INT J ONCOL, V15, P443; THEILE M, 1994, INT J ONCOL, V4, P1067; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Tsuneizumi M, 2002, CANCER LETT, V180, P75, DOI 10.1016/S0304-3835(02)00010-1; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Weimer J, 1999, CHROMOSOME RES, V7, P355, DOI 10.1023/A:1009263913478; Weimer J, 2000, CYTOGENET CELL GENET, V88, P114, DOI 10.1159/000015502; Wilson P, 2003, CANCER GENET CYTOGEN, V143, P100, DOI 10.1016/S0165-4608(02)00850-6; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; ZHANG RD, 1991, INVAS METAST, V11, P204	43	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					869	879		10.1038/sj.onc.1208260	http://dx.doi.org/10.1038/sj.onc.1208260			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15580292				2022-12-17	WOS:000226577100013
J	Sang, NL; Fath, DM; Giordano, A				Sang, NL; Fath, DM; Giordano, A			A gene highly expressed in tumor cells encodes novel structure proteins	ONCOGENE			English	Article						NSP; SMC; ATPase; cell division; actin-binding; protein; coiled-coil domain	COILED-COIL PROTEIN; SPINDLE POLE BODY; CENP-E; ESCHERICHIA-COLI; C-NAP1; 17P11.2-SIMILAR-TO-P12; AMPLIFICATION; INHIBITION; ACTIVATION; BIOLOGY	We isolated several related but distinct cDNA clones encoding novel structure proteins (NSP) when screening a cDNA library. Analysis revealed that these cDNAs and several similar ESTs in the public databases are derived from a single gene of 17 exons that span a minimum of 227-kb region. This gene is located at chromosome 17p11.2, a region frequently amplified in human gliomas and osteosarcomas, and involved in Birt-Hogg-Dube syndrome, a tumor-prone syndrome. The major coding sequences shared by all isolated transcripts are predicted to encode SMC (structural maintenance of chromosome)/SbcC ATPase motifs and coiled-coil domains commonly seen in motor or structure proteins. Two 5'-end and two 3'-end variants (type 5alpha/beta and 3alpha/beta, respectively) were identified, making a total of four possible transcripts. Both 5alpha and 5beta variants were detected in human testis mRNA, but only type 5alpha was detectable in RNA samples extracted from HeLa cells. The unique carboxyl-terminus of 3beta contains a Ca2+-dependent actin-binding domain. Immunohistochemistry studies revealed that NSPs were mostly localized to nuclei. Northern blot analysis demonstrated two major bands and the expression levels are tremendously high in testis while barely detectable in other normal tissues examined. Interestingly, NSP5alpha3alpha is highly expressed in some tumor cell lines. These results suggest that NSPs represent a new family of structure proteins with a possible role in nuclear dynamics during cell division, and that NSP5alpha3alpha may serve as a tumor marker.	Temple Univ, Program Mol Biol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Temple Univ, Coll Sci & Technol, Dept Biol, Philadelphia, PA 19122 USA; Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University; Jefferson University; Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Giordano, A (corresponding author), Temple Univ, Program Mol Biol, Bio Life Sci Bldg,1900 N 12th St,Suite 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NCI NIH HHS [K01 CA098809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA098809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; AMPLE C, 1994, SEMIN CELL BIOL, V5, P175; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; Carugo KD, 1997, NAT STRUCT BIOL, V4, P175, DOI 10.1038/nsb0397-175; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Cobbe N, 2000, J STRUCT BIOL, V129, P123, DOI 10.1006/jsbi.2000.4255; Connelly JC, 1997, J BIOL CHEM, V272, P19819, DOI 10.1074/jbc.272.32.19819; Connelly JC, 1998, P NATL ACAD SCI USA, V95, P7969, DOI 10.1073/pnas.95.14.7969; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Grummt M, 1998, FEBS LETT, V427, P79, DOI 10.1016/S0014-5793(98)00399-8; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; Hirano M, 2001, EMBO J, V20, P3238, DOI 10.1093/emboj/20.12.3238; Hirano M, 1998, EMBO J, V17, P7139, DOI 10.1093/emboj/17.23.7139; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Ikemoto S, 2000, J CELL SCI, V113, P545; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Mayor T, 2002, J CELL SCI, V115, P3275; MIRZAYAN C, 1992, J CELL BIOL, V116, P1319, DOI 10.1083/jcb.116.6.1319; ROZYCKI MD, 1994, CURR OPIN CELL BIOL, V6, P87, DOI 10.1016/0955-0674(94)90121-X; Sambrook J, 2001, MOL CLONING LAB MANU; Sang Nianli, 1995, Molecular and Cellular Differentiation, V3, P1; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Sang NL, 1997, J CELL BIOCHEM, V66, P277, DOI 10.1002/(SICI)1097-4644(19970901)66:3<277::AID-JCB1>3.0.CO;2-M; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; THROWER DA, 1995, EMBO J, V14, P918, DOI 10.1002/j.1460-2075.1995.tb07073.x; van Dartel M, 2003, CANCER GENET CYTOGEN, V140, P162, DOI 10.1016/S0165-4608(02)00683-0; van Dartel M, 2002, CANCER GENET CYTOGEN, V139, P91, DOI 10.1016/S0165-4608(02)00627-1; Viel A, 1999, FEBS LETT, V460, P391, DOI 10.1016/S0014-5793(99)01372-1; Volkmann N, 2001, J CELL BIOL, V153, P947, DOI 10.1083/jcb.153.5.947; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	38	8	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	2004	23	58					9438	9446		10.1038/sj.onc.1207988	http://dx.doi.org/10.1038/sj.onc.1207988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	880BT	15602574	Green Accepted			2022-12-17	WOS:000225764100016
J	Baum, B; Craig, G				Baum, B; Craig, G			RNAi in a postmodern, postgenomic era	ONCOGENE			English	Article						functional genomics; RNAi; cell culture; post-modernism	DROSOPHILA CULTURED-CELLS; IDENTIFICATION; INTERFERENCE; GENOME; COMPONENTS; PROTEINS; PATHWAY; SCREEN	As dsRNA-mediated interference (RNAi) libraries become more widely available, genome-wide loss of function experiments in cell culture are likely to become a routine laboratory tool. RNAi screens can then be conducted to test gene functions in different assays in a variety of cell types and across species. In comparing these large phenotypic data sets, researchers will gain a new perspective, enabling them to see each gene as part of a fluid network that is remodelled in response to changes in environmental and developmental context, and with the passage of evolutionary time.	Ludwig Inst Canc Res, UCL Branch, London W1W 7BS, England	Ludwig Institute for Cancer Research; University of London; University College London	Baum, B (corresponding author), Ludwig Inst Canc Res, UCL Branch, London W1W 7BS, England.	buzz@ludwig.ucl.ac.uk		Baum, Buzz/0000-0002-9201-6186				Agaisse H, 2003, DEV CELL, V5, P441, DOI 10.1016/S1534-5807(03)00244-2; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boutros M, 2004, SCIENCE, V303, P832, DOI 10.1126/science.1091266; Chou TB, 1996, GENETICS, V144, P1673; Forler D, 2003, NAT BIOTECHNOL, V21, P89, DOI 10.1038/nbt773; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Grosshans H, 2002, J CELL BIOL, V156, P17, DOI 10.1083/jcb.200111033; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hartwell L, 2004, SCIENCE, V303, P774, DOI 10.1126/science.1094731; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Karim FD, 1996, GENETICS, V143, P315; Kiger A A, 2003, J Biol, V2, P27, DOI 10.1186/1475-4924-2-27; Lum L, 2003, SCIENCE, V299, P2039, DOI 10.1126/science.1081403; Paddison PJ, 2004, NATURE, V428, P427, DOI 10.1038/nature02370; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Somma MP, 2002, MOL BIOL CELL, V13, P2448, DOI 10.1091/mbc.01-12-0589; Stowers RS, 1999, GENETICS, V152, P1631; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Waterhouse PM, 2003, NAT REV GENET, V4, P29, DOI 10.1038/nrg982	21	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8336	8339		10.1038/sj.onc.1208009	http://dx.doi.org/10.1038/sj.onc.1208009			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517013				2022-12-17	WOS:000224815900002
J	Fraser, A				Fraser, A			Towards full employment: using RNAi to find roles for the redundant	ONCOGENE			English	Article						synthetic lethal; redundancy; genome-wide	FUNCTIONAL GENOMIC ANALYSIS; ELEGANS VULVAL DEVELOPMENT; PROGRAMMED CELL-DEATH; CAENORHABDITIS-ELEGANS; C-ELEGANS; INTERACTION NETWORK; GENE-FUNCTION; CHROMOSOME-I; WIDE RNAI; INTERFERENCE	Cancer is a genetic disease that ultimately results from the failure of cells to respond correctly to diverse signals. Signal transduction and signal integration are highly complex, requiring the combinatorial interaction of multiple genes. Classical genetics in model organisms including Caenorhabditis elegans has been of immense use in identifying nonredundant components of conserved signalling pathways. However, it is likely that there is much functional redundancy in the informational processing machinery of metazoan cells; we therefore need to develop methods for uncovering such redundant functions in model organisms if we are to use them to understand complex gene interactions and oncogene cooperation. RNAi may provide a powerful tool to probe redundancy in informational networks. In this review, I set out some of the progress made so far by classical genetics in understanding redundancy in gene networks, and outline how RNAi may allow us to approach this problem more systematically in C. elegans. In particular, I discuss the use of genome-wide RNAi screens in C. elegans to identify synthetic lethal interactions and compare this with synthetic lethal interaction analysis in Saccharomyces cerevisiae.	Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Fraser, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	agf@sanger.ac.uk		Fraser, Andrew/0000-0001-9939-6014				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chang C, 1999, CANCER METAST REV, V18, P203, DOI 10.1023/A:1006317206443; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Fay DS, 2002, GENE DEV, V16, P503, DOI 10.1101/gad.952302; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERGUSON EL, 1989, GENETICS, V123, P109; FERGUSON EL, 1985, GENETICS, V110, P17; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Fraser AG, 2004, NAT GENET, V36, P559, DOI 10.1038/ng1370; Garigan D, 2002, GENETICS, V161, P1101; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gonczy P, 2000, NATURE, V408, P331, DOI 10.1038/35042526; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; Nelson DW, 2003, GENE DEV, V17, P813, DOI 10.1101/gad.1090203; Ooi SL, 2003, NAT GENET, V35, P277, DOI 10.1038/ng1258; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Piano F, 2000, CURR BIOL, V10, P1619, DOI 10.1016/S0960-9822(00)00869-1; Pothof J, 2003, GENE DEV, V17, P443, DOI 10.1101/gad.1060703; Sternberg PW, 1998, TRENDS GENET, V14, P466, DOI 10.1016/S0168-9525(98)01592-3; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; Zipperlen P, 2001, EMBO J, V20, P3984, DOI 10.1093/emboj/20.15.3984	36	8	9	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2004	23	51					8346	8352		10.1038/sj.onc.1208044	http://dx.doi.org/10.1038/sj.onc.1208044			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867BA	15517015				2022-12-17	WOS:000224815900004
J	Kalaitzidis, D; Ok, J; Sulak, L; Starczynowski, DT; Gilmore, TD				Kalaitzidis, D; Ok, J; Sulak, L; Starczynowski, DT; Gilmore, TD			Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells	ONCOGENE			English	Article						c-Rel; Rel; NF-kappa B; estrogen receptor; ER fusion; malignant transformation	NF-KAPPA-B; INTERLEUKIN-6 GENE-EXPRESSION; TRANSCRIPTION FACTOR; DNA-BINDING; V-REL; HODGKINS-DISEASE; LINE RC-K8; TRANSACTIVATION; ACTIVATION; DOMAINS	Overexpression of the human REL transcription factor can malignantly transform chicken spleen cells in vitro. In this report, we have created and characterized a cDNA encoding a chimeric protein (RELDelta424 - 490- ER) in which sequences of a highly transforming REL mutant ( RELD424 - 490) are fused to the ligand-binding domain of the human estrogen receptor ( ER). Surprisingly, RELDelta424 - 490- ER is constitutively nuclear in A293 cells, and RELDelta424 - 490- ER activates transcription in the absence, but not in the presence, of estrogen in kappaB-site reporter gene assays. Furthermore, RELDelta424 - 490- ER transforms chicken spleen cells in the absence of estrogen, but the addition of estrogen blocks the ability of RELDelta424 - 490- ER-transformed cells to form colonies in soft agar, even though estrogen induces increased nuclear translocation of RELDelta424 - 490- ER in these cells. ERalpha can also inhibit REL-dependent transactivation in trans in an estrogen-dependent manner, and ERalpha can interact with REL in vitro. Thus, the RELDelta424 - 490- ER fusion protein shows an unusual, reverse hormone regulation, in that its most prominent biological activities ( transformation and transactivation) are inhibited by estrogen, probably due to an estrogen-induced interaction between the ER sequences and sequences in the Rel homology domain. Nevertheless, these results indicate that the continual activity of REL is required to sustain the transformed state of chicken spleen cells in culture, suggesting that direct and specific inhibitors of REL may have therapeutic efficacy in certain human lymphoid cancers.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu			NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; CAPOBIANCO AJ, 1993, VIROLOGY, V193, P160, DOI 10.1006/viro.1993.1112; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Evans MJ, 2001, CIRC RES, V89, P823, DOI 10.1161/hh2101.098543; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; HORIGOME T, 1988, ENDOCRINOLOGY, V123, P2540, DOI 10.1210/endo-123-5-2540; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; Maia DM, 2000, LEUKEMIA LYMPHOMA, V39, P365, DOI 10.3109/10428190009065836; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; RAY A, 1994, J BIOL CHEM, V269, P12940; Ray P, 1997, FEBS LETT, V409, P79, DOI 10.1016/S0014-5793(97)00487-0; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Sharma RV, 2001, J APPL PHYSIOL, V91, P2400, DOI 10.1152/jappl.2001.91.5.2400; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STARK JJ, 1981, ANN INTERN MED, V95, P186, DOI 10.7326/0003-4819-95-2-186; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Tzagarakis-Foster C, 2002, J BIOL CHEM, V277, P44772, DOI 10.1074/jbc.M205355200; Valentine JE, 2000, J BIOL CHEM, V275, P25322, DOI 10.1074/jbc.M002497200; VANGOOL A, 2002, KEYSTONE S NF KB BEN; Walker AK, 1996, ONCOGENE, V12, P2515; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	30	8	9	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7580	7587		10.1038/sj.onc.1207912	http://dx.doi.org/10.1038/sj.onc.1207912			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326488				2022-12-17	WOS:000224176500015
J	Loong, SLE; Korzh, S; Price, A				Loong, SLE; Korzh, S; Price, A			Reduced DNA-dependent protein kinase activity in two cell lines derived from adult cancer patients with late radionecrosis	ONCOGENE			English	Article						DNA-dependent protein kinase; radiation injury; radiosensitivity	IN-VITRO RADIOSENSITIVITY; STRAND BREAK REPAIR; INTRINSIC RADIOSENSITIVITY; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; RADIOTHERAPY; CARCINOMA; EXPRESSION; ASSAY	Epstein-Barr virus-immortalized lymphoblastoid cell tines were derived from five patients with late radionecrosis. Two of these cell lines exhibited postradiation viability levels intermediate between normal cell fines and that from an individual with ataxia telangiectasia. Compared with controls, these two cell lines exhibited impaired ability to rejoin DNA double-strand breaks on pulsed-field gel electrophoresis and 6-10-fold reduced DNA-dependent protein kinase (DNA-PK) activity in vitro in cell-free extracts. Immunoblotting showed normal levels of Ku70, Ku80 and XRCC4 and the presence of DNA-PKcs in both cell lines. These findings suggest that DNA-PK might be an important factor affecting the predisposition of radiotherapy patients to late radionecrosis.	Univ Edinburgh, Western Gen Hosp, Div Oncogen, Edinburgh EH4 2XU, Midlothian, Scotland; Natl Canc Ctr, Dept Therapeut Radiol, Singapore, Singapore; Natl Canc Ctr, Div Med Sci, Singapore, Singapore	University of Edinburgh; National Cancer Centre Singapore (NCCS); National Cancer Centre Singapore (NCCS)	Price, A (corresponding author), Univ Edinburgh, Western Gen Hosp, Div Oncogen, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	a.price@ed.ac.uk						Alapetite C, 1999, INT J CANCER, V83, P83, DOI 10.1002/(SICI)1097-0215(19990924)83:1<83::AID-IJC16>3.3.CO;2-#; ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1995, CANCER RES, V55, P5200; Alsbeih G, 2000, INT J RADIAT ONCOL, V46, P143, DOI 10.1016/S0360-3016(99)00409-5; Bjork-Eriksson T, 1998, BRIT J CANCER, V77, P2371, DOI 10.1038/bjc.1998.394; Dibiase SJ, 2000, CANCER RES, V60, P1245; GODSEN CM, 1986, HUMAN CYTOGENETICS P, P31; Herring CJ, 1998, BRIT J CANCER, V78, P1128, DOI 10.1038/bjc.1998.641; ILIAKIS G, 1991, BIOESSAYS, V13, P641; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Polischouk AG, 1999, INT J RADIAT ONCOL, V43, P191, DOI 10.1016/S0360-3016(98)00362-9; PRICE P, 1990, CANCER RES, V50, P1392; Safwat A, 2002, INT J RADIAT ONCOL, V52, P198, DOI 10.1016/S0360-3016(01)02690-6; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Tucker SL, 1996, RADIOTHER ONCOL, V38, P103, DOI 10.1016/0167-8140(95)01669-4; West CML, 1997, BRIT J CANCER, V76, P1184, DOI 10.1038/bjc.1997.531; West CML, 1998, INT J RADIAT BIOL, V73, P409, DOI 10.1080/095530098142248; Woods T, 2002, NUCLEIC ACIDS RES, V30, P5120, DOI 10.1093/nar/gkf625; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073	23	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5562	5566		10.1038/sj.onc.1207771	http://dx.doi.org/10.1038/sj.onc.1207771			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184871	Bronze			2022-12-17	WOS:000222588400017
J	Edel, MJ; Shvarts, A; Medema, JP; Bernards, R				Edel, MJ; Shvarts, A; Medema, JP; Bernards, R			An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression	ONCOGENE			English	Article						functional screen; tumor progression; cancer; transformation	COILED-COIL DOMAIN; C-MYC; CANCER; CELLS; EXPRESSION; ACTIVATION; IMMUNITY; PRODUCT; RAS	Over the past decades, much has been learnt about the genes that contribute to oncogenic transformation of primary cells in vitro. However, much less is known about the genes that contribute to the later stages of tumor progression, in which cells of ever increasing malignancy arise through clonal selection in vivo. To search for genes that confer a tumor progression phenotype in vivo, we have used a functional genetic approach. We used adenovirus-transformed mouse embryo fibroblasts, which are tumorigenic in immunodeficient nude mice, but not in immunocompetent mice, due to strong cytotoxic T-cell-mediated immune rejection. We infected these cells in vitro with several high-complexity retroviral cDNA expression libraries and selected rare variants that formed tumors in immunocompetent mice. Using this approach, we identify here the TRK-T3 oncogene as a tumor progression gene. TRK-T3 does not inhibit T-cell reactivity towards the tumor cells. Instead, we find that cells expressing TRK-T3 enhances in vivo growth rate, most likely by stimulating anchorage-independent proliferation in growth factor-limiting conditions. Our data indicate that cDNA expression libraries can be used to identify tumor progression genes in vivo that cannot be readily identified using in vitro cell culture systems.	Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2333 ZA Leiden, Netherlands	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bernards, R (corresponding author), Netherlands Canc Inst, Ctr Biomed Genet, Div Mol Carcinogenesis, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	r.bernards@nki.nl	Edel, Michael J/L-1954-2014	Edel, Michael J/0000-0002-5619-8680; Bernards, Rene/0000-0001-8677-3423; Medema, Jan Paul/0000-0003-3045-2924				BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Coulie PG, 2003, CURR OPIN IMMUNOL, V15, P131, DOI 10.1016/S0952-7915(03)00009-8; GRECO A, 1995, MOL CELL BIOL, V15, P6118; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Mencinger M, 1997, GENOMICS, V41, P327, DOI 10.1006/geno.1997.4625; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Roccato E, 2003, ONCOGENE, V22, P807, DOI 10.1038/sj.onc.1206189; Roccato E, 2002, BRIT J CANCER, V87, P645, DOI 10.1038/sj.bjc.6600544; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Toes REM, 1996, CANCER RES, V56, P3782; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Xu XW, 2003, J CUTAN PATHOL, V30, P318, DOI 10.1034/j.1600-0560.2003.00068.x	24	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4959	4965		10.1038/sj.onc.1207667	http://dx.doi.org/10.1038/sj.onc.1207667			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077169	Green Published			2022-12-17	WOS:000222237300001
J	Tarbe, NG; Rio, MC; Weidle, UH				Tarbe, NG; Rio, MC; Weidle, UH			SMAGP, a new small trans-membrane glycoprotein altered in cancer	ONCOGENE			English	Article						SMAGP; cancer; cell-cell junction; protein 4.1; MAGUK; glycosylation	CELL-CELL ADHESION; GENOMIC ORGANIZATION; SORTING SIGNALS; METASTASIS; TUMOR; CARCINOMA; BREAST; GENE; PREDICTION; EXPRESSION	Using the Affymetrix array technology, we previously identified an EST strongly expressed in several metastatic cell lines. In the present study, we cloned the corresponding cDNA that encodes a new glycoprotein composed of 97 amino acids and containing a trans-membrane domain. Therefore, we named it SMAGP for Small trans-Membrane And Glycosylated Protein. SMAGP is strongly conserved during evolution. It is expressed by normal epithelia of various organs, the protein being notably localized to the lateral face of the plasma membrane of cohesive well-polarized epithelial cells. In addition, SMAGP contains binding domains for the protein 4.1 and the PDZ domain of MAGUK proteins. Similar protein features are observed in several cell-surface proteins involved via ternary complexes in intercellular processes leading to cytoskeleton assembly as well as intracellular signalling. Thus, SMAGP might similarly be involved in a scaffolding protein complex, and therefore participate in the epithelium organization or in subsequent functions. Immunohistochemical data obtained using human breast, colon and lung cancer samples sustain this hypothesis since they showed that, in both primary tumours and metastases, reduced expression and/or cytoplasmic redistribution of SMAGP is superimposable with low histological tumour differentiation features, namely a lack of epithelial cell polarity and disorganized tissue phenotype.	Univ Strasbourg 1, INSERM, U596,CNRS,UMR 7104, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, CU Strasbourg, France; Roche Diagnost GmbH, Pharma Res, D-82377 Penzberg, Germany	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Roche Holding	Rio, MC (corresponding author), Univ Strasbourg 1, INSERM, U596,CNRS,UMR 7104, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, CU Strasbourg, France.	rio@igbmc.u-strasbg.fr						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Biederer T, 2001, J BIOL CHEM, V276, P47869, DOI 10.1074/jbc.M105287200; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Claas C, 1998, J CELL BIOL, V141, P267, DOI 10.1083/jcb.141.1.267; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; FUKUDA M, 1987, J BIOL CHEM, V262, P11952; Greenwood E, 2003, NAT REV CANCER, V3, P549, DOI 10.1038/nrc1155; Grille SJ, 2003, CANCER RES, V63, P2172; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Hunter KW, 2001, CANCER RES, V61, P8866; Jeanplong F, 2001, MOL CELL BIOCHEM, V220, P31, DOI 10.1023/A:1010801511963; Jensen LJ, 2002, J MOL BIOL, V319, P1257, DOI 10.1016/S0022-2836(02)00379-0; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; MATZKU S, 1983, INVAS METAST, V3, P109; Nawrocki B, 1998, AM J PATHOL, V153, P1521, DOI 10.1016/S0002-9440(10)65740-9; NERI A, 1982, J NATL CANCER I, V68, P507; Nestl A, 2001, CANCER RES, V61, P1569; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Rogers GR, 1997, GENOMICS, V39, P127, DOI 10.1006/geno.1996.4501; Rosel M, 1998, ONCOGENE, V17, P1989, DOI 10.1038/sj.onc.1202079; Skubitz Amy P N, 2002, Cancer Treat Res, V107, P305; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Tarbe N, 2002, ANTICANCER RES, V22, P2015; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; Welch DR, 1997, CLIN EXP METASTAS, V15, P272, DOI 10.1023/A:1018477516367; Wurfel J, 1999, ONCOGENE, V18, P2323, DOI 10.1038/sj.onc.1202542; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	39	8	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3395	3403		10.1038/sj.onc.1207469	http://dx.doi.org/10.1038/sj.onc.1207469			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15021913				2022-12-17	WOS:000220975000014
J	Shen, Q; Singh, P				Shen, Q; Singh, P			Identification of a novel SP3 binding site in the promoter of human IGFBP4 gene: Role of SP3 and AP-1 in regulating promoter activity in CaCo2 cells	ONCOGENE			English	Article						IGFBP4 promoter; Sp3 binding site; AP-1 binding site; colon cancer cells; c-Jun; JunD	GROWTH-FACTOR-II; SMOOTH-MUSCLE; DIFFERENTIAL EXPRESSION; PROTEIN-4 IGFBP-4; SP-FAMILY; TRANSCRIPTION; MECHANISMS; CLONING; ELEMENT; PROLIFERATION	Insulin-like growth factor binding protein 4 (IGFBP4/BP4) gene expression plays an important role in the transition from proliferation to differentiation of a human colon cancer cell line, CaCo2. We recently cloned and identified multiple cis elements (including putative binding sites for activator protein 1(AP-1) and specificity proteins (Sps) ) in the promoter of human BP4 gene, and measured a significant upregulation of the promoter activity in response to c-Jun. We therefore examined the role of the single AP-1 site (-869/-863) and other cis elements, in regulating the expression of hBP4 gene, in the current studies. Deletion of a 25 bp sequence from -872 to -848, which contains the AP-1 site, significantly reduced BP4 promoter activity by approximately 50%. Surprisingly, mutation of the AP-1 site did not produce significant alteration in the activity of the BP4 promoter. However, mutation of 7 bp (5'-TGCTGCA) at the 3' end of the AP-1 site resulted in significantly decreasing the promoter activity by > 50%. Proteins bound to the 25 bp probe (-872/-848) could be supershifted by antibodies specific for JunD and Sp3 in an EMSA. JunD binding was abolished on mutation of the AP-1 site and Sp3 binding was abolished on mutation of the 7 bp at -861/-855; binding of the purified Sp3 protein to the 25 bp probe was similarly abolished on mutation of the newly discovered Sp3 binding site (TGCTGCA). BP4 promoter activity was upregulated in insect cells in response to Sp3 expression, confirming a functional importance of the novel Sp3 binding site. These studies suggest that the Sp3 binding site, rather than the AP-1 site, may be playing a significant role in regulating the expression of IGFBP4 gene in CaCo2 cells.	Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Anat & Neurosci, 10-104 Med Res Bldg,Route 1043, Galveston, TX 77555 USA.	posingh@utmb.edu		Shen, Qiang/0000-0002-1491-5434	NCI NIH HHS [CA 60087, CA 72992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Cohick WS, 2000, ENDOCRINOLOGY, V141, P4583, DOI 10.1210/en.141.12.4583; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; Dai BS, 1997, ENDOCRINOLOGY, V138, P332, DOI 10.1210/en.138.1.332; Dai BS, 2001, J BIOL CHEM, V276, P6937, DOI 10.1074/jbc.M007789200; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Gao JG, 1996, MOL ENDOCRINOL, V10, P613, DOI 10.1210/me.10.6.613; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kao WY, 1997, J CELL BIOCHEM, V65, P231, DOI 10.1002/(SICI)1097-4644(199705)65:2<231::AID-JCB8>3.0.CO;2-V; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kutoh E, 1999, CANCER LETT, V136, P187, DOI 10.1016/S0304-3835(98)00321-8; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Li CG, 2000, BBA-GENE STRUCT EXPR, V1490, P213, DOI 10.1016/S0167-4781(99)00183-9; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P2641, DOI 10.1210/en.142.6.2641; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; OGUCHI S, 1994, AM J PHYSIOL-GASTR L, V267, pG843, DOI 10.1152/ajpgi.1994.267.5.G843; Pan XL, 2000, J LAB CLIN MED, V136, P157, DOI 10.1067/mlc.2000.108149; Park JHY, 1996, J CELL PHYSIOL, V166, P396, DOI 10.1002/(SICI)1097-4652(199602)166:2<396::AID-JCP18>3.0.CO;2-9; Praz V, 2002, NUCLEIC ACIDS RES, V30, P322, DOI 10.1093/nar/30.1.322; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Qin XZ, 1997, BBA-GENE STRUCT EXPR, V1350, P136, DOI 10.1016/S0167-4781(96)00220-5; Shen Q, 1998, GASTROENTEROLOGY, V114, pA1179; SHEN Q, 2001, P END SOC 83 ANN M D; SHEN Q, 1998, CANCER RES, V39, pA1225; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; Singh P, 1998, GASTROENTEROLOGY, V114, P1221, DOI 10.1016/S0016-5085(98)70428-7; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; Singh P, 2000, J CLIN LIGAND ASSAY, V23, P214; Singh P, 1996, ENDOCRINOLOGY, V137, P1764, DOI 10.1210/en.137.5.1764; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; SINGH P, 1994, CANCER RES, V54, P6563; Smith EP, 2001, ENDOCRINOLOGY, V142, P4420, DOI 10.1210/en.142.10.4420; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tseng L, 1997, ANN NY ACAD SCI, V828, P27, DOI 10.1111/j.1749-6632.1997.tb48521.x; Zarrilli R, 1999, GASTROENTEROLOGY, V116, P1358, DOI 10.1016/S0016-5085(99)70500-7; Zazzi H, 1998, GENOMICS, V49, P401, DOI 10.1006/geno.1998.5283; Zhang MY, 2002, J BIOL CHEM, V277, P21285, DOI 10.1074/jbc.M112082200; Zhu Q, 2000, J VIROL, V74, P6348, DOI 10.1128/JVI.74.14.6348-6357.2000	47	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2454	2464		10.1038/sj.onc.1207354	http://dx.doi.org/10.1038/sj.onc.1207354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14767471				2022-12-17	WOS:000220558000003
J	Thangaraju, M; Sharan, S; Sterneck, E				Thangaraju, M; Sharan, S; Sterneck, E			Comparison of mammary gland involution between 129S1 and C57BL/6 inbred mouse strains: differential regulation of Bcl2a1, Trp53, Cebpb, and Cebpd expression	ONCOGENE			English	Article						C/EBP; mouse strain; mammary gland; Involution; Bfl1; p53	PLASMACYTOMA SUSCEPTIBILITY; CELL-PROLIFERATION; EPITHELIAL-CELLS; GENE-EXPRESSION; BCL-2 HOMOLOG; BREAST-CANCER; EGF RECEPTOR; C/EBP-BETA; APOPTOSIS; FAMILY	Genetic engineering has made the mouse an invaluable tool to address the function of individual genes in a targeted manner. Over the last decade it has become apparent that the genetic mouse strain background can significantly influence the phenotype of an engineered mouse. Therefore, it is essential to characterize the biology of the different wild-type background strains. In this study, we have compared mouse mammary gland involution in the 129S1 and C57BL/6 inbred strains and report significant differences at the molecular level with differential expression of Bcl2a1 (Bfl1), Trp53 (p53), Cebpb (C/EBPbeta), and Cebpd (C/EBPdelta). The C57BL/6 strain exhibits dynamic responses with induction of Trp53 and Cebpd and concomitant downregulation of Bcl2a1 during the first phase of involution. In contrast, expression of these genes does not change significantly in 129S1 mice. During the second phase, C57BL/6 glands contain more Cebpb than 129S1 glands. Nevertheless, involution proceeds morphologically with similar kinetics in both strains. The data demonstrate that the genetic response of mammary tissue varies significantly between 129S1 and C57BL/6. These results may provide a basis for the interpretation of strain-specific phenotypes in engineered mice and underline the importance of pure strains for large-scale expression studies with mutant mice.	NCI, Regulat Cell Growth Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sterneck, E (corresponding author), NCI, Regulat Cell Growth Lab, Ctr Canc Res, NIH, POB B, Frederick, MD 21702 USA.	sterneck@ncifcrf.gov		Sterneck, Esta/0000-0001-7716-8766	NATIONAL CANCER INSTITUTE [Z01BC010307, ZIABC010307] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck JA, 2000, NAT GENET, V24, P23, DOI 10.1038/71641; D'Sa-Eipper C, 1998, ONCOGENE, V16, P3105, DOI 10.1038/sj.onc.1201851; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DSaEipper C, 1996, CANCER RES, V56, P3879; Furth PA, 1999, J MAMMARY GLAND BIOL, V4, P123, DOI 10.1023/A:1018764922082; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hodge DL, 2002, MOL CELL BIOL, V22, P1742, DOI 10.1128/MCB.22.6.1742-1753.2002; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; QUARRIE LH, 1995, CELL TISSUE RES, V281, P413, DOI 10.1007/BF00417859; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; STRANGE R, 1995, METHOD CELL BIOL, V46, P355; STRANGE R, 1992, DEVELOPMENT, V115, P49; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	32	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2548	2553		10.1038/sj.onc.1207363	http://dx.doi.org/10.1038/sj.onc.1207363			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14981542				2022-12-17	WOS:000220558000012
J	Yan, DH; Wen, Y; Su, LK; Xia, WY; Wang, SC; Zhang, S; Gan, L; Lee, DF; Spohn, B; Frey, JA; Hortobagyi, GN; Hung, MC				Yan, DH; Wen, Y; Su, LK; Xia, WY; Wang, SC; Zhang, S; Gan, L; Lee, DF; Spohn, B; Frey, JA; Hortobagyi, GN; Hung, MC			A delayed chemically induced tumorigenesis in Brca2 mutant mice	ONCOGENE			English	Article						Brca2; knockout; mammary tumors; DMBA; carcinogenesis	MOUSE MAMMARY-TUMORS; BREAST-CANCER; OVARIAN-CANCER; DNA-REPAIR; GENE; SUSCEPTIBILITY; EXPRESSION; MUTATION; PROLIFERATION; SENSITIVITY	BRCA2 is a breast cancer susceptibility gene. Germline mutations of BRCA2 account for about 10-30% of familial breast cancer cases. Consistent with its tumor-suppressor activity, BRCA2 plays an important role in DNA repair. To assess the susceptibility of carriers of mutant BRCA2 to tumorigenesis induced by DNA-damaging carcinogens, we generated a Brca2 knockout mouse strain and studied its susceptibility to chemically induced tumorigenesis. Similar to previously reported Brca2 knockout mice, our Brca2(-/-) embryos die at E8.5-9.5, while the Brca2(+/-) mice are tumor-free and fertile. Unexpectedly, Brca2(+/-) mice developed tumors slower than did their wild-type littermates when treated with a potent carcinogen 7,12-dimethylbenz[a]anthracene (DMBA). In vitro experiments showed that Brca2(+/-) mouse cells and Capan-1 cells, a human pancreatic cancer cell line deficient of BRCA2, were more sensitive to DMBA-induced apoptosis, than were Brca2(+/+) mouse cells and a derivative of Capan-1 cells that expressed exogenous wild-type BRCA2, respectively. Our results suggest that enhanced sensitivity of Brca2 mutant cells to DMBA-induced apoptosis at the dose of DMBA we used contributes to the delayed tumorigenesis of Brca2(+/-) animals. This suggestion may also provide a rational explanation for a previous unexpected finding that cigarette smoking appears to reduce the breast cancer risk of BRCA2 mutation carriers.	Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX 77025 USA; Univ Texas, Dept Surg Oncol, Houston, TX USA; Univ Rochester, Ctr Aging & Dev Biol, Rochester, NY USA; Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Rochester; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX 77025 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021; Wang, Shao-Chun/P-9904-2019	Hung, Mien-Chie/0000-0003-4317-4740; Wang, Shao-Chun/0000-0002-5477-1682; Lee, Dung-Fang/0000-0003-2387-597X	NCI NIH HHS [R01CA 77858, R01CA58880, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA058880, R01CA077858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; Aldaz CM, 1996, MOL CARCINOGEN, V17, P126, DOI 10.1002/(SICI)1098-2744(199611)17:3<126::AID-MC4>3.0.CO;2-D; Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO;2-C; Boyd J, 2000, JAMA-J AM MED ASSOC, V283, P2260, DOI 10.1001/jama.283.17.2260; Brunet JS, 1998, J NATL CANCER I, V90, P761, DOI 10.1093/jnci/90.10.761; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Ding Y, 2002, CLIN CANCER RES, V8, P3290; Egawa C, 2001, INT J CANCER, V95, P255, DOI 10.1002/1097-0215(20010720)95:4<255::AID-IJC1043>3.0.CO;2-O; Friedman LS, 1998, CANCER RES, V58, P1338; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Goggins M, 1996, CANCER RES, V56, P5360; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Levine DA, 2002, GYNECOL ONCOL, V85, P431, DOI 10.1006/gyno.2002.6646; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; McAllister KA, 2002, CANCER RES, V62, P990; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Morimatsu M, 1998, CANCER RES, V58, P3441; Orelli BJ, 2001, BREAST CANCER RES, V3, P294, DOI 10.1186/bcr310; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pena JC, 1998, CANCER RES, V58, P2111; Sambrook J., 1982, MOL CLONING; Schwab M, 2002, CANCER LETT, V175, P1, DOI 10.1016/S0304-3835(01)00752-2; Scully R, 2002, BIOCHIMIE, V84, P95, DOI 10.1016/S0300-9084(01)01359-1; Sharan SK, 1997, GENOMICS, V40, P234, DOI 10.1006/geno.1996.4573; Su LK, 1998, ONCOGENE, V17, P2377, DOI 10.1038/sj.onc.1202162; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2001, CURR OPIN CELL BIOL, V13, P338; Wang SC, 2002, CANCER RES, V62, P1311; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	36	8	8	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1896	1901		10.1038/sj.onc.1207314	http://dx.doi.org/10.1038/sj.onc.1207314			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14981540				2022-12-17	WOS:000220129500011
J	Koh, EY; Chen, T; Daley, GQ				Koh, EY; Chen, T; Daley, GQ			Genetic complementation of cytokine signaling identifies central role of kinases in hematopoietic cell proliferation	ONCOGENE			English	Article						expression cloning; cytokine signaling; tyrosine kinase; myeloproliferative disease	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY-STIMULATING FACTOR; HOMEOBOX GENE; PROTEIN-KINASE; MYELODYSPLASTIC SYNDROMES; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; TRANSFORMING GENE; MYELOID-LEUKEMIA	Molecular evidence suggests a multistep process in the development of acute leukemia. Since inappropriate activation of cytokine signaling cascades is a recurring theme in human leukemia, we performed expression screens to identify genes that transform cytokine-dependent cells. Using retroviral cDNA libraries derived from peripheral blood mononuclear cells of patients with myeloproliferative disorders, we isolated numerous genes that genetically complement cytokine requirements for proliferation of BaF/3 and TF-1 cells. The majority of recovered genes represent members of the kinase family, including several previously linked to leukemogenesis. Our unbiased screen highlights the central role of kinase activation in hematopoietic cell proliferation and identifies a number of potential leukemic oncoproteins.	Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; Harvard Univ, Sch Med,Childrens Hosp, Dept Biol Chem & Mol Pharmacol, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Daley, GQ (corresponding author), Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.	daley@wi.mit.edu			NATIONAL CANCER INSTITUTE [R29CA076418, T32CA009541, R01CA086991] Funding Source: NIH RePORTER; NCI NIH HHS [CA09541, CA86991, CA76418] Funding Source: Medline; NIGMS NIH HHS [GM07753-22, T32 GM007753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ALLEN JD, 1995, J IMMUNOL, V154, P1531; ALLEN JD, 1993, BLOOD, V81, P3242; AOKI M, 1993, J BIOL CHEM, V268, P22723; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BAKER DA, 1994, LEUKEMIA, V8, P141; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Boudard D, 2002, AM J HEMATOL, V70, P115, DOI 10.1002/ajh.10108; Bourette RP, 1992, GROWTH FACTORS, V7, P315, DOI 10.3109/08977199209046414; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHAN AML, 1993, ONCOGENE, V8, P1329; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Deguchi K, 2002, LEUKEMIA, V16, P740, DOI 10.1038/sj.leu.2402500; DEGUCHI Y, 1992, J BIOL CHEM, V267, P8222; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hariharan I K, 1988, Oncogene Res, V3, P387; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Koh EY, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf142; KOH EY, 2001, CHRONIC MYELOID LEUK, P56; Kulkarni S, 2000, CANCER RES, V60, P3592; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; MCARTHUR GA, 1994, BLOOD, V83, P972; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Spiekermann K, 2001, EUR J HAEMATOL, V67, P63, DOI 10.1034/j.1600-0609.2001.t01-1-00385.x; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tabrizi M, 1998, LEUKEMIA, V12, P200, DOI 10.1038/sj.leu.2400949; TOBAL K, 1990, LEUKEMIA, V4, P486; TRUS MD, 1982, J BIOL CHEM, V257, P2730; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yates KE, 1996, STEM CELLS, V14, P117, DOI 10.1002/stem.140117	61	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1214	1220		10.1038/sj.onc.1207209	http://dx.doi.org/10.1038/sj.onc.1207209			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647454				2022-12-17	WOS:000188892200005
J	Benelli, R; Peissel, B; Manenti, G; Gariboldi, M; Vanzetto, C; Albini, A; Dragani, TA				Benelli, R; Peissel, B; Manenti, G; Gariboldi, M; Vanzetto, C; Albini, A; Dragani, TA			Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration	ONCOGENE			English	Article						cancer modifier genes; genetic susceptibility; polymorphism skin cancer	EXTRACELLULAR-MATRIX; TUMOR INVASION; PTHRP; PEPTIDE; BREAST; EXPRESSION; MOTILITY; RECEPTOR; LINE	The mouse parathyroid hormone-like hormone Pthlh(Pro) and Pthlh(Thr) variants are linked with susceptibility and resistance to skin carcinogenesis of Car-S and Car-R mice, respectively, and with in vitro effects ( Oncogene, 19: 5324 - 5328, 2000). We have identified an additional Pthlh variant, consisting of Thr and three amino-acid changes in the C-terminus (Pthlh(SerAspTyr)), carried by an evolutionarily distant Mus spretus (SPRET/Ei) inbred strain. When transfected into NCI-H520 tumor cells, this Pthlh(SerAspTyr) variant did not stimulate tumor growth in nude mice. Analysis of cell adhesion, migration, and invasion patterns of Pthlh(Pro)-, Pthlh(Thr)-, and Pthlh(SerAspTyr)- transfected NCI-H520 cells revealed a 1.5-fold decrease in adhesion efficiency on both collagen type I and Matrigel, and a 5-6-fold increase in migration capability in Pthlh(Pro) transfectants as compared to nontransfected, vector-transfected, Pthlh(Thr)-, or Pthlh(SerAspTyr)- transfected cells. These findings suggest that the cancer modifier effects of the mouse Pthlh gene are mediated by differential cell adhesion and migration effects of PTHrP variants.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Ric Canc, Mol Biol Lab, I-16132 Genoa, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Genoa; IRCCS AOU San Martino IST	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Manenti, Giacomo/J-3339-2017; Benelli, Roberto/AAF-3143-2019; Peissel, Bernard/E-8187-2017; Dragani, Tommaso A./K-4493-2016; Gariboldi, Manuela/K-4744-2016	Manenti, Giacomo/0000-0002-4887-4482; Benelli, Roberto/0000-0002-9769-0954; Peissel, Bernard/0000-0001-9233-3571; Dragani, Tommaso A./0000-0001-5915-4598; Albini, Adriana/0000-0002-9624-5103; Gariboldi, Manuela/0000-0001-8406-165X				Akino K, 2000, ENDOCRINOLOGY, V141, P4313, DOI 10.1210/en.141.11.4313; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 1998, Pathol Oncol Res, V4, P230; Bakre MM, 2002, NAT MED, V8, P995, DOI 10.1038/nm753; Boccellino M, 2000, J CELL PHYSIOL, V183, P254, DOI 10.1002/(SICI)1097-4652(200005)183:2<254::AID-JCP12>3.0.CO;2-U; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Conlan LA, 2002, FEBS LETT, V527, P71, DOI 10.1016/S0014-5793(02)03164-2; De Miguel F, 2001, ENDOCRINOLOGY, V142, P4096, DOI 10.1210/en.142.9.4096; Fassina G, 1996, INT J ONCOL, V8, P253; Goomer RS, 2000, ENDOCRINOLOGY, V141, P4613, DOI 10.1210/en.141.12.4613; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Luparello C, 1999, FEBS LETT, V463, P265, DOI 10.1016/S0014-5793(99)01635-X; Manenti G, 2000, ONCOGENE, V19, P5324, DOI 10.1038/sj.onc.1203916; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Rabbani SA, 2000, INT J ONCOL, V16, P197; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Ye YM, 2001, REGUL PEPTIDES, V101, P19, DOI 10.1016/S0167-0115(01)00259-2	22	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7711	7715		10.1038/sj.onc.1207088	http://dx.doi.org/10.1038/sj.onc.1207088			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586397				2022-12-17	WOS:000186240200001
J	Usenko, T; Kukushkin, A; Pospelova, T; Pospelov, V				Usenko, T; Kukushkin, A; Pospelova, T; Pospelov, V			Transient expression of E1A and Ras oncogenes causes downregulation of c-fos gene transcription in nontransformed REF52 cells	ONCOGENE			English	Article						E1A and Ras; c-fos transcription; chromatin; HDAC inhibitors	CHROMATIN STRUCTURE; CHA-RAS; ACTIVATION; PROMOTER; SIGNAL; TRANSFORMATION; FIBROBLASTS; REPRESSION; PATHWAY	Stable transformation of rat embryo fibroblast (REF) cells with E1A and cHa-ras oncogenes leads to downmodulation of c-fos gene transcription. This repression is provided in part by the association of Elk-1 transcription factor with histone deacetylases mediated through effects of Ras on MAP-kinase cascades. Here, we focus on the primary effects of E1A and Ras displayed in transient transfection assay on the transactivating capability of Elk-1, which is a key transcription factor of c-fos gene regulation. Our data show that E1A is able to suppress serum-and Ras-induced stimulation of Gal-luc reporter activity by a full-length Gal-Elk1-428 fusion protein as well as the expression of c-fos promoter-driven luciferase constructs (fos-luc). The repression can be relieved by trichostatin A, a histone deacetylase ( HDAC) inhibitor, implying the involvement of HDACs and an inactive chromatin structure formed due to underacetylation of nucleosomal histones. Thus, upon transient transfection of E1A and Ras oncogenes in REF52 cells or their stable expression in E1A+cHa-ras cells, E1A contributes to the formation of inactive chromatin structure through association with p300/CBP histone acetyltransferases at c-fos promoters, whereas Ras mediates its effect through constitutive activation of the MAP/ERK kinase cascade, thereby promoting the recruitment of HDAC1 to the Elk-1 transcription factor. As a result, downregulation of c-fos gene transcription revealed in established E1A+Ras transformants is unlikely to be a consequence of cell transformation itself, but follows from primary effects of E1A and Ras on chromatin remodeling factors.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, V (corresponding author), Russian Acad Sci, Inst Cytol, Tikhoretzky Ave 4, St Petersburg 194064, Russia.		Kukushkin, Alexander/W-7241-2018					Abramova MV, 2003, BIOCHEM BIOPH RES CO, V306, P483, DOI 10.1016/S0006-291X(03)00996-3; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; Kukushkin AN, 2002, ONCOGENE, V21, P719, DOI 10.1038/sj.onc.1205118; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; WANG HG, 1993, J VIROL, V76, P476; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	15	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7661	7666		10.1038/sj.onc.1206975	http://dx.doi.org/10.1038/sj.onc.1206975			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576829				2022-12-17	WOS:000186113000014
J	Calissano, M; Latchman, DS				Calissano, M; Latchman, DS			Functional interaction between the small GTP-binding protein Rin and the N-terminal of Brn-3a transcription factor	ONCOGENE			English	Article						Brn-3a; Pou; Rin; RAS yeast two hybrid	GENE-EXPRESSION; NEURONAL CELLS; DOMAIN; ACTIVATION; FAMILY; SUBFAMILY; OUTGROWTH; GANGLION; DISTINCT	Brn-3a is a transcription factor belonging to the class IV of POU domain transcription factors. It is expressed throughout the peripheral nervous system but especially in postmitotic sensory neurons of dorsal root ganglia. Brn-3a is known to regulate different genes involved in neuronal differentiation and survival. It has been shown that some of these genes require the N-terminal domain of Brn-3a in order to be activated and this effect is observed only in neurons suggesting that it may require a neuronal-specific cofactor. In order to identify this putative factor(s) we screened a cDNA library via a variant of the original yeast two-hybrid system. By using the N-terminal of Brn-3a as the bait, we have repeatedly isolated a protein named Rin, an incompletely characterized small GTP-binding protein expressed only in neurons. In this work, we describe the evidence for a functional interaction between Brn-3a and Rin and demonstrate the role of Rin in modulating the activation of the Brn-3a regulated egr-1 promoter by the N-terminal domain of Brn-3a.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England	University of London; University College London	Calissano, M (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	m.calissano@ich.ucl.ac.uk			Telethon [487/B] Funding Source: Medline	Telethon(Fondazione Telethon)		Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Ensor E, 2001, J BIOL CHEM, V276, P5204, DOI 10.1074/jbc.M007068200; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Lee CHJ, 1996, J NEUROSCI, V16, P6784; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; Liu YZ, 1996, J MOL NEUROSCI, V7, P77, DOI 10.1007/BF02736850; Morris PJ, 1996, MOL BRAIN RES, V43, P279, DOI 10.1016/S0169-328X(96)00207-0; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; PATEL G, 1992, ONCOGENE, V7, P283; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Smith MD, 2001, MOL CELL NEUROSCI, V17, P460, DOI 10.1006/mcne.2000.0927; Smith MD, 1997, MOL CELL BIOL, V17, P345, DOI 10.1128/MCB.17.1.345; Smith MD, 1999, MOL BRAIN RES, V74, P117, DOI 10.1016/S0169-328X(99)00271-5; Smith MD, 1998, NUCLEIC ACIDS RES, V26, P4100, DOI 10.1093/nar/26.18.4100; Spencer ML, 2002, J BIOL CHEM, V277, P17605, DOI 10.1074/jbc.M111400200; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; Xiang MQ, 1996, P NATL ACAD SCI USA, V93, P11950, DOI 10.1073/pnas.93.21.11950; Xiang MQ, 1998, DEV BIOL, V197, P155, DOI 10.1006/dbio.1998.8868; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445	27	8	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5408	5414		10.1038/sj.onc.1206635	http://dx.doi.org/10.1038/sj.onc.1206635			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934100				2022-12-17	WOS:000184735000005
J	Ludwig, L; Kessler, H; Hoang-Vu, C; Dralle, H; Adler, G; Boehm, BO; Schmid, RM				Ludwig, L; Kessler, H; Hoang-Vu, C; Dralle, H; Adler, G; Boehm, BO; Schmid, RM			Grap-2, a novel RET binding protein, is involved in RET mitogenic signaling	ONCOGENE			English	Article						RET; Grb2-related adaptors; mitogenic signaling	CELL-LINE; CARCINOMA; PROTOONCOGENE; SYSTEM; SLP-76; GADS	Signal transduction of the RET receptor tyrosine kinase is involved in developmental processes as well as in neoplastic transformation. Activation of RET initiates receptor autophosphorylation on specific tyrosines that act as docking sites for downstream signaling molecules. Using the cytoplasmatic part of RET as bait in a yeast two-hybrid screen, we identified a novel SH2 and SH3 domain containing adaptor protein previously termed Grap-2/Grf40/GrpL/GRID) and its murine homologue as Gads/Mona, respectively. This protein, predominantly expressed in cells of hematopoietic origin, is involved in signaling downstream of the T-cell receptor and the receptor for monocyte colony-stimulating factor. Here, we show that Grap-2 is also expressed in neuroendocrine tumors and cell lines known to bear mutated forms of RET. Endogenously expressed RET and Grap-2 coimmunoprecipitate from lysates of a medullary thyroid carcinoma cell line. Grap-2 directly associates with RET in pull-down experiments using in vitro translated proteins. Overexpression of Grap-2 inhibits RET-induced NF-kappaB activation, and cotransfection of Grap-2 significantly reduces focus formation induced by oncogenic RET in NIH 3T3 cells. Taken together, these results suggest that besides being involved in tyrosine kinase signaling in hematopoietic cells, Grap-2 plays a tissue-specific role as an inhibitor of RET mitogenic signaling.	Tech Univ Munich, Klinikum Rechts Isar, Med Klin, D-81675 Munich, Germany; Univ Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Halle Wittenberg, Dept Surg 1, D-06097 Halle Saale, Germany	Technical University of Munich; Ulm University; Martin Luther University Halle Wittenberg	Schmid, RM (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin, Ismaninger Str 22, D-81675 Munich, Germany.		Boehm, Bernhard Otto/F-8750-2015					Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; CARLOMAGNO F, 1995, BIOCHEM BIOPH RES CO, V207, P1022, DOI 10.1006/bbrc.1995.1287; EVERS BM, 1994, ANN NY ACAD SCI, V733, P393, DOI 10.1111/j.1749-6632.1994.tb17289.x; Hansford JR, 2000, J MED GENET, V37, P817, DOI 10.1136/jmg.37.11.817; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Liu SKW, 2001, ONCOGENE, V20, P6284, DOI 10.1038/sj.onc.1204771; Ludwig L, 2001, CANCER RES, V61, P4526; LUNDQVIST M, 1991, EUR J CANCER, V27, P1663, DOI 10.1016/0277-5379(91)90441-F; Qiu MS, 1998, BIOCHEM BIOPH RES CO, V253, P443, DOI 10.1006/bbrc.1998.9795; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Taraviras S, 1999, CURR OPIN GENET DEV, V9, P321, DOI 10.1016/S0959-437X(99)80048-3; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176	14	8	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2003	22	34					5362	5366		10.1038/sj.onc.1206517	http://dx.doi.org/10.1038/sj.onc.1206517			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917638				2022-12-17	WOS:000184734900016
J	Bartusel, T; Klempnauer, KH				Bartusel, T; Klempnauer, KH			Transactivation mediated by B-Myb is dependent on TAF(II)250	ONCOGENE			English	Article						B-Myb; TAF(II)250; ts13; transactivation	CELL-CYCLE PROGRESSION; V-MYB; ACETYLTRANSFERASE ACTIVITY; SYNERGISTIC ACTIVATION; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; KINASE-ACTIVITY; MIM-1 GENE; C/EBP-BETA; A-MYB	B-Myb is a highly conserved member of the Myb family of transcription factors, which has been implicated in cell cycle regulation. B-Myb is expressed in most proliferating cells and its activity is highly regulated around the G1/S-phase border of the cell cycle. It is generally assumed that B-Myb regulates the expression of genes that are crucial for cell proliferation; however, the identity of these genes, the molecular mechanisms by which B-Myb stimulates their expression and the involvement of other proteins have not been sufficiently clarified. We have employed the hamster cell line ts13 as a tool to demonstrate a functional link between B-Myb and the coactivator TAF(II)250, a key component of the transcriptional machinery which itself is essential for cell proliferation. ts13 cells express a point-mutated version of TAFI,250 whose intrinsic histone acetyl transferase activity is temperature sensitive. Transactivation of Myb-responsive reporter genes by B-Myb is temperature-dependent in ts13 cells but not in ts13 cells, which have been rescued by transfection with an expression vector for wild-type TAF(II)250. Furthermore, B-Myb and TAF(II)250 can be coprecipitated, suggesting that both proteins are present in a complex. The formation of this complex is dependent on the DNA-binding domain of B-Myb and not on its transactivation domain. Taken together, these observations provide the first evidence that the coactivator TAF(II)250 is involved in the activation of Myb responsive promoters by B-Myb. The finding that B-Myb transactivation is dependent on a key coactivator involved in cell cycle control is consistent with and strengthens the idea that B-Myb plays a crucial role as a transcription factor in proliferating cells.	Univ Munster, Inst Biochem, D-48149 Munster, Germany	University of Munster	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.							Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; Bessa M, 2001, ONCOGENE, V20, P3376, DOI 10.1038/sj.onc.1204439; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Dunphy EL, 2000, MOL CELL BIOL, V20, P1134, DOI 10.1128/MCB.20.4.1134-1139.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Horstmann S, 2000, ONCOGENE, V19, P5428, DOI 10.1038/sj.onc.1203937; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Johnson LR, 2002, J BIOL CHEM, V277, P4088, DOI 10.1074/jbc.M105112200; Kamano H, 1995, ONCOGENE, V11, P2575; Kamano H, 1997, ONCOGENE, V14, P1223, DOI 10.1038/sj.onc.1200945; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; LEVAILLARD T, 1997, J BIOL CHEM, V272, P30651; Li XL, 2002, MOL CELL BIOL, V22, P3663, DOI 10.1128/MCB.22.11.3663-3673.2002; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; Lively TN, 2001, J BIOL CHEM, V276, P25582, DOI 10.1074/jbc.M100278200; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; O'Brien T, 2000, P NATL ACAD SCI USA, V97, P2456, DOI 10.1073/pnas.97.6.2456; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; Robinson C, 1996, ONCOGENE, V12, P1855; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Siegert JL, 2000, ONCOGENE, V19, P5703, DOI 10.1038/sj.onc.1203966; Siegert JL, 1999, MOL CELL BIOL, V19, P846; Sitzmann J, 1996, ONCOGENE, V12, P1889; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; Tahirov TH, 2002, CELL, V108, P57, DOI 10.1016/S0092-8674(01)00636-5; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; Wang EH, 1997, GENE DEV, V11, P2658, DOI 10.1101/gad.11.20.2658; WANG EH, 1994, SCIENCE, V263, P811, DOI 10.1126/science.8303298; Wassarman DA, 2001, J CELL SCI, V114, P2895; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	53	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2932	2941		10.1038/sj.onc.1206494	http://dx.doi.org/10.1038/sj.onc.1206494			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771944				2022-12-17	WOS:000182824800008
J	Molldrem, JJ; Kant, S; Jiang, WD; Lu, SJ				Molldrem, JJ; Kant, S; Jiang, WD; Lu, SJ			The basis of T-cell-mediated immunity to chronic myelogenous leukemia	ONCOGENE			English	Article						chronic myelogenous leukemia; T-cell; antigen; immunity	GRAFT-VERSUS-LEUKEMIA; MINOR HISTOCOMPATIBILITY ANTIGENS; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW TRANSPLANTS; HUMAN GENE MAGE-3; WEGENERS-GRANULOMATOSIS; HOST-DISEASE; PROTEINASE-3 MYELOBLASTIN; LYMPHOCYTE CLONES; TUMOR-ANTIGENS		Univ Texas, MD Anderson Canc Ctr, Transplantat Immunol Sect, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Molldrem, JJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Transplantat Immunol Sect, Dept Blood & Marrow Transplantat, 1515 Holcombe Blvd,Boxc 448, Houston, TX 77030 USA.	jmolldre@notes.mdacc.tmc.edu	Kanodia, Shreya/E-5169-2010		NATIONAL CANCER INSTITUTE [R01CA085843, R01CA081247] Funding Source: NIH RePORTER; NCI NIH HHS [CA81247, CA85843] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Anderton SM, 2002, NAT REV IMMUNOL, V2, P487, DOI 10.1038/nri842; ANTIN JH, 1993, BLOOD, V82, P2273; BALLIEUX BEPB, 1995, CLIN EXP IMMUNOL, V100, P186; Barrett AJ, 2000, BLOOD, V95, P3323; Behre G, 1999, METHODS, V17, P231, DOI 10.1006/meth.1998.0733; BOCCHIA M, 1995, BLOOD, V85, P2680, DOI 10.1182/blood.V85.10.2680.bloodjournal85102680; Bocchia M, 1996, BLOOD, V87, P3587, DOI 10.1182/blood.V87.9.3587.bloodjournal8793587; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Boon T, 1994, Important Adv Oncol, P53; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; Braunschweig I, 2000, BLOOD, V96, p761A; BROUWER E, 1994, CLIN EXP IMMUNOL, V98, P448; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; CELIS E, 1994, P NATL ACAD SCI USA, V91, P2105, DOI 10.1073/pnas.91.6.2105; CHEN T, 1994, BIOCHEM BIOPH RES CO, V200, P1130, DOI 10.1006/bbrc.1994.1568; Clark RE, 2001, BLOOD, V98, P2887, DOI 10.1182/blood.V98.10.2887; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; DENGLER R, 1995, BRIT J HAEMATOL, V89, P250, DOI 10.1111/j.1365-2141.1995.tb03297.x; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Dermime S, 1995, BLOOD, V86, P620; Faber L M, 1996, Biol Blood Marrow Transplant, V2, P31; FABER LM, 1995, J CLIN INVEST, V96, P877, DOI 10.1172/JCI118134; FABER LM, 1995, BLOOD, V86, P2821; Franssen CFM, 1996, LANCET, V347, P116; Franssen CFM, 2000, KIDNEY INT, V57, P2195, DOI 10.1046/j.1523-1755.2000.00080.x; GALE RP, 1994, ANN INTERN MED, V120, P646, DOI 10.7326/0003-4819-120-8-199404150-00004; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Giralt Sergio A., 1996, Current Opinion in Oncology, V8, P96, DOI 10.1097/00001622-199603000-00004; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; Jennette JC, 2001, SEMIN DIAGN PATHOL, V18, P3, DOI 10.1053/sdia.2001.22142; Kochenderfer J N, 2001, Curr Oncol Rep, V3, P193, DOI 10.1007/s11912-001-0050-3; Kolb Hans-Jochem, 1997, Current Opinion in Oncology, V9, P139; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; Kolb HJ, 1996, BONE MARROW TRANSPL, V17, P449; Komanduri KV, 2001, VIROLOGY, V279, P459, DOI 10.1006/viro.2000.0697; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Marchand M, 1995, INT J CANCER, V63, P883, DOI 10.1002/ijc.2910630622; Molldrem J, 1996, BLOOD, V88, P2450, DOI 10.1182/blood.V88.7.2450.bloodjournal8872450; Molldrem JJ, 1999, CANCER RES, V59, P2675; Molldrem JJ, 1997, BLOOD, V90, P2529, DOI 10.1182/blood.V90.7.2529.2529_2529_2534; Molldrem JJ, 2000, NAT MED, V6, P1018, DOI 10.1038/79526; MULLERBERAT N, 1994, CLIN IMMUNOL IMMUNOP, V70, P51, DOI 10.1006/clin.1994.1010; NANDA NK, 1995, CELL, V82, P13, DOI 10.1016/0092-8674(95)90047-0; PARDOLL DM, 1994, NATURE, V369, P357, DOI 10.1038/369357a0; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Rosenberg SA, 1996, J IMMUNOTHER, V19, P81, DOI 10.1097/00002371-199601000-00009; Savige J, 1999, AM J CLIN PATHOL, V111, P507; STURROCK AB, 1992, J BIOL CHEM, V267, P21193; Tanaka F, 1997, CANCER RES, V57, P4465; VANDERBRUGGEN P, 1994, EUR J IMMUNOL, V24, P3038, DOI 10.1002/eji.1830241218; VANDERHARST D, 1994, BLOOD, V83, P1060; VANRHEE F, 1994, BLOOD, V83, P3377; WILLIAMS RC, 1994, J IMMUNOL, V152, P4722; Zarour H, 1996, J INVEST DERMATOL, V107, P63, DOI 10.1111/1523-1747.ep12298177; Zhang P, 2002, BLOOD, V99, P4406, DOI 10.1182/blood.V99.12.4406	59	8	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8668	8673		10.1038/sj.onc.1206093	http://dx.doi.org/10.1038/sj.onc.1206093			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476312				2022-12-17	WOS:000179734300015
J	Forsyth, NR; Morrison, V; Craig, NJ; Fitzsimmons, SA; Barr, NI; Ireland, H; Gordon, KE; Dowen, S; Cuthbert, AP; Newbold, RF; Bryce, SD; Parkinson, EK				Forsyth, NR; Morrison, V; Craig, NJ; Fitzsimmons, SA; Barr, NI; Ireland, H; Gordon, KE; Dowen, S; Cuthbert, AP; Newbold, RF; Bryce, SD; Parkinson, EK			Functional evidence for a squamous cell carcinoma mortality gene(s) on human chromosome 4	ONCOGENE			English	Article						chromosome 4; senescence; keratinocyte; squamous cancer	REPLICATIVE LIFE-SPAN; TUMOR-SUPPRESSOR; INDEFINITE DIVISION; TELOMERASE ACTIVITY; IMMORTAL PHENOTYPE; CERVICAL-CARCINOMA; HUMAN-FIBROBLASTS; BREAST-CANCER; SENESCENCE; GROWTH	Squamous cell carcinoma (SCC) immortality is associated with p53 and INK4A dysfunction, high levels of telomerase and loss of heterozygosity (LOH) of other chromosomes, including chromosome 4. To test for a functional cancer mortality gene on human chromosome 4 we introduced a complete or fragmented copy of the chromosome into SCC lines by microcell-mediated chromosome transfer (MMCT). Human chromosome 4 caused a delayed crisis, specifically in SCC lines with LOH on chromosome 4, but chromosomes 3, 6, 11 and 15 were without effect. The introduction of the telomerase reverse transcriptase into the target lines extended the average telomere terminal fragment length but did not affect the frequency of mortal hybrids following MMCT of chromosome 4. Furthermore, telomerase activity was still present in hybrids displaying the mortal phenotype. The MMCT of chromosomal fragments into BICR6 mapped the mortality gene to between the centromere and 4q23. Deletion analysis of the introduced chromosome in immortal segregants narrowed the candidate interval to 2.7 Mb spanning D4S423 and D4S1557. The results suggest the existence of a gene on human chromosome 4 whose dysfunction contributes to the continuous proliferation of SCC and that this gene operates independently from telomeres, p53 and INK4A.	Beatson Inst Canc Res, CRC, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Brunel Univ, Dept Sci Biol, Uxbridge UB8 3PH, Middx, England	Beatson Institute; University of Cambridge; Brunel University	Parkinson, EK (corresponding author), Beatson Inst Canc Res, CRC, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.							Adra CN, 2000, GENOMICS, V69, P162, DOI 10.1006/geno.2000.6281; Arribas R, 1999, LAB INVEST, V79, P111; Backsch C, 2001, GENE CHROMOSOME CANC, V31, P196, DOI 10.1002/gcc.1134; BenArie N, 1996, HUM MOL GENET, V5, P1207, DOI 10.1093/hmg/5.9.1207; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Bryce SD, 1999, CANCER RES, V59, P2038; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CLARK LJ, 1993, BRIT J CANCER, V68, P617, DOI 10.1038/bjc.1993.396; Cottage A, 2001, GENE CHROMOSOME CANC, V30, P72, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1060>3.0.CO;2-X; CUTHBERT AP, 1995, CYTOGENET CELL GENET, V71, P68, DOI 10.1159/000134066; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; England NL, 1996, CARCINOGENESIS, V17, P1567, DOI 10.1093/carcin/17.8.1567; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Hu W, 1998, GENOMICS, V47, P143, DOI 10.1006/geno.1997.5108; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Karlsson C, 1996, CANCER RES, V56, P241; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; Lee YA, 2000, AM J HUM GENET, V66, P326, DOI 10.1086/302718; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; McGregor F, 1997, CANCER RES, V57, P3886; MITRA AB, 1994, CANCER RES, V54, P4481; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Parkinson EK, 1997, EUR J CANCER, V33, P727, DOI 10.1016/S0959-8049(97)00063-4; Pershouse MA, 1997, ONCOGENE, V14, P369, DOI 10.1038/sj.onc.1200836; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; RIMESSI P, 1994, ONCOGENE, V9, P3467; Robertson GP, 1998, P NATL ACAD SCI USA, V95, P9418, DOI 10.1073/pnas.95.16.9418; Rumpel CA, 1999, AM J PATHOL, V154, P1329, DOI 10.1016/S0002-9440(10)65386-2; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SASAKI M, 1994, CANCER RES, V54, P6090; Shah SI, 2000, ARCH OTOLARYNGOL, V126, P1073, DOI 10.1001/archotol.126.9.1073; Shimada Y, 1998, CYTOGENET CELL GENET, V83, P232, DOI 10.1159/000015188; Snedecor GW, 1973, STAT METHODS; SOININEN R, 1992, MECH DEVELOP, V39, P111, DOI 10.1016/0925-4773(92)90030-N; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; Terada Y, 2001, AM J MED GENET, V103, P176, DOI 10.1002/ajmg.1521; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Virgin JB, 1999, PROSTATE, V41, P49, DOI 10.1002/(SICI)1097-0045(19990915)41:1<49::AID-PROS7>3.0.CO;2-8; Wang XL, 1999, ONCOGENE, V18, P823, DOI 10.1038/sj.onc.1202318; WANG XW, 1992, CARCINOGENESIS, V13, P555, DOI 10.1093/carcin/13.4.555; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723; Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804	52	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5135	5147		10.1038/sj.onc.1205688	http://dx.doi.org/10.1038/sj.onc.1205688			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140764				2022-12-17	WOS:000176975900012
J	Afrikanova, I; Yeh, E; Bartos, D; Watowich, SS; Longmore, GD				Afrikanova, I; Yeh, E; Bartos, D; Watowich, SS; Longmore, GD			Oncogene cooperativity in Friend erythroleukemia: erythropoietin receptor activation by the env gene of SFFV leads to transcriptional upregulation of PU.1, independent of SFFV proviral insertion	ONCOGENE			English	Article						erythroleukemia; oncogene cooperativity; PU. 1 transcription; Friend virus	FOCUS-FORMING VIRUS; LONG TERMINAL REPEAT; TRANSGENIC MICE DEVELOP; CONSTITUTIVE ACTIVATION; PUTATIVE ONCOGENE; SPLEEN; SPI-1; EXPRESSION; KINASE; GROWTH	Cancer is a multi-step, multi-genetic event. Whether oncogenic mutations cooperate with one another to transform cells and how is not well understood. The Friend murine retroviral erythroleukemia model involves mitogenic activation of the erythropoietin receptor (EpoR) by the virus env gene (F-gp55), aberrant over-expression of the transcription factor PU.1, and inactivating mutations in p53. In this report we demonstrate that concurrent expression of F-gp55 and PU.1 in erythroid target cells, in vivo, cooperate to accelerate erythroleukemia induction. Early in the disease, prior to the detection of clonal leukemic cells, activation of the EpoR by F-gp55, but not erythropoietin, resulted in transcriptional upregulation of PU.1 through a trans regulatory mechanism. This could occur in the absence of an integrated provirus within the PU.1 gene locus. The regulation of PU.1 transcription in established erythroleukemia cell lines differed depending upon the level of PU.1 protein present. Our results suggest that the action of F-gp55 contributes to both early and late stages of Friend erythroleukemia and that persistence of F-gp55 expression may be required not only to initiate erythroleukemia but to also maintain erythroleukemia following Friend virus infection.	Washington Univ, Sch Med, Dept Med, Div Hematol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	Washington University (WUSTL); Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, Div Hematol, Campus Box 8125,660 S Euclid Ave, St Louis, MO 63110 USA.	longmorg@medicine.wustl.edu		Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [R01 CA 75315, R01 CA077447-02, R01 CA077447-03, R01 CA 77447] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447, R01CA075315] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnache S, 1998, ONCOGENE, V16, P2989, DOI 10.1038/sj.onc.1202095; Beckman DL, 1999, BLOOD, V94, P2667, DOI 10.1182/blood.V94.8.2667.420k27_2667_2675; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BESTWICK RK, 1988, P NATL ACAD SCI USA, V85, P5404, DOI 10.1073/pnas.85.15.5404; Chen HM, 1996, J BIOL CHEM, V271, P15743, DOI 10.1074/jbc.271.26.15743; CHEN HM, 1995, ONCOGENE, V11, P1549; CHOI SY, 1995, J VIROL, V69, P7054, DOI 10.1128/JVI.69.11.7054-7060.1995; Elnitski L, 1999, BLOOD CELL MOL DIS, V25, P299, DOI 10.1006/bcmd.1999.0257; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ghosh SK, 1999, J VIROL, V73, P4931, DOI 10.1128/JVI.73.6.4931-4940.1999; Hoatlin Maureen E., 1995, Trends in Microbiology, V3, P51, DOI 10.1016/S0966-842X(00)88875-7; HOWARD JC, 1993, ONCOGENE, V8, P2721; HROMAS R, 1993, BLOOD, V82, P2998; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Kelley LL, 1998, ONCOGENE, V17, P1119, DOI 10.1038/sj.onc.1202037; LI JP, 1987, J VIROL, V61, P2782, DOI 10.1128/JVI.61.9.2782-2792.1987; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LONGMORE GD, 1994, MOL CELL BIOL, V14, P2266, DOI 10.1128/MCB.14.4.2266; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; MAGER DL, 1981, P NATL ACAD SCI-BIOL, V78, P1703, DOI 10.1073/pnas.78.3.1703; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Muszynski KW, 1998, J VIROL, V72, P919, DOI 10.1128/JVI.72.2.919-925.1998; Muszynski KW, 2000, J VIROL, V74, P8444, DOI 10.1128/JVI.74.18.8444-8451.2000; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; Pereira R, 2000, ONCOGENE, V19, P5106, DOI 10.1038/sj.onc.1203886; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSEN CA, 1985, SCIENCE, V227, P320, DOI 10.1126/science.2981432; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; Tarr K, 1997, J BIOL CHEM, V272, P9099; TRAN QC, 1997, EMBO J, V16, P5639; Vannucchi AM, 2000, BLOOD, V95, P2559; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WOLFF L, 1985, SCIENCE, V228, P1549, DOI 10.1126/science.2990034; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	45	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1272	1284		10.1038/sj.onc.1205183	http://dx.doi.org/10.1038/sj.onc.1205183			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850847	Green Accepted, Bronze			2022-12-17	WOS:000173729400015
J	Piao, CQ; Zhao, YL; Hei, TK				Piao, CQ; Zhao, YL; Hei, TK			Analysis of p16 and p21(Cip1) expression in tumorigenic human bronchial epithelial cells induced by asbestos	ONCOGENE			English	Article						asbestos; transformation; human bronchial epithelial cells; p16; p21(Cip1)	P21(WAF1/CIP1) EXPRESSION; MALIGNANT-TRANSFORMATION; DIFFERENTIATION; PROTEIN; GENE; P21; CARCINOMAS; INHIBITOR; MUTATIONS; INDUCTION	Although asbestos is carcinogenic to humans, the mechanism(s) by which it induces cancer is unknown. Using tumor cell lines generated previously by asbestos treatment of immortalized human bronchial epithelial (BEP2D) cells, we examined alterations in p16 and p21(Cip1) genes together with their protein levels. Results were compared with untreated BEP2D cells, normal human bronchial epithelial cells (NHBE), as well as nontumorigenic fusion cell lines generated by fusing tumor cells with BEP2D cells. No deletion in the p16 gene was found in any of the tumor cell lines examined. Although p16 protein was expressed at a similar level in tumor and BEP2D cells, there was a fourfold decrease in its expression among NHBE cells. In contrast, both the protein and mRNA expression levels of p21(Cip1) were decreased by about threefold in tumor cell lines when compared with either BEP2D or NHBE cells, which had a similar expression level. Expression of p21(Cip1) mRNA was restored to the control level in all the fusion cell lines examined. The results suggested that down regulation of p21(Cip1) expression is linked to the tumorigenic conversion of BEP2D cells by asbestos.	Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Columbia University	Piao, CQ (corresponding author), Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.	cp16@cp16@columbia.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007890] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05786, ES07890] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUTZ K, 1995, ONCOGENE, V10, P927; CHENG JQ, 1994, CANCER RES, V54, P5547; DeMuth JP, 1998, AM J RESP CELL MOL, V19, P18, DOI 10.1165/ajrcmb.19.1.3077; GABRIELLE IT, 1999, P NATL ACAD SCI USA, V96, P9089; GERWIN BI, 1994, AM J RESP CELL MOL, V11, P507, DOI 10.1165/ajrcmb.11.5.7946379; Hei TK, 1999, ADV SPACE RES-SERIES, V22, P1699; HEI TK, 1992, CANCER RES, V52, P6305; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; Hei TK, 1997, ENVIRON HEALTH PERSP, V105, P1085, DOI 10.2307/3433513; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kokunai T, 1998, INT J CANCER, V75, P643, DOI 10.1002/(SICI)1097-0215(19980209)75:4<643::AID-IJC24>3.0.CO;2-8; LECHNER JF, 1985, P NATL ACAD SCI USA, V82, P3884, DOI 10.1073/pnas.82.11.3884; LezonGeyda K, 1996, MUTAT RES-ENVIR MUTA, V361, P113, DOI 10.1016/S0165-1161(96)90245-9; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIVINGSTON GK, 1980, J ENVIRON PATHOL TOX, V4, P373; Marchetti A, 1996, ONCOGENE, V12, P1319; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Nadal A, 1997, J PATHOL, V183, P156; Nakao Y, 1997, BRIT J CANCER, V75, P1410, DOI 10.1038/bjc.1997.243; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Park SH, 1998, CANCER RES, V58, P1144; Qiu XB, 1996, J BIOL CHEM, V271, P31915, DOI 10.1074/jbc.271.50.31915; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; SHAPIRO GI, 1995, CANCER RES, V55, P505; STANTON MF, 1977, J NATL CANCER I, V58, P587, DOI 10.1093/jnci/58.3.587; Takeshima Y, 1998, CARCINOGENESIS, V19, P1755, DOI 10.1093/carcin/19.10.1755; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, ONCOGENE, V11, P511; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	33	8	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2001	20	50					7301	7306		10.1038/sj.onc.1204908	http://dx.doi.org/10.1038/sj.onc.1204908			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487UM	11704859				2022-12-17	WOS:000171894200002
J	Waddell, S; Jenkins, JR; Proikas-Cezanne, T				Waddell, S; Jenkins, JR; Proikas-Cezanne, T			A 'no-hybrids' screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast	ONCOGENE			English	Article						p53; p53 tumor mutant; S.pombe; functional yeast-based assay system	TUMOR-SUPPRESSOR P53; WILD-TYPE P53; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; DROSOPHILA P53; BINDING-SITE; AMINO-ACIDS; MDM2; ONCOPROTEIN; MUTATIONS	We have developed a functional 'no-hybrids' screen in the fission yeast Schizosaccharomyces pombe based on the transcription transactivator activity of human p53. The screen can be used to identify antagonizers and modulators of p53 activity. Expression of functional full-length human p53 is conditionally lethal to the screen reporter strains. Co-expression of specific inhibitory proteins promotes cell survival and growth. We have validated the 'no-hybrids' system by (a) successful modeling of human wild-type p53 interaction with SV40 large T antigen, Mdm2 and a panel of tumor-derived human p53 mutants, (b) demonstrating the screening system's efficiency through identification of a dominant negative fragment of p53 itself in a library screen context and (c) using Drosophila p53 to demonstrate that the system can detect evolutionarily distant p53 homologues based on their transactivator activity. The 'no-hybrids' screen will be of utility in searches for p53 function-modulators of both cellular and viral origin.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Res, Philadelphia, PA 19140 USA; MIT, Dept Biol, Dept Brain & Cognit Sci, Ctr Learning & Memory, Cambridge, MA 02139 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Massachusetts Institute of Technology (MIT)	Proikas-Cezanne, T (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Res, 3307 N Broad St, Philadelphia, PA 19140 USA.	alexandropolis@yahoo.com		Proikas-Cezanne, Prof. Dr. Tassula/0000-0001-6934-132X; Waddell, Scott/0000-0003-4503-6229				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BISCHOFF JR, 1992, MOL CELL BIOL, V12, P1405, DOI 10.1128/MCB.12.4.1405; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Burch LR, 2000, FEBS LETT, V472, P93, DOI 10.1016/S0014-5793(00)01427-7; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; Di Como CJ, 1998, ONCOGENE, V16, P2527; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Epstein CB, 1998, ONCOGENE, V16, P2115, DOI 10.1038/sj.onc.1201734; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRIMM C, 1988, P NATL ACAD SCI USA, V78, P5445; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LENG P, 1995, ONCOGENE, V10, P1275; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Matlashewski Greg, 1999, Oncogene, V18, P7618, DOI 10.1038/sj.onc.1203157; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; RIOU G, 1990, LANCET, V335, P1171; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SZANKASI P, 1988, J MOL BIOL, V204, P917, DOI 10.1016/0022-2836(88)90051-4; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; TARUNINA M, 1993, ONCOGENE, V8, P3165; WADDELL S, 1995, NUCLEIC ACIDS RES, V23, P1836, DOI 10.1093/nar/23.10.1836; Waddell S, 1998, ONCOGENE, V16, P1759, DOI 10.1038/sj.onc.1201848; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	41	8	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2001	20	42					6001	6008		10.1038/sj.onc.1204702	http://dx.doi.org/10.1038/sj.onc.1204702			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473QF	11593407				2022-12-17	WOS:000171056300007
J	Zhang, F; Taipale, M; Heiskanen, A; Laiho, M				Zhang, F; Taipale, M; Heiskanen, A; Laiho, M			Ectopic expression of Cdk6 circumvents transforming growth factor-beta mediated growth inhibition	ONCOGENE			English	Article						TGF-beta; cyclin-dependent kinase; cyclin-dependent kinase inhibitors; cell cycle regulation	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITOR; TGF-BETA; EPITHELIAL-CELLS; MAMMALIAN-CELLS; P15(INK4B); PROTEIN; INK4; COMPLEXES; P27(KIP1)	Transforming growth factor-beta (TGF-beta) induced growth arrest of cells involves regulation of the activities of both D- and E-type cyclin kinase complexes thought to be mediated primarily by the regulation of p15(Ink4b) and p27(Kip1) cyclin kinase inhibitors. We show here that TGF-beta downregulates Cdk6 and that transient and stable expression of Cdk6 in Mv1Lu mink epithelial cells overrides TGF-beta mediated arrest. The main effect of the ectopic Cdk6 expression was to sequester TGF-P induced p15(Ink4b) and to maintain more p27(Kip1) in cyclin D-complexes preventing the complete shift of p27(Kip1) to Cdk2 invoked by TGF-beta. This led to the presence of an active cyclinD-Cdk6-p27(Kip1) complex and partially active cyclin E-Cdk2 complex and resulted in the failure of TGF-beta to fully arrest Mv1Lu cell growth. Though dominant negative Cdk6, expressed similarly in the cells, sequestered both p15(Ink4b) and p27(Kip1), it lacks kinase activity and was unable to override the TGF-beta arrest. The results demonstrate that downregulation of Cdk6 kinase is required for the enforcement of the G(1)-phase arrest by TGF-beta and results in changes in association of the p15(Ink4b) and p27(Kip1) inhibitors with D- and E-type cyclin kinase complexes.	Univ Helsinki, Mol Canc Biol Res Program, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland	University of Helsinki	Laiho, M (corresponding author), Univ Helsinki, Mol Canc Biol Res Program, Dept Virol, Haartman Inst, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.			Taipale, Minna/0000-0002-1905-2551				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Costello JF, 1997, CANCER RES, V57, P1250; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Easton J, 1998, CANCER RES, V58, P2624; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Parry D, 1999, MOL CELL BIOL, V19, P1775; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tsubari M, 1997, CANCER RES, V57, P2966; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Warner BJ, 1999, MOL CELL BIOL, V19, P5913	36	8	9	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2001	20	41					5888	5896		10.1038/sj.onc.1204745	http://dx.doi.org/10.1038/sj.onc.1204745			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473JF	11593394				2022-12-17	WOS:000171037200012
J	Yin, MB; Hapke, G; Guo, B; Azrak, RG; Frank, C; Rustum, YM				Yin, MB; Hapke, G; Guo, B; Azrak, RG; Frank, C; Rustum, YM			The Chk1-Cdc25C regulation is involved in sensitizing A253 cells to a novel topoisomerase I inhibitor BNP1350 by bax gene transfer	ONCOGENE			English	Article						BNP1350; bax; cyclin B; cdc2; chk1; cdc25C	DNA-DAMAGE CHECKPOINT; PROTEIN-KINASE; OVARIAN-CANCER; FISSION YEAST; HUMAN HEAD; THYMOCYTE APOPTOSIS; ANTITUMOR-ACTIVITY; CYCLE ARREST; DEATH; EXPRESSION	Promotion of apoptosis may potentiate the sensitivity of tumor cells to chemotherapeutic agents, thus improving the efficacy of cancer treatment. The transfection of the proapoptotic bax gene, which results in the overexpression of bax protein, augments the growth inhibition of A253 cells by BNP1350. Increased drug response was associated with the induction of DNA fragmentation in the size of 30-200 Kb, generating a cleaved fragment of 18 kDa from full-length 21 kDa bax and the cleavage of PARP. A253/vec cells treated with 0.07 muM(IC50) of BNP1350 accumulated in G(2) phase at 24 h after drug removal. In contrast, A253/Bax cells treated with an equimolar concentration of BNP1350 primarily displayed a G(1) phase accumulation with a concurrent decrease in G(2) phase. Certain cell cycle regulatory protein expression and activities were altered following drug exposure in both cell lines under similar conditions. Cdk2- and cdc2-associated HI kinase activities were markedly increased in the A253/Bax cell line with marginal increased activity in the A253/vec cell line. A chk1 activity assay was performed with GST-cdc25C (200 - 256) or GST-cdc25C(S216A) (200-256) fusion proteins as the substrate. Increased chk1 activity was observed in the A253/vec cell line, with little change in the A253/Bax cell line, when exposed to equimolar concentrations of BNP1350 (0.07 MM). A Western blot of immunoprecipitated chk1 indicated that increased chk1 phosphorylation following DNA damage induced by BNP1350 was accompanied by the observed G(2) accumulation in the A253/vec cell line, while only a slight increase in chk1 phosphorylation was seen in the A253/Bax cell line. A decreased expression of cdc25C was observed in the BNP1350-treated A253/Bax cells, but not in the A253/vec cell line. Following exposure to BNP1350, increased binding of 14-3-3 proteins to chk1 occurred in both cell lines, with more being observed in the A253/vec cell line. The data have shown that inhibition of the chk1 pathway accompanied by the abrogation of G(2) arrest is involved in sensitizing A253 cells to BNP1350 by bax gene transfer. These findings suggest that bax gene transfer sensitizes A253 cells to BNP1350 through apoptosis promoting and G(2)/M DNA damage checkpoint regulatory pathways.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Rustum, YM (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [P30CA016056, R01CA065761] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, CA 65761] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Arafat WO, 2000, MOL THER, V1, P545, DOI 10.1006/mthe.2000.0071; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Chan TA, 2000, GENE DEV, V14, P1584; Chen L, 1999, GENE DEV, V13, P675, DOI 10.1101/gad.13.6.675; Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063; Collins JA, 1997, J HISTOCHEM CYTOCHEM, V45, P923, DOI 10.1177/002215549704500702; DUBREZ L, 1995, LEUKEMIA, V9, P1013; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GIACCIA AJ, 1991, MUTAT RES, V263, P69, DOI 10.1016/0165-7992(91)90062-9; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Goldwasser F, 1996, CANCER RES, V56, P4430; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo B, 1999, ONCOL RES, V11, P91; Guo B, 2000, CLIN CANCER RES, V6, P718; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; Hsu SL, 1999, EXP CELL RES, V252, P332, DOI 10.1006/excr.1999.4625; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jackson JR, 2000, CANCER RES, V60, P566; Jacotot E, 2000, PATHOL BIOL, V48, P271; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lind EF, 1999, J IMMUNOL, V162, P5374; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; McPake CR, 1998, ONCOL RES, V10, P235; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Ohi R, 1999, CURR OPIN CELL BIOL, V11, P267, DOI 10.1016/S0955-0674(99)80036-2; PANADERO A, 1995, ONCOL RES, V7, P73; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; ROSHAK A, 1999, P AM ASSOC CANC RES, V40, P413; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Shinoura N, 2000, CANCER GENE THER, V7, P739, DOI 10.1038/sj.cgt.7700158; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Strobel T, 1998, CANCER RES, V58, P4776; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Sugimoto C, 1999, INT J CANCER, V82, P860, DOI 10.1002/(SICI)1097-0215(19990909)82:6<860::AID-IJC15>3.0.CO;2-6; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Vogelbaum MA, 1998, J NEUROSURG, V88, P99, DOI 10.3171/jns.1998.88.1.0099; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Xiang J, 2000, J GENE MED, V2, P97, DOI 10.1002/(SICI)1521-2254(200003/04)2:2<97::AID-JGM99>3.0.CO;2-S; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yin MB, 2000, MOL PHARMACOL, V57, P453, DOI 10.1124/mol.57.3.453; Yin MB, 1999, INT J CANCER, V83, P341, DOI 10.1002/(SICI)1097-0215(19991029)83:3<341::AID-IJC9>3.0.CO;2-3; Yin MB, 1999, EXP CELL RES, V247, P189, DOI 10.1006/excr.1998.4346	52	8	9	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 30	2001	20	38					5249	5257		10.1038/sj.onc.1204686	http://dx.doi.org/10.1038/sj.onc.1204686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	465DZ	11536038				2022-12-17	WOS:000170575500001
J	Ruteshouser, EC; Ashworth, LK; Huff, V				Ruteshouser, EC; Ashworth, LK; Huff, V			Absence of PPP2R1A mutations in Wilms tumor	ONCOGENE			English	Article						PPP2R1A; protein phosphatase 2A; Wilms tumor; FWT2; tumor suppressor	PROTEIN PHOSPHATASE 2A; BETA-CATENIN; SUPPRESSOR LOCUS; OKADAIC ACID; PPP1R3 GENE; SUBUNIT; EXPRESSION; ANTIGEN; CANCER; AXIN	Evidence from genetic linkage analysis indicates that a gene located at 19q13.4, FWT2, is responsible for predisposition to Wilms tumor in many Wilms tumor families. This region has also been implicated in the etiology of sporadic Wilms tumor through loss of heterozygosity analyses, The PPP2R1A gene, encoding the alpha isoform of the heterotrimeric serine/threonine protein phosphatase 2A (PP2A), is located within the FWT2 candidate region and is altered in breast and lung carcinomas. PPP2R1B, encoding the beta isoform, is mutated in Lung, colon, and breast cancers. These findings suggested that both PPP2R1A and PPP2R1B may be tumor suppressor genes. Additionally, PP2A is important in fetal kidney growth and differentiation and has an expression pattern similar to that of the Wilms tumor suppressor gene WT1, Since PPP2R1A was therefore a compelling candidate for the FWT2 gene, we analysed the coding region of PPP2R1A in DNA and RNA samples from affected members of four Wilms tumor families and 30 sporadic tumors and identified no mutations in PPP2R1A in any of these 34 samples. We conclude that PPP2R1A is not the 19q familial Wilms tumor gene and that mutation of PPP2R1A is not a common event in the etiology of sporadic Wilms tumor.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, Houston, TX 77030 USA; Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	University of Texas System; UTMD Anderson Cancer Center; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Huff, V (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Pediat, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA78257, CA34936, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672, R01CA078257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFSHARI CA, 1993, CANCER RES, V53, P1777; ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BRESLOW N, 1993, MED PEDIATR ONCOL, V21, P172, DOI 10.1002/mpo.2950210305; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; Everett AD, 1999, J AM SOC NEPHROL, V10, P1737; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUBB GR, 1994, LAB INVEST, V71, P472; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P7330; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huff V, 1997, CANCER RES, V57, P1859; HUFF V, 1990, HUM GENET, V84, P253; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Koesters R, 1999, CANCER RES, V59, P3880; Kohno T, 1999, CANCER RES, V59, P4170; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin XH, 1998, P NATL ACAD SCI USA, V95, P14693, DOI 10.1073/pnas.95.25.14693; Maiti S, 2000, CANCER RES, V60, P6288; MANNENS M, 1990, CANCER RES, V50, P3279; MAW MA, 1992, CANCER RES, V52, P3094; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; McDonald JM, 1998, CANCER RES, V58, P1387; Miozzo M, 1996, GENOMICS, V37, P310, DOI 10.1006/geno.1996.0565; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SVENNILSON J, 1995, KIDNEY INT, V48, P103, DOI 10.1038/ki.1995.273; Takakura S, 2000, ONCOGENE, V19, P836, DOI 10.1038/sj.onc.1203388; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284	42	8	8	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2001	20	16					2050	2054		10.1038/sj.onc.1204301	http://dx.doi.org/10.1038/sj.onc.1204301			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360189				2022-12-17	WOS:000168043800013
J	Kobrinsky, EM; Kirchberger, MA				Kobrinsky, EM; Kirchberger, MA			Evidence for a role of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in thapsigargin and Bcl-2 induced changes in Xenopus laevis oocyte maturation	ONCOGENE			English	Article						SERCA; Xenopus laevis; meiotic maturation; Bcl-2 thapsigargin; capacitative Ca2+ entry	INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; INTRACELLULAR CA2+ STORES; ENDOPLASMIC-RETICULUM; CELL-LINE; CALCIUM-PUMP; PROTEIN; APOPTOSIS; ATPASE; PHOSPHOLAMBAN; INHIBITION	Thapsigargin (Tg), a selective inhibitor of sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (SERCA), causes depiction of intracellular Ca2+ stores, hence activation of capacitative Ca2+ entry (CCE). Incubation of Xenopus laevis oocytes with Tg resulted in an increased rate of progesterone-induced meiotic maturation. Non-mitochondrial Ca-45(2+) uptake by SERCA-containing microsomes prepared from control wild-type oocytes microinjected with sterile water was inhibited essentially 100% by Tg. However, overexpression of Bcl-2, an oncogene known to protect against Tg-induced apoptosis in certain cell types, resulted in only 40% inhibition of microsomal Ca-45(2+) uptake by Tg while non-inhibited Ca-45(2+) uptake remained unchanged, Moreover Bcl-2 overexpression also protected against inhibition of CCE. I-Cl(Ca) was similar in Bcl-2-overexpressing and control oocytes when intracellular Ca2+ store depletion was induced by microinjection of inositol 1,4,5-trisphosphate (InsP(3)) and other means and when CCE was induced by means independent of SERCA inhibition. Our data indicate that Bcl-2 affects neither the InsP(3) receptor nor Ca2+ entry itself. At the end of a 24-h period after progesterone addition to the medium, only 25% of Bcl-2-overexpressing oocytes had matured compared to 85% of control oocytes. Our data suggest that SERCA participates in Xenopus oocyte maturation by controlling cytosolic Ca2+ and/or intracellular Ca2+ stores, hence CCE. An observed progesterone-dependent protein kinase-catalysed phosphorylation of SERCA is further indication of its role in oocyte maturation.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University	Kirchberger, MA (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA.				NHLBI NIH HHS [HL15764] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015764] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antipenko AY, 1997, J BIOL CHEM, V272, P2852, DOI 10.1074/jbc.272.5.2852; Antipenko AY, 1997, CARDIOVASC RES, V36, P67, DOI 10.1016/S0008-6363(97)00183-1; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; BOYER J, 1983, BIOCHIMIE, V65, P15, DOI 10.1016/S0300-9084(83)80024-8; CHOI OH, 1993, J IMMUNOL, V151, P5586; Distelhorst CW, 1996, ONCOGENE, V12, P2051; DURIEUX ME, 1992, AM J PHYSIOL, V263, pC896, DOI 10.1152/ajpcell.1992.263.4.C896; ENOUF J, 1987, J BIOL CHEM, V262, P9293; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Han JK, 1995, BIOCHEM BIOPH RES CO, V217, P931, DOI 10.1006/bbrc.1995.2860; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; KIJIMA Y, 1991, J BIOL CHEM, V266, P22912; Kobrinsky E, 1995, DEV BIOL, V172, P531, DOI 10.1006/dbio.1995.8058; Kobrinsky E, 1999, AM J PHYSIOL-CELL PH, V277, pC665, DOI 10.1152/ajpcell.1999.277.4.C665; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Kuo TH, 1998, ONCOGENE, V17, P1903, DOI 10.1038/sj.onc.1202110; LAMB M, 1994, P NATL ACAD SCI USA, V91, P6569; Lechleiter JD, 1998, BIOPHYS CHEM, V72, P123, DOI 10.1016/S0301-4622(98)00128-8; Mahaney J, 1999, ARCH BIOCHEM BIOPHYS, V372, P408, DOI 10.1006/abbi.1999.1524; Matten Wayne T., 1994, Seminars in Developmental Biology, V5, P173, DOI 10.1006/sedb.1994.1023; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICARD A, 1990, SCIENCE, V247, P327, DOI 10.1126/science.2153316; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Vairo G, 1996, ONCOGENE, V13, P1511; VILAIN JP, 1989, J EXP ZOOL, V250, P100, DOI 10.1002/jez.1402500114; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Wei HF, 1998, J NEUROCHEM, V70, P2305; Xu AD, 2000, J BIOL CHEM, V275, P4407, DOI 10.1074/jbc.275.6.4407; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994; ZHU WH, 1995, LIFE SCI, V57, P2091, DOI 10.1016/0024-3205(95)02202-T	44	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2001	20	8					933	941		10.1038/sj.onc.1204153	http://dx.doi.org/10.1038/sj.onc.1204153			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	404KP	11314028				2022-12-17	WOS:000167097000004
J	Kruzelock, RP; Cuevas, BD; Wiener, JR; Xu, FJ; Yu, YH; Cabeza-Arvelaiz, Y; Pershouse, M; Lovell, MM; Killary, AM; Mills, GB; Bast, RC				Kruzelock, RP; Cuevas, BD; Wiener, JR; Xu, FJ; Yu, YH; Cabeza-Arvelaiz, Y; Pershouse, M; Lovell, MM; Killary, AM; Mills, GB; Bast, RC			Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer	ONCOGENE			English	Article						ovarian cancer; human chromosome 22; tumor suppressor genes; microcell-mediated chromosome transfer	NEUROFIBROMATOSIS TYPE-2 GENE; ADENOCARCINOMA CELL-LINES; FREQUENT LOSS; ALLELE LOSS; LONG ARM; SPORADIC MENINGIOMAS; MAMMALIAN-CELLS; LOW-GRADE; NF2 GENE; HETEROZYGOSITY	The identity of many tumor suppressor genes important in epithelial ovarian cancer tumorigenesis remains unknown. In an effort to localize a novel tumor suppressor on chromosome 22, a psv(2)neo tagged human chromosome 22 was transferred into the malignant epithelial ovarian cancer cell line, SKOV-3, by microcell-mediated chromosome transfer. Complete suppression of the transformed phenotype was observed in 16 of 18 individual microcell hybrid clones as evidenced by the complete abrogation of cell growth under anchorage-independent conditions. In vitro doubling times were also dramatically reduced, as was the ability to, form subcutaneous tumors in CD1 nu/nu mice. Only one polymorphic marker, D22S429, segregated with decreased transformation and tumorigenic potential, suggesting that an unrecognized tumor suppressor may localize to chromosome 22q11-q12, These data provide functional support for the presence of a novel tumor suppressor locus (or loci) on chromosome 22 that is important in ovarian cancer tumorigenesis.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Clin Invest, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Div Lab Med, Houston, TX 77030 USA; Grad Sch Biomed Sci, Houston, TX 77225 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kruzelock, RP (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.		Yu, Yan/GYV-4514-2022; Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462				AKAGI K, 1995, INT J CANCER, V60, P178, DOI 10.1002/ijc.2910600208; ALHADEFF B, 1977, CYTOGENET CELL GENET, V19, P236, DOI 10.1159/000130814; ALLAN GJ, 1994, HUM MUTAT, V3, P283, DOI 10.1002/humu.1380030317; AMFO K, 1995, ONCOGENE, V11, P351; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; Bandera CA, 1997, CANCER RES, V57, P513; BIEGEL JA, 1996, GENE CHROMOSOME CANC, V16, P84; Boente Matthew P., 1993, Current Opinion in Oncology, V5, P900, DOI 10.1097/00001622-199309000-00020; BOLGER GB, 1985, NEW ENGL J MED, V312, P564, DOI 10.1056/NEJM198502283120907; Bryan EJ, 1996, CANCER RES, V56, P719; BUICK RN, 1985, CANCER RES, V45, P3668; BUIJS A, 1995, ONCOGENE, V10, P1511; BURGERS PMJ, 1987, ANAL BIOCHEM, V163, P391, DOI 10.1016/0003-2697(87)90240-5; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Cheng PC, 1996, J NATL CANCER I, V88, P510, DOI 10.1093/jnci/88.8.510; CLIBY W, 1993, CANCER RES, V53, P2393; COGEN PH, 1991, CANCER GENET CYTOGEN, V53, P271, DOI 10.1016/0165-4608(91)90104-3; COLLINS JE, 1995, NATURE, V377, P367; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; DODSON MK, 1993, CANCER RES, V53, P4456; DRACOPLOI NC, 1997, CURRENT PROTOCOLS HU; DUMANSKI JP, 1990, CANCER RES, V50, P5863; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; ECCLES DM, 1992, ONCOGENE, V7, P2069; ECCLES DM, 1992, BRIT J CANCER, V65, P40, DOI 10.1038/bjc.1992.8; ECCLES DM, 1992, DIS MARKERS, V10, P95; Edelson MI, 1997, ONCOGENE, V14, P2979, DOI 10.1038/sj.onc.1201271; EHLEN T, 1990, ONCOGENE, V5, P219; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; Gallion HH, 1996, AM J OBSTET GYNECOL, V174, P1102, DOI 10.1016/S0002-9378(96)70651-8; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; IRVING RM, 1993, ARCH OTOLARYNGOL, V119, P1222; IWABUCHI H, 1995, CANCER RES, V55, P6172; Jacoby LB, 1996, GENE CHROMOSOME CANC, V17, P45, DOI 10.1002/(SICI)1098-2264(199609)17:1<45::AID-GCC7>3.0.CO;2-2; Kerr J, 1996, ONCOGENE, V13, P1815; KILLARY AM, 1995, METHOD ENZYMOL, V254, P133; KINZLER KW, 1993, NATURE, V363, P495, DOI 10.1038/363495a0; Kruzelock RP, 1997, CANCER RES, V57, P106; LEE JH, 1990, CANCER RES, V50, P2724; LEE JH, 1989, CANCER RES, V49, P1220; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MENDEZ MJ, 1991, GENOMICS, V10, P661, DOI 10.1016/0888-7543(91)90449-O; NG HK, 1995, NEUROSURGERY, V37, P764, DOI 10.1227/00006123-199510000-00022; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAPI L, 1995, HUM GENET, V95, P347, DOI 10.1007/BF00225206; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; RIMESSI P, 1994, ONCOGENE, V9, P3467; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAITO S, 1992, CANCER RES, V52, P5815; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANSON M, 1993, HUM MOL GENET, V2, P1215, DOI 10.1093/hmg/2.8.1215; SATO T, 1991, CANCER RES, V51, P5118; SCHNEIDER G, 1992, HUM GENET, V88, P579, DOI 10.1007/BF00219348; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; SHIN E, 1993, JPN J CANCER RES, V84, P402, DOI 10.1111/j.1349-7006.1993.tb00150.x; SHISEKI M, 1994, CANCER RES, V54, P5643; SILVERMAN M, 1997, P AM ASSOC CANC RES, V38, P1018; SMIDT M, 1990, J CLIN INVEST, V86, P1151, DOI 10.1172/JCI114820; STANBRIDGE EJ, 1978, P NATL ACAD SCI USA, V75, P1466, DOI 10.1073/pnas.75.3.1466; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; TAKAHASHI K, 1993, HEPATOLOGY, V17, P794, DOI 10.1002/hep.1840170508; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; YANA I, 1995, INT J CANCER, V60, P174, DOI 10.1002/ijc.2910600207; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359	70	8	8	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2000	19	54					6277	6285		10.1038/sj.onc.1204013	http://dx.doi.org/10.1038/sj.onc.1204013			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175342				2022-12-17	WOS:000166210500011
J	MacLaren, A; Clark, W; Gillespie, DAF				MacLaren, A; Clark, W; Gillespie, DAF			v-Jun sensitizes cells to apoptosis by a mechanism involving mitochondrial cytochrome C release	ONCOGENE			English	Article						v-Jun; apoptosis; p53; cytochrome C	MYC-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; CYCLE PROGRESSION; TUMOR-SUPPRESSOR; DEATH; BCL-2; KINASE; FIBROBLASTS; INDUCTION; PROTEASES	v-Jun shares the ability of the Myc, E1A, and E2F oncogenes to both sustain cell cycle progression and promote apoptosis in the absence of mitogenic stimulation. To gain an insight into the mechanism of apoptosis sensitization,,ve examined the possible involvement of key regulatory proteins previously implicated in oncogene-induced cell death during v-Jun-induced apoptosis triggered by serum, withdrawal, We observed that ectopic expression of the anti-apoptotic Bcl-2 protein, or of two downstream effecters of growth factor signalling, v-PI 3-Kinase and v-Src, partially or completely suppressed apoptosis, Apoptosis was also observed in the presence of serum growth factors when endogenous PI3K activity was blocked using the synthetic inhibitor LY294002, further suggesting an important role for PI3-K in cell survival, Cytochrome C was released into the cytosol of apoptotic v-Jun expressing cells, and this release was inhibited by Bcl-2, suggesting an important role for mitochondrial dysfunction in v-Jun induced apoptosis, In contrast, inhibition of Fas signalling using dominant negative FADD did not inhibit apoptosis, nor was there any evidence for accumulation or activation of p53 in v-Jun transformed cells. Consistent with this latter observation, inhibition of p53 function by HPV16 E6 protein had no effect on v-Jun induced cell death. Taken together, these results suggest that mitochondrial dysfunction is an important component of the mechanism through which v-Jun sensitizes cells to apoptosis, but that the apoptotic signals elicited by v-Jun upstream of the mitochondria do not depend on increased levels of p53 activity or Fas signalling.	Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	MacLaren, A (corresponding author), Beatson Inst Canc Res, Canc Res Campaign, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Crouch DH, 1996, ONCOGENE, V12, P2689; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kilbey A, 1996, ONCOGENE, V12, P2409; Lenahan MK, 1996, ONCOGENE, V12, P1847; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Papas KK, 1999, FEBS LETT, V446, P338, DOI 10.1016/S0014-5793(99)00240-9; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; WELHAM MJ, 1988, J VIROL, V62, P1898, DOI 10.1128/JVI.62.6.1898-1906.1988; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	47	8	8	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 30	2000	19	51					5906	5918		10.1038/sj.onc.1203954	http://dx.doi.org/10.1038/sj.onc.1203954			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	378CA	11127822				2022-12-17	WOS:000165563100010
J	Krucher, NA; Zygmunt, A; Mazloum, N; Tamrakar, S; Ludlow, JW; Lee, MYWT				Krucher, NA; Zygmunt, A; Mazloum, N; Tamrakar, S; Ludlow, JW; Lee, MYWT			Interaction of the retinoblastoma protein (pRb) with the catalytic subunit of DNA polymerase delta (p125)	ONCOGENE			English	Article						DNA polymerase delta; retinoblastoma; cyclin dependent kinase; cell cycle	LARGE-T-ANTIGEN; TRANSCRIPTION FACTOR; REPRESS TRANSCRIPTION; HISTONE DEACETYLASE; BINDING PROTEIN; E1A PROTEINS; RB; PRODUCT; CYCLINS; GENE	The retinoblastoma gene product (pRb) interacts with many cellular proteins to function in the control of cell division, differentiation, and apoptosis, Several pRb binding proteins complex with pRb through an amino acid sequence called the LXCXE motif, The catalytic subunit of DNA polymerase delta (p125) contains a LXCXE motif, To further study the biochemical function of this polymerase, we sought to determine if p125 interacts with pRb, Experiments using GST-pRb fusion proteins showed that p125 from breast epithelial (MCF10A) cell extracts associates with pRb. In addition, GST-p125 fusion proteins bound pRb from the same cell extracts. The pRb that associated with GST-p125 was largely unphosphorylated, Coimmunoprecipitation experiments using cell cycle synchronized cells revealed that p125 and pRb form a complex predominantly during G(1) phase, the phase during which pRb is mostly unphosphorylated. In vitro phosphorylation of GST-pRb by the cyclin dependent kinases reduced the ability of p125 to associate with GST-pRb, Addition of the LXCXE containing protein SV40 large T antigen to GST-pRb blocks the ability of p125 to associate with pRb, suggesting that it may be through a LXCXE sequence by which p125 interacts with pRb, Finally, in vitro polymerase assays demonstrate that GST-pRb fusion protein stimulates DNA polymerase delta activity.	Pace Univ Pleasantville, Dept Biol Sci, Pleasantville, NY 10570 USA; New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA; Univ Rochester, Dept Biochem & Biophys, Rochester, NY USA	Pace University; New York Medical College; University of Rochester	Krucher, NA (corresponding author), Pace Univ Pleasantville, Dept Biol Sci, 861 Bedford Rd, Pleasantville, NY 10570 USA.				NHGRI NIH HHS [NIHGM31973] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; JONES RE, 1990, J BIOL CHEM, V265, P12782; LEE MYWT, 1991, J BIOL CHEM, V266, P2423; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MO J, 2000, BIOCHEMISTRY-US, V39, P2745; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SMITH DH, 1988, MOL CELL BIOL, V8, P3883; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Woitach JT, 1998, NAT GENET, V19, P371, DOI 10.1038/1258; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561	36	8	8	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 16	2000	19	48					5464	5470		10.1038/sj.onc.1203930	http://dx.doi.org/10.1038/sj.onc.1203930			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375JQ	11114723				2022-12-17	WOS:000165396100006
J	Salloukh, HF; Vowles, I; Heisterkamp, N; Groffen, J; Laneuville, P				Salloukh, HF; Vowles, I; Heisterkamp, N; Groffen, J; Laneuville, P			Early events in leukemogenesis in P190Bcr-abl transgenic mice	ONCOGENE			English	Article						oncogenesis; acute leukemia; P190Bcr-abl; cell cycle; apoptosis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DNA-POLYMERASE-BETA; BCR-ABL ONCOPROTEIN; TYROSINE PHOSPHORYLATION; EXPRESSING P210(BCR/ABL); PHILADELPHIA-CHROMOSOME; HEMATOPOIETIC-CELLS; ADAPTER PROTEIN; C-ABL	The activated tyrosine kinase, Bcr-abl, is implicated in a number of hematopoietic malignancies. The exact biological mechanism by which the kinases transforms cells is still not well delineated. Previous data has suggested that the inhibition of apoptosis and the deregulation of cell cycle progression as the result of P210Bcr-abl expression might contribute to leukemogenesis, In vitro systems in which Bcr-Abl is over-expressed have concluded that similar growth regulatory pathways are affected as a result of the expression of both P210 and P190Bcr-abl. Here, we utilized an in vitro P190Bcr-abl leukemia mouse model to dissect the early events that contribute to transformation by this isoform of Bcr-Abl. In this mouse model P190Bcr-abl is expressed as a low but physiologically relevant level in that all mice develop pre-B leukemia lymphomas, We show that cell cycle and apoptotic responses to DNA damage are intact in bone marrow and spleen cells of such animals. We also demonstrate a normal induction of p21(WAF-1/CIP1) in both hematopoietic and non-hematopoietic tissue as a result of genotoxic stress, We suggest that P190Bcr-abl induced transformation is different than that of P210Bcr-abl.	Royal Victoria Hosp, Dept Med, Div Expt Med, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ H3A 1A1, Canada; Childrens Hosp Los Angeles, Sect Mol Diag, Div Hematol Oncol, Los Angeles, CA 90027 USA	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; Children's Hospital Los Angeles	Laneuville, P (corresponding author), Royal Victoria Hosp, Dept Med, Div Expt Med, Hersey Pavil,H5-21, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.		Heisterkamp, Nora/C-1698-2012; Laneuville, Pierre/AAH-2293-2021	Heisterkamp, Nora/0000-0003-2769-2273; 	NATIONAL CANCER INSTITUTE [R01CA050248, R55CA047456, R01CA047456] Funding Source: NIH RePORTER; NCI NIH HHS [CA47456, CA50248] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BERGER R, 1993, LEUKEMIA LYMPHOMA, V11, P235, DOI 10.3109/10428199309047892; BLOOMFIELD CD, 1989, ACUTE LYMPHOBLASTIC, P101; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; DEJONG R, 1995, ONCOGENE, V11, P1469; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; GOTOH A, 1995, EXP HEMATOL, V23, P1153; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HEISTERKAMP N, 1991, HEMATOL PATHOL, V5, P1; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SALGIA R, 1995, ONCOGENE, V11, P1149; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; TENHOEVE J, 1994, CANCER RES, V54, P2563; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	36	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2000	19	38					4362	4374		10.1038/sj.onc.1203804	http://dx.doi.org/10.1038/sj.onc.1203804			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980612				2022-12-17	WOS:000089271900007
J	Xu, XZ; Kelleher, KF; Liao, J; Creek, KE; Pirisi, L				Xu, XZ; Kelleher, KF; Liao, J; Creek, KE; Pirisi, L			Unique carboxyl-terminal sequences of wild type and alternatively spliced variant forms of transforming growth factor-alpha precursors mediate specific interactions with ErbB4 and ErbB2	ONCOGENE			English	Article						TGF-alpha variants; ErbBs; protein interaction; CHO cells	SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; PROTGF-ALPHA; NEU PROTOONCOGENE; VALINE RESIDUES; PDZ DOMAINS; PROTEIN; BETACELLULIN; MEMBRANE; COEXPRESSION	We have previously reported that the human transforming growth factor-alpha (TGF-alpha) gene encodes three forms of TGF-alpha precursors, designated wild type (WT), variant I (VaI), and variant II (VaII), derived from alternative splicing, The two carboxyl-terminal valine residues of WT are replaced by 5 (GCRLY) or 4 (ATLG) amino acids in VaI or VaII, respectively. When overexpressed in Chinese hamster ovary (CHO) cells, VaI and VaII, but not WT, support autonomous growth, We detected tyrosine phosphorylation of ErbB2 in the absence of serum, in CHO cells expressing WT, VaI, or VaII, but not in mock transfectants. These observations prompted us to investigate possible interactions between the ErbBs and the TGF-alpha precursors in CHO cells. All TGF-alpha precursors mere found to co-immunoprecipitate with the ErbBs. but with different specificity, WT co-immunoprecipitated with ErbB4, but not with ErbB1, ErbB2, or ErbB3, VaI and VaII co-immunoprecipitated with ErbB2, but not with ErbB1, ErbB3, or ErbB4. Confocal fluorescent microscopy analysis demonstrated that WT, VaI. and VaII all distribute equally to the cell surface while, as expected, a WT mutant lacking the tno C-terminal value residues does not. Point and deletion mutants involving the unique carboxyl-terminal residues of WT, Val and VaII, indicated that the interactions between the three TGF-alpha precursors and the ErbBs were mediated by their carboxyl-terminal regions, which constitute distinct protein-binding motifs, A chimera of the intracellular domain of WT TGF-alpha linked to exogenous transmembrane and extracellular domains retained both the cell surface distribution and the specific interaction with ErbB4 of full-length WT, confirming that this interaction is mediated by the C-terminus of the TGF-a precursor. While interactions of WT and variant TGF-alpha with the ErbBs all result in ErbB2 activation, they produce different biological consequences, suggesting that the various TGF-alpha precursors differentially modulate ErbB signaling.	Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Childrens Canc Res Lab, Dept Pediat, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA.		xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NATIONAL CANCER INSTITUTE [R01CA062094] Funding Source: NIH RePORTER; NCI NIH HHS [CA62094] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Cohen BD, 1998, BIOCHEM SOC SYMP, P199; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; LEE DC, 1995, PHARMACOL REV, V47, P51; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; NAKAMURA T, 1994, GENE, V140, P251, DOI 10.1016/0378-1119(94)90553-3; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Shackney SE, 1998, CLIN CANCER RES, V4, P913; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Urena JM, 1999, J CELL SCI, V112, P773; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; Xu XZ, 1999, ONCOGENE, V18, P5554, DOI 10.1038/sj.onc.1203091; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	31	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3172	3181		10.1038/sj.onc.1203645	http://dx.doi.org/10.1038/sj.onc.1203645			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918572				2022-12-17	WOS:000088019200006
J	Reddy, DE; Keck, CL; Popescu, N; Athwal, RS; Kaur, GP				Reddy, DE; Keck, CL; Popescu, N; Athwal, RS; Kaur, GP			Identification of a YAC from 16q24 carrying a senescence gene for breast cancer cells	ONCOGENE			English	Article						cell senescence; breast cancer; YAC contig; YAC transfer; functional complementation	YEAST ARTIFICIAL CHROMOSOMES; MAMMALIAN-CELLS; MOUSE CELLS; CELLULAR SENESCENCE; ALLELIC IMBALANCE; IN-SITU; CARCINOMA; FUSION; EXPRESSION; COMPLEMENTATION	We have identified a 360 kb YAC that carries a cell senescence gene, SEN16. In our earlier studies, we localized SEN16 within a genetic interval of 3-7 cM at 16q24.3. Six overlapping YACs spanning the chromosomal region of senescence activity, were assembled in a contig. Candidate YACs, identified by the markers located in the vicinity of SEN16, were retrofitted to introduce a neo selectable marker. Retrofitted YACs were first transferred into mouse A9 cells to generate A9/YAC hybrids. YAC DNA present in A9/YAC hybrids was further transferred by microcell fusion into immortal cell lines derived from human and rat mammary tumors. YAC d792t2 restored senescence in both human and rat mammary tumor cell lines, while an unrelated YAC from chromosome 6q had no senescence activity.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaur, GP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St,AHP Room 201, Philadelphia, PA 19140 USA.							ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; Davies N P, 1996, Methods Mol Biol, V54, P281; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DOGGETT NA, 1995, NATURE, V377, P335; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; GNIRKE A, 1991, EMBO J, V10, P1629, DOI 10.1002/j.1460-2075.1991.tb07685.x; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; HUXLEY C, 1991, GENOMICS, V9, P742, DOI 10.1016/0888-7543(91)90369-P; Julicher K, 1997, GENOMICS, V43, P95, DOI 10.1006/geno.1997.4787; Koreth J, 1999, ONCOGENE, V18, P1157, DOI 10.1038/sj.onc.1202372; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MEDINA D, 1996, J MAMMARY GLAND BIOL, V1, P21; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; NEGRINI M, 1994, CANCER RES, V54, P1331; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Oshimura M, 1997, EUR J CANCER, V33, P710, DOI 10.1016/S0959-8049(97)00090-7; PACHNIS V, 1990, P NATL ACAD SCI USA, V87, P5109, DOI 10.1073/pnas.87.13.5109; PAVAN WJ, 1990, MOL CELL BIOL, V10, P4163, DOI 10.1128/MCB.10.8.4163; Perou CM, 1996, P NATL ACAD SCI USA, V93, P5905, DOI 10.1073/pnas.93.12.5905; PETERSON KR, 1993, P NATL ACAD SCI USA, V90, P11207, DOI 10.1073/pnas.90.23.11207; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; RADFORD DM, 1995, CANCER RES, V55, P3399; Reddy DE, 1999, ONCOGENE, V18, P5100, DOI 10.1038/sj.onc.1202888; Sandhu AK, 1996, ONCOGENE, V12, P247; SKIRNISDOTTIR S, 1995, INT J CANCER, V64, P112, DOI 10.1002/ijc.2910640207; STRAUSS WM, 1992, EMBO J, V11, P417, DOI 10.1002/j.1460-2075.1992.tb05070.x; TSUDA H, 1994, CANCER RES, V54, P513; WADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1693, DOI 10.1006/bbrc.1994.1647; Whitmore SA, 1998, GENOMICS, V52, P325, DOI 10.1006/geno.1998.5457; Whitmore SA, 1998, GENOMICS, V50, P1, DOI 10.1006/geno.1998.5316; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	37	8	8	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 13	2000	19	2					217	222		10.1038/sj.onc.1203264	http://dx.doi.org/10.1038/sj.onc.1203264			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275XA	10644999				2022-12-17	WOS:000084844400006
J	Schlake, T; Schupp, I; Kutsche, K; Mincheva, A; Lichter, P; Boehm, T				Schlake, T; Schupp, I; Kutsche, K; Mincheva, A; Lichter, P; Boehm, T			Predetermined chromosomal deletion encompassing the Nf-1 gene	ONCOGENE			English	Article						neurofibromatosis-1; cre recombinase; chromosome engineering	EMBRYONIC STEM-CELLS; ESCHERICHIA-COLI; SITE; DNA; RECOMBINATION; TRANSLOCATION; EXPRESSION; MICE	Complex chromosomal rearrangements (deletions, inversions, translocations) are a hallmark of human tumour cells, Yet, the generation of animal models for gross chromosomal abnormalities still presents a formidable challenge. Here, we describe a versatile procedure for chromosomal engineering that was used to generate an ES cell line with a megabase deletion encompassing the tumour suppressor gene neurofibromatosis-l (Nf-l) on mouse chromosome 11, which is often deleted in tumours of neural crest origin. Homologous recombination into sites flanking Nf-1 was used to introduce artificial sequences (triple-helix, loxP, vector backbone) that can be employed for in vitro recovery of intervening sequences or the generation of in viva deletions. This strategy may be developed into a scheme by which large chromosomal regions with precisely defined end points may be excised from mammalian cells and reintroduced after suitable in vitro modification.	Max Planck Inst Immunobiol, Dept Dev Immunol, D-79108 Freiburg, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ)	Boehm, T (corresponding author), Max Planck Inst Immunobiol, Dept Dev Immunol, Stuebeweg 51, D-79108 Freiburg, Germany.							Gagneten S, 1997, NUCLEIC ACIDS RES, V25, P3326, DOI 10.1093/nar/25.16.3326; HOCHMAN L, 1983, VIROLOGY, V131, P11, DOI 10.1016/0042-6822(83)90528-7; JOHANSSON B, 1993, GENE CHROMOSOME CANC, V8, P205, DOI 10.1002/gcc.2870080402; KEMPKES B, 1995, P NATL ACAD SCI USA, V92, P5875, DOI 10.1073/pnas.92.13.5875; Li ZW, 1996, P NATL ACAD SCI USA, V93, P6158, DOI 10.1073/pnas.93.12.6158; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Montgomery JC, 1998, MAMM GENOME, V8, pS215, DOI 10.1007/s003359900656; NEHLS M, 1995, MAMM GENOME, V6, P321, DOI 10.1007/BF00364794; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; NEHLS MC, 1994, MAMM GENOME, V5, P183, DOI 10.1007/BF00352354; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; SHENG Y, 1995, NUCLEIC ACIDS RES, V23, P1990, DOI 10.1093/nar/23.11.1990; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; VANDEURSEN J, 1995, P NATL ACAD SCI USA, V92, P7376, DOI 10.1073/pnas.92.16.7376; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417; Zhu H, 1999, NUCLEIC ACIDS RES, V27, P910, DOI 10.1093/nar/27.3.910	18	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6078	6082		10.1038/sj.onc.1203021	http://dx.doi.org/10.1038/sj.onc.1203021			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557097				2022-12-17	WOS:000083359100014
J	Gondran, P; Dautry, D				Gondran, P; Dautry, D			Regulation of mRNA splicing and transport by the tyrosine kinase activity of src	ONCOGENE			English	Article						src; tyrosine phosphorylation; SH2 and SH3 domain; splicing; mRNA transport	C-SRC; RNA-BINDING; CELL-TRANSFORMATION; SH3 DOMAINS; PHOSPHORYLATION; ACTIVATION; EXPRESSION; PROTEINS; MITOSIS; SITES	The regulation of transcription by signal transduction pathways is well documented. In addition, me have previously shown that src can regulate pre-mRNA processing. To investigate which functional domains of src are involved in the regulation of splicing and transport of Lymphotoxin alpha (LT alpha) transcripts, we have used SPC mutants in the catalytic, SH2 and SH3 domains in association with the Y527F or the E378G activating mutation. Our results establish that the regulation of pre-mRNA processing and transcription can occur independently of each other. The splicing and transport phenotypes require an intact tyrosine kinase domain and both are insensitive to the deletion of the SH3 domain, Therefore these phenotypes do not depend upon the recruitment through the SH3 domain of src of RNA binding proteins (Sam 68, hnRNP K), By contrast, deletions in the SH2 domain have no effect on splicing but either abolish or exacerbate the transport phenotype depending upon the activating mutation (Y527F or E378G), These divergent responses are associated with specific changes in the pattern of tyrosine phosphorylated proteins. Thus, the regulation of transcription, splicing and mRNA transport implicate different effector pathways of src, Furthermore, analysis of the transport phenotype reveals the interplay between the SH2 and catalytic domain of the protein.	Inst Rech Sci Canc, CNRS, UPR 9044, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Dautry, D (corresponding author), Inst Rech Sci Canc, CNRS, UPR 9044, 7 Rue Guy Moquet, F-94801 Villejuif, France.							BEUG H, 1978, CELL, V14, P843, DOI 10.1016/0092-8674(78)90340-9; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cabannes E, 1997, ONCOGENE, V15, P29, DOI 10.1038/sj.onc.1201162; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Goodison S, 1998, FRONT BIOSCI, V3, P89; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; NEEL H, 1993, GENE DEV, V7, P2194, DOI 10.1101/gad.7.11.2194; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PYPE S, 1994, J BIOL CHEM, V269, P31457; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SupertiFurga G, 1997, BIOESSAYS, V19, P447, DOI 10.1002/bies.950190602; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WEIL D, 1990, MOL CELL BIOL, V10, P5865, DOI 10.1128/MCB.10.11.5865; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	28	8	8	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2547	2555		10.1038/sj.onc.1202598	http://dx.doi.org/10.1038/sj.onc.1202598			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353598				2022-12-17	WOS:000079907100002
J	Zhang, ZC; Nechushtan, H; Jacob-Hirsch, J; Avni, D; Meyuhas, O; Razin, E				Zhang, ZC; Nechushtan, H; Jacob-Hirsch, J; Avni, D; Meyuhas, O; Razin, E			Growth-dependent and PKC-mediated translational regulation of the upstream stimulating factor-2 (USF2) mRNA in hematopoietic cells	ONCOGENE			English	Article						PKC; USF2; translational; regulation	TRANSCRIPTION FACTOR USF; PROTEIN-KINASE-C; HELIX-LOOP-HELIX; FOS-INTERACTING PROTEIN; MAST-CELL; MESSENGER-RNAS; QUIESCENT CELLS; EXPRESSION; PROLIFERATION; GENE	Upstream stimulating factor (USF2) is a basic helix-loop-helix leucine zipper transcription factor, which is found in most tissues, A critical role for USF2 in cellular proliferation has been proposed based on its importance in the regulation of various cyclins and P53 and its capability to antagonize c-myc., In this paper we report that IL-3, which is a major growth factor for mast cells, induces USF2 protein synthesis in murine mast cells (MC-9), Surprisingly, it does not significantly affect the level of USF2 mRNA in these cells at any of the time points tested, Using polysomal fractionation and RNA analysis we then demonstrated that this translational regulation is mostly the result of increased USF2 translational efficiency. Moreover, protein kinase C (PKC) inhibitors prevented both the induction of USF2 protein synthesis and the increase in USF2 translational efficiency in IL-3-activated mast cells, Two other hematopoietic cell lines were used to determine whether the translational regulation of USF2 is of a more general nature: mouse lymphosarcoma cells whose proliferation is inhibited by dexamethasone; and mouse erythroleukemia cells that differentiate upon exposure to hexamethylen bisacetamide, In both cell types, USF2 translation was repressed in the non-dividing cells, This strongly implies that USF2 is translationally repressed in quiescent hematopoietic cells, Considering the proposed role of USF in proliferation it seems that translational regulation of USF2 might have an important role in cellular growth.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Razin, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.		Avni, Dror/GRE-8325-2022; nechushtan, hovav/Z-3564-2019	Avni, Dror/0000-0002-8738-1840				AVNI D, 1994, MOL CELL BIOL, V14, P3822, DOI 10.1128/MCB.14.6.3822; BARANES D, 1991, BLOOD, V78, P2354; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHAIKIN E, 1994, J BIOL CHEM, V269, P8498; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; FALVEY E, 1991, FASEB J, V5, P309, DOI 10.1096/fasebj.5.3.2001790; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GWILLIAM DJ, 1993, ACTA DIABETOL, V30, P99, DOI 10.1007/BF00578222; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; IHLE JN, 1983, J IMMUNOL, V131, P282; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEWIN I, 1993, BLOOD, V82, P3745; Lewin I, 1996, J BIOL CHEM, V271, P1514, DOI 10.1074/jbc.271.3.1514; LIN Q, 1994, J BIOL CHEM, V269, P23894; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MATHEWS MB, 1996, ORIGINS TARGETS TRAN, P1; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; Meyuhas Oded, 1996, P65; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; Nechushtan H, 1996, CRIT REV ONCOL HEMAT, V23, P131, DOI 10.1016/1040-8428(96)00200-4; Nechushtan H, 1997, BLOOD, V89, P2999, DOI 10.1182/blood.V89.8.2999; RAZIN E, 1984, J IMMUNOL, V132, P1479; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; Sambrook J., 1989, MOL CLONING; Shama Silvian, 1995, Gene Expression, V4, P241; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; West MJ, 1995, ONCOGENE, V11, P2515; YUNG YP, 1981, J IMMUNOL, V127, P794	32	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					763	769		10.1038/sj.onc.1201584	http://dx.doi.org/10.1038/sj.onc.1201584			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488040				2022-12-17	WOS:000071931800008
